<SEC-DOCUMENT>0000950170-24-038064.txt : 20240328
<SEC-HEADER>0000950170-24-038064.hdr.sgml : 20240328
<ACCEPTANCE-DATETIME>20240328161915
ACCESSION NUMBER:		0000950170-24-038064
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		117
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240328
DATE AS OF CHANGE:		20240328

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CalciMedica, Inc.
		CENTRAL INDEX KEY:			0001534133
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				452120079
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39538
		FILM NUMBER:		24799247

	BUSINESS ADDRESS:	
		STREET 1:		505 COAST BOULEVARD SOUTH
		STREET 2:		SUITE 307
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		858-952-5500

	MAIL ADDRESS:	
		STREET 1:		505 COAST BOULEVARD SOUTH
		STREET 2:		SUITE 307
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CalciMedica, Inc. /DE/
		DATE OF NAME CHANGE:	20230322

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GRAYBUG VISION, INC.
		DATE OF NAME CHANGE:	20170717

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GRAYBUG, Inc.
		DATE OF NAME CHANGE:	20150303
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>calc-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-03-28T15:08:10.2195+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:calc="http://www.calcimedica.com/20231231" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2023" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_3b51ddda-abf2-4ef5-94ee-71739a1462f4" name="dei:AmendmentFlag" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca">false</ix:nonNumeric><ix:nonNumeric id="F_ba2097e2-28b9-42c8-a826-10962c35f8b6" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca">FY</ix:nonNumeric><ix:nonNumeric id="F_b06479d2-4d1a-4c24-8588-9ad960f4520c" name="dei:EntityCentralIndexKey" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca">0001534133</ix:nonNumeric><ix:nonNumeric id="F_da62bad0-a016-423e-8fae-6da09a0eaefe" name="dei:SecurityExchangeName" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" format="ixt-sec:exchnameen">NASDAQ</ix:nonNumeric><ix:nonFraction id="F_74cfeaa3-ed05-485f-93be-ecdef817d1a9" name="us-gaap:CommitmentsAndContingencies" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" unitRef="U_USD" xsi:nil="true"/><ix:nonFraction id="F_b94405e4-4bf9-46b4-a0c9-907b7b37b530" name="us-gaap:CommitmentsAndContingencies" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" unitRef="U_USD" xsi:nil="true"/><ix:nonNumeric id="F_96e7d778-f45a-41e2-8962-c4c3904214d6" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" format="ixt-sec:durwordsen">twelve months</ix:nonNumeric><ix:nonNumeric id="F_71b4969f-28c5-4ace-ac88-38cb897a2809" name="calc:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingRightsAnniversaryPeriod" contextRef="C_7ef7e808-55f3-466b-981a-c813c5b91fb6">P1Y</ix:nonNumeric><ix:nonNumeric id="F_10ec6273-2918-45a5-ad26-6251eb098fa9" name="calc:LeaseAmendmentDate" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca">2023-01</ix:nonNumeric><ix:nonNumeric id="F_01fefd8e-092e-48bc-992a-f56011278bfb" name="calc:LesseeOperatingLeaseMaturityYearAndMonth" contextRef="C_9da5c1b9-5f0f-4c2f-99db-43a1ecdbfb83" format="ixt:date-year-month">2023-06</ix:nonNumeric><ix:nonNumeric id="F_5164bc76-6e34-4c80-a8a7-d709dbb4720a" name="calc:ShortTermOperatingLeaseExpirationDate" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" format="ixt:date-day-month-year">30.06.2023</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="calc-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="C_9759fbac-1faf-4bad-935e-6d6df5498635"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2bc4190f-24bd-4383-9a76-813440aa7079"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">calc:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c333f4e-ee8c-4673-aefb-c953498d5405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_18921a4e-cb36-49f6-887d-24dcb1c18c90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f5b9bae3-0548-4930-bb40-f87d4bfbe049"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_63f79bb4-c719-4598-9f7b-e5ab26777c6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0893edf-fb0c-4acf-a7b8-179db40778c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_79aec6d8-c918-443b-a31f-3dd73301431e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">calc:ConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6a19c8ff-3eec-4e73-bbb3-c3b561d13063"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f0c2863c-d6f8-4c28-a7b2-bb4074acd7b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f5cacbc-880d-4602-b949-fa5d6761652f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:CalcimedicaCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-20</xbrli:startDate><xbrli:endDate>2023-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bd0f357b-9782-4dba-b331-d7e9654967b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">calc:GraybugVisionIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_90312dd6-a13b-4f5c-9a39-28a177879bc1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a560d69c-2898-468a-9634-5372f3e638e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_45300d27-3112-43ed-a27a-f1ca2b9647c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ffb1c4c-957c-4089-a01f-27b641fd51e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesDWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_44e3fe9d-1f45-4346-b174-97527637315a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d14e56e9-7918-4c0f-9cbf-a1b9ce18ce28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1945eb61-653c-4d34-aedd-57f80cdc4177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ee603a1-e520-4a05-b7a9-9cc94a461856"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1625384c-df1a-463a-9b14-131ec9a67ba4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesDWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5405b9ae-90f7-42b7-8ea1-97fedf79248d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesCTwoConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d7864a30-f755-4c98-af75-d219e66a55a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">calc:DirectorsEmployeesOrConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bd0bc60c-d4f5-4ec3-a673-0505d888ab7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c76b6693-5f6b-44e3-a453-7bd33b5ddf5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">calc:PostMergerTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d790b41b-1e12-488c-8daa-9f3b3627753e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">calc:ConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c8e84e93-e57a-4e7e-a6fd-3469c8f77e9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">calc:ConvertiblePromissoryNoteWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_69c89aa6-a735-464c-af58-9f7d7d6733ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8b2b8377-2a31-4a6e-8ded-d5abdcfa46af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">calc:OfficersAndDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">calc:PostMergerTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fb58baf9-d75a-4814-b11a-5c4bf3132842"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_83ff265d-5f06-4f96-87f9-d5b6ce1fb1d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">calc:OfficersAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_53c249ce-207a-4c43-a71e-dd5b46a497f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_42abc17e-9eda-4860-b3f8-0efb13eadeae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">calc:AmendedAndRestatedCertificateOfIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9aaecb1b-b009-46d1-a2c3-ad52042541eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">calc:OfficersAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_31761f11-9358-474c-ab64-43e5fe6dd846"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1d04e9a4-5ef0-4df1-8750-14de2723f9bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">calc:PreferredWarrantsLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5d90f9a6-e52f-451e-b3ef-71ea2b53490b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">calc:GraybugMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_824ded8d-e1b3-4524-b35d-2636e88b1f27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_38bc6d68-19a2-4497-aebd-7db45c2ce63b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_80eeb444-2e22-4786-9e02-a20268b73e22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">calc:PriorToMergerTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ca2b5abc-6893-4a09-9891-e889e91a1af0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">calc:PreferredAndCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_033e18f1-c526-494a-af37-d16f8a20d94c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">calc:PostMergerTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6b9f2b4-556e-4252-b411-7c709e13590c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">calc:GraybugMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dc6f3b09-7f0d-4955-b288-aa892fd2868e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">calc:CalcimedicaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a0231b6b-5eb4-4312-ade8-abf82342f64e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesCTwoWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d26b6223-10d2-4e75-97a3-b8b6a3c39933"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">calc:ConvertiblePromissoryNoteWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a3e0ce3a-700f-4c36-8d35-fed370e247a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">calc:ConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea3403be-994b-481a-8da5-05ce7ae02175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f099418b-2bfe-4abc-80ff-3d27b357e283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c2ab8d40-d474-4916-9e68-da10e0f82c62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f9395b99-5d87-4344-87fa-5056b48d26c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesCTwoWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">calc:PostMergerTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_da70ea3c-8eb1-49bf-a910-720ae1e76953"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0812ad75-b2cd-4dd2-8c00-aee77ec17b71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_53e9f125-e7ca-4cd9-96f3-b398eddc05fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">calc:PreferredWarrantsLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f725abd-da2c-4ddd-87a7-b41ccda9c06b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3238f60f-57e8-430b-b3e4-81f554a6a7c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">calc:PreferredWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3e9739ba-3899-4e58-81e1-44a9a303fe9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">calc:PrivateCalcimedicaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a978bf4-30e7-4478-82d1-2929b8c869c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">calc:PostMergerCalcimedicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-20</xbrli:startDate><xbrli:endDate>2023-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d8a1b34-d457-4b45-9c95-b58fcd74a782"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">calc:FederalResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_71e8ce45-e272-4f48-9eff-ba31844ce0d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ac3291f-aa10-49f9-b9db-b6f575d3e347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">calc:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f68eaef2-f138-447b-b9cf-bb7bd3b96085"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-05</xbrli:startDate><xbrli:endDate>2024-02-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0a6fe6b9-36ef-4f25-b46f-fe2f867d0a7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a1517846-ee85-4222-be99-133ea3be307b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a3e2c51e-9ae5-48f2-aa73-7734ac756106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">calc:ConvertiblePromissoryNoteWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_132f40d2-5814-446c-afac-5f97f6db9fc9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">calc:PriorToMergerTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesCTwoWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1f3e1d63-5125-4209-b819-942e8859a17c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_efd6e33a-c854-438b-b83a-602ebf9ebf8c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ccf97b7e-0005-4bf8-ac80-ebcbb11b741c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">calc:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f048298b-299d-47f9-b5bd-5b7c905187ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">calc:ConvertiblePromissoryNoteWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17715ce3-d9ea-4ab1-acb5-cf49f46cbaaf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8fb13e5d-773f-45a3-a1b5-44eb8a210518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c1e00f56-e042-41d9-8c27-e58be2c2e576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">calc:GraybugMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_73195b53-1edf-49b3-a1f9-3ae2ae46a761"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">calc:ConvertiblePromissoryNoteWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_515175dc-1ad3-4b7e-8b77-14527a01e9a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesCTwoWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6bf7869c-2d29-4936-b2b6-f5c3f0c8389e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-19</xbrli:startDate><xbrli:endDate>2024-01-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d6b7e2b-1799-423b-80d4-f0ffdbd4249e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">calc:TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e9aabbcc-ba19-4328-a90c-b2b531c98d96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6557ada0-e212-4e78-b768-866c8fb13b00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">calc:PostMergerTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_13a92f01-c445-4a91-b998-937547a6966a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">calc:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-19</xbrli:startDate><xbrli:endDate>2024-01-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_28b5f7e3-7c54-4635-9e19-0a894d5bce7d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7fa15f5d-da9e-49b1-ad4b-7ac0dffbd31d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9aec901d-664d-416c-9998-1ef7272a19c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesCTwoWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba4cac3d-1b7b-4712-b4af-b00b36992550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5317cbe0-64bb-4729-93e5-b7c5d402fc35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">calc:TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c53f262c-1896-431c-b404-2f2cd328973f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">calc:PrivateCalcimedicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5472c13f-2db0-4124-89dd-bd16af205acf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5ac139a0-0917-47cd-862b-6898ff89d717"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">calc:ConvertiblePromissoryNoteWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e197c94-c9cd-4e85-83f1-c4bac6996bbc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_38046496-ba8c-4f7b-a2ab-17742c50658a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">calc:PreferredWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_923510ce-a803-41b4-a562-244fd50617fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dcf336c2-04f1-4bf9-890c-ca0039d7e325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ba994e5-acb4-4356-85f9-d557fa3db223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesCTwoWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">calc:PostMergerCalcimedicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_faf992f7-2c83-438f-adbe-c70b73ea5b35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">calc:WarrantsToPurchaseConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6739fa84-42ef-4c69-a6c0-24f4f1d63ab1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b6a7e660-bab4-4faa-a6a3-7ce18a7b50c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">calc:TrancheAAndTrancheBCommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-19</xbrli:startDate><xbrli:endDate>2024-01-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_72ea148a-99e6-47b2-bd68-d0f6914854ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">calc:GraybugMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c654b3dc-d8de-4e32-ade7-4c14b46e29eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">calc:GraybugMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d8121a99-b58b-4059-9f6a-950088ae02aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">calc:TrancheACommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9ef48710-53ac-4e62-b939-0912f0ec48d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cf933ca0-5d88-4990-aa20-a3cc722c7bc7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">calc:ConvertiblePromissoryNoteWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9ffcd5c-d377-492d-baf6-7c7ef2c83293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">calc:ConvertiblePromissoryNoteWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_77f977df-d971-4d4d-ae88-a3dd669b55f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c46001b-5fe7-4131-9a1d-ccf9d2e7cfde"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">calc:ShelfRegistrationStatementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_01acfa85-0d49-4317-9517-f41c3568951c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesC1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bb2bd826-29bf-448a-b3fe-756756fb69a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">calc:OfficersAndDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ff6e332f-5b48-43f3-b9ad-0eb9e3c7b9e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d82e695-1745-41a7-8cb2-68d786a08457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5d9b48b9-68d6-41ad-994c-2b74751e5df8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12eaa057-d9c1-42e1-b525-a11412a82bab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">calc:PostMergerTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesDWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fd5366f4-f6f4-4f51-86ec-d2b17b2273e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">calc:OfficersAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07aad975-11de-44fb-9c2a-ae67476d452b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">calc:GraybugMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef21a00c-f705-4ecd-b756-6e2bbd8fbbb1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesC1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d046d1dd-275e-4ce7-b43c-2ca79d4f0e9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">calc:PrivateCalcimedicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fdc3b56d-3340-41e6-abd7-2a87c4565e5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f64735a-ca76-47aa-aadd-323f69769f4e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_577f2bd0-e762-4230-970a-df97b7cca6e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_638c2e40-07d4-4e89-83a6-af9e3d6013a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">calc:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6acf339-8a66-4359-827f-f1d8c3fefcf6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_849e11ac-1955-44ec-aed2-b66fa055ed0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">calc:ConvertiblePromissoryNoteWarrantsLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eccb0df3-d3be-48ca-afe0-3b0886ba2bb6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d630bef2-91b1-4374-b30e-0dae725036e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb55cbd6-a773-4301-9abc-12c18795aee6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">calc:GraybugMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-17</xbrli:startDate><xbrli:endDate>2023-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7547cb73-f5f8-44b0-ad5f-4fe05452061d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1f065a12-57ce-4dcf-9b28-c5b350ecafaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_75c836b2-6496-4ac1-a472-f97feb0d50ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-19</xbrli:startDate><xbrli:endDate>2024-01-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_666c7e89-c8db-48ef-beec-8e67efcb35b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">calc:ConvertiblePromissoryNoteWarrantsLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_33be579f-9303-4157-8599-6e2e245843a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">calc:CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0e01fe61-f63d-4314-9813-8fdd75652190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">calc:GraybugVisionIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_317b6ba6-8a13-4bfe-b342-48339a414824"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2144abf4-0a9e-4b97-a97a-75d1e0d63184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1d913287-6a9c-4c1e-8311-ffb8f8c0200f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6584f473-e3fd-4960-8c14-afa94ca4e2ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">calc:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c7b1abbe-8b62-4f83-bd11-82bf252ed828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6f38265-4614-44ec-85bc-fcffb8b21275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">calc:TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1df30a04-c352-47af-8399-d9257a158c80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0605ef80-c201-4125-b549-78eca9b466e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">calc:WarrantsToPurchaseConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9155f47b-b723-4d6f-9e10-5b401cf33a46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_47c16d4b-a330-4cfb-83cf-9d9c1168ecac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cab222f3-c29a-438f-bc50-d49b23b8991a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">calc:PreferredWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9da5c1b9-5f0f-4c2f-99db-43a1ecdbfb83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ef7e808-55f3-466b-981a-c813c5b91fb6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">calc:TwoThousandAndSixEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3dfbf602-7a4c-49b2-8b99-9805b5186589"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3815767b-a76b-4eab-8224-c12657500927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8796b832-7e69-4299-a51b-d5ad3e94056f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">calc:OfficersAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0e691536-6f2f-49ff-ae16-8151a9648a89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8ab25aef-aa0a-43b5-80d4-c77a6790fefb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesDWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10d7c32a-8834-4078-bcb5-f2abb3c5706a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb28aa96-7bbd-4570-8a6a-cb5c875bd34a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c13bf6e6-7b21-47f6-8c64-15752b0689e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">calc:PreMergerCalcimedicaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-20</xbrli:startDate><xbrli:endDate>2023-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a3d1cb01-530a-4348-9ce4-14d88694eb11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesC2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b409b108-40af-4cb0-85b0-9bb871670447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c40048e-5e83-487d-95e9-572612a5b2a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1cb6ffcd-9a58-41d3-a749-d0783461107f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesC2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3aa562e8-771a-40e1-9e64-d658f147bd41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">calc:AuxoraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec132aef-e24b-4108-817d-1584845fdc60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_70e26569-927c-4f36-a60f-3d66c9bd4f1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f43e59fc-a4b6-4320-b729-ea2f876d663d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">calc:PostMergerTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesDWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d04970cb-4761-47c7-91f6-85af5efbecc9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a90b884a-f2e9-44ca-a156-3042948bd1e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_73969220-1a8a-40c5-9659-158f6f3ab8a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d824885a-bf88-4997-b44b-56b06f10352e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b643f00-2d89-421c-b960-b0008cf81a56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_345b3de8-3757-4586-b754-d61ef7ff0cf5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">calc:ConvertiblePromissoryNoteWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e88cb3f0-85d9-47a7-b525-8fd14ae13f26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f3902d69-3631-4f29-9f8f-24d3fa1a5357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_65b45366-3e2b-42a5-89ff-61739a51bdaf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cfb02dbb-5b66-4ab2-8c28-3198b03e30f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:CalcimedicaPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-20</xbrli:startDate><xbrli:endDate>2023-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8fb4c8dc-dcc1-4352-ad4c-b46434309f12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">calc:OfficersAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_047361c5-453c-47e4-8ce1-9373daa9b02d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">calc:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e069504-00ad-4b62-9b5c-575c0a9feed4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001534133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">calc:PrivateCalcimedicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_Contract"><xbrli:measure>calc:Contract</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_9f0bb873-815a-4c02-aa18-9b124c54fb6a" fromRefs="F_8bb455e8-70b9-4732-be18-0165b2cbda00 F_77a8410c-4e3c-4060-829b-0d8b55ac4402 F_27361f8e-d2e4-4e18-9632-df1df55eaff4 F_e9c6e4f2-b585-4330-83ce-ae3565e5cbbf F_eb32f7f3-f91a-4e57-94ed-8a2cd6277afb F_b1d275c5-c0d4-477b-89db-8c7429a395f6 F_acfe5755-3ae1-4a5a-b7b0-5f043022b2ae F_6e50737b-dc7c-4bbc-97ea-d00034ac8717 F_3fbd2093-cd96-437a-be94-3a27dc8e2bb4 F_a07ba786-30c5-4eb5-b907-fe5e65ee816f F_bcd704f4-ea19-434a-8fa8-9bef64fd9dd0"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_92a35516-dd1a-4ef7-8468-5d018858e544" fromRefs="F_9e6587b8-a085-4060-bcbb-02a3fd9cb98a F_4bd1ee4e-cab4-4321-a744-19504259caa2 F_1b4fc4d8-0455-4e1e-b160-f78a2794e368 F_9c966614-f625-4a8d-9dde-653f387df670 F_ba2bde47-7ce9-4d0a-8bec-2f13de62590f F_df2a12f8-eb45-4e92-a272-43e99d7d9bb8 F_09a89814-82cf-4b05-8abf-d22651e40260"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_817b6b4d-bd23-4519-a81b-d710bbd95793" fromRefs="F_7fa10f53-be99-4967-bf37-e3fa0474e69a F_f773b99e-e092-43b8-b105-11fd67e300ed F_8f2f002b-1bd3-437f-bf29-483769287156 F_b9d8336f-3890-4043-9995-6e780f43215e F_653e16b7-bfd8-48a8-adbe-099c4cbd6e40 F_abfd3d94-e97c-4d7d-93da-21000f70a852 F_4246f750-75ee-4e2a-abd6-1a856a263eff F_a90ba9c6-3e69-4a14-9d5b-e426367ed758 F_b1745aaa-ce03-42da-b1a6-98a0481feb87"/></ix:resources></ix:header></div>
  <div style="min-height:0.5in;"></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f61a9f38-0a3f-45f5-aa61-da91cf12eb7d" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Mark One)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_a3545b76-4096-4ad3-93f4-250d3dd0c89a" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6ee18d0f-844c-43fd-a8de-4bf5e24dc98b" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e3f8a5f3-5083-4675-9934-e75f9ddc3a79" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bd9db630-8703-440f-b727-21725bd74ae0" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">OR</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_d69faea5-20f3-48ab-b681-13e77e51181f" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:DocumentTransitionReport" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">         </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Commission File Number </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0c1e2e97-7d82-49e6-af17-e3d1ef186495" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">001-39538</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:14.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6b5d4f52-555f-4137-80a4-06ef6987dc84" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14.5pt;font-family:Times New Roman;min-width:fit-content;">CalciMedica, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49%;"/>
    <td style="width:2%;"/>
    <td style="width:49%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_edd4f524-9950-44b8-8c81-36b8c60fd194" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_fcf091a6-c55c-4b8d-987a-922af642ee43" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">45-2120079</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or other jurisdiction</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">of incorporation or organization)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_83f48718-06e4-479f-9ce3-ffd5748933d9" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">505 Coast Boulevard South</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7a4deb60-bbdf-4197-a0eb-6e4d1b30e7cd" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Suite 307</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0017bdf5-d29d-4307-ba7d-ff8e952d0ccf" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">La Jolla</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_19054b65-f263-4d1f-8949-996c0effc8c0" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CA</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_609f49a1-8a16-4145-8524-15968e33a6f0" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">92037</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Address of principal executive offices including zip code)</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_41256550-ae1f-4eb2-a61d-d5194ac7733d" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">858</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_59cbb0bc-59b1-4fd9-87d3-27478b53168b" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">952-5500</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39%;"/>
    <td style="width:1%;"/>
    <td style="width:20%;"/>
    <td style="width:1%;"/>
    <td style="width:39%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9.5pt;"><ix:nonNumeric id="F_cfec5d68-c64f-4636-afef-b880a0bfad69" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9.5pt;"><ix:nonNumeric id="F_ff07f38b-cb70-4415-8068-3f96a7a4c0cb" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CALC</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9.5pt;"><span style="-sec-ix-hidden:F_da62bad0-a016-423e-8fae-6da09a0eaefe;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Capital Market</span></span></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">None</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">     </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b54d4008-e61c-4f8c-b644-bb0cf0e5bde9" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:EntityWellKnownSeasonedIssuer"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9744;    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_250c0c3f-2feb-43c4-b1e5-6bf9405bf213" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:EntityVoluntaryFilers"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">N</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">o</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f66d8dfe-376f-47b7-8fbb-b9337bdf70aa" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">     </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_67a67b4c-fc10-4a74-b76f-bf0e60bbdaf4" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">     </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:19.776%;"/>
    <td style="width:1%;"/>
    <td style="width:2.999%;"/>
    <td style="width:49.51%;"/>
    <td style="width:1.06%;"/>
    <td style="width:22.416%;"/>
    <td style="width:1%;"/>
    <td style="width:2.24%;"/>
   </tr>
   <tr style="height:11.5pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_4b151419-7b9b-4ae6-953a-f9d6b45e49bd" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_ec9ec724-4b8f-43ad-b036-9f92b64ee894" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_7d2f1520-e760-4c07-91ff-19786b5d4884" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_d4988321-a1f9-47ab-add4-99b876c7af6e" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:6.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_ef3bff86-bb98-469a-9c7c-1c2b5da4f855" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:6.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_a4a1daa3-e082-4bb2-ac05-451ef6920458" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).  </span><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;min-width:fit-content;">     </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:6.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4e30a62f-446c-4143-b54d-bee00993c8af" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2023, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of common stock held by</span><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;min-width:fit-content;">non-affiliates of the registrant computed by the closing price of the registrant&#8217;s common stock on June 30, 2023 on the Nasdaq Capital Market was approximately $</span><span style="font-size:6.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53133c08-1101-407e-b1f7-d148da4508a9" contextRef="C_90312dd6-a13b-4f5c-9a39-28a177879bc1" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;min-width:fit-content;"> million. Shares of common stock held by each executive officer, director and their affiliated holders have been excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;min-width:fit-content;">The number of shares of Registrant&#8217;s Common Stock outstanding as of March 21, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;min-width:fit-content;"> was </span><span style="font-size:6.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a2eaabc-8e78-4dd3-be1a-fcb717b63ccf" contextRef="C_73969220-1a8a-40c5-9659-158f6f3ab8a8" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">10,740,115</ix:nonFraction></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1b0e54de-480d-478d-9f0c-70f8bce2546b" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true" continuedAt="F_1b0e54de-480d-478d-9f0c-70f8bce2546b_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">                                                                              </span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:continuation id="F_1b0e54de-480d-478d-9f0c-70f8bce2546b_1"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Portions of the registrant&#8217;s definitive Proxy Statement (the &#8220;Proxy Statement&#8221;) for the 2024 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission not later than April 29, 2024 are incorporated by reference into Part III of this Annual Report </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">on Form 10-K</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="text-indent:4.533%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report on Form 10-K contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements, other than statements of historical facts contained in this Annual Report on Form 10-K, including statements regarding our future financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases you can identify these statements by forward-looking words such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221; &#8220;expect&#8221; or the negative or plural of these words or similar expressions. These forward-looking statements include, but are not limited to, statements concerning the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding the success, cost and timing of our development activities, non-clinical studies and clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding the timing and outcome of our current and future clinical trials, and the reporting of data from those trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our research and development plans;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential of our technologies and our ability to execute on our corporate strategy;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to attract and retain key scientific, medical, commercial and management personnel;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to fund our working capital needs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the strength and breadth of our patent portfolio;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the therapeutic potential of Auxora and our other product candidates and the expected patient populations, market opportunities, commercial potential and commercialization strategy thereof;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding our cash runway and expected use of cash, cash equivalents and short-term investment;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our need to obtain additional funding and the ability to obtain such funding for our operations, including funding necessary to develop and commercialize our product candidates, subject to regulatory approvals:</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability and plans to contract with third-party suppliers and manufacturers and their ability to perform adequately;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expected competitive position;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to develop and maintain our corporate infrastructure, including our ability to design and maintain an effective system of internal controls;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">legislative and regulatory developments in the United States and other foreign countries;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential claims relating to our intellectual property or other legal proceedings;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding future economic conditions or our financial performance;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain and adequately protect intellectual property rights for our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain regulatory approval for our product candidates and any related restrictions, limitations and/or warnings in the label of any approved product candidate;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to extend our operating capital;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to continue to satisfy the Nasdaq listing requirements and have our stock continue to trade on Nasdaq; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">statements of belief and any statement of assumptions underlying any of the foregoing.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry&#8217;s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in greater detail under the heading &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K. You should not rely upon forward-looking statements as predictions of future events. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risks and uncertainties.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, after the date of this report, we are under no duty to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">i</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We obtained industry, market and competitive position data in this report from our own internal estimates and research as well as from industry and general publications and research surveys and studies conducted by third parties. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such information or estimates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summary of risks associated with our business</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An investment in our common stock involves a high degree of risk. Below is a list of the more significant risks associated with our business. This summary does not address all of the risks that we face. Additional discussion of the risks listed in this summary, as well as other risks that we face, are set forth under Part I, Item 1A, &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K. These risks include, but are not limited to, the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical-stage biopharmaceutical company with a limited operating history. We have incurred net losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. We have never generated any revenue from product sales and may never be profitable.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will need to obtain substantial additional funding to complete the development and any commercialization of our product candidates. If we are unable to raise this capital when needed, on acceptable terms, or at all, we may be forced to delay, reduce or eliminate the development of our product candidates or other operations.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our proprietary platform or product candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any acquisitions or strategic collaborations may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities or subject us to other risks.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our proprietary CRAC channel inhibition science is based on novel technologies that are unproven and may not result in approvable or marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval and we may not be successful in our efforts to use and expand our science to build a pipeline of product candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business is highly dependent on the success of our product candidates, in particular Auxora, and we may fail to develop Auxora successfully or be unable to obtain regulatory approval.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical development is a lengthy, expensive and uncertain process. The results of preclinical studies and early clinical trials are not always predictive of future results. Any product candidate that we advance into clinical trials may not achieve favorable results in later clinical trials, if any, or receive marketing approval.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have expanded to and plan to conduct a significant portion of our ongoing CARPO trial in India, and regulatory authorities may not accept data from such trial or any future clinical trials we conduct outside the United States or the applicable foreign jurisdiction.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We depend on enrollment of patients in our clinical trials for our product candidates. If we experience delays or difficulties enrolling patients in our clinical trials, our research and development efforts and business, financial condition, results of operations and prospects could be adversely affected.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on third parties to conduct and perform most of our research, preclinical studies and clinical trials. If these third parties do not satisfactorily carry out their contractual duties, fail to comply with applicable regulatory requirements, fail to meet projected clinical trial enrollment schedules or fail to meet expected deadlines, our development programs may be delayed or subject to increased costs, each of which may have an adverse effect on our business and prospects.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We contract with third parties for the manufacturing and supply of certain goods and services for our product candidates for use in preclinical studies and clinical trials, which supply may become limited or interrupted or may not be of satisfactory quality and quantity.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any approved product candidates may fail to achieve the degree of market acceptance by physicians, patients, hospitals, healthcare payors and others in the medical community necessary for commercial success.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to successfully commercialize our product candidates due to unfavorable pricing regulations or third-party coverage and reimbursement policies, which could make it difficult for us to sell our product candidates profitably.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to continue to successfully develop or commercialize our product candidates or otherwise implement our business plan.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ii</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to obtain and maintain sufficient intellectual property protection for Auxora, any future product candidates, and other proprietary technologies we develop, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize Auxora, any future product candidates, and other proprietary technologies if approved, may be adversely affected.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business operations may subject us to disputes, claims and lawsuits, which may be costly and time-consuming and could materially and adversely impact our financial position and results of operations.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">iii</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EXPLANATORY NOTE</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 20, 2023, the Delaware corporation formerly known as &#8220;Graybug Vision, Inc.&#8221; completed its merger transaction in accordance with the terms and conditions of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended on February 10, 2023 (the &#8220;Merger Agreement&#8221;), by and among Graybug Vision, Inc. (&#8220;Graybug&#8221;), Camaro Merger Sub, Inc., a wholly owned subsidiary of Graybug (&#8220;Merger Sub&#8221;), and CalciMedica, Inc. (&#8220;Private CalciMedica&#8221;), pursuant to which Merger Sub merged with and into Private CalciMedica, with Private CalciMedica surviving the merger as a wholly owned subsidiary of Graybug (the &#8220;Merger&#8221;). Additionally, on March 20, 2023, the Company changed its name from &#8220;Graybug Vision, Inc.&#8221; to &#8220;CalciMedica, Inc.&#8221; (the &#8220;Company&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 17, 2023, in connection with the transactions contemplated by the Merger Agreement, Graybug filed an Amended and Restated Certificate of Incorporation effecting a reverse stock split of Graybug&#8217;s common stock at a ratio of 14:1 (the &#8220;Reverse Stock Split&#8221;). As a result of the Reverse Stock Split, the number of issued and outstanding shares of Graybug&#8217;s common stock immediately prior to the Reverse Stock Split was reduced into a smaller number of shares, such that every 14 shares of Graybug&#8217;s common stock held by a stockholder immediately prior to the Reverse Stock Split were combined and reclassified into one share of common stock after the Reverse Stock Split. The information in this Annual Report on Form 10-K as of and for the periods prior to the effective date of the Merger gives effect to the Reverse Stock Split.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since Private CalciMedica was determined to be the accounting acquirer in connection with the Merger, for periods prior to the Merger, the consolidated financial statements were prepared on a stand-alone basis for Private CalciMedica and did not include the combined entities&#8217; activity or financial position. Subsequent to the Merger, the consolidated financial statements as of and for the twelve months ended December 31, 2023 include Graybug&#8217;s activity from March 21, 2023 through December 31, 2023, and assets and liabilities at their acquisition date fair value. Historical share and per share figures of Private CalciMedica have been retroactively restated based on the exchange ratio of 0.0288.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In this Annual Report on Form 10-K, unless the context indicates otherwise, the terms &#8220;Company,&#8221; &#8220;CalciMedica,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to (i) Graybug Vision, Inc., for periods prior to the effectiveness of the Merger and (ii) CalciMedica, Inc. (as a combined company) for periods following the effectiveness of the Merger.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report on Form 10-K contains references to trademarks belonging to other entities, which are the property of their respective holders. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">iv</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.998%;"/>
    <td style="width:81.924%;"/>
    <td style="width:7.079%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART I</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Business</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">103</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">103</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 2.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Properties</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 3.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">105</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 4.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">105</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART II</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 5.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 6.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_selected_financial_data"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">[Reserved</span></a><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">]</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_management_discussion"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">107</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_and_qualitative"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 8.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_and_disagreements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_and_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">119</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">119</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART III</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 10.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_officers"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">120</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 11.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">120</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 12.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">120</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 13.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">120</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 14.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accounting_fees"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">120</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART IV</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 15.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">121</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 16.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">125</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1. Bu</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">siness.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Our product candidates act upon calcium release-activated calcium (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CRAC</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) channels, and would constitute a new class of drugs.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a company focused on the discovery and development of CRAC channel inhibitors. Clinical and preclinical data have demonstrated that the inhibition of CRAC channels may have a therapeutic effect based on a dual mechanism involving both anti-inflammatory and tissue cell protective activities. Our work has shown compelling evidence of the involvement of CRAC channels in a broad spectrum of both acute critical illnesses and chronic diseases that have the common thread of inflammation or immunologic activity in their pathogenesis. We intend to leverage our CRAC channel inhibitor platform to develop therapeutics for indications where this dual mechanism of action has the potential for clinical benefit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our lead product candidate is Auxora, a potent and selective intravenous (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IV</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. Multiple Phase 2 clinical trials with Auxora have been conducted: an open-label trial in acute pancreatitis (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AP</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;), an investigator led open label trial in asparaginase induced pancreatic toxicity (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AIPT</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;)(which we also refer to as &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CRSPA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) in which the first cohort of patients has been completed, a placebo-controlled double-blind trial in severe COVID-19 pneumonia (which we also refer to as &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CARDEA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) and an investigator led open-label trial in COVID-19 pneumonia patients with acute respiratory distress syndrome (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ARDS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;). We observed in all of these trials that patients treated with Auxora experienced a reduced time to recovery and a reduction of organ damage. We believe the consistency of the results we observed from these trials in two different acute critical care conditions are mutually supportive and reinforce our plans to further pursue the use of Auxora in several additional acute critical illnesses.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In a Phase 2a trial conducted in the United States in patients with AP and accompanying systemic inflammatory response syndrome (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIRS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) along with hypoxemia (low concentration of oxygen in blood), a greater proportion of patients treated with Auxora compared to standard of care (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SOC</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) alone experienced resolution of persistent SIRS (SIRS lasting 48 hours or more) and tolerated solid food at 72 hours, an indicator of disease resolution. The majority of patients with respiratory failure treated with Auxora did not require mechanical ventilation. This resulted in hospital discharge for patients treated with Auxora more than two days earlier than those treated with SOC alone. These findings were published in the peer-reviewed journal </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pancreas </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in 2021. We are currently conducting a blinded placebo-controlled Phase 2b trial in the United States in patients with AP and accompanying SIRS (which we also refer to as &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CARPO</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;). We anticipate topline results from the CARPO trial in the second quarter of 2024 and, assuming positive results, to initiate our Phase 3 trial in 2025.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CRSPA, a Phase 1/2 single arm 24-patient trial, is currently being conducted in the United States in pediatric patients with acute lymphoblastic leukemia (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ALL</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) who have developed pancreatitis as a side-effect of asparaginase or AIPT.  CRSPA is an investigator-sponsored trial being conducted by St. Jude Children&#8217;s Research Hospital (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SJCRH</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;).  AIPT is a particularly severe form of pancreatitis and historical data suggests that over half of the patients will develop pancreatic necrosis or pseudocysts and may not receive further asparaginase treatments for their ALL, potentially impacting their prognosis, and develop long term health complications including chronic pancreatitis. The first cohort of nine patients in this trial has been completed, and, the results were presented at the American Society of Hematology (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ASH</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) meeting in December 2023.  Eight of nine patients in the CRSPA study received a full regimen of four daily doses of Auxora </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and these patients were compared to a matched historical control</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">group of patients who developed AIPT within 30 days of receiving asparaginase in the Total Therapy XVI study (T16) being conducted at SJCRH.  Treatment with Auxora, as compared to the matched historical control group, was shown to have the potential to reduce the severity of AIPT in pediatric patients with ALL. Study results showed that Auxora reduced the average number of days patients spent in the hospital and the need for care in the intensive care unit (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ICU</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;). Additionally, no patients in the CRSPA study required total parenteral nutrition (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TPN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;), compared to over half the patients the matched historical control group, who required approximately several weeks of nutritional support on average. Finally, blinded central reading of pancreatic imaging showed a reduction in the development of significant pancreatic necrosis and the severity of acute pancreatitis in patients treated with Auxora</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compared to the matched historical control group. This trial has expanded to additional sites and we expect data in 2025.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to AP and AIPT, we are conducting a Phase 2 randomized double-blind, placebo-controlled trial in patients with severe acute kidney injury (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AKI</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) that also have acute hypoxemic respiratory failure (</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AHRF</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;), which we call KOURAGE.   KOURAGE will evaluate 150 patients with stage 2 and stage 3</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AKI who have AHRF and are receiving oxygen either by non-invasive mechanical ventilation, high flow nasal cannula or intermittent mandatory ventilation (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IMV</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;). Patients will be stratified by classification of stage of AKI as well as the use of IMV. Patients will receive either a four-hour infusion of Auxora or placebo at 1.25 mL/kg as a first dose,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">after which they will receive Auxora or placebo at 1.0 mL/kg at hours 24, 48, 72 and 96. The primary endpoint of the trial will be evaluation of patients through day 30 to determine days alive, ventilator-free and dialysis-free.  Secondary endpoints will include a composite of all-cause mortality,</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">decrease in estimated glomerular filtration rate (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">eGFR&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">), and the incidence of dialysis over a period of 90 days, also known as MAKE-90 (Major Adverse Kidney Events at 90 days).  In February 2024, we received clearance from the U.S. Food and Drug Administration (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) of our Investigation New Drug Application (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IND</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) for a Phase 2 clinical trial of Auxora for the treatment of AKI patients with AHRF called KOURAGE, which we plan to initiate in the second quarter of 2024 with data expected in 2025.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In our CARDEA trial, a Phase 2 randomized double-blind, placebo-controlled trial in patients with severe COVID-19 pneumonia and receiving supplemental oxygen, but not on mechanical ventilation, we observed that patients treated with Auxora experienced a reduced time to recovery and a 56% relative reduction in mortality at 30 days (p=0.0165) and a 33% relative reduction in mortality at 60 days (p=0.1449) compared to placebo. Time to recovery was seven days for Auxora-treated patients compared to ten days for patients receiving placebo (p=0.098). For additional information regarding p-values, please refer to the section entitled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> &#8212;Auxora, a Selective CRAC Channel Inhibitor&#8212;P-Values and Confidence Intervals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; The results from CARDEA were published in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Critical Care</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in 2022. The CARDEA data, along with data from an ongoing Phase 2 trial testing Auxora in COVID-19 patients with ARDS receiving invasive mechanical ventilation, may also help inform future trials in broader ARDS and AHRF patient populations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Finally, we have compiled additional preclinical data supporting the potential to use CRAC channel inhibition for both chronic and acute inflammatory and immunologic diseases. We have available product candidates and have chosen CM6336 for IND-enabling preclinical testing to determine its pharmacokinetics and safety for  potential oral dosing. We have animal model data suggesting CRAC channel inhibition may be useful in treating chronic pancreatitis, rheumatoid arthritis, ulcerative colitis, allergic asthma, and traumatic brain injury.  We plan to submit an IND to the FDA for CM6336 in 2025, for the treatment of chronic pancreatitis and rheumatoid arthritis.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Calcium is an important regulator of multiple biological functions, and in electrically non-excitable cells CRAC channel activation plays a critical role in the activation of calcium-dependent pathways that modulate various responses, including inflammation and vascular permeability. In immune cells, activation of CRAC channels is a key step in initiating the adaptive immune response and the generation of inflammatory cytokines. In addition, in certain acute critical illnesses, CRAC channels on affected organ tissue cells can become overactivated, resulting in excess calcium entry into cells. This excess calcium can cause cellular injury and necrosis, or activate apoptosis signaling pathways leading to programmed cell death further exacerbating the damage caused by inflammatory response. We have developed novel cell-based assays for compound screening that enabled us to identify and optimize a portfolio of potent and selective small molecule CRAC channel inhibitors, including zegocractin (previously referred to as &#8220;CM4620&#8221;) that is the active ingredient in Auxora, from several different chemical classes. These compounds each have different pharmaceutic and pharmacokinetic properties and comprise our portfolio of CRAC channel inhibitors.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Pipeline</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are currently developing our lead compound Auxora in several acute critical illnesses. We have a Phase 2b trial ongoing in AP and an investigator led Phase 1/2 trial ongoing in AIPT. In addition, we are conducting a Phase 2 randomized, double-blind, placebo-controlled trial in patients with AKI that also have AHRF which we expect to initiate in the second quarter of 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates are summarized in the table below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img222477878_0.jpg" alt="img222477878_0.jpg" style="width:547px;height:247px;"/>&#160;</p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Experience with Auxora</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our clinical experience with Auxora is summarized in the table below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_1.jpg" alt="img222477878_1.jpg" style="width:541px;height:303px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have studied Auxora in a number of clinical trials including multiple Phase 2 clinical trials conducted in the United States, two of which have been in our lead indication, AP. We have published results from an open-label SOC controlled Phase 2a trial in AP, results from treating the first cohort of patients in CRSPA have been presented. We have also published results from CARDEA and the 30-patient open-label part one portion of this same trial. With our investigators, we have completed a biomarker analysis with samples taken from over 190 CARDEA patients and have posted the data on-line while it undergoes peer review for formal publication. We observed in all of these trials that patients treated with Auxora experienced a reduced time to recovery and a reduction of organ damage. In CARDEA, we observed a statistically significant 56% relative risk reduction in mortality at 30 days. We believe the consistency of the results we observed from these trials in multiple acute critical care conditions affecting different primary organs are mutually supportive and reinforce our plans to further pursue the use of Auxora in several additional acute critical illnesses.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Auxora for the Treatment of AP</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">AP with SIRS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Completed open-label Phase 2a clinical trial. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We completed a randomized, open-label Phase 2a clinical trial of Auxora in 21 patients with AP and accompanying SIRS who also had hypoxemia at presentation. Patients in this trial treated with Auxora in addition to SOC had multiple improved outcomes compared to patients treated with standard care alone. In addition, there were several patients with severe respiratory failure at enrollment and the majority of those treated with Auxora did not require mechanical ventilation. Results from this randomized, open-label Phase 2a clinical trial conducted in the United States were published in March 2021 in the peer- reviewed journal Pancreas. We have received Fast Track designation from the FDA and orphan drug designation in the European Union (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EU</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) from the European Medicines Agency (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EMA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) for Auxora for the treatment of AP. However, there is no guarantee that Fast Track designation will result in a faster regulatory review or regulatory approval, if at all.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Ongoing Phase 2b clinical trial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We are currently conducting CARPO in the United States, a Phase 2b clinical trial in 216 patients with AP and accompanying SIRS. In the third quarter of 2023, we expanded the trial internationally and expect a significant portion of the enrollment in India. We anticipate topline results from our CARPO trial in the second quarter of 2024 and, assuming positive results, to initiate our Phase 3 trial in 2025. We do not currently have any marketing plans for our product candidates for AP in India.</span></div></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Auxora for the Treatment of AIPT: Pancreatitis as a Side Effect of Treatment for Pediatric ALL</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Ongoing Phase 1/2 clinical trial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. CRSPA, an investigator led 24-patient Phase 1/2 trial, is being conducted in the United States in children who develop AIPT related to the use of the chemotherapeutic asparaginase in the course of their treatment for ALL. We believe this work is providing valuable information on the use of Auxora in critically ill pediatric patients. The first cohort of nine patients in this trial has been completed and the data presented at ASH in December 2023 showed </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">that all patients who received a full course of Auxora treatment had a more rapid resolution of their symptoms as compared to historical controls. These patients spent less time in the hospital or intensive care unit and blinded central reading of pancreatic imaging showed reduction in the development of significant pancreatic necrosis and the severity of acute pancreatitis as compared to the historical control group, 27% of whom had greater than 30% necrosis of their pancreas at 30 days as compared to none of the Auxora treated patients. Over 50% of patients in the control group received TPN for several weeks on average and none received TPN in the treatment group. This trial has expanded to additional sites and we expect our collaborators to have data in 2025.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Auxora for the Treatment of Acute Kidney Injury</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Planned Phase 2 clinical trial. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> In February 2024, we received clearance from the FDA of our IND for a Phase 2 clinical trial of Auxora for the treatment of AKI patients with AHRF which we call KOURAGE and which we plan to initiate in the second quarter of 2024 with data expected in 2025. KOURAGE is a randomized, double-blind, placebo-controlled study that will evaluate 150 patients with Stage 2 and 3 AKI who have AHRF and are receiving oxygen by non-invasive mechanical ventilation, high flow nasal cannula or IMV. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical observations of Auxora for AKI.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  We have both clinical observations and pre-clinical data that support the development of Auxora in AKI.  In our CARDEA trial, which studied Auxora in patients with severe and critical COVID-19 pneumonia, results showed a 40% reduction in reported AKI (a common consequence of COVID-19 pneumonia) in Auxora-treated patients as compared to placebo-treated patients.  In a post-hoc analysis of patients with compromised kidney function (eGFR</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&lt;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 60 mL/min/1.73 m</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) at enrollment, there was a survival benefit for patients treated with Auxora compared to those on placebo.  Biomarker analysis from blood samples taken from over 190 CARDEA patients further showed that Auxora had positive effects on biomarkers that are independently associated with both hospital mortality and long term adverse outcomes. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preclinical studies for Auxora in AKI.</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CalciMedica&#8217;s pre-clinical studies in an ischemia/reperfusion injury model of AKI in rats showed promising results, whereby animals receiving three daily doses of Auxora after injury had improvements in their GFR values while rats receiving placebo had little improvement. Further, in the setting of severe kidney injury, rats receiving Auxora survived where as those receiving placebo died.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Auxora for the Treatment of Acute Respiratory Failure</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Completed open-label Phase 2 clinical trial in 30 hospitalized COVID-19 pneumonia patients on oxygen (Part 1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Initial data in COVID-19 patients were obtained in a randomized, open-label Phase 2 clinical trial of Auxora conducted in the United States in 26 patients with severe COVID-19 pneumonia and 4 patients with critical COVID-19 pneumonia. Patients treated with Auxora in addition to SOC recovered faster than those on SOC alone, with 67.8% (p&lt;0.05) lower incidence of invasive mechanical ventilation or death during the study period, which was statistically significant. Based on these initial results and recommendation of the FDA, we transitioned from this open-label Part 1 of the trial to a randomized, blinded, placebo-controlled Part 2 of the trial (CARDEA). The results from Part 1 of the trial were published in July 2020 in the peer-reviewed journal </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Critical Care</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Completed double-blind Phase 2 clinical trial in hospitalized COVID-19 pneumonia patients on oxygen (Part 2). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In our CARDEA trial, a Phase 2 randomized double-blind placebo-controlled trial conducted in the United States in 284 patients with severe COVID-19 pneumonia (261 having moderate and severe respiratory failure&#8212;our efficacy set) and receiving supplemental oxygen but not on mechanical ventilation, treatment with Auxora resulted in a reduced time to recovery and a 56% relative reduction in mortality at 30 days (p=0.0165) and a 33% relative reduction in mortality at 60 days (p=0.1449) compared to placebo. Both of these findings are clinically relevant particularly in light of patients needing additional therapies on top of current standard of care. Time to recovery was seven days for Auxora-treated patients compared to ten days for patients receiving placebo (p=0.098). Data from this study was published in April 2022 in the peer-reviewed journal </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Critical Care</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Completed the treatment portion of a Phase 2 biomarker clinical trial in mechanically ventilated COVID-19 pneumonia ARDS patients</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In collaboration with investigators from Northwestern Memorial Hospital, we are conducting a Phase 2 dose escalation clinical trial of Auxora in the United States in patients with COVID-19 pneumonia who have ARDS and require invasive mechanical ventilation. We have explored dosing regimens with varying drug exposures in these patients in addition to the three-day regimen we tested in our open label Phase 2 clinical trial and CARDEA. We have completed the enrollment and treatment of patients in this trial and are completing the biomarker analysis from samples taken from these patients. We anticipate results from this trial will be published in 2024. While we have decided to not pursue further development of Auxora for patients with COVID-19 pneumonia, results from this trial may inform the design of a Phase 2 clinical trial for the treatment of AHRF and/or ARDS.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preclinical work in AHRF and ARDS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We believe that the observed treatment effect of Auxora in AP and COVID-19 pneumonia trials, both causes of respiratory failure and ARDS, merits further clinical development in a broader patient population with AHRF or ARDS from etiologies beyond COVID-19 pneumonia. We have tested zegocractin (active ingredient in Auxora) in a lipopolysaccharide (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">LPS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;)-induced respiratory failure model in mice that showed a reduction in both inflammatory cytokines in the lungs of these animals and peribronchiolar and perivascular edema.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Potential Additional Indications.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Oral candidate (CM6336) for the treatment of chronic inflammatory and immunological diseases. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also developing oral CRAC channel inhibitors for use in chronic inflammatory indications. We have selected CM6336 from our portfolio and are currently conducting IND-enabling preclinical testing on this compound.  We have animal model data with other compounds suggesting CRAC channel inhibition may be useful in treating chronic pancreatitis, rheumatoid arthritis, ulcerative colitis and allergic asthma. We plan to submit INDs to the FDA in 2025 for CM6336 for the treatment of chronic pancreatitis and rheumatoid arthritis.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Auxora for the treatment of acute ulcerative colitis</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Recent animal data indicates that CRAC channel inhibition by zegocractin or CM4620 (active ingredient in Auxora) may be useful in the treatment of inflammatory bowel disease, such as ulcerative colitis. In a preclinical study performed with scientists from Charite &#8211; University Medicine, Berlin and New York University Grossman School of Medicine, it was shown that zegocractin, administered orally to mice every other day for a period of 30 days produced a significant reduction in intestinal inflammation in a model of ulcerative colitis. This work was published in EMBO Molecular Medicine in August 2022.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Auxora for the treatment of allergic asthma</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Zegocractin was studied in mouse models of asthmatic airway inflammation and influenza A virus infection to determine if inhibition of CRAC channels reduces asthmatic inflammation without interfering with the antiviral response. Researchers from New York University Grossman School of Medicine showed that oral administration of zegocractin significantly lowered both peribronchiolar inflammation and lung mucus production in the asthma model and did not impact viral response in the influenza A model. This work was published in Science Advances in October 2022.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Strategy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a company focused on the discovery and development of CRAC channel inhibitors. We intend to develop therapeutics to treat acute critical illnesses and chronic inflammatory and immunologic diseases including AP, AKI, ARDS or ARHF, and chronic pancreatitis. Our strategy to achieve this as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leverage our proprietary CRAC channel inhibition science to develop drugs to treat acute critical illness and chronic inflammatory diseases where there are no effective therapies. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Given that CRAC channels are found on many cell types in addition to immune cells, we believe that there will be a number of inflammatory and immunologic indications that can be targeted with the novel mechanism of action afforded by CRAC channel inhibitors. These indications can range from acute critical illnesses, the focus of our current efforts to date, to chronic inflammatory and immunologic conditions. Our portfolio of proprietary compounds with different pharmaceutical properties enables us to explore these indications with agents selected and formulated specifically for each unique clinical setting.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Develop Auxora for the treatment of patients with AP and accompanying SIRS. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AP represents an unmet need in critical care medicine as there are no disease-modifying therapies. We believe we have shown that Auxora-treated AP patients with SIRS and hypoxemia have better outcomes than SOC-treated control patients in a Phase 2a clinical trial. We are conducting a placebo-controlled, blinded Phase 2b clinical trial, CARPO, in a similar patient population exploring three dose levels of Auxora to confirm these findings, establish the recommended dose for a Phase 3 trial and define an endpoint acceptable to regulators. We anticipate topline results from this Phase 2b clinical trial in the second quarter of 2024 and, assuming positive results, to initiate a Phase 3 trial in 2025.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Demonstrate the efficacy of Auxora for the treatment of AKI. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AKI represents a significant unmet medical need as there are no disease- modifying therapies to either prevent or treat AKI. We have a body of clinical observations and pre-clinical data that support the development of Auxora in this acute critical disease. In February 2024, we received clearance from the FDA of our IND for a Phase 2 clinical trial of Auxora for the treatment of AKI patients with AHRF which we call KOURAGE and which we plan to initiate in the second quarter 2024 with data expected in 2025.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Develop Auxora for the treatment AIPT. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CRSPA, an open-label 24-patient Phase 1/2 clinical trial, is currently being conducted in pediatric patients with AIPT. The first cohort of nine patients in this trial has been completed and the results from this cohort as well as results from a blinded matched historical control group were presented at ASH 2023. While </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">initially a single-center trial, CRSPA has now been expanded to additional sites and our collaborators expect to have data in 2025.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Demonstrate the efficacy of Auxora for the treatment of patients with AHRF and ARDS caused by multiple etiologies. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have completed CARDEA, a Phase 2 randomized double-blind, placebo-controlled trial in patients with severe COVID-19 pneumonia and receiving supplemental oxygen, but not on mechanical ventilation, and with our collaborator we have completed the enrollment and treatment of patients of a Phase 2 clinical trial in mechanically ventilated COVID-19 pneumonia ARDS patients. Results from this trial may inform the design of a Phase 2 clinical trial for the treatment of AHRF and/or ARDS and are evaluating next steps for potential clinical development of Auxora in patients with AHRF and ARDS.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Advance a second CRAC channel inhibitor into clinical development for the treatment of an additional inflammatory indication. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that there are multiple indications, including some chronic inflammatory and immunologic indications, that could potentially be treated with CRAC channel inhibitors from our portfolio of compounds, including orally available compounds. In a preclinical animal model of chronic pancreatitis, we observed robust beneficial effects of one of our CRAC channel inhibitors. We are currently conducting IND-enabling preclinical testing on CM6336 from our drug portfolio, which is a candidate for use in chronic inflammatory and immunologic diseases. We plan to submit an IND to the FDA for CM6336 in 2025, for the treatment of chronic pancreatitis and rheumatoid arthritis. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Explore additional indications for Auxora. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent pre-clinical work in both acute ulcerative colitis and allergic asthma have shown that the zegocractin, the active molecule in Auxora, reduces inflammation and symptoms of these diseases in animal models.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursue licensing and partnership opportunities for Auxora and other compounds in our portfolio. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Development of Auxora in different geographies, and commercialization of Auxora in acute critical care indications that will require access to hospital emergency rooms, may benefit from partners with existing development capability and/or commercial channels and sales forces. We are exploring these types of relationships. In addition, we may elect to partner other of our compounds for specific indications.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Team</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our executive team is led by A. Rachel Leheny, Ph.D., our chief executive officer, who has more than 30 years of experience in the life sciences industry as a scientist, venture capital investor and investment banking research analyst. Kenneth Stauderman, Ph.D., a co-founder and our chief scientific officer with more than 30 years of experience in drug discovery and development, is a leading expert in CRAC channels and led the discovery of some of the foundational work in this field. Sudarshan Hebbar, M.D., our chief medical officer, has more than 15 years of clinical development and product development experience and was previously a practicing nephrologist and critical care physician. Raven Jaeger, MS, our chief regulatory officer, who has over 20 years of regulatory affairs experience with several marketing approvals in serious diseases with high-unmet medical need.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Science</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Essential Roles of Calcium Signaling</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Calcium serves as an essential messenger for intracellular signals and plays diverse and important roles in biological systems. The major storehouse for calcium in a cell is a compartment called the endoplasmic reticulum (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ER</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;). Calcium is found there at average concentrations that are 1,000 to 5,000-fold higher than in a cell&#8217;s interior or cytoplasm. When an outside signal stimulates a cell in a particular way, the stored calcium is rapidly and periodically released from the ER into the cell interior, resulting in activation of a number of key cellular processes affecting synthesis and release of other signaling molecules, cell growth, differentiation and division. These processes include, for example, gene transcription and protein kinase signaling. In response to sufficient external stress on the cell, release of calcium from these intracellular stores can trigger cell death.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">CRAC Channels</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A specific set of calcium-transporting ion channels known as CRAC channels are responsible, among other things, for replenishing the calcium stores in the ER. The two principal proteins that comprise CRAC channels are the ER calcium-sensing protein Stomal Interaction Molecule 1 (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">STIM1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) and the cellular membrane calcium channel protein Orai1. When cells are stimulated in particular physiological ways, intracellular messengers are generated that cause the periodic release of calcium from the ER. The release of calcium from the ER is then sensed by STIM1, which unfolds and activates, or opens, the Orai1 calcium channel triggering an influx of calcium into the cell. In certain pathological conditions, however, CRAC channels can be activated in non-physiological ways, such as by a toxin that can cause excessive release of calcium from the ER, leading to overactivation of CRAC channels.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depending upon the extent of activation and the cell or tissue involved, calcium influx through CRAC channels can regulate calcium-dependent inflammatory pathways or can activate cell injury pathways. For example, in immune cells like T lymphocytes, activation of CRAC channels plays a key role in initiating the adaptive immune response and the generation of inflammatory cytokines. In certain acute critical illnesses such as AP, CRAC channels on affected organ tissue cells can become overactivated, resulting in excess calcium entry that is toxic to cells, causing cellular injury or death that can exacerbate an accompanying inflammatory response.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_2.jpg" alt="img222477878_2.jpg" style="width:540px;height:251px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">CRAC channels serve to replenish calcium levels in the ER and to provide calcium for cellular signaling events.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is strong evidence linking STIM1 and Orai1 to the way the cell replenishes its calcium stores and to the physiological consequences of disrupting these proteins from both </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">models, including animal gene knock-out or knock-in models, and human genetics. This linkage is true at both the cellular and phenotypic levels. At the cellular level, manipulating STIM1 or Orai1 activity by genetic inactivation or enhancement has been shown to impact calcium transport. Inactivating STIM1 or Orai1 was shown to decrease calcium entry into cells, whereas creating mutations in STIM1 or Orai1 that enhance their activity was shown to increase calcium influx. At the phenotypic level, people with homozygous genetic deficiencies in the genes encoding Orai1 or STIM1 develop the life-threatening condition of severe combined immunodeficiency. Because these individuals lack the ability to mount an effective immune response, they suffer from an extreme risk of contracting life-threatening infections. People with a heterozygous genotype for the mutated genes encoding Orai1 or STIM1 do not have any notable conditions resulting from or associated with these genetic deficiencies despite a partial reduction in the functional activity of the Orai1 or STIM1 proteins.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In lymphocytes, CRAC channels are critically responsible for controlling the entry of calcium that subsequently initiates calcium-dependent events. Within minutes of activating CRAC channels, alterations in intracellular calcium levels result in both (a) the inhibition of lymphocyte migration and (b) the activation of immune cell activity. Both of these elements of CRAC channel biology are central to identifying potential therapies. Effects of prolonged calcium signaling supported by both calcium release from the ER and CRAC channel-mediated calcium entry include stimulation of cell proliferation; expression of immune-activated genes; production of cytokines and chemokines; and lymphocyte differentiation. These longer-duration effects, too, are central to the backdrop for therapeutic intervention. For example, genes triggered by calcium release and subsequent calcium entry through CRAC channels include many activators of inflammation. This mechanism involves various signaling proteins, including two in particular, calcineurin and a transcription factor called nuclear factor of activated T cells (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NFAT</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;), which form a critical link between calcium elevations and transcriptional activation. Calcineurin is a calcium- activated enzyme that removes inhibitory components from NFAT, triggering it to enter the nucleus and function as a transcription factor. Calcineurin has a well-validated immunoregulatory role; it is the target of two broadly prescribed immunosuppressive molecules, cyclosporine and tacrolimus. NFAT is expressed in a wide spectrum of immune cells and its activity drives inflammation via the production of many pro-inflammatory cytokines such as interleukin-6 (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IL-6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;); tumor necrosis factor alpha (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TNF</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">&#181;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;); and interleukin-2 (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IL-2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;).</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_3.jpg" alt="img222477878_3.jpg" style="width:540px;height:362px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Increased levels of intracellular calcium mediated by CRAC channels activate a number of inflammatory pathways.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inflammatory diseases including AP, respiratory failure, kidney injury or traumatic brain injury are associated with activation or overactivation of CRAC channels. Preclinical experiments have shown that inhibition of CRAC channels has the potential to provide therapeutic benefit in these and other diseases. Multiple compounds have been identified in scientific literature that inhibit CRAC channels, but few of these have advanced to clinical trials as a result of unsuitable pharmaceutical properties required for potential therapeutic use.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Advantages to Our Approach</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe CRAC channels are promising drug targets as they are present on critical organ tissues (such as endothelium cells) and on immune system cells (such as T cells). Overactivation of these channels can lead to organ damage and cytokine-mediated pro-inflammatory processes. CRAC channel activation plays a critical role in endothelial damage and serves as the proximal step in T cell production of pro-inflammatory cytokines. We believe the key advantages of CRAC channel inhibition science are:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our CRAC channel inhibitors provide a dual mechanism to reduce cellular damage by both blocking direct tissue damage and down-regulating inflammation.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our CRAC channel inhibitors act upstream of several approved drugs (such as cyclosporin) affecting multiple pro-inflammatory pathways. This translates into down-regulation of multiple cytokines produced by the immune system in a disease state and may provide broader acting anti-inflammatory action compared to drugs that target a single cytokine.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our CRAC channel inhibitors are small molecule drugs that provide rapid onset of immunomodulatory action as well as rapid offset which can provide rapid recovery of immunocompetence.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that there may be underlying biological pathways common to a number of acute critical illnesses, including those indications we are pursuing, so that there could be the potential for a single agent to treat patients sharing this underlying biology regardless of disease.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our proprietary IV lipid nanoemulsion used in Auxora enhances the delivery of our drug to lipophilic organ tissues such as the pancreas, lung and kidney.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain of our proprietary CRAC channel inhibitors, including CM6336, are orally bioavailable and can be used to treat chronic inflammatory and immunologic conditions.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our approach is applicable to both acute and chronic inflammatory and immunologic diseases.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Auxora, a Selective CRAC Channel Inhibitor</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are developing Auxora, a proprietary IV-formulated CRAC channel inhibitor, for several indications, including the treatment of severe AP, AIPT, AKI, severe acute respiratory diseases including AHRF, and ARDS, and other acute inflammatory diseases associated with dysregulation of intracellular calcium in organ tissues. We hold worldwide rights to the active ingredient in Auxora, zegocractin, which was previously referred to as CM4620. Auxora inhibits the transport of calcium into cells by inhibiting the Orai1 CRAC channel. Testing of Auxora in an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">selectivity panel screen showed that the compound was highly selective over many other ion channels, receptors or transporters, which is consistent with the lack of sequence or structural similarity of CRAC channels with other channels.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Auxora is specifically formulated as an IV lipid nanoemulsion that is designed to facilitate the rapid delivery to lipophilic organ tissues such as the pancreas, lung and kidney, which we believe makes it a promising product candidate for the treatment of acute critical illnesses. The nanoemulsion is composed of nanometer-sized lipid droplets suspended in water. Auxora dissolves into the lipid particles that, once infused, move quickly through the body and are absorbed by lipophilic tissues that are hard-to-reach for aqueous solutions and hydrophilic drugs. We believe it is critically important to block CRAC channel activity as soon as possible in these acute indications to prevent further tissue damage and decrease morbidity or mortality. Auxora was well-tolerated in single dose and multiple dose Phase 1 clinical trials in healthy adults, and in both the Phase 2 COVID-19 clinical trials and the Phase 2a AP clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preclinical Evidence for Anti-Inflammatory Activity of Zegocractin, the Active Ingredient in Auxora</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">treatment of activated human peripheral blood mononuclear cells (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PBMCs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;), which are predominantly lymphocytes, with zegocractin (the active compound in Auxora) resulted in a concentration-dependent inhibition of the release of a number of pro-inflammatory cytokines including IL-2 and interleukin-17 (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IL-17</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) when measured at 48 hours. The breadth of the spectrum of cytokines inhibited by zegocractin is consistent with the central role of calcium signaling in the inflammatory response.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_4.jpg" alt="img222477878_4.jpg" style="width:399px;height:235px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Zegocractin inhibited the release of a number of cytokines from activated human PBMCs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The role of calcium and CRAC channels in inflammation extends beyond lymphocytes and other immune cells. Excess calcium in cells in tissues such as kidney, pancreas, lung and the nervous system leads to cell damage or activation of cell death pathways causing tissue damage and organ failure. These processes, in turn, trigger inflammatory immune responses that further exacerbate cell damage and cell death and can accelerate tissue damage and organ failure.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_5.jpg" alt="img222477878_5.jpg" style="width:626px;height:425px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">CRAC channel overactivation causes cell damage, leading to cell death and triggering an inflammatory immune response.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pharmacodynamic Profile of Auxora</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Auxora is a proprietary lipid nanoemulsion IV formulation of the small molecule zegocractin that is administered by IV infusion. To test the activity of Auxora, we have developed an assay using ex vivo blood samples in which we stimulate IL-2 release as a surrogate pharmacodynamic (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PD</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) marker for immune system activity. After administration, Auxora rapidly redistributes from the blood into lipophilic tissues and is predominantly cleared through the biliary system. Thereafter, the remaining drug is gradually cleared from lipophilic tissues over the course of a few months resulting in trace plasma levels without biological or clinical activity reported to date. Additional toxicity studies will be performed during Phase 3 development and may further address the safety of Auxora as it is cleared from the body. Auxora has demonstrated a rapid onset of immunomodulatory action within 30 minutes post-dosing in this assay performed on blood samples from patients with AP and treated with Auxora. Recovery of IL-2 release was observed within 24-48 hours following dosing completion, indicating offset of immunomodulation.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_6.jpg" alt="img222477878_6.jpg" style="width:508px;height:297px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Auxora has a rapid on-off effect as demonstrated by the onset of immunomodulation after dosing and the recovery of the immune system after the drug infusion is stopped.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that the timely termination of drug action is an important feature of Auxora as it may limit the potential for long-term immunosuppressive effects of prolonged CRAC channel inhibition, which have not been seen in clinical trials to date. In a rat model, administration of Auxora led to high levels of drug exposure in kidneys, pancreas, lung and plasma at two hours and four hours after the start of a four-hour infusion. By eight hours, drug levels dropped, consistent with rapid drug redistribution and/or clearance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_7.jpg" alt="img222477878_7.jpg" style="width:364px;height:319px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Auxora led to rapid increase in drug levels in the pancreas, lung, kidney and plasma after administration to rats.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Potency and Selectivity of Auxora</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Zegocractin (the active molecule in Auxora) is among the most potent CRAC channel inhibitors reported in scientific literature, as observed in published experiments performed in our labs, including experiments published in the journal </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cell Calcium</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The data in the figure below illustrate that Auxora potently inhibits Orai1-containing CRAC channels, as 50% of the activity of the channel can be inhibited with nanomolar (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) concentrations of compound. Further, the compound is selective compared to other channels. For</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">example, on two channels important in cardiac (heart) function, even micromolar (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#181;M</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) quantities of zegocractin do not achieve measurable inhibition of the activity of those channels. All compounds in our portfolio of potential drug candidates have properties similar to those indicated in the table below.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:41.392%;"/>
    <td style="width:1.18%;"/>
    <td style="width:24.695%;"/>
    <td style="width:1.18%;"/>
    <td style="width:31.554%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Channel</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Effect of Zegocractin</span></p></td>
    <td style="vertical-align:bottom;border-bottom:1pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Orai1 CRAC Channel Selectivity Ratio</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Human Orai1-containing CRAC channels</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">IC</span><span style="color:#000000;top:1pt;white-space:pre-wrap;font-size:5.025pt;position:relative;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;= 119 nM</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Human voltage-gated Ca channels (cardiac)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&lt;10% inhibition at 10 &#181;M</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&gt;100-fold</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Human hERG K channels (cardiac)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&lt;10% inhibition at 10 &#181;M</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&gt;100-fold</span></p></td>
   </tr>
  </table>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">IC50 = concentration producing 50% inhibition of channel activity. Activity of each channel was assessed by electrophysiological (electrical) measurements of either calcium ion (Ca2+) or potassium ion (K+) flow through the indicated channel. The maximum soluble concentration of compound (10 &#181;M) was tested on the cardiac channels.</span></p>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assay performed by us in 2011-2012.</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assay performed by a contracted vendor in 2012.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">P-Values and Confidence Intervals</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The conventional method for measuring the statistical significance of a result is known as the &#8220;p-value,&#8221; which represents the probability of obtaining results at least as extreme as those that were observed in the study presuming that the null hypothesis of no effect is true. Generally, a p-value less than 0.05 is considered statistically significant and may be supportive of a finding of efficacy by regulatory authorities. However, regulatory authorities, including the FDA, do not rely on strict statistical significance thresholds as criteria for marketing approval and maintain the flexibility to evaluate the overall risks and benefits of a treatment. A confidence interval (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CI</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) is a range of values within which the true value has a specified probability to exist. It is conventional to set the confidence interval at 95%, which means 95 of 100 times, the confidence interval will contain the true value. If the confidence interval does not contain the value of zero (the null value), it can be assumed that there is a statistically significant effect.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Auxora for the Treatment of AP</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have conducted a Phase 2a clinical trial of Auxora in AP patients with SIRS along with hypoxemia predicted to have moderate or severe AP. Because of the complications of SIRS and hypoxemia, these patients were at high risk for developing severe AP and life-threatening organ failure, particularly respiratory failure. In this trial Auxora treatment was associated with reduced local and systemic inflammation, improved ability to tolerate solid food, and shorter hospital stays. We are now conducting CARPO, a Phase 2b double blind placebo-controlled clinical trial of Auxora in 216 patients with predicted moderate or severe AP, and expect topline data expected in the second quarter of 2024. We have received Fast Track designation from the FDA and orphan drug designation in the EU from the EMA for Auxora for the treatment of AP. However, there is no guarantee that Fast Track designation will result in a faster regulatory review or regulatory approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_8.jpg" alt="img222477878_8.jpg" style="width:556px;height:192px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Treatment with Auxora could offer significant benefits to AP patients and prevent disease progression</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Acute Pancreatitis Background</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Acute pancreatitis is an acute inflammatory process of the pancreas that presents as severe upper abdominal pain, often accompanied by nausea and vomiting. During episodes of the disease, inflammation of the pancreas occurs, which can lead to pancreatic cell death or necrosis and systemic inflammation. Normal pancreatic functions, such as the secretion of digestive enzymes required to break down</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">carbohydrates and fats, are disabled. There are no approved therapies for AP but most cases are mild and resolve after several days of supportive care, including avoiding oral feeding in the short term to not further aggravate the pancreas. Most patients are hospitalized and require IV fluids and monitoring for development of more severe symptoms.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Severe complications arise because of the acute inflammatory response that takes place in the pancreas. These complications can lead to SIRS, in which the function of other tissues or organs, including the lung may be compromised. Approximately one third of patients with severe AP develop acute lung injury or ARDS. Lung failure accounts for approximately 60% of deaths associated with AP in developed countries.</span></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><img src="img222477878_9.jpg" alt="img222477878_9.jpg" style="width:520px;height:251px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are an estimated 275,000 hospitalizations for AP annually in the United States. Mortality in mild AP is less than 1% but climbs to 20-30% in patients with persistent, severe disease. Approximately 40% of hospitalized AP patients present with SIRS and are predicted to have moderate or severe disease, with 15% actually developing severe AP. The target population for Auxora in our ongoing Phase 2b clinical trial is AP patients with accompanying SIRS, which we estimate to be approximately 100,000 patients per year in the United States alone.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_10.jpg" alt="img222477878_10.jpg" style="width:587px;height:235px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIRS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: Systemic Inflammatory Response Syndrome</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Target patients for Auxora in AP are a subpopulation of total number of AP hospitalizations and are selected primarily based on the presence of SIRS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leading causes of AP are gall stones and resulting elevated levels of bile salts, and alcohol metabolites, together accounting for 60-80% of all cases depending on the specific population examined. Other causes include: hypertriglyceridemia, familial (genetic) types, hypercalcemia, abdominal injury or trauma (including endoscopic retrograde cholangiopancreatography), cancer, drug-induced, or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">autoimmune, each making up smaller slices of the total AP population. These different causes all appear to lead to a common mechanism in which calcium within pancreatic cells drives pathology.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_11.jpg" alt="img222477878_11.jpg" style="width:540px;height:261px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inhibition of CRAC channels has the potential to impact multiple pathologies associated with AP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Excessive signaling through calcium-dependent pathways has been linked to multiple pathologies associated with AP. A primary function of the pancreas is to produce enzymes that are required to digest food. The secretion of these enzymes from the pancreas is dependent on the periodic release of calcium from internal stores in cells called the pancreatic acinar cells. In AP, aberrant activation of these cells results in elevated, toxic levels of intracellular calcium and, as a consequence, the inappropriate activation of digestive enzymes inside the cells causes the acinar cells to self-digest.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Acute pancreatitis is also associated with a high level of inflammation. In some patients, the release of inflammatory cytokines and the triggering of SIRS can lead to life-threatening distal organ failure. Previous studies have established a strong link between calcium signaling and the release of inflammatory cytokines. The most frequent systemic complications in severe cases of AP are respiratory dysfunctions ranging from hypoxemia to ARDS. As in the case with ARDS from other underlying causes, AP-associated ARDS is the result of both increased vascular permeability and an increase in inflammation, which we believe are CRAC channel-dependent processes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Acute Pancreatitis Phase 2a Clinical Trial Results</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We completed a Phase 2a clinical trial of Auxora in 21 patients with AP with predicted severe or moderately severe disease as determined by the presence of SIRS and hypoxemia. Patients were enrolled in two cohorts. Fourteen patients received Auxora plus SOC and seven received SOC only. The Auxora- treated patients received a daily IV dose of Auxora for up to four days. As an early-stage proof of concept trial, this trial was not powered for statistical significance for any of the endpoints.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_12.jpg" alt="img222477878_12.jpg" style="width:614px;height:259px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trial design for Auxora AP Phase 2a clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The primary symptom associated with AP is severe upper abdominal pain. Patients with AP are unable to tolerate any solid food without an increase in pain or the occurrence of nausea or vomiting until the pancreatitis resolves. In this clinical trial, only one patient in the Auxora-treated group and one patient in the SOC group were tolerating solid food at study entry. After 72 hours, seven of 14 Auxora patients were tolerating solid food while only one of seven SOC patients was tolerating solid food. At the time of hospital discharge, 13 of 14 Auxora patients could tolerate solid food compared to three of seven SOC patients.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_13.jpg" alt="img222477878_13.jpg" style="width:285px;height:245px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acute pancreatitis patients treated with Auxora were able to tolerate food sooner than matched controls.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patients treated with Auxora were discharged from the hospital after a median of 3.7 days compared to SOC patients, who had a median stay of 6.0 days. Of the 21 patients enrolled in this trial, five had respiratory failure at the time of enrollment, four in the Auxora-treated group and one in the SOC group. Of the four Auxora- treated patients, only one required intubation and mechanical ventilation after several days as a result of a procedural complication. This patient ultimately died of complications from respiratory failure, whereas the only SOC patient who enrolled with respiratory failure required immediate intubation and mechanical ventilation. This SOC patient was on a ventilator for more than 90 days before dying.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An objective measure of the severity of AP is the computed tomography severity index (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CTSI</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) that is based on findings from a CT scan with IV contrast to assess radiographic severity of the disease. CTSI scores have been found to correlate with clinical indices of severity. CT scans were obtained from all the patients in this clinical trial both at study entry and at hospital discharge or five days, whichever was earlier, and sent to a blinded central reader to determine the CTSI score. Twelve of the patients, eight in the Auxora-treated group and four in the SOC group, were found to have elevated CTSI scores at the time of randomization that were consistent with moderate to severe AP. Three of the eight Auxora-treated patients with elevated CTSI scores saw improvement over the course of their hospital stay while none of the four SOC patients experienced improvement.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Persistent SIRS, defined as SIRS lasting more than 48 hours, is an indication of continued activation of inflammatory pathways in patients with AP. Furthermore, persistent SIRS is highly predictive for the development of organ failure in AP. All patients in this AP trial had SIRS at enrollment. Only five of the 14 patients treated with Auxora had persistent SIRS, while five of the seven patients treated with SOC alone had persistent SIRS.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_14.jpg" alt="img222477878_14.jpg" style="width:511px;height:222px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Auxora treatment was associated with improvements in multiple clinically relevant parameters.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The potential impact of Auxora treatment on the inflammatory response is illustrated by one patient in the Auxora-treated arm who was admitted to the hospital with respiratory failure and an extremely high level of IL-6, a pro-inflammatory cytokine, of greater than 7296 pg/ml, a level approximately 450-fold higher than the upper level of normal range. Historically, levels of greater than 122 pg/ml are predictive of organ failure in AP and levels above 80 pg/ml are associated with a 22-fold increased risk of respiratory failure in COVID-19 patients. At 120 hours, and after four doses of Auxora, the level of IL-6 in this patient was reduced to 66 pg/ml. This patient did not require intubation and was discharged on room air, not supplemental oxygen, on the eighth day.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_15.jpg" alt="img222477878_15.jpg" style="width:317px;height:247px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">A rapid reduction in IL-6 levels was observed in a patient treated with Auxora.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Auxora was generally well-tolerated in the trial. Treatment-emergent adverse events (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TEAEs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) were reported in 12 (86%) patients receiving Auxora and four (43%) patients receiving SOC alone. The majority of adverse events (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AEs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) in patients treated with Auxora were mild and considered resolved or resolving at the end of the trial. Severe TEAEs occurred in two patients (14%) receiving Auxora and two patients (29%) receiving SOC alone. Three patients (21%) treated with Auxora and two patients (29%) treated with SOC alone developed serious adverse events (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SAEs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;). One death occurred in the Auxora treatment arm which was attributed to abdominal compartment syndrome and multi-organ failure. None of the AEs were deemed to be Auxora-related by the principal investigators. A summary of AEs reported in two or more patients receiving Auxora is listed below.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_16.jpg" alt="img222477878_16.jpg" style="width:527px;height:160px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Summary of Adverse Events Reported by Two or More Patients Receiving Auxora.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following SAEs occurred in patients treated with Auxora: death, non-infective cystitis, acute pancreatitis, sepsis, ARDS, hypoxic-ischemic encephalopathy (a type of brain dysfunction), pneumonia, respiratory failure and pulseless electrical activity. None of the SAEs were deemed to be Auxora-related by the principal investigators.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CARPO: Ongoing Phase 2b Clinical Trial in AP</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2021, we initiated CARPO, a randomized, double-blind placebo-controlled Phase 2b clinical trial in patients with AP and accompanying SIRS. This is a randomized, double-blind, placebo-controlled trial examining three dose levels of Auxora versus placebo. The clinical trial includes 54 patients in each of the four cohorts. Doses for two cohorts are essentially the same as doses patients received in the open-label Phase 2a clinical trial. A third cohort is receiving half the middle dose level. The fourth cohort will receive matched volumes of placebo. This dose ranging is intended to establish a dose-response in the AP setting. Endpoints include measures of safety, patient benefit and outcome improvement with a primary endpoint of food tolerance and responder analysis. Advisers suggest that food tolerance is the best measure of clinical efficacy, and, in addition to being the primary endpoint, food tolerance will be validated through a responders&#8217; analysis. We anticipate topline results from this clinical trial in the second quarter of 2024 and, assuming positive results, to initiate our Phase 3 trial in 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_17.jpg" alt="img222477878_17.jpg" style="width:544px;height:262px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trial design for CARPO, Phase 2b clinical trial in AP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CRSPA: Ongoing Open-Label Phase 1/2 Clinical Trial in AIPT (Pancreatitis as a Side Effect of Pediatric ALL Treatment)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CRSPA is a 24-patient open-label Phase 1/2 investigator-sponsored clinical trial being conducted by SJCRH and exploring Auxora as a potential therapy in pediatric patients that develop AIPT as a result of treatment for their underlying ALL. Current therapies for ALL result in long term survival for over 90% of pediatric ALL patients. One of the mainstays of therapy in these patients is asparaginase (e.g., ONCASPAR&#153; and RYLAYZE&#153;), an enzyme that degrades the amino acid asparagine, which is essential for the leukemic cells to survive. However, the administration of asparaginase triggers the development of pancreatitis or AIPT in 7-10% of patients of the over 3,000 pediatric ALL patients treated per year in the US, with similar numbers in Europe. AIPT is a severe complication characterized by intense abdominal pain, nausea, vomiting and SIRS. AIPT can lead to further chronic problems such as insulin</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">dependence, exocrine pancreatic insufficiency and chronic pain. Many of these children can no longer be treated with asparaginase which can have a negative impact on their recovery from ALL.   It has been shown that over 50% of patients with AIPT develop pseudocysts or pancreatic necrosis. There is currently no disease modifying treatment for AIPT and standard of care only addresses the symptoms of the disease.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In CRSPA, pediatric patients suffering from AIPT are enrolled and treated with four daily doses of Auxora with the primary endpoints of safety, tolerability and the reduction in development of complications of AIPT, including necrotizing pancreatitis and SIRS. </span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Investigators at SJCRH presented results from the first cohort of the CRSPA study at the ASH meeting in December 2023.  This cohort of patients consists of nine children (average age 8.2 years) with ALL</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">who have developed AIPT (referred to as AAP in the abstract). Eight of nine patients in the CRSPA study received a full regimen of four daily doses of Auxora at dose level 1 (30mg/m</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on day one and 42mg/m</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">on days two through four) administered as a four-hour infusion. Results from these patients were compared to a matched historical control group of 16 patients out of a total of 51 patients who developed AIPT within 30 days of receiving asparaginase in the Total Therapy XVI study (T16) being conducted at SJCRH.</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The comparison showed that Auxora reduced the average number of days patients spent in the hospital from 13.4 to 6.3 days. The need for ICU care was also reduced, with three control patients (18.8%) requiring ICU care compared to one treated patient (12.5%), and the average number of days in the ICU was reduced from five to three days. Additionally, no patients in the CRSPA study required TPN, compared to 68.8% in the historical matched control group, who required 27 days of nutritional support on average. Finally, blinded central reading of pancreatic imaging showed a reduction in the development of significant pancreatic necrosis (&#8805;30%) and the severity of acute pancreatitis by computed tomography severity index (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CTSI</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) scoring in patients treated with Auxora</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compared to the matched historical cohort. Based on these results, investigators have established the dose level used in this cohort as the recommended Phase 2 dose (RP2D) of Auxora for children with ALL experiencing AIPT and will continue to enroll an additional 15 patients at this dose level to reach full enrollment at 24 patients.  CRSPA has been expanded to additional sites and we expect our collaborators to have data in 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:25%;"/>
    <td style="width:25%;"/>
    <td style="width:25%;"/>
    <td style="width:25%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total 16 (T16): All AIPT</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Matched T16 AIPT cohort</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">CRSPA evaluable for efficacy</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Patients with AIPT</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Age: mean (range)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3 (2.2-19.4)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9 (2.2-18.4)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.2 (3.1-17.6)</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Female (%)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17 (33.3%)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5 (31.3%)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 (37.5%)</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Low-risk therapy (%)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9 (17.6%)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 (6.3%)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2 (25%)</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Hospital days (range)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.1 (2-70)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13.4 (2-27)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.3 (5-8)</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ICU needed (%)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11 (21.6%)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 (18.8%)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 (12.5%)</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ICU days mean (range)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.1 (1-9)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5 (3-7)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TPN needed (%)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27 (52.9%)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11 (68.8%)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TPN days mean (range)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37.7 (3-153)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27.2 (4-63)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">NA</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8805;30% pancreatic necrosis (%)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">NA</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4 (26.7%) *</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CTSI mean (range)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">NA</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.4 (0-10) *</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.4 (0-4)</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CTSI &#8805; 7 (%)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">NA</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4 (26.7%) *</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">*</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">One patient in matched T16 cohort was unable to be evaluated for pancreatic necrosis or a CTSI score</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CTSI score definitions:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0-3 mild acute pancreatitis</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4-6 moderately severe acute pancreatitis</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8805;7 severe acute pancreatitis</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to clinical data published by Mauney, et. al., in the Journal of Pediatric Gastroenterology and Nutrition in March 2022, patients who developed AIPT had a median length of stay in the hospital of ten days consistent with that seen in the T16 database which is greater than the six day median length of stay for patients treated with Auxora, reflecting a faster resolution of symptoms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">P</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reclinical Studies with Auxora in AP</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Treatment with Auxora led to a decrease in inflammatory markers in both the pancreas and the lung in a cerulein-induced rat model of AP. In this AP model, rats were given four hourly intraperitoneal injections of cerulein to induce pancreatitis and Auxora was given in a therapeutic mode by a four-hour intravenous infusion, starting 30 minutes after the first cerulein injection. Animals were examined 30 minutes after the end of infusion. Cerulein overstimulates pancreatic acinar cells, causing overactivation of CRAC channels, premature activation of digestive enzymes, mitochondrial dysfunction and death of the acinar cells, as well as enhanced accumulation of cytokines. Auxora administered post-insult decreased the acinar cell damage (50% as measured by histopathology) and decreased mRNA transcript levels (measured by quantitative real-time polymerase chain reaction) of myeloperoxidase (MPO) (80-90%) a biomarker of neutrophil activation, and the inflammatory cytokines TNF&#945; (80-90%), and IL-6 (80-90%) in the pancreas. Similar to AP in patients, inflammatory</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">signals in the cerulein model are also observed in the lungs. The anti-inflammatory effects of Auxora in the pancreas were mirrored in lung tissue.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_18.jpg" alt="img222477878_18.jpg" style="width:462px;height:275px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Auxora inhibited the expression of MPO, TNF</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#945;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> and IL-6 in the cerulein-induced acute pancreatitis model in both the pancreas and lung. These results have been published in The Journal of Physiology.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consistent with the data described above, treatment with the active ingredient in Auxora, zegocractin, decreased pancreatic damage in two other models of AP in mice, gallstone and alcohol models. AP in a gallstone model was elicited by retrograde pancreatic ductal injection of a bile acid and in the alcohol model by intraperitoneal injections of a fatty acid and ethanol. Both bile acids and fatty acids + ethanol induce AP by overactivation of CRAC channels. Zegocractin was given by intraperitoneal injection in a therapeutic mode at one and 13 hours after disease induction and animals were examined 24 hours after disease induction. Under these conditions, zegocractin decreased the amount of inflammation, edema and acinar cell damage (each close to 50% as measured by histopathology; see the figure below).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_19.jpg" alt="img222477878_19.jpg" style="width:378px;height:309px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Zegocractin decreases pancreatic damage in two models of AP in mice. Shown are histology photomicrographs of the pancreas. The top panels are examples from control animals in both the gallstone (left) and alcohol (right) models showing the presence of inflammatory cells (small dark dots), edema (white areas) and acinar cell necrosis (light red). Bottom panels are from animals treated with Zegocractin, showing reduced inflammation, edema and necrosis. White bars = 50 m.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ability of the pancreas to secrete digestive enzymes, fluid and bicarbonate is critical for the ability to digest food. Various toxins, including an alcohol metabolite, fatty acid ethyl ester, or bile acids can cause the premature activation of these digestive enzymes within the pancreas, leading to self-digestion and pancreatic cell death. One of the primary treatments for AP has been to completely stop all orally administered food for several days. A sign of the resolution of a case of AP is the ability to tolerate food, requiring functioning pancreatic ductal cells and appropriate secretion of digestive enzymes, fluid and bicarbonate. Thus, restoration of pancreatic ductal cell secretion is thought to be a critical element in the treatment of AP.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CRAC channel inhibition preserved pancreatic ductal fluid secretion in the cerulein-induced AP model in mice as well as in gallstone and alcohol models of AP. The mouse cerulein-induced AP model was performed like the rat model described above, except that seven hourly injections of cerulein were used and animals were examined 12 hours after the first cerulein injection. AP in the gallstone model was elicited by retrograde pancreatic ductal injection of a bile acid and in the alcohol model by intraperitoneal injections of a fatty acid and ethanol. Pancreatic fluid secretion was measured by collection of pancreatic juice from the pancreatic duct over a 30 minute period. In all three models, CM5480, a preclinical CRAC channel inhibitor model compound, given by intraperitoneal injection after disease onset was able to preserve pancreatic ductal fluid flow, suggesting that CRAC channel inhibition may have a direct protective effect on ductal cells that could help resolve AP.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_20.jpg" alt="img222477878_20.jpg" style="width:371px;height:230px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">CM5480 (CM-C) treatment led to the preservation of pancreatic ductal secretion in a cerulein-induced acute pancreatitis model.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Auxora for the Treatment of Acute Kidney Injury</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are recent examples in the scientific literature where CRAC channel inhibition was shown to reduce damage in animal models of AKI. We have conducted preclinical studies of Auxora in a rat model of AKI. Additionally, we have observed in our clinical trials that Auxora-treated patients appear to have less complications of kidney injury or failure in the setting of acute critical illness. In February 2024, we received clearance from the FDA of our IND for a Phase 2 clinical trial of Auxora for the treatment of AKI  patients with AHRF which we call KOURAGE and which we plan to initiate in the second quarter of 2024 with data expected in 2025.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Acute Kidney Injury Background</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AKI is marked by three distinct phases, the initial injury, the recovery from that injury and then the long-term damage resulting from the initial injury. Patients who do not recover completely from the initial injury are at risk for long-term damage. We believe the administration of Auxora to patients with more severe AKI will result in a greater proportion of patients recovering completely from the initial injury, and in so doing, will lessen the long term complications of the initial injury. This is illustrated in the figure below. AKI is classified as Stage 1, Stage 2 and Stage 3 depending on the seriousness of the disease as measured by serum creatinine and urine output and may progress from one stage to the next as a patient&#8217;s condition worsens. Stage 1 patients have an increase in serum creatinine of &#8805; 0.3 mg/dL or 1.5 to 1.9 times baseline or urine output of &lt;0.5 mL/kg/hour for six to 12 hours. Stage 2 patients have an increase in serum creatinine to 2.0 to 2.9 times baseline or urine output of &lt;0.5 mL/kg/hour for 12 to 24 hours. Stage 3 patients have an increase in serum creatinine to &#8805; 3.0 times baseline, an increase in serum creatinine of &#8805; 0.3 mg/dL to &#8805; 4.0 mg/dL, urine output of &lt;0.3 mL/kg/ hour for &#8805; 24 hours, anuria for &#8805; 12 hours or initiation of kidney replacement therapy.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_21.jpg" alt="img222477878_21.jpg" style="width:475px;height:249px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Time course of acute kidney injury and progression to chronic kidney disease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AKI is caused by a number of factors including infection, trauma and myocardial infarction. According to the Healthcare Cost and Utilization project, there are more than 3.7 million patients hospitalized each year who have AKI in the US. Of these, 71% have Stage 1, 17% have Stage 2 and 12% have Stage 3 so that Stage 2 and Stage 3</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patients represent an incidence of over 1 million per year in the US alone. Additionally, over half of the Stage 2 and Stage 3 patients will have some form of respiratory failure and in these patients the expected mortality while hospitalized and up to 90 days post discharge is 50% or more. Currently there are no drugs that directly treat AKI and standard of care includes fluids, diuretics, nutritional support, and correction of the underlying cause of the AKI. Patients who suffer AKI may over the course of months develop chronic kidney disease and may go into end-stage renal failure. The goal of treatment would include reducing the need for dialysis, kidney transplantation, long-term illness and death.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_22.jpg" alt="img222477878_22.jpg" style="width:540px;height:275px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_23.jpg" alt="img222477878_23.jpg" style="width:555px;height:188px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Early treatment with Auxora could offer significant benefits to AKI patients and prevent disease progression.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">KOURAGE: Randomized, double-blind placebo-controlled Phase 2 clinical trial in severe AKI</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">KOURAGE is a randomized, double-blind, placebo-controlled study that will evaluate 150 patients with Stage 2 and 3 AKI who have AHRF and are receiving oxygen by non-invasive mechanical ventilation, high flow nasal cannula or IMV. Patients will be stratified by classification of stage of AKI as well as the use of IMV. Patients will receive either a four-hour infusion of Auxora or placebo at 1.25 mL/kg as a first dose, after which they will receive Auxora or placebo at 1.0 mL/kg at hours 24, 48, 72 and 96. The primary endpoint of the trial will be evaluation of patients through day 30 to determine days alive, ventilator-free and dialysis-free.  Secondary endpoints will include a composite of all-cause mortality, decrease in eGFR, and the incidence of dialysis over a period of 90 days, also known as MAKE-90.  We anticipate enrolling the first patient in KOURAGE in the second quarter of 2024 with data available in 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img222477878_24.jpg" alt="img222477878_24.jpg" style="width:636px;height:159px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical Observations supporting the potential use of Auxora in AKI</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While the purpose of CARDEA was to test Auxora in severe COVID-19 pneumonia patients, AKI was reported in a number of patients as it is a common sequalae of this disease. We observed ~40% reduction in the frequency of reported AKI in patients treated with Auxora compared with placebo patients. In addition, i</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">n </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a post-hoc analysis of patients with compromised kidney function (eGFR</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&lt;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 60 mL/min/1.73 m</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) at enrollment, there was a survival benefit for patients treated with Auxora compared to those on placebo.  Biomarker analysis from blood samples taken from over 190 CARDEA patients further showed that Auxora had a positive impact on biomarkers in these patients. For example, Angiopoietin-1 and Angiopoietin-2 levels are biomarkers for vascular endothelial cells. Angiopoietin-1 levels correlate with the maintenance of vascular integrity while Angiopoietin-2 levels correlate with endothelial inflammation and malfunction. We observed that Angiopoietin-1 levels increased more in patients treated with Auxora compared to placebo while Angiopoietin-2 levels decreased more. These changes were statistically significant and suggest a potential application for Auxora in AKI where endothelial cell function is compromised.  Finally, work by others demonstrated that elevated serum IL&#8208;17 levels, a CRAC channel mediated cytokine, were differentially elevated in critically ill patients with Stage 2 and 3 AKI when compared to those without AKI and the extent of elevation was independently associated with both hospital mortality and long-term adverse outcomes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_25.jpg" alt="img222477878_25.jpg" style="width:540px;height:248px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Angiopoietin-1 levels show a statistically significant greater increase in Auxora-treated patients compared to placebo patients while Angiopoietin-2 levels show a statistically greater decrease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preclinical Studies with Auxora in AKI</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In collaboration with researchers at Indiana University, we have conducted a series of studies referred to as Study 1 and Study 2 comparing Auxora with placebo in a rat model of AKI. In Study 1, AKI was induced in a rat model through ischemia reperfusion injury (&#8220;I/R&#8221;), a transient ligation of the renal artery, while control animals underwent sham-surgery. Within 30 minutes of injury, the animals were treated with a single intravenous infusion of either 16 mg/kg of Auxora or placebo over a period of four hours. GFR, an important indicator of kidney function, was evaluated at 24 hours post-injury. Study 2 evaluated recovery of kidney function following I/R similar to Study 1 but varying in intensity to mimic different severity of disease. In Study 2, GFR was measured two to four hours after injury but before treatment, and treatment with 16 mg/kg of Auxora or placebo was administered at six, 24 and 48 hours post-injury, with GFR again evaluated at 72 hours.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results from Study 1 showed that at 24 hours post-injury, GFR was significantly higher in rats treated with Auxora 30 minutes after injury versus placebo (61%, p&lt;0.05). Additionally, animals treated with Auxora showed a reduction in Th17 cells in the kidney of approximately 50% as compared to those treated with placebo. In Study 2, in a group of animals with initial GFR reductions of approximately 50%, similar to Stage 2 AKI, GFR at 72 hours was significantly greater in Auxora-treated animals as compared to placebo-treated animals (0.81</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">&#177;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0.03 vs. 0.47</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">&#177;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0.04 ml/min/100g respectively; p&lt;0.001). In a group of animals with GFR reductions &#8805;66%, similar to Stage 3 AKI, placebo-treated rats experienced 100% mortality by 72 hours while Auxora-treated rats had no mortality at 72 hours and were stable, showing modest recovery of kidney function. These results indicate that Auxora has the ability to hasten the recovery of kidney function and improve survival in rat models of AKI.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_26.jpg" alt="img222477878_26.jpg" style="width:532px;height:254px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Study 1 results showing greater recovery of GFR in Auxora treated rats versus placebo as well as a reduction on mononuclear (Th17 producing cells.</span></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img222477878_27.jpg" alt="img222477878_27.jpg" style="width:506px;height:269px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Study 2 results show the effects of Auxora on recovery of renal function after establishment of renal functional impairment. GFR is shown at two hours and 72 hours post I/R. Panel A: results from rats with initial loss of GFR of approximately 50% between two to four hours post I/R show that the recovery of GFR is greater in Auxora treated animals (n=5) compared to placebo (n=4). Panel B: results from rats with an initial loss of GFR &#8805; 66% show that placebo-treated rats (n=3) did not survive while Auxora-treated rats (n=2) survived.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Auxora for the Treatment of Acute Respiratory Failure</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The pathology of COVID-19 is consistent with both a significant increase in the levels of inflammatory cytokines and with the associated deterioration of lung barrier function that can culminate in ARDS. In the first quarter of 2020, we recognized that observations from our clinical trial of Auxora in patients with AP provided support for conducting a clinical trial to assess the potential of Auxora in severe COVID-19 pneumonia patients. In AP patients presenting with markedly elevated levels of IL-6, there was a significant reduction in IL-6 levels over the course of therapy in patients who were treated with Auxora versus SOC alone. Of the four AP patients enrolled in our Phase 2a clinical trial who presented with respiratory failure and were treated with Auxora, only one required intubation and mechanical ventilation. There was only one patient in the SOC control group with respiratory failure and this patient required intubation and mechanical ventilation. This preliminary data and the strong preclinical rationale both led us to propose that Auxora may have therapeutic benefit in the treatment of other diseases with respiratory failure, including severe COVID-19 pneumonia.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2020, we initiated a clinical trial to test Auxora in COVID-19 patients hospitalized and requiring oxygen therapy but not on ventilators. This trial was initially conducted as a Phase 2 randomized, open-label clinical trial in severe COVID-19 pneumonia patients with varying degrees of respiratory failure where time to survival, blood oxygen levels, ventilator use and mortality were evaluated. At our first safety analysis of the data we observed that patients receiving Auxora with SOC were less likely to be placed on mechanical ventilation or to die, and they experienced a reduced time to recovery than those treated with SOC alone. After 30 patients were enrolled in this first part of the trial (Part 1), the FDA recommended that we move to Part 2 of the trial and study Auxora in a randomized, double-blind, placebo-controlled clinical trial. Part 2 was initiated in September 2020, completed in the third quarter of 2021, and enrolled 284 severe COVID-19 pneumonia patients. We observed that patients treated with Auxora experienced a reduced time to recovery, higher rate of recovery and reduced mortality.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">COVID-19 and Acute Respiratory Failure Background</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">COVID-19 is a disease caused by the SARS-CoV-2 virus, a pandemic strain of coronavirus. Respiratory illness is the most common symptom associated with COVID-19; severity ranges from mild disease to life-threatening ARDS.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Most cases of COVID-19 occur approximately four to five days after exposure to the virus. Patients present with symptoms that include fever, dry cough, body ache, sore throat and diarrhea. As the disease progresses, some patients develop shortness of breath resulting from lung injury and are hospitalized. In the majority of these patients, this condition resolves over time, but in up to 20% of patients, it progresses to moderate to severe ARDS requiring mechanical ventilation.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disease progression in severe COVID-19 has similarities to that of severe community-acquired pneumonia caused by other viruses besides SARS-CoV-2 or by bacteria. The immune response to severe COVID-19 infection may result in overproduction of early response</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">proinflammatory cytokines and may also result in complement and coagulation dysfunction, leading to an increased risk of vascular hyperpermeability, respiratory failure, multi-organ failure, and sometimes death.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Completed Open-label Phase 2 Clinical Trial in Hospitalized COVID-19 Pneumonia Patients on Oxygen (Part 1).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We initially conducted a randomized, open-label clinical trial in severe and critical COVID-19 pneumonia patients (Part 1 of the Phase 2 trial). We originally planned to enroll up to 60 patients with severe COVID-19 pneumonia, defined as patients receiving low-flow supplemental oxygen, and 60 patients with critical COVID-19 pneumonia, defined as patients receiving high-flow oxygen through a nasal cannula but not ventilated using bi-level positive airway pressure, continuous positive airway pressure or invasive mechanical ventilators. Two thirds of patients were to be randomized to receive Auxora with SOC therapy and one third with SOC alone. Part 1 was stopped after 30 patients were enrolled and the trial progressed to Part 2. The results from Part 1 of the trial were published in July 2020 in the peer-reviewed journal </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Critical Care</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_28.jpg" alt="img222477878_28.jpg" style="width:540px;height:115px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trial design for open-label Phase 2 clinical trial in hospitalized COVID-19 severe pneumonia patients on oxygen (Part 1).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patients enrolled in Part 1 of the Phase 2 clinical trial were randomized to the Auxora plus SOC treatment group, were dosed intravenously with Auxora for three days at levels of 2.0 mg/kg on the first day and 1.6 mg/ kg on days two and three. The primary objectives of this clinical trial were safety and tolerability. At the time this part of the clinical trial was stopped, 30 patients had been enrolled, 26 with severe COVID-19 pneumonia and four with critical COVID-19 pneumonia.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 26 patients with severe COVID-19 pneumonia were used in the efficacy analysis of the open-label part of the clinical trial. Patients enrolled in the Auxora plus SOC and the SOC only groups were well-matched across age, body mass index and ethnic backgrounds. A higher percentage of patients in the Auxora plus SOC group had diabetes. The severity of ARDS was distributed roughly equally among the Auxora plus SOC and SOC only groups.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of our analysis of the efficacy of Auxora in the open-label trial, we also considered the respiratory failure status of patients at enrollment because we believed that this would best correlate with outcomes for these patients. Respiratory failure is divided into three stages based on the Horowitz index, which takes into account how much oxygen is in the blood compared to how much oxygen the patient is provided. The Horowitz index, therefore, is able to account for differences in oxygenation of a patient on room air versus one on higher concentrations of supplemental oxygen. This index is calculated by taking the ratio of the arterial oxygen partial pressure to the fraction of inspired oxygen, known as PaO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:5.025pt;font-family:Times New Roman;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/FiO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:5.025pt;font-family:Times New Roman;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or the P/F ratio. The P/F ratio may also be imputed from the oxygen saturation by pulse oximetry. Based on the Berlin Criteria, patients with a P/F ratio of 200 to 300 mmHg are considered to have mild ARDS. Patients with P/F ratios between 100 and 200 mmHg are considered to have moderate disease. Patients with a P/F ratio of 100 mmHg or less have severe ARDS. Even in the absence of COVID-19, an increase in ARDS severity is correlated with increased mortality. In historical pneumonia studies, patients with mild ARDS have a mortality of approximately 35% compared to 45% mortality for those with severe ARDS.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_29.jpg" alt="img222477878_29.jpg" style="width:535px;height:242px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Baseline demographics were generally balanced across the treatment groups.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical outcomes in Part 1 of the Phase 2 clinical trial were highly dependent on the baseline P/F ratio. Patients with mild ARDS all recovered in both the Auxora plus SOC treatment group and the SOC only treatment group. Regardless of treatment, none of these patients required intubation and mechanical ventilation. Patients with moderate ARDS treated with Auxora plus SOC had an improved outcome compared to SOC alone. Only one of six of the patients (17%) in the Auxora plus SOC group was placed on mechanical ventilation and later died, whereas three out of four patients (75%) in the SOC only treatment group required intubation and mechanical ventilation with one death. Of the four patients enrolled with severe ARDS and treated with Auxora plus SOC, two required intubation and mechanical ventilation (50%) and one of these patients died (25%). In the SOC only group, one of two severe ARDS patients enrolled required intubation and mechanical ventilation (50%). The other patient progressed to high-flow oxygen quickly, but the family elected not to proceed with intubation and the patient died (50%).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_30.jpg" alt="img222477878_30.jpg" style="width:478px;height:299px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview of the outcome of all 26 severe COVID-19 pneumonia patients grouped by P/F at baseline with the most severe patients at the bottom. Blue lines correspond to patient who received Auxora (denoted CM4620-IE) plus SOC and green lines to patients who received SOC only.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">COVID-19 recovery was scored using an 8-point ordinal scale recommended by the FDA in which a high score of 8 means that the patient was discharged from the hospital without the need for supplemental oxygen, 7 means discharged requiring supplemental oxygen, 6 means hospitalized not requiring oxygen or ongoing medical care, 5 means hospitalized not requiring oxygen but requiring ongoing medical care, 4 means hospitalized requiring low flow supplemental oxygen, 3 means hospitalized requiring noninvasive mechanical ventilation or high flow supplemental oxygen, 2 means hospitalized requiring invasive mechanical ventilation and 1 means that the patient has died.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The number of days for recovery was determined by the first day that a patient satisfied a score of 6 or greater. Patients treated with Auxora plus SOC had a mean time to recovery of five days while those on SOC-only treatment had a mean recovery time of 12 days and the recovery rate ratio was 1.87 (95% confidence interval, with a range of 0.72 to 4.89). For additional information regarding confidence intervals, please refer to the section entitled &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Auxora, a Selective CRAC Channel Inhibitor&#8212;P-Values and Confidence Intervals</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A composite endpoint of death or intubation occurred significantly less frequently in patients treated with Auxora plus SOC than with SOC only treatment. Five of the nine patients (56%) with severe COVID-19 pneumonia who were treated only with SOC required intubation and mechanical ventilation or died compared to only three of 17 patients who received Auxora plus SOC (18%) (95% CI, 0.05 to 0.96; p&lt;0.05).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_31.jpg" alt="img222477878_31.jpg" style="width:336px;height:259px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Treatment with Auxora led to a reduction in the composite endpoint of patients who required intubation or died because of a do not intubate decision.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the clinical outcome measures of the severe COVID-19 pneumonia patients, we assessed the levels of d-dimer, a biomarker associated with clotting and a predictor of poor survival in COVID-19 patients. Increased blood clotting and thrombosis is believed to be a significant contributor to the development of ARDS in these patients. All patients in the trial received anticoagulant therapy, and despite this treatment, two patients on SOC only developed deep vein thromboses with one progressing to a pulmonary embolism, while no patients treated with Auxora plus SOC experienced thrombo-embolic events. On average, patients treated with Auxora plus SOC (n=10) had a median decrease in d-dimer levels at 48 hours of 0.24 while patients receiving SOC alone (n=8) had a median increase of 0.63. Even greater differences were seen at 96 hours although the sample size was small. We believe this is indicative of a protective effect of Auxora treatment on the endothelium.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_32.jpg" alt="img222477878_32.jpg" style="width:473px;height:214px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Auxora treated patients experienced a reduction in d-dimer levels, a biomarker associated with clotting.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In total, 17 patients with severe and three with critical COVID-19 pneumonia were randomized to Auxora plus SOC and nine with severe and one with critical COVID-19 pneumonia were randomized to SOC only. All 30 patients were included in the safety analysis. Similar proportions of patients receiving Auxora plus SOC and SOC only experienced an AE (75% versus 80%, respectively). Fewer</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patients receiving Auxora plus SOC experienced serious AEs versus SOC only (30% versus 50%, respectively). Two patients (10%) receiving Auxora plus SOC and two (20%) receiving SOC only died during the 30 days after randomization. Except for one of the two cases of an increase in blood alkaline phosphatase (an enzyme that can indicate liver damage and bone disorders), which was considered possibly Auxora-related, none of the other AEs were deemed to be drug- related by the principal investigators.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following SAEs occurred in patients treated with Auxora: septic shock, bacterial pneumonia, atrial fibrillation, shock, respiratory failure, ARDS and chest pain. None of the SAEs were deemed to be Auxora-related by the principal investigators.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After 18 severe COVID-19 pneumonia patients were enrolled, the FDA reviewed initial data along with safety data from an independent safety review committee and recommended that this open- label trial be converted into a randomized, double-blind, placebo-controlled trial (Part 2 of the Phase 2 trial).</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Completed Double-Blind Phase 2 Clinical Trial in Hospitalized COVID-19 severe Pneumonia Patients on Oxygen (CARDEA or Part 2)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2020, we began enrollment of our CARDEA trial, a Phase 2, randomized, double-blind, placebo- controlled trial evaluating the addition of Auxora to corticosteroids and standard of care in adults with severe COVID-19 pneumonia. Eligible patients were adults with more than one symptom consistent with COVID-19 infection, a diagnosis of COVID-19 confirmed by laboratory testing using polymerase chain reaction or other assay, and pneumonia documented by chest imaging. Patients were also required to be receiving oxygen therapy using either a high flow or low flow nasal cannula at the time of enrollment and, for the 261 patients in the efficacy analysis set, to have at the time of enrollment, a baseline imputed PaO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:5.025pt;font-family:Times New Roman;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/FiO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:5.025pt;font-family:Times New Roman;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ratio &gt; 75 and &#8804; 200.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were an additional 23 patients in the trial with 200&lt;PaO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:5.025pt;font-family:Times New Roman;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/FiO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:5.025pt;font-family:Times New Roman;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&lt;300 who were enrolled prior to the first independent data monitoring committee meeting, where it was determined those less hypoxemic patients all recovered and were less likely to need therapy beyond current standard of care so going forward, mild ARDS patients, e.g., patients with PaO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:5.025pt;font-family:Times New Roman;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/FiO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:5.025pt;font-family:Times New Roman;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&gt;200, were then excluded from enrollment. The PaO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:5.025pt;font-family:Times New Roman;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/FiO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:5.025pt;font-family:Times New Roman;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was imputed from a SpO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:5.025pt;font-family:Times New Roman;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/FiO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:5.025pt;font-family:Times New Roman;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> determined by pulse oximetry using a non-linear equation. Patients could not be receiving either non-invasive or invasive mechanical ventilation at the time of enrolment. The primary endpoint was time to recovery through Day 60, with secondary endpoints of all-cause mortality at Day 30 and Day 60. All patients received corticosteroids and 99% of patients received anticoagulation treatment as part of their standard of care.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The major findings of the CARDEA Phase 2 trial as reported in April 2022 in the peer-reviewed journal </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Critical Care </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">are as follows:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Time to recovery was seven vs. ten days (P = 0.0979) for patients who received Auxora vs. placebo, respectively.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Day 30 all-cause mortality was 7.7% with Auxora vs. 17.6%, with placebo (P = 0.0165).</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Day 60 all-cause mortality was 13.8% with Auxora vs. 20.6% with placebo (P = 0.1449).</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Serious adverse events occurred in 24.1% of patients treated with Auxora vs. 35% of patients receiving Placebo (P=0.0616).</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_33.jpg" alt="img222477878_33.jpg" style="width:522px;height:122px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SOC included 100% corticosteroid use and 99% anticoagulation use</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trial design for double-blind Phase 2 clinical trial in hospitalized COVID-19 pneumonia patients on oxygen (Part 2).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_34.jpg" alt="img222477878_34.jpg" style="width:466px;height:215px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Baseline demographics were balanced across the treatment groups in the blinded Phase 2 trial of Auxora in severe COVID-19 pneumonia.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overall mortality was significantly reduced with Auxora treatment in the 261-patient efficacy dataset. At 30 days, the mortality rate for Auxora-treated patients with 7.7% compared to 17.6% for placebo (HR 0.42 and p=0.023) &#8211; a relative decrease of 56%. At 60 days, Auxora treatment was associated with a 13.8% mortality rate compared to 20.6% for placebo (HR 0.63 and p=0.130) &#8211; a relative decrease of 33%. Both of these findings are clinically relevant particularly in light of patients needing additional therapies on top of current standard of care. Patients treated with Auxora plus SOC demonstrated a trend toward a faster median time to recovery than those treated with SOC plus placebo. Our primary recovery endpoint was determined in the 261-patient efficacy analysis set where Auxora treatment demonstrated a trend toward a reduced time to recovery with a median of seven days compared to ten days with placebo (p=0.098). In an FDA-required supplementary analysis of our primary endpoint in the 284 patient safety analysis set (which included 23 patients with mild COVID-19 pneumonia (P/F 201 to 300)), the median recovery time for Auxora treated patients was maintained at seven days, while the median recovery time for placebo treated patients decreased to eight days (p=0.042). In both analysis sets, the percent of patients that recovered in the trial was higher when Auxora was added to SOC therapy. The recovery rate ratio, defined as the percent of patients who did not recover on placebo compared to the percent that did not recover with Auxora, was 1.25 for the efficacy analysis set and 1.30 for the safety analysis set. This means that not only did patients treated with Auxora plus SOC demonstrate a trend toward a reduced time to recovery, but that they were more likely to recover than patients treated with placebo plus SOC.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other key findings in the study were that patients receiving Auxora saw their PaO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:5.025pt;font-family:Times New Roman;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/FiO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:5.025pt;font-family:Times New Roman;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ratios recover more quickly than patients receiving placebo and proportionally fewer patients receiving Auxora required ventilation over their course of treatment than patients receiving placebo. There were also fewer patients with reported serious adverse events in the Auxora treated group than in those receiving placebo. These findings are all clinically relevant, particularly given the relative risk reduction in mortality for patients receiving Auxora in addition to standard of care. Finally, there were improvements in a number of inflammatory biomarkers in Auxora treated patients versus those receiving placebo. Specifically, C-reactive protein, ferritin and d-dimer levels dropped over the course of six days and were lower than placebo over that time. CD-25 levels, which are a surrogate for the expansion of pro-inflammatory CD25+CD8 T cells that have been associated with mortality, were statistically significantly lower in Auxora patients compared to placebo.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_35.jpg" alt="img222477878_35.jpg" style="width:521px;height:213px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Auxora positive effects compared to placebo on multiple clinical endpoints in CARDEA (N=261)</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_36.jpg" alt="img222477878_36.jpg" style="width:540px;height:278px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Auxora positive effects compared to placebo on multiple biomarkers of respiratory inflammation in CARDEA (N=261)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_37.jpg" alt="img222477878_37.jpg" style="width:392px;height:203px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Auxora plus SOC demonstrated a significant decrease in mortality compared to placebo plus SOC. (N=261)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_38.jpg" alt="img222477878_38.jpg" style="width:414px;height:248px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Kaplan Meier curve of mortality. Auxora plus SOC (blue), placebo plus SOC (red). (N=261)</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Auxora was generally well-tolerated in our CARDEA trial. The number of adverse events in the blinded part of the study was similar between the two treatment groups (patients randomized to Auxora (331); patients randomized to placebo (342)). Fewer patients randomized to Auxora (34, 24.1%) had SAEs compared to patients randomized to Placebo (49, 35.0%). There were five SAEs that the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">investigators reported as possibly related to Auxora: increase in alanine aminotransferase (an indicator of liver dysfunction), increase in aspartate aminotransferase (an indicator of liver dysfunction), cardiac arrest, respiratory failure and shock. Two of these (increase in alanine aminotransferase and increase in aspartate aminotransferase) occurred in only two patients. There were no SAEs that required expedited safety reporting to institutional review boards or to the FDA. Three patients randomized to Auxora and five patients randomized to placebo discontinued study drug.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ongoing Phase 2 Trial in Mechanically Ventilated COVID-19 Pneumonia ARDS Patients</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Work at Northwestern University has focused on immune cell activity in the lung fluid of COVID-19 pneumonia patients on mechanical ventilation implicates IFN-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-secreting T cells as key participants in the cascade of lung damage in these patients. Evidence suggests CRAC channels are a critical nexus in this cascade.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the data from Northwestern scientists, the mechanism of lung inflammation produced by SARS-CoV-2 begins with virus infection of cells in the nose, throat and upper lung. Viral infection then spreads to deeper areas of the lung and enters lung-resident macrophages which, in response, degrade viral proteins and present viral antigens on their cell surface to T cells; they also release chemokines that attract additional T cells to the area. The arriving T cells interact with the SARS-CoV-2 antigens presented on the surface of macrophages, activating the T cells to produce and secrete the pro-inflammatory cytokine IFN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. This sets up a positive feedback loop that leads to further immune recruitment, activation and inflammation. Based on the role of CRAC channels in immune cell activation, Auxora can block IFN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> release from T cells, potentially inhibit antigen presentation by macrophages, and block the release of chemokines and pro-inflammatory cytokines from monocytes, thereby limiting the lung inflammation produced by SARS-CoV-2.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_39.jpg" alt="img222477878_39.jpg" style="width:413px;height:197px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inhibition of IFN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">secretion in the lung of COVID-19 patients has the potential to block activation of inflammatory cells such as alveolar macrophages.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We, in collaboration with investigators at Northwestern, are conducting a Phase 2 dose escalation clinical trial of Auxora in mechanically ventilated patients with COVID-19 pneumonia to test this hypothesis and to determine an effective dose of Auxora for treating these patients using pharmacodynamic markers from bronchoalveolar lavage (lung) fluid. This trial has completed the treatment portion and samples from the patients are being analyzed for gene expression and biomarker information. Nine patients received either Auxora (n=7) or placebo (n=2) for three, four or five days or an initial infusion followed by four days of continuous infusion. The amount of time that patients remain on the ventilator was measured as part of the trial. Lung lavages were taken before and after treatment to determine the level and activity of macrophages, monocytes and IFN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-secreting T cells in patients receiving drug and placebo. We anticipate results from this trial in 2024. We plan to use the findings of this clinical trial to establish an effective dosing schedule for further studies of Auxora in the treatment of ventilated ARDS patients.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_40.jpg" alt="img222477878_40.jpg" style="width:540px;height:168px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trial design for Phase 2 trial in mechanically ventilated COVID-19 pneumonia ARDS patients.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Planning for Additional Clinical Trials in AHRF and ARDS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on the mechanism of action of Auxora and the reduction in ventilator use that was observed in our COVID-19 pneumonia and AP clinical trials, we believe that Auxora has the potential to bring therapeutic benefit to a broader population of patients suffering from AHRF and ARDS. Our recent work elucidating the activity of Auxora in an LPS-induced mouse model of respiratory failure confirmed that the drug down-regulates inflammatory cytokines in the lungs and likely protects the lung endothelium from damage.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The broader ARDS patient populations include many etiologies including sepsis, viral pneumonia, bacterial pneumonia and trauma. The incidence of ARDS is estimated to be approximately 190,000 cases per year in the United States alone, with sepsis being the most common cause. We believe that the Auxora clinical data in COVID-19 pneumonia suggests that Auxora can potentially be used in most ARDS settings. We are currently evaluating opportunities to continue clinical development of Auxora in the setting of acute respiratory failure particularly in partnership with sponsors such as government agencies both in the US and outside of the US.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preclinical Studies with Auxora in ARDS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Endothelial cells in the lung help to maintain the boundary between blood vessels and air-exchange sacs, or alveoli, by providing an insulating barrier function, preventing fluid from leaking out of blood vessels while allowing the exchange of oxygen and carbon dioxide within the lung alveoli. The integrity of this endothelial barrier is dependent on many things, including calcium regulation. The endothelial barrier breaks down when an excess of intracellular calcium causes the activation of NFAT, driving deleterious changes in gene transcription. This breakdown leads to fluid leakage into the lung and impedes the lung&#8217;s ability to absorb oxygen and release carbon dioxide. CRAC channels, which help regulate the amount of calcium flowing into endothelial cells, sit at a key junction point in this biochemical cascade. Zegocractin, the active ingredient in Auxora, was able to produce a beneficial effect in the lung consistent with inhibiting the breakdown in endothelial barrier function in an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">model of pathogen-induced lung injury. In this model, a bacterial glycoprotein called LPS was instilled into the nasopharynx of mice, which induced a reaction inside the lung similar to what would happen in acute lung injury resulting from an active bacterial infection. Zegocractin was administered two and seven hours after LPS and the animals were examined 12 hours after LPS by measuring several biomarkers in lung fluid using antibody technology as well as lung histopathology. A prominent and well known effect of LPS in this model was to increase levels of two key inflammatory cytokines, IL-6 and TNF</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">&#181;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, in lung fluid. Treatment with zegocractin led to a dose-dependent decrease in the LPS-induced IL-6 and TNF</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">&#181;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> levels (maximum 46% and 57%, respectively) in lung fluid and also decreased the LPS-induced edema surrounding the lung (maximum 61%) compared to placebo-treated controls. The decrease in lung edema is consistent with protection of the endothelial cell barrier. We believe that inhibitors of CRAC channels have the potential to inhibit the breakdown of the lung endothelial barrier in patients suffering from ARDS.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_41.jpg" alt="img222477878_41.jpg" style="width:507px;height:192px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">PBS - phosphate buffered saline, LPS - lipopolysaccharide, Veh - vehicle, Zego - Zegocractin, mpk - milligrams per kilogram, x2 - given twice at 5-hour intervals</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Zegocractin lowered IL-6 and TNF</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">&#181;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> levels in lung fluid and reduced edema in an LPS model of acute lung injury.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preclinical studies for Chronic Inflammatory and Immunological Diseases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are developing oral CRAC channel inhibitors that we intend to take into indications which are not treated in a critical care setting such as chronic inflammatory and immunological diseases. We have obtained or generated preclinical data which support the use of CRAC channel inhibitors in indications such as chronic pancreatitis, rheumatoid arthritis, asthma and psoriasis where an IV formulation would not represent a viable therapeutic approach. Repeated attacks of AP, as well as heavy alcohol use and genetic anomalies, can lead</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to the development of chronic pancreatitis, a debilitating disease characterized by pain, fibrosis and declining pancreatic function that increases the risk of developing pancreatic cancer by a factor of ten to 100. According to the Pancreatitis Foundation, approximately 140,000 people suffer from chronic pancreatitis in the United States alone. We believe this will be considered an orphan indication and intend to apply for orphan designation with the FDA. While there are numerous treatments for rheumatoid arthritis, most patients require injectable immunomodulatory drugs as the disease progresses. The need for safe oral therapies for more advanced patients persists. We are evaluating chronic pancreatitis and rheumatoid arthritis as potential first indications for our oral drug candidate, CM6336.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preclinical Study with a CRAC Channel Inhibitor in Chronic Pancreatitis</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our preclinical studies of CM5480, a proprietary compound, in chronic pancreatitis suggest that CRAC channel inhibition may decrease fibrosis and organ dysfunction in this setting. We are currently performing IND-enabling preclinical studies with multiple proprietary compounds in order to identify one or more candidates with good pharmaceutical properties. CM6336, our current lead oral CRAC channel inhibitor, is structurally distinct from CM5480 but with potentially improved pharmacokinetic properties. We plan to submit an IND for CM6336 in chronic pancreatitis in 2025 and may be in a position to and initiate a Phase 1/1b clinical trial the same year, subject to receipt of additional funding.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We tested CM5480 in a mouse model of chronic pancreatitis, in which animals are given eight hourly injections of cerulein per day on five occasions, each separated by two intervening cerulein-free days. CM5480, a model compound, was given by once-daily intraperitoneal injections for nine days starting after the third round of cerulein injections. The cerulein injections produced pancreatic fibrosis and reductions in pancreatic epithelial (mostly acinar) cells and ductal cell secretion. We found that CM5480 reduced pancreatic fibrosis by 50%, modestly increased epithelial cells, and restored pancreatic ductal cell secretion. These results suggest that there is the potential to treat chronic pancreatitis with a CRAC channel inhibitor, especially one that can be readily administered to patients, such as with an oral formulation.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_42.jpg" alt="img222477878_42.jpg" style="width:501px;height:198px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_43.jpg" alt="img222477878_43.jpg" style="width:515px;height:209px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">CM5480 (CM-C) reduced acinar cell necrosis (top panels), prevented the formation of fibrosis (bottom left) and restored pancreatic ductal secretion (bottom right) in a mouse model of chronic pancreatitis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preclinical Studies with CRAC Channel Inhibitors in Models of Rheumatoid Arthritis</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Previous work by us and others has indicated that inhibition of Orai1 CRAC channels may be an effective treatment for rheumatoid arthritis. A 2015 study</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">published in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">British Journal of Pharmacology </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">examined the effects of YM-58483 (aka BTP-2), a model</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CRAC channel blocker, and showed that the compound produced significant improvements in arthritis severity scores in a mouse model of collagen-induced arthritis (&#8220;CIA&#8221;). Likewise, a 2017 published study</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Journal of Pharmacological Sciences</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> showed that localized reduction of Orai1 mRNA in the joints and lymph nodes reduced the severity of arthritis in a mouse CIA model.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consistent with the findings above, in our preclinical studies, we have demonstrated that several of our Orai1-selective CRAC channel blockers are efficacious at reducing histopathology in a rat model of CIA. Thus, zegocractin (CM4620) and model compounds CM5480 and CM6325 when dosed orally once-daily at 25 mg/kg produced significant reductions in knee histopathology that averaged 61%, 76% and 71%, respectively.  Data from a representative study with CM6325 is shown below.  In this study, the reductions in knee histopathology scores corresponded with reductions in a pharmacodynamic measure of stimulated IL-2 release in an ex vivo blood assay.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img222477878_44.jpg" alt="img222477878_44.jpg" style="width:510px;height:298px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">CM6325 produced significant and dose-related reductions in summed knee histopathology scores (composed of measures of inflammation, pannus formation, cartilage damage and bone resorption) in rat model of collagen-induced arthritis. Blood samples taken at the end of the study showed that a pharmacodynamic (PD) readout, stimulated IL-2 release, was also decreased by CM6325 in a significant and dose-related manner. *p &lt; 0.05</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We  plan to submit an IND for CM6336 in rheumatoid arthritis in 2025.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preclinical Study in Inflammatory Bowel Disease</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent animal data indicates that CRAC channel inhibition by zegocractin (CM4620) may be effective in the treatment of inflammatory bowel disease, such as ulcerative colitis. In a preclinical study performed with scientists from Charite &#8211; University Medicine, Berlin and New York University Grossman School of Medicine, it was shown that zegocractin administered orally to mice every other day for a period of 30 days produced a significant reduction in intestinal inflammation in a model of ulcerative colitis. Consistent with the anti-inflammatory action of zegocractin, reductions in the frequencies of IFN-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, TNF&#945; and IL-2 producing CD4 T cells were also observed in T cells isolated and stimulated </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ex vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">at the end of the study. These data, published in 2022 in the journal </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EMBO Molecular Medicine, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suggest that zegocractin could be effective in treating patients with acute flares of inflammatory bowel disease.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_45.jpg" alt="img222477878_45.jpg" style="width:380px;height:140px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Systemic administration of CM4620 (zegocractin) alleviates colon inflammation in mice. Histological sections of distal and proximal colon were scored for the presence of inflammatory cells (Colitis Score). CD4+ T cells were isolated from animals after</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">treatment with vehicle or CM4620 and stimulated ex vivo with a phorbol ester (PMA) + ionomycin for 4 hours. Frequencies (%) of IFN-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">, TNF</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#945;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> and IL-2 T cells were then determined.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preclinical Study in Allergic Asthma</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The effectiveness of zegocractin (CM4620) was compared in mouse models of asthmatic airway inflammation and influenza A virus infection to determine if inhibition of CRAC channels reduces asthmatic inflammation without interfering with the antiviral response. Researchers from New York University Grossman School of Medicine showed that in a model of allergic airway inflammation oral administration of zegocractin significantly lowered both peribronchiolar inflammation and lung mucus production. Conversely, there was no effect of zegocractin on lung viral load in a model of influenza A virus infection. These results indicate zegocractin may be an effective treatment for allergic asthma but will not decrease the anti-viral response to a viral infection. These data were published in the journal </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Science Advances in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2022.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_46.jpg" alt="img222477878_46.jpg" style="width:415px;height:176px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">CM4620 (zegocractin) reduces lung inflammation in a mouse model of allergic asthma but does not compromise adaptive immunity to influenza A virus infection. Lung sections from control and CM4620 treated asthmatic mice were stained with hematoxylin and eosin (H&amp;E) or periodic acid- Schiff (PAS) to detect inflammation and mucus production, respectively. Influenza A virus (IAV) expression was quantified in lung by quantitative RT-PCR of RNA for nuclear segment 5 of IAV (a specific probe for IAV), and is presented as expression relative to the housekeeping gene Rpl32.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preclinical Study in Traumatic Brain Injury</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In a preclinical study performed with investigators at the San Francisco Veterans Affairs Hospital and UCSF, CM5480, a proprietary tool compound, was tested in a mouse model of traumatic brain injury in which animals were subjected to a controlled cortical impact with an automated impactor to induce brain injury. It was observed that treatment with CM5480 led to significant protection of mice from traumatic brain injury as determined by decreased lesion size, brain hemorrhage and improved neurological deficits with decreased microglial activation. This study was published in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Journal of Neurotrauma </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in 2019.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are conducting preclinical pharmacokinetic and IND-enabling toxicology studies on a number of product candidates from our portfolio in order to identify one that readily crosses the blood-brain barrier. We are evaluating these observations and our preclinical results and will consider whether to submit an IND in this indication in the future.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img222477878_47.jpg" alt="img222477878_47.jpg" style="width:477px;height:174px;"/><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">CM5480 (CM-EX-137) reduced injury in a traumatic brain injury model in mice.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales and Marketing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Given our stage of development, we have not yet established a commercial organization or distribution capabilities. We intend to build a commercial infrastructure to support sales of our product candidates. We expect to manage sales, marketing and distribution through internal resources and third-party relationships. While we may commit significant financial and management resources to commercial activities, we will also consider collaborating with one or more pharmaceutical companies to enhance our commercial capabilities. As our future product candidates progress through our pipeline, our commercial plans may change. Clinical data, the size of the development programs, the size of our target markets, the size of a commercial infrastructure and manufacturing needs may all influence our commercialization strategies.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not own or operate manufacturing facilities for the production of any of our future product candidates, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We currently rely, and expect to continue to rely for the foreseeable future, on contract manufacturing organizations (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CMOs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) for all our required raw materials, drug substance and drug product needs for preclinical research, clinical trials and initial commercialization. We do not have long-term agreements with any of these third parties. We also do not have any current contractual relationships for the manufacture of commercial supplies of any of our future product candidates and do not plan to enter into any until further into clinical development. If any of our products are approved by any regulatory agency, we intend to enter into agreements with a CMO and one or more back-up manufacturers for the commercial production of those products. Development and commercial quantities of any products that we develop will need to be manufactured in facilities, and by processes, that comply with the requirements of the FDA and the regulatory agencies of other jurisdictions in which we are conducting clinical research or seeking marketing approval.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The pharmaceutical and biotechnology industries are characterized by intense competition and rapid innovation. While we believe that our product candidates, as well as our development experience and scientific knowledge may provide significant advantages, relative to current approaches and therapies in the treatment of acute critical illnesses and chronic inflammatory and immunologic diseases, our competitors may be able to develop other compounds or drugs that are able to achieve similar or better results. We face potential competition from many different sources, including large multinational pharmaceutical companies, established biotechnology companies and specialty pharmaceutical companies, and universities and other research institutions. Many of these groups have materially greater financial, manufacturing, marketing, research and drug development resources than we do. Large pharmaceutical companies in particular have extensive expertise in preclinical and clinical testing and in obtaining regulatory approvals for drugs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory processes and direct cellular damage. The molecular targets we are addressing are CRAC channels, and our most advanced clinical candidate, Auxora, is in clinical trials for AP with accompanying SIRS, AIPT with AHRF. Other companies, including Daiichi-Sankyo Company, Limited, Rhizen Pharmaceuticals AG, PRCL Research, Inc., Vivreon Biosciences, LLC and ChemiCare srl, have CRAC channel inhibitors (including both small molecules and monoclonal antibodies) in clinical or preclinical development for various indications. Several of these have reached Phase 1 or Phase 2 clinical trials in indications we are not currently pursuing. Any of these companies could elect to re-direct their efforts and compounds to indications we are pursuing.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With respect to our lead indication, AP with accompanying SIRS, we are developing Auxora as a disease- modifying product candidate, whereas other treatments and approaches in clinical development focus on addressing symptoms or sequelae. These include various types of pain medications, anti-inflammatories, anti-coagulants, antibiotics, fluids and feeding regimens. Amryt Pharma Plc and Regeneron Pharmaceuticals, Inc. also have agents in development that seek to reduce the risk of subsequent attacks of AP after a sentinel attack (known as recurrent AP) due to a particular etiology (familial chylomicronemia syndrome (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FCS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;)). FCS patients represent less than 2% of the AP population.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With respect to AIPT, there is currently no disease modifying treatment for patients who develop pancreatic toxicity as a result of asparaginase. The current SOC addresses symptoms like pain, the inability to eat, and infection.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With respect to our efforts in other acute critical illnesses with Auxora, there are a number of companies, particularly with anti-inflammatory technologies. In the area of AKI, most companies in the space are pursuing strategies to prevent AKI in high risk populations. There is one clinical trial on-going to treat AKI in the setting of sepsis. Currently, to our knowledge, there are no novel compounds in clinical development in the US that are being used to treat rather than prevent AKI. If, however, a strategy to prevent AKI were to be effective, the number of patients we are targeting for Auxora could decrease. In the area of respiratory failure and, specifically, COVID-19 pneumonia, there are a number of companies pursing anti-inflammatory approaches to treating these diseases. Currently, Roche&#8217;s tocilizumab, Imclone&#8217;s baricitinib, SOBI&#8217;s anakinra and dexamethasone are all approved under EUAs to treat severe COVID-19 pneumonia patients on oxygen. Sanofi&#8217;s sarilumab which has the same mechanism of action as tocilizumab has also been</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recommended for use in severe COVID-19 pneumonia by WHO. Some of these drugs as well as others currently in development for COVID-19 pneumonia may prove efficacious in broader respiratory failure, particularly respiratory failure caused by viral pneumonias.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial opportunity could be substantially limited in the event that our competitors develop and commercialize products that are more effective, safer, more convenient or cheaper than our product candidates. In geographies that are critical to our commercial success, competitors may also obtain regulatory approvals before us, resulting in our competitors building a strong market position in advance of our product&#8217;s entry. We believe the competitive factors that will determine the success of our programs will be the efficacy, safety, pricing and reimbursement, and convenience of our future product candidates.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have developed and continue to expand our patent portfolio for Auxora. As of December 31, 2023, we have issued patents and pending patent applications in the United States and other countries throughout the world directed to compositions of matter, various methods of use, formulations, and synthetic processes. For patents directed to compositions covering Auxora, we own four issued U.S. patents and 63 issued patents in the following jurisdictions: Argentina, Australia, Austria, Belgium, Bulgaria, Brazil, Canada, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Luxembourg, Monaco, Netherlands, Norway, Poland, Portugal, Romania, Spain, Sweden, Slovakia, Switzerland, Turkey, United Kingdom, Eurasian Patent Organization, and Taiwan. We also have one pending U.S. patent application and seven pending patent applications in the following jurisdictions: Japan, Canada, China, India, and Korea directed to compositions covering Auxora. Composition of matter patents for our drug compound portfolio have expirations ranging from 2031 to 2036 with Auxora and other pre-clinical drugs having world-wide composition of matter patents to 2036, not including any patent term adjustment or any patent term extension.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For patents and patent applications directed to methods of using Auxora for the treatment of AP, as of December 31, 2023, we own two issued U.S. patents and 33 issued patents in the following jurisdictions: China, Japan, Australia the Eurasian Patent Organization, Austria, Belgium, Bulgaria, Canada, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Luxembourg, Monaco, Netherlands, Norway, Poland, Portugal, Romania, Spain, Sweden, Slovakia, Switzerland, Turkey, United Kingdom, and Taiwan. We also own two U.S. patent applications, and thirteen pending patent applications in the following jurisdictions:  Australia, Canada, China, Europe, Hong Kong, Japan, and Taiwan for other indications. These issued patents and any patents issuing from pending U.S. and ex-U.S. applications are expected to expire between 2031-2041, not including any patent term adjustment or any patent term extension. We have also filed one international application directed to using a subject&#8217;s P/F ratio (the ratio of arterial oxygen pressure to fractional inspired oxygen) as a biomarker when treating acute lung injury and acute respiratory distress syndrome with Auxora. Any patents ultimately issuing from this international application are expected to expire around 2043, not including any patent term adjustment or patent term extension.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we jointly own one issued U.S. patent, 13 issued patents in the following jurisdictions: Australia, Germany, France, United Kingdom, Belgium, Switzerland, Denmark, Ireland, Italy, Luxembourg, Netherlands, Sweden, and Japan directed to treatment for stroke and traumatic brain injury. These patents and any patents issuing from applications are expected to expire around 2036, not including any patent term adjustment or patent term extension. Also, we have filed one provisional application directed to treatment of non-alcoholic fatty liver disease using Auxora. Any patents ultimately issuing from this provisional application are expected to expire around 2044, not including any patent term adjustment or patent term extension.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, for patent protection directed to formulations and crystalline forms of Auxora, we have filed one U.S. patent application, one granted in China, one granted patent in Mexico, and seven pending applications in the following jurisdictions: Australia, Brazil, Canada, Europe, Japan, Korea, and Mexico. Any patents that ultimately issue from these patent applications are expected to expire around 2038, not including any patent term adjustment or patent term extension.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With respect to synthetic processes of Auxora, we have filed two U.S. patent applications, and pending applications in the following jurisdictions: Canada, China, Europe, India, Japan, and Korea. Any patents ultimately issuing from these PCT applications are expected to expire around 2040, not including any patent term adjustment or any patent term extension.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Beyond patent coverage for Auxora, we have 18 issued U.S. patents and 6 issued ex-U.S. patents directed to CRAC channel inhibitors and their uses.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to patent protection, we rely on trade secret protection and know-how to expand our proprietary position around our chemistry, technology, and other discoveries and inventions that we consider important to our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government Regulation and Product Approval</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a pharmaceutical company that operates in the United States, we are subject to extensive regulation. Government authorities in the United States (at the federal, state and local level) and in other countries extensively regulate, among other things, the research, development, testing, manufacturing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug products such as those we are developing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Product candidates that we develop must be approved by the FDA, before they may be legally marketed in the United States and by the appropriate foreign regulatory agency before they may be legally marketed in a foreign country. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the United States, although there can be important differences. Additionally, some significant aspects of regulation in Europe are addressed in a centralized way, but country-specific regulation remains essential in many respects.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">U.S. Drug Development Process</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDCA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;), and its implementing regulations. A new drug must be approved by the FDA pursuant to a new drug application (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NDA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) before it may be legally marketed in the United States. Drugs are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, and local statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. Sanctions brought by the FDA and the Department of Justice (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DOJ</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;), or other governmental entities, could include, among other actions, refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">completion of extensive preclinical laboratory tests, preclinical animal studies and formulation studies in accordance with applicable regulations, including the FDA&#8217;s Good Laboratory Practice (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GLP</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) regulations and other applicable regulations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approval by an independent institutional review board (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IRB</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) at each clinical site before each trial may be initiated;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation of clinical trial material in accordance with current Good Manufacturing Practices (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cGMPs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;);</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">performance of adequate and well-controlled human clinical trials in accordance with applicable regulations, including the FDA&#8217;s good clinical practice (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GCP</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) regulations to establish the safety and efficacy of the proposed drug for its proposed indication;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submission to the FDA of an NDA, including payment of application user fees, after completion of all pivotal trials, and which provides substantive evidence of the products&#8217; candidates safety and efficacy from results of nonclinical testing and clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a determination by the FDA within 60 days of its receipt of an NDA that the application is sufficiently complete to permit a substantive review, in which case the NDA is filed for review;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the drug is produced to assess compliance with the FDA&#8217;s cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential FDA audit of the preclinical and/or clinical trial sites that generated the data in support of the NDA to assess compliance with GCP regulations and data integrity, among other things;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">satisfactory completion of an FDA advisory committee review, if applicable; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA review and approval of the NDA, including consideration of the views on the FDA advisory committee, if one was involved, prior to any commercial marketing or sale of the drug in the United States.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before testing any compound with potential therapeutic value in humans, the drug candidate enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies, to assess the potential safety and activity of the drug candidate. The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs. The sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. An IND is an exemption from the FDCA that allows an unapproved product to be shipped in interstate commerce for use in an investigational clinical trial and a request for authorization from the FDA to administer an investigational drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for human trials. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials and places the IND on clinical hold within that 30-day time period. In such a case, the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose complete or partial clinical holds on an IND for a drug candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA. Submission of a study protocol, therefore, may or may not result in FDA authorization to begin a clinical trial.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials involve the administration of the drug candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCPs, which include the requirement that all research participants provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Further, each clinical trial must be reviewed and approved by an independent IRB at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information related to the investigational product, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is made public as part of the U.S. registration of the clinical trial. Sponsors are also obligated to disclose the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed in some cases for up to two years after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs. Failure to timely register a covered clinical study or to submit study results as provided for in the law can give rise to civil monetary penalties and also prevent the non-compliant party from receiving future grant funds from the federal government.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The drug candidate is initially introduced into healthy human participants and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion, and the side effects associated with increasing doses and if possible, to gain early evidence of effectiveness. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The drug candidate is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases or conditions and to determine dosage tolerance, optimal dosage and dosing schedule. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The drug candidate is administered to an expanded patient population to further evaluate dosage and clinical efficacy at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall benefit/risk ratio of the product and provide an adequate basis for product approval. Generally, two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of an NDA.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Post-approval studies, or Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the Phase 2 trial to discuss Phase 2 clinical results and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the new drug.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected AEs or any finding from tests in laboratory animals that suggests a significant risk for human participants. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA, the IRB, or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research participants or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated check points based on access to certain data from the trial.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final drug. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are also various laws and regulations regarding laboratory practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances in connection with the research. In each of these areas, the FDA and other regulatory authorities have broad regulatory and enforcement powers, including the ability to levy fines and civil penalties.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Review and Approval Processes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, preclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug candidate, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. Data may come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and effectiveness of the investigational drug product to the satisfaction of the FDA. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the PREA requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. Sponsors are required to submit PSPs to the agency for review within sixty days of an end-of-Phase 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 clinical trial. The FDA and the sponsor must reach an agreement on the PSP although a sponsor can submit amendments to an agreed upon PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials or other clinical development programs. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data need to be collected before the pediatric clinical trials begin. Unless otherwise required by regulation, the Pediatric Research Equity Act does not apply to any drug for an indication for which orphan designation has been granted. However, if only one indication for a product has orphan designation, a pediatric assessment may still be required for any applications to market that same product for the non-orphan indication(s).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA reviews all NDAs submitted to determine if they are substantially complete before it accepts them for filing and may request additional information rather than accepting an NDA for filing. The FDA must make a decision on accepting an NDA for filing within 60 days of receipt. The FDA may refuse to file any NDA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the NDA must be resubmitted with the additional information. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA. Under the PDUFA guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision after the application is submitted. The current review goal for priority NDAs for new-molecular entities is six months from the filing date, or eight months from the date of receipt in light of the 60-day filing period. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs, and the review process is often significantly extended by FDA requests for additional information or clarification.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After the NDA submission is accepted for filing, the FDA reviews the NDA to determine, among other things, whether the proposed product is safe and effective for its intended use and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#8217;s identity, strength, quality and purity. The FDA may refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes independent clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions and typically follows the advisory committee&#8217;s recommendations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before approving an NDA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one or more clinical sites to assure that the clinical trial was conducted in compliance with IND study requirements and GCP requirements by each of the entities involved in the clinical trials, including clinical investigators and any third- party CROs. After the FDA evaluates the application, manufacturing process and manufacturing facilities, it may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the NDA identified by the FDA. The Complete Response Letter may require additional clinical data and/or (an) additional pivotal Phase 3 clinical trial(s), and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling or may condition the approval of the NDA on other changes to the proposed labeling, development of adequate controls and specifications, or a commitment to conduct one or more post-market studies or clinical trials. For example, the FDA may require Phase 4 testing, which involves clinical trials designed to further assess a drug safety and effectiveness, and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized; the FDA may prevent or limit further marketing of a product based on the results of post-marketing trials or surveillance programs. The FDA may also determine that a REMS is necessary to ensure that the benefits of the drug outweigh its risks and to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS during the application review process; the FDA will not approve the NDA without an approved REMS, if required. A REMS could include medication guides, physician communication plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA determines the requirement for a REMS, as well as the specific REMS provisions, on a case-by-case basis.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Orphan Drug Designation and Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Orphan Drug Act the FDA may grant orphan designation to a drug intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States or, if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making a drug product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting an NDA. After the FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or inability to manufacture the product in sufficient quantities. The designation of such drug also entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. If an orphan designated product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan exclusivity.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expedited Development and Review Programs and Accelerated Approval</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA has a fast track designation program that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. Specifically, new drugs are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for more frequent interactions with the applicable FDA review team during product development and, once a NDA is submitted, the product candidate may be eligible for priority review. With regard to a fast track product, the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any product submitted to the FDA for approval, including a product with a fast track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review. A product is eligible for priority review if it is designed to treat a serious condition, and if approved, would provide a significant improvement in the treatment, diagnosis or prevention</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">42</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of a serious condition compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six months of the filing date as compared to ten months of the filing date for review of new molecular entity NDAs under its current PDUFA review goals.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, a product may be eligible for accelerated approval. Drug products intended to treat serious or life- threatening diseases or conditions may be eligible for accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials to verify the predicted clinical benefit. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required clinical trials, or if such trials fail to verify the predicted clinical benefit. In addition, the FDA requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A sponsor may seek FDA designation of a drug candidate as a &#8220;breakthrough therapy&#8221; if the drug is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough therapy designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance. The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met. The FDA must take certain actions with respect to breakthrough therapies, such as holding timely meetings and providing advice to the product sponsor, intended to expedite the development and review of an application for approval of a breakthrough therapy.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fast track designation, priority review, accelerated approval, and breakthrough therapy designation do not change the standards for approval but may expedite the development, review, or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. In addition, such designations or shortened review periods may not provide a material commercial advantage.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Post-Approval Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any drug products manufactured or distributed pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling and distribution requirements, and complying with FDA promotion and advertising requirements. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program fees for any marketed products.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, quality control and manufacturing procedures must continue to conform to applicable manufacturing requirements after approval to ensure the long term stability of the drug product. cGMP regulations require among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. In addition, changes to the manufacturing process are strictly regulated, and depending on the significance of the change, may require prior FDA approval before being implemented.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including AEs of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical studies to assess new safety risks, or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fines, warning letters, or untitled letters;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical holds on clinical studies;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product approvals;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mandated modification of promotional materials and labeling and the issuance of corrective information;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA closely regulates the marketing, labeling, advertising and promotion of drug products, including promotional activities involving the internet and industry-sponsored educational activities. A company can make only those claims relating to safety and efficacy that are approved by the FDA and in accordance with the approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion by manufacturers of uses or patient populations that are not described in the product&#8217;s approved labeling (known as &#8220;off label uses&#8221;). Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe, in their independent professional medical judgment, legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested and approved by the FDA. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined companies from engaging in off-label promotion. The FDA and other regulatory agencies have also required that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA-approved labeling.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PDMA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of wholesale drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. Most recently, the Drug Supply Chain Security Act (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DSCSA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) was enacted with the aim of building an electronic system to identify and trace certain prescription drugs distributed in the United States. The DSCSA mandates phased-in and resource-intensive obligations for pharmaceutical manufacturers, wholesale distributors, and dispensers over a 10 year period that is expected to culminate in November 2023.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Patent Term Restoration and Marketing Exclusivity</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depending upon the timing, duration and specifics of the FDA approval of the use of our product candidates, some of our U.S. patents, if granted, may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years, as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA plus the time between the submission date of an NDA and the approval of that application. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may intend to apply for restoration of patent term for one of our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the Hatch-Waxman Amendments to the FDCA authorized the FDA to approve generic drugs that are the same as drugs previously approved by the FDA under the NDA provisions of the statute and also enacted Section 505(b)(2) of the FDCA. To obtain approval of a generic drug, an applicant must submit an abbreviated new drug application (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ANDA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;), to the agency. In support of such applications, a generic manufacturer may rely on the preclinical and clinical testing conducted for a drug product previously approved under an NDA, known as the reference listed drug (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RLD</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;). Specifically, in order for an ANDA to be approved, the FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration, the dosage form, and the strength of the drug. In contrast, Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. A Section 505(b)(2) applicant may eliminate the need to conduct certain preclinical or clinical studies, if it can establish that reliance on studies conducted for a previously-approved product is scientifically appropriate. Unlike the ANDA pathway used by developers of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">bioequivalent versions of innovator drugs, which does not allow applicants to submit new clinical data other than bioavailability or bioequivalence data, the 505(b)(2) regulatory pathway does not preclude the possibility that a follow-on applicant would need to conduct additional clinical trials or nonclinical studies; for example, they may be seeking approval to market a previously approved drug for new indications or for a new patient population that would require new clinical data to demonstrate safety or effectiveness. The FDA may then approve the new product for all or some of the label indications for which the RLD has been approved, or for any new indication sought by the Section 505(b)(2) applicant, as applicable Market exclusivity provisions under the FDCA can also delay the submission or the approval of certain marketing applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve an ANDA or a 505(b)(2) NDA submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the RLD or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the RLD holder. The FDCA also provides three years of marketing exclusivity for an NDA, or a supplement to an existing NDA, if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA filed under section 505(b)(1) of the FDCA. However, an applicant submitting a full NDA would be required to either conduct or obtain a right of reference to all of the preclinical studies and adequate and well- controlled clinical trials necessary to demonstrate safety and effectiveness.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances. Pediatric exclusivity is another type of non-patent market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#8220;Written Request&#8221; for such a trial.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Federal and State Fraud and Abuse, Data Privacy and Security, and Transparency Laws and Regulations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to FDA restrictions on marketing of pharmaceutical products, federal and state healthcare laws and regulations restrict business practices in the biopharmaceutical industry. These laws may impact, among other things, our current and future business operations, including our clinical research activities, and proposed sales, marketing and education programs and may constrain the business or financial arrangements and relationships with healthcare providers and other parties through which we market, sell and distribute our products for which we obtain marketing approval. These laws include anti-kickback and false claims laws and regulations, data privacy and security, and transparency laws and regulations, including, without limitation, those laws described below.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The U.S. federal Anti-Kickback Statute prohibits any person or entity from, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The U.S. federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been violated. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil FCA or the civil monetary penalties laws.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Federal civil and criminal false claims laws and civil monetary penalties laws, including the federal civil FCA, prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. Actions under these laws may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product and for causing false claims to be submitted because of the companies&#8217; marketing of products for unapproved, and thus non-reimbursable, uses.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal Health Insurance Portability and Accountability Act of 1996 (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HIPAA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) also created new federal criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Also, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HITECH</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;), and their respective implementing regulations, impose specified requirements on certain types of individuals and entities, including covered entities, business associates and their covered subcontractors, relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s security standards directly applicable to &#8220;business associates,&#8221; defined as independent contractors or agents of covered entities, which include certain healthcare providers, healthcare clearinghouses and health plans, that create, receive, maintain or transmit individually identifiable health information in connection with providing a service for or on behalf of a covered entity as well as their covered subcontractors. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in certain circumstances, many of which are not pre-empted by HIPAA, differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, the federal Physician Payments Sunshine Act, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) annually report information related to certain payments or other transfers of value made or distributed to physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other healthcare professionals (such as physician assistants and nurse practitioners) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also be subject to state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, marketing expenditures or drug pricing, and state and local laws</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">that require the registration of pharmaceutical sales representatives.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, certain states require, the registration of manufacturers and wholesale distributors of pharmaceutical products. All of our activities are also potentially subject to federal and state consumer protection and unfair competition laws.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the breadth of these laws and the narrowness of available statutory exceptions and regulatory safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the federal and state healthcare laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including without limitation, civil, criminal and/or administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions, private &#8220;qui tam&#8221; actions brought by individual whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti- fraud and abuse laws, implementation of corporate compliance programs, reporting of payments or transfers of value to healthcare professionals, and additional data privacy and security requirements.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pharmaceutical Coverage, Pricing and Reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we or our collaborators obtain regulatory approval. In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the extent to which third-party payors provide coverage, and establish adequate reimbursement levels for such drug products.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, third-party payors include federal and state healthcare programs, government authorities, private managed care providers, private health insurers and other organizations. Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of medical drug products and medical services, in addition to questioning their safety and efficacy. Such payors may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the FDA-approved drugs for a particular indication. We or our collaborators may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain the FDA approvals. Nonetheless, our product candidates may not be considered medically necessary or cost-effective. Moreover, the process for determining whether a third-party payor will provide coverage for a drug product may be separate from the process for setting the price of a drug product or for establishing the reimbursement rate that such a payor will pay for the drug product. A payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. As a result, one payor&#8217;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we elect to participate in certain governmental programs, we may be required to participate in discount and rebate programs, which may result in prices for our future products that will likely be lower than the prices we might otherwise obtain. For example, drug manufacturers participating under the Medicaid Drug Rebate Program must pay rebates on prescription drugs to state Medicaid programs.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Different pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular drug candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The marketability of any product candidates for which we or our collaborators receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we or our collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare Reform</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. For example, in December 2016, the 21st Century Cures Act (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cures Act</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) was signed into law. The Cures Act, among other things, was intended to modernize the regulation of drugs and devices and to spur innovation. Legislative proposals continue to be discussed in the U.S. Congress as potentially leading to a future &#8220;Cures 2.0&#8221; bill that is expected to have bipartisan support. In addition, in August 2017, the FDA Reauthorization Act was signed into law, which reauthorized the FDA&#8217;s user fee programs and included additional drug product provisions. The legislative reauthorization was completed in 2022, which reauthorized four of the largest FDA user fee programs for next five-year cycle. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we otherwise may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, a primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third-party payors in the United States have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products and services, implementing reductions in Medicare and other healthcare funding and applying new payment methodologies. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Affordable Care Act</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;), was enacted, which substantially changed the way healthcare is financed by both the government and private insurers, and continues to significantly impact the U.S. pharmaceutical industry.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As another example, the 2021 Consolidated Appropriations Act signed into law on December 27, 2020 incorporated extensive healthcare provisions and amendments to existing laws, including a requirement that all manufacturers of drugs and biological products covered under Medicare Part B report the product&#8217;s average sales price to the Department of Health and Human Services (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HHS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) beginning on January 1, 2022, subject to enforcement via civil money penalties.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been executive, judicial and Congressional challenges to certain aspects of the Affordable Care Act since its enactment, and it is possible that there will be additional challenges and amendments to the Affordable Care Act in the future. For example, the Tax Act repealed penalties, for not complying with the Affordable Care Act&#8217;s individual mandate to carry health insurance, commonly referred to as the &#8220;individual mandate.&#8221; Following several years of litigation in the federal courts, in June 2021 the U.S. Supreme Court upheld the Affordable Care Act when it dismissed a legal challenge on procedural grounds to the Affordable Care Act&#8217;s constitutionality following the legislative repeal of the individual mandate. Prior to the Supreme Court&#8217;s decision, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IRA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program. It is possible that the Affordable Care Act will be subject to additional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the Affordable Care Act, our business, or financial condition.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other legislative changes have also been proposed and adopted in the United States since the Affordable Care Act was enacted that affect health care expenditures. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and will remain in effect until 2032, unless additional Congressional action is taken.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There has been heightened governmental scrutiny recently over the manner in which pharmaceutical companies set prices for their marketed products, which has resulted in several Congressional inquiries, presidential executive orders and proposed federal legislation, as well as state efforts, designed to, among other things, bring more transparency to product pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the federal level, in July 2021, President Biden issued a sweeping executive order on promoting competition in the American economy that includes several mandates pertaining to the pharmaceutical and healthcare insurance industries. Among other things, the executive order directs the FDA to work towards implement a system for importing drugs from Canada (following on a Trump administration notice-and-comment rulemaking on Canadian drug importation that was finalized in October 2020). On January 5, 2024, the FDA approved Florida&#8217;s Section 804 Importation Program (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIP</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear how this program will be implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the United States or Canada. Other states have also submitted SIP proposals that are pending review by the FDA. Any such approved importation plans, when implemented, may result in lower drug prices for products covered by those programs. The Biden order includes several directives regarding the Federal Trade Commission&#8217;s oversight of potentially anticompetitive practices within the pharmaceutical industry. In response to President Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. In addition, the IRA, among other things, (1) directs HHS to negotiate the price of certain single-source drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions take effect progressively starting in fiscal year 2023, although the Medicare drug price negotiation program is currently subject to legal challenges. It is currently unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry. In response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the Centers for Medicare &amp; Medicaid Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action. We anticipate that such new laws will result in additional downward pressure on coverage and the price that we receive for any approved product, and could seriously harm our business. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. In addition,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is possible that there will be further legislation or regulation that could harm our business, financial condition, and results of operations. Additionally, health reform initiatives may arise in the future.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Privacy and Security Laws</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States and in addition to federal laws described above, state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. For instance, California recently enacted the California Consumer Privacy Act (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CCPA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;), which went into effect on January 1, 2020. The CCPA creates new individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on entities handling certain personal data of consumers or households. The CCPA, among other things, creates new data privacy obligations for covered companies and provides new privacy rights to California residents, including the right to access and delete their personal data, opt out of certain personal data sharing, and receive detailed information about how their personal data is used. The CCPA also creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. Further, a new privacy law, the California Privacy Rights Act (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CPRA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;), was approved by California voters on November 3, 2020 and went effective on January 1, 2023. The CPRA modifies significantly the CCPA, potentially resulting in further uncertainty and requiring us to incur additional costs and expenses in an effort to comply. Both the CCPA and CPRA could impact our business activities depending on how they are interpreted and exemplifies the vulnerability of our business to not only cyber threats but also the evolving regulatory environment related to personal data and protected health information. Other states have begun enacting their own laws similar to the CCPA, and to date both the Virginia and Colorado legislatures have passed such sweeping measures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also are or will become subject to applicable data protection laws in the jurisdictions in which we are established or in which we sell or market our products or run clinical trials. For example, if we conduct EU-based clinical trials, we will be subject to the General Data Protection Regulation (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GDPR</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) in relation to our collection, control, processing and other use of personal data of data participants within the European Economic Area (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EEA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) (i.e., data relating to an identifiable living individual). The GDPR is directly applicable in each EU and EEA Member State, however, it provides that EU and EEA Member States may introduce further conditions, including limitations which could limit our ability to collect, use and share personal data (including health and medical information), or could cause our compliance costs to increase, ultimately having an adverse impact on our business. The GDPR imposes onerous accountability obligations requiring data controllers and processors to maintain a record of their data processing activities and implement policies as part of its mandated privacy governance framework. It also requires data controllers to be transparent and disclose to data participants (in a concise, intelligible and easily accessible form) how their personal data is to be used, imposes limitations on retention of personal data; defines for the first time pseudonymized (i.e., key-coded) data; introduces mandatory data breach notification requirements; and sets higher standards for data controllers to demonstrate that they have obtained valid consent for certain data processing activities. If in the future we conducted clinical trials in the EU we would be subject to EU rules with respect to cross-border transfers of personal data out of the EU and EEA. We would be subject to the supervision of local data protection authorities in those EU jurisdictions where we conduct our trials or are otherwise subject to the GDPR. Fines for certain breaches of the GDPR are significant: up to the greater of &#8364;20 million or 4% of total global annual turnover. In addition to the foregoing, a breach of the GDPR or other applicable privacy and data protection laws and regulations could result in regulatory investigations, reputational damage, orders to cease/change our use of data, enforcement notices, or potential civil claims including class action type litigation.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the GDPR includes restrictions on cross-border data transfers. Certain aspects of cross-border data transfers under the GDPR are uncertain as the result of legal proceedings in the EU, including a recent decision by the Court of Justice for the EU that invalidated the EU-U.S. Privacy Shield and, to some extent, called into question the efficacy and legality of using standard contract clauses. This may increase the complexity of transferring personal data across borders. The GDPR will increase our responsibility and liability in relation to personal data that we process where such processing is subject to the GDPR, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR, including as implemented by individual countries. Switzerland has adopted similar restrictions under the DPA. Although there are legal mechanisms to allow for the transfer of personal data from the EEA to the United States, they are subject to legal challenges and uncertainty about compliance with EU data protection laws remains. There are similar uncertainties around data transfers to and from the United Kingdom following its departure from the EU and the end of the transition period.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, the vote in the United Kingdom in favor of exiting the EU, referred to as Brexit, has created uncertainty with regard to data protection regulation in the United Kingdom. Specifically, while the Data Protection Act of 2018, which &#8220;implements&#8221; and complements the GDPR achieved Royal Assent on May 23, 2018 and is now effective in the United Kingdom, aspects of data protection in the United Kingdom, such as the transfer of data from the EEA to the United Kingdom, remain uncertain. Beginning in 2021, the United Kingdom became a &#8220;third country&#8221; under the GDPR.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">49</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The U.S. Foreign Corrupt Practices Act</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The U.S. Foreign Corrupt Practices Act of 1977 (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FCPA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. Importantly, United States authorities that enforce the FCPA, including the Department of Justice, deem most healthcare professionals and other employees of foreign hospitals, clinics, research facilities and medical schools in countries with public health care or public education systems to be &#8220;foreign officials&#8221; under the FCPA. We also may be implicated under the FCPA for activities by our partners, collaborators, contract research organizations, vendors or other agents. If and when we interact with foreign healthcare professionals and researchers in testing and marketing our products abroad, we must have policies and procedures in place sufficient to prevent us and agents acting on our behalf from providing any bribe, gift or gratuity, including excessive or lavish meals, travel or entertainment in connection with marketing our products and services or securing required permits and approvals such as those needed to initiate clinical trials in foreign jurisdictions.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Europe/Rest of World Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products. Whether or not we or our potential collaborators obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of an application for a clinical trial authorization (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CTA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) much like the IND prior to the commencement of human clinical trials. In the EU, for example, a CTA must be submitted to each country&#8217;s national health authority and an application made to an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is approved in accordance with a country&#8217;s requirements and a favorable ethics committee opinion has been issued, clinical trial development may proceed.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following the United Kingdom&#8217;s departure from the EU on January 31, 2020, the United Kingdom followed the same regulations as the EU until the end of 2020, during the so-called Transition Period. As of January 1, 2021, the Medicines and Healthcare products Regulatory Agency (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MHRA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) is the United Kingdom&#8217;s standalone medicines and medical devices regulator. As a result of the Northern Ireland protocol, different rules will apply in Northern Ireland than in England, Wales, and Scotland, together, Great Britain (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GB</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;); broadly, Northern Ireland will continue to follow the EU regulatory regime, but its national competent authority will remain the MHRA. The MHRA has recently published detailed guidance for industry and organizations to follow from January 1, 2021 now that the Transition Period is over, which will be updated as the United Kingdom&#8217;s regulatory position on medicinal products evolves over time. The guidance includes clinical trials, marketing authorizations, importing, exporting, and pharmacovigilance and is relevant to any business involved in the research, development, or commercialization of medicines in the United Kingdom.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To obtain regulatory approval of an investigational drug under EU regulatory systems, we must submit a marketing authorization application either under the so-called centralized or national authorization procedures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Centralized procedure</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The centralized procedure provides for the grant of a single marketing authorization by the European Commission following a favorable opinion by the EMA that is valid in all EU member states, as well as Iceland, Liechtenstein and Norway. The centralized procedure is compulsory for medicines produced by specified biotechnological processes, products designated as orphan medicinal products, and products with a new active substance indicated for the treatment of specified diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative disorders or autoimmune diseases, other immune dysfunctions and viral diseases. The centralized procedure is optional for other products that represent a significant therapeutic, scientific or technical innovation, or whose authorization would be in the interest of public health or which contain a new active substance for indications other than those specified to be compulsory.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">National authorization procedures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. There are also two other possible routes to authorize medicinal products in several EU countries, which are available for investigational medicinal products that fall outside the scope of the centralized procedure:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Decentralized procedure. Using the decentralized procedure, an applicant may apply for simultaneous authorizations in more than one EU Member State of medicinal products that have not yet been authorized in any EU Member State and that do not fall within the mandatory scope of the centralized procedure.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mutual recognition procedure. In the mutual recognition procedure, a medicine is first authorized in one EU Member State, in accordance with the national procedures of that country. Following this, further marketing authorizations can be sought from other EU countries in a procedure whereby the countries concerned agree to recognize the validity of the original, national marketing authorization.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The EMA grants orphan drug designation to promote the development of products for the treatment, prevention or diagnosis of life-threatening or chronically debilitating conditions affecting not more than five in 10,000 people in the EU. In addition, orphan drug designation can be granted if the drug is intended for a life threatening or chronically debilitating condition in the EU and without incentives it is unlikely that sales of the drug in the EU would be sufficient to justify the investment required to develop the drug. Orphan drug designation is only available if there is no other satisfactory method approved in the EU of diagnosing, preventing or treating the condition, or if such a method exists, the proposed orphan drug will be of significant benefit to patients. Orphan drug designation provides opportunities for free or reduced-fee protocol assistance, fee reductions for marketing authorization applications and other post-authorization activities and ten years of market exclusivity following drug approval, which can be extended to 12 years if trials are conducted in accordance with an agreed-upon pediatric investigational plan. The exclusivity period may be reduced to six years if the designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we or our potential collaborators fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Facilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our corporate headquarters are located in La Jolla, California, where we lease approximately 2,850 square feet of office and laboratory space pursuant to a lease agreement. We believe that our existing facilities are adequate for the foreseeable future. As we expand, we believe that suitable additional alternative spaces will be available in the future on commercially reasonable terms, if required.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Employees and Human Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had 14 full-time employees, seven of whom were primarily engaged in research and development activities. A total of four employees have an M.D., Ph.D. or Pharm.D. degree. Most of our employees are located in La Jolla, California. None of our employees are represented by a labor union, and we consider our employee relations to be good. We also engage various consultants that are primarily engaged in research and development activities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards and cash-based performance bonus awards.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Corporate Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We originally formed in May 2011 as Graybug, LLC, which was converted into a corporation in February 2015. Our corporate headquarters are located at 505 Coast Boulevard South, Suite 307, La Jolla, CA 92037, and our telephone number is (858) 952-5500. Our corporate website address is https://calcimedica.com/. Information contained on, or accessible through, our website shall not be deemed incorporated into and is not a part of this Annual Report on Form 10-K. Our periodic and current reports are available on our website, free of charge, as soon as reasonably practicable after filing. We may use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation Fair Disclosure promulgated by the SEC. These disclosures will be included under the Investor Relations section of our website at ir.calcimedica.com. We have included our website in this Annual Report on Form 10-K solely as an inactive textual reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 20, 2023, Graybug, now known as CalciMedica, Inc., completed the Merger with Private CalciMedica, in accordance with the terms of the Merger Agreement, whereby Merger Sub merged into Private CalciMedica, with Private CalciMedica surviving as Graybug&#8217;s wholly owned subsidiary. Pursuant to the Merger Agreement, Graybug changed its name to CalciMedica, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">51</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Item 1A</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Risk Factors.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RISK FACTORS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with all of the other information contained in this Annual Report on Form 10-K, including our financial statements and the related notes and the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding to invest in our common stock. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. We cannot assure you that any of the events discussed below will not occur. If any of the following risks actually occur, our business, prospects, operating results and financial condition could suffer materially. In such event, the trading price of our common stock could decline and you might lose all or part of your investment.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Limited Operating History, Financial Position and Capital Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are a clinical-stage biopharmaceutical company with a limited operating history. We have incurred net losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. We have never generated any revenue from product sales and may never be profitable.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical-stage biopharmaceutical company with a limited operating history that may make it difficult to evaluate the success of our business to date and assess our future viability. We commenced operations in October 2006, have no products approved for commercial sale and have never generated any revenue. We have devoted substantially all of our resources to organizing and staffing our company, business planning, establishing and maintaining our intellectual property portfolio, raising capital, developing our product candidates, undertaking research and development activities, and providing general and administrative support for these operations. We are conducting several clinical trials and preclinical studies for our lead product candidate, Auxora, which is currently in a Phase 2b clinical trial in AP and accompanying SIRS, an ongoing Phase 1/2 clinical trial for which the first cohort in pediatric patients with AIPT as a side effect of pediatric acute lymphoblastic leukemia treatment with asparaginase has completed, a Phase 2 trial in COVID-19 pneumonia patients with ARDS which has been completed and may inform the further development of Auxora for patients with AHRF and/or ARDS with a broad range of etiologies, and a Phase 2 clinical trial in AKI which we plan to initiate in the second quarter of 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our other pipeline programs, which include new product candidates, are in preclinical development. We have incurred net losses each year since our inception. As of December 31, 2023, we had an accumulated deficit of $146.1 million and a net loss of $34.4 million for the year ended December 31, 2023. We expect that it will be several years, if ever, before we have a product candidate ready for commercialization. We expect to incur increasing levels of operating losses over the next several years and for the foreseeable future as we advance our product candidates through clinical development. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To become and remain profitable, we must develop and eventually commercialize product candidates with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our product candidates, obtaining marketing approval for these product candidates, finding external manufacturing capacity sufficient to meet commercial demand, marketing and selling those product candidates for which we may obtain marketing approval and satisfying any post-marketing requirements. We may never succeed in these activities and, even if we succeed in commercializing one or more of our product candidates, we may never generate revenue that is significant or large enough to achieve profitability. In addition, as a young business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown challenges. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis and we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. Our failure to become and remain profitable would decrease the value of the company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">52</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will need to obtain substantial additional funding to complete the development and any commercialization of our product candidates. If we are unable to raise this capital when needed, on acceptable terms, or at all, we may be forced to delay, reduce or eliminate the development of our product candidates or other operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since we commenced operations in October 2006, we have primarily financed our operations through private placements of our preferred stock, convertible promissory notes and common stock and through the Merger with Graybug. We have used substantial amounts of cash to fund our operations and expect our expenses to increase substantially for the foreseeable future. The development of drug product candidates is highly capital intensive. As our product candidates enter and advance through preclinical studies and clinical trials, we will need substantial additional funds to expand our clinical, regulatory and quality capabilities. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to marketing, sales, manufacturing and distribution. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had $11.2 million in cash, cash equivalents and short-term investments. Based on our current operating plans, we believe our existing resources, including the funds from a private placement which had closings in January and February of 2024, will be sufficient to fund our operations into the second half of 2025 and will allow us to fund the advancement of Auxora in AP, AIPT, and AKI through clinical milestones in 2024 and the first half of 2025. However, our current cash, cash equivalents and short-term investments will not be sufficient to fund any of our product candidates through regulatory approval, nor will it be sufficient to pursue additional indications for Auxora like AHRF, nor will it be sufficient to fund clinical trials on other product candidates in our portfolio aside from Auxora, and we will need to raise substantial additional capital to complete the development and any commercialization of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have based these estimates on assumptions that may prove to be incorrect or require adjustment as a result of business decisions, and we could utilize our available capital resources sooner than we currently expect. Our future funding requirements will depend on many factors, including, but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the progress, costs and results of our ongoing clinical trials of Auxora and our planned trials for our other product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope, progress, results and costs of discovery research, preclinical development, laboratory testing and clinical trials for our product candidates, including our ongoing clinical trials of Auxora;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs, timing and outcome of regulatory review of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to enter into contract manufacturing arrangements for supply of active pharmaceutical ingredient (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">API</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) and manufacture of drug product for our product candidates and the terms of such arrangements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of any future commercialization activities, including product manufacturing, sales, marketing and distribution, for any of our product candidates for which we may receive marketing approval; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the amount and timing of revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights and defending any intellectual property-related claims;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we acquire or in-license other products, product candidates, technologies or data referencing rights;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such arrangements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the payment or receipt of milestones and receipt of other collaboration-based revenues, if any;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of, and development requirements for, other product candidates that we pursue;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">53</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impacts of the ongoing conflicts between Ukraine and Russia and in the Middle East and potential future bank failures; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of operating as a public company.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because we do not expect to generate revenue from product candidate sales for many years, if at all, we will need to obtain substantial additional funding in connection with our continuing operations and expected increases in expenses. Until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including potentially grants, collaborations, licenses or other similar arrangements. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. The impacts of the ongoing conflicts between Ukraine and Russia and in the Middle East and potential future bank failures on capital markets may affect the availability, amount and type of financing available to us in the future. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could adversely affect our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our proprietary platform or product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through equity offerings, debt financings or other capital sources, including potentially grants, collaborations, licenses or other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants further limiting or restricting our ability to take specific actions, such as limitations on our ability to incur debt, make capital expenditures or declare dividends.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we raise funds through collaborations or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our proprietary product candidate development process or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Attempting to secure additional financing may also divert our management from our day-to-day activities, which may impair or delay our ability to develop our proprietary platform. In addition, demands on our cash resources may change as a result of many factors currently unknown to us including, but not limited to, any unforeseen costs we may incur as a result of preclinical study or clinical trial delays, or disruptions in the manufacturing of our product candidates, due to the ongoing conflicts between Ukraine and Russia and in the Middle East, potential future bank failures or other causes, and we may need to seek additional funds sooner than planned. If we are unable to obtain funding on a timely basis or at all, we may be required to significantly curtail or stop one or more of our research or development programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any acquisitions or strategic collaborations may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities or subject us to other risks.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may evaluate various acquisitions and strategic collaborations, including licensing or acquiring complementary products and technologies, intellectual property rights, technologies or businesses. Any acquisition or strategic partnership may entail numerous risks, including, but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increased operating expenses and cash requirements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the assumption of indebtedness or contingent or unknown liabilities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">assimilation of operations, intellectual property and products or product candidates of an acquired company, including difficulties associated with integrating new personnel;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the diversion of our management&#8217;s attention from our existing product candidates and initiatives in pursuing such an acquisition or a strategic partnership;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">retention of key employees, the loss of key personnel and uncertainties about our ability to maintain key business relationships;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals, and the possibility of disagreements or disputes with such other party; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to generate revenue from acquired products, product candidates, intellectual property rights, technologies, and/or businesses sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, if we engage in acquisitions or strategic partnerships, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses or acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities, and this inability could impair our growth or limit access to technology or drugs that may be important to the development of our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to maintain our listing on Nasdaq, it could become more difficult to sell our common stock in the public market.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock was previously delisted from the Nasdaq Stock Market LLC (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nasdaq</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) and on June 12, 2023, Nasdaq approved our application to relist our common stock and we began trading on June 14, 2023 on the Nasdaq Capital Market. If we are unable to continue to meet Nasdaq&#8217;s listing standards for any reason, our common stock could be delisted from Nasdaq. If delisted, we may seek to list our securities on a different stock exchange or, if one or more broker-dealer market makers comply with applicable requirements, the OTC. Listing on such other market or exchange could reduce the liquidity of our common stock. If our common stock were to trade in the OTC market, an investor would find it more difficult to dispose of, or to obtain accurate quotations for the price of, the common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A delisting from Nasdaq and failure to obtain listing on another market or exchange would subject our common stock to so-called penny stock rules that impose additional sales practice and market-making requirements on broker-dealers who sell or make a market in such securities. Consequently, removal from Nasdaq and failure to obtain listing on another market or exchange could affect the ability or willingness of broker-dealers to sell or make a market in our common stock and the ability of purchasers of our common stock to sell their securities in the secondary market.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to the Discovery, Development and Regulatory Approval of Our Product Candidates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our proprietary CRAC channel inhibition science is based on novel technologies that are unproven and may not result in approvable or marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval and we may not be successful in our efforts to use and expand our science to build a pipeline of product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are seeking to identify and develop a broad pipeline of product candidates using our proprietary CRAC channel inhibitor science to address acute critical illness and chronic inflammatory and immunologic diseases where there are no effective therapies. Our lead product candidate, Auxora, is currently in Phase 2 clinical development and we have only completed one randomized, blinded placebo-controlled trial with Auxora to date. We are not aware of any FDA approved therapeutics utilizing similar technology. Further, the scientific evidence to support the feasibility of developing therapeutic treatments based on our proprietary CRAC channel inhibition science is both preliminary and limited. Additionally, there are no drugs currently approved for the treatment of AP and as a result the FDA has not established the endpoints that will be required for approval in this indication. As a result, we are exposed to a number of unforeseen risks and it is difficult to predict the types of challenges and risks that we may encounter during development of our product candidates.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">55</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Given the novelty of our CRAC channel inhibition science, we intend to work closely with the FDA and comparable foreign regulatory authorities to perform the requisite scientific analyses and evaluation of our methods to obtain regulatory approval for our product candidates; however, due to a lack of relevant experience with the indications that we are pursuing, the regulatory pathway with the FDA and comparable regulatory authorities may be more complex and time-consuming. There can be no assurance as to the length of clinical development, the number of patients that the FDA may require to be enrolled in clinical trials to establish the safety and efficacy of our product candidates, or that the data generated in these clinical trials will be acceptable to the FDA to support marketing approvals. We cannot be certain that our approach will lead to the development of approvable or marketable products, alone or in combination with other therapies. If we are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize our product candidates, we may not be able to generate sufficient revenue to continue our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business is highly dependent on the success of our product candidates, in particular Auxora, and we may fail to develop Auxora successfully or be unable to obtain regulatory approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future success is dependent on our ability to complete clinical trials in a timely and successful manner and obtain marketing approval for and successfully commercialize Auxora, our lead product candidate. We are investing the majority of our efforts and financial resources in the research and development of Auxora for multiple indications. Auxora is currently in several studies: an ongoing Phase 2b clinical trial in AP and accompanying SIRS; an ongoing Phase 1/2 clinical trial, for which the first cohort, in pediatric patients with AIPT as a side effect of pediatric acute lymphoblastic leukemia treatment with asparaginase has completed; a Phase 2 trial, in COVID-19 pneumonia patients with ARDS which has completed and may inform the design of clinical development in AHRS and/or ARDS due to a broad range of etiologies; and a Phase 2 trial in AKI expected to be initiated in the second quarter of 2024. We also have additional preclinical product candidates that will need to progress through IND application enabling studies prior to clinical development. None of our product candidates have advanced into a late-stage or pivotal trials for the indications for which we are pursuing development. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although certain of our employees have prior experience with clinical trials, regulatory approvals and manufacturing of pharmaceutical products, we have not previously completed any late-stage or pivotal clinical trials or submitted an NDA to the FDA or regulatory approval filings to comparable foreign authorities for any product candidate, and Auxora may not be successful in clinical trials and may not receive any regulatory approval. The FDA and other comparable global regulatory authorities can delay, limit or deny approval of a product candidate for many reasons. Any delay in obtaining, or inability to obtain, applicable regulatory approval will delay or harm our ability to successfully commercialize Auxora and harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, because Auxora is our most advanced product candidate, if our clinical trials of Auxora encounter safety, efficacy or manufacturing problems, development delays, regulatory issues or other problems, our development plans for Auxora and our other product candidates in our pipeline could be significantly impaired, which could harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The success of our business, including our ability to finance our company and generate any revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of our product candidates, which may never occur. We have not yet succeeded and may not succeed in demonstrating efficacy and safety for any product candidate in late-stage clinical trials for regulatory approval or in obtaining marketing approval thereafter. Given our early stage of development, it may be several years, if at all, before we have demonstrated the safety and efficacy of a treatment sufficient to warrant approval for commercialization. If we are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize our product candidates, we may not be able to generate sufficient revenue to continue our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical development is a lengthy, expensive and uncertain process. The results of preclinical studies and early clinical trials are not always predictive of future results. Any product candidate that we advance into clinical trials may not achieve favorable results in later clinical trials, if any, or receive marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The research and development of drugs is extremely risky. Only a small percentage of programs that enter the clinical development process ever receive marketing approval. Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidate in humans. Clinical testing is expensive, can take many years to complete and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">56</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">its outcome is uncertain. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The results of preclinical studies and early clinical candidates, even those with the same or similar mechanisms of action, may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed through preclinical studies and initial clinical trials. While we have previously received results, some preliminary, from one randomized, blinded placebo-controlled trial, one small blinded randomized SOC controlled trial, one small randomized open-label placebo-controlled trial, and one small open-label single site trial, we do not know how Auxora will perform in the ongoing Phase 2 clinical trials or in future clinical trials with larger sample sizes. Results of clinical trials with smaller sample sizes, such as our completed SOC-controlled Phase 2a clinical trial of Auxora in 21 patients with AP and accompanying SIRS plus hypoxemia, can be disproportionately influenced by various biases associated with the conduct of small clinical trials, such as the potential failure of the smaller sample size to accurately depict the features of the broader patient population, which limits the ability to generalize the results across a broader community, thus making the clinical trial results less reliable than clinical trials with a larger number of patients. In general, clinical trial failure may result from a multitude of factors including flaws in trial design, dose selection, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits. As such, failure in clinical trials can occur at any stage of testing. A number of companies in the biopharmaceutical industry have suffered setbacks in the advancement of clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, we have not completed any late-stage or pivotal clinical trials for any of our product candidates. We cannot guarantee that any clinical trials will be initiated or conducted as planned or completed on schedule, if at all. We also cannot be sure that submission of an IND or similar application will result in the FDA or other regulatory authority, as applicable, allowing clinical trials to begin in a timely manner, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, even if these trials begin, issues may arise that could cause regulatory authorities to suspend or terminate such clinical trials. A failure of one or more clinical trials can occur at any stage of testing, and our future clinical trials may not be successful. Any of these events could cause delays and interruptions in our clinical trials, which could adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may experience delays in site initiation and patient enrollment, failures to comply with study protocols, delays in the manufacture of our product candidates for clinical testing and other difficulties in starting or completing our clinical trials. Other events that may prevent successful or timely completion of clinical development include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inability to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in reaching a consensus with regulatory agencies, the FDA or foreign regulatory authorities, on trial design or implementation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in reaching agreement on acceptable terms with prospective clinical research organizations (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CROs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;), and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in identifying, recruiting and training suitable clinical investigators;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in obtaining required institutional review board (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IRB</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) or independent ethics committee (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IEC</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) approval at each clinical trial site;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in recruiting suitable patients to participate in our clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">imposition of a clinical hold by regulatory agencies for a number of reasons, including after review of an IND or amendment or equivalent foreign application or amendment, as a result of a new safety finding that presents unreasonable risk to clinical trial participants, or after a negative finding from an inspection of our clinical trial operations or study sites;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure by our CROs, other third parties or us to adhere to the trial protocol or good clinical practice (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GCP</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;);</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">57</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">third-party contractors or clinical investigators becoming debarred or suspended or otherwise penalized by the FDA or other comparable foreign regulatory authorities for violations of applicable regulatory requirements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in the testing, validation, manufacturing and delivery of our product candidates to the treatment sites, including due to supply or manufacturing related delays, being ordered by the FDA or comparable foreign regulatory authorities to temporarily or permanently shut down due to violations of current good manufacturing practices (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cGMP</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;), regulations or other applicable requirements, or infections or cross-contaminations of our product candidates in the manufacturing process;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in having subjects&#8217; complete participation in a study or return for post-treatment follow-up;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes to the clinical trial protocols;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical trial sites or subjects deviating from the trial protocol or dropping out of a study;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the SOC on which a clinical development plan was based, which may require new or additional trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">selection of clinical endpoints that require prolonged periods of observation or analyses of resulting data;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of clinical trials of our product candidates being greater than we anticipate;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical trials of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon development of such product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">transfer of manufacturing processes to larger-scale facilities operated by a contract manufacturing organization, and delays or failure by our such manufacturers or us to make any necessary changes to such manufacturing process;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">occurrence of adverse events (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AEs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) associated with the product candidate that are viewed to outweigh its potential benefits, or occurrence of an AE in a trial of the same class of agents as our product candidate conducted by other companies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we have expanded to and plan to conduct a significant portion of our ongoing CARPO trial in India and, to the extent that we conduct clinical trials in foreign countries, the failure of enrolled subjects in foreign countries to adhere to clinical protocol as a result of differences in SOC, provision of healthcare services or cultural customs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patients in different geographies, including foreign countries, may show differences in clinical outcomes than expected due to differences in underlying disease etiologies or genetic factors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conducting clinical trials in a foreign country may also present additional administrative burdens or delays associated with foreign regulatory schemes including different requirements for clinical trial protocols;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conducting clinical trials in a foreign country may introduce political and economic risks relevant to such foreign countries;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">receiving untimely or unfavorable feedback from applicable regulatory authorities regarding the trial or requests from regulatory authorities to modify the design of a trial;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspensions or terminations by us, the IRBs (or the IECs) of the institutions at which such trials are being conducted, by the data safety monitoring board (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DSMB</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;), for such trial or by regulatory authorities due to a number of factors, including those described above;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">lack of adequate funding; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, disruptions caused by the ongoing conflicts between Ukraine and Russia and in the Middle East may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials. Any inability to successfully complete preclinical and clinical</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">58</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">development could result in additional costs to us or impair our ability to raise capital, generate revenues from product candidate sales and enter into or maintain collaboration arrangements. For example, if enrollment in a clinical trial is slowed, certain of our expenses related to the trial would not decrease and therefore the overall costs to complete the trial would increase. In addition, if we make manufacturing changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring product candidates to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">One of our product candidates is, and potential future product candidates may be, developed for the treatment of a pediatric population, for which safety concerns may be particularly scrutinized by regulatory agencies. Trials involving pediatric populations can be difficult to conduct, can be quite costly and, like other clinical trials, may not yield the anticipated results. In addition, pediatric trials are more dependent on a smaller number of specialized clinical trial sites, which in turn can limit site availability and make the trials more expensive to conduct. In addition, as interest in pediatric indications grows as a result of the RACE Act and other market forces, trial recruitment may become even more difficult due to competition for eligible patients. Moreover, it may be challenging to ensure that pediatric or adolescent patients adhere to clinical trial protocols.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and an investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have expanded to and plan to conduct a significant portion of our ongoing CARPO trial in India, and regulatory authorities may not accept data from such trial or any future clinical trials we conduct outside the United States or the applicable foreign jurisdiction.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have expanded to and plan to conduct a significant portion of our ongoing CARPO trial in India. The acceptance of trial data from clinical trials conducted outside the United States or another jurisdiction by the FDA or comparable non-U.S. regulatory authorities may be subject to certain conditions or may not be accepted at all. In cases where data from non-U.S. clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of non-U.S. data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; and (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many non-U.S. regulatory authorities have similar approval requirements. In addition, such non-U.S. trials would be subject to the applicable local laws of the non-U.S. jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable non-U.S. regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any comparable non-U.S. regulatory authority does not accept such data or believes that additional data is necessary to supplement such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in product candidates that we may develop not receiving approval for commercialization in the applicable jurisdiction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Conducting clinical trials outside the United States also exposes us to additional risks, including risks associated with:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">additional foreign regulatory requirements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">foreign exchange fluctuations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with foreign manufacturing, customs, shipment and storage requirements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the failure of enrolled subjects in foreign countries to adhere to clinical protocol as a result of differences in SOC;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">59</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cultural differences in medical practice and clinical research; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">diminished protection of intellectual property in some countries.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We depend on enrollment of patients in our clinical trials for our product candidates. If we experience delays or difficulties enrolling patients in our clinical trials, our research and development efforts and business, financial condition, results of operations and prospects could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Successful and timely completion of clinical trials will require that we enroll a sufficient number of patients to participate in each study. These trials may be subject to delays for a variety of reasons, including as a result of patient enrollment taking longer than anticipated, subject withdrawal from the trial or AEs. These types of developments could cause us to delay the trial or halt further development. Our clinical trials will compete with other clinical trials that are in the same therapeutic areas as our product candidates, and this competition reduces the number and types of patients available to us, as some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Because the number of qualified clinical investigators and clinical trial sites is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. In addition, there may be limited patient pools from which to draw for clinical studies. In addition to the rarity of some diseases, the eligibility criteria of our clinical studies will further limit the pool of available study participants as we will require that patients have specific characteristics that we can measure or to assure their disease is either severe enough or not too advanced to include them in a clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Participant enrollment in clinical trials depends on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the size and nature of the patient population; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the severity of the disease under investigation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">eligibility criteria for the trial;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the proximity of patients to clinical sites;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the design of the clinical protocol;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to obtain and maintain research subject consents;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of competing clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patients&#8217; perceptions of risk in traveling to clinical sites (for patients in non-hospitalized clinical trial settings); </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of new drugs approved for the indication the clinical trial is investigating; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These factors may make it difficult for us to enroll enough patients to complete our clinical trials in a timely and cost-effective manner. Delays in the completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, some of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preliminary, interim and topline data from our clinical trials may change as more participant data become available, and are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may publicly disclose preliminary, interim or topline data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change as participant enrollment and treatment continues and more data become available. Our data to date is based on a small number of subjects, and as a result, data from additional subjects can have a significant impact on the overall data viewed as a whole. Adverse differences between previous preliminary or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">interim data and future interim or final data could significantly harm our business prospects. We may also announce topline data following the completion of a preclinical study or clinical trial, which may be subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim, topline and preliminary data should be viewed with caution until the final data are available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine to be material or otherwise appropriate information to include in our disclosure. If the interim, top-line, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">SAEs, undesirable side effects or other unexpected properties of our product candidates could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our product candidates or, if discovered following marketing approval, revocation of marketing authorizations or limitations on the use of our product candidates thereby limiting the commercial potential of such product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As we continue developing Auxora and initiate clinical trials of our additional product candidates, SAEs, undesirable side effects, relapse of disease or unexpected characteristics may emerge causing us to abandon these product candidates or limit their development to more narrow uses or subpopulations in which the SAEs or undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk- benefit perspective or in which efficacy is more pronounced or durable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of subjects and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to our therapies. Because of our planned dose escalation design for our clinical trials, undesirable side effects could also result in an expansion in the size of our clinical trials, increasing the expected costs and timeline of our clinical trials. Additionally, results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics, which may stem from our product candidates specifically or may be due to an illness from which the clinical trial subject is suffering.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If unacceptable side effects arise in the development of our product candidates such that there is no longer a positive benefit risk, we, the FDA, the IRBs at the institutions in which our trials are conducted or the DSMB could suspend or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff, and inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we believe our product candidates initially show promise in early clinical trials, side effects of product candidates may only be detectable after they are tested in larger, longer and more extensive clinical trials or, in some cases, after they are made available to patients on a commercial scale after approval. Sometimes, it can be difficult to determine if the serious adverse or unexpected side effects were caused by the product candidate or another factor. If serious adverse or unexpected side effects are identified during development or after approval (including pursuant to any toxicity studies, including reproductive toxicity studies) and are determined to be attributed to our product candidates, we may be required to develop a Risk Evaluation and Mitigation Strategy (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">REMS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a communication plan to health care practitioners, patient education, extensive patient monitoring or distribution systems and processes that are highly controlled, restrictive and more costly than what is typical for the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">61</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">industry. Product-related side effects could also result in potential product liability claims. Any of these occurrences may harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such product candidates, a number of potentially significant negative consequences could result, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may suspend, withdraw or limit approvals of such product candidate, or seek an injunction against its manufacture or distribution;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may require additional warnings on the label, including &#8220;boxed&#8221; warnings, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product candidate;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to change the way a product candidate is administered or conduct additional clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the product candidate may become less competitive;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may decide to remove the product candidate from the marketplace; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could seriously harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may seek special designations by the regulatory authorities to expedite regulatory approvals, but may not be successful in receiving such designations, and even if received, they may not benefit the development and regulatory approval process.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may seek various designations by the regulatory authorities for any product candidates that we develop, such as Fast Track designation or Breakthrough Therapy designation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a product candidate is intended for the treatment of a serious condition and nonclinical or clinical data demonstrate the potential to address unmet medical need for this condition, a product sponsor may apply for Fast Track designation from the FDA. The sponsor of a product candidate with Fast Track designation has opportunities for more frequent interactions with the applicable FDA review team during product development and, once an NDA is submitted, the candidate may be eligible for priority review if the relevant criteria are met. A product candidate with Fast Track designation may also be eligible for rolling review, where the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. We have received Fast Track designation for Auxora for the treatment of AP, and we may receive Fast Track designation for other product candidates in the future; however, we may not experience a faster development process, review or approval compared to conventional FDA approval timelines, and the FDA may still decline to approve Auxora or our other designated product candidates. The FDA may rescind the Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program or for any other reason.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A Breakthrough Therapy is defined by the FDA as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug, may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. The designation also includes all of the Fast Track designation benefits, including eligibility for rolling review of an NDA submission.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Seeking and obtaining these designations is dependent upon results of our clinical program, and whether and when we may have the data from our clinical programs to support an application to obtain any such designation is uncertain. Even if we do receive the designations we may apply for, we may not experience a faster development process, review or approval compared to conventional FDA or similar foreign regulatory authorities&#8217; procedures, as</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">applicable. The FDA or similar foreign regulatory authorities, as applicable, may rescind any granted designations if it believes that the designation is no longer supported by data from our clinical development program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may seek orphan drug designation for our product candidates, and we may be unsuccessful or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Similarly, in the European Union, the European Commission grants orphan drug designation after receiving the opinion of the EMA Committee for Orphan Medicinal Products on an orphan drug designation application. Orphan drug designation is intended to promote the development of drugs that are (1) intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions; (2) either (a) affecting not more than five in 10,000 persons in Europe, or (b) when, without incentives, it is unlikely that sales of the drug in Europe would be sufficient to justify the necessary investment in developing the drug; and (3) for which no satisfactory method of diagnosis, prevention, or treatment has been authorized (or if such a method exists, the product will be of significant benefit to those affected by the condition). In Europe, orphan drug designation entitles a party to a number of incentives, such as protocol assistance and scientific advice specifically for designated orphan medicines, and potential fee reductions depending on the status of the sponsor. We have received orphan drug designation for Auxora for the treatment of AP in the European Union, and we may receive orphan drug designation for other product candidates in the future; however, we may not experience a faster development process, review or approval compared to conventional approval timelines, and the European Commission and EMA may still decline to approve Auxora or our other designated product candidates. The European Commission and EMA may rescind the orphan drug designation if it believes that the designation is no longer supported by data from our clinical development program or for any other reason.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Generally, if a drug with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes the EMA or the FDA from approving another marketing application for the same or similar drug and indication for that time period, except in limited circumstances. The applicable period is seven years in the United States and ten years in Europe. The European exclusivity period can be reduced to six years if, at the end of the fifth year, it is established that the drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable such that market exclusivity is no longer justified.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we obtain orphan drug exclusivity for any of our product candidates that obtain approval, that exclusivity may not effectively protect those product candidates from competition because different therapies can be approved for the same condition. Even after an orphan drug is approved, the FDA or comparable foreign authorities can subsequently approve another drug for the same condition if the relevant authority concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. While we may seek orphan drug designation for applicable indications for our product candidates, we may never receive such designations. Even if we do receive such designations, we may not enjoy the benefits of those designations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">63</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may attempt to secure approval from the FDA or comparable foreign regulatory authorities through the use of accelerated approval pathways. If we are unable to obtain such approval, we may be required to conduct additional clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw accelerated approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may in the future seek an accelerated approval for our one or more of our product candidates. Under the accelerated approval program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that such product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verity and describe the drug&#8217;s clinical benefit. If such post-approval studies fail to confirm the drug&#8217;s clinical benefit, the FDA may withdraw its approval of the drug.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to seeking accelerated approval for any of our product candidates, we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and receive accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit an NDA for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent FDA feedback we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval or receive an expedited regulatory designation (e.g., breakthrough therapy designation) for our product candidates, there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. The FDA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidates would result in a longer time period to commercialization of such product candidates, if any, could increase the cost of development of such candidates and could harm our competitive position in the marketplace.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our product candidates must meet extensive regulatory requirements before they can be commercialized and any regulatory approval may contain limitations or conditions that require substantial additional development expenses or limit our ability to successfully commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The clinical development, manufacturing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution of our product candidates are subject to extensive regulation by the FDA in the United States and by comparable foreign regulatory authorities in foreign markets. In the United States, we are not permitted to market our product candidates until we receive regulatory approval from the FDA. The process of obtaining regulatory approval is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target indications and patient population. Despite the time and expense invested in clinical development of product candidates, regulatory approval is never guaranteed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, we have not submitted an NDA or other marketing authorization application to the FDA or similar drug approval submissions to comparable foreign regulatory authorities for any product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our potential future collaborators must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe and effective for their intended uses. Even if we believe the preclinical or clinical data for our product</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">64</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">candidates are promising, such data may not be sufficient to support approval by the FDA and comparable foreign regulatory authorities. In particular, because we are seeking to identify and develop product candidates using new technologies, there is heightened risk that the FDA or other regulatory authorities may impose additional requirements prior to granting marketing approval, including enhanced safety studies or monitoring. Furthermore, as more product candidates within a particular class of products proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA or comparable foreign regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">such authorities may disagree with the design or implementation of our clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">negative or ambiguous results from our clinical trials or results may not meet the level of statistical significance required by the FDA or comparable foreign regulatory agencies for approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">serious and unexpected product candidate-related side effects may be experienced by participants in our clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">serious and unexpected results from preclinical toxicity studies that will be completed in conjunction with late stage clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the population studied in the clinical trial may not be sufficiently broad or representative to assure safety in the full population for which we seek approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">such authorities may not accept clinical data from trials which are conducted at clinical facilities or in countries where the SOC is potentially different from that of the United States;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">such authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">such authorities may not agree that the data collected from clinical trials of our product candidates are acceptable or sufficient to support the submission of an application for regulatory approval or other submissions or to obtain regulatory approval in the United States or elsewhere and such authorities may impose requirements for additional preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">such authorities may disagree regarding the formulation, labeling and/or the specifications of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approval may be granted only for indications that are significantly more limited than what we apply for and/or with other significant restrictions on distribution and use;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">such authorities may fail to approve any required companion diagnostics to be used with our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">such authorities may find deficiencies in the manufacturing processes or facilities of our or our third-party suppliers or manufacturers with which we or any of our potential future collaborators contract for clinical and commercial supplies; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the approval policies or regulations of such authorities may significantly change in a manner rendering our or any of our potential future collaborators&#8217; clinical data insufficient for approval.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With respect to foreign markets, approval procedures vary among countries and, in addition to the foregoing risks, may involve additional product candidate testing, administrative review periods and agreements with pricing authorities. In addition, events raising questions about the safety of certain marketed pharmaceuticals may result in increased cautiousness by the FDA and comparable foreign regulatory authorities in reviewing new products based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we eventually complete clinical trials and receive approval to commercialize our product candidates, the FDA or comparable foreign regulatory authority may grant approval contingent on the performance of costly additional clinical trials, including Phase 4 clinical trials, and/or the implementation of a REMS. The FDA or the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">65</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">comparable foreign regulatory authority also may approve a product candidate for a more limited indication or patient population than we originally requested or may not approve the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate. Manufacturers of our product candidates and manufacturers&#8217; facilities are also required to comply with cGMP regulations and other similar regulatory requirements, which include requirements related to quality control and quality assurance, as well as the corresponding maintenance of records and documentation. Further, regulatory authorities must approve these manufacturing facilities before they can be used to manufacture our product candidates, if approved, and these facilities are subject to continual review and periodic inspections by the FDA and other comparable foreign regulatory authorities for compliance with cGMP regulations and other similar regulatory requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate and could adversely impact our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will need to obtain FDA approval of any proposed product names, including Auxora, and any failure or delay associated with such approval may adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any name we intend to use for our current or future product candidates will require approval from the FDA regardless of whether we have secured a formal trademark registration from the United States Patent and Trademark Office (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">USPTO</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;). The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. The FDA may also object to a product name if it believes the name inappropriately implies medical claims or contributes to an overstatement of efficacy. If the FDA objects to any of our proposed product names, we may be required to adopt alternative names for our product candidates. If we adopt alternative names, we would lose any goodwill or brand recognition developed for previously used names and marks as well as the benefit of our existing trademark applications for such product candidate and may be required to expend significant additional resources in an effort to identify a suitable product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. We may be unable to build a successful brand identity for a new trademark in a timely manner or at all, which would limit our ability to commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the FDA, EMA or any other comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the drug product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration requirements and continued compliance with cGMPs and GCP requirements, for any clinical trials that we conduct post-approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, any regulatory approvals that we receive for our present or future product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require REMS as a condition of approval of our product candidates, which could entail requirements for long- term patient follow-up, a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Later discovery of previously unknown problems with a product candidate, including AEs of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the marketing or manufacturing of the product candidate, withdrawal of the product candidate from the market, or voluntary or mandatory product candidate recalls;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">66</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fines, untitled or warning letters or holds on clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal by the FDA, the EMA or any other comparable foreign regulatory authority to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product candidate approvals;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product candidate seizure or detention, or refusal to permit the import or export of product candidates; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our or our collaborators&#8217; ability to commercialize our product candidates, and harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA and other regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any NDA, other marketing application and previous responses to inspectional observations made by regulatory authorities. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as our product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The government has also required that companies enter into consent decrees or imposed permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which could adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, or approved or commercialized in a timely manner or at all, which could negatively impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies such as the EMA, following its relocation to Amsterdam and corresponding staff changes, that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a prolonged government shutdown or slowdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not identify or discover other product candidates and may fail to capitalize on our proprietary platform or product candidates that may present a greater commercial opportunity or for which there is a greater likelihood of success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business depends upon our ability to identify, develop and commercialize product candidates. A key element of our strategy is to discover and develop additional product candidates based upon our CRAC channel inhibitor science. We are seeking to do so through our internal research programs, and may also explore strategic collaborations for the discovery of new product candidates. Research programs to identify product candidates require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. In addition, targets for different indications may require changes to our manufacturing processes, which may slow down development or make it impossible to manufacture our product candidates. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many reasons, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the research methodology or technology platform used may not be successful in identifying potential product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">competitors may develop alternatives that render our product candidates obsolete or less attractive;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may choose to cease development if we determine that clinical results do not show promise;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product candidates we develop may nevertheless be covered by third parties&#8217; patents or other exclusive rights;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a product candidate may be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a product candidate may not be accepted as safe and effective by patients, the medical community or third- party payors.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because we have limited resources, we must choose to pursue and fund the development of specific types of treatment, or treatment for a specific indication, and we may forego or delay pursuit of opportunities with certain programs or product candidates or for indications that later prove to have greater commercial potential. Our estimates regarding the potential market for our product candidates could be inaccurate, and if we do not accurately evaluate the commercial potential for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic collaboration, licensing or other arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. Alternatively, we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of these events occur, we may be forced to abandon or delay our development efforts with respect to a particular product candidate or fail to develop a potentially successful product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidate that we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face an inherent risk of product liability exposure related to the testing of our product candidate programs in clinical trials and may face an even greater risk if we commercialize any product candidate that we may develop. If we cannot successfully defend ourselves against claims that any such product candidate programs caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">decreased demand for any product candidate that we may develop;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">loss of revenue;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">68</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">substantial monetary awards to trial participants or patients;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">significant time and costs to defend the related litigation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of clinical trial participants;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increased insurance costs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to commercialize any product candidate that we may develop; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injury to our reputation and significant negative media attention.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any such outcomes could adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Manufacturing, Commercialization and Reliance on Third Parties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely on third parties to conduct and perform most of our research, preclinical studies and clinical trials. If these third parties do not satisfactorily carry out their contractual duties, fail to comply with applicable regulatory requirements, fail to meet projected clinical trial enrollment schedules or fail to meet expected deadlines, our development programs may be delayed or subject to increased costs, each of which may have an adverse effect on our business and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have the ability to conduct most aspects of our preclinical studies or clinical trials in-house. As a result, we are and expect to remain dependent on third parties to conduct or otherwise support our ongoing clinical trials and any future clinical trials of our product candidates. Specifically, CROs, clinical investigators, and consultants play a significant role in the conduct of these trials and the subsequent collection and analysis of data. However, we will not be able to control all aspects of their activities. Nevertheless, we are responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the member states of the EEA, and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, clinical trial investigators and clinical trial sites. If we or any of our CROs or clinical trial sites fail to comply with applicable GCP requirements, the data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. In addition, our clinical trials must be conducted with investigational product produced under cGMP regulations (and similar foreign requirements). Our failure to comply with these regulations may require us to stop and/or repeat clinical trials, which would delay the marketing approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CROs, clinical trial investigators or other third parties on which we rely may not devote adequate time and resources to our development activities or perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, otherwise performs in a substandard manner, or terminates its engagement with us, the timelines for our development programs may be extended or delayed or our development activities may be suspended or terminated. If any of our clinical trial sites terminates for any reason, we may experience the loss of follow-up information on subjects enrolled in such clinical trials unless we are able to transfer those subjects to another qualified clinical trial site, which may be difficult or impossible. In addition, clinical trial investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA or any comparable foreign regulatory authority concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any marketing application we submit by the FDA or any comparable foreign regulatory authority. Any such delay or rejection could prevent us from commercializing our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties on commercially reasonable terms, or at all. Further, under certain circumstances, these third parties may terminate their agreements with us upon as little as 30 days prior written notice. Entering into arrangements with alternative CROs, clinical trial investigators or other third parties involves additional cost and requires management focus and time, in addition to requiring a transition period when a new CRO, clinical trial investigator</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">69</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or other third party begins work. If third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain are compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, any clinical trials such third parties are associated with may be extended, delayed or terminated, and we may not be able to obtain marketing approval for or successfully commercialize our product candidates. As a result, we believe that our financial results and the commercial prospects for our product candidates in the subject indication would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, with respect to investigator-sponsored trials that are being conducting and may be conducted in the future, we do not and would not control the design or conduct of these trials, and it is possible that the FDA will not view these investigator-sponsored trials as providing adequate support for future clinical trials or market approval, whether controlled by us or third parties, for any one or more reasons, including elements of the design or execution of the trials or safety concerns or other trial results. We expect that such arrangements will provide us certain information rights with respect to the investigator-sponsored trials, including access to and the ability to use and reference the data, including for our own regulatory submissions, resulting from the investigator-sponsored trials. However, we would not have control over the timing and reporting of the data from investigator-sponsored trials, nor would we own the data from the investigator-sponsored trials. If we are unable to confirm or replicate the results from the investigator-sponsored trials or if negative results are obtained, we would likely be further delayed or prevented from advancing further clinical development. Further, if investigators or institutions breach their obligations with respect to the clinical development of our product candidates, or if the data proves to be inadequate compared to the firsthand knowledge we might have gained had the investigator-sponsored trials been sponsored and conducted by us, then our ability to design and conduct any future clinical trials ourselves may be adversely affected. The investigators may design clinical trials with clinical endpoints that are more difficult to achieve, or in other ways that increase the risk of negative clinical trial results compared to clinical trials that we may design on our own. Negative results in investigator- sponsored clinical trials could have a material adverse effect on our efforts to obtain regulatory approval for our product candidates and the public perception of our product candidates. Additionally, the FDA may disagree with the sufficiency of our right of reference to the preclinical or clinical data generated by these investigator-sponsored trials, or our interpretation of preclinical, manufacturing or clinical data from these investigator-sponsored trials. If so, the FDA may require us to obtain and submit additional preclinical or clinical data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We contract with third parties for the manufacturing and supply of certain goods and services for our product candidates for use in preclinical studies and clinical trials, which supply may become limited or interrupted or may not be of satisfactory quality and quantity.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have any manufacturing facilities. We produce in our laboratory relatively small quantities of product for evaluation in our research programs. We rely on third parties for the manufacture of most of our product candidates for preclinical testing and all of our product candidates for clinical testing and we will continue to rely on such third parties for commercial manufacture if any of our product candidates are approved. We currently have limited manufacturing arrangements for preclinical and clinical trial materials for each of our product candidates, including Auxora, and one component of the latter is provided by a single source supplier in China, and will continue to be for the intermediate future. In addition, our single source supplier in China and any other foreign suppliers we may utilize in the future may be subject to U.S. legislation, including the proposed BIOSECURE Act, sanctions, trade restrictions and other foreign regulatory requirements, which may limit, delay, prevent or impair our ability to obtain preclinical and clinical trial materials for our product candidates. This reliance increases the risk that we will not have sufficient quantities of our product candidates or products, if approved, or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, all entities involved in the preparation of product candidates for clinical trials or commercial sale, including our existing contract manufacturers for our product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in clinical trials must be manufactured in accordance with cGMP requirements. These regulations govern manufacturing processes and procedures, including record keeping, and the implementation and operation of quality systems to control and assure</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">70</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of an NDA on a timely basis and must adhere to the FDA&#8217;s GLP regulations and cGMP regulations enforced by the FDA through its facilities inspection program. Comparable foreign regulatory authorities may require compliance with similar requirements. Our facilities and quality systems, and those of our third-party contract manufacturers, must pass a pre-approval inspection for compliance with the applicable regulations as a condition of marketing approval of our product candidates. We do not control the manufacturing activities of, and are completely dependent on, our contract manufacturers for compliance with cGMP regulations, although the FDA will hold us responsible for any such non-compliance with respect to our product candidates and any future approved products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event that any of our contracted third parties fails to comply with such requirements or to perform their obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, including due to the ongoing conflicts between Ukraine and Russia and in the Middle East or other geopolitical or macroeconomic, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third-party, which we may not be able to do on commercially reasonable terms, if at all. In particular, any replacement of a third-party contractor could require significant effort and expertise because there may be a limited number of qualified replacements. In some cases, the technical skills or technology required to manufacture a certain aspect of our product candidates may be unique or proprietary to the third-party performing such process and we may have difficulty transferring such skills or technology to another third-party and a feasible alternative may not exist. In addition, certain of our product candidates and our own proprietary methods have never been produced or implemented outside of our company, and we may therefore experience delays to our development programs if we attempt to establish new third-party arrangements for these product candidates or methods. If we are required to or voluntarily change a third-party contractor for any reason, we will be required to verify that the new third party maintains facilities, processes and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our or a third-party&#8217;s failure to execute on our manufacturing and supply requirements, do so on commercially reasonable terms and comply with cGMP could adversely affect our business in a number of ways, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in the event of approval, to initiate or continue clinical trials of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in submitting regulatory applications, or receiving marketing approvals, for our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">loss of the cooperation of future collaborators;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subjecting our or any third-party manufacturing facilities to additional inspections by regulatory authorities; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requirements to cease development to market and commercialize our product candidates, an inability to meet commercial demands for our current or any other future product candidates, if approved. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any approved product candidates may fail to achieve the degree of market acceptance by physicians, patients, hospitals, healthcare payors and others in the medical community necessary for commercial success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of our product candidates receives marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. Our CRAC channel inhibitors are a relatively novel technology, and no CRAC channel inhibitor-based therapy has been approved to date. Public perception may be influenced by third-party claims, such as claims that CRAC channel inhibitors are unsafe, ineffective and, consequently, our approach may not gain the acceptance of the public or the medical community. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">efficacy and potential advantages compared to alternative treatments;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to offer our product candidates for sale at competitive prices;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">convenience and ease of administration compared to alternative treatments;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">71</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of coverage and adequate reimbursement by third-party payors, including government payors, for our products, if approved by applicable regulatory authorities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the strength of marketing and distribution support; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the prevalence and severity of any side effects.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, Auxora is an injectable emulsion drug product that must be administered intravenously over four hours, and this dosing regimen may be inconvenient for physicians or patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenue and we may not become profitable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to successfully commercialize our product candidates due to unfavorable pricing regulations or third-party coverage and reimbursement policies, which could make it difficult for us to sell our product candidates profitably.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with those medications. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of our product candidates. Therefore, coverage and adequate reimbursement are critical to a new product&#8217;s acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new products when more established or lower cost therapeutic alternatives are already available or subsequently become available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, there is no uniform policy among third-party payors for coverage and reimbursement. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting reimbursement policies, but also have their own methods and approval process apart from Medicare coverage and reimbursement determinations. Therefore, one third-party payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third- party payor&#8217;s determination that use of a product is:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a covered benefit under its health plan;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">safe, effective and medically necessary;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">appropriate for the specific patient;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cost-effective; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">neither experimental nor investigational.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time-consuming and costly process, with uncertain results, that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of our product candidates to the payor. There may be significant delays in obtaining such coverage and reimbursement for newly approved product candidates, and coverage may not be available, or may be more limited than the purposes for which the product is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a product will be paid for in all cases or at a rate that covers our costs, including research, development, intellectual property, manufacture, sale and distribution expenses. Interim reimbursement levels for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the product and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost products and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors, by any future laws limiting drug prices and by any future relaxation of laws that presently restrict imports of product from countries where they may be sold at lower prices than in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">72</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reimbursement may not be available for any product that we commercialize and, if coverage and reimbursement are available, the level of reimbursement may not be adequate. Obtaining reimbursement for our product candidates may be particularly difficult because of the higher prices often associated with branded therapeutics and therapeutics administered under the supervision of a physician. Additionally, we expect our future products to potentially be more expensive than other therapeutics due to the personalized and proprietary product selection process of our product candidates, as well as our individualized approach to patient treatment, which requires patient hospitalization, in some cases intensive care unit admission and the potential administration of combination therapies, all of which increases costs and may result in reimbursement payment rates which may not be adequate or may require co-payments that patients find unacceptably high. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved product candidates that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize product candidates and our overall financial condition. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used. Further, from time to time, the Centers for Medicare &amp; Medicaid Services (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CMS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) revises the reimbursement systems used to reimburse health care providers, including the Medicare Physician Fee Schedule and Hospital Outpatient Prospective Payment System, which may result in reduced Medicare payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription medicines, medical devices and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the successful commercialization of new products. Further, the adoption and implementation of any future governmental cost containment or other health reform initiative may result in additional downward pressure on the price that we may receive for any approved product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Outside of the United States, many countries require approval of the sale price of a product before it can be marketed, and the pricing review period only begins after marketing or product licensing approval is granted. In the European Union, governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Member states are free to restrict the range of pharmaceutical products for which their national health insurance systems provide reimbursement, and to control the prices and reimbursement levels of pharmaceutical products for human use. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost- effectiveness of a particular product candidate to currently available therapies. To obtain reimbursement or pricing approval in some of these countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. Other member states allow companies to fix their own prices for medicines but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become very intense. As a result, new products are facing increasingly high barriers to entry. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product candidate in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue, if any, we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if such product candidates obtain marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If any of our product candidates are approved for marketing and commercialization and we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we will be unable to successfully commercialize our product candidates if and when they are approved.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have no sales, marketing or distribution capabilities or experience. To achieve commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization, which would be expensive and time consuming, or outsource these functions to other third</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">parties. In the future, we may choose to build a focused sales and marketing infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates if and when they are approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or the profitability of these product revenue to us are likely to be lower than if we were to market and sell any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are favorable to us. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize such product candidates outside of the United States, which would limit our ability to realize their full market potential.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to market any product candidates outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approvals could result in significant delays, difficulties and costs for us and may require additional preclinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our product candidates in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our ability to realize the full market potential of our product candidates will be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Industry and Business Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to continue to successfully develop or commercialize our product candidates or otherwise implement our business plan.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific, medical, legal, sales and marketing and other personnel. We are highly dependent on our management and scientific personnel. The loss of the services of any of these individuals could impede, delay or prevent the successful development of our product pipeline, completion of our planned clinical trials, commercialization of our product candidates or in-licensing or acquisition of new assets and could negatively impact our ability to successfully implement our business plan. If we lose the services of any of these individuals, we might not be able to find suitable replacements on a timely basis or at all, and our business could be harmed as a result.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conduct substantially all of our operations at our facility in La Jolla, California. This region is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options that vest over time. The value to employees of stock options that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">74</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with certain of our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain &#8220;key person&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level and senior scientific and medical personnel.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dr. Rachel Leheny, our Chief Executive Officer and a member of our Board of Directors, and Eric W. Roberts, our Chief Business Officer and a member of our Board of Directors, also provide services for Valence, an investment fund that is one of our significant stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Chief Executive Officer and member of our Board of Directors, Dr. Leheny, and our Chief Business Officer and member of our Board of Directors, Mr. Roberts, are the co-founders of Valence Life Sciences (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Valence</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;), are employed as managing directors of Valence and beneficially own the shares of the company held by Valence. Entities affiliated with Valence together with Dr. Leheny and Mr. Roberts beneficially owned approximately 14.3% of our common stock as of March 21, 2024. Although we expect that each of Dr. Leheny and Mr. Roberts will devote on average at least 40 hours per week to our company and remain highly active in our management, they will also continue to devote time to Valence. Because Dr. Leheny and Mr. Roberts are not required to work exclusively for us, their attention to other activities could slow our operations, which could adversely affect our business. In addition, although we do not believe Valence currently has any investments that conflict with our interests, in the future Valence may invest in companies that may compete with us for business opportunities or develop products that are competitive with ours. As a result, Dr. Leheny&#8217;s and Mr. Roberts&#8217; interests may not be aligned with the interests of our other stockholders, and they may from time to time be incentivized to take certain actions that benefit their other interests and that our other stockholders do not view as being in their interest as investors in our company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We expect to expand our development, regulatory and operational capabilities and, as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we employed 14 full-time employees, seven of whom were primarily engaged in research and development activities. We also engage various consultants that are primarily engaged in research and development activities. As we advance our research and development programs, we may be required to further increase the number of our employees, particularly in the areas of clinical development, quality, regulatory affairs and, if any of our product candidates receives marketing approval, sales, marketing and distribution. To manage any future growth, we must:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identify, recruit integrate, maintain and motivate additional qualified personnel; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manage our development efforts effectively, including the initiation and conduct of clinical trials for our product candidates, both as a monotherapy and combination therapy; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">improve our operational, financial and management controls, reporting systems and procedures.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our need to effectively execute our growth strategy requires that we:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">discover new product candidates, develop the process and analytical methods for IND-enabling studies and regulatory submissions, complete the required IND-enabling studies for each, and receive approval from the FDA and other regulatory authorities to initiate clinical trials for such product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manage our clinical trials effectively;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identify, recruit, retain, incentivize and integrate additional employees; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintain sufficient quantities of drug product for clinical supply and establish manufacturing capabilities or arrangements with third-party manufacturers for commercial supply, if and when approved; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continue to improve our operational, financial and management controls, reports systems and procedures.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future financial performance and our ability to develop, manufacture and commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert financial and other resources, and a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time, to managing these growth activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">75</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals. Furthermore, the United States is currently experiencing an increasingly competitive labor market and we are uncertain as to the employment environment in the future, or how that environment will impact our workforce, including our ability to hire or retain qualified employees, consultants, contractors or other key personnel to facilitate our growth.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing or commercializing product candidates more quickly or marketing them more successfully than us.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The development and commercialization of new product candidates is highly competitive. We compete in the segments of the pharmaceutical, biotechnology and other related markets that develop therapies for the treatment of acute critical illnesses. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize product candidates that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any product candidates that we may develop or that would render any product candidates that we may develop obsolete or non-competitive. Our competitors also may obtain marketing approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Moreover, with the proliferation of new drugs and therapies into critical illnesses, we expect to face increasingly intense competition as new technologies become available. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. The highly competitive nature of and rapid technological changes in the biotechnology and pharmaceutical industries could render our product candidates or our technology obsolete, less competitive or uneconomical.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The amount and type of clinical data that may be required by regulatory authorities may increase or change. Consequently, the results of our clinical trials for product candidates will likely need to show a risk benefit profile that is competitive with or more favorable than products approved prior to ours in order to obtain marketing approval or, if approved, a product label that is favorable for commercialization. If the risk benefit profile is not competitive with those product candidates or product candidate candidates, we may have developed a product that is not commercially viable, that we are not able to sell profitably or that is unable to achieve favorable pricing or reimbursement. In such circumstances, our future product business, financial condition, results of operations and prospects could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is significant investment across the biotechnology and pharmaceutical industries in developing novel and proprietary therapies for acute critical illnesses. We face substantial and increasing competition on multiple fronts, including from larger companies with access to more resources and capital, as well as more experience in research and development, clinical trials and commercialization. Smaller or earlier-stage companies as well as academic institutions, government agencies and public and private research institutions may also prove to be significant competitors. Additionally, we may face competition in hiring scientific and management personnel, establishing clinical trial sites, recruiting patients to participate in clinical trials and acquiring technologies complementary to, or necessary for our programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize product candidates that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any product candidates that we may develop. Our competitors also may obtain FDA or other regulatory approval for their product candidates more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. The key competitive factors affecting the success of all of our programs are likely to be their efficacy, safety, convenience, price and degree of reimbursement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and subject enrollment for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">76</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The key competitive factors affecting the success of all of our programs are likely to be the possibility of other companies developing drugs that address the same illnesses that we are aiming to address. Some of these markets are limited and significant competition could reduce the number of patients we are able to reach. If we are not successful in developing, commercializing and achieving higher levels of reimbursement than our competitors, we will not be able to compete against them and our business would be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may wish to form collaborations in the future with respect to our product candidates, but may not be able to do so or realize the potential benefits of such transactions, which may cause us to alter or delay our development and commercialization plans.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The development and potential commercialization of our product candidates will require substantial additional capital to fund expenses. We may, in the future, decide to collaborate with other biopharmaceutical companies for the development and potential commercialization of those product candidates, including in territories outside the United States or for certain indications. We will face significant competition in seeking appropriate collaborators. We may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. If and when we collaborate with a third-party for development and commercialization of a product candidate, we can expect to relinquish some or all of the control over the future success of that product candidate to the third-party. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of our technologies, product candidates and market opportunities. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidates. We may also be restricted under any license agreements from entering into agreements on certain terms or at all with potential collaborators.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators and changes to our strategies. As a result, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product candidate, reduce or delay one or more of our other development programs, delay the potential commercialization or reduce the scope of any planned sales or marketing activities for such product candidate, or increase our expenditures and undertake development, manufacturing or commercialization activities at our own expense. If we elect to increase our expenditures to fund development, manufacturing or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates may also require specific components to work effectively and efficiently, and rights to those components may be held by others. We may be unable to in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, which would harm our business. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Failure to comply with applicable data protection laws, regulations, and other obligations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation and mass arbitration demands, and/or adverse publicity and could negatively affect our operating results and business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We and any potential collaborators may be subject to federal, state, and foreign data protection laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations that address privacy and data security. In the United States, numerous federal, state, and local laws and regulations, including federal and state health information privacy laws, state data breach notification laws, personal data protection laws, federal, state, and local consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws that govern the collection, use, disclosure, and protection of health-related and other personal data could apply to our operations or the operations of our collaborators. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under federal HIPAA, as amended by the HITECH. Depending on the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">77</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">facts and circumstances, we could be subject to significant penalties if we obtain, use, or disclose individually identifiable protected information provided by a HIPAA-covered entity or business associate in a manner that is not authorized or permitted by HIPAA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, new privacy rules are being enacted in the United States and globally, and existing ones are being updated and strengthened. For example, the CCPA requires covered companies to provide certain disclosures to California consumers (including business representatives and employees who are California residents) and provide such consumers data protection and privacy rights, including the ability to opt-out of certain sales or sharing of personal data. The CCPA provides for administrative penalties for violations, as well as a private right of action for certain data breaches that result in the loss of personal data. This private right of action may increase the likelihood of, and risks associated with, data breach litigation. The CPRA expanded the CCPA&#8217;s requirements, including by adding a new right for consumers to correct their personal information and establishing a new regulatory agency to implement and enforce the law. Moreover, other states such as Virginia and Colorado, have enacted data protection laws, and similar laws are being considered in several other states, as well as at the federal and local levels. Although these laws may exempt some data processed in the context of clinical trials, these evolving compliance and operational requirements impose significant costs that are likely to increase over time, may require us to modify our data processing practices and policies, divert resources from other initiatives and projects, and could restrict the way products and services involving data are offered, all of which may harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Internationally, virtually every jurisdiction in which we operate has established its own data security and privacy legal framework that may also apply to health-related and other personal data obtained outside of the United States. For example, the EU and the United Kingdom have adopted the General Data Protection Regulation (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EU GDPR</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; and &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">UK GDPR</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">,&#8221; respectively), which imposes strict requirements for processing the personal data of individuals within the EEA and the United Kingdom. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to 20 million euros, 17.5 million pounds sterling under the UK GDPR, or in each case, up to 4% of the annual global revenue of the noncompliant company, whichever is greater, as well as private litigation related to the processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA and UK&#8217;s standard contractual clauses, the United Kingdom&#8217;s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers for relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States. If there is no lawful manner for us to transfer personal data from the EEA or the United Kingdom to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and United Kingdom to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activist groups. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers out of Europe for allegedly violating the GDPR&#8217;s cross-border data transfer limitations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the new India Digital Personal Data Protection Act 2023 (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DPDP</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) is likely to come into force in 2024. Like the GDPR, the DPDP has extra-territorial reach and failure to comply with the DPDP may lead to substantial fines. A significant portion of our ongoing CARPO trial is being conducted in India and we and certain third parties upon which we rely will be subject to the DPDP when it becomes effective.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Failure by us or third parties upon which we rely to comply with U.S. and international data protection laws, regulations, and other obligations could result in significant consequences, including without limitation government enforcement actions (which could include investigations, civil or criminal penalties, audits inspections), private</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">78</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">litigation or mass arbitration demands, additional reporting requirements or oversight, bans on processing personal data, data breach reporting requirements and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our information technology systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, loss or leakage of data, and other disruptions, which could result in a material disruption of our product candidates&#8217; development programs, compromise sensitive information related to our business or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course of business, we collect, store and transmit confidential information (including but not limited to intellectual property, proprietary business information and personal data, including health-related information).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As use of digital technologies has increased, cyber incidents, including deliberate attacks and attempts to gain unauthorized access to computer systems and networks, which could result in material adverse impacts to our business, including the theft of our intellectual property, have increased in frequency and sophistication. Despite our implementation of security measures, given their size and complexity and the increasing amounts of confidential information that they maintain, our information technology systems and those of our third-party CROs and other contractors and consultants are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors, consultants, business partners, sophisticated nation-state and nation-state supported actors, and/or other third parties, or from cyber-attacks by malicious third parties (including the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering attacks, malicious code, credential stuffing attacks, credential harvesting, supply-chain attacks, software bugs, and other means to affect service reliability and threaten the confidentiality, integrity and availability of information), which may compromise our or our third party partners&#8217; system infrastructure or lead to data leakage. For example, we have experienced phishing attacks in the past and we may be a target of phishing attacks or other cyber-attacks in the future. In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, ability to provide our products or services, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications (or those of our third-party partners), or inappropriate disclosure of confidential information, we could incur liability and reputational damage and the further development and commercialization of our product candidates could be delayed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also have outsourced elements of our operations to third parties, and as a result we manage a number of third-party contractors who have access to our confidential information. We rely on these third-party service providers and technologies to operate critical business systems to process sensitive information in a variety of contexts, including, without limitation, cloud-based infrastructure, data center facilities, encryption and authentication technology, employee email, content delivery to customers, and other functions. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we invest in our information security systems, we cannot assure you that our data protection efforts and our investment in information technology will prevent breakdowns, data leakages, breaches in our systems or other cyber incidents that could have an adverse effect upon our reputation, business, financial condition, results or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">79</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">operations and prospects. We may not be successful in preventing or detecting cyber-attacks or mitigating their effects, or we may be perceived as having failed to do so. We take steps to detect and remediate vulnerabilities, but we may not be able to detect and remediate all vulnerabilities because the threats and techniques used to exploit the vulnerability change frequently and are often sophisticated in nature. Therefore, such vulnerabilities could be exploited but may not be detected until after a security incident has occurred. Unremediated high risk or critical vulnerabilities pose material risks to our business. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. For example, if a cyber-attack were to occur and cause interruptions in our operations, it could result in a material disruption of our programs and the development of our product candidates could be delayed. In addition, the loss of clinical trial data for our product candidates could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. Additionally, theft of our intellectual property or proprietary business information could require substantial expenditures to remedy. Furthermore, significant disruptions of our internal information technology systems or security breaches could result in the loss, misappropriation, and/or unauthorized access, use, or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information, and personal data), which could result in financial, legal, business, and reputational harm to us. For example, any such event that leads to unauthorized access, use, or disclosure of personal data, including personal data regarding our clinical trial subjects or employees, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal data, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We or the third parties upon whom we depend may be adversely affected by earthquakes, fires or other natural disasters, terrorism or similar unforeseen events and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our headquarters and main research facility are located in California near major earthquake faults and fire zones. If earthquakes, fires, other natural disasters, terrorism or similar unforeseen events beyond our control prevent us from using all or a significant portion of our headquarters or research facility, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. We do not have a disaster recovery or business continuity plan in place and may incur substantial expenses as a result of the absence or limited nature of our internal or third-party service provider disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business. Furthermore, integral parties in our supply chain are operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen and severe AEs. If such an event were to affect our supply chain, it could have a material adverse effect on our ability to conduct our clinical trials, our development plans and business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had federal and state net operating loss (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOL</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) carryforwards of approximately $278.7 million and $103.5 million, respectively. $74.6 million of our federal NOLs were generated prior to 2018 and will begin to expire in 2026, unless previously utilized, but may be used to offset up to 100% of future taxable income before expiration. Under current law, our federal NOLs generated in tax years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to federal tax law. We also have federal and state research and development credit carryforwards totaling $12.4 million and $2.4 million, respectively. The federal research and development credit carryforwards will begin to expire in 2027, unless previously utilized. The state research and development credits do not expire.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Code</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;), and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50 percentage point change (by value) in its equity ownership over a rolling three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and certain other tax attributes to offset its post-change income or taxes may be limited. This could limit the amount of NOLs or other applicable tax attributes that we can utilize annually to offset future taxable income or tax liabilities. We have not undertaken a Section 382 study, and it is possible that we have previously undergone one or more ownership changes so that our use of net operating losses is subject to limitation. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As a result, if we earn net taxable income, our ability to use our pre-change NOLs to offset U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">80</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, we may be unable to use all or a material portion of our NOL carryforwards and other tax attributes, which could adversely affect our future cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">New income, sales, use, or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations, or ordinances could be interpreted, changed, modified, or applied adversely to us. For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act (the &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Tax Act</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;), the Coronavirus Aid, Relief, and Economic Security Act and the Inflation Reduction Act (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IRA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to such legislation may affect us, and certain aspects of such legislation could be repealed or modified in future legislation. In addition, it is uncertain if and to what extent various states will conform to federal tax laws. Future tax reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our business in ways that we cannot currently predict, and may have a significant adverse effect on our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect our ability to profitably sell any product candidates for which we obtain marketing approval. Among policy makers and payors in the United States and elsewhere, including in the EU, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Affordable Care Act</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;), substantially changed the way healthcare is financed by both the government and private insurers, and continues to significantly impact the U.S. pharmaceutical industry. As another example, the 2021 Consolidated Appropriations Act signed into law on December 27, 2020 incorporated extensive healthcare provisions and amendments to existing laws, including a requirement that all manufacturers of drugs and biological products covered under Medicare Part B report the product&#8217;s average sales price, or ASP, to Department of Health and Human Services (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HHS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) beginning on January 1, 2022, subject to enforcement via civil money penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the Affordable Care Act. By way of example, the Tax Act repealed penalties for not complying with the Affordable Care Act&#8217;s individual mandate to carry health insurance, commonly referred to as the &#8220;individual mandate.&#8221; Following several years of litigation in the federal courts, in June 2021 the U.S. Supreme Court upheld the Affordable Care Act when it dismissed a legal challenge to the Affordable Care Act&#8217;s constitutionality on procedural grounds following that legislative repeal of the individual mandate. It is possible that the Affordable Care Act will be subject to additional challenges in the future. Prior to the Supreme Court&#8217;s decision, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. Further, on August 16, 2022, President Biden signed the IRA into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the Affordable Care Act, our business, or financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted that affect healthcare expenditures. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and, due to legislative amendments to the statute, will remain in effect until 2032, unless additional Congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. In addition, new laws may result in additional reductions in Medicare and other healthcare funding, which may adversely affect customer demand and affordability for our product candidates and, accordingly, the results of our financial operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Also, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which have resulted in several Congressional inquiries, presidential executive orders, and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. Moreover, in July 2021, President Biden issued a sweeping executive order on promoting competition in the American economy that includes several mandates pertaining to the pharmaceutical and healthcare insurance industries. Among other things, the executive order includes several directives regarding the Federal Trade Commission&#8217;s oversight of potentially anticompetitive practices within the pharmaceutical industry. The executive order also directs the FDA to work towards implementing a system for importing drugs from Canada (following on a Trump administration notice-and-comment rulemaking on Canadian drug importation that was finalized in October 2020). On January 5, 2024, the FDA approved Florida&#8217;s Section 804 Importation Program (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIP</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear how this program will be implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the United States or Canada. Other states have also submitted SIP proposals that are pending review by the FDA. Any such approved importation plans, when implemented, may result in lower drug prices for products covered by those programs. In response to President Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. In addition, the IRA, among other things, (1) directs HHS to negotiate the price of certain single-source drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions take effect progressively starting in fiscal year 2023. On August 29,2023 HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs as implemented. It is currently unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry. In response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures. For example, California requires pharmaceutical manufacturers to notify certain purchasers, including health insurers and government health plans at least 60 days before any scheduled increase in the wholesale acquisition cost (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">WAC</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;), of their product if the increase exceeds 16%, and further requires pharmaceutical manufacturers to explain whether a change or improvement in the product necessitates such an increase. Similarly, Vermont requires pharmaceutical manufacturers to disclose price information on certain prescription drugs, and to provide notification to the state if introducing a new drug with a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">82</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">WAC in excess of the Medicare Part D specialty drug threshold. In December 2020, the U.S. Supreme Court also held unanimously that federal law does not preempt the states&#8217; ability to regulate pharmaceutical benefit managers, or PBMs, and other members of the healthcare and pharmaceutical supply chain, an important decision that may lead to further and more aggressive efforts by states in this area.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that these and other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and lower reimbursement and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. The implementation of cost-containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs, once marketing approval is obtained.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the European Union, coverage and reimbursement status of any product candidates for which we obtain regulatory approval are provided for by the national laws of member states. The requirements may differ across the EU member states. Also, at national level, actions have been taken to enact transparency and anti-gift laws (similar to the US Physician Payments Sunshine Act) regarding payments between pharmaceutical companies and health care professionals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to applicable fraud and abuse, transparency, government price reporting, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Healthcare providers and third-party payors will play a primary role in the recommendation and prescription of any future product candidates we may develop and any product candidates for which we obtain marketing approval. Our current and future arrangements with clinical investigators, third-party payors, healthcare provider and customers expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may affect the business or financial arrangements and relationships through which we research, market, sell and distribute our product candidates. The laws that may affect our ability to operate include, but are not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Anti-Kickback Statute, which prohibits any person or entity from, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of an item or service reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The federal Anti-Kickback Statute has also been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, and purchasers, on the other the other hand. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but these exceptions and safe harbors are narrowly drawn. Practices that are alleged to be intended to induce prescribing, purchases or recommendations, or include any payments of more than fair market value, may be subject to scrutiny if they do not qualify for an exception or safe harbor. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">federal civil and criminal false claims laws, such as the civil False Claims Act (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FCA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;), which can be enforced by private citizens through civil qui tam actions, and civil monetary penalty laws prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, false, fictitious or fraudulent claims for payment of federal funds, and knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government. For example, pharmaceutical companies have been prosecuted under the FCA in connection with, among other things their alleged off-label promotion of drugs, engaging in improper consulting arrangements with physicians, concealing price concessions in the pricing information submitted to the government for government price reporting purposes, and providing free product to customers with the expectation that the customers would bill federal health care programs for the product. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. In addition, manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. Moreover, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">83</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HIPAA which, among other things, imposes criminal liability for executing or attempting to execute a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and creates federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HIPAA, as amended by HITECH and their implementing regulations, which imposes privacy, security and breach reporting obligations with respect to individually identifiable health information upon covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses, and their respective business associates and covered subcontractors. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal transparency requirements under the Physician Payments Sunshine Act, created under the Affordable Care Act, which requires, among other things, certain manufacturers of drugs, devices, biologics and medical supplies reimbursed under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report to CMS information related to payments and other transfers of value provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners) and teaching hospitals and physician ownership and investment interests, including such ownership and investment interests held by a physician&#8217;s immediate family members;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, that may impose similar or more prohibitive restrictions, and may apply to items or services reimbursed by any non-governmental third-party payors, including private insurers; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">state and foreign laws that require pharmaceutical companies to implement compliance programs, comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or to track and report gifts, compensation and other remuneration provided to physicians and other health care providers; state and local laws that require the registration of pharmaceutical sales representatives; and state health information privacy laws, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus requiring additional compliance efforts.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have entered into consulting and scientific advisory board arrangements with physicians and other healthcare providers, including some who could influence the use of our product candidates, if approved, and have received equity awards as compensation for services provided to us. Because of the complex and far-reaching nature of these laws, regulatory agencies may view these transactions as prohibited arrangements that must be restructured, or discontinued, or for which we could be subject to other significant penalties. We could be adversely affected if regulatory agencies interpret our financial relationships with providers who may influence the ordering of and use our product candidates, if approved, to be in violation of applicable laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Federal and state enforcement bodies have continued their scrutiny of interactions between healthcare companies and healthcare providers, which has led to significant investigations, prosecutions, convictions and settlements in the healthcare industry. Responding to investigations can be time-and resource-consuming and can divert management&#8217;s attention from the business. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">84</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ensuring that our business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. If our operations are found to be in violation of any of these laws or any other current or future governmental laws and regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could substantially disrupt our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our current or future employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures to comply with the regulations of the FDA and applicable non-U.S. regulators, provide accurate information to the FDA and applicable non-U.S. regulators, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to obtain and maintain sufficient intellectual property protection for Auxora, any future product candidates, and other proprietary technologies we develop, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize Auxora, any future product candidates, and other proprietary technologies if approved, may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success will depend in part on our ability to obtain and maintain a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to Auxora, any future product candidates, and other proprietary technologies we develop. If we are unable to obtain or maintain patent protection with respect to Auxora, any future product candidates, and other proprietary technologies we may develop, our business, financial condition, results of operations, and prospects could be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies is highly uncertain and involves complex legal, scientific, and factual questions and has been the subject of frequent litigation in recent years. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our patent applications may not result in patents being issued which protect Auxora, any future product candidates, and other proprietary technologies we may develop or which effectively prevent others from commercializing competitive technologies and products. Further, no consistent policy regarding the breadth of claims allowed in pharmaceutical patents has emerged to date in the United States or in many jurisdictions outside of the United States. Changes in either the patent laws or interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be enforced in the patents</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">85</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">that may be issued from the applications we currently or may in the future own or license from third parties. Further, if any patents we obtain or license are deemed invalid and unenforceable, our ability to commercialize or license our technology could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our actual or potential future collaborators will be successful in protecting Auxora, any future product candidates, and other proprietary technologies and their uses by obtaining, defending and enforcing patents. These risks and uncertainties include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patent applications may not result in any patents being issued;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patents that may be issued may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable, or may otherwise not provide any competitive advantage;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with, or eliminate our ability to make, use and sell our potential product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">other parties may have designed around our claims or developed technologies that may be related or competitive to our platform, may have filed or may file patent applications and may have received or may receive patents that overlap or conflict with our patent applications, either by claiming the same composition of matter, methods or formulations or by claiming subject matter that could dominate our patent position;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any successful opposition to any patents owned by or licensed to us could deprive us of rights necessary for the practice of our technologies or the successful commercialization of any products or product candidates that we may develop;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">because patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to Auxora, any future product candidates, and other proprietary technologies and their uses;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an interference proceeding can be provoked by a third party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications for any application with an effective filing date before March 16, 2013;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop, and market competing product candidates in those countries.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, or maintain all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection for such output. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable over the prior art. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">86</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in any of our owned patents or pending patent applications, or that we were the first to file for patent protection of such inventions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. If we do not adequately protect our intellectual property and proprietary technology, competitors may be able to use Auxora, any future product candidates, and other proprietary technologies and erode or negate any competitive advantage we may have, which could have a material adverse effect on our financial condition and results of operations. For example:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may be able to make compounds that are similar to Auxora and any future product candidates but that are not covered by the claims of our patents;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we might not have been the first to make the inventions covered by our pending patent applications;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we might not have been the first to file patent applications for these inventions;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any patents that we obtain may not provide us with any competitive advantages;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our competitors might conduct research and development activities in countries where we do not have patent rights or where patent protection is weak and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we cannot ensure that any of our patents, or any of our pending patent applications, if issued, will include claims having a scope sufficient to protect our products;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we cannot ensure that we will be able to successfully commercialize our products on a substantial scale, if approved, before the relevant patents that we own expire; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the patents of others may have an adverse effect on our business.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Others have filed, and in the future are likely to file, patent applications covering products and technologies that are similar, identical or competitive to ours or important to our business. We cannot be certain that any patent application owned by a third party will not have priority over patent applications filed by us, or that we will not be involved in interference, opposition or invalidity proceedings before U.S. or non-U.S. patent offices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot be certain that the claims in our issued patents and pending patent applications covering Auxora or any future product candidates will be considered patentable by the USPTO, courts in the United States, or by patent offices and courts in foreign countries. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property internationally.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The strength of patents in the biotechnology and pharmaceutical fields involves complex legal and scientific questions and can be uncertain. The patent applications that we own may fail to result in issued patents with claims that cover Auxora and any future product candidates in the United States or in foreign countries. Even if such patents do successfully issue, third parties may challenge the ownership, validity, enforceability, or scope thereof, which may result in such patents being narrowed, invalidated, or held unenforceable. Any successful opposition to our patents could deprive us of exclusive rights necessary for the successful commercialization of Auxora and any future product candidates. Furthermore, even if they are unchallenged, our patents may not adequately protect our intellectual property, provide exclusivity for Auxora or any future product candidates or prevent others from designing around our claims. If the breadth or strength of protection provided by the patents we hold with respect to Auxora or any future product candidates is threatened, it could dissuade companies from collaborating with us to develop, or threaten our ability to commercialize, Auxora or any future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For U.S. patent applications in which claims are entitled to a priority date before March 16, 2013, an interference proceeding can be provoked by a third party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our participation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">87</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in an interference proceeding may fail and, even if successful, may result in substantial costs and distract our management and other employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For U.S. patent applications containing a claim not entitled to priority before March 16, 2013, there is greater level of uncertainty in the patent law. In September 2011, the Leahy-Smith America Invents Act, or America Invents Act, was signed into law. The America Invents Act includes a number of significant changes to U.S. patent law, including provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. The USPTO is developing regulations and procedures to govern the administration of the America Invents Act, and many of the substantive changes to patent law associated with the America Invents Act, and in particular, the &#8220;first to file&#8221; provisions, were enacted on March 16, 2013. This will require us to be cognizant going forward of the time from invention to filing of a patent application and be diligent in filing patent applications, but circumstances could prevent us from promptly filing patent applications on our inventions. It remains unclear what impact the America Invents Act will have on the operation of our business. As such, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term of any individual patent depends on applicable law in the country where the patent is granted. In the United States, provided all maintenance fees are timely paid, a patent generally has a term of 20 years from its application filing date or earliest claimed non-provisional filing date. Extensions may be available under certain circumstances, but the life of a patent and, correspondingly, the protection it affords is limited. Even if we obtain patents covering our product candidates, when the terms of all patents covering a product expire, our business may become subject to competition from competitive products, including generic products. Given the amount of time required for the development, testing, and regulatory review and approval of new product candidates, patents protecting such candidates may expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we do not obtain patent term extension for Auxora, our business may be materially harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depending upon the timing, duration, and specifics of any FDA marketing approval of Auxora, or any future product candidate we may develop, one or more of patents issuing from our U.S. patent applications may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. Similar patent term restoration provisions to compensate for commercialization delay caused by regulatory review are also available in certain foreign jurisdictions, such as in Europe under Supplemental Protection Certificate, or SPC. If we encounter delays in our development efforts, including our clinical trials, the period of time during which we could market Auxora and any future product candidates under patent protection would be reduced. Additionally, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents, or otherwise fail to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent process. Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on any issued patents and/or applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees due to foreign patent agencies. While an inadvertent lapse may sometimes be cured by payment of a late</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">88</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market with similar or identical products or technology earlier than should otherwise have been the case, which would have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect Auxora.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As is the case with other biotechnology and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly on obtaining and enforcing patents. Our patent rights may be affected by developments or uncertainty in U.S. or foreign patent statutes, patent case law, USPTO rules and regulations or the rules and regulations of foreign patent offices. Obtaining and enforcing patents in the biotechnology and pharmaceutical industry involve both technological and legal complexity, and is therefore costly, time- consuming and inherently uncertain. In addition, the United States may, at any time, enact changes to U.S. patent law and regulations, including by legislation, by regulatory rule-making, or by judicial precedent, that adversely affect the scope of patent protection available and weaken the rights of patent owners to obtain patents, enforce patent infringement and obtain injunctions and/or damages. For example, the scope of patentable subject matter under 35 U.S.C. 101 has evolved significantly over the past several years as the Court of Appeals for the Federal Circuit and the Supreme Court issued various opinions, and the USPTO modified its guidance for practitioners on multiple occasions. Other countries may likewise enact changes to their patent laws in ways that adversely diminish the scope of patent protection and weaken the rights of patent owners to obtain patents, enforce patent infringement, and obtain injunctions and/or damages.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, the United States and other governments may, at any time, enact changes to law and regulation that create new avenues for challenging the validity of issued patents. For example, the America Invents Act created new administrative post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings that allow third parties to challenge the validity of issued patents. This applies to all of our U.S. patents, even those issued before March 16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patents are of national or regional effect. Filing, prosecuting, and defending patents on Auxora, any future product candidates, and other proprietary technologies we develop in all countries throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights in the same manner and to the same extent as laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement of such patent protection is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The requirements for patentability may differ in certain countries. For example, unlike other countries, China has a heightened requirement for patentability, and specifically requires a detailed description of medical uses of a claimed drug. In India, unlike the United States, there is no link between regulatory approval for a drug and its patent status. In addition to India, certain countries in Europe and developing countries, including China, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In those countries, we may have limited remedies if patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">89</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">revenue opportunities. Accordingly, our efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology or pharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. In Europe, beginning June 1, 2023, European applications and patent may be subjected to the jurisdiction of the Unified Patent Court (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">UPC</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;). Also, European applications will have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the UPC. This will be a significant change in European patent practice. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty. As a single court system can invalidate a European patent, we, where applicable may opt out of the UPC and as such, each European patent would need to be challenged in each individual country. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Geopolitical actions in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of our patent applications or those of any current or future licensors and the maintenance, enforcement or defense of our issued patents or those of any current or future licensors. For example, the United States and foreign government actions related to Russia&#8217;s invasion of Ukraine and the conflict in the Middle East may limit or prevent filing, prosecution and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications, resulting in partial or complete loss of patent rights in Russia. We currently maintain one granted patent in Russia.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents rights, trade secrets, or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. For example, we may have inventorship disputes arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing Auxora or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business, financial condition, results of operations and prospects. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our program may require the use of intellectual property rights held by third parties. The growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights. In addition, Auxora may require specific formulations to work effectively and efficiently and these rights may be held by others. We may be unable to acquire or in-license, on reasonable terms, proprietary rights related to any compositions, formulations, methods of use, processes or other intellectual property rights from third parties that we identify as being necessary for Auxora. Even if we are able to obtain a license to such proprietary rights, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">90</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Where we obtain licenses from or collaborate with third parties, we may not have the right to control the preparation, filing, and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties, or such activities, if controlled by us, may require the input of such third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business, or in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such application. Moreover, if we do obtain necessary licenses, we will likely have obligations under those licenses, including making royalty and milestone payments, and any failure to satisfy those obligations could give our licensor the right to terminate the license. Termination of a necessary license, or expiration of licensed patents or patent applications, could have a material adverse impact on our business. Our business would suffer if any such licenses terminate, if the licensors fail to abide by the terms of the license, if the licensors fail to enforce licensed patents against infringing third parties, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. Furthermore, if any licenses terminate, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties may gain the freedom to seek regulatory approval of, and to market, products identical or similar to ours. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The licensing and acquisition of third-party proprietary rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party proprietary rights that we may consider necessary or attractive in order to commercialize Auxora. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, we may collaborate with U.S. and foreign academic institutions to accelerate our research development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate an exclusive license to any of the institution&#8217;s proprietary rights in technology resulting from the collaboration. Regardless of such option to negotiate a license, we may be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are unable to do so, the institution may offer, on an exclusive basis, their proprietary rights to other parties, potentially blocking our ability to pursue our program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us, either on reasonable terms, or at all. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment, or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights on commercially reasonable terms, our ability to commercialize our products, and our business, financial condition, and prospects for growth, could suffer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Third-party claims alleging intellectual property infringement may prevent or delay our drug discovery and development efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including inter partes review, interference and reexamination proceedings before the USPTO, or oppositions and other comparable proceedings in foreign jurisdictions. The America Invents Act introduced new procedures including inter partes review and post grant review. The implementation of these procedures brings uncertainty to the possibility of challenges to our patents in the future and the outcome of such challenges. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing Auxora. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our activities related to Auxora may give rise to claims of infringement of the patent rights of others.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The pharmaceutical and biotechnology industries have produced a proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. We cannot</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">91</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">assure you that any of our current or future product candidates will not infringe existing or future patents. We may not be aware of patents that have already issued that a third party might assert are infringed by one of our current or future product candidates. Nevertheless, we are not aware of any issued patents that will prevent us from marketing Auxora.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents of which we are currently unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of Auxora. Because patent applications can take many years to issue and may be confidential for 18 months or more after filing, there may be currently pending third-party patent applications which may later result in issued patents that Auxora, any future product candidates, and other proprietary technologies may infringe, or which such third parties claim are infringed by the use of our technologies. Parties making claims against us for infringement or misappropriation of their intellectual property rights may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize Auxora or future product candidates. Defense of these claims, regardless of their merit, could involve substantial expenses and could be a substantial diversion of management and other employee resources from our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we collaborate with third parties in the development of technology in the future, our collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability. Further, collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability. In the future, we may agree to indemnify our commercial collaborators against certain intellectual property infringement claims brought by third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any claims of patent infringement asserted by third parties would be time-consuming and could:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">result in costly litigation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">divert the time and attention of our technical personnel and management;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cause development delays;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prevent us from commercializing Auxora or any future product candidates until the asserted patent expires or is finally held invalid, unenforceable, or not infringed in a court of law;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require us to develop non-infringing technology, which may not be possible on a cost-effective basis;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require us to pay damages to the party whose intellectual property rights we may be found to be infringing, which may include treble damages if we are found to have been willfully infringing such intellectual property;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require us to pay the attorney&#8217;s fees and costs of litigation to the party whose intellectual property rights we may be found to be willfully infringing; and/or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require us to enter into royalty or license agreements, which may not be available on commercially reasonable terms, or at all.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are sued for patent infringement, we would need to demonstrate that our products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do either. Proving invalidity or unenforceability is difficult. For example, in the United States, proving invalidity before federal courts requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and divert management&#8217;s time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, which may not be available, defend an infringement action or challenge the validity or enforceability of the patents in court. Patent litigation is costly and time-consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid or unenforceable, we may incur substantial monetary damages, encounter significant delays in bringing Auxora or any future product candidates to market and be precluded from developing, manufacturing or selling Auxora or any future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not always conduct independent reviews of pending patent applications of and patents issued to third parties. We cannot be certain that any of our patent searches or analyses, including but not limited to the identification</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">92</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of relevant patents, analysis of the scope of relevant patent claims or determination of the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States, Europe and elsewhere that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction, because:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">some patent applications in the United States may be maintained in secrecy until the patents are issued;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patent applications in the United States and elsewhere can be pending for many years before issuance, or unintentionally abandoned patents or applications can be revived;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, Auxora, and any future product candidates or the use of Auxora and any future product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases, and the difficulty in assessing the meaning of patent claims;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patent applications in the United States are typically not published until 18 months after the priority date; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">publications in the scientific literature often lag behind actual discoveries.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, the scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history and can involve other factors such as expert opinion. Our interpretation of the relevance or the scope of claims in a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. Further, we may incorrectly determine that our technologies, products, or product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending patent application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or internationally that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our products or product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our competitors may have filed, and may in the future file, patent applications covering technology similar to ours, and others may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import Auxora and future approved products or impair our competitive position. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of Auxora. Any such patent application may have priority over our patent applications, which could further require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent application on inventions similar to ours, we may have to participate in an interference proceeding declared by the USPTO to determine priority of invention in the United States. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful if, unbeknownst to us, the other party had independently arrived at the same or similar invention prior to our own invention, resulting in a loss of our U.S. patent position with respect to such inventions. Other countries have similar laws that permit secrecy of patent applications and may be entitled to priority over our applications in such jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a third party prevails in a patent infringement lawsuit against us, we may have to stop making and selling the infringing product, pay substantial damages, including treble damages and attorneys&#8217; fees if we are found to be willfully infringing a third party&#8217;s patents, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of Auxora. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">93</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">commercialize Auxora, which could harm our business significantly. Even if we were able to obtain a license, the rights may be nonexclusive, which may give our competitors access to the same intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As is common in the biotechnology and pharmaceutical industries, in addition to our employees, we engage the services of consultants to assist us in the development of Auxora, any future product candidates, and other proprietary technologies. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other pharmaceutical companies including our competitors or potential competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents which could be expensive, time-consuming, and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court, and we may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third parties including competitors may infringe, misappropriate or otherwise violate our patents or patents that may issue to us in the future. To counter infringement or unauthorized use, we may need to or choose to file infringement claims, which can be expensive and time-consuming. We may not be able to prevent, infringement, misappropriation, or other violation of our intellectual property, particularly in countries where the laws may not protect those rights as fully as in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we choose to go to court to stop another party from using the inventions claimed in our patents, that individual or company has the right to ask the court to rule that such patents are invalid, unenforceable, or should not be enforced against that third party for any number of reasons. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements for patentability, including lack of novelty, obviousness, lack of written description, indefiniteness, or non-enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution, i.e., committed inequitable conduct. Third parties may also raise similar claims before the USPTO, even outside the context of litigation. Similar mechanisms for challenging the validity and enforceability of a patent exist in foreign patent offices and courts and may result in the revocation, cancellation, or amendment of any foreign patents we hold now or in the future. The outcome following legal assertions of invalidity and unenforceability is unpredictable, and prior art could render our patents invalid. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product candidate. Such a loss of patent protection would have a material adverse impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development or manufacturing partnerships that would help us bring Auxora and any future product candidates to market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions, or other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">94</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to enforce our patent rights depends on our ability to detect infringement. It may be difficult to detect infringers who do not advertise the components or methods that are used in connection with their products and services. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s or potential competitor&#8217;s product or service. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded if we were to prevail may not be commercially meaningful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our issued patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers, and other advisors, and inventions agreements with employees, consultants, and advisors, to protect our trade secrets and other proprietary information. In addition to contractual measures, we try to protect the confidential nature of our proprietary information using commonly accepted physical and technological security measures. Despite these efforts, we cannot provide any assurances that all such agreements have been duly executed, and these agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. For example, the FDA, as part of its Transparency Initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#8217;s disclosure policies may change in the future, if at all. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, such security measures may not provide adequate protection for our proprietary information, for example, in the case of misappropriation of a trade secret by an employee, consultant, customer, or third party with authorized access. Our security measures may not prevent an employee, consultant or customer from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our products that we consider proprietary. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time-consuming, and the outcome is unpredictable. Even though we use commonly accepted security measures, the criteria for protection of trade secrets can vary among different jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">95</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">less willing or unwilling to protect trade secrets. Moreover, third parties may still obtain this information or may come upon this or similar information independently, and we would have no right to prevent them from using that technology or information to compete with us. Trade secrets will over time be disseminated within the industry through independent development, the publication of journal articles, and the movement of personnel skilled in the art from company to company or academic to industry scientific positions. Though our agreements with third parties typically restrict the ability of our advisors, employees, collaborators, licensors, suppliers, third-party contractors, and consultants to publish data potentially relating to our trade secrets, our agreements may contain certain limited publication rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. Because from time to time we expect to rely on third parties in the development, manufacture, and distribution of our products and provision of our services, we must, at times, share trade secrets with them. Despite employing the contractual and other security precautions described above, the need to share trade secrets increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive position would be harmed. If we do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future trademarks or trade names may be unable to be obtained, challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, domain names, copyrights, or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, any trade name we have proposed to use for products in the United States, such as Auxora must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties, and be acceptable to the FDA. Similar requirements exist in Europe. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. If we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">96</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any future collaborations that we enter into may not be successful. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborations are subject to numerous risks, which may include that:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators have significant discretion in determining the efforts and resources that they will apply to collaborations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not pursue development and commercialization of our products or may elect not to continue or renew development or commercialization programs based on trial or test results, changes in their strategic focus due to the acquisition of competitive products, availability of funding, or other external factors, such as a business combination that diverts resources or creates competing priorities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with Auxora and any future product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a collaborator with marketing, manufacturing, and distribution rights to one or more products may not commit sufficient resources to or otherwise not perform satisfactorily in carrying out these activities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disputes may arise between us and a collaborator that causes the delay or termination of the research, development, or commercialization of our current or future products or that results in costly litigation or arbitration that diverts management attention and resources;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborations may be terminated, and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable current or future products;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a collaborator&#8217;s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business operations may subject us to disputes, claims and lawsuits, which may be costly and time-consuming and could materially and adversely impact our financial position and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may become involved in disputes, claims and lawsuits relating to our business operations. In particular, we may face claims related to the safety of our products, intellectual property matters, employment matters, tax matters, commercial disputes, competition, sales and marketing practices, environmental matters, personal injury, insurance coverage and acquisition or divestiture-related matters. Any dispute, claim or lawsuit may divert management&#8217;s attention away from our business, we may incur significant expenses in addressing or defending any dispute, claim or lawsuit, and we may be required to pay damage awards or settlements or become subject to equitable remedies that could adversely affect our operations and financial results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Litigation related to these disputes may be costly and time-consuming and could materially and adversely impact our financial position and results of operations if resolved against us. In addition, the uncertainty associated with litigation could lead to increased volatility in our stock price.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">97</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We, and the third parties with whom we share our facilities, are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Each of our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Each of our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and waste. We cannot eliminate the risk of contamination or injury from these materials. We could be held liable for any resulting damages in the event of contamination or injury resulting from the use of hazardous materials by us or the third parties with whom we share our facilities, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research and development. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business involves the use of hazardous materials and we and our third-party manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how we do business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our research and development activities and our or any third-party manufacturers&#8217; and suppliers&#8217; activities involve the controlled storage, use and disposal of hazardous materials owned by us. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our manufacturers&#8217; facilities pending their use and disposal.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot eliminate the risk of contamination, which could cause an interruption of our research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by our third-party manufacturers and suppliers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, this may not be the case or and we may not eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent over time. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently carry biological or hazardous waste insurance coverage. Any contamination by such hazardous materials could therefore adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Future changes in financial accounting standards or practices may cause adverse and unexpected revenue fluctuations and adversely affect our reported results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future changes in financial accounting standards may cause adverse, unexpected revenue fluctuations and affect our reported financial position or results of operations. Financial accounting standards in the United States are constantly under review and new pronouncements and varying interpretations of pronouncements have occurred with frequency in the past and are expected to occur again in the future. As a result, we may be required to make changes in our accounting policies. Those changes could affect our financial condition and results of operations or the way in which such financial condition and results of operations are reported. We intend to invest resources to comply with evolving standards, and this investment may result in increased general and administrative expenses and a diversion of management time and attention from business activities to compliance activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">98</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, including the U.S. Foreign Corrupt Practices Act (collectively, &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Trade Laws</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;), prohibit, among other things, companies and their employees, agents, CROs, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect our non-U.S. activities to increase over time. We expect to rely on third parties for research, preclinical studies, and clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other marketing approvals. We can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The market price of our stock has been and may continue to be volatile, and you could lose all or part of your investment.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading price of our common stock has been in the past, and may continue to be, highly volatile and subject to wide fluctuations in response to various factors, many of which we cannot control. Market prices for securities of early-stage pharmaceutical, biotechnology, and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of our common stock to fluctuate include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain regulatory approvals for product candidates, and delays or failures to obtain such approvals;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the failure of any of our product candidates, if approved for marketing and commercialization, to achieve commercial success;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any inability to obtain adequate supply of our product candidates or the inability to do so at acceptable prices;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the entry into, or termination of, key agreements, including key licensing, supply or collaboration agreements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the initiation of material developments in, or conclusion of, disputes or litigation to enforce or defend any of our intellectual property rights or defend against the intellectual property rights of others; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in laws or regulations applicable to our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the results of current, and any future, nonclinical or clinical trials of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcements by commercial partners or competitors of new commercial products, clinical progress (or the lack thereof), significant contracts, commercial relationships, or capital commitments;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to meet or exceed financial and development projections we may provide to the public;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to meet or exceed the financial and development projections of the investment community;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse publicity relating to our markets, including with respect to other products and potential products in such markets;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the introduction of technological innovations or new therapies competing with our potential products;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the loss of key employees;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">99</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">significant lawsuits, including patent or stockholder litigation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our business and stock;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the market valuations of similar companies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">general and industry-specific economic conditions potentially affecting our research and development expenditures;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sales of its common stock by us or our stockholders in the future;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">trading volume of our common stock;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the structure of health care payment systems;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse regulatory decisions;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">trading volume of our common stock; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">period-to-period fluctuations in our financial results.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies or the biotechnology and pharmaceutical sectors, including as a result of disruptions to and volatility in the credit and financial markets in the United States and worldwide from geopolitical and macroeconomic events, including the ongoing Russia-Ukraine and Middle East conflicts and related sanctions, and bank failures. These broad market fluctuations may also adversely affect the trading price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against those companies. Regardless of the merits or the ultimate results of such litigation, if instituted, such litigation could result in substantial costs and diversion of management&#8217;s attention and resources, which could significantly harm our profitability and reputation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial reporting obligations of being a public company in the United States are expensive and time-consuming, and our management needs to devote substantial time to compliance matters.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a publicly traded company, we incur significant additional legal, accounting and other expenses that CalciMedica did not incur as a privately held company, including costs associated with public company reporting requirements. The obligations of being a public company in the United States require significant expenditures and will place significant demands on our management and other personnel, including costs resulting from public company reporting obligations under the Securities Exchange Act of 1934, as amended (the &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exchange Act</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) and the rules and regulations regarding corporate governance practices, including those under the Sarbanes-Oxley Act of 2002 (the &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sarbanes-Oxley Act</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;), the Dodd-Frank Wall Street Reform and Consumer Protection Act (the &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dodd-Frank Act</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) and the listing requirements of the stock exchange on which our securities are listed. These rules require the establishment and maintenance of effective disclosure and financial controls and procedures, internal control over financial reporting and changes in corporate governance practices, among many other complex rules that are often difficult to implement, monitor and maintain compliance with. In addition, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain such insurance. Moreover, despite recent reforms made possible by the JOBS Act, the reporting requirements, rules and regulations will make some activities more time-consuming and costly, particularly after we are no longer an &#8220;emerging growth company&#8221; or a &#8220;small reporting company&#8221;. Our management and other personnel will need to devote a substantial amount of time to ensure that we comply with all of these requirements and to keep pace with new regulations, otherwise we may fall out of compliance and risk becoming subject to litigation, among other potential problems.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The relative lack of public company experience of our management team may put us at a competitive disadvantage.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management team lacks significant public company experience, which could impair our ability to comply with legal and regulatory requirements such as, but not limited to, those imposed by the Sarbanes-Oxley Act. Our senior management does not have significant experience managing a publicly traded company. Such responsibilities include complying with federal securities laws and making required disclosures on a timely basis. Our senior management may be unable to implement programs and policies in an effective and timely manner or that adequately respond to the increased legal, regulatory and reporting requirements associated with being a publicly traded company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">100</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our failure to comply with all applicable requirements could lead to the imposition of fines and penalties, distract our management from attending to the management and growth of our business, result in a loss of investor confidence in our financial reports and have an adverse effect on our business and stock price.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Substantial future sales of shares of our common stock could adversely affect the market price of such shares.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, or there is the perception that these sales could occur, this could adversely affect the market price of such shares and could materially impair our ability to raise capital through equity offerings in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot predict what effect, if any, sales of our shares in the public market or the availability of shares for sale would have on the market price of our common stock. However, future sales of substantial amounts of our common stock in the public market, including shares issued upon exercise of outstanding options or warrants, or the perception that such sales may occur, could adversely affect the market price of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on the beneficial ownership of our common stock as of March 21, 2024, our executive officers, directors and holders of 5% or more of our capital stock and their respective affiliates beneficially owned a significant percentage of our voting stock. As a result, these stockholders, if continuing to act together, will continue to have significant influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, amendment of our organizational documents, any merger, consolidation or sale of all or substantially all of our assets and any other significant corporate transaction. The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could delay or prevent a change of control of our company, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company or our assets and might affect the prevailing market price of our common stock. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors&#8217; perception that conflicts of interest may exist or arise.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are a smaller reporting company. We cannot be certain whether the reduced disclosure requirements applicable to smaller reporting companies will make our common stock less attractive to investors or otherwise limit our ability to raise additional funds.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a &#8220;smaller reporting company&#8221; under applicable securities regulations. A smaller reporting company is a company that, as of the last business day of its most recently completed fiscal quarter, has an aggregate market value of the company&#8217;s voting stock held by non-affiliates, or public float, of less than $250 million, or has annual revenues less than $100 million and either no public float or public float less than $750 million. SEC rules provide that companies with a non-affiliate public float of less than $75 million may only sell shares under a Form S-3 shelf registration statement, during any 12-month period, in an amount less than or equal to one-third of the public float. If we do not meet this public float requirement, any offering by us under a Form S-3 will be limited to raising an aggregate of one-third of our public float in any 12-month period. In addition, a smaller reporting company is able to provide simplified executive compensation disclosures in its filings, is exempt from the provisions of Section 404(b) of the Sarbanes-Oxley Act requiring that an independent registered public accounting firm provide an attestation report on the effectiveness of internal control over financial reporting if its public float is less than $75 million, and has certain other reduced disclosure obligations in their SEC filings, including, among other things, only being required to provide two years of audited financial statements in annual reports. Reduced disclosure in our SEC filings due to our status as a smaller reporting company may make it harder for investors to analyze its results of operations and financial prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">101</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading market for our common stock will be influenced by the research and reports that industry or equity research analysts publish about us and our business. Equity research analysts may elect not to provide research coverage of our common stock after the completion of the merger, and such lack of research coverage may adversely affect the market price of our common stock. In the event we do have equity research analyst coverage, we will not have any control over the analysts, or the content and opinions included in their reports. The price of our common stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of us or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause its stock price or trading volume to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provisions in our amended and restated certificate of incorporation and bylaws may delay or prevent an acquisition or a change in management. These provisions include a classified board of directors, a prohibition on actions by written consent of our stockholders, and the ability of the board of directors to issue preferred stock without stockholder approval. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law (the &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DGCL</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;), which prohibits stockholders owning in excess of 15% of our voting stock from merging or combining with us in certain circumstances. Although we believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our Board of Directors, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove then current management by making it more difficult for stockholders to replace members of our Board of Directors, which is responsible for appointing the members of management.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware does not have jurisdiction, the federal district court for the District of Delaware) is the sole and exclusive forum for any state law claims for (a) any derivative action or proceeding brought on behalf of us; (b) any action asserting a claim of breach of a fiduciary duty owed by, or other wrongdoing by, any of our directors, officers, stockholders, employees or agents to us or our stockholders; (c) any action asserting a claim against us or any of our directors, officers, stockholders, employees or agents arising pursuant to any provision of the DGCL, the certificate of incorporation or the bylaws or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; (d) any action to interpret, apply, enforce or determine the validity of the certificate of incorporation or the bylaws; or (e) any action asserting a claim against us or any of our directors, officers, stockholders, employees or agents governed by the internal affairs doctrine; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, that these choice of forum provisions do not apply to suits brought to enforce a duty or liability created by the Securities Act, the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. The amended and restated bylaws will provide that the federal district courts will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. The choice of forum provision may make it more expensive for stockholders to bring a claim than if the stockholders were permitted to select another jurisdiction and limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. If a court were to find the choice of forum provision contained in the bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our bylaws described above.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">102</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including, weakened demand for our product candidates and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our products or services. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 1B. Unresolved Staff Comments.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1C. Cybersecurity.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk management and strategy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have implemented and maintain information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and our clinical trial data (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information Systems and Data</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depending on the environment and system, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example: an incident response and disaster recovery plan, disaster recovery testing, data encryption for certain data, asset management, system monitoring and multi-factor authentication for certain systems, employee training and cybersecurity insurance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">    </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use a third-party information technology consultant to help identify, assess and manage the Company&#8217;s cybersecurity threats and risks. This consultant reports to and works with our management team, including our Chief Scientific Officer and President and Chief Operating Officer to identify and assess risks from cybersecurity threats by monitoring and evaluating our threat environment using various methods and tools including for example by subscribing to reports and services that identify cybersecurity threats, leveraging certain system monitoring tools, and leveraging tools provided through Microsoft Office 365.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our assessment and management of material risks from cybersecurity threats are taken into account as part of the Company&#8217;s risk management processes.  For example, our senior management works with our information technology consultant to evaluate material risks from cybersecurity threats against our overall business objectives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use third-party service providers, including cybersecurity consultants, to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use third-party service providers to perform a variety of critical functions throughout our business, such as hosting providers, application providers, contract research organizations, contract manufacturing organizations, and other third-party service providers. We review the cybersecurity risks associated with the use of these providers. Depending on the nature of the services provided, the sensitivity of the Information Systems and Data at issue, and the identity of the provider, our vendor management process may involve different levels of assessment and due diligence designed to help identify cybersecurity risks associated with a vendor, as well as the imposition of security related contractual obligations on the vendor.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K, including &#8220;Our information technology systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, loss or leakage of data, and other disruptions, which could result in a material disruption of our product candidates&#8217; development programs, compromise sensitive information related to our business or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.&#8221;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">103</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Governance</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Board of Directors addresses the Company&#8217;s cybersecurity risk management as part of its general oversight function. The Audit Committee of the Board of Directors is responsible for overseeing the Company&#8217;s cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our Chief Scientific Officer, President and Chief Operating Officer, Vice President Finance and General Counsel who also serves as our compliance officer. These members of management have prior work experience in various roles involving managing information security programs and are informed about and monitor the prevention, mitigation, detection and remediation of cybersecurity incidents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Chief Scientific Officer and our President and Chief Operating Officer are responsible for engaging appropriate personnel and companies, helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management strategy, and communicating key priorities to relevant employees and personnel.  Our President and Chief Operating Officer is also responsible for managing budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have adopted a Cybersecurity Incident Response Policy which is designed to escalate certain cybersecurity incidents to a Cybersecurity Incident Management Team consisting of our Chief Scientific Officer, President and Chief Operating Officer, General Counsel and our information technology consultant. Depending on the circumstances, cybersecurity incidents are reported to our Chief Executive Officer and Chief Financial Officer. Senior management works to help the Company mitigate and remediate cybersecurity incidents of which they are notified in addition to notifying the Audit Committee of the Board of Directors, as appropriate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Audit Committee of the Board of Directors receives periodic reports as needed from management concerning the Company&#8217;s significant cybersecurity threats and risk and the processes the Company has implemented to address them.  The Audit Committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 2. Properties.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our corporate headquarters are located in La Jolla, California, where we lease approximately 2,850 square feet of office space. The existing lease will expire on December 31, 2024. We believe that our existing facilities are adequate for our current needs.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii_or_information">&#160;</p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Leg</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">al Proceedings.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may be involved in legal proceedings arising in the ordinary course of our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ultimate outcome of any litigation is uncertain and unfavorable outcomes could have a negative impact on our results of operations and financial condition. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputational harm, and other factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently believe there is no litigation pending that could, individually or in the aggregate, have a material adverse effect on our results of operations or financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 4. Mine Safety Disclosures.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">105</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART II</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_market_for_registrants_common"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Market Information</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock trades on The Nasdaq Capital Market under the symbol &#8220;CALC.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Holders of Record</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 21, 2024, there were approximately 92 holders of record of our common stock. Certain shares of our common stock are held in &#8220;street&#8221; name and thus the actual number of beneficial owners of such shares is not known or included in the foregoing number.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dividend Policy</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain any future earnings for use in the operation of our business and do not intend to declare or pay any cash dividends in the foreseeable future. Any future determination to pay dividends on our capital stock would be at the discretion of our board of directors, subject to applicable laws, and would depend on our financial condition, results of operations, capital requirements, general business conditions and other factors that our board of directors considers relevant.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Proceeds</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 29, 2020, we completed our initial public offering (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IPO</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) and issued and sold 5,625,000 shares of our common stock at an initial offering price of $16.00 per share and on October 22, 2020, we issued and sold an additional 843,750 shares in connection with the full exercise of the underwriters&#8217; option to purchase additional shares. IPO proceeds were approximately $92.0 million, including the full exercise of the option, after deducting underwriting discounts and commissions of approximately $7.2 million and expenses of approximately $4.2 million. The offer and sale of all of the shares in the IPO were registered under the Securities Act pursuant to registration statements on Form S-1 (File Nos. 333-248611 and 333-249030), which were declared effective by the SEC on September 24, 2020. The underwriters of the IPO were SVB Leerink LLC, Piper Sandler &amp; Co., Needham &amp; Company and Wedbush PacGrow.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 20, 2023, Graybug completed its reverse merger with Private CalciMedica and we changed our name to CalciMedica, Inc.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Through December 31, 2023, all of the net proceeds from the IPO have been used, of which, (i) an estimated $39.3 million was used toward development of Graybug&#8217;s product candidates, (ii) $6.3 million was used for transaction costs related to the Merger, (iii) an estimated $12.7 million was used for the development of CalciMedica&#8217;s product candidates and (iv) an estimated $33.7 million was used for working capital and general corporate purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Items (ii) and (iii) in the prior paragraph represent material changes in the planned use of proceeds from our IPO as described in the Prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b)(4) under the Securities Act on September 24, 2020.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_selected_financial_data"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 6. [Reserved]</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">106</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_7_management_discussion"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7. Management&#8217;s D</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">iscussion and Analysis of Financial Condition and Results of Operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our audited consolidated financial statements and the related notes and other financial information included elsewhere in this Annual Report on Form 10-K. In addition to historical financial information, this discussion and other parts of this report contain forward-looking statements that involve risks and uncertainties. You should carefully read the sections entitled &#8220;Special Note Regarding Forward-Looking Statements&#8221; and &#8220;Risk Factors&#8221; to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Our product candidates act upon CRAC channels and would constitute a new class of drugs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a company focused on the discovery and development of CRAC channel inhibitors. Clinical and preclinical data have demonstrated that the inhibition of CRAC channels may have a therapeutic effect based on a dual mechanism involving both anti-inflammatory and tissue cell protective activities. Our work has shown compelling evidence of the involvement of CRAC channels in a broad spectrum of both acute critical illnesses and chronic diseases that have the common thread of inflammation or immunologic activity in their pathogenesis. We intend to leverage our CRAC channel inhibitor platform to develop therapeutics for indications where this dual mechanism of action has the potential for clinical benefit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our lead product candidate is Auxora, a potent and selective IV formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. Multiple Phase 2 clinical trials with Auxora have been conducted: an open-label trial in AP, an investigator led open label trial in AIPT (which we also refer to as CRSPA) in which the first cohort of patients has been completed, a placebo-controlled double-blind trial in severe COVID-19 pneumonia (which we also refer to as CARDEA) and an investigator led open-label trial in COVID-19 pneumonia patients with ARDS. We observed in all of these trials that patients treated with Auxora experienced a reduced time to recovery and a reduction of organ damage. We believe the consistency of the results we observed from these trials in two different acute critical care conditions are mutually supportive and reinforce our plans to further pursue the use of Auxora in several additional acute critical illnesses.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In a Phase 2a trial conducted in the United States in patients with AP and accompanying SIRS along with hypoxemia (low concentration of oxygen in blood), a greater proportion of patients treated with Auxora compared to SOC alone experienced resolution of persistent SIRS (SIRS lasting 48 hours or more) and tolerated solid food at 72 hours, an indicator of disease resolution. The majority of patients with respiratory failure treated with Auxora did not require mechanical ventilation. This resulted in hospital discharge for patients treated with Auxora more than two days earlier than those treated with SOC alone. These findings were published in the peer-reviewed journal </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pancreas </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in 2021. We are currently conducting a blinded placebo-controlled Phase 2b trial in the United States in patients with AP and accompanying SIRS (which we also refer to as &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CARPO</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;). We anticipate topline results from the CARPO trial in the second quarter of 2024 and, assuming positive results, to initiate our Phase 3 trial in 2025.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CRSPA, a Phase 1/2 single arm 24-patient trial, is currently being conducted in the United States in pediatric patients with ALL who have developed pancreatitis as a side-effect of asparaginase or AIPT.  CRSPA is an investigator-sponsored trial being conducted by SJCRH.  AIPT is a particularly severe form of pancreatitis and historical data suggests that over half of the patients will develop pancreatic necrosis or pseudocysts and may not receive further asparaginase treatments for their ALL, potentially impacting their prognosis, and develop long term health complications including chronic pancreatitis. The first cohort of nine patients in this trial has been completed, and, the results were presented at the ASH meeting in December 2023.  Eight of nine patients in the CRSPA study received a full regimen of four daily doses of Auxora and these patients were compared to a matched historical control</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> group of patients who developed AIPT within 30 days of receiving asparaginase in the Total Therapy XVI study (T16) being conducted at SJCRH.  Treatment with Auxora, as compared to the matched historical control group, was shown to have the potential to reduce the severity of AIPT in pediatric patients with ALL. Study results showed that Auxora reduced the average number of days patients spent in the hospital and the need for care in the ICU. Additionally, no patients in the CRSPA study required TPN, compared to over half the patients the matched historical control group, who required approximately several weeks of nutritional support on average. Finally, blinded central</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">107</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reading of pancreatic imaging showed a reduction in the development of significant pancreatic necrosis and the severity of acute pancreatitis in patients treated with Auxora</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compared to the matched historical control group.   This trial has expanded to additional sites and we expect data in 2025.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to AP and AIPT, we are conducting a Phase 2 randomized double-blind, placebo-controlled trial in patients with severe AKI that also have AHRF, which we call KOURAGE.   KOURAGE will evaluate 150 patients with stage 2 and stage 3</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AKI who have AHRF and are receiving oxygen either by non-invasive mechanical ventilation, high flow nasal cannula or IMV. Patients will be stratified by classification of stage of AKI as well as the use of IMV. Patients will receive either a four-hour infusion of Auxora or placebo at 1.25 mL/kg as a first dose, after which they will receive Auxora or placebo at 1.0 mL/kg at hours 24, 48, 72 and 96. The primary endpoint of the trial will be evaluation of patients through day 30 to determine days alive, ventilator-free and dialysis-free.  Secondary endpoints will include a composite of all-cause mortality, decrease in eGFR, and the incidence of dialysis over a period of 90 days, also known as MAKE-90 (Major Adverse Kidney Events at 90 days).  We expect to initiate KOURAGE in the second quarter of 2024 with data expected in 2025.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In our CARDEA trial, a Phase 2 randomized double-blind, placebo-controlled trial in patients with severe COVID-19 pneumonia and receiving supplemental oxygen, but not on mechanical ventilation, we observed that patients treated with Auxora experienced a reduced time to recovery and a 56% relative reduction in mortality at 30 days (p=0.0165) and a 33% relative reduction in mortality at 60 days (p=0.1449) compared to placebo. Time to recovery was seven days for Auxora-treated patients compared to ten days for patients receiving placebo (p=0.098). For additional information regarding p-values, please refer to the section entitled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> &#8212;Auxora, a Selective CRAC Channel Inhibitor&#8212;P-Values and Confidence Intervals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; The results from CARDEA were published in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Critical Care</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in 2022. The CARDEA data, along with data from an ongoing Phase 2 trial testing Auxora in COVID-19 patients with ARDS receiving invasive mechanical ventilation, may also help inform future trials in broader ARDS and AHRF patient populations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Finally, we have compiled additional preclinical data supporting the potential to use CRAC channel inhibition for both chronic and acute inflammatory and immunologic diseases. We have available product candidates and have chosen CM6336 for IND-enabling preclinical testing to determine its pharmacokinetics and safety for  potential oral dosing. We have animal model data suggesting CRAC channel inhibition may be useful in treating chronic pancreatitis, rheumatoid arthritis, ulcerative colitis, allergic asthma, and traumatic brain injury.  We plan to submit an IND to the FDA for CM6336 in 2025 for the treatment of chronic pancreatitis and rheumatoid arthritis.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Calcium is an important regulator of multiple biological functions, and in electrically non-excitable cells CRAC channel activation plays a critical role in the activation of calcium-dependent pathways that modulate various responses, including inflammation and vascular permeability. In immune cells, activation of CRAC channels is a key step in initiating the adaptive immune response and the generation of inflammatory cytokines. In addition, in certain acute critical illnesses, CRAC channels on affected organ tissue cells can become overactivated, resulting in excess calcium entry into cells. This excess calcium can cause cellular injury and necrosis, or activate apoptosis signaling pathways leading to programmed cell death further exacerbating the damage caused by inflammatory response. We have developed novel cell-based assays for compound screening that enabled us to identify and optimize a portfolio of potent and selective small molecule CRAC channel inhibitors, including zegocractin (previously referred to as &#8220;CM4620&#8221;) that is the active ingredient in Auxora, from several different chemical classes. These compounds each have different pharmaceutic and pharmacokinetic properties and comprise our portfolio of CRAC channel inhibitors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 20, 2023, we completed the Merger in accordance with the terms and conditions of the Merger Agreement. At the completion of the Merger, the prior Private CalciMedica equityholders and the prior Graybug equityholders owned 72% and 28%, respectively, of the combined company, in each case, on a fully diluted basis using the treasury stock method and excluding out-of-the-money options and warrants.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Merger was accounted for as a reverse recapitalization, with Private CalciMedica being treated as the acquirer for accounting purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to generate revenue from product sales sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our product candidates. Through December 31, 2023, our operations have been funded primarily by aggregate net proceeds of $150.6 million from the issuance of convertible preferred stock, convertible notes, common stock and the Merger. Since inception we have had significant operating losses. Our net loss was $34.4 million for the twelve months ended December 31, 2023. Included in the net loss for the twelve months ended December 31, 2023 were total operating expenses of $38.1</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">108</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which included $16.2 million of one-time charges comprised of $10.5 million related to the acceleration of vesting of Graybug stock awards at the date of the Merger and $5.7 million of severance charges as a result of the Merger. As of December 31, 2023, we had an accumulated deficit of $146.1 million and $11.2 million in cash, cash equivalents and short-term investments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our accounts payable and accrued expenses. We expect to continue to incur net losses for the foreseeable future, and we expect our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase. In particular, we expect our expenses to increase as we continue our development of, and seek regulatory approvals for, our product candidates, as well as hire additional personnel, pay fees to outside consultants, lawyers and accountants, and incur other increased costs associated with being a public company. In addition, if and when we seek and obtain regulatory approval to commercialize any product candidate, we will also incur increased expenses in connection with commercialization and marketing of any such product. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not had any products approved for sale and, therefore, have not generated any product revenue. We do not expect to generate any revenues from product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our product candidates. If we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. As a result, until such time, if ever, that we can generate substantial product revenue, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including collaborations, licenses or similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed or on favorable terms, if at all. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies, including our research and development activities. If we are unable to raise capital, we will need to delay, reduce or terminate planned activities to reduce costs.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Components of Operating Results</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our research and development expenses have included:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">personnel costs, which include salaries, benefits and stock-based compensation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expenses incurred under agreements with consultants, third-party contract organizations that conduct research and development activities on our behalf;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs related to production of preclinical and clinical materials, including fees paid to contract manufacturers;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">laboratory and vendor expenses related to the execution of preclinical studies and previously planned clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">laboratory supplies and materials used for internal research and development activities;</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Most of our historical research and development expenses have been related to the preclinical and clinical development of Auxora. We have not reported program costs since inception because we have not tracked or recorded our research and development expenses on a program-by-program basis historically due to the fact that these costs do not necessarily correlate to the overall research and development efforts attributable to such programs and these costs can vary significantly from period to period. We have historically used our personnel and infrastructure resources across the breadth of our research and development activities, which are directed toward identifying and developing product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expense all research and development costs in the periods in which they are incurred. Costs for certain research and development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and third-party service providers.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, including investments in conducting clinical trials, manufacturing and otherwise advancing our programs. The process of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">109</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the numerous risks and uncertainties associated with product development, we cannot determine with certainty the duration and completion costs of the current or future preclinical studies and clinical trials or if, when, or to what extent we will generate revenues from the commercialization and sale of our product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or if we even continue to pursue such product development, commercialization or sales. We may never succeed in achieving regulatory approval for our product candidates. The duration, costs and timing of preclinical studies and clinical trials and development of our remaining product candidates, to the extent we continue to pursue such activities, will depend on a variety of factors, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successful completion of preclinical studies and initiation of clinical trials for Auxora, our other current product candidates and any future product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successful enrollment and completion of our clinical trials for Auxora and any clinical trials for future product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">data from our clinical programs that support an acceptable risk-benefit profile of our product candidates in the intended patient populations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acceptance by the FDA, regulatory authorities in Europe, Canada or other regulatory agencies of the IND applications, clinical trial applications and/or other regulatory filings for Auxora, our other current product candidates and any future product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expansion and maintenance of a workforce of experienced scientists and others to continue to develop our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successful application for and receipt of marketing approvals from applicable regulatory authorities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtainment and maintenance of intellectual property protection and regulatory exclusivity for our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">arrangements with third-party manufacturers for, or establishment of, clinical and commercial API and drug product manufacturing capabilities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishment of sales, marketing and distribution capabilities and successful launch of commercial sales of our products, if and when approved, whether alone or in collaboration with others;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acceptance of our products, if and when approved, by patients, the medical community and third-party payors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">effective competition with other therapies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtainment and maintenance of coverage, adequate pricing and adequate reimbursement from third-party payors, including government payors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintenance, enforcement, defense and protection of our rights in our intellectual property portfolio;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">avoidance of infringement, misappropriation or other violations with respect to others&#8217; intellectual property or proprietary rights; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintenance of a continued acceptable safety profile of our products following receipt of any marketing approvals.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may never succeed in achieving regulatory approval for any of our remaining product candidates. We may obtain unexpected results from our preclinical studies and subsequent clinical trials, if any. We may elect to discontinue, delay or modify future clinical trials of some product candidates or focus on others. A change in the outcome of any of these factors could mean a significant change in the costs and timing associated with the development of our current preclinical product candidates. For example, if the FDA, or another regulatory authority, were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development, or if we experience significant delays in execution of or enrollment in any of our preclinical studies or future clinical trials, if any, we could be required to expend significant additional financial resources and time on the completion of preclinical and clinical development.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">110</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development activities account for a significant portion of our operating expenses. We expect our research and development expenses to increase for the foreseeable future as we continue to implement our business strategy, which includes advancing Auxora through clinical development and other product candidates further into clinical development, expanding our research and development efforts, including hiring additional personnel to support our research and development efforts, and seeking regulatory approvals for our product candidates that successfully complete clinical trials. In addition, product candidates in later stages of clinical development generally incur higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect our research and development expenses to increase as our product candidates advance into later stages of clinical development. However, we do not believe that it is possible at this time to accurately project total program-specific expenses through commercialization. There are numerous factors associated with the successful commercialization of any of our product candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our general and administrative expenses consist primarily of personnel costs, depreciation expense and other expenses for outside professional services, including legal related to intellectual property and corporate matters, human resources, audit and accounting services and facility-related fees not otherwise included in research and development expenses. Personnel costs consist of salaries, benefits and equity-based compensation expense for our personnel in executive, finance and accounting, business operations and other administrative functions. We expect our general and administrative expenses to increase over the next several years to support our continued research and development activities, manufacturing activities, increased costs of expanding our operations and operating as a public company. These increases will likely include increases related to the hiring of additional personnel and legal, regulatory and other fees and services associated with maintaining compliance with stock exchange listing rules and SEC requirements, director and officer insurance premiums and investor relations costs associated with being a public company.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income (Expense)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our other income (expense) includes (i) interest and change in fair value of our convertible promissory notes; (ii) changes in the fair value of our warrant liabilities; and (iii) other non-operating expenses.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comparison of the Years Ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following sets forth our results of operations (in thousands):</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.37%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.182%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.182%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.182%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:11.202%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,859</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,350</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,509</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,216</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,843</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,373</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">280%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,075</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,193</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,882</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">168%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(38,075</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(14,193</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(23,882</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">168%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,718</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,369</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(2,651</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(42%)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(34,357</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(7,824</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(26,533</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">339%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">111</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses comprised (in thousands):</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.37%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.182%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.182%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.182%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:11.202%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preclinical studies and clinical trial-related activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,939</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,435</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,504</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chemistry, manufacturing and controls</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,006</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,223</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(217</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(18%)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Personnel</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,071</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,853</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,218</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">282%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Consultants and other costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,843</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">839</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,004</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">120%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,859</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,350</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,509</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses were $15.9 million for the year ended December 31, 2023, compared to $8.4 million for the year ended December 31, 2022.  The increase of $7.5 million was due primarily to an increase in personnel expense of $5.2 million consisting of a one-time charge for the acceleration of vesting of stock options of $1.9 million, a one-time severance charge of $1.6 million as a result of the Merger, and an increase in other personnel costs of $1.7 million including stock-based compensation of $0.5 million. The increase in research and development expenses for the year ended December 31, 2023 also includes an increase in preclinical studies and clinical trial-related activities of $1.5 million related to our Phase 2 clinical trials of Auxora and an increase in consultants and other costs of $1.0 million, offset by a decrease of $0.2 million in chemistry, manufacturing and control activities in regard to our Phase 2 clinical trials of Auxora.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses to support our business activities comprised (in thousands):</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.37%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.182%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.182%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.182%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:11.202%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Personnel costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,872</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,285</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,587</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">638%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Facility costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">595</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">245</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">350</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">143%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional services</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,316</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,585</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">731</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Consultants and other costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,433</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">728</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">705</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total general and administrative expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,216</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,843</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,373</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">280%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses were $22.2 million for the year ended December 31, 2023, compared to $5.8 million for the year ended December 31, 2022.  The increase of $16.4 million was primarily related to an increase in personnel costs of $14.6 million driven by a one-time charge for acceleration of vesting of stock options of $8.6 million, a one-time severance charge of $4.1 million as a result of the Merger and an increase in personnel costs of $1.9 million including stock-based compensation of $1.0 million. Additionally, there was an increase in consultants and other costs of $0.7 million, professional services of $0.7 million, including accounting and legal expenses associated with being a public company, and an increase in facility costs of $0.4 million.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income (Expense)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other income (expense) for the year ended December 31, 2023 was $3.7 million, compared to $6.4 million for the year ended December 31, 2022. The decrease of $2.7 million was due to the fair value adjustments to our warrant liability and convertible promissory notes, which resulted in a $3.2 million and a $6.5 million gain on the fair value adjustments for the warrants and convertible promissory notes for the years ended December 31, 2023 and 2022, respectively. This was partially offset by accrued interest on our convertible promissory notes for the years December 31, 2023 and 2022.  We had $0.7 million of interest income on our short-term investments and nil for the years ended December 31, 2023 and 2022, respectively.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">112</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 we had cash, cash equivalents and short-term investments of $11.2 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As further described below, we closed a private placement transaction on January 23, 2024 and the second closing occurred on February 5, 2024. Gross proceeds from the transaction were $20.4 million with net proceeds of approximately $19.0 million after deducting $1.4 million in commissions and other transaction costs.  Based on our current operating plans, we believe our cash, cash equivalents and short-term investments along with the net proceeds from the private placement will be sufficient to fund our operations into the second half of 2025. In particular, we expect that our cash, cash equivalents and short-term investments will allow us to fund the advancement of Auxora in AP, AIPT and AKI through clinical milestones in 2024 and the first half of 2025. However, our current cash, cash equivalents and short-term investments will not be sufficient to fund any of our product candidates through regulatory approval, nor will it be sufficient to pursue additional indications for Auxora like AHRF, nor will it be sufficient to fund clinical work on other product candidates in our portfolio aside from Auxora, and we will need to raise substantial additional capital to complete the development and commercialization of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to maintain sufficient financial resources, our business, financial condition and results of operations will be materially and adversely affected. To fund our operations in both the near term and long term (beyond 18 months), we will need to raise additional capital to develop our product candidates and implement our operating plans. There can be no assurance that we will be able to obtain the needed financing on acceptable terms or at all. Additionally, equity or debt financings may have a dilutive effect on the holdings of our existing stockholders.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the progress, costs and results of our ongoing clinical trials of Auxora and our planned trials for our other product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope, progress, results and costs of discovery research, preclinical development, laboratory testing and clinical trials for our product candidates, including our ongoing clinical trials of Auxora;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of, and development requirements for, other product candidates that we pursue;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs, timing and outcome of regulatory review of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to enter into contract manufacturing arrangements for supply of API and manufacture of drug product for our product candidates and the terms of such arrangements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such arrangements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the payment or receipt of milestones and receipt of other collaboration-based revenues, if any;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of any future commercialization activities, including product manufacturing, sales, marketing and distribution, for any of our product candidates for which we may receive marketing approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the amount and timing of revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights and defending any intellectual property-related claims;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we acquire or in-license other products, product candidates, technologies or data referencing rights; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to receive additional non-dilutive funding, including grants from organizations and foundations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impacts of the ongoing conflicts between Ukraine and Russia and in the Middle East; and </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">113</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of operating as a public company.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since we commenced operations in October 2006, we have primarily financed our operations through private placements of our preferred stock, convertible promissory notes and common stock. We have used substantial amounts of cash to fund our operations and expect our expenses to increase substantially for the foreseeable future. The development of drug product candidates is highly capital intensive. As our product candidates enter and advance through preclinical studies and clinical trials, we will need substantial additional funds to expand our clinical, regulatory and quality capabilities. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to marketing, sales, manufacturing and distribution. Furthermore, following the closing of the merger, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts. The global credit and financial markets have experienced extreme volatility, including in liquidity and credit availability, declines in consumer confidence, declines in economic growth, and uncertainty about economic stability. There can be no assurance that deterioration in credit and financial markets and confidence in economic conditions will not occur. If equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult to obtain, more costly and/or more dilutive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to finance our longer-term expected future cash requirements and obligations through a combination of existing cash, cash equivalents and short-term investments and equity offerings, debt financings or other capital sources, including collaborations, licenses or similar arrangements. To finance our operations beyond that point we will need to raise additional capital, which cannot be assured. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. However, we may be unable to raise additional funds or enter into such other arrangement when needed or on favorable terms, if at all. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies, including our research and development activities. If we are unable to raise capital, we will need to delay, reduce or terminate planned activities to reduce costs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2023, we filed a shelf registration statement on Form S-3 (the &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Shelf Registration Statement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;), which contains two prospectuses, a base prospectus and an at the market offering prospectus that covers the offering, issuance and sale of up to $4.7 million of common stock pursuant to an at-the-market offering agreement (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ATM Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) with H.C Wainwright &amp; Co., LLC, acting as sales agent (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ATM Facility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;). The Shelf Registration Statement permits the offering, issuance and sale of common stock, preferred stock, debt securities and warrants having an aggregate offering price of up to $100.0 million in one or more offerings and in any combination of the foregoing. As of December 31, 2023, $99.7 million remains available for sale under the Shelf Registration Statement. As of December 31, 2023, we sold 92,572 shares of common stock for net proceeds of $246,000 which includes $11,000 of commissions paid under the ATM Facility and $4.4 million remains available for sale under the ATM Facility.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2024, we entered into a Securities Purchase Agreement (the &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Purchase Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) with certain accredited investors, in which we sold the following securities to the accredited investors in a private placement transaction (i) an aggregate of 4,985,610 shares (the &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Shares</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) of our common stock; (ii) to certain investors, in lieu of Shares, pre-funded warrants (the &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-Funded Warrants</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) to purchase an aggregate of 306,506 shares of our common stock; (iii) Tranche A Common Warrants (the &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Tranche A Common Warrants</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) to purchase an aggregate of up to 2,646,058 shares of our common stock (or Pre-Funded Warrants in lieu thereof and, in such case, shares of our common stock issuable upon exercise of such Pre-Funded Warrants); and (iv) Tranche B Common Warrants (the &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Tranche B Common Warrants</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; and together with the Tranche A Common Warrants, the &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common Warrants</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) to purchase an aggregate of up to 2,646,058 shares of our common stock (or Pre-Funded Warrants in lieu thereof and, in such case, shares of our common stock issuable upon exercise of such Pre-Funded Warrants). The purchase price per Share and accompanying Common Warrants was $3.827 (or $4.3915 for directors, employees or consultants</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">114</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">participating in the private placement) (or $3.8269 per Pre-Funded Warrant and accompanying Common Warrants, which represented the price of $3.827 per Share and accompanying Common Warrants minus the $0.0001 per share exercise price of each such Pre-Funded Warrant).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The initial closing of the Private Placement occurred on January 23, 2024 and the second closing occurred on February 5, 2024. Gross proceeds from the transaction were $20.4 million with net proceeds of approximately $19.0 million after deducting $1.4 million in commissions and other transaction costs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations have been funded primarily by aggregate net proceeds of $150.6 million from the issuance of convertible preferred stock, convertible notes, common stock and the Merger. Since inception, we have had significant operating losses. Our net loss was $34.4 million and consisted of total operating expenses of $38.1 million, which included $16.2 million of one-time charges comprised of $10.5 million in charges related to the acceleration of vesting of the Graybug stock awards at the date of the Merger and $5.7 million of severance charges as a result of the Merger, and a net loss of $7.8 million consisting of $14.2 million of operating expenses for the twelve months ended December 31, 2023 and 2022, respectively. As of December 31, 2023, we had an accumulated deficit of $146.1 million and $11.2 million in cash, cash equivalents and short-term investments. During the twelve months ended December 31, 2023, cash used in operations was $25.7 million, primarily due to cash outlays associated with the Merger. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our cash flows for the periods indicated (in thousands):</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash (used in) provided by:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(25,730</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(11,757</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,884</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(4</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,900</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,476</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net increase (decrease) in cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,054</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3,285</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Cash Used in Operating Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash used in operating activities of $25.7 million during the year ended December 31, 2023 was attributable to our net loss of $34.4 million and a net change in our operating assets and liabilities of $0.3 million offset by non-cash items of $8.9 million. Non-cash items consisted primarily of $12.0 million of stock-based compensation, which includes $10.5 million in one-time charges related to the acceleration of vesting of the Graybug stock awards at the date of the Merger and $0.1 million in accrued interest on our convertible promissory notes offset by $1.1 million and $2.0 million change in the fair value of our warrant liability and convertible promissory notes, respectively based on the value the warrant holder and promissory note holder received in common stock and $0.1 million of accretion on the discounts associated with our short-term investments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash used in operating activities of $11.8 million during the year ended December 31, 2022 was attributable to our net loss of $7.8 million and non-cash items of $4.5 million, offset by a net change in our operating assets and liabilities of $0.6 million. Non-cash items consisted of a $3.8 million and $2.7 million change in the fair value that decreased our warrant liability and convertible promissory notes, respectively, offset by $1.8 million of stock-based compensation and $0.1 million of non-cash interest.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Cash Provided by (Used in) Investing Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Investing activities of $8.9 million for the year ended December 31, 2023 consisted of the maturing of short-term investments of $15.1 million, offset by the purchase of short-term investments of $6.1 million and purchases of property and equipment of $0.1 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Investing activities for the year ended December 31, 2022 consisted of purchases of property and equipment.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">115</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Cash Provided by Financing Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash provided by financing activities for the year ended December 31, 2023 was $20.9 million comprised of net cash acquired as a result of the Merger of $14.9 million, the sale and issuance of common stock of $10.3 million in the private placement and $0.2 million in the ATM Facility, offset by transaction costs of $4.5 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash provided by financing activities for the year ended December 31, 2022 was $8.5 million comprised of proceeds from the issuance of convertible notes.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Material Cash Requirements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our material cash requirements from known contractual obligations consisted primarily of our lease obligation. We lease office and laboratory space in La Jolla, California with monthly rent expense of approximately $9,000 pursuant to a 12 month lease agreement that commenced in January 2023 and was amended and renewed in December 2023 for an additional 12 month term with monthly rent expense of approximately $10,000. Over the next 12 months, the Company expects cash requirements for our lease obligation to be approximately $120,000.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We enter into contracts in the normal course of business with third-party service providers for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. These contracts generally provide for termination upon notice, and therefore, we believe that our non-cancelable obligations under these agreements are not material and we cannot reasonably estimate the timing of if and when they will occur. We could also enter into additional research, manufacturing, supplier and other agreements in the future, which may require up-front payments and even long-term commitments of cash.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also, from time to time, become party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Accounting Policies and Significant Judgments and Estimates</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Costs</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We incur substantial expenses associated with clinical trials. Accounting for clinical trials relating to activities performed by CROs and other external vendors requires management to make estimates in regard to the timing and accounting for these expenses. We estimate costs of research and development activities conducted by service providers, which include, the conduct of sponsored research, preclinical studies and contract manufacturing activities. The diverse nature of services being provided under CRO and other arrangements, the different compensation arrangements that exist for each type of service and the lack of timely information related to certain clinical activities complicates the estimation of accruals for services rendered by CROs and other vendors in connection with clinical trials. We record the estimated costs of research and development activities based upon the number of services provided but not yet invoiced and include these costs in the accrued and other current liabilities on the balance sheets and within research and development expense on the statements of operations, and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. In estimating the duration of a clinical trial, we evaluate the start-up, treatment and wrap-up periods, compensation arrangements and services rendered attributable to each clinical trial and fluctuations are regularly tested against payment plans and trial completion assumptions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We estimate these costs based on factors such as estimates of the work completed and budget provided and in accordance with agreements established with our collaboration partners and third-party service providers. We make estimates in determining the accrued liabilities and prepaid expense balances in each reporting period. As actual costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">116</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">become known, we adjust our accrued liabilities or prepaid expenses. We have not experienced any material differences between accrued costs and actual costs incurred since our inception.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our expenses related to clinical trials are based on patient enrollment and related expenses at clinical investigator sites as well as estimates for the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that may be used to conduct and manage clinical trials on our behalf. We generally accrue expenses related to clinical trials based on contracted amounts applied to the level of patient enrollment and activity. If timelines or contracts are modified based upon changes in the clinical trial protocol or scope of work to be performed, we modify our estimates of accrued expenses accordingly on a prospective basis.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity-Based Compensation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense represents the cost of the grant date fair value of employee stock options recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. For periods prior to the Merger, there was no active market for our common stock, we estimated the fair value of our common stock on the date of grant based on then current facts and circumstances. We estimated the fair value of stock option grants using the Black-Scholes option pricing model (Black-Scholes). Forfeitures are recognized as a reduction of stock-based compensation expense as they occur.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense is classified in the statement of operations in the same manner in which the award recipients&#8217; payroll costs are classified or in which the award recipients&#8217; service payments are classified. The fair value of each stock option grant is estimated on the date of grant using Black-Scholes. The following summarizes the inputs used:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Common Stock</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the Merger, since there was no public market for our common stock, the fair value of the shares of common stock underlying our share-based awards was estimated on each grant date by the Private CalciMedica Board of Directors. To determine the fair value of the common stock underlying option grants, the Private CalciMedica Board of Directors considered, among other things, input from management and valuations of our common stock prepared by unrelated third-party valuation firms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk-Free Interest Rate</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities similar to the expected term of the awards.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Volatility</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected volatility is calculated using an average volatility for comparable publicly-traded biopharmaceutical companies over a period equal to the expected term of the stock award grant as CalciMedica does not yet have sufficient historical trading history for its own stock.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Term</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use the simplified method to calculate the expected term for all grants during all periods, which is based on the midpoint between the vesting date and the end of the contractual term. We do not have sufficient data to calculate historical term in another manner.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Dividend Yield</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never paid cash dividends and have no present intention to pay cash dividends. For options granted to non-employee consultants, the fair value of these options is also measured using the Black-Scholes option pricing model reflecting the same assumptions as applied to employee options in each of the reported periods, other than the expected term which is assumed to be the remaining contractual life of the option.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging Growth Company and Smaller Reporting Company Status</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">JOBS Act</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">117</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also a &#8220;smaller reporting company,&#8221; as defined by Rule 12b-2 of the Securities Exchange Act of 1934, because both the market value of our stock held by non-affiliates is less than $700.0 million and our annual revenue is less than $100.0 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250.0 million or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700.0 million as of June 30th. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Note 2 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for information about recent accounting pronouncements, the timing of adoption, and our assessment, if any, of their potential impact on our financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a_quantitative_and_qualitative"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">m 7A. Quantitative and Qualitative Disclosures About Market Risk.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Rate Risk</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable to a &#8220;smaller reporting company&#8221; as defined under Item 10(f)(1) of Regulation S-K of the Securities Act.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">m 8. Financial Statements and Supplementary Data.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item 8 is included as exhibits at the end of this Annual Report on Form 10-K beginning on page F-1and listed under Item 15(a)(1) and (2), and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_changes_in_and_disagreements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a_controls_and_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tem 9A. Controls and Procedures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management, with the participation and supervision of our Chief Executive Officer and our Interim Chief Financial Officer, have evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on that evaluation, our Chief Executive Officer and Interim Chief Financial Officer have concluded that, as of the end of the period covered by this Annual Report on Form 10-K, our disclosure controls and procedures were effective at a reasonable assurance level.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were no changes in our internal control over financial reporting during the quarter ended December 31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">118</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART II &#8211; OTHER INFORMATION</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 9B. Other Information.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c_disclosure_regarding_foreign"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">119</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART III</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executive_officers"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 10. Directors, Executive Officers and Corporate Governance.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information required by Item 10 and not set forth below will be set forth in the sections</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or subsections titled </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Proposal No. 1 Election of Class I Directors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Delinquent Section 16(A) Reports</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Committees of Our Board of Directors and Executive Officers </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">contained in our definitive proxy statement for our 2024 annual meeting of stockholders to be filed with the SEC not later than April 29, 2024 (the &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Proxy Statement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) pursuant to General Instructions G(3) of Form 10-K and is incorporated herein by reference.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have adopted a Code of Conduct and Ethics that applies to all officers, directors and employees, including our principal executive officer, principal financial officer, principal accounting officer or vice president of finance, or person performing similar functions. A current copy of the Code of Conduct and Ethics is available on the Corporate Governance section of our website at https://ir.calcimedica.com. If we make any substantive amendments to the Code of Conduct and Ethics or grants any waiver from a provision of the Code of Conduct and Ethics to any executive officer or director that are required to be disclosed pursuant to SEC rules, we will promptly disclose the nature of the amendment or waiver on our website or in a current report on Form 8-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 11. Executive Compensation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item 11 will be set forth in the sections or subsections titled  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Executive Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Non-Employee Director Compensation, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation Committee Interlocks and Insider Participation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">contained in the Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12_security_ownership"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item 12 will be set forth in the sections or subsections titled</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Security Ownership of Certain Beneficial Owners and Management</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Compensation Plan Information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> contained in the Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13_certain_relationships"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 13. Certain Relationships and Related Transactions, and Director Independence.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item 13 will be set forth in the sections or subsections titled</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Certain Relationships and Related-Person Transactions</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Director Independence</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> contained in the Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14_principal_accounting_fees"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">m 14. Principal Accounting Fees and Services.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item 14 will be set forth in the section titled</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Proposal No. 2 Ratification of Independent Registered Public Accounting Firm</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> contained in the Proxy Statement and is incorporated herein by reference.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">120</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART IV</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits_financial_statement"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 15. Exhibits, Financial Statement Schedules.</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Documents filed as a part of the report:</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The following financial statements of CalciMedica, Inc., together with the report of Ernst &amp; Young LLP, an independent registered public accounting firm, required to be filed pursuant to Part II, Item 8 of this Annual Report are included on the following pages:</span></div></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92.92%;"/>
    <td style="width:7.08%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:24.5pt;vertical-align:middle;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_of_independent_public_acct"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">&#160;PCAOB ID: 42</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:24.5pt;vertical-align:middle;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Balance Sheets as of December 31, 2023 and 2022</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:24.5pt;vertical-align:middle;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_statements_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss for the Years ended December 31, 2023 and 2022</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:24.5pt;vertical-align:middle;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_statements_stockh"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) for the Years ended December 31, 2023 and 2022</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:24.5pt;vertical-align:middle;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Cash Flows for the Years ended December 31, 2023 and 2022</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:24.5pt;vertical-align:middle;padding-right:0.01in;"><p style="margin-left:24.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_condensed_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
   </tr>
  </table>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(2)     </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Statement Schedules. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(3)   </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  List of exhibits required by Item 601 of Regulation S-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> See part (b) below.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b)    </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  Exhibits</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit Index</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:6.999%;"/>
    <td style="width:1%;"/>
    <td style="width:39.992%;"/>
    <td style="width:1%;"/>
    <td style="width:4.999%;"/>
    <td style="width:1%;"/>
    <td style="width:10.998%;"/>
    <td style="width:1%;"/>
    <td style="width:12.398%;"/>
    <td style="width:1%;"/>
    <td style="width:6.339%;"/>
    <td style="width:1%;"/>
    <td style="width:12.278%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Form</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">File No.</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filing Date</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">No.</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filed/Furnished</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Herewith</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1&#135;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/d485425dex21.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, by and among Graybug Vision, Inc.,Camaro Merger Sub, Inc. and CalciMedica, Inc., as amended by the First Amendment, dated February 10, 2023.</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-39538</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 22, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/d485425dex31.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Certificate of Incorporation of the registrant.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-39538</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 22, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/d485425dex32.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certificate of Amendment, dated March 20, 2023 to Amended and Restated Certificate of Incorporation of the registrant.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-39538</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 22, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000156459020053539/gray-ex32_105.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Restated Bylaws of the registrant.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-39538</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 12, 2020</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reference is made to Exhibits</span><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/d485425dex31.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;"> 3.1</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">, </span><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/d485425dex32.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">3.2</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and </span><a href="https://www.sec.gov/Archives/edgar/data/1534133/000156459020053539/gray-ex32_105.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">3.3</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="calc-ex4_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Description of Registrant&#8217;s Common Stock</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312520249556/d796801dex41.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Common Stock Certificate</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1/A</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-248611</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">September 21, 2020</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">121</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:6.999%;"/>
    <td style="width:1%;"/>
    <td style="width:39.992%;"/>
    <td style="width:1%;"/>
    <td style="width:4.999%;"/>
    <td style="width:1%;"/>
    <td style="width:10.998%;"/>
    <td style="width:1%;"/>
    <td style="width:12.398%;"/>
    <td style="width:1%;"/>
    <td style="width:6.339%;"/>
    <td style="width:1%;"/>
    <td style="width:12.278%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Form</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">File No.</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filing Date</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">No.</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filed/Furnished</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Herewith</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.4</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/d485425dex41.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Registration Rights Agreement, dated November 21, 2022, by and among CalciMedica, Inc. and the several purchasers signatory thereto.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-39538</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 22, 2023</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312524011738/d738337dex102.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Registration Rights Agreement by and among CalciMedica, Inc. and the persons party thereto.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-39538</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 24, 2024</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.6</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312520240042/d796801dex43.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Warrant to Purchase Common Stock, dated December 11, 2019, by and between the Registrant and SG DAN Equity Holdings, LLC.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-248611</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">September 4, 2020</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.7</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/d485425dex42.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Warrant to Purchase Shares of Series D Convertible Preferred Stock of CalciMedica, Inc.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-39538</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 22, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.8</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/d485425dex43.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Warrant to Purchase Common Stock dated as of November 9, 2020, issued by CalciMedica, Inc. to SG Dan Equity Holdings, LLC.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-39538</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 22, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.9</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/d485425dex44.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Warrant to Purchase Common Stock, dated as of October 18, 2022, issued by CalciMedica, Inc. to SG Dan Equity Holdings, LLC.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-39538</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 22, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.4</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.10</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/d485425dex45.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Warrant to Purchase Common Stock, dated as of October 18, 2022, issued by CalciMedica, Inc. to Eric Roberts.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-39538</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 22, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.11</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/d485425dex46.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Warrant to Purchase Common Stock, dated as of October 25,2022, issued by CalciMedica, Inc. to Fred Middleton.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-39538</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 22, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.6</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.12</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312523090982/d482049dex49.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Warrant to Purchase Shares of Series B Convertible Preferred Stock of CalciMedica, Inc.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-271115</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">April 4, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.9</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.13</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312524011738/d738337dex41.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Tranche A Common Warrant.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-39538</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 24, 2024</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.14</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312524011738/d738337dex42.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Tranche B Common Warrant.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-39538</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 24, 2024</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.15</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312524011738/d738337dex43.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Pre-Funded Warrant.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-39538</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 24, 2024</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.16</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312524011738/d738337dex44.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Placement Agent Warrant.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-39538</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 24, 2024</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.4</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/d485425dex101.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Offer Letter between CalciMedica, Inc. and A. Rachel Leheny, Ph.D., dated May 20, 2020.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-39538</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 22, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">122</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:6.999%;"/>
    <td style="width:1%;"/>
    <td style="width:39.992%;"/>
    <td style="width:1%;"/>
    <td style="width:4.999%;"/>
    <td style="width:1%;"/>
    <td style="width:10.998%;"/>
    <td style="width:1%;"/>
    <td style="width:12.398%;"/>
    <td style="width:1%;"/>
    <td style="width:6.339%;"/>
    <td style="width:1%;"/>
    <td style="width:12.278%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Form</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">File No.</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filing Date</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">No.</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filed/Furnished</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Herewith</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/d485425dex102.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Offer Letter between CalciMedica, Inc. and Eric Roberts, dated May 20, 2020.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-39538</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 22, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/d485425dex103.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Offer Letter between CalciMedica, Inc. and Sudarshan Hebbar, M.D., dated August 24, 2015.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-39538</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 22, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/d485425dex104.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Offer Letter between CalciMedica, Inc. and Michael Dunn, dated August 29, 2014.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-39538</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 22, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/d485425dex105.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Offer Letter between CalciMedica, Inc. and Kenneth A. Stauderman, Ph.D., dated August 29, 2014.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-39538</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 22, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.6+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/d485425dex1011.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consulting Agreement, dated as of October 26, 2020, by and between the CalciMedica, Inc. and Danforth Advisors, LLC.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-39538</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 22, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.11</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.7+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/d485425dex106.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">CalciMedica, Inc. 2023 Equity Incentive Plan.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-39538</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 22, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.6</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.8+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/d485425dex107.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Forms of Option Grant Notice and Option Agreement under CalciMedica, Inc. 2023 Equity Incentive Plan.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-39538</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 22, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.7</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.9+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/d485425dex108.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Forms of Restricted Stock Unit Grant Notice and Unit Award Agreement under CalciMedica, Inc. 2023 Equity Incentive Plan.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-39538</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 22, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.8</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.10+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/d485425dex109.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">CalciMedica, Inc. 2023 Employee Stock Purchase Plan.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-39538</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 22, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.9</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.11+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/d485425dex1010.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">CalciMedica, Inc. 2006 Stock Plan and Form of Stock Option Agreement thereunder.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-39538</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 22, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.10</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.12+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312520249556/d796801dex103.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2020 Equity Incentive Plan and forms of award agreements.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1/A</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-248611</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">September 21, 2020</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.13+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312520249556/d796801dex104.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2020 Employee Stock Purchase Plan and forms of award agreements.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1/A</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-248611</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">September 21, 2020</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.14+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/d485425dex1012.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Amendment to Stock Option Award Agreement, dated March 20, 2023, by and between Graybug Vision, Inc. and the Holder party thereto</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-39538</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 22, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.12</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.15+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/d485425dex1013.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Amendment to Restricted Stock Unit Award Agreement, dated March 20, 2023, by and between Graybug Vision, Inc. and the Holder party thereto</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-39538</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 22, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.13</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.16+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312520240042/d796801dex102.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2015 Stock Incentive Plan, as amended, and forms of award agreements thereunder.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-248611</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">September 4, 2020</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">123</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:6.999%;"/>
    <td style="width:1%;"/>
    <td style="width:39.992%;"/>
    <td style="width:1%;"/>
    <td style="width:4.999%;"/>
    <td style="width:1%;"/>
    <td style="width:10.998%;"/>
    <td style="width:1%;"/>
    <td style="width:12.398%;"/>
    <td style="width:1%;"/>
    <td style="width:6.339%;"/>
    <td style="width:1%;"/>
    <td style="width:12.278%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Form</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">File No.</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filing Date</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">No.</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filed/Furnished</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Herewith</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.17+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312520240042/d796801dex101.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Indemnification Agreement.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-248611</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">September 4, 2020</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.18+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312520240042/d796801dex1011.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Change in Control and Severance Policy.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-248611</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">September 4, 2020</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.11</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.19</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1534133/000119312523210902/d516230dex12.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">At the Market Offering Agreement, dated as of August 11, 2023, by and between CalciMedica, Inc. and H.C. Wainwright &amp; Co., LLC</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-273949</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 11, 2023</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="calc-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">List of Subsidiaries</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="calc-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="calc-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="calc-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.1*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="calc-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.2*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="calc-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="calc-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">CalciMedica, Inc. Incentive Compensation Recoupment Policy</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.INS</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Instance Document.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.SCH</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
  </table>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">* This certification is deemed not filed for purposes of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of the Exchange Act.</span></p>
  <p style="margin-left:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">+ Indicates management contract or compensatory plan.</span><span style="color:#0000ff;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#135; Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">124</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 16. Form 10-K Summary</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="text-indent:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">125</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.96%;"/>
    <td style="width:1.1%;"/>
    <td style="width:4%;"/>
    <td style="width:43.94%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CALCIMEDICA, INC.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 28, 2024</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ A. Rachel Leheny</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">A. Rachel Leheny, Ph.D.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Executive Officer</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 28, 2024</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Daniel Geffken</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Daniel Geffken</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Interim Chief Financial Officer</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Accounting and Financial Officer)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">POWER OF ATTORNEY</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints A. Rachel Leheny, Ph.D. and Daniel Geffken, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.98%;"/>
    <td style="width:1.04%;"/>
    <td style="width:43.3%;"/>
    <td style="width:1.04%;"/>
    <td style="width:21.64%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ A. Rachel Leheny</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer and Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 28, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">A. Rachel Leheny, Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principle Executive Officer)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Daniel Geffken</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Interim Chief Financial Officer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;March 28, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Daniel Geffken</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Accounting and Financial Officer)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Robert N. Wilson</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Chairman</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;March 28, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Robert N. Wilson</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Eric Bjerkholt</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;March 28, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Eric Bjerkholt</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Frederic Guerard, Pharm.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;March 28, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Frederic Guerard, Pharm.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Fred Middleton</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;March 28, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fred Middleton</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Eric W. Roberts</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;March 28, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Eric W. Roberts</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Allan Shaw</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;March 28, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Allan Shaw</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">126</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92.92%;"/>
    <td style="width:7.08%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_of_independent_public_acct"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Report of Independent Registered Public Accounting Firm PCAOB ID: </span><span><ix:nonNumeric id="F_8fbb48bd-fe4d-4fa5-9cde-a76003d0d3f4" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">42</span></ix:nonNumeric></span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Balance Sheets as of December 31, 2023 and 2022</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_statements_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Operations for the Years ended December 31, 2023 and 2022</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statement_of_comprehensive"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Comprehensive Loss for Years ended December 31, 2023 and 2022</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_statements_stockh"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) for the Years ended December 31, 2023 and 2022</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Cash Flows for the Years ended December 31, 2023 and 2022</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_condensed_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report_of_independent_public_acct"><span style="color:#333333;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Report of Independent </span><span style="color:#333333;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the Stockholders and the Board of Directors of CalciMedica, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#333333;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of CalciMedica, Inc. (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations, consolidated statements of comprehensive loss, consolidated statements of convertible preferred stock and shareholders' equity (deficit) and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#333333;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_355726ef-d9bb-4fa6-99f5-2b3d8d82fafa" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:AuditorName"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2008.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8bfe8678-164e-4d3f-b4d7-211ba7aeb8f1" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="dei:AuditorLocation"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">San Diego, California</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 28, 2024</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART I&#8212;FINANCIAL </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INFORMATION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1. Financial Statements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CALCIMEDICA, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Balance Sheets</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except par value and share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.967%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:13.037%;"/>
    <td style="width:1%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:13.037%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(See Note 2)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2bedd12-1ecd-40c1-9450-b7b36c6fd78a" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,530</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b32203ac-4194-4133-8b43-b68396f002a8" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,327</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23cdb46e-8ade-480d-b660-d5d5f2cf43c4" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0cc2db1c-21ba-4b14-a6ce-7df32ad944bf" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">149</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64da60dd-bb3a-44ad-bdb0-544260b8b1ae" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,708</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88eb81dd-978c-4d0e-9eb9-73271f25e62e" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c8359fc-f1e2-478d-96b5-602c77ce84cf" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">367</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0127ab3b-56f7-4cb9-8af8-02b8136b0568" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">254</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd470b77-7324-4a93-9081-2fdfb8b46091" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,605</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9d436a3-c0ee-4c32-b0ed-ec3d8dce45aa" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,730</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_edae37dd-91e3-4e5d-a779-af390e514efd" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">167</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ace8d82-20e1-47bd-9e0d-91e0894b3a85" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">147</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use asset, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_057641ec-d284-4d9e-a6ef-1a67367cb52f" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d479690-41c0-4945-a262-305cd1e4485b" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b21da684-3e1f-4047-bc3e-964ee261d4ea" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:OtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">413</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce8ec5d2-a29d-46bd-b771-7486bcfadf55" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:OtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,424</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa313d0e-f1a0-4bb3-8291-648cc18e73d2" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,185</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b2bf5ed-eadd-4f86-9ac3-366e2def34ba" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,349</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities and Stockholders&#8217; Equity (Deficit)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9654b1dd-2709-4ea9-960c-4dc03385ec7a" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,419</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0fceda99-9b34-4cc6-af9a-afcf4454b887" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,866</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued clinical trial costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_189c02c2-986f-4bcd-a37e-ae32d648f3af" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="calc:AccruedClinicalTrialCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,141</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d19764c-ef35-400b-8624-2a2487de6cbd" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="calc:AccruedClinicalTrialCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,143</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued other</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f12ec36-8b24-4d9f-92fc-9c83a2d1f377" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,468</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8211d927-9fd9-4b3d-b446-4338afc53552" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">572</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dff7cf29-7384-48cf-8232-d32ae83af5db" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ff3eae6-567e-491a-83cc-bd83bd0f364e" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">199</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b005c1cb-4aa7-4075-9d9e-7606217fe936" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,028</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c214a553-3190-4916-a285-bbbe1822cd27" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,780</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term liabilities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrant liability</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd6e1c42-915c-4fd7-ad14-60a8b7c13746" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="calc:WarrantLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fca9f1dd-e858-4fb5-8e62-048a99c5e8bd" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="calc:WarrantLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,645</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible promissory notes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd0bf320-2834-434f-a72a-3270f2f6f40c" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:ConvertibleNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be201ea7-e5c0-4e78-be46-4bfee9a1c662" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:ConvertibleNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,157</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a9d8b32-d875-4ba0-8687-8699a36e4524" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,028</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d76a206e-b903-457a-965f-bc6d2ef30b8a" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,582</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><span style="-sec-ix-hidden:F_74cfeaa3-ed05-485f-93be-ecdef817d1a9;"><span style="-sec-ix-hidden:F_b94405e4-4bf9-46b4-a0c9-907b7b37b530;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies (Note 9)</span></span></span></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible preferred stock</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">Series A convertible preferred stock, $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_37b41ebb-e9f8-4fb1-a3ce-7a59d6a61c1c" contextRef="C_f5b9bae3-0548-4930-bb40-f87d4bfbe049" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_27f61a76-4876-4215-9ec4-e17764fa22b3" contextRef="C_923510ce-a803-41b4-a562-244fd50617fa" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;par value; </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbbdba5c-512e-47e6-b086-8e2a3261b159" contextRef="C_f5b9bae3-0548-4930-bb40-f87d4bfbe049" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c136b1bb-ce4c-4b69-9e36-064364ee1441" contextRef="C_f5b9bae3-0548-4930-bb40-f87d4bfbe049" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_0225b156-2484-46a3-88b7-c5e23d08c5fd" contextRef="C_f5b9bae3-0548-4930-bb40-f87d4bfbe049" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares and </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58895544-5312-4f6a-bc2c-d813d3e6be8d" contextRef="C_923510ce-a803-41b4-a562-244fd50617fa" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7f53d2ff-21c6-4185-938e-877a6068120e" contextRef="C_923510ce-a803-41b4-a562-244fd50617fa" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b30d389c-7aae-439c-ae7c-4e8a4a45cbad" contextRef="C_923510ce-a803-41b4-a562-244fd50617fa" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">25,751,716</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;authorized, issued and outstanding at December 31, 2023 and December 31, 2022, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c45a1f7-1ff6-4566-9069-569f0ca46101" contextRef="C_f5b9bae3-0548-4930-bb40-f87d4bfbe049" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b52430d-a0b2-4f17-a0c7-ecfce4c3d065" contextRef="C_923510ce-a803-41b4-a562-244fd50617fa" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,107</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">Series B convertible preferred stock, $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c3222dc-b853-470b-911e-533905b02050" contextRef="C_1f3e1d63-5125-4209-b819-942e8859a17c" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_595ccf8e-93fa-4361-a4d8-abc0c67738b9" contextRef="C_9155f47b-b723-4d6f-9e10-5b401cf33a46" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;par value; </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f05387c4-3e60-45e2-a2ed-aedf67b1d85e" contextRef="C_1f3e1d63-5125-4209-b819-942e8859a17c" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares and </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71e7b27b-c61e-421c-bc77-a3cfd429cae9" contextRef="C_9155f47b-b723-4d6f-9e10-5b401cf33a46" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">11,235,460</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;authorized at December 31, 2023 and December 31, 2022, respectively; </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf42a7aa-62e4-4bc6-aeae-647972d0b739" contextRef="C_1f3e1d63-5125-4209-b819-942e8859a17c" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d780a1d1-dfa2-47b0-adbf-43fe7634bf45" contextRef="C_1f3e1d63-5125-4209-b819-942e8859a17c" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares and </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_749589e5-70ac-4b63-a932-c7fdf010580e" contextRef="C_9155f47b-b723-4d6f-9e10-5b401cf33a46" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_71d30eea-c6f5-4e0a-8223-31b11747a390" contextRef="C_9155f47b-b723-4d6f-9e10-5b401cf33a46" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,667,279</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03d54f45-c1a5-4d4a-9a28-32070eabb422" contextRef="C_1f3e1d63-5125-4209-b819-942e8859a17c" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4952996-012e-4692-a491-43a995c4d8d9" contextRef="C_9155f47b-b723-4d6f-9e10-5b401cf33a46" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,224</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">Series C-1 convertible preferred stock, $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bdf47de6-c4d0-41e0-ba36-b388cff7a5db" contextRef="C_01acfa85-0d49-4317-9517-f41c3568951c" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2eda6f6d-f30b-4673-bfc4-2bc7516931f7" contextRef="C_ef21a00c-f705-4ecd-b756-6e2bbd8fbbb1" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;par value; </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2265f112-9c5c-44b5-ab10-491c1b999c11" contextRef="C_01acfa85-0d49-4317-9517-f41c3568951c" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_2e94fed1-fe95-41a1-9dca-92b76bdb8697" contextRef="C_01acfa85-0d49-4317-9517-f41c3568951c" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_17f0af88-9ace-41b3-89da-703cb62ee2c6" contextRef="C_01acfa85-0d49-4317-9517-f41c3568951c" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares and </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a993735a-f576-4d3d-8941-c58d867f68d8" contextRef="C_ef21a00c-f705-4ecd-b756-6e2bbd8fbbb1" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_979ee9bf-d413-41ac-848d-b8f16d5b8dc1" contextRef="C_ef21a00c-f705-4ecd-b756-6e2bbd8fbbb1" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0318f753-3fae-45cb-abb0-82efd2e92a8d" contextRef="C_ef21a00c-f705-4ecd-b756-6e2bbd8fbbb1" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,016,886</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares authorized, issued and outstanding at December 31, 2023 and December 31, 2022, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90ae4899-6842-4417-9fe5-9801924f5fef" contextRef="C_01acfa85-0d49-4317-9517-f41c3568951c" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4b9d705-6796-42ef-a91d-aec0ddb50eab" contextRef="C_ef21a00c-f705-4ecd-b756-6e2bbd8fbbb1" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,683</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">Series C-2 convertible preferred stock, $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d56f2d10-7a45-43a6-a5b4-8adf475a48de" contextRef="C_a3d1cb01-530a-4348-9ce4-14d88694eb11" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_00cf4d9a-1e7a-4e50-8826-98a3b09d15e4" contextRef="C_1cb6ffcd-9a58-41d3-a749-d0783461107f" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;par value; </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2198fa13-87ff-4534-b0c2-318ebb1b0a75" contextRef="C_a3d1cb01-530a-4348-9ce4-14d88694eb11" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares and </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc3c1492-cf01-4150-a12e-310a52672ae6" contextRef="C_1cb6ffcd-9a58-41d3-a749-d0783461107f" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,291,526</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;authorized at December 31, 2023 and December 31, 2022, respectively; </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66522ed1-76fe-417a-b668-d2a7caaefab8" contextRef="C_a3d1cb01-530a-4348-9ce4-14d88694eb11" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_63757be0-8630-44dd-a580-2401177dba20" contextRef="C_a3d1cb01-530a-4348-9ce4-14d88694eb11" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares and </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de4c1aa9-453a-4c59-a1c7-0cc219165808" contextRef="C_1cb6ffcd-9a58-41d3-a749-d0783461107f" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7e94a7cd-e5f4-4d8f-a277-e6901688429c" contextRef="C_1cb6ffcd-9a58-41d3-a749-d0783461107f" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">13,504,959</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e89d9f7-a495-46ff-8746-cab5d2e34678" contextRef="C_a3d1cb01-530a-4348-9ce4-14d88694eb11" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_831e9a1b-d722-44e8-9393-287e05172dba" contextRef="C_1cb6ffcd-9a58-41d3-a749-d0783461107f" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,563</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">Series D convertible preferred stock, $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57ad08be-e5ab-4c03-b7ab-7114aa12f3d7" contextRef="C_7ee603a1-e520-4a05-b7a9-9cc94a461856" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_77a5b69d-4ab5-4903-885b-bf597198aee9" contextRef="C_1f065a12-57ce-4dcf-9b28-c5b350ecafaa" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;par value; </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_031bf55d-0d09-44ef-bbe8-e9dc48cfa87d" contextRef="C_7ee603a1-e520-4a05-b7a9-9cc94a461856" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares and </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4be7615-c0e1-48be-871b-55c2fc9c641d" contextRef="C_1f065a12-57ce-4dcf-9b28-c5b350ecafaa" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">88,875,077</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;authorized at December 31, 2023 and December 31, 2022, respectively; </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0afcb335-5f15-4fdd-bc52-b010e8adb676" contextRef="C_7ee603a1-e520-4a05-b7a9-9cc94a461856" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a32e2522-43e0-47c8-8152-7e46a41b15c1" contextRef="C_7ee603a1-e520-4a05-b7a9-9cc94a461856" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares and </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0f6ee36-0f52-40b4-98c1-785b97f9b4bf" contextRef="C_1f065a12-57ce-4dcf-9b28-c5b350ecafaa" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1cd1b42f-f432-42c2-95c4-46d9a8d52883" contextRef="C_1f065a12-57ce-4dcf-9b28-c5b350ecafaa" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">26,880,040</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02abfbc2-a746-4913-851b-b2395bf99d3f" contextRef="C_7ee603a1-e520-4a05-b7a9-9cc94a461856" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2ac0ee7-483d-42b8-8900-12a65fe8b20f" contextRef="C_1f065a12-57ce-4dcf-9b28-c5b350ecafaa" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,494</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders&#8217; equity (deficit) (1)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">Preferred stock, $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17d0a522-4654-4784-8369-9d67eb10fa21" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3974021d-da97-405c-b4c6-0ed13fbf3266" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;par value; </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f291d768-1671-47bc-8027-28c7cbb3679a" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares and </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_afdda4d3-44cd-4bf8-b27f-64b32f1a59e4" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares authorized at December 31, 2023 and December 31, 2022, respectively; </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eea01db8-24da-43d0-9ed2-1870b9335d11" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_cd8d173a-0c2d-4f70-a1d5-c0ec845a68a5" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_eac08a4e-2082-4dec-8ae4-162ac31aac3c" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7cf54ba6-3089-4845-b283-cdfbb7b3fcc1" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8bb455e8-70b9-4732-be18-0165b2cbda00" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1d275c5-c0d4-477b-89db-8c7429a395f6" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">Common stock, $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3568561-1033-4d5d-9159-ebd9e3ba2111" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="F_42140322-b91c-4c58-98b9-fc03f11be555" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;par value; </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af43c63b-22a0-4b09-b021-3406a98d161a" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;and </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9b7a538-6b8b-4e1a-a873-407a222adc21" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,694,626</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;shares authorized at December 31, 2023 and December 31, 2022, respectively; </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b067f1c4-daac-43e8-addc-a3d5240624a9" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b4518193-e367-461b-a4f4-e7d798b54793" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,754,505</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;and </span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_713a3be0-0ac2-485f-9a57-bfc2fbdbd8b4" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_be6d5c04-6160-4977-b1ef-7a6732d1bcf2" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">84,165</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;issued and outstanding at December 31, 2023 and December 31, 2022, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_acfe5755-3ae1-4a5a-b7b0-5f043022b2ae" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3fbd2093-cd96-437a-be94-3a27dc8e2bb4" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77a8410c-4e3c-4060-829b-0d8b55ac4402" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154,218</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e50737b-dc7c-4bbc-97ea-d00034ac8717" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,402</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a07ba786-30c5-4eb5-b907-fe5e65ee816f" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">146,064</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bcd704f4-ea19-434a-8fa8-9bef64fd9dd0" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">111,707</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive income (loss)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9c6e4f2-b585-4330-83ce-ae3565e5cbbf" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders&#8217; equity (deficit)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb32f7f3-f91a-4e57-94ed-8a2cd6277afb" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,157</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27361f8e-d2e4-4e18-9632-df1df55eaff4" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">71,304</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b10ba49-e638-4c78-a54a-9888966766fe" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,185</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc510887-a4b0-4ae0-873b-595e6b2a11b8" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,349</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:footnote id="FNT_9f0bb873-815a-4c02-aa18-9b124c54fb6a" xml:lang="en-US"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) Retroactively restated for the reverse recapitalization as described in Note 2.</span></p></ix:footnote>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CALCIMEDICA, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_statements_operations"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statemen</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ts of Operations</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.58%;"/>
    <td style="width:1%;"/>
    <td style="width:12.923%;"/>
    <td style="width:1%;"/>
    <td style="width:1.58%;"/>
    <td style="width:1%;"/>
    <td style="width:12.923%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_858639b4-5bce-46d9-bfa6-88f9cd9232a5" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,859</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01b152f1-1ff8-4be9-863f-2a38a9f9517b" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,350</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d8b5919-4250-4506-af50-419773c4e4ca" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,216</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dcf08190-0b11-42c4-af6b-acb23e58d70c" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,843</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_876c462a-a08e-424c-bf29-e217770a1c48" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,075</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d8ab2a8-d7b6-4cee-a22e-694cb917a3b3" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,193</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4e2374c-8a68-4c04-8ff0-ebb9917856b5" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">38,075</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc536ecf-6c25-44a1-9b76-e6a280bbaac2" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,193</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of warrant liability</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7f1dbb9-fc67-4599-9566-712a35be678c" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:ChangeInFairValueOfWarrantLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,146</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab345c4a-ac00-466e-a1ed-59cceeb7298c" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="calc:ChangeInFairValueOfWarrantLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,784</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of convertible promissory notes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18ff4ddb-1c99-4e9d-bc70-b9626c405f2d" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:ChangeInFairValueOfConvertiblePromissoryNote" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,022</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32fc00b0-862a-4143-9f88-71db40940c48" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="calc:ChangeInFairValueOfConvertiblePromissoryNote" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,745</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest on convertible promissory notes payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ad543d7-24c4-46fc-8453-1eb1649bbc54" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:InterestOnConvertiblePromissoryNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">110</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78072663-0a4f-41b5-b4d8-142bf7a21476" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="calc:InterestOnConvertiblePromissoryNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">132</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b27024c-c918-4248-8bd8-6a7fae4470eb" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">660</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41fda656-1e27-4737-bca2-db4e10afb5f2" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">28</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other income (expense), net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d023c234-8782-4880-adfd-d5623ef1c964" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,718</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eec38c97-3c22-4596-bbd6-b986dd0cd36a" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,369</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0a364e8-ff01-4ecb-abf2-7015e18f3d5d" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">34,357</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9988b3aa-2b37-4d97-880e-d1687d76463e" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,824</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deemed distribution to convertible promissory note holders</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6873d706-3731-4900-9f36-10094971ed4e" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4ff2930-21ec-4b24-8eb4-9f2d96e70aa5" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,318</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ab9a246-4e8e-4d65-a2de-73b1338db7ee" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">34,357</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b537570-0d34-4902-9889-334588f40502" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,142</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share&#8212;basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9dd614fb-ab1e-4c1e-997f-46419645d78d" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b6f2c2d6-da63-4555-a581-f13b70e16611" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">7.66</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b56248a5-71d1-480e-be8d-013a22dc22e0" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b987a0aa-f0ec-4b13-a460-adea7cc15d39" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">111.16</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average number of shares outstanding used in<br/>&#160;&#160;&#160;computing net loss per share&#8212;basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0eaa272-8741-487d-a61a-ea08b7bec13b" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_49315e85-d9af-4fe4-af41-3b1613d7b7d9" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,486,258</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b33ca86b-a796-4328-ac0a-9dceed2ab92f" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ae7579bc-a117-4507-b3bc-158deb590d48" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">82,245</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statement_of_comprehensive"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CALCIM</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EDICA, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of Comprehensive Loss</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:64.364%;"/>
    <td style="width:1.738%;"/>
    <td style="width:1%;"/>
    <td style="width:14.241%;"/>
    <td style="width:1%;"/>
    <td style="width:1.738%;"/>
    <td style="width:1%;"/>
    <td style="width:13.920000000000002%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9956d8d-87b5-443b-9d8d-20053af9696c" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">34,357</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae410bef-a8a5-46db-bd92-ae15d9852dca" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,142</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain on available-for-sale securities, <br/>&#160;&#160;&#160;net of tax</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2532b4f8-d1bb-4be6-a618-03f916e35b4a" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a045b45-c407-4b1f-9801-e07427b74c06" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e517ed1-c1cf-430e-a7c7-6f4ad1e14812" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">34,355</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10e8c548-39b2-485a-9084-2b6cdb0e9628" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,142</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CALCIMEDICA, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_statements_stockh"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Stateme</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nts of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:91.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:31.012%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:5.702%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:4.7620000000000005%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:5.702%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:5.242000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:5.242000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:5.821999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.14%;"/>
    <td style="width:1%;"/>
    <td style="width:6.542999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:5.821999999999999%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Convertible Preferred Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional<br/>Paid-In</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Other<br/>Comprehensive</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Stockholders&#8217;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Loss</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Equity/(Deficit)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance&#8212;December 31, 2022 (1)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df2a12f8-eb45-4e92-a272-43e99d7d9bb8" contextRef="C_6739fa84-42ef-4c69-a6c0-24f4f1d63ab1" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">84,820,880</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09a89814-82cf-4b05-8abf-d22651e40260" contextRef="C_6739fa84-42ef-4c69-a6c0-24f4f1d63ab1" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,071</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b4fc4d8-0455-4e1e-b160-f78a2794e368" contextRef="C_44e3fe9d-1f45-4346-b174-97527637315a" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">84,165</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4bd1ee4e-cab4-4321-a744-19504259caa2" contextRef="C_44e3fe9d-1f45-4346-b174-97527637315a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba2bde47-7ce9-4d0a-8bec-2f13de62590f" contextRef="C_fdc3b56d-3340-41e6-abd7-2a87c4565e5c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,402</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e6587b8-a085-4060-bcbb-02a3fd9cb98a" contextRef="C_18921a4e-cb36-49f6-887d-24dcb1c18c90" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">111,707</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c966614-f625-4a8d-9dde-653f387df670" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">71,304</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d24222a4-9cc4-496f-9e81-0574361a9d0f" contextRef="C_63f79bb4-c719-4598-9f7b-e5ab26777c6e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,039</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee267117-88d5-4c13-9d78-760837c10b4a" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,039</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of preferred stock to common stock as a result of Merger</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3fe92a40-00d5-4f4d-9d51-ba201e8548b1" contextRef="C_e88cb3f0-85d9-47a7-b525-8fd14ae13f26" name="calc:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="0" sign="-" format="ixt:num-dot-decimal">84,820,880</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6156894b-b994-4825-92c5-a20feeda6f9a" contextRef="C_e88cb3f0-85d9-47a7-b525-8fd14ae13f26" name="calc:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">62,071</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3bc57a73-6098-46f9-865d-cd33dd29edb4" contextRef="C_f6acf339-8a66-4359-827f-f1d8c3fefcf6" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,442,852</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a403483-c1eb-4aa4-aef8-786ac0860ae4" contextRef="C_63f79bb4-c719-4598-9f7b-e5ab26777c6e" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,071</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3413e6a9-ccc8-4c18-8c50-c6061bbd956c" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,071</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock to Graybug stockholders as a result of Merger and reset to par of $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d117bc76-af0d-4ea5-aaf8-efa32506d1b4" contextRef="C_c1e00f56-e042-41d9-8c27-e58be2c2e576" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78c4b749-8963-4e45-bb44-d0aef4a6d688" contextRef="C_f6acf339-8a66-4359-827f-f1d8c3fefcf6" name="calc:IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMergerShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,571,433</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42d97ee2-c7aa-4366-8679-e884a03ce5ab" contextRef="C_63f79bb4-c719-4598-9f7b-e5ab26777c6e" name="calc:IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,218</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_783fa564-4dca-47bc-97f3-3e5d9c01b0d5" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,218</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common shares from private placement (net of issuance costs)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10cc939b-5ce1-4639-b488-a80d9817806b" contextRef="C_f6acf339-8a66-4359-827f-f1d8c3fefcf6" name="calc:IssuanceOfCommonSharesFromPrivatePlacementNetShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">596,363</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_999730d1-7102-4c21-bf43-4cdc51e24089" contextRef="C_63f79bb4-c719-4598-9f7b-e5ab26777c6e" name="calc:IssuanceOfCommonSharesFromPrivatePlacementNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,340</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0daf86bd-cdce-413f-bf85-c3023130e6b8" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:IssuanceOfCommonSharesFromPrivatePlacementNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,340</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of promissory notes into common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f98fb16a-7ac0-454b-9295-7ee0edb4619e" contextRef="C_f6acf339-8a66-4359-827f-f1d8c3fefcf6" name="calc:StockIssuedDuringPeriodSharesConversionOfPromissoryNotes" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">590,031</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ba40bcf-55d9-4abd-8773-ed253f675fa7" contextRef="C_63f79bb4-c719-4598-9f7b-e5ab26777c6e" name="calc:StockIssuedDuringPeriodValueConversionOfPromissoryNotes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,245</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1672dc8e-6ca1-472d-b80b-7931f1e515e0" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:StockIssuedDuringPeriodValueConversionOfPromissoryNotes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,245</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of Series C-2 warrants into common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_153af6bb-ded7-4c9a-8b33-85731bcbf9e6" contextRef="C_f6acf339-8a66-4359-827f-f1d8c3fefcf6" name="calc:ExerciseAndConversionOfC2WarrantsShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">80,254</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e42107ad-c401-42a6-b191-acdfc423824b" contextRef="C_63f79bb4-c719-4598-9f7b-e5ab26777c6e" name="calc:ConversionOfSeriesC2WarrantIntoCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">442</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1b327e0-8559-48d8-9998-2721f273b4b0" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:ConversionOfSeriesC2WarrantIntoCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">442</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of promissory note warrants into common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a5455d3-ed7c-4191-95d7-b8d91d7b9853" contextRef="C_f6acf339-8a66-4359-827f-f1d8c3fefcf6" name="calc:ConversionOfPromissoryNoteWarrantsIntoCommonStockShare" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">152,875</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_127ffc45-deb8-4560-a841-ffe8b3d340b5" contextRef="C_63f79bb4-c719-4598-9f7b-e5ab26777c6e" name="calc:ConversionOfPromissoryNoteWarrantIntoCommonstock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">841</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb357d5e-270c-4f21-bb17-b5f2e72366e5" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:ConversionOfPromissoryNoteWarrantIntoCommonstock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">841</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Merger transaction costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d57f2fa-d28d-4d69-a3fb-eea091d37120" contextRef="C_63f79bb4-c719-4598-9f7b-e5ab26777c6e" name="calc:MergerTransactionCosts" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,545</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27bccf6d-312e-4c64-b6f4-82580d3965f8" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:MergerTransactionCosts" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,545</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units net settlement</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a151b45-9c5a-4075-854e-649bd711b527" contextRef="C_f6acf339-8a66-4359-827f-f1d8c3fefcf6" name="calc:RestrictedStockUnitsNetSettlementShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">143,960</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_963b7ad7-8132-4212-b560-c0efe257944d" contextRef="C_63f79bb4-c719-4598-9f7b-e5ab26777c6e" name="calc:RestrictedStockUnitsNetSettlement" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">297</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fcc11a0d-97b2-4407-8fe1-bd9786ce7985" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:RestrictedStockUnitsNetSettlement" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">297</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reclassification of warrant liability to equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4680ca76-0261-4097-98be-ec9a5ec5316b" contextRef="C_63f79bb4-c719-4598-9f7b-e5ab26777c6e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">216</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_620a8adb-626b-4096-939f-4307204899cd" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">216</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock from at-the-market offering (net of issuance costs)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_278c6ff8-847b-4962-bd34-02fbdc762c20" contextRef="C_f6acf339-8a66-4359-827f-f1d8c3fefcf6" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">92,572</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb029d07-feb0-46d1-a78a-f11248c8b937" contextRef="C_63f79bb4-c719-4598-9f7b-e5ab26777c6e" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">246</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a01feadc-734c-41ca-aae7-9f239dd349ae" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">246</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain on investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4845c48d-f51b-4b6b-8e8c-540e735b40bb" contextRef="C_a1517846-ee85-4222-be99-133ea3be307b" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b73d297c-d85a-4a35-a7c3-95d4c2fa5775" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9bce2415-3e7c-455e-9cab-a68bd2090560" contextRef="C_f099418b-2bfe-4abc-80ff-3d27b357e283" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">34,357</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_864b9721-627b-4931-8d4d-0a3b9671890f" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">34,357</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance&#8212;December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b3f81f4-28a0-444d-9a2b-0091ef14ee99" contextRef="C_77f977df-d971-4d4d-ae88-a3dd669b55f9" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,754,505</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f21e5d3d-e9cb-4007-891d-59ea88ab8639" contextRef="C_77f977df-d971-4d4d-ae88-a3dd669b55f9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b666d448-f970-4020-bcf7-89be2b0674ae" contextRef="C_0e691536-6f2f-49ff-ae16-8151a9648a89" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154,218</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc6623a2-7a87-4909-b23e-325b0d8c80e2" contextRef="C_d14e56e9-7918-4c0f-9cbf-a1b9ce18ce28" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">146,064</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60582995-92fe-4e92-a20f-630a181e8ab9" contextRef="C_3815767b-a76b-4eab-8224-c12657500927" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_133bf32d-885f-4ce2-a881-7dda5f7c1d87" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,157</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:footnote id="FNT_92a35516-dd1a-4ef7-8468-5d018858e544" xml:lang="en-US"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) Retroactively restated for the reverse recapitalization as described in Note 2.</span></p></ix:footnote>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CALCIMEDICA, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) (1)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.647%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.381%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.381%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.741%;"/>
    <td style="width:1%;"/>
    <td style="width:1.12%;"/>
    <td style="width:1%;"/>
    <td style="width:6.260999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.12%;"/>
    <td style="width:1%;"/>
    <td style="width:6.260999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.12%;"/>
    <td style="width:1%;"/>
    <td style="width:6.920999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.12%;"/>
    <td style="width:1%;"/>
    <td style="width:6.920999999999999%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Convertible Preferred Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional<br/>Paid-In</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Stockholders&#8217;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance&#8212;December 31, 2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_653e16b7-bfd8-48a8-adbe-099c4cbd6e40" contextRef="C_28b5f7e3-7c54-4635-9e19-0a894d5bce7d" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">84,820,880</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_abfd3d94-e97c-4d7d-93da-21000f70a852" contextRef="C_28b5f7e3-7c54-4635-9e19-0a894d5bce7d" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,071</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7fa10f53-be99-4967-bf37-e3fa0474e69a" contextRef="C_bd0bc60c-d4f5-4ec3-a673-0505d888ab7e" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">78,527</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f2f002b-1bd3-437f-bf29-483769287156" contextRef="C_bd0bc60c-d4f5-4ec3-a673-0505d888ab7e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a90ba9c6-3e69-4a14-9d5b-e426367ed758" contextRef="C_70e26569-927c-4f36-a60f-3d66c9bd4f1b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,895</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9d8336f-3890-4043-9995-6e780f43215e" contextRef="C_f3902d69-3631-4f29-9f8f-24d3fa1a5357" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">103,883</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1745aaa-ce03-42da-b1a6-98a0481feb87" contextRef="C_c2ab8d40-d474-4916-9e68-da10e0f82c62" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">63,987</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Issuance of common stock for services</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock for services</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cfd884d5-1492-4801-8aee-6abccadf0736" contextRef="C_0a6fe6b9-36ef-4f25-b46f-fe2f867d0a7c" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,138</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df4b8ac7-51da-463e-9c9c-dbe9dcca068b" contextRef="C_824ded8d-e1b3-4524-b35d-2636e88b1f27" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f53cdfb-67ba-4237-969d-ed0611146511" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of common stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_517b309f-2bec-48a6-9421-c2710b7d70bc" contextRef="C_0a6fe6b9-36ef-4f25-b46f-fe2f867d0a7c" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,500</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05360190-5bd1-462e-bf7b-62f5d8dc51e2" contextRef="C_824ded8d-e1b3-4524-b35d-2636e88b1f27" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca873050-cc96-44d1-8bfa-865790a418df" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53a10c95-e0d7-4999-8f71-8d0c4e705b49" contextRef="C_824ded8d-e1b3-4524-b35d-2636e88b1f27" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,799</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26fee8db-fd6b-4fe9-b409-5e98d2df61d2" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,799</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deemed distribution</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be733402-76c9-42b2-ac17-f92acf5177c3" contextRef="C_824ded8d-e1b3-4524-b35d-2636e88b1f27" name="calc:DeemedDistribution" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,318</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77023610-40d9-41be-b2fa-76e7f8dcce92" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="calc:DeemedDistribution" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,318</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss and comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f773b99e-e092-43b8-b105-11fd67e300ed" contextRef="C_f0c2863c-d6f8-4c28-a7b2-bb4074acd7b8" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,824</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4246f750-75ee-4e2a-abd6-1a856a263eff" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,824</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance&#8212;December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b5f0346-0c24-488f-9425-b68555cebfc0" contextRef="C_6739fa84-42ef-4c69-a6c0-24f4f1d63ab1" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">84,820,880</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86f8a34f-0bf0-4a83-8f0d-9313acb8deb6" contextRef="C_6739fa84-42ef-4c69-a6c0-24f4f1d63ab1" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,071</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d68003c6-190c-4d89-9889-20ee5b4c0a7c" contextRef="C_44e3fe9d-1f45-4346-b174-97527637315a" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">84,165</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f2d26a2-030f-4324-88bf-764c72e52368" contextRef="C_44e3fe9d-1f45-4346-b174-97527637315a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5acdf623-9679-4211-80d3-17ff2a425bd0" contextRef="C_fdc3b56d-3340-41e6-abd7-2a87c4565e5c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,402</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2cd1ea5c-d08c-4219-9e67-70e302644367" contextRef="C_18921a4e-cb36-49f6-887d-24dcb1c18c90" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">111,707</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c6fbfc8-5564-414d-9678-3a300de013b7" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">71,304</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:footnote id="FNT_817b6b4d-bd23-4519-a81b-d710bbd95793" xml:lang="en-US"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) Retroactively restated for the reverse recapitalization as described in Note 2.</span></p></ix:footnote>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CALCIMEDICA, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statemen</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ts of Cash Flows</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.16%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.8%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.8%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Operating activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_321f8514-869b-4786-992e-c17be69b64d0" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">34,357</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c70256d-6b70-439f-b9be-bc38fb2803d8" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,824</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b05dca6-aeb8-4cb8-9627-26e879ca7c0d" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,039</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ffdcdc82-2903-48e5-983d-4f5493465944" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,807</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d40ca9e0-bdef-4ac4-a2ba-2d3536073b13" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27241647-d9d0-4f2b-af61-f39a029f0d0c" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in the fair value of warrant liability</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50f5d0ab-10c6-4f98-bc04-7ea543da3c51" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,146</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_789b497a-e979-4889-88a8-ee33ad9f40b7" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,784</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in the fair value of convertible promissory notes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3b7caf4-c2c1-4054-a2d7-3924958bd389" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:FairValueAdjustmentOfConvertiblePromissoryNotes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,022</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5be64326-5ca9-409c-a168-2ac79b235b87" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="calc:FairValueAdjustmentOfConvertiblePromissoryNotes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,745</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-cash interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4c6ffee-b65a-4d1a-b48c-c166da4c5837" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:NonCashInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">110</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d3ba80d-294a-4a6f-bf2a-50a744e67265" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="calc:NonCashInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">132</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accretion of discount on short-term investment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc8566b0-bdab-440a-889c-3120c64642c7" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">145</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current and non-current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8d72dd0-7725-4924-9aeb-4b1cea6a4f61" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,997</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_926faf54-2a2b-43d6-9117-ac5bcf002d56" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="calc:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,530</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66710324-ad46-45aa-9f92-bdf34677e9e7" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,427</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce6d4772-4c10-4843-b806-9e1fcfc03bdc" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">933</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f6be1bd-ea90-43c9-bba2-923217bfe5c6" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,837</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ccb06f5-e94e-42f2-98a2-4535182e9653" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,202</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0fc7ed5-5aa8-432f-9ac0-0d08f6e5af90" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25,730</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25613843-20d9-4e16-bab0-5dc22124952e" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11,757</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Investing activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc0f247f-c31c-434a-97b8-61c91bab4b8a" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f0ce381-8930-41a0-8716-a6148210fdd9" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8620c546-ddb1-4e3e-88f0-aecad1882ca2" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,118</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Maturity of investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89c332e9-0625-4246-907e-296e36d719e0" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,080</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6e0e707-ef53-4bc6-8383-4261a7cbb8e9" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,884</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f812ef6c-bee1-4b1f-875f-dfc12f359a87" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financing activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuance of common stock, net of issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5040611b-8066-4845-b152-d98d1c16de0d" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,340</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Acquisition of stock of Graybug, net of cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f741cc88-5327-4c56-8b3d-0d4273393e57" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:PaymentsOfAcquisitionOfBusinessesNetOfCash" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,859</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Merger transaction costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6353625f-15c8-4cd1-b060-3b380e4498fc" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,545</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuance of convertible note payable, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a962e11c-bbb9-4cdc-9cfb-824eb76cdd55" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="calc:ProceedsFromIssuanceOfConvertibleNotes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,458</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuance of common stock, net of issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f2e5d6b-007e-4481-8408-cfa84156ce32" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:ProceedsFromOtherEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">246</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d29c1113-3959-4079-9d86-85205935cc44" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:ProceedsFromOtherEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6caeeeb6-54e8-4415-898f-75a8629293fa" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,900</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2edddd36-8a10-4c10-b98b-ed1e1e4268ab" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,476</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net increase (decrease) in cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b473ec85-46e3-41d3-a631-e684421185b6" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,054</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd3a650d-fc54-4136-aec3-fbe1cf281cbc" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,285</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents and restricted cash at beginning of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9072f550-56bc-4cda-aa75-b6aefeaf7fea" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,476</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0973619b-4d90-4af1-9672-802c23ed52d6" contextRef="C_c2ab8d40-d474-4916-9e68-da10e0f82c62" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,761</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents at end of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d75c3c34-5e00-49b0-b62c-cdac5c0ac8a2" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,530</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea8b36e6-1623-4b53-94d2-a49013fb1f19" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,476</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental cash flow information:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Costs incurred in connection with reverse merger included in accounts payable and accrued expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2de02041-b154-45aa-830c-125bb2b2e088" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="calc:CostsIncurredInConnectionWithReverseMergerIncludedInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,313</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of Series A, B, C-1, C-2 and D convertible preferred stock to common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a2da30a-8cad-4d30-af5f-542511f03065" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:ConversionOfStockAmountIssued1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,071</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock to Graybug stockholders as a result of the Merger</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9fe576e-27a6-467e-abe4-fda7403d4744" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,218</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments assumed in the Merger</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ff603a2-87ae-48f7-8863-5a340a09e710" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:ShortTermInvestmentsAssumedInTheMerger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,776</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets assumed in the Merger</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02bf0a87-053f-4d40-9b15-0de8a825c283" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:PrepaidExpensesAndOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,096</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable and accrued liabilities assumed in the Merger</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf8160b6-845e-4ad0-bb37-f21486a377dc" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:AccountsPayableAndAccruedLiabilitiesAssumedInTheMerger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,258</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of C-2 warrants to common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8a5ea31-da83-4f94-9531-0b8388e9da29" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:ConversionOfC2WarrantsToCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">442</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of convertible promissory notes to common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_478c2f17-a407-4d2f-abde-5951c8edeb79" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:ConversionOfConvertiblePromissoryNotesToCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,245</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of convertible promissory note warrants to common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9255ac68-22e5-47ce-9478-f872172f0b96" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:ConversionOfConvertiblePromissoryNoteWarrantsToCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">841</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financing costs included in accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb014fe9-59dd-41f9-bd61-c92d08da9bb4" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:FinancingCostsIncludedInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units net settlement</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b53eda4-9177-4c48-b94e-e60380344892" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:RestrictedStockUnitsNetSettlement" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">297</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reclassification of warrant liability to equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3966a2e-14e9-445e-9e72-d7c61f298cd0" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">216</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CALCIMEDICA, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_condensed_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated F</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inancial Statements</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4329712d-5461-4702-8fe1-24b319608a9d" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:NatureOfOperations" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of Business</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Description of Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CalciMedica, Inc. (&#8220;CalciMedica&#8221; or the &#8220;Company&#8221;) (f/k/a Graybug Vision, Inc.) was incorporated in the state of Delaware in February 2015, following the conversion of Graybug, LLC, which was organized in May 2011, and has its principal operations in La Jolla, California. The Company is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory processes and direct cellular damage.&#8203; The Company has a wholly owned subsidiary, CalciMedica Subsidiary, Inc., incorporated in Delaware in October 2006, which survived the Merger as more fully described below.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reverse Merger Transaction</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 20, 2023, Graybug Vision, Inc. (&#8220;Graybug&#8221;) completed a reverse merger transaction in accordance with the terms and conditions of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended on February 10, 2023 (the &#8220;Merger Agreement&#8221;), by and among Graybug, Camaro Merger Sub, Inc., a wholly owned subsidiary of Graybug (&#8220;Merger Sub&#8221;), and CalciMedica, Inc. (&#8220;Private CalciMedica&#8221;), pursuant to which Merger Sub merged with and into Private CalciMedica, with Private CalciMedica surviving as a wholly owned subsidiary of Graybug (the &#8220;Merger&#8221;). Additionally, on March 20, 2023, Graybug changed its name from &#8220;Graybug Vision, Inc.&#8221; to &#8220;CalciMedica, Inc.&#8221; and Private CalciMedica changed its name from &#8220;CalciMedica, Inc.&#8221; to &#8220;CalciMedica Subsidiary, Inc.&#8221; At the completion of the Merger, the prior Private CalciMedica equity holders and the prior Graybug equity holders owned </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ea2fa75-3e3b-40b9-bb75-4c2889cd6dcc" contextRef="C_dc6f3b09-7f0d-4955-b288-aa892fd2868e" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">72</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00eb1912-2454-46ae-8bfd-86a644ce9380" contextRef="C_bd0f357b-9782-4dba-b331-d7e9654967b9" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">28</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, respectively of the combined company, in each case, on a fully diluted basis using the treasury stock method and excluding out-of-the-money options and warrants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Merger was accounted for as a reverse recapitalization, with Private CalciMedica being treated as the acquirer for accounting purposes. See discussions of the transactions in connection with the Merger in Note 3 - Merger and Related Transactions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has experienced net losses and negative cash flows from operating activities since its inception. The Company has an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55b5673f-fb36-481b-b5e5-de03419cc975" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">146.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023, and a net loss of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2a77077-2f7b-4313-a5a0-8311bd637954" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">34.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2023. Total operating expenses for the year ended December 31, 2023 were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf8b0921-d3c2-43c8-ba61-0991bc9c1a12" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">38.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which included $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fce7f27b-4616-4ea7-84c5-7582b6c3cd21" contextRef="C_0e01fe61-f63d-4314-9813-8fdd75652190" name="us-gaap:SeveranceCosts1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">16.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of one-time charges comprised of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9fbd5699-2ce0-481d-88ab-932c715f77f7" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of charges related to the acceleration of vesting of the Graybug stock awards at the date of the Merger and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ceb5f36d-0a86-4495-a902-b84ba4e8ce0a" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:SeveranceCosts1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of charges related to severance as a result of the Merger. Substantially all of the Company&#8217;s operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company expects to incur significant expenses and increasing operating losses for the foreseeable future as the Company initiates and continues the preclinical and clinical development of its product candidates and adds personnel necessary to operate as a company with an advanced clinical pipeline of product candidates. In addition, after completion of the Merger, operating as a U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) registrant will involve the hiring of additional financial and other personnel, upgrading financial information systems, and incurring costs associated with operating as a public company. The Company expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of clinical development programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From inception to December 31, 2023, the Company has completed financings from the sale of preferred and common stock for total net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_037e5103-80d9-4b35-bc37-bc4131a23209" contextRef="C_ca2b5abc-6893-4a09-9891-e889e91a1af0" name="calc:TotalNetProceeds" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">112.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and has issued convertible debt for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a26c127-4400-43d0-ab97-70a714aca562" contextRef="C_69c89aa6-a735-464c-af58-9f7d7d6733ad" name="us-gaap:ProceedsFromConvertibleDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. In connection with the Merger, the Company received approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fef85283-2237-4fe2-9b3a-4a92612f25de" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:BusinessCombinationConsiderationTransferred1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">29.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of cash, cash equivalents and short-term investments. As of December 31, 2023, the Company had cash, cash equivalents and short-term investments of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_423c5b6c-2252-4d93-9ed9-24951456a58d" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company closed a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> private placement transaction on January 23, 2024 and the second closing of this private placement occurred on February 5, 2024. Gross proceeds from the transaction were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1f3753d-58b9-4959-b495-e7eeba7c18b6" contextRef="C_9ef48710-53ac-4e62-b939-0912f0ec48d0" name="calc:GrossProceedsFromThePrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million with net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b3f3219-fc46-4a2d-baf9-4a1fc48d9eea" contextRef="C_9ef48710-53ac-4e62-b939-0912f0ec48d0" name="calc:NetProceedsFromPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">19.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd4ca947-c618-4700-b7af-9387d216d153" contextRef="C_9ef48710-53ac-4e62-b939-0912f0ec48d0" name="calc:CommissionsAndOtherTransactionExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in commissions and other transaction expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company intends to seek additional funding through public and private financings, debt financings, collaboration agreements, strategic alliances and licensing agreements. Although the Company has been successful in raising capital in the past, there is no assurance of success in obtaining such additional financing on terms acceptable to us, it at all, and there is no assurance that the Company will be able to enter into collaborations or other arrangements. If the Company is unable to obtain funding when required or on acceptable terms, the Company may be required to scale back or discontinue the advancement of the product candidates, reduce headcount, file for bankruptcy, reorganize, merge with another entity or cease operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on the Company&#8217;s current operating plans, management believes its cash, cash equivalents and short-term investments will be sufficient to fund its operations for the period of at least one year following the issuance of these financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b2df8911-3bc2-4f9c-b133-34c590739d97" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Summary of Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_419ba5a2-373c-4e29-ab9d-a237b6e3cd77" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;), and Accounting Standards Update (&#8220;ASU&#8221;), of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The consolidated financial statements include the accounts of the Company and CalciMedica Subsidiary, Inc. for the years ended December 31, 2023 and 2022. All intercompany accounts and transactions have been eliminated in consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since Private CalciMedica was determined to be the accounting acquirer in connection with the Merger, for periods prior to the Merger, the consolidated financial statements were prepared on a stand-alone basis for Private CalciMedica and did not include the combined entities activity or financial position. Subsequent to the Merger, the consolidated financial statements as of and for the year ended December 31, 2023 include Graybug&#8217;s activity from March 21, 2023 through December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and assets and liabilities at their acquisition date fair value. Historical share and per share figures of Private CalciMedica have been retroactively restated based on the merger exchange ratio of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_194cfab8-1367-4b1b-83e7-2611fcd42788" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:StockholdersEquityNoteStockSplitExchangeRatio" unitRef="U_pure" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0288</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e1e1dac8-fb43-4422-b2a7-02e2b1196a28" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">   </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company&#8217;s consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#8217;s consolidated financial statements relate to accruals for research and development expenses, valuation of warrants, valuation of convertible promissory notes and valuation of equity awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5234e33e-5571-48a7-9aec-da4507277bd7" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and other Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments, which potentially subject the Company to concentration of risk, consist principally of cash and cash equivalents. The Company&#8217;s cash is deposited with major federally insured U.S. financial institutions. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is dependent on contract manufacturing organizations (&#8220;CMO&#8221;) to supply products for research and development of its product candidates, including preclinical and clinical studies, and for commercialization of its product candidates, if approved. The Company&#8217;s development programs could be adversely affected by any significant interruption in CMO&#8217;s operations or by a significant interruption in the supply of active pharmaceutical ingredients and other components.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Products developed by the Company require approval from the FDA or other international regulatory agencies prior to commercial sales. There can be no assurance the Company&#8217;s product candidates will receive the necessary approvals. If the Company is denied approvals, approvals are delayed, or the Company is unable to maintain approvals received, such events could have a materially adverse impact on the Company.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_55b2edef-0bc7-4e81-9376-db0ecb4a43bc" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents consist of readily available cash in checking accounts, money market funds and commercial paper. The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_11b32fa3-4cb2-4e82-86ea-faeadefb5394" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Short-term Investments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company invests excess cash in commercial paper and U.S government sponsored entities - mortgage-backed securities. These investments are included in short-term investments on the balance sheet, classified as available-for-sale and reported at fair value with unrealized gains and losses included in accumulated other comprehensive (loss)/gain, net. Realized gains and losses on the sale of these securities are recognized in net loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4ca31dd8-b812-420e-9ec3-934183eadf3a" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The financial information is regularly reviewed by the chief operating decision maker (&#8220;CODM&#8221;), in deciding how to allocate resources. The Company&#8217;s CODM is its chief executive officer. The Company&#8217;s singular focus is on developing highly selective calcium release-activated calcium channel inhibitors to improve outcomes for patients with acute inflammatory indications. No significant revenue has been generated since inception, and all tangible assets are held in the United States.</span></p></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3323028f-4f6f-49b6-b534-447bad76ad9e" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Option</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As permitted under ASC 825, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Company has elected the fair value option to account for its convertible promissory notes due to certain embedded features within the notes. The Company recognizes the convertible</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">promissory </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">notes at fair value with changes in fair value recognized in the consolidated statements of operations located on the change in fair value of financial instruments line item. Changes in fair value as a result of the Company&#8217;s own credit risk is reflected in other income (expense) in the consolidated statements of operations. As a result of applying the fair value option, direct costs and fees related to the convertible promissory notes were expensed as incurred and not deferred.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2cff8d0c-87a1-4282-80f7-5006b0874b65" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally three to five years) and consist of manufacturing and lab equipment, furniture, computers and phones. Repairs and maintenance costs are charged to expense as incurred. Depreciation expense recognized for the years ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a661bd3-532d-4052-8e40-e3a925233784" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:Depreciation" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">58,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1ece8e8-0eef-4444-b19d-65e51f3a4110" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:Depreciation" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">52,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ee8f472f-5190-4d4c-ba02-e49fe89c8447" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Long-lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-lived assets consist primarily of property and equipment. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate the carrying amount of an asset is not recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value would be assessed using discounted cash flows or other appropriate measures of fair value. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_079dd36e-c5e4-40c9-9f86-8c0981b5171c" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e108528b-b612-4718-847f-4893b4021351" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognize any impairment losses for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ba0cd446-1ac3-4268-99c8-1de22a783101" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company leases office space with an original lease term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_96e7d778-f45a-41e2-8962-c4c3904214d6;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">twelve months </span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and does </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00ee5f11-cf9f-43e3-85f9-03fdc01a0579" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="calc:RightOfUseAssetOrLeaseLiability" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t have a right-of-use asset or lease liability recorded. The Company's policy is not to record leases with an original term of twelve months or less on the consolidated balance sheets. The Company recognizes lease expense for this short-term lease on a straight-line basis over the term of the lease. The lease is accounted for under ASC 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and has been classified as an operating lease. Rent expense recognized for the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b68643e-4ad2-4f8f-a4c8-69e4ac4507e5" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:LeaseAndRentalExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">274,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a2039a5-f443-4d4b-8803-1f9ede734b86" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:LeaseAndRentalExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">221,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_039e3ed0-c27a-4067-9e32-ce07d58137a7" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:AccruedResearchAndDevelopmentCostsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs consist primarily of salaries, payroll taxes, employee benefits and stock-based compensation for those individuals involved in ongoing research and development efforts, as well as fees paid to consultants, external research fees, license fees paid to third parties for use of their intellectual property, laboratory supplies and development of compound materials, associated overhead expenses and facilities and depreciation costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. All research and development costs are expensed as incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company estimates preclinical studies and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on the Company&#8217;s behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers,  and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. The estimates are trued up to reflect the best information available at the time of the financial statement issuance. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#8217;s estimate of the status and timing of services performed relative to the actual status and timing of services performed may vary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6fcef053-4469-46fb-b24c-1319141d2e2a" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation, related to executive, finance, business development, legal, human resources and support functions, including professional fees for auditing, tax, consulting and patent-related services, rent and utilities and insurance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cd327fe3-04a9-47f2-a64a-c27b4a190005" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:PatentsCostsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs related to filing and pursuing patent applications are expensed as incurred since recoverability of such expenditures is uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8cde8100-f8c6-4544-9376-263ea5b175f1" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:DeferredPolicyAcquisitionCostsTextBlock1" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Deferred Offering Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company capitalizes costs that are directly associated with equity financings until such financings are consummated at which time such costs are recorded against the gross proceeds of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss. Private CalciMedica had deferred offering costs capitalized as of December 31, 2022 for the Merger of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db83b54d-5e8c-42ea-b3c6-0af1238e26ba" contextRef="C_c53f262c-1896-431c-b404-2f2cd328973f" name="us-gaap:DeferredOfferingCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. As of December 31, 2023, the Company has deferred costs associated with its at-the-market offering of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33a79c37-be0c-447f-be90-df0469ce2ea8" contextRef="C_ccf97b7e-0005-4bf8-ac80-ebcbb11b741c" name="us-gaap:DeferredOfferingCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2822188f-ea9c-4627-94e8-ee9ed705ebf1" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:WarrantLiabilityPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrant Liability</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Private CalciMedica has issued various freestanding warrants to purchase shares of its convertible preferred stock. Prior to the Merger, Private CalciMedica adjusted the carrying value of such convertible preferred stock warrants to the estimated fair value at each reporting date, with any related increases or decreases in the fair value being recorded within other income (expense) in the consolidated statements of operations and comprehensive loss. Pursuant to the Merger Agreement, the Series C convertible preferred stock warrants became warrants to purchase shares of the combined company's common stock. As a result of the Merger, the warrants no longer meet the requirements for liability accounting and, as such, Private CalciMedica adjusted the value of the warrants to the estimated fair value as of the Merger date and reclassified them to stockholders' equity (deficit).</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5e806b44-1d40-43f5-8a74-abef8444e54d" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense represents the cost of the grant date fair value of employee stock options recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. Private CalciMedica estimates the fair value of stock option grants using the Black-Scholes option pricing model (&#8220;Black-Scholes&#8221;). Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. Equity-based compensation expense is classified in the statements of operations in the same manner in which the award recipients&#8217; payroll costs are classified or in which the award recipients&#8217; service payments are classified. The fair value of each stock option grant is estimated on the date of grant using Black Scholes. The following summarizes the inputs used:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Common Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the Merger, there was no public market for Private CalciMedica&#8217;s common stock. The fair value of the shares of common stock underlying Private CalciMedica</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8217;s share-based awards was estimated on each grant date by Private CalciMedica&#8217;s board of directors. To determine the fair value of Private CalciMedica&#8217;s common stock underlying option grants, the board of directors considered, among other things, input from management and valuations of Private CalciMedica's common stock prepared by third-party valuation firms.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Post Merger, CalciMedica uses the closing stock price the day prior to the grant date for the fair value.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk-Free Interest Rate</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The risk-free interest ra</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">te is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities similar to the expected term of the awards.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Volatility</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the merger, since Private CalciMedica did not have publicly traded equity securities, the volatility of the options has been estimated using peer group volatility information. Post Merger, CalciMedica uses an average volatility for comparable publicly-traded biopharmaceutical companies over a period equal to the expected term of the stock award grant as CalciMedica does not yet have sufficient historical trading history for its own stock. CalciMedica will continue to apply this method until a sufficient amount of historical information over a period equal to the expected term of the stock-based awards becomes available.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Term</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CalciMedica used the simplified method to calc</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ulate the expected term for all grants during all periods, which is based on the midpoint between the vesting date and the end of the contractual term.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Dividend Yield</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CalciMedica has never paid and has no present intention to pay cash dividends.</span></p></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5171a2a5-22d3-41dd-8500-827f0e449c7e" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4e69cee-ccc5-4015-b589-3b522d3e817c" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:TaxPostionMinimumPercentageOfTaxBenefit" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e2dd1248-9cb1-46f0-aa6f-48dbce374ec9" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources which are excluded from net loss. The Company&#8217;s only element of other comprehensive loss is unrealized gains and losses on marketable securities.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4139bca2-52a3-4efe-84df-a72b51c99940" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:RelatedPartyTransactionsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Related Party Transactions</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s board of directors reviews and approves transactions with directors, officers and holders of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11c6bcc5-1bfb-4ebd-8f34-18bead2a0f34" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:VariableInterestEntityOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% or more of its voting securities and their affiliates, each a related party. The material facts as to the related party&#8217;s relationship or interest in the transaction are disclosed to its board of directors prior to their consideration of such transaction, and the transaction is not considered approved by its board of directors unless a majority of the directors who are not interested in the transaction approve the transaction.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Beginning in November 2020, Private CalciMedica has paid consulting fees monthly to a consulting firm affiliated with the Company&#8217;s interim chief financial officer in connection with its consulting agreement. CalciMedica recorded expense of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_525c6930-1573-477f-aa70-a6e9f6356a91" contextRef="C_d046d1dd-275e-4ce7-b43c-2ca79d4f0e9a" name="us-gaap:CostsAndExpensesRelatedParty" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">521,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c36d987-1163-48de-9633-961dfcb3bec8" contextRef="C_0e069504-00ad-4b62-9b5c-575c0a9feed4" name="us-gaap:CostsAndExpensesRelatedParty" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">223,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> during years ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022, respectively.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cb896953-b341-4f44-b9a4-b43f32407f09" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net loss is equivalent to net loss attributable to common stockholders for all periods presented. Basic net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. The Company calculates diluted net loss per share using the more dilutive of the (1) treasury stock method, if-converted method, or contingently issuable share method, as applicable, or (2) the two-class method. For warrants, the calculation of diluted net loss per share requires that, to the extent the average fair value of the underlying shares for the reporting period exceeds the exercise price of the warrants and the presumed exercise of such securities are dilutive to net loss per share for the period, adjustments to net loss used in the calculation are required to remove the change in fair value of the warrants for the period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In all periods presented, the Company&#8217;s outstanding preferred stock, stock options, preferred, common and convertible promissory note warrants, and outstanding convertible promissory notes were excluded from the calculation of loss per share because the effect would be antidilutive. Accordingly, in periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_13726212-0945-425a-aa01-5d67cbdad87b" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which changes the accounting for recognizing impairments of financial assets. Under the new guidance, credit losses for certain types of financial instruments will be estimated based on expected losses. The new guidance also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. This update is effective for the Company beginning January 1, 2023. The Company adopted this ASU as of January 1, 2023, which did not have an impact on its consolidated financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt with Conversion and Other Options (Subtopic 470-20)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The ASU provides guidance that simplified the accounting for certain financial instruments with characteristics of liabilities and equity. The new guidance reduced the number of accounting models for convertible debt and convertible preferred stock instruments and made certain disclosure amendments intended to improve the information provided to users. The guidance also amended the derivative guidance for the &#8220;own stock&#8221; scope exception, which exempts qualifying instruments from being accounted for as derivatives if certain criteria are met. Finally, the standard changed the way certain convertible instruments are treated when calculating earnings per share. This guidance is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. The Company is currently assessing the impact that this guidance will have on its consolidated financial statements.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8f3426f6-f735-48ce-9fa8-721e30b4e3a2" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:BusinessCombinationDisclosureTextBlock" escape="true" continuedAt="F_8f3426f6-f735-48ce-9fa8-721e30b4e3a2_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Merger and Related Transactions</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As described in Note 1 - Nature of Business, Private CalciMedica merged with a wholly owned subsidiary of Graybug on March 20, 2023. The Merger was accounted for as a reverse recapitalization under U.S. GAAP. Private CalciMedica was considered the accounting acquirer for financial reporting purposes. This determination is based on the facts that, immediately following the Merger: (i) former Private CalciMedica stockholders owned a substantial majority of the voting rights of the combined company; Private CalciMedica designated a majority (five of seven) of the initial members of the board of directors of the combined company; and former Private CalciMedica's senior management held all key positions in senior management of the combined company. The transaction is accounted for as a reverse recapitalization of Graybug by Private CalciMedica similar to the issuance of equity for the net assets of Graybug, which are primarily cash, short-term investments and other non-operating assets. It was concluded that any in-process research and development assets that remained as of the Merger would be de minimis when compared to the cash and investments obtained through the Merger.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under reverse recapitalization accounting, the assets and liabilities of Graybug were recorded at their fair value, which approximated book value due to the short-term nature of the instruments. The Company's consolidated financial statements reflect the issuance of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49ec7c40-8bd5-44c9-bd2e-a09b62444d2a" contextRef="C_c654b3dc-d8de-4e32-ade7-4c14b46e29eb" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,571,433</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares to the former stockholders of Graybug.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding share of Private CalciMedica capital stock (after giving effect to the automatic conversion of all shares of Private CalciMedica preferred stock into shares of Private CalciMedica common stock, the automatic exercise of certain Private CalciMedica warrants to purchase shares of Private CalciMedica common stock in accordance with their terms (the &#8220;Private CalciMedica warrant exercises&#8221;), the conversion of Private CalciMedica convertible promissory notes into Private CalciMedica common stock and the closing of the private placement (as discussed in Note 7 - Convertible Preferred Stock, Common Stock, and Stockholders' Deficit)), was converted into the right to receive </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2951ef33-8775-4c68-8414-9618ff476270" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:StockIssuedDuringPeriodPrivatePlacement" unitRef="U_shares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0288</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Graybug common stock, which resulted in the issuance by Graybug of an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33f83587-0e0b-4cd0-b1ee-5b4f456778bc" contextRef="C_f6acf339-8a66-4359-827f-f1d8c3fefcf6" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,946,540</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Graybug common stock to the stockholders of Private CalciMedica in a transaction exempt from registration under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), in reliance on Section 4(a)(2) of the Securities Act and the rules promulgated thereunder. In addition, Graybug assumed the Private CalciMedica 2006 Stock Plan (See Note 8 - Stock-Based Compensation), and each outstanding and unexercised option to purchase Private CalciMedica common stock and each outstanding and unexercised warrant to purchase Private CalciMedica common stock (excluding the warrants which were automatically exercised pursuant to the Private CalciMedica warrant exercises) became options and warrants, respectively, to purchase shares of Graybug common stock. Immediately following the consummation of the Merger prior Private CalciMedica and Graybug stockholders collectively own approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c5958ab-f9e7-410d-83fb-5711f1dd490d" contextRef="C_dc6f3b09-7f0d-4955-b288-aa892fd2868e" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">72</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ca4bd3f-110e-4faa-9022-554c1cd5f2c4" contextRef="C_bd0f357b-9782-4dba-b331-d7e9654967b9" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">28</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the Company, respectively, on a fully diluted basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of the reverse recapitalization, Private CalciMedica received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c87be83a-10b4-43f7-b5de-154530397ed0" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:BusinessCombinationConsiderationTransferred1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">29.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of cash, cash equivalents and short-term investments, net of transaction costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Private CalciMedica also obtained prepaid and other current assets of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28fbeca1-adff-47e3-bc1d-de5ea62f4e8c" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and assumed payables and accrued expenses of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ecdfc4dc-1bcf-4d46-97e7-fb36d867a205" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Private CalciMedica also incurred transaction costs of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab95b2c4-e49d-4e6d-b348-29b098fcd952" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:BusinessCombinationConsiderationTransferedCostIncurred" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which is recorded as a reduction to additional paid-in capital in the accompanying consolidated statement of convertible preferred stock and stockholders' equity (deficit). The Company also recorded one-time charges of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ecda2acc-8f48-433c-982f-37c99dae0de3" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the acceleration of the Graybug stock awards and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b94125c-d2dd-4611-babf-80c4de9155b2" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:SeveranceCosts1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in severance charges that are recorded in the consolidated statements of operations and comprehensive loss for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">twelve months ended December 31, 2023.</span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><ix:continuation id="F_8f3426f6-f735-48ce-9fa8-721e30b4e3a2_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 17, 2023, in connection with the transactions contemplated by the Merger Agreement and following a special meeting of Graybug&#8217;s stockholders, Graybug filed an Amended and Restated Certificate of Incorporation effecting a reverse stock split of Graybug&#8217;s common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8239a426-0c4b-4e6f-9c4e-8bfe879f3ff8" contextRef="C_07aad975-11de-44fb-9c2a-ae67476d452b" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, at a ratio of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_131b667d-3b49-44c3-a8b1-f0947cc62801" contextRef="C_bb55cbd6-a773-4301-9abc-12c18795aee6" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">14</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:1.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c8f7472d-0734-441d-99a6-712c6edcfb42" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:DerivativesAndFairValueTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's assets and liabilities which are measured at fair value including short-term investments, warrants for preferred stock (&#8220;Preferred Warrants&#8221;), warrants for common stock related to the convertible promissory notes (&#8220;Convertible Promissory Note Warrants&#8221;), the liabilities are presented together on the balance sheets as &#8220;Warrant Liability&#8221; and convertible promissory notes. All assets and liabilities recorded at fair value are revalued at each measurement period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Private CalciMedica elected the fair value option for the convertible promissory notes and estimated the fair value based on a discounted cash flow analysis, a form of the Income Approach. Several different settlement scenarios were considered, and probability weighted to arrive at the final valuation. Increases or decreases in the fair value of the convertible promissory notes can result from updates to assumptions such as the expected timing or probability of the different settlement scenarios, or changes in discount rates. Judgment is used in determining these assumptions as of the initial valuation date and at each subsequent reporting period. Updates to assumptions could have a significant impact on the Company&#8217;s results of operations in any given period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Preferred Warrants are valued using the Hybrid Method (&#8220;Hybrid Method&#8221;). This method incorporates Private CalciMedica&#8217;s near-term liquidity event prospects utilized in conjunction with the Option Pricing Method (&#8220;OPM&#8221;) framework, representing an alternative exit, to calculate an implied overall value of Private CalciMedica. This value is, in turn, allocated to Private CalciMedica&#8217;s various equity classes.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Convertible Promissory Note Warrants are valued using a series of Monte Carlo simulations and Black-Scholes to determine the fair value, probability weighted for difference scenarios. The Monte Carlo simulations determined the liquidity event price. Black-Scholes is used with the remaining contractual term of the warrants after the respective event date. The warrant value is discounted from the respective event date using the risk-free rate for the period ending December 31, 2022. The Convertible Promissory Note Warrants were valued using the common stock price on day of conversion. See further discussion in Note 5 - Convertible Promissory Notes and Convertible Promissory Note Warrants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following three levels:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 1:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Observable inputs such as unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date. </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 2:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 3:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6d4a9901-118c-48b2-85f3-bfc99b64f044" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true" continuedAt="F_6d4a9901-118c-48b2-85f3-bfc99b64f044_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.34%;"/>
        <td style="width:1.18%;"/>
        <td style="width:1%;"/>
        <td style="width:9.236%;"/>
        <td style="width:1%;"/>
        <td style="width:1.18%;"/>
        <td style="width:1%;"/>
        <td style="width:9.236%;"/>
        <td style="width:1%;"/>
        <td style="width:1.18%;"/>
        <td style="width:1%;"/>
        <td style="width:9.236%;"/>
        <td style="width:1%;"/>
        <td style="width:1.18%;"/>
        <td style="width:1%;"/>
        <td style="width:9.236%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Current assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27b73af8-9855-4395-8fd3-43d18f2cec97" contextRef="C_6c40048e-5e83-487d-95e9-572612a5b2a0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,634</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ee45d7b-6d0d-4909-8cda-a9bfa880a422" contextRef="C_47c16d4b-a330-4cfb-83cf-9d9c1168ecac" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,634</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3db82384-cbdb-4414-b632-f111ef9e5b88" contextRef="C_efd6e33a-c854-438b-b83a-602ebf9ebf8c" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,738</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_839337ab-0e91-4341-b7db-cde9b0018ac0" contextRef="C_7f725abd-da2c-4ddd-87a7-b41ccda9c06b" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,738</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6648dfa7-2015-4cd7-aaa1-6371da64898a" contextRef="C_6a19c8ff-3eec-4e73-bbb3-c3b561d13063" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,634</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36868f76-ebf7-4907-89e1-c5a90d625c60" contextRef="C_7e197c94-c9cd-4e85-83f1-c4bac6996bbc" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,738</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a475d82-ab2c-4186-8f9a-182e814250ef" contextRef="C_7f64735a-ca76-47aa-aadd-323f69769f4e" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,372</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad08648b-ee71-4719-8df7-0de36603276a" contextRef="C_efd6e33a-c854-438b-b83a-602ebf9ebf8c" name="calc:ShortTermInvestmentFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,213</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_139eac0d-f520-4ee5-af34-fec34ea2a754" contextRef="C_7f725abd-da2c-4ddd-87a7-b41ccda9c06b" name="calc:ShortTermInvestmentFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,213</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government sponsored entities - mortgage-backed securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a225a135-1993-4338-9f88-3a16c76a29e6" contextRef="C_31761f11-9358-474c-ab64-43e5fe6dd846" name="calc:ShortTermInvestmentFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">495</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28aad148-f271-4525-90d8-b1590295df64" contextRef="C_8b643f00-2d89-421c-b960-b0008cf81a56" name="calc:ShortTermInvestmentFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">495</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb8de645-87b7-463a-962a-e7b5b508baee" contextRef="C_7e197c94-c9cd-4e85-83f1-c4bac6996bbc" name="calc:ShortTermInvestmentFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,708</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73d0c120-757d-4168-8f02-a71cd6dbd2f2" contextRef="C_7f64735a-ca76-47aa-aadd-323f69769f4e" name="calc:ShortTermInvestmentFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,708</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b4a338a-1f34-45e5-9a62-420a61ef1674" contextRef="C_6a19c8ff-3eec-4e73-bbb3-c3b561d13063" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,634</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9032dfbf-135a-4ccf-ba2e-cdef5cb0fb28" contextRef="C_7e197c94-c9cd-4e85-83f1-c4bac6996bbc" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,446</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6df5d966-7bda-422c-8111-7fb9256ce27a" contextRef="C_7f64735a-ca76-47aa-aadd-323f69769f4e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,080</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds are highly liquid investments which are actively traded. The pricing information on the Company&#8217;s money market funds is based on quoted prices in active markets for identical securities. This approach results in the classification of these securities as Level 1 of the fair value hierarchy.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commercial paper and U.S. Government sponsored entities - mortgage-backed are classified as Level 2 with in the hierarchy and are carried at fair value with unrealized gains and losses included in other comprehensive income (loss) as a component of stockholders&#8217; equity until realized. The Company estimates the fair values of these securities by taking into consideration valuations obtained from third-party pricing sources.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e1bb07b-dd20-4d59-bdf8-1ad681d0ce6d" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> fair value liabilities exist as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_6d4a9901-118c-48b2-85f3-bfc99b64f044_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables present information about the Company&#8217;s financial liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible promissory notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3309b19-14ed-4eda-925e-e147c8c02596" contextRef="C_1945eb61-653c-4d34-aedd-57f80cdc4177" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,157</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e6bd083-8b5f-4d93-a5b8-06c28009f031" contextRef="C_7fa15f5d-da9e-49b1-ad4b-7ac0dffbd31d" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,157</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred Warrants liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e8a36bf-fe27-4307-9e0d-c9be9794f5fe" contextRef="C_53e9f125-e7ca-4cd9-96f3-b398eddc05fa" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,453</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df8e1fdf-f2a9-4ab3-8c6c-8ca0278bc905" contextRef="C_1d04e9a4-5ef0-4df1-8750-14de2723f9bb" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,453</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible Promissory Note Warrants liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc879b6b-70ee-4fbe-8c5a-e32b843cb928" contextRef="C_849e11ac-1955-44ec-aed2-b66fa055ed0a" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,192</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0704ac47-8911-4db6-9924-5706a965040c" contextRef="C_666c7e89-c8db-48ef-beec-8e67efcb35b4" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,192</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities measured at fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_345b0282-7bbc-403b-ab9b-1e5f633e9727" contextRef="C_a90b884a-f2e9-44ca-a156-3042948bd1e5" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,802</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c1e96ff-2162-44b8-b938-387640a167d6" contextRef="C_45300d27-3112-43ed-a27a-f1ca2b9647c0" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,802</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6c843bbd-9e49-482c-a775-7d1a43f0b274" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following provides a reconciliation for all liabilities measured at fair value using Level 3 inputs for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.22%;"/>
        <td style="width:1.9%;"/>
        <td style="width:1%;"/>
        <td style="width:15.88%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Convertible Promissory Note liability</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5029a464-149a-4cfe-8eab-fc8223d286b8" contextRef="C_d790b41b-1e12-488c-8daa-9f3b3627753e" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,157</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in Fair Value of Convertible Promissory Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff7b555b-7a4c-4cb6-ad2b-3add73c9b770" contextRef="C_79aec6d8-c918-443b-a31f-3dd73301431e" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,022</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued Interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fcadfd7d-82e5-470a-a4c0-21a3b159108f" contextRef="C_79aec6d8-c918-443b-a31f-3dd73301431e" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">110</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of Convertible Promissory Notes to equity</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4bfed076-d1c5-4bb6-9347-f6662f0c81d4" contextRef="C_79aec6d8-c918-443b-a31f-3dd73301431e" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,245</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11e66726-b7b3-4b04-bf8d-e17015be30a8" contextRef="C_a3e0ce3a-700f-4c36-8d35-fed370e247a0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Preferred Warrant liability</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_825e47f3-e98a-4948-b45b-4cd23ee09416" contextRef="C_3238f60f-57e8-430b-b3e4-81f554a6a7c5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,453</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in Fair Value of Preferred Warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae8a892e-53e0-4bca-9520-45144481c654" contextRef="C_38046496-ba8c-4f7b-a2ab-17742c50658a" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">795</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of warrant liability to equity</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b8db551-9124-45d5-a982-f8ca0e539828" contextRef="C_38046496-ba8c-4f7b-a2ab-17742c50658a" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">658</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28fd740e-225b-421f-bc87-305748331b64" contextRef="C_cab222f3-c29a-438f-bc50-d49b23b8991a" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Convertible Promissory Note Warrants liability</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97e99fac-f2c2-48c9-8361-2fed2ce9ac9c" contextRef="C_5ac139a0-0917-47cd-862b-6898ff89d717" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,192</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in Fair Value of Convertible Promissory Note Warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c98a6ef-bcee-46df-b280-39fbd4be64d5" contextRef="C_c8e84e93-e57a-4e7e-a6fd-3469c8f77e9d" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">351</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of Convertible Promissory Note Warrants liability to equity</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b89489e9-fdbb-4a22-b1de-f207d5158890" contextRef="C_c8e84e93-e57a-4e7e-a6fd-3469c8f77e9d" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">841</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f67024a1-5cfb-43f8-a27e-5d25a3c2d2aa" contextRef="C_f048298b-299d-47f9-b5bd-5b7c905187ca" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6ef12950-0f12-4e00-9580-6bc9f5f0c2d7" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents information as to cost, unrealized gains and losses and fair value determination of the Company&#8217;s financial assets measured at fair value on a recurring basis (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.34%;"/>
        <td style="width:1.18%;"/>
        <td style="width:1%;"/>
        <td style="width:9.236%;"/>
        <td style="width:1%;"/>
        <td style="width:1.18%;"/>
        <td style="width:1%;"/>
        <td style="width:9.236%;"/>
        <td style="width:1%;"/>
        <td style="width:1.18%;"/>
        <td style="width:1%;"/>
        <td style="width:9.236%;"/>
        <td style="width:1%;"/>
        <td style="width:1.18%;"/>
        <td style="width:1%;"/>
        <td style="width:9.236%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Current assets:</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c78d69b1-a79d-43df-b1be-47b1221370b9" contextRef="C_fb58baf9-d75a-4814-b11a-5c4bf3132842" name="calc:CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,634</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb24c338-30f7-4bbf-9836-7f21c4fb77e1" contextRef="C_fb58baf9-d75a-4814-b11a-5c4bf3132842" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,634</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f857e860-8d2a-417e-a020-56639be41a9b" contextRef="C_e9aabbcc-ba19-4328-a90c-b2b531c98d96" name="calc:CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,738</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f84c93e-0b89-4c0b-bc19-83d03306da54" contextRef="C_e9aabbcc-ba19-4328-a90c-b2b531c98d96" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,738</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d8140cf-0125-4f1b-b2d0-a407c4eb33bb" contextRef="C_7f64735a-ca76-47aa-aadd-323f69769f4e" name="calc:CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,372</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6364a6cd-2195-4399-8bc7-75e3965d06ea" contextRef="C_7f64735a-ca76-47aa-aadd-323f69769f4e" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,372</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9e8ad57-ab7b-4d45-899b-95797270e9cd" contextRef="C_e9aabbcc-ba19-4328-a90c-b2b531c98d96" name="calc:ShortTermInvestmentFairValueDisclosureAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,211</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_197bc75c-3795-4607-865c-c3eeca1568f5" contextRef="C_e9aabbcc-ba19-4328-a90c-b2b531c98d96" name="calc:ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d57bf60-6f1f-449b-a7db-f60610610eb4" contextRef="C_e9aabbcc-ba19-4328-a90c-b2b531c98d96" name="calc:ShortTermInvestmentFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,213</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government sponsored entities - mortgage-backed securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f3fa10f-bf9d-4821-94b3-f1166efa2b8e" contextRef="C_2144abf4-0a9e-4b97-a97a-75d1e0d63184" name="calc:ShortTermInvestmentFairValueDisclosureAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">495</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7bf34894-b0fc-4c15-adbb-694e02fb7b35" contextRef="C_2144abf4-0a9e-4b97-a97a-75d1e0d63184" name="calc:ShortTermInvestmentFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">495</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49116411-7c60-4618-8264-baeec0956f1c" contextRef="C_7f64735a-ca76-47aa-aadd-323f69769f4e" name="calc:ShortTermInvestmentFairValueDisclosureAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,706</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39d0ace4-6178-4657-863b-f7af01064fb0" contextRef="C_7f64735a-ca76-47aa-aadd-323f69769f4e" name="calc:ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d815a63f-eae6-4def-a7ad-b4fc374a0f28" contextRef="C_7f64735a-ca76-47aa-aadd-323f69769f4e" name="calc:ShortTermInvestmentFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,708</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_040a70a7-0652-4b5e-90e8-6bdcac174fa6" contextRef="C_7f64735a-ca76-47aa-aadd-323f69769f4e" name="calc:AssetsFairValueDisclosureAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,078</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83740d3c-2049-4802-8e14-e6cd45530016" contextRef="C_7f64735a-ca76-47aa-aadd-323f69769f4e" name="calc:AssetsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f5b4d31-1339-40b6-a549-8b48c7d74915" contextRef="C_7f64735a-ca76-47aa-aadd-323f69769f4e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,080</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the contractual maturities of all available-for-sale investments were less than 12 months. The Company periodically reviews the available-for-sale for other-than-temporary impairment loss. The Company had short-term investments in unrealized gain positions as of December 31, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03f86d63-4b05-454a-915f-a9145771240e" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cash equivalents.</span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_465461bc-1813-48a0-9a6e-a87d3d3453da" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:DebtDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. Convertible Promissory Notes and Convertible Promissory Note Warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2022, the Private CalciMedica board of directors approved a convertible promissory note financing pursuant to which it could issue and sell up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7092ba1f-7c65-466e-afcf-81b9b4efd87e" contextRef="C_8fb13e5d-773f-45a3-a1b5-44eb8a210518" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of notes convertible into shares of common stock (the &#8220;convertible promissory notes&#8221;) and Convertible Promissory Note Warrants. The funding and issuance of the convertible promissory notes for gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8473a44-7278-4ef3-a19c-a5dbd9849c3a" contextRef="C_8fb13e5d-773f-45a3-a1b5-44eb8a210518" name="us-gaap:ProceedsFromConvertibleDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and Convertible Promissory Note Warrants to purchase shares of the Private CalciMedica&#8217;s common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74f2aa16-8d82-45c4-bf6c-36333917374f" contextRef="C_ba4cac3d-1b7b-4712-b4af-b00b36992550" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share took place in multiple closings through October 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2022, the Private CalciMedica board of directors amended the convertible promissory notes and Convertible Promissory Note Warrants to issue up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68e86ef2-ed48-41b7-900e-8361c4d8bbc3" contextRef="C_cf933ca0-5d88-4990-aa20-a3cc722c7bc7" name="calc:DebtInstrumentPeriodicPaymentPrincipalAdditional" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (for a total of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_028c791b-c1d6-4665-991f-b850afa5248a" contextRef="C_cf933ca0-5d88-4990-aa20-a3cc722c7bc7" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million) and added the automatic conversion for a &#8220;de-SPAC&#8221; business combination or reverse merger transaction. In November 2022, Private CalciMedica issued additional convertible promissory notes for gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a012503-de6d-4988-8809-eda29bbd5fe9" contextRef="C_5472c13f-2db0-4124-89dd-bd16af205acf" name="us-gaap:ProceedsFromConvertibleDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and Convertible Promissory Note Warrants to purchase shares of Private CalciMedica&#8217;s common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84165a6c-04da-4ac9-8a26-7cfb850d618a" contextRef="C_345b3de8-3757-4586-b754-d61ef7ff0cf5" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. The convertible promissory notes accrued interest at a rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8839528-7a79-4ac0-a1d6-241ddebd7cdd" contextRef="C_5472c13f-2db0-4124-89dd-bd16af205acf" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per annum and had a maturity date of December 31, 2023. Immediately prior to the effective time of the Merger, all outstanding convertible promissory notes and unpaid and accrued interest automatically converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4317347-7d35-4848-900b-a354175768f3" contextRef="C_3e9739ba-3899-4e58-81e1-44a9a303fe9b" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">20,487,104</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Private CalciMedica&#8217;s common stock at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a conversion price based on the equivalent valuation of the cash price paid per share by the private placement investors purchasing shares of common stock in the private placement multiplied by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ae69e99-f69d-42c6-891c-670e0ae1df78" contextRef="C_65b45366-3e2b-42a5-89ff-61739a51bdaf" name="calc:PublicCombinationMultipliedCashPricePaidPerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Such shares of common stock were then converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_caaa08e4-7f37-4de3-a209-509efc580979" contextRef="C_a6b9f2b4-556e-4252-b411-7c709e13590c" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">590,031</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Graybug common stock at the effective time of the Merger in accordance with the Merger Agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with each purchase of a convertible promissory note, Private CalciMedica issued to each holder of such convertible promissory note Convertible Promissory Note Warrant to purchase shares of the Private CalciMedica&#8217;s common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f12c1e59-8ad2-4bd5-bf3c-f4cb88aa5b2e" contextRef="C_c9ffcd5c-d377-492d-baf6-7c7ef2c83293" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. Each holder of the Convertible Promissory Note Warrants had the right to purchase up to a number of shares of Private CalciMedica&#8217;s common stock equal to (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9b9afc0-c6ad-430b-a359-db0a8d2918ee" contextRef="C_dcf336c2-04f1-4bf9-890c-ca0039d7e325" name="calc:PercentageOfWarrantCoverage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% (&#8220;Warrant Coverage&#8221;) of the principal amount of the convertible promissory note purchased by such holder concurrently therewith, divided by (ii) the cash price paid per share by the investors in the qualified financing or an initial public offering, as applicable, or in the case of a &#8220;de-SPAC&#8221; business combination or a reverse merger transaction between Private CalciMedica and a publicly traded company (a &#8220;Public Combination&#8221;), the equivalent valuation of the lower of the cash price per share by the investors purchasing shares in the publicly traded company in connection with such Public Combination or the cash price per shares by the investors purchasing shares of Private CalciMedica&#8217;s common stock in connection with such Public Combination, in each case, rounding down to the nearest whole share and subject to the terms of the convertible promissory notes; provided, however, that any holder that purchased convertible promissory notes in excess of the holder&#8217;s pro rata commitment (as defined in the convertible promissory notes) received a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41b35f8d-7135-4709-a74b-400075a0dbb2" contextRef="C_65b45366-3e2b-42a5-89ff-61739a51bdaf" name="calc:PercentageOfWarrantCoverage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">40</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% Warrant Coverage on the principal amount of the convertible promissory notes that is in excess of its pro rata commitment. The Convertible Promissory Note Warrants had a five-year term. In connection with the Merger, the Convertible Promissory Note Warrants were automatically net exercised in accordance with the terms of the Convertible Promissory Note Warrants. Immediately prior to the effective time of the Merger, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_543bf9f8-633b-444c-a635-bd7cb1d431bd" contextRef="C_c9ffcd5c-d377-492d-baf6-7c7ef2c83293" name="calc:ConvertiblePromissoryNoteWarrantsConvertible" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,308,047</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Convertible Promissory Note Warrants were converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0eaa57a-b694-4178-b11e-7b38139079c1" contextRef="C_c9ffcd5c-d377-492d-baf6-7c7ef2c83293" name="calc:ConvertiblePromissoryNoteWarrantsCommonStockConverted" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,308,047</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Private CalciMedica's common stock, which were converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e2c1051-7117-4b20-84db-62dce5ade405" contextRef="C_c9ffcd5c-d377-492d-baf6-7c7ef2c83293" name="calc:ExchangeOfStockForStock" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">152,875</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Graybug's common stock, based on the principal amount of the convertible promissory note.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to the Merger, the Convertible Promissory Note Warrants were not deemed equity and were classified as a liability on balance sheets. The Convertible Promissory Note Warrants were valued using a series of Monte Carlo simulations and Black-Scholes to determine the fair value, probability weighted for difference scenarios. The Monte Carlo simulations determined the liquidity event price. The Black-Scholes warrant value is discounted from the respective event date using the risk-free rate. The Black-Scholes valuation included standard assumptions such as exercise price, expected term, risk-free rate, volatility, and a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">dividend </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">yield of zero. The Company estimated initial fair value of the Convertible Promissory Note Warrants utilizing the following range of assumptions for the difference scenarios: exercise price ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96ec2f5b-8ed4-4353-8700-0cecb1c40c95" contextRef="C_c9ffcd5c-d377-492d-baf6-7c7ef2c83293" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">), risk-free rate (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c596112-97af-47f7-9695-1da866bb27ad" contextRef="C_73195b53-1edf-49b3-a1f9-3ae2ae46a761" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.02</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% - </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3dac68dd-31b4-4a5a-bf91-7816c2649e55" contextRef="C_d26b6223-10d2-4e75-97a3-b8b6a3c39933" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%), volatility (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23d5f976-1b8c-4167-a3ae-e3f80eedcdaf" contextRef="C_73195b53-1edf-49b3-a1f9-3ae2ae46a761" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">63</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% - </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ddec1a2c-9144-4853-90db-c140c0b5dd38" contextRef="C_d26b6223-10d2-4e75-97a3-b8b6a3c39933" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">67</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%), and expected term (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c78fdd8b-21cf-422e-aa12-413f33bdab13" contextRef="C_73195b53-1edf-49b3-a1f9-3ae2ae46a761" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4.1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> - </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_daf74f78-5790-42ce-9f00-21bb54a330cd" contextRef="C_d26b6223-10d2-4e75-97a3-b8b6a3c39933" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4.6</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years). As of the date of the Merger, the Convertible Promissory Note Warrants which were converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95f09b25-4040-4721-a9d0-0aa30571e502" contextRef="C_a3e2c51e-9ae5-48f2-aa73-7734ac756106" name="calc:ConvertiblePromissoryNoteWarrantsCommonStockConverted" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">152,871</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock were revalued, using the price of the common stock of Graybug of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87fdb714-f098-46aa-abba-dfed32e2857a" contextRef="C_a3e2c51e-9ae5-48f2-aa73-7734ac756106" name="calc:ExpectedPerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bc38ac8f-84a3-4fea-baff-4f403efc1d6e" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. Accrued Expenses</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a54e9bec-952f-4647-8b63-2bc67295a25d" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses consisted of the following (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued payroll and other employee benefits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_59314677-6b12-46ef-b9b3-3a863a6bc64c" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="calc:AccruedPayrollAndOtherEmployeeBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">935</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76440eb9-5cf5-45c7-a016-2210600628cd" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="calc:AccruedPayrollAndOtherEmployeeBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued severance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2a581e6-38ef-4e33-b119-4fc72c045237" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="calc:AccruedSeveranceExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f4750a9-40ef-4351-9dbd-ae9e2ee525af" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="calc:AccruedSeveranceExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_031a0a89-92d9-4780-8c0e-9b2010797d86" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">345</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fc94bb6-0df9-4242-8fd7-1a86eb91357f" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">486</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued franchise tax</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f750ae96-9924-46f8-8d59-eb48906cdad3" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="calc:AccruedFranchiseTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f167337b-d098-4888-87c1-f74e41406008" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="calc:AccruedFranchiseTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d8a18ce-06a0-4935-bdb6-e91406830c12" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="calc:AccruedOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dff82ea1-4edc-42f5-9c76-4ae57e14bb51" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="calc:AccruedOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cead25c3-b475-4cb9-83c8-7530f00b49bd" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,468</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_578b09f8-e4cf-46ef-a998-dc0fd12c4b5b" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">572</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span><span><ix:nonNumeric id="F_ec37da14-202d-4b8b-81aa-fd87a72d65ff" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:TemporaryEquityDisclosureTextblock" escape="true" continuedAt="F_ec37da14-202d-4b8b-81aa-fd87a72d65ff_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Convertible Preferred Stock, Common Stock and Stockholders' Deficit</span></ix:nonNumeric></span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_ec37da14-202d-4b8b-81aa-fd87a72d65ff_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Authorized Shares</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's current Amended and Restated Certificate of Incorporation authorizes </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8fdb52a6-0d32-4ba8-a9cb-719c62f6286a" contextRef="C_42abc17e-9eda-4860-b3f8-0efb13eadeae" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9839ca9-e368-46ab-a46e-8a26ce0eb56f" contextRef="C_42abc17e-9eda-4860-b3f8-0efb13eadeae" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c87ae4b3-d2eb-436c-9ca0-0e5204cc69ca" contextRef="C_42abc17e-9eda-4860-b3f8-0efb13eadeae" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of preferred stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f220159b-1356-406a-9fd2-e174afb60ce8" contextRef="C_42abc17e-9eda-4860-b3f8-0efb13eadeae" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Convertible Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Private CalciMedica's convertible preferred stock consisted of Series A preferred stock (&#8220;Series A preferred&#8221;), Series B preferred stock (&#8220;Series B preferred&#8221;), Series C-1 preferred stock (&#8220;Series C-1 preferred&#8221;), Series C-2 preferred stock (&#8220;Series C-2 preferred&#8221;) and Series D preferred stock (&#8220;Series D preferred&#8221;).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Immediately prior to the effective time of the Merger, the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e77a7d9-1b52-4cef-80da-5ad8ffd2455f" contextRef="C_cfb02dbb-5b66-4ab2-8c28-3198b03e30f6" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">84,820,880</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Private CalciMedica preferred stock were converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_518c7715-a87d-4428-8b4c-cc831338b0eb" contextRef="C_cfb02dbb-5b66-4ab2-8c28-3198b03e30f6" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">84,820,880</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> outstanding shares of Private CalciMedica's common stock to be exchanged for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3cdf78a-3075-4a31-b288-bffb65f928d5" contextRef="C_8f5cacbc-880d-4602-b949-fa5d6761652f" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,442,852</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Graybug's common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Classification of Convertible Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Private CalciMedica's convertible preferred stock as of December 31, 2022, was classified outside of stockholders&#8217; equity (deficit) on the accompanying balance sheets because such shares have liquidation rights in the event of a deemed liquidation that, in certain situations, are not solely within the control of Private CalciMedica and would require the redemption of the then outstanding shares of convertible preferred stock. Convertible preferred stock was not redeemable, except in the event of a deemed liquidation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because the occurrence of a deemed liquidation event was not probable, the carrying values of the convertible preferred stock were not being accreted to their redemption values. Subsequent adjustments to the carrying values of the convertible preferred stock would be made only when a deemed liquidation event became probable.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon completion of the Merger on March 20, 2023, as the accounting acquirer, Private CalciMedica is deemed to have issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_371eafe6-2e06-4644-93e0-c821af738876" contextRef="C_7d82e695-1745-41a7-8cb2-68d786a08457" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,571,433</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock to Graybug shareholders.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Private Placement of Common Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Immediately prior to the consummation of the Merger, Private CalciMedica completed a private placement financing pursuant to which certain investors purchased approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0bb49cd-6dcc-4adb-82e6-a90fa59391b9" contextRef="C_9ef48710-53ac-4e62-b939-0912f0ec48d0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares of Private CalciMedica&#8217;s common stock (the &#8220;private placement&#8221;) for gross proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6519241e-1bae-400c-a0c7-5a97fed39ea7" contextRef="C_9ef48710-53ac-4e62-b939-0912f0ec48d0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. In conjunction with the Merger, immediately prior to the effective time of the Merger, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af56b2e6-9a04-4d5f-b5a3-33dcce52bf0f" contextRef="C_c13bf6e6-7b21-47f6-8c64-15752b0689e8" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">20,706,997</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Private CalciMedica common stock were converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e104726-5d09-442f-9ab2-6dc766f355a3" contextRef="C_9a978bf4-30e7-4478-82d1-2929b8c869c9" name="us-gaap:ConversionOfStockSharesIssued1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">596,363</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Graybug&#8217;s common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Shelf Registration Statement and At the Market Offering</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2023, the Company filed a shelf registration statement on Form S-3 (the &#8220;Shelf Registration Statement&#8221;). The Shelf Registration Statement permits the offering, issuance and sale of common stock, preferred stock, debt securities and warrants having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4391c50-73b8-44a0-b53f-5de90ce29919" contextRef="C_1c46001b-5fe7-4131-9a1d-ccf9d2e7cfde" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in one or more offerings and in any combination of the foregoing. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00db6ec9-3d1e-48b2-a541-3ec7a8564808" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="calc:ShelfRegistrationStatementAvaliableForSale" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">99.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">million remains available for sale under the Shelf Registration Statement.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Shelf Registration Statement contains two prospectuses, a base prospectus and an at the market offering prospectus that covers the offering, issuance and sale of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55d8862f-d1c4-4613-b327-aa51b12d2256" contextRef="C_047361c5-453c-47e4-8ce1-9373daa9b02d" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of common stock pursuant to an at-the-market offering agreement (&#8220;ATM Agreement&#8221;) with H.C Wainwright &amp; Co., LLC, acting as sales agent (&#8220;ATM Facility&#8221;). The Company intends to use the net proceeds from the ATM Facility for general corporate purposes, which may include research and development expenses, clinical trial expenses, capital expenditures and working capital. The ATM Facility will terminate upon the earlier of (i) the sale of all of the shares of the Company&#8217;s common stock provided for in the at the market offering prospectus or (ii) termination of the ATM Agreement as permitted therein. The ATM Agreement may be terminated at any time by either party upon written notice. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the Company has sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86842aec-6d79-4af6-a250-3a5ff1acc11e" contextRef="C_f6acf339-8a66-4359-827f-f1d8c3fefcf6" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">92,572</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock for net proceeds of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93dc5af2-a95d-4c6b-b078-845a7ea67070" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">246,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> which includes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$11</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c2dfc3d-51ff-4a69-8ac3-527969e8d160" contextRef="C_047361c5-453c-47e4-8ce1-9373daa9b02d" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of commissions paid under the ATM Facility and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0850eca5-2f91-4060-9b00-d9bf6fc0a1ef" contextRef="C_047361c5-453c-47e4-8ce1-9373daa9b02d" name="calc:SaleOfStockRemainingSalesAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million remains available for sale under the ATM Facility.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preferred and Common Stock Warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the issuance of convertible notes in 2016, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92cc538c-74f6-4485-a154-6ebe40ad418c" contextRef="C_ec132aef-e24b-4108-817d-1584845fdc60" name="calc:StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">568,181</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> warrants to purchase Series B preferred were issued at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4556e805-2e7b-4df3-847d-f560936331ae" contextRef="C_71e8ce45-e272-4f48-9eff-ba31844ce0d8" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.77</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share (the &#8220;Series B Warrants&#8221;). The Series B Warrants were exercisable at any time after February 28, 2017, through the earliest to occur of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1d05c7d1-ea97-4f81-9fbe-42c8786d68b3" contextRef="C_71e8ce45-e272-4f48-9eff-ba31844ce0d8" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> after the issue date or prior to the date of sale of common stock in an initial public offering or a deemed liquidation event. Until the Merger, these Series B Warrants were accounted for as a liability and had a fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64dd2245-efce-4e74-8f8b-7e54e8258b89" contextRef="C_d824885a-bf88-4997-b44b-56b06f10352e" name="us-gaap:FairValueNetAssetLiability" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">45,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Prior to the Merger, the Series B Warrants converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd514b22-8366-4490-a776-e40ce08b89e3" contextRef="C_80eeb444-2e22-4786-9e02-a20268b73e22" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">568,181</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> common share warrants of Private CalciMedica. In conjunction with the Merger, the common warrants converted into</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4dc64ec8-dee7-4213-8d04-79613ffcbf2a" contextRef="C_c76b6693-5f6b-44e3-a453-7bd33b5ddf5f" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,366</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">common share warrants of CalciMedica with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c32bc889-13d7-432d-8e26-ea32c124bd4d" contextRef="C_c76b6693-5f6b-44e3-a453-7bd33b5ddf5f" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">26.74</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and have been reclassified to stockholders' equity (deficit) at its fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6853b382-4164-4ed7-a8ea-a143da9a216f" contextRef="C_ec132aef-e24b-4108-817d-1584845fdc60" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">21,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the issuance of Series C-2 preferred in May 2020, Private CalciMedica issued a warrant (&#8220;Series C-2 Warrant&#8221;), which was exercisable for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1d6d446-ebef-40c1-911f-1b5dcb492595" contextRef="C_9aec901d-664d-416c-9998-1ef7272a19c0" name="calc:StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrantsExercisable" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,786,567</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series C-2 preferred at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79b9698b-03cd-4133-b57f-89b7431dc8a6" contextRef="C_5405b9ae-90f7-42b7-8ea1-97fedf79248d" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.77</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. The Series C-2 Warrant was exercisable at any time after May 20, 2020, through the earliest to occur of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_42b0fe10-5a6f-4657-a1fd-4f1599b38067" contextRef="C_515175dc-1ad3-4b7e-8b77-14527a01e9a5" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> after the issue date or prior to the date of a deemed liquidation, public combination or an initial public offering. Prior to the Merger, the Series C-2 Warrants converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c370256-505a-4e25-bc62-1d1153e96bb8" contextRef="C_132f40d2-5814-446c-afac-5f97f6db9fc9" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,786,567</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> common share of Private CalciMedica. In conjunction with the Merger, the common shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29eea3e2-2f33-4df4-8268-18b9021af2a6" contextRef="C_4ba994e5-acb4-4356-85f9-d557fa3db223" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">80,254</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock at a fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d3e1af9-a020-4ac0-8c58-b0855ed3d848" contextRef="C_f9395b99-5d87-4344-87fa-5056b48d26c5" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Series C-2 Warrant was accounted for as a liability and had a fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06a987f4-8f6b-4cca-9cd8-b38aec65fdfb" contextRef="C_a0231b6b-5eb4-4312-ade8-abf82342f64e" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the issuance of Series D preferred in 2021, Private CalciMedica issued warrants (&#8220;Series D Warrants&#8221;) to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2506b7a-f9b5-4ae6-8ace-c6bc26a10625" contextRef="C_8ab25aef-aa0a-43b5-80d4-c77a6790fefb" name="calc:StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,063,998</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series D preferred with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d00675e4-d4f3-49c7-b132-2f7608882236" contextRef="C_1625384c-df1a-463a-9b14-131ec9a67ba4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.8045</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. The Series D Warrants were exercisable at any time after the date of issuance through the earliest to occur of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b6e192cd-b61c-4e71-be29-7ea99bf8deb8" contextRef="C_1625384c-df1a-463a-9b14-131ec9a67ba4" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> after the issue date or prior to the date of sale of common stock in an initial public offering or a deemed liquidation. In conjunction with the Merger, the common share warrants were converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c57f11cd-d61d-48ea-b7b7-22b2f3751338" contextRef="C_12eaa057-d9c1-42e1-b525-a11412a82bab" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">232,256</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> common share warrants of CalciMedica with an exercise price </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7626d380-4d89-4444-a987-1fd59db35f20" contextRef="C_12eaa057-d9c1-42e1-b525-a11412a82bab" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">27.94</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and have been reclassified to stockholders' equity (deficit) at a fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9dffbace-0ba5-42b3-88db-5ee0c63e65ef" contextRef="C_f43e59fc-a4b6-4320-b729-ea2f876d663d" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Up until the Merger, the Series D Warrants were accounted for as a liability and had a fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2801e158-3d71-4797-bd14-d9ec51d265ac" contextRef="C_1ffb1c4c-957c-4089-a01f-27b641fd51e7" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognized a total change in fair value of the preferred stock warrants of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27ee0dab-85ba-4e30-8e17-165632de2531" contextRef="C_38bc6d68-19a2-4497-aebd-7db45c2ce63b" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">795,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nd $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee8861f5-c427-443c-bdd3-f54e52014767" contextRef="C_3dfbf602-7a4c-49b2-8b99-9805b5186589" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million f</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or the years ended December 31, 2023 and 2022, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2020, Private CalciMedica granted a warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ce9cdcf-e174-47d3-b297-e3777a064f21" contextRef="C_10d7c32a-8834-4078-bcb5-f2abb3c5706a" name="calc:StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">400,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock to a consulting firm affiliated with its interim chief financial officer in connection with its consulting agreement. The warrant has a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a19e499a-4b27-40ed-85e7-b28fc783515c" contextRef="C_17715ce3-d9ea-4ab1-acb5-cf49f46cbaaf" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-year term, an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e4cbe85-5475-410b-aabb-359dd1f13daf" contextRef="C_17715ce3-d9ea-4ab1-acb5-cf49f46cbaaf" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.19</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and vests ratably over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5a6b89ae-7081-42b5-b264-1e960076d28d" contextRef="C_10d7c32a-8834-4078-bcb5-f2abb3c5706a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months commencing on the effective date. At the date of issuance, the fair value of the warrant was determined to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d56bd8b-8598-4a92-b221-986e62a75a11" contextRef="C_17715ce3-d9ea-4ab1-acb5-cf49f46cbaaf" name="us-gaap:FairValueNetAssetLiability" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">120,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, utilizing Black-Scholes with the following assumptions: expected term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_45b67962-3f9a-43d0-892d-d17528632584" contextRef="C_10d7c32a-8834-4078-bcb5-f2abb3c5706a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, risk-free rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44fc133e-c9da-40d0-a108-6325f0096df6" contextRef="C_10d7c32a-8834-4078-bcb5-f2abb3c5706a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.96</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, volatility of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b2beda1-3487-481d-b83b-5e80c39bd192" contextRef="C_10d7c32a-8834-4078-bcb5-f2abb3c5706a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">80.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and a dividend yield of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6684692-891f-4026-b40f-e9946e266795" contextRef="C_10d7c32a-8834-4078-bcb5-f2abb3c5706a" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which has been recognized as general and administrative expense over the vesting period. In conjunction with the Merger, the warrant converted to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb384b51-f300-492f-ab14-6c66ca52957c" contextRef="C_6557ada0-e212-4e78-b768-866c8fb13b00" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">11,520</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> warrants of CalciMedica at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e439e1b3-360d-45fb-b806-90e5a0474c41" contextRef="C_033e18f1-c526-494a-af37-d16f8a20d94c" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.60</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The warrant is classified as equity and the Company expens</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f142d2ee-7376-4ccd-b2fb-f473295d994f" contextRef="C_fb28aa96-7bbd-4570-8a6a-cb5c875bd34a" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">50,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for the year ended December 31, 2022, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2022, Private CalciMedica granted warrants to certain officers and directors to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be3e1f19-5c4f-4cc4-a42a-7ae6f0416e76" contextRef="C_9aaecb1b-b009-46d1-a2c3-ad52042541eb" name="calc:StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">496,970</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. The warrants have a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_be6f75d8-3cd9-4018-8970-cb73ce76d513" contextRef="C_8796b832-7e69-4299-a51b-d5ad3e94056f" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-year term, an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23d51959-889d-4518-9a90-568fa773cb03" contextRef="C_8796b832-7e69-4299-a51b-d5ad3e94056f" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.42</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and vest ratably over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1c4ce5b9-f154-4f12-a6a3-5dccaa6d3a3d" contextRef="C_bb2bd826-29bf-448a-b3fe-756756fb69a3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_596bc652-3be2-4ba7-8327-49168b17ebaa" contextRef="C_fd5366f4-f6f4-4f51-86ec-d2b17b2273e0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months. At the date of issuance, the fair value of the warrants collectively was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f2b8e01-94cb-44ca-ad94-674280c43a8e" contextRef="C_8796b832-7e69-4299-a51b-d5ad3e94056f" name="us-gaap:FairValueNetAssetLiability" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">125,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and was determined utilizing Black-Scholes and will be recognized as general and administrative expense over the vesting periods. Assumptions used in the valuation were as follows: expected term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9592e073-08b1-4c82-94b1-6ac02908bb36" contextRef="C_9aaecb1b-b009-46d1-a2c3-ad52042541eb" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, risk free rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55fb2b79-d8de-4348-bbd3-3b324b15898b" contextRef="C_9aaecb1b-b009-46d1-a2c3-ad52042541eb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, volatility of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1779aca2-f4b3-40b6-9e73-a879a3176096" contextRef="C_9aaecb1b-b009-46d1-a2c3-ad52042541eb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">82</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and a dividend yield of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1ca8c8d-7bb9-489a-962e-77b3cb2f7450" contextRef="C_9aaecb1b-b009-46d1-a2c3-ad52042541eb" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In conjunction with the Merger, the warrants converted to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f32f9de3-2ded-4b4b-9b38-d4d959d0557a" contextRef="C_8b2b8377-2a31-4a6e-8ded-d5abdcfa46af" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">14,313</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> warrants of CalciMedica at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4af48f87-0429-47f3-8303-2f8926b13113" contextRef="C_8b2b8377-2a31-4a6e-8ded-d5abdcfa46af" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.42</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The warrants are classified as equity, and the Company expens</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80a4eaec-4a6a-4fa3-9772-327899ae6cdf" contextRef="C_83ff265d-5f06-4f96-87f9-d5b6ce1fb1d7" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">90,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1268934-14e5-464f-a657-be833e67d832" contextRef="C_8fb4c8dc-dcc1-4352-ad4c-b46434309f12" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">28,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to general and administrative expense in the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p></ix:continuation></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bfddc134-ae1b-4c5b-aa53-2a7cac05ce29" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. Stock-based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2006 Equity Incentive Plan and Amendment to 2006 Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Private CalciMedica adopted an equity incentive plan in 2006 (&#8220;2006 Plan&#8221;) that provides for the issuance of common stock to employees, non-employee directors and consultants. Recipients of incentive stock options are eligible to purchase common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The 2006 Plan provides for the grant of incentive stock options, non-statutory stock options and stock purchase rights. The maximum contractual term of options granted under the 2006 Plan is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dd7a38df-9e05-4f1a-948a-561d6719c7fd" contextRef="C_7ef7e808-55f3-466b-981a-c813c5b91fb6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The options generally vest </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bdfc76e4-9f3d-4a45-a1c5-a4a92260a526" contextRef="C_7ef7e808-55f3-466b-981a-c813c5b91fb6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% on the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_71b4969f-28c5-4ace-ac88-38cb897a2809;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">first </span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">anniversary </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the grant date, with the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">balance </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">vesting ratably over the following </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c5b28c0e-880f-42db-8f3d-1568c095d13b" contextRef="C_7ef7e808-55f3-466b-981a-c813c5b91fb6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months. Pursuant to the Merger Agreement, Graybug assumed the 2006 Plan and all stock options issued and outstanding under the 2006 Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2023 Equity Incentive Plan</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company adopted 2023 Equity Incentive Plan (the &#8220;2023 Plan&#8221;), which became effective at the closing of the Merger. As of the effective time of the Merger, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebb2ef6e-64bb-45ad-9693-2f3a314b1c56" contextRef="C_2bc4190f-24bd-4383-9a76-813440aa7079" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock available for grant under the 2023 Plan. In addition, the share reserve is subject to annual increases each January 1 for the first ten years following approval of the 2023 Plan of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b92ebbc-7ee7-40e2-8507-5ef70c593b18" contextRef="C_6584f473-e3fd-4960-8c14-afa94ca4e2ac" name="calc:PercentageOfAggregateNumberOfSharesOfCommonStockOutstandingOnLastDayOfPrecedingYearAddedToPlan" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of shares of the Company&#8217;s common stock outstanding (or a lesser number determined by the Company&#8217;s board of directors). As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0652a831-ba92-4310-88ab-65317811e768" contextRef="C_6584f473-e3fd-4960-8c14-afa94ca4e2ac" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">96,594</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> options have been returned but are unavailable for future grant under the 2006 Plan. As of December 31, 2023,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c62f3ec9-04bb-4950-b200-0ac46ccb9396" contextRef="C_4ac3291f-aa10-49f9-b9db-b6f575d3e347" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">394,309</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">shares were available for grant under the 2023 Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2023 Employee Stock Purchase Plan</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company adopted the 2023 Employee Stock Purchase Plan (the &#8220;2023 ESPP&#8221;) which became effective at the closing of the Merger. As of the effective time of the Merger, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e6cae5d-bd39-4444-a620-8478fb5f7ad1" contextRef="C_e6f38265-4614-44ec-85bc-fcffb8b21275" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">65,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock reserved for issuance under the 2023 ESPP. In addition, the share reserve is subject to annual increases each January 1 for the first ten years following approval of the 2023 ESPP of the lesser of (1) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b236b5f7-f7b1-40f8-8e49-e5f37acd94bd" contextRef="C_5317cbe0-64bb-4729-93e5-b7c5d402fc35" name="calc:PercentageOfAggregateNumberOfSharesOfCommonStockOutstandingOnLastDayOfPrecedingYearAddedToPlan" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the total number of shares of the Company&#8217;s common stock outstanding on December 31 of the preceding calendar year, (2) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8038fd4-124a-44ff-8e24-743457ebbbd6" contextRef="C_e6f38265-4614-44ec-85bc-fcffb8b21275" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">195,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock, or (3) such lesser number of shares of the Company&#8217;s common stock as determined by the Company&#8217;s board of directors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f05e3ee1-8311-40ba-88f3-781e157f0408" contextRef="C_5317cbe0-64bb-4729-93e5-b7c5d402fc35" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares have been issued under the 2023 ESPP.</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_cdf758a5-c1f5-44bb-801d-0007d0adb8b0" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the stock option transactions for the 2006 and 2023 Plans:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.656%;"/>
        <td style="width:1.111%;"/>
        <td style="width:1%;"/>
        <td style="width:10.953%;"/>
        <td style="width:1%;"/>
        <td style="width:1.111%;"/>
        <td style="width:1.111%;"/>
        <td style="width:1%;"/>
        <td style="width:9.309%;"/>
        <td style="width:1%;"/>
        <td style="width:1.178%;"/>
        <td style="width:1%;"/>
        <td style="width:9.353%;"/>
        <td style="width:1%;"/>
        <td style="width:1.355%;"/>
        <td style="width:1.178%;"/>
        <td style="width:1%;"/>
        <td style="width:8.687%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average Remaining Contractual Term (years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate Intrinsic Value (in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_978c2d0a-b34b-48b1-81e8-e67ee9c17e7c" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">739,511</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33f5ffe9-f4b7-4f53-9838-fdc7a5576e75" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.94</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_3c4f4ff1-3613-42ac-ad56-a376d536b62f" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.36</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b5f2c94-b406-46fb-9ffe-795458482047" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,903</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assumed in the Merger</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11f02576-b61a-470f-9f30-c77289858e6e" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">310,431</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17067b6e-bfcf-4598-9e21-500232dc4dec" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">76.72</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ce7ad64-60c5-49a5-9a1d-c6a8d09c5fde" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">785,922</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51693d55-662d-4487-9a6c-79e5ee792543" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.48</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a888512-67cc-423e-b79c-3d7bd2a6d314" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">96,594</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7f0e0a8-1bf4-4dc5-90d6-a1660f0318f4" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">70.51</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69c4bdae-4dc7-4851-a480-af331ec27443" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,739,270</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5609df98-5c98-4af4-b0df-0bc265feef03" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.71</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_34bbbe80-0f9f-4bae-be32-6fc122a5769d" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.99</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_731c13d8-7993-4fc2-a5f6-75f9f522ff26" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and exercisable at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d43fdda-db0d-4fa5-9d25-4fd8accfa014" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">940,098</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e24be56f-85eb-44c8-92e5-bf5418bbd957" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.18</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_10b9b15a-78d9-47bc-8fdb-e941cacff5a0" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.97</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e9007ad-e61a-4e11-9da6-07a5e5e7bbd5" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f3b38ad-4c78-4adc-a8ee-bb8022b0d2c4" contextRef="C_5317cbe0-64bb-4729-93e5-b7c5d402fc35" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> options exercised during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023. The weighted-average fair value of options granted during the years ended December 31, 2023 and 2022 was</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_444df1b2-9e45-4120-92ef-48557a819867" contextRef="C_5317cbe0-64bb-4729-93e5-b7c5d402fc35" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.34</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c59e970f-cbbe-4f1c-a9ea-8339132c7f5e" contextRef="C_2d6b7e2b-1799-423b-80d4-f0ffdbd4249e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">per share, respectively. The total fair value of shares vested was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65c05e12-5e2a-4208-8b7d-d86c9b613aa3" contextRef="C_5317cbe0-64bb-4729-93e5-b7c5d402fc35" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mill</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ion (which includes $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_104b0790-2866-441a-839e-89236221a1f5" contextRef="C_c654b3dc-d8de-4e32-ade7-4c14b46e29eb" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million related to the acceleration of vesting of the Graybug stock awards at the date of the Merger) for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2cb908d0-cb3a-4815-af55-847ad20cfba9" contextRef="C_2d6b7e2b-1799-423b-80d4-f0ffdbd4249e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, stock-based compensation not yet recognized is</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0bc6a6d3-5ad0-450f-a962-b57751072d1c" contextRef="C_e6f38265-4614-44ec-85bc-fcffb8b21275" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which the Company expects to recognize over an estimated weighted-average term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_332afb97-0699-4546-b645-401524eaf8a9" contextRef="C_5317cbe0-64bb-4729-93e5-b7c5d402fc35" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.4</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cd110862-0457-451c-b768-3d3dd1150203" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following is the range of underlying assumptions in Black-Scholes to determine the fair value of the stock option grants for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.667%;"/>
        <td style="width:1.111%;"/>
        <td style="width:1%;"/>
        <td style="width:13.422%;"/>
        <td style="width:1%;"/>
        <td style="width:1.111%;"/>
        <td style="width:14.689%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk free interest rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95e09065-bebd-4f27-b55e-8c17a63174c6" contextRef="C_d630bef2-91b1-4374-b30e-0dae725036e6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3514cb1-880e-4db3-8780-0f08838d96df" contextRef="C_7547cb73-f5f8-44b0-ad5f-4fe05452061d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.56</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c93e95ee-de2f-41dd-a7d2-994fc0694887" contextRef="C_5d9b48b9-68d6-41ad-994c-2b74751e5df8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5da5bbf4-46ad-41be-ad4b-6c9162c52b73" contextRef="C_ea3403be-994b-481a-8da5-05ce7ae02175" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.28</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f14c56ec-a2da-431b-ba5b-d43ffd3394be" contextRef="C_d630bef2-91b1-4374-b30e-0dae725036e6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8440f6c8-d2d7-4230-b61a-7aee3f5072e5" contextRef="C_7547cb73-f5f8-44b0-ad5f-4fe05452061d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">76</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7fae2c70-eecf-44a7-9d78-8e151ee1092b" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">82</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_aa468320-5d82-403c-a46a-e40497844463" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.25</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f74f8f59-02f7-4346-832b-06a28fed171a" contextRef="C_5d9b48b9-68d6-41ad-994c-2b74751e5df8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.00</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><ix:nonNumeric id="F_c4ed1fde-5e23-4eae-ba8c-37ae91fa9625" contextRef="C_ea3403be-994b-481a-8da5-05ce7ae02175" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.25</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d4c411e-855d-4160-b3f0-d80bf1ae0876" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67336a1a-d1ef-4ee5-94fa-4cad0f86939d" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-based Compensation Expense</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f9c2a566-9649-47da-b32d-5b4fec7b784d" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense recognized for options and restricted stock units granted was as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f477b61-410d-4925-9034-51db06075ea7" contextRef="C_1df30a04-c352-47af-8399-d9257a158c80" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,449</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7db8f63a-b271-41e7-ae77-ad4504ebd122" contextRef="C_1d913287-6a9c-4c1e-8311-ffb8f8c0200f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">499</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5307ce6a-ed00-4a0b-8854-92b50923841f" contextRef="C_eccb0df3-d3be-48ca-afe0-3b0886ba2bb6" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,590</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3525e658-144b-4b92-81c8-38dda752da8b" contextRef="C_a560d69c-2898-468a-9634-5372f3e638e8" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">902</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ee8ea3e-cf6b-42cf-b283-fcb135841172" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,039</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8a08237-25a2-4182-9e09-7bed592d73b0" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,401</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Statement of convertible preferred stock and stockholders' equity (deficit)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Settlement of 2021 and 2020 accrued bonus and employee costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6a7fa6d-0e70-4e59-a579-35a7a0996f65" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:SettlementOfAccruedBonusAndEmployeeCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12d95b09-a7dd-4db7-97af-5ba00c614bb1" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="calc:SettlementOfAccruedBonusAndEmployeeCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">406</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06ba2919-ee4d-427b-a1cd-7fe3541ed06f" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,039</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1cf65d0-c902-439c-aefd-36c3b99dce46" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,807</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The stock-based compensation expense for the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, includes one-time charges for the acceleration of vesting of the Graybug stock options at the date of the Merger of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e42e4503-0f8d-4519-9aa1-b321191019e7" contextRef="C_5d90f9a6-e52f-451e-b3ef-71ea2b53490b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2922730e-1397-4c41-9518-f06fb5bcbba1" contextRef="C_72ea148a-99e6-47b2-bd68-d0f6914854ee" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in research and development and general and administrative expenses, respectively.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock Reserved for Future Issuance</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_85d891a5-3c2b-4b0c-a055-14ba65fe993b" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stock reserved for future issuance consists of the following at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.22%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:16.3%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60cc6b78-b78f-48b9-a735-8430c709d4b0" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">276,437</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options issued and outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd7f0273-492f-4867-af2f-8d91a044c689" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,739,270</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for issuance under the 2023 Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7cfe7d7c-6f95-4ac5-9a79-dbb12a56b323" contextRef="C_4ac3291f-aa10-49f9-b9db-b6f575d3e347" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">394,309</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available under the 2023 ESPP</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b606ca0b-a571-4279-9540-542fb64878e6" contextRef="C_e6f38265-4614-44ec-85bc-fcffb8b21275" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">65,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0754f10-fd84-470f-89b5-19ef40da8cbd" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,475,016</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_173738a2-046e-488c-9c31-4dc45d81823f" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues liabilities for such matters when future expenditures are probable and such expenditures can be reasonably estimated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has historically entered into contracts in the normal course of business with contract development and manufacturing organizations, for the manufacturing process development and the preclinical/clinical supply manufacturing, and its vendors for preclinical research studies and other services or products for operating purposes. These contracts generally provide for termination on notice of 60 to 90 days. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a402fbfe-6709-4939-a1a8-f57a328494d8" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="calc:NumberOfContractCurrentlyInEffect" unitRef="U_Contract" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> such contracts, with two CMO&#8217;s related to its development of Auxora and acquired as a result of the Merger with approximate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ly</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73931216-c20a-462d-995d-0c9287870b2d" contextRef="C_3aa562e8-771a-40e1-9e64-d658f147bd41" name="calc:ContractualObligationOfContractInEffect" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b37da0c1-db94-4a77-8dce-52135cfc7b64" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="calc:ContractualObligationOfContractInEffect" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">million of associated costs, respectively, still in effect for future services, and there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e1ef699-ddf3-4f51-a944-9c8f89743052" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:UnpaidCancellationAndOtherRelatedCosts" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> unpaid cancellation or other related costs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company may also, from time to time, become party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Lease Agreements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has an operating lease for office space in La Jolla, California. In </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_10ec6273-2918-45a5-ad26-6251eb098fa9;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 2023</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, an amendment was executed for a twelve month term and therefore qualifies for the short-term lease exception. The lease was amended and renewed in December 2023 for an additional twelve month term and therefore qualifies for the short-term lease exception. Base rent for this lease is approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed05d53e-b8bc-47e5-94ba-559d9424a46c" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:BaseRent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> monthly.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the Merger, the Company had leased a facility in Baltimore, Maryland under an operating lease with a term through </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_01fefd8e-092e-48bc-992a-f56011278bfb;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 2023</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and was accounted for under ASC 842. The facility has been abandoned and the asset was fully impaired in 2022 and was reflected in Graybug&#8217;s financial statements in 2022 and there is no impact to the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The lease expired in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_5164bc76-6e34-4c80-a8a7-d709dbb4720a;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 2023</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rent expense for the years ended December 31, 2023 and 2022 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c49c9810-5593-41da-a26e-1d7076c9c82e" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:LeaseAndRentalExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">274,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44082f7a-f941-407c-a25f-eb3f215c9ac1" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:LeaseAndRentalExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">221,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">respectively, which is included in operating expenses. The lease obligation was included in other current liabilities in the consolidated balance sheets.</span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d60c86f3-1681-4e4f-a44b-96d80218d520" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. Employee Benefits</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2007, Private CalciMedica adopted a defined contribution 401(k) plan for substantially all employees. Contributions made by CalciMedica to the 401(k) plan were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7fb26844-de71-49b6-86fb-4568f1258563" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $3</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b4df01e-d6e9-408e-bb60-9eb5d97347e4" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_66ac29dc-a67d-47c5-9f1f-0d153e13321d" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. Income Taxes</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9c552365-8f18-4fac-94fb-e7f46d619a0d" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The effective tax rate if the Company&#8217; provision (benefit) for income taxes differs from the federal statutory rate as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:89.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.682%;"/>
        <td style="width:1.813%;"/>
        <td style="width:1%;"/>
        <td style="width:15.102%;"/>
        <td style="width:1%;"/>
        <td style="width:1.813%;"/>
        <td style="width:1%;"/>
        <td style="width:14.588%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax computed at federal statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbfef981-5c48-469d-8ade-eccedef20da5" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,214</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ab60b40-554f-4f5b-ae2a-bb9314f1a1e7" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,624</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State tax, net of federal tax benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7955e47f-5f2c-4160-9a5f-ec26253a2d0c" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6d103c4-59e3-4e5f-aaa6-d4ccafbcbe8e" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ec3d50d-160b-4b80-9c16-b4d730118922" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:IncomeTaxReconciliationPermanentDifferences" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">616</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58cf279b-2931-4105-b4d2-39d77b574bda" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="calc:IncomeTaxReconciliationPermanentDifferences" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1237</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development tax credits, net of uncertain positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c0f1eb3-d55c-41ad-a4f1-2c2418884485" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">705</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ef5456d-ce29-4bf7-abf5-b92ce8d81edc" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">454</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46ecb62d-de74-4213-9112-64ec9f3d9757" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,535</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db2ab9f4-cf63-4f41-8139-f60978e0aef7" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,315</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61e16b1e-7c7b-4651-86b7-8bcfd7b50fb7" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5662cbcb-3d39-47fa-bfaf-b422a4b7a66c" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards. </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7038fda4-b25d-41b8-bcc6-2e5683374910" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true" continuedAt="F_7038fda4-b25d-41b8-bcc6-2e5683374910_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant components of deferred tax assets (liabilities) at December 31 are as follows (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_7038fda4-b25d-41b8-bcc6-2e5683374910_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:89.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.682%;"/>
        <td style="width:1.813%;"/>
        <td style="width:1%;"/>
        <td style="width:15.102%;"/>
        <td style="width:1%;"/>
        <td style="width:1.813%;"/>
        <td style="width:1%;"/>
        <td style="width:14.588%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b243fb0f-bf40-437f-b579-406dad9ba2a5" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,535</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac57932b-8924-4c1d-873b-e66ffcfa7641" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,839</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State tax, net of federal tax benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78ed294b-5921-4783-b9b8-5a9ae7e09331" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:DeferredTaxAssetsStateTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,865</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ccb0e369-34da-45f0-9e44-b0fb121b836c" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:DeferredTaxAssetsStateTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,407</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued and deferred expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9bfa73b6-3ae8-493d-ad43-17deb3cc22b2" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86f24bb6-5b05-4fe9-938c-920c3bf5e337" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">167</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credit carry forwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77276493-aa37-41fc-8e2e-470f1a861221" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,403</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa4a514a-2f64-4e91-80f9-935a9e01d5e4" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,736</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_955441de-ff90-4477-afa0-080dd3e3a54b" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="calc:DeferredTaxAssetLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f1c7fd7-b727-4a0a-834a-e324e97ac816" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="calc:DeferredTaxAssetLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f6159ba-6e7b-4da6-8f7e-6d92cebc573e" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,699</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b9cc461-d1c6-4cb8-8ec6-11227ff946d9" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_593f952d-9ba9-4102-80b0-904891218891" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,595</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f688379-cb97-4d4f-b6da-deb45dc5731a" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,278</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bbc9079b-8c22-4c0f-ad7a-602f8dbe6087" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="calc:DeferredTaxLiabilitiesRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1251f031-2745-47d8-89d3-c001d57f297a" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="calc:DeferredTaxLiabilitiesRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0ea5661-f123-4cfa-acc0-9960d3f3b32f" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="calc:DeferredTaxLiabilitiesValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fc1e7d0-8452-4920-8abe-16c87f328136" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="calc:DeferredTaxLiabilitiesValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73c6504d-be3d-48f4-ad5c-2c947ef758e5" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03ae0230-b6bd-42bc-9de7-8b0767c2e7fb" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b105c7bd-6e75-4233-9722-75c9b6d47761" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="calc:NetDeferredTaxAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,574</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b489068-769c-4a69-910e-c37494fb9c3a" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="calc:NetDeferredTaxAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,240</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_253c8963-2a31-4d92-81aa-eb256decb51c" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,574</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_939ec97f-66c1-46d4-81f1-20dedc452969" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,240</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c377acb5-a75a-4b76-958c-6f38e6216985" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68571ed4-8037-4b75-b363-d8658aac5e29" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company provided a full valuation allowance on the net deferred tax asset because management has determined that it is more-likely-than-not that the Company will not earn income sufficient to realize the deferred tax assets during the carryforward period. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company has federal and state NOLs available of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d7a89d2-0535-4776-b3df-bbcab105b52f" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">278.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c77d3ce-1bc3-4fb4-ae38-7012b1240355" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">103.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, to offset future taxable income, if any, for federal and state income tax purposes. The federal and state NOLs expire beginning in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_75d875cf-e306-4dec-9df9-b6470aa0de33" contextRef="C_577f2bd0-e762-4230-970a-df97b7cca6e1" name="calc:OperatingLossCarryForwardsExpirationBeginningYear"><ix:nonNumeric id="F_58b45a7a-eccf-4aed-a477-ab67464dff4c" contextRef="C_da70ea3c-8eb1-49bf-a910-720ae1e76953" name="calc:OperatingLossCarryForwardsExpirationBeginningYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2026</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company has $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0ee58e7-c27b-40c0-80f1-909ab39759e9" contextRef="C_ff6e332f-5b48-43f3-b9ad-0eb9e3c7b9e1" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">204.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of post-2017 federal NOL carryforwards that carry forward indefinitely. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_060646d5-5a4b-4e39-9d9c-ee17f2cd2248" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, under the Tax Act the amount of net operating losses generated in taxable periods beginning after December 31, 2017, that the Company is permitted to deduct in any taxable year is limited to 80% of taxable income in such year, where taxable income is determined without regard to the net operating loss deduction itself.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Tax Act generally eliminates the ability to carry back any net operating loss to prior taxable years, while allowing post-2017 unused net operating losses to be carried forward indefinitely.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company has federal and state research and development credit carryforwards available of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5d5a71c-8a30-4cda-83fc-b2065051ec4d" contextRef="C_317b6ba6-8a13-4bfe-b342-48339a414824" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6bd7e40b-65e4-4fe5-a887-2b6e08a15a76" contextRef="C_9759fbac-1faf-4bad-935e-6d6df5498635" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. Federal research and development carryforwards expire beginning in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_19d419b8-5588-4f9f-83e4-81c43571591d" contextRef="C_4d8a1b34-d457-4b45-9c95-b58fcd74a782" name="calc:OperatingLossCarryForwardsExpirationBeginningYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2027</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. State research and development carryforwards do not expire.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Pursuant to Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) specifically by IRC &#167;382, the Company&#8217;s ability to use net operating loss carryforwards to offset future taxable income is limited if the Company experiences a cumulative change in ownership of more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f483b4be-1182-4092-a7d5-a1790b259cb6" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="calc:PercentageOfChangeInOwnership" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% within a three-year testing period. The Company has not completed an ownership change analysis pursuant to IRC Section 382. If ownership changes within the meaning of IRC Section 382 are identified as having occurred, the amount of remaining tax attribute carryforwards available to offset future taxable income and income tax expense in future years may be significantly reduced. Any limitation may result in the expiration of a portion of the NOL carryforwards before utilization.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8636a0e4-add4-479e-aef4-086bc0a79437" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The change in the Company&#8217;s unrecognized tax benefits is summarized as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"/>
        <td style="width:1.94%;"/>
        <td style="width:1%;"/>
        <td style="width:15.823%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98291f39-0c39-4f0b-b291-b74c36b9af51" contextRef="C_c2ab8d40-d474-4916-9e68-da10e0f82c62" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,457</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase related to current year tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f84bc6d1-cded-421c-ac6e-425138076c85" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">973</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions for tax positions of prior years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b66900d5-0ba5-42bc-b905-3dc014b6d57e" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70d0cb1a-5fae-4767-8f45-8af48685a84c" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,506</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase related to current year tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0848912-cc89-4629-a043-57857e884373" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,846</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions for tax positions of prior years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f075d523-34c9-4faa-9d2b-d344d5617dd9" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions in connection with the reverse merger</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd166aba-9cca-4543-95f0-98c820e47993" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">847</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reduction for tax positions of prior years</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1520cdd4-f37a-4a08-8367-a291eb3eb591" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">140</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df8fb9fd-9036-4d82-ac90-1c2a02cb538d" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,080</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more likely than not recognition threshold to be recognized. The Company&#8217;s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_269c60e9-075f-474b-be9a-0d5863314556" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f9de1119-63d2-4cd2-b42c-04fe68e65a9f" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> accrual for interest and penalties and has not recognized interest and/ or penalties in the statements of operations and comprehensive loss for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022. Uncertain tax positions are evaluated based upon the facts and circumstances that exist at each reporting period. Subsequent changes in judgment based upon new information may lead to changes in recognition, derecognition, and measurement. Adjustments may result, for example, upon resolution of an issue with the taxing authorities or expiration of a statute of limitations barring an assessment for an issue.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, unrecognized tax benefits associated with uncertain tax positions was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7af9ab17-1184-433c-80c2-5e396e71fae3" contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0" name="calc:UnrecognizedTaxBenefitsNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ef68567-d4d6-40a8-afb3-6b58b3f7ca19" contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2" name="calc:UnrecognizedTaxBenefitsNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million respectively. If recognized, this would affect the effective tax rate, subject to valuation allowance. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company did not recognize any interest and penalties associated with unrecognized tax benefits. Due to net operating losses incurred, tax years from inception remain open to examination by the Federal and State taxing jurisdictions to which we are subject. The Company is not currently under Internal Revenue Services (IRS), state or local tax examination.</span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_399624a6-26cc-49cc-8bfd-208d86a51e84" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12. Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6e58edcc-f799-45d6-b32e-58abf4b5c8b6" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share (in thousands, except per share amounts):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.067%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:11.138%;"/>
        <td style="width:1%;"/>
        <td style="width:3.239%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:12.597%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Numerator:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_377fc435-be30-463c-9b20-fb9a6ada02f8" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">34,357</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9945632d-a48e-4c74-b377-b09fb136af3b" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,824</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Denominator</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average common stock outstanding, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3508f4a5-a8d2-49f3-86aa-caf12f38d10c" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d99816db-cce0-4f96-a7d9-2f636cb223c1" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,486,258</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c939bc5-a825-4965-affa-8c12a0d1f0ba" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f975e95f-56b6-42f9-947e-93fa4026fafd" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">82,245</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a5992fb-420f-43ad-85b8-bf0f5698fa3d" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a3bb575a-fde7-4f6a-9d56-9654d994c30e" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">7.66</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a41a89f6-c916-44b9-bfeb-75cb8f71b4d2" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_57e2db04-a78c-44f2-97eb-06c577fea617" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">111.16</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ecd93b7f-3d68-44dc-97ef-51f43d3d5d8a" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.009%;"/>
        <td style="width:1.64%;"/>
        <td style="width:1%;"/>
        <td style="width:19.356%;"/>
        <td style="width:1%;"/>
        <td style="width:1.64%;"/>
        <td style="width:1%;"/>
        <td style="width:19.356%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible preferred stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fdf34c1f-96cc-4f23-a1a9-57e353a203b4" contextRef="C_0812ad75-b2cd-4dd2-8c00-aee77ec17b71" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54563c67-e50e-46c1-9218-dadc7921d7a5" contextRef="C_f0893edf-fb0c-4acf-a7b8-179db40778c8" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,442,852</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants to purchase convertible preferred stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c68b8d3-471d-4a96-a719-95bd92a42c1e" contextRef="C_0605ef80-c201-4125-b549-78eca9b466e4" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6aa14352-a803-4c21-854a-5792a906edce" contextRef="C_faf992f7-2c83-438f-adbe-c70b73ea5b35" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">328,859</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c569093-f437-420b-ae80-e8c257c8f7f0" contextRef="C_8c333f4e-ee8c-4673-aefb-c953498d5405" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,739,270</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf34f287-95f7-43a9-9eb4-c2c07d5d9371" contextRef="C_53c249ce-207a-4c43-a71e-dd5b46a497f6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">739,544</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f66b7b8b-20e9-4bb3-9192-de3ae20422bd" contextRef="C_d04970cb-4761-47c7-91f6-85af5efbecc9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">276,437</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8cd678f-c1fc-4812-b9fd-9b7b9667c932" contextRef="C_b409b108-40af-4cb0-85b0-9bb871670447" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">11,520</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a269c029-ca85-4b60-aeaf-a2b9d44c9993" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,015,707</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02085cd1-ba04-4e79-8cc9-33e52c2a3677" contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,522,775</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a4ef61d5-c9da-4438-bf4c-595ff3e7dee0" contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13. Subsequent Events</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Private Placement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_09046eed-c941-4f29-a07c-5df977aa210e" contextRef="C_75c836b2-6496-4ac1-a472-f97feb0d50ca" name="us-gaap:SubsequentEventsDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 19, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain accredited investors, in which the Company sold the following securities to the accredited investors in a private placement transaction (the &#8220;Private Placement&#8221;) (i) an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19e3e7c0-3499-40ca-b526-0a1889b262b8" contextRef="C_6bf7869c-2d29-4936-b2b6-f5c3f0c8389e" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,985,610</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares (the &#8220;Shares&#8221;) of common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab66cd02-bc50-4774-8867-ebbb119f72e0" contextRef="C_c7b1abbe-8b62-4f83-bd11-82bf252ed828" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share; (ii) to certain investors, in lieu of Shares, pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f106794-3812-49f6-acb9-e93c7b2063a6" contextRef="C_638c2e40-07d4-4e89-83a6-af9e3d6013a3" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">306,506</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock; (iii) Tranche A Common Warrants (the &#8220;Tranche A Common Warrants&#8221;) to purchase an aggregate of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be370833-5500-438f-8615-d4c29d0d4f2e" contextRef="C_d8121a99-b58b-4059-9f6a-950088ae02aa" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,646,058</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of common stock (or Pre-Funded Warrants in lieu thereof and, in such case, shares of common stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issuable </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">upon exercise of such Pre-Funded Warrants); and (iv) Tranche B Common Warrants (the &#8220;Tranche B Common Warrants&#8221; and together with the Tranche A Common Warrants, the &#8220;Common Warrants&#8221;) to purchase an aggregate of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9169f46e-d5e8-40ad-bca3-a76cb3c53f0e" contextRef="C_b6a7e660-bab4-4faa-a6a3-7ce18a7b50c0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,646,058</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock (or Pre-Funded Warrants in lieu thereof and, in such case, shares of common stock issuable upon exercise of such Pre-Funded Warrants). The Purchase Price per Share and accompanying Common Warrants was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22124bf6-4cd7-4bb0-8ab4-79c77a1abe6f" contextRef="C_c7b1abbe-8b62-4f83-bd11-82bf252ed828" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">3.827</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (or $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae4f3450-b4c5-4421-882b-d372adc48917" contextRef="C_d7864a30-f755-4c98-af75-d219e66a55a8" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">4.3915</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for directors, employees or consultants of the Company participating in the Private Placement) (or $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89ee7ff5-b544-4f0d-a850-1743464aad29" contextRef="C_638c2e40-07d4-4e89-83a6-af9e3d6013a3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">3.8269</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per Pre-Funded Warrant and accompanying Common Warrants, which represented the price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56a1ad9b-22c8-4e14-adb6-f30d19fdc5b0" contextRef="C_33be579f-9303-4157-8599-6e2e245843a2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">3.827</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per Share and accompanying Common Warrants minus the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87f454de-bd96-4ba3-853f-cbd358c633a5" contextRef="C_13a92f01-c445-4a91-b998-937547a6966a" name="us-gaap:WarrantExercisePriceDecrease" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share exercise price of each such Pre-Funded Warrant).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The initial closing of the Private Placement occurred on January 23, 2024 and the second closing occurred on February 5, 2024. Gross proceeds from the transaction were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aecfd3b1-4887-4ff4-a1d3-0b5707c8454a" contextRef="C_f68eaef2-f138-447b-b9cf-bb7bd3b96085" name="calc:GrossProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million with net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_543473f7-6a34-413b-a1be-c8e175d5c9f2" contextRef="C_f68eaef2-f138-447b-b9cf-bb7bd3b96085" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">19.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7534a828-c2e4-4f4a-937c-4924d3da87e6" contextRef="C_f68eaef2-f138-447b-b9cf-bb7bd3b96085" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in commissions and other transaction costs.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>calc-ex4_2.htm
<DESCRIPTION>EX-4.2
<TEXT>
<html>
 <head>
  <title>EX-4.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 4.2</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Description of the Registrant&#x2019;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, CalciMedica, Inc. (the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; or &#x201c;our&#x201d;) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;): our common stock.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The following description summarizes the most important terms of our capital stock and certain provisions of our restated certificate of incorporation and restated bylaws. Because it is only a summary, it does not contain all of the information that may be important to you. For a complete description, you should refer to our restated certificate of incorporation and restated bylaws, which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.2 is a part, and to the provisions of applicable Delaware law.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Authorized Capital Stock</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Our authorized capital stock consists of 500,000,000 shares of common stock, $0.0001 par value per share, and 10,000,000 shares of undesignated preferred stock, $0.0001 par value per share.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dividend Rights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of our common stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that our board of directors may determine. See the section entitled &#x201c;Dividend Policy.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Voting Rights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. We have not provided for cumulative voting for the election of directors in our restated certificate of incorporation, which means that holders of a majority of the shares of our common stock will be able to elect all of our directors. Our restated certificate of incorporation established a classified board of directors, divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Preemptive or Similar Rights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Our common stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Right to Receive Liquidation Distributions</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Upon our liquidation, dissolution or winding-up, the assets legally available for distribution to our stockholders would be distributable ratably among the holders of our common stock and any participating preferred stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights of and the payment of liquidation preferences, if any, on any outstanding shares of preferred stock.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Preferred Stock</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Our board of directors is authorized, subject to limitations prescribed by Delaware law, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares of each series and any of their qualifications, limitations or restrictions, in each case without further vote or action by our stockholders. Our board of directors is also able to increase or decrease the number of shares of any series of preferred stock, but not below the number of shares of that series then outstanding and not above the number of shares of that series authorized, without any further vote or action by our stockholders. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of our company and might adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock. We have no current plan to issue any shares of preferred stock.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Anti-Takeover Provisions</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The provisions of the Delaware General Corporation Law (the &#x201c;DGCL&#x201d;), our restated certificate of incorporation and our restated bylaws could have the effect of delaying, deferring or discouraging another person from acquiring control of our company. These provisions, which are summarized below, may have the effect of discouraging takeover bids. They are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Delaware Law</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">We are subject to the provisions of Section 203 of the DGCL regulating corporate takeovers. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a &#x201c;business combination&#x201d; with an &#x201c;interested stockholder&#x201d; for a period of three years following the date on which the person became an interested stockholder unless:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.84%;"></td>
    <td style="width:3.92%;"></td>
    <td style="width:88.24%;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.84%;"></td>
    <td style="width:3.92%;"></td>
    <td style="width:88.24%;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, (i) shares owned by persons who are directors and also officers and (ii) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.84%;"></td>
    <td style="width:3.92%;"></td>
    <td style="width:88.24%;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">at or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized at an annual or special meeting of</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.84%;"></td>
    <td style="width:3.92%;"></td>
    <td style="width:88.24%;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">stockholders, and not by written consent, by the affirmative vote of at least 66.67% of the outstanding voting stock that is not owned by the interested stockholder.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Generally, a business combination includes a merger, asset or stock sale, or other transaction or series of transactions together resulting in a financial benefit to the interested stockholder. An interested stockholder is a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of a corporation&#x2019;s outstanding voting stock. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our board of directors does not approve in advance. We also anticipate that Section 203 may also discourage attempts that might result in a premium over the market price for the shares of common stock held by stockholders.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restated Certificate of Incorporation and Restated Bylaw Provisions</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Our restated certificate of incorporation and our restated bylaws include a number of provisions that could deter hostile takeovers or delay or prevent changes in control of our company, including the following:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.84%;"></td>
    <td style="width:3.92%;"></td>
    <td style="width:88.24%;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Board of Directors Vacancies.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Our restated certificate of incorporation and restated bylaws authorize only our board of directors to fill vacant directorships, including newly created seats. In addition, the number of directors constituting our board of directors is permitted to be set only by a resolution adopted by a majority vote of our entire board of directors. These provisions would prevent a stockholder from increasing the size of our board of directors and then gaining control of our board of directors by filling the resulting vacancies with its own nominees. This makes it more difficult to change the composition of our board of directors but promotes continuity of management.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.84%;"></td>
    <td style="width:3.92%;"></td>
    <td style="width:88.24%;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Classified Board.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Our restated certificate of incorporation and restated bylaws provide that our board of directors is classified into three classes of directors, each with staggered three-year terms. A third party may be discouraged from making a tender offer or otherwise attempting to obtain control of us as it is more difficult and time consuming for stockholders to replace a majority of the directors on a classified board of directors. See the section entitled &#x201c;Management-Board Composition.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.84%;"></td>
    <td style="width:3.92%;"></td>
    <td style="width:88.24%;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Stockholder Action; Special Meetings of Stockholders.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Our restated certificate of incorporation provides that our stockholders may not take action by written consent, but may only take action at annual or special meetings of our stockholders. As a result, a holder controlling a majority of our capital stock would not be able to amend our restated bylaws or remove directors without holding a meeting of our stockholders called in accordance with our restated bylaws. Further, our restated bylaws provide that special meetings of our stockholders may be called only by a majority of our board of directors, the chairman of our board of directors, our Chief Executive Officer or our President, thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal of directors.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.84%;"></td>
    <td style="width:3.92%;"></td>
    <td style="width:88.24%;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Advance Notice Requirements for Stockholder Proposals and Director Nominations.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Our restated bylaws provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. Our restated bylaws also specify certain requirements regarding the form and content of a stockholder&#x2019;s notice. These provisions</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.84%;"></td>
    <td style="width:3.92%;"></td>
    <td style="width:88.24%;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions might also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#x2019;s own slate of directors or otherwise attempting to obtain control of our company.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.84%;"></td>
    <td style="width:3.92%;"></td>
    <td style="width:88.24%;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">No Cumulative Voting.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;The DGCL provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless a corporation&#x2019;s certificate of incorporation provides otherwise. Our restated certificate of incorporation and restated bylaws do not provide for cumulative voting.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.84%;"></td>
    <td style="width:3.92%;"></td>
    <td style="width:88.24%;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Directors Removed Only for Cause.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Our restated certificate of incorporation provides that stockholders may remove directors only for cause and only by the affirmative vote of the holders of at least two-thirds of our outstanding common stock.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.84%;"></td>
    <td style="width:3.92%;"></td>
    <td style="width:88.24%;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Amendment of Charter Provisions.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Any amendment of the above provisions in our restated certificate of incorporation requires approval by holders of at least two-thirds of our outstanding common stock.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.84%;"></td>
    <td style="width:3.92%;"></td>
    <td style="width:88.24%;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Issuance of Undesignated Preferred Stock.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of preferred stock would enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by merger, tender offer, proxy contest or other means.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.84%;"></td>
    <td style="width:3.92%;"></td>
    <td style="width:88.24%;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Choice of Forum.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Our restated certificate of incorporation provides that, to the fullest extent permitted by law, the Court of Chancery of the State of Delaware will be the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the DGCL, our restated certificate of incorporation or our restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. Our restated bylaws provide that the federal district courts of the United States of America will, to the fullest extent permitted by law, be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, which we refer to as a Federal Forum Provision. Our decision to adopt a Federal Forum Provision followed a decision by the Supreme Court of the State of Delaware holding that such provisions are facially valid under Delaware law. While there can be no assurance that federal courts or state courts will follow the holding of the Delaware Supreme Court or determine that the Federal Forum Provision should be enforced in a particular case, application of the Federal Forum Provision means that suits brought by our stockholders to enforce any duty or liability created by the Securities Act must be brought in federal court and cannot be brought in state court. While neither the exclusive forum provision nor the Federal Forum Provision applies to suits brought to enforce any duty or liability created by the Exchange Act, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all claims brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Accordingly, actions by our stockholders to enforce any duty or liability created by the</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.84%;"></td>
    <td style="width:3.92%;"></td>
    <td style="width:88.24%;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exchange Act or the rules and regulations thereunder also must be brought in federal court. Our stockholders will not be deemed to have waived our compliance with the federal securities laws and the regulations promulgated thereunder. Any person or entity purchasing or otherwise acquiring or holding any interest in any of our securities shall be deemed to have notice of and consented to our exclusive forum provisions, including the Federal Forum Provision. These provisions may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum of their choosing for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers, and other employees.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Transfer Agent and Registrar</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The transfer agent and registrar for our common stock is Equiniti Trust Company, LLC. The transfer agent&#x2019;s address is 48 Wall Street, Floor 23, New York, New York 10005.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Nasdaq Capital Market Listing</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Our common stock is listed on the Nasdaq Capital Market under the symbol &#x201c;CALC.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>calc-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html>
 <head>
  <title>EX-21.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 21.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CalciMedica, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subsidiaries of the Registrant</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CalciMedica Subsidiary Inc., a Delaware corporation.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RainBio, Inc., a North Carolina corporation.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>calc-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:73.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="margin-left:73.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:73.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consent to the incorporation by reference in the following Registration Statements:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1)</font><font style="color:#000000;white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-3 Nos. 333-276793, 333-273949 and 333-271115) of CalciMedica, Inc. (formerly Graybug Vision, Inc.),</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(2) Registration Statement (Form S-8 No. 333-271898) pertaining to the Amended and Restated 2006 Stock Plan, 2023 Equity Incentive Plan, and 2023 Employee Stock Purchase Plan of CalciMedica, Inc. (formerly Graybug Vision, Inc.),</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(3) Registration Statement (Form S-8 No. 333-249033) pertaining to the 2020 Equity Incentive Plan, 2020 Employee Stock Purchase Plan and 2015 Stock Incentive Plan of CalciMedica, Inc. (formerly Graybug Vision, Inc.),</font></p>
  <p style="margin-left:20.747%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(4) Registration Statement (Form S-8 No. 333-254522) pertaining to the 2020 Equity Incentive Plan of CalciMedica, Inc. (formerly Graybug Vision, Inc.),</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(5) Registration Statement (Form S-8 No. 333-263464) pertaining to the 2020 Equity Incentive Plan and certain inducement grants of CalciMedica, Inc. (formerly Graybug Vision, Inc.), and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(6) Registration Statement (Form S-8 No. 333-266980) pertaining to the Amended and Restated 2020 Equity Incentive Plan of CalciMedica, Inc. (formerly Graybug Vision, Inc.);</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of our report dated March 28, 2024, with respect to the consolidated financial statements of CalciMedica, Inc. included in this Annual Report (Form 10-K) of CalciMedica, Inc. for the year ended December 31, 2023.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Ernst &amp; Young LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">San Diego, California</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 28, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>calc-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RULES 13a-14(a) OR 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, A. Rachel Leheny, certify that:</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.796%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.796%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of CalciMedica, Inc.;</font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.796%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.796%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.796%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.796%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.796%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.796%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.806%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.796%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.038132655419459%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.806%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.796%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.038132655419459%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.806%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.796%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.038132655419459%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.806%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.796%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.038132655419459%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.796%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.796%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.806%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.796%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.038132655419459%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.806%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.796%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.038132655419459%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49%;"></td>
    <td style="width:4%;"></td>
    <td style="width:47%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 28, 2024</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ A. Rachel Leheny</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">A. Rachel Leheny, Ph.D.</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>calc-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RULES 13a-14(a) OR 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Daniel Geffken, certify that:</font></p>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.796%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.796%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of CalciMedica, Inc.;</font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.796%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.796%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.796%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.796%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.796%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.796%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.806%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.796%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.038132655419459%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.806%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.796%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.038132655419459%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.806%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.796%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.038132655419459%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.806%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.796%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.038132655419459%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.796%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.796%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.806%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.796%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.038132655419459%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.806%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.796%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.038132655419459%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49%;"></td>
    <td style="width:4%;"></td>
    <td style="width:47%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 28, 2024</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Daniel Geffken</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Daniel Geffken</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Interim Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Financial Officer and Principal</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>calc-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended ( the&#34;Exchange Act&#34;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167; 1350), A. Rachel Leheny, Chief Executive Officer of CalciMedica, Inc. (the &#34;Company&#34;), certifies that, to the best of her knowledge:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#x2019;s Annual Report on Form 10-K for the period ended December 31, 2023, to which this Certification is attached as Exhibit 32.1 (the &#x201c;Annual Report&#x201d;) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act, and</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the undersigned has set her hands hereto as of the 28</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> day of March, 2024.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ A. Rachel Leheny		</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A. Rachel Leheny, Ph.D.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Chief Executive Officer</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Principal Executive Officer)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">		</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of CalciMedica, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:15.582%;"></td>
    <td style="width:7.141%;"></td>
    <td style="width:77.277%;"></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.014in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.014in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.014in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>calc-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended ( the&#34;Exchange Act&#34;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167; 1350), Daniel Geffken, Interim Chief Financial Officer of CalciMedica, Inc. (the &#34;Company&#34;), certifies that, to the best of his knowledge:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#x2019;s Annual Report on Form 10-K for the period ended December 31, 2023, to which this Certification is attached as Exhibit 32.2 (the &#x201c;Annual Report&#x201d;) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act, and</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the undersigned has set his hands hereto as of the 28</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> day of March, 2024.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Daniel Geffken	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Daniel Geffken</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interim Chief Financial Officer</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">		</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of CalciMedica, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>9
<FILENAME>calc-ex97_1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html>
 <head>
  <title>EX-97.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 97.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">CalciMedica, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Incentive Compensation Recoupment Policy</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Introduction</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Compensation Committee (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of the Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of CalciMedica, Inc., a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) providing for the Company&#x2019;s recoupment of Recoverable Incentive Compensation that is received by Covered Officers of the Company under certain circumstances. Certain capitalized terms used in this Policy have the meanings given to such terms in Section 3 below.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D of the Exchange Act, Rule 10D-1 promulgated thereunder (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rule 10D-1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and Nasdaq Listing Rule 5608 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Listing Standards</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Effective Date</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall apply to all Incentive Compensation that is received by a Covered Officer on or after October 2, 2023 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). Incentive Compensation is deemed &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">received</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; in the Company&#x2019;s fiscal period in which the Financial Reporting Measure specified in the Incentive Compensation award is attained, even if the payment or grant of such Incentive Compensation occurs after the end of that period.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Definitions</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Restatement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an accounting restatement that the Company is required to prepare due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Restatement Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the earlier to occur of (a) the date that the Board, a committee of the Board authorized to take such action, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (b) the date that a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Compensation Committee or, in the absence of such committee, the Board.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the U.S. Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Compensation Committee of the Board.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Covered Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means each current and former Executive Officer.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">1</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exchange</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Nasdaq Stock Market.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the U.S. Securities Exchange Act of 1934, as amended.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Executive Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Company&#x2019;s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company. Executive officers of the Company&#x2019;s parent(s) or subsidiaries are deemed executive officers of the Company if they perform such policy-making functions for the Company. Policy-making function is not intended to include policy-making functions that are not significant. Identification of an executive officer for purposes of this Policy would include at a minimum executive officers identified pursuant to Item 401(b) of Regulation S-K promulgated under the Exchange Act.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Reporting Measures</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#x2019;s financial statements, and any measures derived wholly or in part from such measures, including Company stock price and total stockholder return (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TSR</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). A measure need not be presented in the Company&#x2019;s financial statements or included in a filing with the SEC in order to be a Financial Reporting Measure.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Incentive Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lookback Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the three completed fiscal years immediately preceding the Accounting Restatement Date, as well as any transition period (resulting from a change in the Company&#x2019;s fiscal year) within or immediately following those three completed fiscal years (except that a transition period of at least nine months shall count as a completed fiscal year). Notwithstanding the foregoing, the Lookback Period shall not include fiscal years completed prior to the Effective Date.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recoverable Incentive Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Incentive Compensation received by a Covered Officer during the Lookback Period that exceeds the amount of Incentive Compensation that would have been received had such amount been determined based on the Accounting Restatement, computed without regard to any taxes paid (</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">i.e.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, on a gross basis without regard to tax withholdings and other deductions). For any compensation plans or programs that take into account Incentive Compensation, the amount of Recoverable Incentive Compensation for purposes of this Policy shall include, without limitation, the amount contributed to any notional account based on Recoverable Incentive Compensation and any earnings to date on that notional amount. For any Incentive Compensation that is based on stock price or TSR, where the Recoverable Incentive Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the Administrator will determine the amount of Recoverable Incentive Compensation based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or TSR upon which the Incentive Compensation was received. The Company shall maintain documentation of the determination of that reasonable estimate and provide such documentation to the Exchange in accordance with the Listing Standards.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the U.S. Securities and Exchange Commission.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">R</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">ECOUPMENT</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Applicability of Policy. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Policy applies to Incentive Compensation received by a Covered Officer (i) after beginning services as an Executive Officer, (ii) who served as an Executive Officer </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">at any time during the performance period for such Incentive Compensation, (iii) while the Company had a class of securities listed on a national securities exchange or a national securities association, and (iv) during the Lookback Period.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Recoupment Generally. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the provisions of this Policy, if there is an Accounting Restatement, the Company must reasonably promptly recoup the full amount of the Recoverable Incentive Compensation, unless the conditions of one or more subsections of Section 4(c) of this Policy are met and the Compensation Committee, or, if such committee does not consist solely of independent directors, a majority of the independent directors serving on the Board, has made a determination that recoupment would be impracticable. Recoupment is required regardless of whether the Covered Officer engaged in any misconduct and regardless of fault, and the Company&#x2019;s obligation to recoup Recoverable Incentive Compensation is not dependent on whether or when any restated financial statements are filed.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Impracticability of Recovery. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Recoupment may be determined to be impracticable if, and only if:</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount of the applicable Recoverable Incentive Compensation; provided that, before concluding that it would be impracticable to recover any amount of Recoverable Incentive Compensation based on expense of enforcement, the Company shall make a reasonable attempt to recover such Recoverable Incentive Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the Exchange in accordance with the Listing Standards; or</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">recoupment of the applicable Recoverable Incentive Compensation would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Code Section 401(a)(13) or Code Section 411(a) and regulations thereunder.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Sources of Recoupment. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">To the extent permitted by applicable law, the Administrator shall, in its sole discretion, determine the timing and method for recouping Recoverable Incentive Compensation hereunder, provided that such recoupment is undertaken reasonably promptly. The Administrator may, in its discretion, seek recoupment from a Covered Officer from any of the following sources or a combination thereof, whether the applicable compensation was approved, awarded, granted, payable or paid to the Covered Officer prior to, on or after the Effective Date: (i) direct repayment of Recoverable Incentive Compensation previously paid to the Covered Officer; (ii) cancelling prior cash or equity-based awards (whether vested or unvested and whether paid or unpaid); (iii) cancelling or offsetting against any planned future cash or equity-based awards; (iv) forfeiture of deferred compensation, subject to compliance with Code Section 409A; and (v) any other method authorized by applicable law or contract. Subject to compliance with any applicable law, the Administrator may effectuate recoupment under this Policy from any amount otherwise payable to the Covered Officer, including amounts payable to such individual under any otherwise applicable Company plan or program, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">e.g.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, base salary, bonuses or commissions and compensation previously deferred by the Covered Officer. The Administrator need not utilize the same method of recovery for all Covered Officers or with respect to all types of Recoverable Incentive Compensation.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Indemnification of Covered Officers. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding any indemnification agreement, applicable insurance policy or any other agreement or provision of the Company&#x2019;s certificate of incorporation or bylaws to the contrary, no Covered Officer shall be entitled to indemnification or advancement of expenses in connection with any enforcement of this Policy by the Company, including paying or reimbursing such Covered Officer for insurance premiums to cover potential obligations to the Company under this Policy.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">3</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indemnification of Administrator. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Any members of the Administrator, and any other members of the Board who assist in the administration of this Policy, shall not be personally liable for any action, determination or interpretation made with respect to this Policy and shall be indemnified by the Company to the fullest extent under applicable law and Company policy with respect to any such action, determination or interpretation. The foregoing sentence shall not limit any other rights to indemnification of the members of the Board under applicable law or Company policy.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No &#x201c;Good Reason&#x201d; for Covered Officers. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Any action by the Company to recoup or any recoupment of Recoverable Incentive Compensation under this Policy from a Covered Officer shall not be deemed (i) &#x201c;good reason&#x201d; for resignation or to serve as a basis for a claim of constructive termination under any benefits or compensation arrangement applicable to such Covered Officer, or (ii) to constitute a breach of a contract or other arrangement to which such Covered Officer is party.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Administration</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Except as specifically set forth herein, this Policy shall be administered by the Administrator. The Administrator shall have full and final authority to make any and all determinations required under this Policy. Any determination by the Administrator with respect to this Policy shall be final, conclusive and binding on all interested parties and need not be uniform with respect to each individual covered by this Policy. In carrying out the administration of this Policy, the Administrator is authorized and directed to consult with the full Board or such other committees of the Board as may be necessary or appropriate as to matters within the scope of such other committee&#x2019;s responsibility and authority. Subject to applicable law, the Administrator may authorize and empower any officer or employee of the Company to take any and all actions that the Administrator, in its sole discretion, deems necessary or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving such officer or employee).</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Severability</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If any provision of this Policy or the application of any such provision to a Covered Officer shall be adjudicated to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Policy, and the invalid, illegal or unenforceable provisions shall be deemed amended to the minimum extent necessary to render any such provision or application enforceable.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Impairment of Other Remedies</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Nothing contained in this Policy, and no recoupment or recovery as contemplated herein, shall limit any claims, damages or other legal remedies the Company or any of its affiliates may have against a Covered Officer arising out of or resulting from any actions or omissions by the Covered Officer. This Policy does not preclude the Company from taking any other action to enforce a Covered Officer&#x2019;s obligations to the Company, including, without limitation, termination of employment and/or institution of civil proceedings. This Policy is in addition to the requirements of Section 304 of the Sarbanes-Oxley Act of 2002 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">SOX 304</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) that are applicable to the Company&#x2019;s Chief Executive Officer and Chief Financial Officer and to any other compensation recoupment policy and/or similar provisions in any employment, equity plan, equity award, or other individual agreement, to which the Company is a party or which the Company has adopted or may adopt and maintain from time to time; provided, however, that compensation recouped pursuant to this Policy shall not be duplicative of compensation recouped pursuant to SOX 304 or any such compensation recoupment policy and/or similar provisions in any such employment, equity plan, equity award, or other individual agreement except as may be required by law.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">4</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Amendment; Termination</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Administrator may amend, terminate or replace this Policy or any portion of this Policy at any time and from time to time in its sole discretion. The Administrator shall amend this Policy as it deems necessary to comply with applicable law or any Listing Standard.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Successors</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall be binding and enforceable against all Covered Officers and, to the extent required by Rule 10D-1 and/or the applicable Listing Standards, their beneficiaries, heirs, executors, administrators or other legal representatives.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Required Filings</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company shall make any disclosures and filings with respect to this Policy that are required by law, including as required by the SEC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">*	*	*	*	*</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">5</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">CalciMedica, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Incentive Compensation Recoupment Policy Form of</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Executive Acknowledgment</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I, the undersigned, agree and acknowledge that I am bound by, and subject to, the CalciMedica, Inc. Incentive Compensation Recoupment Policy, as may be amended, restated, supplemented or otherwise modified from time to time (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). In the event of any inconsistency between the Policy and the terms of any employment agreement, offer letter or other individual agreement with CalciMedica, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) to which I am a party, or the terms of any compensation plan, program or agreement, whether or not written, under which any compensation has been granted, awarded, earned or paid to me, the terms of the Policy shall govern.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:30pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In the event that the Administrator (as defined in the Policy) determines that any compensation granted, awarded, earned or paid to me must be forfeited or reimbursed to the Company pursuant to the Policy, I will promptly take any action necessary to effectuate such forfeiture and/or reimbursement. I further agree and acknowledge that I am not entitled to indemnification, and hereby waive any right to advancement of expenses, in connection with any enforcement of the Policy by the Company.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:36pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agreed and Acknowledged:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Name: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Title: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Date: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img222477878_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_0.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )-!1<# 2(  A$! Q$!_\0
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MBG_T4KQA_P"#ZZ_^.5P%%'U>C_(ON06._P#^&A/BG_T4KQA_X/KK_P".4?\
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MBG_T4KQA_P"#ZZ_^.5P%%'U>C_(ON06._P#^&A/BG_T4KQA_X/KK_P".4?\
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MO_CE'_#0GQ3_ .BE>,/_  ?77_QRN HH^KT?Y%]R"QW_ /PT)\4_^BE>,/\
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M:PJ?%#U_1B. HHHK<84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJVLC$D +*5VDD@C@]J?XB^'/BSP?8VU]KWA?6M$LKDX@N=1T^:WCE.,_*SJ
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M']M_:_[8^T2?;/[0W_:/.W'?YF_YM^[.<\YSFJ%?2Q;<4V;/<****H04444
M%%%% !1110 4444 %%%% !1110 4444 >_\ [7'^I^"G_9-M'_\ :U> 5[_^
MUQ_J?@I_V3;1_P#VM7@%<.!_W>/S_-DK8****[B@HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^S;\$/$GP9N?B?I/BSQGI_AO1;QK;58M1M;:2ZN2-@"6Z)A49VDCP69@ WS
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M3;XK?M3:C_PE'B30/[%TV"Y^R:'J'V:"_P#] D;R[I-I\Q/DQMR.';UKYU^
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M"ZU:^N+V^N9KR\N)&EFN+B0O)*['+,S'DDDDDGK5>BBK225D,**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#W_\ :X_U/P4_[)MH_P#[6KP"O?\
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MU#F5VGT5SX;HK[!M_P!F3X)ZM\1+KX4Z;XX\3M\0X4DA74IK: :2]VBEGB"
M>8"-IS\V.#AB>*PO@_\ LH>'->\(_%2]^(&K:KX?U#P3<M!*^G^7)$-BL7)1
MDW2$[?EPRYR*G^T\.H.;NDDGL]4W9-=U<=]5&VM[?,^6Z*^EOB5^SUX!F_9\
ML_BG\-=7\17-HM^+"\L/$20B7<6*Y7RE !W;>,MD/U!!%>BZ;^PSX6T%?#.A
M>+(_B%?>)]:@2275/#.DK/HVF._"I/(48G:>I!Z<G:.:<LRP\8W=[W:M;6Z5
MW^#7WH7.M'W_ $=G^)\245]6_"W]B>/7?BQ\1/#'BC5KU[3P;&LKPZ'$OVS4
M5D5GB\D295254<'/+ >]<#\<OAM\,?"&BP3>%M6\7:-XE2;9=>$_&^EF&]$9
MSB99(XQ&!P/E))(/;&#<<PH5*BIP;;:3T3V>J_KIU*6LG'M_PYXA1117HC"B
MBB@ HHHH **** "BBB@#W7]AW_DZ+P5_V^_^D-Q11^P[_P G1>"O^WW_ -(;
MBBOSOB+_ 'N/^%?FS">YQ/[0G_)?/B5_V,VI_P#I5)7 5W_[0G_)?/B5_P!C
M-J?_ *525P%?>X?^##T7Y&RV-;PC?0:7XJT6\N7\JVM[V&:5\$[56123@<G@
M'I7LW[;'Q0\,_%SXV/K_ (3U/^UM).G6\ N/(EA^==VX;9%5N,CG&*\#HI3H
M1J585GO&]OG;_((KEDY+JK?C<]]_8E^*'AGX1?&Q=?\ %NI_V3I/]FW%O]H^
MSRS?.Q3:-L:LW.#SC%<=\/\ XL+\,OC[:>.[*(W]K9ZM-<^6,H9H)&=7 SC!
M,;MC/?&:\SHJ7AH2JRJO=QY6NEM?\R>5<LH]);_=8^U;'X@_L_>&/C1>_&NS
M\7ZUJ6I2R3:C#X,;2)$F2\E#!RUP?W6T%V; /']YL8,?P3^+%K\7/ /QIT'Q
MWINMZ=X:\37TFM2^(-%TF>^MM+G.UR)C$C$*/*B89X(1\E<YKXNKM_AA\:O&
M_P &;VZNO!OB"XT22Z4+.B(DL4N,[2T<BLA(R<$C(R<=:\ZIED?9.,9-RLE&
M[V2::LTNZW:;!IWYD];IW]/^'?3J?57C73_"V@_\$]]1LO"VHWFK:7_PD:)'
MJU_;&T.HRB12TD43$E4PI4 DG]VQ/<#S#]M+XO>$OBUJ'@*7PIJW]JII>B+:
M79^S30^7*"#M_>(N?J,BO+OBA\?OB!\:([6/QEXEN-8@M6WPV_E1P0JV"-WE
MQ*JEL$C<1G!(S7GU/"Y?*G+VM:5Y<SEO?>*CKHK_ "2^XJ*4;6[-?>[GV[/\
M>/A9XX^%/PPMM3\>Z]X./A&VC34O!^EZ?-(NKF(1X4.I6$%C&2&<G'F'(!R:
M[/Q)^U5\*K[QI\5M6MO%GF6WB+PA;Z=8@Z==JS72K=*T1!BX/[R,[C\OS=>#
M7YWT5%3)Z%2]Y2L[]OM.[Z7W[W)A%0M;I;\&FOR/I'PC\7?"6E_L1^,? %SJ
MWE>+=0UE+NVT_P"S3'S(@]L2WF!/+'$;\%@>/<5!\6/BQX5\3?LG?"OP;INJ
M_:?$FB7,TFH67V>5/)5C+@[V0(WWE^ZQZU\ZT5VO TW)RN_C4_FER]MK?\..
M,>1IKIS?^3;_ / "BBBO0*"N_P!:_P"2!^#?^QFUS_TETFN KO\ 6O\ D@?@
MW_L9M<_])=)K"I\4/7]&(X"BBBMQA1110 4444 %%%% !1110!](?LL_%SPG
M\./AC\:M)\1:M_9VH>(M$%II</V::7[1+Y-RNW*(P7F1!EB!S[&G6_Q>\)1_
ML.77P^;5L>+WUL7:Z=]FFYB\Q6W>9L\OH#QNS7S;17G5,#3JU)56W=N+_P#
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MJ*.:M_S\E]X:GGO_  Q[\#/^@G\0O_ BQ_\ C-'_  Q[\#/^@G\0O_ BQ_\
MC->A44<U;_GY+[PU//?^&/?@9_T$_B%_X$6/_P 9H_X8]^!G_03^(7_@18__
M !FO0J*.:M_S\E]X:GGO_#'OP,_Z"?Q"_P# BQ_^,T?\,>_ S_H)_$+_ ,"+
M'_XS7H5%'-6_Y^2^\-3SW_ACWX&?]!/XA?\ @18__&:/^&/?@9_T$_B%_P"!
M%C_\9KT*BCFK?\_)?>&IY[_PQ[\#/^@G\0O_  (L?_C-'_#'OP,_Z"?Q"_\
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M-RGVB-(;)6;<T8"X,,G#$'Y?<9\C\2?&'PK=_L3^#? EIJV_QAINN->SZ?\
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M\L9-;T[[$L7A+2M+<^?')_I,+W!E3Y6/0.AW=#GKUIPG.52S6B?Z3W^:5O\
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M8PHHHH V?&?_ ".&N?\ 7]/_ .C&K&K9\9_\CAKG_7]/_P"C&K&K.E_#CZ(
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M74TCL%%%%>B4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@\2_]#KX/_[[U#_Y#H^NT/YOP?\ D%T?.5%?1O\ PQ!XE_Z'7P?_ -]ZA_\
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M?!__ 'WJ'_R'1]=H?S?@_P#(+H^<J*^C?^&(/$O_ $.O@_\ [[U#_P"0Z/\
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M+%T/;1ESJUG^:"Z/%J*]*_X4'X@_Y_--_P"_LG_QNC_A0?B#_G\TW_O[)_\
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M:*]*_P"%!^(/^?S3?^_LG_QNC_A0?B#_ )_--_[^R?\ QNCZ[A_YT%T?$_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M  J;QA_T I/_  *M_P#XY1_PJ;QA_P! *3_P*M__ (Y1]=P_\Z"Z.2HKK?\
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M_O[9_P#R17PYF;U%8/\ PD>H?]"MJW_?VS_^2*/^$CU#_H5M6_[^V?\ \D4
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MVK?]_;/_ .2*/^$CU#_H5M6_[^V?_P D4 ;U%8/_  D>H?\ 0K:M_P!_;/\
M^2*/^$CU#_H5M6_[^V?_ ,D4 ;U%8/\ PD>H?]"MJW_?VS_^2*/^$CU#_H5M
M6_[^V?\ \D4 ;U%8/_"1ZA_T*VK?]_;/_P"2*/\ A(]0_P"A6U;_ +^V?_R1
M0!O45@_\)'J'_0K:M_W]L_\ Y(H_X2/4/^A6U;_O[9__ "10!O45@_\ "1ZA
M_P!"MJW_ ']L_P#Y(H_X2/4/^A6U;_O[9_\ R10!O45@_P#"1ZA_T*VK?]_;
M/_Y(H_X2/4/^A6U;_O[9_P#R10!O45@_\)'J'_0K:M_W]L__ )(H_P"$CU#_
M *%;5O\ O[9__)% &]16#_PD>H?]"MJW_?VS_P#DBC_A(]0_Z%;5O^_MG_\
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M_O[9_P#R10!O45@_\)'J'_0K:M_W]L__ )(H_P"$CU#_ *%;5O\ O[9__)%
M&]1618ZW>75TD4OA_4;-&SF>>2V*+QGG9,S<]. >M% &O1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%?E?17YU_K?_ -./_)O_ +4_:_\ B&__ %%_^2?_ &Y^J%%?E?11_K?_
M -./_)O_ +4/^(;_ /47_P"2?_;GZH45^5]%'^M__3C_ ,F_^U#_ (AO_P!1
M?_DG_P!N?JA17Y7T4?ZW_P#3C_R;_P"U#_B&_P#U%_\ DG_VY^J%%?E?11_K
M?_TX_P#)O_M0_P"(;_\ 47_Y)_\ ;GZH45^5]%'^M_\ TX_\F_\ M0_XAO\
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MF%%%%<QVA1110 4444 %%%% !1110 4444 %%%% '?\ Q\_Y+%XJ_P"OP_\
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M115$A1110 5H^(/^0M/_ ,!_]!%9U:/B#_D+3_\  ?\ T$4",ZBBB@84444
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M<.EZ7#YL\G+,>$C7N['L!_\ 6ZT>$?".I>-M;ATO2X?-GDY9CPD:]W8]@/\
MZW6OLGX=?#K3?ASHBV5DOFW,F&N;MAAYF_HH[#M]<FOI,GR>IF53FEI36[[^
M2_K0^)XEXEI9'2]G3]ZM+9=O-^79=27X>> [/X=^&XM+M)'G;=YDTSD_O)"
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#':/\ 5/'?SP^]_P#R(?\ $0\J_P"?=3[H_P#R9\!T5]^?\,N_#'_H6?\
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MAM\-A\0]3\417?AZY;59/ \NKPW&C1Z@)7:.8HBL21D/M678&).T98'T:?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 45^5]%?G7^M__ $X_\F_^U/VO_B&__47_ .2?_;GZH45^5]%'
M^M__ $X_\F_^U#_B&_\ U%_^2?\ VY^J%%?E?11_K?\ ]./_ ";_ .U#_B&_
M_47_ .2?_;GZH45^5]%'^M__ $X_\F_^U#_B&_\ U%_^2?\ VY^J%%?E?11_
MK?\ ]./_ ";_ .U#_B&__47_ .2?_;GZH45^5]%'^M__ $X_\F_^U#_B&_\
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MM@Y .6^"_P 7/'OCC]MS7-&\7:#K?@1;3P-#--X5NM56]L!<&[_X^8&B;RY
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MKWR69F^RR7KEMT>YF.1&&P< K@$?3M !1110!^5]%%%?SH?VJ%%%% !1110
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M_@W5O'$WA'7M$^'MC8W&H#Q/<W%A/"T<)PR/%!<O-%*<C;&Z!CSTQ7!^"?V
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M32Y\L=K0,[,Q7;CJ3SFNRH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>+/VCOB1-XIFUK1_#;GPE:Z?;^3)+=-!JL%\MT"5,2![<X*;LAN<[.U?9M%
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M^!&O_%G]DK5/A=I%YIMMX@NM*L[%+F]ED6U$D31%B65&;:?+./DSR.!7N]%
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M3Q!_X$0?_&:/]6<P[+[P_P!>\F_FE_X"?%M%?:7_  Q9X(_Z"GB#_P "(/\
MXS1_PQ9X(_Z"GB#_ ,"(/_C-'^K.8=E]X?Z]Y-_-+_P$^5OA3_R5'P=_V&;/
M_P!'I7+5]P^'_P!D;P?X;U[3=7MM2UQ[FPN8KJ)99X2A9'# ,!$#C(&<$50_
MX8M\$?\ 04\0?^!$'_QFMGPWCW2C"RNF^O>W^1S1XXR=5Y5.:5FHKX>SE_F?
M%M%?:7_#%G@C_H*>(/\ P(@_^,T?\,6>"/\ H*>(/_ B#_XS6/\ JSF'9?>=
M/^O>3?S2_P# 3XMHK[2_X8L\$?\ 04\0?^!$'_QFC_ABSP1_T%/$'_@1!_\
M&:/]6<P[+[P_U[R;^:7_ ("?%M%?:7_#%G@C_H*>(/\ P(@_^,T?\,6>"/\
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MO_(X,/QYE-*C"G)3NDELNB]3X<HK[C_X9 ^'_P#<U/\ \"__ +&C_AD#X?\
M]S4__ O_ .QK+_5;']X_>_\ (Z/]?\H[3_\  5_F?#E:WA?POJ/C'6H-+TN
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M^"=W@+5]+\&V=KXL\;:))X7N+B_M[RQU&W:>ZOIW#2WMPTUO)ON&('S@+@<
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MQ!_X-)__ (NM'Q514%/V3U;6ZZ6_S,EX?8IU72]O'1)[/K?_ "/TFHK\V?\
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MEZGQ%\4JMW.JC5;H "1@!^];WKF_[6OO^?RX_P"_K?XU-3BR-.;A['9_S?\
M -:/AW.M3C4^M6ND_@[_ /;Q^HU%?ES_ &M??\_EQ_W];_&C^UK[_G\N/^_K
M?XUG_K?'_GQ_Y-_P#7_B&\_^@K_R3_[8_4:BORY_M:^_Y_+C_OZW^->V? _]
MH*\\.-#H&OZA.VE,=MO=O*Q-L3_"QS]SW_A^G3MP?%%#$5E2JPY$^M[KYZ+[
MSR\RX!Q6#P\J^'J^U:WCRV=O+5W?E_PQ]M45P:ZI<R*&6[E96&0PD)!'YTO]
MI7?_ #]3?]_#_C7VQ^6V.[HKA/[2N_\ GZF_[^'_ !H_M*[_ .?J;_OX?\:
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MF% \HWJI5,*0?G*Y[9KK: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUS0]6T[5888] UC7M;U-;G2H(XXQ]B^R1+Y!C9X\F3)/S%F1STW_  [^R_\
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MLR_L]S? G2?%5UK.NQ^*/&'BS6)=;UK5X;(6D4DK\+''$&;:B#IDG)9CQG%
M'L]%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^5]%%%?SH?VJ%%%
M% !1110 4444 %%%% !1110 4444 =3\*?\ DJ/@[_L,V?\ Z/2N6KJ?A3_R
M5'P=_P!AFS_]'I7+5TR_@1]9?E$XH_[U/_#'\YA1117,=H4444 %%%% !111
M0 4444 %%%% !1110!TGQ,_Y*/XJ_P"PK=?^CFKFZZ3XF?\ )1_%7_85NO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWUN\@S+V48^RU3?6/9>?D<L>,,C6(E/ZQHU%?#/HY?W?-'RO17U1_P ,-_\
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MGG/45T/_  B/_3W_ .0__KT?\(C_ -/?_D/_ .O0!SU%=#_PB/\ T]_^0_\
MZ]'_  B/_3W_ .0__KT <]6CX@_Y"T__  '_ -!%:'_"(_\ 3W_Y#_\ KU9U
M#P[]NNWG^T;-V/EV9Z #UH Y6BNA_P"$1_Z>_P#R'_\ 7H_X1'_I[_\ (?\
M]>@#GJ*Z'_A$?^GO_P A_P#UZ/\ A$?^GO\ \A__ %Z .>HKH?\ A$?^GO\
M\A__ %Z/^$1_Z>__ "'_ /7H YZBNA_X1'_I[_\ (?\ ]>C_ (1'_I[_ /(?
M_P!>@#GJ*Z'_ (1'_I[_ /(?_P!>C_A$?^GO_P A_P#UZ .>HKH?^$1_Z>__
M "'_ /7H_P"$1_Z>_P#R'_\ 7H YZBNA_P"$1_Z>_P#R'_\ 7H_X1'_I[_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^@M_Y+0__$5QM%'U:A_(ON06.R_X6_XN_P"@M_Y+0_\ Q%'_  M_Q=_T%O\
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M_P"@M_Y+0_\ Q%<;11]6H?R+[D%C[%I:2EKX(R"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ( Q?_$UO44 8/\ P@/AC_H7-)_\ 8O_ (FC_A ?#'_0N:3_ . ,7_Q-;U%
M&#_P@/AC_H7-)_\  &+_ .)H_P"$!\,?]"YI/_@#%_\ $UO44 8/_" ^&/\
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M ,36]10!@_\ " ^&/^A<TG_P!B_^)H_X0'PQ_P!"YI/_ ( Q?_$UO44 8/\
MP@/AC_H7-)_\ 8O_ (FC_A ?#'_0N:3_ . ,7_Q-;U% &#_P@/AC_H7-)_\
M &+_ .)H_P"$!\,?]"YI/_@#%_\ $UO44 8/_" ^&/\ H7-)_P# &+_XFC_A
M ?#'_0N:3_X Q?\ Q-;U% &#_P (#X8_Z%S2?_ &+_XFC_A ?#'_ $+FD_\
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M_P"$N_Z=/_(G_P!:O8/FK$G_  @/AC_H7-)_\ 8O_B:/^$!\,?\ 0N:3_P"
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M\36]10!@_P#" ^&/^A<TG_P!B_\ B:/^$!\,?]"YI/\ X Q?_$UO44 8/_"
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M^A<TG_P!B_\ B:/^$!\,?]"YI/\ X Q?_$UO44 8/_" ^&/^A<TG_P  8O\
MXFC_ (0'PQ_T+FD_^ ,7_P 36]10!@_\(#X8_P"A<TG_ , 8O_B:/^$!\,?]
M"YI/_@#%_P#$UO44 9%CX0T'3;I+FST33K6X3.V:"TC1UR,'! R."1^-%:]%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME(=>UZ$/J[#=;VKC(M1_>/\ M_\ H/UZ>SE>!Q&.Q"5!VMJY=O\ @]CYO/\
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MXB/#>>*?A2GA]IKTQ^&M-FN1XD2".1TA=T:5HSD*K-A>C9XSBNM^$/[#.D?
MV8'PO\3/'TECYLUS+HVJWEG/I]Y-(K M=1I;1O,,MD_O 3@#-<_X&_9@^(MW
M\4/ASJ_C2+X;Z'X?^'KW4FEKX$L)[6>^::,QA98F58[=,'>40N"WMS0!];T4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5B^-O^1,U__L'W'_HMJVJR?%UO+>>%-:@AC:6:6RF1(U&2S&-@
M !ZYK*K_  Y>C.C#NU:#?=?F?F+17:?\*5\>_P#0HZQ_X"/_ (4?\*5\>_\
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MY1G45H_\(_?_ //#_P ?7_&C_A'[_P#YX?\ CZ_XT 9U%:/_  C]_P#\\/\
MQ]?\:/\ A'[_ /YX?^/K_C0!6TW_ )"%K_UU7^8JO6O9:'>PWD#O!A%D5B=Z
M] ?K4/\ PC]__P \/_'U_P : ,ZBM'_A'[__ )X?^/K_ (T?\(_?_P#/#_Q]
M?\: ,ZBM'_A'[_\ YX?^/K_C1_PC]_\ \\/_ !]?\: ,ZBM'_A'[_P#YX?\
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MK_C0!G45H_\ "/W_ /SP_P#'U_QH_P"$?O\ _GA_X^O^- &=16C_ ,(_?_\
M/#_Q]?\ &C_A'[__ )X?^/K_ (T 9U%:/_"/W_\ SP_\?7_&C_A'[_\ YX?^
M/K_C0!G5H^(/^0M/_P !_P#011_PC]__ ,\/_'U_QJYK&CWEUJ$LL4.Y&VX.
MX#L!ZT 85%:/_"/W_P#SP_\ 'U_QH_X1^_\ ^>'_ (^O^- &=16C_P (_?\
M_/#_ ,?7_&C_ (1^_P#^>'_CZ_XT 9U%:/\ PC]__P \/_'U_P :/^$?O_\
MGA_X^O\ C0!G45H_\(_?_P#/#_Q]?\:/^$?O_P#GA_X^O^- &=16C_PC]_\
M\\/_ !]?\:/^$?O_ /GA_P"/K_C0!G45H_\ "/W_ /SP_P#'U_QH_P"$?O\
M_GA_X^O^- &=16C_ ,(_?_\ /#_Q]?\ &C_A'[__ )X?^/K_ (T =3IO_(/M
M?^N2_P A5FH+&-H;."-QAUC52/<"IZ"0HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBL#Q[XF;P9X-UC7$MQ=/86[3B%FVA\=LX.*B<XTXN<MEJ:TJ<JU2-*"NY-)>
MK-^BODS_ (;@OO\ H4K?_P #F_\ B*/^&X+[_H4K?_P.;_XBOG?]8LL_Y^?A
M+_(^T_U*SS_GS_Y-'_,^LZ*^3/\ AN"^_P"A2M__  .;_P"(H_X;@OO^A2M_
M_ YO_B*/]8LL_P"?GX2_R#_4K//^?/\ Y-'_ #/K.BODS_AN"^_Z%*W_ / Y
MO_B*]N\!_&K3/B%H::CIT&&&%GMVE^>%_P"Z>/R/>N["9M@\=/V="=WVLU^9
MY68\.YGE5)5L72M%Z7NG]]F['HM%<[_PEW_3I_Y$_P#K4?\ "7?].G_D3_ZU
M>N?.6.BHKG?^$N_Z=/\ R)_]:C_A+O\ IT_\B?\ UJ L=%17._\ "7?].G_D
M3_ZU'_"7?].G_D3_ .M0%CHJ*YW_ (2[_IT_\B?_ %J/^$N_Z=/_ ")_]:@+
M'145A6_BC[1<11?9MN]PN?,SC)QZ5%_PEW_3I_Y$_P#K4!8Z*BN=_P"$N_Z=
M/_(G_P!:C_A+O^G3_P B?_6H"QT5%<[_ ,)=_P!.G_D3_P"M1_PEW_3I_P"1
M/_K4!8Z*BN=_X2[_ *=/_(G_ -:C_A+O^G3_ ,B?_6H"QT5%<[_PEW_3I_Y$
M_P#K4?\ "7?].G_D3_ZU 6.BHKG?^$N_Z=/_ ")_]:C_ (2[_IT_\B?_ %J
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M?_6H_P"$N_Z=/_(G_P!:@+'145SO_"7?].G_ )$_^M1_PEW_ $Z?^1/_ *U
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MO^NK?S-5ZL:E_P A"Z_ZZM_,U7H$%%%% PHHHH **** "BBB@ HHHH ****
M"M'Q!_R%I_\ @/\ Z"*SJT?$'_(6G_X#_P"@B@1G4444#"BBB@ HHHH ****
M "BBB@ HHHH **** .ZTW_D'VO\ UR7^0JS5;3?^0?:_]<E_D*LT$!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %?*/Q8\4>.?C-^U,?@MX7\8WOP\\-:)X?77M=UC15C.I7C2R
M>7#;PO(C")1PQ8 DYQ7U=7AWQL_9IN?B%XZT;XA>"?&EU\-OB1I=JVG+KEM8
MQW\-U9LVYK>XMI"%D4')4Y!4G/.!@ \C_:"TSXJ?LW_LD_%J_?XM:GXI>S6V
ME\.ZK=VR0ZK81F:-9$FN$P)B2QPVP$#//( \F\6?MR>.;C]E^+P+9RM9?M&1
MF?2]36)E\RSM[6#[1+J9ZX62W"E6Q@N[;>E?0WB']CKQ/XZ^"GQ"\'>,?C+K
M7BKQ!XR$ GUF]T]$L; 1.K*+73XY%2/(4!L/\Q /KGO=<_9;\&:HOB;5;:P@
ML?&VO^%SX5N?$@C=W^S^5Y8;R=X7/W2<88A54M@4 ?%MM^TGXW^(6E_"7P*^
MM_$F>63P%:>)-8F^&]I#<:[J=S*^U6::<;(84"98YRYD"\U]0?#'XN>,_%7[
M./A[5_AO/'\6/$<E[)IU[J'C!DT*33RKOO-[#&C'?" D;+&,L2''!K)T_P#8
MM\1>!--\"7GP[^*3^$_&7AWPU%X5O=6FT*.]M-5LXVWH7M7E_=NKY8,)#Z'(
MK8M?A7XB_9H^!XT#P9X.;XX7VK:G<7?BF/5-2M]/GU$W(8W,ZK(IB()VCR20
M-O&6/) ,#X<?M2?%?XG:/XUT70?A[X9U/QQX3UZ/1+Z_M_$+#0-K1L[7"3&(
MR,(\*KQ ;P77IR!Q?BC]N[Q7I_P#^,>H7VC:3H_C3P3JMOX=&L:'<MJ6DRW%
MPZH)H24#,T0?<T3 G(4'&2!%\&? 7QB^#?A/XA7NG_ ^SF\'^)M8C-I\)7\3
MVS'3;)H72ZE1V#0'S6*,8-P&-PZXS>^!_P"R3KWBOX;_ !>\,>,_#LWPH\$>
M+-0M[SPYX/T_58[Z709(L.;F-TS&A>58Y/*7@;2"!W -/]E/XAW5O\8)/"^O
M^-?BM_:.J:0^H6_A_P"*6C6MO_:#AU,EU8RP\QQH,@V[8*AP<?*:^RJ^>OAK
M^S+XJT_XK:5\0OB=\3I?B1KN@V$NG:''#HL6E6]HLH FF=(W?S97  SD <X'
M3'T+0 4444 %%%% !7#_ !RU>]\/_!?QYJ>G7,EGJ%EH5[<6]Q$</%(D#LK
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M90\7_$#P)\--1\):7;V.8O%MWK%M^YG6Z$4@@@:,O,JC^,JH)+ ?=R?9=?\
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M>\->(HK'4I/^)@D9@C=(#Y2QY"EBI\Q2>F:^QO''P)_X3+XQ?"SQW_;?V/\
MX0=;]?[/^R;_ +;]I@6+_6;QY>W;G[K9SCCK7AMK^P'XAM_A/\0OAF?BR)/!
M/B+43J.F6+^'(_,TJ1KQ+ELRB<-/G84Y*@9W?[- '5:[^V)J<7QLU3X:>$?
MMKXGU+1$L_MR7_BFVTV_G\Z-9"UG:RH3<JB,I9BZ<G [$_3PY .,>U?*OQ\_
M8KUSX^:Q/#J_C_2SX;DGMY;>.\\(6T^K:6D90O%9:@)$:)7*DY9'9=QY;I7U
M/;PBWMXXE+,L:A0SG).!CD]S0!)1110 4444 %%%% !1110 4444 %%%% !7
M"_'/_DD'BW_L'R?RKNJX7XY_\D@\6_\ 8/D_E7'C/]VJ_P"%_D>EEG^_4/\
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M:(^+G_#2FE?#_P 1P^ ?$6FW<-U/JT/@MKN:X\,J@W0F\GD;RR7^[MV(Q/(
M'!H_LK_M8>-/C]\1'AO/%/PI3P^TUZ8_#6FS7(\2)!'(Z0NZ-*T9R%5FPO1L
M\9Q76_"']AG2/@;,#X7^)GCZ2Q\V:YET;5;RSGT^\FD5@6NHTMHWF&6R?W@)
MP!FN?\#?LP?$6[^*'PYU?QI%\-]#\/\ P]>ZDTM? EA/:SWS31F,++$RK';I
M@[RB%P6]N: /K>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJI>:O8Z?=V=K=
M7MO;7-Z[1VL,TJH\[!2Q5%)RQ"@D@=@35N@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R?XK?#SQ!XF^
M)_PT\2:%I/A^XC\.7\UQ?7FI7LEO=^1);RPF*$);2;AF4/AG0$H!WW#&_:L\
M:>,M(\.^&_"7PVU:/0_'_B[5!9:=J,EK'<BTABC:>XF,4@*L D>SD=95[XKW
M&O+OB!^S;X&^*WQ&TGQ=XSTJ+Q4=*TZ;3K31-8MX+K3(_-D5WG\F2,YF^15W
M%L!>@SS0!\7?&+]I#Q9XR\ Z!XATSQ+JNAZC-\*O$D^IVVF7TEL(-7M9;6*1
MRL; ++'()0K8RH8XQFOMOQI\2$^&/P!O_&EZS7,FEZ$+P*[;GGF\D;$R>K/(
M57W+5Y)_P[N^&4$GB9+'4/$.EZ9KEKJMD-)L9K6.TT^+4/(,ZVJ?9_W8!MT*
M E@N6X/&/7?BC\"?#OQ>\":1X.\037S^'["\L[N6SB:/;?+;,&2"X#(P>)BJ
M[E 7..H% 'SKX#_:?\>_!_X9>/K/XL20>-?B#X2OM+D=8EBTW[39:B85B8".
M,J!%(\R$[?F,7)!.:]"^(G[6U[X'UOXLVEMX(.L6GPY32[O49H]4\N6:SND9
MYYHX_);YH54MLW?. ?F4@ N\5_L$_";Q#JVK7NEZ7+X(BU32%TBZL/"45MI]
MJ^RX2XBN3&L)!GCDC4JQRI PRL.*EU']BGPMKR^+/[;\6^+M;E\6S:=)X@DO
M+JU']II9,QCA=4ME5(G!572(("$&-N6+ &;X=_; U3Q\W@JQ\(^!;>^UOQDN
MH:GH\.JZR]E;'1K9PB7T\@M9'C:8LA2$1-P_+C%5O#O[:&H>.-9^'V@^'/ 4
M5QXA\3MJUM=VNH:X+>#2KK3I5CN8WE2"0R)]\JZIEL)\H#$IT&C_ +%_A;PK
M;Z!_PC'BCQ1X8O\ P]=ZA-H^H:?+9O+86UXVZ:QC2:VDB-MNP55T9D(&'%;G
M@W]E/P9X#\0^!=:TNXU87OA&'48[=I[E)/MTM\0UU<7)*;GE=\OE2B@L?EQ@
M  YRW_:[M4_:&T;X87EAX?,FL7-[90-I?BB&^U.RFMX]_P#IUBD6+=9 K[2)
MG/"[E4DA;_Q3_:,\2>#_ (G:UX)\,> [;Q/>Z5X6_P"$JFN[[7?[/A,(EDC:
M'BWE;S#Y8V\;3N.XI@%F>%?V-?"?@_QIH&OV7B'Q+);>']8O];TG1)Y[4V5G
M/>"3[2 1;B9U8R9_>2L5*K@@;@<3XB?L[^(/B3^T[K.OMJ^O>%/"MYX'30FU
MC0;RU66:5KJ1I;=HYDEX,;@^9Y8*G[CJ<T 8G@3]OJS\=:#XX\70^#FL_ 7@
M_2[?5=1U2?4Q]LD2>R2YBBAM1#AI-Q:-@TB*,*P9MQ5=;4/VP]9\#PW0\=_#
MV+1KR;PA<^+])MM&ULZ@;N* *9K:8O;0F&51)&3@2+@N0QVX/8>"?V/_ (=>
M _#OCKP[I]G>3>'/&-G;6%_I-S.&AB@@M1;(D150XR@R69F;=R"*\^^+/['L
MS?"7Q4FD:KKGQ+\8_P#",'PWH<?BJ^MH!:69=&DB@:WA@42N(T_>REB6CC#/
MMW9 ,VU_;TU+_A7_ (Z\72>!M%U;2/#.H:7IL5YX7\5G4;74IKMHPZPSM9Q)
MF$2IN&?O?*=H^:NC\7?MB7WPU\>^%_#'B_P_X3L+[5=5L](N=-TWQK'>:M;/
M<Y\NX2R^S(TEN"4!=VC;);"%0K/@^#?V;O$7Q,M?'V@>-O\ A-/"WPWU"729
M='T77_$D>KZM#<VK"6:83M-=K'%(ZQCR_,/W6("9%=]XC_8U\)^(_&FI:\_B
M'Q+8VVH>(;/Q5<Z+:SVOV-]2MA&$GR]NTW*Q[2GF[,,Q"@X( .-A_;6\1WWB
M#2;.T^&5L]AK'BO4?!FGW<OB0(\E_;&7;))&+8[+=A'\SAF=3N C?"E[NI_M
MM+I_P9\&^-I/"UGIEQK^OS>';E=<UO[)I6E3Q/,CR7%^MO)MB+P%58PC)89"
M\UV]A^R=X1T^X\.31ZCK3-H7BV\\96P:>'#WESYGF1O^ZYB'FMA1AN!ECWGL
MOV9=-T/X<Q>#M \9>*O#UFE[?7CW=E-:/+.+MY'FAD2:WDA>/,IVYCW+M&&S
MDD N^.OC<_@_X5Z%XO>#PU9-JBP$R>(O%5OIVE6YDC+_ #7P20.#@A#%&^\E
M3A5RR^6>"?VW+SXFCX5VWA3P+;WVI^.K?4I MWKPAM;&2QE5)@9EMW,L9&\H
MZIDX0% &)3T#4/V4?"C^"/ASX<T75-<\+GX?R"70-4TR>&2Z@;R6B<L+B*6)
M]ZNV=T9P3\NVJ_PY_9#\'?#'6O!.IZ5J6N3S^$?[5%BMY<0NLG]H2;Y_-Q$"
MVT_=P5P.NZ@#B?!O[>GAWQA\7K#PC#::.-.U+7;OP[9RV_B&.;5Q<VX;]]/I
MHC#16SM'(J2^8Q.$)10_$7Q_^)'Q/A^-OB3P5X#\0G2I8_AM<^(-.@%C;SYU
M&*\55),D;$AD!CVYQ\V<9P:]8^'WP!MOA;X@O;GPSXP\1Z=X<N]1N-4D\(XL
M9--$TY+2[&>U-RBER9-JS@!B<8!Q6W)\(=&F^,\7Q,:XOO[=CT-O#XMMZ?93
M;M,)BQ79NW[AC.[&.W>@#Q[X4_M#:K\=OBQ\.XO#FI?9/##>"!XF\06B0Q.)
M;BY=8;>!G*EHS&\=R2%*D[><@5ROQ@^,&O> OVLM:U+Q"9O^%=^"/ S>(VL]
M.\175NTNZ9T:5[1(UBN92RB)89G**#O#!CM'LWP#_9>\&_LXW7BVX\*OJ4S^
M)+[[;<?VC,DHMU!<I;P;479"ID<A3D_,>36CXN_9Y\)>._&7B/Q#KBWE^WB#
MPT?"E]I[2JML]F96D) "AQ)ER-V_&,8 /- 'E>M?MC:]X$L;X^-?A[9Z-J,O
M@ZY\8Z-:Z?XA-XEY';JK36TSM:Q&"91)&?E653EL,=O/H,WQRUG2?V<=9^*V
ML>$[>R-KH\FNVFBP:L9GFMA")8UEE\@"*1@<,JB15[,U8*_L;>&[[2-3LO$'
MBWQ9XLFN?#<GA.TOM6N+03:9I\@ D2W$-M&A=ML>9)5D<^6O.,@^C:]\(='\
M1?!FY^&=S<WR:#<:+_837$4B"Z$'DB+<&*%=^T9SMQGMVH \$^(7[<>H_"_P
M1I/BGQ)X3\+:3::A9V^JQ:3=>.8DU:YLIW0*UK:_9LSS(K,SQ[E08 663YBN
MG\0/VRM6\'ZA\39K#X>QZMX:^'AL)]8U277!;RR6US#'+OMX/(??(BNQ,;LB
MD*,/EMHUO&G[#O@WQI!>V[>)/%&D6FI>'[+PWJEOIUQ:[=0MK0'[,TAEMW9'
M0G=F(HK$#<I&0>6C_9#O/'/Q5^,Q\4ZCX@T?P+XDGTB..STV_MO(UVUM[5%D
MCG4H\D8#IM)3R78,1N*XP 5M&_:9?PWXX\<:9HFFZUXMU_7/'=KH6C6&N:\5
ML4:338;IGC86Q-G;I$&8QA9F+Y/\1V]'^Q_\0M?UK1?C3J?C2[NTETGQOJ<1
MM;J_:]33X(HHF,,+G'[I?F*@!1@YVJ2172:U^Q[X/U2_U74K35M>T36;OQ';
M^*;74M.EMQ+IEY#;);*+<20.GEF)-K)*L@.YO;'7?"3X%:%\'])\3V&GWVJ:
MRGB35)M7U&;6ITFDEN)8T24Y5% 5MF[;C +$#"X4 'F/@G]K[4/$4_P\U/5_
M \.A^#/B')<0^'-436?/O"Z1O+"+NU-NBP^;%&[ QRS;3@'KFN4M_P!OC5;?
MP3X6\7ZI\+Y(M#\3Z1JM_I4.FZU]LOY)[&)I)(7A%NJJCA'VR"1C@ M&O2O3
M? _[(?A?P/J'AEE\0^)-9T7PJ;EO#GA_4[BW:RT=I@REHO+@260JCNB>?)+M
M5CCGFHX/V/?"ECX3^'FA6/B'Q1IH\"I?+I&H6=[#'=!KI&5W=Q#@LN\E< #@
M!@PR" <;>?MU:;IOPP\-^)KF#P<U[XBUB/2=/DM_&D;Z*F8!.\EU?M;JUOY:
M95XV@WA]J@'<#7)P_M@>-_B?\0O@<_@*RT6/0_$5]K.G:QI\VL+)!<W%G&0X
MCNDLY"85P)(Y8\&7<%94'->J)^Q?X57[1J1\2^)CXTF\0)XF'C)9+--12\6$
M096-;86NPQ91D,!#!B3DX(ZCQ+^SW#XNF\#ZCJ?C?Q/-XH\(7D]W8>)$73TO
M'$R&.6*5%M!;M&R$+Q"&^4$-G)(!P_Q\^,!^$_QJTV^\O6]1%AX%U[6_[+AU
MD6VFW'V5K=L2P>2Q>4[L++N^0;OD;=6_\)_VC-5\>?$33O"VO>#X/#;ZSX7B
M\6:3-;ZO]M:2U>14,=PGD1B*52Z'"-(I!/S<5T'Q4_9W\.?%WQ =8UB]U2VN
M?^$=U'PSML98T3[->^7YKX:-CY@\M=IS@9.5:K?ASX$:!X8\<^'?%5K>:E)J
M&A^&%\*6T<TL9B>U5T<.X" F7,8Y!"X)^6@#Y _:,^/7Q@LO$7Q]T2VNH;+0
M/#-SX<.GR:5JS6][:+<7$?$16V0R&<<.LDRB/.%+@FO:?%7[:3?#73?B-'XV
M\*66CZ_X2GTR"*TM-=$UG>?VAQ;%[J2"+R &#>82C!%4L"_2NG^)G[('A;XG
M>*_$NMW/B#Q'HX\2Q:?'K&GZ7+:BVO&LI!);R'S;>1T92 #L=00.1GFM#QU^
MREX.^(6K>-]3U.[U>.^\5#37EFM;B-&L)[#)M;BU/EG;(K'<=^]21]W&00"7
M]GG]HJP^/6F^*3:P:8=2\.:A]@NSX>UA-6TZX)C62.2VNPD8D5E8 [D0JP8$
M<9/F-I^W]H%CXB\7Z?KUCH;V^@^&[CQ*)_"?B>'6W$<,OEO:W*I&BP7663Y%
M>1<L?G( )^@_#_@6YT_PUJ6BZ_XJUGQM%?!XY+C6H[.&58G3:T:_8[>!=N,G
M)4MDGGICQSP[^PGX%T:W2TU#7/$WB738?#-QX0M[#5;BV6*#2Y61O)4P6\3$
MJ5RKLQ?YCN+87 !KW/[0WBKPSI_P_E\5^ +/2KGQAX@LM&MTL/$'VR*&*Y@>
M42ES;QL9$*%6CV!>05D;G'D_Q<_:V\?W\%F/ FCZ?H\NF_%6+P1>M?:D&&H1
MC:<<VDGE)+O(9ER\>T%=^2![)J/[+=EK7@W1-#U3Q_XRU*^T+4K35-(U^XN+
M+[;82VZ%(@BK:BW<;6<,9(79MY+,2%(S?^&,?""^#M3T)/$'B9;F]\4Q^,AK
MC74$E];ZHFS]]&7@,>"4)*-&R_.P  VA0#D/%G[>^B^#?BA>>$[_ $_0E32=
M4T_1-6_XJ5%U+[7<JFYK*Q:$/=01-)&'E+1G[Y"'817JOQ1^-6I^$_B%X8\!
M>%?#=KXG\6ZW9W>IBWU#5#IUM!:6^P.[2B&9B[/(BJ@3!RQ+*!3-'_9YB\,>
M.M3\4>'_ !UXHT*?6I[:[UNPM5TY[75;B)!&9Y5ELW:-Y$50_D-$#@$!3S6I
M\2O@A8?$3Q5X>\40>(-<\)>)]#BN+6VU;09+<2M;SA1+ Z7$,T;(Q1&SL# H
M"K"@#SCXE?M@P?##XG>'/"VJZ3H21ZKJ=CI4MFWBJ Z];R72Y6?^S8XWW6ZL
M54N9E;[Q"$;2W(:G^WU-I=O<75WX0T/1K!_%EWX/L;[7O%BV-O)=6[L99YY#
M:LL%N(EW;R6?S&$80@ASWFL?L6^$M8\4WFK_ /"2>*;6TO->LO$UQH\5U;O;
M2ZE:B-8YV>2!IR66(*R^;M.YB &P1;_X8]\)0:.MM8:UX@TO5+?Q5<^,+#7+
M6:W-Y87UP3YHBWP-$T3*639)&^5/))P0 2>#_P!J;3_&7[-VO_%?3]#FU$Z'
M!?\ VG2-)NEO!-/:%@ZV\ZJ!+&Q7*RA1E2#M!^6O(/B)^UEX_P#$'PW^&OB;
MP'%X1C.L^--.T>ZDTKQ,FI6EQ#,JN+8RFR+Q,=Q27=$DD10;1)NX^IE\#WLO
M@2X\.WWC#Q!J%Y-&Z?\ "1%[:VU%"3E74V\$<09>,?NL$##!LG/E=Q^QCX3O
M-!UBVNO$?B6Y\0:IXBM?%4_BDR6:7ZZA;A5AD1$MEM@%5=NWR,-N);)Y !PW
MA?\ ;\L/%GCVU\,6ND^'/M&H:I>>'[&*'Q6LM^-0MXV.^>S%MYD-F\D<B)<?
M,Q 1C$N_ \QT+]I[X]WW[/7PG\3M_P (_/J>O>.8M%FU!]15'OX&NYX_L\L0
MTXI AV!/-CW.%4-C<Q4?57PQ_9WA^$>I2GP_XY\41Z!/>3:A/X:N%TY[&6XF
M&9GS]C$Z!Y"9"D<JJ&8[5"_+7.Q?L:>%[;X=KX+M_$_B>WT>SUY/$>BE);,R
MZ'=+.\X%LQMCN3?(WRSB7@XS0!Y_IW[2&J^ ?&WC.P70=5\2:WJ7Q!LO"ZV.
MH>)Q)96<\^F1S VI-JIAME88*;2QR\G4^76OJ_[;DOA_PK)/JWAC1=$\06OB
MZZ\(7PU;Q,;;1;6:&!I_-?4&M=P1T50H, )=MO&,UW2?LF^%F\2?V[<:UKUY
MJ;>*K3QA++++;@2WUO:+:J"J0*!&R+N95P=Q."H^6O-_C%^S+/H_C#P_K?AG
MP_XE\7Z9=>+M0\3Z[#H?B%-*U6WFN++R%6TF$]H!#E5WJ9=_3!(+"@#W+]G_
M .)VI_&;X1^'O&NJ^'5\+3ZS"US'IBWC76R$L1&QD:*(G>H#C"XPPP3UKSSQ
M%XS\8_$O]IG6OAEH'BJ\\":#X9T"VU:^U+2;2SGO;VYN9'6*,&ZBFC2)5C8G
M$>XM_$!UN?L__"/QSI_A#P#J7Q#\7^)!XET(7^_1UU@7%O/#<.?)BOWPWVJ6
M"/8!)OQN#'+=3U7CKX!Z?XN^(%IXYTKQ-X@\#^+H;!M*FU3P_);$W=H7WB&:
M*Z@GB8*^65@@89/S8XH ^<(?VD?B#\.?VK];TGQKXLM]1^&6GW-IH%THTV"U
MCM;R;3!=)<AP#( \D,R[7D8#S !T%8OPO_;!^(=KH_QY\9^)[Y-7TK1/#=GX
MI\.:)-:0PK9Q7:SR6\+O$BN_R>1N+,3UP1UKW3Q]^P[\/_B5X;\<:+KNH>(+
MJ#Q=<:;=7MPU[&]Q#+91+%$\4CQL=S*"'+[R=[8QFNG7]EOP.VH>.YIHKRXL
MO&6B6GA_4-,>1!;1VEO"T,:PA4#*=K')+'D#&* /*_A/\8M>U;1/$/A_Q3XI
M^(6D^.H=$L-<N8]0\.:7>S06LS%6FTNWTV*8OELJ%N!,Z80LC?-FG\)?C#XL
M\9?!7Q9J6M>/?$:KI?BR^TRUU30_"L=]XD^QQD^2EU8PVDB6TNX'=YEJIV;<
MK&6#UZCX0_97TSP;;W\]MXY\8W7B6XM+/3X/$]S=6OVZTM;4'R((U2V6!T!9
MRPEBDWEB7W$+BQX=_9DT_P 'Z7JG]A>-_%VE>)=7U235]4\50SVCWU_,Z[")
M8GMFM2@0*JJ(!LV@K@DD@'S3X;_:J^)GBWP7\%]#2]U+5M?\0:/J6NZ[JW@>
M'2)=2-M:R>7$H6\86<4AW*9EVEE92BHI)Q[#\2_C)IFO_LQ> /&^BZWXHOM-
MU;6-"CCO[.^BTK49_-O8HF%PT<#)C<2)8D15<!E!4'-:\?[$_@S2]#\+VGAW
M7?$OA75M 6^6/Q#I=S;O?W?VT?Z7]H,\$D;F1L.2(UVLHV;0,5V6N?LY^$=8
M^$_ASX=0B]TKPWH%SI]U9)8S+YH:SF2:(,SJVX,T8W<9.3R"<T <W\$_VG/^
M%R?$3Q5X:71M,TD:'>7MD]M)KJOK$9MYEC$ESI[1(T,4H;<CH\H/0[2:\R^$
MW[26M6:^'?">@>'=2\7:UXEU[Q1#;W7BSQ3GR&L+L@AYEM"5A*DA$2-C&%1,
M.,L/:_#O[.VE:+\5+;Q]?^)?$7B;6-/M+JQTJ'6;B!XM.@GD#R1QM'"DLH^4
M*#/)*0!P>]4/!?[*OA/P)XH\-Z]8:AK4UYH-[K-_;)<SPM&\FIR>9<!P(@2J
MG[F""!]XM0!XS)^U;\0_'_C7]GVZ\':/I>FZ/XPEU:#5M&U#5,"2>U5UDC,P
MLW94C:,NCH 9"=K*@YKH?"_[?7AWQ1\5[;PK!9Z.VG7VMWGA^SD@\0QRZO\
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M9]6\,:+HOB"U\77/A&^75?$QMM%M9H8&G\U]0:UW!'0*%!@!+MMXZUM_#_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
=HH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img222477878_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &_ QL# 2(  A$! Q$!_\0
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M_H=/_*59?_&:/VWO^3H/&G_;E_Z105ZU\+O#0L_V*4\3>'?A_HOBSQC_ ,)
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MC3C>6WN6OUZK;3?8/='?\-O?&O\ Z'3_ ,I5E_\ &:/^&WOC7_T.G_E*LO\
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MR/<_^&WOC7_T.G_E*LO_ (S1_P -O?&O_H=/_*59?_&:\,HH_L_!_P#/F/\
MX"O\@LCW/_AM[XU_]#I_Y2K+_P",T?\ #;WQK_Z'3_RE67_QFO#**/[/P?\
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MO$>EQ7^L:_##"L-JMPN(D1&.Y@'=22%Y=B#PHKYV_P"%*:Y_S]:?_P!_)/\
MXBIK/X0>)-.O(+NTU&SM;J"198IX9Y$>-U.596"9!! ((Z8I5N(.&ZW,_K<5
M>UU=V=MKJW0U_P!6,W_Z!I'UM\7OB7\(/A+^U?KWCG4K/Q1>^.-*98O['ACA
M^QRSFU58[@2EPP3RV4%<$AN0"*X'Q1^T]\-_CA\/_#%M\3[;Q#%K&AZI<W\U
MEH<$3PZ@LLC.$$CR HH!53WZXSGCP[6/A=XL\1:E-J.JZS#J>H3$&6ZO+J:6
M63  &YV4DX  Y/0"J7_"E-<_Y^M/_P"_DG_Q%<]/.^'(Q@YXU.44E>[TLK66
MFVK%_JQG'_0-(^IO%7[:GPS\::U\1Q>Z=XKM-(\7^'[#2F>"TMFN()(7NO,P
MIGVE2MPA#$]5;(Z9D_X;*^&\?CKPAXKM-3\>:1I6A6(T\>"--AACL7*A@)FQ
M.$*[7^[MR2B\@#GY5_X4IKG_ #]:?_W\D_\ B*/^%*:Y_P _6G_]_)/_ (BC
M^V.&$K+%K[_*W;L@_P!5\W_Z!I'T'XP_:@^%GQ"^&/BGP7K%KXNM+.^\37>O
M6=Q8VEJ92)I7G"2!IL+MDD93C=E0IZD@;WB[]N+P-X]U?Q'H.JZ1XA'@/Q%H
M-MIMQ)&D*7MI=1/*3+&GF,K*1(G5LYC'RD<'Y>_X4IKG_/UI_P#W\D_^(H_X
M4IKG_/UI_P#W\D_^(JO[:X8_Z"UWW>CTUVWT0?ZKYO\ ] TCZ,^&_P"UI\-_
M@38^%?"GA#3_ !%J/AJTU>?5=<U2]@@6ZO',#1H(8O,VA<^5DEE($?0EC7G_
M (%_:-\->&;SX_RW5CJLB_$"TOH-+\F&(F%IC<%#/F0;0/.7.W?T/7OYG_PI
M37/^?K3_ /OY)_\ $4?\*4US_GZT_P#[^2?_ !%:+/N&O>;Q<6Y6N[O6SOV[
MC_U8S?\ Z!I'G]%>@?\ "E-<_P"?K3_^_DG_ ,11_P *4US_ )^M/_[^2?\
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M#_T%Q_'_ "#_ %9SC_H&D>?T5Z!_PI37/^?K3_\ OY)_\11_PI37/^?K3_\
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MG./^@:1Y_17H'_"E-<_Y^M/_ ._DG_Q%'_"E-<_Y^M/_ ._DG_Q%'^N&0_\
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MAD/_ $%Q_'_(/]6<X_Z!I'G]%>@?\*4US_GZT_\ [^2?_$4?\*4US_GZT_\
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MI37/^?K3_P#OY)_\11_KAD/_ $%Q_'_(/]6<X_Z!I'G]%>@?\*4US_GZT_\
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M.-[J^T>:]FE?<^0J*],_:"\/ZWX>\=Q1:[JT.N74]E%/'?16JV[21DL%\Q%
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M;XE>++/1TTJW\2ZK!IR#:MO'>2*JKC&T8/"X_AZ>U?H%_P *G\$?]"=X?_\
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M17Z3?\*G\$?]"=X?_P#!7!_\14*_"OP5]J=?^$.T#;M!Q_9<'J?]BC_5&O\
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M_P#@K@_^(H_U1K_\_5]S#_B(V%_Z!Y?>C\V:*_2;_A4_@C_H3O#_ /X*X/\
MXBC_ (5/X(_Z$[P__P""N#_XBC_5&O\ \_5]S#_B(V%_Z!Y?>C\V:*_2;_A4
M_@C_ *$[P_\ ^"N#_P"(H_X5/X(_Z$[P_P#^"N#_ .(H_P!4:_\ S]7W,/\
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M_P#/U?<P_P"(C87_ *!Y?>C\V:*_2;_A4_@C_H3O#_\ X*X/_B*/^%3^"/\
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M(H_X5/X(_P"A.\/_ /@K@_\ B*/]4:__ #]7W,/^(C87_H'E]Z/S9HK])O\
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M.\/_ /@K@_\ B*/^%3^"/^A.\/\ _@K@_P#B*/\ 5&O_ ,_5]S#_ (B-A?\
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M'ZE\"?C+XIT_X4:;JG_"&P6OP^U6SNQ-'?7/F:DMLRA&P("(LQJ!CG+9/RC
MJJ=/ 1DI)J^M[O39VMO?IUT_)Z'UK1117S)F%%%% !1110 5 O\ Q^/_ +@_
MF:GJ!?\ C\?_ '!_,T <+\5OC]\/_@?<>'(?'/B6V\/2>(;S[!I@N(Y'\^;*
M@Y**VQ!O7=(^U%W#+#->@UY_\5O@'X ^.$OAV3QSX9M?$+^'[T:AIK7#R)Y$
MPQG.QAO0[5W1OE&VKN4X%>@4 >!_M67'Q!\&^!/$/C?PE\0IO#\.EV2,FC_V
M/:W,4DGF!2YDD4N,AAP#CY:T-2^(UQ^SXND:=X[\4:Y\0M6\2W<EOH\6GZ%
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M\%^(?#FC>"].\7:+XI;7KG2DU"]2RGA-C/:)&UXT4LDLB"93O\F,,!MVKC)
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MOY"CR8_^>:_D* $^T1?\]$_[Z%'VB+_GHG_?0I?)C_YYK^0H\F/_ )YK^0H
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M\F/_ )YK^0H 3[1%_P ]$_[Z%'VB+_GHG_?0I?)C_P">:_D*/)C_ .>:_D*
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MOY"CR8_^>:_D* $^T1?\]$_[Z%'VB+_GHG_?0I?)C_YYK^0H\F/_ )YK^0H
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M$,@C1F *'.]$8$$;<;68 ]8HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"FCV6DSZYXG^UO;W&OZDUA91);"(NN]8Y&>9O.39&%&0LC9 3!QK[X)ZS?>
MO%ND,^E1ZAK7BZW\1!E=S$(X[RUG(9O+SO"VY X(R$Y Y'0_&CPGXB\7V=I9
M:=X7\$^-]"=9%U#0?&320I*QV['298+A1@;P5,)SN!W#&" <SXD^/?B3P3?/
MI?B#PKI]KJ\/@O6_%4T5EJCW,.^PFMHTB20PH2DHN-^XJ"N "I.<44_:&\5>
M$;?PMJ'CGPKI,6D>)K*XN+&3PWJDMW<QRPZ?-?F*2&6"/(:&WE 9&.'"J1\X
M(XCPS^R7XPTJWU/S;[1+2&\\(^)M"M=(MKVYFMM)DU&>SDM[>!Y(@S6T8MI,
ML54@OA8PO"]5X?\ V8=1^''B3PEXA\&7-@=6L] FT6_7Q'>7FHPV\S1*8KNT
M$C%E(E38\:M$)(I.JE%! .U^#/Q,\8_$RQTO7;S1/"Z>%M5LQ=07N@^(GOYK
M=F 98I5-LB,<-@LCG# C!'->KU\Y^"?@7XGMOC/H/C2[\*^!_ !L%N1JEQX+
MO[B27Q")(GC2.YA:U@155V64%FE8-&H# 9S]&4 %%%% !1110 4444 %%%%
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MC0K2:X%S/*\=I:W#/,4167?([L"[X4X4JOTI10 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 9VFW"1V,:D-D9Z*3W-6OMD?H_P#WP:BTG_D'Q?C_ #-7*2V @^V1
M^C_]\&C[9'Z/_P!\&IZ*8$'VR/T?_O@T?;(_1_\ O@U/10!!]LC]'_[X-'VR
M/T?_ +X-3T4 0?;(_1_^^#1]LC]'_P"^#4]% $'VR/T?_O@T?;(_1_\ O@U/
M10!!]LC]'_[X-'VR/T?_ +X-3T4 0?;(_1_^^#1]LC]'_P"^#4]% $'VR/T?
M_O@T?;(_1_\ O@U/10!!]LC]'_[X-'VR/T?_ +X-3T4 0?;(_1_^^#1]LC]'
M_P"^#4]% $'VR/T?_O@T?;(_1_\ O@U/10!!]LC]'_[X-'VR/T?_ +X-3T4
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M>B@"#[9'Z/\ ]\&C[9'Z/_WP:GHH @^V1^C_ /?!H^V1^C_]\&IZ* *>D_\
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M[XU^(],^'OBJ.VUBWTMM-2[T6=)IU@>")RJE,[B(RVS[VTY(P#7H^LV&J_\
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M)/%FAIKH;8=+;4H1=;O[OE;MV?;%=-7P\NFZAX \=36_@7PMKGB&+6?%!O\
M4O"GB_PBSK:EW&^^AU #RU0% 4RS8P">0<_<-?.8K#QH<KB[I_UM_P .NS,V
MK!1117 (**** "BBB@ HHHH **** "H%_P"/Q_\ <'\S4]0+_P ?C_[@_F:
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MT33O ?Q1^+^G^-/AQJWBK_A*KR&?1-0L= >_L[K35L8(8].,R*8[3RI(Y_\
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M06V6.0RWS6<L;_9XT=L#[0O.,LJ@C(![#\/_ (R:GKWCN?P3XN\(S^#?%/\
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M!\-Z5_:FK^./#>E:;]I>R^V7NK6\,/VA3AH=[.!O!ZKG(]*^.OBQX"UOXD>
MOBAXAT4^+O$=Y>Z-IVEG_BD)-%_M)EU&&52D)5;F62W19?G\L*%G8!B5(7V+
MXM69\#>-_"^@Z1HDOA'P3!HT\=IJGA7P8-7F6Y,B!K$*D$JVT31J&YCQ(>-P
MV8(!Z=>?&*WB^,GA'P/:6<5_:^(=#OM;BUB&[!15MY+9 JH%(<.+G.X,,;>A
MSP[Q%\7H?#GQF\.^!+BP18-6T/4=;DU:2Z$:VRVLENA0H5P0PN,[MPV[.ASQ
M\J_L^>'_ !)\/?''P9N->\)>*+2UL8/%WAZ4C0IW%G)<:W%)9B00HR0P&#!6
M7/DA4(#X6O;?BC9W>E_M8?"W7Y]#U;4M FT#5]#FNM/TR>]A@N+BXL#&MP8D
M80QLJ2$R2;4 1LGB@#W"3Q%I4-G8WDFIV<=I?O'':3M<(([AI/\ 5K&V<.6S
M\H&<]JQ+/XM>!]0UB#2+7QEX?N=5GM/M\5C#JD#SR6VW=YRQA]QCV\[P,8YS
M7S;\$O#&JR?&*S^%E_;R-X7^#-Q<WMA=.2R72W<>-(C'/)MK6:\B;/.8XFQS
MD\%X-_9\;_AE#]F?2+WX>W"ZO;>*=*N-?LYM)<744+"=+EKM2N]8RA5'\SY=
MA"GY<"@#[3T/XH>#/$VD?VKH_BW0M6TO[5]A^W6.I0S0?:/^>.]6*^9R/ESG
MVKD_'G[0_A?0/@SXX^(/A;4](\=VWA6QN+J>WT?58I$:2)"QA:6/S!&QQW!(
M]*^4OVEO"=QH'Q.\9LW@^:X\*ZGXN^'K06<5BL=OJ\OVJXBN849PL<K%%@C8
M$X 9 V :T_CUH]U\7/\ A9NK_#?P-XAT_38_AMJVAZDTWAVZTZ76KZ1XFL[:
M&VEB22=X!'<_.$('G[5)W$4 ?8GA/XG>%_&6H3Z5I?B'2+W7[.".>_T>TU"*
M:ZL@P&!+&IW)R<98"GZ'\4/!OB;Q)J'A[1_%NAZMK^GY^V:58ZE#-=6V#@^9
M$K%DY_O 5\_?$CX,:A#JWP[M/ &B+X;U)/!GB'2(]6LK(QI83S6< MO.=1\O
M[X;@&.2RL>N:Y/P[I-MXHTWX%>$/"/PUU[P=XL\&:KI]WJ][?:#+90:1;01%
M;V+[8ZB.Y^T*7B'DO)YGF>8WW<@ ^JV^*?@M?&!\)'Q?H(\5!=YT,ZG!]NVX
MSN\C=OQCOBM*3Q=H4>@P:X^M:>FBSB,Q:DUU&+:02,%CVR9VG<64#!Y) '6O
MECX)II'@GPCX>^'GC3X5:YXC^(MGK;7-_?1^&#-:W5V;MI/[8&H2*+?:01+D
MR^:OW NX!:C\&>$]13X]0_!62U9O!/@S5Y?'MM,"#$;.?<;"Q8<D&.]DO74'
MHEE#ZT >[_"?X_>$OB]H/B+5=*U73UMM"U.]T^[(OX9!'';W$L*W#%6PD4HA
M:1&/!7G-=+X8^)GA#QMH]YJWAWQ7HFO:79EEN;[2]1AN8("HRP=T8JN "3D\
M5\<:UX)\1:Q\)_&_@[2_"VO6%]I?Q+O/$.IVS>'9##JNCG6YKF-;9I%6&\_=
MO'*(59LB,H0"P!W;_P #VWQ.7QMKVJR^/M>TFX\,C0]0DTWP8-&GO(Y)XV41
MP3JDUQ+:[&<8B90LDJ#>Q\L@'U;X-^(WA/XC6MS<^$_%&B^*+>V?RIYM&U"&
M[2)^?E8QLP4\'@^E=%7@7[-OB;Q%X@\5>+%U"TDU;0[>TLDL?&%_X2G\.7U\
MX,ZR6LT$ZJTHA"HPE1(TS,RA<@U[[0 4444 %%%% !1110 4444 %%%% %/2
M?^0?%^/\S5RL[3?/^Q1[!'MYQN)SU-6LW/I%^9_PI+8">BH,W/I%^9_PHS<^
MD7YG_"F!/14&;GTB_,_X49N?2+\S_A0!/14&;GTB_,_X49N?2+\S_A0!/14&
M;GTB_,_X49N?2+\S_A0!/14&;GTB_,_X49N?2+\S_A0!/14&;GTB_,_X49N?
M2+\S_A0!/14&;GTB_,_X49N?2+\S_A0!/14&;GTB_,_X49N?2+\S_A0!/14&
M;GTB_,_X49N?2+\S_A0!/14&;GTB_,_X49N?2+\S_A0!/14&;GTB_,_X49N?
M2+\S_A0!/14&;GTB_,_X49N?2+\S_A0!/14&;GTB_,_X49N?2+\S_A0!/4"_
M\?C_ .X/YFC-SZ1?F?\ "H5\_P"U/Q'NVC/)QU- %VBH,W/I%^9_PHS<^D7Y
MG_"@">BH,W/I%^9_PHS<^D7YG_"@">O-O%_[/WA/QIJ^J:A>/KEDVK*J:I;Z
M1KU[86]^%01CSHH955B4 0M@%E 4D@#'H6;GTB_,_P"%&;GTB_,_X4 1Z1I-
MEH&DV6EZ;:PV.G64"6UM:VZ!(X8D4*B*HX"A0 !V JW4&;GTB_,_X49N?2+\
MS_A0!/14&;GTB_,_X49N?2+\S_A0!0\5>%=+\;>'[S1-:M?M>FW2@2QB1XVR
MK!E970AD=6565U(964$$$ UR_@OX)>&O!'B-_$,#:MJ^OFU-BFIZ]J]UJ,\-
MNS*S11&>1A&K,BLVT L57<3M&.WS<^D7YG_"C-SZ1?F?\* ))8DGB>*5%DC<
M%61AD,#P01W%>8Z'^S;X)T'6-'OXX]9O8]%F^T:5IVI:Y>7=CI\F"JM#;RRM
M&I16(3Y3L!PNVO2LW/I%^9_PHS<^D7YG_"@">BH,W/I%^9_PHS<^D7YG_"@"
M>BH,W/I%^9_PHS<^D7YG_"@">BH,W/I%^9_PHS<^D7YG_"@">BH,W/I%^9_P
MHS<^D7YG_"@">BH,W/I%^9_PHS<^D7YG_"@">BH,W/I%^9_PHS<^D7YG_"@"
M>BH,W/I%^9_PHS<^D7YG_"@">BH,W/I%^9_PHS<^D7YG_"@">BH,W/I%^9_P
MHS<^D7YG_"@">BH,W/I%^9_PHS<^D7YG_"@">BH,W/I%^9_PHS<^D7YG_"@"
M>BH,W/I%^9_PHS<^D7YG_"@#"\!?#[1/AKHMQI6@6[VME/?76I2))*TA,]Q,
M\TS98DX+NQQT&<#BNDJ#-SZ1?F?\*,W/I%^9_P * )ZYR7X?Z)-\1+7QP]LY
M\1VVE3:+%<>:VT6LLT<SILSM)+PQG=C(QCN:W,W/I%^9_P *,W/I%^9_PH G
MHJ#-SZ1?F?\ "C-SZ1?F?\* )Z*@S<^D7YG_  HS<^D7YG_"@">BH,W/I%^9
M_P *,W/I%^9_PH YOP'\,]"^'']MOH\=RUUK5^VI:C>7UU)=7%S.42,%I)"6
MPJ1HBKG"JH %=74&;GTB_,_X49N?2+\S_A0!A^-_A_HGQ$M=)M]<MGN8M+U6
MTUJU5)6CVW5M*)87.TC(#J#M/!Q@UT=09N?2+\S_ (49N?2+\S_A0!/14&;G
MTB_,_P"%&;GTB_,_X4 3URO@_P"&>A^!]<\2ZSIT=U)JWB*Z6[U&\O;N2XDD
M*@K'&I=CLBC4D)&N%7)P.371YN?2+\S_ (49N?2+\S_A0!/14&;GTB_,_P"%
M&;GTB_,_X4 3T5!FY](OS/\ A1FY](OS/^% $]%09N?2+\S_ (49N?2+\S_A
M0!/14&;GTB_,_P"%&;GTB_,_X4 3T5!FY](OS/\ A1FY](OS/^% $]%09N?2
M+\S_ (49N?2+\S_A0!/14&;GTB_,_P"%&;GTB_,_X4 1:3_R#XOQ_F:\E_:8
M^-VK_!_0=(A\+Z5;Z[XKU:6<VFGW(8JT%O \]Q)A2"=JJ.AZL*]:TG_D'Q?C
M_,U\\Z]\$_&'Q3_:4U7Q1K5[JG@[PSH>EKIN@7FE7-HT]VTA)G<JZR[%.64A
ME4D%,="*[<%&DY\U9KEBKZ]>R[[]NEREOJ>CK^T/X(L_ACX;\<ZOJ\>E:5KT
M436L;*\TKRN,F%8XU+NZG*D*IY%1Z+^TQ\-/$%Y8VECXIA>]O;]=,BLY+:>*
M?[2WW8WC= T9/8N .#SP:^6O#_[-WQ3^&OBKPW<6VB3>)O#7P_\ $-U<Z/;-
M?6RRW^GW."S1J7 66,IN(<+N,@V]*]%^*VB_$OXD:MX)\9#X8MI,/A;Q/!J7
M]EIJEM-J5_:84-(4!$:NH0 (92?FQQMR?4E@L)S6C.Z=]>:*MV5GKVO_ , =
MD=;^T=^UOH?P9T?7;31I;?6?&6D26PN-'FAG"1)+L(9Y%7:/D=2/FYSCKQ7<
M:O\ M&?#_0Y-/BN];F%W?6[W<-E#IEW-=>2A(:5X$B,D: JWS.H& 3TKY(^*
MW[/?Q=^*WB'XNZ^? W]ER^)H-.^P64FJV;L?L\D*%&82X#F./?UV]0&S@'OM
M4^&_Q!_X7QK/Q(E\)>*K:Q\1Z?'9G3]!UNRBO["6(*B)(QD\MH9!&KDJYVEC
MGISJ\'@_9P7.N:S;]Z.]HZ>E[_=;JAV1]&7WQ2TO4_A'K'CCPK?6NMV-OIEU
M?6LR$F*1HHW;:PX(^9<$<$<]*^?+;]K#X@Z'\(/"GQ4\0Z-X:NO".L7B6UQ9
MZ9]HCOK=6D=-Z[V97QY9.WC.1[D>A_#_ .#][X3_ &<O%GAVUT&;1];UVVU"
M<Z1-JR7Q2YGA*!?.V1HNXJI('RJ6/S'K7+? G]DNRTWX4^$4\<V&H7/BC25D
MGBTC5-8EN]-LKGS7,<BVZ2F'H5) !!W'(S7/36#I1GS^\E*W2[5GV?IJA:'J
M5O\ M+?#:X\06^BCQ(([VXNS802365S%;S7 ;:8DN&C$3-GC <\UDC]L'X0-
M-'&/&<)#3BV,PLKGR8I"2 LDGE;8R2IQO(R 3TKYM\9?"/XU>.O!NBV6N>'?
M$VO^,-.\0+J.I75SK]F-*EA21C']C@,RJ&V,.JKMPP)RVT6H_P!F3XB)^QWX
MK\$CPRH\67_B?^T8;(7MMF2#=%AS)YFP<*W!;/'2NCZC@4ES5=6TM)1^_;;[
MAV1]-^)_VG/AEX.U_4-&U7Q1'!?:>RI>^5:7$T-HS?=66:.-HXR3QAF!SQUI
M(_VH/A=/XBFT.'Q=;3ZE"\B31PP32)$$&YW>14*+&!SYA8)[UY)\./"?Q&^
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MUY\>_!%CXR;PQ)JEU)J:7D>G2R6^EW<UG!=2!2D$MVD1@BE.]?D>0-\PXYH
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M>>#0!W%%>;ZQ^T9\-]#CT5[GQ99O_;5HM]I:VB27+7T+,%5H%B5C(<G[J@D
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MM^'?A7XE\7:UH']N^%/&VGR>'TFNEG\0>*+.>SAO/LTD*"S2 N\RLLKJ3((
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MVG?AF2)GP B@MM-:/A_X%>,=/_9#L/!<F@K%XI3QI'K$MD+F#/V<>*EOC*9
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M*** "H%_X_'_ -P?S-3U O\ Q^/_ +@_F: /!OVK?@_\6?BM>?#J7X7?$8^
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MD=KO2_%_V31KCPL]@WB302UT]@_V8PR31^5DEX7R?EY#(>F#CY&\10^!M;^
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M_P# I/\ &OS3HH_UNK?\^E][#_B'.&_Z")?<C]+/^%E>%/\ H8M-_P# I/\
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M?I9_PLKPI_T,6F_^!2?XT?\ "RO"G_0Q:;_X%)_C7YIT4?ZW5O\ GTOO8?\
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M?I9_PLKPI_T,6F_^!2?XT?\ "RO"G_0Q:;_X%)_C7YIT4?ZW5O\ GTOO8?\
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M?I9_PLKPI_T,6F_^!2?XT?\ "RO"G_0Q:;_X%)_C7YIT4?ZW5O\ GTOO8?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ^Z?$G[-/A?X@:U<Z_J-Q?)>7>WS%AD
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MV\%?\_6I_P#?Y?\ XFC_ (8V\%?\_6I_]_E_^)KWJBC^QLO_ .?*#_6;.?\
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MR7/2"%U>,-UD8MT5 7/[&R__ )\H/]9LY_Z"9?><5_PQMX*_Y^M3_P"_R_\
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M_P"?*#_6;.?^@F7WG3?\,;>"O^?K4_\ O\O_ ,31_P ,;>"O^?K4_P#O\O\
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M7]H?V5_PG7V&/^Q?M/G_ &?;O\SSMGG?N_.\KRMW\>.:S?'7[5MFOA;XF?\
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M-XI8Y$< 95QD*05'>4?V-E__ #Y0?ZS9S_T$R^\\%_X8V\%?\_6I_P#?Y?\
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M*\H^/?[*OBWQMXR\4Z-X?TZ$^#/$ER/$DE\9XE:SU2*SN8_*$;,&(GE:W9G
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M;XK? /P!\<)?#LGCGPS:^(7\/WHU#36N'D3R)AC.=C#>AVKNC?*-M7<IP*]
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M6]_9ZG:Z/JUW?3WIGA4?:/-DMX][>9$@VO\ ,5D9VDW#8<[P%^SG\3-(\(_
M_0M7F\*6Y^&6H[DNK&]N;C[=;+IUS:I(4:"/;(7FC)CW$!58B0G KUCQY^T7
MX5\+20V6CZKH_BC6T\0:5H-_I-CJT1N; WM[#:^;*B[V789MVU@-VW&1G(]
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M^QN==>/36CNK1I=!O1=O=';N0M<,BN9,?.R@\X%?7M% !1110 4444 %%%%
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MDW-4^#O@/6O!<'A"_P#!7A^\\*6^/(T.;2X&LX<9P4AV[%(R<$ 8[4 ?*?\
MPL&+7/&/PA\&V?B_QMX0T?4-9\0:%KEIK&NK)J"W-O;PNEI]N#R%QN("2K(T
MF)" ZN?E9XD\>>)/ /B_4O ^A>,]:UKP]HOQ"\&64.IWU^]U=Q+?71%[IDUR
M?FF542-B)&9PMR%8G KWOQ1^S+X8UKQ3\.I;+2-#T[PAX5BU."7PPFEQ?8[N
M.[@6+9Y8 0 $9(*G.:[?0_A)X'\->'+#P_I7@_0=/T/3[N._M-.M]-A2""ZC
M8.DZ(%P)58!A(/F##.<\T ?+/P_GT?X6_#OXFI'KGBB[U'5?B'=:!;6]OX@;
M[097OTCC_>SLRP;RX$DV-Y5L@E]E>>_%K6/$>@^!/CQX"U:[O3IFG:)X>U:+
M3]2\22^();&>;4W251>3 3;62&%S')G:3E<*PS]QWOP9^'^I7>OW5UX&\-W%
MUX@C$.L7$NDV[2:D@((6X8IF4 JIP^>5'I26?P6^'VGZ;/I]MX&\.0V-Q:/I
M\]NNE0;)K9WWR0N-GS(S_,RG()Y.30!E?'PZUJ'PIU*V\*>(K'P_KUW/:P6=
MY=WPM$F/VF,R6RSA6,<DT:RQ*ZJ65G! R*^6?B%!IFN>"8O#=[/X\\-ZOX?^
M(/A1-2TS7/%DNH_95N=1M]LD-Z)Y'="NYE\QPT;J"%3@G[)O/ ?A"/P._ABZ
M\.Z(G@Z&W\IM&FL81IZ0+SM,)7RP@QG&,#%9>D_!7X;V'@>;PKIW@;PS'X0O
M2LLVCPZ5;FQN3D,KO%MV.<A3D@] : /GCXX:Y=:U-X^'A/5/%(/@'28DN-87
MQL^EVUG.;,7,4J0J&%Z2C1EFN<HS$J,D-B74/V@O$OPPT_2_%FL7,NLVWC_P
M-9W^A6)/[E?$<<* 6<0S\HNOM,)51QF"0]S7T))\#_AU)JFDZBW@/PV;_2+>
M.UT^X_LF#?:0I_JXXCL^14R=H'"Y.,9-<AXD^$NC^,?B%X#T:TU#P_8>%/AW
M-!KL?@_3[1%N(KKRKB&RD8*P$," RLBB,;GAX.%(H ]#^'/AW4/"?@'P]H^K
MZM<Z[JUE8PPWNJ7DADENIP@\R5B?[S[CCH 0!P*Z.BB@ HHJ'[;;_;#:>?']
MK$?FF#>-^PG&[;UQD$9]J )J**S[[Q!I>EZEIFG7NI6=IJ&IN\5A:3SHDMVZ
M(9'6)"<N5168A0<*I)X% &A16?>>(-+T[5=.TN[U*SM=3U'S/L5G-.B377EK
MND\I"<OM4@G:#@')I^K:YIV@PPS:G?VNG0SW$5I%)=S+$LDTKB.*)2Q&7=V5
M54<LS #)- %VBBB@ HHK/U[Q!I?A;2I]4UK4K/2-,@V^;>7\Z00Q[F"KN=B
M,L0!D\D@4 :%%%4K;6M/O-3O=-M[^UGU&R6-KJTCF5I8!("8S(@.5#!6QD#.
M#CI0!=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@"GI/_(/B_'^9JY5/2?^0?%^/\S5RDM@"N?\
M<^ =!^)&@MHWB/3UU"Q,B3H!(\4L,J'*2Q2QLKQ2*>CHRL,G!KH**8'GVC_
M3P/H>CZEIT.E7%RFI7-M=WUUJ&IW5Y>74EO(LD!ENII7F<1NH*JSD#D8P2#U
M=MX6TNS\5:CXDBM=FM:A96VGW-SYCGS(+>2>2%-I.T;6NISD $[^20%QK44
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M8QFW75KN;2[?48[98YKJ"T:3R%D9MY\T1AB6+<,Q)ZC_ (9<^&W_  EBZ_\
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M +5/Q#USX6^!X6NM+A\6^*_%,^@C6[FU_P!$LHXR@W>6" SDN-H)YP?P]?\
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ML:?WG_[[-0K:I]J=<MC:#]X^IJ[4"_\ 'X_^X/YF@ ^QI_>?_OLT?8T_O/\
M]]FIZ* (/L:?WG_[[-'V-/[S_P#?9J>B@"#[&G]Y_P#OLT?8T_O/_P!]FIZ*
M (/L:?WG_P"^S1]C3^\__?9J>B@"#[&G]Y_^^S1]C3^\_P#WV:GHH @^QI_>
M?_OLT?8T_O/_ -]FIZ* (/L:?WG_ .^S1]C3^\__ 'V:GHH @^QI_>?_ +[-
M'V-/[S_]]FIZ* (/L:?WG_[[-'V-/[S_ /?9J>B@"#[&G]Y_^^S1]C3^\_\
MWV:GHH @^QI_>?\ [[-'V-/[S_\ ?9J>B@"#[&G]Y_\ OLT?8T_O/_WV:GHH
M @^QI_>?_OLT?8T_O/\ ]]FIZ* (/L:?WG_[[-'V-/[S_P#?9J>B@"#[&G]Y
M_P#OLT?8T_O/_P!]FIZ* (/L:?WG_P"^S1]C3^\__?9J>B@"#[&G]Y_^^S1]
MC3^\_P#WV:GHH @^QI_>?_OLT?8T_O/_ -]FIZ* (/L:?WG_ .^S1]C3^\__
M 'V:GHH @^QI_>?_ +[-'V-/[S_]]FIZ* (/L:?WG_[[-'V-/[S_ /?9J>B@
M"#[&G]Y_^^S1]C3^\_\ WV:GHH @^QI_>?\ [[-'V-/[S_\ ?9J>B@"#[&G]
MY_\ OLT?8T_O/_WV:GHH @^QI_>?_OLT?8T_O/\ ]]FIZ* (/L:?WG_[[-'V
M-/[S_P#?9J>B@"#[&G]Y_P#OLT?8T_O/_P!]FIZ* (/L:?WG_P"^S1]C3^\_
M_?9J>B@"#[&G]Y_^^S1]C3^\_P#WV:GHH @^QI_>?_OLT?8T_O/_ -]FIZ*
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M\D[_ '%+<[Z;]D'P/?>'-0T_4+O7=4U:]OX]4?Q+=Z@6U1+E!A)(Y0H5-H)
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MYF?/&K?L2^$/%$.J7'B+Q!XCUOQ!JE[;7UYKDT\"W+M K*D2@0[$BPWW0O\
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MH4WB/^S573[.\:Y^S)'*YD#,&F*IOB5U4N Q4@@>E_&#7K[PM\)?&VM:7/\
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M_P 2:7X:MM"USQ?XHU&WDO8M%\.V\4DZ6L;*CW$C2R1QQQAG5<LX+$X4,<T
M>BT5\W> _P!J2 :'XJU/6EUC6KJX\;77A_PYX?M-,$>IS;+:*7[,(6$>&CQ.
MSO*0%"G<X&*ZR+]J;PR-!U.XO-%\0:9XBT[4;/29_"5Y:1KJ@NKL@6L8 E,+
M++D[9!+Y?RL"X*L  >RT5Y9>?M 6>CZ%97.K>$/%.DZ]J&IG2+#PO<6L#ZC>
MW B,I\DQS- T8C5F,OF^6H1MS C%4YOVFO#]CHNI2ZEH?B#2O$5AJ%GI<OA2
MZMX3J37-TVVU5"DK0.LI#;91,8_D<%P58  ]?HKF_ OC"X\9Z7<7-WX:UOPI
M=6]PUO+I^NQ1+,"%4[E:&26*1"&X9'89!'4&N%T?]H*'QHETVA>%/$_]BR?;
MH++Q8]K;G3I9K;S%?@3&9%WQ,H:6%%8@ $Y% 'KU%?,/[./[63^+?AY\(D\7
M:3XDFU/Q986]N?%TVF10:9=:F8&D>$;65E9O+DPPA$1*D*U=?_PUMX5^U_:O
M[#\2_P#"%?VA_97_  G7V&/^Q?M/G_9]N_S/.V>=^[\[RO*W?QXYH ]OHKQ_
MQ'^U+X+\)^%SKVJ)J=M9+JE_HDJ&V!EBOK5)F-LRAOORB!O*QD2%XP#EU!J?
M$CXY:?8>,M%\,VFK:KH=_;^(M'L-0DMM.@NH9I+Q9G33Y&=OW;%(U=W3+(KQ
M$$[Z /:Z*\&7]L;PE-";Z#P]XKN/#]OK3Z!J.O1Z8HLM-NENS: 2L9 S*90O
MS1+(%$BEMO(&IXD_:C\/^']9\2VT'ASQ3KVD^%V>+7?$&CZ<L]CITR1B1XG)
MD$DCJK*6\J-PF[YRN#@ ]EHK@_$/QH\.^%_@RWQ/OS=)X872X=78K$#,MO(J
MLI*YQD!QD9]:YJW_ &B]/U+6GT"Y\.^)O".I:A97-SH5UX@T]((-5\J(R/Y.
M'9E=4^<Q3K')M5CL(5L 'L-%?,/[./[63^+?AY\(D\7:3XDFU/Q986]N?%TV
MF10:9=:F8&D>$;65E9O+DPPA$1*D*U>DVO[0=BOC/2-!U?PCXJ\,V^M7;6&D
MZUK%E%%97UR$>01 +*TL3,D;E?.CCW;<#)P" >JT5X./VRO!'_"&ZQXO;3?$
M<?A32;B.SN]:DTW;;+<-?)9>4AWYE99) S&,, H89W@I3T_:VTI_$-YX:_X0
M#QVOB^.U34+3PX^EPK>7]FQ8?:HB9_+2-60JWG/$RL54KEE! /=:*\EM?VB+
M/7O!?A[Q+X7\%>+_ !?:ZQ;O<K;Z78PQRV@1BDB3FXFB19%=64QJ[,2IP".:
M@N_VHO"\^@^$[[PYI6O>-=0\3VLM]I^AZ'9I]M\B)E2>299Y(D@$;LL;>8Z_
M.=HR>* /8:*\AU+]I;1;'1_#\D/A?Q9?>)-<>YCL_",>F"+53]F;;<,R3.D2
MQQDJ#*9/+8NFQFW#-:3]JSPBOAB&_BT[7KG7YM7?0$\'Q62_VQ_:*1^:]L8B
MXC!$0\WS#((MA#;\$&@#V>BOFKP_^U(8?BIX^'B2TUS1/#.E6OABU&EZEIT<
M<^E7FH75] \DS*2&C8I: NLDB*.5/WZ]"^)_[2'A#X1WFM0Z[]O,>BV>GWVH
MW%G;B6.VCO;T6=N&^;.YI-[;0"=D;'^Z" >IT5Y1X9_:*TOQ!KVN:+<^$_%V
M@ZKINE_VU#9ZII0$VI6>XIYEM'&[L6W@*8W"2 LN4&:H_P##4&B:9;^*O^$E
M\,>)O!U_X?T"Y\3R:=K-M;F:[TZW&99K<P3R1L5)52C.K*73<!D4 >RT5X,O
M[8GADZQI6G-X4\9))KUJ]UX;D;25V^( FS>MH/,W A763,ZQ+LR^[:"0W3/V
MB=,\<>+?AQ'9WVO>$I;[7=6T;4?#>IZ7!YLES:V,TSP7,F]O)"!5F5X68/A1
MG:QH ][HKR#P=^TMI7CG6-+33/"'C!_#>KS&#3/%ITM6TN\.&*NI21IDB;82
MLLD21D%2&PP)U?B3\>M$^&GB[2/"]QI.N:YXBUBQN+_3].T2R%Q)<+#)$DB
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MOU8<S/D&#]D?Q#X0U3QA8Z-H_A?Q-I&O:A+?V5]KVH7D#Z>)/]9%+#"N)QC
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M76MPSK++]G6&36?MRJS>7N#^5\I 4C=QDCYJ\U\9>,V^"]G\:O#.E>,? O\
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MJ +M%4O[6M_[Q_*C^UK?^\?RH NT52_M:W_O'\J/[6M_[Q_*@"[15+^UK?\
MO'\J/[6M_P"\?RH NT52_M:W_O'\J/[6M_[Q_*@"[15+^UK?^\?RH_M:W_O'
M\J +M%4O[6M_[Q_*C^UK?^\?RH NT52_M:W_ +Q_*C^UK?\ O'\J +M%4O[6
MM_[Q_*C^UK?^\?RH NT52_M:W_O'\J/[6M_[Q_*@"[15+^UK?^\?RH_M:W_O
M'\J +M%4O[6M_P"\?RH_M:W_ +Q_*@"[15+^UK?^\?RH_M:W_O'\J +M%4O[
M6M_[Q_*C^UK?^\?RH NT52_M:W_O'\J/[6M_[Q_*@"[15+^UK?\ O'\J/[6M
M_P"\?RH NT52_M:W_O'\J/[6M_[Q_*@"[15+^UK?^\?RH_M:W_O'\J +M%4O
M[6M_[Q_*C^UK?^\?RH RO[)N_P#GE_X\/\:/[)N_^>7_ (\/\:Z*BHY4.YSO
M]DW?_/+_ ,>'^-']DW?_ #R_\>'^-=%11RH+G._V3=_\\O\ QX?XT?V3=_\
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M_C7144<J"YSO]DW?_/+_ ,>'^-']DW?_ #R_\>'^-=%11RH+G._V3=_\\O\
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M]DW?_/+_ ,>'^-']DW?_ #R_\>'^-=%11RH+G._V3=_\\O\ QX?XT?V3=_\
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MB)(_$'B'4;WPK'J):76-*\/ER+:2XMYU,VWS4D5$ES*1(BJK['"?1.H>*O\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img222477878_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_2.jpg
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M/#]X<&%C:V5T(&5N9#TB<B(_/O_M $A0:&]T;W-H;W @,RXP #A"24T$!
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MK(MKC5'B\:8T[9%4 Y9DQZ##'C-C1XA16K/WL/\ ,_\ )/#RQDE_R0F87O\
M,3A>)Y%,F6IBIAOS+I_=IN#YIY97_#YC9$^-6:Y8_%0O*'MSBVAW_P &&:_K
MVOM]38/NY?X?UNV^F\KXVKNO\"K\(O=?/)D>G_Y(W'1?=KVW^@)2<L1^-_\
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M<;-R=LCK;<L2(TLNR^F\QHP2X(W$7!%Z\\3/6#ZG&Y0F7-YDRU;/S?F_EQ)
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M_P#4(<(N8G'/K XUYIJ(3$9%K<EMJBVGR@C1&C$?_:IQL-XG]#=OAM>SV/\
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M.(QYN*&27%D)D*78HXG]5"QC1@2I*2*386M:XN*I'J#Y@#;_ $WK%K>#/2;
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M; @@,(8K(=="(16L:Y[NG9J*NR:DX6'D<AF18&(N_*GD6-%\W=@JC734D"E
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M2">]I6M-1A_^8+R$TT;(DTF[U23&RKZ*;60@%BI59@C(+$;[$"QL#U-Q\_\
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M,K41[%\NX2;#8NQD5R[Z>3B.[8]PCY;<S,+;X]=$%["W2_7\])OXQAK P-O
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MPVCGD?%&TQD+TWD=K]SB215Y$LT;W?8\[E6M8&RK\Q-K*R[KJ Q(6UZO3?\
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M<:PJ9&N29?/R;&<@E)*J26+A3,B/B,M\V+,0,J76GA3"C<&:%5LW*X_-<1#
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M/,B+W?Z09^_TZAYS#+[NF/54V(/^%03^DFKIQ"#BO:W"4Z/.)9C_ ,;M;_E
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MJHW@%E!DS2H\AXX3LAI(BM*UOF422]SB@48RM$Q-E57)JU#F^\^7!/%X<6-
M+?-(=SZFUP/LZ=2"+V%35P..B2\LK2-K]D6 TOK?\P/F:M>Q%/F%*^UO9Y7-
MD3837N*D"''D,KG'KG]4]7=4*4O61PC!V0FW2_X=1<C@G,1G[FY61Q'\K('$
M<9OJ/EZFG(\M$ CPH%#6\1<^7Y6JF-GX[6G 2.(+$ >$YH/+N-(:)M0X=M4$
M/:(4HD&(G4)A!*-7$:C7(YRZ@Q<GV9Q;)_#<49<VEA$C2L"1:U]=?IIXP<A(
MK&<A%\3?3K>X _*U(^839(Q#CU1U:V-#BK(F/()R!AE?+$HQR58R+)B(Y@.C
MPB =LY6JB-1$R"!N^.52W$\>N+A,+!I2%/P^6UQ;RJ \G$QD^KD;Y5U( MUH
M6/=2.V79#CM<YSB1X(W>$-QR.--2,TG0(,>8O2QX%84*L1>E$5RZGP>W//YG
MS<YRLB@WND%P!?PN>M_&HQY[#B_Z.$GXL01I4!TD-/\ 2'2)GP/'TR#*X708
MJ',- L1C% 0K47PW=3$1J(B(B;:R#"]L^U<0B26$Y&4/[25F)(\B ;5&?N/.
M-UC"*GZ:J((T:,FP(X0[=B*,;&NVZNO;K1.M4ZUW[^_688O%X.&1]UQ\>)0.
MBH+?3KK?SJV29^3(I!=MQ/G3ZN5>_MU,(L#HJ_!=*9.0P%]U"?BTV:JCG+BY
MO3:N1%]OXN_56TE=PZ6I\3@ "QKDO]]WQ/)Y8^[EYF)6UYK*ZXMML)Y?JPQH
M[Y,H<?$[X5?DAA""UY>B/B5_/*5439HAN<NS6JNLD[.RQA]PP/(=L;[D/_$-
M/T@5JWWGXT\W[=YJ1)NFQC'.-+Z(VUS]4;N?H%>.G@6U4T*./KW3I8W=%W3M
M3;O[E[-=I=I3AXE'B?T5XI>ZN#Z&8S@?M7JKTG#')<GD3/LHH,2L)>),NW3A
M6;7  *4Z;'#.E#K1',,]@Z,4[FO437(CD5NZN14U*P.U>??F<O.PL9WXWUB0
MV@#%K,1&"07()U"@FYMUIS/[Q[:E[*XSC\[+B7E_NWIE-25V%D3>0"$WA+KN
M(N!?06-;0T'"MUR_CAG09K*MM></AR#1"2GK*CJTCFN"TH',8U6]+EWW1?9V
M:SJ/MX\WQXDDE7'0-925+$LNI%A;IH#<@ZZ V-M2X7-MP')O)' V1\C;D4A?
ME-P/F.ESU&EC;J*M#*<?O<,FU/'TR%9V6;9-*'58-4XW66-O;Y7=$,,-?#QV
M!$CDER[)9;F?N6M\1BJBK\/Q:L7<SXO;'&M!S\B)$T3;6_8=0-2I-AIXJ2".
MIT()R;LG@N=[V[FAD[-QY9\M<A+HO]9&Q-U# 7(O;Y2+AOV2:]XF'&R$V&8<
M;+H25^7%Q#&"977-,.2D')WT5>[((22!*X1UBVZF&KVJK7*W=%5.W7G).(_7
M?[N?W&]MM^NVYV_HM7T:<=D99X[&/)(%Y'[O%ZP!N!+L7U #X@/NL?&KA\1/
M\E?IWV3_ .ZNHY<@VJ;ZS^'2A")_D_E3_P##I/4-'K2>=+5R;;]G?MWIO^1-
M+ZA\>E*)I+]:9W=[_P WZM.WJ?\ >!Y&CJ<GM_-^K33IN8-Y4>N/(U!2HO9O
MMMV*BJG;M[=4^FU/"Y%[4GJ;[T_&FJT4KUJH$CPJ#GHFW9OO[OJ3330EF)OU
MH-SK2?$_WJ_C32?=SYT:T(_WHJ_BTGH'SI0+U!SE7V;)[NS1]W/G3^_X4E%5
M.U/T:/NY\Q1O^%0<14[^WO[MOU:40$:W%.#P-(\7Z/QJG9^35?IM^7^VG/4-
M14B)]/U+_NZ/2;S'Y?71ZAI"D5>[L3[%_1H])O,56LH4ZBO+)_\ 4B%N9&3>
MBZK4D?\ EYT/F6<P*26+,??>>P"-(*^%^VV(*L\%K#?LN>][.Q6]NV?:J(?>
MLG2\A,8OX ?,?UUQ5^,G,E3 X?4#&$66;7UW$P FW6P &O37X5Q[HC)CG'=]
M<.V9\MQZSEM7NV(& 9XD1?>I6HB?2NNN\9ON?"39 /V('/\ R&WZ2*\<<^/^
M,=XXF!U$N7&OU&07_1K6(N *UR1XYWMW<_8CUV[5<[M557;VKK'>SL?]T#;Y
MJSSW:S T[1+T!M69,L>DO+J*$B[I' :0]$_RGN&--_J3?65<@?4Y**$?L@G]
M0_DK6_ *<?MW+RCU=P!]0)KI5]VYB_\ -/KDX C.'XD?&)69YM)14W:QN-8+
M?.A%=V+MX=M*C[+_ )6VM=>^V9]T]O<F%39YWCC'UR*3^@&NE/P'\'_&?Q%<
M9EL+PX<>3.WPV8\FP_\ [1D^NO7GW?A_1K@-XSNKW]64 6 -"KV*GL7L5/>G
MN7WZH])C^U;ZK_KI[U!3!8L:1_GXX2=B-57#:KE1N_2U7;=2M3J5-M]E1=6K
M-XO$R6O/%&\ENNT#3ZJ/4TT4'XD5+?+A,=U@+( [J&Y6H3QQ/\%C@B:04GQ4
M()@'JQ!JO1T[)LNR;8Q/V+PDA,T FQLCP:)B+7ZZ'37H:66*"9/39%L?*IP,
MN^B*,@9[)GEWQR,9+1RN>^.)T53%\3QAGE%@/42.7H&+H:Y&[IJ O =R\6Q?
MB>1D<$_9D&XFV@UZ=-*M\G!84XO8K;33XZU,#OBQX_@3JV2V,V)#AD6 B/1T
M*'9>;-&&)B%CDD60-GE(X81M()4W7?5<O.=S<<H_C&$9UTNR6W$>)L002WE5
MLG[<E4E\<E0+G7]?PITDNCLEEF7RI)AAWA7]+%C*>P+)#Y=S9$)$8:'4"4<M
MBO$X6Z/3?5L?/['Y>;_/P>AG&]]X:-KG3J+*;==-!5L^Z\CBG]V=P%NH)%A]
M/YO.J]%';5Q7.H\AFC$^58"88Z^>@NCU\(4F;8F+$<K7 !:.5H!HP0E$;9=^
MS5RA[>RH!ZG;')R)'?1&82QV&I .O4]?IJB7+QY+#/@6]OV!M()Z?HJZ(.?Y
M+&\/YE4!L0N9"*\E>]'R0-LQ.?!#)8!KE668XGB0; HB;L<KNWMFCGN[.,L>
M4PER(3;YH;W!/2XUZ:@Z=;:U$;!P9A_EY"C^3=-.O^FKOJ^1<7L_A\XZ"7=C
M7"G#4/0\@O%8)Y6J\#3JC7)T=76CF.14WVWNV#WKP.8_I/+Z&0/V)1L/TZZ6
M\M=;4S-P^?"N_9NC\QK^CK5["*(S&D"1A1N1%:\;FO:Y'(CD5'-545%:J+]2
MZRF.6.5!)$RLA\001^<5;""ILPL:<U724:**-%%&BBC111HHHT44:**-%%&B
MBC111HHHT44:**-%%0541-U5$1/:O8FBBK,N<^QNF1S236RSILB!B*TB*[H<
M5PW27.;$&5 M5W0Y[7+NG^4FL4Y/O/@>,)C,OKY0_LXOG;Z[:#ZS4^#C<N<;
M@I">9T'^FK$G9[DU@YHZRN!3 >?RWB63GCE.*D9TQT5S7"\:)*>WI&Q? *-Z
M]:H[X=TLTG-]U\L=O%XT>#AVUFG.Y@>H"H--Q! %P1<U/^X<?CD>K+ZLGBHT
M_3?7ZC5I%%(EEC2;RTFV:JE1/:.2Y\)DN <CTEO%$8XDQ)<2>J*KHWAIT,:B
MLV1VULR^$XY ,KNWD))F!W-&3L!4Z6"KM .XCI8V%NEZEKE,M\?!A5200"!<
M@^&I^'G5/%;UD<+8=<QTDQ(T9A"UT9$<:3&L7FK[1A@N<:9U1VD<?=X3]"[[
M=2IIS&YW"AW<=VOQ\D^:!L&Q $NO0[O$V.IO3)QY -V=*$4'Q/Y]/"HN?>S>
MMX1QZ<9GRRKN[Q9+5LB?QC%ZD>65&)&;VC.K'C*15:[X4VOD?;ON!RZB3/DQ
MN,@/10=Q^LZFY_75KFYOA\!B(/\ ,L;:=.A^'2Q_/24H6%<KYTR5,>YA!*Q2
M/$% E5OB1=D>\Y8:#8T;1E(1&L39._5YX_VR[?67UN8:;+E&MG9@I;P*@$77
MZ:ML_=F9*3'"BPQMXA5/ZQ53!&BQ=TCQAA545KG"8C7N:KNIS7$W4CFJ[MV5
M536>X7%<=QZ;<*"&%K:E%"F_G<:W^/6K)+D3S-NDE=CYW(O]0T^JG^M-MEZM
MMMNW_=U<-HMK<GXF_P"NFM+W\:3NS_)7\/MTH%A86 JK<W04C55+O;SHT4;V
M\Z-4D Z&D0 MKTJ"KM_1I/36I*D+H*0JM7L5%W]F_O\ QZ6PM8=*JWGSJFVU
M9"NZFXHK,?CUE[4VE'9A1&N\:NN:^16SQ;.^%R%ARWMV7L7?9>S0J[6#+]I2
M"/I!N*1E$R/!)K&Z%3\0P(/Z#7ALY0^ZQ]6GICY4SSC?CR7QOS-5X%QK:\W6
M5MC5W*!D6.<11<@#2TUAF.)64,!J7+;YCY!:^K$>4^R#6331WO#'<_72':'N
M"'3&C1/3GR,J/&3>+JTKV'RF^J@D;FM925!()M7FW[I_AKS#D<ADSY"3X.#@
M39LAC:S+!$"UY%(!5W 8HHW;@CD$@5T?Q;!JBIX]@Q!,&[PZ\;5*C6IXCD$G
M47W=1'[N[/?KL:7+DQ.23$B)"060=+V&FMO'K?XWKS4QN.AR.'.3,H,LREC?
MR/1;F^BC0?Z:L;A6H=06V4QIH(@J:WR.P)1F#U+^\'%KR64:6US&L'*'-.XC
M4:KD<%[5[%1R)9).XN-Y/GN9[4P-R\MPLN)-D)8 >GR6-Z\4B?,259HYD.BC
M<AL+6)RP=C<OP/:';7?W)!7[>[GCY*'&DN21/P^9]UR(7NH 94EQI5 9KQR@
MDAK@;#\<YW&X.YXX]Y/""(^##N$H<B<6+&*5F*Y0\-3>&B2#">6!+A@(V2PH
MG,>J@Z%56.<U;?WQVI'[@]@YW;[C=R$<+9&*?%<B%2R@>8D4&)AXAO,"LL]E
M?<F?V7]Y.'[RQV"\-+DIB<@@%U?"R&$<C'QW0$K/&1T:.W1C?T5NZ6NZ6N1[
M>WI>WM8]O>U[5]K7-[4^C7F8-1KH:^A VOH05\QT/Q'P-)5$7W;_ (M!13X4
MF[XTTJ;*J:;=0.E5J;T(BJJ(B*JJNR(B;JJ^Y$]NJ+$Z>-57 U/2HJUR)NJ+
MMNK=_9U)WIO[TTI#CK>U*)2= 1?ZJAI+M\:JWMYTE6-5%[M_K73RG36I0F>W
M6FE1$[_SKI;TOK/YT=Z)[D[M%Z599"1KI>DZ6IMQYT:*-3]DT+OMV=BZ*/F\
MZAUIO[?P7;254I/C27*BIW=OX?3HJO<WG2-OP_!=%+N;SI*Z6G5)(N:P%R-Z
MHN!^'LM%AG+6?!XSL)59#M:^\S>@RF@X_M 37F&V-7<FRZ1./CVT5X%23"=9
M,EQ^IBO&B/:NKCB\3R.=$9L*(S*#8A"I<?2E]]O(VL:L?(=R\'Q.4,/E9QC2
M%00TBNL3 ^ F*^E<>*[]P\JXR?>E\5\,?>)%X;%Z5N:*?EGU.\?SIN.XIA/&
MB.Y%X_L</S&VJCY!9<H9M0N-B?$=7BY(/G4MY\U''&CXC(T@SP(S-.T,OD^U
MLB7*Y&'T..8 LTOR-N6]E16!9RW0J%\020*T![X]F\![OX&)@<!F_>>XX6*)
M'C_O8S'(REVFD7Y(!'8MZC-9M4",Q6W%+./1UZV:OTO<J\H6?#]%,XJPNPR[
M&,GR_%LUI+NQ8WC[D:;QSFMC7XE"DDR653U%_12O'D/B!:. -TIR()-];IE]
MU./R(1VW*HCR<B-"&(90%D59 #?0%EM;6VMJX+__ .1.\>W\I_<51ZW$<;-*
MS*KQN6,4CP,54-OVHX+,2HLJEM!K6O/!\BH^6!\"R@.<@F[-24%'JJ-[MG/1
MR]J:VCVG)BB.WJ)O O;< ?S'6N4?<_'Y)L]B\$H4DG[+6^GI3]QFV,U/(Y6W
MMJ&O:V,!D8QVO2,5K'D4_A'1%$]1/['[*O2O8O;HFYCCXNX'7)D"V MXCQ/A
M?Z:3![2[AS.R8IN/QI)$DD<Z"QTL.AKN[]RG1 S?U$<A\J4S"VN*X-Q-8XT/
M(XL8[Z-N49ED6/\ AU(;-PDAEM$HZ>65P6/<08EW<B(Y-])?B&[CX[+X?#XK
M!GCDE;(]1@IN0JJP!/PW$5W5_P#IS^W7</&][\SW;S.%D8^'#QC01NZ%5,LL
MT1VJ3H6$:,;#4 Z]:].#>UNZ]JKO^==<EE5)N>M>NPZBH+JEE &E/WJ&F[&E
MI;4W5/ITP68Z>%2 V@O3J,3;M[5^M=-LN[K_ **K5V7[)IQK._;L[M]]^WOU
M25LMM3].M+ZCWZFF#PH\G?S  &ZD1'*]B;N1&JWI<Y$1SF]*JFV^RHNVK7E<
M5QV:I7+@CD!\U%_J/44AU)) UJ7^6E$Y71)L@/6G2417O.$PW1O*/$1W6.2L
M=8_2WPD(@]V-547;6.R]C8J?O>(ER,-SXJ2R?F:]AY_74:3$Q9?ZQ :G06M]
M#,,DL0[%K9 9*RQKM)62V*Z"LTJC0,EQ(Z=!1!$BHCFN3J[=,&/O?B-(VQ\_
M'.O4H=OP*V-_(=#5JR. QIF+8[[5M\?Y:=!;4\Y8L68UL4XATD)2S@HTL$39
MYS61620^#)!-F351$03R$09NU=09NX.W,X_=^YL(XKD!2TJ +](D4;[7Z"]J
MM+\;GX-VQBS@$F]S^:QTZ?IJ<AMG5XWRZ*PFU_1&9-\E%,D^,%9%J4=/3^$G
M1(%*.!"L.XH3O:U$]VGL?MV'9]Z[5Y(XRKJ%!W1W)LH93?KTU%^AJ++E GTN
M0A5KFQ-MIT&IN/CY:5>\3/\ (*U?#MZP5M'":=&?.J55[WNK5864K!-ZU=X$
M(S7O>5D=G4-_T:N"\YW3PP*<UA_>8$T,L/6PZL4^(UT &G6HWW' R/\ II=L
MA_98>?07^G3QJ^Z;-L?N6,\*:.-(?UIY:6YH7*\;V,(T)57P)*-4C5W&YR*C
MD75]XGNSA.8 7'F"9!ZH_P K ^5CH3\ 34/)XW,Q3^\0E?,:C_5]=7;NB]W;
MK)*@4:**-%%&BBC111HHHT45SC]2<?UUS.7<\L/3]D28[QIA'!^-9#2Q)L;%
MK,&:<AR&\XNR7%:#%K#C&^M\HRF6E9BC(\@F54,&G(09'Q+%IC@>45AAGJP^
M\;-968HWI%!Y!EKF$&F9/PO+8ED80L0A6>+2;5ZYNE#'K:G)WR(=E(!.*ZR8
MQGRP9MW/0HJ_?_F%]?=)EF%XY<^GBGR.MM>4J*FR#*\<P?**VFC<=2.3!X+>
MV#FEY#R*327,/#!DRX,HZ%@.C.\FY$*,:S"BNHVBBI&?9U]6'Q["9'ABV<K7
M2"L'U]"(KFC:Y4<1_:GPM1555U$S,_"X^$SYTJ11#Q8@?FOU/P&M.1PRS-MB
M4L?@+UC.UY/&KI$?'*\D\T=7--*E,*&%%_?#AL68B(DB&-TPG2A"-0?2-R[[
M:PS([U?*D^[=NXTF3*>CL"L0^D]1KYCI5UAXI0-^;(L:VO8:M^;I?X7JQ[23
MD-WXOS:X5 JZUC,A1U9'A-GP&B;Y*7(>]M<\AHJ$>,L=ZE1Y-]O@U;7XCF>5
MB;([ES&50;>A WIHI'BS&V[2_3KX5+CGQ8+?<X-Y'[1ZV/B1X?1X52G65#6R
M"NC"20XKYC%%&ZR3#PY=<%QJN3/EA)*\Y >T31-*!J*JM:C^Q5TQC\SVWQ&2
M,/MW&&5F_9_=H2=K?;#26^8BPM>JFBRI4,N7((X@/$VU'C;X_"D-+>RD8H@B
MKOBAJZ4=2MEE)6QE'%D[-*6;&E#.54W:7PGL9VM^+5ZQN%[]YZ-O7,?%8(:Q
ML/WMOV?KM8WOIIY5:I>9XC!!9 9YEN!<?*0?C>HBHX_8LN1(GO1[2+XCO "I
M6L<-IO+QU8QI_P!X]RO145SW*J^S66\7[:]O8;#)Y$R9^:1JT_S"_F 3U^/T
M^=8YF=V\E+\N*!!&3^R;_557&(0&>& 0P,[%5@6-&U51$:B[-1$54:B)NNZ[
M)K.L?$P\2()B1I$!^R@LOT_2:QZ;+R<B3U9'WOYGK2]_K_)^3MT];QJKU$I*
MN1._?\7].EH]1/.H=;?>OXM%'J)YU!7,7OW_ !?TZ*/43SIM=M^S?;\/IT4>
MHGG4/Q_D_7I:/43XT?C_ "?KT4>HGQJ.DIU" USTJ"JB)OHI[U%IM7-7V+]'
MX;Z/"JQJ+UJ]F'"G.68Y)>R6^L;DK!L$L[ QZS"^-.+.%\?OJ*J*C493Q^3L
MBQ?,\BD.$B.1)J1PR^W='-<B*ES@S<&"(#[E%)D :L[RD'X[%95^JY'A:K/-
MQ_)3SLW\1GBQ6.B11PJ0/+U&1V^L 'QO5;QOTY\?<;<6<EX#QK53X]IR53Y0
M7+<PR2^M\PY"Y"S&ZQN92!R7/\[R2789'E5R@RL")TDZAB1T0,880H@TE\?S
MDT//8/+9A!BQ,J&0* %1$CE5RJH+*!8$]+DZDDU;N<[7Q<[L_E^V^-5ER.2X
M[*A+LQ:222?'DB5G=B68W86OHHT  TKSR RY:W%4KYN\2;7!+ GQS;C+%F0>
MJ/+CF:_91ECG"YKD5-T5->I?\-&9R/WK%^>":SH1J"K?,IT\""#\1KTKYSSR
MC<=Q1P<P&/,Q]T<B/HRO'=&5ET((92ITZBU;G<?^GR)9XEQAQ=D9VXIF_.'%
MDOE+"[Z: G30\E5&6Y/98Q76S&IXWD,IX\MEARAI^\7I&YC7$$Q->:'>7OI%
M[?\ XY<K/Q[S]M\WP</'S1AOEG;C))%LIOM$NUY_1;H7C &C&O=[VR_"5)[P
M?_I9<9P/)6P^^.W.Y<GF,:9D)?%7FXXY+2*/WAQV"XXR5%F2.8R6#Q@5K#F7
M"_/,O-('#]GQIE$;.+63Y.$P-?(G4TR$V0"*?(X.01ADJI&-PO,,(:9XK1A:
MY$)T/7IUZ#\7[D>W,7!/W;C<MAMQL<+.8V=4R P%Q$8&/J>J3I95-ST)!!/C
M=S/L1[X/WE#[;9W;_(IW'/.(T=87DQ'4N%.0F6BG'.,JGU&D9U*J"KHI-AZ5
MX0/)P*^"\OF"0:^%!?([4\<D2*&,\_;V_OG"5W;[]>7<Q::9Y[6#NS6\MQ)M
M]5Z^AW%3[KB0XK-O:*%$+?SBB!=WUVO3^F]C_"I8((O0J+I"&7K52L!6COKJ
MY)RW!, Q>EQ2?-I5S>ZLX%Q<UQ2QIPZVJ@ E.JHLT*M+#=9EE(I'#<TC@A<U
M%V<[7-/XGN\.?[8[0P\+@99,8\CE/%+-&2KK'''O]-7%BAE)U((8HC $ FNO
MOP<=B=K]Z=_9^?W+#%ECB<))H,>4!XVEEE],2O&;K((0/E5@5#NK$$J*YT<
M<IYQ@/*>&%HKBWE0[_*L?H+['2SI4JOR"OOK>)4R GAF(42S@MF>+'.C4*(S
M$5'=*N1>3_97O?N;M[W!XW%P<C(EP<_,C@G@9V=)4E;86VL2!)'?>KBS#:;D
MJ2#W!^(;VZ[0[I]K.7S>1Q<6'D^,P)<G&R5C1)(7A0N$WJ 3%)M]-HS=3N!
MW!2.^Y6]#W;*CD8JM1??LJIO]2Z]17A<GPKQH5A;6FNMW=LGXE_7IHQM56X5
M(#M:R3-+6 M*P]G'1SCU@+"&6Q UJ;N4T 9W2Q(U$[>IB;>W49<G%DR&Q(YH
M6RT'S1AU+K_O(#N'U@5+;"SH\5<Z6"=,%S996C=8V/\ 1D*A&^HFI[4L, +&
MJ%< 6/6C2A@=!508-H*2JHB[+JJI,<@0?&C2U,IER[JOT=GY=%%)3O\ Q?GT
M4G[0_+SI6DIVD/[$^O\ -MHIQ6'2FE=U")')L2,9-C1RHA(Y4]Q0/1PB)_\
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M5E^4V8BM>_C)]FNR>V>WL/W"[3P\?C<YL]<7(A@41PSB5)'241+9$EC,9#%
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MF ]=-@V+(Y85A'E"<&1 D DHH90I 7JUXU1R.:O=IZ>#&G@?&S%23&E4HRN
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M0BN[,%!)"W)-@222!>UR23XF]3D7:@6]R!55TS55&BBC111HHHT45-?^0_\
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M8GI]#TUM3L#._B79?'9-[N,94;_>CO&?_P!VM]^S_+?QKVRX7/8WE^XI&_\
MOPWA;]*5M8BZS UM!>@J5GPX=C!F5MC%#-K[&))@3H4EB$CRX<P+X\J,<:_M
MA. CFN3W+IB>"#*@?%R463&D1D=6%U96!5E(\0P)!'D:DXV5DX61'F8<C19<
M3JZ.ILR.A#*RGP*L 0? BM!Y?H P0U^Z7$SW*Z_%WR%*N.#@5LBR!'5W5\OB
M9,<BO8!K?@:4D,IVM[W.=\6N6IOPD]D2<S]]CS^0CX4ON^Z@1D@7OZ:SGYPG
M@"5+@:;KZUVEB_CB]QX^WA@3<;Q<O<(CV_?3Z@NUK>JV,/W9D\2 ZQEM=@'R
MUO%0T51B]'48WC\ -71T-?%JJFO!U**'!AB00!(Y[G$([I3=[WJKR/57.57*
MJKU#Q^!A\7@P\;Q\:PX&/$L<:+HJ(@"JH^  ^D]3K7'V=R6=S')S\MRDKS\E
ME2O++(QNSR2,6=F/F22?(=  *J;T15^S]>I6M46!UI.BJJ9>NZ_5NGY=)^T/
MKIV/[)IO55.+U'TTEZJU$V]O;^C2  =*D!0.E-)MOVZ4]*JI]?P_)J-3R_:%
M)TM/4:2XZ4M&EI*X+X[*EX_ZN/O;H<!7CERL!RNU%X:.1_388[Q;-D$9MMVI
M&MRNW]RKJQ>R$4)_$_!CY(_R\N5A,1I8E9XRM[_TB.OA7G][M9>7Q7-^\+X.
MF8_M_D.GG]A58@C7[$A/TD59F'SX8,;1J=",;#VV^%/A0>R=R]R(FO7KE89V
MY ;O/]-_Y#7CGQ.1&G%;00!Z?UV _P!5;4V_)-GC7HXX3XTJIAH-GRV7-7SY
M 2.%*B\<5^67!Y\<+T5"!;?DGQHO4FW5%<9J+\6^N?\ C.SL+GO?[N'N?/02
M<?PKXY56L5?->",(6\#Z01Y".F\)>W2N_.ZO=CE^Q_P+=C>W/#3/C\[W<N<K
MNI*R1<1%G3O*%-]P&2988-UQ>%Y0M@16H7(5=#%2 J*L+5DG=%@5X0-1'++D
ME'&B#$QJ?M.,]J-1/;MKH;ALE_O#YN4Y$*J[NQZ!0"6)O?P!-S7G[S. LF/#
MQG' '+EEBBB51J9'940+;6Y8J!;X 5L?Z\;_ "/U+<]<$_=ZX)9&0-?(QCD'
MG^WBJI15\F-5><H:VRZ%5CVXKCHY>12!/['S9%6U4ZE1->(GN-E/W%SN/V3Q
M=Q'DS-+.5O9,?<647\/EU%_':*]^O>O(Y/O;FN!_#_Q<C'+S$AFY613K'CP(
MADW$6ZZO\7:(>-=I*BK@T5744=8TK*VCJZZDK62#/D2&U]5#!7PFR)!%<20=
M(T9G61RJY[MU7OUL142)%BC_ *M%"CZ +#] KK3%QH</&BP\<$8\,:H@)N0J
M*%4$G4FP%R>IUJLC]OV?ITM/TZB[.^O9/S:44\O2IAKMNQ>[Z-+2U,L<C>U?
MP[M-MJ:=0@+K4QJBJZ=1=T^I$33<GA5#L5.E.-<J=F_9NF_9]GYETW35S?=X
MTXBHO=O]NBGD8M>]1T4Y1HHHT44:**-%%&BBC111HHHT44:**-%%37_D/_IO
M_J^D\:9_^H_]O_U5&S>J6ECW;)/E_P#."?3J0OV!]%6N#3$BOXQK^H5*(J*N
MZ=NRI^C584GI5OF_:%,OE1 2(<0\R$";8N*E="/+CAF6+@-ZCMKXA2LD3G ;
MVO037]"=^VGA&[(64$HO4@$@?21H+^%ZLL_V1^7C4ZU'N5-FJO4B;;-5=UW5
M.SOW^S3L-KD'RJU9#!GL*5LJ;[]^ZHJ>W?VHJ?1J01?I\*M>5\WRCK2D1RL<
MJ-56MVZG(BJC>I=DW7N3?V:E:#3QJRR?9IW^JB[*B+MMNB]N^R=GO[=-.+G2
MF P4ZTTN[7KV;*CE[%]G;W+IQ/LBHCF]S3CG+THNW8[=-]EVW3;=$7N7;?1<
M>'6HU--5$<OU;?FTZGV+4R_VC3KAO5$V8Y>I5Z=FJNZ-15=MLG;TIWZ0:=?*
MF&8$6%,ZKJFHHU7=B(JKLJ]B;]B)NOXD31TI5-C<TA&N5=FM5SE_9:B*JJOL
M1$3M72WIT$'I39&D;MXC',WWVZFN;OLNSMMT[=E[%TEP>E+36EHI/6WW_DT4
M\CJ%L>M:V\\>J'!^""U]190++)LJM(OS ./4YHT1T2K<0D=D^VL92/%"#**)
M[0C:,A2]#EZ4:G4NFO=/WN[9]JY(<'.BGS>=G3U%QX2JE8[E?4ED;1 Q!" !
MF:Q.W:+UT7['_AK[T]](LCD^+FQN.[8Q)?2?+R%=P\U@QB@B3YI&12K2,61$
MW*"Q8[:<X%]2>"\Z1[.MH8$W&,BHPLL+'%;/RCGK7G.V/\VJI<%&1;"(V2]H
MS+T",(CV=;.E['+-]K?=_MGW3Q9QQ$<N)RF* 9<:7;N56) D1D^62,FX) 4J
MU@RBX)@>]_X?N]/8_/QV[@E@SN$SBRP9L&_8[H 6AD23YXI54[@I+*ZW*,=K
M!<]6M357]5:T%[!!9T=[66%+=5LH(9$:PJ+6(:!909$>0P@#!E0I#V.:]KFN
M1VRHJ:VLP!4@]*T4A(8$=:QQPQ<6I\+=BF3RI<[+^,+B?QGDEA.26Z3>OQH<
M1V,Y<25,KZIUD3-,'G5EH>4(#(I)\J2P*JT6^FXB;;6ZC2GI1\VX?9.OY?0:
MRD]CT1^[539$5?HZTW;O[NI.[?O]FG;$"Y!M3BNILM]:E=%5TA[NG\WY-]4;
M23?PJ5&/D%JY&_> Q<B'R7A\^<R3_*A\/'#QTZ]:P&6X;*<7(8K7;>$.R(TD
M8CFK\;P="INUJ[<!?B]Q.:7N[C,_)#GMXX'IPG7TUF$CM,OD)&4QMYL@%M%-
MO4_\!6=V\W8O,\7B&,=UKR@ER%T]5\8PQKC.!]HQ(PF73Y5=C>Q87L[T-1,C
MD<["FTS9/R2MQ3(&YH<:.\BRNFQFCI84YZ?N_-RL@8 L9B_&J *]J=+7ZM?X
M3,3F9/</(S<(..$CXZ1,IM=A+%?00GH7W@LHZA0YZ$U??QS9W;\/M5B<=R)C
M/<<O*Q/AJ;>J%17&3(!]H1^F0CG[)=D&I M:WWNN,PJ[DCT=\HSD&.KGW7(?
M"N3'?T,:M5DL6CR2,(KW_"YKJ^ON$1J^Q[O>NNL?=>&.*7B.9;I!FB-OBDI
M(_-N%OB:\%_?R)<&;MWN=A\F)RR12'^[G(5A]!&ZLF?<T99*L_2[E6 SWO)/
MXFY5NL5EHYA$=&ER*NO^80#*Y-F2H]S6RW$&J];/$17(G4F\OVE:2#@\OB)@
MP?#Y&5-0>C6;Q\+[NE7?\/GWG"[7Y+M[)211QO-9,:%E(!1R)!MN!<!BP-M
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M#^[/;"MJF7]L#[ Z'JWVN@\1U\A58XN5!JR6/Q/^BEO\0;#.<!VP(\665&D
MYS8LURLBE1$*G4I')LK4^)OM3;;3_P#^5>U01N:=1N(),>@ Z,;'H?(:CQ%"
M\?)?Y2I/TG\W2DE')80HG1)"*"2"&54:QZ#ER6M='C*HR/1Q#->BHK=VINFZ
MHNI*>Z78[6W9@0D'[2L+?3UZ^%.#"RR+[#32M(CE8H9'4ARQ=DCF<KI0&N>:
M.Q&L<KS#8U7*B;_"F^KAC^X/9F5I#R$%]M]21\+:CK\!K5#8N0@)9&  \J4A
MAJC?C;N]'*SO3K1CU8[H54V=T/:J.V_95.W;5W3G>#R%O!EX[ $=)%\>GCX_
M[:14=&NP-J6CFJFZ.:J;]/8J+\6V^W9OV[:GI)'*+QLK &VA!U\M#U^%/ W\
MZ3U]O<FWOV7\._4AKA+&G-XVV\;4O35-UQYXTPXLS[U;UE8M?TEJS'.3.'X9
M%DEKI@8%O377''%558'K9Y0MA3GBDP9 U\)[W#*)R.1.E=M<\%+R7"^\TG/8
M:NC18D4L4I!"B6.2)E%^A^9>E[US"_:/\>_$+W%QG+8L[]L<OV>^+.^P^FR3
M^C%(JM;:6V[K"]P5)M6)HGHU]2$3-B\8AQPO\NNL%ACY2<>+_*3<:0O0E^I4
M/YI;'R/;\O\ #\SYCX-NG]YKU@F_$'[82]MCNI\J_,^B&/'[6^\?>+:Q=-GI
M[M?6W;-FOV_EKRD@_ A^(>+W#;VWAP&':GWDH.;WQ_<AA;O^HOO]3UA%_P#2
M[/5]0;/LG?64_7)CX.*\JX*AUD<T?"*#B@N$T$DB;";.QZU1\L)B(GA?,)<*
M5'D/3?=Z]2IV(NL0_#?R\G=O'=QS9SA^X<KEAES =2DR6#!>HC5PR ]%T6]R
M*VK_ /J&]H1>W'.]@X7$0O'V+QW:TG&8K$?*LN+,I96;[/JR1/%(PO=SN(%@
M:P-QI(AU=;E/JKY'@F=PQZ?HCLJ"(J.#_M)Y+BE%%P'C['U(G382;#+)4-IW
MLZF">HV._:=TO?B-]SN']L.Q,WA()E/<6;CE9%4_-!C$$.S6/RM,"8HP;$AV
M<:+>M>_A ]I<GO#NG_\ .G><#1>TO:#??!)(+)G\C#KBXT!(M*L,NR69A= R
M1Q&[2';MC]UOPYDQ,=Y!]7O+2_,.6_4=D%S;LL#L5'Q\;E6RS+69 0B=<>OO
M;N,R/#:FR-J*F(C?@=V^7'MYQV5DKD=X\H#_ !#D7N@/5(%8[0/+>1?_ '0M
M>M/X=.WN0Y&#DO>/N=2>X^Y)BT.[K%@HW[L*#]D2L-P'C&D?A76=J=J?6GY]
M;$(VFQKIW<M/]VRZ2E!!Z4\U=T1=%+4PW]E/P]NBBG$=M]7Z=+5:L +5,-<K
M4V3;WZ:/6I:_9%/-7N7L5?J]NW].DI; ]:=ZF[)W;JJ>SVZ-2"/A5#@!=*5I
MEE*]:9HU311HHHT44:**-%%&BBC111HHHT44:**-%%3O^KO_ $__ -6TE];4
MU_;_ /!_ZJ5:.3YI9(O?Y^6G_P#??VZD+JH^BH6.Y?&BOX1K^H5(HNR[_AW:
M<6H4W5OJ_77F)^\8] 'KFYK]:?(O)'%]#;9K5Y_%X<A^GWE&-=8E H_34/$W
MTQ<J/96]KE-+G''-G37-6>=&/1PYX+@5C(4HRR?#:+J'VZ[^[(X;LO&XWDY$
MAEQSD'+@*R%LSU-VRRJC13*RL%(D9#&46Q"W)M)/GTKMURCP3S5E^7Q;K'^<
M9=)A\C',4K<SQ[S5U5CR7(HU>ZMRVWBRH)F-Q]F1/QC'UAL K% \]LJM<^4W
M?3?%<UPN'B&*?"#Y8DD,;64[$)W1J01\^S?+N)O<"+^;5HD=%8W'S?E^7YJD
MZWC#U95TFLK9G.\0.'U-?B]2$PV4[\D+70[FO;E/SB[LL,(DR_E4BE'6SV#8
MX*A8(S7.*\ZNR<IVM(K2)@DY;L[?M;+E3LVJ)-%#6WK>QN2+6"U:ILB&Q<K\
M_P"CX>-7C>\>\[R)M1?1[7'+W+0\,8_B8+J5FF48O PCD^*&Z;G>84N)U&/R
ML<RW^?DM8K FG#C/K'UH^D?A/5J4P<APBHT++(F*<QG*B-',D)V^G&SLX=/2
MVFX4D/O-S<7JTF>$'TR"(RY/0&X\ 3?2WPZWJ\>/N-LTJ,:L)N7Y[-N^2\@Q
MH\/*BTQ(==B7\X%PVAQPMJROA5D4<B5&FT:3@R7Q@&&2=(ZQO8HFLB9_(84V
M0J8L"IQT<@*;KF3T_49[7+&P(;:5N00JV(-[Q<B5#( B@1 Z>=KWZ_7^@59^
M,X;Z@X?'L/';CE7'XV25^? ;&RN++@6"FQ6)@\V!'Q6:!V,0H*OC<BLCJL,
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M_;.9VYRTN&X(R\24%3;J!9XV'P92/TUU5VUR4>7 JR])4LP\CT;2K7XDN+'
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MMR*='FK+M*:WBV4_)[]M*C?E,FI7PQ"KG=?C.W(U.Q=$>^WX@N(]U^W</MG
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MTE,;'G&48E@-K#R:"%<55]R:OK/GC46-)5C&3(X8,BV4]=/(V-_TU3ZQO<6
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M:4V"?&H=:^_\B:IJ6L@8V\:;<]&HKG+LB(KG*NR(B)VJJJJHB(FD9E52[$!
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MJ*EF.07G.PC^M#E["YL[/LSG.EY=+Q&KBXX4<3'XTB/6'0HEE-... +;/GG
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M7V1R'9W//AO??&WJ026TDBO\K#XD JX\&!'E6Y.$Y*'+QO1DU5QM8'J"=?\
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MT"LCCJI!!Z]0=PN#>M^_1C19!3\?9'9VH)42JR;)A6>-QY;""<>'%J8L";<
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M?$G8J[KK8_:GN9BY\R<)W(OW/G;J@+?8FD.GRV%DN? FVO6K-F\6T.Z;'^:
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M+&AO>ZJY"W/B0-"?$BJ'R#SMQOQG8BI\DM)9K@@AG)54T!UG,AQS-Z@FG[$
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M_ J"^1_NS_$/Z-1)?2N/L=/[RD/WC^^_P*A_ _W9_B+3)]'^A_B4O^9_OO\
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J

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img222477878_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_3.jpg
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M/#]X<&%C:V5T(&5N9#TB<B(_/O_M $A0:&]T;W-H;W @,RXP #A"24T$!
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MV"<3<E0;W#,BR+!6,]L[+&Y=#8V=/C-KGMSD5D03@N'Y-Z\R^;A)''_*'N@
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MP+F?G+ N0\73CS%;J:=G>2*]Z_\ W5C32J&KARVICL:4XX,4RF6#S LH#1.
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M?%U=A>3?ZJ&G<VHX>&<C4>293R@,?BUMLRLY4>/\DY AMO-!3M/2RBK-B?\
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M4#=>]6-%&RXJ*NNQ?0Q#_P 0#DO/F*F&R8(<@/J:WPDV(]-0%R#G\ITF(H3
MR-1<.TQAJJ;5JHK5C-O.S8Y/-(^C[$8P=94W7$==<0%!=T'4@ZFZ^?<)XH\9
MF8)_-B.RQ B^H.?C;C>U^/=42X.TH@,S>[V'5S-^1MPM5 [FF1'$.P*VR5W"
MT?!H+AMLH]@MR;*D,/YAAIF8Y7B ;]![!>7M)>W9-8\[KYAOM_C SG&\2VOP
M[/?E:U@=/LM?MJPN)M&OP[+\W;X;^[;ON>%ZD2SY*>L8E2;]U'S66RS+JT>D
MLLU"4Y-$HN3HXD5?YXQV'/F!4"<60BDFR(FUU3YCON4(E:42NG #2$ MS?\
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M1#)QZ-7QGS'S36'V?N4:V%XG!#VIJ<=%]9)E8B'-U,(K>-KXQ>A1S/=PJ/\
M:.U%3.L($*FS1V^,V^(GD.^H!@W_ )-U+;A.1XN,*$;+:UNP=^:R@AEFQY@
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MSU5^EKHO;)Y.E=IFO^H;:<07MV_+Q@C[;UN%+[&ER#^,DKIP8P]#6I\U'?\
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M-QZ@A$GA[9&/!':WPW[U4?<2?95OAVT6Z%[)87(3MO&:!V-(NJ#)J)JECI%
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M=AKXD^9;:LUQVZC6F,=V<Y7S<MTV/+KA=TWZ]L]T>B+X;*.M5P6+]19,I_\
MYA[^O4:Z9OB>%T)MB=VWQ?V@KIK.EVQ/M]BG$';VJA.@FRZW[<VT[:0>TK^,
M5Q#I47W\=]G/W&KC'_Y(2=__ +/D]-O;Y'NU;BX;=<<])JE.?_J".W]^4?\
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M].\0/*J3>H%)I2?0*\S6YY.UG&^0DJH;,E:N4O7[OSD="["]B;/Q]NNW5=>
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M>2(4N+88) C9%CCOF5>,8M<N2[.96*P@W4Q(K,EW\/;E0YEL0@2^( GB6L6
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M5BV%_P"?AU1J>/:"Q;^Q]%>=N2U7X5 Y&H&54TQ'-9]A6D@[^95A;?BE9)!
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M?XI/_P!8<89ABV-74(X[)\FN-X&TCFC3YB!=Q([YJH CL"#3&_==;SE3X6%
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MOJ0KOW)MT+RVF=-_..MM,L)O_8D'V\"37F_ZH<-<KR]BS26$N/FBP'$$212
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M7C;SRZ=SM@\UYH=PQSCQ;IM$$L:$ZAIB0XXL>T!8E%B2P %S>O:/D7U"F_\
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M+FQ'<>5QZ#>]:_C=,])[?/\ .XNWXD62#<.L:@J>PKV*>XK;N%;\XQM<=L<
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M!Z$KZ _1]O[;CT5O_1\K7FP<J+-B';HF7PY+>@/$I];5P[VNL8;V'_OW <H
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MD3TPUTVUL(7!^!QYEW6V5-9O)%L' ?J+FBR7&KBK9C/63L2O@6U)FEPS)9C
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M C,H1DHF1M\- 01W5;QL>-/UB_%R!OV</P_]M=9?*R=O][O[;=V_E.?L^_\
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M1<:3;-^-W+N W_C<GXBFNY2R (FY/S<#N K,UABB=2"!^-*G795T_74BR/\
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M]OXM-M_E-O\ POY59=?]+JT7WS7OTZR^)QQT_1KS[GNPS91_'-6==E39=]6
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M8<BW,W'O@ &UK\3VKB/I]#BNPHY/'.)\5NO8;AG^KC$\US5,GNN4XG'J3!M
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M>$PVJ\:29*J\T!'-S?-#4D)#Z$;5NJCNJ)X O7IT155&P^=7F1DY*(V>H4L
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MKG&X8.=MN;+M^XQ209T+E)(W!#(PY@@_;W$6(N"*OX-[>*;[>Y.G7W_=U(S
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M/"M7S,F';]4N:?$SCQ"?P3V-SY7Y\^55+;(-[]B"'<X3CB VVVAF9*1$HM"
M"FZ]$1-D3PUV?9]HP=CP(]NVY=./&+ FVIO2QL-1])_%6GY67/G3G(R#=R?8
M/0!V#\?,U/XIK)U7_.'X=HJ$MNY%WWZ>[IXK[=]+5D&QO0B[_9IO,7J56O1N
MGO\ #Q^&BG5$2KNNRKM\%Z>":*4'2;U'I:E5M0O1HIU)M[?;HHI4_+]:JO1$
M3VZ#4B2:!:U:<R#EF%%>=BXW#"Y<;,FSLY#Q1Z<7!78DBJV)2;-!+=.\/+97
M;[KA:\$>='U[^7_E]N$_3?06+_63J&!BDDJR^%M\4BD@J)@&?)*G@W@J([@@
M3$UQKJ[SQV+8IGP-DB_:&>A(9@VF!6',:P"TA!X'0 O\<UJ3*LEOLTH+[%[]
M^N>H,EJ;"DMZMBHA?+R:ZSC.193*G-2>^A*VYN!H2$!HA)LJ(J>+-Z_Z@OU!
M[ED>)MS[+M^+?^;BPEDX7^$OD/*Q[B18]UC7'L[SXZ[RF/@'#@A/YJPAN'=J
MD9C[>'LK'^,"LN(L&Q?CW#Y[08YB=8W6P&+&L@2GI*^8Y(ESK"4PU$E2K"RF
MO.//NDYW&X:K[D1N)_U!/J#Q=QDRI'V6?;WE9EQY,)="(6)$:R1O'*0H]T,S
MLY NQ)O3<?SVZZQY2;XCXVHD1M"+ 7O8,I5^'*Y8D]I-;NI.7&U<!C)ZX(0$
MJ"MO6$\_";]G?,@N]\R*U[S;)\13=504W77K/RD_ZAO1O5&;%LGFGM_[ S96
M"KF0NT^#J/ >,K 3XZD_G_KHUYNRBYKJO2GGWL^Z3IA=30?(S,0!,A+P7_C@
M^_&/XWOJ.T@<:V^+K;X \RXVZR\#;K3K1BXTZTX"&VZTX"J#C;@$BB2*J*BZ
M^B<$\.3"F1C.DF/(@='0AD=& 965@2K*P(*L"0000;5Z#30R"2-E:-E!!!N"
M#Q!!' @CB".!%"ZD?X:?6-9)EM1BS+13S=?F21,H59#$')TI 78G$%P@:CQ0
M+H3KI""+T3<ONZY#YP^>?EYY';&N\=<93+DSZAC8D($F7E%>?A1W4!%-@\TC
M)$A-BQ:RG7.K^M^G^B<$9F]RD2R7\.)!JEE(YZ5N %'(NQ"COOPK3\_E'*)9
M%\A'JZ9E5^ZGE':S.W_#D2%8B(?_ &+"HGO77S0ZT_ZC_F+N.0\?06R[9M6!
M<Z'RM>;D$=A8!HH%/H".!RU&O-F\_49U%D2%=AP\;%@[#+>:2W>>*(#Z #ZZ
MTLUB\=GF&7SFW)VY!FX>QA3UC^'5/D+6L2?-^;&+\CY0VKL00B')1/-*(V+6
M_;KF/_W[_49X 09VV?->.7,GR$'%"H40E+:= 8%]0 D))!8J *U3_GEY@!O&
M$V-\S?XO C^&P&FUK6'._P 79>W"MT0>3\EBD/XA&K+AE%^_V-G4S.WV]CK2
MR(9%\"9%%]Z:ZGT3_P!2#K[;\A(?,+9-MW/;R1KDPR^'D =I56:6!SVZ2L=_
MX0K;]D^HW?L>0)O^%CY./VM%>&3V ET/J(4>D5M_&LJJ<F8==KS=;D,=B3:Z
M4(M3H9.*O83K8F8.QW%1>QULC;)45-]T5$^F/E-YS^7_ )W=/G?^A,SQ3"57
M(QI1X>5BNPX+/%<V#6.B1"\4ECI>X('I7I+K/I_K/ .X;%+KTD"2-AIEB)Y!
MUN>!_-925:QL;@BLGWUU$BQM6UZKU9+_ "&JQJ$DVT?(!<-6HL9D/.FSGT'O
M5B''115TQ'J1*HMMCU,A3KKGWF5YH]$>4?3;]5=>9J8FV!M$:@%YIY;7$6/"
MOO2R$<3:RH/>=E7C6%ZDZLV/I+;3NN_3"'&!LH U/(UKA(T'%F^X#BQ XUIN
MQY4R"41)50*^H8W^X<Q"M)ZC[S07(T%DO\%!>1/[Y=?,OKO_ *D'567D/C^6
MNQ8>%@ D)/GLV3.P_A&&)HX8[\].N6W>:\S;]]2>ZRR-'TS@0P07X/D$R2$=
M^A"J+ZKO;O-:1O\ &6,FY3PCF*VD(]F_']3=T^/SAKJD6 CW*(B.RHWR*MRI
M-3YLA81GW%'*4ZHJBJFW'_\ []?J*,,JG-VSYAY(V1Q@0#PE77K15L582ZEU
M%]3+H&@KJ:^C/Y[>84C^.\V+\R"-+""/W1QN .1O<<6N1;@1<WW+"Y.RR*2+
M+&JN&4V[FWHQ5LA4_P &5"(F!+;^^CDFM\Z0_P"HMYJ;9.B=:;5M&[X%_>,2
MOA3V[2K(982?TH@/2*V?9OJ/ZJQ9%&]XF'F8X/'0&@>WH(+)?UI6VL8S.HRA
M'&8R/0K-AOS9-3-\M) -(HBLB,ZV2LSHB&2(IMKN"JB&(*J)KZ2>2?U#^7/G
MMM\DO24\D.^XZ!LC R-*94*GAK !*30ZN'C1$J"0'",0#Z5Z*\Q.F^O<9I-H
MD9,^,7DQY+"5!RU"Q(=+\-:$@<F"D@5ENNZUO-&BBG)^7VZ0U:A^&E151%1%
M5$7=%3?HJ+[%3P5-,T+S[:G#, 0"0#S]-6*=C&-62J5ACU),,O%QZKAJZJ^_
MSA9%[_Y6LKB;WO> +8>9E1*.Q97 ^S5;[JUG<^C.C]Z8ON^T[;DN>9DQH68_
MV>C5]]61SC7!3153'FF"Z;+$GVT1$^@(\]L$^I-9A.NNKH1_3I&'\9(G_MD)
MK4,CR1\J<DDG9,9"?[V\\7W1S*/NJSR>/^.H4NKAS D19=U+?@U,9S(KP'+"
M9&@RK23&B!\^OF/,UL)Y\DZ;-M$OLU*/,3JWE\PG_N8?_P"'5(_3]Y376^W2
M#4> ^;S!?A<@?K^[C5X#B[!AV[J=Y_;V2+B\>3_N2LNU4^K0_7O5S<LO3^C%
M"#]HCO5Z'R%\I(?]CJ]OX>1EO]QGM5TBX)A<(D*/BU&ACMLX] :F.)M_AS4D
M'O\ 7K'9'574V6")]PRRI[!(RC[$TBMDV_RO\MMK8/@[#M22#DQQXY&_[4H<
M_?67L-,QF ;C-,QFME3R8S3;#2(G@B--" (GU:U>1WGE+S,SR7/%B6/VFY^^
MMWQXXL6,08J+% .2HH1?8J@#[JD7V:@;XC4R=M*'[2?7^A=)4E3:**F#]E/R
M]JZ**=MI:>& %JN/^AO^.?\ T=I/SO9^6DO_ )3?L\'^56:Y#_GZW_\ +7OT
MZR^)PQ(S_$%>;L_^G3?IFK.2]NR]>NI5.LV;E53G4*JJKNNI  !84M)I:*-%
M%&BBC15H<A1HI:79%3KO[>J*J+[=0NQ!L.5)3.]$54Z]-TW7K\-2?$O'MI:B
M4E5=] 4#E2@VY4(J^SII;"EU&INY%'JOL3?X_I]NDIX-C5NE5S$@O,%59=4@
M-3;4VD>5OS107_)-EUQ.QXTZ&*[$NZKK3>INC-JZAMD'5C;JOPY$7"1;FYO8
MC7>UO>/MK.[5OV;MI\-;28O;&W(]@L3?3;ARX<*L#L5YKRFYT=)30?AS?F@K
M8>8,*.ZU%8,E!N-$KV9;33KG>JNFBK]Y53?7.=XV[J+:\=EZBPDW3:4][QH%
MO(J+[H!C(OJ:^IK$UNV!O.WY3"3$E./EGFC<$)MV=G#EQM5 $5IU8PM2@>)U
M*\128!-DX"Q9K\N7^]('0@Q&5<88'S.PG&AV15\=$DZ5Z6W>1EV3-\+,4V,6
M1S!TAC?4%TVOV7)[;5M,>Z9N. <J-GU<VCY'MX#D:8V,X!8[PD*CC5<:=0D(
MOSX.-1O\>($;THVPD*J'V@R1(([IK7L[RXZAQ1XL<:RJ>(,;@W!XBVJPXCCS
MO62Q>H8BQ0S +_!8:6'KL>R@)1H@J0-IW()*1,21 0\PHS[B*V3R*VW/%&!V
MZFA":[#OK6INF]W@-IL?(2U[WC8V/=<7!]E9./=T/O(T;"W+Q%!^P\14GSO;
M_C&66E3J:F4M490%4)).;1551KW]FGMM_OF*BBCNNJIVC.5@/"EM:_\ -OV^
MRK W<,.*#V.MOQT)-/KW1Q;[5+S%5N8\;/D KLX2;!H$<>KV^U3!"^_WHH*J
M(NIX=BW&8V$,Y]43?N5"VZQKS"@^EU'Y:<CT]PA!0(#[MC;:1IM>]J*<^0R#
M[A/DO?$0?)=0% B)>\1V36:PNAM^S.*XTH7O8A!;M/$\;5CY^H8X;7ECX]@#
M.3Z@!2!%>(VBE2!;V*M(I#Q+^[;G0Y,F)8BW)[Q:863L#P^2ZQLVB[CLNMHQ
M/+R#"*R[]G18RG1=4(+6:Y%[\APYCMK$S;]).WA8B22,>5QIN?9SX<A4L<V&
MUBJTPX\^ 5RJC@N_N&W8#S-A"4!<^<.LEL(!-DR?E 3@_=3JFMGVAMLA;Y;I
M#;Y,W-*+9V0F.Z_'^M("@BX(MS[*Q6;+)8ON>1'!C\M X,2>5P/QT]J.^J,^
M>?EDRU$:065$7$2/'>:1HW&4:8?9%)!(*N-DZ@HB*?36^;?Y>9>YS#.ZTR!.
M.(&-$2(;7!C+'@69#JM8<CSK7<CJ%4C\+:D*<+>(UM5NT <0 >^]5C;8-"(-
M@( *;" "@BB;(B;(FR>":Z?##%CQ"#'1(X5Y*H  ]@K7&9Y&+R,6<\R3<TY%
M[D^A=E^GW:DI*"_9+Z/UZ7MI/SA^':*IM+5BE3?3'X+<<Z6Y'*F=VW<FR[^W
M?PZKMT^/73](M>IQ\-_12:90.(O2+I14J<J313Z-%%:_Y0DRHV%6BQ2,$DO5
MT&8XVJB3=?-FLQYGWDV4!=;-&B7^]<77FKZO-]ZAZ=^G;J3<>F6DCW P0PO)
M'</%CSSQQ9#J1Q7]4Q0L/A5B;CG6@>:69G8'0>?/MY99RB(67FL;NJR$'L]T
MD7[ ;UX8^L3G7G3ACD_*+S ITZ=Q1@?I$S7.>0</J,79NKVKLK#)+6AHN7\2
M=9@R;"=9\5S:^+(L*?9]B=0OS709*3%8!WXS^5_1W2'4_3V/A[O'&G4&5U'!
MCXTS2F.-D6-7?#E!8*J92LRQS>ZT<ZQ*6$<CE?+72NS;/N6W1QYBJ,V3-148
MOI!L.,3<; 27LK"Q#A02%+$:WXEYGY^IXOJ"]0?)5KR%EN!<5N976XKC[&=8
M:QC>5Y1$X\X^'%,$A\3UW$T/*2L\BS;)#8C6?\4FVY-D"JLHTJ &?ZCZ6Z,R
M3LO1FQ1X6/O&X>$TTA@F,D,1R<CQ9VRVRS%IC@C#-'\J"(U/O%@2<EG;9LLN
M/A;3BK"F7D$%VTL65/$?4Y<R6LJ@7 3X?2#>PP.0O4EE'%&.X?R/R=SSQ/SS
MQGZE^".,<[E5M3Q9C5KG_%?J+Y$PIJ%F5C3P<?Y(Q9EJIJ+6[HJN372P6._1
MN/R@5TE%+<VR=#;=U%/N>R8&S[CTAG;%GY4 9\N1,?+VW&GU0J[28TQ+ND&1
M*LB$,LZI&=-C4KX6S8>=)DXF/BS[;-AS2("9&"28\;G0"61[DA';4+6< 5W_
M ,>9SSLYSIG/%>4\23(G#V&83@[F(<UVN95%G;YM<R7LM@VDJSK8%7 9DV-J
MS2Q'I$>.#)U;AJ;R*$R.+?&=[VCH\=(XG4.W[DK=3Y67/XV"D+JD" 0LH5F9
MB%0NZJS%A*!9>,3DZ1N&'LO[)CW#'R0=SDE;5"%L$%E( ))-@20#?CRYJ;^B
MO$K\ES&YD9Q26)7W4J+7*NZH$<HT24_';5?_  ,>9(<043H/<HIT3;7V3^@3
M?.H=Y^GZ&+?&DDQ<#=<K%PW>Y)Q4$3A%)YI#+)+&G8H&@<% KUSY%9VX9G0"
M)FEFB@RI8X2?[V K:0>U4=F4=PX=E;1W_HV^'5.OYDU[5/*NQJ+FU<HY0_(E
M97DCTM2^8:MY,$0/?=B%!+R:]@$7]EKY51=1/!2=4O[2KK\]7U?;[U#O?U%]
M3+U"TFK"S1BXR->T>)$B> $'(*ZL9KCXGD9CQ->!_-W.W#-\PMR&>6O#,(HU
M-[+$BCPPH[B#KOVEB>-<#<F\I\C4?.%WC)9;D^&U==!XZ?XLQ&@XE_C^LYE2
M\6[_ -8LB\O1J7YM3_"CT=EEQ8EG5C1QFQL)8369 ,+H^P=.[#E])19XQL?*
MR7?)&7-)E_+MA: GRPCCUA7\4$D:XY?'8F&,Q,C-6+V_;-MFV9<C1'+,2_B,
MTOAF(@#0%6X#:CP%U;63I72037$-=ZBO6!32N,:OD_)\KP2#E6,X1DU[99'$
MX[K)KZWW%5_D%A:5^=4GIMRK#L=QV7F4=J"UCTVC>R.#/@OA)F!%DP_.ZO/T
M-Y9Y29^1L&/C9DN///%&L39+*/#RXXU1H'W.&:200DN<A)QC21R(4C,B2Z=J
MDV#IF43-MZ12LA<*%9R+AU !4Y"LS!3<N'"$$ +J5K=0^GKF_FG,/4SGN#95
M:V=[@$.PYPCPF#HZX&L=@8CFV(P.++"4[!XXPZ3CT3*<3L9SC#TJYR'\?-$?
M8:@ R0ES_K7I+I7;.@L/>-OCCAWATP"Q\1B9&E@F;+4!LF82&*98PRI#C_+_
M  NTQ8$:_O>S;3B]/Q9F.J)F,(KG626+(QD'&1PVE@!8)'IY'42#7IYB$B1%
MR_''(JDCK\](#XA_X>ODLN%-;<3VM--->=UZ"32+XIK=_HKWSJ'9_J-V#&V$
MR>!N#S8V6BWTOB&&1Y#(.1$3(LJD_"R@BU^.5\E\[<,3S%P(L$MHG9XY0.31
M%&9M0[E*A@>P@&NI4^]LOQ]OPU]]W;B0*]\5S5R&_(?S.R"2I=D&)71H#9*O
M:U"?B-2W76Q\$^9FF?>2?M*VB+^RFWP__P"H#O?4&?Y\G9=S:0;)M^U8OR2&
M^C1.GB3RJ.1:2;4CMSM$JG@MJ\1_4!G;A/UX<+)+#!Q\2(0K^;I<:G<>EGN"
M>?N =E>-OJ*]0/J^X_R/F.MPBCM++&97(=_C_$614G'"W,G%BQ/TO'G=CCV3
M*Y4VL6PJ,KSB='FT=T<9T$GP9M4]YG=%:<Y9T3T7Y:;SM^V9&ZRQIGKA1R9D
M;Y.@2B7=/EUEBLZ%7B@5DG@# ^&\60EK2,NM;+LG3&7!COE,HG$(:53+8-JR
M- 9>(-U7@RWY%7'YQ'5>59CS/QIP/GDJQI,QN^1:/CCD/*:_,I,_C;-*>JR"
MKI;VQQJMF!CF.<72LA;^9@1A\F)BJ.&LA&NYXD5S7.]OVOI;?>L,.."7%BV2
M7.QHF@"Y,#O&[QK(P\67+6/@S&[Y=AIU64>[6O8^'M.=N\2QO$N$TT:E!XB%
ME)4,1K:4#F><EN%^'*N*>1?5?ZAF?]7KV+S\AI,I*ES^5GO&LG"*M9M9R/0Y
M=PU'I>+ZWMXZR\>4@GX;DEM)J3JK;'1R,)"2FK*(#"LQ^K;)Y<]$L,U=P2"7
M;Q)CC'RA.VEL:2+-+Y3?Y3#\KIFBB642PY)QBIC:"0MJ?:L'IO8F$WCB-X!X
M?AR!R!H(FU2'WUT694#:DD\/D4/,^S->_(AW-/+@=R36+BO&(@JJFX4F6U$<
MBJ@K]\);#Q-F/@HDNN?_ $_[YU#T[YU],;ATN7&[-O.-!I4G];%/*L4\3#\Y
M'A9PX/"PU<U!&O\ E_G;AMW7.V3[06^:.=&@ _.21PCH1VAD+7'=Q[*ZV5Z.
MOF$+[*@V9 1HX"B))OL!*A+L7:GAX]-?HVEW#;HM9,\(B1]))D6P/&P)OP/#
MESKZ5-"^H@ _8>7X=M"NLH7:KS2%V=_:K@(O9LA=R?>_9[5WW]VD.Y8"OX;3
M0B0+JMK6]K7O:_*W&_*W'E3?"<]A^PTU9#"(VJR&4%TE!M5=;1'"%40A!5+[
MQ"J[;)UTG[3VXA&\>#3(;+^L3WCVA>/$CN%^SOIR+*M[ _8:D\UK9Q?-;_<]
M'OOC^Y7W.KOL"_3MIYS<0:SXL5H_C]]?=_2X\/;:K*ARH)!XTY"15[4(5+;N
M1$)%51Z+W(B+NH[+X^&IED1P"I!!%Q8WN/1WT<C8\Z5%14W%4)%\%%=T7KMT
M5.B]4VTX&XN.(HK5^=],WX-7_P#'O*5^K_51G?Z-(>)'KHE_G<?]-O\ RVK;
M"+NF^GU;I=%%3(*( K[2\?J1/UZICXS[?QT>BE7V:B;XC3T[:4/VD^O]"Z2I
M*FT44Y%5/#114R*BINGOV_+KHHJY?Z'_ .-]_K^0VT=OLJ+6WS-N%O"^[56:
M9#TO;?\ \M>7[=]93##?+1GLTBO.6>&_:$W^$-6%5W7?PU=J"DT44:**151.
MJ]$T44SS/A]O]6BBCO\ A]O]6BK =;<Z>ACXJOZ?U:8UR.%!=>^@C%15$7Q_
M7J,JUN5*./$<J@U,.5.HTM%&BE%.\>NWLV\5^WXZ2GTJ"IJ@IMNOAOOM[_9U
MTAY7I:XCXH]=_$/)^&-<FVM+EG$'%]C6X]88QGO*E[PZU7Y:_ET\X&+4-/C7
M'O+'(?($/*<A5LCAUME3P);^RL@"R?W&H$RHSQXJ.\V'V<:L/C2*VD$,W:!?
M\H K*,F]87I8I+WCR@D\NX183.3VF+JDL*2[K95%78M_JWS+F2)GN6WRRF*6
MEQ-<)P2;.;>D.&_V&TYY'DNJZ.!W;IWIG>#_ /I'%@DE8&S@!6&H<3J%C?AP
M)N:RV)N&Z8@MBRR*BD>[<D&W"UCV<;<*N,7U/>F=Q_#V8'J$XYB2\YLY5?B$
M:5D PY\^WJLCJL;EK*KI;<6=3O4V29+!K'"M68K,:1:18Z]IRHR.:C+Y<;?!
M)X^S[GG88+:@@?Q(P5%@ K<>!])YV[JSD74^>?Z7!%,0 +D6/?V<.7XKUCF)
M>L#TZ93C&/Y(O+6(XDU><?-\C!19W,BT%SC^(0:C^.&V\D62$NL@6U10E^)S
M("S7;)RJ,7T:1E1<6I_53K*)0,;=L>51&@ EB/"S78W%[V!N._MM5T;_ +6>
M#8;H^HW*$$'L[;'CRX<!Z:KK+U:^F>J2I9MN=N,:YS)(3\FLKY-F;%[+B6%]
M?53X)2.P$MJ^YE9=A]G65\.7':ERIE=)@@T]+:)I*C;'YAJ+>-M3G2_$@@WU
M64?#VK<WY"VGG5D;KLI?4$R0 0+ "UK7OSXVX _:.%2Q_59P+,?823RWQS61
M\@R"!1XG:.Y'CDBIS=_,,3X\R>/:XT[53+9^/BTZGY,HX[$JT&N5FQL&$7=N
M5#6183I[KR9^.?MT*DN 5C))#*MCRY7'$'B.=0R;QM)((@G9@/XH[>1X^B_W
M5E>6\\<-X->Y+C.9\P8GCF28DUCTO)Z!ZPE.WU YE@,0,)"775D5V6UD-]$>
M1*Z(VV<VT95Q\([C;3AA8'06[Y!"[QODV@:+K"BQ\OB <DL+GD0.7$CE4#=0
MQ+9L/$4-QXL;^H@#[Q]AK75;ZQ?3%8Y%DU' Y/QY^+@S\QG*<H6RJH.'U!#Q
M_P :Y_!.IL7;%F9E-?D.)\KTH0BI&+%AR9(*,:-O&TCV4P?+WI+$?7/&^7,H
ML6GD+\00X(' 7Y"X'+A;B:I9._[OD7LPC#=B"QMRL3S_ !<:RZZ]5'I\H^,\
MHY3@<G8CDV*8E26UQ*8Q"WK;.YL)-5@>2<F+C%13'*A/.YE887B%E-CUCRQY
M)-PGN\6_*<[=Z3Y;'BT0A$B''2H"COX 6%ZPA$KO=[ESVFY]',U<[GU(\!8_
M3UN0Y!S!@%+67'SXUAS,AAG)GRZC)PP:XJJZ!#*7/M+FHSD_P21$BMO2!MO\
ME0%>V%;'BQJH+,!>G(C6%@>=7[C/FCB+FB':6/$?).'\D5](=2%K.Q"W9MXL
M,;ZN2WH9)/-(@/U]Y5JK\.4UYD64 'Y3A*VX@L5U?X"#ZJE-QSX5L7WZE6D/
M$4[NZ;;>/N_3X:0@W]%'YP/X<Q46BK%(705^C?[=-(++84NDMR%0IJ7L]E6!
M<)8\[4]/!/JU%35N184BZ*F0$#C1HI](G5-T\-+RHJFFQ(T^')@S6&Y,26R<
M>3'=3=MYAT5!P"1-E3<5Z*FRHO5%W36/W7:]NWO;,C9MW@BR=IRX7AFAD&I)
M8I%*NCCM#*2#V]H((!I7QL?-Q9,3+19,:52CJPNK*PL5([B/WN-<[WW%MW6.
MN/4(I?UVR^6P;K+-W&:WW1@_/5J-9@&_0Q,'"3Q!5W)?D1YS?]/?J_:,^;=_
M)>:/=.GV8NN!/*L69!?CX<<LA6')1>2%GCFM8,'/O'RYU=Y$;MB3OE=(.,G!
M)N('8+*GH5FLD@'825?O!/&M?28,R"JMSJBT@JA(2A*J)K(H8JA"2$4;RB45
M%%145>J)LNO%&^^3'G!TU.8-]Z8W_'E6XN<+(=?8\:.A![PQ!KCN;TAU=MTA
M3-V[.C<7_N,A'VJ&'V&F,Q9$MQ!BUEC,=)0':-4SI!JH$1 BJW%+;L,E5-U3
M955=5]G\H_-C?IAB[+TUO^1*38!<') X][-&JB_:20.^H\/I7JK.<18>WYTC
M<> @D[>?$J!Z^-9Q2\<Y);. 5@TN/5^Z*X[*5IZU,/:,6O;)UN.9)X'((>WQ
M\LO#7KWRD_Z?GF9U/FQ;AYH.G3W388,\(=)MPE7@2B(A>+'U#AKE<LO,1,:Z
MQTIY#=1[G.DW4Q&!MUP2EU>=AV@*"5COWN21_ -;_JZR#2U\6KK6?(A0VU!H
M%)3,B(B<=>>=+<WI#[I$;AEU(R5=?87I+I/8.ANF\/I'I;'3$Z>P(!%#$MSI
M4<2S,>+R.Q+R.Q+.[%CQ->N=KVS;]EVV':=KC$6! @5%'8!VD\RQ-RS'B223
M5<2]J;IX^'P_3OK8F!(L*O5KK,L ;R)[\5JWVJ^[1IMI[SQ-8%HTRFS(3/*0
MGF)+(?<!\!->S83$D0>WQ_\ 4Q])73_GSHZDVK(3:O,>"$1KD%2T&5&G\W%E
MHOOW3X8YTNZ*=+*Z!0O*/,;RIV_KNVX8D@Q>H433XA!*2J/A64#WKKR5UN0.
M!# "VE;''\DIR5NQH[)I%[E1Z&T5G$=0-NXP?K_/^X.Z?MB"HBINB:^3_6_T
MH>?W060\>Y].YF7AK>T^#;,A91^</!O*HMQ_61(1VBO+>\>57F!LCLDNWSS0
M _'C_KD/<?<NP]3*#Z*LX.N$9 TW-)Q$[B;;AS2<1.FY$ L*:>*=537'/ZE]
M9"3P3M&Z"6_+Y3(O?U>'>M67I_J97\-<'<!(3R\":]_^Q615>)Y;>NP&*['[
M0@LG%;AR[%HZFM-10B,DEV*,H8@B+OY0.$O@@JJHFM^Z;\@O-;J65!%M4V'B
M,;&7+MCHH[[/^M:W<D;&MRV+R@\Q^H7"0[=/!C_WS)_4H!WV?WSZE0FMLXE@
MRXRQ97EC(KY5Y#?*J(5D*C$%'4!7FZQH1<=>\U##O?<0#<!%%!;3="^E_P!.
M7EET=Y!1R;VD4F\=?9>/X<N8R^''CHW%L?#C.HA&8+XLSD22@!0L:#2?6GEK
MY.X70*'-R'&3OTJ:7FL0D:$W*0@\0#;WG;WF  LJ\#LHVV6)!MR+>*W!2$C[
M-E'CDZRY/-%(:W[Y.M>:C8J6W<)D/NV7?TG/YI]23(!AX*B;5Q.EC<=@L>7K
MO[!76_EL;L>L(R[!6\J:BOM.3Z[*:>)(=N.^O-QF)5J@/BQ,BIY3[S#;SBD"
M@9. A$H[[J)>=//7RJG^H#"AGWN'Y3J+$5ABY*)<QHQU&"5>!E@+>]I)U(Q+
M(1J8-SSS%\K^GO,' 199?EMZ@4B&<#58'B8Y%X:XR>/,,AXKS(.E;##\OJ0A
M/2\?L7HMB+BUTZH;*WB3 :=1M5!(2',CDIDFP/LM&NZ=-?.GJSZ6?._I.1V.
MR9&XX Y380\=2.\QK:9?4T?M->..H?)WS Z=F93B-EXHY2XI\52O.^D6D7OL
M4'&L9(U9(Q<:ELFT: X+L.6TXTXI** X)LB;;BDBHB*B+NFVN42= =>Q3>!+
ML>\K-_!.%DW^SPJT0]/=0QR:&P,U90>7@2@W_P"Q5[K:')+=U(];26CI+%=F
M>9*:6IA#"9864Y)<FVI0HJ1QC[GNA$I#U1%UT;I'Z:?/3K2=8]IZ;W"''8_S
MV6GR<*CO+Y!C) _BJQ[A6T;/Y9^8&].(\/;LI(FX:YAX* 'O,FGAZ@?56VL-
MX]B0?P*VN[*IF3KYV36QHP*3[&+/I)"&[-;:56W+>Q-IU4!]$::CHJJ&Y??3
MZ >27T>OY:92=3=09469UHJD(8P? Q=0LQA+69Y2+KXQ5=()"*+EJ]4^5GE!
M@="Y*[]O$J9?4B@B/3?P8+BQ*7 +R$$KXA T@G2HO>MJ'.6/\W:([2?,8ZZW
M2)#%I%BV 2''F')8O]VR2VTAGN"?>0._8MB0E].#H+/E%Y9^-^_[SWGB:[O\
M\UK FQ]-/5MAMP*)+&M&)&AAE@378B*93ECN605\UI#0X4;9OM[BZ"':*IOU
M62/R]S&;4T]SIMQ/9W>KLI?G[&XO>CYP)+466Z_7-.9:^]5RVEA]Y5C,)P&V
MY$-H5$I2(!$9+]U$/9>J"J:K2^7^8"-,_(W''D?1Z>%#9W#B3PIKD@(R3I8.
MT;Q86XM:U&';R[R/)E.0W9)O*1-(ZT[&(T:'JV0DJ+X+IW]2=U-QXQX\^//U
M]]5AN%A>_/G3TKFGGVZ)HZ5'+",.2-SFE5AXA=86>5,+2*LAD7VV2!"4^Q0V
MW3ILJ'HOJ9/?Q<UD;D/>X@=W.G#<\12&="9 +7_?]5('RY-1;9NMKQB9 :TT
M& Q+5D*N6WVBLV3V=K;(2&Y *IMAW"*#NOWM]4I.F_,+& 6+.?PB2;:NWOJ1
M-QVXC2T;!0;CG6K,X89A9QPDS/ARS6EY"R>#?2&)+AO3WG>*\[%E^,VTZVXK
M#I"JB8B*H/15\=9O'B\P]OP,S,FS'EF\%2O&YU>(ER/3HU#AV&FR9F)-/$L>
MI=3GOX>XWX7K9Y1Y0!(B-,7"VSR-V=/#1L)0K0FWNU(E$&Z.JK:&;FYJ:*B)
MMTV6MB]8^86.4\4%U7L900?TCS/V]E7UEA!'ZP%0./I]OY:G0HAN=[-EV5;D
M4CA6$R*0E,L ^\Y7MHB-BZ0(2;H ]_141=^NKD7F9U? "F5AJUF^+2>7=P(%
MCV=H[Z<)D XL#Q^ZFL&\:5:J40G+=TF6XHO$,F$Z .&92Q,51 $0^\FPD*JB
M==]9B#S4)=FRL)U2W  F]_22.1^T>FG>/'S7B/R]U/\ F' 9G//,$C5;(2-+
M>8,9#*'T[G&E%?--D4)%W4454\$547;,8?F=TYDLL>1XD,A'O:A=5-^_@3?U
M4WYA> *L">?#@/;^Y4CLAM@Q;D(]&=(!<1J0P^VYY1)NCZBH*J1^U=R<_8%/
MVE36Q0=5].Y2&6/*C"W ][W3Q]'=Z>7?4R2H4U7]V]N/"JIMUH_N@X!%VB6P
MD*JHD**A(B+NHDB[HO@N^L\DL,K:8G1FM>P(/#L/"E'%KCB*D_+VZDTFI*45
MV7JNR=??_1IM+5X_T/\ \;?\!T=OLJ#_ #K_ !7\JLQR,M[VW1.G^7/HOQZ[
M:S&'_18_T!7G7<'MGS"WYYJR;:L7JGK]%&VB]&OT4U5V_+QTM/!N+U"I*OT>
M[12TFBBC111HIRKJHT584:5M1HI:-%%-4MOI]VBBD0U5=DW_ #I^I-)3P;\*
MD!SL)%W3N%=]NY$7[%14Z:0\13AP->=?"?\ +QQ?A:#QI10N3FKO&^)\SXPS
MC&8U=P/PAQWEEO:<36<NPQIOD#D/!\?K\HSX9#<]YN6[/)7G7362A"^JDM 8
M"\0S&Q%OR<N7W5>^?DN#8 @_AQY_?RL.P5C$O^6%QG+PV%QFYR]RJUQ@EHQE
MM]AT:OP('K_DJ#PSD'!57GJ9,_CDFXIWZW"[>*\E8QW5KUE5LNN 3+TF.[*<
M5"--SI]G=;GZJ1,IM=PHU=_'E>_XZJKST"VV3\P9#F>2\W9'=8QRQA&3P?46
M^F/8;4Y/R_DUSGW"]Q!I(4"%CIU/'&$P\'X7KZQ7ZE]+-2)XR)QYX9,>+Y+W
ME%_U8OZ^0 ]!Y6]1[^-6?FVLQ(&H_NW_ !\:QUG^5KQJU-HW9?,?)EU"QK&K
MK&J6MR3&N,<JC1(F0\'3>";6!\OE.+W=0>(N4DP[4:+Y)()V[\ER0LAM\ CR
M?)IVLW+MMW6IHR3W#G?[[UM/C;T%X+QO+I;!CDGD;()E-FG">;LC<.UKM>Q)
MX*Y7Y>Y<Q/&*2+*&RFT.");\QS8#%8,N1^&UL*,$9U#\PR3Y-=!0DFXM]E_W
M:><LDW"@'CR]G'[JL/%?\O/$^%)<&RXSYLY4QNV.BJ\*RBT"JX^GR\IX[K:/
MABI/$T2TQN=%QV7,D\(P)*VL1I9;:64YH1V6*<55PU4A@3<'\EOP_P#92G,)
MN"!Q_=O6Q.8?1E@/,-QG>2VV49)2Y%E_+'$'-%5,AQ:R;6XCFO#?%]OQ#2#'
MJ7TC'?4EWAN0SPFQY,D'A?D(Y'>:)L-.DPTF8NQ-_P#V?N4^*=PHTCAQK3\'
M^6QQA3ECGX#R9R#3,X-8XSE. ,Q:7 A;Q/D'$\:X!HJK,&HL?'HE58QOQ#TW
M8]8N4YQ6Z]7G9K*(++[:,GR@[SP]79;]P4OB-W#\+_NFKEFW\ORGY$DY/(R[
MU \L6R9[*EY'R"+F.\9,.Y1R!*X1Y4]/[>7-2(6+Q#Q^OK, Y7D#$I8B)#"3
M6PW'''5^8\]'PU8DDF_LYTHE8<E'X$'\E72@] N'47)& 9^G*W(5C!XJSV^S
M[CS"I-1A3%30S<KYF+GG)JZ9=1*9G(;UBQY ?>\EY]Y'H=<01VU4F_.-KXR%
MP6)(4GAP_.Y]E*)V"Z0+$C]ZMR>GWTT8MZ=(IQ<9R3),B!>)^"N($+(6ZIL@
MHN Z;+J7&K($K(L81L[MG,I#DX=O(%QH/)$$4D66*,1GAW ?93R=1OZ3]]=$
MZGHH]ND+=E%N-Z;MIE[<ZD5[FQIA^'7QVZ?G]WC[-/3E[:LQ=OKJ+3CRJ4\J
M?[$^K[51/Z=14U#;CZ*314RFXO32+MVZ;[_';13JB0B1-D7I]6E)O24Y3W3;
M;;P]NDJS#P7VTG326J;@:C==)IIQ44D06S7[I;;*@&NZ==NFVGJ[H/<)'J-J
M<K,I(4D</RUK[B"PG6?$O&5A9S9=A/GX%BTR=.F/NR9<R5)IHKS\F5(=(W'G
MWG#4C(E4B)=UTT2R.H#LQ'I)I(VD:)=1)X#F:SYP@%/%$1%V7HJ]5VV3P557
MKX:K9&3C8D33Y3I'"O,L0 .SC>I(U=F 47-4Y.[1GY;;3TB/&=\A\V!0A9>4
MQ:\MTB(4!1,T0O[S?<MM:9N?F/TEM4H@ERA)*5N/#&H'T7N!?[;5E(MNRI!J
MT!1Z3QJ=UDV)3T2;*A5I-0$FMNF7SC3Q.=&VA["8%$Z*JJBJJBJ*B>[0MQ\Y
M,G2!M. Y;5Q9SJ6W"U@ .)X^KASJR-H<BP8:JCCM#(<AM>59R)<6*=IDE03?
MR9QH(@3D<XG?Y+ZB!]I((KW/M(J^W6'/6/7N\!SBZX$>QLJCW0/X)M<7Y'O[
M:!!C8_#( ;N_+34:;=C0A,8;,7);8@C61._-6="TQ+9:.&_'4A4E)Q0V "[1
M%W8]T1=4Y.E^J=TD$F;G3O)IM<MQMW7[J2/+QXF)B0!A]M:\DY#=ES#=-I</
ML)7<5QVG:ZN%XJJ3(?Y!2O"6C9H1-V)0X_<+RB2MLIV^*[:RF-Y>M'MW@94I
M:;Q]6HDWTZ+:;WY=MN^FMN<QR@+G1X?*YM>_/\E;3;@!^+/505T]^ F*G-JH
M=A-'SH,P:QF:KE4JN?OG_,(D0]B15 U'MV[=6\7HK8=O8S9J1R*187)X'G?G
M3,C<LD >&6UD\2!V>GA5+"=W8P>T5*N,L:1):LI("Y(?1MN='4?Q!A0[W1^7
M==-7S3O+NWZ%OJQXG2^$PC6&$+>U^/#T\Z09F7)$REF-Q4GD2BK[^G:?;1V;
M?QK"MBQXGFPK%(SS@RWJ]QWN:,D5$)TMT_R8NT=UWTZ?J+8<#^CRJ/5:J\,,
M[&[ FJHC:.REW3KMP[#<IV: I)NMA+KK5R!&A>2^/<VDMN.^RG>[OL2OGML@
MZQ7_ #$P8W.A0UNWAQ]-6S@S-QTF_MJ!J$$+\'C/,M).P\'+.;&D63BQ["$[
M*9F-(TXI$133*+MWJFR&(JB;+JCG^9,#.A^7$I /'NX^BW.IHMNR7X@$5J_(
MS%>2.*Z9BY9@U&50^4KR6U\VZ;3+U;68R57^+L>:VU9R8'SA^6KJ"C;JDHIW
M$JJY/,B67;,B9,<JT;1 "[?GE_3V:?OH?;<PY,<3%BK!^''C8+W>NMEE8USC
MLNV5*U)$Q@L;F5R-/J#\1MMF$]<MD*$?6/& P;3]VB"G7JN^&/F-DD\8"3ZS
M5D[#,>)7C>CYV#&*,W'L675Q@1ET,QN"BE;O//#+=@2B%L@5D'FMD1M 7[Z]
M>NJYZ]W,_P!R-O;5@;#+_!-1!)K7F2@N/JW"N5&SM$9KS0J6R;5QQJ-%=("5
MD2*00;N"1=B(F^HVZ[W:_NQM:E_84E[Z34SMR!FY8&3B6DQC\&GQ_P ,(FSH
M7FF8JV+K:IWO2'8X"2%W**'O]WHND_K[NZ<=#4'8)CV&A+.-&1M691N_PT^Y
M+QPW82]]J\XZ4AZ(^J-IYT<9'W/N(VJ>82[KIG]?MT8\8R>-'[!D/YO&H_/K
M#9>K?G!;A71#;64M*[L2KM&$>VB1.@LLMNE)/HYN:]>JJ2:G_K[N9-A&U-_J
M\X_-_'3BL(3LA+9U:\I5M'+')T8F'(IQXG8,1NZ<5$\X#4&1<041 $"0?!5W
MD7S$R([>)CWE',\>-,.R9"^Z!P]5()U<9N.JE3/CATEV0CJ=K9W;4R2$V0U'
MC;*PT3:@C8D*D704).W;:8>9,[D:\>X7U]M1/L^6 !Q%_16JL_K&7<SX9JHR
MQ5GW6?Y3>-RH\UWLC1(W%6?&$&3),OF#?;=?3;;M$O+WZ;JB9_;O,))\?(+P
M!!'&I)]<J)_*JCD[9DQ/%>Y!9AR_B,?R5N)/*6?$MXHV42))I'*/'09DMR'(
MEN,)F$C#<<R(!BN&V[VN&73N55W7;5N+KK;Y/B532?(S_P $U3L1WB9Q2N>E
M266ZFW.1=J]':D#3S"D,(P^LPP;: ?DF44E;$NY2)5^]J\_5NQS(!+*MN[AP
M]'LIDN/.HL ;U13GI!UV93I05Y2;FZ@MNL^5(B&@#)^:<L8+N_S*QS,/W;J(
M@[[*O1%T^#*Z4W")BS1ZKV[*JH,Q6NNJPJYG#CLWK\9^O:>A4>+-/W+-;,\F
M/9RVH /-6P1FT3>2$B:V(^:2]6U4U7PU6;I'I?.>[>'(I'PG[CP(/"KS9N8L
M5@QO?T5;XKTI@,:D'*MRNKMUV \3T891?@B.L,L2(K+3?RS3J/27#/N/9>PB
MUC<CRXAD:^W2")>X'L[N=*F;(5*R\1^7]RE%V*,6>,=RLG5>)SVXP(T1-2KY
MB6^;9)W[=J+X.*B;J:(G39$U2EZ'W?"N<+*D0D6]UNP\QZJ?#F11&[+Q/XJJ
MB9E,O3(,>)**PD@W<TK$%P)E:W3.A\P1O**@H@(=ZDVBJ:J8H/@@ZAQ\OS V
M.58TR)9L.,BRM8J1S(/"]N?;5Y,Z-V'AV"_AVTC3_G/*$2?%DPU@_.-V$W_)
M&7'0W\Z*P8 #,AL>B]XDJ@*_>157;6>Q_,O<\2Z;IBAB3P(NOK%K<?0:M!Y]
M 8!68GU<*O?SI?PI^*?+.^1\W\]V][7?\I\A_CMN[P]O;^UM[/9K=/Z\[3^P
M_P"L&B7Y3Q?!TV&K7:__ &>R_P!U)J/S5['^;_E5G.1DJ7]SU_\ X]_W?WVN
ME8G]%C_0%><]Q_UA-_A#5F[R^"_3TU9JG1WE[_L3]6BBF$JJO72U,OPTFBG4
M:**:1;?2N^VBBH^\O?\ 8FBE#%>5'>7Y)HIWB-1WE^2:*/$:CO+W_8FBGHS,
M>/*FJJKXZ*EI-^WK[M%%,%>XOS^Q$7V^U.NDIX-ZEV3X_G7]>BEH445-M)2@
MD&XYU3DNR=4\=TV_7UT5/&Q;G4&EI]&BBD55]F@5-&JL+M4#A;]/:FWZ%TZK
M"@ 6'*H]%+1HHIP^&H6^(TT\Z:1)LJ==^G]&GV%6ARJ-?!=+2'E1J,\Z=2:0
MB_"CE43B)N*^W;]>GIRJ6-V%Q4::<>56@;KZ;4_9%1-]0T@Y4NBG D<JA<]G
MU_T:6IAQ -1Z*6C]7V]/Z-]%*&(%ARJ$Y++1*!.#WH@JC(+YD@N_?L0& W=,
MC45V1$Z[:Q^?NVV;:C/GSQ1:5N0S -;]'F?LJY'',ZC0I*GMM^7E5)8'+2%<
MNM,"GX7#><EMRS**\B%#==!&6B C<)$V5>B)LNR+OX<[W?S7V7"G3'VM&S&;
MG8E+'D +CB>_D+=M9/'V\O<SOH]E_36O^%A8:XCXL?<=E6=5&XHPJ3/6K:,#
MK9SU#6-QFY;@'WHT9JOCTV155%39-:7O?676^;D2X.W*,:**=PKH#J95)47/
M#APOZ35C$QL2''CD<AV*#AZQ6T8T9UB7C<*2["KI;C+UG67"]DTILMT)!1HM
M@R(]R%N.SI)]Y$#[NW3?#0]+]0;HQR-WR9"TWO,2#Q/ \03V?94_SF+&28XP
M&'I_%5L^=(JJ%<]LR0_(R20Q?1G1%JDFFPP,ECN!2 XC HR+:*2KYN_F+W(H
MJNPXG0G3^*OB9)&1->X)]W3Z+<;WYWO37W*60Z5%A5TFQ58?S.C$84.,3D2T
MK(SX%,\U0E]\;Y"62>4;\F&^@LM"2_=7M7;;=<F9]AVN,B<1IBCGR/'L^^H+
MY9.M')/=;\M5!HH3H=M(<LYK=1C(P,@:)P:^QA.'$=CJZ#I>4W+DDPI$V2]!
M0E3KN/;BY^O=EPC_ )'I91[*<,+*GXL3S[JMS P8#517/R:^"K!OWL*VC(3[
MT=H_DO+KY37:8*3SL1LE</<20-@0=M]:ID>8.?+_ #6/I/Z=_P"2*R\>R2N;
M6[.ZM7MV22N=);RP7W"M>'83E]7-,MQXC["\DV$EOY3S51&VG7&T=Z%WJ1*B
M*B=-0S]1[WE[/\PA*L<LKS[!$#^,TL>Q.=P\!A<B$-_WB*V<7S+[$I@8Z,J1
M %7+DRE>ETL(!1?E&VQV5(PN(JH'=NB&J;KOK77R]]S#IFG95''D?W:V&/I1
M NN1^'Z/[]5".VBR),P7H$5U^$->ZU%@BH&R*+YCI":M$+RJO[2[ILGM34!Q
M,J3A).3?T=_MJ]%T[ K 7N+]W[]4J-. $,$LIG;6CVUO83;10U\.]'&P$G5
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M_P#HU_OK^16CW_\ UB:>S]F?RZVOEYHF37J*O^DI*^"^\4]VVO9&#_1(_P!
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MX(FV8]$[3 D4"3Z4U2RT22(PR!6A:X92 586Y,IN"/013)462-HY &B86*D
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M&YULK@J%%XAYKY,],^0M1W\1LY2Y%Q^S9LC*AECN0OR;#'U8:>40)VFLGY$
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M76S*0-DV7+,_"+-R+<PWYM<!;/0S'R;.(&^RN13=V%X4VW0#7M5/V237E?\
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MRHJ+NB^W68!ORJA^.L=E95C\*]B8Q*N(<>]LFE>@U;I&+\MM.]?W)*'E$XJ
MJH'=WJB;[=4WUJ;JWIV#J!>EI<V!.HI$UICEK2,O'BH(L38$Z0=5A>UJR,6S
M[ID;;)O$,$C;7"X5Y +JC&W!K<1S'&UNR]ZO>WN368E))%ZQU/(FF6R>=,&6
MVP4W773%MML!3<S<,U0  4\5541-5IG6.,NY54',D@ >LGE2J&)LO%C38LN)
M.:\^#,BS6.Y0\^')8E,]X_M!YK!N!WC[4WW353'RH,R'Q\62*7'-QJ1@RFW
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M4XZ$]"L\+_A3/&&_O.&W0GY1V(-BF[TRI9\MTQ3[Q,L'MU3;7AWJ+>,SR_\
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MMT:**-%%&BBC111HHI=%%R.5'7XZ3A2W;TTJ?%>GT[Z#2J;GC01HG05W^/\
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M%%-VW\=1TM&VWAHHI=%%7K?_ -6]O_Q@_P#16NL6'_)2_;^W/Y%:!_ZFV_\
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M8?B/]&J7L_VKR%1^S_H[_+?43<_\VY4O_%*/^KKZM,;X?\VH_P"*4?\ 5YJ
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M/_9W^M__ (;X?_,K1_\ U _S_P#U=_COB_M*_]D
:                                   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img222477878_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #K 8\# 2(  A$! Q$!_\0
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M*S:.N,N:*EW"BBBI*"BBB@ HHHH EMO^/N#_ *Z+_,47/_'W/_UT;^9HMO\
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MRHR_:=P8$98=<T2>&]':5V;[3DL2<,.N:TD^^OU%(_WV^II^QI6^%"]O5O\
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M_>9O_",Z-_T\_P#?0H_X1G1O^GG_ +Z%:5%'L*7\J#V];^=F;_PC.C?]//\
MWT*/^$9T;_IY_P"^A6E11["E_*@]O6_G9F_\(SHW_3S_ -]"C_A&=&_Z>?\
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MT7]_]*/.B_O_ *47068^BF>=%_?_ $H\Z+^_^E%T%F/HIGG1?W_TH\Z+^_\
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MH\Z+^_\ I1=!9E67_72?[QIE/E_UTG^\:969NM@HHHH&%%%% !1110 4444
M%<S=Z[>0^();)-GE+J%G;#*\[)8V9OQR!735CWOARTO;B:X,L\4\L\-QYD;8
M*O$I52/P)IHF2?0T+B^M+2:&&XN(XI)CMC5C@L<XX_,5S.D>([N_U."69FBL
MKJ>6"%6@PI*E@H#_ -X[2?2NBM=/6WC"S327;JVY9+@!F7V!QQTJG!X<M(+V
M.=99VBAF:>&V9_W<<C9RP'_ F^F31H#N;%%%%(H**** "BBB@ HHHH ****
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M@CZ$9K8L?#]M;:MJ.HS10R7%S>&XBDV_-&NQ% S_ ,!/YUT?V:/^\U'V:/\
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M1DCW(/I7076@:5>WOVRYL(9;G"@RLOS87IS[5&OAK24U>WU.*QACN8$D12B
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MBCE#G1__V0
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img222477878_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ? "VD# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#G_' +>"=7 &?]')_+%>:_![4
MH+77KRQE8*]W$IB)[E"3C\B3^%>QWUI'?6%Q:2_<FC:-OH1BOE^Z@N=(U:6
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MABO7_"WAJU\*Z*FGVK&0Y+R2L,&1CWQV]*,35@Z7)S<S![&U1117FDA1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME.01[&G4@"BBB@ HK-UK7M-\/V7VO4[I8(^B@\LY] !R37+1_%WPJ\H0RW2
MD#<T/'Z&M(TJDU>*N!W=%(K!E# Y!&12UF 4444 %%%% !1110 445@_\)KX
M;.I_V=_;%M]IW;-N3C=Z;ONY_&J492V0&]1114@%%%% !1110 4444 %%%%
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M.1[\$FL#Q5K/BC5(;9?$,5PB1LQA\VV\K).,XX&>U.\&>,)O!E_<S"P2Y\Y
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCC/^N8'&XXZY/0>E$7PC\4RZ>+K9:HY7<+=YL2?3IM!_&N*.#BHIU96N*Q]
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M7B=5',#WJTCYKG[>[!QS6I#,"!5)G-.G8T :>*@1\BI0:LP:'4444""BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ***#0 A.*;O'K44LFW-47N\'K5)7'8U X-*#6;%=;CUJ]&^X4FK
M!8EHHHI""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** /$+KX-:_/>33)?Z:%=V8 R29P3_N5J^$OA;K.@^)[+4[J\L)(8&)
M98W<L<@CC*@=Z]:HKKEC:LH\K'<*^=?BM_R4*_\ ]R+_ -%K7T57SM\5@3\0
M;_ /W(O_ $6M7E_\5^G^01.[U_\ Y(+!_P!>EK_Z&E<_\$O^1@U+_KU'_H8K
MH->'_%A8/^O2U_\ 0TKG_@D"/$&I9'_+J/\ T,5LO]WJ>K_0?0Z/XU_\BM8?
M]?H_] >L_P"!W^HUO_>A_D]:'QK!/A:PQ_S^C_T!ZS_@<"(-;R/XH?Y/4+_<
MG_74.AS/Q?\ ^1Z?_KVC_K7L7A7=_P ('I.S.[^SX\8ZYV"O'OB^"?'3X'_+
MM'_6O9?!W_(EZ)_UY1?^@"EB/]WIB>Q\T6?VS^UX?L)<7GG#R=I^;?GC'OFN
M[\OXJ>NK?]]"J_Q#\"WF@ZK/J=C"TFF3N9 T8_U!)SM..@R>#4%K\5_%5K9"
MV^T0RE1@2RQ O^??\:[9-U8J5-)^I13O/!GC/4+R2[N])O)9Y#EY& RQ]ZW?
MBFEY%IWAB*Z5U=++$BMV<!<Y]ZC\":IXQU+Q:-0MS/>1R,J7;S$B+9Z9Z C.
M0!^76O2_B%X3;Q5H'EVV!?6S>9!DX#>J_C_,"L:E9PK14[6785]3,^#OD?\
M"%MY>/-^TOYOKG Q^E=^XC.TR!>&!&[L>WXU\QZ7KGB'P5?S16[S6<I.)8)8
M^"1ZJ?YU9U3Q?XG\6SP6KS2R$2!HH+5-OS=C@<DBHJX*4ZCFGHPL?2;_ '&^
MAKY<TS_D<K3_ *_E_P#0Q7T;X776!X=M5U[RS?[</MZX[;NV['7%?/OBO1M0
M\+>*Y]\;1@3&:VE ^5EW9!'T]*G V4IPN"/IJOF.W_Y*1%_V%A_Z-KTGX=>/
M]8\1^(I+#5'B,9MRT?EQ;?G!'7ZC->;VX/\ PL>+@_\ (6'_ *-J\+2E2E.,
MNP(Z+XS^9_PF-OOSM^QIL^FYOZYKTKX8"$?#_3O*"\[]^W^]O.<^]4?B=X,F
M\2Z;%>6"AK^S!PG>5#R5'N#R/QKR'0_%GB#P@\UM9RM"I;,EO/'D!NF<'D'C
M%*,?K&'4(O5!NCT[XUFW_P"$;L ^/M'VK]WZ[=IW?KMK"^&!D_X0SQ8#N\OR
M&QZ9\M\_CTKB;V_\0^.-7C$OG7UT1MCBC3A![ < >]>T:)X8/A7X;ZA:2E6N
MY;6:6<KTW%#P/7 XIU$J-%4F]6_U#9'E'PR4-\0--R <%R,_[AKV[QUSX%UG
M_KU:O$_AB"/B!IW!_C_] ->V>.O^1&UG_KU:HQ?^\1^7Y@]SR7X,_P#(ZS?]
M>3_^A)7O=>"_!H$>-9LC_ER?_P!"2O>JRQ_\;Y">X4445Q""BBB@ HHHH ;L
M4G[H_*@QH1@HOY4ZB@"+[-!_SPC_ .^!3);&SF39+:P.O]UHP15BBG=@4?[%
MTK_H&6?_ 'X7_"HYO#NB7  FT?3Y .@>V0X_2M*BGS2[@8__  B?AS_H :7_
M . D?^%0R^"?#$S!GT&P!QCY(0H_(8K>HI^TGW8'._\ "!^%?^@%9_\ ?%0/
M\./"+N6.BQ DY^61P/R#5U-%/VM1?:?WA<Y3_A6OA#_H#1_]_9/_ (JJW_"J
MO"7_ #X2?]_V_P :[2BG[>K_ #/[PN<2_P */";H5%G,I/\ $L[9%0?\*@\+
M?W+S_O\ _P#UJ[VBG]8J_P S'=GG\OP=\,NH"->QG/42@_S%0_\ "F?#W_/S
M??\ ?:_X5Z-13^LUOYF%V>:2_!71'8&/4+Y!CIE3_2H_^%):1_T%+W\E_P *
M]/HI_6ZW\P79Y3)\$+(N3'K,ZIV#1 G\\TW_ (4A:_\ 0:F_[\#_ !KUBBG]
M<K?S!=GCO_"C9/\ H/K_ . G_P!G2/\  Z8(2FO1EL< VI /X[J]CHI_7:_?
M\$%V>*?\*1U+_H+VG_?MJCE^"6KA,PZI8NV>CAU&/J :]OHI_7JW<+L^2]2L
M)=+U2ZT^9D:6VE:)V0G:2IP<9[<55KH?$EG<W_CW6+:T@DGGDOY@L<:Y)^<U
MW?A7X.N_EW?B*4H.&%I$>?H[?T'YUZLJ\*<%*;*N><:'X<U7Q%=?9],M'F(^
M^_1$_P!YN@KV3PK\)],T@1W6KE;^\'.PC]RA^A^]^/Y5WMC86FFVJ6ME;1V\
M"#Y4C7 JQ7F5L;.II'1$MB*JHH50%4#  & *6BBN(04444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !16#XK\5V?A'3HKR\AFE
M$LGEHL0&<X)[GVJEX'\9-XQM[ZX^Q"U2WD5$7S-Y((SDG K3V4^3GMH!U=%>
M:_&%]7CT>Q;3VN5M1(WV@P$C!P-N[';K[?I5/X-3ZU,NH_:Y)Y-/ 7RS,2<2
M9YVY]NOX5HL/^Y]K<=M#U:BBBN<04444 %%%% !15/5=1ATC2[G4+@,8;>,R
M.$&3@>E<CX5^)$7BSQ&^FVVGO! D#2^;))EB00,8 P.OJ:TC2G*+DEH@.ZHK
MGO'#ZI'X/OVT??\ ; @P8_OA<C<5]\9KR/X8W>OR^,K=8IKR2U.?M0=F*!,'
MDYXSG&*TIX?GIN=]AV/?:***YQ!1110 4444 %%%% !1110 &JMPV%-6C5:=
M=PIH$8\\AS3(I#N%3S0$GI38H#D<5K=6+-*V8D"K@JK;H5 JT*R9+%-,8TXU
M$YQ2!$4KX%9MS/@'FK%S)@&L.^GP#S6<F=5*%RO=W78$Y-2>79Z+:K?ZOEYV
MYAM1U/U'^<469@TZP?6KX;@IQ;QG^-O\_P!37%ZA?W&IWLEU<ON=ST[*/0>U
M=V P/UA\\_A1M4G]B/S+FK^(K_5W(ED,<'\,,9PH^OK63117TL(1@N6*LC)*
MVP5T$X.O?#G4[2<>9-IP$T#'JH'/\@P^E<_72>#&674;JPDR8[NV>,C_ #[9
MK#&1O2<NJU!NWO=CQYA71:#XZUO0"L<5Q]HME_Y83_, /8]1^%8=S"UO/+ X
MP\;E&'N#BJS5S.,9JTE<[:L4SWOPY\2M#UH+%<2?8+KND[#83[/T_/%=LC!E
M#*05(R"#D$5\EFMG1_%NN:"0+#4)DC'_ "R8[D_[Y/ _"N.I@$]8,X)T/Y3Z
M=HKQG3OC1?1X74M+AG'=X7,9_(Y!_2NCMOC%X?FQY]O>P'OE P'Y&N26$K1Z
M&+I370ZWQ-_R+5__ -<C5ZPD673K:1#E6B4CZ8%<'JOQ)\.ZKI=Q86LUP9YT
MV(&A(&?K2VWQ2\.Z=IMM;.;J2:&-8W5(NA P>2?45S*C5]NX\O1?FSH=.7U9
M:?:?Y(]#HKRB^^-<(!&GZ.[G'#7$H7'X '/YUQVK?$KQ+JRM']L%K$V1LMEV
M<?7K^M=D,%5EOH8*C)GM>O>*]&\.Q$ZA>*LN,B!/FD;\.WXUY7X@^*^H7X:'
M28?L4)X\QB&D/]!_GFO.W=Y'+NS,S')9CDFE%=M/!4X:RU9TTZ,5N32S37,S
M2SRO+(QRSNQ))]R:[_X76<4=YJ>M3(&&GVY*9[.V?Z C\:\^45Z=X6B^P?#.
M^N2 'OKH(#W*K@?S#5I57,E#NTCHK:4GYZ%.XN);NYDN)F+2R,68^]1445ZJ
M5E9'*3VEY<V$XFM9GBD'=3U^OK79Z?K5EXD5;740MOJ'2.=1@.?3_P"M7"T=
M#D5SXG"T\1&TEKW#K=;G<2)/IUV;>X&&'0]F'J*U+6XR!S67HVHKXCT\Z;=O
M_I\*EH)F/WQZ'^M):RO%(8Y 5=3M8'L:^5KT94*CA(V3]I'7='5PR9'6KB-F
ML:UER!S6I$V0*29QU(V+(I::#3JHQ"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0TM(: *5SG!K'E)
MW5O31[@:SI;4ENE:19295@)W"MBV^[5.&V(/2M&)-HHDP9,.E%%%9DA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTPQ@]JDHH C6,#M3P,4M% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5D^)M).N>&K_ $Y2 \T1"$_WAR/U K6HIQ;B
MTT!\P:!K6H>"O$GV@0%9HB8I[>3C<.ZGTKN]<^,RWFCS6VF:=+;W,R%#+(X(
MCR.2,=37HFO^"M!\2.)=0LQYX_Y;1'8Y'H2.OXU@0?!_PS%*'?[9*H_@:7 /
MY"O2>(P]1J=2.I5T>=_"OP[/JWBJ#4"C"SL6\UI,<%_X5^N>?PKWG4=/M]5T
MZXL+I-T$Z%''L?ZT:?IUGI5E'9V-O';V\8^5$&!]?<^]6JY,17=6?,M+;";/
ME/6M%N=&UZYTJ52TT4NQ<#[X_A(^HQ7T7X)\/+X:\,6UD5 N&'FW!'=SU_+@
M?A3]1\'Z3J?B*TURXC8W=KC;@C:V.06'?%;U:8C%>UA&*^8-GD7QG\/SRM::
M[!&7CC3R+@C^$9RI^G)'Y5S/@_QWINB:>+#5]#AO8T8F.98T,@!.<'(Y_.OH
M&2-)HVCE17C8896&01Z$5Q.H?"?PO?7!F2":U+')6"3"_D<X_"KI8F'L_9U5
ML"9Y_K/Q,LI6C71O#=A H8%WN($8L/3 &!7I$5[I^J?#;4=2T^Q2T2XL)BZ+
M$$^8(P/3J,YP:CTWX6>%].G69K62Z=3D"X?<O_?/0_C76W%I!<V,ME)&/L\L
M9B9!P-I&"..G%16JTG94T] 9\]_"S_DH-A_NR?\ H!KZ!U*.272KN.'_ %KP
MNJ?4J<5BZ3X#\/:)J,=_8631W$>0K&1CC(P>"?0UTE3B:T:M12B#9\M^&KS3
M])\36UQK-D;FUA<B6$J"0<$ X/7!YQ[5U?CGQKH&K:9_9VAZ4D6]@TERT*QG
M YPN.?SKTO7/AMX=UV[:[EMWM[ASEWMVV[SZD=,^]0Z;\+?#&GB4FVDN6D4I
MNG?.T$8.,8P?>NIXJC)JH[W0[HX3X)C/B#4@?^?3_P!G%<KXKTF]\)^,)@H>
M/;-Y]K+CAESD$?3I^%>^:'X/T7PY<RW&F6IADE38Q,C-D9SW/M5S6-"TS7[3
M[-J=I'<1CE=P^93Z@CD5G]<BJSFEHQ7U/-;3XW0+8(+S2)7NPN&,4@",?7GD
M?K2^"_BAJ6L^*&L-0M?,@NV_<B!,F#COZKZD]*V7^#OAEI=P:]5<_<$HQ_+-
M=3H7A;1_#<;+IEFL3.,/(3N=OJ34SJ891?)'5AH<?\9[6:;PI:S1H62"Z#2$
M?P@J0#^9%<'\/_'UOX/MKV"YLI;A9W5U:-@""!C!S7OUU:P7MK+:W422P2J5
M>-QD,#7%2_"/PK)<>:(;E%Y)C68[?UY_6BCB*:I>RJ+0$S#^*6I1ZO\ #W1]
M1B4HES.D@4G.W*-Q4WP2_P"0%J?_ %\K_P"@UV=QX-T2ZT.UT::U9K&U;=%'
MYC9!Y[YSW-6="\.:9X<@EATN PQRMO<%RV3C'>I=>'L'27<+Z!XDT2+Q#H%W
MIDN!YJ?(Q'W''*G\Z^9(])O9=9725A;[:9O(\O\ VLXKZPK"'A+2E\5GQ&(F
M^W%-O4;<XQNQZXXHPV*]BFG_ $P3L6O#VC0^']!M-,@QM@3#,/XF/+'\3FO&
M_C/#,GBZWF<'R9+51&<\9#-G^8KW>LS6] TSQ%9?9-3MEFC!RISAD/J".E9T
M*_LZO/+4$SRG1/'?@[2O"UM;OH1EOX8PKJT"$2/CEMY[$^V17FT]VU_K#W;1
MI&9IM^R-0JKD] !VKW-/@]X92<.QO'0'/EF48/MP,UJ3_#?PK/.LITP*R@ !
M)&4#'3@&NR.*H4VW&^H[HO\ B^VEN_!NK00(7E>U?:HZDXS@5X!X)\3+X2\0
MC4);=IXVB:)T4X;!P<C\0*^FZXW5/AAX8U2Z>Y:TDMY'.6^SOM4G//'09]JY
M\-7A"+A46C$F9M]XMMO%_P --?N[>WD@$*&,I(02> <\?6O/_A'_ ,C[!_UQ
MD_\ 0:]CT[P3HFEZ->:5;P2?9;S_ %RO(26_'M3='\#:!H.H+?:?9M%<*I4,
M9&/!Z\$U4<12A"<(IZ[!<\=^*6@7&D>+9KW8?LM\WFQOVW?Q+]<\_0UT.B?&
M9;/2(;;4M.EGN84""6)P X X)ST->M:CIMGJUD]G?V\=Q;O]Y''Z^Q]ZXJ?X
M/^&992Z?;(@?X5ER!^8JHXBE."A66P7[GCVNZSJ'C7Q+]H,&9YBL4$$?.T=A
M^O6O4_&FDG0O@Y%IC/O>#RE=AT+%\G'MDFNNT#P7H7AMS+I]F!.1CSI#O?'L
M3T_"M#5]'LM=T]['4(C+;N0Q4,1R#D<BE4Q47**BK1B%SR3X(?\ (7U7_K@G
M_H5=)\9_^10MO^OQ?_06KJM"\(Z-X;FFETNU,+S*%<ERV0.>YJUK>@Z=XALU
MM-2A,L*N'"ABO.".WU-1*O%XA5>@7U//?@A_R"=5_P"NZ?\ H)KU2LG0O#>E
M^&X9HM+MS"DS!G!<MDCZUK5C7J*I4<EU!A1116(@HHHH **** "BBB@"-ZI7
M'2KKU2N.E)FD#"U \&LN_;R?!UTPY\^Z5/ICG^E:>H#@UE:AF7P?<(H_U-VK
MM]",5I@[?687[G;+^%]QR%%%%?7F04444 %%%% %OQ>GVWP#I-W@%[.X>W8^
M@(R/Y"O.&KT\)]N\#:]9X):%4ND'IM/S'\J\Q:O,2Y9RCY_GJ==!WIM=F0FF
M&GM336J(D)111007M'!.J0X[9_D:AO\ _D(7'_71OYU8T7_D*1_1OY57O_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%JW]N^(K[4PA1;B4LJGJ%Z 'WP!6.%I3C6FVM/\ @B6YZI\8O^13T7_KL/\
MT"J?P>\-Z9J%C>ZI>VL=S,DWDQK*H94&T$D ]SG]*N?&+_D4]%_Z[#_T"K7P
M4_Y%>_\ ^OP_^@+67,UA-._ZAT.,^+.@V>B^([>6PAC@ANH=[1(, ."02!VR
M,?K7:?"WPMI$OA"+4KFR@N;F[9]S3(&VJK%0!GITS^-8'QO_ .0OI7_7!_\
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M>E&*J.R=^[&?0W@6Y>[\#Z/+)][[.$/.<[?ES^E=#7,?#O\ Y$#1_P#KD?\
MT(UT]>-5_B2]60%%%%9@%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[UNWOA/3M2\+6^@WH:6&"%(XY> ZE5VAAZ'_ !K>HINM4:2OML%SQZ;X'O\
M:/W.N+Y!/\=O\P'X-@_I6D_P4TIH(434[I9$4^8^P'>?7'8>U>GT5H\96?VA
MW9G:#I":#H=KI<<K2I;J5#L,$\D_UK1HHKG;;=V(****0!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)"SE#M->NV?Q<T&[LU&K6,T4PZHL8E0GU!K'\6?%:&^TR;3=#M71)D\MYYU
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** &FJ\PX-634$@XI,J)CWBY4
MUS=RQ@N(YEZQN&'X'-=3=K\IKF=13(:LIGHX=F!XA@$&OWBK]QI/,7Z-R/YU
MF5N>)$WG3[O'^NME5C_M*=I_3%8=?886?M*,9>1A:V@4445T %%%% !6#XM0
M#7#("I$T$3\?[@!_4&MZLGQ>@+Z9,&)+VFTY'0J["N;$]&;4'[YR^YD<.C%6
M'((."*T/[>FF4+J%M;WX' :9<2#_ (&,'\\UG-41K#E3W'46IT^E+HUZDK'3
M[B(J1PEUD?JM1ZI-I>GSQK!I0E<KG=<3LPZ^@Q47AS_57'^\/Y5#XB'^DP'O
ML/\ .OGZ=:?]K.BW[O;_ +=N>E*C#Z@JG7_@E>[U>\O8Q"[K';CI!"H2,?@.
MOXU62HA4R5] TEL<-)'=V:B/PWI*!0"R22L0>I,A'\E%+4\HV6.F1;5&RQB!
MV]\C=G_QZH*ZJ"_=HYI.\FPHHHK8D**** "NL>/RK?3;7O';!V'NYW?RQ7,6
MT)N;J&!>LCA!^)Q777;++K5SL^XC>6H] HQ_2O$SJ=H1AW9M07O7[&E8ITK>
MMQP*R+).E;4(X%>)$PK/4LKTJ04Q>E/K0Y&%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 AJ-S3S4,C<4F-%.Y? -<_J$O!K8NWP#7-:C+P>
MYK*;._#QU)K20V'A[4]3SB1QY$1]SZ?G^E</76^*V^PZ3IFE X;:9I1[G_\
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MVH/>'S.@M'RHYK5B;(K LI,@5M0-P*X(G-5C9EP4ZF*>*?5G,%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)37S,4^X4445T#"BBB@ HHI55G=412S,< #J30!T?@JQ%QK)NY,""T0R,QZ
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M:=IX2XC5?F((^S  91>/F!Z9XZ5Z;X'F-SX'TEV?>PAV$YST)&/TKYQKZ.\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **:7 J,S*.] $U%0B93WJ
M0,#0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BD9@JEF("@9))Z5S]_XY\-::Y2XU: N."L
M69"/^^0::3>Q482EI%7.AHKC5^*7A0RLAO9@HZ.8'P?TS^E;.F^+-!U8A;/5
M+=W/1&;:WY'!IN$ENBI4:D=7%FS1114F84444 %%%% !112$XH 9)(%%9EUJ
M CSS3[ZXV*>:Y*_O27.#6M.%RXQN;$FL '[U":P"?O5R;3L3UH6<@]:W]DB^
M1'>VVHB0CFM2.3>*X&QO"''-=;87&]!S6-2%B)1L:M%(#D4M8D!1110 5XE\
M7=%>TU^+54!,-X@5CZ.HQC\1C]:]MK(\2Z!;^)-#GTZ?Y2PW12?W''0_Y[5I
M2GR2N;X>K[*HI=#Y_P!#\7:WX<!73KUDA)R87 ="?H>GX5HZA\2O%&HVS6[7
MRPHPPWD1A&(^O4?A7/ZKI=WHVI36-]$T4\1P0>X[$>H-4J]-4X/6QZKA3D^:
MR-?0/$^J^&KQ[C3IPIDQYJ2#<LGU']>M:U]\2O$M]?6]T;J.'[.^](H4PA/3
MD')/'J:Y&DJ_91;NT1*,6[M:F[XE\6:CXJFMY-06!3 I5!"A4<]<Y)]*PJ*2
MMH0459$:15D7=)TZ?5]5MK"W&99Y @]O4_@.:^H[:VCL[.&VB&(X8UC0>P&!
M7G7PN\%OID/]N:C$5NIDQ!&PP8T/5B/4_P OK7I=>7C*JG+E6R."O4YG9=!C
M#-021Y[59(II6N(Q3,N:#(Z5FSV><\5T+QY'2JSP ]JEQ.B%2QRKVCQR!XR4
M<=&7@BKD&N:E;#;)MN$_VQ@_G6I):@]JJO9@]JBS6QT>TC-6DKE=[_2[H_Z7
MHL;'N0JG^E.CU&RLE;^R],CAD?JVT#^5.^Q#/2GI9@'I6GM:C7+?0GEI=C,=
M+B\F\VX=I'/<]OI5^WM,8XJ[':@=JN1P =JA1%.MI9$4$&!TJ[&F*$CQ4P%6
MD<LI7 "GT@%+5&9XEK__ ",&H?\ 7P__ *$:L>$_^1IT_P#ZZ?T-9^H$G4KH
MDY/G/_,UH>$_^1IT_P#ZZ?T-?,0=ZZ?G^I]Y55L+)?W?T/9"*C9<BI::17TY
M\(BE-%D'BLZXML]JVF7-0219[5+1K"=CEKBS.<@8-6[;5IHHC;WT0NH#Q\PR
M?UZUIRVX/:JCV8/:H2:=T=//&:M(J"XT*$[HM$CW?[BBG/K]R$,=G:0VZ]N,
M_ITIYLAGI3ELAZ54JE27Q,$J2Z&5*+J^D#W4K2'MGH/H*MV]EC'%:4=H!VJU
M';@=JE1'*MI9%:"VQCBM"*+&*>D0':IE7%6D<LYW!5Q4@%(!3JHR"BBB@044
M44 %%%% !7EGC:[EU'Q/]CB4OY 6)$'=CR?Y@?A7J=>::<8O^%G3>=C_ (^)
M=N?[W.*TI[MG3AM&Y=D6K/X?1I;K)J=_Y3M_!'@!3Z9/6LCQ)X1ET.!;J*X$
M]LQP21AE/;ZBK7Q$-Q_;4*R;OL_E Q#MG//XUSDIU*86<<PGD4@"V60$@C/0
M9ZUO!2=G<Z8.;M)RW*JQ2.I9(W91U*J2*GTVR&HWT=L;B*WWY_>2G"C%>IPR
MZM!<6L<[:5:128!MLG>P[@'@9K"\4QZ3I7B:SO;JQ\V-XF+Q(  S@\$CO_\
MJIQJ7=K$>W<G:Q@7WA&YMA9-:W4%ZEX^R-HN!G'\N#S[5J>%HKSPYXN_LR\
M47,>/E.58CD$?D15'7_$UKJ1MY[&.ZM[J!P8RSC8@'HHX]*HZ9J%WJ'BS3[F
MZG:29KA 6/'&>F!P*OEE*/O$OF<?>/9:***X#B"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHS0 449HH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ]?U/OJO^[R_PO\ (]GHHHKZ@^!$(IA7-248H KM&#49A'I5K%)MI6*4BIY
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M_P!GT7\*=>:A#S9G5G9'04445YIR!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !112&@!&;%0-.!WIMQ)M%94LYSUJXQN-(V%F![U,
MK9%8<$Q+5K0OD4G&P-%BBBBI$%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_'2!^%=A7EOP58_V;JR]A+&1^(/^%>I5PXB/+4:1PUE:;L%%%%8F84$9HHH
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M4$DX Y)->1^+?B_)!=R67AY(F5"5:[D&X,?]@?U/Y5K2HSJNT0L>NT5\Y_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]+5SXN+3BWN<F)3NF]PHHHKC.8**** "BBB@ HHI"<4 +13=XH# T .HHHH
M**** .2^)6JRZ3X'O9(&*RS;8%8'!&X\_IFO,OA/X6M==U:XOK^)9K>R"E8F
MY#.<XR.X&#7H/Q:M'N? D[H,^1-'*WTSM_\ 9JY?X):C"CZGIK,!,^V9 ?X@
M,@_S%>C2;CA9..]REL>O"*,1^6(T"?W=HQ^55=/TG3]*\_[!:16PG?S)!&N
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M49 5CU_"IO''Q!U_0/&=S8V<\8M(O+(C:,'.5!(SU[FN0^'7_)1M+_ZZO_Z
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M_9X?/F%N I?"EOF[?-6'\/=-D\2^/X[JY =(G:\GST)SD#_OHC\,UZY\2_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*UO/',@!:-@PSTR*\*+LTSZZ2O%I'O5%>7_\+$UC_GC9_P#?MO\ XJGP^/\
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M6;"YX/\ &!&;QOPI/^C1]!]:]JTG_D6+'_KRC_\ 0!5]X(9&W/$C'U90:>
M,  #TK"I7YX1A;8+GSS\-$8?$JQ)4@9F[?\ 3-Z](^,(+>"  "3]JCZ?1J[M
M;>%&W)#&K>H4 TYXTD7:Z*P]&&:NIB>>K&I;8+GEWP24KI&JY!'[].O^[7J=
M,2*.($1QJ@/7:,4^L*U3VDW/N)A11168!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^==S6?HNEQZ-I4%E&<[!EV_O,>IK0K@J2YIMHXYOFDV%%%%02%%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%8FO>+M$\-K_Q,KY(Y2,K"@W2-_P$?S/%.,7)
MV2 VZ*\HO/C=9*S"ST>XD Z-+($S^ S5#_A>-U_T 8?_  */_P 372L'6?V1
MV9[-17C/_"\;K_H P_\ @4?_ (FC_A>-U_T 8?\ P*/_ ,33^I5^WXH+,]FH
MKQG_ (7C=?\ 0!A_\"C_ /$T?\+QNO\ H P_^!1_^)H^I5^WXH+,]FHKQG_A
M>-U_T 8?_ H__$T?\+QNO^@##_X%'_XFCZE7[?B@LSV:BO&?^%XW7_0!A_\
M H__ !-'_"\;K_H P_\ @4?_ (FCZE7[?B@LSV:BO&?^%XW7_0!A_P# H_\
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M_0!A_P# H_\ Q-'_  O&Z_Z ,/\ X%'_ .)H^I5^WXH+,]FHKQG_ (7C=?\
M0!A_\"C_ /$T?\+QNO\ H P_^!1_^)H^I5^WXH+,]FHKQG_A>-U_T 8?_ H_
M_$T?\+QNO^@##_X%'_XFCZE7[?B@LSV:BO&?^%XW7_0!A_\  H__ !-'_"\;
MK_H P_\ @4?_ (FCZE7[?B@LSV:BO&?^%XW7_0!A_P# H_\ Q-'_  O&Z_Z
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M8K?F\)2KIKW=IJ%K>>60'2%NF<8P3]:ZGQ@L5UX4M;YPERRO&WFHI7<IZX]
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M  KLJ1%5$5$4*JC  Z 4M?2T:2I04$?"XG$2Q%5U)=0HHHK4P"BBB@ HHHH
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M/@R"6PNI+>229(V>,X8J5;(SVZ5A?&[_ %&B?[\O_LE:/Q@_Y$:T_P"OJ/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1169X
M@UB+0=!O-3E&X6\98+_>;H!^)Q32;=D!QWQ&^(0\/1MI6EL&U21<O)U$"GO[
MMZ#MUKPJXN)[NX>XN97FFD.YW=LDGZTMY=SW][->7,ADGG<R2,>Y-0U[]"A&
ME&RW+2L%%%%;C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&?BC_P!#+:_]_3_\;KU2BM:=9P5DE\T%S"\)V6N6&D-#X@O4N[PREA(C9&W
MP.@]ZW#]T_2EI#]T_2HE+F=P/&/@S_R,FL_]<1_Z'7M%?.'@[QBO@[5[^Y:R
M-UYZ^7M$NS&&SGH:[FU^-4=U=PVZ: ^Z5U0?Z5W)Q_<KOQ6'JSJ.45H-HY_Q
MW=7H^+B-;VHNY[<P_9X"I._"A@,#KR371_\ "9_$/_H4C_WXD_QI_P 3O#.I
M-J-GXGT9))+FU $JQC+#:<JP'?N#4=C\;-/^Q@:CI=TEV!@B#:R$_B01^M5\
M=.+C%2LK>@SFM7MO&&N^)['69O#4]O<6[1\QP-AMK9!.:],\;>.;7PC##'Y!
MNKZ<$Q0@X '3<3]>*P/"OC7Q)XL\5)+;:>L&AJI64,,@>^_'+9[#C'YUG?%.
MSO=-\5:3XG2W-Q:6XC5P>55E<M@^@.>M)KGJ1IU$E9;)_@!97QM\0)5$D?A(
M[&&5_<2=/SJC\&FD?7M>>5-DC*I9<8VG<V16A>?&6RN+-H=)TR^?4)1LB$BJ
M%#'OP23SVQS5#X-Q3P:]KT5TI6X15616ZA@S9S^-.46J,[QY=OS#H0?#%!>_
M$?6KRZ3_ $E5E< _PLT@!_F17M%>*>);'5/A]XYD\1Z?;M-87+L[9'R_,<LC
M$=.>0?I6O<?&JTDLU73](NGOWX"2$; Q]"#EOR%9UZ,ZS4Z>J:^X35RKX9MH
M+3XX:K#;;?*"RD!5P%)VDC'L2:UOB!X*U;4=7M_$6@2_Z?;JH,6X*WRG(92>
M,\]#7,?#N+48OBC/_:R.E]);O+*K]06"MSZ<'I76>+?'&M>%?$J>?I/F:'LP
M)4ZN3CG=T!'(P>M7-359<FKM]X^ICV7Q6U;2;J.T\4Z,\1SAI40QMCUVG@_A
M7JMI=V]_:17=K*LL$JAT=>C UXOXW^(FF>+=$72]/TJZ:Y>52KS(N4(_N[22
M2>G:O4/!>G7&E>#],LKM-D\<7SI_=))./KS6.(II04^7E?83-ZO%OB;_ ,E-
MT7_<@_\ 1IKVFO'?BY8W=GXCTOQ D+2VL2HK$#A65RP!/;.?TI8-_O;>3!'J
MFM2R0:%J$T6?,2VD9<=<A3BO-?@C:P_8M6O.#<&5(R>X4 G]2?TKH_"WQ"T[
MQCJ$NF1V$\+?9S(_FD%6&0"O'UK@8VU;X3>*;AS;-=:1<G&X<!UR2O/0.,_S
MJZ5.7).B]).P>1[C)&DL3QR*&1P593T(/45Y!\(U6W\6:_;0M^X4$*.V Y _
M2I=9^,*W]BUGH.FW0O)UV*\H&4)_NJI.X^E;OPM\)77A_3+B^U%#'>WI!\L_
M>1!TS[DG/Y4E"5&C+GTO:R#9'?UQ?Q5_Y)_>_P"_'_Z&*[2N6^(FFW6J>"+^
MWLXS), L@11DL%8$@#N<5ST&E5BWW0D+\.O^1!TG_KFW_H1KBOBW_P C1X;^
MO_LZU4\'_%&UT/1+31K[3IVD@8Q^9&1C!;N#W&:M_%LY\3^&R.F?_9UKLITY
M0Q-Y+>Y74['Q_P"$G\6Z&L%O*([NW<R0[ONL<8*GTSZUPEGXU\8^"X8K+7M'
M>XM80$65P0=H_P"F@R#[5W7CS7==T#3X+K1].%S$'W7$F"VQ01QM'8^O:N5O
M/C)HUYHTT$FCW,D\L15H9-IB)/8G.<?A4T%4E32<>:/Y"1WWAWQ%I_BO1_ME
MDQV'*2Q-]Z-NX->8/X<\8?#W5;JZ\/Q_;=.F.2JKORHR0'7KD>H_^M6Q\(M*
MU'3O#VIW[VQ#714VT4AV;]H.#GL"6QG':H+/XM7>DWEU9>*=)FBG5R4%NH!4
M=@0Q&1_M9IQA*$YQI+F7;^NP&KX3^*5MK>H)I>IVAL;YVVH<Y1F_N\\J?K6+
M\3?^2A>&?K%_Z-K&EO3\0?B5I]YH]C/;PPF,RRD , K%BS$< ]AR>E=!\8-'
MOFDTW7K-&D6T^23:N=F#N5C[=?TJXPA"M&VEUMV'U/5:\C^'O_)4O$GUF_\
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MZE0>3^+$_D*Z7->S]OU:M\Q^9Z91117F$A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?/\ 7OOPG@:+P-$[*!YL\C@^HSC^E&)IQA2LNYG7BHPLNYW%%%%>:<04444
M%%%% !1110 4444 -V)_=7\J-B?W5_*G44 %5I-.L97+R6=N[GJS1*2?TJS1
M0G8!%144*BA5'  & *'19$*.H96&"",@BEHH KQ6-G ^^&U@C?IN2, _I4X
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M[#;Z]XUF$ERYMM.SD8&%QGL/XC[UKZ'X"M;,K/J3+<S#D(/N*?ZUV"J%4*H
M X ':I5&K7UK.R[+]2Y8G#X73"KFE_,_T7]?,HZ5H]EHUKY%G%M'5G/+,?4F
MK]%%=T8J*LMCRISE.3E)W;"BBBF2%%%% !1110 4444 %%%% !1110 4444
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M%N2BD$9]1GH?I6[I5)+5ESA5DM9'M?B*SEE^%MS"EC'9S16ZR?9@X80E&#$
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@>Y@LFG4M.OHNW5_Y&[JGBR^UB]C,A\NU1PP@0\'![^IKUQ6W(K>HS7@:G#
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M>,%3FO+=6C\7#X@6"WSQ'72$\@@IMZG;TX]:['X($_V9JXR<>='Q^!J#Q/\
M\EQT3Z0_S:KIVIU9P25K-CZG7^$%\7Q37;>*9(3"$!A*%.#SG.WVKD+[QUXF
M\6:[+IG@^,16\1.9\ E@#]XEN%![#K7H7C&>2V\&ZO+$VUUM7P?PQ7C?@+6?
M%.E:9=#0-"BOHI)LR3-$S$, ,+D,.F<_C6=&*FI5;*_3L)&_J%]\3/":_P!H
M7TT=_9I@RX5751GO@ CZUZ)X9\3V?B705U2']V%RLT;=8V R1_7Z&N#N?%'Q
M$N[66VF\(P-%*A1U,$G((P?XZG^$VBZQI#:K;ZII\UM;S*C*)5P&/((_(T58
M)TW*5DUVZ@9L7BGQGXXUN[C\-3QV5G;=,[>AX!)()).#TK6T34/B%I/B6WTW
M5[7^TK6?DRJ%PBYY8.  ,>AZUBW'AGQ=X!UBZO\ PY']KL)3N9%7>=H.0K+U
MR,]172>%/BE;ZS?QZ7JMF;&_=MBD9V,WI@\J?8Y^M747NWIQ3C;YC/0ZP?&F
MI76D>$-1O[*01W$**48@'&6 Z'V-;U<M\1_^2?:O_P!<U_\ 0UKAI).I%/NB
M44O GB#4=:\#W.I7TPDND>4*X4# 501P*X/0_&_COQ'YNF:88Y;D_.UP45?*
M3IWX'/U-=3\+_P#DF5Y_UTG_ /015/X(QH--U:4*-YF12WL >/U-=K4(>TER
MIV:L495_XD\?>"-2MIM<F%Y9R'&,*4?U 8 $-_GFKD&L?$+QF9-1T0QZ?IP9
MEB4E1NQ[D$D^_ K>^,,*2>"1(P.Z.Y0KSZ@BM_P( / NC8&/]%6DZD?9*KRJ
M][;?H(XKP?XVUZV\6_\ ",^*/FF=BB2,H#*^,@9'!!'3ZBKGQ,\7ZMX8U72T
MT^8+#*C/*A4'?AAQDCCBL;QK\OQGT4KP3]GY'^^:C^-G_(8T?_KD_P#Z$*N,
M(2JP=MUL/J6ED^*.N6S:K:R)9P2#?%;#8I*]L!AGIZGFL[3_ (G>*KJW&AQ6
MB3:T\OEI,4PP Z@KTR,=>G6O:XN(D _NBO(_#,:)\<M7"H  )B !T/'^)J*5
M2$U*\%HKH1!J]U\3O#5FNJ7MZLMNC#S%4(X3/ W #I]*]"\/>)O^$B\&G5XT
M$4XC<.@Y"2*#^G0_C4WC8 ^"-:R ?]$DZ_2N.^%?_).M3_ZZR_\ HL5$FJM'
MG:2:?0.AI?"[Q)JGB33;^;5)Q,\4RJA"!< C/:M#XC:U?:!X4:^TZ413B=$W
M%0W!SGK7,_!'_D#ZK_U\)_Z#6M\7_P#D16_Z^8_ZT2A'ZURVTN@ZEBYU_48_
MA.NN+,!J!M$E\S:/O$@$XZ=ZXK1?$_Q!\7VJV^E/''Y!_?7A55#$G(&2,<#L
M!717G_)!U_Z\(_\ T):T/A+$D?@&V95PTDTK.?4[L?R JDXPIRERIOF Y"/Q
MEXO\&^(8+3Q2PN+68@L2%^[TW*RCMZ5ZAXC\0VOAO0IM4N 75 !&BG!D8] *
M\_\ C>J_V=H[X^82R 'VP/\ "H?C#*X\.^'X@?W;$L1ZD(N/YFG[.-9TY6M>
M][>0;D6GZI\2/&(;4-,FBL;(L0F0JJ?ID$GZT^V\;^*O!^LPV/B^+S[64_ZX
M*,@?WE*\''IUI=+\4?$"TTFTM[/PI;FVCA58B('Y7'!X?OUK.\43^.O%FG1V
M=]X65%CD$B20PN&!QCNQXYK513ERR4>7Y7&>VQR)+&DD;!D<!E8="#3JP?!4
M5[;^#=+@U"%H;J*'RVC88("D@9_ "MZO,DN631)X_)XK\8>,O$=W9>&)$M;2
MU)^<@#(S@%B0>3V K0TW4/B+HGB"UL=3M1JMM<MS(NW"CN=X QCKR*S-0\+>
M*O!/B"ZU;PPGVFSG8DQ(NXA2<[2G4X[$<UN>&?BK%J6I1Z7K5@UA>2,(U89V
M%CT!!Y7]:]":O&].*<;?,HC\6^+-:\+^/+%)+@-HMSL8QE%X'W6&>O'7\:]*
MW KNR,8SFN$^+.A_VIX1:\C7,]@WF@_[!X8?R/X5F?\ "8G_ (4R+TR9O/+^
MPY/4O]W/UV\U@Z:J4X.*UV8A_A/Q9K'BCQY?QQ70&BVV]@HC'*YVKSC//7\*
MRY?%?B[QCXFN[#PQ-':6MJ3\QV\J#C<20>IZ 5T?PET3^S/"(O)$Q-?OYIS_
M '!PO]3^-<UJ'A3Q5X+\0W6K>%T^TVDY+&)%#$*3G:R=3CL16R]E[644E=:*
M^PS1TV_^(VB>(;6RU.W&JVUR>63;A1QD[P!MQ[U6^)D?C#[/JKEXO^$>RF%R
MF['R_C]ZM+PQ\58]0U&/2]<LC87KOY8<9"%O0@\J<\=ZVOB=_P D^U/Z)_Z&
MM2G*%:/-!)_\'<74X+PE#\0V\.V9T:6 :;SY88QYQN.>O/7-=SX^\<KX2M(H
M+:)9]2N03$C=$'3<?7G@#O\ A4GPR_Y)_IOT?_T,UYSX^FO/^%M1&VM%O)X1
M#Y%O("5<A=P& 1W)JDE5KM22LK_/U'NS9M[7XK:C;?;1?);;QN6!]BMCZ;>/
MQ-:'@[X@:E)KI\.>*(/)O\[8Y=NTENRL!QR.A']:K_\ "8?$G_H4X/\ OQ)_
M\77.:K:>,_$/B6PU6Z\./:SP,@+V\3+D!L@G)/2JY%--344O*P'5_$SQAJWA
MC5],33Y@L,B%Y8RH._##C)''%9JR?%+6[4ZK:RI:02#?%;#8I*]1@$9_,U4^
M-?\ R&='S_SQ;_T(5[.G"*!Z5DYQI4H-13;ON+H>)6/Q.\57-N-#BM$GUII?
M+24H P Z@KTSQUZ5/J]W\3O#-HNJ7MZLMNA'F*H1PN?[P Z?2K'A6*-?C?K(
M5  HG*@=CN'^)KT7Q>BR>#M85NAM)/\ T$UI4G"%2,5!6=K_ #&-\(^(D\4>
M';?4EC$<C926,'(5QUQ[=_QK<KSOX-?\B=-_U]M_Z"M>B5Q5XJ%2442S@_B!
MX^?PR\6FZ;$LVJ3J&Y&X1J>!QW8GH*YZ.T^+%Q:?;!>",M\PMV,8?'TQQ]":
M@BACO_CY(+M@1%(6C5L<E8_E'X=?PKV2NB<HT(Q2BFVKNX]C@? 'B[6]9N[K
M2M;TZ1+FT'SW(3:H/]UAV/<8ZUF^*_B!JL_B!O#GA2$272L8Y)PNX[QU"YX
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M Y2BG(CRN$C1G8]%49)_"GSVMS:D"XMYH2>GFQE<_G6EQD5%% ^8@+R3P *
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MN:$N62EV$><_#%&7X:7BLI!\R?@C_9%5?@HC)I&J[E*YG3J,?PUZ>J*J[54
M>@%"HB#"*JY]!BMI5^935OB'<X;XN*S>!9 H)/VB/@#ZUM^!@5\#Z,"""+5>
M#6^RJXPRAAZ$9H "@   #L*AU+TU3MUN(\>\:QN?C)HK!&*C[/D@?[9IGQJC
M=]7T?:C-B)^@S_$*]C,:,P8HI8=R.:&C1R"Z*V/49K:.*Y91=OA5AW"/_5)_
MNBO)O#:./CCK#%6"D3<XX_AKUNFB- Y8(H8]\<UC3J<BDK;JPC$\:@GP3K(
MR3:2<#Z5ROPA@\SP3>02JP62Y=3V."BBO1B P((!!Z@T*BH,*H4>@&*%5M3=
M.W6XSP;P[KMU\,?$>HZ?J=E+);2G'R\$[2=KKG@@@_R]*/'?C*Y\9Z?&MAIE
MQ%IMK*&DF<9RY!"@XX'&>*]SN+.UO$VW-O%,OI(@;^=/2W@CC\M(8U3.=H4
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M2+O2?"&;Q'B>YF:98W&"JX &1[XS^5=U11652;G)R?404445 !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YE\;?^18T_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"A=Z%I%_/Y]YI=E<3?
M\])K=7;\R*NQQI%&L<:*B*,*JC  ]A3J*;;>@!1112 **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME%Q=F<THN+LPHHHI$A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !2$ C!&1Z4M% 'SS\1O!4OAO5GO;6,G2[IRT9'_ "R8\E#Z>U</
M7UO>6=OJ%I+:7<*302KM>-QD,*\?\2_!NYCE:X\/3K+$3G[+.V&7Z-T/XX_&
MO6PV-BURU-RDSRBBM>]\*Z_IS$7>CWL8'5A"67\QD52_LS4/^?"Z_P"_+?X5
MWJ47LQE6BK7]F:A_SX77_?EO\*/[,U#_ )\+K_ORW^%.Z&5:*M?V9J'_ #X7
M7_?EO\*/[,U#_GPNO^_+?X470%6BK7]F:A_SX77_ 'Y;_"C^S-0_Y\+K_ORW
M^%%T!5HJU_9FH?\ /A=?]^6_PH_LS4/^?"Z_[\M_A1= 5:*M?V9J'_/A=?\
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M0H&!@5#:6EO8VL=K:PI#!$NU(T& HJ:O%Q%=UI7Z$MW"BBBL!!1110 4444
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MC)H'AZSTU,$PI\[#NYY8_F36K117AMMN[/.;N[A1112$%%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "B@G%,:0+WH ?15<W*YZTHN%/>G8">BFJX(IU( HHHH **** "BBB@ HHH
MH **** *M_IMEJEN;>^M8KB(_P ,B@X^GI7'7OPE\-7;EXA=VN3DB&4$?^/
MUW=%7&I.'PLJ,Y1V9YI'\%]'#GS=3OF7L%V*?SP:Z#2_AQX9TIQ(EA]HD'1K
MEM_Z=/TKJZ*N5>I+1R*=6;W8BJ%4*H 4#  Z"EHHK$S"BBB@ HHHH *8SA13
MF.!67?W/EJ>::5QI%MKI0>HIR7"L>"*X^XU-@_6K-CJ)9QS6KI.Q7*='J%A:
MZOITUC>1B6WF7:R_U^M>%^*/AQJ^A3O+:0R7UCDE9(EW,H]&4<_CTKW6UEWH
M*MBBG5E2>A=*M*EML?)K1NIVLC ^A%:.D>'-7UVX$.GV,TN3R^W"+]6/ KZ;
M>TMI7#R6\3L#G+("<U*JJBA54*HZ # %=3QVFD366+;V1R'@;P-!X4MFFF99
MM1F7$D@'"#^ZO]3WKL***X9SE.7-(Y92<G=A1114B"BBB@ HHHH **** "BB
MB@#A/$WPNTK6Y&N;%_[/NVR6V+F-S[KV^H_*O.[_ .%?B>T<B&WBNTS@-#*!
M^C8KW^BNBGB:D--S>.(G%6/FQ? ?BEG"#1+K)..5 'YYQ6SIGPE\17K W8@L
MD[F1PS?DN?YU[U16CQU3HD-XF;.1\,?#S1_#;+<!3=WH_P"6\P'RG_97M^I]
MZZZBBN6<Y3=Y.Y@Y.3NPHHHJ1!1110 4444 %%%% !1110 4444 %<1\28V;
M3K*0 [5E8$X]1_\ 6KMZQ_$^EG5M!N+=!F51YD?^\.WX\C\:J#M),THRY9IL
MQ98CXL\#P1V;H+B+;E"<?,HP0?3/:N9D\#:I!ID]Y</!$8OF\MGZJ.IST%8=
MGJ%[IDQDM+B2"3H=IQGZBI;[6]3U) EY>RRQC^ G _(5U1A);/0[5"<':+T.
M[M]*2P\.:>[1:AJ+N%*QV\Q41[N<@ C 'K4OCJ2ZL[73]1M@H>VF)W, =I(P
M.#UKA+;Q'J]G9_9(+Z5(>@7@E1['J*AN-<U*[T]+">Z>2V0@A6 )XZ<]335&
M7-=F7LY<UV6-3\3ZKJ]K]FO)D>+<&PL87D>X^M+X3C:3Q5IX7/$FXX] #6-7
M<_#G2VDO)]3D7Y(E\N,GNQZG\!_.M9VA!CFU&+L>CT445YIQ!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444US@4 0SS"-3S6+=
MZF$S\U3:G<E%/-<C=W3,QYK>G"YI&-S3?5SN^]3XM7.>M<V9"3UI5E(/6M_9
MHOE1WEGJ DQS6O'('&:X+3[LJP&:Z^PGWH*YZD+&<HV-*BD%+6) 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 U^E8.JJQ4XK?(R*H7=MY
MH/%5!V8TS@KB-]]6M/1_,%;4VD[F^[^E36NF;&!V_I72ZBL:\VAHV (C&:TA
M5>"+8HJQ7*W=F3"BBBD(**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ."\7^#GED?4M,C+
M.QS- O<_WE_PKSY@58JP((."#U%>_5E:EX=TK5B6NK1#(?\ EHORM^8KHIU^
M721T0KM*TCQ6DKU!OAYHV21+= >F\?X59LO!>@V;AV@:X8?\]FR/RZ5O]8@B
MW7B<%X?\,WFNW"E5:*T!^><CC'HOJ:]<LK*#3K.*TMD"11KA1_4^]21A$14C
M5511@*HP *DKEJU74?D<\YN04445D0%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !4<OW34E,D&5- ',ZP3AJY.<_,:[/5H2P/%<C
M<Q%6/%=E)Z&T"G12E32A2:V++=F3Y@KLM*)V"N4L("SCBNRTV(J@XKGK,SF:
MBTZD'2EKE,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I
M"N:6B@",Q*>U*(P.U/HH 0"EHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I
MK-@4ZH9C\M %&[O1$#S6;_:PW_>_6J^K2L":YXS-YE=,*::-8Q.YM;X28YK3
M1LBN.TN5BPKK+<Y05E4C9D25BQ11169(4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %(1D4M% %*[MQ(IXKG+S3,DG%=>5!%026ZO
MVJXSL4I6.#?32&Z&GQ::2>AKL38(3T%*MBB]A6OMBN<R+#3@F,BM^"((HXI4
MA5!P*F Q6,I7(;N%%%%2(**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.5<
MK4E(1F@#G-2M"^<"L3^S6W_=KN)(%?J*@^Q)G.*VC4LBU(Q]/LBC#BNAB3:H
MIL<"IVJ8#%9RE<ENXM%%%2(**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHJ.1]HH 5I *9YZYZUDWM_P"63S69_:_SXW5H
MJ;92B=8KANE/K%LK_P S'-:Z-N%2XV$U8?1114B"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** #%&*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *,444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !5:YSL-6:CD7<#30'':H7WFL
M,,_F5V-_8F0GBLC^RVWYVUU0FK&T6K$FE%MPKK+?[G-8]A9&/'%;<:[5 K&H
MTV9R9)11161(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 44$U&S@4 2457,ZYIZR@T[ 2T4@.:6D
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MEFNF:K<6L5S%<)#(0D\+AE<=B"*UC"CB$THV?W!HSZ?\1?\ (M:I_P!>DO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.&HQVBCDJ8[$U/BF_O((;&TM\>3;0QXZ;$ J>BBMDDMCE;;U84444Q!1110
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M^@M6C\)_^2?VG_767_T(UG?&C_D4;7_K\7_T%JXH_P"]_,74X'X2?\C];_\
M7&7_ -!KZ$;[I^E?/?PD_P"1^M_^N,O_ *#7T(WW3]*>8?Q?D#/D63_7/_O&
MOHKQ7XDE\,> H;RV -U)''#"2,A6*]?P /XXKYUD_P!<_P#O&O=OB/IUS?\
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M_P#9:SHT)TJ\>;K<26IE_!/_ )&34/\ KS_]G6O:;[_CPN?^N3?R->+?!/\
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MU&#GLS;3^M:,4\,PS%*D@_V&!K>,XR^%W.6=*</BBT244451F%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !28I:* $P*,4M% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG&2O%W//G3G!VFK>H44451 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%([K&C.[!549))P *
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MI3_#-P/SZ5T (8 J00>017H0J0J*\7<\:K1J47RU(V8M%%%69!1110 4444
M%%%% !1110 4444 %%%% !1136.* $=PHYJE/>*@ZTEY.$4\US5]?<G!K2$+
ME*-S6DU-1WJ-=4&>M<M)=L3UJ,7+9ZUO[)&G(=S!J ;O6C%,'%<':WI!Y-=)
MI]WOQS64Z=B'$W@<TM1QMN%25B0%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?E_F>E&"PE)59_'+X5V7?U[%R&&.WA2&%%2- %55' %/HHKLV/-;OJPHHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME]!6F&PLZ[[+N98W,*>%5GK+M_F8GAOP,D&R[U90\O5;?J%_WO4^W\Z[< *
M   . !2T5[U&C"E'E@CY#$XJKB)\]1_\ ****U.<**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M117)"<H/FB[,]&I3A4CRS5T>QZ'XHL-<4)&WDW..87//X>M;=>!H[1N'1BK
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>ZOM_P $(88[>%(845(T&U548 %/HHKW#Y1N^K"BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\<VV[L****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!0UN W6AWT(ZM"V/KBO$.]>^.@DC9&&0P(->;Z'X&FN[QYM05H;5'("
M=&DP?T'O7EX^A.K./(CWLGQ=.A2J>T=EH8N@>&KO79QL'EVRGYYF' ]AZFO5
MM*TBTT>T%O:1[1U9S]YSZDU9M[>&U@2""-8XD&%51@"I:Z<-A(45?=]SBQV8
MU,4[;1[?YA11176><%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 9GB*W^U>';^+&XF%F 'J.1^HKQNTL[B^N4M[:)I
M)6. JBO=)8Q+$\9Z,I4_C6;HF@6>A6WEP+OE;_63,/F;_ >U<&*PCKU(OIU/
M7P&8K"T9QM=MZ&9X9\'P:.JW-UMFO<9S_#'[#W]ZZBBBNNG2C3CRQ6AYU>O4
MKSYZCNPHHHK0Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &3(
M\D+HDAC=E(#@9VGUKS/6O!.LI/)<I+]OW'<S X?\0?Z9KT^BN>OAH5U:1V83
M&U,+)N%M?Z]3P26&6"0QS1O&Z]5<8(_"F5[G?:99:E'LO+:.4=BPY'T/45R&
MJ?#J%]TFF7)C/_/*7D?@W4?K7E5<NJ1UAJ?08?.Z%32HN5_>CSNBM/4O#^IZ
M42;JU<(/^6BC<OYBLRN"491=I*Q[$)QFN:#N@HHHI%!1110 #K7NFFS?:=+M
M)^\D*L?Q KPNO8O!\XG\+61'\*E#^!(KT\KE:<H^1X6?0O2A/L_S_P"&-RBB
MBO:/E@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $(# @@$'J#6!J?
M@W2-2RWD_9Y3_'#Q^8Z5T%%1.G":M)7-:5:I2?-3E9GENI^ =3L\O:%;N,=E
MX;'T/]*Y>:"6WD,<T3QN."KK@BO>JJWNFV6HQ^7>6T<R_P"T.1]#U%>?5RR+
MUINQ[.'SVI'2LK^:T?\ E^1X717HNI_#J"3+Z;<F(_\ /.7E?SZ_SKCM1\/:
MII1)NK1P@_Y:+\R_F*\VKA:M+XEH>YA\?AZ_P2U[/1F77J'P\G\S0)8CC]U.
M0/H0#_C7E]=[\-9\2W\'JJ./PR/ZUI@)6KKS,,XAS823[69Z#1117T)\8%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% #)?]2_^Z:\$KWN7_4O_NFO!""#@C!KR,TWA\_T/I.']JGR_4****\D^B"B
MBB@ HHHH **M6&G7>IW @LX'E<]<#@#U)["O1-"\"6MB5GU$K<SCD1X^1?\
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MP.01Q7745@\-2<U.UFCKCCJZINDY7B^X4445N<@4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\+U/\
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MV8_B4_F1^-<N-H<R]I'=;GE-'K]%%%>22%%%% !1110 4444 %%%% !1110
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M&84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% ')?$K5CI'@B]=&VRW&+=#G'+=?\
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MKJ&XA/1XG##]*L5\JZ#XAU+PYJ"WFG3F-A]]#RD@]&'>OHOPCXJM/%FCK>0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTZ_6NTKS9PE!\LD<H4445 !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"VG_H;5U]>#65JDO5GF,****S **** "BBB@ HHHH **** "BBB@ HHHH
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MFW%B_P"\ V=G7H:I 9.*Z#2-1VD6MP=T9X0MS@^E7B%7PD74HOFBMXO]'O\
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MM6_1VT7G86)H4<-J_>EY[+U7?R)FU"2.YAEL\VP@8/%L/(([D]S7TQX3UO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5N[A[J=I&Z=%'H*IRC@5985!*.!7KT.6$5&.B1Y>)3DFWN05[E\%/^18O_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K/URP_M30;^Q'6
MXMWC'U((K0HIIV=P/DV -&SPR K(I(8'L1UJ<5Z%\4O!,MI?2>(=.BS;3-FZ
M1?\ EFY_C^A[^_UKSGRW*X,A_*O7YXU%S)GMX.M*5.R5["R2KM(!R3Q3TA4
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M0TK5%U6 SQVUQ#%GY&F7;O'J!FK];1DI*Z.:<)0DXRW04444R0HHHH ****
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M2,\YZ*!5FOG)N\FS$****D HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBBF(**** "BBB@ HHHH **** "BBB@ HHHZ#)H X/XCZEMBMM-1N6_?2#V'
M_7/Y5Y[6IXBU ZIKUW<[LH7V1_[HX%9=?,XJK[6JY'W6 H>PP\8==WZLZ+P?
MH7]LZL'E4&TM\/)GHQ[+_GL*]<Q@8%8OA;21I&A01,N)Y!YDOKN/;\.E;5>W
M@Z'LJ:ON]SY;,\6\17=OA6B_KS"BBO,?B!XTD$SZ-I4Q4+Q<S(<'/]P'^?Y>
MM=,I**NSEP]"5>?)$V_$_P 0=/T=)+:P9;R^Y&%.4C/JQ[_0?I7C4\LMW<RW
M$S%Y97+NWJQ.2: E/5.:YI5CZ3"X*%%6CN^HL!\IO8]:N$ C!Y!JH5J>%LKM
M/45PXB-_?1ZU)V]TS;B$PRD=NH-1[O7\ZUIXA)'TY'2LQXO2N_"XA5(Z[G'5
MHRIRO#8N6MSO 1SSV/K4=U9DDO$,YZK5$[D/I6C9W?G#RW/SCH?6IJTYX>7M
MJ.W5%TZT:O[N>YFLI!P00?>F&KUQ/,KM&^PX[[15)N3FO6H5)3BG)?B<]2*3
MLAAI#3C3379%G/)"445%.^U,=S6\==#"I)0BY,K.VYR?4UK^$M/_ +4\6Z59
M[0RO<*7![JIW'] :QJ]*^#.DM=>)+K4F7]W9P[0?]M^/Y UI6GR4VSPI.^K/
M<Z***^>,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *\F^+WA$2PCQ'9Q_O$PEVJC[R] _X< ^V/2O6:CG@CN;>2"9 \4BE'4]P1
M@BM*55TIJ2&G9GR='#FKJ1DIR.:V=:T%M"\07>G-DK$_[MC_ !(>5/Y5$UKL
M3=ZT\1F%I6/IL'A5R\RV9E&/FE$1-6_+&ZK,=MN7.*F>8<JU.Q89&8B;94_W
MA_.M/63N$'U/]*@>'$JC_:%.U9QF)>XR:Q=7VV*HM=+_ )#]FH4I_(DM+DE0
MLG/O5E[>-DW# K)ADVXJV;G*8S7+B<+*-2]/0VIU4XVEJ5[A &(!!^E53&<U
M<^^:D^S$KG%=M+%>Q24F95**F4$7!K1MU4@9JJZ;#3HY=O>C$.5:-XA2BH/4
MMS1+T%;?@5_L7C739<9#NT1YQ]Y2/ZU@"8$C)K5TF[6WU2PE4X=+F,@XSCYA
M7GTY5*<XQ?5CQ<(U*4UY,^@Z***] ^)"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ KYU^*MJ+;Q]>,$VK-''(.O)VX)_,5]%5XW\
M;=,9;K3-54'8R-;N?0@[E_FWY5V8&5JUNXUN>2U.IRHJ$ L0 "2>@%:4-K;V
MB@WTF7/(@3[WXGM7JUJT::UU;V2W?]?<=F&A*4GV[]"LB-(VU%+'T S5N/2+
MV09$)4?[1 I[:M*B[+6..W3T49/YU5>[N)#EYY#_ ,"-<KEC)_"HQ7G=O\++
M\6=R5".[;]-"Y_85[Z1_]]5&^CWR#/DY_P!U@:J^?+_SU?\ [Z-2IJ%Y']VY
MD_$Y_G4<F/6TXOU37ZE<V&>\6OFO\AKV5TGWK>0?\!IHMIV.!!)G_<-7$UN]
M7JZ,/=:>=>O".!&/?;4^TS!:<D7\W_D/DPK^T_N_X)+I^EO"XNKO$:1\A3U_
M&L^_N?M=X\H^Z>%^@I+B]N+K_72EA_=' _*J]7AL-555U\0TY6LDMDB:U:'(
MJ5)66^N[85%+U%3HCR-M168^@&:E;2KY\%;60C\*[)UJ5-^_)+U=CEG2G./N
M)OT10KV?X'_\@[6/^NL?\FKQN6&6!MLL;(WHPQ7N'P7T^2W\-7EZX8"ZN,)G
MH548S^9(_"L<9*+H-I[G!)-:,[W6?^0'J'_7M)_Z":^3T^Z/I7US=0BYM)H"
M0!(C)R,]1BODVYMI+.]GM95(DAD:-ACN#BL,N:M)!#<:M6UIL>GWCJ&%O)CW
M&*F:"6+_ %D;+]13J5J<G:,DWZGLX:G.*NTQR5JQXN;=1G#K64E68V*D$'!K
MR<73<]4[-'JT)\N^S+BQ.IY4U9C3V-5X[E^Y!JPLY/I7CUO:=4=L.3H3&/BH
M'A8^E2&4XZU!)(3W-84HSN7)Q(I+:0] #^-4Y8G3[R$?A4[NW9C^=1_:I4_B
MR/0\UZM%55M9_@<L^1E)ZJ2\L:TWDMYN''DO_>'3\15"Y@>!L.,@\JPY!^E>
MQAJJ;Y9*S_K8\O%1M&ZU14:OJ3PK:?8?"FE6Q384M8]RXQ@E03^I-?->C:>^
MJZY96**6,\RH0/3//Z9KZIC0)&JKT  %:8Z6D8GA5MQU%%%><8A1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !6;KF@Z=XBTYK+4K<2Q$Y4
M@X9#ZJ>QK2HIIM.Z \*U[X/:Q8NTFD2I?V_9"0DH_ \'\#^%<7<>&M=M9/+G
MT:_5_3[.Q_D*^J:*[H8^HE:2N.Y\M67A3Q!J$XAMM'O2Y./GA* ?4M@5[#X$
M^&<.@HU[K BN+^1"@13E(E(P1[D],_E7HE%16QLZBY5H@N>%^%=0B\*>/Y89
MVV6WFR6KLW&!NP"?Q KW,$, 000>017SSXVM6L_&6IQD, TQD!8=0W/]:[?X
M6^*9[AFT*\<R;$+V[GD@#JOT[BG7I\T541Z^-P[J4U7CVU/39H8[B)HIHUDC
M<896&017'ZK\/;.X9I-/F-LQY\MOF3/\Q^M=G17FU:-.JK35SSZ&*K8=WIRL
M>-ZEX5U?3,M+:F2,?\M(OF7_ !'XUBU[]5&XT73+M]\]A;.W7<8QD_C7G5,L
M5_<E]Y[5'/FE:K'[CP\ DX KN?#MG'X5TNZ\2:SF%%CVQQG[Q!/IZDX KMK;
M1-+M)?,M["WC?LP09%>0_&3Q ]SK$&AQ/^YM0)9@#UD8<9^BG_QZNK+\J_?)
MS=[&.-S?ZQ#V5-63W,K6_'>N>)KAP+B2SLR?DMX&*\?[1'+']/:L-HYX&W^=
M*&/<.<U1LYQ&0:NW-X95KOKJK&KRQ5HG3A8452OU.ATSQCK6GQXCU2X( X65
MMX_)LU=D^)?B&:$P">WB!X,D46'_ #SC]*\_>X8'O48N&S6D,NJ--I[F53$8
M;FM*"^XZ#4KG[9F6>5YI6Y9Y&+$_B:Q[?4+O2[L3V-S-;2 Y#1.5/Z4Z)FFX
MI\MDP7)%&&4,,^2;O<O$1EB(W@CT#P_\8;NT@$&LVQO,#Y9HR%<_4=#]>*RM
M8\;ZIXEN2))VMK3/RV\3D#'^T?XC7%?93G@4]&>&M:]&G.+]D]3FP]/V4^:<
M#3OXHAR,,?4UGQ2E&P!Q3'N2YP35RRMQ*1FN?V?U>C^]U.U5?;5/W9+'>E%^
MM+&!</SWJ*]@$.0*KVDS"3V%8PP\:E-U*6YT.LU45.9H7L"QPD>U<_(,-6I>
MWFX;<_6LIFW'->IEE*I"'OGF9M5A*?+'H>F_!6"QEUO4))8@U[%"K0,?X5)(
M;'O]VO;J^?\ X02NGCI45L+);2!AZXP:^@*QQRM6/$>X4445QB"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M12Y>?J^ILYN22Z%@=**:ARHIU6=B=U<***55+L%49)Z"DW;5C$HHHH ****
M)(IY8&W12,A/]TU*VKWZ 8N&/U -5J9(/EK*>'HU'><$_5(;JU(0?))KYFA_
M;37$9BOH$F0]U^5A]*^A/ FJZ5JGA6U_LE#%#;J(7A;[T; <Y]<YSGOFOF:O
M4/@KJ1AUR^TYF.VXA$BC_:4_X$UR5\%2ITFZ2MUMT^XXZU>I6M[1W:^\]M)"
M@DD #DDU\[>,M?T>Z\77E_I%KO+85I6X5G'!=1[^M>T>.M3_ +(\%:I=*Q60
MPF-"/[S_ "C^=?,8XK+"8:-6,N?;8BC4E3ESQW-,ZS>R/GS0H]%44XW=Q(-K
MS.1Z9K.C^\*LJ:WEA*$/@@E\D>M0Q%6:O*3?S)U-3HU55-2JU<E6%SNIR+B/
M4RR525ZD#UYU2C<ZXS+GF5&TE0[SC/:FEZSC0U*=05VJ!S2LU1,U=U*G8YYS
M(I3S3$N"BF-QOB/53V]QZ&DD;)-0,:]*%)25F>55JM2;1ZU\*/"R"4Z_,0^=
MR6P]!T9C[]OSKU^N5^'NF2:;X-T^*92LK(9"IZC<2W\B*ZJO.K2<IN[N>55E
M>04445D9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% ''>,_ </B=TNX)Q;WR+M+,,JZ^A]"/6J?@WX>R^'-5;4+N\2
M:0(4C2(''/4DFN]HK3VL^7EOH="Q554_97T"BBBLSG"BBB@ KY9\4WQU+Q7J
MEV6)$ER^W)S\H. /R KZBG8I;R,IP54D?E7R3,Q>>1V.69R2?<FO2RY:R941
M8L[JV[.S\U,GGVK"1MK9K;AN_)MU(/45&9QJM+V>Y[F5.&KGT$N52#(_E5,3
MHY^Z3^%%U<^9WIUDBLPS2I.5*AS3W.B>(=2KR0M8LV[QJ0=N/PJY+<1R(%R*
M9<PQI$"IYQ6--*ROQ7GTJ*QDN='35Q/U>-I)&W%'&5.:8]CY@) K.@N'%7TU
M K&1FLJM"O2G[CN:PKT:D+M6,V>S=&X J:W:6/MC\:9<73LQ*X_*JS74P[*/
MPKV:=*5:DHU#RYU,/1GS1N:$NZ8_,WY5$X$*80<U';2-(PW-6L]O$+?=D9KC
MJUEA9*".RFU6BY05GW>YSDF[<2QR33*UK31K_6K\6>F6KW$Y&=J8X'J2> /<
MUZ3X8^#962.Z\13J5!S]DA/!]F;^@_.O66*IQ@I29\Y7CR3:;&?!GP[.L]SK
M\\96(IY%ON'WB3EF'MP!^)]*]AID,,5O D,,:QQ1J%1$& H'8"GUY%:JZLW)
MG,PHHHK( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (Y[>&YC,<\,<J'^%U
M##]:Q+GP3X:NB3)H]L">IC!CS_WR16_11<J,Y1UB[')/\-O##.6%E(@/99WQ
M^IIA^&7AANMI-_W_ &_QKL**=S5XJLU9S?WG'_\ "L?"_P#SZ3?]_P!O\:L+
M\._"RJ!_98.!U,\G_P 5744478OK%9;2?WF /!'AH #^Q[8@>H)_K5@>%?#R
ML&&B:>&!R"+9!C]*UZ*5R75J/>3^\S_["TC_ *!=G_WX7_"F2>'=%F39)I-B
MR^A@7_"M.BG=D\TNYQ^H_#/PW? F*VDM'/\ %!(0/R.1^5<7K'PAU**-VTN^
MANAU$<H\MC]#R"?RKV2BKC4E'8WCC*T5;FNCY<U70-8T1R-1T^XMP#]]ERI^
MC#BL[S9&^4'K7UFZ+(I5U#*>H(R#7,:G\/?#.J,7?38[>4_QVO[L_D./TKJA
MBX_:14,2[V>B\CYT^SL>K"@R/#A6 8=C7KFH?!LX+:;JW/9+F/\ ]F7_  KE
M-4^&/BFVC.RQ2Y YS!*#G\#@UU4\13D[-G4ZE%1<J4K,Y(2QD9W"JTT@D<;>
M@K7D\'^(H6(FT6^0 X)$);^6:?%X;UA#@:1J!).,FU?_  K?FA'5,E3J8B-G
M9(R$N"BA74\4R6<R# &!_.NKB\!>)KX;4T>=<\!I<( ?Q-=#I'P6U*<J^K:A
M#:IP3'"/,?Z9X _6I]O1CJV9UZDX+DYKH\XB@4*"XR3VI9(@JEHR5(]#7T=H
MW@7P_HJ@PV*33?\ /6X^=OUX'X5YA\5O#<6B:C'J%E"([2]R&1!A4D'7Z CG
M\ZQIXI5*G*BHUJ#3@E;3<\[@&^7+<X&>:MU5ABD!#@@?6IW<HN=I/TKIGJ]#
MHPON4VY*P^H;@ *)!]X&D6Z'\2G\*BFF\S@#"T1B[BK8BE*F[/4LI(L@X//I
M3ZSJ7<W]X_G5.GV,HXYV]Y%N9MP\M>6/Z5']E./O#-%J/O'O5FI;<=$;0IQK
MKVDR"!"A=3UXJ>H)F83($!+=, 9S7J?@7X;3W+1:IX@A\J$?-%9M]Y_0OZ#V
M[]ZSJS4%SR$J].BG3?0?\,_!3S3QZ]J4.V%/FM(V_C/]\CT';UKUVD "J%4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI/4J3#YU-6[6,$BJTPPN?0U-;R[<48N\J?NG+32C5=SW?X7$_P#"(%3T2YD
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/G,1<ZBXP\Y'"^R#L/U-=?7GXG$\_N1V..<[[!1117&9A1110 4444 %%%%
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M1L'*GT/!J,3R=F->E3P'VF<T\SBG8O,_-21DDUGB=QU4&K,-P,\@BMJU&T-
MHXN,I:LU8(-])/!LI;>Z51UHN+E7_B%>!^^]K;H>MSPY;W*3L5J/<6-)+(N?
MO#\ZC65 ?O"O<I4O<O8\^I67-:Y=BCW"I6L\)G%0P3@D>E7Y+M?)QQP*\?$S
MK1J)1.F/LYQNSV'X7P-#X'MRRA1)+*XQW&XC/Z5V587@NT-EX,TF%L;C;K(?
MJWS?^S5NUTS^)GQ\WS2;"BBBI)"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "HKBWANX'@N(8YH7&&210RL/<&I:*
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M)Q:D@/D26*2&5XI4*2(Q5U;JI'!!IM>M_%_PG;6ZKXCM62)Y)!'<19QO8]&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'EGB_P"(OB#1?%\N
MC:996EP/D$:M$[.Q8 XX89Z^E4W\=_$>)"\GA=511EB;&;@?]]50\2?\EQL_
M^OBW_DM>W5WU)4Z48>XG=#.%\%?$BW\3W1TZ[MQ9ZB 2J;LK)CJ!GG/M7=5X
M;XL1+/XSVC:8H$[3P.ZQ\_.2,\>XQGZUW_BOQ+X@L=5BTC0-$:ZN)8Q(+A^8
MU&<>P&/<U%6@G*+IZ75_0&CLZ*\KU#5/B?HEHVH7<%C/;0C=*D:JQ"]R0,''
MTKL/!GBZW\7Z0UTD8AN(FV3P[L[3V(]C_0UC.A*,>:Z:\@L=)17F6J_$JYT3
MQW>Z;>K!_9=LA;Y4/FL=F0H.<9+'TK,O?&GQ!O+5]5T_1OLVF!2ZGR=YV_WC
MGD_4#%6L+4=GHDPL>P45PWPY\<R^++:XM[Y(TO[8!B8Q@2(>^.Q'?ZBD\;_$
M6'PS.-.L8!=ZFP!*D_+'GIG')/M4?5ZGM/9VU"QW5%>/2>)/BC;61U*73$%L
MN793 N0O7E0=P%=GX&\<P^,+656MS;WL&#(@R5(/0@_TJIX:<(\VC7D%CKJ*
M\J@^*ES::OKD.J1P-!9ETM8X4(>5P^U022>V2>*V?!WB;Q%JEU?WNOV7V#2T
M@\V)FA**,'GYCR>*)8:I%-L+'>45Y7)X^\2^*-3EM/!VG)]FB;#7,RCD=B<\
M*#@\<FFS^,_&OA*Z1_$^FPW%@Y \Z  8^A'&>O!%/ZK/:ZOVOJ%CU:BLZ'6+
M>]T'^U]/!NH6A,L:KP7P#\OL<C'UK@X]<^(_B#_2=+TNVT^T/W/M &YA_P "
MY_05G"C*5^ENXCTVBO*K;X@^(?#FO1:9XQLHEBE(Q<1 #:I.-W&0P_6N^\1Z
M_;>'-!GU6<>8B ;$4_ZQCT -.="<6EO?8=C7HKRK3]<^)7B*T_M+3;:QM[.3
M/E*X4%AD]-QS[9XKH/"7B'Q/=ZM-I/B'1?(EBCWFZCX3K@=R#G_9/8TY8>44
MW=:>86.UHHHK 04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7G-OX]U67XFOX;:&T^Q"=H]X1O,P%)Z
M[L?I7HU>(67_ "7J7_KZD_\ 0#73AH1DIW6R&CVUW6-&=V"HH)9F. !ZFO-_
M^%@:QX@\6G2O"=K:36<8_>W5RC$#GEN&'R^G<UF>-?%=YXKUA?"7AIQ)'(=E
MQ,AX?U&?[@[GO_/O_"?A6R\*:0EI;JK3L 9Y\<R-_AZ"FH1I0YIJ\GLOU8;'
M/_$76O$VC1Z;_87F,\@?SS%;"0$C&."#CO7=0,S01L_WBH)^N*X;XD>,M3\)
M#3_[.2W;[1OW^<A;IC&,$>M=7J6M6NC:$^J7[[(8XPS;1R2>@ ]2:F46Z<++
M>_JP-*N1^(^N:AX>\+?;M-F$-QYZ)N*!N"#G@@CM7$6_C[QSXGO93X>TV-;9
M#C C#!?]YV.,_E5'QGXNU._\+OHOB'36LM429)$(4A)5&<G]1T)K:GA91J+F
ML^Z"QZ?X#U:\USP=9:AJ$HEN93)O<*%SAV X''0"NDKC/A@Q7X;Z>PZCSC_Y
M$:N3TOXNWWV6]%[:0W-[YBQV=O;H5W$YR6Y/' Z>M9RH2G4GR+9A8]?HKQ;5
MO&OQ%T>-;Z_T^.UM788#6X*CV)SD?B:]-\)>(H_%'AZ#4E01NQ*2Q@YV..H_
MD?QJ*F'E3CS.S7D%C<HKS37/B+J5YK;Z'X/L5O+E,A[AAD C@X' P/4\55O?
M$/Q'\-(+[5;"UN[%1F7RE!VCW*\CZX(IK"S=KM)OI?4+'JM%<@_BZ36? MSK
MGAWRS=0+N>"==VPKRRG!';D&E^'OBV7Q;HDL]V(EO()2DBQ# P>5.,G'<?@:
MAT9J+D^F@K'745R_CWQ._A7PXUY;^6;N218X5D&03G)R,CL#^E7_  K>:CJ/
MANSOM4$2W5PGF%8E*A5/W1R3VQ4^S?)S] -FBBBH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L'QI+)#X+
MU>2)V21;9BK*<$'V-;U<_P".?^1&UG_KU?\ E5TOC7J!ROP;N[F\T/47N;B6
M=A<@ R.6(&T>M>E5Y?\ !+_D :E_U]#_ -!%>H5KBOXTAO<**X3XMS2P>"M\
M,CQM]I0;D8@]ZO?#.22;P#ISRNSN3)EF.2?G:I=+]U[2_6P6.MHKRKXTW,]O
M:Z08)I(B7DSL8C/"^E=%J<LB_"!I1(XD_LI#OW'.=@YS3]A[D97^)A8[.FB1
M&;:'4GT!KPCPG-XH\5:2OA_3+J2UM(F9[R\9B2=W1<]>W0=><U%XN\&ZKX'6
MUU6UU:6=#)M,JY1HWZCN>#C]*V^J1Y^1SU"Q[]2,RH,LP ]S7-6WBI$^'T7B
M2Z"DBU$CJI'S/TQ^+<5Y;HVD>(OB?J%SJ-YJ36]G&VW/.U3UVHH]!W_G65/#
M\UW)V2"Q[N"&&001ZBEKQK6?#OB/P!I=U<6&IO?:3/&T-Q&V0T>X$!@,G&">
MHK<^#-Q-<>'+]IY7D87> 78G V+ZTYX=*FZD9706/2:***YA!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 >?_$?QOJ?A&XT^/3X;607"N7\]&;&",8PP]:P$\=_$>1%=/"ZLC %6%C,
M01_WU4/QP_X_=%_ZYR_S6O3M,U;35TFS5M0M 1 @(,R\?*/>N_W(482Y;MW'
MT/-K;XLZ[IFJI;^)=&CMXFQN"1/'(H_O88G->NPRQSPQS1,&CD4,K#H01D&O
M(?C#J>F:E'IEC92QW5^LA/[E@^U2,8..Y../:O0+5;KP_P##^,-M^UV.G9PW
M(WK'T/XBHK0BX1FE9OH#.AHKR.Q^+5])X?+/:176M37#1P6\",%" #YF&23R
M3]<>U=+I/B/Q%;^";W5]9TJ62_BF.RV6/RR4.W! Y. 2?RK.6&J1W] L=O17
MF:7_ ,4=43[5;V-E8PL,I#*%#8_$D_GBE\-_$+5$\1CP[XJLTMKQFV)*HVC=
MV!'(.>Q''-#PTK-IIV[,+&[\0]4UO2="@GT$2&Y:X"MLA$IV[6[$'N!6QX9N
MKV]\-:?<ZB&%Y)"&FW)L.[Z=JQ_B)XFO_"N@P7NGK"TKW C(F4L,%6/8CT%3
M0^(+R3X;G7RL7VS["UQC:=FX GIGIQZT<K=*.BU>X'445Y'I_P 5]4O-'B@@
MT^.]UV>5UCBA0A$0 8)&22<Y_*L^_P#'_CWP[=P/K5E$D4AR(WA #CN P/6K
M6#J-VTN%CVRBJ6D:E#K&D6NHV_\ JKB,2 >F>H^H.1^%7:Y6FG9B"BBBD 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7G7CWQYJOA?Q!96%C#:/%/$'8S(Q8$L1QAAZ5Z+7B?QA_Y'
M/2O^O=?_ $-JZ<)",ZMI(:/:U.5!/<4M8'B[5[G0?"-WJ5F(S/ J%1(,KRP'
M(R/6N%M_BEJVH:596FEZ<E]KLX9I1&A\N(;B!QG.<8ZD 9J(4)SCS1V"QZS5
M74[PZ?I5Y>A YMX7E"DXW;03C/X5X]/\1/&OAO5($\064?E/\QB:(*77OM8=
M_P Z[7QOJ&O3^&TN/#UM;W%C<6LCW3RD K&5R",L.<$^M6\-*,HIM6?W!8L^
M!?&4GC&TO)Y+);7[/(J +)OW9&?05UM>!?#NZ\86]E>CPS86MS$9%\XSLH(;
M'&,L*]B\1>);7POH?]H:A_K" J0KUDDQ]T?XT\10Y:O+#KT!HVZ*\ILO$'Q)
M\21&_P!+L+2ULF&8A(%&\>Q8Y/UP!5S0OB)J5IKB:'XOL5LKER%CG484D\#/
M48/J#BI>&FD[--KI?4+'I5%<MXY\8IX0TJ.5(A->7#%(8R<#CJQ]AQ^=<Q%=
M_%:XM5O4MK%5<!U@(0-CTY/]<U,*$I1YFTEYA8]0KB[[QU+9_$&#PP+!&25D
M'G^:01N7/3']:F\-^(/$&LZ+J1N]&-GJ5J&2/?PDLFTD#!.1SCOCGK7D^HW'
MBIOB7;37-E;+KP9/+@5AL)V_+SNQT]ZVH8=.4E.VB[@D?0<I987*_>"DCZUP
M7P[USQ-J]]J*:^LHCB53#YEL(N23GH!GM6_X:N?$DFEW4GB2TM[:Z1SY2PD$
M%=O4X8]\US_PY\:ZIXKOM1AU!+95ME4IY*%3R2.<D^E1&#4)Z)VMK_D!Z#17
MF.J?$NYT7QW?Z;>K!_9EJI(VH?,<^6&"@YQRQ]*S;[QI\0;JU?5;'1_LNF!2
MZGR=YV?WCGD_4#%"PE1V>BN%CV"BN'^'7CB7Q9:7$%\D:7]M@L8^!(I[X[8[
M_44>-/B OAZ[CTG3+;[;J\N (^2(\_=R!R2?2H]A/VGL[:A8[BBO+7O_ (K0
M6HOGLK1T'S&W5$+@?0'/X YKI/!7CJV\612V\D7V74H!F6W/0CIN7\>".U.>
M'E&/,FFO(+'745YUXG\=:O\ \)-_PC7A>RCN+Y>)))!D*<9( ) XZY/%5;C5
MOB=HB&\O+"SOK9!F1(0"0/\ @)S^AIK#2:3;2OYA8]/HJIIEW+?:9;74]J]K
M++&':%R"4SV.*MU@U9V$%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=^3D>:Z1N1V4GG^6/QKD?AVK#XL:\2I *7'./^FRUZCK^CPZ_H=WIDYVK.F
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M?0_]!%>H5XGI'@OXBZ#!)#IEQ%;1R-N95F0Y.,9Y%:']C_%C_H)K_P!_8_\
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M#]?]]JZVN6M_$EZL04445D 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !371)$*.H93U##(-.HH 9'%'"FR*
M-47KA1@4_ SG'/K110 4444 %%%% $0MH!-YHAC\SKOV#/YU+110 4444 -=
M$D0HZJRGJK#(-)'#'"NV*-$7.<*H I]% !4;6\#RB5X8VD'1BH)'XU)10 =1
M@T444 12VT$Y!EACD(X!=0<5*!@8'2BB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@".6"*< 2Q)(!R Z@XJ0    8 HHH 0 *,  #VI:** "BBB@ (!&
M",@U'%;P0$F*&.//78H&:DHH *\4^(?CR/Q%:KH&E6]QO-P5FW+RY4X"J!UR
M>?RKVNL^VT+2;2\>[M]-M8KESN:58@&)]<UO0J0IRYI*[Z#12\&Z)_PC_A6Q
MT]AB54WR_P"^W)_+./PK=HHK*4G)N3ZB"BBBI **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH IZM8OJ6DW5E'<R6SS1E!-$?F3/<5Y=9Q?$GP=']@M;2+5;
M)"5B+#>%'M@AA]#P*]=HK:G6<$XM)KS'<\>U#3/B%X[$=IJ=K#IFGAP77&T$
MCN1DL?ITKT[P_H=MX=T6WTRUR4B'S,>KL>K?B:TZ**E9S7+:R[(+A1116(@H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** (Q;P++YHAC$G]\*,_G4G6BB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!AAB,HE,:&0# ?:
M,@?6GT44 1RV\,^/.BCDQTWJ#BG@!0   !P *6B@ J(VT#2^:8(S)G.\H,_G
M4M% !39(TE0I(BNIZAAD4ZB@!%4*H50 !P .U+110 4444 %%%% $0MH!+YH
MAC$G7?L&?SJ6BB@!" P((!!X(-1Q6\$!)BACC)ZE% S4M% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%-=TC0N[*JCJS' %9L_B70K8$RZQ8K@X(^T*2#^=-1;V0&I16
M)_PF/AO_ *#=C_W^%'_"8^&_^@W8_P#?X57LY]F!MT5B?\)CX;_Z#=C_ -_A
M1_PF/AO_ *#=C_W^%'LY]F!MT5B?\)CX;_Z#=C_W^%'_  F/AO\ Z#=C_P!_
MA1[.?9@;=%8G_"8^&_\ H-V/_?X4?\)CX;_Z#=C_ -_A1[.?9@;=%8G_  F/
MAO\ Z#=C_P!_A1_PF/AO_H-V/_?X4>SGV8&W16)_PF/AO_H-V/\ W^%'_"8^
M&_\ H-V/_?X4>SGV8&W16)_PF/AO_H-V/_?X4?\ "8^&_P#H-V/_ '^%'LY]
MF!MT5B?\)CX;_P"@W8_]_A1_PF/AO_H-V/\ W^%'LY]F!MT5B?\ "8^&_P#H
M-V/_ '^%'_"8^&_^@W8_]_A1[.?9@;=%8G_"8^&_^@W8_P#?X4?\)CX;_P"@
MW8_]_A1[.?9@;=%8G_"8^&_^@W8_]_A1_P )CX;_ .@W8_\ ?X4>SGV8&W16
M)_PF/AO_ *#=C_W^%'_"8^&_^@W8_P#?X4>SGV8&W16)_P )CX;_ .@W8_\
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MX4?\)CX;_P"@W8_]_A1[.?9@;=%8G_"8^&_^@W8_]_A1_P )CX;_ .@W8_\
M?X4>SGV8&W16)_PF/AO_ *#=C_W^%'_"8^&_^@W8_P#?X4>SGV8&W16)_P )
MCX;_ .@W8_\ ?X4?\)CX;_Z#=C_W^%'LY]F!MT5B?\)CX;_Z#=C_ -_A1_PF
M/AO_ *#=C_W^%'LY]F!MT5B?\)CX;_Z#=C_W^%'_  F/AO\ Z#=C_P!_A1[.
M?9@;=%8G_"8^&_\ H-V/_?X4?\)CX;_Z#=C_ -_A1[.?9@;=%8G_  F/AO\
MZ#=C_P!_A1_PF/AO_H-V/_?X4>SGV8&W16)_PF/AO_H-V/\ W^%'_"8^&_\
MH-V/_?X4>SGV8&W16)_PF/AO_H-V/_?X4?\ "8^&_P#H-V/_ '^%'LY]F!MT
M5B?\)CX;_P"@W8_]_A1_PF/AO_H-V/\ W^%'LY]F!MT5B?\ "8^&_P#H-V/_
M '^%'_"8^&_^@W8_]_A1[.?9@;=%8G_"8^&_^@W8_P#?X4?\)CX;_P"@W8_]
M_A1[.?9@;=%8G_"8^&_^@W8_]_A1_P )CX;_ .@W8_\ ?X4>SGV8&W16)_PF
M/AO_ *#=C_W^%'_"8^&_^@W8_P#?X4>SGV8&W16)_P )CX;_ .@W8_\ ?X4?
M\)CX;_Z#=C_W^%'LY]F!MT5B?\)CX;_Z#=C_ -_A1_PF/AO_ *#=C_W^%'LY
M]F!MT5B?\)CX;_Z#=C_W^%'_  F/AO\ Z#=C_P!_A1[.?9@;=%8G_"8^&_\
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M4?\ "8^&_P#H-V/_ '^%'LY]F!MT5B?\)CX;_P"@W8_]_A1_PF/AO_H-V/\
MW^%'LY]F!MT5B?\ "8^&_P#H-V/_ '^%'_"8^&_^@W8_]_A1[.?9@;=%8G_"
M8^&_^@W8_P#?X4?\)CX;_P"@W8_]_A1[.?9@;=%8G_"8^&_^@W8_]_A1_P )
MCX;_ .@W8_\ ?X4>SGV8&W16)_PF/AO_ *#=C_W^%'_"8^&_^@W8_P#?X4>S
MGV8&W16)_P )CX;_ .@W8_\ ?X4?\)CX;_Z#=C_W^%'LY]F!MT5B?\)CX;_Z
M#=C_ -_A1_PF/AO_ *#=C_W^%'LY]F!MT5B?\)CX;_Z#=C_W^%'_  F/AO\
MZ#=C_P!_A1[.?9@;=%8G_"8^&_\ H-V/_?X4?\)CX;_Z#=C_ -_A1[.?9@;=
M%8G_  F/AO\ Z#=C_P!_A1_PF/AO_H-V/_?X4>SGV8&W16)_PF/AO_H-V/\
MW^%'_"8^&_\ H-V/_?X4>SGV8&W16)_PF/AO_H-V/_?X4?\ "8^&_P#H-V/_
M '^%'LY]F!MT5B?\)CX;_P"@W8_]_A1_PF/AO_H-V/\ W^%'LY]F!MT5B?\
M"8^&_P#H-V/_ '^%'_"8^&_^@W8_]_A1[.?9@;=%8G_"8^&_^@W8_P#?X4?\
M)CX;_P"@W8_]_A1[.?9@;=%8G_"8^&_^@W8_]_A1_P )CX;_ .@W8_\ ?X4>
MSGV8&W16)_PF/AO_ *#=C_W^%'_"8^&_^@W8_P#?X4>SGV8&W16)_P )CX;_
M .@W8_\ ?X4?\)CX;_Z#=C_W^%'LY]F!MT5B?\)CX;_Z#=C_ -_A1_PF/AO_
M *#=C_W^%'LY]F!MT5B?\)CX;_Z#=C_W^%'_  F/AO\ Z#=C_P!_A1[.?9@;
M=%8G_"8^&_\ H-V/_?X4?\)CX;_Z#=C_ -_A1[.?9@;=%8G_  F/AO\ Z#=C
M_P!_A1_PF/AO_H-V/_?X4>SGV8&W16)_PF/AO_H-V/\ W^%'_"8^&_\ H-V/
M_?X4>SGV8&W16*OB_P .,P4:W8Y)P/WRU?MM4T^];;:WUM.WI%,K']#2<)+=
M 6Z***D HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **0D*"2
M0 .237D'CKXJMNDTOP[+@#*RW@[^R?\ Q7Y>M:TJ,JLK1!([KQ-XZT7PN#'=
M3^;=XR+:'YG_ ![+^->4:W\7M?U%V33Q'IT!X 0;W_%C_0"N >1Y9&>1F=V.
M2S'))IM>O2P=.&^K+2+5YJ=_J+[[V]N+AO660M_.JM%%=:5MAA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2ABIR"
M0?44E% &_I7C;Q%HS#[)JMQL'_+.5O,7\FS7HWA[XSQ2LL&O6?E'I]HM\E?Q
M4\C\,_2O&J*PJ8>G4W0K'UM8W]IJ=HEU97$=Q XRKQMD?_K]JL5\M>'?%&J>
M&+T7&G3E5)'F0MRD@]"/Z]:^@_"7C'3_ !;8&6V/E7,8'G6['YD/J/4>]>5B
M,)*EJM42T=%1117((**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M74K*:U:5=T8E7!8>M*ZO811HHHIC"BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "K^CZQ>Z%J<-_83-%-&<\=&'<$=P:H44FDU9@?4?A7Q+:>*=%C
MO[;Y'^[-$3S&_<?3N#Z5MU\W?#WQ2_AGQ'&97(L;DB*X7/ '9OP/Z9KZ1!!
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M1OASP-;^&/#5W;08GU&Z@99ISQN8J<*/10:\BD^%WBRWMWEDL8@D:%F/GKP
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M6J$STOQ]XQ;P;'8-#IT-S]I9P=YV[=N/0>]<9%\8X)Y574O#=O)!G^!P2ON
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M<?\ )(/^X,O_ **%?./:HP.TO42"BBBNXH]U^"W_ "*=W_U^-_Z"M>4^./\
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M"(HR$CE*@$KZ5P5W>WFI3K)=W$US-@(K2,6..PY^M==\6?\ DH%U_P!<8O\
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M1)%[]C7D]O!+=7,5O"A>65PB*.Y)P!7N/QIM1)X4M+G!W0W8 Y[,I_P%>6>
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M_P"A"NH^,'_(]M_UZQ_UKE_#'_(UZ1_U^1?^A"G2_@+T!;'KWQK_ .16L?\
MK\'_ * U>(VPB-W")SB$R*'/^SGG]*]N^-?_ "*UC_U^#_T!J\.BBDFE2*)&
M>1R%5%&2Q/0 5G@?X/WB6Q[Q\1=>M].\$?9M$U&WCD+1Q!;>8;EBQ_#@Y'0?
M@:\J\,^,M7T+6;>?[=<S6Y<":&20N'4GG@GKZ5T6G_".YCLEOO$&J6VEV^,N
MO#,H]R2 #^=3K<?#/P[*JP6]QKET#@._,>?QPI_(UG3]E&#A'WOE^H'5_&'3
M8+OP@FH%0)[692CXYVMP1_(_A7AMI?7>GS>=9W,MO+C;OB8J<>F17O\ \5SG
MX>W1 Q^\BX_X$*^>:O :T;/N"V/I3P[=7$WPRM;J6:1[@Z>SF5FRQ;:><^M?
M/Y\3:[)%M?6+YE9<$&=N17O7AG_DE%I_V#6_]!-?."_='TJ,'%.4[KJ".G\!
M^&E\4>)X;.8'[)&IFN,'!*#M^)(%=O\ $+Q7J^FWR^'_  Y#/9VEJBJ\EM"<
MDXSM4@< #TI/@<B>;K4G_+0+"!]/FJ#QE\0O%&@^+;_3K>XB2WC<&(/ "=I
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ME*XY PV.??)_*N&E6E'#2?5:"OH4OB+X[N],OSX=T"064%HJK+)#@-G'W%]
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS#J[1L"?R8"LX4:M&3]GJGT%:Q/\,_ NI/KT&LZE:RVMI:'?&)EVM(_0<'D
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %>;?%[PR=2T:/6;:/=<6
M0Q+CJ8CU_(\_B:])ILD:2QM'(H9&!5E89!![5I2J.G-20'R'178?$#P;+X5U
M@O"I;3;EBT#_ -WU0^X_45Q]?0PFIQ4H[%A1115#"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBE52[!5!+$X '>@#3\.Z)/XAUVUTV ',K_ #L!]Q/XF_ 5]26=I#864%I;
MH$AA01HH[ # KB?AIX+_ .$;TO[=>Q@:G=*-P//E)U"_7N?_ *U=Y7B8RO[2
M=H[(AL****XQ!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!2U72K+6M.EL+^%9;>4
M8(/4'L0>Q'K7SQXR\#:AX3O&+*T^GNW[FY4<8]&]#_/M7TI45S;07EM);7,2
M2PR+M='&0PKIP^)E1?D-.Q\C45[%XH^#@D=[KP],J9Y^R3'C_@+?T/YUY5J>
MCZCH]R;?4;.:VD["1< ^X/0CZ5[-*O"JO=95RE1116HPHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** ,]*Z
MSP_\._$'B!D=+1K6U8C,]P"HQZ@=3^%3*<8*\G81RT44DTJQ1(SR,<*JC))]
MA7MWP[^&XTCR]7UJ(-?]88&Y$/N?]K^7UKHO"G@#2/"RK+&GVF^Q@W,J\C_=
M'\/\_>NKKRL3C>=<L-B6PHHHKSQ!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !4-S:V]Y"8;J"*>(]4D0,#^!J:B@#CK_X7^%+YBWV!K=CWMY"OZ=/
MTK"F^">C,P,.IWZ#N'V-_05Z=16\<35CM(=V>6_\*1TS_H+W?_?"T?\ "D=,
M_P"@O=_]\+7J5%5];K?S!=GEO_"D=,_Z"]W_ -\+1_PI'3/^@O=_]\+7J5%'
MUNM_,%V>6_\ "D=,_P"@O=_]\+1_PI'3/^@O=_\ ?"UZE11];K?S!=GEO_"D
M=,_Z"]W_ -\+1_PI'3/^@O=_]\+7J5%'UNM_,%V>6_\ "D=,_P"@O=_]\+1_
MPI'3/^@O=_\ ?"UZE11];K?S!=GEO_"D=,_Z"]W_ -\+1_PI'3/^@O=_]\+7
MJ5%'UNM_,%V>6_\ "D=,_P"@O=_]\+1_PI'3/^@O=_\ ?"UZE11];K?S!=GE
MO_"D=,_Z"]W_ -\+1_PI'3/^@O=_]\+7J5%'UNM_,%V>6_\ "D=,_P"@O=_]
M\+1_PI'3/^@O=_\ ?"UZE11];K?S!=GEO_"D=,_Z"]W_ -\+1_PI'3/^@O=_
M]\+7J5%'UNM_,%V>6_\ "D=,_P"@O=_]\+1_PI'3/^@O=_\ ?"UZE11];K?S
M!=GEO_"D=,_Z"]W_ -\+1_PI'3/^@O=_]\+7J5%'UNM_,%V>6_\ "D=,_P"@
MO=_]\+1_PI'3/^@O=_\ ?"UZE11];K?S!=GEO_"D=,_Z"]W_ -\+1_PI'3/^
M@O=_]\+7J5%'UNM_,%V>6_\ "D=,_P"@O=_]\+1_PI'3/^@O=_\ ?"UZE11]
M;K?S!=GEO_"D=,_Z"]W_ -\+1_PI'3/^@O=_]\+7J5%'UNM_,%V>6_\ "D=,
M_P"@O=_]\+1_PI'3/^@O=_\ ?"UZE11];K?S!=GEO_"D=,_Z"]W_ -\+1_PI
M'3/^@O=_]\+7J5%'UNM_,%V>6_\ "D=,_P"@O=_]\+1_PI'3/^@O=_\ ?"UZ
ME11];K?S!=GEO_"D=,_Z"]W_ -\+1_PI'3/^@O=_]\+7J5%'UNM_,%V>6_\
M"D=,_P"@O=_]\+1_PI'3/^@O=_\ ?"UZE11];K?S!=GEO_"D=,_Z"]W_ -\+
M1_PI'3/^@O=_]\+7J5%'UNM_,%V>6_\ "D=,_P"@O=_]\+1_PI'3/^@O=_\
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ME11];K?S!=GEO_"D=,_Z"]W_ -\+1_PI'3/^@O=_]\+7J5%'UNM_,%V>6_\
M"D=,_P"@O=_]\+1_PI'3/^@O=_\ ?"UZE11];K?S!=GEO_"D=,_Z"]W_ -\+
M1_PI'3/^@O=_]\+7J5%'UNM_,%V>6_\ "D=,_P"@O=_]\+1_PI'3/^@O=_\
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ME11];K?S!=GEO_"D=,_Z"]W_ -\+1_PI'3/^@O=_]\+7J5%'UNM_,%V>6_\
M"D=,_P"@O=_]\+1_PI'3/^@O=_\ ?"UZE11];K?S!=GEO_"D=,_Z"]W_ -\+
M1_PI'3/^@O=_]\+7J5%'UNM_,%V>6_\ "D=,_P"@O=_]\+1_PI'3/^@O=_\
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? HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img222477878_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $I ?P# 2(  A$! Q$!_\0
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MK,N_B19VFHW2_P!F7DFDV=XMC=ZHNWRH9R0-NW.X@$@%@, F@"A=^$O%FO\
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M)5?]Y]=ZJ/Q JOX?^(/B;1[":SOHY=6UJZU)TC1PQ6%%A21E 4$\;@ /J>U
M'9M\.[J?2K>VN-1L4FCU2WOR;/34MXPL1SL"J<G/JQ/6G:Q\.9=3.MRQZHL,
MU]J5OJ,#&#<(GA55"L-WS X]JQ]3^+=W9Q:=-'H\8,D4,E[;22.983))LQ\J
ME5'<%B-V>!5]/B%JXU4F72K/^R1KYT0RK.WG;LX5]N,8]>: +DGP\DNM*\66
M=UJGS>()%D:2*';Y3!5'0DY!*]/0XK,D^%=[=6FN1W6MV_G:I!:H#!8B)('@
M;<NU WW3W'7KS6UXXUSQ+I-WI,>B:4MQ!/>PQRR^<!OSNS&00=H.!\_:IO&M
MSK?_  A\3:=-'8:G/-"K1?:$5WR?FBBD8;=Y&0"10!FW'PXGU)M=FU'5U-UJ
MGV.19K>WV>1-;CAP"QR"><>G&:BO?AM>ZM;ZC<:GK<<VK7TUJ7GCM=D4<<#[
ME14W$\\Y))YKE9O$>L3VFC:?%J.OR3?VS/:75NOEQ7J*(MZQ,_W7(Z[^,CWJ
MQXFU;Q#H4?AU[&ZUJ B>YNKJWU*5))9HH@C,IV\8V[L"@#TG3/#S:?XLUW6S
M<B1=4%N!#LP8_+3;USSGKT%<Y>_#:6ZN;^S36?+\/ZC?C4+NQ^S@R-)N#%5D
MSPA902,$^AK.\!^)M4U_XBZU)+>RR:/<68N=/@;A5C$K1A@/]K83^-=+XG\1
MZQIWB31]$T:QL[BXU&&XDWW4S(J>4%/8'.=U %[P]X=;0[_7;EKD3?VI?F["
MA-OE@JJ[>O/W>O%<38_#?QEI6K:EJ.G>.((I]0F,LTDFEI*[#LNYF)P!V&!3
MQ\3[VZTK3+^#^R;7[7:B5X;H7#,K;F4X,:$%?EX[U6N/B%+J'Q%\/V=MJMK!
MIL=RUK>1I)@W$QA+'@\A%;:HSC+$^E &[IGPY;2O$CWMO>V1L'O&O3%)IL;W
M&]N2@F;)";OF&!D>M<9:Z#K#:SI.@VUIJZ:78:[]M6"ZL!&D4669B;@,5D&6
M^4#!YYKJOBEXCN+&32]$L-6ETNYN_-N)+J)"[1I&AVC !X9RH_ U@77BS4_$
MD_A&6RDUGR[[39Y+JVTJ5(Y/.C9%;)?C ;=^8H Z;3_AM)9W&G6<VK^=X?TN
M\:]LK'[. ZR$DJ'DS\RJ6.!@=LT6/P_U73[";1X/$A70Q#<Q6]H+4;OWP;B1
M\_,%+$C !]34L>K^(?"OPJN-6UR,7.JVB/)Y<\B[BN_"!V3C=M(R1WK/N/B/
MJNFO?6&IZ?IT6IQQV\ML(KEY(I%F8@+PNXN,'Y5!W=J +=Q\.;AM+\*PVVK1
M1W6@P& 236@ECD#(%+;"W##&0<G%06/PUU#2-.T;^RM>C@U32X)[5;E[3>DL
M4KEN4W<,#R"#^%8\/C[Q%KEWX<N+>*WL[>X745N[?>P+F  $@E<C Y ]2<]*
M99_%74[>RTJWM=$N-1*:?;75Z[.SR$2]@P7&0.<M@$\4 ='J'P]O[O4#>+K^
M^6XT5])O)+BV#-,#DB0;2 IW$9X/ _&G6GP[EMDNE.IJWG^'8M$_U.,%%*^9
MUZ'/W?UJG_PL/6O[1D;^R;+^S%UTZ*)#.PEWG 5RN,8!(SS]*QK#X@>+--\)
M6-Y>6%K?R7$UT9+D,Y6-(W("LJ*2,G(#8P !GO0!VVI^#WU'X:?\(D+U4?[%
M':_:?+R/DV_-MSWV],UG:A\.Y+ZV\6Q#4U3^WX;>-3Y.?)\I N3S\V<>U6=(
M\03W?CM+99_-L-2T6+48D5PZQ.'VMM/<,&'Y>]=G0!S7BCPLWB+1M.T];M8#
M:7EO<ES'NW^6<XQD8S5?7_!$>O:W<WLEWY4%QHTVE-&D?S#S'#;P<]L=,5UM
M% 'F3_"_5;N&Z&H^(H)Y)=$.CQE++8(UW AOOG)XY_I6IJ'P_DOO[6QJ2I]O
MT2/2A^YSL*[OGZ\YW=/UKN:* /+]8^$USJ(O4@UR&&.]M;6&;S+(2.&@ "[&
MW JA*@E?UK2O_AU-?:9XGM/[31&UN^BNPWD$B'84.W&[G.WKQUKOJ* "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *K:C8P:IIMU87*[H+F)H9!ZJPP?YU9K&O=
M7NHM7DL+:WA<QVWV@O+*5!&<8Z&IG-15V:4Z<JCM$J6_@G2&TI;34[:/4)6M
M(;.XGE4@SI$<IN .,@\\=ZGO/!GAV_CN$NM*AD%Q<?:I"203+MV[L@Y!QQQV
MI]KXGL9K"WNIA+ LRJ26C8JA)P 6 QUJM'XH\_S0(E@\N]%MF4-A@?3 X/L:
MS]O3TUW-5A*VON[!=> O"UZZ-/HELQCA2!< J B_=& >W8]15S_A%]$\LH=/
MBVF^_M$C)_X^<Y\SKUIZ^(=,;D3MMPY5S&P5]O+;3C#8P>E4[OQ=I\>GSW%J
M7GDCB\U(RC)O7.,@D=/>FZU-*[DB8X6M)V47]Q-J_A+1-=NUNM2LS-,J",,)
MG3Y<DXPK =S5B[T#2K_15T>[LHY[!555ADRP 7[O)YR,=<YIL>O63F-"91*T
M:R,BQ,QC#=-V!Q^-376KV5E,\5Q,49(Q*V5.-I.W/YU7M(6O<GV%2]N5W,E_
M /A9]/AL#H\(MX9FG159E(D88+;@<DD=R:FM?!?AZS\KR=-3]UYGE[Y'?;YB
M['^\3U7BGW/B2T40"VF1FD:,G>C_ '&) Q@=3CC-48/&"S"QD>V:*.>66-_E
M9B-HXVX')/Z5#Q%-.US6.#KR5U'^M_T);KP1HTEHD%I;+9E(H;=9(LY$,<F\
M(.?7//O6S-I=E<:G:ZE-;J]Y:*Z02G.4#XW ?7 IUI?VU]9B[MY-T!S\Q!&,
M=<@].E9FF>)(;V*ZEN4%JD*B56=OO0G.U_QP:MU(*VNYDJ%1IM+;<T=+TNRT
M73H=/TZW6WM(01'$F<+DDGK[DU#<:#I5W?6U[/I]N]U;2&6&4H-RL003[G![
MU&GB+36,:^;(K2.B('A=2Q;[N,CH?6H+[Q-;6M[#;11O,S7/V>7:I_=G&?3D
M^PJ76II7N5'#5F^519H#2K%=8;5Q;K]O: 6YGYW>6#NV_3/-5+/POHNGZ@+^
MTT^.*Y#2N'4G@RD&3 SCD@&IAKFGFX\GSCGS?)W[&V;_ .[NQC/XU!?:K=0Z
MQ_9]K;PNWV8W!>64H/O8QT--U8)7N)4*C=K6ZZZ"^*-"7Q-X9O\ 1GG:!;N/
MRS*J[BO(/3\*H0_#[PK#ISV(T6V\F1TD?@Y+H,*=V<C';!XS5NU\46,^GV]U
M,)8%E4%BT;%4)..6 QUJ;_A(M,^UFV\]O,$WD$^6VT/V!;&*%6IM7YD-X:LF
MURO3R*@\#^&E@MH%TB!8[65YH%4L/+=_O$<]\<CI2/X&\,2-8L^C6S&P18[?
M(/R*IRJGGY@#R <U<_X2/3/WA$[%$#DR")MIV_>PV,''M2+XDTUT5DDE?<I<
M!8')*CJV,?=]Z/:T_P"9"^KUOY7]PA\,:*493I\6UKX:B1D\W(.?,Z]>!5&;
MX?>%)XFCDT6W*M*\Q +#YG^_C!X![@<'TK3EU[3HD21IF,+JK"98V* 'H2P&
M!6:OBD2-< 1"+R;Q;?,BL0X/I@?>]J4JU..[*CA:TE=1+-AX:M;#Q#+JL9 _
MT..QMH%0*L$2$D@?4D?]\BMNN<L_%274%I/(J6T<LDJR"7=T0$Y4XQVYS6Q9
M:C;Z@NZ#S,;0P+Q,F0>A&1S3A6A/X6*IAZM/XE_6Q;HHHK0P"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH RO$MQ/:>%]5N+:3RIX[61HY"#\C;3@\ GCKP*\?3Q!J4?AJWBN?$-['9K
M>7"3:Q;7;R"9UMP\01V7(4OD%<<E<=Z]UIGE1^6(_+38.B[1@?A0!S]IK6I0
MZ=H;7EAO-Y' D\QD"%)77)^3'K71UC^(/^87_P!A"'^M;% !1110 4444 %%
M%% !61<Z!;WNMF_NECFC^SB$0NF<'=G.?TK7HJ90C+21<*DJ;O%V.9U+PM-?
M27*QW4:02A/+5XR3"%_A4 @8-))X5FD\Z-KQ/(EO!=E?*.[/<9S73T5D\-3;
MO8Z%CJZ22>WDO+_(YB'PHT=L+5I8&AB1UB<Q$N"P(!/. 1GL.:==^%#=6T,)
MNPOEV!M,^7U/'S=?;I72T4?5J5K6#Z[7YN:^ISD_AZ]G:%C=V\4J!%^T0Q,D
MBA>V=W(/O5W6M$&K^3B;R2N4D(7.^-OO+^.!6M15>PA9JVY'UJKS*5]5L<W%
MX6,=JD;7>^5;N*<R%.J1\*G7L.]+I_AJ:RN;)FO$>&TFED11%ACO!X)SVSZ5
MT=%2L/333ML4\96::;W\EVM^1A1Z#-#H%UID5X%>XD=O-"?=#G)&,^G%5[OP
M=;3;5MYW@C-N;>4$EMR\%<9/&",UTM%-X>FU9H4<96B[J7G_ %_6A@7.C:G>
MP0BXO[<R6\L<L(6 A=R'JW.>?:J__"+W9G-T;^(W'VP78/DG;D+MQC/2NGHI
M/#TWJ_S8XXRK%65ON1S=KX7-O((VD@EM?/\ /P\9+9SG;UQU[XS5Z[T&WOM:
M6^NECEB6W\D0NF>=V<Y_2M:BJ5"FE:Q,L56<N:^IS.I^%Y;Y[E([J)()E18U
M:,GR O9 "!@U*WAEGLY8#=#]Y?+=D[.PQ\O7VZUT-%3]7IW;MN5]<K62OM_7
MZ'.Q^'[Z+3)=*34(A8F.2-!Y.7PV<9.>V>W6EF\./]H@N()HC*EJMLXE5BI
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MI#K,^G7OAD0?9KJUMKF1;]7V&X/R$#;\WO7H= !1110 4444 %%%% !1110
M4444 %%%9VLZI_9%A+=M"7C1<D[@.>PJ9245S,J$)3DHQW9HT5QO@SQ)<ZE%
M):7"M-<(Y<ON ^0GW]#_ $KLJBC5C5@IQ-<3AYX>HZ<]T%%%%:F!C^(/^87_
M -A"'^M;%87B.!7GT>8O(#'J$8"JY"G.>H[UNT %%%% !1110 4444 %%%%
M!1110 4444 %(74'!8?G2UA:UI=A)<64KV<#227BAV*#+<-U]:J*3=F!N @C
M(.:6HH+>&UB$4$211CHJ# %2U(!1110 4444 %%%% %*?41;R!&M;AMS[%95
M!#'\ZM12&6,.8WCS_"X&:JZC]ZS_ .OE?Y&KM0KW9I+EY59!1115F84444 %
M%%% !1110 4444 %%%% !6%XFG%N-)E9)' U"/Y8T+,?E?L*W:Q]>_UNC_\
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M,\.7EC)93Z/:O;27#7+1[< R'@MQZ@D>F.*W:* ,77(TABTF*-0D:7\*JJC
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MQL]Z,HP@X;+_ #@\$E<=*[O6X]2'AX066GVFKW3*L;Q7D@CCD&/F9N#]<8H
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MD*Q]>_UNC_\ 803_ -!>MBL+Q,)V&DBW>-)?[1CPTBEA]U\\ CM[T ;M%%%
M!1110!Y-J[:3_P )!J6Y?$']@?VE'_:9A\K[)]JRG7/[S;NV;MO&?QKT?Q!>
M?V?X>U"[^T26_DP,_FQ0B5TP.H0_>/M7FFLW-A_PE&H:HWA^VDL[+4HH+I&U
M-DDGF^0++]G^XQ&5QGDXS7I>N3V2>';Z>\NI8+)8&:6>WD*NJ@<E67D'TQS0
M!P'AS5[S_A/;;^U(O$=W=7%DT<,EQIT5O'#'O4DL$.3SMY/3TYKU&O-_!RVH
M\9"33M<U>YLYM-9C9ZK<3/(DBR[6(#]",8(SD9'K7I% !1110 4444 %%%%
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MI,+H^XQ+O!(.T$ 9Z8XKI_B-??9/#T$4D%DUI=W207-Q?6_G0VR$$^8R=^0
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MPH9))'. J@9)-<^?B!X772!JK:J@M#,8-QB?<'"[B"N-PPOS9QTYH N^(/\
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MNF\2^,O#@TS1]5@-XUS=V\<&LP0@I+&SC>DJ_P #[<\C@UZC0 4444 %%%%
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M%%% &%XBG1)]'A8/ODU",KB-B.,YR0,#\3S6[6/X@_YA?_80A_K6Q0 4444
M%%%% !1110 4456O[K['923[=S*,(G]YCPH_$D4)7 K)_INM-)UALAL7T,K#
MYC^"X'_ C6E5;3[7['91PLVZ3[TC_P!YSRQ_,FK-.3U *K30.)//M\"7^)3T
MD'H??T-6:*EJXTVF103I.FY<@@X93U4^AJ6J\\#%_.@(68#'/1QZ'_'M3#J5
MM&J>?((7:01;'."'/;_Z]+FM\17)S:Q+$TJ01-)(<*OZ^U0V\3ES<3C$KC 7
M^XOI_C3(@;N87#@^2A_<J>_^T?Z5<H6KN#]U6ZA1115$!4-W;)>6LEO)G:XQ
MD=0>Q'N#S4U% %/3;EY[<I/@7,+>7,!_>'<>Q&"/K5RLV]_T&^COQQ$^(;GV
M&?E;\"<?0^U:55+N@"BBBI **** "BBB@ HHHH **** "BBB@ HHHH *QM?
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M.48 ^A'(/N*\?O/#6H1>#M(M9]#O;VRMKO4!+8(-TA+F0028)!(!(.<\9!H
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MSR .[ X&*XZ7X?\ B">&_M##8(EO%<"TG\TDWADNEN '&/E V[3UY.:]9HH
MY[P?IE]INF7;ZC!!;W5[?37C6\+[UBWG(7=@;CQR<=370T44 >?R?!WPQ++)
M(TFH;G8L<3CJ3G^[6_J.CRV'@*ZT?19)DEBLFAM7\P!P=N =QQCZ]JZ&L;Q<
MEC+X/UB/4YY8+%K203RQ ET0J<D =3[5I.K.:M)W XWX<IJTVL333W5J;&UM
MFMUAAU<7S<R;D#'L5&\9/)!'I7I=>6>&=2TFV\;:=$EEJL=W+I2VRG^R?LT3
M ,-TC@<\G;CLO/K7J=9@%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!A^(H(7FTB9XHVECU",(Y4%ESG.#VS6Y6/X@_YA?\ V$(?ZUL4 %%%% !1
M110 5FZG_I4MOIJ\B8[YO:)<9'XG _$UI=*S=+!N7GU%@?\ 2#MBSVB7[OY\
MM^-5'34#2HHHJ0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#+O=*N+R=
M'_M.:-8Y1+&BQIA2 ?4<]:OV\<D4(26=IG'5V4 G\!Q4M%-R;5@"BBBD =>M
M59M,L+DYFLK>1O5HP3^=6J*:;6P&;_85BO\ J1/ 3WAG=/Y&C^S;J,?N-6NE
M]!*J2#]1G]:TJ*?,P,WR]9CQMN;.<?[<3(3^()_E7SWXOU?5XO&.K(=1NHBM
MRP\N&Z?8OL.G'X5]+5SE[X"\+ZA>S7EWH\$MQ,V^1RS98^O6NC#5XTY-R0TS
M,^%5Q/=>!8);B>6:0S2 O*Y8_>]37;52TO2;#1;%;+3K9+>V4EA&F<9/7K5V
ML*LE*;DNH@HHHJ "L+Q,)R-*%LT2S?VA'M,JDK]U^H!!K=K'U[_6Z/\ ]A!/
M_07H V**** "BBB@ JAK<<LNB7L<*W+2M"P5;614E)Q_ S< ^YJ_4%[:1WUE
M-:RM(L<R%&:)RC 'T8<@^XH \Z\,VMT_B;^S[^;Q=:7"P"Y3[?J,,J2(KKE1
ML!ZG (]/J*],K"T;PCI6AWTE];?:IKMX_*\ZZNI)V5,YV@N3@9YXK=H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "N"^)FJW.G1:7&-5GTFQF,YGO(6
M"L'2(M$F2#PS=N^,=Z[VF21QRKMD177.<,,B@#DY9]=U#1] E72C<2@6UU<.
M9DB^;;EAM/N:UO[2UK_H '_P,CK9HH QO[2UK_H '_P,CH_M+6O^@ ?_  ,C
MK9HH QO[2UK_ * !_P# R.C^TM:_Z !_\#(ZX?1?B9JU[J$QN=-AEL(5NWF:
MVAF5K=8=V"SL-C;MN,*>I]C6BOQ9TM+K2K:[TZ\M9=0CBF"R%"8XY6VQL0#S
MGK@9('6@#R?QAJNI_P#"7ZLKW%U;G[008!<$A.!QP<5ZA\,]2U;_ (0N 1Z=
M)>J)9 )6NE!Z],-SQ53Q7>>"_/O);'0H==UADN)9E@.?+,2C>9#N'0E1@<\U
MHZ#XQTG2X+#3;719K>U;[,ES/;@>1!<7"JZIR=QSO7G'&1FNVMB83I*"6J&V
M=3_:6M?]  _^!D=']I:U_P!  _\ @9'7/'XH:;'I>JW]Q87=O'82K$(Y619)
M&9]@RF[*<]V &.:Z3PWX@M/%&APZK9JZQR%E*/C*LI((XX/(ZCK7$(9_:6M?
M]  _^!D=']I:U_T #_X&1ULT4 8W]I:U_P!  _\ @9'1_:6M?]  _P#@9'6?
MXQ\2:AH9LK;2K6VGN[E9Y?\ 27*H$ACWL..<G@#ZYJOXD\6ZC8^%=*U/2-.:
MYN=0,;"(PO,(T:,NQ(3G@"@#8_M+6O\ H '_ ,#(ZKW6OZI:/;K+H#YN)1"F
M+N/[Q!/\E-4]2\6W%EX5T35[6"/4'U">WB*6X(#B3KL#$8/INZ=Z9I?CNWUN
M^TFUM=(O'>]BDG=FV 6HCD,3[N>S CC.: -?^TM:_P"@ ?\ P,CH_M+6O^@
M?_ R.LJ^\?6NG^)9])FTV\,-O/;V\]\NTQ1O.!Y>1G=R2!P.,U7A^)-G+;W4
MYTC4UB6UDO+0^6K&\B1@K,@!R.2#@XX.: -W^TM:_P"@ ?\ P,CH_M+6O^@
M?_ R.L2R\=S:CJWAZVM=(8V^JK.TLOVF-_(\L#^Z2#U'OR.*[2@#&_M+6O\
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MN@/F>41)B[C^\03_ "!K.'C^*2WT\VNCWMY<743W#V]H\<IAB5@K,2&P>2,
M'-0V/CLS^*+O2+W2Y!''J$MI;7<>/++)"LN&R<AL%N<8Z4 ;W]I:U_T #_X&
M1T?VEK7_ $ #_P"!D=<Z/B;;FSF<:->M=1WT-D+9)(V,C2@E"K!MI!QZU*OQ
M)LA?-'-IE]%9K]J_TU@IC)MU+2@ '/!##ISB@#=_M+6O^@ ?_ R.C^TM:_Z
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M 4444 %%%% !1110 4444 ?_V0
0                      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img222477878_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $_ 6P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6\$ V\+B52W9BV"1WQGM0!WU%%% !1110 4444 %%%% !1110 4444 %%%%
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M=F=[17GS:CX?B6XDGU(P6\)C'VB74&$;[UW+M._GBITN- EU!=/CU97O&^[
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MBNC!D89#*<@BO$?'*:?HOBS5(U7PU:%K9;M&UC36N9;R1BVX(Y)R 0!@=,@
M8KMOA8X_L&]@^QVUL8+O:PM8WBC+&-&($;$["I;:P'&Y30!W5%%9D6O6,VLR
MZ5$9Y+F$[9"MNYC0[0V#)C:#@CC/>@#,\1W?_$\T"S^S7'_'^LGG[/W7^KE&
MW=G[WM735A>(_P#CZT#_ +"B_P#HJ6MVKELA!1114#&32I;P232';'&I=CZ
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MQ;S2!;!Y6#WHMXRBBY95+\'ZCUXQ0!U%%%9\>N:7-JTFEQWT#7T8RT ;YA@
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M B.=%).3L\Q25'MG [5MZ)HXT6S: WU[?2R/YDEQ>2[W9L =@ !QT  K2HH
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MWT:Z\)[SG0_F6GJM5^J^9M6]Z$:GR?R_X'Y'8T445SF04444 %%%% !1110
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MRQ?8R=;G/FQW+LD0D9B5.5!QR2,X[U[K_P )#XAM?^/_ ,(W+*.KV%W',/\
MOEBK?I7N9ID]7"U^56L]5JE\M6KV>ASPJ*2.HHKE_P#A/M%AXU!-0TUO2]L9
M8Q_WU@K^M:MCXBT74P/L.K6-P3VBN%8_EG->5/"UX*\H-+TT-.9,TZ***P&%
M%,BECF3?%(LB9(W(V1D'!_48I]&P!1110 4444 %%%% !1110 4444 %%%%
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MWV>)< #GE>>]>E5T8[-*6*KNM0@DGO=)Z_<1/#5*#Y*NC.8&G^-"26U_25]
MNFM_66D&E>,2#N\3V()_NZ7P/_(E=117)];GVC_X#'_(CE1R_P#8OBTK@^+X
M@>Y72D_^*H.A>*#C/C)P,\[=-A!KJ**/KE3M'_P&/^0<J.8_X1[Q$S MXSN\
M#LEC /\ V4T?\(UKA)+^--3]@MM;C_VF:Z>BCZY4[1_\!C_D'*CF!X5U,YW^
M,M;))_A6W'_M*D_X1"[*;6\7>(#ZGSHA_P"TZZBBCZY6\ONC_D'*CF#X-=@
M?%'B/'M>*/Y)2?\ "%(3\WB/Q&<=O[18?R%=111]=K_S?@@Y4<O_ ,(/:EMS
MZWX@<XQ\VIR?T-*/ NG9);4=;<DYRVJ3?_%5T]%'UW$?SL.5'+_\(#HNW:TV
MK-Z[M5N.?_'Z4_#_ ,.D -;WC#T;4;@_^U*Z>BCZ]B?^?DOO8<L>QS!^'WA@
M\MITCXZ!KN8_S>O%]1^%OCBX\0RZG8Z5%: 3^9;(MXA,0!^4 EL\<5]'T5VX
M+.\7A&VGS7_FN_U)E3C(J:5)>S:5:R:C L%ZT2^?$K!@KXYP1QC-6Z**\F3N
MV[6- HHHI >;SZA=3?$**Q?QE93Z:;EEETXB(2(<<0E2I+<XYR"/UKT9$2-
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M!C\V?;IFLR3P=I,EE+;F(LSG(FD DD3Z%@:N[ZK\?^&(YZ3WBUZ-/](_F;Q
M(P0"#7"_$;P.?$FBQQZ5:V$-ZLXD>:10AV '(W $]Q6C)X,$-G%'INIW5G<(
M?FE61\/]5# #\*RO%^B>(4T:5;35;F\L=H,\+@&5L'G! &5]145''E?,G8UH
MUJ=&:JQDU;75?HF_Q:7F<EX(^%-Y:ZZMWJTUC<V"QLI%I=ONW=N5Q_.O1_\
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MK?VMXJ7[WA>V;C^#4U_J@H_MSQ&OWO"$Q'^Q?PG^9%61K>H<[O#E^#[/$?\
MV:@:]=XY\.ZH#["(_P#L]')+O^0>RE_)'_P+_P"V*O\ PDFKK_K/"&ICG!V3
M0-_[/0/%=TO^L\*Z\O\ NQ1-_*2K7_"0R[<G0-7'MY2'_P!GH_X2,@9.B:Q_
MX##_ .*HY)=P]C+_ )]K[_\ @E;_ (3 #[_A[Q O&?\ CP)_D37BU]\7?%T=
M_<QQ7D:1K*P17M4# 9. <CK7N1\2(.ND:Q_X!L:\ UO3=+E\07D\5K.D/GL3
M%)(0QY.<^A//':HG1JS^%GL91@HU924Z?3KJ?1'A^[FU#PYIMY<,&GGMHY)"
M!@%BH)XK2JAHD<,6A:?';(Z0+;1B-7.6"[1@$]S5^K5TM3YRI\;MW"BBBF0%
M%%% !1110 5674;)[]K!;N WB+N: 2#>!ZE>M6:\[L=)U!?&42M8SHT.KW5[
M)=F/]VT$D6U '[G) V]MM "_$SQ7INEZ;"L5_ VH6MUDP)(#(A,4B@E>HY85
MT/@6SLM/\&:;;6$T4\*1<R1,&#-GYN1U.<C\*\&\97DD/C;5D>]MC<K<E9I3
M 560;%'RCGE<$8SR:]/^&46K7?@F"33-4M;6U\Z8+#+9%V3YSP3O'UZ=ZZIX
M?$PI1=2#C'776W]VZMVNUJ]'T(C5A*I.$;Z6]'W_ .!OH>F45RVEQ>,;NS\V
M^O[&RF\QU\K[#O\ E#$*V1+W !QVS4DUOXM2]M8H]3L9()-_FS?8"/*P../-
MYR>*PY%>UT5<Z6BL%[+Q.L;%=;L68 D+_9QY/_?VJVF0^+[O3+>XO=1L;.ZD
M0-);_82_EGTR)>:.16O=!<Z>BN3:3Q*OB"/2O[8L/GM7N/,_L\\;75<8\S_:
MZ^U6+VV\606%Q-;:K8W$\<;-'#_9Y7S& X7/F\9/&:.3S"YTE%<];6GBJ6UA
MDFUBQAE=%9X_[/)V,1R,^;SBHTM_%K:A-"VJ6*VZ1HR3_8#\[$MN7'F\8PO/
M^U1R+N@N=+17+ZI%XPM--FGL=0L;VY0#9;_8=F_D=S+QQD_A5O[#XE_Z#MC_
M ."T_P#QVCD5KW07-VBN3LI/$MWJ6I6?]L6"_8I$CW?V>3OW1J^<>9Q][%/U
M*+QC:P1/97]C>.TR(Z?8=FQ"<,^3+S@<X[T^36UPN=316%]A\2_]!VQ_\%I_
M^.U7M+?Q;-Y_VC4[&#9,R1_Z 6\Q!T?_ %O&?2ERKN%SI:*Y:]B\8V]Q9);7
M]C<QS3;)W^P[?(3:3OQYO/( Q[U<^P^)?^@[8_\ @M/_ ,=HY%W07-WI17)Z
M-)XEU?3$O/[8L(]TDB;1IY;[CLG7S.^W-/GB\8QZG9V\6H6,MK*LAFN/L./)
M( VC;YO.[)^F*?)K:Z"YU-%8+6/B8*2-<L20.!_9QY_\BU#96WBR>Q@FN=5L
M;>=XU:2'^SRWEL1RN?-YQ2Y5W"YTE,\J/+'RU^88;Y>OUKF3%XP_MD6O]H6/
MV(VYD-W]AZ2;L;-OFYZ<YIVJ#Q+IND7M]_;5A)]F@>;8=/(W;5)QGS>.E'LU
MW0&Z=-L3;/;&SM_(<Y:+RQM8^I%13Z+IUS;0VTMI&88?]6BY4)],5FP6WB6>
MWBE_MRQ&] V/[./&1G_GK5>&+QB^K75M)?V,=I'&C17/V'/FL<[EV^;D8P/K
MFI]C![V_KY$.G![Q-Z73;::]BNV$GG1 !=LK 8]U!P?QHBT]8KZ2Z%Q=,9 0
M8VF)C'T4\#I6+?V_BVWLI);74[&YF7&V+[ 5W9(!Y\WL,G\*L?8?$O\ T';'
M_P %I_\ CM'LH;Z!R1O>Q>ATZ6"VGB74KMVD^[)*59H_I\N/SS2-9Z@-/2"/
M5&%PK9-Q) K%AZ%1@?\ ZJQK.+QC/=WT5Q?V-O##(%@E^P[O/7:"6QYORX)(
MQ[4S59/$NF1VK_VQ82>?=16^#IY&-[!<_P"L[>E'L([)_BQ>SC;K][_S-^>+
M4M]O]GNK<(N!,)(22_J1AN/UIW_$Q_M'_EU^PX_VO-SC\NM9OV'Q+_T';'_P
M6G_X[5/3HO&-REP;S4+&T:.=XXQ]AW>9&#\K\2\9].U'LEOS?F/DUZFY#+J6
MZX^T6UN%4$P>7,27] <KQV]:8MYJ T]II-+87 ; MTG5B1Z[C@5E7%OXMCGM
M4AU2QECED*RO]@(\I=I(;'F\\@#\:L?8?$O_ $';'_P6G_X[2]E_?_K[@Y9=
MW^'^1>FU&6"V@E;3;MWE^]'$%8Q_7G^6:X36K/3+CQ)?Z@^D1,EDZ^>'+J)S
M\N>1\N[YA@$?-BNATN+QA=Z='/?:A8V5PQ;=!]A+[<,0.1+W !_&HA97$7B_
M3TU1M.OGGAE=9%LO+=#'LQSO;/W_ ,*BI2J[4YZ_UY?,3GBJ>M"HXO[OR^^Q
MUJX"@ 8&.!CI2T459J%%%% !1110 4444 %%%% ',:_XGLM&U$6\FG-<B&-;
MFZE7;_H\;/L#X/+'.>!V!KIE55&%  ]A7*^(O"$NMZC+/#>1PPWELEI>(\19
MFC5]XV'(P>2.<\&NK P,#M3NP"BBBD 4444 85SXCLH/%]CH(A,EY<Q2.TJ@
M8A4#< 3ZG'3VS6[7)2>"5'BVSUNWU.\58[B6XF@>3<&9U"X7C@8 !'/  &*Z
MV@ HHHH ***0C*D9(R.HH YKPWXMM]?U">"*PEMBT7VB.1RI\U Q3+ <JV5^
MZ><5TU<AX4\&S^'=2EN9;V&53"8?W4)1ISO+>;,<G=)R1GW-=?0 4444 %8F
MO>)K?0;BPMY+>XGEO)TA7RT.U S!=S-T R>G4UMUD^(-'?6K2UACF6(P7D-R
M2RYR$<,1^.* *DGB,66NV^F2Z5/;VUQ<&V@N25 DEVESA.NW&?F]:Z&N3C\.
M:L?'#Z]=7=C<P#]W;QO&^ZVBQR$^;;N8]6(]JZR@ HHHH *PKCQ+:+XIA\.M
M;3.\T3O),R8B4*H.W)^\<'MT[UNUD7^C->^(M+U+SE$5G%/&\97E_,"C@]L8
MH I^&?%UKXFFN$M(-D,0#(_G(Q922!E <H>.A'3\JZ.N2\+^#I= ODFEO8YX
MK:U-G:K'%L/E&3?ESD[FS@<8'YUUM !1110 5R5UXUM[26Y35=)N;5(H)+N#
MS=K-*L;!2=N<H22,9ZYKK:X-/ VIW9UL:O?V=P^J(R-=)"XEB4$&-%RVT(N.
M@')ZT =/HFM'5ENHYK1[2\LY?*N+=W#[25# AAP00PK5K&T#1[C36O[J^N(I
MKZ_F$LS0H4084(H4$D]%[GJ:V: "BBB@"*ZG-M:33B*28QH6\N)<N^!T [DU
MSD/B^V^R:I<ZE8265SI07S8699&_>+E54KU9N!CUQ707Z74FGW$=C,D-TT9$
M4DB[E1L<$COCTKCM.\!7":/]BO\ 4-LZ3FY6[LBR233%2"\I8MN//&,8[4 =
M5HFJ+K6AV.II$T*W<*RB-B"5R,X.*OUD^&-'?0/#=CI<ERUR]M$$,A[X]!V'
MH/2M:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .*NO'MW;>*F
MT'_A%=2>0!I1,)(MC0A@IE^]G;DCW]JMP_$3PU]EM9+S4[>TDN(8YA&[9"J^
M=I+ 8P2.M6;OP]-<>,1K:SQB(:7)8^45.[<SAMV?3BN3MOAA>P:++8-J-NS2
M66GVN[RSC-M*9&/T8' H Z\^-/#@TM=2_M6'[*\S0*P#$F1?O+MQNR "3QP.
M:3Q'XNT_PYX8_MY]]W;-Y8A%O\WFER N#TQSG-<M?_#6[N)YKN.\M7G.KW-_
M'%,)!&4FC5"K%&#9&T'(.#TKH=2\*-<^![?P]:206YA-OAE0B,>7(CD 9) .
MTXY.,T 2P>./#\EO<R2ZA% ]F@-VCY_<,<#:3C!;+ 8')I9O'7ABWLK>[EUB
M!8+GS!$V&)8Q_?&,9!7/(/(K(G\"W4NFZG$E]"ES-K@UFU8QDHK*4*HXSR/E
M.<>OM52'X>7PU%=2GU"W-U,]]-<JD;! ]Q&L:A 3T4(,YY- '7Z3XDT;79)X
M]+U&"Z: *9!&<X#9VGW!P>1QQ6'9_$&VO?$4NF1:3J)M8[M[(Z@$4Q"9 <J0
M#N4<$;B,4_POX1N- U..ZENHI531[33MJ*1\T(;+?0[NE8Y^'NJOXVAUE]4L
M1!%>?:O/BM/+O)$Y_<.ZD*R=LD$X% &S9?$CPQ=Z2-2:_-O;--)$#/$RGY#A
MFQCA>AR>!GG!XJ36OB%X;T*._P#M%\9)K&-9)H((V=@&P5Z#'.X8YKDK_P"%
MVL7FCC2CJMDUH@O$C22.3 \^3S%E(# &122!G(P<]:UKGX?7=UI'BBS>_A1]
M9CMEC94)$311(G/J"4_(T =;=:]IECI$>JW=VD%G($*.X(+%ON@+C))],9K'
MG\>Z5_;&AZ=8![]M7#-%+#]Q$4X9F)[@\8Z\'.*FU_0;_6=.TF1+FVBU33;J
M.\0LC-"\BJ592,YVD,<'J.*S]$\$W.E:MIFH2WT4LD+7TUT$0JK2W+HQV#/"
MKMQSR: -"X\;:38:OJ=AJ$AM%L#;JT\GW9&F#%5&.<_*:J7GQ%T6&YT:&R+W
MPU61TCDA&%C"??+$],<\=>*KZGX&NK_Q1<ZLMY"L<U]IUT(V0D@6V_</J=PQ
M]*2T\"7$.JV]U)>Q&..^U&Y=54Y*W.=H'NN>: -P^,?#RVXG;5K=8C9B^#L2
M 8"VT/TZ%N/7--C\7:7<7&F1VDZ31W\TL*ONV%&C0LP*M@Y '2N/L?AIJ<=J
M;>^N]*NXHM&72H8WMW*,%E#JSC=G/'\)&#R*LV?PXOEATV*]U;S8K:YNY&3?
M(YCBF@,0CC=R6.W.[+>M '21^.O#$ME=WB:S;&WM IGDR<*K-M5NG*D\!AD>
M]:.E:YIFN6\MQIMY'<1Q2&*0KD;'')!!Y!P0?QK@9_AEJE[I36UYJEF98-/M
M],M&BA95\J*9)"T@).6(0# X'/K77Z9X?DL;OQ%+).K+JUSYR!!@QCRDCP??
MY2?QH R8OB?H7G6?VLR6=M=VLEW#<3?=:-9-@.!DC(^;V'6M+5/&^C:<-0CC
MG-W>6%O]IGMH 2XCVAMV>GW>1SS7*:)X(U&ZT&V%RR6D\?AZXT-XI(SD.7P)
M/=2%S[@BM"?PS?:)H7BR:(?;IM1L(8(((4.XNEN(?R)Y]A0!W<,T=Q!'/"X>
M*10Z,.A!&0:?5+1K)M-T/3[!V#-;6T<)8=RJ@9_2KM !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% '_]D
%       !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img222477878_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_8.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #  BP# 2(  A$! Q$!_\0
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M1_PO&P_Z =W_ -_DKQ>BCZE1[!9'M'_"\;#_ * =W_W^2C_A>-A_T [O_O\
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M7OGFB;QOJ<D]F\-O86L5I/\ :5M[:#9&\G]YAG)/XUS?:BM_90[ ;EAXJO\
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MS+?;($MY_P!ZPW1I]T=>,>HHNA\LNYS&I?$*[L]4MQ;QV4]HT\,,D2)*SH9
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M[Q=_T ;K_OI/_BJ/^%?>+O\ H W7_?2?_%5],T4?VC4[(.8^9O\ A7WB[_H
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MT4?VC4[(.8\-\._"+4YKA)]<406ZG)@C<,[^Q(X KUN*Q:"%(88-D:*%55Z
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M_P !S_\ %5K]0J^069]!45\^_P#"X/%G]^Q_\!S_ /%4?\+@\6?W['_P'/\
M\51]0J^069]!45\^_P#"X/%G]^Q_\!S_ /%4?\+@\6?W['_P'/\ \51]0J^0
M69]!45\^_P#"X/%G]^Q_\!S_ /%4?\+@\6?W['_P'/\ \51]0J^069]!45\^
M_P#"X/%G]^Q_\!S_ /%4?\+@\6?W['_P'/\ \51]0J^069]!45\^_P#"X/%G
M]^Q_\!S_ /%4?\+@\6?W['_P'/\ \51]0J^069]!45\^_P#"X/%G]^Q_\!S_
M /%4?\+@\6?W['_P'/\ \51]0J^069]!45\^_P#"X/%G]^Q_\!S_ /%4?\+@
M\6?W['_P'/\ \51]0J^069]!45\^_P#"X/%G]^Q_\!S_ /%4?\+@\6?W['_P
M'/\ \51]0J^069]!45\^_P#"X/%G]^Q_\!S_ /%4?\+@\6?W['_P'/\ \51]
M0J^069]!45\^_P#"X/%G]^Q_\!S_ /%4H^,'BL'):P(]/LY_^*H^H5?(+,^@
M:*\F\.?&,7=PEKK5K%;,YPMQ$3LS_M \CZUZ2+]V ("$$9!'>N6M"5%VFBE3
M;V-"BJ'VZ3^ZGZT?;I/[J?K6/M(C]E(OT50^W2?W4_6C[=)_=3]:/:1#V4B_
M15#[=)_=3]:/MTG]U/UH]I$/92+]%4/MTG]U/UH^W2?W4_6CVD0]E(OT50^W
M2?W4_6C[=)_=3]:/:1#V4B_15#[=)_=3]:/MTG]U/UH]I$/92+]%4/MTG]U/
MUH^W2?W4_6CVD0]E(OT50^W2?W4_6C[=)_=3]:/:1#V4B_15#[=)_=3]:/MT
MG]U/UH]I$/92+]%4/MTG]U/UH^W2?W4_6CVD0]E(OT50^W2?W4_6C[=)_=3]
M:/:1#V4B_15#[=)_=3]:/MTG]U/UH]I$/92+]%4/MTG]U/UH^W2?W4_6CVD0
M]E(OT50^W2?W4_6C[=)_=3]:/:1#V4B_15#[=)_=3]:/MTG]U/UH]I$/92+]
M%4/MTG]U/UH^W2?W4_6CVD0]E(OT50^W2?W4_6C[=)_=3]:/:1#V4B_15#[=
M)_=3]:/MTG]U/UH]I$/92+]%4/MTG]U/UH^W2?W4_6CVD0]E(OT50^W2?W4_
M6C[=)_=3]:/:1#V4B_15#[=)_=3]:/MTG]U/UH]I$/92+]%4/MTG]U/UJY"Y
MDB5SC)':FI)["E!QW/F;QUK$NM>,M2N)')CBE:"%>RHA('YG)_&N=JYJ_P#R
M&]1_Z^Y?_0S5.OIX)1BD@"BBBJ&%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7N?PSU674O"JQ3L6DM'\H,>Z]17AE>O_"#_ ) V
MH?\ 7=?Y5P9E%.A=]"Z?Q'HU%%8MCJ&MS>)+^SN](2#2XE!MKT2Y,Q[C;VKY
MXWN;5(651EF ^IQ2UY]\7(#=>']-@%F+PR7\:_9C)Y8E_P!G=VSZT)78I.RN
M>@ AAE2"/4'-+7AN@WUUX3L_$NIV&F1Z2\)BMO[',[SF%RW^M;=C(^AQ70GQ
MCXIMM+:&Y-ND\MY%;P:C/;HBJK]2T:N0".V3S5<I*J(]1R"< @XZ\T5XWIVM
MZGH>I:[+_:%I<3RZU;V\]S'&!&ZE<' R0I_&M:;QQK$L]S:6MW9QF76/L,%X
M\0=((]N<D9 8_4TN5A[1'IU (/0@_0UY;JUQK=QK?A5)/$NG2N+N6-Y;.(&-
MBH_B&[&['&.U5="\2:K)!8Z/IL^FZ0UU/=R/=O; Q_(WW0N0-QZDYHY0YSUR
MCZUY?!XR\2:P-%@LKFSLY[M;A9IFMO,1S$>'0$]#]<5OZ=KEUK'PQN-3O4A>
MY^S2B0!/D<KD?=]#Z4<K!33.QR",@Y^E%>1Q>)_$:62PZ5=6%G!::+'?&-K,
M.">ZCD8!KL=9\475AX AUV&*+[3-'%C>#Y<;/@;C["AQ8*:9U=%>6:AXR\1Z
M5!JEB=2T^_N[9;>2*]AMPJ#S&P49<D<>N:L:KXC\36-]=V UK3HI-.TX7DDT
M]H +IF_A4;OE _&CE8<Z/2Z*\GOO'^M1Z3;WEK=I)/#;02W4*60* R'G>[,,
M9[! 3ZU8UCQ=XFM[W6KBTO+..RTR2#-N]KN:0/C(W9&.O7K1RL/:(]0R ,D@
M =S17GWQ5BN;_P +:9%#<B&.YOH$E0Q[P^[IGD<#T[U4'BO4=/U_3["QN8Y]
M-%\-/=$LA'$N%Y <MN+#V&VA1T!SLSTO<O\ >7\Z6O&;6]>75] F6*"%HM3U
M *(8]H)5>"1W-:]GX[U6XMM%/VJV::ZLKJ>X58UR&C!V\=NE/E#VB/3Z*\G/
MC#Q4FA:!(]]"]UK99UDBL%;[.JKG:%+@.Q]21BN^\*:CJ6J>'K>ZU:V6"])9
M75"-K8. PP2!GKC/%)JPU*YM4445)04444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !6I;?\>T?TK+K4MO^/:/Z5I3W,:VQ\I:O_R&]1_Z^Y?_ $,U
M3JYJ_P#R&]1_Z^Y?_0S5.OK([(R"M7_A&]6/APZ_]E_XEH?9YNX9SG&<=<9X
MS6=;V\MW<Q6T"EIIG$:*.[$X%>S(VAG53X.&LY3^S_[,^Q_9FV^=]XR>9G&<
M^W6L:U5PM;^D#/%<TF1ZUZMH^B7=UH_A**&V61]-U:1+\_*/*P_\6?I^HK6T
M6-/[5UT:I'9BS&KL-*-RN/\ 2N>%Q_#T_&HEB4KZ;?YV"YXGD>M&1ZUZIIT?
MB"+1)&T>WAD\0G5'75@T:,X7^$8;I'].U2:E?V^BZ9XON] ^SQ[;VW19(D5E
MC=AA]F01US5?6-;)?C_7R"YY/D9QD5?TW2+W5A=&SC5_LL#3R[G"X0=3SU^E
M>NV&G7(\,36MYLN[271VEC,=O$D'F$9X/+M)W)X%<?\ "SSS?ZS]F"-.=,?R
MQ(!M+9&,YXQGUI?6+QDUT"YP88$9!XHR,9R*]IT^&.2]T-_$<$*^)/LMP1&$
MC61B,>7D?=W8SC-1PS!_&&FO<Z/=6UZEA<&22_6'?< +P66/C(]P*7UGR_$+
MGC61ZBK-A97&IWT-E9Q^;<3-L1 0,GZFO4](N+37+7PEJ.O+;O,]S/'O,2(&
M(4E%( QC.,9]JO\ VV>+Q3H"SZ9?VMZUU)']JNU@#2Q$'*8C[9Q@X_&B6):N
MK:Z_K_D%SRZ[\+ZG9RK"XM9)GF$"Q074<CESVP#G\:R[RVEL+R:TN5"3PN4D
M7(.".HKUFUU*?[#:ZA-,@G_X24Q-,44'9]W'3IBM2T;5?[;UI+JPN_,:\'E7
M=JD#R+%_"&1N3'UY^M3]9DMTA7/#:EM+>2]NX;6W ::9PB G&2>G-=#J-NEI
M\19(5^R7ZK>J2J[8HI#D$KZ+Z'M7HGB""2=]-NI_.M#'J<02UO(8MQR1Q$Z=
M4'O6LZ_+;3<=SQR]M)M.OY[*Y4+<0.4D4,#@_457R,XR*]=U6\75K7Q9#JBP
MM:V-[%Y6V)5,8)^8@@9R>^:EU:.XQK4>HV]FGA-+0'3Y$1 N[ V^6PY+9S4+
M$/JOZT_S"YX[D8SFKM]I=WIUO:3W2*D=W'YL)# [ESC\*]:329[C6[75XK>-
M].&@[/.&W:7V'(]S53241TT#8D+Z@-$E-BLH!!EW<8!XS1]9[+^M0N>8W&E7
MEMIEKJ,L:BUNBPA8."21UX[52KT+QY_:?_"(^'O[8C6._,DGG*JJIS[A>,UY
M[6U*;G&[ *]?^$'_ "!M0_Z[K_*O(*]?^$'_ "!M0_Z[K_*N7,?]W?R+I_$>
MC445BV+^(SXDOUOHK)=%"C[(\;'S2W?=7SIT7-JL_5AI'DQ2:PUHL44@>-[I
MU55<=""3UK0K@/BQ!)<Z+I<$4%M/))J,:K%<Y\MSZ-CM0MQ2=D=3':>'M9FG
MOH8].OI)8_(FFC*R[T_NL1G(^M$/A?0+?39M.AT6Q2RF.98%A&US[CO7D=C<
M7_AB/Q3?16MAI6LPK%"VG646V**,M_KQN)#?7IZUIKXLU^+0I<Z]"UJ][%#_
M &F)H)I;9&^]O\OY![$BJY69J:ZH]#M_#OA9K6[TVVTO3&@9E^TVT:*1N'3<
MHZ&IE\+Z FGS:>NC6(LYF#20"$;&(Z''K7D]AKDNDS:Y>V>OBZA;6[>.;40$
M DC*X.X@;<>XK3E\:ZC<)=F'7!#ITNL_9?[24(RVT.W/RDC')[FCE8<R['HC
M^'/#RV=M9/I-@MM"^^"$Q*%5_51ZU&N@>&-3TP6J:;IMW8K*SA%17029^8\=
M#GK7GFISK=:IX3N&\9M>PI>S1"^1(XUR!P"2,%NV1P:@TSQ-?FUT^RGUU-$L
M;BXNVDU%(HERR-\J<C:/7IDT68^9=CU@:/IJO;.MA;JUJAC@*Q@>4IZA?04+
MI^FV6ER6BV]O!8;6WQX"Q@'[V?:O,[;Q#XCUH:!;C6)K(W4=SON(84S.J?=<
M!A@9]JZ31]9O=2^%D^H7<PEO%MYE:4HOS%<@$C&/TI-,%),Z"#1-"D@\RWL;
M-X98!!NC *O%V7(ZK5W[#:?8?L)MHC:;/+\@J"FWTQZ5Y&NM^()K8K::[-91
MVFA1WHCAACPS_0KP#[5V'B+7K^#X6'6K>Y^SWIMHI/.50=I)&3CI3:8*2-Z#
MPQH-M8/8P:/916CN)&A2(!68="?<5C^+/ P\47,4AU"*W1(_+VO813LH/78S
M<J?SKD(_&=W:#48/^$FGU2T\NW,=]!#$7BED/,>[A%^IZ5'#XK\07&D-!'K+
MQS)KBV2W ,<SB)AT+ !6^N*+,7-%K8]"7P5X=-K;07&DVMT8(5@66>,,Q5>F
M35Y]!TB5+A)--MF6YV^<"G^LV_=SZXKS-_%6MVV_2KO7W@@CUA[*;6)(XP\<
M87(SQM!)XR16BFJ:GJ&J^'=-L/&,MU;W/G>=>VT"*90AX'((SVR*+,?-'L>A
M7>G65_#%#=VL4\<3K)&DBY"LO0CW%4Y/#&@/?G4'TBR-WO$IG,0W;A_%GU]Z
M\WTKQCX@G\1LT^IQJL=S-%/I\TL *Q(#@I'Q(7XSZ&J\/B?4]7N+RQ76+J2S
MO=&N+@>:T)D#+G&%0?NP1QM))Q1RL.=/H>G1:9X>BN[98K>P6Y5GN+=5*[LM
M]]U&>_<T0^$_#MM</<0:)813/NW2)" 3N&&Y]Z\JTS6[W2M/T5],O5U&2/0I
MYE#)&Y1P1\N0,@+Z9[<UW'@C51>S.A\8KKDCVZ3/;^4FZ!CU^9 !CMM/(H::
M!23Z'1S^'M&NM+CTNXTNTEL(L>7;O&"B8]!VJW:6=KI]K':V=O%;V\8PD42!
M54>P%>8:SKOB"#4]?O(-=FBMM,U*&&.T$2%&1\9!)&<<U'%XN\1W/C.6%-0A
MA,>H"W&FSSP1J\..H5OWC,>H(XHY6'.NQZU17EN@^)[R_G>ZO?%RP7[O<HVA
MF!#LV [<8&Y2,9R>#56WUW78O#7A^ZOO$UQ!%K$Y6YU"2.,+9JH.%7*X!;U:
MERC]HCURHFN;=+A+=YXEGD!9(BX#,!U('4BO)9O%6NS:'&R>(H5MH;^:!;T2
MPV\U]$H&UHVD'EG!SGIFIQXGNK^;1;JQU,;I-*NF%WJ,$:$2*<;F(! 'NIP>
MO-'*'.CUBBO/_A[XBFU*_O+"[UBZU"YCB24[G@FB7/4I)%Z_W6 (KT"DU8I.
MZN%%%%(84444 %%%% !1110 4444 %%%% !6I;?\>T?TK+K4MO\ CVC^E:4]
MS&ML?*6K_P#(;U'_ *^Y?_0S5.KFK_\ (;U'_K[E_P#0S5.OK([(R%!(.02"
M.XHR<[LG=USGFDHIC%W-S\[<G)^8\T%F/5F..1DFDHH 7>VXMO;<>IW')J7[
M+<K9"Z\B86K/L$NT["P[9Z9K?\":59ZQXF2WOHO/BCADF$&<>:RC(7C_ #Q7
M:V26NL>&?#4=QHD-C;7&ME9+1 P1QM(SAN?;Z@UA4K*#M;^M?\A7/+(;:\FM
MY9X(9WAMQF5T4E8P?4CIFH02.A(SUP:]&*Z9-9>,'AT>TMH]-*I#'%OPX$A&
M7R>2<5)J_AS1+'3;G5TMX%M=7-O'IJDY$&\?O&'N,&E[=7LU_6G^87/-223D
MDD^I/-&YMV[<V[UR<UZ9XNT;PMIMCJ=A%'##=VB)]F:&VG\PMC_EK(?D;=ZC
M%8O@O3();&ZO[S2[&YMUFCA$UWYC[23RJQH,L3GJ2,52KIPY[!<XW)(P2<#H
M,\5-<V]W:2JMU%/#*5#*)05;:>A&>U>E:OX?T?03XAO+;18M1:WNXH(K64NR
MPJZ@DX4YZGCTJ]XBTVRDU+4]5N-,6[FT_2[<PZ?(6*C.<E@.2%J/K*=K+3_A
MO\PN>0[FQC<<=<9I\8FEE"1>:\K< )DL?;CFO4+'P[H]QJ-C>OH<8-YI4MS)
MIF6VJZD;2O.1FI_#5O8"^\-ZU%HMM875Y)- ]NH?;A5)#J"<@\8_$T/$I+1?
MUK_D%SRM[&ZCM1<R6LRVY<QB5D(4L.JYZ9]JA+,2"68XZ9)XKU.VT;3M>L].
M-U9QVOVC69DDCA+*&55)"@$\9(Z^]5;?2=*UBVFN9O#\&EO9:G%;HL88+<(S
MX*L&/) YR*?UA=4%SS;<W/S-SUYZT9.T+D[1T&>!7H^N:;HEQI7B@6NBVUE)
MI,Z+!+"S;F!/.[)Q7F]:4ZBFKV 4,P& S #H 31N;CYCQTYZ4E%:#%+,>K$_
M4TE%% !7K_P@_P"0-J'_ %W7^5>05Z_\(/\ D#:A_P!=U_E7#F/^[OY%4_B/
M1J**Q;'_ (2/_A)+_P"W&Q_L7:/L@CSYN[ONKYTZ+FU5+4[O2[*W2?5I[."%
M7&V2Z954-VP6[U=KSOXP;!X<T_S9;:)/M\>7N8]\:CU9>X]J$KL4G97.QL;_
M $/6I9)]/NM.OI%79)) Z2,%/8D9X]JMI864=LUM'9VR6[?>B6)0A^JXP:\G
MT[6[#2_#UU]CUK29)I[F.(RZ!9I9[0>SNXPH/][!Q45GXCUW5++2+,:_<0-/
MK4EF]Q!(DCF(+D#=MPWUQ5<K(YT>GM/X>A6:V9]+C7S%AEB/E@;S]U6'KZ U
M>%A9+#) +*V$4GWXQ"NUOJ,8->0S7-QIFLZXMO<.S_VY:Q,\FUF<;._'4^M2
MZ+XI\0WOB&3S-8C$AEN$N-/FN8QY:*#M,<07>".#DGFCE#G78]9-A9M#' ;.
MW,,9RD9B7:I]AC JK VAW_GV$']G7(@?,UN@1Q&W^THZ'ZU@?#TZA?\ A./4
MM0UB]O)[Q6_UA7$."0-F!U]SFO/M"GGT71(=FMW-A9ZAJ\\5[J.$W0JI.,-M
M^4L>I.:+ Y=;'MIMK<NCF"(M&-J,4&5'H/04);01P&!((EA.<QJ@"G/7CI7D
MZ^*M5ETVQAN?$$UMI$FHR6YUY457DB4?*=Q&T9/&['-,C\5:K/:Z9#>^(Y[+
M2)+N:(:VJ*C3HOW,DKMY]<<T<K#G1ZE:KI5W$TEHEE-'@PLT2HPP.J''8>E5
M]6TBQ\1:!+IAEVV<H"[K8KQ@]!U':N1^&RBY^'FH+%=R/ON+G%P@ 9N3\PXP
M"?I7)Z#J[V6BZ)IS>*[G3M,E$S7-Z'0M#*IXBR5POK@\FBP<RML>P+;Z3:)'
MI;)9*9UXMV1 9L#D[?XO?BITTZPC4*EC:J P8!85'(Z'IU]Z\C_MS6+J3P_J
MLH,^H1VEX8',>#.%^Z^WW'-5K?Q9XA/AG5KN'Q"+@K9+*2;J.2:WE+ <*JC:
MO;:<D4<K#G78]G:QLWCEC>TMV24[I%,2D.?5ACD_6E6TMD,12VA4Q#$96,#8
M/1>./PKROQ/K=_H6GPVD?B+4Y+Y;#[899KB*%68X[[<OCH$ QZFF:GK>O7MQ
M?RV_B"[LUM-%@O@EN$VO(1SG(/![@4<K#G2Z'JXL[471NA:P"X(P9O+7>1_O
M8S3(].L(9/,BL;6-^?F2%0>>O('>O,&\47-UK)_M7Q;-H*Q0VTEK#'$K+=;P
M-Q*D$OD\8'2H8?%/B"X\;20_VO'!)'J @73[BXCC22#U$97>6(Y#9Q1RL.='
MJT5A90,K0V=M$R@A2D*J1GKC [TZ"TM;3?\ 9K:"#><MY483<?4X'-345!I8
M@:RM'\S?:P-YC!GS$IWD=">.3]:#9VK7*W)M8#<*,"8Q+O ]-V,U/10%D0"R
MM!</<"U@$[C:\OE+N8>A.,FE-G:FU^RFU@-OC'DF-=G_ 'SC%344!9%>2PLI
MK9;:6SMI(%^[$\2E!] 1@4[[);90_9H<HNQ#Y8^5?0>@]JFHIA8@MK.ULU9;
M6U@MPQRPAB5,GU.!4]%%( HHHH **** "BBB@ HHHH **** "BBB@ K4MO\
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MG5DFM#__V0
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img222477878_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_9.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $$ AP# 2(  A$! Q$!_\0
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MJN#HH^KT?Y%]R"QWG_"_/B9_T4'Q+_X-)O\ XJC_ (7Y\3/^B@^)?_!I-_\
M%5P=%'U>C_(ON06.\_X7Y\3/^B@^)?\ P:3?_%4?\+\^)G_10?$O_@TF_P#B
MJX.BCZO1_D7W(+'>?\+\^)G_ $4'Q+_X-)O_ (JC_A?GQ,_Z*#XE_P#!I-_\
M57!T4?5Z/\B^Y!8[S_A?GQ,_Z*#XE_\ !I-_\51_POSXF?\ 10?$O_@TF_\
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M_P#B*/:0_F0'/45T/_"N?%W_ $*>O?\ @KG_ /B*/^%<^+O^A3U[_P %<_\
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MPRDY\V-2>6 &1C//'AO_  KGQ=_T*>O?^"N?_P"(H_X5SXN_Z%/7O_!7/_\
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M/D0&6*(QQ(OF#/RL?+)V]0",\Y%>%G&(I0PUI26K1,GH?8=%%%?E!SA1110
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MXF\<ZA)9:;<7L5C$MO$99I)')^Z@Y8*H9FQR IP"< _*G_#+O[9__1S.G?\
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M *.9T[_P6C_XS1_PR[^V?_T<SIW_ (+1_P#&: /O:BO@G_AEW]L__HYG3O\
MP6C_ .,T?\,N_MG_ /1S.G?^"T?_ !F@#[UVCCCITH(W<'D5\%?\,N_MG_\
M1S.G?^"T?_&:/^&7?VS_ /HYG3O_  6C_P",T ?>U%?!/_#+O[9__1S.G?\
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M .CF=._\%H_^,T ?>N!UI:^"?^&7?VS_ /HYG3O_  6C_P",T?\ #+O[9_\
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MM>L1<VQ8 ,8Y(I%VR12#[R.O\+#T_'H0: +]07EC;:A:S6UU;Q7-O,NR6&9
MZ2*>"&!X(^M3T4 (JA0 !@4M%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!EZIX7T;7+*2SU'2;&_M))EN'M[JV22-I5(99"K @L"JD-U! ]*U***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#P;]LW_ ))/:?\ 85A_] DK
MXHK[7_;-_P"23VG_ &%8?_0)*^**_(>)_P#D8/T1_2/ ?_(F7^*7Z!13H89+
MB5(HHWEED8*D<:EF9CP  .2:Z<?"_P 4&^U6S_LF076EJINXFD0,A9#(J#+?
M,^P%MJY;"GCBOEX4JE3X(M^B/O:E>E1_B34?5I=4OS:7S1RU%=-)\-O$D-O:
MSOIC)%<VTEW&3*G^KCB$K;ANRK>60^UL$@@@57;P+K::Y9:,UELU6\A$\=HT
MJ"0*4+C>,_(=H)VM@XQQS5O#UEO!_<^I"Q>'EM4CU>ZV6[]%U,&BNBTGX?ZY
MK5I;7=O;0I9W$#W*W5S=1PQ+&LGE%F=V 7YR%&>I/%8VJ:;=:+J5S87L)M[N
MVD,4L3$$JPZC(X/U%1*E4C%2E%I,N%>E4FZ<)IR6Z35UT*U?8_[$W_)/]=_[
M"A_]%1U\<5]C_L3?\D_UW_L*'_T5'7TG#7_(QCZ/\CX?CG_D2S_Q1_,^B:Y7
MP_\ $[PSXIUK4M(TS4Q<:AIIVW<+021^2<@ ,64#)W @9Y!!''-=57EWB+X)
M1>)/$=YJ5S?Q20W&MP:R+::U$JJT6GM:HI!.&(<K*"1U4#'>OV(_FD]+6ZA8
M*1-&0S% 0PY89ROUX/'M43:I:+-Y9G3.QGW9^4!2%;+= 02.,YKYP\*_L<RZ
M*L\E_P");6]NMT<MK)%IOEK:3*]DS2QCS#L9A9G)7;_KCV',?_#&]Y_8LE@O
MBR&.!9WFALXK!EMF!DMVV2_O2\BG[.2=S$@LN#A<$ ^DM0U:RTF(RWMW!:1A
MHT+32!1N=PB#G^\Q"CU) JSYB>9Y>]?,QNVYYQZXKYX_X9%MH[6'&K6MU>12
MQ2-/?6!F,XB-@8HY"TA9E5K$D L<>:<<@DP?%_\ 9#F^*?B[Q/JZ^*DTQ-:@
M=1(+$O>0%K$VGD"<2C-H0WG&':,R_-NH ^C!=0LK,)4*JNXG<.!ZGVX/Y4JS
M(VS#J=XRN"/F'J/6OCCQ-^R'XGUSXOZY_8T>D^&O",T5RUOJC6L4\I66WLXE
ML_*##,"?9I J%5\OS&*L2>.O^&?[&)^'^N>%=6D\4KJ-]H,]F8;@V+)(;>"*
M^C>!6,K%5D^V1DC)'[A<@\8 /H'1_&FA:_J6K:?IVJ6]Y>:3<BSO8HGR8)B@
M?RV/3=M() Y&>:3PWXVT+QA]J&CZG#?M:^5YZQDAHO,C66/<" 1N1E89[$5\
M[^*/V+7U3QNOB'3_ !3::3%_PE,GBB6"/20)&E:>UEQYRR*V<6SH2<J1*3MR
M.<B3]BN_DT,V.F?$:!+RYTQM.EN)-/,OF6[Z=!9/(JB<'?F!75B2!N(P>M*Z
M'9O4^MC/$) AD0.3@+N&<XSC'T_E2F>-9#&9%$@7>5W#(7UQZ5\R7/[$]M)X
MH\/ZW'XD$-Q8ZY?:Q>;;5U:Y,]^EW&RLLJLLL:QK ')8%"1M X/0?$']F]_&
M7Q0OO$]YXEL[>PO%2-K"2Q&]X@(%:)W#@.F8<_,#_K,=AD!)O1'N%UKNGV5S
MI]O/>0QS:A)Y5I&7&9FV,^%]?E1C] :M^?'YGE^8N_.-NX9Z9Z?2O$?"O[-H
M\+^/='UV#4]/ELM.OI[R*%M-_P!(@1ENT2U@E$F(H%6Z!*!3\T>1C=@</=?L
M2V%OKD^O-XJCTZ^:\-XVI06@BN8F;4KNZ9EE+_*_E72P!NPB'&#M#VW#5Z(^
ME]=\2Z5X8T.]UG5=0M['2K.-YKB[F<".)%!+$GVP<_2KRW4+*S"5-JXR=PXR
M 1G\"/SKY U#]AC^U?",FDKXRT?=-%):FW&B[M/A66S@MUN8;?S_ )+PB 2&
M;<=QE?Y><UTGA_\ 8FM],\=-KNH>)?[:MO\ A(/[;:UO+1G,X'VQD6;=*4=T
M>\7:^P86!1@YX5[[ TUN?2$VO:9;:A9V,NH6L=Y>-(MM;M,HDF,8W2!%SEMH
MY..G>F6_B72KS7+C1H+^"75+>UBO9;5'RZ02,ZQR$?W6:.0 _P"R:^2M/_X)
M^7,-C<I>>.8)K^=K[_3[?2/)DA^U6"VDCQ 2XC<M&DAVX4[G7 X(76_V*]>T
M/P_;P>'-=$FM736=B;RV5K:+3+<W%\U[(@>5V*-;W\T2Q+T<(PP/NL1]AF:-
M71"ZAW!*KGEL=<>M$<T<J[D=77^\I!'7%>$_%#]EM?'GC_PKK^E>(6\+V^B:
M6VD".TMC).(-DJ@1.S[(R!+PP3>-HPW8<CX3_8;C\/:7X:LY?%\ZK8WDDFII
M86[PIJ-L1"T4.&E?RRMQ:P3EEX+&0;?G)H ^HQ<1E01(A!;:#N'WLXQ]<UD>
M+?&V@^ _"]]XD\0:M:Z3H-B@EN=0N9 L,2E@H);W) ^IKYI\*_L&0:+H46G7
MWBUKMXK'5+2*[BM'5XIKJUMK9+Q \S!)T6W9RRXW-*3P>3TMI^R+)_PJ7P_X
M!G\6S6>F6FNMK>H/I=J%^T8WM'!$D[3)&@E,;D%6!*'"KNR #U9?C9X$?QM!
MX07Q3IW_  DDXC,6G^;\[EXO-0*>A9H\N%SDJ"0*U]:T6YM[XZQHP4:B%"SV
MS-MCO4'16/9Q_"_;H>.GC7P6_9"TWX:ZPFK>(=;N?&6HV)LETN2X>:&*W%I:
MFTAE> 2F*2<0\>:4W#)QC.*^A: *&BZU;:]9"YMBP 8QR12+MDAD'WD=>S#T
M_'H0:OURGBZ(>'O-\26<BP7<:JEQ;L<)?KG"QD#_ ):9.$8#.3MY!KIK>8W%
MO%*8WA+J&,<@ 9<C.#@]10!+1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X-^V;_R2>T_
M["L/_H$E?$[,%&2<#WK[8_;-_P"23VG_ &%8?_0)*^7?A'J6G:1XEU&[U.58
M(8](O#&Y6-G$NSY/+$@*E\_=![U^3<14U5S10;M=+4_HC@NJZ&0.K&/,U*6G
M?;U.+BN)(666WF:"93N26)BK*>Q!'0UZI9_&JQCU;4[V?2KF1I)[:^LU2=1M
MN(;1K;][D'*'<6XYXQWK1A'@SQ_;^(-;O;>TTV3R&@MXY;E(+@RQ6A*S,B,B
M9ED SL1N<C"]3J:IIO@?6-4$<CZ;96DEP)K:TM;I?*EQIR&,,=X*!I0RD%UY
M7!()S7G4,/6HKFHU59M6\]U?78]S%XW#8A^SQ-"5U%W\OA;5T]=O+9]&8D'Q
MZAL+BWO++2YX]0*22W,DDB.@N38K:1M&I7[@V[R&SDG':N</Q,MF^(VE>,/[
M+;[: 'U6%9 J74Q0I)+'Q\F]3NP0<-GM71:EH'P^M8;V*!8I)'74G223426@
M:&*)X$4(Y5@\AD0$DE@.#D9K3\:>'_!&H6WC"^M4TNPNHRTM@UO?AHB@AB,:
MI&LF59CO&-C G@[,5M..+G%MU8OE:=O.U[[>7XG/3EEU.24</-<\7&_]UNUO
MBO;7U5K]CGM)^*FD:#)IMIIL&N6>G:?826D-U'<0FY9I)S,_F1E3%(A^[M8'
MIG.:X3Q;K=KX@\3:GJ=G8QZ5:74[2QV<>-L0]. ![G  R>!7H7@GPW\/=5\*
MV5[K=^MGJ)#":W^U%3F!VDD.,\>=$4C7_:!QS74>$+CP@L.A2SQZ2\L<NE2W
M,EU<H'AC,$XE3!/(5]BD8)RP)Z C+V%;%0A"I4BHO5>6GX:?\';3?ZUAL#4J
M5:-";DKIM]==;-O6[O\ HM=? *^Q_P!B;_DG^N_]A0_^BHZ^6O&MOH\<NC7&
MC1Q6Z7>F13W5K#.TJP3EG5DRQ+#A5."?XJ^I?V)O^2?Z[_V%#_Z*CKKX>A[/
M,XQO?1_D>9QI45;(I32:O*.^^Y]$T445^O'\WA1110 4444 %%%% %+6+5[[
M2;VVB($DT#QINZ9*D#->'>&?@?XH\,S0S17UKFULTT^*.&YDB8VJRPRF 2!<
MIN/V@;AR 5]\>_45PXC!TL3*,YWNMCUL'F>(P,)4Z5K2M>ZOL>1#X:^*[@V4
M^H:NU_/9W5C/%&;^9(]L9<R@@#YCRGS$9;9VR:H6OPQ\;7'ERZCJ5O/<1R2-
M&S74DOEA_LQ95+J2 3#(<$G&X>]>V45@\MHOJ_O.J.=XF.RC]VWIV\SR3P7X
M1\2^'O%&GZ9)=W7]C6Z37=T_GR/&\GFRB)%9NN]90SKT!A7^]S<\9?##4]<7
M6";_ /MJ&\ECEBM;R=H#"JR*_E(P#)L^7/,>XX )/;T^BM%@:7L_9-MK_@6,
MI9OB'76(BDI==-];W[[]FM+'D+?"_7](N+*_TJ:Q;58X[9[J2;B&:=4,;.L8
M7"JJYP/^FAQMP*]>HHK>CAX8>_)U_K_ASCQ6-JXSE]K:Z\OP]%T[!11174<
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MMX?O#T\0ZD/^ V__ ,:K:HH PCX<O3_S,FJ#_@%M_P#&:3_A&[[_ *&;5?\
MOFV_^,UO44 8/_"-WW_0S:K_ -\VW_QFC_A&[[_H9M5_[YMO_C-;U% &#_PC
M=]_T,VJ_]\VW_P 9H_X1N^_Z&;5?^^;;_P",UO44 8/_  C=]_T,VJ_]\VW_
M ,9H_P"$;OO^AFU7_OFV_P#C-;U% &#_ ,(W??\ 0S:K_P!\VW_QFC_A&[[_
M *&;5?\ OFV_^,UO44 8/_"-WW_0S:K_ -\VW_QFC_A&[[_H9M5_[YMO_C-;
MU% &':^%4CU"&]O;^[U::WS]G%YY>V%CP65411NQQN.2 2!C)SN444 %%%%
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M:WO:]4?]L1_C3&L]0[:@@_[=Q_C6A10!F&QU/MJ:#_MV'_Q5,;3]6[:M&/\
MMT'_ ,56M10!BMINM=M:C'_;D/\ XJFMI>N=M=B'_;BO_P 56Y10!S[:3X@[
M>((1_P!P]?\ XND_LCQ#_P!###_X+U_^+KH:*8'/?V1XA_Z&&'_P7K_\71_9
M'B'_ *&&'_P7K_\ %UT-% '/?V1XA_Z&&'_P7K_\71_9'B'_ *&&'_P7K_\
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M-O9/,81A@#(22(\#[I!-=S\$=$A\,_&SPU+H%XL]C?1WD%S#YX>555&<AP.
M%/EC.3DJ3W%?&Y?G&-J8J,*[C*,G;3=:V^Z^]S],SGAO*J.!G4PJG"I!7][5
M2LKM/I>VUK>EF?8+0W7:Y0?]LO\ Z],:WO>UY&/^V'_V57:*^^/R$SS:ZCVO
MXQ_V[_\ V5,-GJG;4HA_VZ__ &5>4?M*>(-=\/VNARZ1J-_8PXN7EBLA)$;F
M147RD6=(9MLF2Q2)TV2G()& #QB_&_XI:3XI;37\--J=H^H7.Q[G39H9!#O&
MR#*$J'CB(D+X97W8&W!:@#Z':QU?MJL(_P"W/_[.HVT_6^VL0#_MR_\ LZ^<
M-7^,7Q8T&Y>].B-=%K:W\_;IT_V.W:6&TE:7RRV\[#(\.T/URQQ@@=9\0/C%
M\2/#[>$I-)\)03I=:1;ZIJ\#VES,\<KWEG!);1,NW8P2YFDRZD@0G*XS@ ]A
M;3=>[:W;C_MP_P#ME,;2_$/;7K<?]P[_ .V5\TZ3^TM\6[ZQ:;4_!$7AZ(ZL
M]H]U)HNH7AM L4KBW>"+YI'9UC03H=F9.5^Z#IZA\?/BY87-A*?!MO);WVI7
MT-K:1:5>-+.D&HK:QV[2!ML,DD/F7(FD CVJ  1E@ ?0/]E>(_\ H/VW_@N_
M^V4?V5XC_P"@_;?^"[_[97S$G[1'Q>U"*^E;P9+%J.EZE?PQ+%IE['8SQI8W
M,D0<[6EDQ)'&#A(SEU !R*]9^'/Q/\1>//A#=ZIJ-J^C^*_[)N)_[,%@\$Z.
MLD\<<R(SOE'\I2@YSC/1@!,I<L7+L73A[2:@NKL>B?V5XC_Z#]M_X+O_ +91
M_97B/_H/VW_@N_\ ME>1^'?&_C^TOI9-3@NC;QV\%D\MS8.\<;QNRRW12,!G
MWD#Y0> 0>@-="WCSQM/)87<NE+IEFEW#%<V:V4L\[AK(S,,Y&!YI$8P.#@$C
MD5Y<,RI32?*U\OZ_KYGOU,CKTY.//%V6Z?X>O3_@--]W_97B/_H/VW_@N_\
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M)9SA0<A)%!<%2_*CZ>HH ^6+7XC?'"#5+>1="N9(-0N[65X;[29%%JIM;0&
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M9C)_B45G2S"C6:235_Z[_P!?<;XC)L3AXRE)I\O17O:[\EV_III>&>%?B_\
MM#ZPW@:VO/!XL1>WDMOJ>H7FCSK&V)X5SL'SP1B)Y75Y53<T>/\ ?MQ_%O\
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M@.GAK4C_ -M;;_X[3F\/71_YF'5!]!;_ /QJF'PU=G_F9-6'X6__ ,9H /\
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M&75ORMO_ (S0 ?\ "1:A_P!"SJ7_ ']MO_CU'_"1:A_T+.I?]_;;_P"/4?\
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M#8/_ (NC_AEWXF?]"\O_ (&P?_%U\K_9N-_Y\2_\!?\ D?H/]N95_P!!5/\
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M_1?_ *],:^*_\NUP?H@_QH M451;4RO_ "YW1^D8_P :8VKE?^7"\/TC'^-
M&C166VN,O_,-OC](A_C3#X@8?\PK43_VQ'_Q5 &O28K&;Q*R_P#,(U,_2 ?_
M !5,;Q4R_P#,%U8_2W7_ .*H W,#TJEJNCV6N6?V74+:.[M]ZN8I1E25.1D=
M^16:WBYU_P"8%K!^ENO_ ,53?^$P?_H ZS_X#+_\52<5)6:*C)Q:E%V:.BI*
MY[_A,'_Z .L_^ R__%4?\)@__0!UG_P&7_XJF2=#C%-"*,$  ].E8'_"8/\
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M;S"((88W\A07;S@QP,*??V\5,O\ S!-6/TMU_P#BJ8?%SC_F ZP?^W9?_BJ
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M4GENY[:&&+4I=\[*URK1O*2 !N;(R?FKZ#_X3!_^@#K/_@,O_P 51_PF#_\
M0!UG_P !E_\ BJ /F[2_V.?%6GZ]X1U:'Q?I^GMH^J_;FT^TMYWL[>+%N'2W
MBDE;#2>0[,QP0\[$$C*MTGP7_9A\2_"_XG:9XFO/%\6J6D.@PZ5=P-%+)+<R
M)%%&&#2.?+4&(MA3@EON@Y9O;?\ A,'_ .@#K/\ X#+_ /%4?\)@_P#T =9_
M\!E_^*H Z*O!/C=_R.:?]>L?\VKUG_A+I6X3P_K#.>B^0BY_$N /Q-9;?#^#
MQ--+J7B&$"^F;Y((9,K!&  J;OXCP23TRQ X JEH)ZG;4445(PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;I;8<^:8I<':[(?X>I9' '\6QMN=IQ>N/C!X0M=0-A-K"Q7PD6/[,]O*),L
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M,9GAW]FKP?KF@SF]_M"=VN;JW#M.,B%+J4I'C;@J' ?Y@22.21Q110!V.B_
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+ %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img222477878_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #K DL# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M .?BP_[^-_\ $U[S11]?K!=G@W_"F?$?_/Q8?]_&_P#B:/\ A3/B/_GXL/\
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MEP<?>(!STJ63XCQQ^'[+4SHE\\EY>?8X;:,H[NY!(((;!'&.M'U^L%V>??\
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MW]O<QVQL)@HD9I!N0@YVX(!.<]J/K]8+LX3_ (4SXC_Y^+#_ +^-_P#$T?\
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M$T_0;!;+3K=88EZXZL?4GN:T*Y,1BY5?=CHA-A1117&(**** "BBB@ HHHH
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MZ"-/N]-L4@+02,8&0'(8R -@^FU?UKC.G2BLE12E>X6.VM;WPND:P,EOY:[
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MX5Z'X!U.[UCP-I-]?/YES)%AY,??P2N[\0,_C1];K?S!=G)?\*2TO_H*W?\
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M.[#E/I:#Q'X/MM1N[^+5;1;F[""9_,/S; 0O'L#5O_A-?#7_ $&K3_ONOE[
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5L0K?.X!)'3C@'KBKESJFGV=U#;7-[;PW$_^JBDE"L_T!ZT?VC/^5!S'S/\
M\(=XD_Z EY_WQ_\ 7H_X0[Q)_P! 2\_[X_\ KU[[JOC?3=,U[2=("2W$^HS+
M$LD2YC3.<$MT['@>AJJOQ"L6\4G1_L=R+?[2]F+\X\HW"KN:/UZ=_6C^T9_R
MH.8\,_X0[Q)_T!+S_OC_ .O1_P (=XD_Z EY_P!\?_7KW7PSX_L_$NJM91V-
MS;"2$W-G-,!MNH@VTLN.G..#ZTW4/B#8V'BG^QFL[F2))X;:XO5QY<$LHRBG
MOSQSVS1_:,_Y4',>&?\ "'>)/^@)>?\ ?'_UZU_#WPUU[6=0$5U:R6%LN#)+
M,.<>BCN:]8L_B3IMUK<ED]I<P6O^D""^<#RYS!_K0.XQSUZXJUX5\<6_BB[E
MM1I]U92BW2[A$^/WT#DA9!CL<=*4LPJ-620KFEX>\-:;X9L!:Z? %_OR'EG/
MJ36Q117!*3D[L04444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH \PD\$>)X-(6RL[BP:.34[N
MXN896;;)%*<IR.<KUQWJ;PY\/[_29](>^>WDCL=$DT]S&26\PR%@RY'I^M>D
MT4 ?/GA+3]0\1ZC8Z)-:FTCLM*OK!IA:M&Z!_D5I">"QZX%=!IWPIU>#PQK-
MG.UH+^XMHK>W?[1)(C"-@PW;ON].@'&37L05020H!/4@5Y[XV/CC1_,U#1=0
M^TV(^9X?(0O%]..1^M:4X<\N6]@-'Q5X7O\ Q3X2TK3;E+1)X[JVFO(T8B,J
MAS(JGKZXJ+5O!<NG:!]D\&PV=G,]TDUPDV=MP@!!1F'([<BO*O\ A:?B[_H(
MI_WX3_"C_A:?B[_H(I_WX3_"NO\ L^KW0[,[G2_A_KVD)H,D7]G2SZ?J=S<2
M*S-L,,PQ\O?<.< _G61>?"/6I-.T=$FM99+>UEM+F)IY(U*M*S@@KR>#@@US
MO_"T_%W_ $$4_P"_"?X4?\+3\7?]!%/^_"?X4?V?5[H+,[W4OAO?W%OXEBMW
MM<W\-A%9O(3N3R  V3C(SCBIM4\#ZO<7OBCRK72[FUU.>&ZMQ.[JZ2*JJ>5Z
M8QD$=Z\\_P"%I^+O^@BG_?A/\*/^%I^+O^@BG_?A/\*/[/J]T%F>M^%='\2:
M)H^GV=]+9W;BZ=IR[,Q@A(^58V/+$'')[&MK6/"^B:\2VIZ=!<N5"AW7YE .
M>#U'/I7A7_"T_%W_ $$4_P"_"?X4?\+3\7?]!%/^_"?X4?V?5[H+,]@UOPF;
MAO"\6EI!!:Z1J$=PR'C]VJ,N!ZGYJPQX"U<^*"K7%I_8/]JRZOD9\\RNA&ST
MV@G.:\[_ .%I^+O^@BG_ 'X3_"NG\):W\0?%EP##?K!8J<27+VZ8^B\<FHG@
MIP7-)JP6-/1?"7B7PR/MTGV&Z.BZ9)9Z5%'NW3[FW R>AP .*GOO VNW_B*2
M<2VD>E:C>6FH7JMGS8Y(5 *)V()4<GI7H\$;Q01QR2M*ZKAI& !8^O%25QB/
M+[/X<ZN=32UO;JU&BV;7SVC1Y\YS<@C#YX&W<>G6M3P3X3UO2=6^WZY-9LUM
MIL6EVPM<_-&C$[VST8\<"N\HH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P9_&.AVUQ)!+=D
M21L48>6W!!P>U1_\)OH'_/X?^_;?X5YCK7_(>U'_ *^9/_0C5&O#EF552:LC
MZN&1X>4$VWKZ?Y'KG_";Z!_S^'_OVW^%'_";Z!_S^'_OVW^%>4VIM5N ;U9F
M@ .X0D!O;K72:CX=L%>.VTX7'VB2W6Y\RXF58T0^IQUJX8ZO--I+\3*IE6$I
MR49.6OI;\CLO^$WT#_G\/_?MO\*/^$WT#_G\/_?MO\*\^7PIJAN+B$K I@57
M=FE 7:W0@^E+;^$]4NEC,8M_WF=@,P!8#JP'<>]/ZYBOY/P8GEF7I7]I^*_R
M/0/^$WT#_G\/_?MO\*/^$WT#_G\/_?MO\*\XB\.:G-9?:DB3;AF6,N [@<$A
M>XJ;7-!&D6EC.LZ2>?$&<!P3N/H/[N.]+Z[B>5R<58?]EX'G4%-W?FO\CT'_
M (3?0/\ G\/_ '[;_"C_ (3?0/\ G\/_ '[;_"O/8O"VJ36T4\:P$2Q>=&GF
MC>ZXSP*CM_#>IW5FES'%'B12T<;2 22 =2J]Z/KN*_E_!A_9> _Y^/[U_D>C
M?\)OH'_/X?\ OVW^%'_";Z!_S^'_ +]M_A7GL'A75+FUAN(U@VS(7C1I0';'
M8#UJO%H-_,;$*B WN[R06Q]WKGTH^NXG^7\&/^RL"[^^]/-?Y>3/2O\ A-]
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M!)IJV;%5&X,.I STIL/B6QBU.SN-DYB@T[[(?E&2V,9Z]*UO^%:)_P!!5_\
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MO=TL(MK9?*9MN96''S>Y]JJZ-J=K:VE_87RR_9KQ%#/#C>I!R.M=3_PK./\
MZ"C_ /?D?XT?\*T3_H*O_P!^1_C2>&Q/-S\NORZE+'8%4_9\^FEM'I;Y=]3"
MBU31%LM0TPQ7J6<[1NC@AG)7KG/3-6-5\2V%Y9ZG!!'.OVJ*&./<!QLSG/-:
MO_"M$_Z"K_\ ?D?XT?\ "M$_Z"K_ /?D?XU7L<7:W*OP\_\ ,CZUE_-S.;[]
M=]/+R1BCQ+;Q:MHUY'%(RV5KY$JG ).""1^=7!XMM4U.WD,M]<01I)N:4*#N
M88 "CCCUJ]_PK1/^@J__ 'Y'^-'_  K1/^@J_P#WY'^--4L8ME^7]="98C+9
M;RZ6V?GY>;,73/$=I8V^D*\4K/9SR/)@#[K CCWYJQ;:K#--IEII/FF6"\DN
M";C:@*-DD9SZ$UI?\*T3_H*O_P!^1_C1_P *SC_Z"C_]^1_C1&CBTK<OY>7^
M2'+%9?)M\^NO1VUOY>;.;\7WD%QK!M[38+2T3RH]O3/5C^?\JW;26\75=)O?
M[*U!H+:Q,#8BZL0>1STY%3_\*SC_ .@H_P#WY'^-2CX?3 8&O70 Z *?\:(T
M,0IN;COYKH*>+P3I1IJ>R:U3ZK4K6S3A["]N-%U/[=81&**-$'EN.Q)ZBLS1
M+&_M-5GN;_1;QUF1@"D(8QN3G< >#6[_ ,*_G_Z#UU_WR?\ XJC_ (5_/_T'
MKK_OD_\ Q54Z%9M/EV\T0L7ADI)5%KY2]=/O+*&74&NC-8Z@D8T[R&,L8#R'
M=V[$XYJOI\,K.UJNFWT=C;::\*M,@$DA+ G';/I2?\*_G_Z#UU_WR?\ XJC_
M (5_/_T'KK_OD_\ Q5:\E:]W#\48>UPJ32J?A+0K(]S;0)9VVD:F;>&QE@C=
MXAO9W[G!X%5=/MISIEA;:CI&IB33Y3)"8(QA\\X;/3ZUI_\ "OY_^@]=?]\G
M_P"*H_X5_/\ ]!ZZ_P"^3_\ %5G[&M?X?Q7]=#7ZSA;6]HN^TO/_ #94M+W6
M(X]4>71;SSYY&EM=L>1$S#!Y^F*?I]UJ=MHUK;/I^K136R,H2"-0LN>A)/(_
M"K'_  K^?_H/77_?)_\ BJ/^%?S_ /0>NO\ OD__ !5-4L0OLO[T*5?!R^TO
MNET5B*PDE6?3;V]TC5?MEG$82L<0*,#WZYSS6-X?LM3TK6#<W&D7S0NCHVR/
MYAN[UO?\*_G_ .@]=?\ ?)_^*H_X5_/_ -!ZZ_[Y/_Q5)T*S:?+MYK^NA2Q>
M%2E'VBM+3:7GM]Y307%O=Z%Y.E:FT&G!U8O" S ],#-6XK_4!8HATW5X9(=X
M2."-0L@)RI)/(/TI?^%?S_\ 0>NO^^3_ /%4?\*_G_Z#UU_WR?\ XJJ5.NMH
MO[UY?Y$2KX25N::^Z7=O]698BO7GT-KC1+V9+*,K.C1<,2>H]:W+.2XN=1TV
M/[#?HEM+(WF3PJB[2A '' QTQ5?_ (5_/_T'KK_OD_\ Q5'_  K^?_H/77_?
M)_\ BJ(4Z\7\/;JNEO\ (*E?"S5O:+KTEUO_ )LJ);WT(L;/2=,OQY=Z;IY+
MI0H'4%<^F":SO&\%PM^JQV<D6GVJ^7&^W"%F.3C\?Y5N?\*_G_Z#UU_WR?\
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M%% !1110 4444 %%%% !1110!__9
2

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img222477878_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_11.jpg
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M/#]X<&%C:V5T(&5N9#TB<B(_/O_M $A0:&]T;W-H;W @,RXP #A"24T$!
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M>\U)<"XL5A/=-DK/(GN?6>7WG7@#<0,;)[H#>X5L(+R61@#G.]?LHHBS92@
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MF@^\"-0&*D I@NM^CO@-KEW/;7N?;QA7M=BYK5Q<"$5H^\"% Q4A:O=GL/\
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MZBO;0;8YT4#[5]S.)WM$@N+R618KF...2/X?0T:M):6QOD<UK7@:BWRGN&G
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M,VA>WGO;>PQF'B4C!L&D0;RGVI6B'<RZ^)77#];,8KHM@_,A&2@C;[-U!-=
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M7;BNRC-,&6Y/C4N-0I+"W9*67")OFC[?I_JCXJ.ZF9/YK7R,C+I?RX77-A,
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M$._1;Q!81R7$5C=SRN,4DQ?-;VD$C)8W%X?)XIG^;;N_$<X1RQMU'RR AKU
M9 G)<@/HF=19M9OMM7AOIVQC&K3^&[C<W"JK?V1B5=F6WD+/JJ@RG</=OTGS
MJ2YA0\HHKO%'+6;MQ@F6I#[S3J8Z4*;6$NOL!1/=-DW2\ZAEN8O,9MLSK42&
M.4Q.<R*"^#FDL<U^D2RP8 A<\FN1SF.+R1D4]@/VD5.DGU(^E%JVO;VMQ+9M
MJ>QO=8T>*1T^GC&UU$#TVGU-8%>0(K-++PMVI<L1L0<AB"7+:>R$1)"XQ?\
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MU[=-=.*RGV59XUIGL][+P'7N</N.I.G#F8::JSQ$L<N551WFQ!O+L1S#%'D
MMY%CMS3@D#X'IT%]J*X =1W,RE(6#X%/&WV._%O=03,!U,E:3W8K7)^L-KCW
M';+JP>,)8G  _M)AZ E<\O3-D#LO%ZMF62F7"!@36CH"W*B*5'D-JYZA2'FU
M \=;Z@MVR1>:W'5XO7C7S7\N;G2'63CIDC>05_FN(^S"K^U$@J:;*2!J![#R
M(_T\<TN6$/[!7T':2!T8<WC0ONBT',7^<'(U=Q33B3^RV9B83YTY]&II/W<6
M.GY S<2W%)(W,/IR]%!NKX'.V?S,/PIV'N!S/<.-1\_H]\@I03^[7KIS(YH*
M%=>70\:&(>27D_>(K-N#)G0D^X"OJJ6<+GQ'*&QIK)EF2BICK4TS(2EUN54/
M$N1$*;7W!7RSVK/^KVH/(D<9?>+?R[MEW!J&IW#@>9K9]/7+)MOEL+H,='&'
M!@?D [%6_P ZAY.!RX02]0SN]"R77*NT<6X$NK/>X(EEHX\TA2B0E#R7 /!0
MXO\ \6;(?*N@ &X:AQ3B:#'IR2(:[&5SM>):\\\4"+Z*(*VR?K&VH5K$D5T@
M2@&FY+94V]YZ2WI'DL^9'?[5Z:]JNX#PXJ2,BN-1MW @!3V<J,V=VZWB;%=L
MD:]4&"KW)PJ7H<^)%@MH,EH$ZN?B0"2I(',:Z\QSY\9E[)/,+@,%^JMS;7-O
M'"8R\:G(>(X<5%4)];'I1]+/J^1@^/;^8%5Y'8U3=TJ@RVLL96,Y[05X#!DP
M*?+:=UFR%5(G2 ZN$_\ ,0E.CO\ *[R5<="Z(W_J/I:.ZNMFF=&TENMA ?$]
MQ"AQ8[!0 FH(Y,%2@VY=8W>R;A;Q;;/Y?F@E[2 0[3@5:5YX$(>VN?L7Z#GT
MX'AJL;X^[MWDTTU^W%^?&V?\Y?F$UH?_ '+21_Y'[]'(/F)N$KD+X$_H?KHB
MB?0$^FW*  ;WW4LG0!&]&I/V#^%]3Q1=\\/F$T:C\$ /_0_?HA%US?2-77"O
M]#]=$#'\O3].&00$0]_U 'XU)WF41[2!_P!5>J1UXJO^?/S!C74;!.']W_?H
MQ!U/?S@:71'M#</KIY:_EUOIPK07%0/4&$@:@#>5>I&FO_\ :W:/O/%7_G_\
MP-6D.L/\/_K*(MWJ^&+]"=U:HG\NA].^P6'40]_8,'O ;6O>-;\J2G^VAO\
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MCC%7MM);.='+Q) KH^T7L&XV\=Q Y=1 3BTYD'NRJ0L;CIGVBY2M"Q6H2&R
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MEDG_ )19^!"0? :GA+3P"#2E*0=?,6>8T[6P0-#R^)9U6KD>@TX]TNIZ&OI
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MK0-/$<"KT"*S=(_WG*@YUHMI/Q%^QF>ERD=E3]6KDQ'D3(,EZ++"1J\VK0+
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M)Y\BF,VT-=->K[R#I]W%.?J6STK"P^VC$/RJWDD>?/!$U,5*GT)2!W<N0O\
MYK03%ZZZ*?FLM)]W)MITZ??Q2/4[]*MA!Y*M%/\ E7;@#XC<6M/)K<_738]G
M>3OC_#55=%!U!4\Y(E$#KK\)8!/%=_4][(C8X6M=1&#Y<=-1$?$W-Q(\<&@!
M>_"F&5<Y;/(4]/:C!)[DF'$::4/ A+BPXZ 1[^?%=^\[MBTR%IY ##N*4=MN
MC^C("AMA*>3RY?8X"AJP8GS4K1/LY\II:>Q33TEWREI*2%)4VAQ*"D@Z=.G
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M4?F1ZLQ$I$6?.= 3.L8Y;"4.,(2D,M+&H4.]0)"@>#-C;RV,1^))-[(5)7$
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M\3I' MJ,<GOX5-"=E2EE0 (;8:279$IUPAMF-&CH"G'WWW%I2A"02I1 XK2
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MPQH >KO=3'T5<$WQ&#4U8"K%855M0J^/'T"G"@N2'#U<D+<6'>?]E.H"1X)
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M4I(U'$EM8JY6 ''%<A45U?ED(GN"/+=@UB^)SN2?L]M*J9N9&8+SDAF(])*
M(L%26VT:<VXB)"M9$EM@*YJU3W*U5H-1Q#>&.0>0YJZ?4.ZK&UB:)GFDZ9'G
M+,@<,Z*X\1]WXW;:P>6KXBR)L@,>/(,^84:#IJK4^_@9(]NM- X8^BC5M:NU
MD&64_P!8@>H4]Q660$I>0EI7A(;6YVE70!P:E39)\1J/LXJ2%R)JQ7E1B!K(
M\"2B4^(GRZI(6W-<0WU\N6X7HQU\-'U$I! Y=I!XKFW%R=+VZL,Z(Q7,T#-=
MO( U<C6Q6YN/,Z,V-@U#ED:(8[9#GS:AIRA^6PI;RO\ 5T*A[QSX@.PW8.N/
M28N*U(.J]KCC+;F4"?(!K7$DT[0(4?,"'[!Z(]4Z)6BH9D(>=E@ZD?F;2%_N
MF0.K1^)1.BNT<C3?,+$ED37&<A%3 >FCUA:0[OIFNY(S /NA5[ 0:?TP+2L4
M40VTSH?,MI2\AJ4TG]EIQ+I0V\$#D%)() &HUX%2.;+C(3YG'OK46]O):N+;
M=@\I<!R%))2KV4E2!$3"0.2WIC[7:A.A)7V,K=<7IKTY?;Q%^#&A53Z*OI<R
M'0@:*:XS$*N8>E2)21'<4@RI\Q263-[2>QM/<H)9@))^!L$]_,G77G'<3.E.
MF(%>S*K<%H(&N$SFJ<CRICM,_JXX*8K4N:E)&BVF"S'Y:Z!+K_82G3Q2@C3I
MQZ-OE>4<6AO.I&7T3&Z6AQJ/;+<*VT=7&@P&&D)4X7);\A8;0 2I3JD?+MH2
MD#4G73B=MG:V\:W4@;CG@B5-#-<W4C8;*/5,XII1R]^%5RRC>Z_L%SH=*U"G
MN(AOM)EMQY:(*5K/;HPM;_?*T(ZZ]A]_&5WSJ[;[1IM]F+I+S)2$ 3,A/2E=
MKZ,^3F\;GIW'J[^Y[8X^&('\60=O[(.?-,*K,[C>3Y;8(G9;/D3WNY+C3:P1
M&9YZI2VR?W;90>FGX?#CF-S<W5]*9KQQ+N 4H*^F-GVG9>G+9MKL,3+5C6H"
MP#4G%2?>)YG+A27=_'7:O!<>9KHTJ1+L]SMN*=<"#?2L7D7$>SR!N+(IU7\-
MQN36-62#Y:W0?A!U(Y<8+Y@MG_@5M':B1TDNZ64>ADSH#(U\P!C\YI#F!X\)
M<,NVNB_+R:V_XBNI+ES&Q1;1?2ZY(FW C,<!<)?)>")#&?$&G.F2;:;A[-5O
MR+DR#CR\UR*_ML5Q>WO?\S9.+8[BN'09%K'&69KD6&4H:L;K_%OMOSW%1F'"
MB(V\X5]F9N+[J3HNW,#I&6[KZXFD@@DE^.=!#!;M+Q\1<S6T2/E_$<'2DL:2
MV%KW$Z3=O;=+=?7AF8R2Z;M]K!'<W$4/P#;B>YNGMC/PUI!=2K'%^&QS(6B1
M[=4[XVANI]QC?;<.YAUN7I&*KQY-SL51S<3A4LQVUMI&[>&5=W9+K\B7<GY%
MVNM; "$T8COF()0X20E7%G;NONI+R"+>!\(=N\[:XG0-C<7R.O[9DKRR8R>$
MLD?^$WRW*/"XG T+W;Y<=+;=<S;"?C1NIM]XF;<OE:(XF[;=211A\ B\8?&S
M\5WF-TGQ, Q%/6.[R;AY =JZZMW VKD7&ZT_"WI,.KQ6RLK+;B%D]/F=E855
MA$_B(5UI)AO8XB,PJ3)B3C)9D>;&#7:4VK#K/J'<3M4%MN&U.O=U?;%S60/>
M^S;-'</?&]OG:'EIA#&E[XY=;9-46A"!FZ]!=+;2S>KN[VO>FV&R1W8:Z2YC
MC9?NMY;2-DC'>1KC:\3ND>(XY8@Q\6B;6H(S$]5.XOREA8V<7%JUFTAY U50
MI$&FD6&)6]5G]/A5;%DU-=N _?7*IWYF6Y)N(V/1XMD6PIY,4K4!$7S4ZB\J
M2XNFVL3)62B-I;&7P21W4=LQI8RZ,LFK60_XAEHQDVE7B(N(-3?)KI;SXK6S
M?>S/A? 9'M?*UES%)92W<CFR/LFPQ!GEAT?PLE\^2#6C#,&@C.1;X;B9##D3
MK#*J>'$QVKW\QV?4QDMU<?*YF(3]KUUDN7*PW/9L*)D$6'DZ@#66,E#*8[Y;
M40^ORAFX=;=0[A$ZXGNH60V\6Z1.C",$[K=UD6.<ZWNG-;*ULY_)F>&ACRTG
M6[25VOY=]*[7.RVMK*>2>[FV:=DKED=;-NF;@)&M;=6;'N@<ZW'_ +B",O+X
MPYJQMUVTVPW3O\PS1,6WR?!&(]G<[H54?;"-66#>>XPWMWDZ:*+/L;1J?,8D
M"?$2)$U,V- 0DRV!$+OQ ];Z8ZIW#>-Z\J\N;!L<LUZP608\74(M)_*:][PY
MP.IOBD$C(@/,C$)?BO$>L>C-LV'8#-8V>Y.EAM]OD=N#I&&SN#?6_G.9'&6,
M+=#O!$89)B?*E,X9@E8*_-]P<<C8_7W-UD-WBNY7JI4WA]XS-F.3,;M,:WSM
M*G)=L+.:EY3AQ[(L;KTRZQMQ7D]S<N*4]OEIXY?;[YU#ML=O;WD]Q/M6Y=5)
M;RASBZ%\.YOCFLGN5?)FA8)(03I42Q$)I%=BN>G>E]VENKJPM[6WWG:>BUNH
M2QH;/'<;1'+!N$;$3SX)WF*X+1J1T$P.K4:>*7U5;G6C%>],B874LYBBG4Q/
MGMTGD;4IM=Q:O#7IE]75>>6=S<U55"LE(><MF*!UNU9"%I#*U!N]8_-7J>Z8
MR29EE$R\\M'/$:6/F7;+<NE8RZ?))&QKR'&=MJX3MTD!A(;0W#Y,='V4LL=N
M_<)Y+#S0YC#*NX^78R70;#))9QQ12R/C!8VV?>--LXN:3(T%S[:;\[C0OX_D
M5^5;<Y75[:X;"M9EE2XS;IK<CM;3/\IP<6,N4Y=?]#U6+1JEN;9IA&9'=<C/
MH8D!I7>@E==>=1PG<)K>ZVV[M=LLFR.?%#)HF>^ZGM=;G&3\.. 1B2;RO,8X
ML>V.305 RP^6O2MR-LAN['=;*[W;<'QMCFN(S)!''96]WH:T1?BR7+I716YF
M\I[6OC=)%K&EPAF?J(W Q:9>U<#)=O\ )&\6M[5N3F]55UI:R&MB8=29-Y=;
MC,[-Z^OEBAE6BF+@UUG)G(8+"F(RG%.!(K>/F'U'MC[BSM[C;[EMI-)JN8V,
M29C;>*=&0/N6,=Y+GEMQY,SY0TQF.,N+D/\ 3_RLZ7W:"VO;FUW.T=>P1:;2
M6218)'74MNK[AEH][?.;&'VPG@CB+Q())0T-)97_ %"YI63;B53.X^SCJ,PR
M6VN#,9E6MPJ ]D>.5D=1H\ARNJR.%1F+8K2!31ILF-,4A)@MHU"ZKOF)N]E<
M2S6KK9NV?&S22:@Z6729H6 ^5+<1S,BTO('PS97LD(!@:U0XA%\L=BN[:""_
M%T_=C86\<6@MBBUB">1P\Z&VD@?-JC!_O3XHY(@YPN7.33T5CX8ZZX7+F874
M)5J(47O2T0#H ^^KL>6?:$A(/'T2+)S7ZG$EJY5\I/ZBC:TLVUNE<W.S[P,L
M:=9D2/!:2(@1%+* EHM)0D)'/]V4#1*D*/4'[>O/A[VB-NH9U5MY)[B1927A
MV:_7WTTX]7V6X4YV+#4NNI(#JV+F_:3JAUQLZ/5^/K<2IF3.Y://'5N)KH>Y
MS1/%C;;!^Y2'PN$(Q<4P[A0SJ3?K/I*V$9>R3<Y03&U<ASDX@\AQ"5/S,W'<
M3JH=33)B+#"%QJZHA265NN*02IUV0L+== 2M?>^^ON4I2M3JHZ'?V.WG2&1-
MT6;1BOUCM[*^<=ZWUUQ<27ER_P [<92@QR7%.[MK\@_U>?2_MC:>M6YW*G;B
M9#E&=[N3-I[?>79S8C*-F]HLXVFV!J\;=H,@WJW)ERL9LMPMTZ7&K3&V+BJ$
MU_YV/.:93$6G]QV2RQL8XB,K'P7 UCY'2/>72IYAS3&N>6Q.Z$/(?45BF29;
M/P+-L8R/!E;'T=U6Y?EVYU1F/IJQVZ@9SMI.S7;Y[(J;(\7]1FXL.F>O7)LJ
MB=4^W6RICS,=Q;JEQ4ROT 5F;XN[C.V<7'H-300,7NHUYDT292"RDU=#-SJF
MR2RHYV 1TL6.6HMJS'I7<RY%45(<;6R7"I2E>^$H#SI%-! ]ZK1;T6UIO9MI
M5Y3@>69#4P+9^DL+:[H:V3@$[<O'V7(,3''\9OHMM$=JX3%M):=<KUR&K-Q;
M$R$H-)'RW$CT>3I/IR4?3A4;'.8T!WLQ0^KVU4WU5YB]%P/!**WI:V1N%45D
M27FTNTKI7\7X[56\LP*^EG2739U2I&6JB2KV8VF2Q,$MTKE1]3YHC>QN .?U
M?3.G1.!=J/NY=_;]GHKN/MD8D3:K;R+6+;^18PS'6XRF4A"2/RR.MP]B'' C
M]\I6H"B->AXW>U1 6D;F@%GEC]?M6N7[[<RC<)@01^*?KP]B56CU%2_5G99#
MM!5[ 974X+24.5O76>7MGDJ*BLNZU>98!+_(+FK=J9S%A"DX1'R*(GSU.LIF
MR8Y\E"EIF0K>[;/=7!BO;'2Z+2%:N(]'&A&Q=1[;M\4FW;N2R34?+<02'%W:
M,C[$J-%;3>L&FRO9].;;XS\]P+'\_P!A\]R%F7O'45URY:8C)V4R[=R9D=96
M8"S+W1QNZR7'\JCXS1QW8#58'VEG6,\VU%#V^U;C=D0Z2JYG!,03PRP^F5:&
MZW_9MK89I)&,+FDZ/>4$'20A0+QX\.TIMV*[U_Y)D]G9;+[I6E71N[N7^0?G
M,C-J=S';3 9$_+'MKX>*878X+43-OJ?;RGF547*:R386_P#%4R"X^(SR>_YJ
MPS8-QUELKF,87#CBGJ-4'=:;'<QMDLHY)U:?%I(8'88'$.Q*@$! 46HMIO3-
MZOJ?:>SIZS/J*JW(9W>R+.,4EM90JSK:"GM?3Y+V]K[&#.R&DN4L9#!SY$5Y
MI*V%I9C)<<')QYIP[# ;2P?:V2"[=-J+UQ(T:4&'/&LI-/\ Q+?F[ENJFSC@
M01 >$.\S4IQ7W$%)*/;OUSR-Y-R,4PK(I5[C%/F5;%J\KSZ^K:V<]@T'<+$<
MPPW*W\CFX._(W)L\?VPC3L:F)2$E=G/6V'EJC27V(GNW"SLIY"[Q/6-I.&:$
M.R*H%:<<RBFGPQ[7NE[:Q@((B))&M"@%'#00'(W6[2\=C<@H6[FP6+^IO'-R
MY6.[K[@93E^WF(;,;=V5G>9&AJ5(RSU"9Q25,+<J@JLA-!3LY'M[M\YAKUO7
M.P4H:CSLQ<A+"40&F&L[ )FRAKRK0/:?T"MC>FW,!=$P->YY.>30$'<3]0])
MXH[[;-[P[W_6>]2>,[*>I+*_3!DM5Z7MJ;VSSC$*87=A>T3-=@L!W%),55O3
M^5#D3IK,HN>8K1<5([>>H^HMBW;:]H^4^WW&[V$>XP/W&9HC>[2&N)D.L'2[
M$ $(G$T3FW&PVSHJWN-QM([V W;VACR@!5YU*AQ0$>FF?(/1'ZS+#=[;O!Y_
MU+]V+FWN<C;7 OYF%(\Z@D5;#]N+AB+_ !>L2'X9@]Z$]Z?B Y\$9.K.EK78
MYKYNQ6P@:W&,/P<"<ET?97%?^/>@KSJ^#9STC9/O'/43&7%I'W@WRL_372O:
M/Z<_U ZC.,'R*W^L!OAD./4&7XQ?WV'RMNFF8.64M/>0+*VQ>;)_CQTL1,AK
MXSD-QSRW.QMXGM5IH>4[[U_T*ZRGMHNE+)LSX7L;)YN,;G,(:\#R\V$Z@%"D
M5]";9N6U3IY%A'$XX*'9<.0RJW?U0L(W-]2L;:#T;;<;;JW"H-R)V3;K;XLV
MV7WVU^()VSVKBPHV,8[/W,K,.S-FIR"[W?RJAM(,)$1Z3+8QZ5R;:"W4XGY9
MWNV]..N^K]QN?AY[=K(+;3&V:3SIR2]XA,D>IC8&2L<XN :96YE =3 6L61Q
M0C <<3V=U4>G>LSUCXWMG?8SF2-X\3WLA^G/97:;'*BFVHR3*J[(/53M%ZF,
MXVT]1^6XO>QL$LH,ZKRG;>+1Y J9-=;KU4-BU+CA/:ZL;2/H_I&YW)ES9FSE
MV9VX7$[W.G8PLLI[..:TC>TR@AS)C)%I:"_S6%CN J7RHR5"%JDY\"%'MPIQ
ML_4/ZU6<DWLC/YQZC86RD?,ZZ#L'N+#V/A/9==^F"3ZEZ;'?5+O%-B1L1OY]
MCN;L9BLE==@[4NKAO3\%(R5%=9RBXXS''T_T:;:R<V#;W;R82;J(W)\MMZ+-
MS[*W!,C0(;EXUW):]P;<_P!V,D;4#O R)![NI,0O%,!W'CVX4\8QNWZO+RWS
M^VJ=S?5ADNR^S^ROK&W2V OJ7;3&V-PO4.G;O(-GZ_9A69UF4;=U;>8RT3\F
MR>)3PBU3.Y975L>8\V^GN==BN=JZ2@B@BEMMJBWF\O-OANFNF>8K3S67!N/+
M+)7>6$9"Z1RR"![W,!:< BV) $:'DA<<!FOV=U6B^EEO!OQN1<^I"BW;RS-<
MWQ#&_P#)&^VNR/,49%;IEG,\/OU[@QJ+/LDV0V"D9?!@Y/0H3(9C4A@U,Y3T
M:.^XSV:9GYG;3L>W0[=/M44,-W)\2V9D>AJ>7(WRBZ)ES=",ECL"9-4C4<YH
M*TRX8QH:6A#BOV<377OCDU5J9<@ 56/)4.Y*ELI4GVI+J00=>6A!XL6HU3!"
MA&/JQJEN+&R6;XW>ZX(>XX53S!"8L!N$K\5;*G5:@=>1K9TB !UUY)8''1MP
MTN>7G)T32#S) 6N*[$XQVIA?^8R=X_JAQ ]E37J/R7_Z=KX]?EM=-/MY<951
M\3Z/MKH?F?[N^G*IK/4_:?U\9NMI7G"I5\K_  *_V5?J/"I4&Y(V5Q%=H!.G
M,?8/;P3M"CF\"M"=Q9K8X(OAKE?ZZ8!3@^(W80%+H=S\<>\PD!2&K.);5COB
M- IQYL<=DZ&>[X]S%.ET+@!S=P]/*OE+YT6NO863HGE7+2/34A;7R0]15;FH
M45L-:^!'PC7P]W#-]:]MY(' @U:Z+F#[")[G*$/U59*I.J4ZCEKI[?#[.,;,
M?Q$KJ=I[S4RI_D5[%C#D0I;#<B)+9<CR&'4ZH>9<24+0H<M H=#R(/,<P.*K
M)GP2^=$XMD!504-%9K6*XM76T[5MGC$)ACQJ#Y]5-PIY,:T<,JD<?#%7>J.B
M4)4K2/!N#H$QI[8^!+IT;D: @A9*>-7!<0[FW5;DMN&M\0_:[0/KXUSZY@GZ
M?)CO3JVXN\$@50OW7.]2+VU\V-B&F&F&7 E^62E!&A*&4 ><Z-"-#H0E)]JM
M?#AMO;&5Q?)D#QYTZ]N&M8UD1.H@(<SC7L.MAOL%AQI#C7:AL@I"N3JTMJ(.
MG)003S]_77CR6:5LGA<1W&HK:QAG_,#7.)4K]=/2,=K8[(:APV(S2#W!##*6
MF21U*D(&G?J/Q=2>O%1]W(J%Q-%7[7 QOE-8T,<,0!GWU&KNW,-VQDOUDF75
M!3BUOJC]IC+=<T4KRH[B=/,65:J["D:]=3P8&]S^0SXC2XC,9GLK*.Z3@?>.
M?9R.MV#%6C#MPRK[E4AHS&B0IBK>\G]_Y?7(AMH=4$ *=G37S(6B%7Q4D%U]
M0 UT2D%1 X]BO67AUR LMVYD8+V5+=64NWM:VT>;B^?@ 6H .+B.P\:=,>VX
MG2W'<@O+)5E8E;L>$K\O2W!@,A02MNKC//J6&W'->]Y8#KHTZ) '%>\WJ%G]
MWM6 0G$GB1R=]M7]OZ2NYI?XCN#RZX!1I]X#M8O#E4GU>"J0H%5G^^4-"MVO
M22.XCX0I,@!"1^C@#<;H]Q0#PUK[;I\N<'.G(?Q)CQ2BA& R1H18-\_VQ#(Y
M$]04R1P.?N8#T<W&C;>FYRW7%,TLYHA]5()6-R(2U,MSG9I3R(:BLM)23U[U
MOR="![ "1P_XZ-^!: *ADVWR&:1,9?ZB>W[*10J0%],>U5/D+?"ODVT/-MMM
M*2%*4SW-H*T-E()!)!U&FO0<6)+HZ5M='VK4%K91O?Y<X<YRY=G"B1O#JI0#
MS41MF6GXF911WR6%I_"6WW>]X>Q0[OC!(/7BA)N-RW .<(^..'T6M%!L=J7"
M72?B&X@D!1]!3@O&XTMEN26DLRD'L4ZR5,NMNMGM66W4%+J 2-1H1R/ MVY2
MAQ9BYKO31^+;HI/QG@MD/ 8(E-O\9(Q^2FNOYRGV'26F)X9>>?C.$?NX\XQF
MG M+I&B%JT7W$!6NH(B?8.O6_$6OA< CF?:!5]NZ-L3\/>ESH\PX>\G(GG26
MTSBJ[6T-RH[TR6=(%2\M45^00/\ G,I#R6WD14?V=.Y73B&+;KA[3(UI,0S*
M?3&BSMPLV:2[&0^ZPYX\2.5"S[,BP>$FVD*E/C4MI4 &(XU_!'C\D,I Y:@=
MQTYDGCQDS(3Y<*H/75V.SU>*X1P./9CCAW4.Y _ JX#EC.=;9AQ$+4^ZM24]
MH.@3V(U)<=4KX4H3JI1.@!XK7=Y:V4!N;AP#&Y!<SP'IH[M>Q7N[W3;+;&%]
MS)@"B@+Q/(#G5<+RTFYFL->6[!HD.$LUW<4.34A7POV90='2H#4-#]VCQ[CS
M'+MVWJ_WB4L*1V)":1ACS3M"5]7]']#;;T9;-EETR[T6JYY (:X\&E,$I1"Q
MN(D#M82D!/)*4I&@'+0#3H.G T0(<#B0G>G;6DN=W=B05/$UND5#;2DA#8[3
MHDC0=/?RTX\,+1GB>VF0[BYP)?A7VFMC.>4B3&CR$MO-OL)?::>#<AE7F,OM
MI<2L(?86.Y"QHI*N8(/'CH8G@"1K7!K@X* 4(Q!"Y$'$',<#2FOG@$PN<USF
MEI+21X2$(*9@C C(C BG.155-HVPU;5=99M1GVI<9JSKX<]N/+9)\J6PW,9>
M2Q);U^%Q("TZ\CPKBUL[IK6W,44K6N#@'L:\!PR<-0*.' C$52AN[RS<Z2QF
MFAD>TM<8WN87,.;7%A!+3Q:5!Y4J;@4T1 ;CU-4RVAV,^E+%?"90E^$$B$^E
M#<=*4OP0D!E>G<T .PC0<.;:V;&HR.)K5:4#&@*WW2@&;?NG-OW2*JS76X2O
M+I)9W.+7-4O>3I?[[5)R?]\9.^\#3/?VF';?XUDF:SZ2#&KZ&/.RVX<IJ" ;
M&5*AQG/.LVVH[+*I-PXTXIL2%K"PE:NYQ*.X\4-PN-HZ>VZYWJX@C9;0-?<2
M&.)NLN:TJ\!H!=(02-1(*$JX!35[;+3?.J-TL^GK:>5]U<O9:Q"69_EM:YP2
M,EQ(;$" [0 0H"-+D%-N%9-@N?8K>YG!Q2##CV+^0566Q;.FQR1.LY6*2),.
MTAVLRL=LZG*8K;L57DO)E2HKH(*5ZZZ5-EW+8M_VJ?>8+6-D<CI63M?'"7/=
M 2U[7N87QSM5ITN#Y&.X'-+?4&T=0],;U;=/W-[(^6)L$ELZ.6=K(VW(:Z-\
M;)!'+;N(<-;3''(TJK<E8<&SC%LYJ:>Y.S%QB>$R*#^+ZG+LRQ_;FOQ6/7/5
M4<LS4?)9#9RZUV92E*0XN,TE,=OL<4A*0.!VQ[[M6^6L-X=FFM-D=!\1'/<1
M6;( PL".&F5[F%T:!2QJ,".( 2B'4?3F]=.WT^WC?X+WJ%MU\++;6LU^^Y+Q
M(Y6G7!&V0,E4Z1(XE[E8UQ)-.]%O#LW->S')H5[A57'J;^JQ.WSN188Q75V3
M64J@KL@@L0LG;DA5XW%A3TH*7'.YIUEP!(2CNXMV/5W1T[[S<X;BRBCBN&02
M71?"QDSS$R5H;,'?BAK7@(XJUS7!$:M4=QZ Z\MX[#:+BWW&::>VDN8K-K+A
M[[=C9GP/<^W+?P2Y["5:U'-<TJKDH@M=P=JJ5]5-;9AMY5289_/7:FPO,:B.
MQE);1<"Y$)^0A3,A3<M,M$D(#B_-\U*CW=Q(76_]*V;S97=YMT4K/Q?+?+"T
MM*>9YFDD(?$'AZ*5U E5H59=+]:W\8OK"PW6:%_X(E9#<.#@IB\K6&E0"TQE
MBH-.@@(E#\O+=J&9:8(M=ND3MPX[,UF&F3BXEYU#EA:(TI;*3YN3,3!WAM:P
M\ETZA))UXK_Q+I1DS;8S;:+C<6AP;J@U737>ZY,Y@[$-)U!V("XT9M]BZT?;
M_$>3NSH-K>6%VFXTV;FXN:#E;EN!< 6%N!*4[UE,FQ'RU'4UM?7HBHK52&:^
M+%@MU[/F%NM9988;1(B,^<OMCI'DH*U<@5'4PRRB:T0P0LCB# SPL:T: J,P
M &@*4;[H4H,30R^W46;C+>S3376LO+2]SGZW(LA4DZR@5_O% IP%&=5MGAM?
M7Q:Y6,X]+B17A*C1IE'4N0XDM*RY\Q!KU0S!@NAU14%-(2O4ZE1//B:+9=JB
MM6V9MK9ULQVIK3%&6-<JZFMTZ6N7%0 >VLY?]8]0SW3[T7=TV:1NE[VS2![F
MY:7/#]3FI@CB1V4Z6>)X])DQ;)=)1/6=?,<M(4J545S[C5BYV^;-;><BN/1K
M!XMIUDME+Q*1JH@#B:;;[*:5LS[>!\K'E[7&-A<UYS>TEJAYP5P1Q3$X51M-
M\W>&-]NV>Y;931B.1K99&@QC)C@' &,*48?"%*#&M4G*845AU4MU,9;')]+R
M@A:7#R2A/=J7"ZH_!IKWD\M>)GW1:2QZ@]OTXU,W:'3!8BL?[7!.9/##U4WQ
MJZPR1]"K)B7'JRKO%.E;D.PLD$:MBVF(_?5$%8([F&A\ZZDZ*\@'4Z':]AN+
M]C9-R_!B.('NN([1V\*P?4'S LMC\S;NG0+G=A@97.U11GB@R<[-.25*D?&I
M,V-%AR"AF!#0EJ%55[8@54)M']VU%A1U! 2G7\3A<4>I.IXV\)L[:'X:W:&Q
M (% 'I-<3O);[<IG7FX3.FN'E7.*A3W'+E6]5"VB>H.(1&7&\MF-(0EM&J4H
M[E@@#D7%J/<#HE0XN-FU6XC+E8N5 IK6,SZ\&.&(.2]E<Y/67])GTX^M#=7;
MW?!]^QVH]1NW^18+D#F[V%U-,YD.4TF R)#U%@V4N3XRC/QAU+Z4+(U?#33:
M$J[4 <4YX=?B;[O.H ULDHB;@\Y_I]-<;_4-_+V>IC =MLDO?3KNC4^I?>-Y
MB5"9DYU+;V;R#<5C([*SB6\C>',,8FUUSF3.%X78B#C$9B=%=K'VB\'E!SR4
M4W1%N1!KU\+F!2A%2;NIB>YF(V==59SB>1;72-MZ>A-J:R%D$>HL<I<I:MNS
MB5C,ZL7'MJ>OA^8ZQ)=F35%MU"5)[%]@A"IX@AJ*HYQ_>AJLF8SFUO5OUF9X
M)+S%W$,LQ>ZLF:.ML)+(E2+F3CSL67C]S%M_FUMNKDLJ6T7-5ZN-)X]#@"H(
M45X0' @Y'Z<*K<W<W^0Q<IM)UA60;BT#TMB!:6$=3]XY*4W)DWAF27Y-E.ME
M^0A'F//O.=A6D*2%:<>:@<217J5^G?T9Y3(R+TT;62G%*_,(>.,Q;*"Z%MRF
MPVZIQ,MIE\(?=C.>?R.GQ::IY$ [_8)2[:FDJC7N:O XJGMKD_5K3%OC_*</
M-=$U^@G,$%I(',:3C5M6:Z),9#C@2ZEU.BCS*5ZC4CJ#V@'0CEKP69+)$Y(W
M%KDX&L\V"&ZB4AKAS(JNGJ:V>F[E[';C;;84^[CMQF,;&H0F4EA$QZ0:QK-L
M:G93$_,WX<YF-'N,5AS8TA'EGYEMQ36H+FO'L\MU<PF+S'%Q[>"A?94,-G9;
M=,V5K(VQM)*)@I!0IS5#7.^VV8^H+;W&-6+&>5D"]Q4VCV/2<BSS&7ZAK.W?
MX&F65_!J,/Q>IJ5;4W-OC;CN.T-K#GV-/'2\W-2M,GR##/:;E<0LG)\3>9"\
M,<![O(%2..=/MK[9X7F(A8'Y$ HGB0!2?&%1SFD!Q1,EJ26\1^I-,RK&*'$L
M^IFL8MK>6_;5><7VW.2[FX5AUEDEI1M-9)E..80K%KW(<9Q"3'O6YL=EV-)L
MF6X)$D!TNM;#N$,#;BZ>&6[2,2FKN;S*8\EP*YU,Z?:;B8VEG&Z3<'C#2'%N
M S=BH:OA*H4Q &57_P#1E@>^^";.KJ_4M.1<[KO9=?2)F0JMZ"WL;K'5M5_Y
M*]9N8NR*&M6S+,QN/#CORDM0PTXI3*W5PXHN2]NKOQ7)6(*&MXYYD #'MQK1
M6VRV&W/<ZT:!+(6F0A4)' $XH.'U59NP':@A).@4?'GVZ:\,C"R85'." X&J
MO7&T6U53N=D6]U;M_C,+>+*<:A8?DNY,>%Y>676*UIA*KJ&PG^80]61%5L?L
M;[1IY*>?+C;6>Y[E)MT>SRS2':XI#(V(GP->55P',J5/;65WN^N'6(L'RN^"
M:\N#%\(<05<G/$^NJOX-'%[ZO*(G1;>,XIEESST4EMUR*Q3-*'+0*!M#]@XU
MF_.;%TRT*&L>0.0=@?77">DH_COF8YY:GP\3G+Z0A]*UU_PED!#2M.8*2.7/
M\0(&OLUXX;N9!*$\,:^ONGF.\ICG ZSC4Q-/+4#KIR.G3_CXS1SK=5M[S[OZ
M?Z^/*59WGW?T_P!?"I5G>?=_3_7PJ59WGW?T_P!?"I5A<(&IT 'V_P!?"I4-
M74E];"F%%*4**2?@(5J@A8T.OM'%JV'CU<:'7[WAN@>Z153ZY)A9+E\(\@QE
M5C(0DG31NS1&M4\O9W33QT.8MDLK9XQ!@./:"E<8A!@WB\M<49<RE>37:"P=
MV+D]-2SYG_0'=W'7Y_3K_P";:Z?HXSND?%Y<*VVMW\-_K?94]'J?M/Z^,I70
MJ\X5*LZ\O;QZ,Z5#60-@Q5A T(!U^\ _T:<7K8I(TG.J%XP^6YZYA*YL^MFK
M5*V.S-Y*4]]1,QF]2HCDG\LRBI4XH'0\PRZOV<=8Z/F3=X "FHI7S=\W;0R]
M(7J#4]CF/'HIEV4E_,XG3.=VI+#7/4']@'^G@YU- 1>N>2NJLIT)*V39XB/I
ME5KZASX6SIRZD>T\AKTXY_.U),>5=EL\FGLH[B .=@/X>9(]HZZ<"9,'GDOV
MUJ+8![4X"E4N S*C.,NL-OL.)4AUEYM#S+C9T[D.MK2I+B5:<P1IQ&9G1D/C
M<YL@.!!^NI9;5DC"PH6NS:X L</YV"X<$2JWY+@:#DDQR@LU5'RL2(ANL?9,
MZH[WDK>=*&E.-S('?W :-.=@ &B.-K8;PYM@UMTS7$[),",>)XXURG>.F W=
M)?X5,^W$; [RQC'XD\+1F 25QYTV14954._XZE<G1P"ER31.)L&TI&A\SY10
MCV""% *T#2^G4\3O_AUPSS('Z)3P.-5HG;OMX#+J%SVC[S,?9G1G7WD&:VM7
MGEI+9[7VG6G6GPZ-/W0CN(2\2H^';J->FO+@4ZSN&..H#'',4?MK^&>+S$>.
M&+2#ZJ4NP+:2TN7(971TS?E-IE26.ZTGK6H(:CU=4=%(4\LZ(<?[0>H0H:GA
ML5Q'#^&TB:[(/A& "#%3W5.8KBZ!FF;\/8M1=>#W<@UF94HIY8TT8=0.6]I:
M6C_^!CNS7(;49A?FS7H=:\XS'1/LU@N/K<<"WG4MAML+=[0"E/.UN=Y\)$VT
M0.?H!)& &K%/10_IRQ-]=/OR"(G/+6M.) &!Q[<ZGD5C;,>&VEL);3W]H"3X
M))TZ\R=?>>,B;E\@<X8(M=-CLXX8HX#P(IX9A-]J=4A(Y)'($_>#KIRXIR7#
MSA5^.V9C@*624*AQ%+8YJ40VVA6O85'JI//X2$ZG[>(V.,CE.=6G@0P Y@\*
M9D--O)*6DZNCM*TK_$V5Z_&Y[=3J==>?$SG:<4JEY3)/"&^(5\FM2WJX-%.)
M(<"]-5E:"%Z_#J GD>7@.$)WM;X00*];8L!\Q$DI^EL1XR ZI6GF *;:2DE:
MNX!6@ ]@/7D.*;I'.4$X&CS&-: 4Q2AHSW) EQD-&.V5M%.J@7W0L*2H#L^%
MO7L&IUUX4C1&6N)X4^!YD>6@%10C<TT<Q9#\I">UIIUP-Z\FE(!6%:G4+?[T
MZ@GH0.)8;I[9 R(Z=11:FGL87L,DHU$!:CZ;0(M6Q93&$J>F--.E)0%>6@H!
M2T/8&]>OMU/%LW;H&^3&<%)/(FG1;>)VB1XQ(3NH0D7SV*/--6DT&F><3'"Y
MCH\^"20E*VWEDN/1DG0*0K4I','0:&"0_%M=( &RM"N*8!/U44LFNMYHK4$N
M\V70QIQ*G%3V+5;\QW2ILUR9RLA7<'\EI9"V(B77_(;LK%H^5)G#SDM)>0A>
MK;',@)!4.:M1Q7==X.YW;VAQT-.7 ]H[J^V^@NCF]*;,V62-O\6N!J>2%+4X
M-Y#G176MQ6FTN.N(\L@*3W+ !']I//10]XXIQ!6XX%:,7DEPZ4LC8]SSB4&'
MK^RGMR]JHZ1H\A2M- A.@UY:>W7Q\.O#C-$.-#1MU[)[S UG,G*F9[(8ZW.P
MGM"R-$J2I*M!T*>\#N/+PXC=<QZ@"H%76;9*6+J9AR*K6_YZ.I/PN)/+4<P"
ME7/0$:\.\UAQ:5%,%C,'(<@:U_FN@ )Z<NHZCD>G77AFL<C5EMD5Q:E:Q9=R
MC\0/(<C]PX0E'*G_  *YB@S="AL<[P:QQBKGQ(4F7+II#[%@Y-9J;ZNK+>%8
M6>*W<BM/YBQ29/ C.0I2V0I89=/PK25(4"ZJVRZW_9)=KLWL9(]\;B'EPCE8
MR1KWV\I9XQ%.P&-Y:ITN.#@H)CH_<[3IS?X=XO(I)(HV2M:Y@8989)(G,CN8
M6R?AF6W>X2QAZ#4T8M*. KLUMWEVWE!FN-V]W4/X]=EQ6$8[5V-[85VW59(B
M648X;6.6S,?YBBK%R&W&I"&6GGE+6EQL!MK4%T;TSN_3UC?;=>2Q.L)U-K"Q
M\KV6;'->WX9AD 6)B@M>&M<XEP<T!K:,]?\ 4VQ]4[GM^[65M.W<[=/BYY&0
MLDOI&NC=\5((B[3-)I<US"YS& -+7$N?47XWZ=<@K< E8&_CNSE#*E8+$QB5
MG>/3\TL+VYG53]18QS=U%G5PJUZER"RID"S:;="PPXL-A1Y'*;;\M[^WV!VP
MR6NS6\SK%L+KJ)UP^61T9C>/-C>QK#'*^,>< Y=).E<JV>[?-';;KJ9G4L=U
MOUS"S<77#;.9EHR&)D@EC=Y4D<CY!+#'*XP.<U-8!<F=*+W8[/KW(K//)4K"
M:N^L<LR&[_A3&LDRR@QYNOR/ ,8PN0M620*%%JJUCO8WYCP^1\F;%E.M%3:B
M%<3WO0&_W^X2[[(^QBOY+N63R(9KB*$,FM8+<_C,B\S6TPZG?A:9&/<PEI0U
M#MGS#Z;L-LAZ:ACW&;;(K*"'XFX@MIIR^"]N+IH\A\QC$;A/I:?.U121L> \
M!*5XYLB[B[^.,_-8Y:"EW)VLR]MMJ%82)4BJV^VN3@KM8PFQ%E-+RK75^&EZ
M0ZEN/IWN>9J.+^V?+V;:C;^*VE9;[E8W'NN4QVEC\,6#7K<OF>*,.>X!B:G:
MJK[Q\Q(MT9=O>VZ@-QM.XVN+V "2]W W@D/EZ&H(_!*6L:2]=+=-#]1Z3=S^
MW'&960X>W4U=EM_9KA)L+JLT:PS,I&1R*Z=6UE$IO(I$Z-)*8<B;+[*TE3:&
M--' &M/E9U,&V\7Q-G\-#):/35+&GPURZ8L,;(DG+@4CDE>D.+6QHCJ(7_SP
MZ//Q;HK6_P#CIX;V,.+(9,;NU; V1LDDJP-8X RQPQK.@<Z7-M=)D?+M("&T
M-M,IU#;:$I0E"=?A2$@Z :> X^A?"#X?=KY-?YCO%(2Z3B:;[._@5,9R7,FQ
MX<5E!4[(DNH::;',ZJ<<4E(/L'4GIQ"Z>-KM)RIT&WS71 A!<XG )F>'MJ,V
MMP9^6/+C8'C]ED*4*+:[N0/R7&HZM>:E64Q"I,PI/5$:.ZL_T\.M(KK<I$LV
M.\H%"XX!?MP2KNYR;9TO;^?U!-'%,F$+2'R.=R 'UY4;5>)_+>19W,5R7DW<
MGR\A4\'(-&E0T>;I*PLH,53B=4"2X79"1J0I!( V^S].6EE.+F[(EF3 )@#V
MKRKA75_S"WO>(3M6W1OL-DU'!A >['.0IQX@(F533CU.EM#:2A !3JEQ.BT.
MIZEQ+FI&I)U.O/7KP;NI5>I"'LK#QM:R((I)Q).))/,U(L:"$]J$ +5J"3R(
M3KIS)U\=>*+CB34HD "&DAIF5.OEX%SN>63W %/)1(Y=.G3BQ%*!&,#C0Z;2
M9"UV9P'8>=(HL<IGOKZJ:D+;0O3XDAH-@).NI[%)T&O0<7M2Q:/3ZZ"AQ:\G
M[ZHM'["HQ;;6@*<[DZ!+>BBE7[:5'7M!U]_%0,*Z7X&K4DK71JW$<ZUR(<9Q
MJ6TNMANQYSA=FQI3;<AF8\IAF(7)$=U*V'"J*PALZCFE('$L<90XXU3DE<QA
MT@56^R]('IJRA^[F9#L-M78S)TR3(D3&</KJB0M<]9>=0IRC36^84#M"7% N
M'M!)[N?$C[:W"!S1J/'+/]%#A<73PXL<!AR-5'ROZ5/I7L;(7D+'LHQJQ2[)
M5Y..95+<J4M//R%,M1ZW)(]^B$6(KP0E3:@4D$CD=.)F;3:R *X@GEE[5JA/
MN]_;OQ:QT?:"J\U!Y]E2R-I4[;8]2UVVCLAJ'BL./7UE);RU.38[$5/:6D7,
MGX9R9@U+R)*NU:E$I<3\*1T/8I;2S@;MLC&BW<#I=F2YV!<>*K]6%<8ZKAW:
M?<']0VLI?>M0&-$ 8W$-;P#0%[R22<:E:OO6)%9%L7F9%6Z_&;DRJ^<PY&DL
MJ<2%.I#2TZK4TYJDE'<E7;J->()+9S;IS 06C!?U42M]P;<V<=U(TQNT8M S
M//"A^?;6EMJU1TUE-;6I/^+6TF# [1J&P)D]3*7$$**E%M+G,Z>'!"&&UMO'
M=2-;Z%H+>WES??A6$#W=KCH9_;((IHE85>28YFW%TU7(CK:E)@TB2MY7DN)7
MV/VDMM/E]VFBBTP%:'DL=>)F[Q;M:6V8#RA&HY#T4/EZ;O+EIFW&9T,;2"&Q
M8.P(P#C@AR.&(JTM%05=3%#-;!CPFUA"UEI'<Z^OM!#LJ0LJ?DO'7\2U*/&#
MNKE]S(6SEQ#3@ 4:N>5=?VW;;3;XVBUCC;(6-)>AU.4?>//NPITDI"4:<M3J
M.FGAIK]AXA;)KD0YDU<E9Y84E10G8Z]JBDZ?"HGW\M.+\/O]M9^ZF"G"H9RI
MP!N03U#:R3]B=1I]@'&GL0KP.T"L-O6+#V@_55/_ $VQ_P T]2.Z-L0IQ%1A
M5;6H64\D/6^0!]0!!Y%354>1\!QK.KG@;+:PC .)*<M*CVK7*?EA&;CK'=+P
MG",-8/2G'T5UWPUD!IOP/P\]#R'7Q/'$+\JXGLKZ^V*,Z14GI2$CD--=-> )
MSK5U]<*E6<*E6<*E6<*E7RH=R2/:.%2H=M4A37<KF1U]^O+_ $\6[7%Z<*I7
MC-3:J[=MJA[AWS?X180*"S3X!2_(DUKI&O7_ .K$\;JU/F[0QV7EO='WKXEK
MC>XM\KJFZX-EC;(.U$:G?QH^\P_P[IW#_P"L_=_\SU_5P*T?WK^K]M:OS!_#
ME3[WV58D]3]I_7QCZZ-7G"I5G"I4RVZ Y'>&G, :'[0D>_BS;N/F <!5:[ \
MDU1?U14YM]G=UZ]([E.X/D3S:!W:EV#"78-%/;H>X.Q!I]G'1>EK@,W.WD=[
MWG-"]AS%<(^9%L)^G=PB8/$;<GTC+U57'TX3TS,"I7M2>YB.4G4'\3#9ZCC>
M]4 _%&N._+>=LFRQI[P-74ICJVC]'/CG-S^8HY?IKO5B26M6I!KU#5 TU_9^
M_0<![CPO09$UJ[)$0T0=&CH.8/(==1R\#K[>*C\".2T2#&U$.0MB-E<G4=J+
M&KARFSX..Q5/0Y"0/[2$ALG_ &AQHK$^9M\?%PE(/]%%'MXUA=W'D;T^-V4U
MN"WT'(=M-:7U>>AAH@.RI#45A)TYO/N):;U U5H-=3RZ#B::+4PR#)@U'NH>
MU[Q*R)A(>]P:,3F<?LJ:H5:Q#C,L-'5+2.T+4-5J4?[QQ2CJHK=5S//C*S7,
MLLA?J<&\,3E71;2QBMX&Q.:TNS)(52>TT%6Q599"XUJ50L?2E/;IJ%V+K0=?
M=/+XU,,K0T/[)4OV\$K=PMK+S),9)N/$ >T+0*\'QFY.81J9;X!<<2$S.:+E
M6R@JTU4M^ 4]J2^]-;\.]F<M4KN!]H?<6DGVCCV\G,S1(OBTH3W8"O=JM197
M!@1#J4]I/$?JJ09+ ^59=3R##P"AK^R[^Z!Y^(64_IX$6[B9"PGPEOMK4SM&
MEK_OZ_92AI'<E)/@1KKX@ =/Z>('^\0,A4T:M<1V5HM7%=D)EO\ &IQ]1) (
M;2E"1J=>7?S.@/$D"Z_13+ASB(XW>Z57UFFYIKRU!;8[EI220?\ >#4%041\
M1)TY<^7"+R0ARKV$!KE&:4K?>92P'$J&CR4)00>8#A[5:C7\0&O+V\+Q$<:G
MD</*U*%YX4DD/N275J0GGJ$E9YI:2!R1J.1('@/OXC<T<*M0E\C$7Q<ZR)#0
MV'G5)*UO+2"XKJI* ==!^PD*5H![N*=RXN+<<EHM;0"%NL#Q$T(Y6\68J64I
M"DR'AY@.I/DLI+SA'77FE/+QX=;*[M2IY_=7B1C0Y/L([$&-'C.M"08[:"HZ
M+# "1KJCQ<]QT_HX]!<9BN5$ -#6MC32E5@W@2J)C=S*:=2_82V?D(SSBDJ=
M\Z8"T5("AH/*;*UZ#0?#Q2ZDW,[=LDT3<'28 C/+&N@_*K86;UUK ^=NN&V_
M&<#EI& 'K"CC5=Z+ ES&6676_EXZ66TK<#25K5HD? WW@IU '-1UT/@3QQJ-
MCW -;@G97V5>;C' [%%RQ-&U?B<'%G/GHC"I;;?QR85E(DRXDEL#N6E+#CGD
MQ7] >U;:4\SS!'+BRV/0-4I5O+^2A$\_QT+[=LCHBX8.:4(//MJ2H^68JPE#
MT*BE]JD(6'8]3'8T[D)5V@.N,/\ PZZ'X0->+HNK4(0P5E#L>]O\$DI<WM?G
MV^FO9V88C8L.1KB-,;84>?SM6ZXVCH>]+T7SU,*1_:!21[>$ZXM)0CT:.[.O
M8]BWRTD$]LA(Y/7V$H:BN\I_-2Y881D,.SCI.JJZ7*\TM$ZGL1.;[W&BGP2\
MWK[5<4)H& !\!&G/T=U:K;]PNG)!N423C[R(J=F7JJ()V>3J"4J-D4693K<5
M^Z=FHU@O*&B5"/8ME<)P'0'3O!Y].*NMX^@K3"!L[ ]B)RI^@Y]&= (E-+"A
M\*DK2H'7GX'IQYYDAX5 Z$M.C FB%K/( *4^<E2CH.UI7F+U5X=J0I0X<)4Q
M:[&H#MX(0@)1!'REV2G]U'6GN_"Y(<1&0?>4J)=Y_P"SKQ.R1R8NJM+M\;7!
M>7.EKEG/6WW&; :^'DE*G'5==-$E1:!U^SCW6,E%,^%B;DU3WYUJ=DH*2'+-
MYSX>Y26RB-W>)T"05D#Q^(\>$M/&GLA /N 'L4T28/:0T0[%W5E"HUBZA4ET
MI\Q+"F6'PEV0YS[4%P]5: <36[VL)<2$[:SF_P!M-+<,:W45 P"Y\B!]5+9^
M[>)0%^0W8*L9"3IY%1'>LEJ5T[ XPA4?OU/3O!XM_%L&(]YV2 E?50[_ (<O
M)(O.ET0QG[SSI ])(QK;&R[)KEM3M7AN11F"E:F9][%:K8)(22@^4V[,M74K
M5HG]W&5UU) Y\%;+;-ZO6@Q1H#Q.'UUE]UWWH_I^/_>5_%)(,"R$.=)W_LH<
MQ1/CNSL>_DMWF;VJLNGI4'6*L(<A8Q5*)[@S%J0LR)"F^A<DJ4MP\U) .@.6
M?2K()!+N+M;Q]WAWX)E6#WGYMW4L+K/IF$6ED</-< Z>0'BA!#>T@ C@:L56
M8NS':::9CMQV66TMM---H:9:0D:!#33:4H;1H.@ '&D\V.W2.-H  X #UIF>
M^N43SW$TQN+E[Y)W8ZG$N([B<L>5/[E*CY9:0T"H:$:I!Z$'0<NA'NX3)7:]
M0.*K5.X)>PEY)*<32R)4.,@>6\IA*Q\: TVMK7^T$J')7O&G$A<U=4@4U2$C
M@$&5$E:E;)\I_P#>C4E+Z4]I5KT2M('(@CEIRXKNTDE/=KT2.)&(SI<\R/-6
M1V]J@E:0-1U':HZ_[0X=&.'W14$_YA(H1<6A%[*A=ZD)?9CS%JT /:M(9<92
MH=%%30*O'10]O!>-H-KYA'B4XUFW7 -^;7B@/KHMI4HB^?%(!924O,I(YMA9
M*5C0#FCNY^[ALQ\QK)3C(A4T^%QB<^V)PS%/<@@ =-/=I]GW\>1C#M6F3/.0
M/AK(+0$-U\CXI#[K@)_L-Z,I_I03]_'DA)>UIR6JT.$1=][7[*:K%I)&NB>8
M).O]/$['.:\ ' 57NF->SQ#$U&-S"2I,E#;2'5NI4VVRH I<40-$G4<T<_B]
M@XT-I*6/$CS@P8?76.O8(R7!HS!![B/T5OP)H-U*Z)]2GE8XJ/"9==5YKKL)
MUGS8BEK4.Y2F]%M]W[00->*^[$PW#;IA<&RA<"</LI_3[&NL7[;.&NFM7>(H
M%<UV+0,. PP]-,.1-MU5JN,CX6)3/SL8$$^6DN%N0RDDGDV[H0/V4J X(63O
M.B\W$D%,<:%;E&;6?RFH(7#4&_=Q[#AWT/6(4_%;AH^)ZS?BP&D#D7#,?0RH
M)]G8TLJ)\ #Q;9I;J(P :?JH?.&^6UN>MS1WJ0,.ZK (0E*4H&G:D!*-.0[4
MC0>\].,DUQ+G%^>JNBL8&?AN]YK6CV8>JD,L#4Z^ T'W=.'6ZN>IX.-0SXL<
MO#*@NS)">7L4?MTT_KX*0^_65N@%-05F3OEQIBR=.UEY0/+P;6-.G4CC6;4T
M/E"\Q]8K";Z\MC<3D&GZJKEZ-HAF9COI>J"=5Y'BM(A7(DIAUUE/=2/VNWNL
M4GGX\'.N7ECK:)I1HB)3D2<:P'R<C$DNY7B>)UT&KS 6NL^)M:,(( &B=3KK
MSY#3^D\<2OY'*['&OKG:6>7&TM'#]%'XZ#[!P*K05[PJ59PJ59PJ59PJ59PJ
M5,4]OO85KIH ?;_HXMVOO+PJK<^Z*K!N V8N<8_)UT%A06D4_P"LY5V,62@#
M7Q#=FH_9QN-I(?ML\.;HYFN]82N0=3M#.H8)Q@U\! [P:)?,/\-=WC^:Z=!T
M^1Z>S33BC_\ E_U?MHOK=_#%7'5_X:LP>I^T_KXQ5=2KSA4JSA4J;)Z.YI\G
MH$@_T <N)H"DGHJ"Y!=$4SJK.[-<FRQS*8!"2FQQS((7Q:J!,FKEL#N3XC5?
M0:Z\;?97M$L1*_FM=Z&YUR3K"$2;=/%(%!MWHE<^_27(#VW5,DG534>,@\M#
MW(;""?L!1QU;JEIUM>?=<,*^<OE@X#;Y(N+7GZZO[2\T-C3F3]W,<<RN@CM7
M 5]!V#@  :D"$>T)/B%C]7MU]W >Y:20\99UJ[)X((%$[6I2/MZG[3X\4W_3
MV44CS/-!0!G]1(D5[-M#:<>GT;KTU#+7-<R ZCR[&*E.H*UAA <0D=7&@/'@
MKLESY4QA.$;L#W\*SW4MG)-:1[A:M+KJUE)_JD8FHG1* RK [!ISOKK*Z;C%
MQ)):\Y^#*5#U)Z!U[3M]^G&C=$1M]W"2!*UA*<T(RYUBA.7;[MDC"#;R7"./
M(Z'G'U59YDA26_N!_2..=M*L'8*Z]#K\L!_H[EPJ/J/RER+MYY0!=L;52W%$
M #LG/IY^]"4!/W<'+J)QAB[OLK,V+VNEG<5 ^)/?D:*G8Z)S+3D4*1,C@J8=
M=!"%!6A7&=.FODN$ @Z$H4-0.HX'LG:U6.]PYT;GC$H;+$OGM&'*OIFX04NU
M\V-)C/%M2)+*@DN)2H !QL@D.(!T*%IU22!S\.'-A9K\V(J%7#AW\J\@NY'M
M=;SAS92",<B>SF.5(XV1,^8N(^HB;&7Y#H4DA*NT B2G_P "ZV0L'PUT\.'2
M69:=4*>6<?3QKR#=V?E2E)U1.P94^2WVG(\1U"TK'G$*5KU\QLCF3[2GBK&T
MMFT(22*NS3!\>LG(CVG"F>59QXB2X5E" %=ZT@K5H!J0@>)/370Z<2QVKWH3
M[M0SW;;=I<5RINK@[-A"5(;<8C">XAE@J7YB_,*G"[(622D'X@E'(_$>G3BS
M-$(WZ1DUH-16NNX@$LB>0YQ ''APY>FB-E/F$-M#M;1H%D#1*$G4$:#EJ1T'
M =Y##C6JMAX-(I<]HA("!HA([4@\R$C7WCGSX&O.)(XFCD;=+ 3E48YBI2Y=
M9"0>U<WSP2=>YMALM%]T 'IV?"/>K@C8D1QND=EE5:5NJ=L?-*:Y<1OR -!V
M 'M^'4:\^7LUTX;K >78H:+Q1-8T!OIJHV^D,2$T\!HK:#DB1*46R4ZJ0&HR
M/A'(Z>>H\QQANMIW.;#:LR<J_97T/\BK%D)W+=3^8C8QSU$ ^I.-:<:;?KH3
M#;VLB.$("R4:N'P[SIU)\=.G&/MFEK,:ZIO;V7$VO_2K3O;"L>2I(?6 $]Q0
ME!/Q'D H].0\.)7M83J=G5"RFNXI-3PPM';^JO8];!4PD)6H<M/B2E(Y:>WW
MCCSRF9U[/?SM)!3&FBRJ&"E10I![N[\0 Z<M!U!UXCDB3W**6%]([.H*R^A>
MA>9:5;CL">PVM;4V$ORWFU(YI[PG1+S6O5M84A0Y$<4GL>TEX116IA/Q$:<#
MFM0E;6&X.:6#%3'LHM>'"E#R8-8RMA+8; E2);LUN>0VYW*^ ! U4 .G$VV[
M?/O=]'81N +CB> [\,*'=1;YMO1VQR[]N#2YD#5# 4<\\@./<N5.,'TX47EN
MR9N1Y:JRD]I<74VSE) 0HJ)4MJLAH3%"B5=>W50ZCCK%I\K=ECB<+N:9]P1[
MP<@7N[*^4]W_ ,R_5<UVUVT6D$.U$JA&IY':>WOPK<YM!E50ZE&-[@37&&AJ
MW'MJMF8GN[M/WCT9D]_:.1)[3J>O B[^5MSG;7D;V\G#1[0#ZJV=E_F6VJ>)
MAWG;)&3 (?+=J'H)(I1%K]UHSPKG8N-/.D]R;5N9:LQ2TD _O*[Y!Q],D?V0
M[V$<^X=.*7_+3J/[K[=[>!UGU>[1D?YBOE^6@NM[\.Y&-KO4?,HI3@>Y%BSY
MCU^0E9'<BJC2$-HY<]=((>*1R'-?$\/RSW<M/Q-[ UW8%3L5!EE5*;_,?TK$
MY;/;KV0C(^%COZI+G >HU]-;.;B]ADLY5D$;0ZI\N*W);40=-5-6<U3.A\=&
M^G$L/RWF\W1+N,99V,!JK>?YD; P:K79KI\G#S9FX=VAHSXJM3SM[L>T[6,.
MYC8760-R9+TIV.7Q75S;JE>3^_@UC,<2D]C*0E960!T3IJ>+C>B=LM)G1RO=
M.AX@ 'N'*LO<_/7JS<XVOL[>WL@1@4UO')20-1&=6HQO;+&:5MLU%#6P2 !Y
MK49"GBG33_G+G>\KEX]W3@E#9;?8'3;0,!''E6/W'J;?][.O=+VXD#\' .+6
M'N:,!1HK&8W80H:J(TT\?8"202>+CKF1Q7A6=#(F* OI*GU_1*^8E,RV?,80
M6WD'^]3W@E0Y:$DCO'+H1H>/77)<"TY5")"TJVC.$LD(:?9#9(*2\A6J%*TT
M3R(26^X_=[^!YC)).&=)TX'YBK1 F)\"AIR(TY]5:C3EKT''@P=C4;\6DC*L
M;BE (401H!IH1H #RXL(=.JJ;CI0GC2Q,<=J>T)]OO!'CKX\^/6,)Q-5W2-U
M<:^7HZGV@ZT?W["NU8YGS4$<^Y(TT[@-?M'%INDAP?R^VH9I% <S,'[*BV7-
M'S<B<#H]%FR4J2-%%<74-.I;(_&I"6@L ?V--.-%'&L7EG\IS G?6&N[\MF,
M\?OL>5[>ZB.HNTN6+#9".Q^$]Y;JG %+[%-E([5<R%))T.NO$$UIY49D 4X5
MY;[GYMXP2$:'-/HP7'E3Y*LE-*:BM:JE3G41*YLG52Y3Q*4-Z<SY:->Y1Z!*
M3Q#!&\$R.P8T8DU9N+P0D0M\3I'($QSPQH$V+W58W>Q#),LKDL+Q>!NINC@.
M%SXVBD7E!MAE4O;Z5D <!T?;MLJQRS<:6/A4P&].+.\[<[:[MEJ_"X-M#)(#
M]UTS!*&^ACF+VK1&+48CJ3-!_1"(?3G4DS77%+2AM'FNJU2EM/70#FHZ\@D)
MZD\AP.B;XEPPJI.]A2-H*XTR/P!$8==<*')*P>Y:1JA"5G13;1/AIU/(G@@)
MGO<6L]T4.GMVPPN>/S2TK0KBNB<CO$#4!RKKG%#P*FY<]*5>W7M<TX)WH2UB
M^G"@FTX;I<-XZ&?507N6XX[DV$U\=12XZQ>R9&A_#!8-:%+7U^ OJ"1[SP3V
M(AEE<R'W<&]Y/TQH'UA*]V\[=:PXO(D+AR&"4MQ&O7<Y$;$H5^68X'&HZR/W
M<FZ?9+2@D'D45T-Q141_O74CJD\5]RF%I:>6X@7,B*.P%14FS6HW7=/.<"+.
MV!T)D20GUU- 2 G3Q2!IS]PUU^_C)^8][U=SK>Z7,;J=GQIMFCP/L3K^@<$+
M0JWL6J=X5C!H+M>:?N5^H?Z!Q?A]\5EKO,U7O<%WRZNT42 $Q7R/M+2@/Z>-
MELK2ZY#1FH]AKG'5#PRSE)XC[*BWT0PA_"N>VRM"NWW5OOB&FO965E)!2#H-
M=.Y*M-3Q8ZZ<#?MB'O,B"_ULJSWR4@#MADN?O/O) .X.QKJ3CB.V*/:$IZ$Z
M?\.7''+I$*9*:^LMM", [*,AT'V#]7 ZBM>\*E6<*E6<*E6<*E6<*E37+:_<
M+2="=">ITTZ>[QXLP.08Y57N&ES<.%5JW<8+/\)V:1_S')$P73[&;J!+B@'Q
M[3,99^_3C8=-N!EGC'O/AU#M (7TUROKB-D;+&[(Q;<%CS_2! ]&5>^=_P!5
MM=.?YMVZ:<O^8:]?9Q[I=\9KX)_XJCUC^$:\=/G:>U4^KMJU)ZG[3^OC"UV"
MO.%2K.%2I%.3^X6?'333^G_1Q)#[]1R_EGNJO^9QTNJ>1K\+J7&CKI_O$E!Y
M:>U7&PVMY;I>,VG"N;;\T.#@[$.86^@Y^FN7_I+U;Q21#*NXP[*PB:^Z+/DL
M:^XZIZ>''8NI_'%$XYZ1]5?*WRUD+?BHPFELI_[QKH12*(::(T) 3S/O XYA
M=J0:^AK KI)J1(G4?[6O^@?KX$S_ )8'8/JK5V.:451_P ^P_P!2O]/ V8H
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MEI 0DH.OX^S34=>6O%2YD5QD9D31"W:8XF-*J!4@Q(<B+V-^:5QAH-.Q'F-
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M.2'W25K6>:E$GC.W-Q+=3NGFQ>?9W5L+&PM]OMV6]NH:SMQ<3^UAC3D[IY9
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M*,-N[@"276NY%78+6AS2,\V4_8_R ^;^W]4[.WY5]?!O\9$!@@\_W+ZWTZ3
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M7N)HQ<SO50#I&"8*5[/JKM]GT7;LMD<A&D$@^]CCBXUUGVEWIAY:W1T>3_\
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MW:'(S 5KHF,N&ATGO =U?$FK?2CX?+D)YD?LK ]I"CV$C[>',E8"-2@KG2=
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M1VV7@2G:/UT2,A[3XU2BGWH;3RT_9['%<N!]$F(F&O56Y6O+0R >?[*"/O\
MB']/'GC]%/<FDKYGLH<LP-6^YQ0/<>WN9;(U[?VM'QQ/"JFJ4VG2-.KTI^FH
M0RQ%?^?.&Y?4&ODVODDKB1U10SW?X@I6]-2"^9.G>.T$)[.>G&PVPR_!'R %
M7%25S[!6#WL0?&_[Q=^$HT8#3PS\2YTZ!-$6VO*=FI5Y2=3%CL+BZ?\ @DR)
M*#Y?LT.GLY:<5Y#=>;B&^DG]%33"Q\MFHO5,-(")Z7?57J$4 [?GG[!;'=\?
M=$C-,@:C^^,>:\\6?[7;RTZ\0RF\T^$,3L)7ZJ;"-L7\<S>7VANC_O$K1@@5
M.J/*7\'EM^6&VFO+[.W]WV%+VG;VZ::#IP.?\4ASU<>?IK2L^$TMTD>4F& 3
MZZ*ZX,_#Y2E:>.J .?\ \H?'BH_4H5-7TSHO%H5NE>S*GU07\7Q#35.OPGKS
M_#\>FG%=VE"N=7CK3A031A/Y@KSEJ+WSD[7]VE(^9\Y_77]ZHZCGI]W%^?W!
MI_9'TRK.V8C^-&HG5K.0P^NI".F@[2>@\![O];@9^)P2M($Q7-30OD(MBQ_T
M<L)&BO.+;8<E'IV!@..MH2HC74ZE7L'%RT\GS/Q5U8IR^KU4,W3XSR#\.0&I
MB@5R]F("4,XX*@$?-./+EZ\C+90VSYG=\80"^ZDO!74N'N)\.+=WY^GP:?+X
M(OMPSH7M?\/P\XK<<5"#TXDK4B?X;MZGH/#GTY?M?BTX%#S5X_96F_#3P:=/
M9E0ZV(WYK+\M2NWM3YX*!_91X^9IW=^O4>WW<7)->ENK-#0EOD_$NT$IW#]-
M>VP@?)/^>H"/Y#WF_ DCRO+/F=VK@_9U]W"M?.\X:/?U<<L_JJ6[^'^$D\SW
M,<_>]'"@"J2_\Q3:N/$?ETGY<O,Z/&!\V/DB^/F#VN!.NG,ZITZ=."DIC\@H
M,=7 \4QX9>VLS")OBF>82B888Z>"^*I09"_*3YBE:<M/@(&O_NSP&;JX)6L8
MND:LZ&LC$3Y9WYA9 \=&^[EW#VNI'Z>+]EYOF,\M-2X9YXYX9=U"]U\CX9^H
M\.7;WYTGCBN_/)>JU>9I#T!;0/W?RZ>S4^:3KUUY</D^(^#" :%/$JJE>%*W
M^&^.D0CS-#4P^Z@[<\ZD*/Y7ECL(_![!KIXZ?%IKKP%[\Z-Q^7Y1T^[[:%<F
M#?RJ_B6$\N\A"5'33ER\Q/+NTXMV2^9]%H5NB?#.Q.E>6/UBD^."/\HOY91,
M?YESRM6TCX.UOS  '".WSN[3WZ\6+O7Y@U?F:?HM1[3Y/DNT'P:\,/UTX2@/
MGF/FU*^5_P#(@E \KS?]X7E>9K\R?V01H$=">?%;@=*:DQ7[*MR?F_C9+X4R
M7UT1L>5V)\LC73P'/[M3[>*AUKCGVT5AU>6-:KVI]E;1V_%H3IW'J!K^OIIQ
MZ%6O3EP2F>R"=.:B!RU(0">W0^!6D$_?Q8M]6O!%7T53NO+3QY)4/7::LR7/
MRUUU-]Y+_:78[*E_+=I\[1*Y*&PDIU[.T^9WZ:<';;XM#YP_ [#C[16(W(6"
M_P!V)%RI]X CMR(-'V,!7R,7R')!9\IKL$UEL.Z:<@LA\R.[3KWCNUZ\^!=]
MJ\QVM$3A^L9\Z/[1H^':A?J_G ?83ARH[YZ#NT"M!^'FG\(TZZ'IP.;[F&5:
M)JX?M+0[(#GSTCL4?[P<NQ/X_*&O,N:E.FFGW\6F+Y87):'^+6]$][Z<:6L=
M_+4G73]I(TU\=>U6FNG$<FFI O'.O7P.X>8K]D=$ZC34]=5CGKQ(/=[/IV4B
MB8Y4AD"+J?B5W:']A)_^&.?'GB7^;3'^7H.I$H>: _-&S5+5\R-/FAY0^54Q
MH>4U2'M4DC^[(!6#T!&O%ER>5_>@%3PJ?%V:<$]=#(T\\? EVK5CAX?ZV*IW
M4=C7R3J5=G/M[DCNZ^&BM"->!F/MK0^+2,M28\J#,@"?*7JLCD>C85X^.KJ>
M"%DFH*J_3LH!O'N%3XN[]=;L*#8H*?L6M0^6',MI1JKS'>_D'5Z)[M=.9Y<>
M7R^:Y>=2["G\-AT$EGCS"%5QXGT>VC7E[3^C_CXIXT;I _VZKU)_$.B0?9_K
M#A\:ZAW_ *:8_P!VD+H3J-%*Z'J@>W_;X>%2J$NA1J7T4U2@CS$:K5W>YL:=
M$_\ A0>'^)."56=Y>DXN]7ZZ9Y89U<U6YT/^Z3IIIS_WW7BS#JX +W]O=51P
M\.!\*<L?KH8L$L\_WK@^$_[A)Y<__.1P1A+M 4!._P#506[$>C GU?KJ,,A3
M%[#W/R >>FD1L^'+_P M3X<:"P,GW0U>TG_X:Q^X-C3WG9_LA..?C^F%!/IU
M0REW='Y25*=KSN?/,8/0&F.R7^0T LT-ENQDAU@2@"% (^(J!3RU)'JLDS0:
MVM$GPS5\2\7(GA':J^B@WRN:P-W3R7N-O\;)IU, 0HS5D]R]F7;5YJ;^Z1VG
MPY:I Y]O/711\/Z>.77B\4^AKZ L4T8YH*?^*%7ZSA4JSA4JSA4JSA4JSA4J
MSA4JSA4J_]D
%       !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img222477878_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $# F8# 2(  A$! Q$!_\0
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M$M;Z[FV3W%Q+"ML4YVQG!?.>F>.E:/A+1=*U32=?NM1ED62SM=\6U"P7/\6
M1DCTJWAL.H\UOS"R.Y_X7E;_ /0 G_\  A?\*/\ A>5O_P! "?\ \"%_PKB)
M/ S)');#5(FU>.S^V/8^4W"8SC?TW8YQBMK5O EO=WD<MBIL[&'3;>:<PPO.
M[R/GH@Y)..?2I='"KI^861N_\+RM_P#H 3_^!"_X4?\ "\K?_H 3_P#@0O\
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M%H+35[F"RMFD@O4LXXV@E"(2>GW\DG/WNGM4.GA;Z1O]X:%W_A>5O_T )_\
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M1(>I^@Q[U#XGTG3K/QG;V,2?9;-XX"^P%L;AR<9H5##.7*E^861W/_"\K?\
MZ $__@0O^%'_  O*W_Z $_\ X$+_ (5@>)O"6E#5KXVTT.F:7IJ(DTJP.[,[
M=!C<=Q]QBLN3P(MHFH37^KQP6MJD<J3) 7\U'^Z0,@@^U*-'"M7M^861V?\
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MI76+X,L)_#LT&FW,=_J)U%;87!C:/R_48)Y'O3EA\-&UU^861T?_  O*W_Z
M$_\ X$+_ (4?\+RM_P#H 3_^!"_X5QJ^ ?M<BC3=8@N46Z^RW#O$T8B?\?O"
MB7P#+_;EOI5O?.TSAFD\^T>(QJO5@#D,/3!I>QPO;\PLCLO^%Y6__0 G_P#
MA?\ "C_A>5O_ - "?_P(7_"N37X;7,E_!''>G[--"TJN]LR2G;U7RB<Y_&N:
MUG25TO4_L4-P]P2!]^!H6!/8JW?\Z<</AI.R7YA9'J/_  O*W_Z $_\ X$+_
M (4?\+RM_P#H 3_^!"_X5Q<G@41B:$ZM&U_:PK/<VRPM\B'KALX8@=N*7X@Z
M=I.D7]E8Z5 B8MTDD8(P9RPX)))!S[ 8I*AAG)12_,+([/\ X7E;_P#0 G_\
M"%_PH_X7E;_] "?_ ,"%_P *Q+_P7:0^"&$>GRKJ]M;I=RW)5MKANJ#MD"L"
MT\%/=7VGVHOU4WE@;T-Y7W0/X>O/UI1HX5INWYA9'=?\+RM_^@!/_P"!"_X4
M?\+RM_\ H 3_ /@0O^%<0W@J,>'3KHUB%K+9@8B.\S9QY>W/ZTL_@5XH9X5U
M.)]4M[874UF(FPJ$9X?H2!VQ3]AA>WYA9';?\+RM_P#H 3_^!"_X4?\ "\K?
M_H 3_P#@0O\ A7%W7@JTM-1MK"36F:ZGB68QQ63N0I&1C:3DUF^*?#$WAB\M
MH7G\Y;B(2H3&8V&>,,I)P:<</AI-)+?U"R/1O^%Y6_\ T )__ A?\*/^%Y6_
M_0 G_P# A?\ "N$O?!T5EMM&UFV.KE8V^PE"N=_0*_0GGIBIY_ @4W,-KJ\5
MS=64D<=Y"L++Y6\@9!/WL$\]*7L,+V_,+([3_A>5O_T )_\ P(7_  H_X7E;
M_P#0 G_\"%_PKE+CP!9VHO&E\11A;&98;C_1'.TMC;CGGK44G@*&TBNYM0UN
M.WAM[M;7<MLS[RP!!P#QUI*CA>WYA9'8?\+RM_\ H 3_ /@0O^%'_"\K?_H
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M[Q[V:'2K6UNKU4CN)XY&)=%Q\N#P.G6DN?B#>7,]U*UA;J;FZANF <_*8L8
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MW2W+%6)PP&,#VJ>;QW<74]S]KTVVN+2YBCCEM6=@"4& P8<@U[9_PKSPE_T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%6'_ "$;;_KJO\Z]U7[B_2O8RK:7R/FN(/BI_/\ 06BBBO6/G0HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PKXU
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M -^A2=:HU9R87#^W-*_Z"-M_W\%0)K6G:M8WHL+N*<PJRR!&R5.*G_L+2?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$C&:SD\/6J.'$DAD4@AB<]"3^/6K=A8+8K(%D9][;CD8 ^@H N4444 %%%%
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M[L')V@(22!W^G(J>W@A'VB2)B?M#[F/O@+_2L]-$@@N%,=Y+'</G!4@97C(
M_*@"W)K-E$[I)*59"!@KR<G Q^/%2#4K8V(NPS&(G'W>0<X(Q]15-/#ULMRD
MQEE8HVY03_M!OQY%3R:3$]NL2R.NV9I@0>[$D_A\QH ?9:G!?SSQPAB(@AWX
MX8,H88_.L_QG_P B;JW_ %[M5[3M*BTPD0R2%"BIM8\?*, _E5'QG_R)NK?]
M>[5=/XUZ@;@^Z/I10/NCZ45 &#XI_P!7I'_84M__ $*M^L#Q3_J](_["EO\
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M\B;_ )XR?]\&CR)O^>,G_?!KW+SK'_GI;_\ ?2T>=8_\]+?_ +Z6C^RG_-^
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M:/@R+[&NAHH Y*'2M3AM@-C_ "D%8Q)D$^]3'3+V>-XYXG\UI%9Y1+\I&X'
M'TKIZ* .7EL-620)"&V1R$Q/YG.W)X/X56GAN[1XH6>>2X81[")#\IW#=GU[
MUV-)@$@D#(Z'% &%I=EJ<4DS3RL',97<3E6?LU5[?3=1:>$/YL<(93,#+DR$
M9R1[=*Z:B@#G[VQN9;R]C2T5EN-FR8L/DP!SZYXJI*FJV;2W95E*@;4#9#ON
MQCZ$&NKH(!ZB@#G-6MKB*RM0=\["-E*\_?(X;COFBQT^_2_ADG0^8&WR7&_[
MRE<;<?7^5='10 4444 8*_\ (]R_]@]/_0VK>K!7_D>Y/^P>G_H;5O5<^GH
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MFE>22$,7!#9Z'(QG'KBKE%0!0.C6)P3#R.^3DU)%IMG ,10*H!4\>J]*MT4
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M:)_^>TG_ 'V:/M$__/:3_OLU'10!)]HG_P">TG_?9H^T3_\ /:3_ +[-1T4
M2?:)_P#GM)_WV:/M$_\ SVD_[[-1T4 2?:)_^>TG_?9H^T3_ //:3_OLU'10
M!)]HG_Y[2?\ ?9H^T3_\]I/^^S4=% &AI4\QUBR!FD_UZ?Q'U%?45_\ \@:Y
M_P"O=O\ T$U\LZ3_ ,ABR_Z[I_,5]2Z@0NB71)P!;MR?]TUY>8[Q)95\+_\
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M2RRQ&.59DDB;:RLIR"#5#_A&YO\ H.ZK_P!_ZWJ*I3DE9 8/_"-S?]!W5?\
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MZ"B@#G_(\5_\_P#IG_@,W_Q55;&#Q'#I6K_V[=6TRE7, A0@A<=ZZJJ>J_\
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MM_*KE-DC26)HY%#(PPP/<4T[,#Y#/4_6BOIG_A7_ (5_Z EK_P!\T?\ "O\
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M!Z"C SG I:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH __]D
:                                   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img222477878_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_13.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #U 1T# 2(  A$! Q$!_\0
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M/-/(X +LW7@ #% '):1XVU=/#7]N:K:2S1OL6.*.V6%69GVC:YD;(^H%.O\
MXD3'3+HZ=I$GVZWCE>999%V0[&"D]?FY(X%=);^#/#UM$8HM-01$@^69'*#!
MR,*3@<^E+<^#?#MX,7&DP.-[/W&2QRV<'G)[4 <^/B9!#$\MWI=PD"L\23(Z
MD22(H8@+G(!SP31>?$86=P8[C3YX9K?S/M-L"K_=CWC#Y Y'M6QI_@30;"6[
MF-FMQ)=.Y=IOFPK  J!T P/K[U97P=X>6!8/[*@,:[L;LD_,-K9).3D<<T 8
M$/CZ\O-8TZP@T8Q//=B&?S9U)13%Y@*XZ\?RKNZR3X9T4S+-_9\0E259E<9!
M#JNU3G/8<5K4 %%%% !1110 4444 %%%% !1574M0M]*TZ>_NV9;>!"\A5"Q
M 'L.:ATK6K'6HGEL7DDC0@%VB9 <C/&X#/7M0!SGBK6=<TW5/*LF5;1K8.9!
M;&0Q-OP2?7/3'OFH-$\5:UY.H7.KV%Q(+>-7:W@M]K0GG(RQ 88 /XUW54M8
M_P"0'J'_ %[2?^@F@">UN%N[2&Y0,%E0. W4 U-5'1?^0'8_]<$_E5Z@ HHH
MH **** "BBB@ HHJMJ$#W.G7$,9(=XRJD''.* +&Y>/F'/3F@$'H0:X&W\.:
MDUM9PW%@L9\XEFAEVB-.A'WLC/7BMS1+"_TJ_P#LB6J_V;L^69YBSKCHN* .
MCHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH H:U)#'
MH]T+AWCADB:-Y$8*4!!&<GOZ>^*YSX=Z=;V&DW/V>>257F/)144=\!5)P>>:
MU_%-A8W^E1KJ%]]BBAN(YUF)7 =3D [N",]JA\,6FGQS:E>V6JKJ,EW*K3NA
M3:K!0  %X' % %CQ3'?RZ#,NFRW,5T""IM@"YYZ<GIZURUG_ ,)9!I&M'4XI
M+B4VQ#":94BSALF/ /&,<'O7H54M8_Y >H?]>TG_ *": &Z+_P @.Q_ZX)_*
MK]4=%_Y =C_UP3^57J "BBB@ HHHH **** ,W7W>/0+YXW9'6(D,IP17CPU7
M4L?\A&[_ ._[?XU[!XB_Y%V__P"N)KQ,=!7BYG)J<;/H?3Y%",J4[KK^A<_M
M74O^@C=_]_V_QH_M74O^@C=_]_V_QJI17F\\NY[OLX=D>M^"7DF\-Q2RR222
M,[;F=RQ/YUT=<WX%_P"16@_WV_G725]+AOX,?0^%QO\ O,_5A1116YRA1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 9?B*:UBT2X6],8MYD:&0O.
ML( 8$<,Q !]*Q_ X@>"]GCE\V5Y%5W^TPRC"J H_<_*O'XFM;Q)?06&BS--,
M87F_<0.L>\B5^%('?!Y_"L+X?70GM;]!(5$<J8MRSN4!0'=N< D/G</3.* -
M7QAI5YK7AV:RLFVRNZG_ %FPD YP#VKG+/P]K^DZ3K3RW%L))+8@R.[RK+@,
M2=I(VG! 'TKO+BZM[2$S7,\<,0ZO(P4#\35#4;RUNM%U(6]S#,4MGW"-PVW*
M'&<4 2Z+_P @.Q_ZX)_*K]4=%_Y =C_UP3^57J "BBB@ HHHH **** ,SQ%_
MR+M__P!<37B8Z"O;/$7_ "+M_P#]<37B8Z"O$S3^)'T/J<@_A3]?T%HHHKS#
MWCUKP+_R*T'^^W\ZZ2N;\"_\BM!_OM_.NDKZ?#?P8^B/@L=_O-3U84445N<H
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %#6H-/GTBX.J0)-9PH
M9I%8= HW9^HQ61X>U?1'U"XT^PL)K&Z<>?(DL.POPO/4]BOX$5M:MYG]CWPA
MA2>7[/)LB=<JYVG"D=P>E8'@S2+2T@>Y6VG2Y/!:YMO*< @9 ]1P/RQVH V]
M:TXZMI,UCN11+A6+KN&W(W#\1D?C7,R>$9=,LM=G@OQ;I/"YC\B%0P7YFVMG
M(/WL=.@KK;_4+72[1KJ]F$4*D L03R3@# Y-9ESK6G:GI>KP65TDTL%NXD50
M?ERI]>O0]* +NB_\@.Q_ZX)_*K]4=%_Y =C_ -<$_E5Z@ HHHH **** "BBB
M@#,\1?\ (NW_ /UQ->)CH*]L\1?\B[?_ /7$UXF.@KQ,T_B1]#ZG(/X4_7]!
M:***\P]X]:\"_P#(K0?[[?SKI*YOP+_R*T'^^W\ZZ2OI\-_!CZ(^"QW^\U/5
MA1116YRA1110 4444 %%%% !1110 4444 %%%% !1110 4444 97B59#X;U"
M2$H)HK=Y(R\7F $*?X>]<W\-KZ>[M=02XMK6VEBE56CML;1\HY) ZGK^(KK-
M88KHE^P:52+:0AH1EQ\I^[[^GO7,_#G69M9T>=YVCD:*39YL<84/@8R2.K<<
M_6@#H-=T6'7M--G-++#AUD26)MK(PZ$&L*X\'6FGZ-JQ%Y>RB2W8KNF*E<!F
M/S+@G)))S70ZSJUOH>F27]RLC1H0"L8!))..^!W[UD-XFL-8TO5X8!*AAMG^
M:0 *X(894@D$9!% &OHO_(#L?^N"?RJ_5'1?^0'8_P#7!/Y5>H **** "BBB
M@"%[NVCF\E[B)9=N[8S@''KCTI4NK>0X2>)B5###@\'O]*Y?6= N[O79;VWM
ME;="%+O.-L@'_+/;CC/K5?\ X1J\M8%O]/L;6'4RO,32$QJ,\)C@8'J,4 =%
MXB_Y%V__ .N)KQ,=!7M.N^9_PC%YYH D\@[@O3/>O%AT%>)FG\2/H?4Y!_"G
MZ_H+1117F'O'K7@7_D5H/]]OYUTE<WX%_P"16@_WV_G725]/AOX,?1'P6._W
MFIZL****W.4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#/UR)Y=
M'N3&UV'CC,BK:2;)'*@D*#[]*Q?!%W+<VEV))+J94D&V::1F5LJ"0NX C&<'
MWK1\2Z1<ZQ86\-M?M9-#=13M,O7:AR0.W/OQ5K2D5(I0NJ2:A\^"SLAV''3Y
M0* )=1T^#4[-[6X\SRWZ^6Y0_F*P;SPEH=CH>J"&P0H]NQ\MR75=JDC:#TY)
M/%:GB'7+?PYH=SJ=RI=(5R$! +MV )KGCXUM-2TG5Q<1I:0I;MY4KS B3(9>
MG8Y!XH Z;1?^0'8_]<$_E5^J&B_\@.Q_ZX)_*K] !1110 5Y5XZN[JU\32);
MW=Q$AC5BJ3,!G'IFO5:\D^(/_(TO_P!<D_E7=EZO5U[#6Y@_VIJ/_00N_P#O
M^W^-']J:C_T$+O\ [_M_C52BO:Y8]BC5T^\N[J>2*XN[F6,PN2KS,0<#TS6>
M.E6M(_X_)/\ K@_\JJCH*^,XE26(A;M^I]/D/\*?K^@M%%%?.'NGK7@7_D5H
M/]]OYUTE<WX%_P"16@_WV_G725]/AOX,?1'P6._WFIZL****W.4**** "BBB
M@ HHHH *HZQ->V^E7$FG6_VB["_NTW <^O/'%2ZA<M9Z=<7*J&:*-G"D\' K
M@!\2KW'_ "#K?_OXW^%85L33HM*;.O#8&OB4W25[>99@O]9U!H+>/4KBVN7L
M1)<"2#/E,-IS@#'/S<@GKC'%=-H&J/?K<P3I.+FV8"5I(]JDD<;?RKD/^%E7
MO_0.M_\ OXW^%'_"RKW_ *!UO_W\;_"L?[0P_?\ !G3_ &-C/Y?Q1Z116#X6
MU^7Q!93SS0)"8Y-@",3G@&MZNJG.-2*E'9GGU:4J4W3GN@HHHJS,**** ,SQ
M'(L7AK4FD@FGC^S2!XX" [ J0=N>,US_ ,/(M/6QNY+!+C:[KO>=DRQVYZ(<
M#K72ZU&)=!U&-HGE5[:13'&/F?*G@>YKG/AWJU]JNCS->-(XBD\N.1HO+! X
MP. 3TY/O0!UES:V]Y;O!=01S0N,-'(H93^!K,O\ 2["ST?5)+:S@A:6W<R%(
MP-V%.,T[Q)J<VD:%<7L#VJRQC*_:FVH3Z9R.3VY'-<M;^-I-5TK6OM%KB-+8
ME$MXW>1-P88D7MTSVX- '8Z+_P @.Q_ZX)_*KU4-%_Y =C_UP3^57Z "BBB@
M KR3X@_\C2__ %R3^5>MUY)\0?\ D:7_ .N2?RKNR_\ C?(:W.6HHHKW"R_I
M'_'Y)_UP?^551T%6M(_X_)/^N#_RJJ.@KXKB7_>(>GZL^FR'^%/U_06BBBOG
M#W3UKP+_ ,BM!_OM_.NDKF_ O_(K0?[[?SKI*^GPW\&/HCX+'?[S4]6%%%%;
MG*%%%% !1110 4444 9^N?\ (!O_ /K@_P#*O$!T%>WZY_R ;_\ ZX/_ "KQ
M =!7BYI\<?0^HR#^%/U%HHHKRSWSTKX;_P#((O/^N_\ [**[2N+^&_\ R"+S
M_KO_ .RBNTKZ3!?P(GP^9_[W/U"BBBNHX HHHH RO$KS0^';^YMBOG6\#S)N
ME>-<JI/)3FL+X?:I+J5K>^<DT3QR*#'-<22LIV\\N[$#.?2M7Q8NK/HHCTA&
M:9YD68)MW>43\^-W&<4WPC!/#HZ?;=+6QORJ_:2JJ!*X4 M\OTH W9(TE0I(
MBNAZJPR#5'5HXTT74F1%5FMY"Q P3\IZU5\5WT^G>';FYM99HIUP$:&W\YLD
MX^[@_B<' R:YBUUOQ#/IFN+?6LMULMB-D<(A5"0PRK-C<,8;U&?PH [/1?\
MD!V/_7!/Y5>JAHO_ " ['_K@G\JOT %%%% !7DGQ!_Y&E_\ KDG\J];KR3X@
M_P#(TO\ ]<D_E7=E_P#&^0UN<M1117N%E_2/^/R3_K@_\JJCH*M:1_Q^2?\
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M03S_ ,"JY_9_B+_H/V__ ( #_P"+KVJ,'"G&+Z(^6Q-2-2M*<=FV;M9VO?\
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MW4J_#*5V95\2!F7[P%HI(^OS5\]G4'C*D)4NBZGM97F%'#0DJE]6<717;_\
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MAE$LA4K@<D$=ZHP^&]5-K>175XK--=+,CQR,I"A<8SV.?2L&(ZT *H4#  P
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MRMO<$8"D8XP>?PJ)/"_B":-([R^)560AH[IU(4-DC'0D]<UT'$=U17 MX?\
M$PDN+B[OP85CR([>:3+E1QGW(]*M^$M+UV&[2^U"YF%L\)"V\LI9D^8X!SWZ
M<T =G1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9
J

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img222477878_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_14.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #> ?\# 2(  A$! Q$!_\0
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MI)=/NX9Y(7MY#)& 6"J3@>M'UO$=_P  ^H8/^7\7_F=5_P )^?\ H'?^1O\
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MG7WF%16[_P (AJW]VW_[_"C_ (1#5O[MO_W^%'U>K_*P^MT/YU]YDVGWY?\
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MY$,[/]\;MJX '?!ZX'O6Q)IL,B,HM1&2I4/'&%91[$#(ZTL.FP6\4$<5FBK
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M:6*Y6,-T'J3V&/6K6DWPU32+2^ C'GQ!R(VW*">H![U;6S1(3"MJBQ$8,8C
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M_8)S3W\*:7(Y=UN6D9MTDC3L6D.006/?&T?@,4-X4TIE4-'.2F-CF8ED +$
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M@\]JIZ5I$.D13Q6\DK1RR^8%D8ML&  H]N* +]%%% "K]X4E*OWA24 %%%%
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M?O-_N-_*HZ[/R8O^>:?]\BCR8O\ GDG_ 'R*?U9]P^NJ^QQE%=GY,7_/)/\
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MFOUU?RG&45V?DQ?\\D_[Y%'DQ?\ /)/^^11]6?</KJ_E.,HKL_)B_P">2?\
M?(H\F+_GDG_?(H^K/N'UU?RG&45V?DQ?\\D_[Y%'DQ?\\D_[Y%'U9]P^NK^4
MXRBNS\F+_GDG_?(H\F+_ )Y)_P!\BCZL^X?75_*<94A_X]U_WS_(5U_DQ?\
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MGL]=6^N6AE=X02(1YV T>  .O# Y.<#ZUR^TEW.SV4/Y3N/[87./(.?3?_\
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M[87_ )X'_OO_ .M1_;"_\\#_ -]__6K*HH]M/N'U>GV->/5E8M^X/"D_?_\
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M -:N"33=8:]L6NVEG$%Q%+O\Y0BH%8$%.[9/7OZUU%)U9KJ.-&F^AJ_VPO\
MS[G_ +[_ /K5O1-OAC;&-R@XKC.U=C;?\>L/^X/Y5M0G*3=SFQ=.,$N4AO[B
M.WA5Y,X+8X&:S_[4MO5_^^:FU[_CR3_?'\C7GEY]NM=4U&>U-P^R"%H$=G>+
M>SD-\N<' P<=J*E22E9#H4HRI\S.]_M2U]7_ .^:/[4M?5_^^:\_DU?5X[JY
MC> [(V9 5A)P 0%D'J#G)';\*@MM3UJ>XC8[HWF6*/8ULQ1?WC*[CWV[3@^M
M9^TF:^QI^9Z/_:EKZO\ ]\T?VI:^K_\ ?->=MJVNQ01-+ K&55+NEN1Y/S,#
MQWSA3[9I+C4/$$NGS,(Q$Y4QJ(H"6!\K<'!/^UQCWQ1[28>QI^9Z+_:EKZO_
M -\T?VI;>K_]\UP^H:EJ$$5C]CC\U98MS2M$?F<8PI'5<Y-98.M6\KWADN9V
M59I?)*,%W>8%'&>0%Y [T*I,'1I^9Z9_:EMZO_WS1_:EKZO_ -\UP5MJ>J33
M)'/B%6'[IQ;,WG_,1SV0@ 'GUK2T.2:70[)[F1Y+CR@)6>,HQ;OD&AU9HI4*
M;[G5_P!J6OJ__?-']J6OJ_\ WS6)14^WD5]6@;?]J6OJ_P#WS3O[2MO+W9?&
M['W:PJD_Y=C_ +X_D::K2$\- U_[4M?5_P#OFC^U+7U?_OFL2BE[>0_JT#;_
M +4M?5_^^:/[4M?5_P#OFL2BCV\@^K0-O^U+7U?_ +YH_M2U]7_[YK$HH]O(
M/JT#<34[8NH!?)('W:0ZI;9/+_\ ?-8\/^OC_P!X?SIK?>/UI^VE87U:%S:_
MM2U]7_[YH_M2U]7_ .^:Q*YJ;5[Y;N[AWX^<F,Q*LOEQ*ZJS%1D[L'.#[^E"
MJS8G0IH] _M2U]7_ .^:/[4M?5_^^:\^^U:@(X[R22\=,%&6.+:63<0K[3T9
M@/PJWJ-_J<$]T;6 -!%#"5!C)8L[,&.>^U0#BG[68O8T_,[;^U+7U?\ [YH_
MM2U]7_[YKSB;5-8E6%'#0DR0E?+MV)G7S1N)(X3"CD'U-2C7=1E\D>4T$9C0
MSSFT=O*?#Y 7OR%'MFCVDQ>RI^9Z%_:EKZO_ -\T?VI:^K_]\UYRVHZM!=7!
M'FS8F<C,#[8HRL>"!_$.6..O!J>+4]8D8L(P88V7#&W8&=3)MS@_=^7G_P"M
M1[28>QI^9W_]J6OJ_P#WS1_:EKZO_P!\UB'K14^WD:?5H!16_P#V!#_SV?\
M(4?V!#_SV?\ (4>PF+ZW2[F!16__ &!#_P ]G_(4?V!#_P ]G_(4>PF'UNEW
M,"BM_P#L"'_GL_Y"C^P(?^>S_D*/83#ZW2[F!16__8$/_/9_R%']@0_\]G_(
M4>PF'UNEW,"BM_\ L"'_ )[/^0H_L"'_ )[/^0H]A,/K=+N8%%;_ /8$/_/9
M_P A1_8$/_/9_P A1["8?6Z7<Q(?O-_N-_*HZZ%="B4D^<_((Z"F_P!@0_\
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M]CCOL]Q_SQE_[Y-'V>X_YXR_]\FNQHH^K+N'UU]CCOLT_P#SPD_[X-'V:?\
MYX2?]\&NQHH^K+N'UU]C_]D
..                   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img222477878_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_15.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #W 3T# 2(  A$! Q$!_\0
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M--EFB@3?+(D:Y W,<#)Z5Y:FA^,/M6LO)+J7G-;W0@*S+Y+JT0$2CG(8-G'
MP<^M17GA77)="N+6>WOKN,+IEP(7N2S-*F?/VDGKT^M 'J%WJ5C8&(7EW# 9
M6VQB1PNX^V:%U*Q>_:P6[A:[5=S0AQO ^E<5XZ\/ZEJET9;*Q-TEQI,U@@+
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M&PZ]HP6_&O5? Z3!O$4I_P"/:769WM^,?+P"1[%@U '64444 %%%% !1110
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MK0?^P=;_ /HM:A@_XE/BJ:V/%KJBF>+T6=1\Z_\  EPW_ 6]:F\(?\B5H/\
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MXSV.:/LZ_P!^3_OL^N?\^U $U%0FW4Y^>3G/1SW.:#;J=WSR<[NCGO\ YXH
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M[B$^P/WF_P!H_@!6CI^F6FEP&&TB"!CN=B26=O[S,>6/N:MTR HHHH ****
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MH **** "BBB@ J&[ -G.",@QMP?I4U5M0B$^FW43,ZAX64M&Y5AD'H1R#[T
M9_A#_D2M!_[!UO\ ^BUK9K&\(?\ (E:#_P!@ZW_]%K6S0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(*_,&&,$9[C."0<5DKX%>'6K;4K759(&BGD>2-$(5XV</LP&QP>Y!^@KL:*
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MH4?0  <5:HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /_9
2

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img222477878_16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_16.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "@ @\# 2(  A$! Q$!_\0
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M_)^E'_"2:Q_S_P GZ4?VE3[,/['K?S+\3U6BO*_^$DUC_G_E_2C_ (236/\
MG_E_2C^TJ?9A_8];^9?B>J45Y7_PDFL?\_\ +^E'_"2:Q_S_ ,OZ4?VE3[,/
M['K?S+\3U2BN$\+ZSJ-[KD<-S=/)&48E3]*[NNNA65:/,C@Q.&EAY\DG<R/%
M'_(MWG^X/YBN+\)32+KL4?F,L95R5W8!.*[K7;66]T6YMX0#(Z@*"<=Q7!_\
M(GJXZ11_]_!7%BXS]M&<5>W^9Z6 E2>&G3G)*_\ D6=.A%SI_P!I%LE]=M<^
M5()6SLC_ *?6M:>P@GLK>RLDMY($NW!+\A0/Q_"L$>%-87.U$&>N)12#PIK
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MU&@7D7K;Q1I\VGV5T[2(UU'YBQB-BP'<XQT'K5F_U1K:XLH((O.DN22!G&$
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M(%.&!P2 3C!Q^=%D'.SK_)B_N_K2>3#G&W]:XN3Q-JS3Q6Y MY&MC=!A$&#
MGY5Y([8S]:C@U?4C<ZM<PHB7KPVQ$+N/ESNSM!.":+!SL[@PQ 9*X_&E\F+^
M[^M<W_:[77@R]O#*+B2+<C;X]F""."/6L]?$&L;6NEDMUM(+N.V,.S)<,!SG
MMUHL',SM/)B_N_K2>3$1D+^M<QKTEW'XQT]([Q8K=K2<M&P^\0/YUD:=KFK:
M/I5A+.\=S;S6LKI"J_,I4DCGO19!SL[_ ,F+^Y^M)Y,1Z+^M<[X>UG4+Z^BB
MN#YT4T'G;_+">6?3@G(K$AU74=.EUB[BO;=H(=3*&T89>0' P#V/I19!SL[T
M0PGHN?QI?)B_N?K7":3JUY]BM;"UNHK>2YNK@M<3_-L"G.W![U+;^)=5U)TM
M([FTLY(HY'>Y=<I-M./ESV]:.4.=G;>3%_=_6D$4)Z*#^-<&WB75-9T^Z\N>
MVL!#8^:ZRKS,3D97T'%:?AB5_M\"I(7CETV*249R _0'\119!SLZKR8O[GZT
M>3%_<_6GT460[L9Y,7]W]:/)B_N_K3Z*+(+L9Y,7]S]:/)B_N?K3Z*+(+L9Y
M,7]S]:/)B_N?K3Z*+(+L9Y,7]S]:/)B_N?K3Z*+(+L9Y,7]S]:/)B_N?K3Z*
M+(+L9Y,7]S]:/)B_N?K3Z*+(+L9Y,7]S]:5H8MW*_K3J5OO46079'Y,7]S]:
M/)B_N?K3Z*+(+L9Y,7]S]:/)B_N?K3Z!UHL@NQGDQ?W/UH\F+^Y^M<KINI7E
MWXH:.VU3[99J9%N RJJ*1]U8^Y(YR:ZVBR#F8SR8O[GZT>3%_<_6L#7=1O+#
MQ#H:)?016=S<&*:%@-S_ ".<Y/09 JK9^*1J7C"&TM;F#^SS'*@7<-\LB%<M
M[ 9('KS19"YF=3Y,7]S]:/)B_N?K3Z*+(=V,\F+^Y^M'DQ?W/UI]%%D%V.MH
MT68%5P<5=JK!_K?PJU5QV,IO4CF($+9.*SS';M<+<%8S,BE%?N%."1^@_*KM
MW_QZ2?2N5NM8AM-;M=.FV()[>282NX &PJ,?CN_2HD[,TI135V6M7T.VU6R-
MEYD<-M-<+-=*J@F;!!Q[9VCFDN_#VFW^LR:A>)'.&MDMQ"X^5=K,V?\ Q['X
M5G6WB6RFBNY9&5$@NVM4*G<92JJ<C'^]^E3S:_I<%M%</=#RI 2K!2>!USZ8
MJ>9FG)'N:ESI6EWCPO<6EO(T(Q&67[H]/I4KV5C() \,+"1Q(^1]YAT/U&*Y
MW6/%.FZ5:W#^>DD\5N9UC'0C&1D]L]JM+KEA]IAMI)@EQ*% 4@XW,,A<],T<
MS#DCW-&/1=(B8LEE;*2&&=O9N"/H<T?V+I&(1]BML0C$8V_=&<X_.LJ3Q%IH
MDN((;A9+B%';8 <$J,D ],U'IOB?3-0M5E^THD@MUGE4\!5(YY[XZ4<S#DCW
M.A-I9-NS#"=\@E;CJXZ-]>!2/96,DAD>"!G+[RQ');&,_7'%9UEJ5IJ(?[-+
MN*8W*001GH<'M5NCF8_9H=:Z7IEC()+6U@B<*5#*.0#V^E++INFSR-)-;PNS
M.LA+#^(< _6F44<S#V:'P:9IEK=O=P6T$=P_WI%7DTJZ?IR2K*MM;K(LAE#!
M1D.1@M]34=%',P]FB/4]&L]6O+.:Z*NEMO\ W3#(?<,<U))H^DRV4=G)9V[6
MT9RD>WA?I111S,/9H?)IFF2F$O:V[&%=L65^X/0>U1)HFCQHR)96P5EV'Y>H
M]*=11S,/9H8="T9H4A-C;&-#E5QT)J2?2=*N8S'-:6[H6#$%>X& :2BCF8>S
M1+#I^GVY4PV\$>W.W:N,9Z_G3TM;./R=D4*^3GR\#[F>N*KT4<S#V:))--TV
M::::2V@:29=DC$<N/0TBZ9IJV360MH/LS'+1$94GWIE%',P]FB2ZT[3KT1BY
MMX9?+^YN'W:9/I.E7,ADFM+=W*!"Q'.T=!244<S#V:)HK*QALS:1PPK;GK&!
MP:/L5CL9/(AVLX<C'!8=#]:AHHY@]FB:ZLK&]>)[J&&9XCF-G&2I]J46EDHC
M AA B!5!C[H/4"H**.8/9HEM+#3[!G:T@AA9_O%!C-1G2=*-V+LVEN;@-N$F
MWG/K]:2BCF8>S0DFC:1+%)&]E;%)7\QQMZMZ_6EFTC2KBWBMYK.W>&+_ %:%
M>%^E%%',P]FA;C2=*NVB:XM+>0Q#:FY?NCT^E36UG9698VT<46X ';QP.E04
M4<S#V:+^Y/[Z_G1N3^^OYU0HHY@]FB_N3^^OYT;D_OK^=4**.8/9HO[D_OK^
M=&Y/[Z_G5"BCF#V:+^Y/[Z_G1N3^^OYU0HHY@]FB_N3^^OYT;D_OK^=4**.8
M/9HO[D_OK^=&Y/[Z_G5"BCF#V:+^Y/[Z_G1N3^^OYU0HHY@]FB_O3^^OYTK,
MN[[P_.L^G2??-','LR[N3^^OYT;D_OK^=4**.8/9HO[D_OK^=&]?[Z_G5"BC
MF#V:$M]%T>SN_M5M96T5QDGS$7!R>M:&Y/[Z_G7.0:_8SZF+!?-69MP0O&56
M3;][:>^*U*.9B5-=!U[I6EZC-'->VMO/+%_JWD&2OTJ!= TA-5M]1CMH8[B!
M75"@ ^]C)^O%5;K6+&SU*TTZ:4BZNR1$@4G. 3R>W -2-J-HFJ1Z:91]KDC,
MHC']T'&3^=',P]FC:W)_?7\Z-R?WU_.J%%',/V:+^Y/[Z_G1N3^^OYU0HHY@
M]FC4MV4R@!@>*MUDV'_'V/H:UJTB[HYZJM*Q!=_\>DGTKCM0T&'4M?L[ZZCB
MEM[>VEB,;C)W,R$$?]\FNTF ,+ C(Q5#9"&"E5W$9 SR:F2U+I22C9G GP=-
M;S?:+)XT:.]FGBA5BB[)$12,CH05S^-+/X5OC;+!')%Y<L4HF0R, LKG)<>O
MIBN]V0EBH5=P&2,\BAE@5E5@@+'"@GJ?:E9EWB>??\(IJL6EWNGPR6;QW]JD
M4TD@),;K&$^7U' ^E27/AC5+FY1GGA98[F&X1BY^54VY3'U!Y]Z[_P J/_GF
M*0QQ 9** .YHLQWB<9::)J=I:OIBFS-B!+LF8'S3OS@'W!/)J"]\'R7EC9VP
MGCB\C3_LI*C&7!4@_3*UW)2%5+,JA0,DD\8II-L(RY,80#);=P*5F'-$YO1=
M)GM+J:[NP@F=%C&V0OP.>I]ZVJO>5'_SS%'E1_\ /,4<K&II%&BKWE1_\\Q1
MY4?_ #S%'*Q^T11HJ]Y4?_/,4>5'_P \Q1RL/:(HT5>\J/\ YYBCRH_^>8HY
M6'M$4:*O>5'_ ,\Q1Y4?_/,4<K#VB*-%7O*C_P">8H\J/_GF*.5A[1%&BKWE
M1_\ /,4>5'_SS%'*P]HBC15[RH_^>8H\J/\ YYBCE8>T11HJ]Y4?_/,4>5'_
M ,\Q1RL/:(HT5>\J/_GF*/*C_P">8HY6'M$4:*O>5'_SS%'E1_\ /,4<K#VB
M*-%7O*C_ .>8H\J/_GF*.5A[1%&BKWE1_P#/,4>5'_SS%'*P]HBC15[RH_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<[*WV=_44?9W]15FBBR#G9!%$R/DXJ>BBF)NY__9
;

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img222477878_17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_17.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $& B # 2(  A$! Q$!_\0
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MD7?[0LO^?R#_ +^"C^T++_G\@_[^"J7_  B_A_\ Z FG?^ R?X4?\(OX?_Z
MFG?^ R?X4>YYAH7?[0LO^?R#_OX*/[0LO^?R#_OX*I?\(OX?_P"@)IW_ (#)
M_A1_PB_A_P#Z FG?^ R?X4>YYAH7?[0LO^?R#_OX*/[0LO\ G\@_[^"J7_"+
M^'_^@)IW_@,G^%'_  B_A_\ Z FG?^ R?X4>YYAH7?[0LO\ G\@_[^"C^T++
M_G\@_P"_@JE_PB_A_P#Z FG?^ R?X4?\(OX?_P"@)IW_ (#)_A1[GF&A=_M"
MR_Y_(/\ OX*/[0LO^?R#_OX*H_\ ",>'_P#H"Z=_X#)_A2_\(OX?_P"@)IW_
M (#)_A1[GF&A=_M"R_Y_(/\ OX*/[0LO^?R#_OX*I?\ "+^'_P#H":=_X#)_
MA1_PB_A__H":=_X#)_A1[GF&A=_M"R_Y_(/^_@H_M"R_Y_(/^_@JC_PC'A\=
M=%T[G_IV3_"E_P"$7\/_ /0$T[_P&3_"CW/,-"[_ &A9?\_D'_?P4?VA9?\
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M*T*"BBB@ HHHH **** "O7O@#_R,.H_]<!_.O(:]>^ /_(Q:C_UP'\ZY<9_
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M 6BDR/449'J* %HI,CU%&1ZB@#!\9_\ (L3_ /76'_T:E;_:L#QD0?#$_/\
MRUA_]&I6_P!JM_ OG^@^@5C:IX4T'6[H76IZ7;W4X78'D7)QZ5LT5*DXNZ$F
MT<S_ ,*\\(?]"_9?]\4?\*\\(?\ 0OV7_?%=-15^UJ?S/[Q\S[G,_P#"O/"'
M_0OV7_?%'_"O/"'_ $+]E_WQ7344>UJ?S/[PYGW.9_X5YX0_Z%^R_P"^*/\
MA7GA#_H7[+_OBNFHH]K4_F?WAS/N<S_PKSPA_P!"_9?]\4?\*\\(?]"_9?\
M?%=-11[6I_,_O#F?<YG_ (5YX0_Z%^R_[XH_X5YX0_Z%^R_[XKH7GV7$4/E2
M-Y@)WA?E7'J>U9=SJ%U:7=SO>-H(E1PJQG<=Q(QG/M1[6I_,_O'S/N4O^%>>
M$/\ H7[+_OBC_A7GA#_H7[+_ +XJT?$0C4O-9R)&,<[@>HR.*E;6F-M#,D!
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M7GAP Q#%3PH^O>CVD^X78[_A$=+_ +UY_P"!DG_Q5'_"(Z7_ 'KS_P #)/\
MXJE?79@T;K:YB9&<@.,[1CG]>E*WB.(2,J0.^!N!4C!7!.?TH]I/N%V-_P"$
M1TO^]>?^!DG_ ,51_P (CI?]Z\_\#)/_ (JE;Q&L<AB>U?S!R0K C& >H[\]
M*VU.Y0WJ,\T>TGW"[,/_ (1'2_[UY_X&2?\ Q5'_  B.E_WKS_P,D_\ BJW:
M*/:3[A=F%_PB.E_WKS_P,D_^*H_X1'2_[UY_X&2?_%5NT4>TGW"[,+_A$=+_
M +UY_P"!DG_Q5'_"(Z7_ 'KS_P #)/\ XJMVBCVD^X79@'P=I#%?,2YD56#!
M7NI&&0<C()]16_114N3>["["BBBD(**** "BBB@ HHHH **** "F-%&^=R*V
MX8.1UI]% $9@A(P8D_[YI/LT'E"/R4V Y"[> :EHH A6TMUC:-88PCG+*%X-
M)]BM<Y^SQ9*[?NCIZ5/10!"+.V$BR"",.OW6VC(I6M;=W5VAC+*<@E1P:EHH
M KFQM"I4VT6TMN(V#KZTY[2WEQO@C;"[1E1T]*FHH @^QVW_ #[Q\8_A';I2
MM:6[D%H(R1TRHJ:B@"%[6WDQO@C;!R,J.*?'#%$6,<:KN.3@8S3Z* "BBB@
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M=UPI25D>8!.25QT_(4 6+;2K.V0JL0;<VXE@#S5VBB@ HHHH **** "BBB@
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M?*$5MP9B,ET)^M:BZWI[''G@>Y&!2MK=@H_UV21G '(H&93:IJ$LO",(U#8
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M>N#FM"B@"@VDP-#%%NE C!4$-R5/4'VILNDQ-#;PQ2/$D+EAM//0_P"-:-%
M&7'H%C'*D@#Y0Y4%NE/_ +&M06VF15<Y= W#'U-:-% &8=!LB6(#KN.>#T]:
M0:!9J% ,HVX*_-]TXQD?E6I10!4?3X9$59"[[49-Q/)!ZU730;.+F(.C Y1E
M(RG7I^9K3HH SGT:U<#)D')W$-][)R0?QIO]A6FYF^?+<=1Q^%:=% $<,2P0
M)$F=J *,G)J2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH P[#_D;=5_ZXP_\ LU;E8=A_R-FK?]<H?_9J
MW* "BBB@#ROX@?\ (R?]L5_K6"-1DP T:,!]WCI7H/B70M+U#5?.N]46VEV
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M7KHI4ZDU[GZ#1Z-_9&H_]!VY_P"_:?X4?V1J/_0=N?\ OVG^%><_\+7\1?\
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M%F>C?V1J/_0=N?\ OVG^%6=*TPZ:MP6N9+B2>7S'=P <X [?2O,/^%K^(O\
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MQPM9NSM^ 69ZW<>'[J\B\FYUFXDA+*S)L4;MI!QT]JWJ\S^'?CK6M>D6RO\
M3Y)T7@WJ#"C_ 'O_ *U>F5SUH3A+ED#"BBBL1!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 8=A_R-FK?]<H?_9JW*P['Y?%VJ*>"T$3 >H^:MR@
M HHHH \L\??$'5/#7B/[!:0V[Q>4KYD7)R<UR_\ PN'7O^?:S_[]U'\8/^1V
M'_7NG\S6/<Z%ILEFPTZY,M\D:.T9<8YQGD_RKV:5&C[.+E'<M&Y_PN'7O^?:
MS_[]T?\ "X=>_P"?:S_[]UCS>'-.AA\R.Y%TP10T:3*I5OXCD]A5M?"^C,\J
MM<LJJBE7\X8)(Y/X57L\/_*!=_X7#KW_ #[6?_?NC_A<.O?\^UG_ -^ZP9M"
MTY+FWC6X(#EAS(#Y@ R&&.@)[&HSX<M?MD$*:K&RR'!^7YAZX I^RP_\H'1?
M\+AU[_GVL_\ OW1_PN'7O^?:S_[]UAW'A1;*RGN;BY7:I=4 <9&!D$_7TKF.
MU5&A0EM% >A_\+AU[_GVL_\ OW1_PN'7O^?:S_[]UYY15?5:/\J ]#_X7#KW
M_/M9_P#?NC_A<.O?\^UG_P!^Z\\HH^JT?Y4!Z'_PN'7O^?:S_P"_='_"X=>_
MY]K/_OW7GE%'U6C_ "H#U30?BGK6I:]8V4MO:".>4(Q5.0#7M5?+?A#_ )&_
M2O\ KX6OJ2O-QU.$))15A,****X23#\._?U3_K]DK<K#\-G=_:3CE6O9,'UY
MK<H .HP:9Y4?]Q?RI]% #/*C_N+^5'E1_P!Q?RI]% #/*C_N+^55I[RPM;J*
MVGDBCFF#-&K#[P'6KE8>M^&K;7;NWFN9&"PJP"KP>??_ #UH O6M_IU[ DUO
M- \;@LIR.0.]-GU/3+<KYL\"AN W!&<XQGZUS*_#]$C\E+]ECVD<)\R\$8![
M#GI4S^!(MS&.ZVKD,B%,JI!!Z?A^M%V,ZCSK,!CYD'RG#<C@TR&ZL9T5HY(3
MN7< < X]<5S,?@J&"XBEN;\,BR A2H ?K][U.3^E0S^!4BLY&6\8S?PM]TGY
M=H7/I1=@=3=:AIUG:_:9I8?)+! RX.6)P ,=ZF$UFPR)(.NWJ.OI]:Y72O##
MW6C207CQ+OO1<!8L$+MXQ[&IK'P2EK>V]Q+=>:L#AE39@-@$ GU;GK1=@=*9
M+16VEX <XP2.OI4-O?:==0--%- 8U)#$D#:0<<^G-<_>^"([NX,PNV5GG>5^
M/O!B./J,<&J\O@BVMHD87ZQ%>ID4;9&W,WS#OPWZ478CK3+:+G=) ,#)R1P/
M6H'U+38[E+=YH1)(0$!QAL@D8/?I7*7/@FX%NALKT2!C%N#C(<*0<GUX'2I5
M\'10,L@U1!-#(IRR@A"0PP!V^]Q^%%V,Z6?4M-MW17EB)<%EVC.0" >GU%3B
M>R;&)8#DX^\.OI7)IX#E7)_M,G<26_=^NW./Q4?G4DO@J::$H=056:4RLR18
M))((/7MC%%V!T,.IZ9<$^5-"P )+<8&#@\_6K'FV@;:9(-V-V,CIZURI\#'J
MMZHVNS(OE?*<ONPP[]:%\ Q+'@WC.^>6=>HV;=OT[T78'7((9$#H(V4]"H!!
MI?*C_N+^55=(L7TW2X;22<S-&,;R,9YJ[0(9Y4?]Q?RK-UOP_I^OV<=I?1;H
M$E64JO&XC/!]N:U:*:DT[H""TL[:PMUM[6!(8D& B+@"IZ**5[@%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 9NHZ/'?31W,<\MM=Q A)H
MCSCT/8BJO]D:M_T'[C_ORG^%;E% &'_9&K?]!^X_[])_A5:]T'6[BW"0^)+B
M)MP.X1)T!]A72T4 ?/OQ;5D\81H[EV%J@+'N>>:Y>319E12DJLQP-O0\C/Y5
MU?Q@_P"1V'_7NG\S7#)=7$;,R3.K,,$@]:]_#W]E&W8M;%H:+>[V3:@91EAN
MZ4LNC7<6[!1E7C(;J<9Q]:K&^NCUN)#_ ,"I#>W3 @W$A!&"-W:MO> F;39%
MMQ/YB[-FXG^[Z"A-/N5NDBW".8KO7YNU5?.E*;#(VTXXSQQTJ1+R>.3S!(2X
M& 6YQ1J,LQZ9=7%NTWF+C[Q#,>GJ:4:)?$$[%XZG=Q55+RYC4*D\BJ.@!H^V
MW6,?:),>FZBTA$JZ;/\ :&B8HFP LQ;@ _SJQ_8LGF+&)1O?)C!7A@.^:SVG
ME>02-(Q<="33VO;I@0T\A!Z_-1:0#;B)89-JR%QW.W'-14^6:29MTKLY QDF
MF52&%%%% &OX71Y/%.FI'(8G:=0' R5]Z^B_[(U;_H/W'_?I/\*^=_"'_(WZ
M5_U\+7U)7DYC\<268?\ 9&K?]!^X_P"_2?X4AT34I04FUZZ,9X8(B*2/J!Q6
M[17G$E>RLX-/M([:W39&@P!_6K%%% !1110 4444 %%%% !7'W^B:_=:O/)'
M>"*UD< A)&!V[@?P.,BNPHH X9?#&N?;+0SW8GA@F1UWRM\JJ3QCN>>IJ34O
M#>M7MW=,;H-"T@D4&5@' 8%5Q_#@ \CUKM:*!W.$_P"$5UR"!Q:7WE>8Q>6,
M2-AOG)P/3@UH6V@:O%INH)+J,DEU,BI"YD/R  9_'.>:ZNB@+G#R>%]>C1Q;
M:HXR6R'E8Y3<"%]N,\U#<^%=>G$*R7@GV!2K22M\F 01CH>3G-=]118+G%+H
M.O1VTT1G61WVCS3,P^7^Z%Z#'K4EGX?UJ/3KV&XGC:XG>!Q,&.25VAL_@M=C
M10*YQ*:#XB41@78^25L%I6/RGN?4^E1RZ#XIGC0-?K&%"*524\X3;NSZYYKN
MJ*!W,'0=.U.QO;PWMQYT,A!C9G+-GO[ 5O444""BBB@ HHHH **** "BBB@
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M HHHH *YO7?'?AWPU?K9:K?^1<,@D">6S?*>_ ]JZ2OF[X\?\CW!_P!>:?\
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M?E^51DGFJOEOM5MC8;[IVGGZ4?V=1[L/8Q[GU1_PMSP5_P!!@?\ ?E_\*/\
MA;G@K_H,#_OR_P#A7ROY<F0/+?)Z?*:/+?+#8WR_>^4\?6G_ &;2[L/81[GU
M1_PMSP5_T&!_WY?_  H_X6YX*_Z# _[\O_A7S!::;=WT<\EO"62",RR,3@!1
MU^M(^G7D=A#?/;N+:9BD<F.&(ZBE_9]':[%[&/<^H/\ A;G@K_H,#_OR_P#A
M1_PMSP5_T&!_WY?_  KY7*.&*E&##J".:%CD896-VXSPI/%/^S:7=C]A'N?5
M'_"W/!7_ $&!_P!^7_PH_P"%N>"O^@P/^_+_ .%?,YT*_6TCNFB189(3.C-(
M!N0'!(_PJ$:7>G36U 0-]F$@B+=]QY QUJ?[/H_S,7L8=SZ>_P"%N>"O^@P/
M^_+_ .%'_"W/!7_08'_?E_\ "OE^+3;R>WN)X[:1H[8 S-C[F>F:K%&4 LK
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M]EXZT(0PIY/V'%F(D6*)BMLX?<VT@[B'^O%1_P#"6Z-J%M>02N8?.N"\,-O
M8MS$K@L<D%3C)!Y':N,_X1/Q)_T+^J_^ <G^%'_")^)/^A?U7_P#D_PK#V5+
MHR.6/<])U?Q?H>G:]<PW5Q+?E;W=%B!=MB-I&4/1N2#CVK'N?'-C;VTPL[R>
M?41;QQ?V@\ 5YB)-Q..V%XSUKCO^$3\2?]"_JO\ X!R?X4?\(GXD_P"A?U7_
M , Y/\*4:-);L%"/<]!@\>Z"E]Y\5U<V<2W,DDL,=J"+H,H )/8@YJH?&^A+
MIEK#%$ J+'&]NT+$*5;)D!SMR>O3-<3_ ,(GXD_Z%_5?_ .3_"C_ (1/Q)_T
M+^J_^ <G^%/V-+N')'N;=KXEL[CQI?ZK?W,Z1.)!:NBD;.?E!5<'&/2MZ;Q]
MI,%ZLNGO+&DUW%+<X@ +($VN._4_G7#?\(GXD_Z%_5?_  #D_P */^$3\2?]
M"_JO_@')_A3=.D]V/EB=M'XO\-PZ:\"27#*2KQQO$28W$F[@YP!CI@4^?5]/
M70M3U='\PI=NNG2R(H9A+]\%<Y^6N&_X1/Q)_P!"_JO_ (!R?X4?\(GXD_Z
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M(0?/'CT/K4:^-] ^SRLD<MO #+OTU8%*71;HS-VQ_P#JKB?^$3\2?]"_JO\
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M]5_\ Y/\*.>/<+HQZ*V/^$3\2?\ 0OZK_P" <G^%'_")^)/^A?U7_P  Y/\
M"CGCW"Z+'@7_ )'S0_\ K\C_ )U]@U\I^"_#.OV_C71II]$U**)+M&=WM755
M&>I)'%?5E>1F33G&W8Y:[U"BBBO-,0HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#__V0
3                          $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>img222477878_18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_18.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $3 <X# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH *YO49O#D>I,NH1Q?:FV99XF.X9.WGIC@Y[#O72=JYO4X/#DNJ@ZC)";S*
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M_P!_7_QK3HH S/\ A'],_P"?=O\ OZ_^-'_"/Z9_S[M_W]?_ !K3HH 0  8
MI:** "BBB@!#7 Z;;6UG\3KR"W00A5R$!/S[D#$\GGECTXKOZ3'/6@#BM/LY
MD\?37"Q3S0LK#[2WS#;C(^<#!&<J%ZC&:V==U]=%DMU^S>>TV_Y%?:PVC.<8
MY'K_ %K,TCP]J6CZW++!(#:RR,S![HLNTDG 3;D$9/?%=-+-;0E3/)$A.=OF
M$#.!DXSZ"@#)T741JNHK=B!X?,L8WVMTY8]#W'O705E6LD<NN-)$R/&]HC(R
M'(8;CR/:M6@ JEK/_(#U#_KVD_\ 035VJ6L_\@/4/^O:3_T$T ?%2_P?[M7M
M'_Y&/2_^OJ/_ -"%45_@_P!VKVC_ /(QZ7_U]1_^A"@9]I/(D2,[L%51EF/0
M#UK"UC6M+DTBY5-0MF8IP!(#GFK^NC_B0:E_UZR_^@&O.HXU\I/E7[H_A'I0
M(]$36]+.U1J%L2< #S!R:T <UY1<(H@)VKU7^$>HKU<"@!:*** "BBB@ HHH
MH *P-4\,P:G<FX\YX9"8R61>?D)P>O7YC6_7.:SX9;5;X7,=]+!\T995R?NY
MZ<\'G\Q0!>T&-8K6Y1<[1>3XW,2?OGN>:U:RM"39;72[V?%Y/RQY^^:U: "O
M.OC9_P DVNO^OB'_ -"KT6O.OC9_R3:Z_P"OB'_T*@#YEKO_ (+?\E/L_P#K
MUG_]!%<!7?\ P6_Y*?9_]>L__H(H&SZ?SVK%U33K.34-.=[2!FDNCO)09;]T
MYY_*J?C=0^C0J<[3=)D D9ZUQOV"V(&8P2.1R>/UH$>J0Q)#&L<:*B*,!5&
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MX]*YO4=.U2ZO[B2W8QPD*$ N6&_CG(Q\N#C&/?UH Z-.G7-.J.%66-0S;F
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M!R.K^#IM7N+2[EU69;J%B20#Y:Y !,:Y^4_*.Y^E=:O"BEHH **** "BBB@
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M]/NQ_P"[6AH?_(T:1_U]Q?\ H0H&?:5)@4M% @HHHH **** "C%%% !1110
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MIHO%%A=-=*8)@J?9B77<%)R"0RC!+ XZDKZ5W]9FJ:%::M/;S3M*LEOG88V
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MC<<E7< T 6:*I_VMIW_/];?]_14\-Q%<1^9#(DB$XW(V10!\O?&;_DJ^H?\
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M3+\].G(K9/B'2XRH>Z(+G"YB?D^G2@!;V&-=2THK&JG[0_08_P"63UQ?QO\
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MW4#0SQK)&WWE89!HHH 9%:P0.SQ1(C,,,P') Z5.*** /__9
A

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>img222477878_19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_19.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /?Z "@ H * "@ H * "@ H * "@ H * #.* $R/6@!<CUH
M3(]: #(]10 N1ZT &1ZT &10 9'K0 F1ZT +D>M !F@ H * "@ H * "@ H
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M92NCJ4E*-SZ,T?;_ &-8E1A?(3 ]MHKS7N>/+<O4A!0 4 % !0 4 % !0 4
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M0+&QLM5TVUU"]&+C;E_WAX/<"N5R<966QYTYR3LANM031:,SV,322QC"C=G
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M+B4C>K #GGH?K7>EH>ZGRH=;WA\QO,01 G;A,@8[#FFT2D^44+//;SO,A&P
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M*OL!2:L;QIP4;GTKHA)T2P).28$_]!%>>]SPI_$S0I$A0 4 % !0 4 % !0
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MDJ1EE/N#_2JL;=;,^D-&=I-&LF8@DP(3CZ"O->YXTU:3+U(D* "@ H * "@
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M!MNH[U1)$WFQQ_,-N&'H:::"R>J()(TF8-+RP.03US0F5:YJV\$5[!&;JX6
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M^QK3<[O:J4+'HFH>.+(^'9)--4"\O<QS(^3L.!N;^6*P47>YY].F^:QP<+&
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M!#'9LI5MA4\$$T;#3ML9K>'=#9MQMH@?9B*KG9?M9=QS:#HK  P(0/\ :/\
MC1SL7M&AH\/:&%VBWCV^F\XHYV/VLA6\/:$ZD-;18[_,::G(?M9$;^&-!D@:
M!K9#&>J[S_C1SL/:SO<:/"?AX# M8_\ OL_XT>T97MYD4OA'PR$)DM(0HYR9
M",?K3]I+8/;395_L/P67*#[&7/! FR?YU:G-;%*K4Z%:2V\ P,T,MQ8(R'#
MS\@CMUIWJ#YZKU6P)%X  *K=V!SU G_^O1>H)5*KT0-'\/XW4-=:>K#D?O\
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MNR%T:6YAUJRG,81U<$*1GO2EL#BW&Y]41',:G&,BO+/,V'T % !0 4 % !0
M4 % !0 4 (:0'BWB'6[C1/BEJ$UG,JW+PHJB1<ITYKKA%2C9G5&"E&QYE?W4
MU]>M=O&D1)P O2M4EL=D8N"N5B'DW%7*@\-CBJVT"SEJ@BA26%G+-@OL]C@9
MH>PH).5F:IU6./23!-;QW,J$1QO)]Z,?U]*%L.:2EH)HFEV^IF]GNKIH([./
MSGVKG>,XP/2DV1)N+L5!='4=4!GD$: !4S]U5'0"FAQML126K!E=%,D1;:C
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M?'4?G0KIG)?WA-/#MJ]NP.&\U< ]^:4MCIJ-*!]11Y\M<]<5Y9X['T""@ H
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M0U?Q3++H\5I<Z?;RV\)54"Y5UQZ-4<MM48SI^RV90?4ULKUWMM/C:!XP!%<
MME3SDGCGWILR;<C<DU5H_)N-%BL("T*^<@0%HVQR,GJ*23V",')V9FG6-32=
MI%O'!/!08"G\*OE2.B5)15T4M1U"ZU7[+]HVQ1V_RJH'ZGU)H2,>3JR>R;.J
MVHV@8D7@#WI2V.F<8J)]2P_ZM/\ =%>7U/(9)0(* "@ H * "@ H * "@ H
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M_A1[2/<N52"V-;2?A_J[WUA>^7<6Z*RM-'+;."ISSCCD5G.HFCD=34^AT&%
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M^5%QW8;5'\(_*BX78;5_NC\J+B%H * /_]D
7                               !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>img222477878_20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_20.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #F 7,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1VHH *XCPW_R4WQ=_N6O_H+5V]<1X;_Y*;XN_P!RU_\ 06H [>BBB@ HHHH
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M4+E+GP[IZZ=*]M)J<$C7@8;$8/PI'J:]%33K*)K9DM8E-JFR A1^[7&,#T&
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MH **** "BBB@ HKFKW6[R#X@Z9HR%/L=Q9RS2 K\VY2,8-=+0 4444 %%%%
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M69UWY')X/';@58\"^$;WPNM]]MOVNWN)-ZDR,0F>2,$^I//4]Z["B@ HHHH
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M_P"A4 =]VK%\7?\ (G:Q_P!><O\ Z":VNU8OB[_D3M8_Z\Y?_030!\-T444
M=#X#_P"1^T'_ *_8O_0A7V[7Q%X$_P"1^T'_ *_8O_0A7V[0 4444 (WW&^E
M?"WB3_D:-6_Z_)?_ $,U]TM]QOI7PMXD_P"1HU;_ *_)?_0S0!ET^#_CXC_W
MA_.F4^#_ (^(_P#>'\Z /NW1O^0%I_\ U[1_^@BKU4=&_P"0%I__ %[1_P#H
M(J]0 4444 %%%% !1110 4444 %%%% '.^/+ZZTSP-J][93-#<PP%HY%ZJ<B
MMC39'FTNUDD8L[PJS$]R17/_ !*_Y)QKO_7L?YBM[2?^0/9?]<$_D* +E%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!SGCN6.#P;J$TD;/L564K(
M4*,'&U]PY 4X;/M67X4U2SA\ S:C'%<W,6YWDD.9GN&.-S>IY./PKH/$T.I3
M^'[J/2-OVX[3&&;:& 8%ES@XR,C\:I>&-.U'2/"[6FKR&YEC+X^;<67T_$YP
M.P(% ')_#I))M2DFLM4O(H HEFTR2T:*V5'#;3#O);J.N:GN];U"/XFB,:C*
ML"7L5G]CWXC,36[R,Y7U# <^U2_#-X6FO0K)*Y@A>-TO6N/)A.[9"=WW67GC
MWKM9M#TNXU+^T9;"W>\\LQ>>4&_8>HSZ<F@#D_M<\WQ/A@L=:GN(PAEN[8RC
MR(HBF$4+W=F^;/H#67\6=3D2Z\.Z8+"=HY=2@E-T!^[0A_NGW-=M;>$] L]1
M34;;2+2*\0!5G2,!@ NT#/TXKFOBK_R"M#_[#%M_Z%0!WW:L7Q=_R)VL?]><
MO_H)K:[5B^+O^1.UC_KSE_\ 030!\-T444 =#X#_ .1^T'_K]B_]"%?;M?$7
M@/\ Y'[0?^OV+_T(5]NT %%%% "-]QOI7PMXD_Y&C5O^OR7_ -#-?=+?<;Z5
M\+>)/^1HU;_K\E_]#- &73X/^/B/_>'\Z93X/^/B/_>'\Z /NW1O^0%I_P#U
M[1_^@BKU4=&_Y 6G_P#7M'_Z"*O4 %%%% !1110 4444 %%%% !117COQH^(
M/B'P7J.F0Z+<Q1)/"SR!X5?)!QWH [CXE?\ ).-=_P"O8_S%;VD_\@>R_P"N
M"?R%?)>J_&3QGK6EW&FWM[;O;7";)%6V121]0*LP_'+QU;P1PQW]L$C4*H^R
MIT'X4 ?6]%>9_!CQEK7C/0]0NM:GCEEAN?+0I$$PNT'M]:],H **** "BBB@
M HHHH **** "BBB@ HHHH **** ,+Q;J+Z;H,LT-U%!.K(R^9,L6]0P+J&;@
M$KD?C5#1-=N[GPE=ZOL>\=YI7@M[:1)G52?E3*G:2/3/ IWQ 24>&6N(KK[.
M89HV8BU6X:0%@-@5NY) I?A_,MQX;,@>9F,[[O.MT@*GC@(O '_ZZ ,KX<IJ
M<4M\M[9ZC;I(D<K_ &Z*--TYW>9LV'[OW>#7?444 %<#\5?^05H?_88MO_0J
M[ZN!^*O_ ""M#_[#%M_Z%0!WW:L7Q=_R)VL?]><O_H)K:[5B^+O^1.UC_KSE
M_P#030!\-T444 =#X#_Y'[0?^OV+_P!"%?;M?$7@/_D?M!_Z_8O_ $(5]NT
M%%%% "-]QOI7PKXD_P"1HU;_ *_)?_0S7W4WW&^E?"WB3_D:-6_Z_)?_ $,T
M 9=/@_X^(_\ >'\Z93X/^/B/_>'\Z /NW1O^0%I__7M'_P"@BKU4=&_Y 6G_
M /7M'_Z"*O4 %%%% !1110 4444 %%%% !7SI^TG_P AC1?^O=O_ $(U]%U\
MZ?M)_P#(8T7_ *]V_P#0C0!X91110!])_LW?\BMJW_7Y_P"R+7M=>*?LW?\
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M7_T,U]TM]QOI7PMXD_Y&C5O^OR7_ -#- &73X/\ CXC_ -X?SIE/@_X^(_\
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M.R9=/H:T:YB_\=Z+IWBFVT*>\MEFE5B[M.H\IAC"D>ISQ73T %%%% !1110
M50UC2+77-,FT^\4F&4 -M.#USP?PJ_10!'!"EO D4:@(BA0![5)110 4444
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MHH **** .<OO!6D7_B>UUR:UA,T*,&0Q*1(3T8G&<C'%='110 4444 %%%%
M!6=K>B6?B'2Y-.OQ(;>0@L(Y"C<>XYK1HH K6%E#IMA!96X80PH$3<Q8X'J3
MUJS110 4444 %%%% #)H8KB%X9HUDB<;61AD$>A%87AOPAIGAEKM[."(27$[
MREQ&%*ACG8,=A7044 %86N>#]%\174-QJ5LTDD2[<I(R;USG:V#\RY[&MVB@
M#FKGP%X=NYY)IK',DA<DAR/OXW8_[Y%7]7\-Z7K=DEK>0':C!T>)BCHP&,AA
MR#C-:U% '/W/A6T70['3--5;5+&>.>#J0"IYSW.06&?>J,/PV\.06ES;)!<^
M7<N)'!NG.UP2=R\_*<D\CUKKJ* ,"'P9H=N\;0VFSRI(Y$"N< QQF->/9217
M-7_PN@N=:LW@D@@TN!8E,05_-(12H&[.#UZD9 XKT2B@#G3X(T$ZQ%JAM7^T
MQ&,K^];83&NU"5S@[1TJ%?A[X:1)533PHE@FMVPY^Y*^]Q^)_*NHHH \_P#%
M/PTBUE!%IKV]I'*9O/\ ,1F(\W;N*8(Q]W.TY&><5U6B:,=);4)'E$DMY=&9
MB!C"A51%_!47\<UK44 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% '__9
8

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>img222477878_21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_21.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #Y =L# 2(  A$! Q$!_\0
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M &;=?]!:Z_[Y3_"C^S;K_H+77_?*?X5I44 9O]G77_06NO\ OE/\*/[.NO\
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M- $^:"<#)XJ#[,6^_/,W_ L?RI19P9R8]Q]6)- #C<PKUE0?C3?M<9^Z'?\
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MC/\ A9>G_P#/G=?D/\:Z71=7BUNP6\@C>-&)&'ZU@_\ "M](_P">UU_WV/\
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M;Y+^S68#:X.V1#U1AU%6\"G%V:9,X\T6CQ_[=K__ #]7_P"34?;M?_Y^K_\
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M4XZ5G7&DV\DQG@+VMR?^6L!P3]1T;\:B^TZC8C_2H/M40_Y;6P^;\4_P/X4
M:U%5K2]M[V/?;3+(H.#CJI]".H_&K- !1110!E^(_P#D7-2_Z]G_ )5>M/\
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MY76-;U>'Q%900VMW#9"X6-BL.X3Y'KV KK+:'R;:*$.7\M F]NK8&,FI2N:
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ML8;SF&<#&?NU9WZW_P ^UC_W^;_XFM.EIN3;,U3LK7,OS-<_Y]K#_O\ -_\
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MG&>3TH 6BBB@#+\1_P#(N:E_U[/_ "J]:?\ 'G!_US7^54?$?_(N:E_U[/\
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MM(1C_EFO\J )Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0
9                                  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>img222477878_22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_22.jpg
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M/#]X<&%C:V5T(&5N9#TB<B(_/O_M $A0:&]T;W-H;W @,RXP #A"24T$!
M    #QP!6@ #&R5'' (   (  @ X0DE-!"4      !#\X1^)R+?)>"\T8C0'
M6'?K_^X #D%D;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$!
M 0$! 0$" 0$" @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,#_\  $0@!$P(< P$1  (1 0,1 ?_$ 0   0
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M' '<-.ZI_4%+!*5([CN-4J'<P@M*9<:D\5S4I6[W*0WA&7WB0G<@X!0MI8>
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M?9[TG>V>\W9],?FZ<&]/'@;.CYTD4_D[R%R3QSRVXER=Q/R@X[^K\BO+#C'
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MJJ6@PRAE28WC14DT<.$::G2-/#W#QK,L0;##<-^%:U[;+\$0@7_D$"]A6K4
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M]1N=(IJ8[X*SNT/;AC[4FC;(I''9P* [J8:_)P12X!.(1MP=ZJ*WM[%D6=F
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MP 6((RQY4+$ D*< @:9]2 1 3@OM 0&X<1VN$D-_0#;UMO2JH;EYTTU:RS!
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M?*)?.9VWW_B7I_\ ^XTY_P"WF"O#/Q;?]_Y+_P '/_K(U]9O\./_ )0WH_\
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M=>G!FGPP'^2RIQ(2F3A$>OB4A#A_'\EB\<;$"EN)43HF0Y4=WQA7'W!M:RD
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M#_-N<^F[R= /1CU<,8> O=Z>YGLLZBR_T??3YH/B#_-N<^F[R= /1CU<,8>
MO=Z>YGLLZBR_T??3YH/B#_-N<^F[R= /1CU<,8> O=Z>YGLLZBR_T??3YH/B
M#_-N<^F[R= /1CU<,8> O=Z>YGLLZBR_T??3YH/B#_-N<^F[R= /1CU<,8>
MO=Z>YGLLZBR_T??3YH/B#_-N<^F[R= /1CU<,8> O=Z>YGLLZBR_T??3YH/B
M#_-N<^F[R= /1CU<,8> O=Z>YGLLZBR_T??3YH/B#_-N<^F[R= /1CU<,8>
MO=Z>YGLLZBR_T??3YH/B#_-N<^F[R= /1CU<,8> O=Z>YGLLZBR_T??3YH/B
M#_-N<^F[R= /1CU<,8> O=Z>YGLLZBR_T??3YH/B#_-N<^F[R= /1CU<,8>
MO=Z>YGLLZBR_T??3YH/B#_-N<^F[R= /1CU<,8> O=Z>YGLLZBR_T??3YH/B
M#_-N<^F[R= /1CU<,8> O=Z>YGLLZBR_T??3YH/B#_-N<^F[R= /1CU<,8>
MO=Z>YGLLZBR_T??3YH/B#_-N<^F[R= /1CU<,8> O=Z>YGLLZBR_T??3YH/B
M#_-N<^F[R= /1CU<,8> O=Z>YGLLZBR_T??3YH/B#_-N<^F[R= /1CU<,8>
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M3VVNT=;T;':QB$QN2.!AZJ]P&A*+]?47+^R!MW;MM(]X'6)<[7N>ZU#VMP^
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MSZX=#:@[$^QYALAEVJ>:913MY2"-Q""R(M[-;47$F0AZG;J@NSQY 05:Z=*
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MVXP.0[^Y342H,E"@+HF/2K$K@4$D)@+;L-ZY;>KLJW2[3NQ#,1O/'*Z>PSF
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M0!/VG_9HM[[%GURG:^$ZTKPF3HG_ (BR1TI/CF&FOI;RQ< 7+8G-M",HB]A
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M6FIK^X3&7[PCI]1U-CW;_GKGV5O]Y2C.,\G?3RTU-?W"8R_>$=/J.IL>[?\
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M))U*\6M2N;*&X]*2&$P<MO>7<#I-W*RFXTR50)(G& H=Q'AO:UKK[</=BR?
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MQK%(;6V;;B5G6M;;W+=VYFSNWJ#+(!4N=3])YU(@C=H;&PG_ "&\R!4G#MM
ML4BMW>Z%6=>W<]'NV,V=RIUDE*XG4_RCSHZ"-IHZ-@/^2WF46_4^^E?PH_\
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MZ)&YR0W5"1.+>F7*"$2]$):0F6B1K4H &E7.++-N 5KC"$6VUNG;MD45W+%
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M/8XTU)HO(GIQ/46< (!L [$72DIK!3KE0#KJ!GV,*(HTFB=N0M3FV)=0NI4
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M*(E$2B+_V0
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>img222477878_23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_23.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "\ BL# 2(  A$! Q$!_\0
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MM[./8M?;G_N+1]N?^XM5:*.>0>SCV+7VY_[BT?;G_N+56BCGD'LX]BU]N?\
MN+1]N?\ N+56BCGD'LX]BU]N?^XM'VY_[BU5HHYY![./8M?;G_N+1]N?^XM5
M:*.>0>SCV+7VY_[BT?;G_N+56BCGD'LX]BU]N?\ N+1]N?\ N+56BCGD'LX]
MBU]N?^XM'VY_[BU5HHYY![./8M?;G_N+1]N?^XM5:*.>0>SCV+7VY_[BT?;G
M_N+56BCGD'LX]BU]N?\ N+1]N?\ N+56BCGD'LX]BU]N?^XM'VY_[BU5HHYY
M![./8M?;G_N+1]N?^XM5:*.>0>SCV+7VY_[BT?;G_N+56BCGD'LX]BU]N?\
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MK)Y0\M2RIGMNR*TO$"W,NN^(;RX@1[:+0A)92M&NTN!&20>_-3]8;LTM'_P
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MS@IG "GUHY0YSU$,K$A64E3@@'.*6O-_!^FW*ZKH\JQW5I):VC+>JUN464D
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MTL26W$<-)C  ^G6L<1-0I2;[#BKL]MHHHKY0Z0HHHH **** "BBB@ HS110
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MG$BIM)/3[V<UT"ZYI9U!; WT NV.WRMW.[&<?6BS%S(T**P_#?B:U\0Z;:W
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MGVC1W4DT;6\*2;HV/W#NZ$8ZU'-56B0:F(G@751!+/=R6ME%%<FUD:XE"[7
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M'"GEL'PC%<DG@DX/ Z47>X6CL<QK/@[7=?TZ*+^SK33I+/29;)%BE4BX=PH
MXZ(-N>>YKK/$?AR35? LVAV7E6\AAB"*!A"4*MM..QVX/UJ*'XA^&[CR##=R
MN+D$VY$#XF((!5./F89Z"K'_  FVA-:6EQ%<R3?:@YBBBB9I"$.'RH&1@\'-
M&HTHG'>(_"7B#Q'<W]TNDVEC]HT?[ L2SJ27$R/DXXQA2!]*M7GAGQ+>7UJ\
M\:2-;:S'>B59T6,P*PP N,[@O4GKBNF/CC0#+;10W;7$MS!]HA2"-G+)DC/
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MPAS&$YW,AZ@L22/I6%XDUB*^M;&PM;KSX+;>Y*VP@0.W7:HYQQWJXSJ.5FM
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M3JJ,>4SG/F/_V0
'          $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>img222477878_24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_24.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #? WT# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&G1114 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5#>?\ 'E/_ -<V_E4U0WG_ !Y3
M_P#7-OY4UN!\E3?ZY_\ >-+]GF%NMQY3>2S[!)C@MZ9]:2;_ %S_ .\:[OPW
M>Z;:_#Z:'5H1+97.I"*0J?GA^3(D7W!_2OHYS<5=*Y9P]U:7%C<&WNH7AF4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,K 0*3$,<R$$!OP!.*+5>[!N@NB^[^NY!_;6J?\ 00N?^_IH_MK5/^@A<_\
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MG,2HYX;Y<\>] T6Z8J@:+S<KNBW?,FXX!-*U7?4+T$VFEIY#?[:U3_H(7/\
MW]-']M:I_P!!"Y_[^FDCTJ=[4W)>)(@"<LWHVW'YFH[RQDL9UAD="Y'(4_=I
M-U$KMLI*@W9)7]"7^VM4_P"@A<_]_31_;6J?]!"Y_P"_II[:).B>:\T*PA"Y
ME)('! /;/<5+:Z#(]ZD%S-'$&<J!NY? Y*U2C5O;4ARPZ5[+[BO_ &UJG_00
MN?\ OZ:]=\/R/+X?L))'9W:%268Y)KQ.O:O#?_(MZ?\ ]<%KNRR3=1W?0\G/
M81C1CRJVOZ&I1117M'S 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %02WMK"Y26YAC<?PM( :GKBX=&T
MW5O'FO\ ]H6,%UY<=OL\U VW*<XS5PBG=OH!U7]I6/\ S^VW_?U?\:/[2L?^
M?VV_[^K_ (UF_P#"&^&O^@'8?]^11_PAOAK_ * =A_WY%.U/N_Z^8&E_:5C_
M ,_MM_W]7_&C^TK'_G]MO^_J_P"-9O\ PAOAK_H!V'_?D4?\(;X:_P"@'8?]
M^11:GW?]?,#2_M*Q_P"?VV_[^K_C1_:5C_S^VW_?U?\ &LW_ (0WPU_T [#_
M +\BC_A#?#7_ $ [#_OR*+4^[_KY@:7]I6/_ #^VW_?U?\:/[2L?^?VV_P"_
MJ_XUF_\ "&^&O^@'8?\ ?D4?\(;X:_Z =A_WY%%J?=_U\P-+^TK'_G]MO^_J
M_P"-']I6/_/[;?\ ?U?\:S?^$-\-?] .P_[\BC_A#?#7_0#L/^_(HM3[O^OF
M!I?VE8_\_MM_W]7_ !H_M*Q_Y_;;_OZO^-9O_"&^&O\ H!V'_?D4?\(;X:_Z
M =A_WY%%J?=_U\P-+^TK'_G]MO\ OZO^-']I6/\ S^VW_?U?\:S?^$-\-?\
M0#L/^_(H_P"$-\-?] .P_P"_(HM3[O\ KY@:7]I6/_/[;?\ ?U?\:/[2L?\
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M,><,,X;Z\FHY-0N958.X.Y%C/'4*<C^==C_PK:;_ *"$?_?!_P :/^%;3?\
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M(7/I3DOY%LUM6BADB4DJ73+*3UP:['_A6TW_ $$(_P#O@_XT?\*VF_Z"$?\
MWP?\:7U/$_R_D-YE@7O+\'_D<:+QHK][JW18FR2@QG9GT]Q3X=3N(+?R5\L@
M;MKLN63=][!]ZZ__ (5M-_T$(_\ O@_XT?\ "MIO^@A'_P!\'_&A83$K:/Y
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M2Q.KQN RLIR"/45SUZ$J,K/8&K#Z***P$%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5RLW_)4K3_L$
M2?\ HU:ZJN5F_P"2I6G_ &")/_1JT =51110 4444 %<SX _Y$RS_P!^7_T8
MU=-7,^ /^1,L_P#?E_\ 1C5HOX;]5^H'34445F 5S7BR>*VNM"N)W$<,=^"[
MMT4;&ZUT>]-I;<N%ZG/2FF:!IC 9(S*!N\O<,X]<4 <-?7D:W&MZM9Q3?V=-
M%! 9(V,*RR[\&3=CA0I +>@JA8ZO?6&G7.JB5YK2POFB\J.1I$:)XU VL>6
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M?VC<82:V+L#O.><BM%\#^0'H=%<M]@\;?]!O2_\ P";_ .*H^P>-O^@WI?\
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M=4E*VLN&MK=Q\R#U]@?2N^KP:D%";BG<@****@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y6;_DJ5I_V"
M)/\ T:M=57#Z[%J<WQ'LETFZ@MKC^RY"SSQ&12OF#C (YZ4 =Q17+?8/&W_0
M;TO_ , F_P#BJ/L'C;_H-Z7_ . 3?_%4 =317+?8/&W_ $&]+_\  )O_ (JJ
M&MZ7XXGT.]ACU>QE=XF54AMF1V/^RV[@^] '<5S/@#_D3+/_ 'Y?_1C5/X1L
M=>L-&2'Q!?QW=SQ@JO*#T+?Q'WJ#P!_R)EG_ +\O_HQJT7\-^J_4#IJ**JW^
MI6>EPB6]N%A1CM4G))/L!R:S YS4=%OI/$)MH%8Z3J#I<7;;O]6T?51[/A?R
M-9-CH]Z-:5;G[2EXNH//YT=H#N3<2,RY^[MP-O7VKK[CQ)HUJL33:C HEC$J
M8.=R$XW<=O>F:KXDTS2H)&FNXO-$)F2/=]X 9'/8'U-(9S&D^'W@M_#SMIS)
M,9;@7I*\E&#\/Z@G%4K32+I-$T^V@TV>*2"SO(;A?+*YD,9 ^N>QKO(]6MUT
M6#4[MTMH9(4E8N>%W ''OUK,@\6V]YJ4EM:*DL230Q>:9-O,@8]",Y&WI[T
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M\>%M_P!<E_D*GKD+6Q\:&S@*:UI87RUP#9MTQ_O5-]@\;?\ 0;TO_P  F_\
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M:\(?ZW7O^PI+_P"@K72UI5^-@PKF=(_Y'SQ'_P!<[;_T UTU<SI'_(^>(_\
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M1112 **** "BBB@ HHHH **\5\<>/_$6C>+[ZPLKQ4MXBH13&#C*@_UKGO\
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MDM&+?,Q;D[O>NQI,CU%7&;BK(#FOL7C'_H,Z7_X!M_\ %4?8O&/_ $&=+_\
M -O_ (JNER/449'J*?M'V7W(#FOL7C'_ *#.E_\ @&W_ ,51]B\8_P#09TO_
M , V_P#BJZ7(]11D>HH]H^R^Y <U]B\8_P#09TO_ , V_P#BJ/L7C'_H,Z7_
M . ;?_%5TN1ZBC(]11[1]E]R YK[%XQ_Z#.E_P#@&W_Q5'V+QC_T&=+_ / -
MO_BJZ7(]11D>HH]H^R^Y <U]B\8_]!G2_P#P#;_XJC[%XQ_Z#.E_^ ;?_%5T
MN1ZBC(]11[1]E]R YK[%XQ_Z#.E_^ ;?_%4?8O&/_09TO_P#;_XJNER/449'
MJ*/:/LON0'-?8O&/_09TO_P#;_XJC[%XQ_Z#.E_^ ;?_ !5=+D>HHR/44>T?
M9?<@.:^Q>,?^@SI?_@&W_P 5534]!\5:MIEQI]SK.G>3<(4?;:,#CV^:NPR/
M449'J*:JM.Z2^Y ,@C\FWCBSG8@7/K@5)29'J*,CU%9 +129'J*,CU% "TUU
MW(R^H(I<CU%&1ZB@#D-,T#Q3I&G0V%IK&G>1""$WVC$XSGD[JM?8O&/_ $&=
M+_\  -O_ (JNER/449'J*U=63=VE]R"YS7V+QC_T&=+_ / -O_BJ/L7C'_H,
MZ7_X!M_\572Y'J*,CU%+VC[+[D!S7V+QC_T&=+_\ V_^*H^Q>,?^@SI?_@&W
M_P 572Y'J*,CU%'M'V7W(#FOL7C'_H,Z7_X!M_\ %4?8O&/_ $&=+_\  -O_
M (JNER/449'J*/:/LON0'-?8O&/_ $&=+_\  -O_ (JC[%XQ_P"@SI?_ (!M
M_P#%5TN1ZBC(]11[1]E]R YK[%XQ_P"@SI?_ (!M_P#%4?8O&/\ T&=+_P#
M-O\ XJNER/449'J*/:/LON0'-?8O&/\ T&=+_P# -O\ XJC[%XQ_Z#.E_P#@
M&W_Q5=+D>HHR/44>T?9?<@.:^Q>,?^@SI?\ X!M_\51]B\8_]!G2_P#P#;_X
MJNER/449'J*/:/LON0'-?8O&/_09TO\ \ V_^*H^Q>,?^@QI?_@&W_Q59'Q"
M\8W_ (2O=+EM%CEAEWB:)Q]X#&,'L:U?#'CW1?$Z*D$WD7F.;:8X;\#_ !?A
M6KC4Y%4LK>B&7O#FCW6D6]W]LN8[BXNKEKAVC0HH) & ,GTK:HHKGE)R=V(*
M***0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 4;G1M,O)?-NM.M9I/[\D*L?S(K U.'1M,N7C?PY9R
MJ(FEW)$F=H('(QQR<5UM4Y=.BDN)K@/*DTL8CWJV"J@Y^7TYH PI[;0(-*AO
M?[%TUQ+*L8"HFT$G'+8J S>%DM/.DT.W5_)>41_9%)8)G(4XP>A_"M]=$LQ:
M+;.&D03_ &@ESDL^=V3^-0W'ANPNK][N02;V0H5#8 !4J<>G!I#,?S?":Y\[
M2;2(X5@C6J[@I56)(QQC<*)YO"<4,DB:-!,$( $=D#O&\)E>.0":U)/"VGR.
MLK&4S !?,)!) 55QR/11^52/X<L&B\L"51M(!5^F7#\?B* *]GIOAN_DG2#2
M+0F!RCEK50-P.".GM3!X'\/#7!JW]FPFX555%V@(F.X4<9]ZU+32H+.]N+M&
MD::XP'+'CC)Z?B:O4Q'S?\3/^1_U/_>3_P! 6N1KKOB9_P C_J?^\G_H"UR-
M?1T?X<?1%A1116@PK2BUV]A&F!"H&G-NA&/O?/O^;UY%9M%)I/<1TEQXVU2Y
MTJ2P>.V"2<,ZH0V-^\#KCKWQFB?QE=71NOM&G:=,MP_FLDD18++MVF1<G@D=
M>WM7-T5/LH=@-^'Q?J<$PE00;A'!'RG:+[O?\ZDM/&%_%J GD945U@BD:)/F
M"1MN&W/&>O6N<HH]G#L!U?B?Q+8Z@NF1:7!Y:V<CS%C L09V8'[H)].3GFLH
M^(]0;6;G56=6N+A9%8-DJH<$' SQUK)HHC3C%6 ZN?X@:O.\):&TV1LS-'Y9
M*R[EVL&!/0CL,5#:^-;ZR6YBM[*QCMYF#K L9"1,!C*X/7'KFN:HI>RAM8#H
M?^$QU 6(MTAM$F$(@%VL?[[RP<[=V?6H-8\37>LVP@E@M8$:7SY?(CVF:3&-
M[>^*Q:*:IQ3ND 44458PHHHH *^CO!NA:1<>#=(FFTNSDD>V0L[P*23CJ3BO
MG&OI[P/_ ,B/HW_7JG\J\_,?@7J2R[_PC>A_] >Q_P# =?\ "C_A&]#_ .@/
M8_\ @.O^%:=%>029G_".:(#G^R+'_P !U_PK25510J*%4#  & *6B@ HHHH
M**** "O(YOA!J<L\D@\0 !V+ ;6XR?K7KE%:TJTZ5^3J%SR#_A3FJ?\ 0PC_
M +X;_&C_ (4YJG_0PC_OAO\ &O7Z*U^NUN_X(=V>0?\ "G-4_P"AA'_?#?XT
M?\*<U3_H81_WPW^->OT4?7:W?\$%V>0?\*<U3_H81_WPW^-'_"G-4_Z&$?\
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MY!_PIS5/^AA'_?#?XT?\*<U3_H81_P!\-_C7K]%'UVMW_!!=GD'_  IS5/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
=44 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>img222477878_25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_25.jpg
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M/#]X<&%C:V5T(&5N9#TB<B(_/O_M $A0:&]T;W-H;W @,RXP #A"24T$!
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MRBW_  %>@>0FUXB$@X?;%UCXF'BF%QE&S&-C(]K,)MF3%FW3*1)),I2$(
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MOZ2P/*U5O'0SJO,>1<=H!&SK/EKR#M&4G$YEK/1T<#8R+AF<4Q>% 2+CK/\
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M6D@F3[8IF.F*B:B2@IG,05$50$%43B40[:2I3"!BCU*8!Z" A@M!UZ=*57P
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M2G<H]GL]TGV>IS=GL%Z=I0# H;IT]U0##VA]_KY<*B=RC\+\TG\(! WP"]#
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MDNM/,'3PKU5>QG3,4I@3 B11 .HCGF+J^ZXLTZOLGER>RLK:XBEN#,72.>'
MEC&81A(%*,![]25)AN70MP@ BJ@-^%DX]^U?O;YKZV]#YW?:>W@Z+L?+FXRS
M<O=XH\*?A9./?M7[V^:^MO0^.T]O!T78^7-QDY>[Q1X4_"R<>_:OWM\U];>A
M\=I[>#HNQ\N;C)R]WBCPI^%DX]^U?O;YKZV]#X[3V\'1=CY<W&3E[O%'A3\+
M)Q[]J_>WS7UMZ'QVGMX.B['RYN,G+W>*/"GX63CW[5^]OFOK;T/CM/;P=%V/
MES<9.7N\4>%/PLG'OVK][?-?6WH?':>W@Z+L?+FXR<O=XH\*?A9./?M7[V^:
M^MO0^.T]O!T78^7-QDY>[Q1X4_"R<>_:OWM\U];>A\=I[>#HNQ\N;C)R]WBC
MPI^%DX]^U?O;YKZV]#X[3V\'1=CY<W&3E[O%'A3\+)Q[]J_>WS7UMZ'QVGMX
M.B['RYN,G+W>*/"GX63CW[5^]OFOK;T/CM/;P=%V/ES<9.7N\4>%/PLG'OVK
M][?-?6WH?':>W@Z+L?+FXR<O=XH\*?A9./?M7[V^:^MO0^.T]O!T78^7-QDY
M>[Q1X4_"R<>_:OWM\U];>A\=I[>#HNQ\N;C)R]WBCPI^%DX]^U?O;YKZV]#X
M[3V\'1=CY<W&3E[O%'A3\+)Q[]J_>WS7UMZ'QVGMX.B['RYN,G+W>*/"GX63
MCW[5^]OFOK;T/CM/;P=%V/ES<9.7N\4>%/PLG'OVK][?-?6WH?':>W@Z+L?+
MFXR<O=XH\*?A9./?M7[V^:^MO0^.T]O!T78^7-QDY>[Q1X4_"R<>_:OWM\U]
M;>A\=I[>#HNQ\N;C)R]WBCPI^%DX]^U?O;YKZV]#X[3V\'1=CY<W&3E[O%'A
M3\+)Q[]J_>WS7UMZ'QVGMX.B['RYN,G+W>*/"GX63CW[5^]OFOK;T/CM/;P=
M%V/ES<9.7N\4>%/PLG'OVK][?-?6WH?':>W@Z+L?+FXR<O=XH\*?A9./?M7[
MV^:^MO0^.T]O!T78^7-QDY>[Q1X4_"R<>_:OWM\U];>A\=I[>#HNQ\N;C)R]
MWBCPI^%DX]^U?O;YKZV]#X[3V\'1=CY<W&3E[O%'A3\+)Q[]J_>WS7UMZ'QV
MGMX.B['RYN,G+W>*/"GX63CW[5^]OFOK;T/CM/;P=%V/ES<9.7N\4>%/PL?'
MOVK][?-?6WH?':>W@Z+L?+EXR<O=XH\*N+^&HT/]$/T0?:;W3\6?2O\ 2Q\<
M>K>O?C'XQ]1_4?XH[GXI\T\P\T_/]OL][WODZ]GR9K>T9GGK;UMZML]KR788
M<<M*;7:XOC5K71WJ*WEKL6+"*THO2IGKHH281,(F$3")A$PB81,(F$3")A%
M;Q*N6<KPYXM36QJ<]K+/:]UO6N-*:7&XU^SVVL);*VK;(^NL9VPU2D_\L++7
M*%73R=EE&49_CJ\7"N"IB4?A 18]-=^..VE]3<=+;+Z'?6R7MFHJ+=.1<Q7[
M8UIK'5UE6Y=5?@YLJ(KU'LT6_M,S+0.Z9\9%K#O58]<8(AN\<%<@DFX(OC'Q
MP8^WV37<:QTW+T2 N-FT]:XJ7;V2L[3GK%I;9.W=[ZF*UL%*B%JY*:VV6H\T
M6^=JQ?>S"K0'"+<@N7(.$T"+LX[QR6TO'T6/C^,B7K_L^'I%YI$*_P"1>O6-
M#-K;9O&+</*BC2-MVEZOKQ57V$M2])2S"4K163U1A(KLCHO'C%QYX0BZ"W>.
M[4Y76-\OU TU:X"K'UCMA[K>Y6.8K<I>$MJZPX?UCF+*Q5RT-YU$2<10$Z%;
M$6;6>/.=P]ET03,BW9NV3YP1;LCXX$[:9*Q5K3O&.8?/Z_R2TII%C<-FV&2I
MU+L,);.9%>X?[,EW[L]7195:SL;3)J.H!HV?SK1PP/YR\7;KMEHLY%5NE_&5
M7MLEIVNSVDINPQ5SMFA:A>MJM+#7JMZL2O*#<O)G4NJ"1.KD#VJ2L:<9+<='
M 3 I2J)DVKU)P@5=4#M2D4I8?FW?[[S;XNZPU]7ZH;BAR!T)R5OT5>;)$;)J
MVZ)[86B[+J>#>QQ]=7NJ4AY0*?#DOJA06>I/7<TLH!TDVC= BCPBMVAXFX:W
MT;XC.[MPPL59B<-^6&TM,4S7^NBBTM]IIE<0U#&TL\LT>2$P[%\ZL^RNS)2B
M+;N&[$!6*U.*0D4(J!K'C65&1E-=52U\:MK5"][20GY"CUE5Z5<UO@-/W7<=
M<Y26FJ#,UZLSC^!T)6=2)SZ@/8V-?RS*QQ2 M63M55%$BCHEX\=EME:U+M>H
M\:+#$4V6:;IFK5KVPR(H678<'!<6J?R&U(.MKQ9V%$B8N4=GNC=G8$58R2(F
MLB=.*4E2+,7#LBS/\+N4<'S'X\U#>\+"MJNI.RMTK=@J3><=V ]3M="N4[2K
M%7GLA)5NG3!)%A)01^^;OXB,?M3F%%PV25(8H$4J,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PBX[MVU8-7+Y\Y09LF;=9V[=NE4V[9JU
M;IF6<.7"ZIB)(H()$$QSF$"E* B(] PB\V/&;QVIS8C7DC/W*AP%W;>MNA;E
MQ#I%.C;1JZP6O1/(_E5]DVG-KE9=E(K0%EL]1FY2M6>9EX-,\6,/;V:21!62
M-VR*^43XW\5,2]5@PXVR<8\"]ZHU1M@SW<=0(YHVQ-Q<MMP</JZWUY%.X)B^
MW55X:\:0FI.3D&P0ZC>,59@#8ZRCE-F14G1_'3A0U?1KQ9M*3]IAC:NUB^O-
MLC[/5ZG:7.W-G<2[IRZKL)6M-&5L<@YURXH]*.R?V0DPHA&RKDQ$VSMJR?.V
MY%VBWCLPB,3--AXT.C7RLTNQ[FGH0-\40*)]!E8XS:YY4OYJ!VH:""$G]NJT
M'9K)FG32-D@^,D5E#RA(P$Y)0BU0_C?0B&[$M.%TELS8[BQ[VG*HTDX:N/*R
M[IFLWMZTEK.G.UH=JSMY+'96UHW FXEDI)W60:QK542"J]%LQ<D5)Z8\:#;]
MR)I9"U<?*[*;)WQ ZPBJCJVF7Z.C:C'W+:'(WEKIZ EY?:\VE)R+6);Q/'(A
MY-F$"NLT45,JB9<RGFB9%>;<'BQ1-EX243D+HVW5/1VQ+MKW3FTUJUO?4FT-
MDE69;AC)%&EZ@U&%2>:]H>Z-Y7C8)&4&PC65J;E9LU74F]301;&*!%))MR\V
MS!\@_#[U'M2.U91 Y*<2]Z;@W:P:3B4RSK&VM71_&Q5&LZ_NX3A8:4J[23VM
M-I&6[#P7R#9NJDL!2F,H118'QT-71]PW:2RZ$V77-,:(V;)4^];S?NET:W6Z
M/4N0#KC1L+:5KCW]7CD(V&J^QS,W:36-?S2CBN+K/7"K)RT68816OV=XZ<RT
MKVY*[3N+E]H^R:5Q-MNYF4Q?O/)ZOT3:"O$":Y@Z_J^PH>&AHF-<5):B(L&L
MD[;SZ,DC..3,BL!;)GD2D4W.%?B4LN5^_=O\<Y?5RFM[9J>L'LL;*/K@TEU]
MF0D+9T*/:+9!P+"$"'95MO9G*!4S,9V=4:>=)M9+S"0*HS*192<(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB8112Y1\MZ+Q/6T<OL.,DE:[N3:4_KE[96
M2B?F5 85?1^W][3]TG694G$C)Q$=6-.O4C-V22KLZJZ8D(;H("168A?%5X56
M5@P=5N^; L4G)V0U?9TR"T%OF6V2HS)KJF[=/>3:S8ZW7OJ>L"ZNV'!SWK*:
M."%&/E6Q@<"=0"81<&?\6S@55YN5@Y[<LE%JP>R;MJJ6E'NK-M-:VSL^L;*P
MINT7HV=Q2$H%S3-86V881MAL"+A2$B7L@V2<.B&5 ,(NEVGXFOAX5N?NC7:U
ML5/<^-&Q*FR+$6+1&SI:Y0M]ODGL#5U6G]2Q3K7SJ;L2\X\KEEB$9BOD734;
M).0!<6K@AER+N:-O[PU]J[[?Z#J4-J*9W3=XP+C*Q4AHP\0>U2LA'TCD?)PD
MO8[#18Z,DMG1[&:K]VE8)TX&=8K';R#INFY0,=(BQ!<=^0/!G1W)WQ )^.XZ
MR1MD:7E;-9+=+\@-U4.6VM#*:IY"+,:_/.--SU:1VG3J]=KQNAY8Z9>4VUS7
MDHI9$KR7C^K)GA%,B];7\%N^3E>BYZKTY.)T5MBR;-BJ) \8KHWU;MS8.S+A
M)\'9"UL*K&:B7I_(PLWMB[J59L^C"2W:GT$U"JB1N"F$7 VSXC/ UK-QMGH7
M%RL<A;-R 8<?=$,Y:)U$UC[C9*GO:T;VH,A0]W-[/K$;32]?:\-QJGVDC$3"
M;H5G+$[,&"?<&/A%?#7W*[PV]HUVR6@=/TV3D=FZAUSO'?+NG\6[5MBI/NFN
MZ_ONDU38^S:CIY_6+KLF%IKYA/0L,_5-."D9LNU:$541()%]KG._PH10ULZK
M32B-/766JKN +$\8;<DI3I:D<B;!HJI2EZ4C=7F0U<O1N35N?0C!U,'8?%U@
MG#JMSE\^,LJ1;&EO%:X?\@-IZI>2%$M&NGMIU^+S4^T-RZ]4KL]'2>P]Z;?T
M>YUNFLO%/Y2C)W6:XVK/3/EGC>$DBE8M3KF>D(@!%WU_W?X1^O(.O<N-DT_C
MO5V_)34-JVE%[MLG&]JVM>V-4S2FNZ;:GDS85];&M\VC:&&U8%%Q&2 B[DXI
M[W@MU6B*YTB*A/O"N NN=H:SU=K;4$+8&U2V+7./.D9W2NH$GC6@67<<MR*A
MKPQA8R.ID0.N=9K3O%.:;/I6(6783RC<%BIJ-&QW($59<(]Z>'7S"T$XMFO>
M/^KM:0\-K2!W;M'5%YT!"TQM1:_R3H$B^D[0X&7HD)5+M7-AU:K24>_L4,+Z
M+G&\2NBHNJFEV0(M'!/Q'^*&T]*5-.LZP-Q&A5-VPN@M8:0=UB'BRN#[(U,I
MR2TO8(*NZVC58"KUC<.CW9K,Q[Y-JFW.#AJN8':9B&(KMQ'BM<"9LYR,]\-4
MA1TB7DLZ^,J-LF)*QX]JT:/V TW0^-)5!J5KKJ2B91!DTDCB"+N?,,,CVY8A
MV92+D-O%%X;.96#K);GL4EYF@V@9SK4W'_?9MG5!'3$-4K'LIQL37J.ME;;K
MMM6Z_?H)[WDRT9%>-IIB=J*X.4NT12/XY<E].\KM>+;0TC97=EJK*V6FARXR
M=>L-3FX"Z4F44A[36)ZNVF,B)N*EX:03["B:J!0$IBF*)BF 1(K\X1,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A%%KF7R:2XB:$F]V#0I39[UG=-2:_@Z-#
MSD567D_9]R[8I>H:LW-/S9%(N(9(V&[ME7*ZI3%3;D./01Z!A%%.G^+GQF;N
M7-*Y##-<;-WU_<5FTA>]369,]^]3[+6E=6@-O?WK732=JK;4<PEO"H>:6604
MC&8.)U)LX*@X2<)I$5SWGB>\/&3<CP;CL1ZQD]L1FD:3(P^@M\3D7M?9$O)7
MZ%9PFFY6'UP]CMLMBS.K; U7?0"K]BU4BU#++)IG144(J'FO%G\/.4UGM*Y/
MMK.;=KFAJHP>Q/,-0[2MC!:HV1A?!3NIHAE1I U@TY,Q^N+&F%D226K[KXJ<
M(%<'4,DFJ14U+<X_"O=O[G$R!]=39.)M:HM>!^3CS8YJNTQA-6K4)]>ZSU-/
MDURY@I2><7B4HYHRM5U=5V$D2-50;=MD"C<BA[SFE?#SC=3<:/$[B==R6U=?
M0&VJ-%T!G79P-/<?*9;/I>N.P5MJ<@%GM#EY'34'3=Y1;X]JD"L&QWMI,V:3
MR#H.HHD5Q5.5/AP;/UZ>,V?I2AZP>7GBYJ[5M33T]4ZMN3<,=J_E#J;=TS,Z
MVU/.\9JIL!1*B4W6&M+'+FDJS(O8-*'15>*D:=V9(Q%S8SECX/E2TFPU;KNE
M:COE+UKKR1WG0Z[/\>9:+UU/6ZA<6HCDS&3#K8-BU&-#8;KL''@&EC,Z5$UA
M4CBJJF2,H@HB!%TU0\2+@=>=IV^7V%QDJ6NH33FX]SO:KN*_:O8N[E9=T:\C
M./25^NVGJJUUH\N,[;;3:MR5F$9/XYQZP33DC'H@85FZ92*3H<EO#1UY<].1
M<CK:MZKN>X'TA;->+V?B'=-:R+:Z0TYMFRKM9N2G=3P:M,V:%F@;C((M'YVL
MJH\4=.B%$9%)5T11UV5XA_A67[6FK=5-=$1W(?6SQ6<>ZXU5)\37J>N*>UK'
M%&Z<IJ/<$ZCM/7L/#52E7W3L2Y"NSS*.48J).US]XFT;/U42*06K-K^&KSFJ
M?'2D2FE])7V:6H-C7UOH_8>@8*X'THQHE'TY.;#J$:QL%"<UNCQ53A=HU%H1
M=GYI%RR3QC\7G<H]WV2*V]GYX>$FUJ>][#4V_'V\VJW:IC;/M&F$U 2'E=L5
MMWIS;.X*M ;7=/=;.%7D,77FDK$H]&<0=(P"; 47B2*RK=!8BM;:O%#\.22W
M)+*[6XVR38S2+Y.Z1V7O>Y<:75I2A:3Q^@=&.=G0[]_&T.QVV<X_R\1R!3!S
M(*E1@FK%DNI(I().FX*$4G.4_*GBOX=&T-3R<?QWK/K9REM#?Z8-E:HJNO*I
M*T?3]=LFOZ'+[ZW-/-V<=-VBA4JX;8K4>8!4<N"EDA52#NVZW0BOG</$:X=4
M,+$:T;=+'IU&7WK#VE5*EW^01KRO&:S:]J>^I&75CJL[(RK^KI7:4*>5DCB#
M%%BX4> J9HU=+(D751OB8\,IB2UBPB]J2+UKMQA29BIV1'7&S0IC2#VI>IW6
MFF[!<[DI3R5K7L#N^[5MVQI3R<<Q[>T]@BT<9PW6054(N@I_BI\)[T\TFA7M
MB708[D5;T*+IJTS6C]WU:EWFQR$N:N0;:)M]GU[$5\6MFLB2T=&.3N"MWSMN
MJ5(Y@+VL(LB6$3")A$PB81,(F$3")A$PB81,(F$3")A%&_DCQ4U#RMA:9 [?
M83DA'4*P6NS5XD'//(%5&5N>H=E:/G%'2K/X3I%2A;9F$DR&\B;E1)8/A)%P
MBC8Y\*OBQZP-KE7U]RT.\M35)JC?-<[DNM&NB=9JVD-<\>G%)1LE<?,9)K5;
M;K34\ C*I(G3<J/X]-\W7;.P!4"+[</"CX<7D=?JSM0LZCS6VV-X;<KTFC;I
M#XS4E.1NTVFY=PU>2>N4W*SFF6R^QC-R+8@INFJ;4J3=RD11P"Q%;9;P4^$/
M3=OF$;MB&-OQPFM>31>TIP@&31VE<MPHL$$7:3QM+1A+EL"8$S>9)*I*M'1&
MZ@'3:,@;$5Y=!^&#Q!XR[?BMU::I$Y5[5"T:$HL>Q6MLU-0A$H'7U4U2ULSM
M.96?3$G;5]=4F-BUW+IZLBH1$Z_<@[<.7"I%:'<GAF<,V3'<VZ][W3>$[18K
M7>[)!PWOVY;18JKH:@7ZS0>Y-WJ:M%XDZLE=B9V7H+5R9LX>R2$6T0,TBTF3
M8YD1(L17'ZL^'M!\L)E?9G*"Q6 K_DRWX[Z:T,RUQM_5L=I;:NNMY1?B>I)3
MQ[M=[BPK5+K$\SCTWKED2,KJZJ;QLKW8F29,"+))3>.WA&04GK2TUK?5!47M
M$^VV?K=XKR.A%V5G>:-O?*+9;^4BQ5F"H24;5+-R5O1Y(H#V")$(DKT!AY"*
MGJEQ!\)"TU:(TAKGDF#VA[UUJUT*PU/KOF%()U3<,AIO7=9TDWMSFKUBV$97
M?:=0H=5B(E5TL1PT7,T;*+M%G/85$BJ2@\&O"YK-@V]HBI7B1D;IIFIU^V[<
MI3?9TC(6.F5IUR@'FHPDW<5%M$R))J;OI2CY=LQ1,+-D8& HH(+MTS$6,O:4
M'X;&[.,[*DZ"LG(JDL>6I":KJ$_/ZTV)L>96T11=O.><\XZT ^:W2GP=>E8^
M6W JXKL\O,2+BMJ.OB]_'F=M#LB$4Y.37(GP>.12.I=&;G:V:<-QBY';SU%0
M=9U^A[ 9.ZSL?BWQXG)+:E;>0T1&BI+:X@=53HF:'-WD7)RK)J1J99VT(4I%
M,'7WA:\*&-5TU*ZP:W6/AM?U;BT?5-HK.R)KOOB'C;#[;3U7,$D1%9.</:X#
MD%:"S[AP54TZG,'45Z*E34*17&JOAL<9J3JG:&FZLTV!"T_;W%[4W#ZX*,K]
M,ISQ]):7JM[I5+B(F<#_ !R(G"US8\JW=R*(@Y<]\4PB!DRB!%0#GP@>#+%^
M]D-:ZVE-!J.I/3-B;MN/UD>ZDC8FY:(8;$KU'O<3%U9-K'M;HM2=JS=?DY 4
MSK24,Z(BMU.W;JI$72PG@U<(84C5 ]>V=--$./#;B2NQG-N75ZRD.,D?08^C
MQ&DWK9.0;)^I\'(QJ=I9'1!*2:W(QY@CH'2AQ$BK%+PJ>)ZS#8"5A;[5N=AV
MWJW>.I=KW^V[7MDGL+8]?Y!(:H87R3M%L2=-)!2R-X/2-9C8IRV\V)&1\85!
M)/LJ*]LBD1Q0XDZ@X9:WF-5Z5:SS2JSU^M6S)0EAERR[M:W74[)>R/&YDFC!
MG',GSMD"Q&;9%%HV,<Q44TTNRF4BDWA$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$5A.2_'+7W*[4$UI79SBU,:K,SU$M)9.D6)S5+9#V36MZKFR*7-P4^T
M366CG\-;ZHQ=$,!#%-W79, E$0PBAR?P@>%[N7U[;)BO[ L>Q*-?[7LF5VC9
M]B3=AV/M*R7B?H-EM7TJ6F6\Z=V*.DY+5E=(FBV!B#!A$I,68MV*CANL17#I
M/AK\;Z!9*;/0#G;HQNL]T!O35-!E-N7*5UCJJW';;;2>1VOZ"]?*UZOUJ1=;
MOL+A=N5(ZYA7;H L5FR:-D2*/4MX&'A\RU!F=8C1[U'4N4N#NUM(:*V#+LV]
M>:/JKL*FKTZ$3[I1+U6) [3FR("[*[E&BSE)9!ZDJT9G0(JFLW@O\&+G8;A:
M;=5M@V>9MVNZEK9-Q.[)L,HG5(NDR&LIJORE4;O#JHLY5C8-/5Y^BDZ*\C&J
M[-4C9F@@\?(N2*2$IP:U2IH#5W'JGW#=&J('3,XRL^O+QJO9TM4MD1-B0"?+
M(R4G-$0>0=M:60EJD@DHN8C7\*Y\[$?,RBBW%$BP,\JM,^&OQZ5AM$:2W=8.
M->Y=<Q]T(WV5,P.[M@L6T%PZXV;*N>[H."N]%N='=1^Q)#6',>3>394WSD+"
M\?K1:;0'9$Q9D4CM*<9?"&E.*5)A9;D)%RM>B] Z\V=>)BV[6;:RN"-4VYP1
MJ'!&/O=UH#Z3+*ZV&Z:%G(]NC&.2 =C-2;90.TX51[PBN[:..7@ZRA+''V#?
M^MO.8"-V3NB04:\GH9K,4U+>KCC1*+;2C7478DI&#=,IO4NNY*M/B& &KU=J
M=$%2R!2*D78[2X6>&*QOW&#>VYMY6V;O=[=4VC:-V/L'D7/6]]N6P(M-KV^L
MR*=@F'DL$B5Y#[0L)>TR580(MGC-OW)1;Q1$2*P.VJ)X3>C]H;!U-:"\A&5H
MXI:1H4]LRR4P]\L,11-<ZEX0[!TY 5*T/H9N^<F"X\4+3+).%UF7Q;*2"B21
M'R<OW382+HN.6W^!/!S?.V.1E^O]NJ#K<G%E=#2E.G-/7F&=TOBUX>VK:C%W
ME>2DU+3?$;QN"[PR$(#YTU3B5K$E6(UJW8&78F.J12+X\>'MX5_)%+<&Z=+T
MBTJ/MH0G).C[$=O96W5><91?/K7]$V1L K*%F4T',"G+:QO#!:KJHI@E"QDX
MZ1:]D%EB%(I+V#PF.(5F=;66EHO8ZS7<-3WI3;3$%V+-EBF43R1J&GZ9N-2M
MMA RD(^MT?HV <&4(<Q6[U)95$I.^,7"*O>17AH\..6=HG[AR)U-&[8F9C0Q
M^.L0>W*%E4-?41Q*S,W(2NLD7*)_478$I*2R2SB?8BG)F&-8 "I0:IAA%:>0
M\'_B1*SMQG)&0WL[]?H;9L!:X=7=MP"#DXK>JNJU>03<K BY!9'WZ.GXLML4
M;G25D$EWJ29D$W:A,(JHK_A3\2JT[UF:.8[0/":OC-;5YA37NU[@\IMNJ>BM
MAV#:/'&H;&@E7PHW>N<<+99%QIJ#PQCQ[)%LS<'=-6R"1"+I$O"&X:(6GC!<
M4(/8*<WQ$K6I*IIU4VP9=P@SBM'["DMFZZ^.T7:;@)%U&VB;>B[43%O\:MG(
M)/0<%;M/-R+)]A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBL]R%
MT]%<A-#;FT3-R#B'BMQ:OO.M'LPT3!9W#I72M25?^-VJ!E$B.'$4=^#@B9C
M10R8%-\$1PBQFSG@A<0]BW>Q[:VPOL6Q[-V2E8W^UE8.UHP--LEAOK^T3%]<
M1$(6&7E(*.DWMS>M&HD?&?M8E-NV\Y/W0G.1<=_X&O$R4AJ+ O[_ ,@5(RCL
M;BEYDUM&N(J-L\Y=BW1K+W6PP</JIA (748:]NX\\A%M8U1ZS;LRO@=&:I'
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M3:J[R<H5SH+*%@E-8QYJE'WW4T_IJR$J=[=ZRD=K1]:D*Q9'3Y:K+3[FGN+
M)9-:*4<@)C$5&7;P8^+>THG745M"T;0MP:L7.:GKQ;#1NJ6[1BO>J3?GL2[K
MND=*:TJ+]G+R-)(SD#J1PNI*-?O&[I58%$C(D4M.)'$R'XIL-DQL59'EE;7*
M:UNU@E'R)4WL)K[36BM7:!UQ 2CE,2(S5@2K&L4WLE($1:D=/WZO8132(F4"
M*7V$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3"*"_.?>.[M'P&FW^DJV%A>VO;T-7+>52B6.\%)531TB]7CFB-=<H*
M1TU//&Z35D*W83<+'[H%VYC IA%"=KS9YPJ3[!FEJA.2!7:<U!MX4-,[ CCS
MTLA*4-E(Z%";<21FD&^HM=L,U,GNBQ31<J$(*228 5;M$5\*!S,Y%0G&-]O3
M8.BW6RXRJ+7>6N-FAS):+=-ZC5HNO2[E^PUSLA9[.2#F.DI"8B !-<A7)X$5
M@$/.2]-[D64VF<W+;*6Z%O=22-9&#&YX<7:!4M^**T&GOU6">5\+<;6XF@5.
MD"GPZUE/*(&*4P>X8 ,'7\@AU#-$LZ^X1,(F$3")A$PB81,(F$3W/=PBT=ZG
MV2G[PG8/V.P?ME[!^\$ 3[)NO0W;$0Z=/=Z^3"+7A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB818W.8')'=&JMM5J@Z=DJ\[D)73&T+LM5K!I_
M9=D8GD8&JW1:N2@[%IQ9=L,P>UQD:#:M-HIP[<QC:5765((QZ:A%:?CMRTY@
M7B\1\!8M7.;>W+IR9L:$.YH4KJLUPE8E6")#;&B]BSJZE1C:OL">?R<9%1;A
MHA(>81J+]9)$RRJ)<]M'#+<,CN9-E 3PGX2["._A&D^\%:XD-):*N[VI9 >/
MVZ)+=4!=7L]0'VM+-K[9=EUA9ZL^L,/:BH3-;:0[]1XQG8,",7K!ZSG$3$'L
MD.4W:*8H"&;#.,KCRN:)L,PG@F@;*UX:6<%Q<*%KM((+2L<,IE!);A<UQ!&O
M4K]9J%F3")A$PBVA61!8K<54P<&2.L5 3E!8R*9B$.J5+KVQ2(=0H";IT 3
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M<YHM:N&R/62*-,/&]2F8^-D)E:ON'BA4C*=MR<I5SRVW-JR0$,U$'%0#52I
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MUH,,TK]2\/6!AXAA=HS8K)H3DDX>"UN$&Q;Q<!*-W,AJUV[21KL0S191S,%
M91[%!)LW1203(F6KO:JZEWG$Z?>,FE/W;;ZCK_\ ['NZSWSI3_M\=>GI>[//
M+G^XJ]QO';LI"F./#E'H4!,/_6*9=>@>[T__ $[[N83[4?4B!7:[Q:/_ -;!
M_P"HJYO^'QU[.(:+O=FI_P#YES_<5E?CMH<R)./823?C#I4&\BR9OT 4Y6V
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M&B:098L^M<I*8LZCA=R8ZJ0O'*I_-E$^R()]@I>QWR,IN;(SNB?+ZNAJ8\.
MZ7_%P!K-6@X1KKW:J'9TPOH"!M#KK7N:ZZ5D"SCE,7E0_K47\S'#[]<&POT"
M0SVA]F#]]9M^J1?I5.L?C.]Y>,'/<=;)=?*?\!4_PS'_ "]KD2^_X5W]9GX;
M51VI=B;W1_A'^WDLZU5:1]P?X!_M81?I_>%Y_P"'1PG_ -FO4WZ)1V?,_K+_
M )@YS\XS_I"M)/\ EG_UC]=3PSAUB7F]\;G^>'1?ZM;1^E#//0_VM_XIR?\
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M'^UO_%.3_J$OZ9J^M_\ AT?P#O+\[V_[.Y84L]3U]#TPB81;*_\ $J_X,_\
M:',<OQ#[Q62+\HWWPO>C3?\ -"J_Z-P?\F-<^RN5_NRV_L(_P OS*;P?OZ]_
M6YOTCE4F3UJ$PB81,(F$3")A$PB81,(F$7P1 H"8P@   B(B/0  /*(B(^0
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M3>,@[)52+TF:J29H:OUNA'IM$F"-"IZ3%)@$>5BFS3KT<1LFS+$Q,#%%:$1
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MP$IM]*/F6<U/5N1C):.M%?8V2994&W*R,),6"&>25LH2$;(NU6KUPDJX<G.
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M&DB F(<'I3)D(F13.XHZ<GN/W'O6&F[)9 M4I08$\*$F28NU@;MHXL@]<P\
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MK$ZC)M)(*G$JZ:)C)$5 P$$2@ X1=SA$PB^#Y0$.G:Z@/D\GE\GN>7R>7"*
M7A\1D?#53DA%Q.N?HDCFG+G;I6NN>S6"A5B*1-(7.V M,DYJK%!\JJ9YT9NE
MDP\Y^$(*=LH=?OC(^6XLI))^4O.70UDX?#TOT\,-?HU<(#5WJ*'9@!KP!A&T
M.C1HU=[0I_9R"F)A$PB81,(F$3")A%YO?&Y_GAT7^K6T?I0SST/]K?\ BG)_
MU"7],%];O\.C^ =Y?G>W_9W+"EGJ>OH@NBF_XVN_Z3,?\AE,E6VJ;]7=^$Q:
MW,OCVOZXS\"5=[D4:ELSK6RO_$J_X,_]H<QR_$/O%7Q?E&^^%[T:;_FA5?\
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M,QAK=D]HH0:FM351&^Y'TY_SV;4_^W4ST-GC+LC;K=+YCY$'FUYU_P"XOO\
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M;V6<4U1E0]A*%B+G'RS_ +5<!/N6",7--E5P!1Z45.PL[3#LE[1Q[7D 0 1
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M&DC05LA2=AE3[HM)V 5$"F+W):I:BH]DZB2IR]T$<!.R=9 AQ#IT$Y"F'RE
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MNZR6M<F$7__9
&

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>img222477878_26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_26.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #^ A0# 2(  A$! Q$!_\0
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M)Q19^"M%L0!!!(H$XG4&0_*PSC'MR>*MZGX<T_5FG:Z63,\8B<J^,J"2/YT
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MK-TO0K'1Y9I+-'5IDC1]SDY$:A%_05I4 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI']J.%G#!Q\J]=W-;]5/X@04445(!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4R:/SH'BWLF]2-RXR/SI]5M0O8M-T^>]G#&*!"
M[!1DX'I0!S7A'3]#TN[NH=&N[^57=GD$D)$1;/)#[ I_ UUU>>>#6DMO$TUM
M-%M\^$W$,F7)D4G/(\UE'_?(KT.@#)N/$FEVFH36=S<>2T"*\DD@VHH)P/F-
M07'B[2H)?+6228F$3*8DR&!.  >Y)J;4?#>GZK=2RWJ-*DT(A>(MA64'/..:
MAN?"EA<"(*TL2PP"&(*V=H!R#SW!H MV6LPZ@T0MXI=LD7F!V  7G&#SP<U7
MT'S_ +3JGVCR_,^T\^7G&,#UJW;:19VNG"S$9>,)L8D_,PZ]1[UG>&(XHGU-
M(8)($%R<))G(X'N:M?"Q'04445 PHHK@/BOIGB_5-!MHO",\D<RS9G6*41NR
M]L-QP#UYH [R66.")I9I%CC499W. ![FB&:*XB66"5)8V&5=&# CV(K@-2T"
M\\5_#Q/"NJ:Y;QZ_Y"-<%'#'</[R@YQ6Q\/?"$G@GPM%I$U\UY(KEV?!"@GL
MH]* .JHHHH **** "BBD=UC0N[!549+,< 4 +14,%W;76[[/<13;>OEN&Q^5
M34 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <#_96J#Q)
MYW]EVVPWPDV;!Y.S(_>;M_\ K._W.OYUWU<)'I,>G^,)S;6L=^TUPMQ.TEJ<
MVQ;IM<' Z9Q@UW= !2'.TX.#CK2TC<J>,\=/6@#%\.[_ /B8^9.L[?:SF15V
M@_*O;)K;K"\-+L745^RK;8NV_=)C"_*OIQ6[53^($%%%%2 $@#)Z"N7TCXA>
M&M<\1W.@V%_YM];YW+M(5B.H4]\5TY 8$$9!X-<5H/PM\.^'?%=SXALDG^TS
M%BL;OE(RWWL=^?>@#MJ*** "BBB@ JO>WT&GVS7%P9!&O7RXFD/Y*"?TJQ10
M!@-XST1%+/)>JH&23IUP /\ QRA/&FB2(KI+>,C#(9=/N""/^^*Y[XP:WK.A
M^"FN-$+BX>41N4BWG8>OT^M,^#6M:QK?@KSM:9VFBF,49>/8=@ QVYH [JQO
M[?4;87%L9#&3C]Y$\9_)@#^E6:** "BBB@ HHHH **** "BBB@ J.>(3P20L
M6"NI4E3S4E0W<<DUI+'"^R1E(5LD8/U% '$>#;^P_MZZL-/2<QJIW22VB(Q8
M'H77'Y$5WM>?^"];^V>(KRQ>[FEDA!4AW9@2.^">/QP:] H **** $/0\X]Z
MP_#C!IM4*W0N1]J/[P8YX'''%;IZ5A^'_,^T:IYL,<+_ &H_)&^X=!WP/Y52
M^%B-RBBLOQ'<S6?AO4KFWD,<T5N[(XZJ0.M)*[L,U*Q+CQ%)!<21#0=8E"-C
M?'"A5O<?/TKP ?$7Q8R[AX@G(]0J?_$U2A^+'BFYF>*#6;V1DZX6(9_,5V2P
M,HM)R6OJ.QVVF>%ELOBQ<^)!%X@D?F?[']E7>-^1\S>9@KP?RKUFRUZ2\ND@
M;1-5MPW_ "UGA0(/J0QKYJC^)'BC^V)I5U6Z^TM$L;8,6[ )./UJP?BKXI2Z
M2WEUN[CD?IN$7]!2^IO^9?C_ )!8^I:*^9Q\0O%Q(_XGMSU_NI_\37TE:.SV
M<+L<LR D^IQ6=?#2HVYGN#5B:BBBN<05C^*]*GUOPIJ>EVS(L]U;M$C.< $^
MM;%4]5U.VT;2KK4KPL+>VC,DA5<G ]!0!YS\(?ASJ_@)]4.ISVTHNA'L$#$X
MVYSG('K7J5<MX0^(&A>.#=#1GG8VNWS/-B*?>SC'Y5U- !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% '&7X/\ PFL(58C, GF-@H=NXX_Y
M:#=^1KLZX.7GQG]I74+28M*D30B(JZX)[E6!(SVQ7>4 %(V-AR2!CJ*6D.<'
M&,]LT 87AAHFCU P32S1_:VP\I)8_*O7/-;U8WA\7 .I"Z,1F^U'<8@0OW5]
M>:V:J?Q"04445(PI@EC9V174NOWE!Y'UIS E2 <$C&?2O)O!GPPU_P ._$>_
MU^\UB.:RE:0JJ.Q>7<> X(P,?4]* /6J*** "BBB@#B/&GB'5-(U&WBL;@1H
M\99@8U;)S[BN9_X3CQ#_ ,_J_P#?E/\ "M+XC_\ (7M/^N)_G7$32-%&62%Y
MC_<3&3^9 KY_%5JJKRC&37S/L<OPM"6%A*4$W;L3>,/B5XFTO0GDANHF,A\L
MAX%Z'Z4WP7\2?$VI: C2W<2^2WE*%@7H!QUKB_'5W/)H 5K*X@'FCYG*8_1C
M2> [J:/075;*XG'G'YHRF.G3EA6W/4^J\W-K?N<OLZ']H<G(N7EVY?\ @'JW
M_"<>(?\ G]7_ +\I_A74>"?$&IZQ>W,=]<"14C#*!&JX.?85YE#(TL>YX9(3
M_<<C/Z$BNZ^&W_(2O?\ KD/YUEA*U5UXQE)OYG3F.&H1PLY0@D_3S/2****]
M\^/"BBB@ HHHH **** "JNI07%UIMQ!:W!MYY(RL<H'W#ZU:HH YG1='U2VU
M<7EU]G@C%N(I$BD,AG<?QL2!C^==-7">$9-6A\07=G<07J68WNBS.7"9/3=C
M]*[N@ HHHH 0_=.?3M6#X:,)DU3R#*4^U'F7=NZ?[7-;QZ5B>'S(;C5#)-'*
MWVD_-&,#H*M?"Q&Y6#XUA-QX)UF(.R;K1QN7J.*WJQO%G_(I:M_UZO\ RI05
MY)#/DG2].:PBD5Y1)O/0=!4UKIUM9RO)"I#/ZG./I5L=**^AC2A%));;%F?'
MI$,>HF\#MDG(7L#3I]*M[B\6Z?=O&"0#P:O44>QIVM;S"QF:I9WEU)";:7:J
MGD;L8/K7V-I:R)I-HDLGF2"%0SXQDXZU\FC[P^M?6UE_QX6__7-?Y5YN84U%
MJ2ZB9/1117G$A5+5]+M];T>[TRZ+BWNHS%(4.&P?0TFKZE;Z3IDUY<W=M:QH
M.);I]L8)Z9-<A<>,=4'AG4-=TZ\\/:E;64;._P!EE=LD#.,]C0!H>"_AUHO@
M0W9TE[MS=;?,^T2!ONYQC 'K76UY1\//B9XA^(+7RVVGZ9:?9-F?,>1MV[/I
M]*])T[^U<2?VG]B[;/LV[\<[J +U%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 <;?">3QHLK)(]FBQ[)/+=T5@3N^97 7MG(-=BK!E#*00>
M01WKSL:UH6J>*9-/?PS:S73S$><S1X*J^TL^>AR.%Y)KT15"J%4 *!@ =J (
M9;VUAN8K>6XC2:7_ %:,P!;Z"FI>VEQ--;Q3QRRQ#]Y&C LOX5CZMH%Q?:[;
M:A#+$$C";E<'/R/O&/J>#1:Z/J U74+ZZF@A:5!' ]N.8DR"001@DGDGV% #
MO"Z11Q:@L-L]M&+ML1.,$?*ON:WZPO#)!34"+K[4/M1_>\?-\J^G%;M7/XA(
M****@845BR^%=+FE>5_M^YV+';J-PHR?0!\#\*Q-.T'2[GQ!JMH;F^=+<1[(
MQJEQE,@Y_P"6F?2@#M:*Y&+4/"&@^)X=)_M5X]6F7"6\]]-+G/3AF*@GMGFN
MNH **** /-/B/_R%[3_KB?YUQE=G\1_^0O:?]<3_ #KC*^:QG\>1]SEG^Z0]
M/U,S7-&BUVP^R2RO$NX-N0 FC0M%BT&P:TBF>52Y?<X -+K>LPZ'8_:YXWD7
M<%VIUHT36H==L3=01O&H<IA\9S4?O?9?W;_B:?[/]9_Z>6_ TJ[;X;?\A*]_
MZY#^=<37;?#;_D)7O_7(?SK3!?QXF6:?[I/^NIZ11117TA\.%%%% !1110 4
M444 %,E:187:) \@'RJ3@$_6GT4 >?>#[*TM_%%U<+.YEN4:1(S<;QUPV/E&
M[GN2:]!KS[PL()/&EY-86^IBWV.)9;M(_+9MW_+(J.GXUZ#0!634+62]>S28
M&XC&60 \?CTIMQJ=C:.R7%U%&RIYA5FYV^M<_J_A&36;VX:2ZCM;>48+6R%9
M6/JQSC(['K4=SX*),!M;B)6AMEA#O'R[*VX%L=J .EAU"TN7$<$Z2LR>8 IS
ME?6LSPX LVJ 6HMO]*/[L8XX'/'%+I_AR&QLTS,Z78B\MIX3@CG/&<_K4?A<
MQ$ZEY-V]V@N2/-=@2>!W  JU\+$=!6-XL_Y%+5O^O5_Y5LUC>+/^12U;_KU?
M^5%/XT,^6ATHH'2BOI#0**** %'WA]:^MK+_ (\+?_KFO\J^21]X?6OK:R_X
M\+?_ *YK_*O,S+:/S)D3URWC;6;_ $:UM'L95C:1V#$H&R,>]=37#?$K_CQL
M/^NK?R%>%C).-"3B[,[,MA&>*A&2NO\ @' ^*]5U?Q9X?GTB[OD6*4J21"O8
MY[5@:2FI^$/!6K:79W$=U'<*SM&UL&#9&,8.<UK.BR(R-]UA@\XJD=*L$4LR
M.H'))G<8_6O$ABZJT<F?4U<NP[=XTUMZ?A:QE_"[Q!K6DC41!!#9K(5RPLU4
ML<GC..<>G:O1?^$Y\0_\_B?]^5_PKBH=,TMP1!A@#DA+ACC/_ JN6]I#:AO)
M5ANZY=F_F:JMBYSFY1DUY?TR,+E]*G349PC+S_I'H'AGQ7K&HZ_;VMU<H\+A
MMRB)1V]17HM>0>"_^1JM/HW\J]?KT\NG*=)N3OJ>%G-*%.NE!)*W3U84445W
MGD!1110 4444 %%%% !1110 4444 %%%% !1110!PUE)=P>*RE\=%FCDD=(E
M$T8FW[\@XQDD*0,=:[FN9/@RU-^LQN9#;K=?:UA,:Y$FX-]_&[;D XKIJ "D
M.=IP 3[TM(V-ISG&.U &+X=$@_M$2PQQ/]K.4C.5'RK["MNL'POY/E:A]G$P
MC^UMCS]^_P"ZO7?\WYUO54_B$C!\:N\7@O5WC=D=;5R&4D$<=B*^:O[5U+'_
M "$KW_P)?_&OI/QQ_P B1K/_ %ZO_*OF'M7J9>DX/U+1;_M74O\ H)WO_@2_
M^-<WI,T\'B"YFBU2;SCG<R2L&?ZG/-:9M+9B2;>,D]25%9UK8:8+^3RW620?
M\LCR%K>K!N479;]QLM7&G"ZU4:A+<S--D,27))(Z'/6NFT;5-1.N6(.HWA!G
M3(-PY!Y^M8*6\$3;HX45O4+BM/1?^0Y8?]?"?SK54XQ3:6X'U>.@I:0?='TI
M:^=(/-/B/_R%[3_KB?YUQE=G\1_^0O:?]<3_ #KC*^:QG\>1]SEG^Z0]/U*>
MI:7::O;?9KV-I(MV[ 8KS^%&FZ5::/;&VLHVCB+;B&8MS^-9OBX:D=&_XE?G
M^?Y@SY&=V/PI/" U(:.W]J^?]H\TX\_.['XU/++V/-S:7V*YX?6N3DUM\5OP
MN;]=M\-O^0E>_P#7(?SKB:[;X;?\A*]_ZY#^=7@OX\2,T_W2?]=3TBBBBOI#
MX<**** "BBB@ HHHH **** //O!]W.GBB[TX7#-'&KM);F?<+=MW  W'((YZ
M#%>@UP'@NZN8]?NM/,D3VP#ND:6X62'YCQ(V>I[5W] !1110 '...M8N@F<W
M.J?:!&)/M/(C)(Z#UK9/0YK!\-+$LNJ"&&2)/M1^20$'I[U2^%B-^L;Q9_R*
M6K?]>K_RK9K&\6?\BEJW_7J_\J=/XT,^6ATHH'2BOI#0**** %'WA]:^MK+_
M (\+?_KFO\J^21]X?6OK:R_X\+?_ *YK_*O,S+:/S)D3UPWQ*_X\;#_KJW\A
M7<UPWQ*_X\;#_KJW\A7@XW_=Y'=E7^^0_KHSR7Q%J<NCZ)->P(CR(5 #YQR?
M:LK2-2N_%OAN_298896S$I4$+T[]:ZEE5UVNH93V(R*1(TC&(T5!Z*,5X,:D
M8PM;WK[GUTZ,YU>9R]VUK'+>&?#MUX9@OY9YH92Z941Y_A!/.0*B\+>++W7-
M4DM;F"!$6,L#&"#U]S784Q(8HSE(D4GJ54"J==3YG45V^O8SCA'3Y(TI6C'=
M=SHO!?\ R-5I]&_E7K]>0>"_^1JM/HW\J]?KU,L_A/U/ SW_ 'A>GZL****]
M(\0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#G:<$ ^II:1ON
MGC/'3UH Q?#ID/\ :)EFCF?[6<O&N%/RKVR:VZPO#0"KJ(%K]F_TMOW0QQ\J
M^G%;M5/X@1S_ (X_Y$C6?^O5_P"5?+LWF>0_E8\S;\N?6OJ+QQ_R)&L_]>K_
M ,J^8>U>IE^M.12,O1VOV67[;OQGY=_6GVND0VMZURKL2<X4]LUHT5V1HQ22
MEK;N.QD7#ZH-718@WV?(Z#Y<=\UTNB_\AVP_Z^$_G5&KVB_\ARP_Z^$_G0H<
MJD[WN!]7C[H^E+2#[H^E+7SI!YI\1_\ D+VG_7$_SKC*[/XC_P#(7M/^N)_G
M7&5\UC/X\C[G+/\ =(>GZA1117,=P5VWPV_Y"5[_ -<A_.N)KMOAM_R$KW_K
MD/YUU8+^/$X,T_W2?]=3TBBBBOI#X<**** "BBB@ HHHH *IZM%<3:1=16A<
M7#1$1[)/+.[MAL''UQ5RB@#@/ NC>,-.U.>3Q!>SS6S1XC26=92I]V&,_P#?
M-=_110 4444 (>AYQ[UA>&W#S:HPNENO]*/[U<8/ XXXK=/3IFL3P]O\_5/,
MMT@;[2?W:L& X'< 52^%B-RL;Q9_R*6K?]>K_P JV:QO%G_(I:M_UZO_ "IT
M_C0SY:'2B@=**^D- HHHH 4?>'UKZVLO^/"W_P"N:_RKY)'WA]:^MK+_ (\+
M?_KFO\J\S,MH_,F1/7#?$K_CQL/^NK?R%=S7#?$K_CQL/^NK?R%>#C?]WD=V
M5?[Y#^NC/.J***^;/MPHHHH W_!?_(U6GT;^5>OUY!X+_P"1JM/HW\J]?KW,
ML_A/U/D\]_WA>GZL****](\0**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ I&P$;)(&.2.U<MKFGZA+XHL+R""66&(*0R,/W>&R_!(^\O%0Z18:S
M!K.I78M_+:4,5:X?Y9"6!3[I)^5<C\: -'PN\4D6H-#<27$9NVQ)(3N/RKZ@
M5OUSUI:^(K62Y<#2V\^7S#\TG' &.GM5G/B/^YI7_?<G^%:25W>XD5_''_(D
M:S_UZO\ RKYA[5],:SIWB'6=&N].<Z7$MS$T9<&0E<CKC%><?\*0U7_H-6?_
M 'Y;_&N_!UJ=*+4V4F>745ZC_P *0U7_ *#5G_WY;_&J\/P<U*:\N+8:O:!H
M-N28FYSGW]J[/K='^8?,CS:KVB_\ARP_Z^$_G7H?_"D-5_Z#5G_WY;_&I[/X
M,:M9WL%R-7LG,3APIB<9P?K4O%T6OB#F1[*/NCZ4M8^?$?\ <TK_ +[D_P *
M,^(_[FE?]]R?X5XG+YDW.,^(_P#R%[3_ *XG^=<97HNO^%-=U^ZBGDN--A,:
M[0%$C9K)_P"%;:S_ ,_^G_\ ?#UXF)P-:=64HK1^:/J<#FF%I8>$)RU7DSD*
M*ZJX^'FL6]O),U]8$(I8@(_.*+?X>:Q<6T4ZWU@!(@< H_&1FL?[-Q';\4=7
M]LX/^;\'_D<K7;?#;_D)7O\ UR'\Z@_X5MK/_/\ Z?\ ]\/6QX?\+:[X?N)I
MHY]-F,J[2&\Q<5MAL#6IU8RDM%YHY,?F>&K8>5.$M7Y,[>BL?/B/^YI7_?<G
M^%&?$?\ <TK_ +[D_P *]OE\SY>YL45%;^?Y"_:1&)L?-Y1.W\,\U+4@%%%%
M !1110 4444 %%%% !1110 W<I# ,..N#TK"\,F(R:H8999$^U'YI22>GOS5
M71M'U.QU'49R(XS*N$=FW"1MQ.X@>QQ5JUT[7;::ZD%Y8DSR;S^Y;CC'K5QM
M9B-^L;Q9_P BEJW_ %ZO_*G^5KW_ #]6'_?EO_BJK:EIFMZGIMS8RWEDJ3QF
M-F6%L@'\:<$E)-L9\P#I17KG_"CG_P"@Z/\ OQ_]>C_A1TG_ $'1_P!^/_KU
M[/URCW*YD>1T5ZFGP9D;4I;3^V,!(EDW^1P<DC'7VJS_ ,*.D_Z#H_[\?_7I
M_7*/<.9'D@^\/K7UM9?\>%O_ -<U_E7DG_"CY,_\AP?]^/\ Z]>DQ6VNQ0I&
M+NP(10H)A;M^-<.,K4ZJ7*]A-FS7#?$K_CQL/^NK?R%='Y6O?\_5A_WY;_XJ
MLG7?#6K:_##'<7]I&(F+ I"W.?J:\K$TG4I.,7JSJP%:-'$1J3V7^1Y;17;?
M\*SO?^@M#_WX/^-'_"L[W_H+0_\ ?@_XUXO]FU_+[SZ;^VL)W?W'$T5UMC\/
MKV\@,IU**/#LF# >QQGK5G_A6=[_ -!:'_OP?\:;RRNNWWA_;6$[O[C(\%_\
MC5:?1OY5Z_7!Z5X$U'2=1CO8M3MW>/.%: X.?QKIO*U[_GZL/^_+?_%5Z>!P
M\J--QGW/ S7%4\364Z>UC6HK)\K7O^?JP_[\M_\ %5<LEO51OMLD#MGY?*0J
M /?)-=C7F>:6J***0!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGUH Q#I>EY=/[:<O,&?Y$7<%')Q@<#Y?QJ;38-&PMS'JIS\P.]?+R"O0 XP
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D
@                                           !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>img222477878_27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_27.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &E Q8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ -%!HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  T4&B@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,':PR,C\:M5\_7MYJVH:KX>T(,O]G1>'8;F.&346LD=RH!?>HRQ7' J2]O\
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MJ7*; ,E7*_=<#G%&D?$?4]8:RU"#PK=-X?O;G[/#>1R;Y1SCS'C X3(/.>*
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MY!Y<:@X!SCD]\=J],T+6+?Q!H5EJ]J'6"[A65%<88 CH?>@"\D:1J%C144=
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MXO\  VF(TZ,(K_3X$51-&>I Z ]CCV/K4WC-GU?XG> +:&&1)4,M[*CC#1(
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MD>C)9VAU'[8EN\A=O*V-$T@<#KD;2"OZTC^-Y(=;@LY(K=HI+\6#",NS(QR
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MCGGCMK>2>9@D42%W8]@!DFI*Q/%-I=ZCI::;:JX%Y,L4\JX_=1=7//J!C\:
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MK;,T*R(S2JW3GN/3WKJK24SV<$Q&"\:MC.<9%9)ZL[*D?]F@_.7Z$U%%%,Y
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M2?X96?B>65F!Q=:7') Q_P!]P&45[9X%O/%5[H)E\76$%GJ D(5(2/F3 P2
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MA$A97(SU/M6)X:^%>JZ)K&B7-YXI>^LM(:1K:T:V"A2ZD'!SGOF@#U"BB@D
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M^:_X!LT444& 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQUX1\/V7A74M2MM)M8KT%9!,J88,9%R<_B:]!K65N16[O]!+<J7W6U_X^/\
M7K_J?H?O?[/K^%8O@UF$.K0M_P L]1F_4[OZUM7QYM>9Q^_7_4CV/WO]GU_"
ML7PPP&K^(X?[M_NQ]47_  K-[+^NYT4M:=1>2?XK_,Z6BBBD8!1110 4444
M%%%% !1110 44C,J*69@JCJ2<"L>?Q-IR2&&V:2^G'_+.T0R'\2.!^=)R2W-
M*=*=3X%<V:1F"@EB !U)K#\_Q#?_ .JMK?38C_%.WFR?]\C@?B32KX9@G;?J
MEW<Z@W]V9\1_@BX'YYJ>9O9&OL81_B37HM7_ )?B27'B;38I3#!(]Y/_ ,\K
M1#(?S' _.HOM'B"__P!1:0:=$?X[AO,D_P"^5X'XFMB"V@M8A';PQQ(/X44
M?I4M'+)[L/:TH?!#YO7\-%]]S#'AJ*X.[5+RYU!O[DC;8_\ OA<#\\UK6]K;
MVD0CMH(X4'\,:A1^E344U%+8SJ5ZE16D].W3[M@HHHJC(**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ ILF_RW\L O@[<],]J=37#&-@A ?!VD]
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M*VORKW$$+*%9U  ;)4D?='&<''2NC PH'H*6BI<Y223&%%%%2 4444 %%%%
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MI;&=2M4J:2>GX?=L%%%%49!1110 4444 %%%% !1110 4444 %%%% !1110
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M#Y87YEY;DGN#V^AJW52-\ZI<)YL1Q&A\L+\Z\MR3Z'M]#5NH8PHHHI %%%%
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M59O'?AP?ZO4/._ZXPN_\A4NK!=4=$<%B9;4Y?<SHZ*YK_A-M.?\ U%EJL_\
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M^#)-FLT+V[+ T4;;H_F* D\9'7N<UV-# ****0!1110 4444 %%%% !1110
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M]ZK-I]V9M%G^P7?V.TM+5=4B (\]@!LPN/F\L\M['':M_KM5_':7JD_QM?\
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MG\C5KY[F18HEN)2K/'%&<K&.,8Y(SUYK5&D1#Q$=9\Q_.-K]EV?P[=V[/UH
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MG?"^NW>M7OB&&Y6)5T[5'M(?+4@E B,"V2<G+'TK?DECA7=+(J+G&6.!7#^
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M>XT5DV'BG0-4.+'6;&=O[B3KN'U&<BM4$$9!!![BL9TYTW:::?F4G<6BBBH
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MULI8#;Q?:!))ET!<!W/J=W)H2N!.EBUG\5K>1KVZN!<:?<2!)W!6']Y'\J8
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M&3ZTZO%K8BI52C-WMY+R^_9:LT22"BBBL!@:*#10 4444 %%%% !1110 4$
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MR$0G/X#K33: ].HK,\.J4\.:<C7POV6W13= Y$I P6SWS6G2 **** "BBB@
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M3U##(-,EMH+C'G01R8Z;T!Q^=2T4 -1$C0(BJJ@8"J, 4ZBB@ HHHH ****
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MHHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH
M,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9H
MHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,
MT9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HH
=H ,T9HHH ,T9HHH ,T9HHH ,T9HHH 2BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>img222477878_28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_28.jpg
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M/#]X<&%C:V5T(&5N9#TB<B(_/O_M $A0:&]T;W-H;W @,RXP #A"24T$!
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MM.CX.V8JTP2IK8YIDG(.20M;])G/4 AD"]L7Y$DTH<V^[PGC:&QY1)P"173
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M?FZ_GK?M8_NO%?@"I\9*?:>Z4N?EODQ\*GV#>@#F9WY:WYNO[ZW[6/[KQ7X
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M9.N(S[J2E:&10:.8J=XJ^1W(.><ASR+NK.O<\O,CB:0NCLC3&""<D(,+,$(
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M'&E"&,P5@AO8-[UGWB;8V6[F791;WEM=W45S=R/,!>YK6RBV# 2^./2=F[0
M: :]*E] QK002"=7W%>NN'6)*(E$2B)1$HB^1YY*4DY2I.*3ITY1AZA0>8 H
MD@DH%S#3CC3+A 444 -Q"$*]K!M;;>B*ASEJ+T#^4)5,W+6-@ +R%W9'%Q8E
M.H7%HF2[Q$F=X8F(9S68_P!QD&L]GM2?8%AAM=;8LT=KC(*W,1=%6N(5ZZR8
M)*4PGD*TA\R?V8#\VIVI1J<TS(D0'EWD"T+1J(QRU'/;L\OG?(I6ORI)*BU+
MJI3O&TU.::.YJ8 AE%B"2::6."83PCE4@2C@/(OBWY)[,!O?Q28.J'38K>C5
M!+@H6N&HS'*PU2\E#"(3Z:(V4W&%T4%%A*-$7<!8RPVMN=S;3%#KJ*]=*3:J
M'D6SP;/O9U8[>2'N,ZO=/:<](S+6!(F4ZDL=J4)#4M<^=Q)1DBE(1KPI5HAW
M3<4,_A FF6)W.4'O2'1 U#ARJ"V4ZVGD4Q0;7)H]R;EM'@G'.I3#4[RPY18R
M9-,.B$]C\C6O+ G4K$RXYF5M"U6V.R]KN@,-5HDYYBY*FW3S20$C 9>PD83A
M!%5!C>&XB"&KR3:FK[-1^H*^R]]F:,G7V=RU[[)@[]SNWM:VW^&OD?T@:-^\
M[_S6[_/R+^C;H=T]$NZP_P#U[+OU2)2(P:7;FSV$,,BEM[0V58:59M6RYCC4
MD2%D,Z)GDSH=&&XIZ8KK5<@N=&#B@C"B.Y0NPCB2#@!M8>YLNCPNSFTL[ZZ_
M^E7.5.OW3QQ2@!C62O,31)'B=+6)P!V;JBKV,>  >6S3IF#-V<RS/*K'_P#(
M++>!N4,M9KBW<72OEMXQ</,4V!D%+ACBTS-PFD<DL;G'#SHYIJF!<ORDA8<E
MMV.#L>2Y\@@%;NNE"1[?+)81+<C'$<7 &UT()('"8:K/4V-&67<ZP"MSE!;@
M<MAN#FC<SS&&SS!E@ZQNI+<%[IFR288)KHC%;-> -A ]SZD#%1M,1H/&S;I>
MR!^09+<YED\N;1YK80WI;$RV=##BN[6P:<-[)&21=W<3(RT.(9BDQ86XCQI3
MHZG<7C[Z^@DD<D1C<UAD3*S1YHFJQ?,(ZHDT3B+:N9U0XV6THWEV>IBDL2T+
M5!#IR6\9<K=N#>IF/1=G.7V4UX+B"=S(MK''&R=SIXC+#"QS"8L#7ODG9A@D
M<V:E7%M"*YLEZ?=V<YS6VRUUI=VC)9MA-+/+:,9:SMM[FZD9*T7!E?%%%:2X
MKJ)C[?%1H?4.P[&@TT.LBAL_CT5R*O='7$CS#$V0&$YWWL>IYB_LDW<9*VQ9
MM0FJCI&YQ9>Q(FPY>23<JQO'JS!%MZ;B+>=#N!<WV57MEEM\^2YRR6 7,>/_
M '83R1W#Y60M:297PNCCB,C6TQ;>5Q;!'C6HN>F"QRK>#*\USO*8H++/;>[=
M8S"+_?G6L$UFRWDN9'AH@CN632W#8'N#L/BL# ^ZFV1P@=*)S!DF)0V8R8UW
M:9(RYJ=3CH(QOB20A6X1;9(.0,J)LG+"SB4*'!^C@TR12$DY,H('8XL5[7L&
MWB#HW?99_;93FEP9;:>*^>3;QR"3%8-EVD;67$;*ETD18QX:YKFG&WB6Q=TW
M1YINA?;P9!9B"^M+C*8@+V:%T&#-Y+<03/DLYI<+60W DEC+FR1O!C<!0E;"
M[Z092ZIK.S;.#VV&ML5AS\T)\L(G=G?(M&Y03$W1Z:'E&@"Z-C,L@JC("90X
MIDU@EB3G\5N%"."6+S;GHPS*YC\9MKLQY5';02,%XU[)(8IA"^1CVMQM8ZW-
MRQTK64!:[:4:7AIU5AT\Y)8S&QO,M;-O!->W<,KLL?%+#<W%N;J.&6)S]G)*
MR\;92,@DDJX/9L<3Q&YS8OG&F&;8\A,CESZZ,0G"'JV9%,(6WENBF11(YY*9
MS2.^47!%(&PHF\@2%\IOC)$>9<K?";8(!\]F_1]F^191/FEY)#M[5S&SP-#S
M+"9 PC:]R&L VK!6I:7$MJ'4![3=OIDW<WJWBM,BRV&Y\4OXY7VMV\QM@N1$
M90?%^[+Y"=A*[#0.#&A^$LJYO^IWIQ<H"JC@7:8M"5O<8JUR^5&2%L50Z10=
MI='/@"1*81(5J>2R50>FN%:G2MI1K@8C, 8:F3V&#>OG&XMQDLD N;J)L,EL
MR>8RL,$ENQ[\(K;R.$LI(I(UD0=(8R'.C94*N[72U9[SPW9L<OG?=17TEK;"
M"1MU!>2QQXSAO(&.M[=K75A?)<.; V5KF,FE+74C?+6.%.)YXYP=4\)'\2!!
M'G0AW0I3T1"M%)H^V2-!824\U18E40D= %G6*.4D6- +DSC0;!7T.\F1R;MY
MS)D\DK9RQD3P]K2T.;+&R5N@DT(:\!U'.;B!PN<-*ZW<;>R+?C=F'>2&W?:B
M66>,Q/<'EK[>>2!_= -JUSHRYA<R-^$C'&QU6B-ZT:ZU74[/*>0?&6KO%TUR
M/,8M 8<TIIL!UE<T?VJ,1MM&X0I]0( KWMZ5(FU&):N4%DE6,-#RAHPA#M%>
MUJ]T_5YT=+V5DZL%S^K2K\O?7._\<,_X]I8_KT"]-_3MT2=<#3#Z>,7^-%?3
M3:Q\X<J^$NSDYIY$Z=NB3K@:8?3QB_QHIM8^<.5-G)S3R)T[=$G7 TP^GC%_
MC13:Q\X<J;.3FGD4DXWU$X S(O6M6(\XXARBZMJ;C7!KQ[DB'3)R0([C"598
ML01UY<529+<T=@\H, 0;U]FW;4AS7: 02H<Q[?; CKA3'5E5*(E$2B)1$HB4
M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1%232=^=_M OVO&O_"GIFJC/;.Z_L!9'^U9^#[)5VZNL:41*(E$2B)1$HB41
M*(E$5"-9C0DR?D72%IQE7+*L4YHRW-%^6HT4>:0FG\8Q+B*9Y$:,?R,)0@V7
MP=^F;:V'/"$>TES2(^"/L-,H/+,QOTEK3J)]A98] <\:P/7-%;U!B_&C6B2-
MK9CN"MS<@3E)$*!!$F!&B1)2 6+(3)$J=O+(3IR2PV"$  V"&UMEK5>@XECJ
M5R_)] OZ$1#P:9O>5*!*E/)] OZ$1#P:9O>5*!*E/)] OZ$1#P:9O>5*!*E8
MEMQ!BEGFXLEM.-H,V9#''28CW[((LRI)2"+IUJQQ+CY+X0B X$,_'KSCA)P&
M!*&8/>%:][6V,+:UH*IB-*5T+QA:FMG2/U!;VS=\M&3M[>V;-G?@[[=NWN;-
ME?(W?^GIWG==7[5N_P _(OZ..AVOT2[K4U^CV7?JD2V^&XZU'36;L<,42.>Q
M20-4&2Y-CIDP?Y^4I;84E0E',[W$VQF(?I0JL8B<_O0EI1&G@)&;?< 6 ZX=
MAE>1;]YMF\.5/GO;:]BLQ=1&>2Y!9 &@QR0L8))C5KNX;#&7!I=H#0ZFBW@W
MMZ)=WMW+G>"*TRR]RN?,G9?.+6"R+9+MSR)8;F24PV[:/C]]==3-87A@Q.>Z
M,'[,^GC,[R DB.RIG=)A(P=]B> H)F])YL^Q=WDBK'MLF'I5R) W"9'-:Y'!
M,,5JRW7FE28I.3!2C,O5K7<?>N[ 98W,4F:3C;"V;/(+B2)\IMO&B'-:W9N<
MYP)>\3;%SGOC$9<52_Z5>C[+BZ3-K*X@R"T/BKKU]I"ZSAN8H&WW[/#F/?()
MHV1L+1%$ZV\9C9#',9FL"PTGR'DG',>/Q>QY@B4LCKR86Z.+[CEP5KG.RQM=
MTHK-#C*7-E8I6F&@<XZE.(M;[0U,0G$0<--N!MXU_G>?9'8G=ZTS2VN;&4XW
M26KBY^)KQW#IGQQS#"^)CF\!8UA8XQT"V&3[J[H[V9JW?/,LAOK'-K<&..&_
MC:R/#)$[WV.VCFFMG!\<\C7\+9'RB6-LV(F"&]Y>&D01-;LY-]PJ@+=U&N5)
MRQJRR%20*@XHHT)1YO!KCR;W&$6\0H-+OM 8,(N/AN;JW(-O+(RCL7<N(!<
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M?KGPR?;"^L?_ *GN/)K+YLGJS=#WF':?"J?>-=/H Z(?,T7?KGPR?;"^L?\
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M."-,N-ED75)E#%'2WY\C:V"(ETP3HDCG(VUV99(@.B]U"TE4^.+T\-B54>6
MU394,8KV!8)YEC&%@4%SW+19KCK3(SL5TA1\TDK'DB5@BI\7QD[R.>E/DGC;
M+*I YDF-4?N]&M[FBCZ=6)4H+NG5)PIB.2&6>$NXH(8./2K OKP5ZJVQY@6F
M'-;P1*ETM*<E$W:6AZM'"<AND>)=Q',;OC5M?UT,NYMRXI]YEE)[&+ER &@.
M$64,NRHDNX)HQQK77_(J@O;HXEE9[CO385(4\CF\A;FA=-9,N;AIU4\5-C9+
M)&4_P=2<UJD(7,M.I/9I)C]J#8H.YPJFPBA;+GB ,0SAX2@+Z:-04IXF>\9A
M8PXYQQ+T4F(Q4B;8<M2A?.?7=H(:2SF=O3NJPP8E*L9=V@Y-Q KCL8>D.!<=
MS2C;!L"-0X%#JZSPJJ;=A;#F5]9>I]5E+$V,\E*F3&FF1,S*9_ XM,5#2F6
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M-%(#34ZP54N=H%*46BM\0T<,2Q5'1S2..IV2#5C>Z+W#(A"]K=W6&/N.35;
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MW!*6<7O!ONF L*W=M7J'IV:U_1?F+7"HQ6_ZQ&L%R2V$D&AT+WG^KFT'=4;
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M2B)1$HB41*(E$2B)1$HB41*(E$2B+\KG71\MK6#^T[G/]9,CKZ?;C_P9E/\
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M2B)1$HB41*(E$7__V0
*              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>img222477878_29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_29.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #R A<# 2(  A$! Q$!_\0
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MJ">'9X]/='D6X:ZC/RKGG:.>2*/J5+S^\'F%==5]W_!(_P#A#=5];;_O[_\
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M_P!_?_K5U5%'U*CYA]?Q'=?=_P $Y7_A#=5];;_O[_\ 6H_X0W5?6V_[^_\
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MX5UQ8?)6XC$7]P7!Q^51?\(9JOK;?]_?_K5U5%+ZG2\_O&L=76UON_X)RO\
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MIW<Y!8<]#6]7*^&_"\NFZH^I7<-I#,MO]FBCMI9)1MR"26?GG:,+T SZUU5
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M7_GG^M'VI?\ GG^M*Z#DD3T5!]J7_GG^M'VI?^>?ZT70<DB>BH/M2_\ //\
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MW7;@_=Z9YHT!)FS1112*"BBB@ HHHH **** "BBB@ I[?=C^G]33*>_W(_\
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M;R31@ED60$C'7\N_I3;;6]+O/-^S:A;2^2NZ39(#M7U^GOTI<S'R+N;N^/\
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M&^/_ )Z+^=4:*.8/9HO;X_\ GHOYT;X_^>B_G5&BCF#V:+V^/_GHOYT;X_\
MGHOYU1HHY@]FB]OC_P">B_G1OC_YZ+^=4:*.8/9HO;X_^>B_G3F=-JY=>GK6
M?3W^Y']/ZFCF#V:$;3=-?48;\PP_:88WC1P ,*V-W'_ 10--TT:DVH"&$7+0
M?9RP P8\YQCIUK'_ .$ETAK;4)X+Q+A=/XN!#EBK8R%'8D^U5HO$Q73KZ]OM
M.DMHK2/S"8YDF##^[E>C>QZ>M/F8N2)U3QVLCQO(L+M'RC,H)7Z>E/WI_P ]
M%_.N9TG77U&]FLKK3Y+*ZCB6<(TJR!HV) .Y>_'2MBES,:@F7M\?_/1?SHWQ
M_P#/1?SJC11S![-%[?'_ ,]%_.C?'_ST7\ZHT4<P>S1>WQ_\]%_.C?'_ ,]%
M_.J-%','LT7M\?\ ST7\Z-\?_/1?SJC11S![-%[?'_ST7\Z-\?\ ST7\ZHT4
M<P>S1>WQ_P#/1?SHWQ_\]%_.J-%','LT;D)!A4@Y&**9:?\ 'I'_ +M%:K8Y
M);B7?_'I)]*X;Q)I-YJ5Q:O:HK".WN48LX7#/$57]:[R=0T+*>A%4/L\7HWY
MU$D[FU*24;,X"X\,7GV33HK:V@3R-#GLI K ?O71 ![C*MS44_A_5A'K5K'8
MQ2)J.GP1),)E&R2-"I4@\\D]1Q7HGV>+T;\Z/L\7HWYU-F:7B><:GHFOWCLA
MMVD,5W#-$ZW$:1&-"IQMQNW\'D_G6_X?L[VP_M6WN;<)')?37$$PD#"19&R.
M.JD>]=1]GB]&_.C[/%Z-^=%F"E&]SA_#_A!+*PLWOY+B6Z@9Y%@DN2\,;EF*
ML%Z< _A6;#X=UJ^OM.;4X) L<=Q!>/\ :(RI\R-DW1JH&%R0<'FO2OL\7HWY
MT?9XO1OSHLPO$X.73?$%]H$?AJXLX$@*+;S:@LX*O",#*Q_>#D#'/ -7AK.H
M7<FI6FEQV4TD"[(9%GX5]VTA@>NT<G'TKKOL\7HWYU&EA9QNSQP*CM]YE4 G
MZG%%F',CE;WPZ8_!-YHUE^]N)XFW22-@S2,<LS'U)S3=0\-1KH36NF6ZK.\E
MNSAI3@A'!/)/L:[#[/%Z-^='V>+T;\Z+,.:)YV_A[5#:/HJV,)C;4!>?VJ95
MR%\T2?=^]OXV^F.]=%HVL/J=Y>+_ **\,#@))!)NW')!!!],=>F<UT7V>+T;
M\ZCCT^TB+-% L9;[Q10,_7 HLP4DCA5\-W4EGI>FSVR/:6.H3;RSC]Y;M'(%
M/U^< BDA\&3V<MB4O)+F43R&>[D(#I'Y12-1Z[00/UKO_L\7HWYT?9XO1OSH
MLPO$\ZTWP]K$5O8VLR2+)IT3>3.\T1B,@0JI"JN\J3R0Q_.JY\.Z[=2B6:U=
M7;2Y[24S7,9S(^T@J% PN5/YUZ;]GB]&_.C[/%Z-^=.S"\3B)M&OK.:SN+&S
MA9K?2'M-BL%_>G;@>XX)S70:79#3-(LK!7+BV@2$,>^U0,_I6O\ 9XO1OSH^
MSQ>C?G2LQJ444Z*N?9XO1OSH^SQ>C?G2Y6/VB*=%7/L\7HWYT?9XO1OSHY6'
MM$4Z*N?9XO1OSH^SQ>C?G1RL/:(IT5<^SQ>C?G1]GB]&_.CE8>T13HJY]GB]
M&_.C[/%Z-^='*P]HBG15S[/%Z-^='V>+T;\Z.5A[1%.CM5S[/%Z-^='V>+T;
M\Z.5A[1%.ZSLDQ&)3L_U9(PW'3GUKC-.N-;T'0M6DFT4PW,MTTEG%%,LNYI"
M H.WH!U)]*]!>"(MSNZ>M-^SQ?[7YT[,GF1P=]X7GATK1[5+9=4AM96EO;9Y
M1&;F1@29-QX)#'.#6KX5TVYTK2'M[F-(%:=Y(;5'WBWC)R$W=\?UKI_L\7HW
MYT?9XO1OSHLP4HIW*=%7/L\7HWYT?9XO1OSI<K*]HBG15S[/%Z-^='V>+T;\
MZ.5A[1%.BKGV>+T;\Z/L\7HWYT<K#VB*=%7/L\7HWYT?9XO1OSHY6'M$4Z*N
M?9XO1OSH^SQ>C?G1RL/:(IT]ONQY]/ZFK/V>+T;\Z5H(MJ\-P/7WI\K%SH\V
MGT'5]3F\26\ND16=KJ"1&W?[2C*6B PK!>0&QU[5-)H.J7RZC-:Z=#HCRV M
M5A656\YMP))*< ;05!Z_-7H7V>+T;\Z/L\7HWYT[,5XG$^&=%N-/U:>Y32H]
M(LGMEB-JLXE,D@/W\C@ #CU.>:ZJKGV>+T;\Z/L\7HWYTK,:FD4Z*N?9XO1O
MSH^SQ>C?G2Y6/VB*=%7/L\7HWYT?9XO1OSHY6'M$4Z*N?9XO1OSH^SQ>C?G1
MRL/:(IT5<^SQ>C?G1]GB]&_.CE8>T13HJY]GB]&_.C[/%Z-^='*P]HBG15S[
M/%Z-^='V>+T;\Z.5A[1%VT_X](_]VBG0*%A0#H!16RV..6[%E_U3?2N$\9ZA
M]DU+1()=8O-,LYWF\Z2T^\V$RH^Z>,^U=W+_ *IOI6/<:;!=:C9WTF_SK/?Y
M0!^7YQ@Y'?BD]RX[')Z3XEU2)[.P6VGU,7MS.ME=7)\EF@C"'>^1G^(\X&<#
MCFKI\87 0:C_ &6/["^U?9?M?G_O,[_+W[,?<W\=<]ZWY]-@N-4LM1<OY]DL
MBQ 'Y<.%#9'?[HQ66?"%@;K=]HO/L7VC[3_9_F#R/-SNW8QG[W.,XSSBD59E
M6+Q@\EQJ0:T@1+%9F>%KC%P!'GYC&1]UL<$>HIO_  F4ME%;7FLZ8+/3[NV:
M>WF2?S&&V/S"KK@8)4$C&>E3:GX3%S'<W O;NZNEMYTLX[B1=D32(5/.T$C!
MQ\Q.*;I?@VVBM;$:E<75X;>S%NEM/*'BAW(%?;@ G/(R2>#Q0&I7C\>0Q)YM
M]#;K$]N]PGV2Z6=EVC.QP.C$=#TSQ4>O:[XEMO"6IWO]DQ64J6ZRP2I=!]N6
M4$-Q][!^E;-MX8M88)+>>ZO+RV: VX@N'!18SQC@ DXXR234/_"(V\EA=65W
MJ>J7=O<0?9PDTXQ$F01MPHY&!\QR>* U*E_XCFTK4W>[M9-T.GP3W,:3[HXT
M:5E9AQR5 R3W Q4VH^,(;&>XB6&-METEG#)),(XWE*[FRQ^Z%&,GOD5H1>'K
M5)GFGGN;N62S%E(]PRDO&&9N< #/S'FJ\/A'3H-!M=)CDN0MK()H;DR S+(/
MX]Q&"<''(P10&I8\/ZXNLO<PLL(GM759#!,)8V##(*L/H>.V*XZRN=8L_ R^
M+#KM]<SQ[II;6Y96AD02$% , J<=#GK7>:;8_P!G1,OVFXN9'?>TD[ DGZ
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M0 '\ZN7'@_1KI(5EBN3Y<0@8BZD!FC!R$D.<NOLV:EO/"VE7VHVM_,ERL]H
M(!%=21H@ QPJD#IQTY% 68R;7H[NUU!+&;['/:CY[B^MW6)!NP3SC=T.,'TK
M#BU_7FTY(O-B:2\U!+2QU&6U,0>-ERTAB)[8('(S76:OI5IKFG26&H(\ELY5
MF5)&0Y4@CE2#U JBOA72AITUA(MU/!*ZR'S[N21T9?NLC,25(]B* LS#DU[6
M8+N30#=6[Z@;^*UCOS#A0CQF3+1YQN 4@#."2*VO#^H7L]UJNFZA+'//ITZQ
M_:(TV"570.,KS@C.#3QX6T@:9)8F"1TEE$[RO,QF,HZ/YF=VX8&#GM5S3-*M
M-(MF@M$<!W,DCR.7>1SU9F/)/UH"S+M%%%(84444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% %76;M[#1[Z\C7<]O;O*J^I"DBN1\-O=V6I:6VH1WBR
M:K;LRR->F99'"ACO0\(<'(V<=C7<2JKAE90RL,$$<$5D:;X9TO2KI;BUCF+Q
MH8X1+.\BP*>JQAB0@^E,12W7]WXEUG[+.D<]I;10VR39,:[\LTA4=<X '^Z?
M6L.3Q?J46F:H([VVNI+>^@M(+Y;-@,N1YF80225&>G6NNO=)\^XEO;.X:SU!
MX/($ZJ&&T-N&5/!P<_F:SH?#NI0S7E^-9C&JW+QDRI9@0A4! 4QEB3G)R=V>
MG- &5*]WK.@"\'B."3[-)(DLB0R6NQB !E =V]3R >#FI[J[%]H.M2'4V2_B
MMS*D2,1Y'E\CV8EAAB,C)Q6OIGAQ;:2>ZOIOMM[/<BZDD$>Q X7:N$R> .F2
M33I?#&ES+,'BDVS JP\UL!2X=E49X!8 D#K0*QH6%P]WIMI<R+M>:!)&7'0L
MH)'ZU8H^@Q["B@H****0!1110 4444 %./1?I3:' :/:>05(-,#FX/$5Q>^+
M[>QM8T.E-#< W!',LL93.S_9&\C/<_2I#<Y\97C7,YAM=.L%=0S80[R2SGUP
M%Q^-06G@/1-/UZQU2Q@-O]DCD1859BI+X^;KQC!X]ZU=2T#3=7E9[ZW\W? U
MM(NX@21DAMI]>0#0+4RM,\42SRZO=:C$+73K:.*:V!4^8T;;L%AZMMX7W%5H
M[C5M?TF\DO&BTY[2]+&%I&0>4$R%D93D$;@QQW&*EA^'?A^.[OI'M3+#="(>
M2SMA-G(P<^N#^%6](\&Z9I*WZ11M)'>7(G9&9B%QC:O7D ^M :E/2Y(M4CDL
M;O59#,;0V\<2ED;&WYI"?[YR#C.5&,]:UO#%[-J/A?3+RY8--+;J78#ACCJ/
MKUIT_AW3KB>XG9)5DG#ABDK  NNUF Z!B !GKQ6A##';P1P0H$BC4(BCH .
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MRZ@O?#VMS/J#B_2V:=/O!8?*R5VGHV'7#$9R<BNOLY7GL;>:5=LDD2LPQT)
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9
>

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>img222477878_30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_30.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M_P 30!6N-#6YF2::]G:5. V(P<9S@X7D9YP>.!Z4 619W .!J5QT_NQ__$T
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M ./^'W_,T_\ 8>NO_9: .QH Y_74TQ;O[3J<;-'%#C<-VT*=P8$ \@CC'/\
M.@"&&;P_ 9R8T1XH9//:6-BVW/SAF.=QS[GK[T (DFBV[RAXI48 H_F!V.<!
MB.2?FVE3GN,<\8 !+J#Z.TY-TAD9CY(*;MI?&=H .-V/QQQF@"UHTNFS13/I
M@18BY8X4@$GN >@Z].,YH D@W?\ "1WO(_X]8.W^W+[T :6']5_+_P"O0!1U
M?R%TR=KT;K95RX /0<]C0!D63:%)/'+9QD'[0T89595WYY&,],C.,<8S@8)H
M Z3#XZK^7_UZ (;P/]BG^8?ZMNWM]: .4TR'5/[*L]MY;@>0F ;<G^$?[=;+
M8R>Y;\G5?^?VV_\  9O_ (NF >3JO_/[;?\ @,W_ ,70 >3JO_/[;?\ @,W_
M ,70 >3JO_/[;?\ @,W_ ,70!6U!]6LM/GN5N[5C$I8 VS<_^/TG= C7_LK4
MO^@C;_\ @*?_ (NHYRN41M+U,#/]H6__ ("G_P"+HYV/E0O]E:E_T$;?_P !
M3_\ %TN=ARD4NC7LAC6:^B,:31R$+;E2=KA@,[SW%#DV@2L;V']1^7_UZDH8
MX?:/F'4=O?ZT /P_J/R_^O0 UP^!\PZ^G_UZ '8?U7\O_KT -8/N3E>OI['W
MH 4!_P"\OY?_ %Z &L'W)\R]?3V/O0 _#_WE_+_Z] #6#[D^8=?3V^M #L/_
M 'A^7_UZ &X?</F'3T_^O0 [#^J_E_\ 7H ;A]P^8=/3_P"O0 [#^J_E_P#7
MH :0_F#YEZ'M]/>@!V']5_+_ .O0 W#[OO+T]/\ Z] #L/ZK^7_UZ &X?<?F
M'3T_^O0 [#^J_E_]>@!,/N/S#IZ?_7H 7#^J_E_]>@"I>Z=#J!B%R"WDN)$*
MLR$-@C.01V)_.@"&WT.RM)%DAA"NG0Y8]MN>3U X![#@8'% $B:9;AE.S<8V
MW*SLS'/!SDGGH/RH CFT*QGFEFD@4RRD%G!8'@$#!!XX+=.N3GJ: )(-,MX"
MNQ%_=R&12<\,5V^OH<>PH CBT*R@DCDBA"-&%5,$X4#&,#.!]U<^N!F@"^H<
M$X8?E_\ 7H =A_5?R_\ KT -&_)Y'7T_^O0 [#^J_E_]>@! 'R?F'7T_^O0
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M@!,'<>3TH 7!]30 @!W'D]* %P?[QH 3HQRQZ4 +@_WC0 @!R?F/6@!<'U-
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MC/&.O.: -33I+FX@9[N$P/E<(">!M!()[X)(_"@".%!_PD=[R?\ CU@_B/\
M?EH TM@]6_[Z- %+59)[;3)I;57>=1\BA2^3GI@']>W6@"HLVI"YMU:)/*:X
M*2$!SA/++ C_ ($,$_A[T :X08'+?]]&@"&\0?8I^6_U;?Q'TH Y/3-&MGTJ
MS8R7?,"'B]E ^Z.VZMEL9O<M?V+:_P#/2[_\#9O_ (J@0?V):_\ /2[_ / V
M;_XJ@ _L6T_YZ7?_ (&S?_%4 ']BVO\ STN__ V;_P"*H /[%M?^>EW_ .!L
MW_Q5 !_8MK_STN__  -F_P#BJ #^Q;7_ )Z7?_@;-_\ %4 ']BVO_/2[_P#
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MS/+(82MM7'^LR&YYXQU[T 6]'\/65W'(][I[1D$ +NE3'&2.6YQTR.N">F*
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M_O\ O_C0-:["?\(OH8/-K_Y'?_XJE=E<K$'A;0R_RVI/!Z3O_C33)::Z$O\
MPB6B?\^;?]_I/\: $_X1/1-V/LC=/^>TG^- "_\ "):)_P ^;?\ ?Z3_ !H
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M\20P@B--<N5 ))Q@*.] ':4 <_KUW=V<[O90B:7R 1&8'?<03CD<+WZ]>@H
MK1ZIJ:/>*=-,@BAD,)2W=?-<-\O7H""/?@GIB@".YU/5X(KGR;6.=XPPCQ9N
MN_"J5.,]"24QZC/M0!8OM0OTE'V2UPA8)M>V<E!C/F'!Y&>,=: +/A^]O-0M
M)I=0T]K.59658FCP0N>.<G/KGCK0!8A1/^$CO?E'_'K!V_VY: -'RT_N+^5
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MX:.2GV#GEW#[9??\_4W_ 'V:7LX=@YY=P^V7W_/U-_W\-'LX=@YWW#[9??\
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MKZ4 +Y:?W%_*@!!&G/R+U]* %$:#^%?RH Y'X?C'_"48&/\ B?77_LM '8T
M<]K^HW&G76ZU5))3#E8F5B9"">!CI]?H #F@""'6]0+W(-GYXB@D>)XHI )W
M5L+MZX!&.YYSVH @FUS4XHKAHO(N'C5MACB<!^ 0WWNA.4QZCJ>E %J_U>\@
MF"VJH%.%V2Q/N08SYAY'RY^7IG/?M0!9T/4+S45N#>V9MFC?"J<C YP#SR<
M'/'WL=LT 6($'_"1WW+?\>L'\1_ORT :.P>K?]]&@"KJ+S6]C++;1^9*HR%8
MGG\O;- &/;:S>SW*PO82H/M;Q.6C8!(P.#D$\G@YXX[=,@'1;!ZM_P!]&@"&
M\0?8I^6_U;?Q'TH Y/3-)MFTJS8R7>3 AXNY0/NC_:K9;&3+7]CVW_/2\_\
M R7_ .*H /['MO\ GI>?^!DO_P 50!3U?3((=%OI$EN]ZP.5S=RGG:>Q:@+7
M-0>"/#O7^S^O_35__BJGVT^X_9Q[ W@KP\J$C3QP/^>K_P"-/VL^XO9Q["_\
M(3X>_P"@?_Y%?_&CVL^X>SCV$;P5X>"\:?\ ^17_ ,:/:S[A[*/84>"?#W_0
M/_\ (K_XT>VJ=P]E'L(W@KP\!QI_<?\ +5_7ZT>VJ=V/V4>P[_A"?#W_ $#_
M /R*_P#C1[:IW#V4>PUO!7AX#C3^X_Y:OZ_6CVU3N'LH]AW_  A'A[_H'_\
MD5_\:/;5.X>RCV&MX)\/ #&G]_\ GJ_^-+VT^X>RCV%_X0CP]_T#_P#R*_\
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MH_\ &F ?VKX<_P"?_2_^_P!'_C0 ?VKX<_Y_]+_[_1_XT ']J^'/^?\ TO\
M[_1_XT ']J^'/^?_ $O_ +_1_P"- !_:OAS_ )_]+_[_ $?^- !_:OAS_G_T
MO_O]'_C0 ?VKX<_Y_P#2_P#O]'_C0 ?VKX<_Y_\ 2_\ O]'_ (T ']J^'/\
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M_JV[#TH Y;3-2TA=+LU:[M0PA0$%UST%;+8R9:_M/1O^?RT_[[6@ _M/1O\
MG\M/^^UH /[3T;_G\M/^^UH /[3T;_G\M/\ OM: #^T]&_Y_+3_OM: #^T]&
M_P"?RT_[[6@ _M/1O^?RT_[[6@ _M/1O^?RT_P"^UH /[3T;_G\M/^^UH /[
M3T;_ )_+3_OM: #^T]&_Y_+3_OM: #^T]&_Y_+3_ +[6@ _M/1O^?RT_[[6@
M _M/1O\ G\M/^^UH /[3T;_G\M/^^UH /[2T8?\ +Y:?]]K0&HG]I:-_S^6G
M_?:T!J+_ &GHW_/Y:?\ ?:T:!J)_:FB[@/MEID]!O6C1!J._M#2/^?JU_P"^
MUI7069+IT^GW&LH()()<0OD(0<<I4R:*1O[+?^[%^0J"Q-EON'RQ]/04 +LM
M_P"[%^0H 0I;^8/ECZ'L/:@!=EO_ '8OR% ";+?=]V/IZ"@!=EO_ '8OR% "
M;+?<?ECZ>@H =LM_[L7Y"@!H2WW'Y8^GH* %V6_]V+\A0 ;+;<?ECZ>@H -E
MO_=B_(4 ($M\GY8_R% "[+?^[%^0H 0);Y/RQ]?04 .V6_\ =B_(4 ($MLGY
M8^OH* #9;_W8OR%  $M\GY8^OH* #9;_ -V+\A0 !+?)^6/KZ"@!=EM_=C_(
M4 (J6W/RQ]?04 *$@SPL8/MB@#D_AZ%4>* O3^WKK_V6@#LJ ,'7)K^.=ETY
M)&N&ARI"@J"-V,Y'4]!R!R<GB@"K]I\1F6\$5J9(Q%)]G>7:FY@?E) YS['
MP!TYH =//K&9A T^PN0CM",A,+AB O7<6XQ]T=.AH ENI]9&W8CJ?, 81J&'
ME[?O D?>+=NP_.@"UHLNJ/#*-37]YNR"%"@=?E&"<XP.>^>V* )8/^1CO?\
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M#.E?W;7_ ,=HM3\@]X,Z5_=M?_':+4_(/>#.E?W;7_QVBU/R#W@SI7]VU_\
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M?^-.Z6P68O\ PD7AS_H+Z9_X$Q_XT^8+,/\ A(O#G_06TS_P)C_QI\R"P?\
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M/M;<ZGH(\[3M]ON]<@':JP!Q_2@!=Z_Y% !O7_(H SH&7_A([[_KU@[?[<M
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M?3VH =O4?_JH :SKN3Z^GL: ';U_R* &LR[D^OI[4 .WJ/\ ]5 ";EW#Z>E
M"[U_R* $W*&'T]* %WK_ )% #=Z^8OT/;Z4 .WK_ )% ";EW_AZ4 +O7_(H
M3<N[\/2@!=Z_Y% ";U#'Z>E "[U_R* $W+N/T]* %WKT_I0 @903]?2@!?,4
M?_JH  RY/'Z4 &Y?3]* $#KD_7TH 7>O^10 @9<GZ^E "[U_R* $#*"?KZ4
M+N7_ "* $#+D_7TH 4.I./Z4 <C\/_\ F:/^P]=?^RT =C0!@:['J$DSIIN]
M9S#Q() JQGYL$@_>/8=ADGL* *GD^)5GO?),8B:&1;82S\QMGY21M.2,GN>
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M_1_C1= *M]9RNL<5U"[D\*K@FBXRQD>M,!&(W)]?Z&@!<CUH :Q&Y.>_]#0
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M* $!BR<[/TH 7,/^Q^E " Q<_<ZT *#%G@IGZB@#DOA]C'BC&/\ D/77_LM
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MOX9_Z#5K_P!]T<\>X<R$;QOX9)7_ (G5KU_O^U'/'N',A?\ A./#/_0;M?\
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M_P#3E?\ _@!-_P#$UIR2+Y9!]K_Z<K__ , )O_B:?)(.60?:_P#IRO\ _P
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MXZ_8I\,/]6W?VI,3/.].U73ETZU5KZW!$* @RKQQ]:Y);F#W+/\ :VF_\_\
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M4K&SUR_:YO;>%6MP 7D503N]S750;7Q'A9S+#RY?8V^1ZO\ \)%H7_08L/\
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M='_PD_A\?\Q:Q_[_ *_XUT<IK9A_PDWA_P#Z"]C_ -_U_P :.4+,/^$G\/\
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M2W_Y[Z@?^XC/_P#%T ']B6__ #VU#_P8S_\ Q= "'0K9E*M+J!!&"/[1G_\
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M2W_Y[:A_X,9__BZ #^Q(/^>VH?\ @QG_ /BZ #^Q+?\ Y[:A_P"#&?\ ^+H
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M  B.C?\ /";_ ,"I?_BJ #_A$=&_YX3?^!4O_P 53N ?\(CHW_/";_P*E_\
MBJ0;!_PB.C?\\)O_  *E_P#BJ!W#_A$=&_YX3?\ @5+_ /%4"N'_  B.C?\
M/";_ ,"I?_BJ #_A$=&_YX3?^!4O_P 50 ?\(CHW_/";_P "I?\ XJ@ _P"$
M1T;_ )X3?^!4O_Q5 !_PB.C?\\)O_ J7_P"*H /^$1T;_GA-_P"!4O\ \50
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M3\ZX'?=P>2/P[T =8I&T4 +D4  ([&@ W =Z %^E !0 4 % !0 4 % !0 4
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MNT,R2*TA)^5ERV1C;Z$?CZ4 +%I^I1ZLL_VK-KOWM&9&)QB08 Z <Q\>Q_$
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M$@"G*Q+M.<C'S$'/&<\=>E $4%CXD58UN=0@<!XR?+3:<"4%@3CG*#';D^E
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /_V0
?                                          $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>img222477878_31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_31.jpg
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M/#]X<&%C:V5T(&5N9#TB<B(_/O_M $A0:&]T;W-H;W @,RXP #A"24T$!
M    #QP!6@ #&R5'' (   (  @ X0DE-!"4      !#\X1^)R+?)>"\T8C0'
M6'?K_^X #D%D;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$!
M 0$! 0$" 0$" @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,#_\  $0@! P%0 P$1  (1 0,1 ?_$ /,  0 !
M P4! 0             *!@@) 0($!0<#"P$!  $$ P$               (!
M P8(! 4'"1    8" @ # @8*"0H0"@L  0(#! 4&  <1""$2"3$307$B%!46
M48&1,G*R,Q<8"F&AL<$C<R2V-_#1E=4F-E<X6!KQ0E)BDF,T=-0U=J;6)W=X
MX:)35$:'ERA(&4.$155UA8:61V=H$0 " 0("!00*# H* 04      0(1 S$$
M(4$2!091<1,'88&1L<'1(C)R"/"AX4(S<Q14%346-E*2LM(C4],T-QAB@J+"
MXH.3)"47H_%C1$55_]H # ,!  (1 Q$ /P"?Q@# & , 8 P"/G^FWNMIW3VQ
M(7I]N&%TI0>TLAUJI,?5OJ$;4\G*LM6.K##0]SA9 IK\YE+5,I"N>3;&*DVY
M233 0$> /1.F?9/>[W8^B9O9.TY[;L!V7ZR[IWK9Z8WBHQ5#7%AUQ?&3*)C=
M=QT4Q;2 1KN'?*18M%U%3K/F_(&\XB  7Q5WOWK&9N^NJ',ZP[$Z^D=I65*G
MU"4V+IR>J=>>61=FZ?MXE>6>+'1:N5FC-0Q0,'L+G*EE+D;2O5BXM5QT]L%\
MV<4# & , 8 P##-H[N7<MD]DKVE.]KM;L:5 7K=47!=90TLXC[5-5?5R<K'I
M&CMS2$HA&R%@,ZC32"[5-,ZH- #Y %'S!<=J:U=P#J?W7W#N[<! 6W/H6]PM
MRIMPN+3KU6ZG9JS<]<,HQFY<U!K ;+E1-#;=E)!=-%&92;D2+'&7$Q>2$Y%*
MU*"VG@"O=8]L-YRD6\KMH5AG%VN+NAMZQ*RM9-58O7L[()RTQNNO3R+E-FUD
MH;2=?CTC&>J*"=PZ<I)*&.*A1RKM22;Y 946#ML_9-'C-ZVD6KINDLW?LU4E
MVKQ(Y ,5RW50.HBHBJ'RBB0QB\#X#EH'+P!@# & , 8 P!@# & , 8 P!@#
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MC6_=M7;L[?1N*6S37SIG79[.RRC225&C% 'ZQ'V,$ _Z@]->P/\ [5M_V/\
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M)F[5(W1*<H\&M(UB8WJQGWLA() [N4R9(KQJ42*(JF#W@";V6Y**2IB#.!D
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M;JR0=2<FW9MF!9QXF)(-@@HX;F-/V5!-5%HNJ8&S82"=3G@ SC)5=$#B[/\
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M9DNH;S&\OL&/2-O:DDY5K4%:-.I5JU!T4K?3K0%G0:R#"IQ.M'FPY\XQ[QK
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M$OR2SU5I&.GBH,T%'28',(% !, <^WCL<DF\OF)KS>CI[9%M-JG*91,ZXD,
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MD O( /(8!?3@# & 6"]VO[^^B/\ WSJ3_,+8N=CD?@;_ ,4R,M7.7]9UQ(8
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M&>?TV^O=]ZJ=&NMO7O:*\,XV#JW7C6NVQ6O.1>0AI@)&0>N C70D3%=J4'8
M4WE#G +W\ 8 P"P;NR'-[Z)!\/Z9U*'[0:_V.8?VBYS\DZ6;_P 61EJYR_G.
M 2& , BO_K)X@"W541]GNMHA^S]]3Q^YFQWJ[WH6M^7]O!T[QC'$7FPYB-07
M[T./9P'[GAFW2TJIAYNP!@# & , K34W]-NEP^SLRF 'QC9(H _;S$N.)*/"
M^;?]#P,N6-.8MKL^%'Z7R7Y-/\ GXH9\Y-=3U)8&_!48 P#8"9"F,<I"@<_'
MG.!0 Q_* @7S& .3>4!\.?9@&_ -! ! 0$.0'P$!\0$!\! 0'PX$, VB0@\
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M@:-TU!PE?E(*8<TS9-H).SS[8CA6079O)A&);HQB0,BII^Z(*@CYQP"D]_\
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M[,5ZWV_3"=,03ME/H4TYKULMAW4W%,X*M1$PV<-3,59JP.&J"BAS^Z(D<PG
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M^?\  YP[>]MVW:]'?M.CH_*6/L9W'V7XDHG\@S=&JK]%/Q&OYZ-0?X4=??\
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MG_[4_$5M!S\)9HY&7KLO&3L4X,H5&2B'S>18K&2.9-4J3IHHJBH9-0H@;@?
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M0H  <!@'98 P!@%@W=K^_OHC_P!\ZD_S!V+G8Y'X*_\ %,C+5SE_.=<2& ,
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M6H?3^VWHFB1>M]9=YMPPE2AW$@Z9L'.O-4RBI%I-R=V[$SEY!G4$#N5#'X^
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M'8PVS[_=XBJS>T]VU6P6^NZ=U!)5NK/WH,FT/6%CKV680332.];$^CC""QB
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MPW-UIGVSMS8E9N2E5"JHIL4FB: *F*MR4HX!*>P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P#0?8/]0?;_8P#7[OMP!@# -/L?'\/V_9@&OP_
M#^]_HX P!@&GV/;_ %?9P#7 & :?"'V_C_T, U^[_5S]O - ^W]O^KC +9^Y
MOS']%+L!])?F8^8?FMM?SS](GZP_F+]Q]'*>\_.M]4_[I?J3Y?\ =WS'^4^Z
MY\GC@'=]5/FGZ-&A?H_\UGS'\TE"^:?F.^F_S-_-_JW'^Z_-;]9?[H?J%Y./
MHOY]_*OF?D]Y\KG /?L 8 P!@# & , 8 P!@# & , __V0
?                                          $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>img222477878_32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_32.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M^64(W+RJE3G:0>=Q/!% #O\ A&IX+5XK2Y16F@,,YE0R;LEFRN6X.7;KGM2
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M)B*R>VCN>& ))4GG#Y/)]7]>U,"2Y\---AH[CRV2WBB3;E<&-B<Y4@XY[8I
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M[]B@ _X1_1_^@;;?]^Q18->@HT#2,_\ (-MO^_8H /\ A']'_P"@9;?]^Q0
M?\(_H_\ T#;;_OV* %_X1_2/^@;;?]^Q0 G_  C^C_\ 0-MO^_8H /\ A']'
M'_,,MO\ OV*  >']'Z_V9;9_ZYB@ _X1_1_^@;;?]^Q0 ?\ "/Z/_P! RV_[
M]B@!/^$>T?\ Z!EM_P!^Q0 ?\(]HW_0,MO\ OV* #_A'M&_Z!EM_W[% !_PC
MVC?] RV_[]B@ _X1[1O^@9;?]^Q0 ?\ "/:-_P! RV_[]B@ _P"$>T;_ *!E
MM_W[% !_PCVC?] RV_[]B@ _X1[1O^@9;?\ ?L4 '_"/:-_T#+;_ +]B@ _X
M1[1O^@9;?]^Q0 ?\(]HW_0,MO^_8H /^$>T;_H&6W_?L4 '_  CVC?\ 0,MO
M^_8H /\ A'M&_P"@9;?]^Q0 ?\(]HW_0,MO^_8H /^$>T;_H&6W_ '[% !_P
MCVC?] RV_P"_8H /^$>T;_H&6W_?L4 5Y-,L;#5-.:TM8H&>1U8QKC(\MCC]
M* -N@!K,$!9B  ,DGM2 JVM_:WN?L\N\A0V,$9!Z$9Z@^M "VNH6MW(8X)=S
M!=X^4C*],C/4>XI@.N?^/FS_ .NI_P#0&H F?<%.T#=VS28&)HU]?7%Q%%<;
MMPC8S!E4!6R,8QU[^O0?BP-[O0 4 % !0 4 % !0 4 % !0 4 !Z4 5+C4K&
MTD$=S>00N1D+)(%./7FA+JB922T9%_;>E?\ 03M/^_R_XT68N>/<KWFH:+?6
MDUK-J5J8I5*MB=1Q^=.S'SKN9Z0Z"D=PAUE'6Z+FX#7*?O2RA><>@'&,4FF'
M-$9]FT,-(ZZ^PEE/[R07B N-NT CH1CV]Z=F+F1J6>H:)864-I;ZA:)#"@1%
M\]3@ 8'>BS#G1/\ VWI/_03M/^_R_P"-'*Q\R[DUOJ5C=2>7;7L$SXSMCD#'
M'T%)IH::>Q:H&% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M],* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * ,^_P#^0EI?_79__1;4 :% "9H 8KJWW2",X.#T]J '*PW%
M<\CMGI0!!<_\?-G_ -=3_P"@-0 ZZMXKB!XY84E4\[9%!7/T-)@<[X=:/[='
M&MO#'<)"WV@)$B[3D;0"O)'7U' H0'4]Z8!0 4 % !0 4 % !0 4 % !0 4F
M!Y!\4?\ D9[?_KU7_P!#:O0PWPL\O$_Q#B:[3DZ!0 4 % !0 'I2Z!U.S^&/
M_(T/_P!>S?S6N7$_"=6%^(]A[UYQZHM !0 4 % !0 4 % !0 4 % !0 4 %
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M:'_Z]F_FM<N)^$ZL+\1[#WKSCU1: "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * ,^_\ ^0EI?_79_P#T6U &
MA0 4 )D4@#([4P*]S_Q\V?\ UU/_ * U $&JR7$=JIMS(K>8H9HTW,%SS@8/
M;V-(#/TQ[HZDC$7+HZ2>:\T.T<,-F#@=03Q30,-82-=1ME%KYGFJY810HTA(
MVXY?C'/UZ>E);AT-FS %I$ K( H^5@ 1]0O'Y4P)Z "@ H * "@ H * "@ H
M #28'D'Q1_Y&>W_Z]5_]#:O0PWPL\O$_Q#B:[3DZ!0 F10&PO3B@ H #TI=
MZG9_#'_D:'_Z]F_FM<N)^$ZL+\1[#WKSCU1: "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * ,^_\ ^0EI?_79
M_P#T6U &A0!7NY'AM)Y8UW2(C,J^I X%(#'T349KJY,;W@N8_LT4I?"C:[;L
MKQ[ ''6@";2;JXN-0FVW1N+-8QMD8*-SYY*X_AQZ_A3 T+G_ (^;/_KJ?_0&
MH FD)6-B.H!/-)@9.B7=Q>P03SR2,9(@Y!@V)DXZ'O[4P(-<M8)[B!)4:>?:
M[0H85<*!C=QD'N._>D!H:+<PW&FQB$!1'\A4(5V\<<'IP13 T: "@ H * "@
M H * "@ H #28'D'Q1_Y&>W_ .O5?_0VKT,-\+/+Q/\ $.)KM.3H% &A81V3
M6Q-R%+F>-!ER,(<[CP?85G-OH7"UM2S9MI:-9L'Q.C*S;H2!Q_M%R.O?;4-2
ML6G&Y#KLL,U[%+$P):%=X#!B&''+#ACP#GWJZ=TM2:MNAF=JOH9]3L_AC_R-
M#_\ 7LW\UKEQ.QUX7XCV'O7G'J"T % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0!D7_B33]-U!+.<R;SMWLJY6,,VU2Q]SQQFD NI^(;+29E
M2Y$F N^1D7(B3. S<],\<9H 6UUQ+G5GTYK&ZAE2/S"TFS;MS@?=8GGMD=C3
M U1TH * "@ H * "@ H S[__ )"6E_\ 79__ $6U &A0 F* (4LK6)2J6\:@
MMOP$ &[U^OO0!':Z9864C26MG! [##-'&%)'U H 6Y_X^;/_ *ZG_P! :@":
M3_5O@9XZ9QFDP.9\/VK6EW%A) &A)D1O- A;CY?F)![^_'O0!>UZT^U+ !,8
MF7=\RQ2L?SC92!['K^% %S18/(TJ &%89"H+JJD?-CT//YTP+] "T )F@ S0
M 9H ,F@ R: #)H 7F@!#TH \A^*/_(SV_P#UZK_Z$U>AAOA/,Q*]\XFNPXPH
M$)BD%P_&F"%HV&!Z4N@=3L_AA_R-#_\ 7LW\UKEQ*]TZ\+\1[%7G'J!0 4 %
M !0 4 % !0 4 % !0 F: #- !F@ S0 9H ,T &: %H 3)HV$A :5]1BYI@<[
MJWA6+4]4^U_:6CCE$8GCVYWB-]ZX/\//7KQ^=(!FJ^&9-54B:_VF:/R;DK%C
M?&'W +S\I[9YS0%R_IFCK8ZAJ-Z\QEEO9%/W<;$485/PY_.F(ULT##/% "!L
MT@>@H-- +0 4 % &??\ _(2TO_KL_P#Z+:@#0H * ([B9;:VEG?.V-2QQZ"D
MP,S1]5N+V9X;N%(I/*2=/+.1L;. ?<8-,"Y=G;<6A/ $AY_X U $6HW$T=HQ
MM42>3(_=[@"P[X).,TF!GZ"UU#;00W$5Q#''" /-DB*C ''R_-^= B_<ZDMK
M=0HR%H9%8F1 6VD8P, 'KS^5,HL6LW^CJ9)@['G)79^G:@1+YL?_ #T7\Z0$
M+7]JC%6N8@PZ@N.*+V*4&]A/[1L_^?J'_OL4N9#Y)]@_M&R_Y^H?^^Q1S(.2
M?8/[1LO^?J'_ +[%',@Y)=@_M&S_ .?J'_OL4<R#DD']I67_ #]0_P#?8HYD
M')(/[1LO^?J'_OL4<R#DD/CO()<B.>-\>C XIB<;$AECQ_K%_.@@\L^(]A>7
MOB*"2UM9YT%LH+11E@#N;C(KOPTDEJ<&(BW/0X_^Q-5_Z!MY_P!^&_PKK]I'
MN<:IRML']B:K_P! V\_[\-_A1[2/</9R[!_8FJ_] V\_[\-_A2YX]P]G+L']
MB:K_ - V\_[\-_A1[2*ZA[.78/[$U;_H&WG_ 'X;_"CVD>X>SEV#^Q-5Q_R#
M;S_OPW^%+GB"A*^QUOPZT^\LO$CRW5I/!']G8;I8RHSD<9-88F47'0ZL-&2E
MJCU?S8_[Z_G7GGI!YL?]]?SH /-C_OK^= !YL?\ ?7\Z #S8_P"^OYT 'FQ_
MWU_.@ \V/^^OYT 'FQ_WU_.@ \V/_GHOYT )YL?]]?SI ,DN88EW/,BKZE@*
M!I-D?]HV7_/U#_WV*7,BN2?8/[1LO^?J'_OL4<R#DGV#^TK+_GZA_P"^Q1S(
M.20?VE9?\_4/_?8HYD'LY]@_M*R_Y^H?^^Q1S(/9S[!_:-E_S]0_]]BCF0<D
M@&HV?3[7#_WV*+BY&B<31D9$BG\:HG8RO$=Q.GAZ]:Q=OM0C_=^7RV<]A50M
MS*YG4OR-H\J_M+QKN(W:I_WZ;_"N_DI'F\U07^TO&G]_4_\ OTW^%')3#FJ"
M?VEXT_OZG_WZ;_"CDICYJ@O]I>-?[^I_]^6_PHY*8<U03^TO&O\ ?U/_ +]-
M_A1R4Q<U0/[2\:_W]3_[]-_A1R4PYJ@'4O&H'W]4_P"_3?X4<E,.:H>N:1.[
MZ/9-<O\ OS GF;^&W;1G/OFN"5DVD>E!^ZN8O"6/^^OYU"-+"^;'_?7\Z8!Y
ML?\ ?7\Q0 >;'_?7\Z *%ZP?4M,VD'$KDX[?NVH TJ "@!DJ+)$T;J&5A@@]
MQ28%#2](BTQI&26:5V58PTIR0B_=4<=!G_ZYH0%BY_X^;/\ ZZG_ - :F!.Y
M(4[<$]LT 8&AZI>7ER(;A7#*K>:'CV@-NX"G^(8SZ]!SZH!?$*+Y]D_F*SH6
M(@>-G#C@$X4$\#CI_%1U#H:VF((M-MXP[,%0 %@0>GH>1^-,"R:0+<\1\5_\
MC3?_ /74UY59VFS[#+X7H1N9%8\S/0]E$*.8/9104<UA>RC>P $G Y/I3YA.
M$5N+M;;NVG;G&<<4KM$J,$^42ESMFGLHG>?"[BYU3_=C_FU>AA-F?.9M&S1Z
M4*[3PA: $Q0 8H%8,4!8,4!8,4!8,4#%Q0 4 % !0 4 % !0 4 % !0 AI <
M?\1?^1<'_75:Y\1I!GIY8KUT>4UYG,SZSV:"CF8>S04<S'[-!1S,/9H*.9A[
M)!1S,7LD(.IJHO4QKTDH/T9] 61_T*#_ '!_*O8CLCXJJK3?J6*HS$Q0 8H%
M8CFG@MHC)/+'%&" 6=@H&>!R: L5WU/3T$>Z^ME\P93,J_,/4<\T@L5]/U9+
MZ[EM_LMS;NB!U\]5&]22 PP3Z=#@^U,+&H!Q0%@Q0.PM !0 4 % !0!GW_\
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M<-N>41E78]LDL> . !@"F!J@8&* %H * "@ H * "@#/O_\ D):7_P!=G_\
M1;4 :% %.]TV"_ \XR J& V2,HY&#D X/XYI6 J6.ERVDPF>Y$KB%(!^[V_*
MN??J<]?TH DTS3YK.::6::*:68Y=UB*DGL,ECP!P!_\ 7RP+-S_Q\V?_ %U/
M_H#4 329\ML#)QP,XI,#EO#L;17Z(;5X?W)+(1+^[^Z0,LQ!ZD<<_+3 6^C4
MZG=O?V6HRJ'5;=X9"J(-HZ88<[L\_A2 Z#23<'2K8W0<3[!OW_>S[^]-@6CU
M]*%N'4\_UCP#=ZGJ]Q>1WD2+*^X*5.17#/#<TKH]S"YG"C34>5Z%+_A6=_\
M\_T/_?)J?JLNYU?VS#LQ/^%:7X_Y?H?^^31]4EW%_;$'T?\ 7S#_ (5G?_\
M/]!_WR:7U27</[9@NC_KYA_PK2_/_+]#_P!\FCZI+N']L171A_PK._\ ^?Z#
M_ODT?59=Q?VQ%]&+_P *TOQ_R_0_]\FG]5EW'_;,.S_KYG1>$?"\_AR:[>:Y
MCE\\* %!&,9_QKHH4W#<\K&XR.):LCJQUKH/.V'4#"@ H * "@ H * "@ H
M* "@ H * "@ H * "@!#2Z@<?\1?^1<'_75:YL3\#/3RO^/$\IKRS[ *!BT
M% !0 4 (.IJH;F%?X'Z,]_LO^/*W_P!P?RKV8[(^'J_Q)>I8JS(* "@ H *
M"@ H * "@ H * "@ H S[_\ Y"6E_P#79_\ T6U &A0 G2D!##<P7 8PS1R[
M3@[&#8-,!R31O*\:R(73&Y0>5STR.U $5S_Q\V?_ %U/_H#4 ,U*Y-K8R2;U
M0\ $J6Y/& !R32 R=$LX=/O!;-' +E81F01LKR#C+9/7MGWI@3W4T^HS75LB
M6PBMI4QYK'+N-KCIT&2/6D!I:==?;=/@N2FPR*&*YS@]Q3 LX% ;!M H 7%
M&-X@UK^Q[.0QP32W!ADDB"Q,R95<X9AP/QJ7H!F^&M9N;JZU*TN[Q9UMS'Y4
M[!5+%H]Q'& <>W;K5 9-OXIU)+>]:*9[F!YEAM+FXC5!G!WR$* -@QQW/K2V
M0):G8Z)=-?:)87,D@DDE@1V8<98J,]/?--B1H8H&)M /2@+W%QB@ H * "@
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MNC"O\#]&?0%E_P >4'^X/Y5[4=D?#5?XDO4L51F% !0 4 % !0 4 % !0 4
M% !0 4 9]_\ \A+2_P#KL_\ Z+:@#0H 3.* #<*  '- %>Y_X^;/_KJ?_0&H
M DFV^4^[[N#GC-)@<WX;U.266WLA"5MUM\Q.RJ"0NT#.&/."*8&MJ.D#47B:
M1D_=$[<AP0#C^ZP]* +UM#]GMHX000BXXS_4D_K0!+0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % "&EU X_XB_\ (N#_
M *ZK7-B?@9Z>6?QXGE->6?8(*!BT % !0 4 -'4U4=T85_@?HSZ LO\ CR@_
MW!_*O:CLCX:K_$EZEBJ,PH * "@ H * "@ H * "@ H * "@#/O_ /D):7_U
MV?\ ]%M0!H4 4=1GO(8R+2V$I*MEM^-A XX[\T@,70)'C>5(YY9HWMHW8S.6
M_?G=N7)Z'@$KV]J &>%VN!> RS/*\]J))QO8B.7/*D'.#R>!@<=*8'0W/_'S
M9_\ 74_^@-0 E^URELS6JHTJG.';:"._.#_*DP,#P_/=R:G%)<I#BZMC(&1D
M+<$8!P@/?UH0'54P"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@!#2Z@<?\1?^1<'_ %U6N;$_ ST\L_CQ/*:\L^P0
M4#%H * "@ H :.IJH;HPK_ _1GT!9?\ 'E!_N#^5>U'9'PU7^)+U+%49A0 4
M % !0 4 % !0 4 % !0 4 % &??_ /(2TO\ Z[/_ .BVH T* $P*  *!T% "
MXQ0!5N?^/FS_ .NI_P#0&H FE<1HQ+*OH6.!28'.^';BXDO75[?RW*L;AO*5
M S[N-I'WAR>>>@YYY$!TW>F 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 (>M(#C_ (B_\BX/^NJUS8CX&>GEG\>)
MY37EGV""@8M !0 4 % #1U-5#=&%?X'Z,^@++_CR@_W!_*O:CLCX:K_$EZEB
MJ,PH * "@ H * "@ H * "@ H * "@#/O_\ D):7_P!=G_\ 1;4 :% %.^OH
M[&%W8@OM9E7NV!G%("AIFI7%S<^3<>4<VT=P&C! &_/RG)/3'7BCH!'H6MW&
MI7DD4T:H@B$B$(5W<D94DG>O3YN.O2F!K7/_ !\V?_74_P#H#4 4O$0A.CS"
M?3Y-0C)'[B,9).>OJ,=<BD!F>&$\NY(^RO -APLEH59!D<>:0,_0@_6F!U-
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M5CIP_P"7VX_\=_PH^J06J%+-:K5K':11>5&D8.0@ %=25DDCRI/F?,2TR0H
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M^H?^_@H /MUI_P _4/\ W\% !]NM/^?J'_OX* #[=:?\_4/_ '\% !]NM/\
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M@ :QLVN!<-:PF8?\M#&-WYT *]C:2"(/:PL(?]7F,'9]/2@">@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@")K:!IUG:&,S(,+(5&X?0
MT $=M!%)))'#&CR'+LJ@%C[^M "B"%=N(D&UBRX4<$YR?J<G\Z (S86925#:
M0[9CF0>6,.??UH 6.SM82IBMHDVYV[4 QGKC\A0 L-K;VV[R+>.+><ML0+D^
MIQ0!-0 4 % !0 4 % !0 4 % !0 4 % '__9
8

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>img222477878_33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_33.jpg
M_]C_X1;T17AI9@  34T *@    @ # $   ,    ! @H   $!  ,    ! +$
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ #J8
M   G$  .I@   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M,SHP.#HQ,2 Q,CHP,CHQ-      $D   !P    0P,C(QH $  P    '__P
MH ( !     $   (*H , !     $   !Z          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
M 7X" @ $     0  %6X         2     $   !(     ?_8_^(,6$E#0U]0
M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(               $  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  E * # 2(
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M3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M  !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O
M &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU
M;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0
M !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O
M;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O
M;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0               !"
M;&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q 6
M  IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M         %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I
M;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T
M3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P
M4F5C=%1O<&QO;F<      #A"24T#[0      $ !@     0 ! &     !  $X
M0DE-!"8       X             /X   #A"24T$#0      !    !XX0DE-
M!!D       0    >.$))30/S       )           ! #A"24TG$
M"@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F
M  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M      $X0DE- _@      '   /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z   .$))300(
M       0     0   D    )      #A"24T$'@      !      X0DE-!!H
M     T,    &              !Z   ""@    < 9 !S '  ,  R #$ 8@
M  $                          0             ""@   'H
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   'H     4F=H
M=&QO;F<   (*    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   !Z     %)G:'1L;VYG   ""@    -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
M  (_\        #A"24T$$0       0$ .$))3004       $     SA"24T$
M#      5B@    $   "@    )0   >   $5@   5;@ 8  '_V/_B#%A)0T-?
M4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #$
M &%C<W!-4T94     $E%0R!S4D="               !  #VU@ !     -,M
M2% @(
M        $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&)K
M<'0   ($    %')865H   (8    %&=865H   (L    %&)865H   )
M%&1M;F0   )4    <&1M9&0   +$    B'9U960   -,    AG9I97<   /4
M    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P    #')44D,
M  0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P>7)I
M9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C
M     !)S4D="($E%0S8Q.38V+3(N,0              $G-21T(@245#-C$Y
M-C8M,BXQ
M              !865H@        \U$  0    $6S%A96B
M        6%E:(        &^B   X]0   Y!865H@        8ID  +>%   8
MVEA96B         DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R]W
M=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                                         &1E
M<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P
M86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@1&5F875L="!2
M1T(@8V]L;W5R('-P86-E("T@<U)'0@                            !D
M97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#
M-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET
M:6]N(&EN($E%0S8Q.38V+3(N,0
M=FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(
M3 E6 %    !7'^=M96%S          $                        "CP
M  )S:6<@     $-25"!C=7)V        !      %  H #P 4 !D '@ C "@
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MY?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$
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M]#[3ZGYF_P"U;.#_ *;]!]%?-*22GZJ27RJDDI__V3A"24T$(0      50
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MP  1" !Z @H# 1$  A$! Q$!_]T ! !"_\0!H@    8" P$
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ML[/Q,_[R'ZY_]".#_KW[]_KM>VW_ $V>V?\ 92_^;KW_  ,OW@?_  CN^_\
M9-)_T'U[_9V?B9_WD/US_P"A'!_U[]^_UVO;;_IL]L_[*7_S=>_X&7[P/_A'
M=]_[)I/^@^O?[.S\3/\ O(?KG_T(X/\ KW[]_KM>VW_39[9_V4O_ )NO?\#+
M]X'_ ,([OO\ V32?]!]=_P"SK_$[_O(;KO\ ]"*#_KU[]_KM>VW_ $V.V?\
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M.N%!U!V1EAM!L/M&KS";Y7-MM"+%R4>7J,W4[4Q]-F=PT4Z4'VC469IJ:LI
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M "B_Y^_T)_Z3KV'_ /=7>_?4<K_],SN7_<TC_P"]7U[M_B_E_L]>_N_\HO\
MG[_0G_I.O8?_ -U=[]]1RO\ ],SN7_<TC_[U?7NW^+^7^STDOCIVEV1OC<7R
M*V;V/4;4R.5Z1[JH.JZ#,[-V[G=H46Y:*HZ+ZD[3;(KM_<&\=^U%')]]V/-
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MDHLSO??E'MS[',.]%#NR*K[#K9\E7:%GDA6"B=RJJGLLN-_W/^K4?+Z[)/\
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MV7_SO^YO_2C/D%_]M+W[]YWG^^+7_G!#_P!:NO?[7_5^WKW^@G9?_._[F_\
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M:_\ ."'_ *U=>_VO^K]O7O\ 03LO_G?]S?\ I1GR"_\ MI>_?O.\_P!\6O\
MS@A_ZU=>_P!K_J_;U[_03LO_ )W_ '-_Z49\@O\ [:7OW[SO/]\6O_."'_K5
MU[_:_P"K]O0%0TM;U_\ ,OJ38VW=T]D5.T]X_&/Y,;NS6WMU=D=C[YQ]5N/8
M7;GQ0Q^W,C3T^_MQ9REHJZ#'=A9FG61-$BT]0%5EC-B;!H[ODS>;I[2)+I-W
MV]!((U5E1UW#6H*@$(Y1"RC#:5P=*T<H">'1X_87Z9Z__]3?X]^Z]T3+^8=_
MV0-\X/\ Q3_Y,?\ ODM]>Q)R#_T\?D;_ *7=E_U<'5X/P?ET.V#QLF5ZBP>)
MC:F%9D>OL/1(]:[11:S@HU1W\/J B-VNO( O^/9!N8_Q[=Z?Q-_EZKU43U[\
M"/DQL_JKKK#R1_%[=.=ZGDW=L7K_ *+WV^Z=T]!P=5;LZCVGUMC\EN/<J=5;
M7[)W%OK:]+MV+[1-Q8S(Y&GV_D*_;ZYL"NCR<2*K>IZOCTZ2.+_E@]Y;0J][
M;BV]N[I+-;JW/O+L3>&W*.:JKNOMI;7CW'\\.H/DEM[$8=L;U1O2IR]+4[,Z
M^2C,.=7<:[<S%'24^-"T5=5-[KX4O^_&_;_L].^-'_OI?]7Y=.$7\N[Y-[KK
MOECB^PI^@JC8GRWV[UC0;M?;V]]Z'/X"LV-U?U)UUNC 4AQ71&P5JX\F_5-4
M:7+4>8V[0HE<M\,I-O?O"E_WXW[>O>+'_OH=1>XOY37:_<>_L95=G=R8GLW8
MB[NK(L]F,]6[@VMVON3KINS?@MN^*#(YC8VWL1*G8,/7/Q3R>-&8P\U)6_QV
M3'Y(.)JBJ?'^\*7_ 'XW[>O>-'3^R6OV=*'8G\OKY5]50YBKVIO#XS=B[QWQ
MV=V%NO.]@]O[7K*_>&SL56_)K='=^T-Z;*HAL??6TI=_9''[L:CW-1O!#3KE
MZ"AR,.3>:GC=?>%+_OQOV_[/6O%C/^A#_5^75ZGM5TGZ][]U[KWOW7NO>_=>
MZ][]U[HD/Q6_YG5_,&_\6TVM_P# =?%7V,.;/^27R-_TI#_W<MRZ=/ ]'>]@
M_IKKWOW7NO>_=>Z _OKOOK;XR]2;P[J[?SS[>V#L7%G)9JN2%ZJKG0"RT6*I
M'F6LR.1D8^E%LSBY'T:QKL6Q;MS'ND>S;+:F6Z:M,$X&:FE?D,^9 ZWU5=_*
ME_FD="?,"?LGIC;%/N/979F-WWW3VS@-L[M_AK#=W6_9W=>]M^83/X;(4=7%
MY-PXRAWI ,SBE)DQY4>+4I.D?>X/M'S#[=QK<WX-UM1H/%BJ17SX T!\C4Y(
M'VOS6[6YH_#J\'W%G2?KWOW7NO>_=>Z][]U[JKKOK^6;U-\ANT=Q=M[SW[V=
MAMP;A&%6:FV[/M>.@6/![=H\%&@@S>T\JQ#0XVYU,;K<D\GW 7//W>>5>?>9
MIN:[O<;J*]ET:XPY57\--":A45*IVK4$!>U:+CK++VH^^=SW[0\C;!R+M?+6
MT3V%B9"SRIN+$^+(\K Z9P"I>1R>%=1)JS$D)!_)=^/H,C#LON8-*M0DK"HV
M6#(M6)!5+(?[H7=:D3/Y ?UZS>]S[!Z_=/Y01F9-]W0,W$@0 G[<9ZDF;^\4
M]T;A52XY%Y<= F@!H+]@$X:0#.>W^CP^778_DO\ Q^5BR]F]SJS,[EA4[,#%
MY/\ .,2-H7+/^3]3[TOW3N3T%$WO= *UP+<9]?AX_/CT\O\ >-^["BB\E\O@
M4IB'<.'I_;\/EUYOY+_Q^9F=NS.YV=V+L[5.S"S.?'=V8[0N6/B3D\^D?T'M
MP_=3Y3+:SO\ NI;U_0K_ (.F7_O%/=&1HG?D7EPND?AJ3!?DK'_ I\?"?T1V
M_+KMOY+_ ,?W96;LWNAF2/PJS5.S"RPZ8D\2D[0)$>B!!I'%D4?@>]#[J/*0
M?Q!OVZZ_6D%?VTZN/[QCW5">&.2.7M'IX&X4_9X_7'_AEWX^_P#/R^YO_.C9
MG_V(>Z_\"?R?_P!'S=/V6_\ T#UO_DXQ[J_],1R]_P X-P_ZW]>_X9=^/O\
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MDLV"<'H1/9CT5]>]^Z]T&O;O_,J^TO\ Q'>[_P#W0Y?W[KW3)\>O^9"])?\
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M3!+N.MKS08R@ALL>/4K!$@ 1!<EA1[?,W]:V -%\/<#3'$[:]3C[!^S'2F
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MIIH1,%I8@GNO=9?]'W3.:VWE^N]E9BEPVY-TT>ZZ2AFS&W8=H1Y7<>!R_6U
M^[Z(TFV]F?QO-]99/%X-Z2JI!#52S0P.DC&.-H_=>Z$;>_1'4&[:JCGW!D9,
M52':<74^#QM'DMN4F+HL931[TV\FW-K#*15U3B<_/CMYSXW(+32)'6>"EBD0
MF!%'NO=-6V=G=/U>1_O_ +0['K%H>U=U;/S>0@3<NUYZ/>.Z-@U6"RF"V]0T
MSXZLJ:;(8*DV^ZRXS&"GJ*F*60,Q6"#Q>Z]T84[TV_)F4P]/GJ.IK'ILJTB0
M5$,E+CY<!)B(\O39"HBG"XVKF_O%0F%9V=K2W46(U>Z]TO/?NO=$XW5_V7UT
M7_XJ!\K_ /W]/PO]B>V_Z=[O_P#TO=N_XYN73P\NCC^PQTSU_]??X]^Z]T3+
M^8=_V0-\X/\ Q3_Y,?\ ODM]>Q)R#_T\?D;_ *7=E_U<'5X/P?ET97KS_CPM
MD?\ AF;7_P#=)![#VY?[G;O_ *=O\)ZKU"WOFNO\!2XC+]@O@*."#.TU#@Z_
M<5+!4"FS^4J1@\7]C+-#(::JR/E\>I"A96()L?=.M= 5C]U?%9,AMV:@J=BU
M5?A8-X4^UYX*5*\O_?&OI)MY"A:JAE-=E<QD</215TLS&6IK2OEUR'W[KW2I
M?>OQNQ#P4]7D>LJ)LWA<0]!0G&X@U%7MAJ_+5.WZ:>)<>\DN,&XL/DJJ"-[H
ME8DDBC7=C[KW3?D>U_CE2XC,YV;([,R]-CL0^\<@4PT&2JDH*7&9C*T;WK:9
MS][64.0R>F[:VJZ^I^DD\NOW7NI>3[7^/L<@&0R6S*K,X7$^<8 8."IW+0TI
MP4.:_AT&WEIGR4,RXG<8J1"#_P !*Z3^Q(S-[KW0E['GV#O?:=!N;:^&Q#8'
M<J5^6AB.&HZ5:R;+P-292>OA6'345&3@_;J&?49D]+EAQ[]U[I45^SMHY6>>
MIR>U=N9&IJH13U-17X/&5D]13A:9!!/+44LDDT(2CA&EB5M$@MZ5M[KW76-V
M;M##5*5N'VKMO%5D<=/$E7C<'C*&I2*DH?X921I/2TL4JQTV-_R>, V2#]L6
M7CW[KW7.LVCM3(TM-0Y#;&WJZBHJ44-'1UF%QM52TE$OVNFDIJ>>F>&"E'V4
M-HT 3]E./2MO=>ZD8K;NW\"M4F#P6&PR5U745]:F*QE%CEK*ZK(:KK:I:."$
M5%74L 9)'N[D<D^_=>Z)U\5P&[K_ )@Y8!BWRSVL&N+Z@/AS\5; W^H'L7\V
M ?NKD84Q^Y#_ -W+<NG3PZ.]["'377O?NO=</''R="79E=CI7U.FG0QXY9=
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M?:__ * _;O\ ]K_W[_64]U?^F+G_ .<Z_P#077O!;^#KW_#VW\KK_O+?:_\
MZ _;O_VO_?O]93W5_P"F+G_YSK_T%U[P6_@Z]_P]M_*Z_P"\M]K_ /H#]N__
M &O_ '[_ %E/=7_IBY_^<Z_]!=>\%OX.O?\ #VW\KK_O+?:__H#]N_\ VO\
MW[_64]U?^F+G_P"<Z_\ 077O!;^#KW_#VW\KK_O+?:__ * _;O\ ]K_W[_64
M]U?^F+G_ .<Z_P#077O!;^#KW_#VW\KK_O+?:_\ Z _;O_VO_?O]93W5_P"F
M+G_YSK_T%U[P6_@Z]_P]M_*Z_P"\M]K_ /H#]N__ &O_ '[_ %E/=7_IBY_^
M<Z_]!=>\%OX.O?\ #VW\KK_O+?:__H#]N_\ VO\ W[_64]U?^F+G_P"<Z_\
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MC$X3??86^\)MV3#0T>,K*KMWM-^RL[!O%<$<?N3(P8+(ULL.,_A]5@],3/\
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M*NCD$8--.\Y0IK9O?NO=0W^+5)A9.T<]@-QO/N/L7%=B1*<U0T@Q&,K-U8S
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M +L<7;^IY/OW[OO/^4&?^?7JCKL;SV<.1NS;8.HOQF,8/6006_S_ .H@VO\
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M(:H5K,#]20+<M.=5/]>.=6TU7]];AZ>3$G/'%0?3TXGH.L*\>C*_[/U\0?\
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M_P"C;V!_]?\ W[^K?,W_ $R]_P#\XY>O:)?]]_RZ]_LT'QJ_[R)Z0_\ 1M[
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MH&CD\4KI?2S ^ZW4^O7SN?Y^'_;TSY%?]0O2G_OD>O/>?_W?O^G6[+_S4?\
MZN-T>6_^XO\ J].B8_&;9/1FY.W.O:'>M%D>U,3/UWV/N#>NP<QE]G]/KA.R
MJ1]Q24& 7=6\>].H<?N3:N1Q6-I,^U+2YO 9YS+]N923;V.^;K[>MNV7>&MX
M6VTJ1IXW9%:#'Q4R?+ &2>-&>K&<#\4?Y?T[T^'W1O'KY<(FZVJLKVUA?E!C
ML7G#V(WRABZW/QXINKL]!4[C7IUNC(4W(>S_ .$_:_8(,U_$; 8GW&UUSCS]
M;L\%IM4C:HO%;M<J8_W9]3]66III];^A]&333C13JWCW-*^%CJL;Y*XW8NT]
MS5>"Q/3VU^JL\TNS\_/1;!^0]/WILW:J9/;[^/:E/N#&Q[PIZC([KKI7S2U:
M9K5CI&-."K$CW(_*%X9[(D<U?O0_*U^E_B^2_P ;_P"]-_$:^UO_ !G]O182
M25"$DHIU*A/I!,:1$A?H"8HU7_@J@?0#V,F9G%'8D?//2W0G\(_9UU_:U_V_
M'+#J_M>&>>IJIXM7U\<U36S2.OT9Y78\LQ-_%EUS2^(WB2?$:FK?Z8\3^=>O
M:$_A'[.N[G7Y+GR:I&UW]>J;3YFU?JU2Z!J/]JPO[HK,CO*C$2-Q(P3]IXG\
M^O:$_A'[.O D1B($B(1S0B(&T8BJ(TBJ(@GZ1'/%&JNMK,J@&X'MWZFX&ND[
M]W'N.?MSG\^O:$_A'[.NPS*@C5F6-7:54!(19'G6I>0*. [U*B0GZEP&^O/M
MLNY;46);UKGJW7BQ;3J);0GC2Y)TQ_ZA;_I3_ <>]$DLCDDLO ^8^ST_+JNA
M/X1^SKC[UU;KZI7PM1'^'7Q.9E5F/QJZ,)9E!),O5VV&E))!),C&[?U/U]\L
M.=_^5[YU_P"EU??]7&Z#<Y(X&G'HTMA_0?[8>R7IOKUA_0?[8>_=>ZZ*JPLR
MJ1<-8@$:E8,IY_*L 1_0^_=;J?7KVE;6TK8DFUA:[-J8V_J6-S_C[]UKKE[]
MU[H+.V.NZ+MOJ_LCK#*5M5C\;V5LC=^P:^OQZI/4XZEW9MVIP%950O(K$2T8
MG<K]!J O:P(=VVZEVW<(;M4UJCJPKGX3PX_ZOLZL#2O6N5_T"[_''_O)GNW_
M ,\&S/\ ZF]Y*?\ !1<Y?]&:R_WA?^@>E7[PN/X?Y==_] O'QR_[R:[N_P#/
M!LW_ .IO?O\ @HN<O^C-9?[PO_0/7OWA<?P_RZ]_T"\?'+_O)KN[_P \&S?_
M *F]^_X*+G+_ *,UE_O"_P#0/7OWA<?P_P NO?\ 0+Q\<O\ O)KN[_SP;-_^
MIO?O^"BYR_Z,UE_O"_\ 0/7OWA<?P_RZ]_T"\?'+_O)KN[_SP;-_^IO?O^"B
MYR_Z,UE_O"_] ]>_>%Q_#_+KW_0+Q\<O^\FN[O\ SP;-_P#J;W[_ (*+G+_H
MS67^\+_T#U[]X7'\/\NO?] O'QR_[R:[N_\ /!LW_P"IO?O^"BYR_P"C-9?[
MPO\ T#U[]X7'\/\ +KW_ $"\?'+_ +R:[N_\\&S?_J;W[_@HN<O^C-9?[PO_
M $#U[]X7'\/\NO?] O'QR_[R:[N_\\&S?_J;W[_@HN<O^C-9?[PO_0/7OWA<
M?P_RZ]_T"\?'+_O)KN[_ ,\&S?\ ZF]^_P""BYR_Z,UE_O"_] ]>_>%Q_#_+
MKW_0+Q\<O^\FN[O_ #P;-_\ J;W[_@HN<O\ HS67^\+_ - ]>_>%Q_#_ "Z]
M_P! O'QR_P"\FN[O_/!LW_ZF]^_X*+G+_HS67^\+_P! ]>_>%Q_#_+KW_0+Q
M\<O^\FN[O_/!LW_ZF]^_X*+G+_HS67^\+_T#U[]X7'\/\NO?] O'QR_[R:[N
M_P#/!LW_ .IO?O\ @HN<O^C-9?[PO_0/7OWA<?P_RZ]_T"\?'+_O)KN[_P \
M&S?_ *F]^_X*+G+_ *,UE_O"_P#0/7OWA<?P_P NO?\ 0+Q\<O\ O)KN[_SP
M;-_^IO?O^"BYR_Z,UE_O"_\ 0/7OWA<?P_RZ]_T"\?'+_O)KN[_SP;-_^IO?
MO^"BYR_Z,UE_O"_] ]>_>%Q_#_+KW_0+Q\<O^\FN[O\ SP;-_P#J;W[_ (*+
MG+_HS67^\+_T#U[]X7'\/\NO?] O'QR_[R:[N_\ /!LW_P"IO?O^"BYR_P"C
M-9?[PO\ T#U[]X7'\/\ +KW_ $"\?'+_ +R:[N_\\&S?_J;W[_@HN<O^C-9?
M[PO_ $#U[]X7'\/\NO?] O'QR_[R:[N_\\&S?_J;W[_@HN<O^C-9?[PO_0/7
MOWA<?P_RZ]_T"\?'+_O)KN[_ ,\&S?\ ZF]^_P""BYR_Z,UE_O"_] ]>_>%Q
M_#_+HF'>O_";'?,7<_7&P?C=V-D<IUYE]I97.=C]N=LTM*F'VI48W<5/C\3M
MW;-'M$T]=E\_58ZOGJC1SC[+53JYL5N!3L?WC[8[+O5]S78QC<RU%B@4*#@'
MX5 IYCTX9J:=*!<H172*_9ULC_R^_@1UW_+ZZ;;K#96]-X[WR.;R5-G-Z9_=
M69KUP]9NB9(FGEVIL02R[?VM!+)$/\FIXQ6L+%YF.C3CES[SS><^;L]_/9QV
M\8KI"*%(! K4BF33R  K0UI7HL:C#.?MSU8?[!76NO_3W^/?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U\YS^
M?A_V],^17_4+TI_[Y'KSWG_]W[_IUNR_\U'_ .KC='MO_N+_ *O3JG(>FVGB
MTKSBW%IY"#),+?260@%F^I(Y]S5"3;H\=N=$;<0O:#]H% ?SZ4Z$_A'[.N)1
M&C\3(IB_XY%08_\ .^?]!&G_ #WK^GZN?K[T %X8[]?^WK77_IJYU<:YKU;K
MG_;\G]LJR%_[>EZG[UUU?72U9^Z1]#+ZOU<^W))))5TRR,R^A)(_GU70G\(_
M9UU[IU;KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KZIGPK_ .R.?B;_ .*T
M]$_^^LVQ[Y8<[_\ *]\Z_P#2ZOO^KC=!JX_S]&D]DO5.O>_=>Z][]U[KWOW7
MNO>_=>ZX>..Q7QII.NXTK8^1BTEQ:Q\C&[?U/U][!(X'KW7*P_H/>NO5/7K#
M^@]^Z]4]>L/Z#W[KU3UZP_H/?NO5/25W?-EJ;:6YYL)'42YFEV]EI,5'1B.2
M>;)QXV5J..'S<M(:G3IY!/\ K^_=>J>J%NJNZ?YOV%V'TUFNT=B5"3Y#K#8&
MQ]VUM7UB=Y[DPN6SN\^E]T[N^1^\NJ-F9#%[OW!NG"]:[WRFW/[C8RL@RL>7
MVOF,J: 41CB+&IOXCTJ\*'_?I_;TOMS]Z?S3L[U7M?=\O5%)M3-9_</4&V<Q
MUMM?JO>L^\,7+68OH#<N[>R$WB.PE%-M7+56XMST<NW?X(9<"E#)'D<M(**N
M$WM3?Q'KWA0U/ZO\^I^]/DG_ #(=D=5XRLV?LNL[6[,V]U)E<G7[8SWQ.[7Q
M.1[#[*7!]Q5N4I*;.[6W-0;4P-'UEF]L;5I53PJN\SDIUQ_C-91^+6IOXCTS
MCI3YOM?^97LZFW7646W<!O"IVOVIAZ[*Q/T[O>+#;^VC5Y[XG;.R>"V).^_W
MJ]@[7Q^"W[OO+FOD&=F$N!:4W-)7>;VIOXCU['0;8?Y-?-SY"?$;NFHZVWG@
M9NZJ+(_$6BPF[^L.@M_8F7:B=S[AZ[JN\,%1[5RV_P#>=9NZGZZVAGJZ>+<6
M,F@CCQ(%2B"1?XB=ZF]3TXH\ TD%1\\]"EM'N[^8Y7=E=*[&.W<#6[:WGO3&
MT?<&[\]\9>V]JTW1.W\-MSN?.[GVL^X<OV7-@.U,GE7V1@:"CW+CD3&&LJR
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KV0                                                        $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>img222477878_34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_34.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MN0_DW_Q5'UZKY?U\P_LRCY_A_D'_  FFJ?W(?R;_ .*H^O5?+^OF']F4?/\
M#_(/^$TU3^Y#^3?_ !5'UZKY?U\P_LRCY_A_D'_"::I_<A_)O_BJ/KU7R_KY
MA_9E'S_#_(/^$TU3^Y#^3?\ Q5'UZKY?U\P_LRCY_A_D/C\9:FR2DK#\JY'#
M>H'K[TUC:EGL2\MHIK?\/\AG_"::I_<A_)O_ (JE]>J^7]?,K^S*/G^'^0?\
M)IJG]R'\F_\ BJ/KU7R_KYA_9E'S_#_(/^$TU3^Y#^3?_%4?7JOE_7S#^S*/
MG^'^0?\ "::I_<A_)O\ XJCZ]5\OZ^8?V91\_P /\@_X335/[D/Y-_\ %4?7
MJOE_7S#^S*/G^'^0?\)IJG]R'\F_^*H^O5?+^OF']F4?/\/\@_X335/[D/Y-
M_P#%4?7JOE_7S#^S*/G^'^0?\)IJG]R'\F_^*H^O5?+^OF']F4?/\/\ (/\
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M\$^J"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MR?B'_"'I_P!!-?\ OR?\:/J/][\ _M)_R?B'_"'I_P!!-?\ OR?\:/J/][\
M_M)_R?B'_"'I_P!!-?\ OR?\:/J/][\ _M)_R?B'_"'I_P!!-?\ OR?\:/J/
M][\ _M)_R?B'_"'I_P!!-?\ OR?\:/J/][\ _M)_R?B'_"'I_P!!-?\ OR?\
M:/J/][\ _M)_R?B'_"'I_P!!-?\ OR?\:/J/][\ _M)_R?B'_"'I_P!!-?\
MOR?\:/J/][\ _M)_R?B'_"'I_P!!-?\ OR?\:/J/][\ _M)_R?B'_"'I_P!!
M-?\ OR?\:/J/][\ _M)_R?B'_"'I_P!!-?\ OR?\:/J/][\ _M)_R?B'_"'I
M_P!!-?\ OR?\:/J/][\ _M)_R?B'_"'I_P!!-?\ OR?\:/J/][\ _M)_R?B'
M_"'I_P!!-?\ OR?\:/J/][\ _M)_R?B'_"'I_P!!-?\ OR?\:/J/][\ _M)_
MR?B'_"'I_P!!-?\ OR?\:/J/][\ _M)_R?B'_"'I_P!!-?\ OR?\:/J/][\
M_M)_R?B'_"'I_P!!-?\ OR?\:/J/][\ _M)_R?B'_"'I_P!!-?\ OR?\:/J/
M][\ _M)_R?B'_"'I_P!!-?\ OR?\:/J/][\ _M)_R?B'_"'I_P!!-?\ OR?\
M:/J/][\ _M)_R?B'_"'I_P!!-?\ OR?\:/J/][\ _M)_R?B'_"'I_P!!-?\
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M_P!MMC '^IR/RZ?ATH^J/^;\!_VDKW]E^/\ 7^8?\(>O?5%_[\G_ !J/J/\
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MJ184 % !0 4 % !0 4 % !0 J]&^G]:!,S[F_FM]4L[7[(3#<,4,Y< *P1F
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M,Y_$G)-*S*YH]R3R9?\ GD__ 'R:+,.:/</)E_YY/_WR:+,.:/</)E_YY/\
M]\FBS#FCW#R9?^>3_P#?)HLPYH]P\F7_ )Y/_P!\FBS#FCW#R9?^>3_]\FBS
M#FCW#R9?^>3_ /?)HLPYH]P\F7_GD_\ WR:+,.:/</)E_P">3_\ ?)HLPYH]
MQ1#+AOW;]/[IHLPYH]RE<Z-'=WEO=2Q7)EMV#1[99%4'D9V@@'@D<CH<468K
MQ[F*G@R>YU.2ZUB=;Y/(:W5$M/)9E+*V9&!^9AL&"-H') S3UZ(7NWU9M66B
MPZ?+-+!;R^=/M\V21F=WP, %F).!D\=.32LQIQ74N>3+_P \G_[Y-%F/FCW#
MR9?^>3_]\FBS#FCW#R9?^>3_ /?)HLPYH]P\F7_GD_\ WR:+,.:/</)E_P">
M3_\ ?)HLPYH]P\F7_GD__?)HLPYH]P\F7_GD_P#WR:+,.:/</)E_YY/_ -\F
MBS#FCW#R9?\ GD__ 'R:+,.:/</)E_YY/_WR:+,.:/</)E_YY/\ ]\FBS#FC
MW-+3U9(&#*5.[N,=A6D-$<U5IRT+569$<W^J-)[%1W,)]<LHO$,>AR,Z7<D'
MVB/*_(ZY((!_O#&<>GT.)-;]#,L?'GA^]M[JX^V"W@M[DVP>?""9@@?<@SEE
MVL#GTYZ<T6%=&R-4M?,GS*HAAMTN6F+#9L;=SGTPA.:0QMKK%A?64UW97"W,
M<.0XBY8$#.TCJ#@C@^HH JZ=XELM5E$5FLDQWE2R%74 !26W*2N!N ZYSGC@
MTPN;%( H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H </
MNFF!@W_BS3-,OA:7<=_&QE2$2?8)C$7<@*!(%V\D@=>M KV);'Q/I&HZD]A:
MW):=2X7,3JDA0@/L<C:^TG!VDXH'<CO/%FE65Y-9R/<-<1JY");2$2,J%RB/
MC:S[1G:#F@+DUAXAL=2DCCM"TK/G_5E755 &6+*2,9..N<@^AP!<U:0!0 4
M% !0 4 % !0 HZ&@#(OO$%M8ZC]@$4L]R(UD9(R@P&+!1EV&2=C8 R?E-,+F
MA+=P02VT4L@22X<I$IZLP4L1^2D_A2 S[GQ#;6^J-IR0RSW"!2P0HN-V< ;F
M&XX&<+G''J*87(8O%>GS7,EM&LKW*2&+R5VER^YAC ;Y?NL?FQP">QH%<W*0
MPH * "@ H * "@ H * "@"U;_P"K/UJT9SW):9!'-_JC2>Q4=SF-5\-P:S=S
MO=,R*8XA#)$Y66)T,F6![9$F/<$@U)I8R#X8U:QUJZN=--H-/FFR+3SG@ 06
M\,2G*+QM,3?+T(;U H"Q!9^$=7M_#MOI$DEJ1'800-*D[@[X'9DXV\JV0#R"
M!D<]: L=+I%G=P-=7%W;P0SRE0%CN9)LJHXW,X'.2>@_.@93.E:TLT,RWB//
M(T;3R&0J$ ?+*J8(92I*C.,=>I)H$=#2&% !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % #A]TTP,:ZTR34/$5K<7()L;&/S(4)&UYR2-Q
M'^PHXS_?/I0!A:7X5U:QFTN"66T:ST02FR96;S)BR,B"08^7:K')!;<<'CI0
M*Q=&G:]+XF-U=VNGW%E%,9+9VO)0\(V%1B/R]N[DY.2?F//:@-2:#2M9AU)+
MF2[CE\U8S,0Q38P=BP50/F4J0H!(QMSU)- '0TAA0 4 % !0 4 % !0 HZ&@
M#C?$7A.XU#6+J^L[73;G[=9K9S"^!/D[2Q#I@'=]\Y7Y<X7D4Q-$<7ASQ%:>
M(=/NC=V=[;V\JHLLX<S10B/:P'.,L1DG&22,\   68S6_!]]J-YJ$L4&FL=5
M@BCGFGW%[1U&-\7R_-Q@CE<%0<GH &C8O=,UB64W,<\;R!F2.+SFB5(]I"G>
M%)+%MK'C';M\P!O1*ZPHLC[W"@,V,9/<TACJ "@ H * "@ H * "@ H M6_^
MK/UJT9SW):9!!>,4MF93@\?SJ9:(TIJ\K&*^J1QEP]U"IC*JX+*-I;A0?3.1
MCUK*[.GEB1MKEHJ!SJ%OM._!WKSLSOQZ[<'/ICFB[#EB2SZDMJ(S/.D8D<1I
MNP-S'H![FB[#EBAT-]]HA2:&9)(G&5=,$,/4$478<D1MSJ<=E 9KJZB@B! +
MRE54$\#DT78<L42"[<L5$BE@ 2,#.#T/Z&B[#DB.^T2_WA^0HNQ\D0^T2_WA
M^0HNPY(A]HE_O#\A1=AR1#[1+_>'Y"B[#DB'VB7^\/R%%V')$/M$O]X?D*+L
M.2(?:)?[P_(478<D0^T2_P!X?D*+L.2(?:)?[P_(478<D0^T2_WA^0HNPY(A
M]HE_O#\A1=AR1#[1+_>'Y"B[#DB'VB7^\/R%%V')$/M$O]X?D*+L.2(?:)?[
MP_(478<D0^T2_P!X?D*+L.2(?:)?[P_(478<D0^T2_WA^0HNPY(A]HE_O#\A
M1=AR1#[1+_>'Y"B[#DB'VB7^\/R%%V')$/M$O]X?D*+L.2(Y9Y/+8[NX["G=
MD\BN-^T2_P!X?D*5V5R1#[1+_>'Y"B[#DB5/[;M?MDMF-0MOM42[Y(?,7>B^
MI7J![T78N6.P^#5H;J!)[>\@FB<[5>-E92?0$478<L2Q]HE_O#\A1=CY(A]H
ME_O#\A1=AR1#[1+_ 'A^0HNPY(A]HE_O#\A1=AR1#[1+_>'Y"B[#DB'VB7^\
M/R%%V')$/M$O]X?D*+L.2(?:)?[P_(478<D11<2X;YAT]!1=BY$5;K6+>Q\K
M[9>P6_FOLC\UU3>WH,]3[478<L46?M$O]X?D*+L?)$/M$O\ >'Y"B[#DB58M
M:MIDE:*_MY%B;9(5=2$;.,'T/M1=BY8EK[1+_>'Y"B['R1#[1+_>'Y"B[#DB
M'VB7^\/R%%V')$/M$O\ >'Y"B[#DB'VB7^\/R%%V')$/M$O]X?D*+L.2(?:)
M?[P_(478<D0^T2_WA^0HNPY(A]HE_O#\A1=AR1#[1+_>'Y"B[#DB:%@[/ Q8
MY.[T]A6D'='-524M"U5F17OO^/1_P_G4RV-*7Q(X#Q-!>I<DVMJ\\6H6[6<A
MC7)BDSF*0^BC<^3VXK)'3*YF66F7$WAV^6;39+>ZL=-?3XAL)+2%29'CSG<K
MG9@\YQ]:?426A?U6VO[:_BALC>R6S7-HS$N\F 7<2?,<D#:%SSQUXS20W=;'
M.Z+-J>E^'M#MCI^H^1;6I@N8W^TQ%;@!<?=1F*X!P5^3)/.<53(5TD=C':SR
M>&K-=9B:[OH@I_=DAC(?E!RH&.#R< #GM4]=#3IJ&@--%/=6<]G(CP!5\]L[
M9 ,X"@C 4=@I/'7#9R,(]C=I%!0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@DD' &>G.*+!<W]+U&#5M-@O[4GR9EW+NZCMC\Z0RW0 4 % !0 4 % !0 4
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M(_O+^8H&&1_>7\Q0 9']Y?S% !D?WE_,4 &1_>7\Q0 9']Y?S% !D?WE_,4
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M2V::ZD)DDD9U(9B!TPN/P Q3N+D.TJ30* "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * 'K_JG^HHZ">Z.9\26-YJ3VL5M:W.8+J"7=YB"!PLBLV]
M2V3@ XXZ@$4UH*2N1:9IFNQ7&JM=6^FQ17LL>U8)W;:@4(W5!@[5R/<X]Z-!
M)/431-!U2#4K&YU66U(TVS:SM_LV?WH8IEV! VG$:_*,@<\T-@D[ZG4TBPH
M* "@ H * "@ H * %7HWT_K0)G-^+K2^U/29K"QLYGF.QTDWH(F8-G;("V2O
MJ #P>.::T%)-JR(K?3M?MO%FJ:BD&G?9+N.&)/W[[P(W<Y(V8R1(W?J!Z\&E
MA6:=R;0M.U>TU_6+N^AL8[:\9&B%O,S,-JA1D% !D#/!-#M8:33=SHJ104 %
M !0 4 % !0 4 % !0 4 :>F_\>[?[W]!6L-CEK?$7*LQ(YP#"P(R*3V*AHS/
M#0&9H08S*JABG&X Y ./0X/Y&HL;78V&6TG>9(9(9'@?9*J$$HV <''0X(.#
MZBBP<S)&6)%+,JA0,DD=*+(+LB@GM+H*8)(I T:RC;@Y1L[6^AP?RHL',R;R
MT_N+^5%D%V4M1U32-'C234[^SL4<[4:YE6,,?0%B,T6#F:ZC++6M%U)HEL-1
MLKLR[]GD2K(&VXW8P>VY<_446#F?<T/+3^XOY46078>6G]Q?RHL@NRI+J.F0
M:C#ITMS;I>S*6C@+#>P]0.N.#^5%@YGW+?EI_<7\J+(+L/+3^XOY46078C+$
MBEF"*H&23@ "BR"[*UA?Z9JL)FTZ[M;R)3M+P2+(H/ID46#F?<M>6G]Q?RHL
M@NP\M/[B_E19!=C7\B/;OV)N(4;L#)/046"['>6G]Q?RHL@NP\M/[B_E19!=
MC9/)BC:238B*,LS8  ]Z+(+L@L;W3M4MA<:?<VUW 3@20.KKGZCBBP<S[EGR
MT_N+^5%D%V'EI_<7\J+(+L9$UO.K-"T<@5BA*D'# X(^H/%%@NQ_EI_<7\J+
M(+L/+3^XOY46078>6G]Q?RHL@NP\M/[B_E19!=CA&FQOD7MVHL%W<;Y:?W%_
M*BR"[#RT_N+^5%D%V'EI_<7\J+(+L;(8(5#2;$4L%!/')( 'XD@46"['>6G]
MQ?RHL@NP\M/[B_E19!=AY:?W%_*BR"[#RT_N+^5%D%V'EI_<7\J+(+L/+3^X
MOY46078>6G]Q?RHL@NP\M/[B_E19!=BB-,'Y%_*BR"[$\M/[B_E19!=AY:?W
M%_*BR"[#RT_N+^5%D%V17$UI:",W#QQ"1Q&F[ W,>@'N:+!S,E\M/[B_E19!
M=AY:?W%_*BR"[#RT_N+^5%D%V'EI_<7\J+(+L/+3^XOY46078>6G]Q?RHL@N
MP\M/[B_E19!=AY:?W%_*BR"[#RT_N+^5%D%V'EI_<7\J+(+LMVRA8R  .>U5
M'8RGN351!'-_JC2>Q4=SB->TK5I=>DU31&$=_;V\*)YI(BF0O+O1NV1E6'<$
M#L34FC\CFXM/UGPUJM^EG:W=QI)OR]S(7E62=S;08DS&C.P+^:6VC&[K@ T"
MV-))-2CM%77#JC">%A9BT29]K,[X64HH.0IC +@#@YYS0 B7>HV&A:6JZ=>O
M&;&SC;"S1^2P67<65%+G!" @#N,X% !HHU^_T_9J;:C%)!;72E1OCW.)F$1W
M8!8[-N.>>IS0"N;7B.VN-0^&VI1O;//?2:5*!'Y>7,AB/ 7&<Y["@;V,[Q!%
MJUO-I<>DQW,*?V?<>8;>+.V3=!MSQC=C?@'T/I0#+<]C?V\VHO#<:BZPSV_V
M9#*[#&4WG_:!YR#D#!QCF@"G876OOKPM+RWE2X%Y(S2K+,8OL^XE1M\ORN4V
MC[V[/OD4!J.U:POQX@\1WMFMY%,^G6B6\T6[!;?-NVCHQ *G&#C.>] ":V;^
MQ>]MK1]5?4&11I17S9(2^,_O&&5&7SGS#C:!B@&6[FTU&:\,OG7Z9U-4Q'(Z
MJ(-@R,#C;G/S=0>A% %FYT];WP=?:?J*7LL3O-&1&2TQC\U@N-W+?+CKG(]<
M\@=#G+.\UFS@U&\@MS+;62PS_:Y; V4UPB$^9$Z,!N(0L58 +DB@1H[M2U6X
MTJ=)+]+*ZLKRY;RV=,$O$8%8C[I",<#V/7F@9SVH77B33M&T6Z:YU-);K3[5
MKUFS\MP;FV4KAN$8J\HV\9YR.*8M32NGNKB>XN%@U>30H+JU=!)%/YZN&82[
M%QYK( 4/3KG' I :*7=V^J010#4_[0:\WL)8IEM_LI;U(V9\O''WMWXT#)M+
MTZ]N#IYOKC4AYMO.;@&>1/G#ILZ$;2%+8 QGOG% ":K97M_X=\/M=6TMY%"\
M4NHVK+\\RB)LY4XW$.58KWV]#TH S=56ZN%NM1\.6%]I_FFVBDE6U:&28_:(
MP6\MAN^6/?DLN,-W H%Z#=0EUG3KG5%1[U[.WOU^SQRK<N)8S;H2!)&K. )"
MW.",@CTH 9=7?BF2YN84M+F":Y6(Z;(992L \M<^8%C920^[=YA&>U :FSX)
MA:S&L6DUO=PW U&YE/G))Y;(\SLA1F^5LJ03M.?7FAC1U=(84 % !0 X?=-,
M#DM0U%K+QIM:'5YK9[&0.L%O,\._*E0I4;0V _.<Y.,]*!=2#PYJ-S/;:C<"
MUU"V>0I'#;W$-RVPG< Y:51DDD;MO"X&2>M (;X<%\VLV/DQZG%;PV;IJ0OB
M^'N,IM*[R0QXDRR?+@CGI@!!<R3RZE+;72:DU\-1ADC$44IM_($J;?FQY?W1
MD_Q9!["@#.%UXBU+61!;17^FQW$=U"S.)I!#+C,3,67:.A.5.WD+DY&06I;;
M5]1U+P[-K$?VB*07*Q&V42%?W8*R+F(,ZCS-XWJ#]U>U SJ]#GDN=%M9IK:>
MVD=,F*X8LZ\]R>?SP?4 T#1?I % !0 4 % "CH: .<U:]6U\3Z4BKJCO)(!)
MY,$SVZH5=1N*C8#OVYW<@8/ IBZE3P_J%R[:W9(FI^=]I<VLE];3!,>6,89U
MQMW*W XY]Q0")/#4@DO8Q;PZC&L5L4O/M:2J&FRF,;^&/#Y9<CD<GB@$8-ZM
M_/<6D=W%J\NHV^LI/*!#(T MQ,0A7 *8"E.GS<$GC- B]9SZIJNHW-HHO=/2
M:VG028N#Y,VY=A+.H3(PY^7Y>W((R#*TVHZW>::-=,D\44EPJQV828JT:HRM
MN,(+)F0LV[!&%7/6@1W.G2-+IEI*\4D+O"C-'*270D#@D\DCOFD46: "@ H
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M''"SMYA17V@ <_*P.>@&<]#0.Y;L[R&_M5N("VPDKAE*L""000>00012 GH
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MHX^;([YH"QOZ78OI]BL,LHFF+,\DBJ5#,3G@$DCTY)/'4TAER@ H * "@ H
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MV_\ OH?X4<J#GD'V:'_;_P"^A_A1RH.>0?9H?]O_ +Z'^%'*@YY!]FA_V_\
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M(/(?T'YT68<R#R']!^=%F',B:%"B$'UJEH1)W9)3)"@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _
L_]D                                                        !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>img222477878_35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_35.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( -4""0,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /?Z .+G^).F67B/5]'O+:X1].YWQJ9 ZB+S7; 'RA5_.@"=
MOB-H:3& I>F=8WF:(6K;U18TD+$?[LBGUYQU&* *\/Q5\+W"2/!-=2JAFR4M
M7.1$H:1NG101S[C&30!9;XD>&%L].NA?,T>HN4M0L9S(P<(!CMDGC.,@$]!0
M!#:?$_P[?NR69O)BDT=NX6U8;)78JJ'/0Y4C_P"M0!$_Q9\)1PRS-=SB.%D2
M9C;O^Z=@=JMQP?E/L.,XS0!>M?'-C?ZMI^GVEK<NUVQ5C(OEF(>4)5)!Y.5(
M^GUXH HV'Q-TJYU+5;&XC>*73KU[9VB#R*%$BQAF)5=I+,!@9^IYP +J/Q(L
MM+U?Q%I]S9R!M'CB9&#@_:6=4(0#L<R*._4GM0 K_%+PW;:3#J-Y/)!"^U"5
MC+@2E WEC');#>F.#Z&@ T_XB0WFMW^GS:;+;+:/*N7?YVV>1R5P H_?CJW&
M!USP 3:3\2_#6MR0+87$\J3/'&LI@8('<L%4DC@DHP_"@"_=^+].T_5I--O8
MKFWE2"2X#&,,&C0@$C:2>20!D#)X% %#4_B#IMGX8M];M4^T^?)$@MC($E >
M0)G:,GC.<=Z &+\4/"Y\[-S.BVY"W+-;OMMR9#$-YQQEP1^O2@"6Y^(_AVUN
M-*MVEN'FU2&":U1(&)=9MWE_0G:>O2@"+4O'\.F>*FT1[-9"L]O!\LX\YS,.
M"L>/F5<?,<\#F@""_P#B1!!=K'9V(GMFOSIRW4TQBC,RJS/CY6)5=H&0.23Z
M4 6-=\=+H26IEM[1S-927AS>; P0J-D9*?.QW<# SB@!NN_$C2]$OH=.-M/+
MJ$LD:" @(=K2*A;/3@L.#C/TYH 73?B1H]Y8BXGWQ;;@6\QB5I(X6:5HT#-M
M&,E/3 R.<$$@$TGC0V_BJYTF?3G%O'*MO',C[G>4Q"4C9C 4(2=Q/:@"*Z^)
MOAVR-L)GNE>ZA%Q OV=LR1%68.!Z81CZ_F* %C^(^BWFB:OJ.G":<Z9:I=/%
M)&T1='4LA!(Z$"@!%^(>G6VFW][JB""&QG\F22W<S(?D1\@D*Q^^!C;V.,XH
M F3XB^'I8XGBGEE\^:2"%4C):1TSO '48"D\XZCU&0#%D^,6@1(UZW.D!]HN
ME+%F'EQMPFW^])M()&,9YZ  U8?B9X:G:[5;B9392&.[#PE?LY#A/FS[GMGH
M3T% '84 % !0 4 174YMK2:<123&)"_EQ@%GP,X&2!D_6@#F8OB-X<D6T9KI
MXUNK6*Y3<F3^])")A<DN=K?* ?NF@!MQ\2_"D-G/<Q:G]J6&$RE;>)GW#RS)
M@'&,[58X)'0YQ@X &6?Q*T*]UAM,C2\$JV_VAF,.0JX0X*@EMW[Q>-OK0!*W
MQ&\-QWL]O+=R11PVXN'GDA98\&1H]O(SNW*1C'48Z@@ %^Q\8:!J=_!8V6H+
M/=3(SK&D;D@ D'=Q\N"I&&QS0!7/CWPPJVI&JHQNXTE@5(W9I58L%*J!DY*-
MQ[4 7;/Q1HM_J?\ 9MM?+)=X8A-K ';C< 2,$C<,@'(SS0!1T[Q]X;U.\ALH
M-0Q=RLJ+$T;<,REE4L!MR5!(&: (6^(&D1W-Q%)#=(EO?+I\DI1=HE9BHZ-G
M&1UQ0 D_Q'\.PS^2D]Q-(J2O($MWS%Y:ACO! *Y!!!/'N* )KWX@^%=.9UO-
M7CAV<,61B,@J"H(&"064$ DC/- #;;X@>'KNYDBM[B>1(XT<RK;2%<M(8PG3
M.[>N,8Y)P,T :=WXDTNQL8+VYGDBMYAN5S!)P!C)8;<J.1][% &5#X_TFX\.
M)K<4%Z;9[T6*HT(5S(9/+'!(&,]\_J"* 'Q^/M"W7B7+W%I+9SF"X26W8^6P
MV\LR!E .Y<'.#F@"3_A._#9L)KV+4EFAALC?L8T8_N02N[IURI&.O% %#_A:
M'AE;2.XDN9%1P[ 1*)R%10SLWE%MH 89W8- '7PS1W$$<\+J\4BAT93D,",@
MB@!] !0 4 % !0 4 % !0 4 % !0 4 % !0!7NK^TLMGVJXCAWYV[VQG%1.I
M"'Q.QK3I5*GP*YR\^C^"+G4[[493;M=W\;1W$GVEQO5D$9&-V!\H XQ^=1]8
MI?S(T^J5_P"1_<4=3\,^$-4U]-4FU (/)>*:**Z>/S=RHF2RL"!MC QT/>CZ
MQ2_F0?5*_P#(_N)#X6^'QMOLZQ6\<7F2R8BNY$.90!(,JP.U@!E?N\=*/K%+
M^9!]4K_R/[B1_#G@!S,3#:#S3$V%G91&8QA#& W[LC_9QGO1]8I?S(/JE?\
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M?S(/JE?^1_<;2S>&X[V^O$NH$N;Y52>19R&8*"!CGY< GD8H^L4OYD'U2O\
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M'%92CRR:[&T)<T5+N1TBPH * "@ H * "@ H * "@#US1_\ D!Z?_P!>\?\
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M<ZT5?IZ(2IX><G%:OU=S*=VD=G<Y9CDD]S7.W=W9UI)*R$H&>G^$O^18L_\
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M_,BOKI+N97CA,0"A<%LDGUX 'Y"IJ34W=(NE3=-6;N5J@U"@ H * "@ H *
M"@ H * "@ H * /7-'_Y >G_ /7O'_Z"*^DH_P */HCXW$_QI^K_ #+M:F 4
M <G+XV6*[E@$%M*4NTM@L-X&==URD!+KM^0_O-P'.<$9% &RGB#3))9(H[AG
MEC<(T:Q.7!(8@;<9Z(WY&@"O<^*]+@=8DG\R9IU@"!6&6+ ,HXY8#)V]?E([
M' !9.O:< Q\YLINWKY3[H]N,[AC*]1UQP<T :5 !0 4 % !0 4 % !0 4 %
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M.<M]T#G/ Q0!IT % !0 4 % !0 4 % !0 4 % &%!X4T^&[DGW3D'R_*43R
MQ;5*_*P;/(8_G0!:/AW26MX(/L2".W\OR@"1L\L$(!ST&3@>Y- &G0 4 % !
M0 4 % !0!4O]/AU&.&*X^:%)5E:,]'V\J#[!MI_X#0! N@::MPTZP,'9G;B5
M]H9_OD+G"D]R .I]30!/9Z796$T\MK;K$\^WS-I.#M&!QT&!QQ_2@"W0 4 %
M !0 4 17%M#=1>5.@>/<K;3TRI!'Z@4 4[S0M-OY4DN+;<T84+M=D "G(X!
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MBA8=%M;O5!F26UBN7:"/:BB0@*O+$YR<9Z=^*+#OIJ31>+-/EGAA1)B\K!
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MCQ*;M+&.RMRES?PK-#'.5#A" 2S)G. #CJ.<#(SFG85RQ!KT9TNXOI?+=;=
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MO'*MYWW=N(B3QGJ!S@>X -6'XC>%)E5UU7;&PC(>2"5% ?.PEF4 !L'!/7%
M"ZIXZTJR\-:GK%F6O180)</"%:,LK_=(W#H<'GV/I0!HP>)]'N+]+*.[(N))
M7A17B= TB#+("0 6 ZC.>#Z&@#DK/XM:?)K?V&\M/L\)FN(?-CF\UHS$P7,B
M!<J') 7KDG% '2P^-/#]S<3V]O?F::W&9TCAD8PC.,N ORCZXXYZ<T ,A\=^
M&IGC1=3"M)!]I3S(I$W1;6?>-RCY=J,<]\&@"O\ \+(\);8S_:X(E<QQX@D/
MF." 57Y>3EAP.?R- &I9^)=(OY1#;71:4W#6OEM$Z,)%4LP((!& #STXQG-
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MT*.:/<.278/M,'_/>/\ [Z%'-'N')+L'VF#_ )[Q_P#?0HYH]PY)=@^TP?\
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M% '%?$#_ )AW_;3_ -EKRLQ^S\_T/<RC[?R_4XNO+/="@ H * "@ H * "@
MH * "@ H * +-C82W\CI$T:[%R3(X4=<#]2!^-73IN;LC*K5C25Y"P6$MQ=O
M;1M&77OORIYP "/4D#\:<:;E+E0IUHP@IL?%I-Y-:FX6,"/ *Y8 ME@O ^I^
MG!IJC-QYOZWL3+$4XRY6]?\ @7&0Z==W$7F10EDQD'(YZ\#U/!X'/%3&E.2N
MD5*M3@[-BOI=Y$FYX@HQG!=02/89R:;I32NT)5Z<G9/\R.YLKBSV^?'LW9QR
M#TZCCN/2IE"4/B1<*L*GPL@J30* "@ H * "@ H * "@ H * -/PY_R,-C_U
MTK?#?QHG)C?]WGZ'JU?1'R)PGCW_ (_K/_KF?YUY&8?%$^@RGX)>IR->:>R%
M !0 4 % !0 4 % !0 4 % !0 4 % &O_ &+&XC$%S([R6YG4&(*,9(P3N]17
M3[!.UGTOM_P3B^LM7YEL[;_\ J_V5<$JJ&.1G^ZJ."3\VW^9Q6?L9=/ZZ&WM
MX+?3_AK_ )"'398YD25E0.C.&Y(^4$_7M2]DT[,%6BU=>7XD,EK)%")&*X^7
M(!Y&X9'Z"I<&E<N-12=E_5B&I- H * +UGI4U]:O+ RF175!&>"V?0UK"BYQ
MO$YZF(C2DHRVMN2MH=UO(AVRKCY64X#_ "ACC\_QJGAY7TU)6*A;WM/TUL-D
MTAXH0QF0N692%Y (91U_X%^E)T6E>_\ 6G^81Q";M;^K-_H,FTFZMQF78GR[
ME!;!88SP.O2E*C*.Y4<1"7PEFR\/W%[#:S1N/+F+!C@?)@X]>:TIX>4TFNIE
M5Q<*3E%[K\2K_95SQ@*?[P!R5^4M@X]@?RK/V,OZ^\V^L0_KUL21:-<2-& T
M;!P&^1@3MW;=V/3--4).W]>1,L3"-_+\[7L(-(GDD5(&65C$LF.G49Q^E'L9
M-VCV#ZS&*O+36Q4NH/LUPT6[=MQSC':LYQY78VIRYX\QZOH__(#T_P#Z]X__
M $$5]%1_A1]$?(8G^-/U?YEVM3 XKX@?\P[_ +:?^RUY68_9^?Z'N91]OY?J
M8YBLKE(+?S%W"-7;;$J%0$Y&1RY)(XQV-<UH22C^GE^)W<U2#<K=6M[]?P'7
M>G6<,B6Z28CSM,QP< LO7W )_*G.E!/E7W_-$TZU22<FM>WR8?V3IP>-3/*=
M\\<7W@N Q;+<CM@4O8T[K7JE^8_K%:S=EHF_NMIN5ELK>?<?FC(A1E/\#'9\
MW...?Z\U"IQE]R_(T=64//5^N^G4RJYSL"@ H * "@ H * "@ H GM;R:SW>
M2VW<03R><'./S_E5PFX;&<Z4:GQ$MO+>);2&WCD =P6F0-NR.V?QS^5.+FHO
ME^\B<:;DN9_(FDUJ>2-U:"'>R;/, 8,%W;@!SC@@8X[5;KR:V7]:D+"QBTTW
M_2MV)%UV]DE9(XH\R."B1AAM;&/E /Z'/-4L1-NR1#PE.*NWMWMMOJ0)JT\;
M2LJ('<YW9;Y3C'3.#^(-0JTE=FKP\79/IZ?Y$=]J,VH,IE55P2V%+8R>IY)_
M3BIJ574W'2HQI;%2LS<* "@ H * )K-MMU'B)9"> K8QDC'?CWYXJH:2V,ZB
MO%ZV-1;>W35[/(@\B1]QQR,'GG( Z$<=./7-='+%5([6.1SFZ4M[H9<M9S65
MRT.V21!&/,$0CSRV2%'M@4I<CB[>72Q4%4C.*EHM>M^W4R*YCM"@ H T_#G_
M ",-C_UTK?#?QHG)C?\ =Y^AZM7T1\B<)X]_X_K/_KF?YUY&8?%$^@RGX)>I
M5N;?3KJZ> .H$1R3%$J%0<#'&=_KG''K6<HTY2Y>WE_5S6$ZT(J7?N[_ /#%
M9-/M7NXK9Y!''M9&E..2)2/P.,?F*S5.+DHO[_F:NM-0<TKOM\A)M-T^,1!)
MY"S\') VG!Z@C/8>G6ATJ:M9CC7JN]UM_7<B-C!+;2RJ&C=(U90S84C8"><=
M<]N,U/LXN+?];%*K*,E%ZZ_J95<YV!0 4 % !0 4 % !0 4 2V]M)<NRQ[,J
M,G>X48SCJ2/6JC%RT1$YJ"NRR+S4+=@0S*8D^SYV#@9SMZ>M7SU(_+0R]G2D
MO77_ ()$DMY"P"!T:-1C"\J V[^?-2G..W]=2W&G+?K_ )6_(>UY>SW23'YI
M5!4 1+COD;<8/4]J;G.4K]?0E4J<8N/3U_4;//=S0!95Q&I'(B"].!D@<XZ4
M2E-JS_(<(0C*ZW]2J05)!!!'!![5GL:[A0,* )$N)HXC$DA5"V[ XYP1U^A-
M-2:5D0X1;NT3IJE['"8EFPF,?=&1P!P<<< =*M59I63,W0IMW:'G6;[<K"55
M*DL-L2+R2">@]5%/V\^_X(7U:EM;\62/)J6H1QRL58*#'&/D0D'@@+QGKBJ;
MJ5$G_D2E1I-Q7J]V1^;J-K)$@#JUH[*GR [6)Y'3GFIO4@TNQ7+1FF_YAIU*
M\'EDNOR\KF)><#&3Q\Q XR<T>UGH/V%/5?J_Z1--KM[)Y9#A'489PJY8[BW7
M'3/;IQ5/$3=OZ\R(X6G&^G]6M_3W(X=9O[=56.90%  S&IQC('4>AQ4QKU([
M,J6&I2=VOQ95GN)+F0/*06  R% SCUQU^M9RDY.[-804%9'K&C_\@/3_ /KW
MC_\ 017T='^%'T1\AB?XT_5_F7:U,#BOB!_S#O\ MI_[+7E9C]GY_H>YE'V_
ME^IQ=>6>Z% !0 4 % !0 4 % !0 4 % !0 4 % &G:WMJNCO9SEU<R,X80K)
MP5 [L,'BMX3BJ?(_RO\ J<E2E-U54CV[M?HRW#K-I"3Y:2QEUWNX7+>82-V/
MF'R\>O>M(UX+;^G]^QE+#5);M.WY=.CU(;;6S!=0L-Z01N'\J/@ ^9N./^ D
MC]*F%?EDNW_!_P BIX7FBUU?7Y6_/4BO[^&XLHH$DF=HR.70*.^3]XY))Z\?
MC4U*BE%)?U^)=&E*$W)I:_UV7]=C,K ZPH * "@ H * "@ H * "@ H * -/
MPY_R,-C_ -=*WPW\:)R8W_=Y^AZM7T1\B<)X]_X_K/\ ZYG^=>1F'Q1/H,I^
M"7J<C7FGLA0 4 % !0 4 % !0 4 % !0 4 % %BSNS9N["*.3<NW$BAAU!Z'
MZ5<)\CO8RJ4_:)*]O0TO^$A(CPMJ/,!QN+ @C?OY&.N>];_6=-OZO<Y?J>NL
MM/\ @6[C+?6H[4*L=O*5202INGYW#/!.WE>>G'?GFE&NH[+SW_X&Q4\,YZMK
M:VW_  =_,2/6E5@9+4,&CV28;&X_+R.#CA!Z]_6DJ]MU_6G^0WAGTEUNOQ_S
M)AKGVF]$DX"0")E:-B6#?,6&,#KG;S[5?M^:5Y;6_P""1]5Y(6CO=:_*W^9B
M.[22,[DLS'))[FN1MMW9W)**LA*!A0 4 % !0!HVNJ+:V1MS"TASN&Y@5!]<
M8R#]"*VA5Y8\MOZ_KS.:I0YY\U[?G^?Z$\NLPR+-Y=J\4DKEQ)YH.TE@V?NY
MZ@=,?GS5NNG>RM?S\[]C..&DK7E=+R\K=REJ5TMU=9B4+#&-J >F22?Q))_&
MLJLU*6FQM0IN$==V5*S-PH * /7-'_Y >G_]>\?_ *"*^DH_PH^B/C<3_&GZ
MO\R[6I@0S6MO<[?/@CEV]-Z!L?G4RA&7Q*Y<:DX?"['.SZKHULY$^B-&AN%M
MXW,,1$A,ZP9&&R '=<Y ..@-3[*G_*ON+]O5_F?WLO\ F^'\'$-L2"!M$&6.
M02,+C)&%8Y'H?0T>RI_RK[@]O5_F?WL@N-0\,6P^861^95^5$[E1UZ<!@3W
M.:/94_Y5]P>WJ_S/[V3F7P\L:R&*T"MNZPCY=I ;/'RX) .<8R*/94_Y5]P>
MWJ_S/[V7O[+T_P#Y\;;_ +]+_A1[*G_*ON#V]7^9_>P_LO3_ /GQMO\ OTO^
M%'LJ?\J^X/;U?YG][#^R]/\ ^?&V_P"_2_X4>RI_RK[@]O5_F?WL/[+T_P#Y
M\;;_ +]+_A1[*G_*ON#V]7^9_>P_LO3_ /GQMO\ OTO^%'LJ?\J^X/;U?YG]
M[#^R]/\ ^?&V_P"_2_X4>RI_RK[@]O5_F?WL/[+T_P#Y\;;_ +]+_A1[*G_*
MON#V]7^9_>P_LO3_ /GQMO\ OTO^%'LJ?\J^X/;U?YG][#^R]/\ ^?&V_P"_
M2_X4>RI_RK[@]O5_F?WL/[+T_P#Y\;;_ +]+_A1[*G_*ON#V]7^9_>P_LO3_
M /GQMO\ OTO^%'LJ?\J^X/;U?YG][,^6X\.P33PR1VBR6^P2+Y(."[;5'3DD
MD  <Y(]:/94_Y5]P>WJ_S/[V%K<>';VZ2UMXK5YV5V">1@@(VULY'!!X(/-'
MLJ?\J^X/;U?YG][-#^R]/_Y\;;_OTO\ A1[*G_*ON#V]7^9_>P_LO3_^?&V_
M[]+_ (4>RI_RK[@]O5_F?WL/[+T__GQMO^_2_P"%'LJ?\J^X/;U?YG][#^R]
M/_Y\;;_OTO\ A1[*G_*ON#V]7^9_>P_LO3_^?&V_[]+_ (4>RI_RK[@]O5_F
M?WL/[+T__GQMO^_2_P"%'LJ?\J^X/;U?YG][#^R]/_Y\;;_OTO\ A1[*G_*O
MN#V]7^9_>QLFGZ;%&TCV-N%0%B?)!P!^%'LJ?\J^X/;U?YG][*,$^@7-P+>&
MVA>;<5,8M3N0C&=PV_+]Y>N.M'LJ?\J^X/;U?YG][#3I-)U+B/21$_4I+;*"
MH[$]AGTZ]>.#@]E3_E7W![>K_,_O9H?V7I__ #XVW_?I?\*/94_Y5]P>WJ_S
M/[V']EZ?_P ^-M_WZ7_"CV5/^5?<'MZO\S^]A_9>G_\ /C;?]^E_PH]E3_E7
MW![>K_,_O8Z/3[*)P\=G CKR&6, BFJ<$[I(3K5)*SD_O+-69$4MM!,0988Y
M".A90<5+C&6Z+C.4?A=CFX?$&CR7FGVTFD20'4)&2V:2*/:X6-W+<,<#$9Z\
MY(XZX7LX=D/VU3^9_>:3W6A11>9(ENBY*X:'## W'(QD<$'/H<T>SAV0>VJ?
MS/[R.74= BB9PEO(%=4(CB!)+.(^/[V&(!QGGCKQ1[.'9![:I_,_O'&^\/*\
M2,]FK2%0H* 8)8HH/'!+ J <9((ZT>SAV0>VJ?S/[S1^P6?_ #Z0?]^Q1[.'
M9![:I_,_O#[!9_\ /I!_W[%'LX=D'MJG\S^\/L%G_P ^D'_?L4>SAV0>VJ?S
M/[P^P6?_ #Z0?]^Q1[.'9![:I_,_O#[!9_\ /I!_W[%'LX=D'MJG\S^\/L%G
M_P ^D'_?L4>SAV0>VJ?S/[P^P6?_ #Z0?]^Q1[.'9![:I_,_O#[!9_\ /I!_
MW[%'LX=D'MJG\S^\/L%G_P ^D'_?L4>SAV0>VJ?S/[P^P6?_ #Z0?]^Q1[.'
M9![:I_,_O,I=4\.-&)$\AU/F?<@+8$9PY( X ) )Z<BCV<.R#VU3^9_>&MZG
MH.@6TDU[% &2,R^4L:EV4$#('U('..2!1[.'9![:I_,_O+*R:,TRP^5 )&<(
MJM#C)(8C&1S]UN?8T>SAV0>VJ?S/[PLI=&U%0UG';SH5#!TB!4@@'AL8/!'Y
MT>SAV0>VJ?S/[RY]@L_^?2#_ +]BCV<.R#VU3^9_>'V"S_Y](/\ OV*/9P[(
M/;5/YG]X?8+/_GT@_P"_8H]G#L@]M4_F?WA]@L_^?2#_ +]BCV<.R#VU3^9_
M>'V"S_Y](/\ OV*/9P[(/;5/YG]Y6O?[)TZ%);N*WBC>18U)B!RS' ' ]:/9
MP[(/;5/YG]Y#'=Z#+!>3I]E\JR<QSL8P!&P4-@Y'HRG\11[.'9![:I_,_O(8
MM2T&2&:9HH8HHI3$S20A1D8R3QP/F R<<T>SAV0>VJ?S/[RPTVB(BL5MB& *
MA8P2<DC@ 9['\CZ4>SAV0>VJ?S/[RVME8N@9;6 J1D'RQ1[.'9![:I_,_O'?
M8+/_ )](/^_8H]G#L@]M4_F?WA]@L_\ GT@_[]BCV<.R#VU3^9_>3JH10J@!
M0, #H*O8AN^K%H$% &%-X1TB6&<) ()Y[A;E[F)5$I=9A,/FQR-ZC@]A0!6M
M?!D-E+)-!J^HK<.$Q,3$SJ4#@'F/YB1(P);.>._- "MX*T\W;7(N;I6\W[0@
MRA$<V<F1<KG<>>^/F/% $[>%H2"?[0O!)+N^TR#R]UP&QE6^3 &% ^4*<=\\
MT ;U !0 4 % !0 4 % !0 4 % !0!A7OAF._U.XO9]3O?WB1K'"OE!(&1@ZN
MAV;LAAGYBPY((Q@  2S\+I9ZK:7ZZK?2-;I*ICD\HK*9&W.S83=DD+T( V@
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MW0M]L?F/YBLH0!-YR2,#"\T 3Z?JJ:C<WD4<3HMLRKEU92V5#?=8 CK0!H4
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M#VQ2L"9KTAA0 4 % !0 8YS3 *0!0!&L$:W#W 7]ZZA2V3T&<#VZFF!)2 *
M"@#2B_U*?[HKH6QRRW8^F(H:C<0P>6)9DCSG&Y@,]*QJR4;79T482E?E5RC]
MOL_^?N'_ +^"L?:0[HZ/95/Y7]P?;[/_ )^X?^_@H]I#N@]E4_E?W!]OL_\
MG[A_[^"CVD.Z#V53^5_<'V^S_P"?N'_OX*/:0[H/95/Y7]P?;[/_ )^X?^_@
MH]I#N@]E4_E?W!]OL_\ G[A_[^"CVD.Z#V53^5_<'V^S_P"?N'_OX*/:0[H/
M95/Y7]P?;[/_ )^X?^_@H]I#N@]E4_E?W!]OL_\ G[A_[^"CVD.Z#V53^5_<
M'V^S_P"?N'_OX*/:0[H/95/Y7]P?;[/_ )^X?^_@H]I#N@]E4_E?W!]OL_\
MG[A_[^"CVD.Z#V53^5_<'V^S_P"?N'_OX*/:0[H/95/Y7]P?;[/_ )^X?^_@
MH]I#N@]E4_E?W!]OL_\ G[A_[^"CVD.Z#V53^5_<'V^S_P"?N'_OX*/:0[H/
M95/Y7]P?;[/_ )^X?^_@H]I#N@]E4_E?W!]OL_\ G[A_[^"CVD.Z#V53^5_<
M9NM16NIV92*_ACG17"'S!@[D*D'VY_04U4@NJ$Z-1_9?W#6T_2);D7-S>_:)
MEE296:<+M91\O"X!'7KFCVL.Z#V,_P"5_<+%9Z=';R0?VH722%8#NDCX0!@
M,#_://7I1[6'=![&I_*_N&-I^G-<?:6U4FZ^8><7B+8954C&W&/D!Z4>UAW0
M>QJ?RO[B+^R-*%Q%-_:KEX'1X<R1GRBJ,@Q\O/RNPYS^='M8=T+V%3^5_<6=
M+M-,TJ6:6.^2221$CW/(O")DA>,#JSG_ ($>V!1[6'=#5&HOLO[C2^WV?_/W
M#_W\%+VD.Z'[*I_*_N#[?9_\_</_ '\%'M(=T'LJG\K^X/M]G_S]P_\ ?P4>
MTAW0>RJ?RO[@^WV?_/W#_P!_!1[2'=![*I_*_N#[?9_\_</_ '\%'M(=T'LJ
MG\K^X/M]G_S]P_\ ?P4>TAW0>RJ?RO[B6UO+62YC1+F)F)X <$FKA.+DDF1.
MG-1;:9L5TG$5+M)&==D3.,=B!_,UG--[(VIM):LK^3<?\^[_ /?2_P"-9\LN
MQIS0[_F'DW'_ #[O_P!]+_C1RR[!S0[_ )AY-Q_S[O\ ]]+_ (T<LNP<T._Y
MAY-Q_P ^[_\ ?2_XT<LNP<T._P"8>3<?\^[_ /?2_P"-'++L'-#O^8>3<?\
M/N__ 'TO^-'++L'-#O\ F'DW'_/N_P#WTO\ C1RR[!S0[_F'DW'_ #[O_P!]
M+_C1RR[!S0[_ )AY-Q_S[O\ ]]+_ (T<LNP<T._YAY-Q_P ^[_\ ?2_XT<LN
MP<T._P"8>3<?\^[_ /?2_P"-'++L'-#O^8>3<?\ /N__ 'TO^-'++L'-#O\
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MYFC&"(D!&" ,BMUL<SW'4Q!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '__9
J

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>img222477878_36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_36.jpg
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M/#]X<&%C:V5T(&5N9#TB<B(_/O_M $A0:&]T;W-H;W @,RXP #A"24T$!
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M/&,RJ>#3VW:7][VK_'U4]+8ZX:)=*8=G,G=I\/-/^@\8S*IX-/;=I?WO:O\
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M.$3"+] GV3O_ $ W;_K;F?\ DO4L_<W[L7_D>L_M29_F9"_F%^^Q_P!3L/\
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ML$O_  @O.%TW,^N-:D:P"ZFQXD5Y,:X2?39V&$60KR$U,2",M.(D6:-G4@A
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MZQ7L>62@V[=1%FW3([3(D_BT6KHX)@ '3*14>'Y7E]1M7C.%N$QKZBG=,E
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M;=C=)"2NS2133VSJ6K<QK3)(_9Q<PRGB9%AWRX0]UYSV3&3&N<^_"^ Y:_%
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M7B99.I#$H]]>1#478_T3I5GRK/#($K)GRA=:]HR&WQQ&IEV5EJ:*I<'3&O=
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M;FWE4;I,6N0:AV8.#L46 .VJ8 +Y18I%E=CTP;6M_2S=M-S]S?MW&X9VQMY
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M1U[ I&6.118R6QD4S+*)D*DFHL8E2 RITTB@4HFXB4H  >0 #'$-*N0R<['
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M#11DP1-&&Z?[":/%(&YF@)BS&@"W$@-3BD <O $Q$OP#PRW/$O+O=='^J5?
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M3")A$PB81,(F$3")A$PB81,(F$3"+J<Y$R'44,4A$RF.<YA "E(4!,8QA'R
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MHP_H6HSB7P:=QG%_Q)29I-X9/O>:U[B;)XXA_0F.]/A_0M1G$O@U'<9Q8?\
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MFL7LIU?;EC(QHYD)*1NT<QCV#-$[AV]>NJ_ (MFC5!,#*+.'"QP(0A0$3&$
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M '#F#XPPB<Q?Q_@X_P"=R@81_K 4>/\ 6\N(A3:N0$! 1#B(!P$1 !$  1$
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ME:UA&_F:' OB"73G$0+B"/VQ#8B+6M: <L?3P'0G"M',0&(8<YX=Q82"TB7
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M:<W( B < '-J7H_IQ)O[U0XNW?(7KLFI%Z&2]!HO0&2,8:BT9VE79E4;WO\
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MZH5G>UV_23I9](5>[/7B_)VSEQ6I]14_9)E12*(C'\ (DBF4A"@ %(0H%
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MI3MS%O7=0J[IY!R*4O"NW%?B5G,/+($?)H2D6NHT,K'R**<FY*1=(2*E*X5
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M*>X1,(F$3")A$PB81,(F$7FL90B*IT4NV5(F<R2(G!+M5"E$2)=H8!*GVA@
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MQ[U_6W-@KZ[61*H@Y2CGK1K(LEC).TEA AB5-7/(@2/X1!69A5,PQ$;I $/
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MH)M.YY?,!A=$ /%'5_A64T]>R4V7)<V)<22=:V&H=?S!2"[:0W-=9.OO64S
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M^ROR,L8PV(9=5:7-F$\Y7.<I5SBT;V\3X1WSU878QU8Y/&O_V0
B                                              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>img222477878_37.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_37.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M(CG<I)(.8_*/4_W!MH HZ?X-M;#Q.FL";<MO:"SM(-G^ICX/+$DL>N,] 2*
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ML>A())XQC:#DT =6!Q2&&!0!&+>$7)N/*7SBNPOCYMN<XSZ9H EH * "@ H
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MOQC& ,4OJ]3L'/$Z_2=?TO74E?3+Q+E8B%<J",$].M9SA*&Z&FF:52,* "@
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M3^&?B'I/BK4GL+&&[CE2(RYF10" 0#T8^HK"I0G22;*C44GH=A6)H% !0 4
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M')L.H * "GYBW.]^#O\ R.UQ_P!>;?\ H2UY^-^!&M+1GO->2=(4 % !0 4
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M@9)P.: . \*ZIH%]XVNUTVZ\V$1![*(^?^[8EC,0K_*F?EZ8[T >C#I0 UN
M:2W YJV>,_$&X1$N%=;([S(6V-\RXV9XQZ[>_7FM/L$]3IA6:*.4^)'_ "(&
MJ_[B_P#H8K?#?Q$1/X3YUKWUL<H4 % "'H: /7_@E_QYZQ_OQ?R:O*Q^\?F;
M4>IZN*\\V1R/Q*_Y$N\^J?\ H:UC7_AL]3*O]YC_ %T/$5^Z/I7F'WHM !0
M4(3/4?A'_P >>J?]=%_D:[L+\+/D,]_BQ]/U/2ZZSY\* "@ H * &2D+&2=V
M/]GK0!YCH_B2TU;Q/IMKHAU&:.1G>22\U)QM6,C</*R3GYA@-M_*@#U!3D4
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MUY)TG/\ C?\ Y$[4?^N?]1657X&=V _WB/S_ "/ 4[_6O+ZGZ!'9#J"@H *
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M /(G:C_US_J*RJ_ SNR_7$Q^?Y,\!7O]:\OS/T&.R'4#"@ H [SX4\>([O\
MZ]C_ .A"NO#?$SYS/5^Z7JOU/7@1FNU:GR.PZF,* "@ H * *>JPW<^E74-A
M*D5V\3+%(XR%8C@D?7V/T/2@#"\,>&+C2;2U>YFV749D#)'('C\LDE4^ZH&.
M.55<D=Z .I' Q0 QB-O!H6]P.=MXE3X@3NMM)&7LCND9@5D^9>0,G&.G0?UJ
M_L$]3I*S*.4^)'_(@:K_ +B_^ABM\-_$1$_A/G6O?1RA3L 46 0_=-%@/7_@
ME_QYZQ_OQ?R:O)Q^CC\S:CU/5QQ7G&VQR'Q)_P"1+O/JG_H:UE6_AL]7*E_M
M,?ZZ,\27[H^E>8?=W%H *!A3$]CU'X1_\>FJ?]=4_D:[<+\+/D<]TJQ]/U/2
MZZSYX* "@ H * "@ H * ,3Q)K9T*VAF%OYYDD*[=V  J,Y_'"D >I% ')^(
M=>TVW^(6C7+W=T4L3,EPGD.4C)C(!&%Y))QQGH.E:QBW'83>IO?\+!\-_P#/
MW<?^ 4W_ ,14JE-;(+F9XC\;:%?>&=4M+:XN'GGM9(XU^R3#+%2 ,E:N%.:D
MFR6]+'A"VEVJ@?9)_P (S7M<\4<W*QWV2[_Y\[C_ +]&CVD4'*Q!;W)R!:SG
M!P<1GBAU(K6X<K%^RW?_ #YW'_?HTU4B^H*+1UWPUOX= \437FII/! ULR!A
M [_-N4XPH)[&N/%-S@E$TIJSN>M?\+!\-_\ /W/_ . <W_Q%>=[.78WN8_BG
MQIH>H^&KVTM9[B2>1,(OV249.?4KBHJ4I.-K'9@JG)7C+U_(\A7S!G_1[CK_
M ,\6_P *\[ZK4['V4,RP\=+_ ("YD_Y]KC_ORW^%-X6IV!9IA_YOP!69@2L$
MY ..(F_PH>%J=A_VIA^_X!E_^?:X_P"_+?X4?5:G8/[3H=_P.M^'VM6FB:S<
M7&H"XAB>#8I^SR-D[@>P-=&'P\XRNT>%G&*HUJ:Y'K?_ #/1_P#A8/AL?\O<
M_P#X!S?_ !%=:I22V/G;IZ$MMXZ\/W5U%;0W4YEE<(@-I* 23@<E<"I=*<=T
M.YT@.:D!: "@ H * "@ H Q-:U>32C;E85E1CF3+8.W>B<>IS(#CVHM?1 <R
MOBO1;7QE->O?WCQ&V,1#6TA6-@PX4!.AP3WK94I<FB)V9L?\+"\-_P#/W/\
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MT>SEV/%N6++QKH5_>16EM<S--*=J@VLJ@GZE0!4N#CN.]SH :D!: "@ H *
M"@"&>U@NE59X4E56# .H8 CH>>] $NT4 &* $*@]:5K@9TVLV\%^]H8Y28VB
M5W &U3(=J9YSR?04P(;3Q-I%Y'"5O8HWFC,BQR.%;:,\D$\< G\*!"66I:)'
MA[6^@/VZ8E<2@^8^ #C\A^?O0]0%MO$NDW5E-=+>Q)' <2^8P!C^8KR.V2.*
M!FG!+%<P)-#*LD3C*NAR&'J#2L!+BF %0: >IGZGJEIH\4,EV[*DL@B! S@G
MN?0>] +0DEU.RMXY'FNHD2-BKDL,*0,D'TXYH KP7FE6"QPI>0H+B:0QAI!E
MW9R6 ]?F)H =_;NEB01MJ-L',IA"F49\P8ROUY'YT :.T'F@5E>X;0*!^8NT
M4"L 7% Q: "@ H * "@ H @FLK:Y>)YX(Y6A;?&74$HWJ,]#1L!+L%"T 7%
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M@ H * "@ H * "@ H * "@ H PX_#>GI>WUZ8@]S=,Q,K*"T>4"D*>PP/U-
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M % !0 4 9>H>)="TBX^SZCK%E:3;=VR>=4;'K@F@#261'4,K J1D$=Q0 NX
M9SQ0 V.:.5%>-U=&&0RG(/XT .W#UH 9)-%#&TDLBQQH,LS' 4>Y[4 0:AJE
MAI-H;O4+R&UMP<&25PJY],F@"6VN[:]MH[FUGCF@D&4D1@58>QH ER* #(H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 ?_V0
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>img222477878_38.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_38.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M_M&__P"@4W_?P?X4 ']HW_\ T"F_[^#_  H /[1O_P#H%-_W\'^% !_:-_\
M] IO^_@_PH /[1O_ /H%-_W\'^% !_:-_P#] IO^_@_PH /[1O\ _H%-_P!_
M!_A0 ?VC?_\ 0*;_ +^#_"@ _M&__P"@4W_?P?X4 ']HW_\ T"F_[^#_  H
M/[1O_P#H%-_W\'^% !_:-_\ ] IO^_@_PH /[1O_ /H%-_W\'^% !_:-_P#]
M IO^_@_PH /[1O\ _H%-_P!_!_A0 ?VC?_\ 0*;_ +^#_"@ _M&__P"@4W_?
MP?X4 ']HW_\ T"F_[^#_  H /[1O_P#H%-_W\'^% !_:-_\ ] IO^_@_PH /
M[1O_ /H%-_W\'^% !_:-_P#] IO^_@_PH /[1O\ _H%-_P!_!_A0 ?VC?_\
M0*;_ +^#_"@ _M&__P"@4W_?P?X4 ']HW_\ T"F_[^#_  H /[1O_P#H%-_W
M\'^% !_:-_\ ] IO^_@_PH /[1O_ /H%-_W\'^% !_:-_P#] IO^_@_PH /[
M1O\ _H%-_P!_!_A0 ?VC?_\ 0*;_ +^#_"@ _M&__P"@4W_?P?X4 ']HW_\
MT"F_[^C_  H /[1O_P#H%-_W]'^% !_:%]VTMO\ OZ/\* #^T+X?\PMO^_H_
MPH /[1ONVEMGT\T?X4 ']H7_ /T"F_[^C_"@ _M"_P#^@4W_ ']'^% !_:%]
M_P! MO\ OZ/\* #^T+_MI;?]_1_A0 ?VA?\ _0+;_OZ/\* #^T+[_H%M_P!_
M1_A0 ?VC?#_F%M_W]'^% %JRNQ=Q,VPHZ,4=.NUAVSWH LT % !0 4 4=0L3
M=R6SK+Y;0/O&5R#2 S=7L!;^&]8WW$LK212RY)VD'9C'RXR..],#H* "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * ,7Q% ]S#%!&C/(V_:JMC)"G%)@8XL=0M[E85TR%K9MP1Y3N<
M$D[0<-T'4^R]R: )SHUV=4=C;QFU,BE3P,*/O#&3D=3ZY/H,T 07.C7WVA_L
M=KB)VPWFLK8&\\KA@<;>.3Z8[T -2QUR*,HND6,F#\KO(06Z9S\W'?UZ4P)X
M[75280VBV:@R 29?&$R<D?-UQCM0 D7A^Y6"Z:10'+[X8]W0*Y."?]I<#VQ2
M0#&L=32Y81Z3"\"$JA+#+C'!/SCG(]N#TH0S5@TP2:7NGL8(KPH?E5B5#<X_
MI0(J#19'$"O:C:$8. X!)[<YZ_=Z>_M0!!_8]Q%,Y: "!6<Y+@DKLX/J/FH
MU?#I)M[AB<YF))/7[JTP-F@ H * "@ Q0!E^(A_Q3>J#_IUE_P#030!J4 %
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M1_K=0_Z^G_D* -.@ H * "@ H R_$7_(MZI_UZ2_^@F@#4H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@#,TC_6ZA_U]/\ R% &G0 4 % !0 4
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M^2NT?<Z'.?3FF)'0T#"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M S-(_P!;J'_7T_\ (4 := !0 4 % !0!E^(O^1;U3_KUE_\ 030!J4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!F:1_K=0_Z^G_D* -.@ H #
MP* *D=\)+^2T\J0,B[MY7"GIT/?K0!;H R_$7_(MZI_UZ2_^@F@#4H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@#,TC_6ZA_U]/_(4 := !0 '
MH: .8T98Y/$ES=):&!I(VWDPLH8[EQ@E1GIS_7K0!TXH R_$7_(MZI_UZ2_^
M@F@#4H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#,TC_6ZA_U]
M/_(4 := !0 'I0!@6M[)=:_-#%/.$49,;(/+*@ <'KG)_3&.N0#>7('- &9X
MB_Y%O5/^O27_ -!- &I0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 47 * "@
MH * ,S2/];J'_7T_\A0!IT % "'H10!S^G0I'XIO EL(0D>/D;Y3D@@XV@#/
MU/\ .@#H,XH S/$1_P"*;U3_ *]9?_030!J4 % !0 4 % !0 4 % !0 4 %
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MH6MM+Y4LRI)@-M/7!Z']#349/8",:O8X_P!>/R-/DEV /[7L<?\ 'P/R-*S
MJ*^IWMLLT%S!$IEX!A.=@?UW=P/3OVHT M"/4L?\?5L/^V#?_%4: +Y6I?\
M/W;?]^#_ /%4: 'E:E_S]V__ 'X/_P 71H!%<6=]<PF&:Z@,;$;@L!R0#G^]
M1= 7E@BQ_JT_[Y%( %K N=L*#)R?E% "?98-VXQ)D#'W10 +:VZ A84&22<*
M.M.X#OL\/_/)/^^12 1K6!U*M"A4C!!44 )]FA#*PB0,O0[1Q0!2TC_6ZA_U
M]/\ R% &G0 4 (>AH R+:Z9_$MU;&XR$B!$0=3MZ<D=1UXZ=3UH U\4 9GB+
MCPWJG_7I+_Z": -2@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M: #.* $S0 9H A-Y;+(D9GC#N,J-PY'M2N.Q3TC_ %FH?]?3_P A3$:= !0
M=J *Z6-O'=-<I$JS,NUF'&1]/PH L4 9?B+_ )%O5/\ KTE_]!- &I0 4 %
M!0 4 % !0 4 % !0 4 % "9]J $)YI("G;0--:Q2-<S;F4$X;OCZ5=[ 2_8S
M_P _,W_?5',P'V]LEM"L,?"*,#/-2!+B@ Q0 FWG-(!U, H * "@ H * "@
MH * "@ H * "@ H * "@ H 0G% #/-0G 8$_6@+""5#GYEX]Z MY"?:(@P4R
M+N/.-U [2[$3WT*6\LP<,L0.[:0>1U% 6:W0U&O6F!*P>3GU.[%("#9J,YN8
MIUA2)LJC+G."HY_,FC4?NEP6L6Z-C&I:,84XZ4"NRII'^MU#_KZ?^0IB-.@
MH * "@ H R_$7_(MZI_UZ2_^@F@#4H * "@ H * "@ H * "@ H :S;3U%+4
M"C+?SB[>WM[42[$5F8R!0,YQ_*J275@0W O[T1PO:^1'Y@+NL_.T?3!IV2V8
M$XTFU/'[_P#\")/\:5P+D4201+%&,(HP!G.!2 ?0 4 % !0 4 % !0 4 )S0
M <T '- !S0 <T !R!0!674+1BX6YB)098!AP/>@=F"ZC:.CNES$53[S!QA?K
M0%F U"U,32BXB,:G!8., T!8/[0M1%YOVF+R\[=V\8SZ9H"PAU&T"*YNH=C9
M"MO&#B@+ VHVD:J7NH5##()<#(]:0K#8Y+N:-W1X0K']W\I/&>IYYR*95D.'
MV[RB"\'F9X.PXQ^= M!LL5Y+;!!-&DA;YF53T]N>M(-"6.RMD)9;>-6.<D(
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M8U0F)?E P!QTQ0#+84>E,5V&Q?04#N&Q>F!2L%PV+Z#\J+!<-J^@_*G80H
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MEYUNT,D\A5A@GC)'Y4A7+&P"F(-OO0 ;?>@ V"@+ %QWH 7&* %H 3% !B@
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MYP&VX/'3N:2*;L:'%,D7% !@>E !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &9I'^MU#_KZ?^0H
MTZ "@ H * $) ZT 9GB(C_A&]4_Z]9?_ $$T :F<4 )D4 5+N]-O+#%' \SR
M9P%(&,=>IH2 C^VW73^SI?\ OXG^-/E7< ^VW1_YATO_ '\3_&CE7<!U@DB/
M<S2Q^7YTF\*2"0 JKSCZ4G9; 7-P]:0% 0I>W-R+A"PB<*F"1QM!_F33*V+R
M($4*!@#B@G<<* %H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * ,S2/];J'_7T_\A0!IT % !0
M4 4-0:\26U-LI*>9^]  SM_'^GM2 R=5;4!X6U=IHT+^7,/WC;<1X/(P#V[&
MF!K7&HQJ ()K5SW#SA?Z&D"11EO9;F*6"1[)$?Y0PNN0"![?6@K1%E(]'0DA
MK4$@KG<,X[T$BJND*C()+8*WWAO'-,8!=)6(Q"2V"$Y(WC!/YT!<7_B4^2(?
M-MC&#NV[QC- 7!O[)>)8VEMBBYP"XP*!7)8[FPB0)'<VZJ.@#CB@+DGV^S_Y
M^X/^_@H /M]G_P _<'_?P4 'V^S_ .?N#_OX* #[?9_\_<'_ '\% !]OL_\
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M^_@H /M]G_S]P?\ ?P4 'V^S_P"?N#_OX* #[?9_\_<'_?P4 'V^S_Y^X/\
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MVM_:7H9K6ZAG"'#&-PV#[XH L9H * "@"O<V5M=D?:+=)<# W*#_ )Z4@+
M' &*8!0 4 % !0 4 % !0 4 % !0 4 (RAE*D9!&"* *]M8VUJY:"WCB8J%)
M5<9 Z"@"S0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 )D4 +0 4 %  >E '.-X5'G/+%J%Q$Y+;=K'"Y(.,9Z<?X8Q0 Z'
MPY)!J9N1>W#B0YD+2D9 .0N/KCD8X!'<T ,?PQ+Y*JNHS*R$']U^ZWJ"S;20
M?5CS^E): ;%A:/:6RI)*TLG5W9LY/]!3 N4 % !0 F10 M !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M * "@ H _]D
%       !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>img222477878_39.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_39.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /?Z "@ H * "@ H * "@ Z4 -WCWH -PH -XH 7<!0 ;@*
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M@>4Q)-&S@D;0P)R,9'X9'YTBR4.2.F/PH :9U5UC+ .P)5>YQUX_$4 .W^U
M!OYZ<4 )O.".A]Q0 D<RRQ))&RNC@%67D$'H10 AN(U?89$#<<$\\]* %EN$
M@0O*ZH@_B8X'YT 'GJ)!&642$%@N>2!C) _$?G0 23+$@9W5!D+EO4\ ?F0*
M %2998DDB971P&5E.00>X]: )* "@ H * "@ H * "@ H * "@ H * "@ H
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MS'@XZDD@^HQ@ O>&]#N=#B:&6^-S&(HHT&" -H(SR3C(('X#V  .@H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ R/6@ R/6@ R/6@ R* #(H ,T
M&10 F1ZT 17$@CB9^N!QP3_+F@#YQ^(^LW'_  D=Q \'V:")LQPL&*YXR5#
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M#0 <>U "T )D#N* %R/6@ R/6@"IJ5_%IMA)=2AV"X"I&,L[$@*J^Y) 'N:
M*-IXBL[N81?O(7,"3_O0%P&W_*>>&'E/D>U $JZ_IK11R"Z&R3'EG8W[S) P
MO'S') P,\F@")/$=@]S/"LCD0Q+*SJA8%6W>F3QM.<@8H GCUO3Y+>:Y2Z!@
MA8H\F#MW!BN <<G(Q@=Z $&MZ>+A8#=JLK!3M8$8W%@N?3)5L \\&@!!KVGX
M?_2#F,$NOEME1@')&,@8(YZ<T 6+;4+>ZD*0R[CMW#Y2-P]1D<CW% %O(]:
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M8XF>^LKFRV\GS4#*!ZED)4#ZD5G<;CV--)DD0,I#*1D$'(-40_=W)<4 )B@
MQ1L 8H ,4 +B@!,4 &* #% !B@ Q0 N* #% "8H ,4 &* #% "XH * "@ Q0
M 4 % !0 8H 0B@"G MP-7NF>93;&&(1Q \JV7W''N-O_ 'R:=K"1=I#"@"O<
MM,LEN(E!4R$2>R[6_KBFK"9.O2IV&+3 * "@ H * "@ H * "@ H * "@ H
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M$C2I#"@"M="$RVAE8AQ*3&!W;8W]-U-"9.O2I&.I@% !0 4 % !0 4 % !0
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M]X_()^=4)%VD,* *MV0)K0&+>3*0&_N?(W/]/QIH3+ Z5*0QU, H * "@ H
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MMH?.";92=N?O_(PQ^N?PIH3)P0!R:0QV1ZT &1ZT )D>HH 7- !D>M !D>M
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M3Q8=SQ187G:LACW?<DZX.,[Q'C'&&&>^ !\EWXD@MKB9[=Y'0!X8UV'>N_\
MU;8R=Y7'(PH/>@"")?%L4CQF1FC7SB&*1N6):0J?OC P8\#V(.* .HL3<-8P
M&Z7;<>6OF#CAL<]./RH LT (:0%"W=3KM[&+78RV\),__/0%I/E_X#@G_@=4
M]A+<T*0PH I:C#;3_9HKG=AY"$VDCG8W<>V::OT)9@)I^N6-S9)8+_HRQPK+
MN<-D[F\PDL<C@@C&>>/<2O,HC(\9F!%41"0H2681\$>9U /4YBQ@D<')]6!H
MW$6O'283;RJM\(R7RJX9MR\8SC.W=WQG'.* *$D'BQY4$;)A8]P+A  _DL!T
M)/WR,C&!ZD'  &VMMXLCEV&39;,^\!]C.JM,206S]X(>, CMVY +)B\10P7F
MSS'G>:)D8LCA4\M ^U20,[E;C('.1Z4 0Q6OBN'2L),GVD[W96"OAO.S@9.#
MF,G R "%Y S0 20>)V"*02T9#Y#(JM\@XQG.=V[.3CICV +^FQZZ=-F-^X^U
ME'$>%08;<^TX&1G;L[D?U *-U%XL5XEMW#@ABSL(R 0_R@C(X*\Y&>>WH 2@
M>(?LS2B.9'4H/*=X2S\?.1@;1SC&3TSTR, %>WC\1WJJTS2(\%U)\P*HK@"9
M1@==N?+X/UH BFO?$UM/MGC?;(CB-(XT.),C;DC.4 ^C'L.#@ N0#7CH^-1+
M-.;B$.$15/E[E$F-I/'WO0X!X% %/_A%[U>8WFC*?:F4"X/),H,0Z\?(,9[?
MI0 7.E^*+AI[B6>/-PRHD,1V&!!(K@EMV"0-RG YR.<4 6]&M-7MM8EDO2Y2
MXWS.-^Y$)2$*H] &$@'MD]Z.@MU8M^$V4>'+6(L/.AS'..A$@)W9]R<G\:F*
MT-:SM)MFE?P3SV,T5O,L4C*0'9=V./K5K0R:=M#P#PWX-\1MXKMFFM;E+>)E
MD=SNCRF><'@Y(/Z\XYQURG'ELCA47HDCW^>ZM]/M#-.WEPQCDX)Q7$W;4[F]
M3RS7$\0/XXN4T]+E(IKN)H2^1$7"*=V#Z8.< ^]4[:(Y+8AU6X;':VT>J6VJ
MZ2=;N;>=R)55H8RBK(0NT9)Y. _85$VKZ'0N9;F]J5J+[3;BVV*YDC("MTSC
MC]:HT,S4K+5+>W2#0EB@C$,BHORJJ2'&UCD'*_>Z<YQZ\ &8=-\2FX-YYV)A
M'M7)4D')_A^[T/K^([ '2Q0O+9P"]2)YU56< 94/CDC/OF@9Y+X+M[G1/B1>
MZ79)<'393)#YL<1*($):++8(X!9?J:P@FKV.^M4C4HIOXO\ ASU8O?6YR8TN
M8^OR'8X_ \'\Q6RNEJ</NMV1R'CWQ=J&B6]@VEE$>9W$GG1'(P!C@_SK.K/D
M5SOP.#6(GR29RI\>^,19I=Y@\AW\M7\D<MZ=:P]M.W-;0]3^R\.ZC@I;$0^(
MWBP_=:$]N+?_ .O0J\NQ?]D44KN7]?>'_"QO%A"G=#ACQ_H_7]:2Q$G]D7]D
MT5O('^(WBV-=SF%5SC)M\#/YTGB7:]BEE%"3LI'8IXLU(?#5=;:(2WS;UW(N
M%3#, Q'H,#-=U/WTF?.8JDJ51P3+>C:EK.L>&)Y["**'4%G*![@$12_=)<8&
M<8)''<&JTO9G/)-)V--'OM9N)HB6M;&+]V[1.0\C_P 05N"%'(R,$D=L<YWN
M]#:R@M=6:=EIMIIT(BM8$B7J2HY)]2>I/N:=DB7)O=CA<0K=FU,L?FL-ZH2-
MQ'?CTJK:$KS(;[2;/4 OGQ?.IRDB$JZ'U##D?G4V17/)*U]"M:RW5IJ1L+J0
M20R+NMY3PQQ]Y6[$CJ".HSZ9)LQR2<;Q*MW_ ,)#_:!^S,!;FX  ,<; 1X3G
MEE(Y,F>IX&!3((X;CQ$L\,KV<K0)M$D6Z'>_RN&(.0  PCQSTSU[ %"-?%T3
M-]]=Z@\B.15;<W&"X(&,$_4 >P!N:'_:0DO&U&.=?,D!C\QT( $: [0IX&[=
M@>Q)ZT ;0(Q0 !@> : $)!Z&D'H5(&O#J]TDB@60AB,1XY?+[_T"?G5:"5[E
MVD,* *MVX26T!A#[I2,D?<^1CG],?C30F6%Z5*&.I@% !0 4 % !0 4 % !0
M $9% " 8H ".<T )M]Z '4 !% #2OO0!DW=E<V]U->:<8S)(H\R&0860CH<C
MH<<9P>WI2V-%*+TD%OX@MI 5NXI;&4<%+E=H_!ONG\#0G<3@^FHZ75=.4&5+
MZW,BJ<#S5Y]J2:W%RR3LC-M?$3W=K T>F337[J0T:8,<?UD^Z!T/<^QQ4J7,
MKC4-/>T-2ST^7[4;Z\E22Y,810BX6->I R2>3U/? XJDA2M:R+5[91WMJ\$A
M(#<@CJI'((]P0#^%#BF041J-QI\HCO[=Y(S]VYMXV9?^!*,E?KR/<4DVM&+8
MN+JE@W2\M\^GFBGS(=Q'U:P0$F[A)'97!/Y#K1S+H%S/:XN=421(U>TL"-K3
MRY21O7:IP5_WC^ [U.K$V:EO!##;QPVZJD**%15Z 5:T&M";'&*-QL\P^+^1
M;Z/A?^6DGMV%88GX3VLG7[^7I_D<E9^)OL=G%:+IL;1QA/F,AW%E??GTZENW
M?K7*JEH\O0]JI@E.;GSZL(O$8ANWFCM)5#1NF!<8^\Q8G.WJ,\>XS5^U2=T@
M>$;CRN76_P#6HZQ\4/8M&RVLC[ H"M/\JX0K\HV\'G/Y^M)5;*UB7@KN[G_7
MWE6ZUU[K1A8-;L6RK&5YBY)!/8CCK4N=X\MC>CA>2KS\VAZ;X E0^![.WN[;
M-N_F@LP#(P\QN".WXC'O7=2=HI'R>/BI5Y'7VR01VR):K&L*C"K& % ]@.*T
M9Q+3XBIH1VZ5'$QS)&SH_P#O!CG]>:4=-BZGQ71ICM3(T&&WB,R3%5,B A6(
MY /4 _E1=B<4V/S0D&JW,77 9;W1XHP3(+OS,C^%0C9/TYQ_P(4C2GLV9MY8
MZT^JZC+:K.-S,T;/<?NI(_("B-5W?*?,^;.%Z'GGED(;8V'B#3[O*SS3K+,F
M\S%9 $$<>>K @;C+TR<@<8Z@%B!?$K7J1SR;(2P#R+'&<+M)R.2=V[@@KCT]
M2 4HAXN@24B)WFRS*6:-@Q\R0A<;AA=K(,_>&/;@ U]'_ME;MDU#/V=8E"$J
MF2=JY)(;.[._MC&WOF@#.,?BI%MW'SNH8M'E-H/SA023DC&SOU/;G !TE@US
M]AC-XN)\'<.,CGC..,XQG'&<XXH ;!"5UF[N/M6X/#$OD9_U>&D^;\=V.G\-
M/H)%ZD,* *]SYV^W\H#9YA\W_=VM_P"S;::$R=>E2ABTP"@ H * "@ H * "
M@ H * "@ H * "@ H * &E<DT (4%&PK6V.0T:61OB+XD@:5VACC@V(6.U?D
M'0=JUE%*FF2I-SL;&IQ:D9((=-E\GS)&>60@810N,#(/)8@]/7ZUDDEH6M5J
M57U378C_ ,@^-T,)D&%;(.2%4CO_  DXYY/''(+;0=#JNN223(^G)&$+[3AC
MN .%'89;*G@D#D=0:!E1=3\0O%&C60# )N<0L"Q,3,0,\ ;@J\],\C-(-"[:
M7NI7,\:S6*BW.S+M$RDDAMW!.1@J!SUR*5DPLA;6?5;J_A1[?[);(TA?$?WL
M8"KSV.XG<.NWL.KY4%BYKFEIK6C76G/*T2SKM+J 2.<]#]*N+Y6)JZL<MX%O
M?[)DF\)WRK%>6C,T1Z"9"=V1ZGG/T^AK2JD_?CL90;^&1VDMS# FZ:5(U]78
M"L+):&O0R=3A\.:TD::E]ANEC.4$CJ=I]JEV>C+A4<=8NQ2B\)^#9VVPZ9I\
MI]$"G^5+ECV-OK57^9E@>!?#'_0$M/\ OV*?*NP?6:W\S#_A!?"__0$M/^_8
MHY5V#ZU6_F8?\(+X7_Z =I_W[%'+'L'UFK_,_O-BRL+73;..SLH$@MH\[8T&
M%7)ST^IJE9:&#O)W;&36$9<S0L8)CU>/^+ZCH?Q_"F'/;XC(N[._TZ^FU&Q5
M)#*H\Z(9"R$< [1D@X&-PSZ8/!$6:U1K'EEHV+'XPTR(*FIRC3)NA%S\BY]
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M6J2+"-.GCB(8F0N>H[#[IX_+MS4+0LR9;#Q!$&GDU#[08T&  !GY,G"A>OF
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M ,;KHG_#1C%>\SOEZUSWN;#J .?NTU[[=/+;2!HUF7RX6V!6C^3.3C/>3O\
MPK[@@%*%O%IA59(T#8(#L8P1\QY8 X)QMQCC[V>U  TOB9+AHD25AMRC-Y6#
M(#SG'_++!''W\Y[4 .,?B6W%O'$PE59$W.^P_)A-P;H3C,F,<\#.: *^GW7B
MF\C\U8]L1\P+YJ*&) .">1_%MQ@'^+/:@#I].%U]A@-Z,7 7Y\D9^IQQGU X
M^M %LTF!4A-Y_:MR),?8O)C\KIG?E]_OTV4]+"1<H&% %>Y=DEM5$>X/(5)Q
MG8-C'/Z8_&FA,F7I4H8ZF 4 % !0 4 % !0 4 % !0 4 % #2V#C% !O'I0
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MK-QJAN(;LP_:(%0MY S&=V>5;<<@X/!"L,<CD4#-Z@!"N: $VB@ V"@!0,#
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M;L: +U !0 4 % "&D!2@GD;6;NW-N%CC@B99L??),@*Y]MH/_ JK9"+U(84
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M]YDE:Q@9T9F4L@."Q)8_CD_F: )[.QM]/@$%K"D,0).U!@9/4_6@"S0 4 %
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M# XH -H]!0 M !0 4 % !0 4 % !0!__V0
6                              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>img222477878_40.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_40.jpg
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M/#]X<&%C:V5T(&5N9#TB<B(_/O_M $A0:&]T;W-H;W @,RXP #A"24T$!
M    #QP!6@ #&R5'' (   (  @ X0DE-!"4      !#\X1^)R+?)>"\T8C0'
M6'?K_^X #D%D;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$!
M 0$! 0$" 0$" @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,#_\  $0@ J (< P$1  (1 0,1 ?_$ /0  0
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MJI=TJ=Z402*4HW+O=W*+"W;?;=[[%LH&+$P;=@8Y](6@8VN+@V*KJBCC,.2
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MYP:U\1?**?J5"Y1E&,M8W$:XFF$O(*M'<O7G#9./3)TC6]?1>24<5O+/Y/\
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M.D8,,L%8GMD>V5CGTPF,UL?G%%]%3")A$PB81,(F$3")A$PBV3_*6_KKT_\
MV$V/_J9#/O/LT_YM6W_1W7Z 747VY?\ QWO_ -YV']:5ZR,])UX=K&WF5_5
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M-(^7]5JY8+.^Y3ZJ>,JY"2L\\:0\X$K+NFL0P7D'#:*BVB1W4E(KHMQ*@W2
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M=D5ZA)S"<<](21?,XUDND@LB)5TG#U\1,A2G%4XE/V2&[ Y9LLLGOX)+B"2
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M-1/.T.T[8BVT$]</5X^WQ4M+U[4<D](HZAT8TZB1DTG2G;1%61(TFG"2CHG
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M4$A4@(F"S)@@CV" 4A$DB%*!0* 90[,<P>7N=,\F1SG.U:2X!KN#A:UHH*
M "@"N1Y)E$38VLMXP(F,:S7R6L<Y[!6M31[WNJ:DN<XDDE5/.;5MT_ $K[QT
MB1!8QSS,@B109:QG,@1L 3+]95555$K=,"=TGW:8E_%Z=V!2%S[S>'-+VR%E
M*X!I[MP!QRZ*<MQ))%-%!04T=S1JT^6[E9%EF:'-8&.,K0!$PD;*#27?-,
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M2G9>80BFLD],Y:PC,S"); @U;(,6JAP55312:(($$ZRA0,HH8#**& !,81S
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MNU='T!^4/@*E'RZ_ZOUI_.EYI?[V>Y,N]8'_ 'Z+]V9?_@;=)NZ'R6_ %?\
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M=>'*0JJJIRB<U8%!0:E03B-3K6FW_P!]C_Z,_P#9AS[;_P#C/^__ /<65_\
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M?=">UL)+N6<N($@B:UKFXC&)'2DXNYC(C.!Y+1*-+23R#IK;K)M;_-H<M@M
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M%9=@@196/%NW4=@D!&YP5:3JTIA<!H.@56=V7%;3")A$PB81,(L!:O\ B_-
MW6 ?^=X+\;SG_P"4R6]^3A"=/['0IQRV/I3\D?"5=/T(^4?@"SZRXK281,(M
M5/S.>(^Y>5#;3"6HF5:=GI#N\K3WUBL!8$$R3[>L)QWA!,S=^*$QHI;M_P!K
MV.@?AZ_1UP]H+JSWKZQF92W=AMNXV;K@R;639TV@B#</)=7N'5XM"[L^QQUZ
M]7_4I-O"_?N2\8W,H[,0["#;5,#K@R8N6W#02-IKKIXEJC)\I/FPF!"IQ^O4
MRI]H4BDV4)"I"?M=L4REB0*F)^V/7L].O4>OX1SK>/9GZV@*!ED -7]JU=CD
M:%W</MS^SLXDNES4DZZV%:TU5^=TTX*\0447Y4/.9-,B*9:41%-%5NFDGM5T
M1))NN8QEVZ:98T")MUS',)R  $.)A$0'J.7![-G6^&AH\4#0" /&S0 ZP!AI
M0UTC459=[;_LW/<9'G,3(7!Q)RUI)<*4<3M*EPH*$Z10474?Y3/-]1-)%1K1
M%$4!6,@BIM!51%$SA4B[@R*1XL4TC.%TRJ*"4 $YR@8>H@ Y2?9IZW"T-<+,
MM;6@\;-!4U-!@H*G2>,BITJMOMR>SFQYD8_,Q(X"I&7 $X06MJ=I4X6DM;74
M"0* K[3^4]SC12(W11I"+=-R#U-NEM-PD@F] Y5/&IHDC2ID>=XF4W>@ *=H
MH#UZ@&2WV:^MYK0QHM P.Q4%V0,6O%3!3%7\K7[JI=[<'LX/>97NS)TI9@+C
MES2XLI3 29*EE"1AKAH2*:5T'^4IS94.LJK'Z^54<**+.%%-EF44<+*@<JRS
M@YXH3KJJE5,!S&$3& P@(B CE#O9GZV7$N<RR+G$DDW6LG63R-)-34G2:GC5
MUOMS^SLQK6,ES5K&@!H%A0- I0- EH " 0!0 @$:@IVZ^5OSR>036M.":_4@
MVBXNDX\NP6B1%7(BX$%GBZ,$FYD#I^*5['B#J=GO#=/PYER>SKURRV;;"3Q$
MV;75#?&6BITZ7'9U=2IIB)UE:Z#VT?9FM\R?G$1S49E(W"7^(N)#>3H8#,6L
M!PMK@#:X15*_\K?GC5G"KR!2U]'.E4 ;BL78#-P<A"=WW1F_C(%P#5=#NB]V
MJGV%" 4  0 .F++V=NN3+I#+9"Q9(12OC+30:*4Q1FA%!0BA%*53-/;1]F?.
MHFP9H[-9H&NQ4-D]H)-:XL,S<0-35KJM-34$E2E'Y3O.)L#H&[>D-_'% K[N
M-IK(^.* & "O13C2B\#H<?\ RG:_"/\ 9',=GLU];L>+ +1N/NJ79&+Y5&\K
M[]5G2>W#[.,V S/S)^S[C%EP.#Y%9.3J'<TU!<N?E/<XGJI'#QM172Z;=DT(
MNXV>=58K6-1(WCVX*GBQ/W+% A2(EZ]$R@ %Z9+_ &;.MR5P?(VS<\-:VINZ
MFC11HK@K1HT-' -2IA]N#V<+>,Q0/S-D1>]Q#<O !=(2Y[J"2E7DDN/Y1UU7
MU^JBYSAVNB=+#M-4&)NFUG(=IBU'M-61ND=^,S:F'JDD/Y-,1_% ,?PV];XU
M"TTM#?[X>Y&IO<]R. :AP!1_&][-NBIS'0]S_P#MK>[=W3_I.[=^4[NG<)*Z
M3?*9YO'(@D=E0SI-3JJ-4C[..9)JHN;MKJMDS18D;J+F^DYB 43C](B.4'V:
M>MPAK2RR+6DD#QLT!.LCD:">$C2>%76^W)[.;7.>V3,P]X <1EX!<!H <=I5
MP T &H' N%OE+\VW!$DG+&A.$D$$FR"2^S3+)H-FXG%NV035BSD10;BH;NR%
M "D[0]D ZCAWLT=;4@#9&63@   ;LD #4!5F@"IH!H%336D?MR^SK"YSX9<T
M8]SBXEN7T+G.IB<XB05<Z@Q$U)H*Z@IG)?*PYX2YU#R7U(=BLS0CEBGV:5))
M=BU5.N@T7;MXA%NN@FY4,KT.0>TL<R@]3F$PW[CV<^N.Z)=/XHXE@:?[70%H
M-0T@, (!).D=T2XZ22L.T]M7V9[%H;:><F!LCI!3+ZD/< USFN=*7!Q: VH(
MHT!HHT *7(_*:YOMQ,9LSHC8QTE&YS-]GJ(&.W51*W50.*4803(*MR%3,0?Q
M3)E HAV0 ,L-]FKK<9I8RS;4$:+LC010C0W41H(U4%-2RY/;C]G*4 2R9F\!
MP<,67 T<"7!PK(:$.)<#K#B2-)*[ ^5!SE S8X)4KMLBHE9'^]5QVF96Y>PW
M*S-Y.[34K<@=E,$^SV ^@O0,J_ALZWZM-+2K*8?[8>335AY.BG!2E.!4?QO^
MS<0]N+,<,E<8\W"C\6EV+YSE8CI=BK4Z359@<"/E]\E>/W)>!VIL^/IR588U
MFYQKYU$W(LY*'?SL>F@S-X48]!18%5P$5#B?J'X1Z]<^H=3'4GO]N3O_  [Q
M[PQVHRYEO.QQ9/M'XI&@-T8034ZS5?!O:<]J7JAZTNI^ZW*W-ES!V<RWEI(Q
MLMKL8PR%Y<[E8W 4'<BGN:%OJSN8O,A8V\ROZH'*S\VW>?\ -A:,I?W![!5<
M?TC>R%<+2'\2^H?Y+Z!_!2)PW4H?W9[)5T,J5*U\?,VU;R\W#Q;DJ9PAOCS7
M&]5KU1Y)E9F%[=:Z<)U6.DE%K0R"R-&CU9,CUD(%%#L=%@#H(AG/>K;,]T\H
MWF;>;Z0"XR002 L,0E&,CD' 2!H/#70KT#HVR5E%64[*\ZON ?M)'Q>6;]+6
M=]'L[!>OGL[>B8^@MYZR]M9][[R>X!^TD?%Y9OTM)WT>QZ^>SMZ)CZ"WGJ=M
M9=Z.TGN ?M)'Q>67]+2=]'<>OGL[>B8^@MYZ;:S[WWEP/ #]I)_<Y>68?_[:
MSH?]G<>OGL[>B8^@MYZC;67>^\GN ?M)/Q=V;]+:=]'<GU[]G7T3'T%O.4[:
MR[WWD]P#]I)^+NS?I;3OH]CU\]G7T3'T%O.3:V7>^\GN ?M)/Q=V;]+:=]'<
MCU\]G7T3'T%O/3:V7>_^E/<!_:2OB[LWZ6LV/_CKHY/KY[.OHF/H+>>FVLN]
M][\:>X#^TE?%W9OTM9OT=QZ^>SKZ)CZ"WGIMK+O?>_&N/<!_:2OBZL_Z6LWZ
M/8]?/9U]$Q]!;SDVMGWO_I"Y]P']I*^+JS_I:S7H]CU\]G7T3'T%O.3;67>C
MM+CW OVDKXNK/^EI,^CV/7OV=?1,?06\]-M9=[[WXT]P+]I+^+FS?I:S7H]C
MU[]G7T3'T%O/3:V7>^\GN!_M)?Q<V;]+6:]'\>O?LZ^BH^@MYZG:V7>C\U/<
M#_:2_BYLWZ6DR/\ V>QZ]^SMZ)BZ"WG*-K9=[[RY]P/]I+^+FS?I:3/H]D>O
M?L[>B8^@MYZ;:R[WWD]P3]I+^+BS?I9S'H]D^O?LZ^B8^@MYZ;6R[WWEQ[@?
M[29\7-G_ $LY?T=QZ]^SKZ*CZ"WGIM;+O?>3W _VDSXN;/\ I9R_H[CU[]G7
MT5'T%O/3:V7>^\GN!_M)GQ=6;]+.7]'<>O?LZ^BH^@MYZ;:R[WWEQ[@?[29\
M7-G_ $LY;T=QZ]^SKZ)CZ"WGIMK+O?>_&GN!_M)GQ<V?]+.6]'L>O?LZ^BH^
M@MYZ;6R[WWES[@G[2;\7%F_2RE?1W'KU[.OHJ/H+>>FULN]]Y:=]6\2OF1[.
MYR;+J^HB;%L'+#5FV)Z.VQO>L7.2C8FGWYK(F)8+!:MT@$>S*5ZX(8YTS"H[
MDB=2D:+=>P/US,]Z^KG+=R;:YS;Q>/=:ZM6F"V?&"Z2(CD-9;Z3H'#H:PZWC
M6LATD+8@74V9&@>YV%[H_N<^8Q[CWW9>]EJCWT_)G=??K]SH_5#N^SV/(ODC
MREW/EON/R?UE\D=GO/RWD;M?1G23SQU>^NGG+S5=>IN+^[>,?.?*Q4[FNG8[
M35HVRU>*':XL)V7%57$V7OG:FN92W2$KK9O]0QD'B= EYA%PFFX4J47)J2#"
M01@U)N:"3O-A8(! J'8MTR-E3+G[PB?XWSHN(X-"I#0[4=*B6NZ]^2<U))1^
MAY-")8 \<).9UO,117[%C'J2X-&;<(IRN-C>' (P@=\9GXD.]*8Q.A#"YW $
MPMX]*^-A[.WZ>[/8BB:T.TK=7FFQY*QS5.G9@+371?&C9:&C468E,H<Y4O**
M:[0ZHK(&1+V"G*H4PEU= T( VE2=*G<-L[>UBA;?('TLA5GT;5%Y>'"2&0>R
MCVQ^+111A4HI5I&H2CNLM".!.9-X"<FLFD#4R::HF)-7'33@4$-'#50J&TMT
M,G;2O5_7DE<47#IJU:W"SU"ST %6\E)IG=6^9BDH4S-DPC <J-E& "WE72R(
MO.X1:*=X#$[51,+=9-%3#C>^]A<R5;'2OA9IE&U68?M8:.M$X 1]O:2<W(.T
ME%H%I$G&!4C%8MTW65(\?OU#JMTNB1DS1B=JHIPMUU7VCN?D$=ZQ?*Z-6B8I
M1I'$*P)!V1\^B5E%9)M./I9VSBESK1]0;+-B'9,43/)<6YE&!C$4[HDXG<28
M6\:JV"OVTSH62UO]$-(9^>K-6$4=)*;<S"[:%E8)$I99B2#3D3PPI6^0E&D6
MT34D11CW"(IB[4!--4\2@ANJJDJMZW\-0=VEU5%HPX;&C&T11X>E2S^>^H4=
M3V2_2)\1$/"M96P6HRBB:LJDQ;M6Q@9J*LG)3+!%74K3A2C:TJJ9@MD;-JE=
M"-B^/9HRU2[^1E[3,1E&NJ-9:OR1D$HRG5HQK$RDO,/74VNZBDVK1PY.B#,K
ML#%8F*8 )'!I4D-.LZ%5[?:^T;+3FSGZMR-6FZY<*[3[C-P51>WZ00?*5AY.
M69Y"59FR7=^3VZ[N'9+F[!SM7JSQJH!3->]R:FBBC05U*;[W; 5SQMPTDLUE
MCLVSHIV SJD+',VA;,WLDO99 D8\8PJ<:I#LGB;0KE=5RVD2I-U%U4S&&,3@
M-(3"TZBLA-379SL6A0MP=LV[)64<3R)"-"R)&;MK$6*6A64LR3EFC&2293C*
M.3>HD62*<B:Y2B)NG:&L&HJJ2*&BN-DJ$PB81,(L!:S_ ,4'<_YBO'/^?GDS
MEL?2GY(^$JZ?H1\H_ %GUEQ6DPB81>4;]I^V/L;7T;PM-K_85\H1I66WJ65-
M2+E9*B,H5G'ZO,S+)#7I.-%^5H9PH*0+=L$Q4-V>G:'KVD]FC+LNOY<Y\?MX
M)\++;#M(V28:F:M,;32M!6FNBS[%H.*H!U?A7E]+:.=YJ<QV(6Z<O!H$G%S$
MY'7?Z\[F^J;Z&KY'JDY*M;!Y;\EK,(HD8Y%=4%>R0&ROT_DC]GLN;?<87CLO
MV&4>/M>UICV=OC#G4PM+,.(%V)M!3A'&%G88:TY->+0K8FY*<BRB8IN1.^BF
M()0.4VY]E%$@FZ]D#@-G 2B;H/3K^'-IZN;O4J,OL.CP\Q3LV=Z.T%-GN]N4
MT;$PD](;SY%L82RFEB5Z7=[<V@A'3AX!Z6-G$XMVI92HO3P\@<$'($$115'L
MFZ#]&68\DW7EE?!'8Y>9H\.-H@A);B%6XA@T8AI'&-(48(SH ;V@I5[R?(WH
M(AR)WV/01*/3<^ROH, ]D2__ )G_ +8#?1T_#U^C+QW=W>'_ /GV'1X>8IP,
MXAVE-#[XY2I12DZKO7D2E#)3!:\K)*;?V<FT2GCLU)$L,HH>S%[$D+!(ZW="
M '[LHCT^C+(R3=@R[ 6.7F8LQTV$-<-:8NXU5T5XTP1ZJ#M*H&&S.:$K2IS9
M,7L[E7(Z[K+M)A8[XQV'N)W3H)ZN+0J;26L:$X>)8+B9^W 2J*E$@N$@-T%5
M/M69,MW.BO69;+;96W,)!5D1BMQ(X:=+6%N(C0=0X#Q%1ACKAHW%]Y4^ZWQR
MF8P\38GF].1;2!GG<Q'PDRXV[M!&,EG]>.Q3GF4>\/901=.H923;%<D((F1%
MPF!@ 3!E]N1[KR3/MF6.7&>-K2YH@AJT/KA)&#0'4-#PT--2G!&=%!7L+X8[
M]Y1RC:9>1F]N1DBTKD<$O873';>TW;:"B32+.(+*3*Z%C.E&1XRTBW:]\L)$
M_$+II]>V<H#$N0;L1NC8^QRYKY'86 P0 N=0NPM&#E'""Z@J: G4$P1C6&]H
M*"#D=R3'O.SR%Y &[H.TL(;CV<((E$X) 980LW1(HJF H";H F$ _"/3).[>
M[H('B%AI_P#YX?>Y&E,$?>M[076/)3D:40 >1>^RB( 8 '=&RP'LF#M ;Z;1
M_:B7Z>OX.GTY5ZL[O>06'1X>8F!G>CM!3Q3=O+-)E7Y$^ZN2W@+8A)N:L[+M
M7:ZB-C;PS]:+EUX0R=B/Y32BY)NH@N9'M DJ0Q3=! <QAD>ZIDDB%GENTB(#
MQL(*L+@'-#N1HQ @BNL$%,,?$/>4E]Y+DA^YR*WYT$.O\=&R_P!W_P#=&9'J
MSN[Y!8='AYBG"SB':3WDN2'Q$[\]M&R_2C)&[6[H-?-]AT>'F)@9Q#M+GWDN
M2'Q$[\]M&R_2?*_5S=WT?8='AYBC SB':7'O)<D/B)WY[:-E^E&6_5G=WR"Q
MZ/#S%.!G$.TMT'R!-T;FNOS+->U^Z;AVQ<H!?5FXG*\%;=E76RPJSAK7&JC5
MPM$S<X^CU5VJ@B9,YDQ,F8>I1 <^/=>^2Y/9=7-Q/9VEK%<"ZMQB9#&QU"\U
M <UH-#PZ=*Q;MK1#4  U' O?-G15:I8V\ROZH'*S\VW>?\V%HRE_<'L%5Q_2
M-[(5PM(?Q+ZA_DOH'\%(G#=2A_=GLE70RI4IA$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3"*3PU=K]<3D$J]!P\$E+2\E8)5.'C64823
MGIE<74O-R!62*)7LO*.1%1RY4[2RY_QCF,/TY>FN+BX+3</?(6,#6XB31K11
MK14FC6C0 - &H)4G6IQEE%B7.U_DR[MMP?5^SU-K7Y>3>/(6,7.VF'-0^JD!
M+MZG&^$E6"[%(M_EUHU_(JI=5V*15"I"!CE4+00XG0J^333K5,HON6;>Q.G#
M].$ )F4AZW&QS5Q&3C.MQTMXU63L$HT8%9I@I5S+*.F:ZI4/*;-DFV< FX5)
MCEJ?FZ>ZJNI*/*5&S0Z]M\@K0*Z4DVF$CO(<HE41C'Q(J:>)QY%S-#+R1&_6
M,C0$@)J&,J^4,GT5#'73J4'!31K5/M:1R9L$=<W=DN2\-.2%)B:S463*88,V
MD=++3[)_;[&Y0JR483OQ(B=&+63<$=IQ(I)J'2>'<*F .X3IHIJP4HHR0A.4
M$*XG*W4E(B7AW$Y"+P5GLMD=+ RBVC(YYM-R1Y(2=M%"1>&:D11\2LJD"#HQ
MEC=XGWBC]02K#I.M=):;R:F(!BNZN3V"L[799)Y45'];6:KUDFM8F!/'.&41
M'$C',(WO(OI!HQ$2F4*""CL3J"H08H^GNU_ HJSBT?C7VE&<M7ST[=Q=JY7V
MI5>Z;B2.J$A(RCL%DTII=B0T<JW1KK-L458HBJ8R(&$WCNV %(,\OC3D*%F:
MIRE=;%"9@I]I$1KIE52.E7$KXVK,2F@*^TMB#*MN)1V@L\2GF[U9N(Q:9^[5
M[SQINR#0\4?6H4@LPT*B$F7,)5@H\\M5QNX;#'HIPSIM5%9"0278RP6IVI(-
M&/DMN_9R:;<:X0.P@+=1+RGWAP7#'SB?-U4.>"Y7Q@.'["?;S"$D_F'R<7.O
MZPC,5I-R46,2FU791Z4!*KD1<BY<-%^K$KA(I&YDBCVA<M1R#V54T"'(J&B:
M^[EH!.?L:L'M-K/L&-J@VL$WM4Y8H*;I$N4\CU5&!CF)'K,A2)KN&J8]D45"
MF V3RA[Z' =6I4\<O,KZN.$C)49W, HH9@=52%25<INGLJ1LTL+,$%(H6K%C
M#,O&F9+$46\N+=Q]+$A5H^<I[JGYNO#14Q6Y3F1/.GWA21T% L._CR*SU5@V
MDDK,H03!21-$Q3I:O>)IJ<NHLA!JG,FZ[9 %Z=9(HF%R_O(<'WUF533V52J5
MX]R;H-;4,2S\OH-G;=\BG* B4'?8=-&;!HKVE $1[I$B8"(@7J4 $:Q6FG6J
M#2NC4JER5"81,(M?\0X28?-+OS1V<&Z]IX$:H=02:GXGE9*C\@MQ(VDS01Z
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MB+=%Y'0K)[8;;"R2;B8CG8)V>QVDMJ-)2)ZC.KD<-$$NUWJ28%6(O]! %KN
MH'-KI"K^SZ<V?,2<V2#V<6J0$M?4[L?R*C*LK Y*XJL;6W<0^D$GPH WCGC
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MO:XAP[DT:=0TM%-!(TBM"0LXL:>RIW8>3EVM46>&GJY27\>+2/:(I"WMK99
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M7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>img222477878_41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_41.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MT0NQ9#DDH3LZ?-C/% &A_P ([XHCAO&BU8-<R?ZKS+J4J/W;@\=OF*$8Z8_
M@$]]X7U/5/"^GZ9>7BO<)=%[AWE,A> LP=-VT9)C;;T% &?'X(U;2TLCI=S"
M/(>?S$,[Q>:ADB$2;E!(Q%$%)]0!R#0!!9>!];M(+U1<P12S$2Q2Q74H*2"W
M>,=N@9E.>XSD<<@'HEHDL=G D[[YEC4.WJV.3^= $U !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 <#XKU'Q':^,+.#3([YK)HX"?(@+IDS'>"=A7.P?Q,N <
M_4 C?7/$=K?S2W%IJ)T^XN4F@=+0R-'$)-KH40%AE"K#(S][TH T]"N=9U#Q
M3J=S(+M=(1T%L)PT.08D)Q&T8)^8MR6&#QCB@"'1-9U:/7M3M-2M]0E0G-H/
MLC!#AI,CS,!1D!<;F':@!^F:GK9U376N;6[Q!&SP0R+\F1G:H(4 DC'W7?OG
M'% &3%XYUD6E^\5HEPEIB-9?)D()W1+O)'#'#L=B_-\OO0!.OB?Q-=6DFH6&
MG^:BVI;RVMY"'D0,Y"@<_,"BC/?/4@@@&AIGB#5)-5BCU:RO+=9XVB58;25H
M_,69TW%@IV J%;YB!@]>] '2Z3-)<Z-8SS',LD".Y]25!- %R@ H * "@ H
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M%<]: % P: %H * "@ H * "@!KMLC9MI;:,X'4T 9=OXBT^?YO,,<>YT\QR
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M(3^6/,VX;C=UQ0!VBC H 6@ H * $)Q0 ;L4K@+3 * "@ H * "@ H * "@
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MD:-V$I)R..!M]:YZ524[W6QK4A&%K/=&P.@KJ,1: "@ H * "@ H * "@ H
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M#X7MK'4(9;B2X=+^8&64 ,_/4[0!GZ 4 =%0 4 (: V$J;AL4KW_ (^;(_\
M34_^@-64WJBXV=RZ.U;$#J8!0 4 % !0 4 % !0 4 % !0 4 %  3B@!-PH
MBE,GEOY2J9,':&R!G'&:2 S?#7GG2 ;I8UN/M$_F",DJ&\U\X) )&?:J>XD;
M%(84 (1S2: Q==UL:)'$_D&4R-@#=C'Z5R8G$^P5TCIPV&]N[7.>F\;>;) _
MV CRG+8\WK\I'I[UY[S%-I\O]?<>@LL:37,:&E^+QJ.IPV?V,Q^9GYO,SC )
M]/:MZ./]I-1M_7W&%? >R@Y\QU."17J:+8\W?1G/>,-+L[CP[J=[-;J]Q!9R
MF.3/*84D8_'FJCN2T:6C:59:=;!K2V2$RHI<KWX_^N:&VV-&E2&% !0 4 %
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M <OXP/S^'A_U%X/Y-0!U Z4 +0 4 -;O]*E[,:/';S_D(7/_ %T;^9KY.O\
MQ'ZGU>'_ (2(JQ-SO? G_((N/^NY_D*^AR[^$SYW,?XAU8KTSSA: "@ H *
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MM@&[' /3->F>:<N=5\5_VE]B_L_2O,\KS<_:Y, 9Q_SSJ[1M>Y%V=2A8J-P
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M8.E "T % #6[_2I>S&CQV\_Y"%S_ -=&_F:^3K_Q'ZGUF'_A(BK$V.]\"?\
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M+5;6PM8;6W7.V.% BC)R>![T 6* "@#E_&(P_AX#C_B;P?R:@#IQTH 6@ H
M:W?Z5+V8T>.WG_(0N?\ KHW\S7R=?^(_4^LP_P#"1%6)L=[X#_Y!-Q_UW/\
MZ"*^@RW^&SY[,?XAP/Q?_P"1KL/^O/\ ]G:OJ,%\+/$K;HX&O0,#M?A/_P C
MP_\ UY/_ .A+7#C/@-J.YZEXP\1MX8T-M02W$[^8L:H6VCGW^F:\VG3]I-(Z
M)RY5<\XO/BS=WD"Q'2(%VRQR B8G[KAO3VKO6#MK<P=4T=-^+5W>:M8V4FE1
M(MQ.D199B2-S 9QCWK*6#Y8-ME1JW:1ZJ#Q7!ML;W&R2>7&S!2Q )VC&3^=-
M 4-/UNVU"=8HED!=792P&&"E02"#R/G4@]"#D9H OS2)%$TDC;40%F)[ =:
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M22J;_E^9C)D 9^0'Z@'?#I0 8 H Q?#7W-5_[",_\Z -N@ H #0]@.2\=_\
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M@RW^&_4^=S+^(<#\7_\ D:[#_KS_ /9VKZC!?"SQ:W0X&O0,#MOA/_R/#_\
M7D__ *$M<.,^ WH[G;?%G_D3A_U\Q_UKCPG\5&E7X3Q.O:.0O:'_ ,C-H_\
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M]&:9XET.+2+)'UJP5E@0$&Y0$?*/>O!E&5VSM3T/ -2N(7UB_=)D9&N9"I#
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MB^9'T-_PEOAT'']OZ;_X%Q_XUXG0ZS:CD26))(V5T8!E93D$'N#0,=0 4 %
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M5 (WO0VQG8@6PYV\@_-DL#[;>>!@ U_#MGJ%AHEK;:I<_:;N) KREBVXX]2
M30!K-TH Y!_[:EU.]FT^X#$7:1^69E>.., [LC<3N)(R,#"X [D@#-(N?%4U
M]"=06**V\]PRNJJS#8O [XW>9CN<#/% '9=%_"@#G==GN_M5NE@R"6,/RUP%
M!E*GRT9<C()Y[GY>!R: ,=9O&!NDM6W@_)ND2*,KY>1N;<>/,ZX'3&.* .NT
MN2Y;2K4WI0W?E@3&,\;Q][]<T 7: "@ H * "@ H * "@ H *  C- "!0!B@
M!>E !0 FT#I0 N,4 % '$26GC.-6CM+F)5\R0AY,,[CRODR"2!^\&,#C:<X!
MZ #-"CU_SK*2S^R+HQ<F18E13R<,%"\8W <GGEN^* .X7H* .4N[#Q*NH3M;
M7CO$UXLD1=U&V+]UN4@ <8$H Z\@GUH QX(?%$6JSE)K)]2:+=)L2(,,2,%W
MGKM,8CR>O!QTH [#P^NJ1Z6J:PRM>*Q#%""I7^''X8SGOGMB@#5H * "@ H
M* "@ H " : $VB@ VCTH 6@!",C% !@"@!>@H PM?M]5G2U;2Y&1XI-SH#A7
MXP QR#CZ9[<&@#EK^+7XKFP75)+&>Z>Y1;5W2+</W3,V,_\ 358^G. ,<C-
M'4^&8]<@T^2/79(WG63$;1G(*8&,^^<_I0!;UR&]N="OX=-F:&_:!Q X(&),
M?+R?>@#GKVR\2->W@FNH!I,DN9!($;$7.[A@0/EP.>X/K0!2TF+Q0\%B;-[1
M;!6A:4V^Q4<[?WQCQP07+G)[X[9H [\=* %H * "@ H * "@ H 3% !M'I0
M8 - "D9H 3 ]* #:/2@ ;@4 <;J>A6-C(]W>:K>I%<W+A8DR5WRE<* H_P!D
MCZL?6@!FD^'FN2\\FJ7IDM[U2/,(*DQ,_7J&R'P3_L@<%: .UZ+^% '-ZCX5
MLKJYFNR\D?F7,-W(L2CYFB!QVR<_GQQ0!SEMI5KJ"V%C8:UJ.V>W9O.+\O&
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M#Z D_F: -%5PH&!0 M !0 4 ?__9
2

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>img222477878_42.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_42.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MD(D51"583'NWF;>O/!- ':>  1\/O#H/_0/A_P#0!0!TE !0 4 % !0 4 %
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MF+PHH 6@ H * "@ H * "@ H * "@ H * "@ H :SHGWF ^IH ;Y\7_/5/\
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M_!UO;VNL^(8[7'D^?$5P<@YA6FF979U]4 4 % !0!@3_ /(^6'_7A<_^AV]
M&_0 C#*D4 (J[5 'ZT .H 2D 8HL!%+)Y:$XS@9Q0%KG.W.H1ZIX.O+MIBL+
M1.-\8*Y'J._^-"W-8JTDD<CIUS+/>6T5S<">PFV6OE&-@C;D!+@=NO7W]*T>
MAURMRW2U(M6:W>_:REMW1+/>X"J-NQCM4%3QP,=^".E3S%1=HJ2ZG=^&U%CX
M4M1([D1HVYI!AOO')/O4]3@K/WF%D$O]:DU!3E(D\H \$-WX[8'\ZU;M#E.9
M0]]R&:="EQJEWJ ;S,R%5.>-H&./Q!I2TBHDTXWJ.;*D&M2?;[2W2Q5UEE8H
MX;:44?>)SG) YSQG/%*VAUJGIS&Q!K,,D'FJCNHN#;ML_@()!+9Q@<>_6HV)
M:L:BG(!% A,T ** %I@4-5B=K-WBB\R1/F4*,L<$' Y')Z=:1479G#W.G:C%
MI2QQ6=^(%GW)':G$LK8_Y:'*Y3.1VZ+CUJ[VW-F[O4WK#3]99HEO?),8:1)6
MWDR2)M&TJ1]TEAD@$8J;Q>QG=(S-/\2V\-U,+B>(VMM;,J[(F$A:+B1>3ENQ
M YX&3UJN4<H-(;<ZQJ@NY;Z%K")9$5[7<0-\;X"^9G##KQ@\DC\:MH/E31UL
M%G"]FL+J6'/)/(!.< YR*SV,F^A<MX/L\"1!V8*N,MU- B7L?I0!G^'_ /D6
M]+_Z]8O_ $ 4 :- &/XJ!/A?40O7R3B@#F]3N]1;P@0N])U*HVYM[D="#Z&H
MBK:,T<;R5SE?L$MI(L<+171CD\XQL Q=SM&X9X'T'^%6KO5E>UNTSJ/#OAV9
MQ#=:PWG7<090'Q@C/!('?'3TS63=]MC-M[(Z\$2(V4*A3C#=\5&Q&Y+@8P2!
MQ@8IC(I7$8))XH%L)&PDD?@;1QG%%F)&'JWB :9<"WABDN"6&]4.WRP>Y-:*
M-]RHQN9-MXR6YU!;$6A5W.%F+[E#C^'G&>*.6R*]F^6YRVMWVH7,ENE[)-$F
MUGEC4D;F/0;<\'&/Q],U:LC>%-)Z'9^&=6M+?P_+++*T:Q9E(DY8(3A3CT)!
MQ6;6IC./O6ZERP\9:9>W"6J&5+B3&U'3!/3\.^:.2Q,HR6YC:OH>KZGKOVV'
M:(2VT-YFWRQ@?,1W[U7,DK%1<>7<YKQ#HU[HERE_-!&8G.5: ,RAL'!P1\I[
M^_-5&4;:F\7"2L4+6ZDM&6>W@"+'^]>%XQNP#D!?3/KZ5=M=2I*ZLS7U2WU.
M[TN2.UB86Y"RM.C#"X!;"C@D\?J*B/*C"FDEKN-TF[&S4M4),D5K8?N" %\D
MX 9< \$GG\Z'LDD7*-HF/%<D65T_R+*4&'"G[I) ;/4'J?UJVK,V<7S=SO/#
M.J6EIX4$>J/"]M"VR1RV\%F8\$'IU'<UG).^AA--2T*&J^'-*@?^V+?4BM@Z
MLIA"%U(<D$K@C')_2B+D@573DY=3.L=,2\DFLX-=A17D$*C[.P+-C/'/3C]*
M;;ZC;MNCJCX,TRX9?,:5W3J>@!QR?;UK+F9"K-/0TUT33(K2*&>UC=(EVJTW
MSL..>>U*[(4[&2FE>&K6\D+^5),T_P J.X_=L<C:J]AUXIV97/)FX+&QEC*"
MWA9>1P@X'I^8_2D9\US-N_"UO<S+-&S0<AMH[XY_S]*I2L4JC7067PJD@5HK
MIHIM^6E9 Y*\Y&3]:7,-3TV'^%+5;+7/$-NKEU2:$ G_ *XK5IDMW.KJA!0
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MX5/+RLB-.TM7H7-!\%QVUY'?W-P+A_D:*1&.6PO5NQYR:3G?1#E4NK([-4
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M6<';2W\NMZG--+^_^R@L%R F3@ ?@#^5;Z#F[1+$BS6T#)YC+((]Y7.&52<
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MKFY;3M.>2]D9?-C&WGA!QG&W ZY/8\'ZT+5V$TKG>>'=-%]H=K+>R23JW[U
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MRQXGT2>^DLI+601_9F+ ?>+L0 !ST' R?:G%I*R(@^5EFYLK-=2M;R^90\2
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M#<FV->%'TJ)8U!< 3F/S-IR#TSGV/Y4IN[-J3Z]Q98!(5U5HWC6:-7E\DGS
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M35C0M[Z%[7S@C)\V"C=0:;BXDWL9GAN7S?$GB5LYS<0]^G[E::&CJ*H84 %
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MR5GN7#$Y<GOVP*3;8.5]C3DL[2:2-I+>,O&VY#LR5/3(]Z3)NR? !5=C$^M
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MFG\C;@CF2>TM[7S(FA*K(" T:1J3ALXP7*A5QG(#9Q4VZF+:N[BZ[=QSLD:
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MCGKWINR+DDD-L_$Z0S?9M5FC26279$\<;"-@>5 8\$XZD&FXZ"=/2YK^'_\
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MGGGZ^].[(E=%MHVAMD2PBC4 @ =%49YX^F:-17NBV >] A=OZ4!87% "]*
MT 1GS">, 5+3&-D@65=LGS*>H-'+W$.2)8T"HH51T XIV0#L8-%@!A\I^E &
M?X?_ .1;TO\ Z](O_0!3 TJ ,KQ)QX=O?^N=)[ 6'?S@556(SC=CBLKB/./$
M6E76C:BU[$%*RH8F;'&/?TYQ_DUTZ25T:4Y?993L(M1^TSSVL<)DA"B%7<$,
M"3DX]@.*IM6L.32)Y=/OO$@M;IX! 4)CF0'/E_-D'\0:R225C2%54MNII:A9
MPWTPNB8A=>:5\A,B3)&W)&<-PHZBJ27+RG$I/22((_"\FD:G;WUI<QVB1OE;
M?.[.5^<#ZXJ;Q:Y35U7+<JZW::G=Q/,;S<TTQ+J8BH"CE5&3VY^N:T228J50
MBBTVZ32HK:\A9/LX(A<,(U5CP1@\$=\>M3=(V<]=";3]'N'^RI+<*4M9Y-Z;
MCM(..&]#QW[TFXVLC-S()X%AC5[VUCL#!/)-&K9=)SL)"CGVY'O2N]EL;JI9
M:,REMM3N[@RWFZ&.1BT@* *PQP,=.">!_+ JDET*G.,-@D^Q65ZLEBC*Z.QW
MLV0>.<#IBF[FT(2DKR-KPS;YN)-5,WDQVPPR%1MF)R1DX[$@U,F[<J,:K4?=
M0FO:JZZS/-;R*TC*H=R V,=L=../UI):6*I4;QNRL)9M9>%C-DQ#[B_* >N>
MG':GHB&_9MQ1<AL]-N9&>[ADNM0E'RMYA*XP <=,8'>C4PYG'8CN+2.QM)+N
MU,S00)\T:X)4[LEN!SU%#UW+C)R]UE66UO9!.TR3S/>,$B CR,+AF)QZ\8_&
MBR-8N)I130Q):V=M<-!JH89(3<I&>8\GCL/I4VOOL96?38U$U"Y5$TMRTTL9
M!FF\X;D')8GV7@?C2WT,Y)OWC.O_ !!?7-W#:Z?*EP'38CJF6#GJ0/3'\Z$K
M:FL(J*YGN)';6NA017FJ(9=216>WCD.1&,CDG'7D'%/1JR"_/IT&>&L:MJWV
MAF,Q?$DTA'WCQ@\=.U#7+L14D]F>DJ05![=JS,[B.0$W;@%'4FD J'@$<Y[T
MT \=J ,70?\ D:/$W_7>'_T2M6AG150!0 4 % 'FOQ$M[RX\0:4MG%)*XM[E
MBJ9Z8BQD#J,XIIV.K#R47JRWX6L[^(1OJ-I:P1Q.9&82,60!%P1G..ASR/\
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M0,=FV?P_2E-F-62D]#K!'ND7<6PO0#I]:R1GY$K;=F"./2F JX &*+@.'44
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M,:!V'$9%,8@4"D 8XI@)D@CC(I"%I@*.U S$T+_D:/$W_7>'_P!$K5(#HJH
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MT1H%U)VA@#4C'*NT9!YH =3 .] !C%(!*8!C% K!@T#% Y% &)H7_(T>)O\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 ?__9
2

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>img222477878_43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_43.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MXR"3T)SCB@"SX;\5'Q%+=7$2,EHMM#*D;+\Z,3('!]>4Q0!0T[Q%J;^'-/\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@!,T +0 4 % !0 @)H 6@!,T +0 4  H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M! P,CF@#T5&#H&!R",@T .H * "@ H * "@ H J2:C9Q:A'8/=PI=RJ72$N
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M?"'AYK!;$Z)9?95D\T1>0NT/C&['KCCZ<4 23^&-$N0JSZ1:2(LIF"O""-Y
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MVC*-@'!# =B/SH YCX0_\DPT?Z2_^C6H [B@ H SH-<L+F(2V[S2QGHZ6\C
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MU)YDVZ16;:%SM=E' XZ 4 :] !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % #=V#0 ;O:@ WT 9%_X>M-0U:'4W>5+J!<1LC8"D!P&QCJ!(_Y^U $
MT.BV5KIEU9",O!<F5YE<YWF0DMGZY/X4 <S\( %^&&C@<#$O_HUJ .YH #TH
M Y[P42?"-ADYX;_T,T =#0 4 % !0 4 13@^3(58JVTX([4 5=#FEN=!T^>>
M0R32VZ.[$ 9)4$].* +] !0 4 % !0!E^(N-#G^J?^AB@#37O0 M !0 4 %
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M<Q01&X$4IDGFC!4]OW?)/R]_?UH W?"DC3>$=,D6[6Z)@&)QOP_O\Y+$?4T
M>>Z7IUKJ/Q+N].O[PSRP,;EXHK62)1)F-RV3*Q +(O5<'& ?4 ],O-#TZ_NA
M=75I&]RL31+*1\RJV00#VZG\SZT +I^C:=HUO/%IUG%;)*Q=UC7 +4 <U\(?
M^28:/])?_1K4 =Q0 4 % !0 4 % !0!%/<0VT?F3S)$@XW.P4?F: *DNL:68
MG U*USM/_+9?\: *'A_5]-3PYIBMJ%JK"UC!!F4$?*/>@#9M[NVNT+VUQ',H
M."8W# 'TXH FH * "@ H * "@ H * "@ H * $R* %H * "@ H * "@ H *
M"@ H * "@ H 0CB@#F_$F@7.K:GH]S;K;*;*<R-+(6WH.,A0.#G'/([=1E2
M9OA7P=JV@Z/<VC:OY,LMPL@>!0^0(U0D[P?F<J7/N>IZT ;/@X,GABV5Y#(P
M>8%R "Q\UN<#B@#>H * "@ H * "@ H * "@ H QIO\ D<[+_KPG_P#1D5 &
MS0 4 % !0 4 % !0 4 <=\1(H)_#T,=SC[,UW$)6,!E5%YR6 (8#W4@C/UH
MU?"CI+X3TQXK06:&W7; (S'Y8QTVDDC\: .:T2QU6'XG:Q=_V>#ILJ[3=R0(
MC[@!\BM@.R_F.* .EN_$=M9^([31989C)=+E90!L4X=@IYSDB-^V./>@"OH'
MBVR\0Z7>WT<,MK!;%@QG*@E0,[L G QZXH R_A 0?AAHQ'3$O_HUJ .XH *
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M<4 % %*,8UBX_P"N$7_H4E %V@ H * "@#R[X_?\DPE_Z^HOYF@#Y1/6@ H
M^F?V;_\ D2=4_P"P@?\ T6E 'LU !0 4 % !0 4 % !0 4 (6VT )O3^\/SH
M HZ8Z 77S#FX<]?>@"]O7L0?8&@!0<B@!: "@ H * "@ H * "@ H * "@!"
M<"@"":\M[>6&*:>*.29ML:NP!<^@]: %@NH+I"]O-'*H8J3&P8 C@CCN* ,G
MPCQX=@_ZZS?^C7H W: "@ H * "@ H * "@ H ^=-6'_ !/=1_Z^9/\ T(T
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M;EY_[*TO<Z*A^23&%)(_C_VC0!L^&?CWXCUKQ1I>ESZ;IJ0W=S'"[(LFX!F
M./FZ\T ?0HY% "T % 'E_P ?O^282_\ 7U%_,T ?*!H * /IG]F__D2=4_["
M!_\ 1:4 >S4 % !0 4 % !0 4 % !0!SOCT?\6_\1'O_ &?/_P"@&@#XD\Q_
M[[?G0 OFO_>/YT >I?L_LS?$O!8G_0Y>_NM 'U2HP,4 +0 4 % !0 4 % !0
M 4 % !0 4 (>!0!S?B'0+K6-5TN=)K5+6TD\R6.6 LSG(QA@PQC&>XR 3TH
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M "@ H * "@ H * "@ H 2@#$\(_\B[!_UUF_]&O0!N4 % !0 4 % !0 4 %
M!0!\ZZM_R'=1_P"OF3_T(T 5*  =: /I-?NB@!U '*?$'CPY;_\ 82LO_2F.
M@#JZ "@ H * .6\<W-[:^'C+974UMB9/-DA1F81_Q8(1]O;YMIQSTH T?#D\
MUSX;T^:XO8;V62%2UQ <I+[C &?R'T% '':-'?1?%._1$OGLV,DCF55\N,D#
M&TE=V#@]#V- &_J^LZKI_BJS@2V9](\AI+B00,VW"N2=XX!!5!M[[_:@!GA;
M5=;O]-U.34K=C-%*1;A[=K8N-@."&)Z-D9!(]S0!3^$&?^%8:.3P<2_^C6H
M[=_NF@#X+U#_ )"5U_UU;^9H K4 =%X!_P"2A>'?^PA#_P"AB@#[=% !0 4
M>7_'[_DF$O\ U]1?S- 'R@: "@#Z9_9O_P"1)U3_ +"!_P#1:4 >S4 % !0
M4 % !0 4 % !0!SOCW_DGWB+_L'S_P#H!H ^(J "@#U3]G[_ )*9_P!N4O\
M[+0!]5#I0 M !0 4 % !0 4 % !0 4 % !0 4 4KS5K*QO+.TN)U6XO'9(8\
M\MM4L3] !R?IZT 5]&\0Z;K]O+/IMQYL<4GEL2I4YP&!P1G!5@0>X(H @\)?
M\B[ /^FLW_HUZ -R@ H * "@ H * "@ H * /G75O^0[J/\ U\R?^A&@"I0
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MWB+_ +!\_P#Z : /B*@ H ]4_9^_Y*9_VY2_^RT ?50Z4 +0 4 % !0 4 %
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M /7O'_Z"* +U !0!SOCW_DGWB+_L'S_^@&@#XBH * /5/V?O^2F?]N4O\UH
M^JA0 M !0 4 ,DSM(!()'!'44 -MHWBMHHY)FF=5 :1@ 6/J0.* ): "@ H
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MVTZ+';)@Q%B"Y"R#;QQ@EU)_W!QZ "Z1X>GT?3]9MH[V3_3)Y)H9&8R/$&0
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M NT>@H :0J]1UH J/;V\FIQ7>X^?#"T84'C:Y4DD?\ 'ZT 7 HQP*  (!V%
M"[1Z"@#%UN'2M5F@T6[N@ER72[CA1@'/E.K X(/&5 _.@#9P/2@!=H]!0 A0
M'&.* % P,4 +0 4 % "9Q0!5@O[2^AE:SN8KA48HQB<,%8=5..A]J .2^$/_
M "3'1_I+_P"C6H [9SQB@#X+U $:E=#_ *:M_,T 5L'TH Z+P"#_ ,+"\._]
MA"'_ -#% 'VX#0 M !0!Y=\?O^282_\ 7W%_6@#Y2(YH 3!]* /IG]G#CP5J
M8_ZB!_\ 1:4 >S4 % !0!\F?'GGXI7A_Z=X?_0: /,\'TH 51S0!]X:+_P @
M+3_^O>/_ -!% %Z@ H YWQ[_ ,D_\1 =?[/G_P#0#0!\18H ,&@#U3]G[CXF
M?]N4O\UH ^JEZ4 +0 4 % !0 4 % !0 4 % !0 4 % !0 4 !X&: *&IZB--
ML7N6ADE5,%EC&6QW('? R<#)..,T >:7%G_PL'7<VEQ>V]D^7D8(Q@9%($3#
M>"I9@3P!C;D-S@T >GZ781Z7I=M8Q.\B6\80-(<L<=S0!;/2@"O<72VMM+/(
MKE(D+L$0LV ,\ 9)/L.: /+CXUA^(EU<^'+*)8XY3%/;7:2GS(0"'W,F,JP9
M#C/&=N>&!8 [_P /Z)-I4=S+=ZC)J%Y=2"2:9U" D*% 5!PHPHZ=\GO0!M#I
M0 A.!F@#CO%OBG["CZ:MC),9_D+HS'$>/G8!/G)7*Y P<'(X!H I^#/!DNG:
ME)XAO;RXDNKJ,8C=B."!AG4C(?  89P2,X'0 '?#@4 (3@9H Y;QEXRA\+V0
M"HKWTT;M;K*&6)BF,JS@$+P>,X'N,T 8%IIMSXUFN]9MKN;2+348H[>YA5"T
MDRKD[E8@!>&(#KG(.>". #TA0  !0 M !0 4 % !0 4 (RA@0>XQ0!S'AKP=
M;^'M(N]-^V374-P!'D@1LD80(%!7'( ^]UH V])TFRT/2X-.TZ 06D"[8T!)
MQWZGKS0!<(S0!S#?#?P8[%F\-:>6)R281R: &_\ "M?!7_0L:=_WY% $UK\/
MO"-E=PW5KX>L89X7#QR)$ 58<@B@#I ,4 % !0!2U72-.UNR-GJ=G%=VQ8,8
MY5W+D=#0!A?\*U\%?]"SI_\ WY% !_PK7P5_T+&G?]^10!L:-H&D^'K9[;2+
M"&RA=][)"NT%L8S^0% &E0 4 % &#JG@KPUK5ZU[J>B6EW=$ &66,%B!T&:
M**_#?P63C_A&-._[\B@!W_"M/!6<_P#",:?_ -^10!U$<:0Q)%&H5$ 55'0
M=J '4 % $-W:07UK+:W,2RP3(4DC89#*1@@T <T/AKX*48_X1G3N/^F(H 7_
M (5KX*_Z%C3O^_(H O:5X-\-Z'>?;-+T6TL[G:5\R*,*V#U&: -L<4 (6Q0
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MGY@V2?2@#LXHXXH4CC141!M55&  .U #Z "@ H * "@ H * "@ P/2@ H *
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M!MCH6HR&WAC\<"XO L3LR,"T@CD?>< Y*DN%QR!C'I@ ]#7WH =0 4 % !0
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M0 A&1Q0!AR^&8IO%D&OM=W(DAMS"(%F<1G)!R1NQVZ8Y//4"@#<' H 6@ H
M* "@ /2@"M:VOV5ICYTLOFR&3]X^[9GLOH/:@"S0 4 % !0 4 97B'0X/$>B
M76EW+R1QW"E2\3%6'OQ_*@"]:6R6=M';Q;O+C&U=SECCW)R30!,: ,'5/"&D
MZQ>27-Y"[M*BI*HD(5PI)7(]1DX/O0!1_P"%<^'2-IMI2H4*!Y[#&&#9X.2<
MCJ<]_4T 6]&\&:3H5Y'<V,4J-'&8P&E9@1DG)!/)^9AGT- '14 % !0 4 %
M!0 4 % !0 A.!0!S&K^,K2QNUM+6,7LWG?9W\J>,"&4C*I)DY4L <9'48[B@
M#G= \/:GKNMOK?B) ]MD_9X9X0LJ ]8V R"H8 CN&7@D'+ 'HZ($ "@ #M0
M^@"M?R30V4TEM!Y\Z(S1Q%MN]@.!GMGUH \HT]=8\7^)I+>:^N;&5(&>[CM[
MK?';2AMJ?*&95DPN"F65EW$[2>0#U#2-'L]%L8[6RACB1>6V+C<?4_YXZ4 :
M% !0!@:]IUY=:AI]U J7$%L7,EH\AC5V(&U\@'E<'@C^(^G( OAC03H=E)YC
M(+FZ?SITA)\I9".=B\8!ZG@9.30!O4 % !0!2O-)L-09#?65O<[,[/.B5]OT
MR.* +:H%Z#% #J "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H 0C/:@#D(? UO'XGEOR(&L'9I#;/#O9G8$'+LQ^3+$[ H&<'M0!UP0 8
M P/04 .Z4 % "$ T ((U'08[G'>@!PX% !0 4 (5!ZT &,4 +0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0!__9
,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>img222477878_44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_44.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" =)#'0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH KWU[;Z;I]S?W<GEVUM$TTS[2=J*"6.!R> >E?-,7Q9\<F%"^MY;:,G[)!
MU_[XKV_XHWTVG_#37)8%1GDA6V(<$C;*ZQ,>".0KDCWQUKY?KDQ,VK),]_),
M-3J<\ZD4]EJKG:?\+8\;_P#0;_\ )6'_ .(H_P"%L>-_^@W_ .2L/_Q%=-X
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MIMQ-8ZW%?7:+NCMFM?)$A[KO,C '&<9XSC) Y%>SKKK^)DL9E<G9P2_[=_X
MOA[XY7L#)#X@L$NH0@7[1:#9+D*<L5)VL6.WH4 YZ\"O:=-U*SUC3H-0T^X2
MXM)UW1R)T(^G4$'((/(((/(KX_N;>:SO+BTN$V7%O*T,J9!VNI(89'!P0>E>
ME_!KQ<VEZV?#]U(BV-^Q:(D*-MQ@ ?,2.&"[<<G=MQC)S5&O+FY9F68Y72]E
M[?#^MNC7='O]%%%=A\V%%%% !7E7Q;\>ZIX:OM,TS0[Q+>YDC:XN280[!,[8
MP"P*X)$F>_R#H#SZK7R7XP\0/XG\6ZCJIF\VW>4QVA&X*(%.(\!N5R/F(X^9
MF.!FL:\^6&AZ65895\0E)72U9L_\+8\;_P#0;_\ )6'_ .(KV;X8>*Y/%/A;
M?>W7GZI;2LET65%)R2R,%7HNT[0<#)1O3-?,M>A?!WQ"VD>,ET^1T6TU1?)?
M>RJ!(H)C.2,DYR@7(R9.Y %<U"K+GM)[GN9I@*3P[E2BDUKHK>I]&T445WGR
M(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 445'//#:V\EQ<2I%#$I>221@JHH&223P !WH DHK%_X3#PQ_P!#
M'I'_ ('1_P#Q5:%AJ5AJD#3Z?>VUW$K;&DMY5D4-@'!()YP1Q[TDT]BY4YQ5
MY)HM445!>7MIIUJ]U?74-K;)C?-/($1<D 9)X&20/QID$]%8O_"8>&/^ACTC
M_P #H_\ XJIK3Q)H5_=):V>M:=<W#YV10W2.[8&3@ Y/ )_"ES+N:.E42NXO
M[C4HHHIF84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !167=^)=!
ML+I[6\UO3;>XCQOBFND1UR 1D$Y'!!_&BT\2:%?W26MGK6FW%Q)G9%#=([M@
M$G !R> 3^%*ZV+]G.W-9V-2BBBF0%%9$OBOPY!-)#-K^E1RQN4='O(PRL#@@
M@G@@@C%3V.O:/JDY@T_5K&[F5=YCM[E)&"Y S@$\9(Y]Z5UL7[.:7-9V-"BH
MYYX;6WDN+B5(H8E+R22,%5% R22>  .]9/\ PF'AC_H8](_\#H__ (JAM+<4
M82E\*N;5%5;#4[#586FTZ^MKR)6V,]O*LBAL X)4GG!!Q[BK5,333LPHHHH$
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M45G7VOZ-I=P+?4-6L+28J'$=Q<I&Q4D@'!(.,@\^QH;L.,7)V2-&BLRT\2:%
M?W26MGK6G7-P^=D4-TCNV!DX .3P"?PK3I)I[#E&47:2L%%%%,D**** "BBB
M@ HHHH **R)?%?AR":2&;7]*CEC8HZ/>1AE8'!!!/!!&,5-8Z_HVJ7!@T_5K
M"[F"ES';W*2,%! )P"3C)'/N*5UL6Z<TN9IV-&BBBF0%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P!G:<WF^800KS#!1 00<@D.<9'R@$?,*\_BBEGF2&&-Y99&")'&I9F8G
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M96#A]QEMK?<Q&#\I\PN,<YZ9X'/6N+UC6=1U_4FU'5;M[J[9 GF. ,*.@
M4=3@ <DGJ371/$Q<6D>/A<FKQJQE4:23N4:^F_A,<_#+2,?]-O\ T<]?.^@:
M!J/B75XM-TR'S)WY)8X2->[L>RC/\@,D@'ZNT?2K70]'M-+LDVV]M&(UX +>
MK'  +$Y)..22:C"Q=W(Z,^K1Y(TNM[GA'QR_Y'VU_P"P9%_Z-FKCO"'_ ".N
M@?\ 82MO_1JUV/QR_P"1]M?^P9%_Z-FKCO"'_(ZZ!_V$K;_T:M9U/XWS.O!_
M\BY>C_4^MJ***]$^./ _CKI,5IXGTW5(RBM?VSQR(L8!+1%?G+?Q$K(J\] @
MY]/+XI98)4F@E>*:-@R21L59&'(((Y!![UZ]^T#_ ,??AC_=N_\ VC7CU>?B
M-*ET?8Y/+GPBC+HVC[(LKRWU&PM[ZUD\RVN8EFB?:1N1@"#@\C@CK4]8G@WC
MP-X?_P"P;;_^BEK;KT$?(25I-!11102<5\5]971_AYJ*AD\Z_7[#$KJQ#>9D
M/TZ$1B0@GC('7H?F4# P.E>D?&S7?[3\9Q:4L6V/2(MI<K@M)*%=L'/*A1'C
M@'.[J,5QOAC1F\0^)M.TE0Y6YG59#&RJRQCEV!;C(4,>_3H>E<&(ESSY4?69
M125#"NM/KK\D:^O^#?[%\ ^'?$139/J$KK<[Y=Q(<;H-H' 78C,<G=F3GT7E
M8I98)4FAE>*6-@R21L59&'(((Y!![U]9^+=#'B3PGJ>D80R7,!$)D9E591\T
M;$KS@.%/?IT/2OD>-Q)&KCHPS1B(<C3091BGB(SA/>]_DSZ]\-ZY!XD\.V.K
MVZ[4N8]S)DG8X.'7) SA@1G'.,CBM">>&UMY+BXE2&")"\DDC!510,DDG@ #
MO7DGP,\0K+87WAZ9W,T+&Z@W,S#RSA64#&% ;!Z\F0\<$UV?Q-^W_P#"M=>_
ML[_7?9CO^[_J<CSOO<?ZO?[^G.*[(3YHJ1\YBL.Z->5+S_#H>*>*_BIKWB+4
M';3KRZTO3%8&W@@?RY"!GYI'7DDYY4':..I&X\,JJHPJ@#T I:]A^'WC'P!H
M^C6@U"S2RU:S4YO9;,322%BV=DD:%L8.,$# (&6P37 FZLO>=CZR<8X"BO8T
M^;TW]6>0Q2R03QSPR-'-$P>.1#AD8'(((Z$'O7I/@;XM:CH][':>(;N>]TM_
ME,TGSRVY))W9^\Z\\@Y( &WIM/;^+?!?AOQYIMQ)X7GT8:U#,)6GM94"N7;Y
M_.\L,6R Q!(SN'7!;/$-\#/%(^[>Z.?K/*/_ &G6BIU*<O<U..6-P>+I-8A<
MK_'Y:'T'7SWX^^*NJ:KJMQI^@7LEEI4#F+S[:0>9=,K#YQ(O*IE?EVD9!))(
M;:/9%TW5='\ /IFG3QSZI::<\%G*D0C#.J$1?*[, >%SDX)R>!P/DV''D1[>
MFT8_*M<1-QBK=3@R?"TZU:3GJHDLLCS3R3RNTDTKEY)'.6=B<DDGDDGO3" 1
M@@&O3_AKXF\$:/8>3KVGHNH1SFYCOI[59PI&W:$*J70C&<8(R"=PR .^U_1?
M!WQ'TJ[&DW&E2:Y- +F"YA=4G#!0$,N 7V<JK*PX!Z @8PC1YU=2U/4KYF\/
M-PE2?*NO]*WXGE_A+XJ:[H&HI_:5Y<ZGIKL?.BG??(,X&Y';G(QPI.TY/0G<
M/HRRO(-1L+>]M7\RWN(EFB?:5W(PR#@\C@CK7@9^!GBG'%[HY/\ UWE_^-U[
M#X(\/W7A?PI::1=W,$[P[FS#&5"[CN9<DG=AF;YL+D8X'?HH>T6DSR<U>$FU
M.@U?JE^9SOQ.^(I\)P+I6FC.LW,7F+(R92WC)*A^>&8D, .G!+< !OG_ %34
M[[6K]K[4[N6[NFR/,F;<5!).U>RKDG"C &>!7K?B[X0>(M;\57VK6VJZ?.MY
M)YA-R&A:,#Y50!58,%0(-V03@Y'<Z/@?X/KI&H3W?B:.PU#:H6WA1C)%DY#%
MU9 "<8QU').,@$14A4G.W0Z<%B,%A</S[S_'T1X16KHWB76_#S Z1JES:*'+
M^6C9C9BNTDH<JQQCJ#T'H*^H?$FF^';[3FF\26^GM:Q*R?:+S:ODA\*=LAP4
M).T9!!SCOBOD:%F:%&<88CGBL:E-TK-,]#!XVGC^:$X;?/\ 0^AKC7-2\>_"
M&YU+2))K77+4[F2REFC/FQD,RKMY;?&>%^89<#.5R/%1XQ\3$ CQ'JY!_P"G
MZ7_XJO4/@'-*R>((&E<PH;=UC+':K'S 2!T!(5<GOM'I7FOC7P\OA;QAJ.DP
MHZVB.)+7<K &)QN4*226"Y*;L\E#WXK2JW*FIG+@(TZ6+J89K3=?U_6Q[E\(
MO$4NN^#S%=W+SWME.\<KS7!EE=6.]7;/(')49S]P\]AU'BC5SH'A75=55X%D
MM;622+SSA&D"G8IY&<MM& <G.!S7B'P4UEK#QD^F,7,.HP,NU54CS$!=68GD
M *)!QW8<=QW/QQU7['X)ATY'@+ZC=HC(Y^?RT_>%E&>S+&">1\V.XK>G4O3Y
MNQY>-PG+C?91VDU;YGBJ^+_$ZJ ?$FL' QDWTO\ \57N/P=75KGPS<ZMJVH7
M]TUW/M@%S<F51&G&Y022I+EP<]=B\=S\\10RW$R0P1/++(P5(XU+,['@  <D
MGTKZ[T'28M!T"PTJ+85M8%C+I&$#L!\S[1T+'+'KR3R:PPUW)MGIYVZ=.E&G
M%)-_DC1HHHKM/F0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *P?&_P#R(/B/_L%W/_HIJWJP?&__ "(/B/\
M[!=S_P"BFH8X[GR=7T!\"O\ D2K_ /["3_\ HJ*OG^OH#X%?\B5?_P#82?\
M]%15Y^%^,^NSS_=?FOU/2YYX;6WEN+B5(8(D+R22,%5% R22>  .]?-7Q+\<
M?\)CK21V4DXT>TX@C?Y1+)SF8KC(R#@ Y('/REF%7/B;\0[CQ1J$VD6#^7HE
MM*5RC@_;'4_?)!P8\C*COPQYP%X"**2>9(88WDED8(D:*69F)P  .22>,"KK
MUK^Y$Y<JRY07UBM\EV\V3Z=IUYJVH06%A;O<74[;8XTZD_T '))X !)KZ4\
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M3,CX3_\ )3='_P"VW_HEZ^G*^8/A=/#:_$73+BXE2&")9WDDD8*J*()"22>
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MT_XWWGUF+_Y%?_;L?T/H2BJFIZG9:-IL^HZC<I;VD"[I)7Z =.G4DG  '))
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M(L42>7$-S,< 9,F!R>]>CTHSC+8NMAZM%I5%:X44451B%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTJV,?F;3-,[;I)2!C+'\S@8 ). ,FMNBBM4DM$<$I2F^:3NSYZ^.7_(^VO\
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M"LU[QQT,5EM.?[II-Z;/_(Y;P5K[^&O%NGZB)O*MQ*([HG<5,+'#Y5>6P/F
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M\^"#D4G4G4GRIV*I83#8/#>WJ1YG9/ON>=W=W/>W4EY>W$EQ<28WS3.7=L
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)%#$H2..-0JHH&  !P !VJIK>CVFOZ)>:3?)NMKJ(QO@ E<]&7((# X(.."
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"*BO'EJ7>QOE57VV#=.+M)77W[,^@O\ A1?AC_G^U?\ [_1__&Z/^%%^&/\
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MXAO/"^NVVJ6;ONB8>;&K;1-'D;HSP>#CT.#@CD"OIOQQ_P D_P#$G_8+NO\
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M77V'QLM]3UW2M-M="EQ>20PRR2W(7RI'8*VT!3N49!!)4GT%<A\<O^1]M?\
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M @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#QR1L&5U(R""."".]?#'B/P_?>%O$%YHNI*@NK5@K&-MRL" RL#Z$$'G!YY
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%[=VT\<\%U-%-$P>.2.0JR,#D$$<@@]Z,.\(HOVZDWTLTE\[I@^;H??%</\
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MB2*&)0D<<:A510,  #@ #M6=>>&/#^HW3W5]H>F7-S)C?-/:1N[8&!DD9/
M_"G1>%]H_;*7+TLU?RO=6V\@?-;0GT?6+#7]*AU/3)_/LY]WER;&7=M8J>&
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M([45GAO:KV2ER=;M7\]E;\!J]M3DK+XJ>"]1O[>QM=9\RYN95AB3[+,-SL0
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MA^(/'GAKPO?I8ZSJ7V:YDB$RIY$CY0D@'*J1U4_E5KP]XKT/Q5!--HNH)=)
MP24!61D)&1E6 .#S@XP<'T-6]1T72M8\O^T],LKWRL^7]I@639G&<;@<9P/R
M%/T_2]/TF!H--L;:SA9M[1VT*QJ6P!G"@#. .?:B3POL$HJ7M/5<OW6O^(>]
M?R+=%%%<A04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P?''_)/
M_$G_ &"[K_T4U?#QZFON'QQ_R3_Q)_V"[K_T4U?#QZF@#[ ^"?\ R2+0OI/_
M .CY*N_%C3IM5^%OB"W@9%=+<7!+D@;8F61AP#SA#CWQTZU2^"?_ "2+0OI/
M_P"CY*[>^LK?4M/N;"[C\RVN8FAF3<1N1@0PR.1P3TH ^"*^V/AS>V^H?#?P
MY-:R>9&NGPPD[2/GC4(XY]&5A^''%?'&O:+>>'=>O=(OTV7-I*T;X! ;'1ER
M 2I&"#CD$&O3/AI\:F\&>'YM%U2QDO;6!'>P,&U65R2QC<G^ DD[N2.>&! 4
M D_:/_Y*!IX_ZA<?_HV6L/X&V\TWQ:TF2*)W2%)WE95)"+Y+KEO0991D]R!W
MKE_&/B:;QAXKO]=GMTMVNF7$*$D(JJ%49/4X49/&3G@=*]H_9R\*30Q:AXKN
M Z+.ILK53D!U#!I'Y'(W*J@@]0X(X% &/^TGITT7B?1M49D\BXLVMT4$[@T;
MEF)XQC$JXY['\>+^#M[;Z?\ %?09KJ3RXVE>$':3EY(V1!QZLRC\>>*]P^/O
MAB36_ R:G;0>9=:3+YQ(W%A PQ)A1P>0C$GHJ,<]<_+UA?7&EZC:ZA9R>7=6
MLJS0OM!VNI!!P>#R!UH ^]Z^ 6Y<_6O</$/[00UCP/)I4.BE-3OK62VO)7?$
M,>X;2T8Y9LJ6."1M./O]_$K>WFN[F*VMXGFGE<)''&I9G8G   Y))[4 ?4'[
M.UO-#\.+EY8G1)M2E>)F4@.NR-<KZC*L,CN".U>MU@>"?#G_  B7@S2]#,GF
M26L7[UPV09&)=]IP/EW,V,C.,9YK?H *\_\ C;_R2'7?^W?_ -*(Z] KS_XV
M_P#)(==_[=__ $HCH \__9E_YFG_ +=/_:U?0%?/_P"S+_S-/_;I_P"UJ^@*
M "BBB@#G_'?_ "3SQ+_V"KK_ -%-7Q!7V_X[_P"2>>)?^P5=?^BFKX@H ^P_
M!?@OPK=>!?#UQ<>&M&FGETRV>222PB9G8Q*222N22><UN?\ "">#_P#H5-#_
M /!=#_\ $UY7X:^ 7A76?"ND:I<:AK*SWME#<2+'-$%#.@8@9C)QD^IK4_X9
MQ\'_ /02US_O_#_\:H ] _X03P?_ -"IH?\ X+H?_B:/^$$\'_\ 0J:'_P""
MZ'_XFO/_ /AG'P?_ -!+7/\ O_#_ /&J/^&<?!__ $$M<_[_ ,/_ ,:H ] _
MX03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FO/_\ AG'P?_T$M<_[
M_P /_P :H_X9Q\'_ /02US_O_#_\:H ] _X03P?_ -"IH?\ X+H?_B:/^$$\
M'_\ 0J:'_P""Z'_XFO/_ /AG'P?_ -!+7/\ O_#_ /&J/^&<?!__ $$M<_[_
M ,/_ ,:H ] _X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FO/_\
MAG'P?_T$M<_[_P /_P :H_X9Q\'_ /02US_O_#_\:H ] _X03P?_ -"IH?\
MX+H?_B:/^$$\'_\ 0J:'_P""Z'_XFO/_ /AG'P?_ -!+7/\ O_#_ /&J/^&<
M?!__ $$M<_[_ ,/_ ,:H ] _X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X
M+H?_ (FO/_\ AG'P?_T$M<_[_P /_P :H_X9Q\'_ /02US_O_#_\:H ] _X0
M3P?_ -"IH?\ X+H?_B:/^$$\'_\ 0J:'_P""Z'_XFO/_ /AG'P?_ -!+7/\
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MM#L))Y+6U\K8\[ N=T2.<D #JQ[5ZO\ LR_\S3_VZ?\ M:@#Z HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ'_X,8?_ (JN?_X4E\//^A>_\G;C_P".4?\ "DOAY_T+W_D[<?\ QR@#H/\
MA._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJY_P#X4E\//^A>_P#)
MVX_^.4?\*2^'G_0O?^3MQ_\ '* .@_X3OP?_ -#7H?\ X,8?_BJ/^$[\'_\
M0UZ'_P"#&'_XJN?_ .%)?#S_ *%[_P G;C_XY1_PI+X>?]"]_P"3MQ_\<H Z
M#_A._!__ $->A_\ @QA_^*H_X3OP?_T->A_^#&'_ .*KG_\ A27P\_Z%[_R=
MN/\ XY1_PI+X>?\ 0O?^3MQ_\<H Z#_A._!__0UZ'_X,8?\ XJC_ (3OP?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.\'_ /0-US_OQ#_\=KV"B@#Q_P#X:.\'_P#0-US_ +\0_P#QVC_AH[P?_P!
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'S_^TU_S*W_;W_[1KT#X)?\ )(="_P"WC_THDKS_ /::
M_P"96_[>_P#VC7H'P2_Y)#H7_;Q_Z424 >@4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ^?_VFO^96_P"WO_VC7H'P2_Y)
M#H7_ &\?^E$E>?\ [37_ #*W_;W_ .T:] ^"7_)(="_[>/\ THDH ] HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML%% 'C__  CWQS_Z'/0_^_*__(]'_"/?'/\ Z'/0_P#ORO\ \CU[!10!X_\
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MGXUZO^S+_P S3_VZ?^UJX#XV_P#)7M=_[=__ $GCKO\ ]F7_ )FG_MT_]K4
M?0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S_\ M-?\
MRM_V]_\ M&O0/@E_R2'0O^WC_P!*)*\__::_YE;_ +>__:->@?!+_DD.A?\
M;Q_Z424 >@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y_P#&W_DD.N_]N_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!?#UQ<>&M&FGETRV>222PB9G8Q*222N22><UN?\ "">#_P#H5-#_ /!=#_\
M$UY7X:^*?BK3O"ND65O\,=9O(+>RABCN8S+MF54 #C$)&"!GJ>O4UJ?\+?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]_E_^2* /8**\?\ ^$A^.?\ T)FA_P#?Y?\ Y(H_X2'XY_\ 0F:'_P!_E_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUS\IO_C]'_"H/&'_ $5G7/RF_P#C] 'L%%>/_P#"H/&'_16=<_*;_P"/T?\
M"H/&'_16=<_*;_X_0![!17C_ /PJ#QA_T5G7/RF_^/T?\*@\8?\ 16=<_*;_
M ./T >P45X__ ,*@\8?]%9US\IO_ (_1_P *@\8?]%9US\IO_C] 'L%%>/\
M_"H/&'_16=<_*;_X_1_PJ#QA_P!%9US\IO\ X_0![!17C_\ PJ#QA_T5G7/R
MF_\ C]'_  J#QA_T5G7/RF_^/T >P45X_P#\*@\8?]%9US\IO_C]'_"H/&'_
M $5G7/RF_P#C] 'D'QM_Y*]KO_;O_P"D\==_^S+_ ,S3_P!NG_M:O*/B)H]Y
MH/CO4M,O]6GU:ZA\K?>SYWRYB1AG+,> 0.IZ5ZO^S+_S-/\ VZ?^UJ /H"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\DAT+_MX_P#2B2@#T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=HU+' ? R2>E;'_"DOAY_P!"]_Y.W'_QR@#H/^$[\'_]#7H?_@QA_P#BJ/\
MA._!_P#T->A_^#&'_P"*KG_^%)?#S_H7O_)VX_\ CE'_  I+X>?]"]_Y.W'_
M ,<H Z#_ (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJN?\ ^%)?
M#S_H7O\ R=N/_CE'_"DOAY_T+W_D[<?_ !R@#H/^$[\'_P#0UZ'_ .#&'_XJ
MC_A._!__ $->A_\ @QA_^*KG_P#A27P\_P"A>_\ )VX_^.4?\*2^'G_0O?\
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M_P"3MQ_\<H Z#_A._!__ $->A_\ @QA_^*H_X3OP?_T->A_^#&'_ .*KG_\
MA27P\_Z%[_R=N/\ XY1_PI+X>?\ 0O?^3MQ_\<H Z#_A._!__0UZ'_X,8?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5@>,_%EGX
M*\+W6M7B^;Y6%B@#A6FD)PJ@G\2<9(4,<'&*WZ^>?VE-9W7VAZ&CSKY<3W<J
M9Q&^X[$.,\L-DG4<!N#R: /(_%/B_6O&.J/?:Q>/*2[-% &(B@!Q\L:YPHP!
M[G&22>:PJ[WX1>#+'QOXU^Q:G(XLK6W:ZEB3@S!65=F[JH);DCG (&"<CN/V
MB-)T[1[3PS;Z9I]K8P,]VYCMH5B4MB$9PH S@#GV% $G[.=[;Z;IGC"_NY/+
MMK:.WFF?:3M11,6.!R> >E>%PW,]I=QW-M-)#/$X>.2-BK(P.001R"#WKWC]
MFV"&ZM/%EO<1)-!*MLDD<BAE=2)@00>"".U<W\=/ NE>$M:L=0TA?(@U3S6:
MT5<)"Z;<E/13O^[VP<<$  'L?PA^($OCOPU+_:'E_P!K6#K%<E%($BD?))C&
M 6PP('=2< $"O0Z^4?@!J?V#XGQ6WD[_ .T+2:WW;L>7@"7=C'/^KQCCKGM@
M_5U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\_
M_M-?\RM_V]_^T:] ^"7_ "2'0O\ MX_]*)*\_P#VFO\ F5O^WO\ ]HUZ!\$O
M^20Z%_V\?^E$E 'H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M '$>-OBGX?\  >H6UAJD=]-<SQ><$M8E;8F2 2691R0W3/W3G'&>8_X:-\'_
M /0/UO\ [\1?_'*Y/X^^&M=UGQQ8W&EZ)J5]"NFHC26MJ\JAO,D."5!&<$<>
MXKRK_A!/&'_0J:Y_X+IO_B: /H'_ (:-\'_] _6_^_$7_P <H_X:-\'_ /0/
MUO\ [\1?_'*^:M2TC4M&N%M]4T^[L9F7>L=U"T3%<D9 8 XR#S[&J8!/09H
M^H?^&C?!_P#T#];_ ._$7_QRC_AHWP?_ - _6_\ OQ%_\<KYVO?"7B33;22[
MO_#^JVMM'C?-/92(BY( RQ&!R0/QK'H ^R/!/Q4\/^/-0N;#2X[Z&Y@B\XI=
M1*N],@$@JS#@E>N/O#&><=O7SC^SWH.L:?XPNM0O-*OK>RN-+;R;F6W=8Y-T
MD3#:Q&#D<C'45]'4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G_QM_P"20Z[_ -N_
M_I1'7H%>?_&W_DD.N_\ ;O\ ^E$= 'G_ .S+_P S3_VZ?^UJ^@*^?_V9?^9I
M_P"W3_VM7T!0 4444 <_X[_Y)YXE_P"P5=?^BFKX@K[?\=_\D\\2_P#8*NO_
M $4U?$% 'U/X3^+_ ($TSP;H=A>:[Y=U:Z?;PS)]DG.UUC4,,A,'!!Z5L?\
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M_P#Z%30__!=#_P#$T <__P +M^'G_0P_^25Q_P#&Z/\ A=OP\_Z&'_R2N/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFOH:OE7]G_1)M1^(RZDN]8-,MY)781DJS.IC5"W120S,/78>.X^JJ "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#F_$OC[POX0N(+?7=6CM9YT+QQB-Y&V@XR0BD@9R
M3C.#CH:\S^*7Q2\&^(_AQJVDZ3K/VB^G\GRXOLLR;MLR,>60 < GDUUGQ)^$
MUC\0KBTOAJ$FGZA;IY)F$?FK)%DD*4W#!#,2"#W((/&/)/&WP+_X0[PA?:__
M ,)']L^R^7^X^P^7NW2*GWO,.,;L].U &_\ LR_\S3_VZ?\ M:OH"OG_ /9E
M_P"9I_[=/_:U?0% !1110!S_ ([_ .2>>)?^P5=?^BFKX@K[?\=_\D\\2_\
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M?G-_\8H_X6_XP_Z)-KGYS?\ QBO8** /'_\ A;_C#_HDVN?G-_\ &*/^%O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5\^_M)>('\[1O#L;2*H4WTP*KM8DE(\'KD8ER.!\PZ]OH*O)?
MCCX0TOQ!I5K>OJVG:=K5LKBV6\GCA%X@P6CW,0<@G*G. 6(.-VX 'C_@_P")
M7C>35;30EU6/4X-1N!;M;:RIN(I#+B/#L<OLY!P#CKP<D'Z'U+X3>!-5N%GN
M/#5HCJ@0"V+VZXR3RL94$\]<9Z>@KY TG4I]$UJQU2!$:>RN([B-9 2I9&#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %> _M,_<\,?6Z_]I5[]6?J>A:/K?E?VKI5C?^5GR_M5NDNS.,XW XS@?D*
M/A"BOM__ (03P?\ ]"IH?_@NA_\ B:XS4M>^"FE7"P7,/AAW9-X-MIJ7"XR1
MRT:, >.F<]/44 ?*=%?5FFZ]\%-5N&@MX?#".J%R;G34MUQD#AI$4$\],YZ^
MAKKX/!?@JZMX[BW\,^'YH)4#QR1V$+*ZD9!!"X(([T >"_LX?\E U'_L%R?^
MC8J^GJR]-\-:%HUPUQI>B:;8SLFQI+6U2)BN0<$J <9 X]JU* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y_\ VFO^96_[>_\
MVC7H'P2_Y)#H7_;Q_P"E$E>?_M-?\RM_V]_^T:] ^"7_ "2'0O\ MX_]*)*
M/0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBLCQ5>W&F^#
M];O[23R[FVL)YH7V@[76-BIP>#R!UH ^8/C%\0+CQ=XHN-/M;K=H=A*4MTC(
MVRN!AI202&R=VT_W<8 );/+>&_ _B7Q=YC:'I$]U''D--E8XP1C*[V(7=\P.
MW.<'.,5@#YG^IK[RTK2K'1-+M]-TVVCMK.W39%$@X4?S))R23R223R: /DW_
M (4C\0_^@ /_  -@_P#BZX>^L+W2[Q[._M)[2ZCQOAGC*.N0",@\C@@_C7WM
M7BO[1^E6+>%-.U<VR?VA'>K;"X PWE,DC%3ZC*@C/3G&,G(!I_ _X@7'BS0I
M]*U:Z\[5M.QMD<C?- > QYRS*<AFQW3)))->KU\D_ F]N+7XK:?##)MCNX9X
M9QM!WH(V<#GI\R*>/3TS7UM0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>?_&W_DD.
MN_\ ;O\ ^E$=>@5Y_P#&W_DD.N_]N_\ Z41T >?_ +,O_,T_]NG_ +6KZ KY
M_P#V9?\ F:?^W3_VM7T!0 4444 <_P"._P#DGGB7_L%77_HIJ^(*^W_'?_)/
M/$O_ &"KK_T4U?$% 'T7X:^ 7A76?"ND:I<:AK*SWME#<2+'-$%#.@8@9C)Q
MD^IK4_X9Q\'_ /02US_O_#_\:KI/!?C3PK:^!?#UO<>)=&AGBTRV22.2_B5D
M81*"""V00>,5N?\ "=^#_P#H:]#_ /!C#_\ %4 >?_\ #./@_P#Z"6N?]_X?
M_C5'_#./@_\ Z"6N?]_X?_C5>@?\)WX/_P"AKT/_ ,&,/_Q5'_"=^#_^AKT/
M_P &,/\ \50!Y_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-
M5Z!_PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\ %4 >?_\ #./@
M_P#Z"6N?]_X?_C5'_#./@_\ Z"6N?]_X?_C5>@?\)WX/_P"AKT/_ ,&,/_Q5
M'_"=^#_^AKT/_P &,/\ \50!Y_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"
M6N?]_P"'_P"-5Z!_PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\
M%4 >?_\ #./@_P#Z"6N?]_X?_C5'_#./@_\ Z"6N?]_X?_C5>@?\)WX/_P"A
MKT/_ ,&,/_Q5'_"=^#_^AKT/_P &,/\ \50!Y_\ \,X^#_\ H):Y_P!_X?\
MXU1_PSCX/_Z"6N?]_P"'_P"-5Z!_PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H
M:]#_ /!C#_\ %4 >?_\ #./@_P#Z"6N?]_X?_C5'_#./@_\ Z"6N?]_X?_C5
M>@?\)WX/_P"AKT/_ ,&,/_Q5'_"=^#_^AKT/_P &,/\ \50!Y_\ \,X^#_\
MH):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5Z!_PG?@_P#Z&O0__!C#_P#%
M4?\ "=^#_P#H:]#_ /!C#_\ %4 >?_\ #./@_P#Z"6N?]_X?_C5'_#./@_\
MZ"6N?]_X?_C5>@?\)WX/_P"AKT/_ ,&,/_Q5'_"=^#_^AKT/_P &,/\ \50!
M\D?$3PW9^$?'>I:'823R6MKY6QYV!<[HD<Y( '5CVKU?]F7_ )FG_MT_]K5Y
MQ\7[^SU/XI:S>6%W!=VLGD;)H)!(C8@C!PPX.""/PKT?]F7_ )FG_MT_]K4
M?0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 53U35+'1-+N-2U*YCMK.W3?
M+*YX4?S))P !R20!R:N5X;^T?X@FMM)TG0+>X14NW>XNHU<ARJ8$8(!^X6+'
MD<F,8^Z: /*_'?Q4\0>.93#-+]BTL9"V-L[!'&[<#(<_O&&%Y.!\N0!DUPU=
M!X*\)7GC;Q1:Z+:/Y7F9>:<H66&,<LQ _ #. 6*C(SFOJ30/@[X(T"-=NCQZ
MA/L*--J.)RP+9^Z1L!' !"@X'N<@'QW76>!OB%K7@75(YK*>2:P+DW&GO(1%
M*#@$XZ*^ ,,!D8&<C(/U!K7PH\$:Y;^5-X?M+5U1U26Q06[(6'WODP&(P"-P
M('IR<_-'Q,\ 3> /$@M%EDN-.N5,MI.ZD$KG!1CC!=>,X[%3@9P #ZR\,^)M
M+\7:'#J^D3^;;R<,K</$XZHX[,,_J",@@G8KYM_9R\036_B/4?#\MPBVEU;F
MXBCD<@F9" 0@SC)0L3@9(C'9:^DJ "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#Y_P#VFO\ F5O^WO\ ]HUZ!\$O^20Z%_V\?^E$
ME>?_ +37_,K?]O?_ +1KT#X)?\DAT+_MX_\ 2B2@#T"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M D'9J^DJS/#N@6/A?0+/1=-5UM+5"J>8VYF))9F)]2Q)XP.> !Q6G0 4444
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M*2^'G_0O?^3MQ_\ '*Y__A;_ (P_Z)-KGYS?_&*/^%O^,/\ HDVN?G-_\8H
MZ#_A27P\_P"A>_\ )VX_^.4?\*2^'G_0O?\ D[<?_'*Y_P#X6_XP_P"B3:Y^
M<W_QBC_A;_C#_HDVN?G-_P#&* .@_P"%)?#S_H7O_)VX_P#CE'_"DOAY_P!"
M]_Y.W'_QRN?_ .%O^,/^B3:Y^<W_ ,8H_P"%O^,/^B3:Y^<W_P 8H Z#_A27
MP\_Z%[_R=N/_ (Y1_P *2^'G_0O?^3MQ_P#'*Y__ (6_XP_Z)-KGYS?_ !BC
M_A;_ (P_Z)-KGYS?_&* .@_X4E\//^A>_P#)VX_^.4?\*2^'G_0O?^3MQ_\
M'*Y__A;_ (P_Z)-KGYS?_&*/^%O^,/\ HDVN?G-_\8H Z#_A27P\_P"A>_\
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M^W3_ -K5Y1\1-8O->\=ZEJ=_I,^DW4WE;[*?.^+$2*,Y53R #T'6O5_V9?\
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MS8[IDDDFO5Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKQ__ (1[XY_]#GH?_?E?_D>C_A'OCG_T.>A_]^5_^1Z /8**\?\ ^$>^.?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M44 %%%% !1110 4444 ?/_[37_,K?]O?_M&O0/@E_P DAT+_ +>/_2B2O/\
M]IK_ )E;_M[_ /:->@?!+_DD.A?]O'_I1)0!Z!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#"DOAY_P!"]_Y.W'_QRC_A27P\_P"A>_\ )VX_^.4 =!_PG?@__H:]#_\
M!C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5<__P *2^'G_0O?^3MQ_P#'*/\ A27P
M\_Z%[_R=N/\ XY0!T'_"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/
M_P 57/\ _"DOAY_T+W_D[<?_ !RC_A27P\_Z%[_R=N/_ (Y0!T'_  G?@_\
MZ&O0_P#P8P__ !5'_"=^#_\ H:]#_P#!C#_\57/_ /"DOAY_T+W_ ).W'_QR
MC_A27P\_Z%[_ ,G;C_XY0!T'_"=^#_\ H:]#_P#!C#_\51_PG?@__H:]#_\
M!C#_ /%5S_\ PI+X>?\ 0O?^3MQ_\<H_X4E\//\ H7O_ "=N/_CE '0?\)WX
M/_Z&O0__  8P_P#Q5'_"=^#_ /H:]#_\&,/_ ,57/_\ "DOAY_T+W_D[<?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#YY^/WA3Q!K'C#3K_ $O1KZ^MOL A+VL+2[761R00N2.'7KUY
MQT./)_\ A O&'_0JZW_X+Y?_ (FOMZHYYX;6WDN+B5(8(D+R22,%5% R22>
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MX/\ ^A4T/_P70_\ Q-'_  @G@_\ Z%30_P#P70__ !- '/\ _"[?AY_T,/\
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MS_\ PNWX>?\ 0P_^25Q_\;H_X7;\//\ H8?_ "2N/_C==!_P@G@__H5-#_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.#T(^4!GP>#MQWKXSN+B:[N9;FYE>:>5R\DDC%F=B<DDGDDGO0![Y_PTT/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;=DG(^=P,D"@!,$]!1TZ5]T>&?#.E^$=#ATC2(/*MX^69N7E<]7<]V./T &
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M#%L >8.1P02655&#D\<^IP3PW5O%<6\J302H'CDC8,KJ1D$$<$$=Z )****
M"BBB@ HHHH **** "BBB@ HHHH *^<?VB?%WVO5;3PI;/^ZLL7-WQUE9?D7D
M?PHV<@D'S.>5KZ*GGAM;>2XN)4AAB0O))(P544#)))X  [U\,^)=;F\1^)M2
MUF?>&O+AY0CR&0QJ3\J;CU"KA1P. .!0!W'P,\++XA^($5Y<1N;324^UDA&V
MF4$"-2P(VG/SCKGRR,$9Q]95Y;\ =$ATWX;QZ@NQI]3GDF=A& RJC&-4+=6
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$\ ]RG('09XW/^&<O!__ $$-;_[_ ,7_ ,;K?_X7;\//^AA_\DKC_P"-T?\
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M=CUR-H5.W._KP:^AJIZ7I=CHFEV^FZ;;1VUG;ILBB0<*/YDDY))Y)))Y-7*
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M#_[\K_\ (]'_  CWQS_Z'/0_^_*__(]>P44 >/\ _"/?'/\ Z'/0_P#ORO\
M\CT?\(]\<_\ H<]#_P"_*_\ R/7L%% 'C_\ PCWQS_Z'/0_^_*__ "/1_P (
M]\<_^AST/_ORO_R/7L%% 'C_ /PCWQS_ .AST/\ [\K_ /(]'_"/?'/_ *'/
M0_\ ORO_ ,CU[!10!X__ ,(]\<_^AST/_ORO_P CT?\ "/?'/_H<]#_[\K_\
MCU[!10!X_P#\(]\<_P#H<]#_ ._*_P#R/1_PCWQS_P"AST/_ +\K_P#(]>P4
M4 ?%'Q$M]=M/'>I0>);V"]U=?*^T3P !'S$A7 "KT7:.@Z?C7J_[,O\ S-/_
M &Z?^UJX#XV_\E>UW_MW_P#2>.N__9E_YFG_ +=/_:U 'T!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS_P"-O_)(==_[=_\
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M!_\ T->A_P#@QA_^*H_X3OP?_P!#7H?_ (,8?_BJ //_ /AG'P?_ -!+7/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y__::_YE;_
M +>__:->@?!+_DD.A?\ ;Q_Z425Y_P#M-?\ ,K?]O?\ [1KT#X)?\DAT+_MX
M_P#2B2@#T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBO/?C7K[Z#\,[\1,ZSZ@RV,;*JL 'R7SGH#&K
MC(YR1TZ@ \?^)_QGOO$=S<Z/X>N'M="*F&20+MDO 2,DDC*)Q@*,$@G=UVCR
M*MSP=X9F\8>++#08+A+=KIFS,X)"*JEF.!U.%.!QDXY'6OK31OA=X+T33TM(
M?#]C<XP6FO85GD=L $EF!QG&<#"Y)P!F@#XOKTGX?_&'7/"-Y;6NH7,^HZ$N
M$>VD8,\2X !B8\C:%&$SMZC@G</H^^^'/@S4+-[6?POI2QOC)@MEA<8(/#H
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M_P"@;KG_ 'XA_P#CM'_#1W@__H&ZY_WXA_\ CM '0?\ "DOAY_T+W_D[<?\
MQRC_ (4E\//^A>_\G;C_ ..5S_\ PT=X/_Z!NN?]^(?_ ([1_P -'>#_ /H&
MZY_WXA_^.T =!_PI+X>?]"]_Y.W'_P <H_X4E\//^A>_\G;C_P".5S__  T=
MX/\ ^@;KG_?B'_X[1_PT=X/_ .@;KG_?B'_X[0!T'_"DOAY_T+W_ ).W'_QR
MC_A27P\_Z%[_ ,G;C_XY7/\ _#1W@_\ Z!NN?]^(?_CM'_#1W@__ *!NN?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAMC=& R.02.1ZUE=* /O^BOCWP_\8_&^@.H&KOJ$ <NT.HYG#$KC[Y.\ <$
M,!D>YSZ_X?\ VBO#FH.L6M6%WI+LY'F*?M$2J!D$E0&R3D8"'MSUP >QT5F:
M+XCT7Q';^?HVJ6M\@17<02AFC##*[UZJ3@\, >#Z5IT %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'S_ /M-?\RM_P!O?_M&O0/@
ME_R2'0O^WC_THDKS_P#::_YE;_M[_P#:->@?!+_DD.A?]O'_ *424 >@4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M '%:= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M05J?\)#\<_\ H3-#_P"_R_\ R10![!17C_\ PD/QS_Z$S0_^_P O_P D4?\
M"0_'/_H3-#_[_+_\D4 >P45X_P#\)#\<_P#H3-#_ ._R_P#R11_PD/QS_P"A
M,T/_ +_+_P#)% 'L%%>/_P#"0_'/_H3-#_[_ "__ "11_P )#\<_^A,T/_O\
MO_R10![!17C_ /PD/QS_ .A,T/\ [_+_ /)%'_"0_'/_ *$S0_\ O\O_ ,D4
M >P45X__ ,)#\<_^A,T/_O\ +_\ )%'_  D/QS_Z$S0_^_R__)% 'L%%>/\
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M/_!C-_\ %4?\)WXP_P"AKUS_ ,&,W_Q5 'V_17Q!_P )WXP_Z&O7/_!C-_\
M%4?\)WXP_P"AKUS_ ,&,W_Q5 'V_17Q!_P )WXP_Z&O7/_!C-_\ %4?\)WXP
M_P"AKUS_ ,&,W_Q5 'V_17F?P0\5ZOXI\%2MK!DGEL;C[,EX^,S*%4@,<Y+K
MGEB!D%>6.XUZ90 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_A'OCG_T.>A_]^5_^1Z/^$>^.?\ T.>A_P#?E?\ Y'H ]@HKQ_\ X1[XY_\
M0YZ'_P!^5_\ D>C_ (1[XY_]#GH?_?E?_D>@#V"BO'_^$>^.?_0YZ'_WY7_Y
M'H_X1[XY_P#0YZ'_ -^5_P#D>@#V"BO'_P#A'OCG_P!#GH?_ 'Y7_P"1Z/\
MA'OCG_T.>A_]^5_^1Z /8**\?_X1[XY_]#GH?_?E?_D>C_A'OCG_ -#GH?\
MWY7_ .1Z /8**\?_ .$>^.?_ $.>A_\ ?E?_ )'H_P"$>^.?_0YZ'_WY7_Y'
MH ]@HKQ__A'OCG_T.>A_]^5_^1Z/^$>^.?\ T.>A_P#?E?\ Y'H ]@HKQ_\
MX1[XY_\ 0YZ'_P!^5_\ D>C_ (1[XY_]#GH?_?E?_D>@#V"BO'_^$>^.?_0Y
MZ'_WY7_Y'H_X1[XY_P#0YZ'_ -^5_P#D>@#R#XV_\E>UW_MW_P#2>.N__9E_
MYFG_ +=/_:U>4?$2WUVT\=ZE!XEO8+W5U\K[1/  $?,2%< *O1=HZ#I^->K_
M +,O_,T_]NG_ +6H ^@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP']IG
M[GACZW7_ +2KWZO*?C+XCT+PU=>'KK6?"T&O.3<^0L\^Q(N(PV4*LKYR.HXV
MY'- 'S=X>\*:[XKNS;:'ID]Y(OWV0 )'P2-SG"KG:<9(SC YKUSPO^SE?3ND
M_BC4TMH2BM]FL3OER5.59V&U2IV] X//(X-68/VDX+6WBM[?P:L,$2!(XX[\
M*J*!@  18  [5)_PTTO_ $*1_P#!C_\ :J /3_#OPO\ !_ACRWL=%@DN4\LB
MZNAYTF].C@MD(V>?D"\XXX&.OKP'_AII?^A2/_@Q_P#M5'_#32_]"D?_  8_
M_:J /?J^=?C[X:UW6?'%C<:7HFHWT*Z:B-):VKRJ&\R0X)4$9P1Q[UH0?M,6
M[7$:W'A62. N!(\=\'95SR0IC )QVR,^HKN_#'QE\'>*+R&R@NY[*^GE\J&W
MO8MAD.,C#*63GH 6!)XQR,@'"? #P1K6CZOJFN:M8W6GI]G^R0PW,)C:4LRN
MS '! 7:HZ8.XX/RFO>J** "BBB@ HHHH **** "BBN8\8>/_  _X'L_.U:[S
M.VWR[. JT\@)(W!"1\O#?,<#C&<X! #QMX\T?P%IUO>:J)Y/M$OE1PVP1I&P
M"2VUF7Y1P">Q9?6N?\+?&KPWXN\1VNAV%EJL=U<[]CSQ1A!M0N<D2$]%/:OG
M#QWX[U3Q[KAO[X^5;1Y6UM%;*0(?YL<#+=\=@ !K_!'_ )*]H?TN/_1$E 'U
M_117$?%?QC<>"? \VH67%_<2K:VKE RQNP)+$$]E5L=>=N01F@ \8_%?PMX)
MN_L6H3SW-^-I>ULXP[QJP)!8DA1T'&<_,#C!S7+_ /#1W@__ *!VN?\ ?B+_
M ..U\S_Z9JNH_P#+>\OKN7WDDFD8_FS$GZDFNM\2_"KQ7X3\/P:SJEE&MN[%
M)EAD$C6QSA?,QP W8@D= <$@$ ^LO#WBG0_%5F;K0]3@O8U^^$)#Q\D#<APR
MYVG&0,XR.*V*^'?"'BF^\'>);36+&1QY3@3Q*^T3Q9&Z-N",$#K@X.".0*^V
MK&]M]2T^VO[23S+:YB6:%]I&Y& *G!Y'!'6@"Q1110!\_P#[37_,K?\ ;W_[
M1KT#X)?\DAT+_MX_]*)*\_\ VFO^96_[>_\ VC7H'P2_Y)#H7_;Q_P"E$E '
MH%%%% !1110 4444 %%%% $<\$-U;RV]Q%'-!*A22.10RNI&""#P01QBO+]2
M_9]\$7UPLMN-2T] @4Q6MR&4G)^8^8KG/..N.!QUSZI10!X__P ,X^#_ /H)
M:Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\
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M0W$BQS1!0SH&(&8R<9/J:U/^&<?!_P#T$M<_[_P__&J /8**\?\ ^&<?!_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$% 'U/X3^+_@33/!NAV%YKOEW5KI]O#,GV2<[76-0PR$P<$'I6Q_PNWX>?\
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MS_\ PNWX>?\ 0P_^25Q_\;H_X7;\//\ H8?_ "2N/_C==!_P@G@__H5-#_\
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M_P#&Z/\ A=OP\_Z&'_R2N/\ XW70?\()X/\ ^A4T/_P70_\ Q-'_  @G@_\
MZ%30_P#P70__ !- 'RA\4M;T[Q'\1]6U;2;C[18S^3Y<NQDW;844\, 1R".1
M7I_[,O\ S-/_ &Z?^UJ\X^+]A9Z9\4M9L["T@M+6/R-D,$8C1<P1DX4<#))/
MXUZ/^S+_ ,S3_P!NG_M:@#Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNI2();J9I6"B.,XRQ)QDGCW->I4 %%%% !1110 4444 %%%% !1110 4444
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MUS\YO_C%'_"W_&'_ $2;7/SF_P#C%>P44 >/_P#"W_&'_1)M<_.;_P",4?\
M"W_&'_1)M<_.;_XQ7L%% 'C_ /PM_P 8?]$FUS\YO_C%'_"W_&'_ $2;7/SF
M_P#C%>P44 >/_P#"W_&'_1)M<_.;_P",4?\ "W_&'_1)M<_.;_XQ7L%% 'C_
M /PM_P 8?]$FUS\YO_C%'_"W_&'_ $2;7/SF_P#C%>P44 >/_P#"W_&'_1)M
M<_.;_P",4?\ "W_&'_1)M<_.;_XQ7L%% 'C_ /PM_P 8?]$FUS\YO_C%'_"W
M_&'_ $2;7/SF_P#C%>P44 >/_P#"W_&'_1)M<_.;_P",4?\ "W_&'_1)M<_.
M;_XQ7L%% 'C_ /PM_P 8?]$FUS\YO_C%'_"W_&'_ $2;7/SF_P#C%>P44 ?%
M'Q$UB\U[QWJ6IW^DSZ3=3>5OLI\[XL1(HSE5/( /0=:]7_9E_P"9I_[=/_:U
M<!\;?^2O:[_V[_\ I/'7?_LR_P#,T_\ ;I_[6H ^@**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB2@#T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X KZ_^"7_ "2'0O\
MMX_]*)*^0*^O_@E_R2'0O^WC_P!*)* /0**** "BBB@ HHHH **** "BBB@
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M;&.7:DT>0VUBP5QUP2I!P?8@^XKRN:7->_S/OE1HNE[-P7?ETWW]-^O<0*%
M50 !T KV7X*W+/HNJVPMV$272RBXSE7=D"E.G50BD\_QCIWW/ K^$]8T^WOM
M(TBRM;VS41R*8E:> [2O^L(W,",X?/S<YYW =G7J8;"\C]HI7/A<\SWZU3EA
M)4>5I]7JFO*WZA1117>?)A1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT!7S_P#LR_\ ,T_]NG_M:OH"@ HHHH Y_P =_P#)//$O_8*NO_135\05]O\
MCO\ Y)YXE_[!5U_Z*:OB"@#Z+\-:[\98?"ND1:7X3T:?3TLH5M99)5#/$$&Q
MC^_')7!Z#Z"M3_A(?CG_ -"9H?\ W^7_ .2*] \"?\D\\-?]@JU_]%+704 >
M/_\ "0_'/_H3-#_[_+_\D4?\)#\<_P#H3-#_ ._R_P#R17L%% 'C_P#PD/QS
M_P"A,T/_ +_+_P#)%'_"0_'/_H3-#_[_ "__ "17L%% 'C__  D/QS_Z$S0_
M^_R__)%'_"0_'/\ Z$S0_P#O\O\ \D5[!10!X_\ \)#\<_\ H3-#_P"_R_\
MR11_PD/QS_Z$S0_^_P O_P D5[!10!X__P )#\<_^A,T/_O\O_R11_PD/QS_
M .A,T/\ [_+_ /)%>P44 >/_ /"0_'/_ *$S0_\ O\O_ ,D4?\)#\<_^A,T/
M_O\ +_\ )%>P44 >/_\ "0_'/_H3-#_[_+_\D4?\)#\<_P#H3-#_ ._R_P#R
M17L%% 'C_P#PD/QS_P"A,T/_ +_+_P#)%'_"0_'/_H3-#_[_ "__ "17L%%
M'C__  D/QS_Z$S0_^_R__)%'_"0_'/\ Z$S0_P#O\O\ \D5[!10!\4?$2XUV
M[\=ZE/XELH++5V\K[1! 043$2!<$,W5=IZGK^%>K_LR_\S3_ -NG_M:N ^-O
M_)7M=_[=_P#TGCKO_P!F7_F:?^W3_P!K4 ?0%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\S9M4X.0V$S@@<,IYS0!G_L[:W]A\;W>DR7&R'4;4E(MF?,FC.Y><<80RGJ
M?KBOIZODWX":;-??%*TN8F0)8V\UQ*&)R5*^7@<=<R+UQP#]*^LJ "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y_P#VFO\ F5O^
MWO\ ]HUZ!\$O^20Z%_V\?^E$E>?_ +37_,K?]O?_ +1KT#X)?\DAT+_MX_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M: . _9R_Y)W??]A23_T5%7KU5-.TK3M'MVM],L+6R@9R[1VT*QJ6P!DA0!G
M'/L*MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5Y_P#&W_DD.N_]N_\ Z41UZ!7G_P ;?^20Z[_V[_\ I1'0!Y_^S+_S
M-/\ VZ?^UJ^@*^?_ -F7_F:?^W3_ -K5] 4 %%%% '/^._\ DGGB7_L%77_H
MIJ^(*^W_ !W_ ,D\\2_]@JZ_]%-7Q!0!]%^&OA9XJU'PKI%[;_$[6;."XLH9
M8[:,2[859 0@Q,!@ XZ#IT%:G_"H/&'_ $5G7/RF_P#C]=)X+\:>%;7P+X>M
M[CQ+HT,\6F6R21R7\2LC")0006R"#QBMS_A._!__ $->A_\ @QA_^*H \_\
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M,/\ HK.N?E-_\?H_X5!XP_Z*SKGY3?\ Q^O0/^$[\'_]#7H?_@QA_P#BJ/\
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MXR;>&.%^"#PZ*&'3L?;I7#<D^]>R6_[-_BEKB);G5M'C@+@2/')*[*N>2%*
M$X[9&?45Z9X+^!_A_P )ZA:ZI<7$^J:E;Y*-,JK"KY^5UCY(8#IECSR,'& "
M/X'>![[PEX:NKW58G@O]4='-NQYBB0'9N&,JY+L2,G VC@@BO4Z** "BBB@
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M)F3S7DRYDD!.7)/11^5;'[./_)0]0_[!4G_HV*G5QE6M55:=N9>26WDE9_-
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MR*"4-);3QNR2I_$I#2D<C(S@XZCD5Z/110QE6A"4*=K2WND_S3!Q3W"O,?\
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MSQ[75#CY22S%L'<<D]\= *J>,O#6K^)8+2'2_$USH:1,SRFVC):4D +\P=2
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M=SW=S)C?-/(7=L  9)Y/  _"K?ASP_?>*?$%GHNFJAN[IRJF1MJJ "S,3Z
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M3! .U!EFQN&< XSD\5Y/\4OBEX-\1_#C5M)TG6?M%]/Y/EQ?99DW;9D8\L@
MX!/)H S_ -F7_F:?^W3_ -K5] 5\_P#[,O\ S-/_ &Z?^UJ^@* "BBB@#G_'
M?_)//$O_ &"KK_T4U?$%?;_CO_DGGB7_ +!5U_Z*:OB"@#ZG\)_"#P)J?@W0
M[^\T+S+JZT^WFF?[7.-SM&I8X#X&23TK8_X4E\//^A>_\G;C_P".5C^$_B_X
M$TSP;H=A>:[Y=U:Z?;PS)]DG.UUC4,,A,'!!Z5L?\+M^'G_0P_\ DE<?_&Z
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M+X>?]"]_Y.W'_P <H_X7;\//^AA_\DKC_P"-T?\ "[?AY_T,/_DE<?\ QN@
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M,_D^7+L9-VV%%/# $<@CD5Z?^S+_ ,S3_P!NG_M:@#Z HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *XGXNW]YIGPNUF\L+J>UNHQ#LF@D*.N9D!PPY'!(_&NVK \
M:^&?^$P\(WV@_:_LGVK9^_\ +\S;M=7^[D9SMQU[T ?'_P#PGGC#_H:]<_\
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M7H?_ (,8?_BJ/^$[\'_]#7H?_@QA_P#BJ //_P#A4'C#_HK.N?E-_P#'Z/\
MA4'C#_HK.N?E-_\ 'Z] _P"$[\'_ /0UZ'_X,8?_ (JC_A._!_\ T->A_P#@
MQA_^*H \_P#^%0>,/^BLZY^4W_Q^C_A4'C#_ **SKGY3?_'Z] _X3OP?_P!#
M7H?_ (,8?_BJ/^$[\'_]#7H?_@QA_P#BJ //_P#A4'C#_HK.N?E-_P#'Z/\
MA4'C#_HK.N?E-_\ 'Z] _P"$[\'_ /0UZ'_X,8?_ (JC_A._!_\ T->A_P#@
MQA_^*H \_P#^%0>,/^BLZY^4W_Q^C_A4'C#_ **SKGY3?_'Z] _X3OP?_P!#
M7H?_ (,8?_BJ/^$[\'_]#7H?_@QA_P#BJ //_P#A4'C#_HK.N?E-_P#'Z/\
MA4'C#_HK.N?E-_\ 'Z] _P"$[\'_ /0UZ'_X,8?_ (JC_A._!_\ T->A_P#@
MQA_^*H \_P#^%0>,/^BLZY^4W_Q^C_A4'C#_ **SKGY3?_'Z] _X3OP?_P!#
M7H?_ (,8?_BJ/^$[\'_]#7H?_@QA_P#BJ //_P#A4'C#_HK.N?E-_P#'Z/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>#_^A4T/_P %T/\ \37G_P#PM_QA_P!$FUS\YO\ XQ1_PM_QA_T2;7/SF_\
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MG_MT_P#:U 'T!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1110 4444 %%%% !6?J>A:/K?E?VMI5C?^3GR_M=NDNS.,XW XS@=/05H44
M?.'[0^A:/HG_  CG]DZ58V'G?:?,^R6Z1;\>5C.T#.,GKZFO3_@E_P DAT+_
M +>/_2B2O/\ ]IK_ )E;_M[_ /:->@?!+_DD.A?]O'_I1)0!Z!1110 5\_\
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M2^'G_0O?^3MQ_P#'*/\ A27P\_Z%[_R=N/\ XY7/_P##1W@__H&ZY_WXA_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^_*__(]'_"/?'/\ Z'/0_P#ORO\ \CT >P45X_\ \(]\<_\ H<]#_P"_*_\
MR/1_PCWQS_Z'/0_^_*__ "/0![!17C__  CWQS_Z'/0_^_*__(]'_"/?'/\
MZ'/0_P#ORO\ \CT >P45X_\ \(]\<_\ H<]#_P"_*_\ R/1_PCWQS_Z'/0_^
M_*__ "/0![!17C__  CWQS_Z'/0_^_*__(]'_"/?'/\ Z'/0_P#ORO\ \CT
M>P45X_\ \(]\<_\ H<]#_P"_*_\ R/1_PCWQS_Z'/0_^_*__ "/0![!17C__
M  CWQS_Z'/0_^_*__(]'_"/?'/\ Z'/0_P#ORO\ \CT >P45X_\ \(]\<_\
MH<]#_P"_*_\ R/1_PCWQS_Z'/0_^_*__ "/0!Y!\;?\ DKVN_P#;O_Z3QUW_
M .S+_P S3_VZ?^UJ\H^(EOKMIX[U*#Q+>P7NKKY7VB>  (^8D*X 5>B[1T'3
M\:]7_9E_YFG_ +=/_:U 'T!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M44 %%%% !1110 4444 %%%% !1110!\__M-?\RM_V]_^T:] ^"7_ "2'0O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !69XCTZ;6/"^K:9;LBS7EE-;
MQM(2%#.A4$X!.,GTK3HH ^ ?NO\ 0U]:>*M:T7XC_!W79='U*,JME]JDC.#+
M"8SYFR1,Y4DQ%<].XW#KY?\ %#X+ZOI^LW.K^&;%[[3+AS*UM;(/,MF9A\BQ
MKRR9/&T< $$<;CVG[-]C;Q>#-5OECQ=3:@89'R>42-"HQTX,C_G["@#POX?^
M($\+^/='U>5D2"&X"SNZLP2)P4=L+R2%9B,=P.#TKUSX^^-?#^K^'-/T32]2
M@O[K[4MVSVLBRQHBJZX+ XW$MT'8'.,C/E?Q#\#7W@;Q+-9S12&PF=GL;@G<
M)8L\9( &\ @,,#!]B">2H ]-^ FHS67Q2M+>)4*7UO-;RE@<A0OF9'/7,:]<
M\$_6OK*O#?V?? U]I<=UXJU&)X/MMN(+*-C@O$6#-(5QD E4VG/(R<8*FO<J
M "BBB@#XY^+WB&X\0_$G56F&R.PE:P@3(.U(V()R ,Y;<W.<;L9( J_\+_A/
M<>/_ #M0NKS['I%O*(G= &DF<;2R*,_+\I^\<\D8#<X\]NH)K6[FM[B)X9XG
M*21R*59&!P00>00>U?77P4_Y)%H7TG_]'R4 =?H>D6^@:'9:3:/.]O:1+%&T
M\AD<@>I/\A@#H   *N3PK<6\D#EPDB%&,<C(P!&.&4@J?<$$=JDHH \!\=_L
M_6T&GSZEX2GG\V+S)I+&X8R;D +!(2J[BW&T!LYR/F&.?G_D'T(K[^KXA\>_
M\E$\2_\ 84N?_1K4 ?6_P[\0W'BGP!I&L7:XN9XBLQR/G=&*,W  &XJ6P!QG
M':NGKR7]G:>:;X<7"2RNZ0ZE*D2LQ(1=D;87T&68X'<D]Z]:H **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS_ .-O_)(=
M=_[=_P#THCKT"O/_ (V_\DAUW_MW_P#2B.@#S_\ 9E_YFG_MT_\ :U?0%?/_
M .S+_P S3_VZ?^UJ^@* "BBB@#G_ !W_ ,D\\2_]@JZ_]%-7Q!7V_P"._P#D
MGGB7_L%77_HIJ^(* /M_P)_R3SPU_P!@JU_]%+705X7X:^ 7A76?"ND:I<:A
MK*SWME#<2+'-$%#.@8@9C)QD^IK4_P"&<?!__02US_O_  __ !J@#V"BO'_^
M&<?!_P#T$M<_[_P__&J/^&<?!_\ T$M<_P"_\/\ \:H ]@HKQ_\ X9Q\'_\
M02US_O\ P_\ QJC_ (9Q\'_]!+7/^_\ #_\ &J /8**\?_X9Q\'_ /02US_O
M_#_\:H_X9Q\'_P#02US_ +_P_P#QJ@#V"BO'_P#AG'P?_P!!+7/^_P##_P#&
MJ/\ AG'P?_T$M<_[_P /_P :H ]@HKQ__AG'P?\ ]!+7/^_\/_QJC_AG'P?_
M -!+7/\ O_#_ /&J /8**\?_ .&<?!__ $$M<_[_ ,/_ ,:H_P"&<?!__02U
MS_O_  __ !J@#V"BO'_^&<?!_P#T$M<_[_P__&J/^&<?!_\ T$M<_P"_\/\
M\:H ]@HKQ_\ X9Q\'_\ 02US_O\ P_\ QJC_ (9Q\'_]!+7/^_\ #_\ &J /
M8**\?_X9Q\'_ /02US_O_#_\:H_X9Q\'_P#02US_ +_P_P#QJ@#R#XV_\E>U
MW_MW_P#2>.N__9E_YFG_ +=/_:U>4?$3PW9^$?'>I:'823R6MKY6QYV!<[HD
M<Y( '5CVKU?]F7_F:?\ MT_]K4 ?0%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_L%2?^C8J /I^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "HYX(;JWEM[B))H)4*21R*&5U(P00>"".U244 <-
M>?"7PK<6Z16\%W9,KAC)!<L[,,'Y3YF\8YSTSP.:\A\7Z1IFB>(YK#2=2>]A
MB^64/&,PN, IO!PYSNSA1MX')#8]&^)WCZYTNY/AS2O-M[N2(27%V04*QMG
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;-S!$6F&!\CNQ=EX)!VEBN0><9[UT]%% !1110 4444 %%%% !1110 4444
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MOP\_Z&'_ ,DKC_XW70?\()X/_P"A4T/_ ,%T/_Q-'_"">#_^A4T/_P %T/\
M\30!S_\ PNWX>?\ 0P_^25Q_\;H_X7;\//\ H8?_ "2N/_C==!_P@G@__H5-
M#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q- '/_\ "[?AY_T,/_DE<?\ QNC_
M (7;\//^AA_\DKC_ .-UT'_"">#_ /H5-#_\%T/_ ,31_P ()X/_ .A4T/\
M\%T/_P 30!S_ /PNWX>?]##_ .25Q_\ &Z/^%V_#S_H8?_)*X_\ C==!_P (
M)X/_ .A4T/\ \%T/_P 31_P@G@__ *%30_\ P70__$T <_\ \+M^'G_0P_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O//
MB]\0)O GAJ+^S]G]K7[M%;%U)$2@?/)C&"5RH /=@<$ BO0Z^:?VDOMG_"7Z
M3O\ /^Q?8/W6[/E^9YC;]O;=CR\XYQMSVH \:N+B:[N9;FYFDFGE<O))(Q9G
M8G)))Y))[U'7>_"+P98>-_&GV'4Y'%G:V[74L2<&8*RKLW=5!+<D<X! P3D?
M1^G?";P)I=PT]OX:M'=DV$7):X7&0>%D+ 'CKC/7U- 'QG17V_\ \()X/_Z%
M30__  70_P#Q-'_"">#_ /H5-#_\%T/_ ,30!X#^SA_R4#4?^P7)_P"C8J^G
MJR]-\-:%HUPUQI>B:;8SLFQI+6U2)BN0<$J <9 X]JU* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y_P#VFO\ F5O^WO\ ]HUZ
M!\$O^20Z%_V\?^E$E>?_ +37_,K?]O?_ +1KT#X)?\DAT+_MX_\ 2B2@#T"B
MBB@ KY__ &FO^96_[>__ &C7T!7S_P#M-?\ ,K?]O?\ [1H \X^$%_9Z9\4M
M&O+^[@M+6/S]\T\@C1<P2 98\#)('XU]3_\ "=^#_P#H:]#_ /!C#_\ %5\H
M?"W1-.\1_$?2=)U:W^T6,_G>9%O9-VV%V'*D$<@'@U]'_P#"DOAY_P!"]_Y.
MW'_QR@#H/^$[\'_]#7H?_@QA_P#BJ/\ A._!_P#T->A_^#&'_P"*KG_^%)?#
MS_H7O_)VX_\ CE'_  I+X>?]"]_Y.W'_ ,<H Z#_ (3OP?\ ]#7H?_@QA_\
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M .%)?#S_ *%[_P G;C_XY1_PI+X>?]"]_P"3MQ_\<H Z#_A._!__ $->A_\
M@QA_^*H_X3OP?_T->A_^#&'_ .*KG_\ A27P\_Z%[_R=N/\ XY1_PI+X>?\
M0O?^3MQ_\<H Z#_A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\ BJY_
M_A27P\_Z%[_R=N/_ (Y1_P *2^'G_0O?^3MQ_P#'* /%/C[JVFZSXZL;C2]0
MM+Z!=,C1I+6995#>;*<$J2,X(./<5<_9Q_Y*'J'_ &"I/_1L58_QK\+:-X1\
M96=AH=G]DM9-/29D\UY,N9) 3ER3T4?E6Q^SC_R4/4/^P5)_Z-BH ^GZ***
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MC_R5W1/I<?\ HB2NX^/?@+0M$TBR\0:/906$LEU]GGA@0JDFY"5(4':F/+/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>2UM?-WI H+G=$Z# ) ZL.]>[_\ #1W@_P#Z!NN?]^(?_CM>0?!+_DKVA?\
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M HKD/ASXY_X6!X=GU;^SOL'E736WE>?YN<*C9SM7^_TQVKKZ "BBB@ HHHH
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M%'_"0_'/_H3-#_[_ "__ "17L%% 'C__  D/QS_Z$S0_^_R__)%'_"0_'/\
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M ._*_P#R/1_PCWQS_P"AST/_ +\K_P#(]>P44 >/_P#"/?'/_H<]#_[\K_\
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M (9P\7?]!/1/^_TO_P ;KZ+U_P 1:3X7TMM2UJ]CM+0,$WL"2S'H H!+'J<
M'@$] :\GUO\ :0T2TN/*T;1KO445V5Y9I1;J0#\K)PQ(/)^8*1QQSP <9_PS
MAXN_Z">B?]_I?_C='_#.'B[_ *">B?\ ?Z7_ .-UW_@CXY_\)EXOLM!_X1S[
M']J\S]_]M\S;M1G^[Y8SG;CKWK1MOC?X>3Q;>>'=6MY].F@OY;-;IF5X"$8J
M'=N"F2,="!P2V,D &?\ "7X2ZOX#\07NJZK?V,OFVOV:.*U+MG+JQ)+*N,;
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M]#_\&,/_ ,50!Y__ ,*@\8?]%9US\IO_ (_1_P *@\8?]%9US\IO_C]>@?\
M"=^#_P#H:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5 'G_ /PJ#QA_T5G7
M/RF_^/T?\*@\8?\ 16=<_*;_ ./UZ!_PG?@__H:]#_\ !C#_ /%4?\)WX/\
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M3AB#SZ5Z_P#\(-X1_P"A6T3_ ,%\7_Q- 'P_17W!_P (-X1_Z%;1/_!?%_\
M$UJ:=I6G:/;M;Z986ME SEVCMH5C4M@#)"@#. .?84 >'_ +X?7]C<-XOU2!
M(HYK<QV$4L>9"&(S,,_<! *CNP8G@8W>]U@:5XV\-Z[KEQH^E:O!>WL$7G2+
M!ET"?*,B0#8>64<$_H:WZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#Y_\ VFO^96_[>_\ VC7H'P2_Y)#H7_;Q_P"E$E>?_M-?
M\RM_V]_^T:] ^"7_ "2'0O\ MX_]*)* /0**** "OG_]IK_F5O\ M[_]HU]
M5\__ +37_,K?]O?_ +1H \H^'?ANS\7>.]-T._DGCM;KS=[P, XVQ.XP2".J
MCM7N_P#PSCX/_P"@EKG_ '_A_P#C5>(?"W6].\.?$?2=6U:X^SV,'G>9+L9]
MNZ%U'"@D\D#@5]'_ /"[?AY_T,/_ ))7'_QN@#G_ /AG'P?_ -!+7/\ O_#_
M /&J/^&<?!__ $$M<_[_ ,/_ ,:KH/\ A=OP\_Z&'_R2N/\ XW1_PNWX>?\
M0P_^25Q_\;H Y_\ X9Q\'_\ 02US_O\ P_\ QJC_ (9Q\'_]!+7/^_\ #_\
M&JZ#_A=OP\_Z&'_R2N/_ (W1_P +M^'G_0P_^25Q_P#&Z .?_P"&<?!__02U
MS_O_  __ !JC_AG'P?\ ]!+7/^_\/_QJN@_X7;\//^AA_P#)*X_^-T?\+M^'
MG_0P_P#DE<?_ !N@#G_^&<?!_P#T$M<_[_P__&J/^&<?!_\ T$M<_P"_\/\
M\:KH/^%V_#S_ *&'_P DKC_XW1_PNWX>?]##_P"25Q_\;H Y_P#X9Q\'_P#0
M2US_ +_P_P#QJC_AG'P?_P!!+7/^_P##_P#&JZ#_ (7;\//^AA_\DKC_ .-T
M?\+M^'G_ $,/_DE<?_&Z .?_ .&<?!__ $$M<_[_ ,/_ ,:H_P"&<?!__02U
MS_O_  __ !JN@_X7;\//^AA_\DKC_P"-T?\ "[?AY_T,/_DE<?\ QN@#G_\
MAG'P?_T$M<_[_P /_P :H_X9Q\'_ /02US_O_#_\:KH/^%V_#S_H8?\ R2N/
M_C='_"[?AY_T,/\ Y)7'_P ;H Y__AG'P?\ ]!+7/^_\/_QJC_AG'P?_ -!+
M7/\ O_#_ /&JZ#_A=OP\_P"AA_\ )*X_^-T?\+M^'G_0P_\ DE<?_&Z .?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU">:W^T.QN!"J*6*J!\K$G*MG@8XZYX /3*\_P#C;_R2'7?^W?\ ]*(Z\_\
M^&FO^I1_\J7_ -JK \;?'3_A,?"%]H'_  CGV/[5Y?[_ .W>9MVR*_W?+&<[
M<=>] &_^S+_S-/\ VZ?^UJ^@*^?_ -F7_F:?^W3_ -K5] 4 %%%% '/^._\
MDGGB7_L%77_HIJ^(*^W_ !W_ ,D\\2_]@JZ_]%-7Q!0!]3^$_A!X$U/P;H=_
M>:%YEU=:?;S3/]KG&YVC4L<!\#))Z5L?\*2^'G_0O?\ D[<?_'*Q_"?Q?\":
M9X-T.PO-=\NZM=/MX9D^R3G:ZQJ&&0F#@@]*V/\ A=OP\_Z&'_R2N/\ XW0
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MN$BUJ\:/%M*8(D?<.73>6&.O =/S]C7ENJ7,%[K>HWUM%+%%=W#7.R5PQ5W
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M%% !1110 4444 %%%% !1110!\__ +37_,K?]O?_ +1KT#X)?\DAT+_MX_\
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M_P#Q->?_ /"W_&'_ $2;7/SF_P#C%'_"W_&'_1)M<_.;_P",4 >@?\()X/\
M^A4T/_P70_\ Q-'_  @G@_\ Z%30_P#P70__ !->?_\ "W_&'_1)M<_.;_XQ
M1_PM_P 8?]$FUS\YO_C% 'H'_"">#_\ H5-#_P#!=#_\31_P@G@__H5-#_\
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M9)$MM=%MSJ'<[QN13@EB.G\)YKI/V<?^2AZA_P!@J3_T;%0!]/T444 %%%%
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M"-R<C!R1S@<@>6?$CX&ZM;ZI>ZQX7ACN["5VF-C& DL&=S,$4 !D&,*%^;D
M*<9/BUQ;S6EQ+;W,,D,\3E)(Y%*LC X((/((/:@#[(UKXK^"-#M_-F\06ET[
M(S)%8N+AG*C[OR9"DY &X@'UX./ESX@>-;CQYXH?5YH/LT0B2&"WWA_*1>2-
MP49RQ9N1_%CL*Y;K7J/@3X)>(/$MX)]9MY]'TR*4+-]IC:.>48R1&C#Z#<W
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M 'N?[,O3Q1_VZ?\ M:O8_$O@_0/&%O!!KVFQWB0.7B)=D9"1@X92#@\9&<'
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MQ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)^M?65?//[.W@^Y-_=^*[RVVVRQ&WLFDB!\QR?G="3D;0NS('.]AG@BOH:@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^?_ -IK
M_F5O^WO_ -HUZ!\$O^20Z%_V\?\ I1)7G_[37_,K?]O?_M&O0/@E_P DAT+_
M +>/_2B2@#T"BBB@ KY__::_YE;_ +>__:-?0%?/_P"TU_S*W_;W_P"T: .
M^"7_ "5[0O\ MX_])Y*^OZ^*/AW;Z[=^.]-@\-7L%EJ[>;]GGG *)B)RV05;
MJNX=#U_&O=_^$>^.?_0YZ'_WY7_Y'H ]@HKQ_P#X1[XY_P#0YZ'_ -^5_P#D
M>C_A'OCG_P!#GH?_ 'Y7_P"1Z /8**\?_P"$>^.?_0YZ'_WY7_Y'H_X1[XY_
M]#GH?_?E?_D>@#V"BO'_ /A'OCG_ -#GH?\ WY7_ .1Z/^$>^.?_ $.>A_\
M?E?_ )'H ]@HKQ__ (1[XY_]#GH?_?E?_D>C_A'OCG_T.>A_]^5_^1Z /8**
M\?\ ^$>^.?\ T.>A_P#?E?\ Y'H_X1[XY_\ 0YZ'_P!^5_\ D>@#V"BO'_\
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M[!4G_HV*@#Z?HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_ #ENY/S8)( QU5%%.,5%6BC.M6J5YNI5E=OJPHHHJC(**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+O([S3[N>TNH\[)H)"CKD8.&'(R"1^- 'WG!!#:V\5O;Q)#!$@2..-0JHH&
M !P !VJ2O//A#\0)?'?AJ7^T-@U:P=8KDHI D4CY),8P"V&! [J3@ @5Z'0
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M\?\ ^&<?!_\ T$M<_P"_\/\ \:H_X9Q\'_\ 02US_O\ P_\ QJ@#V"BO'_\
MAG'P?_T$M<_[_P /_P :H_X9Q\'_ /02US_O_#_\:H X#]H[_DH>G_\ 8*C_
M /1LM'[./_)0]0_[!4G_ *-BKF_BSX*TWP'XJM=+TN>[F@ELDN&:Z=68,7=<
M#:JC&$';UKI/V<?^2AZA_P!@J3_T;%0!]/T444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% '.>*V\,:;9MK/B#3[*X:-1%&TMLDDLAY*QIN&2>IQG Y)P 3
M7SG<-!)=S2VUJ+6!VS';B5Y1&O0#<Y+'W)ZDG@# '2?$&?Q'+XG+>)8/LS-O
M%C$C[X!$&Q^[;^(G"EB0&.5RJC:!+\//##>)/$D;2HCZ?9,LMV&*_,#G8FT@
M[@Q7!XQM#<@XSY6)E*M5]E%6/O\ )*-'+\"\=5GS:;)Z+R]7U[''QR)-'OC<
M,IR,@U[=\.9?".M:?!##HEA;ZM8XD9)(Q))D-D2H[Y<C<1U)*G Z;2<#XO>%
MGM-2'B>VYM[HI!=H%8E)0-J2$\@*0%0],$+U+''$^&8=6F\16CZ';O<:C;M]
MHCC5MO"]=QRN%.=IR0#NQWQ4P4L-6Y;73-L1.EG66>VY^24=];)/JGY/I_PY
M].T4R$RM!&9T1)2H+JCEE5L<@$@9&>^!]!3Z]<_.@HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH ^8?VC_ /D?]/\ ^P7'_P"C9:/V</\ DH&H_P#8
M+D_]&Q4?M'_\E T[_L%Q_P#HV6J?P!U73M'\<7]QJ>H6ME"VFNBR7,RQ*6\R
M,X!8@9P#Q[&@#Z+\<_\ )/\ Q)_V"[K_ -%-7P_7V-XQ\9>%[KP/K]O;^)-'
MFGETVX2...^B9G8QL   V22>U?'- 'I/PW^$.J>./*U*Z?[#H0EVO,?]9.!G
M<(AC!Y&TL> 2<;BI%?3?ACPEHO@_2TL-'LHX5"*LLQ4&6<C/S2-C+')/L,X
M XK \&^,O"]KX'\/V]QXDT>&:+3;=)(Y+Z)61A&H((+9!![5M_\ "<^$?^AI
MT3_P81?_ !5 &_169IWB/0M8N&M],UK3KV=4WM';722L%R!DA23C)'/N*TZ
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M?]_X?_C5'_#./@__ *"6N?\ ?^'_ .-4 >P45X__ ,,X^#_^@EKG_?\ A_\
MC5'_  SCX/\ ^@EKG_?^'_XU0![!17C_ /PSCX/_ .@EKG_?^'_XU1_PSCX/
M_P"@EKG_ '_A_P#C5 'L%%>/_P##./@__H):Y_W_ (?_ (U1_P ,X^#_ /H)
M:Y_W_A_^-4 >P45X_P#\,X^#_P#H):Y_W_A_^-4?\,X^#_\ H):Y_P!_X?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:'_X+H?_ (F@#G_^%V_#S_H8?_)*X_\ C='_  NWX>?]##_Y)7'_ ,;KH/\
MA!/!_P#T*FA_^"Z'_P")H_X03P?_ -"IH?\ X+H?_B: .?\ ^%V_#S_H8?\
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M$\'_ /0J:'_X+H?_ (F@#YH^-?BG1O%WC*SO]#O/M=K'IZ0L_E/'AQ)(2,.
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MC'FFVE_B_P""8UX9C0ASU)22_P 7_!+/_">^)?\ H)?^0(__ (FC_A/?$O\
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MBKZ>KG/#?@+PQX0N)[C0M)CM)YT"22>8\C%0<X!<D@9Z@8S@9Z"NCH ****
M*&N:-9^(=#O=(OTWVMW$T3X )7/1ER" P."#C@@&O$/&OP%T;1?"-_J&@MKE
M_J<.SR;;*2[\NH;Y4C#'"DGCTKWZB@#XQT#X<^([_P 1:99ZCX<URWL9[J**
MXF^Q2)Y<;, S;BN!@$G)X%>W_P##./@__H(ZY_W_ (O_ (U70>)_C)X.\+7D
MUE/=SWM]!+Y4UO91;S&<9.68JG'0@,2#QC@XY_\ X:.\'_\ 0.US_OQ%_P#'
M: #_ (9Q\'_]!'7/^_\ %_\ &JL6/[/7@JTO$GFDU6]C7.8+BX4(_&.=B*W'
M7@CIZ<57_P"&CO!__0.US_OQ%_\ ':/^&CO!_P#T#M<_[\1?_': /6X((;6W
MBM[>)(8(D"1QQJ%5% P  .  .,5)7.>"O&NF^.]&EU32X;J&"*X:W*W2*K;@
MJMG"LPQAAW]:Z.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "O/_C;_P DAUW_ +=__2B.N;^-7Q+\1^#+VSTO18([9+JW
M\W^T9(MYW!\%$##9D #=D-Q(.%X)\4UOXI>,O$>CSZ3JVL_:+&?;YD7V6%-V
MU@PY5 1R >#0!Z?^S+_S-/\ VZ?^UJ^@*^?_ -F7_F:?^W3_ -K5] 4 %%%%
M '/^._\ DGGB7_L%77_HIJ^(*^W_ !W_ ,D\\2_]@JZ_]%-7Q!0!]A^"_&GA
M6U\"^'K>X\2Z-#/%IELDD<E_$K(PB4$$%L@@\8K<_P"$[\'_ /0UZ'_X,8?_
M (JN'\)_"#P)J?@W0[^\T+S+JZT^WFF?[7.-SM&I8X#X&23TK8_X4E\//^A>
M_P#)VX_^.4 =!_PG?@__ *&O0_\ P8P__%4?\)WX/_Z&O0__  8P_P#Q5<__
M ,*2^'G_ $+W_D[<?_'*/^%)?#S_ *%[_P G;C_XY0!T'_"=^#_^AKT/_P &
M,/\ \51_PG?@_P#Z&O0__!C#_P#%5S__  I+X>?]"]_Y.W'_ ,<H_P"%)?#S
M_H7O_)VX_P#CE '0?\)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__
M !5<_P#\*2^'G_0O?^3MQ_\ '*/^%)?#S_H7O_)VX_\ CE '0?\ "=^#_P#H
M:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5<_\ \*2^'G_0O?\ D[<?_'*/
M^%)?#S_H7O\ R=N/_CE '0?\)WX/_P"AKT/_ ,&,/_Q5'_"=^#_^AKT/_P &
M,/\ \57/_P#"DOAY_P!"]_Y.W'_QRC_A27P\_P"A>_\ )VX_^.4 =!_PG?@_
M_H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5<__P *2^'G_0O?^3MQ_P#'
M*/\ A27P\_Z%[_R=N/\ XY0!T'_"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AK
MT/\ \&,/_P 57/\ _"DOAY_T+W_D[<?_ !RC_A27P\_Z%[_R=N/_ (Y0!T'_
M  G?@_\ Z&O0_P#P8P__ !5'_"=^#_\ H:]#_P#!C#_\57/_ /"DOAY_T+W_
M ).W'_QRC_A27P\_Z%[_ ,G;C_XY0!T'_"=^#_\ H:]#_P#!C#_\51_PG?@_
M_H:]#_\ !C#_ /%5S_\ PI+X>?\ 0O?^3MQ_\<H_X4E\//\ H7O_ "=N/_CE
M 'SQ\7[^SU/XI:S>6%W!=VLGD;)H)!(C8@C!PPX.""/PKT?]F7_F:?\ MT_]
MK5YA\4M$T[PY\1]6TG2;?[/8P>3Y<6]GV[H48\L23R2>37I_[,O_ #-/_;I_
M[6H ^@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ']H;7=8T1/#O]DZK?
M6'FFY\S[+</%OQY6,[2,XR?S->W5R'CKX<Z/\0!8#5;F^A^Q>9Y?V5T7._;G
M.Y6_N#T[T ?%Y))R:4$CH2*^GO\ AG'P?_T$M<_[_P /_P :H_X9Q\'_ /02
MUS_O_#_\:H ^822>I)I*^G_^&<?!_P#T$M<_[_P__&J/^&<?!_\ T$M<_P"_
M\/\ \:H ^8=S?WC^=&YO[Q_.OI[_ (9Q\'_]!+7/^_\ #_\ &J/^&<?!_P#T
M$M<_[_P__&J ,7]FBXF>T\26[32-"CV[I&6)5682!B!T!(5<GOM'I7O5<AX%
M^'.C_#\7XTFYOIOMOE^9]J=&QLW8QM5?[Y]>U=?0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!\__ +37_,K?]O?_ +1KT#X)?\DAT+_M
MX_\ 2B2O/_VFO^96_P"WO_VC7H'P2_Y)#H7_ &\?^E$E 'H%%%% !7S_ /M-
M?\RM_P!O?_M&OH"OG_\ ::_YE;_M[_\ :- 'E'P[N-=M/'>FS^&K*"]U=?-^
MSP3D!'S$X;)++T7<>HZ?A7N__"0_'/\ Z$S0_P#O\O\ \D5Y!\$O^2O:%_V\
M?^D\E?7] 'C_ /PD/QS_ .A,T/\ [_+_ /)%'_"0_'/_ *$S0_\ O\O_ ,D5
M[!10!X__ ,)#\<_^A,T/_O\ +_\ )%'_  D/QS_Z$S0_^_R__)%>P44 >/\
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M4 ?3]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>3?$_\
MY&6V_P"O-?\ T-Z]9KR;XG_\C+;?]>:_^AO7FYK_ +N_5'DYU_NC]4'PP_Y&
M6Y_Z\V_]#2O6:\F^&'_(RW/_ %YM_P"AI7K-&5?[NO5ADO\ NB]6%%%%>D>L
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&CO!_P#T#=<_[\0__':]@HH \?\ ^&CO!_\ T#=<_P"_$/\ \=H_X:.\'_\
M0-US_OQ#_P#':]@HH \?_P"&CO!__0-US_OQ#_\ ':/^&CO!_P#T#=<_[\0_
M_':]@HH \?\ ^&CO!_\ T#=<_P"_$/\ \=H_X:.\'_\ 0-US_OQ#_P#':]@H
MH \?_P"&CO!__0-US_OQ#_\ ':/^&CO!_P#T#=<_[\0__':]@HH \?\ ^&CO
M!_\ T#=<_P"_$/\ \=H_X:.\'_\ 0-US_OQ#_P#':]@HH \?_P"&CO!__0-U
MS_OQ#_\ ':/^&CO!_P#T#=<_[\0__':]@HH \?\ ^&CO!_\ T#=<_P"_$/\
M\=H_X:.\'_\ 0-US_OQ#_P#':]@HH \?_P"&CO!__0-US_OQ#_\ ':/^&CO!
M_P#T#=<_[\0__':]@HH ^*/B)XDL_%WCO4M<L(YX[6Z\K8DZ@.-L2(<@$CJI
M[UZO^S+_ ,S3_P!NG_M:N ^-O_)7M=_[=_\ TGCKO_V9?^9I_P"W3_VM0!]
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MM2M=-\[R3>3);B7;NV;V"YQD9QG.,U]3SSQ6UO)//*D4,2EY))&"JB@9))/
M '>L,+7E63<CU,_RJAEU2$*+;NFW>WZ)$E%8>D^,=!UW4YM.TR_%Q<PJ[.JQ
M.%VJP4D,1M8988()SG(R*W*ZDT]4>%.G*#Y9JS\PHHHID!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M  J#QA_T5G7/RF_^/UZ!_P )WX/_ .AKT/\ \&,/_P 51_PG?@__ *&O0_\
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MUGQU8W&EZA:7T"Z9&C26LRRJ&\V4X)4D9P0<>XJY^SC_ ,E#U#_L%2?^C8J
M/I^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O)OB?_P C
M+;?]>:_^AO7K->3?$_\ Y&6V_P"O-?\ T-Z\W-?]W?JCR<Z_W1^J#X8?\C+<
M_P#7FW_H:5ZS7DWPP_Y&6Y_Z\V_]#2O6:,J_W=>K#)?]T7JPHHHKTCU@HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#,\1:_8^%] O-:U)G6TM4#/Y:[F8DA54#
MU)('.!SR0.:^7/$_QO\ &&ORS1VEY_9%B_"PV?RN &R"9?O[L8!*E0<=!DUV
MG[26ON9M&\.QLX0*;Z92J[6))2/!ZY&)<C@?,.O;ROX?^"KCQYXH32(;C[-&
M(GFGN-@?RD' .TL,Y8JO!_BST!H L:9\5?'6D^;]G\2WLGFXW?:B+G&,]/,#
M;>O;&>,]!7M_PX^.%MXJU"+1M>MH-/U*7B":)CY,[DG" -DHV, 9)W'/() .
M/X@_9NLFLPWAO6;A+I>L>HD,DG(_B105P-W\+9XZ=:\$U;2;_0M5N-,U.V>V
MO+=]DD3]0?Y$$8((X(((XH ^\J^6OC!XM\2:7\4=7L]/\0:I:6L8@V0P7DB(
MN84)PH.!R2?QKMO@]\8/[6$'AGQ+<_\ $PX2SO9#_P ?/I&Y_P">GH?XNA^;
M[WF'QN_Y*[K?T@_]$1T =I\ _$NO:UXXOK?5-:U&^@737=8[FZ>10WF1C(#$
MC.">?<U]%5\P_LX?\E U'_L%R?\ HV*OIZ@ HHHH *YSQYXDF\(^"=3URWMT
MN)[5%\N.0D*69U0$XY(!;..,XQD=:Z.N8^(7AR[\6^!=2T.PD@CN;KR]CSL0
M@VR*YR0">BGM0!\::MJ":GJMQ?1V-K8"9]YM[166)#WV@DD#/.,X&<# P*[_
M $7X\>-](M_(FN+34T"*B&^A+,@48^\A4L3QDL23CZYU?^&</%W_ $$]$_[_
M $O_ ,;H_P"&</%W_03T3_O]+_\ &Z $_P"&CO%__0-T/_OQ+_\ ':/^&CO%
M_P#T#=#_ ._$O_QVE_X9P\7?]!/1/^_TO_QNC_AG#Q=_T$]$_P"_TO\ \;H
M]C^$_C74?'?A6YU35(+6&>*]>W5;565=H1&R=S,<Y8]_2N[KA/A/X*U'P)X5
MN=+U.>UFGEO7N%:V9F7:41<'<H.<J>WI7=T %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5Y_\ &W_DD.N_]N__ *41UZ!7
MG_QM_P"20Z[_ -N__I1'0!Y_^S+_ ,S3_P!NG_M:OH"OG_\ 9E_YFG_MT_\
M:U?0% !1110!S_CO_DGGB7_L%77_ **:OB"OM_QW_P D\\2_]@JZ_P#135\0
M4 ?1?AK7?C+#X5TB+2_">C3Z>EE"MK+)*H9X@@V,?WXY*X/0?05J?\)#\<_^
MA,T/_O\ +_\ )%>@>!/^2>>&O^P5:_\ HI:Z"@#Q_P#X2'XY_P#0F:'_ -_E
M_P#DBC_A(?CG_P!"9H?_ '^7_P"2*]@HH \?_P"$A^.?_0F:'_W^7_Y(H_X2
M'XY_]"9H?_?Y?_DBO8** /'_ /A(?CG_ -"9H?\ W^7_ .2*/^$A^.?_ $)F
MA_\ ?Y?_ )(KV"B@#Q__ (2'XY_]"9H?_?Y?_DBC_A(?CG_T)FA_]_E_^2*]
M@HH \?\ ^$A^.?\ T)FA_P#?Y?\ Y(H_X2'XY_\ 0F:'_P!_E_\ DBO8** /
M'_\ A(?CG_T)FA_]_E_^2*/^$A^.?_0F:'_W^7_Y(KV"B@#Q_P#X2'XY_P#0
MF:'_ -_E_P#DBC_A(?CG_P!"9H?_ '^7_P"2*]@HH \?_P"$A^.?_0F:'_W^
M7_Y(H_X2'XY_]"9H?_?Y?_DBO8** /'_ /A(?CG_ -"9H?\ W^7_ .2*/^$A
M^.?_ $)FA_\ ?Y?_ )(KV"B@#XH^(EQKMWX[U*?Q+9066KMY7VB" @HF(D"X
M(9NJ[3U/7\*]7_9E_P"9I_[=/_:U<!\;?^2O:[_V[_\ I/'7?_LR_P#,T_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2^'G_0O?^3MQ_P#'*/\ A27P\_Z%[_R=N/\ XY7/_P##1W@__H&ZY_WXA_\
MCM'_  T=X/\ ^@;KG_?B'_X[0!T'_"DOAY_T+W_D[<?_ !RC_A27P\_Z%[_R
M=N/_ (Y7/_\ #1W@_P#Z!NN?]^(?_CM'_#1W@_\ Z!NN?]^(?_CM '0?\*2^
M'G_0O?\ D[<?_'*/^%)?#S_H7O\ R=N/_CE<_P#\-'>#_P#H&ZY_WXA_^.T?
M\-'>#_\ H&ZY_P!^(?\ X[0!T'_"DOAY_P!"]_Y.W'_QRC_A27P\_P"A>_\
M)VX_^.5S_P#PT=X/_P"@;KG_ 'XA_P#CM'_#1W@__H&ZY_WXA_\ CM '0?\
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MZP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO);W$230RH4DCD4,KJ1@@@\$$=JYC1/ASX:T&Y^T6]D9Y5DWPM=-YOD#(*A
M>/E*C#'+=?FYHKX3GFI0=@RKB'ZKAYT:\7/M\]T_+K]YI^&-5O\ 6-"AN]2T
MR;3[LDH\4J[=Q!QN4'Y@I[!L'ZC#'8HHKM2LK'S-22E)R2LGT[!1113("BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HYX
M(;JWDM[B))H)4*21R*&5U(P00>"".U25YA\8/B-K'P_71CI5M8S?;3-YGVI'
M;&S9C&UE_OGU[4 ><?$#X#:IIUY<ZCX3B^VZ:<O]BWYGAX)(7/\ K%&!C!+G
M<!@XW'QZ^T^\TR[DM+^TGM+F/&^&>,QNN0",J>1P0?QKZ ^'7QJ\1^+O'6G:
M'?V6E1VMR)=[V\4@<;8V<8)D(ZJ.U>[T ? EO;S7=Q%;VT,DT\KA(XXU+,[$
MX  '))/:O3/!7P0\2Z_J%K+K5G/I.D-EY9)=JS, <;%C/S*Q[%@ !SSP#]7U
MY#\</'/B7P8NCKH=[!;1WOF%V^S!Y 8\9&6)7:?,'&W(*]<'% 'J6E:58Z)I
M=OINFVR6UG;ILBB0<*/YDDY))Y)))Y-7*\(^"_Q/\0^)_%EUI'B'4X+B.2U,
MMOOBCB?S%895=H&[*EB1@GY,C !S[O0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 445S?B7Q]X7\(7$%OKNK1VL\Z%XXQ&\C;0<9(120
M,Y )QG!QT- 'D?[37_,K?]O?_M&O0/@E_P DAT+_ +>/_2B2O(/CIXV\.^,?
M[!_L#4/MGV7[1YW[F2/;N\O;]]1G.UNGI7K_ ,$O^20Z%_V\?^E$E 'H%%%%
M !7S_P#M-?\ ,K?]O?\ [1KZ KY__::_YE;_ +>__:- ' ?!+_DKVA?]O'_I
M/)7U_7Q1\.[C7;3QWIL_AJR@O=77S?L\$Y 1\Q.&R2R]%W'J.GX5[O\ \)#\
M<_\ H3-#_P"_R_\ R10![!17C_\ PD/QS_Z$S0_^_P O_P D4?\ "0_'/_H3
M-#_[_+_\D4 >P45X_P#\)#\<_P#H3-#_ ._R_P#R11_PD/QS_P"A,T/_ +_+
M_P#)% 'L%%>/_P#"0_'/_H3-#_[_ "__ "11_P )#\<_^A,T/_O\O_R10![!
M17C_ /PD/QS_ .A,T/\ [_+_ /)%'_"0_'/_ *$S0_\ O\O_ ,D4 >P45X__
M ,)#\<_^A,T/_O\ +_\ )%'_  D/QS_Z$S0_^_R__)% 'L%%>/\ _"0_'/\
MZ$S0_P#O\O\ \D4?\)#\<_\ H3-#_P"_R_\ R10![!17C_\ PD/QS_Z$S0_^
M_P O_P D4?\ "0_'/_H3-#_[_+_\D4 >P45X_P#\)#\<_P#H3-#_ ._R_P#R
M11_PD/QS_P"A,T/_ +_+_P#)% 'L%%>/_P#"0_'/_H3-#_[_ "__ "11_P )
M#\<_^A,T/_O\O_R10!P'[1W_ "4/3_\ L%1_^C9:/V<?^2AZA_V"I/\ T;%7
M-_%F]\5WWBJUE\8:9::?J LD6.*U8,IBWOACAWYW%AU[#CUZ3]G'_DH>H?\
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M'I6Q_P +M^'G_0P_^25Q_P#&Z .?_P"&<?!__02US_O_  __ !JC_AG'P?\
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M_P"AA_\ )*X_^-T?\+M^'G_0P_\ DE<?_&Z .?\ ^&<?!_\ T$M<_P"_\/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ5]95S'@;P+I?@/0Q8:>OF3R8:ZNW7#SN.Y]%&3A>V>Y))Z>@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR/QW\#8?&?BRYUZ+7Y+%[
ME$$L+6HF&Y5"94[UP-JKP<\YYYP/7** /D#XF_#+_A7/]E_\3?\ M#[?YO\
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M>O\ $>*Z3]G'_DH>H?\ 8*D_]&Q4 ?3]%%% !1110 4444 %%%% !116/?\
MBO0M-E\JZU*$29*E8\R%2.H8*#@_6IG.,%>3L1.I"FKS:2\S8HKG/^$]\-?]
M!+_R!)_\31_PGOAK_H)?^0)/_B:R^M4/YU]Z,?KF&_Y^1^]'1T5SG_">^&O^
M@E_Y D_^)H_X3WPU_P!!+_R!)_\ $T?6J'\Z^]!]<PW_ #\C]Z.CHKG/^$]\
M-?\ 02_\@2?_ !-'_">^&O\ H)?^0)/_ (FCZU0_G7WH/KF&_P"?D?O1T=%<
MY_PGOAK_ *"7_D"3_P")H_X3WPU_T$O_ "!)_P#$T?6J'\Z^]!]<PW_/R/WH
MZ.O)OB?_ ,C+;?\ 7FO_ *&]=M_PGOAK_H)?^0)/_B:\\\=ZO8ZSKD-QI\_G
M1+;+&6V,N&#,<8('8BO/S*O2G0M&2;NNIYF;XBC4PSC":;NMFB[\,/\ D9;G
M_KS;_P!#2O6:\9\":O8Z-KD]QJ$_DQ-;-&&V,V6+*<8 /8&O0_\ A/?#7_02
M_P#($G_Q-&6UZ4*%I22=WU#*,11IX91G-)W>[1T=%<Y_PGOAK_H)?^0)/_B:
M/^$]\-?]!+_R!)_\37H?6J'\Z^]'I_7,-_S\C]Z.CHKG/^$]\-?]!+_R!)_\
M31_PGOAK_H)?^0)/_B:/K5#^=?>@^N8;_GY'[T='17.?\)[X:_Z"7_D"3_XF
MC_A/?#7_ $$O_($G_P 31]:H?SK[T'US#?\ /R/WHZ.BN<_X3WPU_P!!+_R!
M)_\ $T?\)[X:_P"@E_Y D_\ B:/K5#^=?>@^N8;_ )^1^]'1T5FZ7K^E:SN&
MGWL<S+G*<JP QSM.#CD<XQ6E6L91DKQ=T;PG&:YHNZ"BBBJ*"BBB@ HHHH *
M*** "BBB@ HHHH *\@^/>F:O?:3I,UC;W,]A;-,]V(<LJ':I5V4=@!)\V,#)
MY&>?7Z*[,!C'@\3'$)7Y>GRL3./,K'P[17W%17UG^N?_ $X_\F_^U,/J_F?#
MM%?<5%'^N?\ TX_\F_\ M0^K^9\.T5]&_'[_ )$2Q_["<?\ Z*EKP[P7_P C
MWX>_["=M_P"C5KZ3+\S^N8-XKDM:^E[[>=E^1C.'++E,.BON*BOF_P#7/_IQ
M_P"3?_:FWU?S/AVBON*BC_7/_IQ_Y-_]J'U?S/B2SLKO4;I+6QM9KFYDSLA@
MC+NV!DX Y/ )_"OLW1;:[LM!TZUOY_/O(+:..>;>6\R15 9LGDY()R>:O45X
MF<YV\R4(\G*HWZWW^2-*=+DZA1117A&H4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %8'C7PS_P )AX1OM!^U_9/M7E_O
M_+\S;MD5_NY&<[<=>];]% '@(_9F (/_  EIX_ZAW_VVO?J*^=?CYXEU[1?'
M%C;Z7K6HV,+::CM';73QJ6\R09(4@9P!S["@#Z*HKYU^ ?B77M:\<7UOJFM:
MC?0+IKNL=S=/(H;S(QD!B1G!//N:^BJ "BBB@ HHJO?7MOINGW-_=R>7;6T3
M33/M)VHH)8X')X!Z4 8GBKP)X=\9VQCUG3HY)@FV.ZC^2:/AL8<<D L3M.5S
MR0:\KOOV:+*2[=K#Q//!;'&R.>T$KCCG+!U!YS_"/QZUP'Q ^,6N>+KRYM=/
MN9].T-LHEM&0KRK@@F5AR=P8Y3.WH.2-Q]S^"%Q%-\)=(2.5'>%ITE56!*-Y
MSMAO0X93@]B#WH X>W_9G@6XB:X\5220!P9$CL C,N>0&,A ..^#CT->F>$?
MAEX7\%[9=-L/-O1G_3KHB2;^+H< )PQ'R@9&,YKC/VC[B%/ FG6YE03R:DKI
M&6&YE6.0,0.I ++D]MP]:\?\%_%OQ-X/N54W4FI:=M2,V=Y*S*B*>!$<_NSC
M(&,CGE3@8 /L*BL_0]9L_$.AV6KV#[[6[B65,D$KGJK8) 8'((SP016A0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G_
M ,;?^20Z[_V[_P#I1'7H%>?_ !M_Y)#KO_;O_P"E$= 'G_[,O_,T_P#;I_[6
MKZ KY_\ V9?^9I_[=/\ VM7T!0 4444 <_X[_P"2>>)?^P5=?^BFKX@K[?\
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MZ/\ LR_\S3_VZ?\ M:O*/B)K%YKWCO4M3O\ 29])NIO*WV4^=\6(D49RJGD
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M!'!!'>I*\)_9W\8W%Y;W?A*Z^=+.(W5FP0#:A?\ >*QSS\SJ1QW;)Q@5[M0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?/_ .TU
M_P RM_V]_P#M&O0/@E_R2'0O^WC_ -*)*\__ &FO^96_[>__ &C7H'P2_P"2
M0Z%_V\?^E$E 'H%%%% !7S_^TU_S*W_;W_[1KZ KY_\ VFO^96_[>_\ VC0!
MYQ\(+^STSXI:->7]W!:6L?G[YIY!&BY@D RQX&20/QKZG_X3OP?_ -#7H?\
MX,8?_BJ^4/A;HFG>(_B/I.DZM;_:+&?SO,BWLF[;"[#E2".0#P:^C_\ A27P
M\_Z%[_R=N/\ XY0!T'_"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/
M_P 57/\ _"DOAY_T+W_D[<?_ !RC_A27P\_Z%[_R=N/_ (Y0!T'_  G?@_\
MZ&O0_P#P8P__ !5'_"=^#_\ H:]#_P#!C#_\57/_ /"DOAY_T+W_ ).W'_QR
MC_A27P\_Z%[_ ,G;C_XY0!T'_"=^#_\ H:]#_P#!C#_\51_PG?@__H:]#_\
M!C#_ /%5S_\ PI+X>?\ 0O?^3MQ_\<H_X4E\//\ H7O_ "=N/_CE '0?\)WX
M/_Z&O0__  8P_P#Q5'_"=^#_ /H:]#_\&,/_ ,57/_\ "DOAY_T+W_D[<?\
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M !1110 4444 %%%% !1110 4444 %>?_ !M_Y)#KO_;O_P"E$=>@5Y_\;?\
MDD.N_P#;O_Z41T >?_LR_P#,T_\ ;I_[6KZ KY__ &9?^9I_[=/_ &M7T!0
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M'_W^7_Y(H ]@HKQ__A(?CG_T)FA_]_E_^2*/^$A^.?\ T)FA_P#?Y?\ Y(H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYM_:3U&:7Q/HVELJ>1;
MV;7", =Q:1RK \XQB)<<=S^'TE7SS^TIHVV^T/7$2=O,B>TE?&8TVG>@SCAC
MODZGD+P.#0!R_P  ]&L]6^) FO$\S^S[5[N%" 5,@94!((/3>6&,$,%.>*L?
MM":S_:'Q#33D>?R]-M4C:-S\@D?]X649[JT8)X/R^@%<_P#"KQO9^ O%DNI7
M]K/<6L]J]LX@QO3+*P8 D \H!C(ZY[8/-^)=;F\2>)=2UF<.K7EP\H1Y#(8U
M)^5-QZA5PHZ< <"@#I/@_HW]M?%#1HV2<PVTINY'B'W/+!92QP<*7"*?][&0
M2*]$_:8MX5F\-7 B03NMRC2!1N95\LJ">I +,0.VX^M9?P.%GX8T;Q)X\U;S
MTLK2);.,Q8;S"S*S+MZ[L^2 3A?G.3P2.3^*7Q&;XA:Q;206TEKIUDKI;Q2,
MK,Q9N9#@<$J$&W) V\'DT 7/@3>W%K\5M/AADVQW<,\,XV@[T$;.!ST^9%/'
MIZ9KZVKYA_9VT3[=XWN]6DM]\.G6IV2[\>7-(=J\9YR@E'0@?7%?3U !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\__ +37_,K?
M]O?_ +1KT#X)?\DAT+_MX_\ 2B2O/_VFO^96_P"WO_VC7H'P2_Y)#H7_ &\?
M^E$E 'H%%%% !7S_ /M-?\RM_P!O?_M&OH"OG_\ ::_YE;_M[_\ :- 'E'P[
M\26?A'QWINN7\<\EK:^;O2!07.Z)T& 2!U8=Z]W_ .&CO!__ $#=<_[\0_\
MQVO(/@E_R5[0O^WC_P!)Y*^OZ /'_P#AH[P?_P! W7/^_$/_ ,=H_P"&CO!_
M_0-US_OQ#_\ ':]@HH \?_X:.\'_ /0-US_OQ#_\=H_X:.\'_P#0-US_ +\0
M_P#QVO8** /'_P#AH[P?_P! W7/^_$/_ ,=H_P"&CO!__0-US_OQ#_\ ':]@
MHH \?_X:.\'_ /0-US_OQ#_\=H_X:.\'_P#0-US_ +\0_P#QVO8** /'_P#A
MH[P?_P! W7/^_$/_ ,=H_P"&CO!__0-US_OQ#_\ ':]@HH \?_X:.\'_ /0-
MUS_OQ#_\=H_X:.\'_P#0-US_ +\0_P#QVO8** /'_P#AH[P?_P! W7/^_$/_
M ,=H_P"&CO!__0-US_OQ#_\ ':]@HH \?_X:.\'_ /0-US_OQ#_\=H_X:.\'
M_P#0-US_ +\0_P#QVO8** /'_P#AH[P?_P! W7/^_$/_ ,=H_P"&CO!__0-U
MS_OQ#_\ ':]@HH ^//BSXUTWQYXJM=4TN"[A@BLDMV6Z158L'=LC:S#&''?U
MKI/V<?\ DH>H?]@J3_T;%1^T=_R4/3_^P5'_ .C9:/V<?^2AZA_V"I/_ $;%
M0!]/T444 %%%% !1110 4444 9OB'_D6M5_Z\YO_ $ UX'7OGB'_ )%K5?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!\Z_'WQ+KVC>.+&WTO6M1L86TU':.UNGB4MYD@R0I S@#
MGV%>5?\ ">>,/^AKUS_P82__ !5?4GC;X3Z%X\UB'4]4N]2AFAMQ;JMK(BJ5
M#,V3N1CG+'OZ5S7_  SCX/\ ^@EKG_?^'_XU0!X!_P )YXP_Z&O7/_!A+_\
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M?\,X^#_^@EKG_?\ A_\ C5 'L%%>/_\ #./@_P#Z"6N?]_X?_C5'_#./@_\
MZ"6N?]_X?_C5 'L%%>/_ /#./@__ *"6N?\ ?^'_ .-4?\,X^#_^@EKG_?\
MA_\ C5 'L%%>/_\ #./@_P#Z"6N?]_X?_C5'_#./@_\ Z"6N?]_X?_C5 'L%
M%>/_ /#./@__ *"6N?\ ?^'_ .-4?\,X^#_^@EKG_?\ A_\ C5 'L%%>/_\
M#./@_P#Z"6N?]_X?_C5'_#./@_\ Z"6N?]_X?_C5 'D'QM_Y*]KO_;O_ .D\
M==_^S+_S-/\ VZ?^UJ\H^(GANS\(^.]2T.PDGDM;7RMCSL"YW1(YR0 .K'M7
MJ_[,O_,T_P#;I_[6H ^@**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN0^*&MZA
MX=^'6K:KI5Q]GO8!%Y<NQ7V[I44\,"#P2.E '7U@>,_"=GXU\+W6BWC>5YN&
MBG"!FAD!RK '\0<8)4L,C.:^7_\ A=OQ#_Z&#_R2M_\ XBO2OB1\0_%.@>#?
M ]_IFJ>1=:G8>=>/]GB;S'\N$YPRD#EVZ8ZT >3:U\+/&FB:@]I)X?OKL#)6
M:QA:>-UR0""H.,XS@X.",@9HT7X6>--;U%+2/P_?6@."\U]"T$:+D DE@,XS
MG"Y. < XJ_\ \+M^(?\ T,'_ ))6_P#\11_PNWXA_P#0P?\ DE;_ /Q% 'T#
MJ7A#2_#'P7UC0[>V@DCATJ>25S%_KIUB)\T@D_-N4$<G;A0. *^6_"WA#6_&
M.J)8Z/922DNJRSE2(H <_-(V,*,*?<XP 3Q71_\ "[?B'_T,'_DE;_\ Q%'_
M  NWXA_]#!_Y)6__ ,10!].>!_!MCX%\-1:/8R/,=YEN)WX,TI !;'11A0 !
MT '4Y)Z.O"?@I\1/%7B[QA>6&N:I]JMH[!YD3[/%'AQ)& <JH/1C^=>[4 %%
M%% !1110 4444 %%%% !1110 4444 %%%5[Z]M]-T^YO[N3R[:VB::9]I.U%
M!+' Y/ /2@"Q17D'_#1W@_\ Z!NN?]^(?_CM)_PT=X/_ .@;KG_?B'_X[0![
M!17C_P#PT=X/_P"@;KG_ 'XA_P#CM>JZ5J,.L:/9:G;JZP7EO'<1K( &"NH8
M X)&<'UH MT444 ?/_[37_,K?]O?_M&O0/@E_P DAT+_ +>/_2B2O/\ ]IK_
M )E;_M[_ /:->@?!+_DD.A?]O'_I1)0!Z!1110 5\_\ [37_ #*W_;W_ .T:
M^@*^?_VFO^96_P"WO_VC0!Y1\.[C7;3QWIL_AJR@O=77S?L\$Y 1\Q.&R2R]
M%W'J.GX5[O\ \)#\<_\ H3-#_P"_R_\ R17D'P2_Y*]H7_;Q_P"D\E?7] 'C
M_P#PD/QS_P"A,T/_ +_+_P#)%'_"0_'/_H3-#_[_ "__ "17L%% 'C__  D/
MQS_Z$S0_^_R__)%'_"0_'/\ Z$S0_P#O\O\ \D5[!10!X_\ \)#\<_\ H3-#
M_P"_R_\ R11_PD/QS_Z$S0_^_P O_P D5[!10!X__P )#\<_^A,T/_O\O_R1
M1_PD/QS_ .A,T/\ [_+_ /)%>P44 >/_ /"0_'/_ *$S0_\ O\O_ ,D4?\)#
M\<_^A,T/_O\ +_\ )%>P44 >/_\ "0_'/_H3-#_[_+_\D4?\)#\<_P#H3-#_
M ._R_P#R17L%% 'C_P#PD/QS_P"A,T/_ +_+_P#)%'_"0_'/_H3-#_[_ "__
M "17L%% 'C__  D/QS_Z$S0_^_R__)%'_"0_'/\ Z$S0_P#O\O\ \D5[!10!
MX_\ \)#\<_\ H3-#_P"_R_\ R11_PD/QS_Z$S0_^_P O_P D5[!10!\>?%F]
M\5WWBJUE\8:9::?J LD6.*U8,IBWOACAWYW%AU[#CUZ3]G'_ )*'J'_8*D_]
M&Q4?M'?\E#T__L%1_P#HV6C]G'_DH>H?]@J3_P!&Q4 ?3]%%% !1110 4444
M %%%% &;XA_Y%K5?^O.;_P! ->!U[YXA_P"1:U7_ *\YO_0#7@=?/YS\<?0^
M7S_^)#T/?/#W_(M:5_UYP_\ H KG-3_Y*UHW_7FW\I:Z/P]_R+6E?]></_H
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M$2Q_["<?_HJ6O#O!?_(]^'O^PG;?^C5KW'X_?\B)8_\ 83C_ /14M>'>"_\
MD>_#W_83MO\ T:M?H_#_ /R)Y?\ ;QQU?XA]C4445^<'8%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#,T_\ ;I_[6KZ H **** .?\=_\D\\2_\ 8*NO_135\05]O^._^2>>)?\
ML%77_HIJ^(* /L/P7XT\*VO@7P];W'B71H9XM,MDDCDOXE9&$2@@@MD$'C%;
MG_"=^#_^AKT/_P &,/\ \57#^$_A!X$U/P;H=_>:%YEU=:?;S3/]KG&YVC4L
M<!\#))Z5L?\ "DOAY_T+W_D[<?\ QR@#H/\ A._!_P#T->A_^#&'_P"*H_X3
MOP?_ -#7H?\ X,8?_BJY_P#X4E\//^A>_P#)VX_^.4?\*2^'G_0O?^3MQ_\
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MS_H7O_)VX_\ CE'_  I+X>?]"]_Y.W'_ ,<H Z#_ (3OP?\ ]#7H?_@QA_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*SKGY3?_ !^N@_X7;\//^AA_\DKC_P"-T?\ "[?AY_T,/_DE<?\ QN@#G_\
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MH_X5!XP_Z*SKGY3?_'ZZ#_A=OP\_Z&'_ ,DKC_XW1_PNWX>?]##_ .25Q_\
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M_H!K.E_NL?\ "OR,Z/\ N4?\*_(SO 7_ ")>G_\ ;3_T8U='7.> O^1+T_\
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M?]^9?_CE>YAN'<?B:2JPBDGM=VT[F4JT4['T;17SE_PO[Q5_T#]&_P"_,O\
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M\Q=K*02"I'J"".,CC@D<UI5\_.$H2<)*S6C-EJ%%%%2 4444 %%%% !1110
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M_P#H&ZY_WXA_^.UZ!X$_Y)YX:_[!5K_Z*6N@H \?_P"&CO!__0-US_OQ#_\
M':/^&CO!_P#T#=<_[\0__':]@HH \?\ ^&CO!_\ T#=<_P"_$/\ \=H_X:.\
M'_\ 0-US_OQ#_P#':]@HH \?_P"&CO!__0-US_OQ#_\ ':/^&CO!_P#T#=<_
M[\0__':]@HH \?\ ^&CO!_\ T#=<_P"_$/\ \=H_X:.\'_\ 0-US_OQ#_P#'
M:]@HH \?_P"&CO!__0-US_OQ#_\ ':/^&CO!_P#T#=<_[\0__':]@HH \?\
M^&CO!_\ T#=<_P"_$/\ \=H_X:.\'_\ 0-US_OQ#_P#':]@HH \?_P"&CO!_
M_0-US_OQ#_\ ':/^&CO!_P#T#=<_[\0__':]@HH \?\ ^&CO!_\ T#=<_P"_
M$/\ \=H_X:.\'_\ 0-US_OQ#_P#':]@HH \?_P"&CO!__0-US_OQ#_\ ':/^
M&CO!_P#T#=<_[\0__':]@HH ^*/B)XDL_%WCO4M<L(YX[6Z\K8DZ@.-L2(<@
M$CJI[UZO^S+_ ,S3_P!NG_M:N ^-O_)7M=_[=_\ TGCKO_V9?^9I_P"W3_VM
M0!] 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'C_P ;-566?2-#0QL8
MRU_,"K;EX,<6#TP<RY')^4=._F%O<3VEPEQ;3RP3IG9+"Y1UR"#AAR."1^-?
M45_H^EZJT3:CIMG>-#GRS<0+(4SC.-P.,X&<>@KSCQ]X:\#>'M'GN9+.:'4+
MQR;:*TN65W?()VJVY$09P3MPH. ,E0?/Q6&G.7M%*UCZ[(\ZP^&H+"3I.3D^
MEG>_D[>AY9JVJWFMZD=0OVB>Z:)8Y)4B6-I2"V&?;@%L$+G'1%J72]?U71;>
M^@TR\:U6]"+,\8_>84.,*W\.?,SD88%1@COEIF.$>:X)4?,^,#W/M4B[=Z[P
MY3<-P1@K$9Y )! ..^#CT->:JD^?FOKW/MGA,.\/[%T_=6O+^-M[;_(0DM))
M*[,\DCEY'8DL[$Y+,3R23R2:]K^#FKM=:!>:7(78V,H>,E5"K')DA01R3N5R
M<_WASV%GPEX3\"ZIIMGJNFV/VHQKL<W4C.PDVX82QYV;N<],<@KQ@UVMCIMC
MI<+0Z?96UI$[[V2WB6-6; &2 !S@#GV%>GAL-.G+G<KW/A\[SO#XJA]5A2<;
M/K96MY:^A:HHHKO/DPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X'XU_P#)(M=^
MD'_H^.N^K/UO1-/\1:1/I6JV_P!HLI]OF1;V3=M8,.5((Y /!H ^$**^O_\
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M<F[;C=]QCC&Y>OK7T_\ !+_DD.A?]O'_ *425Y_^TU_S*W_;W_[1KT#X)?\
M)(="_P"WC_THDH ] HHHH *^?_VFO^96_P"WO_VC7T!7S_\ M-?\RM_V]_\
MM&@#SCX06%GJ?Q2T:SO[2"[M9//WPSQB1&Q!(1E3P<$ _A7U/_P@G@__ *%3
M0_\ P70__$U\D?#O6+S0?'>FZG8:3/JUU#YNRR@SOES$ZG&%8\ D]#TKW?\
MX6_XP_Z)-KGYS?\ QB@#T#_A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@N
MA_\ B:\__P"%O^,/^B3:Y^<W_P 8H_X6_P",/^B3:Y^<W_QB@#T#_A!/!_\
MT*FA_P#@NA_^)H_X03P?_P!"IH?_ (+H?_B:\_\ ^%O^,/\ HDVN?G-_\8H_
MX6_XP_Z)-KGYS?\ QB@#T#_A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@N
MA_\ B:\__P"%O^,/^B3:Y^<W_P 8H_X6_P",/^B3:Y^<W_QB@#T#_A!/!_\
MT*FA_P#@NA_^)H_X03P?_P!"IH?_ (+H?_B:\_\ ^%O^,/\ HDVN?G-_\8H_
MX6_XP_Z)-KGYS?\ QB@#T#_A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@N
MA_\ B:\__P"%O^,/^B3:Y^<W_P 8H_X6_P",/^B3:Y^<W_QB@#T#_A!/!_\
MT*FA_P#@NA_^)H_X03P?_P!"IH?_ (+H?_B:\_\ ^%O^,/\ HDVN?G-_\8H_
MX6_XP_Z)-KGYS?\ QB@#T#_A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@N
MA_\ B:\__P"%O^,/^B3:Y^<W_P 8H_X6_P",/^B3:Y^<W_QB@#T#_A!/!_\
MT*FA_P#@NA_^)H_X03P?_P!"IH?_ (+H?_B:\_\ ^%O^,/\ HDVN?G-_\8H_
MX6_XP_Z)-KGYS?\ QB@#T#_A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@N
MA_\ B:\__P"%O^,/^B3:Y^<W_P 8H_X6_P",/^B3:Y^<W_QB@#S3X^Z3INC>
M.K&WTO3[2Q@;3(W:.UA6)2WFRC)"@#. !GV%7/V<?^2AZA_V"I/_ $;%7-_%
MGQ)J7BCQ5:WNJ>'KO0ITLDB6VNBVYU#N=XW(IP2Q'3^$\UTG[./_ "4/4/\
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M536?^V'_ *(CJCX,\ :KXY^V_P!F7%E#]C\OS/M+LN=^[&-JG^Z?TJ]\8?\
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MB_\ CE'U[B'_ )]_@@Y:/<X?_A0/BK_H(:-_W^E_^-T?\*!\5?\ 00T;_O\
M2_\ QNNX_P"%_>%?^@?K/_?F+_XY1_PO[PK_ - _6?\ OS%_\<H^O<0_\^_P
M0<M'N</_ ,*!\5?]!#1O^_TO_P ;H_X4#XJ_Z"&C?]_I?_C==Q_PO[PK_P!
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M&1Z5]!?\+^\*_P#0/UG_ +\Q?_'*\$\0ZA%JWB75=2@5UAN[R:>-9  P5W+
M'!(S@^M>SDV(S.K.2QL;*VFEM3.HH)>Z>]_ '_D1+[_L)R?^BHJ]5KRKX _\
MB)??]A.3_P!%15ZK7P>>?\C&KZG52^!!1117E%A1110 4444 %%%% !1110
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M >/_ /"0_'/_ *$S0_\ O\O_ ,D4?\)#\<_^A,T/_O\ +_\ )%>P44 >/_\
M"0_'/_H3-#_[_+_\D4?\)#\<_P#H3-#_ ._R_P#R17L%% 'C_P#PD/QS_P"A
M,T/_ +_+_P#)%'_"0_'/_H3-#_[_ "__ "17L%% 'C__  D/QS_Z$S0_^_R_
M_)%'_"0_'/\ Z$S0_P#O\O\ \D5[!10!X_\ \)#\<_\ H3-#_P"_R_\ R11_
MPD/QS_Z$S0_^_P O_P D5[!10!X__P )#\<_^A,T/_O\O_R11_PD/QS_ .A,
MT/\ [_+_ /)%>P44 >/_ /"0_'/_ *$S0_\ O\O_ ,D4?\)#\<_^A,T/_O\
M+_\ )%>P44 >/_\ "0_'/_H3-#_[_+_\D4?\)#\<_P#H3-#_ ._R_P#R17L%
M% 'Q1\1+C7;OQWJ4_B6R@LM7;ROM$$!!1,1(%P0S=5VGJ>OX5ZO^S+_S-/\
MVZ?^UJX#XV_\E>UW_MW_ /2>.N__ &9?^9I_[=/_ &M0!] 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^&/%]Q/;Z%JT=W/ @>2/RWC8*3C(#@$C/4C.,C/45T= !1110 4444 %%%%
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M ._*_P#R/1_PCWQS_P"AST/_ +\K_P#(] 'L%%>/_P#"/?'/_H<]#_[\K_\
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MG]QZK17E7]O?&;_H4M&_[^K_ /'Z/[>^,W_0I:-_W]7_ ./T?V3/_G[3_P#
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M/U-?4<+X.6'K5&YQE=+X9)]?(QKRND>]_ '_ )$2^_["<G_HJ*O5:\J^ /\
MR(E]_P!A.3_T5%7JM?+YY_R,:OJ;TO@04445Y184444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\_\
MC;_R2'7?^W?_ -*(Z] KS_XV_P#)(==_[=__ $HCH \__9E_YFG_ +=/_:U?
M0%?/_P"S+_S-/_;I_P"UJ^@* "BBB@#G_'?_ "3SQ+_V"KK_ -%-7Q!7V_X[
M_P"2>>)?^P5=?^BFKX@H ^B_#6A?&6;PKI$NE^+-&@T][*%K6*2)2R1%!L4_
MN#R%P.I^IK4_X1[XY_\ 0YZ'_P!^5_\ D>O0/ G_ "3SPU_V"K7_ -%+704
M>/\ _"/?'/\ Z'/0_P#ORO\ \CT?\(]\<_\ H<]#_P"_*_\ R/7L%% 'C_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /G_\ ::_YE;_M[_\
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MSCX/_P"@EKG_ '_A_P#C5'_#./@__H):Y_W_ (?_ (U0![!17C__  SCX/\
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M1\/?\BUI7_7G#_Z */$/_(M:K_UYS?\ H!H\/?\ (M:5_P!></\ Z */$/\
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M5?\ 13]9_*7_ ./4?4L%_P!!*_\  9_Y!S2_E/5:*\J_X57XJ_Z*?K/Y2_\
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MD5<GT 8 #V'%<>*P\ZMN5GTF0YQALO4_;0;;V:2OZ:M'SM17T-_PK/PA_P!
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !115>]OK/3;22[O[J"UMH\;YIY B+DX&6/ Y('X
MT 6**S-.\2:%K%PUOI>M:=?3*A=H[6Z25@N0,D*2<9(Y]Q6G0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
M/_[37_,K?]O?_M&O0/@E_P DAT+_ +>/_2B2O/\ ]IK_ )E;_M[_ /:->@?!
M+_DD.A?]O'_I1)0!Z!1110 5\_\ [37_ #*W_;W_ .T:^@*^?_VFO^96_P"W
MO_VC0!YA\+=;T[PY\1])U;5KC[/8P>=YDNQGV[H74<*"3R0.!7T?_P +M^'G
M_0P_^25Q_P#&Z^>/A!86>I_%+1K._M(+NUD\_?#/&)$;$$A&5/!P0#^%?4__
M  @G@_\ Z%30_P#P70__ !- '/\ _"[?AY_T,/\ Y)7'_P ;H_X7;\//^AA_
M\DKC_P"-UT'_  @G@_\ Z%30_P#P70__ !-'_"">#_\ H5-#_P#!=#_\30!S
M_P#PNWX>?]##_P"25Q_\;H_X7;\//^AA_P#)*X_^-UT'_"">#_\ H5-#_P#!
M=#_\31_P@G@__H5-#_\ !=#_ /$T <__ ,+M^'G_ $,/_DE<?_&Z/^%V_#S_
M *&'_P DKC_XW70?\()X/_Z%30__  70_P#Q-'_"">#_ /H5-#_\%T/_ ,30
M!S__  NWX>?]##_Y)7'_ ,;H_P"%V_#S_H8?_)*X_P#C==!_P@G@_P#Z%30_
M_!=#_P#$T?\ "">#_P#H5-#_ /!=#_\ $T <_P#\+M^'G_0P_P#DE<?_ !NC
M_A=OP\_Z&'_R2N/_ (W70?\ "">#_P#H5-#_ /!=#_\ $T?\()X/_P"A4T/_
M ,%T/_Q- '/_ /"[?AY_T,/_ ))7'_QNC_A=OP\_Z&'_ ,DKC_XW70?\()X/
M_P"A4T/_ ,%T/_Q-'_"">#_^A4T/_P %T/\ \30!S_\ PNWX>?\ 0P_^25Q_
M\;H_X7;\//\ H8?_ "2N/_C==!_P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T
M/_P70_\ Q- '/_\ "[?AY_T,/_DE<?\ QNC_ (7;\//^AA_\DKC_ .-UT'_"
M">#_ /H5-#_\%T/_ ,31_P ()X/_ .A4T/\ \%T/_P 30!S_ /PNWX>?]##_
M .25Q_\ &Z/^%V_#S_H8?_)*X_\ C==!_P ()X/_ .A4T/\ \%T/_P 31_P@
MG@__ *%30_\ P70__$T ?-'QK\4Z-XN\96=_H=Y]KM8]/2%G\IX\.))"1AP#
MT8?G6Q^SC_R4/4/^P5)_Z-BJG\?=)TW1O'5C;Z7I]I8P-ID;M':PK$I;S91D
MA0!G  S["KG[./\ R4/4/^P5)_Z-BH ^GZ*** "BBB@ HHHH **** ,WQ#_R
M+6J_]><W_H!KP.O?/$/_ "+6J_\ 7G-_Z :\#KY_.?CCZ'R^?_Q(>A[YX>_Y
M%K2O^O.'_P! %<YJ?_)6M&_Z\V_E+71^'O\ D6M*_P"O.'_T 5SFI_\ )6M&
M_P"O-OY2UZ5;^%3]8GK8C^#2_P 4/S1VM<5XU_Y&7PI_U^?^SQ5VM<5XU_Y&
M7PI_U^?^SQ5>-_@OU7YHUS'_ '=^L?\ TI':UQ7C7_D9?"G_ %^?^SQ5VM<5
MXU_Y&7PI_P!?G_L\5&-_@OU7YH,Q_P!W?K'_ -*1VM<5\3_^1:MO^OQ?_0'K
MM:XKXG_\BU;?]?B_^@/1CO\ =Y^@9E_ND_0[6N<\>_\ (EZA_P!L_P#T8M='
M7.>/?^1+U#_MG_Z,6M,5_ GZ/\C3&?[M4_PO\C1\/?\ (M:5_P!></\ Z */
M$/\ R+6J_P#7G-_Z :/#W_(M:5_UYP_^@"CQ#_R+6J_]><W_ * :/^7'R_0/
M^8;_ +=_0SO 7_(EZ?\ ]M/_ $8U:/B'_D6M5_Z\YO\ T UG> O^1+T__MI_
MZ,:M'Q#_ ,BUJO\ UYS?^@&LZ7^ZQ_PK\C.C_N4?\*_(SO 7_(EZ?_VT_P#1
MC5T=<YX"_P"1+T__ +:?^C&KHZTPO\"'HOR-,'_NU/\ PK\CBOAA_P BU<_]
M?C?^@)7:UQ7PP_Y%JY_Z_&_] 2NUK/ _[O#T,\M_W2'H<5X*_P"1E\5_]?G_
M +/+6EX]_P"1+U#_ +9_^C%K-\%?\C+XK_Z_/_9Y:TO'O_(EZA_VS_\ 1BUA
M#_<I>DOS9S4_^1=/TG^;/%*^CJ^<:^CJY<E^W\OU.'A__EY\OU"BBBO</I H
MHHH **** "BBB@#Y5^,/_)5-9_[8?^B(ZW?@SXPT'PG_ &W_ &W?_9?M/D>3
M^Y=]VWS-WW5./O#KZUA?&'_DJFL_]L/_ $1'75_ C1=*UC^W_P"T],LKWROL
M_E_:8%DV9\W.-P.,X'Y"OTS%>R60Q]LGR\D+VM?[/>YQ1O[73S/1_P#A</@/
M_H._^2D__P 11_PN'P'_ -!W_P E)_\ XBMS_A"_"O\ T+.C?^ $7_Q-'_"%
M^%?^A9T;_P  (O\ XFOB.;*OY:GWQ_\ D3I]_P C#_X7#X#_ .@[_P"2D_\
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M_P!$FUS\YO\ XQ0!Z!_P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\
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M.;_XQ1_PM_QA_P!$FUS\YO\ XQ0!Z!_P@G@__H5-#_\ !=#_ /$T?\()X/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_2>2OK^@#Q__ (6_XP_Z)-KGYS?_ !BC_A;_ (P_Z)-KGYS?_&*]@HH \?\
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MF%_@0]%^1I@_]VI_X5^1Q7PP_P"1:N?^OQO_ $!*[6N*^&'_ "+5S_U^-_Z
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M![!17C__  D/QS_Z$S0_^_R__)%'_"0_'/\ Z$S0_P#O\O\ \D4 >P45X_\
M\)#\<_\ H3-#_P"_R_\ R11_PD/QS_Z$S0_^_P O_P D4 >P45X__P )#\<_
M^A,T/_O\O_R11_PD/QS_ .A,T/\ [_+_ /)% 'L%%>/_ /"0_'/_ *$S0_\
MO\O_ ,D4?\)#\<_^A,T/_O\ +_\ )% 'L%%>/_\ "0_'/_H3-#_[_+_\D4?\
M)#\<_P#H3-#_ ._R_P#R10!Y!\;?^2O:[_V[_P#I/'7?_LR_\S3_ -NG_M:O
M*/B)<:[=^.]2G\2V4%EJ[>5]H@@(*)B) N"&;JNT]3U_"O5_V9?^9I_[=/\
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M<'C(S@X'H* /CSP1X8_X3+Q?9:#]L^Q_:A)^_P#+\S;M1G^[D9SMQU[UZ_\
M\,RC_H;O_*;_ /;:NZWKGPP^$NL>=H.B1WVOHCIL@NFD6W^;:P=W9A&^ PP%
M+<$' ;GS_4OCUX[OKA9+:]M-/0)M,5M:HRDY/S'S-YSSCKC@<=: .S_X9E'_
M $-W_E-_^VT?\,RC_H;O_*;_ /;:XO3?CUX[L;AI+B]M-00H5$5S:HJ@Y'S#
MR]ASQCKCD\=*]<^'_P <-*\5WEMI.JVW]F:M-\D;;LP3O@<*3RK,=V%.>@&X
MD@4 6/AQ\(/^%?>(+C5?[=^W^=:M;>5]D\K&71LYWM_<QC'>O3Z** "BBB@
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MM:K_ -><W_H!H\/?\BUI7_7G#_Z */$/_(M:K_UYS?\ H!H_Y<?+] _YAO\
MMW]#.\!?\B7I_P#VT_\ 1C5H^(?^1:U7_KSF_P#0#6=X"_Y$O3_^VG_HQJT?
M$/\ R+6J_P#7G-_Z :SI?[K'_"OR,Z/^Y1_PK\C.\!?\B7I__;3_ -&-71US
MG@+_ )$O3_\ MI_Z,:NCK3"_P(>B_(TP?^[4_P#"OR.*^&'_ "+5S_U^-_Z
ME=K7%?##_D6KG_K\;_T!*[6L\#_N\/0SRW_=(>AQ7@K_ )&7Q7_U^?\ L\M:
M7CW_ )$O4/\ MG_Z,6LWP5_R,OBO_K\_]GEK2\>_\B7J'_;/_P!&+6$/]REZ
M2_-G-3_Y%T_2?YL\4KZ.KYQKZ.KER7[?R_4X>'_^7GR_4****]P^D"BBB@ H
MHHH **** /E7XP_\E4UG_MA_Z(CJ_P#"JP\9WO\ :W_"(ZM9:?L\G[3]I0-O
MSOV8S&_3#>G4=:H?&'_DJFL_]L/_ $1'7<_L[?\ ,R?]NO\ [5K],Q59T<AC
M423M"&C5U]GHSBBKU;>IN?V#\9O^AMT;_OTO_P 8H_L'XS?]#;HW_?I?_C%>
MJT5\1_:T_P#GU3_\ C_D=/L_-_>>5?V#\9O^AMT;_OTO_P 8H_L'XS?]#;HW
M_?I?_C%>JT4?VM/_ )]4_P#P"/\ D'L_-_>>5?V#\9O^AMT;_OTO_P 8H_L'
MXS?]#;HW_?I?_C%>JT4?VM/_ )]4_P#P"/\ D'L_-_>>5?V#\9O^AMT;_OTO
M_P 8H_L'XS?]#;HW_?I?_C%>JT4?VM/_ )]4_P#P"/\ D'L_-_>>5?V#\9O^
MAMT;_OTO_P 8H_L'XS?]#;HW_?I?_C%>JT4?VM/_ )]4_P#P"/\ D'L_-_>>
M5?V#\9O^AMT;_OTO_P 8H_L'XS?]#;HW_?I?_C%>JT4?VM/_ )]4_P#P"/\
MD'L_-_>>5?V#\9O^AMT;_OTO_P 8H_L'XS?]#;HW_?I?_C%>JT4?VM/_ )]4
M_P#P"/\ D'L_-_>>5?V#\9O^AMT;_OTO_P 8H_L'XS?]#;HW_?I?_C%>JT4?
MVM/_ )]4_P#P"/\ D'L_-_>>5?V#\9O^AMT;_OTO_P 8H_L'XS?]#;HW_?I?
M_C%>JT4?VM/_ )]4_P#P"/\ D'L_-_>>5?V#\9O^AMT;_OTO_P 8KP3Q#'>Q
M>)=5CU*9)K]+R9;F6,85Y YW,.!P3D]!]!7VA7QSXT_Y'OQ#_P!A.Y_]&M7U
M'"^,EB*U1.$8V2^&*77R,:\;)'N/P!_Y$2^_["<G_HJ*O5:\J^ /_(B7W_83
MD_\ 145>JU\OGG_(QJ^IO2^!!1117E%A1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 ?)E?0WPS_Y)[I?_;7_ -&O7SS7T-\,_P#DGNE_]M?_ $:]
M>/E_\5^G^1^C\7_[C#_&ORD=;1117L'YP%%%% !1110 4444 %%%% !1110
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MLB&:(A9"IPVQNC 9'*DCD>M95??]9%[X4\.:G=R7=_H&E7=S)C?-/9QR.V
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M!+XAY_Y%\?\ @;!_\77T'\)?![>#_!%O;WNG1VFL3L[WQ#J[.0[!,L"1@)C
M!P,GN30!\?SV\]I<R6]Q%)#/$Y22.12K(P.""#R"#VKWGX,?%J^N-3A\+>([
MI[K[2Q%G?7$N75SD^6[,<L&/"GDY(7D$;;_[26FZ:=$T?5&:--46X-NB@J&E
MA*EFSQN(5@N.<#S#_>KQ3P'_ ,E#\-?]A6U_]&K0!]O5\4_$F^N-0^)7B.:Y
MD\R1+^6$':!A(V*(./154?ASS7V7JNHPZ/H][J=PKM!9V\EQ(L8!8JBEB!D@
M9P/6O@QCEB?>@!**^M/AIX!T%?AQH;ZMH.C7EY/;_:&GDLXY&99&+H"S+DD*
MRCVQ@<5U?_"">#_^A4T/_P %T/\ \30!Y#^S-]SQ/];7_P!K5[]6?IFA:1HG
MF_V5I5C8>;CS/LMND6_&<9V@9QD_F:T* "O/_C;_ ,DAUW_MW_\ 2B.O0*\_
M^-O_ "2'7?\ MW_]*(Z //\ ]F7_ )FG_MT_]K5] 5\__LR_\S3_ -NG_M:O
MH"@ HHHH Y_QW_R3SQ+_ -@JZ_\ 135\05]O^._^2>>)?^P5=?\ HIJ^(* /
MM_P)_P D\\-?]@JU_P#12UT%>%^&OA9XJU'PKI%[;_$[6;."XLH98[:,2[85
M9 0@Q,!@ XZ#IT%:G_"H/&'_ $5G7/RF_P#C] 'L%%>/_P#"H/&'_16=<_*;
M_P"/T?\ "H/&'_16=<_*;_X_0![!17C_ /PJ#QA_T5G7/RF_^/T?\*@\8?\
M16=<_*;_ ./T >P45X__ ,*@\8?]%9US\IO_ (_1_P *@\8?]%9US\IO_C]
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&#SO,EV,^W="ZCA02>2!P*^C_P#A=OP\_P"AA_\ )*X_^-T <_\ \,X^#_\
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M5Q_\;H_X7;\//^AA_P#)*X_^-T <_P#\,X^#_P#H):Y_W_A_^-4?\,X^#_\
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M_P#9XJ[6N*\:_P#(R^%/^OS_ -GBJ\;_  7ZK\T:YC_N[]8_^E([6N*\:_\
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M ,;H_P"% ^%?^@AK/_?Z+_XW6[_PN'P'_P!!W_R4G_\ B*/^%P^ _P#H._\
MDI/_ /$4?6,_[5/_  %_Y!:EY&%_PH'PK_T$-9_[_1?_ !NC_A0/A7_H(:S_
M -_HO_C=;O\ PN'P'_T'?_)2?_XBC_A</@/_ *#O_DI/_P#$4?6,_P"U3_P%
M_P"06I>1A?\ "@?"O_00UG_O]%_\;H_X4#X5_P"@AK/_ '^B_P#C=;O_  N'
MP'_T'?\ R4G_ /B*/^%P^ _^@[_Y*3__ !%'UC/^U3_P%_Y!:EY&%_PH'PK_
M -!#6?\ O]%_\;KP3Q#I\6D^)=5TV!G:&TO)H(VD(+%4<J"< #.!Z5],?\+A
M\!_]!W_R4G_^(KYJ\3WD&H^+-9OK63S+:YOIYHGP1N1I&(.#R.".M?1<.U<Q
MG5G]<YK6TYDU^AE64$ERGO'P!_Y$2^_["<G_ **BKU6O*O@#_P B)??]A.3_
M -%15ZK7Q^>?\C&KZG12^!!1117E%A1110 4444 %4=6UC3]"L3>ZE=+;VX8
M+N8$DD]  ,DGZ#H">U7J\H^-<L@AT6$2,(F:9F0'Y21L )'J-Q_,^M95ZCIT
MW-'H95@XXW&0P\G9._X)O]#4_P"%R>'O^?/5/^_4?_Q='_"Y/#W_ #YZI_WZ
MC_\ BZ\5M;6XO;A+>TMY9YWSMCB0NS8&3@#GH":MW6@:S96[W%WI%_! F-TD
MMLZ*N3@9)&.I KRUC*[5U^1]U+AK*XR4973?]X]?_P"%R>'O^?/5/^_4?_Q=
M'_"Y/#W_ #YZI_WZC_\ BZ\/JW8Z5J.I^9]@L+J[\O&_R(6DVYSC.!QG!_*D
ML;6>B*EPQEL%S2NEZGLO_"Y/#W_/GJG_ 'ZC_P#BZ/\ A<GA[_GSU3_OU'_\
M77DO_"+>(?\ H ZI_P" <G^%9DL4D$SPS1M'+&Q5T<892.""#T--XRNM_P B
M8<-Y5/2#;])'MO\ PN3P]_SYZI_WZC_^+H_X7)X>_P"?/5/^_4?_ ,77BMK:
MW%[<);VEO+/.^=L<2%V; R< <] 36A_PBWB'_H ZI_X!R?X4+&5WM^0I\-Y5
M!VF[>LCUK_A<GA[_ )\]4_[]1_\ Q='_  N3P]_SYZI_WZC_ /BZ\:OM*U'3
M/+^WV%U:>9G9Y\+1[L8SC(YQD?G52D\;66C+CPQELUS1NUZA7JG@_P")>C>'
M_"UEI=W;7[SP;]S11H5.YV88RP/0CM7G\7AO79X4FAT749(I%#(Z6KE6!Y!!
M Y%$OAO78(7FFT748XHU+.[VKA5 Y))(X%8TI5*3YHH]''T,'CH*C6DK)WT?
M75?J>N?\+D\/?\^>J?\ ?J/_ .+H_P"%R>'O^?/5/^_4?_Q=>'U;L=*U'4_,
M^P6%U=^7C?Y$+2;<YQG XS@_E6RQM9Z(\Z7#&6P7-*Z7J>R_\+D\/?\ /GJG
M_?J/_P"+H_X7)X>_Y\]4_P"_4?\ \77DO_"+>(?^@#JG_@')_A69+%)!,\,T
M;1RQL5='&&4C@@@]#3>,KK?\B8<-Y5/2#;])'MO_  N3P]_SYZI_WZC_ /BZ
M/^%R>'O^?/5/^_4?_P 77B444D\R0PQM)+(P5$099B>  !U-:?\ PBWB'_H
MZI_X!R?X4+&5WM^03X;RJ&DVUZR/6O\ A<GA[_GSU3_OU'_\71_PN3P]_P ^
M>J?]^H__ (NO&K[2M1TSR_M]A=6GF9V>?"T>[&,XR.<9'YU4I/&UEHRH\,9;
M-<T;M>I[A_PN3P]_SYZI_P!^H_\ XNNG\->+-+\56\LNG/*'AQYL4J;6CR3C
M/4'.TG@GWQ7S=/:W%KY7VBWEA\V,2Q^8A7>AZ,,]0?6N]^#?_(WW?_7@_P#Z
M,CK:AC*DJBC+J>?FG#N"HX.=>C=..N]T>X4445ZA\&%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 ?,/[1__)0-._[!<?\ Z-EK+\$_&WQ%X3MX-/NT35M+A0)'!,VR2)0#@)(
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MWFF?[7.-SM&I8X#X&23TK8_X4E\//^A>_P#)VX_^.4 =!_PG?@__ *&O0_\
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M0!T'_"=^#_\ H:]#_P#!C#_\51_PG?@__H:]#_\ !C#_ /%5S_\ PI+X>?\
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M-;X3,:TZRIU%N=."S:O.NJ55+7Y-'J]%%%>Z?2!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7@/[2FB931->BM^F^
MSN)M_P#P.)=N?^NIR!]3TKWZLSQ%H%CXHT"\T74E=K2Z0*_EMM92"&5@?4$
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M,LI !;'11A0 !T '4Y)Z.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ^?\ ]IK_ )E;_M[_ /:->@?!+_DD.A?]O'_I1)7G_P"T
MU_S*W_;W_P"T:] ^"7_)(="_[>/_ $HDH ] HHHH *^?_P!IK_F5O^WO_P!H
MU] 5\_\ [37_ #*W_;W_ .T: /./A!86>I_%+1K._M(+NUD\_?#/&)$;$$A&
M5/!P0#^%?4__  @G@_\ Z%30_P#P70__ !-?)'P[UB\T'QWINIV&DSZM=0^;
MLLH,[Y<Q.IQA6/ )/0]*]W_X6_XP_P"B3:Y^<W_QB@#T#_A!/!__ $*FA_\
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M7_T!Z[6N*^)__(M6W_7XO_H#T8[_ '>?H&9?[I/T.UKG/'O_ ")>H?\ ;/\
M]&+71USGCW_D2]0_[9_^C%K3%?P)^C_(TQG^[5/\+_(T?#W_ "+6E?\ 7G#_
M .@"CQ#_ ,BUJO\ UYS?^@&CP]_R+6E?]></_H H\0_\BUJO_7G-_P"@&C_E
MQ\OT#_F&_P"W?T,[P%_R)>G_ /;3_P!&-6CXA_Y%K5?^O.;_ - -9W@+_D2]
M/_[:?^C&K1\0_P#(M:K_ -><W_H!K.E_NL?\*_(SH_[E'_"OR,[P%_R)>G_]
MM/\ T8U='7.> O\ D2]/_P"VG_HQJZ.M,+_ AZ+\C3!_[M3_ ,*_(XKX8?\
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M,-9_.7_XS1_PM3Q5_P!$PUG\Y?\ XS1_9V:=_P#RI'_Y(.>']([G_A"_"O\
MT+.C?^ $7_Q-'_"%^%?^A9T;_P  (O\ XFN&_P"%J>*O^B8:S^<O_P 9H_X6
MIXJ_Z)AK/YR__&:/[.S3O_Y4C_\ )!SP_I'<_P#"%^%?^A9T;_P B_\ B:/^
M$+\*_P#0LZ-_X 1?_$UPW_"U/%7_ $3#6?SE_P#C-'_"U/%7_1,-9_.7_P",
MT?V=FG?_ ,J1_P#D@YX?TCN?^$+\*_\ 0LZ-_P" $7_Q-'_"%^%?^A9T;_P
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M_BG0_%5F;K0]3@O8U^^$)#Q\D#<APRYVG&0,XR.*UZ^8?V</^2@:C_V"Y/\
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MR3T= !7G_P ;?^20Z[_V[_\ I1'7H%>?_&W_ ))#KO\ V[_^E$= 'G_[,O\
MS-/_ &Z?^UJ^@*^?_P!F7_F:?^W3_P!K5] 4 %%%% '/^._^2>>)?^P5=?\
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MBB@ HHHH **** "OG&OHZOG&O#SK['S_ $/F^(/^7?S_ $/:_ 7_ ")>G_\
M;3_T8U9OQ/\ ^1:MO^OQ?_0'K2\!?\B7I_\ VT_]&-6;\3_^1:MO^OQ?_0'K
MJJ?[A_VZOR1W5?\ D6?]NK\D=K7.>/?^1+U#_MG_ .C%KHZYSQ[_ ,B7J'_;
M/_T8M=>*_@3]'^1VXS_=JG^%_D:/A[_D6M*_Z\X?_0!1XA_Y%K5?^O.;_P!
M-'A[_D6M*_Z\X?\ T 4>(?\ D6M5_P"O.;_T T?\N/E^@?\ ,-_V[^AG> O^
M1+T__MI_Z,:NCKG/ 7_(EZ?_ -M/_1C5T=&%_@0]%^08/_=J?^%?D<5\,/\
MD6KG_K\;_P! 2NUKBOAA_P BU<_]?C?^@)7:UG@?]WAZ&>6_[I#T.*\%?\C+
MXK_Z_/\ V>6NUKBO!7_(R^*_^OS_ -GEKM:,%_!7J_S89=_NZ]9?^E,XK3/^
M2M:S_P!>:_RBKM:XK3/^2M:S_P!>:_RBKM:,)M/_ !2_,,#\,_\ %+\SBM3_
M .2M:-_UYM_*6NUKBM3_ .2M:-_UYM_*6NUHPN]3_$_R08/XJO\ B?Y(XKXG
M_P#(M6W_ %^+_P"@/7:UQ7Q/_P"1:MO^OQ?_ $!Z[6BE_O%3TC^H4?\ >ZOI
M']3G/'O_ ")>H?\ ;/\ ]&+6CX>_Y%K2O^O.'_T 5G>/?^1+U#_MG_Z,6M'P
M]_R+6E?]></_ * *%_O3_P *_-@O]]?^%?FSSCXG_P#(RVW_ %YK_P"AO1\,
M/^1EN?\ KS;_ -#2CXG_ /(RVW_7FO\ Z&]'PP_Y&6Y_Z\V_]#2O&_YF/S/
M_P"9K_V\>LT445](?6!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!XP_Z*SKGY3?_'Z /8**\?\ ^%0>,/\ HK.N?E-_\?H_X5!XP_Z*SKGY3?\
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MR)>G_P#;3_T8U:/B'_D6M5_Z\YO_ $ UG2_W6/\ A7Y&='_<H_X5^1G> O\
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M,QOTPWIU'6OTS%4E5R&,')1O"&KV^SVN<47:K?U/INBO*O[!^,W_ $-NC?\
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MO0_"W_(H:+_UX0?^BUH\4_\ (H:U_P!>$_\ Z+:NSZM2Y>>VNY\W_;>/]O\
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MSC(SCJ*/^%)_]3#_ .27_P!LKSOPM_R-^B_]?\'_ *,6OIVC#Q6)3=76W]=
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"B3:Y^<W_QBO8** /'_P#A;_C#_HDVN?G-_P#&*/\ A;_C#_HDVN?G-_\
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M[JVFZSXZL;C2]0M+Z!=,C1I+6995#>;*<$J2,X(./<5<_9Q_Y*'J'_8*D_\
M1L58_P :_"VC>$?&5G8:'9_9+633TF9/->3+F20$Y<D]%'Y5L?LX_P#)0]0_
M[!4G_HV*@#Z?HHHH **** "BBB@ HHHH S?$/_(M:K_UYS?^@&O Z]\\0_\
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M_00__ /_ +8.:?;\3U6BO*O^% ^%?^@AK/\ W^B_^-T?\*!\*_\ 00UG_O\
M1?\ QNCZMEW_ $$/_P  _P#M@YI]OQ/5:*\J_P"% ^%?^@AK/_?Z+_XW1_PH
M'PK_ -!#6?\ O]%_\;H^K9=_T$/_ , _^V#FGV_$]5KXY\:?\CWXA_["=S_Z
M-:O<?^% ^%?^@AK/_?Z+_P"-UX)XAT^+2?$NJZ; SM#:7DT$;2$%BJ.5!. !
MG ]*^HX7I8:%:HZ%1R=EO&W7U9C7<FE='O?P!_Y$2^_["<G_ **BKU6O*O@#
M_P B)??]A.3_ -%15ZK7R^>?\C&KZF]+X$%%%%>46%%%% !1110 5Y-\;/\
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MV#]QYFW9MW;,9QN;&>F3ZUZ'_P )3X>_Z#VE_P#@9'_C7#_$339_&O\ 9O\
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M&C6/AS5+RSTBPM[J"TEEAFAMD1XW5"596 R"" 01TKPG_A*?$/\ T'M4_P#
MR3_&O>=:UO2-4T+4-/L=7TZ>\NK:2""%+N/=)(RE54?-U)(%>._\*S\7_P#0
M(_\ )F+_ .+HQ<9.2]DON_X <.UJ-.E-8Z23OISM7MY7.M^%W_%3?VK_ &]_
MQ-?L_D^3]O\ W_E[M^[;OSC.U<XZX'I7H?\ PBWA[_H Z7_X!Q_X5P_P[TV?
MP5_:7_"2R6NF?:_*\CS[J(>9LW[L8;MN7\Z[C_A*?#W_ $'M+_\  R/_ !KI
MPZBJ24]_,\?.959XV<L*VX:6Y;VV5[6TWO\ ,^>_%DLC^*=2A:1FBMKF6"!"
M<K%&KL%11_"H[ <"NJ^#?_(WW?\ UX/_ .C(ZYOQG8W%GXIOIIE7RKV:2[MG
M21762%W8JX*D\&ND^#?_ "-]W_UX/_Z,CKSJ5_K"OW/L<P<7DTG';E1[A111
M7N'Y8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5Y_\;?\ DD.N_P#;O_Z41UZ!7G_QM_Y)#KO_ &[_ /I1'0!Y
M_P#LR_\ ,T_]NG_M:OH"OG_]F7_F:?\ MT_]K5] 4 %%%% '/^._^2>>)?\
ML%77_HIJ^(*^W_'?_)//$O\ V"KK_P!%-7Q!0!]%^&M"^,LWA72)=+\6:-!I
M[V4+6L4D2EDB*#8I_<'D+@=3]36I_P (]\<_^AST/_ORO_R/7H'@3_DGGAK_
M +!5K_Z*6N@H \?_ .$>^.?_ $.>A_\ ?E?_ )'H_P"$>^.?_0YZ'_WY7_Y'
MKV"B@#Q__A'OCG_T.>A_]^5_^1Z/^$>^.?\ T.>A_P#?E?\ Y'KV"B@#Q_\
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MUWP'XHNM3U2[TV:":R:W5;61V8,71LG<BC&%/>O8Z** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "OGCXM?$_P ;>&OB!=:7IE[]@L(H
MHC /LD;><&4$ON=3GYBR\8'R8QD'/T/10!\0>)_&WB+QC]E_M_4/MGV7?Y/[
MF./;NQN^XHSG:O7TKZ?^"7_)(="_[>/_ $HDKS_]IK_F5O\ M[_]HUZ!\$O^
M20Z%_P!O'_I1)0!Z!1110 5\_P#[37_,K?\ ;W_[1KZ KY__ &FO^96_[>__
M &C0!Y1\._$EGX1\=Z;KE_'/):VOF[T@4%SNB=!@$@=6'>O=_P#AH[P?_P!
MW7/^_$/_ ,=KR#X)?\E>T+_MX_\ 2>2OK^@#Q_\ X:.\'_\ 0-US_OQ#_P#'
M:/\ AH[P?_T#=<_[\0__ !VO8** /'_^&CO!_P#T#=<_[\0__':/^&CO!_\
MT#=<_P"_$/\ \=KV"B@#Q_\ X:.\'_\ 0-US_OQ#_P#':/\ AH[P?_T#=<_[
M\0__ !VO8** /'_^&CO!_P#T#=<_[\0__':/^&CO!_\ T#=<_P"_$/\ \=KV
M"B@#Q_\ X:.\'_\ 0-US_OQ#_P#':/\ AH[P?_T#=<_[\0__ !VO8** /'_^
M&CO!_P#T#=<_[\0__':/^&CO!_\ T#=<_P"_$/\ \=KV"B@#Q_\ X:.\'_\
M0-US_OQ#_P#':/\ AH[P?_T#=<_[\0__ !VO8** /'_^&CO!_P#T#=<_[\0_
M_':/^&CO!_\ T#=<_P"_$/\ \=KV"B@#Q_\ X:.\'_\ 0-US_OQ#_P#':/\
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M_A</@/\ Z#O_ )*3_P#Q%;G_  A?A7_H6=&_\ (O_B:/^$+\*_\ 0LZ-_P"
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MH_X7#X#_ .@[_P"2D_\ \16Y_P (7X5_Z%G1O_ "+_XFC_A"_"O_ $+.C?\
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M:NF>EEN987+,+'!XR7+4C>ZLW:[;6J36S74Y+QW_ ,RU_P!@&U_]FK6^#?\
MR-]W_P!>#_\ HR.N>\97WVC5XK#R]O\ 9$ TS?NSYOE,PWX_ASZ<X]370_!O
M_D;[O_KP?_T9'44W?$KU.C&1<<EFG_*_Q=SW"BBBO;/S **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:Y_W_A_^-5Z!_P )WX/_ .AKT/\ \&,/_P 51_PG?@__ *&O0_\ P8P__%4
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M !5'_"=^#_\ H:]#_P#!C#_\50!Y_P#\,X^#_P#H):Y_W_A_^-4?\,X^#_\
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M$3>'5H7T]#JC>VNX4445RE!1110 4444 %%%% !1110 4444 %%%% !1110
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MZK?V,OFVOV:.*U+MG+JQ)+*N,; ,8.<GICGUZ@ HHHH **** "BBB@ HHHH
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MF3_MU_\ :M?IF*G"&0QE4CS+DAI=J_P]5J<44W5T\S<_X6IXJ_Z)AK/YR_\
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M/KN"_P"@9?\ @4_\PY9?S'E7_"U/%7_1,-9_.7_XS1_PM3Q5_P!$PUG\Y?\
MXS7JM%'UW!?] R_\"G_F'++^8\J_X6IXJ_Z)AK/YR_\ QFC_ (6IXJ_Z)AK/
MYR__ !FO5:*/KN"_Z!E_X%/_ ##EE_,>5?\ "U/%7_1,-9_.7_XS7@GB&[EO
M_$NJWD]J]I-/>32R6\F=T3,Y)0Y .03CH.G2OM"OCGQI_P CWXA_["=S_P"C
M6KZCA>O0JUJBI4E#1;-OKYMF-=-)79[C\ ?^1$OO^PG)_P"BHJ]5KRKX _\
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ME9O9-]/(YJ#2;N>G45P__"X? ?\ T'?_ "4G_P#B*/\ A</@/_H._P#DI/\
M_$5\/_9>._Y\S_\  7_D=7/'N=Q17#_\+A\!_P#0=_\ )2?_ .(H_P"%P^ _
M^@[_ .2D_P#\11_9>._Y\S_\!?\ D'/'N=Q17#_\+A\!_P#0=_\ )2?_ .(H
M_P"%P^ _^@[_ .2D_P#\11_9>._Y\S_\!?\ D'/'N=Q17#_\+A\!_P#0=_\
M)2?_ .(H_P"%P^ _^@[_ .2D_P#\11_9>._Y\S_\!?\ D'/'N=Q17#_\+A\!
M_P#0=_\ )2?_ .(K<\/^,?#WBC>-&U2&YDCSNBP4D &,ML8!MOS 9QC)QFHJ
M8#%4H\]2E)+NTTOR!2B]F;E%%%<A04444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !7C/[0?@^XU?0;/7["V\V;3=ZW0CB!<P'G<3G)5"#Q@XWL> #7LU>
M0_'/QMXA\'+H1T'4/L?VHW'G?N8Y-VWR]OWU.,;CT]: /)_@AXGTOPOX]:75
MY_L]O>6K6BSM]R-RZ,"Y_A7Y2,]LC.!DCZVKX$N)WN;F6>01AY7+L(XU102<
M\*H 4>P  [5<TS7M9T7S?[*U:^L/-QYGV6Y>+?C.,[2,XR?S- 'W?17Q!_PG
MGC#_ *&O7/\ P82__%4?\)YXP_Z&O7/_  82_P#Q5 'V_17SK\ O$NO:SXXO
MK?5-:U&^@737=8[JZ>50WF1C(#$C.">?<U]%4 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% 'S_\ M-?\RM_V]_\ M&O0/@E_R2'0
MO^WC_P!*)*\__::_YE;_ +>__:->@?!+_DD.A?\ ;Q_Z424 >@4444 %?/\
M^TU_S*W_ &]_^T:^@*^?_P!IK_F5O^WO_P!HT >4?#O1[S7O'>FZ98:M/I-U
M-YNR]@SOBQ$['&&4\@$=1UKW?_A4'C#_ **SKGY3?_'Z\8^$%_9Z9\4M&O+^
M[@M+6/S]\T\@C1<P2 98\#)('XU]3_\ "=^#_P#H:]#_ /!C#_\ %4 >?_\
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MG7/RF_\ C]>@?\)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5
M'G__  J#QA_T5G7/RF_^/T?\*@\8?]%9US\IO_C]>@?\)WX/_P"AKT/_ ,&,
M/_Q5'_"=^#_^AKT/_P &,/\ \50!\N?%GPWJ7A?Q5:V6J>(;O79WLDE6YN@V
MY%+N-@W.QP"I/7^(\5TG[./_ "4/4/\ L%2?^C8JI_'W5M-UGQU8W&EZA:7T
M"Z9&C26LRRJ&\V4X)4D9P0<>XJY^SC_R4/4/^P5)_P"C8J /I^BBB@ HHHH
M**** "BBB@#-\0_\BUJO_7G-_P"@&O Z]\\0_P#(M:K_ -><W_H!KP.OG\Y^
M./H?+Y__ !(>A[YX>_Y%K2O^O.'_ - %<YJ?_)6M&_Z\V_E+71^'O^1:TK_K
MSA_] %<YJ?\ R5K1O^O-OY2UZ5;^%3]8GK8C^#2_Q0_-':UQ7C7_ )&7PI_U
M^?\ L\5=K7%>-?\ D9?"G_7Y_P"SQ5>-_@OU7YHUS'_=WZQ_]*1VM<5XU_Y&
M7PI_U^?^SQ5VM<5XU_Y&7PI_U^?^SQ48W^"_5?F@S'_=WZQ_]*1VM<5\3_\
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MB.K66G[/)^T_:4#;\[]F,QOTPWIU'6J'QA_Y*IK/_;#_ -$1UW/[.W_,R?\
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MF<]'S+MKT:/*_!_A#6_#/BFRU?6K6*RT^WW^;<2W405-R,HS\W=F _&O5/\
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M]_E_^2*/^$A^.?\ T)FA_P#?Y?\ Y(H ]@HKQ_\ X2'XY_\ 0F:'_P!_E_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBP=%P=SL,88]J]CH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /G_P#::_YE;_M[_P#:->@?!+_DD.A?]O'_ *425Y_^TU_S*W_;
MW_[1KT#X)?\ )(="_P"WC_THDH ] HHHH *^?_VFO^96_P"WO_VC7T!7S_\
MM-?\RM_V]_\ M&@#S#X6Z)IWB/XCZ3I.K6_VBQG\[S(M[)NVPNPY4@CD \&O
MH_\ X4E\//\ H7O_ "=N/_CE?-'P[\26?A'QWINN7\<\EK:^;O2!07.Z)T&
M2!U8=Z]W_P"&CO!__0-US_OQ#_\ ': .@_X4E\//^A>_\G;C_P".4?\ "DOA
MY_T+W_D[<?\ QRN?_P"&CO!__0-US_OQ#_\ ':/^&CO!_P#T#=<_[\0__':
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M ,=H Z#_ (4E\//^A>_\G;C_ ..4?\*2^'G_ $+W_D[<?_'*Y_\ X:.\'_\
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M_P#;3_T8U:/B'_D6M5_Z\YO_ $ UG> O^1+T_P#[:?\ HQJT?$/_ "+6J_\
M7G-_Z :SI?[K'_"OR,Z/^Y1_PK\C.\!?\B7I_P#VT_\ 1C5T=<YX"_Y$O3_^
MVG_HQJZ.M,+_  (>B_(TP?\ NU/_  K\CBOAA_R+5S_U^-_Z E=K7%?##_D6
MKG_K\;_T!*[6L\#_ +O#T,\M_P!TAZ'%>"O^1E\5_P#7Y_[/+6EX]_Y$O4/^
MV?\ Z,6LWP5_R,OBO_K\_P#9Y:TO'O\ R)>H?]L__1BUA#_<I>DOS9S4_P#D
M73])_FSQ2OHZOG&OHZN7)?M_+]3AX?\ ^7GR_4****]P^D"BBB@ HHHH ***
M* /E7XP_\E4UG_MA_P"B(ZO_  J\ :5XY_M;^T[B]A^Q^3Y?V9U7._?G.Y3_
M '1^M4/C#_R536?^V'_HB.MWX,^,-!\)_P!M_P!MW_V7[3Y'D_N7?=M\S=]U
M3C[PZ^M?I]66(CDD'AK\_)"UM7]F_P"!Q*WM?>VU.X_X4#X5_P"@AK/_ '^B
M_P#C='_"@?"O_00UG_O]%_\ &ZW?^%P^ _\ H._^2D__ ,11_P +A\!_]!W_
M ,E)_P#XBOD_K&?]JG_@+_R-[4O(PO\ A0/A7_H(:S_W^B_^-T?\*!\*_P#0
M0UG_ +_1?_&ZW?\ A</@/_H._P#DI/\ _$4?\+A\!_\ 0=_\E)__ (BCZQG_
M &J?^ O_ ""U+R,+_A0/A7_H(:S_ -_HO_C='_"@?"O_ $$-9_[_ $7_ ,;K
M=_X7#X#_ .@[_P"2D_\ \11_PN'P'_T'?_)2?_XBCZQG_:I_X"_\@M2\C"_X
M4#X5_P"@AK/_ '^B_P#C='_"@?"O_00UG_O]%_\ &ZW?^%P^ _\ H._^2D__
M ,11_P +A\!_]!W_ ,E)_P#XBCZQG_:I_P" O_(+4O(PO^% ^%?^@AK/_?Z+
M_P"-T?\ "@?"O_00UG_O]%_\;K=_X7#X#_Z#O_DI/_\ $4?\+A\!_P#0=_\
M)2?_ .(H^L9_VJ?^ O\ R"U+R,+_ (4#X5_Z"&L_]_HO_C='_"@?"O\ T$-9
M_P"_T7_QNMW_ (7#X#_Z#O\ Y*3_ /Q%'_"X? ?_ $'?_)2?_P"(H^L9_P!J
MG_@+_P @M2\C"_X4#X5_Z"&L_P#?Z+_XW1_PH'PK_P!!#6?^_P!%_P#&ZW?^
M%P^ _P#H._\ DI/_ /$4?\+A\!_]!W_R4G_^(H^L9_VJ?^ O_(+4O(PO^% ^
M%?\ H(:S_P!_HO\ XW1_PH'PK_T$-9_[_1?_ !NMW_A</@/_ *#O_DI/_P#$
M4?\ "X? ?_0=_P#)2?\ ^(H^L9_VJ?\ @+_R"U+R,+_A0/A7_H(:S_W^B_\
MC='_  H'PK_T$-9_[_1?_&ZW?^%P^ _^@[_Y*3__ !%'_"X? ?\ T'?_ "4G
M_P#B*/K&?]JG_@+_ ,@M2\C"_P"% ^%?^@AK/_?Z+_XW7@GB'3XM)\2ZKIL#
M.T-I>301M(06*HY4$X &<#TKZ8_X7#X#_P"@[_Y*3_\ Q%?-7B>\@U'Q9K-]
M:R>9;7-]/-$^"-R-(Q!P>1P1UKZ+AVKF,ZL_KG-:VG,FOT,JR@DN4]X^ /\
MR(E]_P!A.3_T5%7JM>5? '_D1+[_ +"<G_HJ*O5:^/SS_D8U?4Z*7P(****\
MHL**** "BBB@ KR;XV?\P/\ [>/_ &G7K->3?&S_ )@?_;Q_[3KEQG\"7R_,
M]SAO_D:4O^WO_26>=^&=$_X2/Q#:Z5]H^S^?O_>[-^W:A;ID9Z8ZUZ)_PA/_
M  KK_BJ_[0_M#[!_RZ^3Y6_?^[^_N;&-^>AZ8KDOAG_R4+2_^VO_ **>O6?B
M9_R3W5/^V7_HU*XL-2BZ,JEM5>WR1]/G6.KQS&E@U+]W445)66JE)IZ[JZ[,
MY/\ X79_U+W_ ).__:Z/^2Q?]0C^RO\ MX\WS?\ OC;CR_?.>V*\EKUKX)_\
MQS_MW_\ :E*C6G6FJ=1W3-,RRW"Y9A98S!QY:D;6=V[7:3T;:V;Z!_PI/_J8
M?_)+_P"V4?\ "T?^$9_XD/\ 8_VG^S/]#\_[5L\SR_DW;=AQG;G&3C/4UZS7
MS%XI_P"1OUK_ *_Y_P#T8U;8B*PR3I:7_KJ>;DU66=5)4\P?.HJZZ6?_ &[8
M]$_X3;_A8O\ Q2G]G_V?]O\ ^7KSO-V;/WGW-JYSLQU'7-'_  I/_J8?_)+_
M .V5R7PS_P"2A:7_ -M?_13U]#4\/".(CSU=7M_5C/.,35R:NL/@'R0:YFM]
M6VKWE=[)'DW_ "1W_J+_ -J_]N_E>5_WWNSYGMC'?-'_  NS_J7O_)W_ .UT
M?&S_ )@?_;Q_[3KR6L*U:=&;ITW9(];+<MPN9X6.,QD>:I*]W=J]FTM$TMDN
MAZU_PJ[_ (2;_B??VQ]F_M/_ $SR/LN_R_,^?;NWC.-V,X&<=!1_PJ[_ (1G
M_B??VQ]I_LS_ $SR/LNSS/+^?;NWG&=N,X.,]#7H?A;_ )%#1?\ KP@_]%K1
MXI_Y%#6O^O"?_P!%M79]6I<O/;7<^;_MO'^W^K^T]R_+:RVO:U[7V///^%V?
M]2]_Y.__ &NC_DL7_4(_LK_MX\WS?^^-N/+]\Y[8KR6O6O@G_P QS_MW_P#:
ME<=&M.M-4ZCNF?29EEN%RS"RQF#CRU(VL[MVNTGHVULWT#_A2?\ U,/_ ))?
M_;*/^%H_\(S_ ,2'^Q_M/]F?Z'Y_VK9YGE_)NV[#C.W.,G&>IKUFOF+Q3_R-
M^M?]?\__ *,:ML1%89)TM+_UU/-R:K+.JDJ>8/G45==+/_MVQZ)_PM'_ (2;
M_B0_V/\ 9O[3_P!#\_[5O\OS/DW;=@SC=G&1G'44?\*3_P"IA_\ )+_[97G?
MA;_D;]%_Z_X/_1BU].T8>*Q*;JZV_KH&<U99+.-/+WR*2N^MW_V]<\F_Y([_
M -1?^U?^W?RO*_[[W9\SVQCOFC_A=G_4O?\ D[_]KH^-G_,#_P"WC_VG7DM8
MUJTZ,W3INR1Z66Y;A<SPL<9C(\U25[N[5[-I:)I;)=#HO&5C]GU>*_\ ,W?V
MO -3V;<>5YK,=F?XL>O&?05T/P;_ .1ON_\ KP?_ -&1UD^._P#F6O\ L VO
M_LU:WP;_ .1ON_\ KP?_ -&1U%-6Q*]3HQDG+)9M_P K_!V/<****]L_, HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#YA_:/_ .2@:=_V"X__ $;+1^SA_P E U'_ +!<G_HV
M*C]H_P#Y*!IW_8+C_P#1LM'[.'_)0-1_[!<G_HV*@#V#XU_\DBUWZ0?^CXZ^
M/T^^OUK[ ^-?_)(M=^D'_H^.OC]/OK]: /OZOF']H_\ Y*!IW_8+C_\ 1LM?
M3U?,/[1__)0-._[!<?\ Z-EH /V</^2@:C_V"Y/_ $;%7T]7S#^SA_R4#4?^
MP7)_Z-BKZ>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#_[\K_\ (]'_  CWQS_Z'/0_^_*__(] 'L%%>/\ _"/?'/\ Z'/0_P#ORO\
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MS?$'_+OY_H>U^ O^1+T__MI_Z,:LWXG_ /(M6W_7XO\ Z ]:7@+_ )$O3_\
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M ->;?^AI7C?\S'YG@?\ ,U_[>/6:***^D/K HHHH **** "BBB@ KXY\:?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M )'H_P"$>^.?_0YZ'_WY7_Y'H ]@HKQ__A'OCG_T.>A_]^5_^1Z/^$>^.?\
MT.>A_P#?E?\ Y'H ]@HKQ_\ X1[XY_\ 0YZ'_P!^5_\ D>C_ (1[XY_]#GH?
M_?E?_D>@#@/VCO\ DH>G_P#8*C_]&RT?LX_\E#U#_L%2?^C8JYOXLV7BNQ\5
M6L7C#4[34-0-DC1RVJA5$6]\*<(G.X,>G<<^G2?LX_\ )0]0_P"P5)_Z-BH
M^GZ*** "BBB@ HHHH **** ,WQ#_ ,BUJO\ UYS?^@&O Z]\\0_\BUJO_7G-
M_P"@&O Z^?SGXX^A\OG_ /$AZ'OGA[_D6M*_Z\X?_0!7.:G_ ,E:T;_KS;^4
MM='X>_Y%K2O^O.'_ - %<YJ?_)6M&_Z\V_E+7I5OX5/UB>MB/X-+_%#\T=K7
M%>-?^1E\*?\ 7Y_[/%7:UQ7C7_D9?"G_ %^?^SQ5>-_@OU7YHUS'_=WZQ_\
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MER7[?R_4X>'_ /EY\OU"BBBO</I HHHH **** "BBB@#Y5^,/_)5-9_[8?\
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M\7_] C_R9B_^+HQ7/=>QO\O^ &0?5?9S_M'EO?3GM>WES'<?#O4I_&O]I?\
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M?_BJY_\ X4E\//\ H7O_ "=N/_CE'_"DOAY_T+W_ ).W'_QR@#H/^$[\'_\
M0UZ'_P"#&'_XJC_A._!__0UZ'_X,8?\ XJN?_P"%)?#S_H7O_)VX_P#CE'_"
MDOAY_P!"]_Y.W'_QR@#H/^$[\'_]#7H?_@QA_P#BJ/\ A._!_P#T->A_^#&'
M_P"*KG_^%)?#S_H7O_)VX_\ CE'_  I+X>?]"]_Y.W'_ ,<H Z#_ (3OP?\
M]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJN?\ ^%)?#S_H7O\ R=N/_CE'
M_"DOAY_T+W_D[<?_ !R@#H/^$[\'_P#0UZ'_ .#&'_XJC_A._!__ $->A_\
M@QA_^*KG_P#A27P\_P"A>_\ )VX_^.4?\*2^'G_0O?\ D[<?_'* .@_X3OP?
M_P!#7H?_ (,8?_BJ/^$[\'_]#7H?_@QA_P#BJY__ (4E\//^A>_\G;C_ ..4
M?\*2^'G_ $+W_D[<?_'* .@_X3OP?_T->A_^#&'_ .*H_P"$[\'_ /0UZ'_X
M,8?_ (JN?_X4E\//^A>_\G;C_P".4?\ "DOAY_T+W_D[<?\ QR@#H/\ A._!
M_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJY_P#X4E\//^A>_P#)VX_^
M.4?\*2^'G_0O?^3MQ_\ '* /GCXOW]GJ?Q2UF\L+N"[M9/(V302"1&Q!&#AA
MP<$$?A7H_P"S+_S-/_;I_P"UJ\P^*6B:=X<^(^K:3I-O]GL8/)\N+>S[=T*,
M>6))Y)/)KT_]F7_F:?\ MT_]K4 ?0%%%% !1110 4444 %%%% !7SC7T=7SC
M7AYU]CY_H?-\0?\ +OY_H>U^ O\ D2]/_P"VG_HQJS?B?_R+5M_U^+_Z ]:7
M@+_D2]/_ .VG_HQJS?B?_P BU;?]?B_^@/754_W#_MU?DCNJ_P#(L_[=7Y([
M6N<\>_\ (EZA_P!L_P#T8M='7.>/?^1+U#_MG_Z,6NO%?P)^C_([<9_NU3_"
M_P C1\/?\BUI7_7G#_Z */$/_(M:K_UYS?\ H!H\/?\ (M:5_P!></\ Z */
M$/\ R+6J_P#7G-_Z :/^7'R_0/\ F&_[=_0SO 7_ ")>G_\ ;3_T8U='7.>
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MO^B8:S^<O_QFC_A:GBK_ *)AK/YR_P#QFO/_ +.S3O\ ^5(__)%<\/Z1W/\
MPA?A7_H6=&_\ (O_ (FC_A"_"O\ T+.C?^ $7_Q-<-_PM3Q5_P!$PUG\Y?\
MXS1_PM3Q5_T3#6?SE_\ C-']G9IW_P#*D?\ Y(.>']([G_A"_"O_ $+.C?\
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MROQWT72M'_L#^S-,LK+S?M'F?9H%CWX\K&=H&<9/YFN4^#W_ "531O\ MO\
M^B)*O_%7Q5JOB;^R?[3\+WNA_9_.\O[26_?;MF<;D7IM'K]X50^#W_)5-&_[
M;_\ HB2OLL/3JT\BG"M\2A.^M_YNJ;.=M.KIY'U51117YB=H4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7FOQ>^)&H_#ZUTD:996L\]\\NY[G<514"
M\!5())+CG/&#P<\>E5Y#\<_!/B'QBNA#0=/^V?93<>=^^CCV[O+V_?89SM/3
MTH \_P#^&C_%W_0,T3_OS+_\<H_X:/\ %W_0,T3_ +\R_P#QRN>_X4E\0_\
MH7O_ "=M_P#XY1_PI+XA_P#0O?\ D[;_ /QR@#H?^&C_ !=_T#-$_P"_,O\
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M\/\ \:H ]@HKQ_\ X9Q\'_\ 02US_O\ P_\ QJC_ (9Q\'_]!+7/^_\ #_\
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M E=K6>!_W>'H9Y;_ +I#T.*\%?\ (R^*_P#K\_\ 9Y:TO'O_ ")>H?\ ;/\
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M_P"BGZS^4O\ \>H^I8+_ *"5_P" S_R#FE_*>JT5Y5_PJOQ5_P!%/UG\I?\
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MMNP9QNSC(SCJ*[/K-+EY+Z['S?\ 8F/]O]8]G[E^:]UM>][7OL>2UZU\$_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP?\ ]"IH?_@NA_\ B: .?_X7;\//^AA_\DKC_P"-T?\ "[?AY_T,/_DE<?\
MQNN@_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\ T*FA_P#@NA_^)H Y_P#X7;\/
M/^AA_P#)*X_^-T?\+M^'G_0P_P#DE<?_ !NN@_X03P?_ -"IH?\ X+H?_B:/
M^$$\'_\ 0J:'_P""Z'_XF@#G_P#A=OP\_P"AA_\ )*X_^-T?\+M^'G_0P_\
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M (7;\//^AA_\DKC_ .-T?\+M^'G_ $,/_DE<?_&ZZ#_A!/!__0J:'_X+H?\
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M#C_F'M/)_<>JT5Y5_;WQF_Z%+1O^_J__ !^C^WOC-_T*6C?]_5_^/T?V3/\
MY^T__ X_YA[3R?W'JM%>5?V]\9O^A2T;_OZO_P ?H_M[XS?]"EHW_?U?_C]'
M]DS_ .?M/_P./^8>T\G]QZK17E7]O?&;_H4M&_[^K_\ 'Z/[>^,W_0I:-_W]
M7_X_1_9,_P#G[3_\#C_F'M/)_<8?[1/_ #+?_;U_[2KAO@]_R531O^V__HB2
MK_Q5O_&=[_9/_"7:39:?L\[[-]F<-OSLWYQ(_3"^G4]:H?![_DJFC?\ ;?\
M]$25]OA:+HY#*FVG:$]4[K[75'-)WJW]#ZJHHHK\S.T**** "BBB@ HHHH *
M*** "BBB@ HHHH YWQQK-YH/A*\O[%,W"[45R 1%N8#<03SC/'7DC(QFO!/^
M$I\0_P#0>U3_ ,#)/\:^E;^PM=3L9K*]@6>VF7:\;="/Z'N".0>:XFZ^$/AJ
MXN'ECDO[9&QB**92J\=MRD^_)[UPXJA5J23@]#ZG(<TP&$I2IXF'O-WO:^FF
MGY^1Y!_PE/B'_H/:I_X&2?XT?\)3XA_Z#VJ?^!DG^->M?\*;\/?\_FJ?]_8_
M_B*/^%-^'O\ G\U3_O['_P#$5R_5,1W_ !/>_P!8,G_E_P#)3R7_ (2GQ#_T
M'M4_\#)/\:/^$I\0_P#0>U3_ ,#)/\:]:_X4WX>_Y_-4_P"_L?\ \11_PIOP
M]_S^:I_W]C_^(H^J8CO^(?ZP9/\ R_\ DIY+_P )3XA_Z#VJ?^!DG^-'_"4^
M(?\ H/:I_P"!DG^-9->J>#_AIHWB#PM9:I=W-^D\^_<L4B!1M=E&,J3T [UA
M2C4JOEBSUL?6P6!IJK6@K-VT2WU?Z' _\)3XA_Z#VJ?^!DG^-'_"4^(?^@]J
MG_@9)_C7K7_"F_#W_/YJG_?V/_XBC_A3?A[_ )_-4_[^Q_\ Q%;_ %3$=_Q/
M)_U@R?\ E_\ )3R7_A*?$/\ T'M4_P# R3_&C_A*?$/_ $'M4_\  R3_ !KU
MK_A3?A[_ )_-4_[^Q_\ Q%'_  IOP]_S^:I_W]C_ /B*/JF([_B'^L&3_P O
M_DHSX5^*-6UV&^M-2D:Y6U6,QW#!=P!R-K'.6)VY!P3][)Z5Z-67HOAW2?#T
M,L6E6:VZRL&D(9F9B.F2Q)P/3IR?4UJ5Z=&$H049N[/ALRKT<1BI5:$>6+V6
MW3RTW"BBBM3A"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH]Y)$0ZM+ 6)BG S\LBYPPP3[C.00>: /N*BN<\#^,K'QUX:BUBQC>([C%/
M_)BE !*YZ,,$$$=01T.0.CH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /G_ /::_P"96_[>_P#VC7H'P2_Y)#H7_;Q_Z425Y_\
MM-?\RM_V]_\ M&O0/@E_R2'0O^WC_P!*)* /0**** "OG_\ ::_YE;_M[_\
M:-?0%?/_ .TU_P RM_V]_P#M&@#S#X6ZWIWASXCZ3JVK7'V>Q@\[S)=C/MW0
MNHX4$GD@<"OH_P#X7;\//^AA_P#)*X_^-U\\?""PL]3^*6C6=_:07=K)Y^^&
M>,2(V()",J>#@@'\*^I_^$$\'_\ 0J:'_P""Z'_XF@#G_P#A=OP\_P"AA_\
M)*X_^-T?\+M^'G_0P_\ DE<?_&ZZ#_A!/!__ $*FA_\ @NA_^)H_X03P?_T*
MFA_^"Z'_ .)H Y__ (7;\//^AA_\DKC_ .-T?\+M^'G_ $,/_DE<?_&ZZ#_A
M!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\ B: .?_X7;\//^AA_\DKC
M_P"-T?\ "[?AY_T,/_DE<?\ QNN@_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\
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M.N<\>_\ (EZA_P!L_P#T8M:8K^!/T?Y&F,_W:I_A?Y&CX>_Y%K2O^O.'_P!
M%'B'_D6M5_Z\YO\ T T>'O\ D6M*_P"O.'_T 4>(?^1:U7_KSF_] -'_ "X^
M7Z!_S#?]N_H9W@+_ )$O3_\ MI_Z,:M'Q#_R+6J_]><W_H!K.\!?\B7I_P#V
MT_\ 1C5H^(?^1:U7_KSF_P#0#6=+_=8_X5^1G1_W*/\ A7Y&=X"_Y$O3_P#M
MI_Z,:NCKG/ 7_(EZ?_VT_P#1C5T=:87^!#T7Y&F#_P!VI_X5^1Q7PP_Y%JY_
MZ_&_] 2NUKBOAA_R+5S_ -?C?^@)7:UG@?\ =X>AGEO^Z0]#BO!7_(R^*_\
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M_BZ/^%/> _\ H!?^3<__ ,77Q'+E7\U3[H__ "1T^_Y&Y_PFGA7_ *&;1O\
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MGA7_ *&;1O\ P/B_^*H_X33PK_T,VC?^!\7_ ,56'_PI[P'_ - +_P FY_\
MXNC_ (4]X#_Z 7_DW/\ _%T<N5?S5/NC_P#)![_D;G_":>%?^AFT;_P/B_\
MBJ/^$T\*_P#0S:-_X'Q?_%5A_P#"GO ?_0"_\FY__BZ/^%/> _\ H!?^3<__
M ,71RY5_-4^Z/_R0>_Y&Y_PFGA7_ *&;1O\ P/B_^*KY2\73Q7/C379X)4EA
MEU"X>.2-@RNID8@@C@@CO7TC_P *>\!_] +_ ,FY_P#XNOFKQ/9P:=XLUFQM
M8_+MK:^GAB3).U%D8 9/)X ZU]1PNL&JU3ZNY-V5^9)=?)LQK\UE<]X^ /\
MR(E]_P!A.3_T5%7JM>5? '_D1+[_ +"<G_HJ*O5:^7SS_D8U?4WI? @HHHKR
MBPHHHH **** "O)OC9_S _\ MX_]IUZS7DWQL_Y@?_;Q_P"TZY<9_ E\OS/<
MX;_Y&E+_ +>_])9Y+76_#/\ Y*%I?_;7_P!%/4/P\M;>]\=:;;W=O%/ _F[H
MY4#JV(G(R#QU ->M>,+.R\,^%KW5]%TZPLM0M]GE7$5I&&3<ZJ<?+W5B/QKS
ML/1;7MKZ1?Y:GV><9G&$_P"SU&\JL;)]%S7BKG95Y-\;/^8'_P!O'_M.N2_X
M69XO_P"@O_Y+1?\ Q%=Q\.]2G\:_VE_PDL=KJ?V3RO(\^UB/E[]^[&%[[5_*
MNN6(AB5[*-TW_P .>!0RC$Y-46/K.,HPW2;OK[O5+N>-5].^%O\ D4-%_P"O
M"#_T6M'_  BWA[_H Z7_ . <?^%>.ZUX^\2Z7KNH:?8Z@L%G:W,D$$*6T6V.
M-6*JH^7H  *F$5@_>F[W[&V)KRXB2I8=<KAJ^9]].B9Z7\3/^2>ZI_VR_P#1
MJ5\\UZ3X/\7ZWXF\4V6D:U=17NGW&_S;>6UB*OM1F&?E[,H/X5ZI_P (MX>_
MZ .E_P#@''_A2G3^MOVD':VFI6&QKX>A]4Q$>9R]Z\7I9Z=4NQYY\$_^8Y_V
M[_\ M2O6:\Q^(FI3^"O[-_X1J.UTS[7YOG^1:Q#S-FS;G*]MS?G7#_\ "S/%
M_P#T%_\ R6B_^(JXXB&&7LI7;7_#G/7RC$YS4>/HN,8SV3;OI[O1/L9'BG_D
M;]:_Z_Y__1C4>%O^1OT7_K_@_P#1BU[SHNB:1JFA:?J%]I&G3WEU;1SSS/:1
M[I)&4,S'Y>I))HUK1-(TO0M0U"QTC3H+RUMI)X)DM(]T<BJ65A\O4$ UE]2=
M_:7\SM_UEI\GU3V;O\-[Z7V.DKR;XV?\P/\ [>/_ &G7)?\ "S/%_P#T%_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+C_]&RT 7/V;-2FB\4:SI85#!<62W#,0=P:-PH YQC$K9X[#\?I*OD'X(_\
M)7=$^D__ *(DKZ^H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /G_P#::_YE;_M[_P#:->@?!+_DD.A?]O'_ *425Y_^TU_S*W_;
MW_[1KT#X)?\ )(="_P"WC_THDH ] HHHH *^?_VFO^96_P"WO_VC7T!7S_\
MM-?\RM_V]_\ M&@#RCX=ZQ>:#X[TW4[#29]6NH?-V64&=\N8G4XPK'@$GH>E
M>[_\+?\ &'_1)M<_.;_XQ7D'P2_Y*]H7_;Q_Z3R5]?T >/\ _"W_ !A_T2;7
M/SF_^,4?\+?\8?\ 1)M<_.;_ .,5[!10!X__ ,+?\8?]$FUS\YO_ (Q1_P +
M?\8?]$FUS\YO_C%>P44 >/\ _"W_ !A_T2;7/SF_^,4?\+?\8?\ 1)M<_.;_
M .,5[!10!X__ ,+?\8?]$FUS\YO_ (Q1_P +?\8?]$FUS\YO_C%>P44 >/\
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MP%_R)>G_ /;3_P!&-71USG@+_D2]/_[:?^C&KHZTPO\  AZ+\C3!_P"[4_\
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MO^@=_P#@?_VH<L^_X'E7_"_O"O\ T#]9_P"_,7_QRC_A?WA7_H'ZS_WYB_\
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M+_\ H$?^3,7_ ,776_!/_F.?]N__ +4KUFKCAX8E>UE=-_\ #'/7S?$Y-4>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M )'KV"B@#Q__ (1[XY_]#GH?_?E?_D>C_A'OCG_T.>A_]^5_^1Z]@HH \?\
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M]K5P'QM_Y*]KO_;O_P"D\==_^S+_ ,S3_P!NG_M:@#Z HHHH **** "BBB@
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MW\I:[6N*U/\ Y*UHW_7FW\I:[6C"[U/\3_)!@_BJ_P")_DCBOB?_ ,BU;?\
M7XO_ * ]=K7%?$__ )%JV_Z_%_\ 0'KM:*7^\5/2/ZA1_P![J^D?U.<\>_\
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M%_\ %4?\)IX5_P"AFT;_ ,#XO_BJP_\ A3W@/_H!?^3<_P#\71_PI[P'_P!
M+_R;G_\ BZ.7*OYJGW1_^2#W_(W/^$T\*_\ 0S:-_P"!\7_Q5'_":>%?^AFT
M;_P/B_\ BJP_^%/> _\ H!?^3<__ ,71_P *>\!_] +_ ,FY_P#XNCERK^:I
M]T?_ )(/?\C<_P"$T\*_]#-HW_@?%_\ %4?\)IX5_P"AFT;_ ,#XO_BJP_\
MA3W@/_H!?^3<_P#\71_PI[P'_P! +_R;G_\ BZ.7*OYJGW1_^2#W_(W/^$T\
M*_\ 0S:-_P"!\7_Q5'_":>%?^AFT;_P/B_\ BJP_^%/> _\ H!?^3<__ ,71
M_P *>\!_] +_ ,FY_P#XNCERK^:I]T?_ )(/?\C<_P"$T\*_]#-HW_@?%_\
M%4?\)IX5_P"AFT;_ ,#XO_BJP_\ A3W@/_H!?^3<_P#\71_PI[P'_P! +_R;
MG_\ BZ.7*OYJGW1_^2#W_(W/^$T\*_\ 0S:-_P"!\7_Q5'_":>%?^AFT;_P/
MB_\ BJP_^%/> _\ H!?^3<__ ,71_P *>\!_] +_ ,FY_P#XNCERK^:I]T?_
M )(/?\C<_P"$T\*_]#-HW_@?%_\ %4?\)IX5_P"AFT;_ ,#XO_BJP_\ A3W@
M/_H!?^3<_P#\71_PI[P'_P! +_R;G_\ BZ.7*OYJGW1_^2#W_(\X^.^M:5K'
M]@?V9J=E>^5]H\S[-.LFS/E8SM)QG!_(URGP>_Y*IHW_ &W_ /1$E;OQF\'Z
M#X3_ +$_L2P^R_:?/\[]\[[MOE[?O,<?>/3UK"^#W_)5-&_[;_\ HB2OM\+[
M)9#+V+?+R3M>U_M=KG-*_M=?(^JJ***_,SM"BBB@ HHHH **** "OGGXF?\
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MM2INGS6?=6T/IVBBBOH#\@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@LM7;S?L\\X!1,1.6R"K=5W#H>OXU[O_ ,(]\<_^AST/_ORO_P CUY!\$O\
MDKVA?]O'_I/)7U_0!X__ ,(]\<_^AST/_ORO_P CT?\ "/?'/_H<]#_[\K_\
MCU[!10!X_P#\(]\<_P#H<]#_ ._*_P#R/1_PCWQS_P"AST/_ +\K_P#(]>P4
M4 >/_P#"/?'/_H<]#_[\K_\ (]'_  CWQS_Z'/0_^_*__(]>P44 >/\ _"/?
M'/\ Z'/0_P#ORO\ \CT?\(]\<_\ H<]#_P"_*_\ R/7L%% 'C_\ PCWQS_Z'
M/0_^_*__ "/1_P (]\<_^AST/_ORO_R/7L%% 'C_ /PCWQS_ .AST/\ [\K_
M /(]'_"/?'/_ *'/0_\ ORO_ ,CU[!10!X__ ,(]\<_^AST/_ORO_P CT?\
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MBO&O_(R^%/\ K\_]GBKM:XKQK_R,OA3_ *_/_9XJO&_P7ZK\T:YC_N[]8_\
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MRY+]OY?J</#_ /R\^7ZA1117N'T@4444 %%%% !1110!\J_&'_DJFL_]L/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+7/^_P##_P#&J/\ AG'P?_T$M<_[_P /_P :KT#_ (3OP?\ ]#7H?_@QA_\
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M,6NCKG/'O_(EZA_VS_\ 1BUUXK^!/T?Y';C/]VJ?X7^1H^'O^1:TK_KSA_\
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M - >NUHI?[Q4](_J%'_>ZOI']3G/'O\ R)>H?]L__1BUH^'O^1:TK_KSA_\
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MY^9C6=*D\*^>H]'IH=N/QT<^IK"X.+YD^;WK)65UW?='I/BG_D4-:_Z\)_\
MT6U?,5>F:?\ $[5]?U*UT:^L=.-GJ$R6LX1)%8QR$*V#OX.">:[K_A6?A#_H
M$?\ DS+_ /%T58?6VI4WMW)P&(_U?BZ6,B[SU7+9[:=T>>?!O_D;[O\ Z\'_
M /1D=>X5YSXEM=.^&NFQZSX=TR!+R:86KF>261?+(+'@OURB\URO_"Y/$/\
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M'G_0P_\ DE<?_&Z .?\ ^&<?!_\ T$M<_P"_\/\ \:H_X9Q\'_\ 02US_O\
MP_\ QJN@_P"%V_#S_H8?_)*X_P#C='_"[?AY_P!##_Y)7'_QN@#G_P#AG'P?
M_P!!+7/^_P##_P#&J/\ AG'P?_T$M<_[_P /_P :KH/^%V_#S_H8?_)*X_\
MC='_  NWX>?]##_Y)7'_ ,;H Y__ (9Q\'_]!+7/^_\ #_\ &J/^&<?!_P#T
M$M<_[_P__&JZ#_A=OP\_Z&'_ ,DKC_XW1_PNWX>?]##_ .25Q_\ &Z .?_X9
MQ\'_ /02US_O_#_\:H_X9Q\'_P#02US_ +_P_P#QJN@_X7;\//\ H8?_ "2N
M/_C='_"[?AY_T,/_ ))7'_QN@#G_ /AG'P?_ -!+7/\ O_#_ /&J/^&<?!__
M $$M<_[_ ,/_ ,:KH/\ A=OP\_Z&'_R2N/\ XW1_PNWX>?\ 0P_^25Q_\;H
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M8M%T32-4T+3]0OM(TZ>\NK:.>>9[2/=)(RAF8_+U))->._\ "L_%_P#T"/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5Y_\;?\ DD.N_P#;O_Z41UZ!7G_QM_Y)#KO_ &[_ /I1
M'0!Y_P#LR_\ ,T_]NG_M:OH"OG_]F7_F:?\ MT_]K5] 4 %%%% '/^._^2>>
M)?\ L%77_HIJ^(*^W_'?_)//$O\ V"KK_P!%-7Q!0!]3^$_A!X$U/P;H=_>:
M%YEU=:?;S3/]KG&YVC4L<!\#))Z5L?\ "DOAY_T+W_D[<?\ QRN+\-?'WPKH
MWA72-+N-/UEI[*RAMY&CAB*ED0*2,R XR/05J?\ #1W@_P#Z!NN?]^(?_CM
M'0?\*2^'G_0O?^3MQ_\ '*/^%)?#S_H7O_)VX_\ CE<__P -'>#_ /H&ZY_W
MXA_^.T?\-'>#_P#H&ZY_WXA_^.T =!_PI+X>?]"]_P"3MQ_\<H_X4E\//^A>
M_P#)VX_^.5S_ /PT=X/_ .@;KG_?B'_X[1_PT=X/_P"@;KG_ 'XA_P#CM '0
M?\*2^'G_ $+W_D[<?_'*/^%)?#S_ *%[_P G;C_XY7/_ /#1W@__ *!NN?\
M?B'_ ..T?\-'>#_^@;KG_?B'_P".T =!_P *2^'G_0O?^3MQ_P#'*/\ A27P
M\_Z%[_R=N/\ XY7/_P##1W@__H&ZY_WXA_\ CM'_  T=X/\ ^@;KG_?B'_X[
M0!T'_"DOAY_T+W_D[<?_ !RC_A27P\_Z%[_R=N/_ (Y7/_\ #1W@_P#Z!NN?
M]^(?_CM'_#1W@_\ Z!NN?]^(?_CM '0?\*2^'G_0O?\ D[<?_'*/^%)?#S_H
M7O\ R=N/_CE<_P#\-'>#_P#H&ZY_WXA_^.T?\-'>#_\ H&ZY_P!^(?\ X[0!
MT'_"DOAY_P!"]_Y.W'_QRC_A27P\_P"A>_\ )VX_^.5S_P#PT=X/_P"@;KG_
M 'XA_P#CM'_#1W@__H&ZY_WXA_\ CM '0?\ "DOAY_T+W_D[<?\ QRC_ (4E
M\//^A>_\G;C_ ..5S_\ PT=X/_Z!NN?]^(?_ ([1_P -'>#_ /H&ZY_WXA_^
M.T =!_PI+X>?]"]_Y.W'_P <H_X4E\//^A>_\G;C_P".5S__  T=X/\ ^@;K
MG_?B'_X[1_PT=X/_ .@;KG_?B'_X[0!XA\4M$T[PY\1]6TG2;?[/8P>3Y<6]
MGV[H48\L23R2>37I_P"S+_S-/_;I_P"UJ\H^(GB2S\7>.]2URPCGCM;KRMB3
MJ XVQ(AR 2.JGO7J_P"S+_S-/_;I_P"UJ /H"BBB@ HHHH **** "BBB@ KY
MQKZ.KYQKP\Z^Q\_T/F^(/^7?S_0]K\!?\B7I_P#VT_\ 1C5F_$__ )%JV_Z_
M%_\ 0'K2\!?\B7I__;3_ -&-6;\3_P#D6K;_ *_%_P#0'KJJ?[A_VZOR1W5?
M^19_VZOR1VM<YX]_Y$O4/^V?_HQ:Z.N<\>_\B7J'_;/_ -&+77BOX$_1_D=N
M,_W:I_A?Y&CX>_Y%K2O^O.'_ - %'B'_ )%K5?\ KSF_] -'A[_D6M*_Z\X?
M_0!1XA_Y%K5?^O.;_P! -'_+CY?H'_,-_P!N_H9W@+_D2]/_ .VG_HQJZ.N<
M\!?\B7I__;3_ -&-71T87^!#T7Y!@_\ =J?^%?D<5\,/^1:N?^OQO_0$KM:X
MKX8?\BU<_P#7XW_H"5VM9X'_ '>'H9Y;_ND/0XKP5_R,OBO_ *_/_9Y:[6N*
M\%?\C+XK_P"OS_V>6NUHP7\%>K_-AEW^[KUE_P"E,XK3/^2M:S_UYK_**NUK
MBM,_Y*UK/_7FO\HJ[6C";3_Q2_,,#\,_\4OS.*U/_DK6C?\ 7FW\I:[6N*U/
M_DK6C?\ 7FW\I:[6C"[U/\3_ "08/XJO^)_DCBOB?_R+5M_U^+_Z ]=K7%?$
M_P#Y%JV_Z_%_] >NUHI?[Q4](_J%'_>ZOI']3G/'O_(EZA_VS_\ 1BUH^'O^
M1:TK_KSA_P#0!6=X]_Y$O4/^V?\ Z,6M'P]_R+6E?]></_H H7^]/_"OS8+_
M 'U_X5^;/./B?_R,MM_UYK_Z&]'PP_Y&6Y_Z\V_]#2CXG_\ (RVW_7FO_H;T
M?##_ )&6Y_Z\V_\ 0TKQO^9C\SP/^9K_ -O'K-%%%?2'U@4444 %%%% !111
M0 5\<^-/^1[\0_\ 83N?_1K5]C5\<^-/^1[\0_\ 83N?_1K5]CP=_'J^B_,Y
M\1LCO/AAJ?Q L_#5S'X4T/3[^P-XS22W+@,)-B97F5>,!3T[]:[7^WOC-_T*
M6C?]_5_^/T? '_D1+[_L)R?^BHJ]5KDS?,(T\=4@Z$'9[M.[_P#)BJ<+Q6K/
M*O[>^,W_ $*6C?\ ?U?_ (_1_;WQF_Z%+1O^_J__ !^O5:*\[^TX?] ]/[I?
M_)%<GFSRK^WOC-_T*6C?]_5_^/T?V]\9O^A2T;_OZO\ \?KU6BC^TX?] ]/[
MI?\ R0<GFSRK^WOC-_T*6C?]_5_^/T?V]\9O^A2T;_OZO_Q^O5:*/[3A_P!
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ME!G?+F)U.,*QX!)Z'I7N_P#PM_QA_P!$FUS\YO\ XQ0!Z!_P@G@__H5-#_\
M!=#_ /$T?\()X/\ ^A4T/_P70_\ Q->?_P#"W_&'_1)M<_.;_P",4?\ "W_&
M'_1)M<_.;_XQ0!Z!_P ()X/_ .A4T/\ \%T/_P 31_P@G@__ *%30_\ P70_
M_$UY_P#\+?\ &'_1)M<_.;_XQ1_PM_QA_P!$FUS\YO\ XQ0!Z!_P@G@__H5-
M#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q->?_P#"W_&'_1)M<_.;_P",4?\
M"W_&'_1)M<_.;_XQ0!Z!_P ()X/_ .A4T/\ \%T/_P 31_P@G@__ *%30_\
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MT/E\_P#XD/0]\\/?\BUI7_7G#_Z *YS4_P#DK6C?]>;?REKH_#W_ "+6E?\
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M_KSA_P#0!1XA_P"1:U7_ *\YO_0#1X>_Y%K2O^O.'_T 4>(?^1:U7_KSF_\
M0#1_RX^7Z!_S#?\ ;OZ&=X"_Y$O3_P#MI_Z,:M'Q#_R+6J_]><W_ * :SO 7
M_(EZ?_VT_P#1C5H^(?\ D6M5_P"O.;_T UG2_P!UC_A7Y&='_<H_X5^1G> O
M^1+T_P#[:?\ HQJZ.N<\!?\ (EZ?_P!M/_1C5T=:87^!#T7Y&F#_ -VI_P"%
M?D<5\,/^1:N?^OQO_0$KM:XKX8?\BU<_]?C?^@)7:UG@?]WAZ&>6_P"Z0]#B
MO!7_ ",OBO\ Z_/_ &>6M+Q[_P B7J'_ &S_ /1BUF^"O^1E\5_]?G_L\M:7
MCW_D2]0_[9_^C%K"'^Y2])?FSFI_\BZ?I/\ -GBE?1U?.-?1U<N2_;^7ZG#P
M_P#\O/E^H4445[A](%%%% !1110 4444 ?*OQA_Y*IK/_;#_ -$1UN_!GP?H
M/BS^V_[;L/M7V;R/)_?.FW=YF[[K#/W1U]*POC#_ ,E4UG_MA_Z(CJ_\*O%6
MJ^&?[6_LSPO>ZY]H\GS/LQ;]SMWXSM1NNX^GW37Z?5C7EDD%AW:?)"SO;^7K
M=6T\SB5O:Z^9['_PI[P'_P! +_R;G_\ BZ/^%/> _P#H!?\ DW/_ /%UA?\
M"U/%7_1,-9_.7_XS1_PM3Q5_T3#6?SE_^,U\G[#.O^?K_P#!J_\ DC>]/M^!
MN_\ "GO ?_0"_P#)N?\ ^+H_X4]X#_Z 7_DW/_\ %UA?\+4\5?\ 1,-9_.7_
M .,T?\+4\5?]$PUG\Y?_ (S1[#.O^?K_ /!J_P#D@O3[?@;O_"GO ?\ T O_
M ";G_P#BZ/\ A3W@/_H!?^3<_P#\76%_PM3Q5_T3#6?SE_\ C-'_  M3Q5_T
M3#6?SE_^,T>PSK_GZ_\ P:O_ )(+T^WX&[_PI[P'_P! +_R;G_\ BZ/^%/>
M_P#H!?\ DW/_ /%UA?\ "U/%7_1,-9_.7_XS1_PM3Q5_T3#6?SE_^,T>PSK_
M )^O_P &K_Y(+T^WX&[_ ,*>\!_] +_R;G_^+H_X4]X#_P"@%_Y-S_\ Q=87
M_"U/%7_1,-9_.7_XS1_PM3Q5_P!$PUG\Y?\ XS1[#.O^?K_\&K_Y(+T^WX&[
M_P *>\!_] +_ ,FY_P#XNC_A3W@/_H!?^3<__P 76%_PM3Q5_P!$PUG\Y?\
MXS1_PM3Q5_T3#6?SE_\ C-'L,Z_Y^O\ \&K_ .2"]/M^!N_\*>\!_P#0"_\
M)N?_ .+H_P"%/> _^@%_Y-S_ /Q=87_"U/%7_1,-9_.7_P",T?\ "U/%7_1,
M-9_.7_XS1[#.O^?K_P#!J_\ D@O3[?@;O_"GO ?_ $ O_)N?_P"+H_X4]X#_
M .@%_P"3<_\ \76%_P +4\5?]$PUG\Y?_C-'_"U/%7_1,-9_.7_XS1[#.O\
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M/F_[$Q_M_K'L_<OS7NMKWO:]]CR6O6O@G_S'/^W?_P!J4?\ "D_^IA_\DO\
M[91_R1W_ *B_]J_]N_E>5_WWNSYGMC'?-<=&C.C-5*BLD?29EF6%S/"RP>#E
MS5)6LK-7LTWJTELGU/6:^8O%/_(WZU_U_P __HQJ]$_X79_U+W_D[_\ :Z/^
M%7?\)-_Q/O[8^S?VG_IGD?9=_E^9\^W=O&<;L9P,XZ"ML1)8E)4M;?UU/-R:
ME+):DJF8+D4E9=;O_MVYYWX6_P"1OT7_ *_X/_1BU].UY-_PJ[_A&?\ B??V
MQ]I_LS_3/(^R[/,\OY]N[><9VXS@XST-'_"[/^I>_P#)W_[71AY+#)JKI?\
MKH&<TI9U.-3+USJ*L^EG_P!O6#XV?\P/_MX_]IUY+7K7_)8O^H1_97_;QYOF
M_P#?&W'E^^<]L4?\*3_ZF'_R2_\ ME8UJ,ZTW4IJZ9Z66YEA<LPL<'C)<M2-
M[JS=KMM:I-;-=3DO'?\ S+7_ & ;7_V:M;X-_P#(WW?_ %X/_P"C(ZY[QE??
M:-7BL/+V_P!D0#3-^[/F^4S#?C^'/ISCU-=#\&_^1ON_^O!__1D=13=\2O4Z
M,9%QR6:?\K_%W/<****]L_, HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(>B_(,'_ +M3_P *_(XKX8?\BU<_]?C?^@)7:UQ7PP_Y%JY_Z_&_] 2NUK/
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M#5S>:;XQU#184O&B:WM@^UF"(=_RR*,D,!T[=:[7_A5?BK_HI^L_E+_\>H^
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M9'MOB6ZT[XE:;'HWAW4X'O(9A=.)XY8U\L J>2G7+KQ7*_\ "F_$/_/YI?\
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M !%=EH7B#1/ VC6_AS6M4B34+/=YJQ0RNHWL7&#LY^5A7?5\\_$S_DH6J?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>/\ _"/?'/\ Z'/0_P#ORO\ \CT?\(]\<_\ H<]#_P"_*_\ R/0![!17C_\
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M_H!K.\!?\B7I_P#VT_\ 1C5H^(?^1:U7_KSF_P#0#6=+_=8_X5^1G1_W*/\
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MGVOS?/\ (M8AYFS9MSE>VYOSKA_^%F>+_P#H+_\ DM%_\15QQ$,,O92NVO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *\_\ C;_R2'7?^W?_ -*(Z[#4]=T?1/*_
MM;5;&P\[/E_:[A(M^,9QN(SC(Z>HKS?XO^+/#>I_"W6;.P\0:5=W4GD;(8+V
M.1VQ/&3A0<G !/X4 <O^S+_S-/\ VZ?^UJ^@*^?_ -F7_F:?^W3_ -K5] 4
M%%%% '/^._\ DGGB7_L%77_HIJ^(*^W_ !W_ ,D\\2_]@JZ_]%-7Q!0!]O\
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M>^.?_0YZ'_WY7_Y'H_X1[XY_]#GH?_?E?_D>@#V"BO'_ /A'OCG_ -#GH?\
MWY7_ .1Z/^$>^.?_ $.>A_\ ?E?_ )'H ]@HKQ__ (1[XY_]#GH?_?E?_D>C
M_A'OCG_T.>A_]^5_^1Z /8**\?\ ^$>^.?\ T.>A_P#?E?\ Y'H_X1[XY_\
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M ,4OS# _#/\ Q2_,XK4_^2M:-_UYM_*6NUKBM3_Y*UHW_7FW\I:[6C"[U/\
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M!X\\->%_"=U8ZSJ7V:YDOGF5/(D?*&., Y52.JG\J] _X7#X#_Z#O_DI/_\
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M[_Y*3_\ Q%'UC/\ M4_\!?\ D%J7D87_  H'PK_T$-9_[_1?_&Z/^% ^%?\
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M-&_[;_\ HB2MWXS>,-!\6?V)_8E_]J^S>?YW[ETV[O+V_>49^Z>GI6%\'O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M48P@[>M=)^SC_P E#U#_ +!4G_HV*@#Z?HHHH **** "BBB@ HHHH S?$/\
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M )$O4/\ MG_Z,6M,5_ GZ/\ (TQG^[5/\+_(T?#W_(M:5_UYP_\ H H\0_\
M(M:K_P!><W_H!H\/?\BUI7_7G#_Z */$/_(M:K_UYS?^@&C_ )<?+] _YAO^
MW?T,[P%_R)>G_P#;3_T8U:/B'_D6M5_Z\YO_ $ UG> O^1+T_P#[:?\ HQJT
M?$/_ "+6J_\ 7G-_Z :SI?[K'_"OR,Z/^Y1_PK\C.\!?\B7I_P#VT_\ 1C5T
M=<YX"_Y$O3_^VG_HQJZ.M,+_  (>B_(TP?\ NU/_  K\CBOAA_R+5S_U^-_Z
M E=K7%?##_D6KG_K\;_T!*[6L\#_ +O#T,\M_P!TAZ'%>"O^1E\5_P#7Y_[/
M+6EX]_Y$O4/^V?\ Z,6LWP5_R,OBO_K\_P#9Y:TO'O\ R)>H?]L__1BUA#_<
MI>DOS9S4_P#D73])_FSQ2OHZOG&OHZN7)?M_+]3AX?\ ^7GR_4****]P^D"B
MBB@ HHHH **** /E7XP_\E4UG_MA_P"B(Z[G]G;_ )F3_MU_]JUPWQA_Y*IK
M/_;#_P!$1U?^%7@#2O'/]K?VG<7L/V/R?+^S.JYW[\YW*?[H_6OTS%1IRR&,
M:LN6/)#6U_Y>ET<4;^UT\SZ;HKRK_A0/A7_H(:S_ -_HO_C='_"@?"O_ $$-
M9_[_ $7_ ,;KXCZMEW_00_\ P#_[8Z>:?;\3U6BO*O\ A0/A7_H(:S_W^B_^
M-T?\*!\*_P#00UG_ +_1?_&Z/JV7?]!#_P# /_M@YI]OQ/5:*\J_X4#X5_Z"
M&L_]_HO_ (W1_P *!\*_]!#6?^_T7_QNCZMEW_00_P#P#_[8.:?;\3U6BO*O
M^% ^%?\ H(:S_P!_HO\ XW1_PH'PK_T$-9_[_1?_ !NCZMEW_00__ /_ +8.
M:?;\3U6BO*O^% ^%?^@AK/\ W^B_^-T?\*!\*_\ 00UG_O\ 1?\ QNCZMEW_
M $$/_P  _P#M@YI]OQ/5:*\J_P"% ^%?^@AK/_?Z+_XW1_PH'PK_ -!#6?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \K^+GPLU
M+Q]<:?>Z7JD<4]LAB:VNW80;22=Z[02'S@'CD!>1MY\<\4_!3Q)X1\.7>N7]
M[I4EK:[-Z02R%SN=4& 8P.K#O7UO7G_QM_Y)#KO_ &[_ /I1'0!Y_P#LR_\
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M/@__ *"6N?\ ?^'_ .-4 >P45X__ ,,X^#_^@EKG_?\ A_\ C5'_  SCX/\
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M H/7OTKM?^%J>*O^B8:S^<O_ ,9K+-<%F$\;4E2?NMZ>_%?AS#A*"BKG<_\
M"%^%?^A9T;_P B_^)H_X0OPK_P!"SHW_ ( 1?_$UPW_"U/%7_1,-9_.7_P",
MT?\ "U/%7_1,-9_.7_XS7G_V=FG?_P J1_\ DBN>']([G_A"_"O_ $+.C?\
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M]K/MTV.B_P"$6\/?] '2_P#P#C_PKYX_X2GQ#_T'M4_\#)/\:^A_^$I\/?\
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M_P#Z%30__!=#_P#$T <__P +M^'G_0P_^25Q_P#&Z/\ A=OP\_Z&'_R2N/\
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M"CQ#_P BUJO_ %YS?^@&C_EQ\OT#_F&_[=_0SO 7_(EZ?_VT_P#1C5H^(?\
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M1_PA?A7_ *%G1O\ P B_^)HYLJ_EJ??'_P"1#W_(P_\ A</@/_H._P#DI/\
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M11_PN'P'_P!!W_R4G_\ B*W/^$+\*_\ 0LZ-_P" $7_Q-'_"%^%?^A9T;_P
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M:E<6&I1=&52VJO;Y(^GSK'5XYC2P:E^[J**DK+52DT]=U==F<G_PNS_J7O\
MR=_^UT?\EB_ZA']E?]O'F^;_ -\;<>7[YSVQ7DM>M?!/_F.?]N__ +4I4:TZ
MTU3J.Z9IF66X7+,++&8./+4C:SNW:[2>C;6S?0/^%)_]3#_Y)?\ VRC_ (6C
M_P (S_Q(?['^T_V9_H?G_:MGF>7\F[;L.,[<XR<9ZFO6:^8O%/\ R-^M?]?\
M_P#Z,:ML1%89)TM+_P!=3S<FJRSJI*GF#YU%772S_P"W;'HG_";?\+%_XI3^
MS_[/^W_\O7G>;LV?O/N;5SG9CJ.N:/\ A2?_ %,/_DE_]LKDOAG_ ,E"TO\
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M^G:,/%8E-U=;?UT#.:LLEG&GE[Y%)7?6[_[>N>3?\D=_ZB_]J_\ ;OY7E?\
M?>[/F>V,=\T?\+L_ZE[_ ,G?_M='QL_Y@?\ V\?^TZ\EK&M6G1FZ=-V2/2RW
M+<+F>%CC,9'FJ2O=W:O9M+1-+9+H=%XRL?L^KQ7_ )F[^UX!J>S;CRO-9CLS
M_%CUXSZ"NA^#?_(WW?\ UX/_ .C(ZR?'?_,M?]@&U_\ 9JUO@W_R-]W_ ->#
M_P#HR.HIJV)7J=&,DY9+-O\ E?X.Q[A1117MGY@%%%% !1110 4444 %%%%
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M_P ?KSO[)G_S]I_^!Q_S*]IY/[CU6BO*O[>^,W_0I:-_W]7_ ./T?V]\9O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P 8KV"B@#Q__A;_ (P_Z)-KGYS?_&*/^%O^,/\ HDVN?G-_\8KV"B@#Q_\
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M/KN"_P"@9?\ @4_\PY9?S'E7_"U/%7_1,-9_.7_XS1_PM3Q5_P!$PUG\Y?\
MXS7JM%'UW!?] R_\"G_F'++^8\J_X6IXJ_Z)AK/YR_\ QFC_ (6IXJ_Z)AK/
MYR__ !FO5:*/KN"_Z!E_X%/_ ##EE_,>5?\ "U/%7_1,-9_.7_XS1_PM3Q5_
MT3#6?SE_^,UZK11]=P7_ $#+_P "G_F'++^8\J_X6IXJ_P"B8:S^<O\ \9KP
M3Q#=RW_B75;R>U>TFGO)I9+>3.Z)F<DH<@'()QT'3I7VA7QSXT_Y'OQ#_P!A
M.Y_]&M7U'"]>A5K5%2I*&BV;?7S;,:Z:2NSW'X _\B)??]A.3_T5%7JM>5?
M'_D1+[_L)R?^BHJ]5KY?//\ D8U?4WI? @HHHKRBPHHHH **** "O)OC9_S
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M'-4L[/5["XNI[26*&&&Y1WD=D(554')))  '6O"?^$6\0_\ 0!U3_P  Y/\
M"C%RDI+V3^[_ ( <.T:-2E-XZ*;OISI7MY7/3_AWJ4_C7^TO^$ECM=3^R>5Y
M'GVL1\O?OW8PO?:OY5W'_"+>'O\ H Z7_P" <?\ A7GGPN_XIG^U?[>_XE7V
MCR?)^W_N/,V[]VW?C.-RYQTR/6O0_P#A*?#W_0>TO_P,C_QKIP[BZ2<]_,\?
M.8U88V<<*FH:6Y;VV5[6TWO\SP'QG?7%YXIOH9F7RK*:2TMD2-46.%'8*@"@
M<"ND^#?_ "-]W_UX/_Z,CKE?%D4B>*=2F:-EBN;F6>!R,++&SL5=3_$I[$<&
MNJ^#?_(WW?\ UX/_ .C(Z\ZE?ZPK]S[',%%9-)1VY4>X4445[A^6!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/SF_^,5[!10!X_\ \+?\8?\ 1)M<_.;_ .,4?\+?\8?]$FUS\YO_ (Q7L%%
M'Q1\1-8O->\=ZEJ=_I,^DW4WE;[*?.^+$2*,Y53R #T'6O5_V9?^9I_[=/\
MVM7 ?&W_ )*]KO\ V[_^D\==_P#LR_\ ,T_]NG_M:@#Z HHHH **** "BBB@
M HHHH *^<:^CJ^<:\/.OL?/]#YOB#_EW\_T/:_ 7_(EZ?_VT_P#1C5F_$_\
MY%JV_P"OQ?\ T!ZTO 7_ ")>G_\ ;3_T8U9OQ/\ ^1:MO^OQ?_0'KJJ?[A_V
MZOR1W5?^19_VZOR1VM<YX]_Y$O4/^V?_ *,6NCKG/'O_ ")>H?\ ;/\ ]&+7
M7BOX$_1_D=N,_P!VJ?X7^1H^'O\ D6M*_P"O.'_T 4>(?^1:U7_KSF_] -'A
M[_D6M*_Z\X?_ $ 4>(?^1:U7_KSF_P#0#1_RX^7Z!_S#?]N_H9W@+_D2]/\
M^VG_ *,:NCKG/ 7_ ")>G_\ ;3_T8U='1A?X$/1?D&#_ -VI_P"%?D<5\,/^
M1:N?^OQO_0$KM:XKX8?\BU<_]?C?^@)7:UG@?]WAZ&>6_P"Z0]#BO!7_ ",O
MBO\ Z_/_ &>6NUKBO!7_ ",OBO\ Z_/_ &>6NUHP7\%>K_-AEW^[KUE_Z4SB
MM,_Y*UK/_7FO\HJ[6N*TS_DK6L_]>:_RBKM:,)M/_%+\PP/PS_Q2_,XK4_\
MDK6C?]>;?REKM:XK4_\ DK6C?]>;?REKM:,+O4_Q/\D&#^*K_B?Y(XKXG_\
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MB/PU<WFF^,=0T6%+QHFM[8/M9@B'?\LBC)# =.W6NU_X57XJ_P"BGZS^4O\
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M4]5HKRK_ (57XJ_Z*?K/Y2__ !ZC_A5?BK_HI^L_E+_\>H^I8+_H)7_@,_\
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M1XI_Y%#6O^O"?_T6U>-:KXY\1Z)J][I6GZCY-C93R6UO%Y$;;(T8JJY*DG
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MOWU&<[6Z>E=?\+?BEX-\.?#C2=)U;6?L]]!YWF1?99GV[IG8<JA!X(/!K/\
M^&9?^IN_\IO_ -MH_P"&9?\ J;O_ "F__;: /0/^%V_#S_H8?_)*X_\ C='_
M  NWX>?]##_Y)7'_ ,;KS_\ X9E_ZF[_ ,IO_P!MH_X9E_ZF[_RF_P#VV@#T
M#_A=OP\_Z&'_ ,DKC_XW7D'QT\;>'?&/]@_V!J'VS[+]H\[]S)'MW>7M^^HS
MG:W3TK?_ .&9?^IN_P#*;_\ ;:/^&9?^IN_\IO\ ]MH \8\+:G>:/XCM+^PU
M6#2KJ+?LO)XC(D>48'*A')R"1]T]>W4>D?\ "S/&'_14]#_\%DW_ ,AUO_\
M#,O_ %-W_E-_^VT?\,R_]3=_Y3?_ +;0!@?\+,\8?]%3T/\ \%DW_P AT?\
M"S/&'_14]#_\%DW_ ,AUO_\ #,O_ %-W_E-_^VT?\,R_]3=_Y3?_ +;0!@?\
M+,\8?]%3T/\ \%DW_P AT?\ "S/&'_14]#_\%DW_ ,AUO_\ #,O_ %-W_E-_
M^VT?\,R_]3=_Y3?_ +;0!@?\+,\8?]%3T/\ \%DW_P AT?\ "S/&'_14]#_\
M%DW_ ,AUO_\ #,O_ %-W_E-_^VT?\,R_]3=_Y3?_ +;0!@?\+,\8?]%3T/\
M\%DW_P AT?\ "S/&'_14]#_\%DW_ ,AUO_\ #,O_ %-W_E-_^VT?\,R_]3=_
MY3?_ +;0!@?\+,\8?]%3T/\ \%DW_P AT?\ "S/&'_14]#_\%DW_ ,AUY_XV
M\,?\(=XOOM ^V?;/LOE_O_*\O=NC5_NY.,;L=>U>O_\ #,O_ %-W_E-_^VT
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M_A=OP\_Z&'_R2N/_ (W1_P +M^'G_0P_^25Q_P#&Z\__ .&9?^IN_P#*;_\
M;:/^&9?^IN_\IO\ ]MH [/6?C+X N]#U"W@U_=++;21HOV.<98J0!DIZUY%_
MPF&@_P#/_P#^07_^)KJO^&9?^IN_\IO_ -MH_P"&9?\ J;O_ "F__;:X\3@J
M>):<V].QP8S+J6+DI5&U;M_PQV>C?&7P!::'I]O/K^V6*VCC=?L<YPP4 C(3
MUK$OOBMX*F^(>FZK'K6;*&V,<DOV6;AL2<8V9_B';O6/_P ,R_\ 4W?^4W_[
M;1_PS+_U-W_E-_\ MM;RHQE&,7TL_N.B=",XQB_LM/[CT#_A=OP\_P"AA_\
M)*X_^-UR_BCXK>"M1USP]<6NM>9%:7/F3M]EF&Q=R'."G/"GIZ5C_P##,O\
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M *F[_P IO_VVH5"*I.ET=_Q(CAH*BZ-W9W]=;_YG*_\ "8:#_P __P#Y!?\
M^)KVK_A=OP\_Z&'_ ,DKC_XW7G__  S+_P!3=_Y3?_MM'_#,O_4W?^4W_P"V
MUGA<'##7Y&]>YE@\!3PG-[-MWMOY?(] _P"%V_#S_H8?_)*X_P#C='_"[?AY
M_P!##_Y)7'_QNO/_ /AF7_J;O_*;_P#;:/\ AF7_ *F[_P IO_VVNL[3T#_A
M=OP\_P"AA_\ )*X_^-T?\+M^'G_0P_\ DE<?_&Z\_P#^&9?^IN_\IO\ ]MH_
MX9E_ZF[_ ,IO_P!MH ] _P"%V_#S_H8?_)*X_P#C='_"[?AY_P!##_Y)7'_Q
MNO/_ /AF7_J;O_*;_P#;:/\ AF7_ *F[_P IO_VV@#T#_A=OP\_Z&'_R2N/_
M (W1_P +M^'G_0P_^25Q_P#&Z\__ .&9?^IN_P#*;_\ ;:/^&9?^IN_\IO\
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M[1O_  6S?_(E:O\ PS+_ -3=_P"4W_[;1_PS+_U-W_E-_P#MM']K3_Y]4_\
MP"/^0>S\W]YE?\+/\1_]%.T;_P %LW_R)1_PL_Q'_P!%.T;_ ,%LW_R)6K_P
MS+_U-W_E-_\ MM'_  S+_P!3=_Y3?_MM']K3_P"?5/\ \ C_ )![/S?WF5_P
ML_Q'_P!%.T;_ ,%LW_R)1_PL_P 1_P#13M&_\%LW_P B5J_\,R_]3=_Y3?\
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M7RACC .54CJI_*N__P"%V_#S_H8?_)*X_P#C=>?_ /#,O_4W?^4W_P"VT?\
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MO_VVLZ6#ITY*:;.O'<1XK&4)8>I&*3MLG?1W[OL>@?\ "[?AY_T,/_DE<?\
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MQG625M-+_JV,^*/Q'\)^(_[*_LK5?M'D>=YG^CRIMW;,?>49Z&O//^$@TO\
MY^O_ "&W^%>C?\,R_P#4W?\ E-_^VT?\,R_]3=_Y3?\ [;657!TZDG-MG;@>
M(\5@Z$</3C%I7W3OJ[]UW.;\6>-/#^I_V']CU#S/LNDP6TW[F0;9%W;EY7G&
M1R.*T/AIX]\,^'_$=Q=ZIJ7V>![1HU;R)'RQ=#C"J3T!K4_X9E_ZF[_RF_\
MVVC_ (9E_P"IN_\ *;_]MIK"04^>[N14X@Q4\*\*XQY7IL[]^_Z'H'_"[?AY
M_P!##_Y)7'_QNC_A=OP\_P"AA_\ )*X_^-UY_P#\,R_]3=_Y3?\ [;1_PS+_
M -3=_P"4W_[;74>$>@?\+M^'G_0P_P#DE<?_ !NC_A=OP\_Z&'_R2N/_ (W7
MG_\ PS+_ -3=_P"4W_[;1_PS+_U-W_E-_P#MM 'KGAKQ]X7\7W$]OH6K1W4\
M"!Y(S&\;;2<9 =02,X!(SC(SU%=)7E?P_P#@G8^"?$']M7&JR:E=Q(5M<0>2
ML18%68C<VXE3@=AD\$X(]4H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH \P^/6LWFD?#5X[1]G]H726<K@D,(RKNP!!'79M.<@J6&.:^5+>WFN[F*
MVMXGEGF<1QQQJ69V)P  .22>U>^?M,_<\,?6Z_\ :5>/^ _^2A^&O^PK:_\
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M'XY_]"9H?_?Y?_DBC_A(?CG_ -"9H?\ W^7_ .2*/^&CO!__ $#=<_[\0_\
MQVC_ (:.\'_] W7/^_$/_P =H /^$A^.?_0F:'_W^7_Y(H_X2'XY_P#0F:'_
M -_E_P#DBC_AH[P?_P! W7/^_$/_ ,=H_P"&CO!__0-US_OQ#_\ ': #_A(?
MCG_T)FA_]_E_^2*/^$A^.?\ T)FA_P#?Y?\ Y(H_X:.\'_\ 0-US_OQ#_P#'
M:/\ AH[P?_T#=<_[\0__ !V@ _X2'XY_]"9H?_?Y?_DBC_A(?CG_ -"9H?\
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M?O&7QQ\,^(=(BM+2QU9)$G$I,L48& K#M(>>170_\-'>#_\ H&ZY_P!^(?\
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MBO'_ /AH[P?_ - W7/\ OQ#_ /':/^&CO!__ $#=<_[\0_\ QV@#V"BO'_\
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M%%>/_P##1W@__H&ZY_WXA_\ CM'_  T=X/\ ^@;KG_?B'_X[0![!7SS\3/\
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MR5X?5WP#\4-$\*Z[/?7UKJ$D4ELT($$:%LEE/=QQ\IKT;_AH[P?_ - W7/\
MOQ#_ /':4\-+$/GE[OEN:8?/*640^JT5[5+7FOR[]+6>WJ;OP;_Y%"[_ .O]
M_P#T7'7H=?+/C[XH:)XJUV"^L;74(XH[982)XT#9#,>SGCYA7*_\)58_\\KC
M_OE?\:TC.K27(H7MU.2KAL#CYO%5,2H.>KC:]O*]U?[CL_%/_(WZU_U_S_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDSM:ZAY!BO64^0BB)58NXR%P4;@_,<# .1GZ7H **** "BBB@ HHHH ****
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M$XR?0UXA\"/!WB/P_P".M5N-7T>[LH(K)[8R3)M5I#*A 0]'&$8[ER.G/(R
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M_02US_O_  __ !JC_AG'P?\ ]!+7/^_\/_QJO8** /'_ /AG'P?_ -!+7/\
MO_#_ /&J/^&<?!__ $$M<_[_ ,/_ ,:KV"B@#Q__ (9Q\'_]!+7/^_\ #_\
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M (9Q\'_]!+7/^_\ #_\ &J/^&<?!_P#T$M<_[_P__&J]@HH \?\ ^&<?!_\
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M_P#Z"6N?]_X?_C5'_#./@_\ Z"6N?]_X?_C5>P44 >/_ /#./@__ *"6N?\
M?^'_ .-4?\,X^#_^@EKG_?\ A_\ C5>P44 >/_\ #./@_P#Z"6N?]_X?_C5'
M_#./@_\ Z"6N?]_X?_C5>P44 >/_ /#./@__ *"6N?\ ?^'_ .-4?\,X^#_^
M@EKG_?\ A_\ C5>P44 >/_\ #./@_P#Z"6N?]_X?_C5'_#./@_\ Z"6N?]_X
M?_C5>P44 >/_ /#./@__ *"6N?\ ?^'_ .-4?\,X^#_^@EKG_?\ A_\ C5>P
M44 >/_\ #./@_P#Z"6N?]_X?_C5'_#./@_\ Z"6N?]_X?_C5>P44 >/_ /#.
M/@__ *"6N?\ ?^'_ .-4?\,X^#_^@EKG_?\ A_\ C5>P44 >/_\ #./@_P#Z
M"6N?]_X?_C5'_#./@_\ Z"6N?]_X?_C5>P44 >/_ /#./@__ *"6N?\ ?^'_
M .-4?\,X^#_^@EKG_?\ A_\ C5>P44 >/_\ #./@_P#Z"6N?]_X?_C5'_#./
M@_\ Z"6N?]_X?_C5>P44 >/_ /#./@__ *"6N?\ ?^'_ .-4?\,X^#_^@EKG
M_?\ A_\ C5>P44 >/_\ #./@_P#Z"6N?]_X?_C5'_#./@_\ Z"6N?]_X?_C5
M>P44 >/_ /#./@__ *"6N?\ ?^'_ .-4?\,X^#_^@EKG_?\ A_\ C5>P44 >
M/_\ #./@_P#Z"6N?]_X?_C5'_#./@_\ Z"6N?]_X?_C5>P44 ?%'_"-V?_"T
M_P#A%_,G^P_VW_9_F;AYGE^?Y><XQNQWQC/:O=_^&<?!_P#T$M<_[_P__&J\
M@_YN%_[FO_V[KZ_H \?_ .&<?!__ $$M<_[_ ,/_ ,:H_P"&<?!__02US_O_
M  __ !JO8** /'_^&<?!_P#T$M<_[_P__&J/^&<?!_\ T$M<_P"_\/\ \:KV
M"B@#Q_\ X9Q\'_\ 02US_O\ P_\ QJC_ (9Q\'_]!+7/^_\ #_\ &J]@HH \
M?_X9Q\'_ /02US_O_#_\:H_X9Q\'_P#02US_ +_P_P#QJO8** /'_P#AG'P?
M_P!!+7/^_P##_P#&J/\ AG'P?_T$M<_[_P /_P :KV"B@#Q__AG'P?\ ]!+7
M/^_\/_QJC_AG'P?_ -!+7/\ O_#_ /&J]@HH \?_ .&<?!__ $$M<_[_ ,/_
M ,:H_P"&<?!__02US_O_  __ !JO8** /'_^&<?!_P#T$M<_[_P__&J/^&<?
M!_\ T$M<_P"_\/\ \:KV"B@#Q_\ X9Q\'_\ 02US_O\ P_\ QJC_ (9Q\'_]
M!+7/^_\ #_\ &J]@HH \?_X9Q\'_ /02US_O_#_\:H_X9Q\'_P#02US_ +_P
M_P#QJO8** /'_P#AG'P?_P!!+7/^_P##_P#&J/\ AG'P?_T$M<_[_P /_P :
MKV"B@#Q__AG'P?\ ]!+7/^_\/_QJC_AG'P?_ -!+7/\ O_#_ /&J]@HH \?_
M .&<?!__ $$M<_[_ ,/_ ,:H_P"&<?!__02US_O_  __ !JO8** /'_^&<?!
M_P#T$M<_[_P__&J/^&<?!_\ T$M<_P"_\/\ \:KV"B@#Q_\ X9Q\'_\ 02US
M_O\ P_\ QJC_ (9Q\'_]!+7/^_\ #_\ &J]@HH ^*/B)X;L_"/CO4M#L))Y+
M6U\K8\[ N=T2.<D #JQ[5[O_ ,,X^#_^@EKG_?\ A_\ C5>0?&W_ )*]KO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@"AJ>A:1K7E?VKI5C?\ E9\O[5;I+LSC.-P.,X'Y"J5OX,\+6EQ%
M<6WAK1H9XG#QR1V,2LC Y!!"Y!![UN44 %%%% !1110 4444 %%%% !1110
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MB7'/7I7O>EZI8ZWI=OJ6FW,=S9W";XI4/##^8(.00>000>10!<HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*YSQUXJA\&>#[[69"AFC39;1OC]Y,W"#&02,\D YVJQ'2O Q^T=XO)_Y!NA_
M]^)?_CM 'T_1110 45Y!\1_CA;>%=0ET;0;:#4-2BXGFD8^3 X(RA"X+MC(.
M"-IQR2"!Y_\ \-'>+_\ H&Z'_P!^)?\ X[0!]/T5Y1\/_CAI?BR\MM(U6V_L
MS5IODC;=F"=\#A2>59CNPIST W$D"O5Z "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5_JFNV,=G UD;>-3.DC.S.C9&PD  (<Y(ZC&><>Z444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 ?/'PP^$OB[PU\3+34]4LX(K"Q\_-PMPC";*-&NQ0=W.X'Y@O .<'@_0]
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% 'SY#\(_%#?&XZU/;QIH_]L-J(O$E1AMWF95V%
M@^2<(>."2>0.?H.BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y\^(_PC\4>)_BI/J-G;QG
M2;][</=K*F;=0B1N61F4L1M+8&<@CG.0/H.BB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#'J"Q()7MM7//"@'K=%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME03@ 9P/2OHO]G(Y^'E]_P!A63_T5%0!Z_1110 4444 %%%% !1110 4444
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MY7S$^R:WF 66(\XW $C! R""0>>X('1T %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!3U35+'1-+N-2U*YC
MMK.W3?+*YX4?S))P !R20!R:\ UO]I+47N-N@Z':PP*[C??,TC2+GY3M0KL.
M,Y&6Z]>.6?M$^+OM>K6GA2V;]U98N;OCK*R_(O(_A1LY!(/F<\K7F?@;P9?>
M._$L>D64B0J$,UQ._(BB! +8ZL<L  .I(Z#) !W]O^TAXI6XB:YTG1Y( X,B
M1QRHS+GD!BY ..^#CT->X>!/B!I'C[2VN=/WQ74"(;NU=3F!FW8&[&&!VM@C
MMC(!XKP#XK?"*'P'8P:MIVI27.GS7 M_)N%'FQL4+ [E # [7[+C@<\FN/\
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M /H&Z'_WXE_^.UZ1\/\ XX:5XLN[;2=5MO[-U:;Y$;=F"9\#A2>59CNPIST
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M **** ,?Q-XFTOPCH<VKZO/Y5O'PJKR\KGHB#NQQ^A)P 2/"-9_:1U=]0?\
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M26UMYN]+>61G.Z-D& 8P.K#O7NU !1110 4444 %%%% !1110 4444 %%%%
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M$20P?(SS1(JY(V *#F0L>7Z-[ 5Q5Q^TAXI:XE-OI.CQPER8TD25V5<\ L'
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MZG1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM/\ O6&L2QVLZ! 6WDD1,#D8PS<_[)/!(&/K:@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)H P/@G_R2'0O^V_\
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M SX83"XB\7Z[:((=F[3;>93N+9!$^.@ &=N0<YW#&%)^@J** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWQ2IU!_D01D$'@@D'B@#[SKX=\;00VOCSQ#;V\20P1:E<)''&H5442,  !P
M!VKT34_VB?%%YI$5M965C87W/G7<:E\_,"NQ'R%XR#NWYSD;:\B@@FN[F.WM
MXI)IYG"1QQJ69V)P  .22>U 'T+^S3>W$FF>(;!I,VT,T$T:;1P[APQSUY$:
M?E[FO=JXCX4>#KCP3X&AT^]XO[B5KJZ0.'6-V  4$#LJKGKSNP2,5V] !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/EKTN@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** ,#QGXLL_!7A>ZUJ\7S?*PD4 <*TTA.%4$_B3C)"AC@XQ7QQXH\4:IXO
MUV;5M6G\R>3Y41>$B0=$0=E&?QR2<DDGK/C3XKF\2?$"\M@76RTIVLX8VR/F
M4XD?&2,E@1D8RJID9%>?6\[VUS%/&(R\3AU$D:NI(.>58$,/8@@T >V_!_X/
M?VI]G\3>)K;_ $#B2SL9%_X^/220?W/1?XNI^7[WT=7R!_PNWXA_]##_ .25
MO_\ &Z/^%V_$/_H8?_)*W_\ C= 'UAK>M:?X=TB?5=5N/L]E!M\R78S[=S!1
MPH)/) X%>7G]H[P?_P! [7#_ -L(O_CM=YI,;^*OAM8QZI,[/JVD1K=2QA58
MF6$;V'& ?F)Z8]J^./$GA^^\+>(+S1=25!=6KA6,;;E8$!E8'T*D'G!YY /%
M 'V]I.HPZQH]CJ=NKK!>6\=Q&L@ 8*ZA@#@D9P?6O*?VCYX5\":=;M*@G?4E
M=(RPW,JQR!B!U(!9<GMN'K7D_P /_C!K7@6V_LXP1ZEI.XN+:5RC1$@Y\M^=
MH)()!!'!Q@DFN?\ &?CK6O'>IQWNKRQA8EV0VT *Q1#C.T$DY)&2223P.@
M!CZ/#?7&MV$&F%QJ$EQ&EL8WV,)2P"8;(VG..<C%?>5?*OP,\$S>(/%\6MW-
MN_\ 9>E-YHD((62X&"B Y!R"0YQD?* 1\PKZJH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (YX(;JWDM[B)
M)H)4*21R*&5U(P00>"".U>.>(?V=-"U&\$^B:G/I"'[\#Q_:4'  VY8,.A)R
M6Z\8 Q7L]% '@EO^S/ MQ$USXJDD@#@R)'8!&9<\@,9" <=\''H:]@\+^$M%
M\'Z6EAH]E'"H15EF*@RSD9^:1L98Y)]AG  '%;=% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>2>
M*_@!X<URX-UH]Q)HD[OND2./S86R6)PA(*G)'0A0!@+WKUNB@#P#_AF7_J;O
M_*;_ /;:]$\#_";PYX'>.\MXWO=65"IO;@\KE0&V*.$!P?5L,1N(-=W10 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %9'BCP[9^+/#MWHE_)/';76S>\# .-KAQ@D$=5':M>B@#Q_\ X9Q\
M'_\ 02US_O\ P_\ QJO5-)TZ'1]'L=,MV=H+.WCMXVD(+%44*"< #.!Z5<HH
M *Y3QE\.O#OCJ-#J]LZW42;(KRW?9*B[@<9P0PZ\,#C<<8)S75T4 > ?\,R_
M]3=_Y3?_ +;74>#O@-X?\.7GVW59_P"W+A=PC2X@58%! &3&2VYA\W)..>F0
M#7J]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEZ78Z)I=OINFVT=M9VZ;(HD'"C^9).22>222>35RBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"_$W_QVLCXZ:S_ &M\3[R%7@>+3X8[2-HCG.!O8,<GY@[NIZ8QC&0:\VH
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MQC&>0_:*\+M?^'K+Q';QIOTYS%<D(H8Q2$!26SDA7X"X/^L)XP:\;^&'B_\
MX0OQS9ZC*VVQF_T:\XS^Y8C+="?E(5\#D[<=Z /LZBBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?VKJMC8>;GR_M5PD6_&,XW$9QD?F*KV/BSPYJ=XEG8>(-*N[J3.R&WO(Y';
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!(8W7((.&!R,@D?C7V!X"^&6A>"].M)%L8)=:$2_:+YB9&\S!W>62!L7YF'
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M%>D:7<,ZP7E[#;R-&0&"NX4D9!&<'TK[F@@AM;>*WMXDA@B0)''&H544#
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M[=(BZ1B,2,!\S[1T+'+'KR3R:\P_:.N(5\!Z=;M*@GDU)72,L-S*L<@8@=2
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M?$/Q8\5Z^]A,NKWUA-!:K!/]BNGA2=PS'S2BD ,0P!Q_=XP, ?4_B#P7X?\
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M;BYFDFGE<O))(Q9G8G)))Y))[UT/A3Q[XC\&7(?1]1D2 ONDM)/GADY7.4/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI\/^*[ZVU#0M5M--O+7,CSVAB02(PV$LX!Z,XPN2=V2,#( /9_'7_)/O$O\
MV"KK_P!%-7P_7W!XZ_Y)]XE_[!5U_P"BFKX?H *^Q/@]KZ^(/AGI3[D,]DGV
M&945@%,8 7KU)3821QDGIT'QX1@#WKZ _9KUOY=<T&6XZ;+R"#9_P"5MV/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^
M8/VC_P#DH.G_ /8*C_\ 1LM<!X"_Y*)X:_["EM_Z-6N__:/_ .2@Z?\ ]@J/
M_P!&RUYYX*N(;3QWX?N+F:.&"+4K=Y)9&"JBB1222>  .] 'W%17/_\ "=^#
M_P#H:]#_ /!C#_\ %5S&N?&_P3I-G>&UU(:C>P96.VMXWQ*X.,"0KLVYYW G
MCD9X! /*/VC+_P"T>.[&S2Z\R.VL%W0B3(BD9W)RO\+%?+/J1M[8KR?3K&XU
M/4[6PM(_,N;F9(8DW ;G8@ 9/ Y(ZU<\2>(+[Q3X@O-:U)D-U=.&81KM50 %
M50/0  <Y/'))YKT3X#>#[C6?&<>O36V=,TO<WF21!D><C"H,G[R[M^0#C:O3
M<#0!Z9^T1/-#\.+=(I71)M2B2558@.NR1L-ZC*J<'N >U?+5?:'Q1T:[U_X:
MZWIU@GF7+PK(D8!)?RW60JH )+$*0!W)%?%] 'W!X&_Y)]X;_P"P5:_^BEK?
MKR3X%^-['5?!]KX?N[Y%U:Q9H8X9I\R3Q<NI0'J%7*[1G:$!X!%>EZSKFE^'
MM/>_U>^@L[5<_/,^-Q )VJ.K-@'"C)..!0!\H_&[_DKNM_2#_P!$1T?!'_DK
MNB?2X_\ 1$E<OXK\0W'BOQ3J&N7*[7NY2RID'RT PB9 &=JA1G'.,GFO2/@)
MX>O)=7U3Q3%IWVO^S+61+.-I#%YMTR\*K8V_=W*<_=\Q3CN #J/BK\%-0UO7
M+CQ#X8$$DMSAKFQ8K$3)P"T9X4YY9MQ!R"<DM@>!:EI&I:-<+;ZII]W8SLN]
M8[F%HV*Y(R P'&0>?8UZS<?M'^*3<RFWTG1XX2Y\M)$E=E7/ +!P"<=\#/H*
M]$^&OQ'L_B7IU]I/B>WTK[=YHV610>7<QXW#:DC,792C$\8 VF@#Y6KK?"_Q
M*\5^$$2#2]5D-FKJWV2<"6+ 8DJ >4!).=A4G/7.*^C_ !%\'O &HV]W=W&F
MQZ6=@>2ZM)O(6%5 R0I_=J,+R=O<GKS7R(P 8@=* /MOP/XRL?'7AJ+6+&-X
M3O,5Q _)AE !*YZ,,,"".H(Z'('Q(?O'ZU] ?LR_=\4?6U_]K5XGXFT2;PYX
MFU+1Y]Y:SN'B#O&8S(H/ROM/0,,,.3P1R: +_AJ#QLMM/<>%HO$ @=PDTFEK
M-M9E&0&,?!(#=#TW>];G_%W_ /J>?_)NNI_9[\86VDZW>^'K^Y\J+4=CVADE
M(03CC8!C 9P1SD9V*.217T5JFJ6.B:9<:EJ5REM9VZ;Y97/"C^9).  .22 .
M30!\87'@SQM=W$MQ<^&O$$T\KEY)9+"9F=B<DDE<DD]Z]5^ .A>(]$\8:C_:
M6E:K864U@<_:;>2*-Y!(FW[P + %\=\%O>I_^&FAG_D4?_*E_P#:J](^&WQ#
M'Q#TZ^NAH\^G_995CRTGF1R9&?E? ^8=QC@%3GG@ [>BBB@#YE_:0GF;QOIE
MNTKF!--5TC+':K-)(&('0$A5R>^T>E>=^ O^2B>&O^PK;?\ HU:]P_:1T:\N
M]!T;5X4WVUA+)'/@$E/-V;6.!@+E,$DCEE'.:^<[>XFM+F*YMY7BGB<21R1L
M59&!R"".00>] 'WU16!X0\7Z7XRT.WU#3[F!I6B1KFV27<]LYSE&& 1R& )
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M87$(99&8$X(_=ACCKVQGB@"*X^#/P_N;B2>3P[&'D<NPCN)HU!)SPJN H]@
M!VKK]+TNQT32[?3=-MH[:SMTV11(.%'\R2<DD\DDD\FO@TDGJ37U!\&?B5I>
MI>%[#P_JNHP6^KVG^C0QS-L\^,;1'M. N[Y@@4$L=F>] '1_&'0$U_X9ZJNU
M#-8I]NA9V8!3&"6/'4F/> #QDCIU'QW7T[\;/B)I%IX3OO#FFZE'/JUTRP3)
M;2G,$88[]S*",_(4*$@X?D8Z_,5 'UI\!]1BOOA796\:N'L9YK>4L!@L7,F5
MYZ;9%ZXY!^M>EUR'PNT:[T#X:Z)IU^GEW*1-*\9!!3S':0*P(!# , 1V(-=?
M0 5\0^/?^2B>)?\ L*7/_HUJ^WJ^.?C%8V^G_%?78;:/RXWD28C).7DC5W//
MJS,?QXXH ZC]G#_D?]0_[!<G_HV*OIZOF']G _\ %P-0'_4+D_\ 1L5?3U '
MR#\;O^2NZW]+?_T1'1\$?^2N:)])_P#T1)1\;O\ DKNM_2W_ /1$='P0_P"2
MN:)])_\ T1)0!]?5\0^/?^2B>)?^PI<_^C6K[>KXA\>_\E$\2_\ 84N?_1K4
M >@?LX?\E U#_L%2?^C8J^GJ^8?V</\ DH&H_P#8+D_]&Q5]/4 ? 4G^L;ZU
M[!\'O^2??$S_ +!8_P#15Q7C\G^L;ZU[]^S+]WQ1];3_ -K4 ?/]?4'[.7_)
M/+[_ +"LG_HJ*OG#7M&O/#VO7VD7Z;;FTE:-\ @-CHRY )4C!!QR"#7IGP,^
M(-CX4U.[T?6)WAL=1=#%.\G[JWE&1EAT 8%06[;5SQRH!]15\@_&_P#Y*YK7
MT@_]$1U]/^(/&GA_PSH8U;4-2@%O)%YMNL4BL]T.,>4,_/G<O(X&020.:^./
M%?B&X\5^*=0URY78]W*65,@^6@&$3( SM4*,XYQD\T =1\$?^2NZ)]+C_P!$
M25Z1^TGK.S3-$T-'@;S9GNY4SF1-@VH<9X4[Y.HY*\'@UYO\$?\ DKNB?2X_
M]$258^.FL_VM\3[R%7@>'3X8[2-HCG.!O8,<GY@[NIZ8QC&0: +'P!TS[?\
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M "3NQ_["D?\ Z*EKY>K[0^*.C7>O_#76].L$\RY>%9$C )+^6ZR%5 !)8A2
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M;F&*"&-]QX1RY88Z<F-/R]S7T-0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5@>.O^2?>)?^P5=?^BFK?K \=?\ )/O$
MO_8*NO\ T4U 'P_7U!^SE_R3R^_["LG_ **BKY?KZ@_9R_Y)Y??]A63_ -%1
M4 >OU'/!#=6\EO<1)-!*A22.10RNI&""#P01VJ2B@#X!888CWKVS]FS4IHO$
M^LZ6JIY%Q9+<.Q!W!HW"J!SC&)6SQV'X^*/]]OK7K_[.'_)0-0_[!4G_ *-B
MH ]S^(OC)/ O@^XU<1I+=,RP6D4F[:\K9QG'8 ,W;.W&02*^.-6U:_US5+C4
M]3N7N;RX??)*YY)_D !@ #@  #BO5/VB=;^W>-[328[C?#IUJ-\6S'ES2'<W
M..<H(CU('US7G?@SP^WBGQCI6BA7*75PJR^6RJRQ#YI&!;C(0,>_3H>E &OX
M2^%7BOQE;17FG64<.GR,R"\NI D>5'.!R[#/RY52,Y'8XR/$W@W7_!]Q!#KN
MG/:-.I>)MZNK@'!PRDC(XR,Y&1ZBOMZ""&UMX[>WB2&") D<<:A510,  #@
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MIZ5YOG?8KN6W\S;MW['*YQDXSC.,F@#U#]G#_DH&H_\ 8+D_]&Q5]'Z[J?\
M8OA_4M5\KSOL5K+<^5NV[]B%L9P<9QC.#7SA^SA_R4#4?^P7)_Z-BKT_X^:G
M_9_POGM_*W_VA=0VV[=CR\$RYQCG_58QQUSVP0#Y0^\WU-?=^A:9_8OA_3=*
M\WSOL5K%;>;MV[]B!<XR<9QG&37R!\*M,_M?XH>'[?S?*\NZ%SNV[L^4#+C&
M1UV8SVSGGI7V=0!\ O\ ?;ZU[I^SSJECHFE>,-2U*Y2VL[=;5Y97/"C][^))
M.  .22 .37A;_?;ZU<@U:_M=*O-,@N7CL[UXWN8EX$ICW;-W<@%B<=,X/4#
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MGJ+_ &9((+U([F+9M <%0K-@="9%?.>2<GOD_75?,/[1_P#R/^G_ /8+C_\
M1LM %?\ 9[UG^S_B&^G.\_EZE:O&L:'Y#(G[P,PSV59 #R?F]":^IJ^+?AAJ
M,VE_$[P[<0*C.]ZEN0X)&V7]VQX(YPYQ[XZ]*^TJ "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#XF>$?\ A-/ ][IL:YO8_P#2;/G_ );*#@=0/F!9,G@;L]J^+R,'!K[_ **
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K \=?\
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MT/XJM;>.WM](\/PP1($CCCMI55% P  ),  =JD_X:.\8?] W0_\ OQ-_\=H
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MX]17W%10!Q'PR^'=M\/M">$S?:-3N]KWLZD["5SM1 ?X5W'D\G))QP!V]%%
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M_AC3](NK_P"WR6<0A%QY(BW(.$&T$XPNU>ISC)Y-:]% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
J4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>img222477878_45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_45.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MK\ V>K6=P"X0>5.K98]!P>O!H#8DNM:TJQ65KO4K6W6)@LAEF5=A/0')XS0
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M6(,J^5M [D9)P.A&><Y[4Y:2L@CKN=19&<VD+7)!FV#?M7:,XYXR<4WHQ(M
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MV#CFIC\(/J>D:/#-'8@W%G':3%CNCCF,H'I\Q _E5$1U6II#I04% !0 4 %
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MUH 6_P##VCZK*LNH:7:7<BC:&FA5R!Z9(HV OQQ)#&L<:A44!54<  =J 'T
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MUH&:FG_;5LT%^83<9.[R00OMC.30(L[J ,7PK_R#;O\ ["-W_P"CWH VVZ4
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M/?Z4,>YT6B?\@'3_ /KVC_\ 017 >F7) &7:PR#P128(XS0&TR/7IET_1Q"
M[QF=[D,01U C)R!^%-; ]#M=PH S]</_ !(K\=/W#_RH ?K'_($U#_KWD_\
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M1G\Z ([+3M3BU"_E@UZR>:XD5YE^QD[2%"CCS..%% &A!_R.%Y_UXP?^AR4
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MMM RAK@QH5__ -<'_E2 DUC_ ) FH?\ 7O)_Z":8%F#_ %$?^Z/Y4 5]6_Y
MU]_UP?\ ]!- $UM_Q[1?[@_E2Z <+I774?\ L(7/_HUJ[*?PG!6^-FA6AD7_
M  =_R!)?^ORX_P#1K5Q3^*YZ%/X$;S#BH-#B(/"%Q+J=Q?2VVCKNNGD!FL-\
MV-V0=X8=NG%-:#9VX&5% A<8%(#%\(_\BU:_[TG_ *,:@!/!W_(LV_\ UTF_
M]&M3 W: ,_2?^/.7_KYG_P#1K4=0.4B_Y&#7_P#K\'_HF.NFC\)Q5])%NMCG
M%\,_\C1K/_7O;?SEKEJ[G;0^$ZT]*Q9T'/\ B/0[G5Q!]GO$@\K.[<91G/\
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M*)%*7\ND3LT>Q);<^4%QM8*5^8Y(R<ECDYH$V=[I\#1:5:P38+I$JM]0 #2
MEMK2WLX1#;0)#$.0B+M _ 4 2/&DB,CJ&5A@@]"* (X+6"U@6&WA2*)>B(-H
M'X"@!^Y?4=<=: ([B%+BWDMWR4D0HP![$8H D7:J#!X'?- "[10 QF2-@I8
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M9QNR72FQO=IQB%B#N]B,'_OJ@"J8?$=U?3V\X$-C%<QB!(H_F1%E7# D8/R
MY'/T% #-)D\1QWTSWT$T44MR \T4"EW C4*2,'@G=DX].@H DT$^)H=;^RW,
M0ATQ99&3<F2ZDL>H!P=Q'4CCM0!I:]8FZU>Q:]M'O-)6.020JF\"7*[6*CJ,
M;A[9H Y2\TK7[>]EAL[&5[%[P7R<XV,LNP)]"N&_ T ,32_$DJZC_:.FNBS7
MOVAE0B99&\KY5QW0,!^F?6@">32KN]O9KJ[T>6 ?N4NK:&,[;D!@TC$]&P>
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MUTYLY;:)[>$2^9_RTN!N\QA^8Y[T =@.E !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 )B@ VT &* #% "XH 3%  1QB@ Q[F@!>E !0 4 )B@ Q0
M8H -O- "XH ,4 )B@ Q[F@!: "@ H 3% !B@!<4 % "8Q0 8H ,>YH 4#% !
M0!__V0
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>img222477878_46.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_46.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@!,BD HI@% !0!1UEWCT2_>-BKK Y# X(.TT
M <&=<UNTLO#EU?1HEMY;NS07+2238@8_,I4#MGDGFD/J58-;N[?1M8TVZNY7
MU%K?SUD2<E IQ@A\Y!.3D <8IL6QUOAB"2-IFE:+>0,"/47NN/<,!B@2.G'
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M>%'(63<Q#Y'\6!GZ4 ='9:H+O4;^Q\AXGLV4%F(PX89!&#0!HT % !0 4 %
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MDT4\CN S&)<B)2P7<WH,F@":[U^VL]8M]->.4R3#.\#Y4SP,_4\<4 5M)/\
MQ56O_P#;#_T"@#?H * $9<C':@")[:*1 CQ(R 8P5R* )$C6, * JCH , 4
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M $"@#>H * "@ H 0]* ,32_$D&IZI=V*Q-&8C^Z=CQ, <,5'H#Q0!MCI0 M
M!0 4 % "'H: .4U^_@T_Q!:22WT-DSVSJ)+B+?&?F''!&#^/-(?0T=+T^VC\
M.)9V\ZW$+*Q$C+PQ))S@=LGIFG(E'GVAK9?V]8-]GQ/YX)NHK!E23);&'9\
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MV^W7/[N7&>96/;TSCZ@T#/-OCA_R'--_Z]F_]"KIH=29'E@Z"NLDZ?X>?\E
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M<#]U(2I?/W/1B.I7U(Z5+U&<_P"#;O4)M3N1<2WCJR_O8[C<5B<'JK$8(;/
M7@ #UJK$G;T#&NP12Q. !DFD!PVJZU_;+VK);WJ6,:M<.J2&-IXON[UVG/RD
M@X.,Y!H0&OX3U#[9;SQ)J*ZE!;N%BNUYWJ1G#'NP[GWJA'24AA0 4 % !0 4
M % !0 4 % !0!R_C"YD&G?8XI1"\[JH(,>6'.1A^.@ZF@"'P.VFPV][8:=;R
M0/:R*)PT@<,S#.00=O0]!0!K:CXCL-+NTMKAW\UE#D*A8*I8+DD=.2/_ -5
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M7,[2,8S&3E9$;HC#@ #GDYI[ >@6]LD"#&&<@;W( 9R!C)QU- $Q8*.>*3T
M\W\2>)X-4%WI\HO='NM.G66*<D!)<9QRIZ,,XSP>E&O0>QK:3X7COM0DU74H
MS]J699K>2&3]V/E&63'.&QR#_P#7I[*R$=D%P.,4 .H * "@ H * "@ H *
M"@ H * "@#D_',<$&D&](2.8$)YS*S;!R>@/<\?C0!'X O7O;&Z<6ZK;JZ".
M9<XF)0%N#Z,2/PH ["@ H 2@#"U_5+NRCMX]+C6XO9&W+"5)#H,!N1T^\.:
M.=\-SZ[?Z@;U7W6WVAD9VDSF/)X*D\,#M P,8S0!WR]* &R2I$A>1@B#J6.
M* ."UV[O]8N[:W-M'':?:)&2.0D>=Y8Y5\\;6!.#V(% '3Z!:O:BY"B=+-RK
M01RL&\OCD+@GY>GZT ;6* "@ H * "@ H * "@ H 0J#D'I0!BW_ (4TJ_EB
ME,3V\D<BR;K=S'N*D$;@.#T[BE8#: Q3 "..* .,OKRQT[4-1BU2P::[F8M:
MRFV\T2J5P$4XX(Y&#@<^](;+WA;0/[/T^WFOH(C?X+;B@W0AAR@;KC.>.V<=
M!31+W.E48H&+0 4 % !0 4 % %2ZTVSOEVW5M%,.V] <?3TI 26UI#:6L5M
MNR*)0B+G. !@#FF!.!@8H YWQ5#.;>SN%M7N[:WG$EQ;H,F1-I'3^+!(./:E
M'XM1E*T^P^(]6@:QCDCL+*/[ZPF(,Q/^KY'*XSD8QTH0CK418T"JH50,  8
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M5#/*,EB&#CY2<H?DXSV- '6H@10JC '0#M0 Z@ H * "@ H * "@ H * "@
MH * "@!-H]!0 8 [4 +0 4 % !0 4 % !0 4 % !0 8H 0 #H,4 +0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 (5!ZB@ "@=!B@!: *5[<W%L5:*S:YCYWA&&
MX>F <9_.@#@-/T0Z[>W$L$[ PR>5(EW$P9%R3&RYZ.%.W\,T >BVUM%:0K#"
M@1%Z #% !=W,5E:RW,[B.&)2[L>P'6@#CO$&MZS L.H6UJK:0\>V:"Y3YCGG
M=P2<8SGT]* '^&_"\**DMY:YA16CA@G(D11GADY(&5ZT =H%"C &* %H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H 0 "@!: *U_90:C8S6=
MRF^"=#&ZYQD$<T 8=MHVHS7%FFIS0RP61+1L@(>0XV@MV''7'6@#HT144*H
M51@ =J '4 % !0 4 % !0 4 ?__9
2

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>img222477878_47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img222477878_47.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M0 F: #- !F@ S0 N: "@ H * "@ H * "@ H * "@!,XH ,T &: #(H 4&@
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MCXAUJ6TE26]?;L8%5 &>/:FI-,PE&*6QU'P@Y^'EGD\^;+_Z$:[#ST=[0 4
M% !0 '@4 (#0 M !0 4 % #6.!F@# M=4U%7M)+P6AM[A&8"%6WKA=W<\T 2
MOKHA\K[1"%66,M&4?<6; (7IP3D_E0!(-8$GV411H?.3<=S$;3QQT_VJ &P:
MZLNGW%T(@#"I/E[N25 +#IQUX]>M  =9G^UM;I:HQ#HO^LZJV>1QUX/Y=: -
MJ@ H AN7:.WE=8C*RH2(QC+\=.?6@#A[34KJXUIHYK26(_;5#!9+?:G0A6QE
MMV/?- %OXC7\MGX?C@B.!=3+&Y_V>I%;T%>9,CG_  ]!;"97<@$ *H]2>M;U
M&QQ1J:Y>:)I+1#5H56ZE4LT2*6:7DJ,=AG'4^E8151_!L)M(T--\6:5#X?CN
M!;FV"L8_LZC)4C'?OU'/O2E3:=F-&1J&OR:R#;W.CJ(W^5&W9D4_Y[5<8\FT
MA-7-/PAI$^@1W[2PR>7(5*G&. #V-37J*HT**Y33T_QAH>IW(MK;48C,3M"-
ME2WTSUJ'2DE=H7.KF^*R-!:8!0 4 % !0 4 % &!XTW?\(EJ15W1EBW HQ4Y
M'TH Y[Q'<2SZ[=V\L[Q6]IH[7<&UBO[S)^?WQ@?3- $]UXNUC2?"FG:H^AR7
MP>T$UU*LJQ^6<#.0?SXH ["PN?MNGV]SM*>=&LFW.<9&<4 6: "@ H CFACG
MA>*5 \;J592,@@]0: *5MHFF6CLUO80QLRE"0@Y4]1]* +(L;0)L%M%MZ8V#
M% "O96LC[WMXV?IN* F@!PMX0K*(D 9MQ&WJ?7ZT +'!#$ (XD3!)^5<=>M
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MF@TJ\U.!;Z2*U52 _DCN2W4 @B@#I/#VL+KVBP:DD#PK-GY'.2N#C^E &I0
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MV9^SUN>DOJUA#<BUENXHY\#$;MM)_ UR<KMHC2Y># C@TMABT % !0 4 &:
M$R* *NH:?;:I9RVEVC/!*,.H8KD>F1S0!5NO#^G7J0K<V_F>2I12SG)4]5)S
MR#Z&@"AXW39X#UE0, 6KX'IQ0!J:%_R =._Z]H__ $$4 :% "9% !D4 +F@
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M!S'P^_Y$NR^K_P#H9H Z>@ H * "@ H * "@ H * "@ H * "@ [4 -*CTI
M<!XN\#/<W$NK:, +H@F:W/2;Z>AK>%5K1B.)26YMK]H[VWDMY$.T))&4(';K
M79&2DM";:G22ZPEAI;M"<3",PKSW/?'M6:@F]1[&9H^F),RAH\@<G^E.<FE8
M45J==:Z:EQ9'3Y4Q&%VQ*BX8CO\ 7''YUR\R6IHU8T[7PC9(JFX8O(.Z?)CV
MXJ74DQ%'QFMW8Z= =,DDM\$EI$.2,#@<]JNBHM^\1/571/X#U>_U;3;AK^82
MO%)L5MH!(QWQ55X*$K((;'65SEA0 4 4M1BC33[N0+&&\LN2X^7('!/Y#\J
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M:G]H6,2%,1YVYQG[WK0!M:9J$U_"[S:?<614X"3[<M[\$T 7Z "@ H * "@
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M %UD_P#0C7:<9WC9VG'6@#S?7/[2CU&ZM85E$,UPOF%[] CH7!VHG53CC_\
M70!W.D"X72;87:%)MO*$Y*^@/N!B@#A+:TCAU)2EYIKK]OR-NF/OYEZ>;TS[
MT ==XIUN30])$UO#YMW/*D$"$=78\?XT 0VWB:T336F=KRXDBF-O,JVY9TD
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M9(]YCB7C@8/)/?L,T 4O&^O:</ UTBS22_;;-C!(L3,&&.I(&!^.* .HT/\
MY &G?]>T?_H(H J>+_\ D3M9_P"O.7_T T ?))ZTAB4 "_ZX?2@#ZHUC4+_2
MO L5YIJ![B.V0XVDX&SD^G'7GBF(HWNO^((?!0U1;0+?9),7EG*KCKGIGH<]
M#^- '2Z#=7MYI44^H0B&X;.Z,*1MYX'/7COT- &G0 4 % !0 4 (>AH \O\
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M([FSNHYK'EQYBG<"*Y>5IZFEKD.GW43:U;1_<8EB%<8.,5<KV)9UHZ5@A"T
M5M1$9TZY\TL(_*;<5Z@8.<>] 'GN@0>9?:8(+R)M,M[@M'##;>6\<A0@"3)R
M.#V&#UH ]*7[O3% &-J/A^WU#4/MOFRPSF!K9V3!#1GJ"#W]#0!G>*[&#3?A
MMJ=E;*4@@LFC0$Y( % &WH?_ " -._Z]H_\ T$4 5/%__(G:S_UYR_\ H!H
M^232&)0 +_KA]*8'UD;Z\L=!TUK/2I=0+PH&6-U7:-HZ[B*!&:/&&I-J+:</
M"UV;I(Q*4\^+[A) .<^QH Z'2+V[OK=I+O39;!PVT1R.K$C'7*DT :- !0 4
M % !0 A]* . N?@[X4O+F6>5+LR2N7;$V.2<^E $/_"D_"'_ #SO/^__ /\
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M6W8D+*A0D=1D8XH YVP\)Q65XET9X6E$B'(M@I"(NU47GY1U)]<F@#IU^Z*
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MRN"I0,(VQY@^7H>OM0!R=KHUMIM_!<FY@O[AIE3:ZX6V!.<1@$[/7!Y/KVH
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M@6'49Y% #B>#0!Y+I?B#XA^(YM1?2)=.%O:W3P8E3!X/% &CL^+'_/32/RH
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MK$ 8 +\?\#- &EXG_P"15U?_ *])?_030!\ATABT"!?]9^% 'V/IO_(+M/\
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MH * "@#F/A]_R)=E]7_]#- &CXG_ .15U?\ Z])?_030!\A]Z0PH 5/]9^%
M'V/IO_(+M/\ KBG_ *"*8BU0!B^+O^10U?\ Z]9/Y4 6M!_Y%_3O^O:/_P!
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MV1@BA.PY+0@ND17;;&%7J,4V[FL%H9C1^9G Q46-D8GB3>/#]ZISA87X_P"
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M^V_QH /^%8>#N^AQ?]]M_C0 ?\*P\'?] 2+_ +[;_&D #X8>#ATT2+_OMO\
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MUCC7*,QRQZ=#6E36)F]#UP=*XB!:8!0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 AZ4 94]AJ45W-/IUU;H)R&D2XA+@$ #((8=@.* +EG;R6MHL<LOFR
M99G<+M!8DD\=N30!P7PCXM?$(_ZB<E(#T8]*8'-:[X434)'NK9PEPWWE;[K'
M^AJ'&Y2E8XZ;1-3M79'LI>.ZKN'Z5DX,U4D/L=+UHMA;"8[>A8;?YTE!E.2-
M';?*&BN+62)AW(X/T-3R#YT8'B"&;^QKYBIP(G_]!J4K,IR3B=+\'O\ DG=G
M_P!=9/\ T(UV+8XNIWM,84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 ,>%)%VR*'7T89% $?V*U_Y]HO\ O@4 (;&U[6\0_P" "@"9$6- B*%4
M= !@"@!U !0 4 ,>-9%*L 5(P01U%&P'-#X>>&5OC=C3E#DY*AB$S],U?/(+
MG21P1Q1B.-%1!P%48 _"INP*LFCV$E['>-:Q&YB.4DV\@T*3!ZEX#%( H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H 0]* /GK2?&NK^#[O5[6R
MM;.>.>]DD)FW9'/M0!I_\+C\1_\ 0.TS_P ?_P : #_A<?B/_H':;_X__C0
M?\+C\1X_Y!VF_P#C_P#C0 ?\+C\1_P#0-TW_ ,B?XT -?XO^(9%*MIFF$>AW
M_P"-+0#&O?'>JWD%W$;*TC%RC(VV20@ C' )J>5#N>I_".,P?#^T1B"?-DZ?
M[U6([N@ H * "@ H * "@ H * "@ H * "@ H * "@ H __9
A

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>58
<FILENAME>calc-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-03-28T15:08:13.5783+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.calcimedica.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:calc="http://www.calcimedica.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" namespace="http://xbrl.sec.gov/stpr/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails2" id="DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails2">
        <link:definition>100020 - Disclosure - Fair Value Measurements - Summary of Company 's Financial Assets Measured at Fair Value (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" id="StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>100040 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" id="StatementConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>100050 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" id="StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited">
        <link:definition>100060 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical" id="StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical">
        <link:definition>100070 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100080 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusiness1" id="DisclosureNatureOfBusiness1">
        <link:definition>100090 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactions" id="DisclosureMergerAndRelatedTransactions">
        <link:definition>100110 - Disclosure - Merger and Related Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100120 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>100130 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrants" id="DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrants">
        <link:definition>100140 - Disclosure - Convertible Promissory Notes and Convertible Promissory Note Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficit" id="DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficit">
        <link:definition>100150 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders' Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensation1" id="DisclosureStockbasedCompensation1">
        <link:definition>100160 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100170 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureEmployeeBenefits" id="DisclosureEmployeeBenefits">
        <link:definition>100180 - Disclosure - Employee Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100190 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100200 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100210 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100220 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100230 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>100240 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables" id="DisclosureStockbasedCompensationTables">
        <link:definition>100250 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100260 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>100270 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100280 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails" id="DisclosureNatureOfBusinessAdditionalInformationDetails">
        <link:definition>100290 - Disclosure - Nature of Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100300 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails" id="DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails">
        <link:definition>100310 - Disclosure - Merger and Related Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100320 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3InputsDetails" id="DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3InputsDetails">
        <link:definition>100330 - Disclosure - Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value Using Level 3 Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100340 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails" id="Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails">
        <link:definition>100350 - Disclosure - Fair Value Measurements - Summary of Company 's Financial Assets Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails" id="DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails">
        <link:definition>100360 - Disclosure - Convertible Promissory Notes and Convertible Promissory Note Warrants - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" id="DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
        <link:definition>100370 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails" id="DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails">
        <link:definition>100380 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders' Deficit - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" id="DisclosureStockbasedCompensationAdditionalInformationDetails">
        <link:definition>100390 - Disclosure - Stock-based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" id="DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>100400 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsingBlackScholesToEstimatedFairValueOfTheStockOptionGrantsDetails" id="DisclosureStockbasedCompensationScheduleOfAssumptionsUsingBlackScholesToEstimatedFairValueOfTheStockOptionGrantsDetails">
        <link:definition>100410 - Disclosure - Stock-based Compensation - Schedule of Assumptions Using Black- Scholes to Estimated Fair value of the Stock Option Grants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedForOptionsAndRsusGrantedDetails" id="DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedForOptionsAndRsusGrantedDetails">
        <link:definition>100420 - Disclosure - Stock-based Compensation - Summary of Stock-Based Compensation Expense Recognized for Options and RSUs Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfCommonStockReservedForFutureIssuanceDetails" id="DisclosureStockbasedCompensationScheduleOfCommonStockReservedForFutureIssuanceDetails">
        <link:definition>100430 - Disclosure - Stock-based Compensation - Schedule of Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100440 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails" id="DisclosureEmployeeBenefitsAdditionalInformationDetails">
        <link:definition>100450 - Disclosure - Employee Benefits - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" id="DisclosureIncomeTaxesScheduleOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails">
        <link:definition>100460 - Disclosure - Income Taxes - Schedule of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" id="DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>100470 - Disclosure - Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100480 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails" id="DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails">
        <link:definition>100490 - Disclosure - Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" id="DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails">
        <link:definition>100500 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
        <link:definition>100510 - Disclosure - Net Loss Per Share - Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100520 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="calc-20231231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" xlink:href="calc-20231231.xsd#StatementCondensedConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="calc-20231231.xsd#StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="calc-20231231.xsd#StatementConsolidatedStatementsOfOperations" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:href="calc-20231231.xsd#StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" xlink:href="calc-20231231.xsd#StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical" xlink:href="calc-20231231.xsd#StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="calc-20231231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusiness1" xlink:href="calc-20231231.xsd#DisclosureNatureOfBusiness1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="calc-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactions" xlink:href="calc-20231231.xsd#DisclosureMergerAndRelatedTransactions" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="calc-20231231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpenses" xlink:href="calc-20231231.xsd#DisclosureAccruedExpenses" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrants" xlink:href="calc-20231231.xsd#DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrants" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficit" xlink:href="calc-20231231.xsd#DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficit" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensation1" xlink:href="calc-20231231.xsd#DisclosureStockbasedCompensation1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="calc-20231231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureEmployeeBenefits" xlink:href="calc-20231231.xsd#DisclosureEmployeeBenefits" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="calc-20231231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:href="calc-20231231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:href="calc-20231231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="calc-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="calc-20231231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpensesTables" xlink:href="calc-20231231.xsd#DisclosureAccruedExpensesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables" xlink:href="calc-20231231.xsd#DisclosureStockbasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:href="calc-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="calc-20231231.xsd#DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:href="calc-20231231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails" xlink:href="calc-20231231.xsd#DisclosureNatureOfBusinessAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="calc-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails" xlink:href="calc-20231231.xsd#DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="calc-20231231.xsd#DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3InputsDetails" xlink:href="calc-20231231.xsd#DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3InputsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="calc-20231231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails" xlink:href="calc-20231231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails" xlink:href="calc-20231231.xsd#DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:href="calc-20231231.xsd#DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails" xlink:href="calc-20231231.xsd#DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:href="calc-20231231.xsd#DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="calc-20231231.xsd#DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsingBlackScholesToEstimatedFairValueOfTheStockOptionGrantsDetails" xlink:href="calc-20231231.xsd#DisclosureStockbasedCompensationScheduleOfAssumptionsUsingBlackScholesToEstimatedFairValueOfTheStockOptionGrantsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedForOptionsAndRsusGrantedDetails" xlink:href="calc-20231231.xsd#DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedForOptionsAndRsusGrantedDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfCommonStockReservedForFutureIssuanceDetails" xlink:href="calc-20231231.xsd#DisclosureStockbasedCompensationScheduleOfCommonStockReservedForFutureIssuanceDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="calc-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails" xlink:href="calc-20231231.xsd#DisclosureEmployeeBenefitsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:href="calc-20231231.xsd#DisclosureIncomeTaxesScheduleOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="calc-20231231.xsd#DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="calc-20231231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:href="calc-20231231.xsd#DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:href="calc-20231231.xsd#DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="calc-20231231.xsd#Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="calc-20231231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails2" xlink:href="calc-20231231.xsd#DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails2" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PostMergerTransactionsMember" xlink:label="calc_PostMergerTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShortTermInvestmentFairValueDisclosure" xlink:label="calc_ShortTermInvestmentFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_OperatingLossCarryForwardsExpirationBeginningYear" xlink:label="calc_OperatingLossCarryForwardsExpirationBeginningYear"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TrancheAAndTrancheBCommonWarrantsMember" xlink:label="calc_TrancheAAndTrancheBCommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PreMergerCalcimedicaMember" xlink:label="calc_PreMergerCalcimedicaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConvertiblePromissoryNoteWarrantsMember" xlink:label="calc_ConvertiblePromissoryNoteWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredPolicyAcquisitionCostsTextBlock1" xlink:label="us-gaap_DeferredPolicyAcquisitionCostsTextBlock1"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_FairValueAdjustmentOfConvertiblePromissoryNotes" xlink:label="calc_FairValueAdjustmentOfConvertiblePromissoryNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_MergerTransactionCosts" xlink:label="calc_MergerTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_IncomeTaxDisclosureTable" xlink:label="calc_IncomeTaxDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_GrossProceedsFromIssuanceOfPrivatePlacement" xlink:label="calc_GrossProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AccruedClinicalTrialCosts" xlink:label="calc_AccruedClinicalTrialCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AccruedFranchiseTax" xlink:label="calc_AccruedFranchiseTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_WarrantsToPurchaseConvertiblePreferredStockMember" xlink:label="calc_WarrantsToPurchaseConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="us-gaap_WarrantExercisePriceDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PercentageOfChangeInOwnership" xlink:label="calc_PercentageOfChangeInOwnership"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MD" xlink:label="stpr_MD"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TrancheACommonWarrantsMember" xlink:label="calc_TrancheACommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_IncomeTaxDisclosureLineItems" xlink:label="calc_IncomeTaxDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AccruedPayrollAndOtherEmployeeBenefits" xlink:label="calc_AccruedPayrollAndOtherEmployeeBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesBWarrantsMember" xlink:label="calc_SeriesBWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="calc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_RightOfUseAssetOrLeaseLiability" xlink:label="calc_RightOfUseAssetOrLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:label="calc_TwoThousandAndTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_DirectorsEmployeesOrConsultantsMember" xlink:label="calc_DirectorsEmployeesOrConsultantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryNotesSecuritiesMember" xlink:label="us-gaap_USTreasuryNotesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TrancheBCommonWarrantsMember" xlink:label="calc_TrancheBCommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:label="calc_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesC1ConvertiblePreferredStockMember" xlink:label="calc_SeriesC1ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TemporaryEquityDisclosureTextblock" xlink:label="calc_TemporaryEquityDisclosureTextblock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_WarrantLiability" xlink:label="calc_WarrantLiability"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_BusinessCombinationConsiderationTransferedCostIncurred" xlink:label="calc_BusinessCombinationConsiderationTransferedCostIncurred"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingRightsAnniversaryPeriod" xlink:label="calc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingRightsAnniversaryPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TwoThousandAndTwentyThreeEquityIncentivePlanMember" xlink:label="calc_TwoThousandAndTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="us-gaap_ProceedsFromOtherEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PublicCombinationMultipliedCashPricePaidPerShare" xlink:label="calc_PublicCombinationMultipliedCashPricePaidPerShare"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndNoncurrentAssets" xlink:label="calc_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_FederalResearchAndDevelopmentMember" xlink:label="calc_FederalResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="calc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_RestrictedStockUnitsNetSettlementShares" xlink:label="calc_RestrictedStockUnitsNetSettlementShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_DeemedDistribution" xlink:label="calc_DeemedDistribution"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="calc_DeferredTaxLiabilitiesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_InducementGrantsMember" xlink:label="calc_InducementGrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="calc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_GrossProceedsFromThePrivatePlacement" xlink:label="calc_GrossProceedsFromThePrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesBConvertiblePreferredStockMember" xlink:label="calc_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ExpectedPerShare" xlink:label="calc_ExpectedPerShare"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AccruedOther" xlink:label="calc_AccruedOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PreferredAndCommonStockMember" xlink:label="calc_PreferredAndCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesDConvertiblePreferredStockMember" xlink:label="calc_SeriesDConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TransactionFeePercentage" xlink:label="calc_TransactionFeePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="us-gaap_CostsAndExpensesRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConversionOfC2WarrantsToCommonStock" xlink:label="calc_ConversionOfC2WarrantsToCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesAConvertiblePreferredStockMember" xlink:label="calc_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ExerciseAndConversionOfC2WarrantsShares" xlink:label="calc_ExerciseAndConversionOfC2WarrantsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PostMergerCalcimedicaMember" xlink:label="calc_PostMergerCalcimedicaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ContractualObligationOfContractInEffect" xlink:label="calc_ContractualObligationOfContractInEffect"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PercentageOfMoreBeneficialOwnership" xlink:label="calc_PercentageOfMoreBeneficialOwnership"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="us-gaap_USTreasuryBillSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PercentageOfWarrantCoverage" xlink:label="calc_PercentageOfWarrantCoverage"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_RelatedPartyTransactionsPolicyTextBlock" xlink:label="calc_RelatedPartyTransactionsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShortTermOperatingLeaseExpirationDate" xlink:label="calc_ShortTermOperatingLeaseExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="calc_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_FinancingCostsIncludedInAccountsPayable" xlink:label="calc_FinancingCostsIncludedInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConvertiblePromissoryNoteWarrantsLiabilityMember" xlink:label="calc_ConvertiblePromissoryNoteWarrantsLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CommissionsAndOtherTransactionExpenses" xlink:label="calc_CommissionsAndOtherTransactionExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesAndFairValueTextBlock" xlink:label="us-gaap_DerivativesAndFairValueTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_NumberOfSharesIssuedFinallyOnTransaction" xlink:label="calc_NumberOfSharesIssuedFinallyOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SummaryOfSignificantAccountingPoliciesTable" xlink:label="calc_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesC2ConvertiblePreferredStockMember" xlink:label="calc_SeriesC2ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:label="calc_TwoThousandAndTwentyEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_NumberOfSharesIssuedInitiallyOnTransaction" xlink:label="calc_NumberOfSharesIssuedInitiallyOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_BaseRent" xlink:label="calc_BaseRent"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PreFundedWarrantsMember" xlink:label="calc_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShortTermInvestmentsAssumedInTheMerger" xlink:label="calc_ShortTermInvestmentsAssumedInTheMerger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AssetsFairValueDisclosureAmortizedCostBasis" xlink:label="calc_AssetsFairValueDisclosureAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PreferredWarrantsLiabilityMember" xlink:label="calc_PreferredWarrantsLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CostsIncurredInConnectionWithReverseMergerIncludedInAccountsPayableAndAccruedExpenses" xlink:label="calc_CostsIncurredInConnectionWithReverseMergerIncludedInAccountsPayableAndAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMergerShares" xlink:label="calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMergerShares"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember" xlink:label="calc_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_UnpaidCancellationAndOtherRelatedCosts" xlink:label="calc_UnpaidCancellationAndOtherRelatedCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_BeneficialOwnershipPercentage" xlink:label="calc_BeneficialOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SettlementOfAccruedBonusAndEmployeeCosts" xlink:label="calc_SettlementOfAccruedBonusAndEmployeeCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesCTwoConvertiblePreferredStockMember" xlink:label="calc_SeriesCTwoConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_NonCashInterestExpense" xlink:label="calc_NonCashInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConvertiblePromissoryNoteWarrantsCommonStockConverted" xlink:label="calc_ConvertiblePromissoryNoteWarrantsCommonStockConverted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_DeferredTaxLiabilitiesValuationAllowance" xlink:label="calc_DeferredTaxLiabilitiesValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CommonWarrantsMember" xlink:label="calc_CommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConvertiblePreferredStockSeriesABC1C2AndDMember" xlink:label="calc_ConvertiblePreferredStockSeriesABC1C2AndDMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AmendedAndRestatedCertificateOfIncorporationMember" xlink:label="calc_AmendedAndRestatedCertificateOfIncorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_NumberOfContractCurrentlyInEffect" xlink:label="calc_NumberOfContractCurrentlyInEffect"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConversionOfPromissoryNoteWarrantIntoCommonstock" xlink:label="calc_ConversionOfPromissoryNoteWarrantIntoCommonstock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis" xlink:label="calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CalcimedicaIncMember" xlink:label="calc_CalcimedicaIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AccountsPayableAndAccruedLiabilitiesAssumedInTheMerger" xlink:label="calc_AccountsPayableAndAccruedLiabilitiesAssumedInTheMerger"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_DebtInstrumentPeriodicPaymentPrincipalAdditional" xlink:label="calc_DebtInstrumentPeriodicPaymentPrincipalAdditional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_IssuanceOfCommonSharesFromPrivatePlacementNetShares" xlink:label="calc_IssuanceOfCommonSharesFromPrivatePlacementNetShares"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PercentageOfAggregateNumberOfSharesOfCommonStockOutstandingOnLastDayOfPrecedingYearAddedToPlan" xlink:label="calc_PercentageOfAggregateNumberOfSharesOfCommonStockOutstandingOnLastDayOfPrecedingYearAddedToPlan"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_OfficersAndDirectorsMember" xlink:label="calc_OfficersAndDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PatentsCostsPolicyTextBlock" xlink:label="calc_PatentsCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PreferredWarrantsMember" xlink:label="calc_PreferredWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_GraybugMember" xlink:label="calc_GraybugMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AccruedResearchAndDevelopmentCostsPolicyTextBlock" xlink:label="calc_AccruedResearchAndDevelopmentCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_IssuanceOfCommonSharesFromPrivatePlacementNet" xlink:label="calc_IssuanceOfCommonSharesFromPrivatePlacementNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xlink:label="calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_LeaseAmendmentDate" xlink:label="calc_LeaseAmendmentDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SaleOfStockRemainingSalesAmount" xlink:label="calc_SaleOfStockRemainingSalesAmount"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_NetProceedsFromPrivatePlacement" xlink:label="calc_NetProceedsFromPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConvertiblePromissoryNoteWarrantsConvertible" xlink:label="calc_ConvertiblePromissoryNoteWarrantsConvertible"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_IncomeTaxReconciliationPermanentDifferences" xlink:label="calc_IncomeTaxReconciliationPermanentDifferences"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PercentageOfOwnershipDuringElection" xlink:label="calc_PercentageOfOwnershipDuringElection"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_StockIssuedDuringPeriodSharesConversionOfPromissoryNotes" xlink:label="calc_StockIssuedDuringPeriodSharesConversionOfPromissoryNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsStateTaxes" xlink:label="us-gaap_DeferredTaxAssetsStateTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_RestrictedStockUnitsNetSettlement" xlink:label="calc_RestrictedStockUnitsNetSettlement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:label="us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConversionOfConvertiblePromissoryNoteWarrantsToCommonStock" xlink:label="calc_ConversionOfConvertiblePromissoryNoteWarrantsToCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_LesseeOperatingLeaseMaturityYearAndMonth" xlink:label="calc_LesseeOperatingLeaseMaturityYearAndMonth"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShelfRegistrationStatementAvaliableForSale" xlink:label="calc_ShelfRegistrationStatementAvaliableForSale"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PreferredWarrantMember" xlink:label="calc_PreferredWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_InterestOnConvertiblePromissoryNotesPayable" xlink:label="calc_InterestOnConvertiblePromissoryNotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ChangeInFairValueOfWarrantLiability" xlink:label="calc_ChangeInFairValueOfWarrantLiability"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TaxPostionMinimumPercentageOfTaxBenefit" xlink:label="calc_TaxPostionMinimumPercentageOfTaxBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TwoThousandAndSixEquityIncentivePlanMember" xlink:label="calc_TwoThousandAndSixEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityOwnershipPercentage" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PrepaidExpensesAndOtherCurrentAssets" xlink:label="calc_PrepaidExpensesAndOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesCTwoWarrantsMember" xlink:label="calc_SeriesCTwoWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_UnrecognizedTaxBenefitsNet" xlink:label="calc_UnrecognizedTaxBenefitsNet"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_WarrantLiabilityPolicyPolicyTextBlock" xlink:label="calc_WarrantLiabilityPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PriorToMergerTransactionsMember" xlink:label="calc_PriorToMergerTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CalcimedicaCommonStockMember" xlink:label="calc_CalcimedicaCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConvertiblePreferredStockAbstract" xlink:label="calc_ConvertiblePreferredStockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesDWarrantsMember" xlink:label="calc_SeriesDWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsDate" xlink:label="us-gaap_SubsequentEventsDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AmendmentToTwoThousandAndSixEquityIncentivePlanMember" xlink:label="calc_AmendmentToTwoThousandAndSixEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_StockIssuedDuringPeriodValueConversionOfPromissoryNotes" xlink:label="calc_StockIssuedDuringPeriodValueConversionOfPromissoryNotes"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_DeferredTaxAssetLeaseLiabilities" xlink:label="calc_DeferredTaxAssetLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_StockholdersEquityNoteStockSplitExchangeRatio" xlink:label="calc_StockholdersEquityNoteStockSplitExchangeRatio"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConversionOfPromissoryNoteWarrantsIntoCommonStockShare" xlink:label="calc_ConversionOfPromissoryNoteWarrantsIntoCommonStockShare"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ClassOfWarrantRedeemOutstandingDescription" xlink:label="calc_ClassOfWarrantRedeemOutstandingDescription"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PaymentsOfAcquisitionOfBusinessesNetOfCash" xlink:label="calc_PaymentsOfAcquisitionOfBusinessesNetOfCash"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis" xlink:label="calc_CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConvertiblePromissoryNoteMember" xlink:label="calc_ConvertiblePromissoryNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_JonesTradingMember" xlink:label="calc_JonesTradingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_StockIssuedDuringPeriodPrivatePlacement" xlink:label="calc_StockIssuedDuringPeriodPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PlacementAgentWarrantsMember" xlink:label="calc_PlacementAgentWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TotalNetProceeds" xlink:label="calc_TotalNetProceeds"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrantsExercisable" xlink:label="calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrantsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AccruedSeveranceExpense" xlink:label="calc_AccruedSeveranceExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AccreditedInvestorsMember" xlink:label="calc_AccreditedInvestorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_GraybugVisionIncMember" xlink:label="calc_GraybugVisionIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_NetDeferredTaxAsset" xlink:label="calc_NetDeferredTaxAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConversionOfConvertiblePromissoryNotesToCommonStock" xlink:label="calc_ConversionOfConvertiblePromissoryNotesToCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AuxoraMember" xlink:label="calc_AuxoraMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CalcimedicaPreferredStockMember" xlink:label="calc_CalcimedicaPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="calc_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ExchangeOfStockForStock" xlink:label="calc_ExchangeOfStockForStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShelfRegistrationStatementMember" xlink:label="calc_ShelfRegistrationStatementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AtTheMarketOfferingMember" xlink:label="calc_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConversionOfSeriesC2WarrantIntoCommonStock" xlink:label="calc_ConversionOfSeriesC2WarrantIntoCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PrivateCalcimedicaMember" xlink:label="calc_PrivateCalcimedicaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger" xlink:label="calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ChangeInFairValueOfConvertiblePromissoryNote" xlink:label="calc_ChangeInFairValueOfConvertiblePromissoryNote"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ProceedsFromIssuanceOfConvertibleNotes" xlink:label="calc_ProceedsFromIssuanceOfConvertibleNotes"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PostMergerTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Post merger transactions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PostMergerTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Post Merger Transactions [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PostMergerTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Post Merger Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ShortTermInvestmentFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ShortTermInvestmentFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investment Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ShortTermInvestmentFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short-term investment fair value disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ShortTermInvestmentFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total short-term investments, Aggregate Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ShortTermInvestmentFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short Term Investment Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commissions paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Liabilities Measured at Fair Value Using Level 3 Inputs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_OperatingLossCarryForwardsExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards expiration beginning year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_OperatingLossCarryForwardsExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carry Forwards Expiration Beginning Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_OperatingLossCarryForwardsExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carry forwards expiration beginning year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short term investment fair value disclosure accumulated gross unrealized gain before tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investment Fair Value Disclosure Accumulated Gross Unrealized Gain Before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total short-term investments, Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TrancheAAndTrancheBCommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche A and Tranche B Common Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TrancheAAndTrancheBCommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche A and Tranche B Common Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TrancheAAndTrancheBCommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche A and tranche B common warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PreMergerCalcimedicaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre Merger CalciMedica [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PreMergerCalcimedicaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Merger CalciMedica</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConvertiblePromissoryNoteWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible Promissory Note Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConvertiblePromissoryNoteWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Promissory Note Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConvertiblePromissoryNoteWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Promissory Note Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredPolicyAcquisitionCostsTextBlock1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Policy Acquisition Costs [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredPolicyAcquisitionCostsTextBlock1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_FairValueAdjustmentOfConvertiblePromissoryNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of expense (income) related to adjustment to fair value of convertible promissory notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_FairValueAdjustmentOfConvertiblePromissoryNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment of Convertible Promissory Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_FairValueAdjustmentOfConvertiblePromissoryNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in the fair value of convertible promissory notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_MergerTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Merger transaction costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_MergerTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Merger Transaction Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_MergerTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Merger transaction costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of information about income tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_GrossProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from issuance of private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_GrossProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds from Issuance of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_GrossProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from issuance of private placement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AccruedClinicalTrialCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Clinical Trial Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AccruedClinicalTrialCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Trial Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AccruedClinicalTrialCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical trial costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for services, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Issued for Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AccruedFranchiseTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued franchise tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AccruedFranchiseTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Franchise Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AccruedFranchiseTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued franchise tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Available For Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities measured at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, convertible preferred stock and stockholders' equity (deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock (net of issuance costs)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options issued and outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of options, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of options, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted averagefair value options, granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_WarrantsToPurchaseConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to Purchase Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_WarrantsToPurchaseConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants to purchase convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_WarrantsToPurchaseConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants to Purchase Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease in warrant exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant, Exercise Price, Decrease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total prepaid and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PercentageOfChangeInOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of change in ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PercentageOfChangeInOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Change in Ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PercentageOfChangeInOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of change in ownership.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MD_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MARYLAND</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MD_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Baltimore, Maryland</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TrancheACommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche A Common Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TrancheACommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche A Common Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TrancheACommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche A common warrants member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total common stock reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Merger and Related Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of information about income tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AccruedPayrollAndOtherEmployeeBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued payroll and other employee benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AccruedPayrollAndOtherEmployeeBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Payroll and Other Employee Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AccruedPayrollAndOtherEmployeeBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Payroll and Other Employee Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Other than Long-Term Debt, Noncurrent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SeriesBWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SeriesBWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SeriesBWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Promissory Notes and Convertible Promissory Note Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, stock issued during period, shares, conversion of convertible securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock to common stock as a result of the Merger, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions for tax positions of prior years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_RightOfUseAssetOrLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Right-of-use asset or lease liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_RightOfUseAssetOrLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset or Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_RightOfUseAssetOrLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset or lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TwoThousandAndTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TwoThousandAndTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TwoThousandAndTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_DirectorsEmployeesOrConsultantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Directors, Employees Or Consultants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_DirectorsEmployeesOrConsultantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Directors, Employees Or Consultants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_DirectorsEmployeesOrConsultantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Directors, employees or consultants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryNotesSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Notes Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryNotesSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TrancheBCommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche B Common Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TrancheBCommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche B Common Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TrancheBCommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche B common warrants member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants converted to common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock and warrants issued during period shares common stock and warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock and warrants issued during period shares common stock and warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets measured at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total asset measured at fair value, Aggregate Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SeriesC1ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C-1 Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SeriesC1ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C-1 Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SeriesC1ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C-1Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TemporaryEquityDisclosureTextblock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TemporaryEquityDisclosureTextblock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [TextBlock]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TemporaryEquityDisclosureTextblock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock, Common Stock and Stockholders' Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development tax credits, net of uncertain positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits, net of uncertain positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_WarrantLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_WarrantLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_BusinessCombinationConsiderationTransferedCostIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination, consideration transfered cost incurred.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_BusinessCombinationConsiderationTransferedCostIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transfered Cost Incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_BusinessCombinationConsiderationTransferedCostIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingRightsAnniversaryPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, vesting rights, anniversary period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingRightsAnniversaryPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Vesting Rights, Anniversary Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingRightsAnniversaryPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award vesting rights, anniversary period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingRightsAnniversaryPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Award vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Separately Recognized Transactions [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrecognized stock-based compensation expenses related to outstanding unvested stock awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TwoThousandAndTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty three equity incentive plan member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TwoThousandAndTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Three Equity Incentive Plan Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TwoThousandAndTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Other Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance or Sale of Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance and sale of equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PublicCombinationMultipliedCashPricePaidPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public combination multiplied cash price paid per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PublicCombinationMultipliedCashPricePaidPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Combination Multiplied Cash Price Paid Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PublicCombinationMultipliedCashPricePaidPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public combination multiplied cash price paid per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in prepaid expenses and other current and noncurrent assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Expenses And Other Current And Noncurrent Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current and non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_FederalResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_FederalResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Federal Research and Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_FederalResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares new issues.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_RestrictedStockUnitsNetSettlementShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock units net settlement shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_RestrictedStockUnitsNetSettlementShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units Net Settlement Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_RestrictedStockUnitsNetSettlementShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock units net settlement, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax computed at federal statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax computed at federal statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Severance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Severance and termination benefit expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_DeemedDistribution_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deemed distribution</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_DeemedDistribution_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deemed Distribution</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_DeemedDistribution_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deemed Distribution</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options to Purchase Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of stock, shares converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Right of Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities right of use assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_InducementGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Inducement grants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_InducementGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inducement Grants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_InducementGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inducement Grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, by Balance Sheet Grouping [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value By Balance Sheet Grouping [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, stock issued during period, value, conversion of convertible securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value Conversion Of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock to common stock as a result of the Merger, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from issue of convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gross cash proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares available for grant (shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_GrossProceedsFromThePrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from the private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_GrossProceedsFromThePrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds From The Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_GrossProceedsFromThePrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from the private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term, options vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series B Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ExpectedPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Expected per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ExpectedPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expected Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ExpectedPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Assets fair value disclosure accumulated gross unrealized gain before tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure Accumulated Gross Unrealized Gain Before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total asset measured at fair value, Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock issued for services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Consideration Transferred, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consideration Transferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AccruedOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AccruedOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AccruedOther_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued other.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision or benefit for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reduction for tax positions of prior years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature of Operations [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Acquisitions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of stock issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of options, Assumed in the Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award vesting rights, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PreferredAndCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred and Common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PreferredAndCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">preferred and common stock member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PreferredAndCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred and Common stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SeriesDConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series D convertible preferred stock member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SeriesDConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SeriesDConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase related to current year tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TransactionFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction fee percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TransactionFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Fee Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TransactionFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transaction fee percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of stock, price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Costs and Expenses, Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Costs and expenses related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConversionOfC2WarrantsToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of C-2 warrants to common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConversionOfC2WarrantsToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of C-2 Warrants to Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConversionOfC2WarrantsToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of C-2 warrants to common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized gain on available-for-sale securities, net of tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain on available-for-sale securities, net of tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A Convertible Preferred StockMember</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ExerciseAndConversionOfC2WarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of Series C-2 warrants into common stock, share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ExerciseAndConversionOfC2WarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise and conversion of C-2 Warrants, Shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ExerciseAndConversionOfC2WarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise And Conversion Of C-2 Warrants Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PostMergerCalcimedicaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Post Merger CalciMedica [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PostMergerCalcimedicaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Post Merger CalciMedica</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ContractualObligationOfContractInEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual obligation of contract in effect.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ContractualObligationOfContractInEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation Of Contract In Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ContractualObligationOfContractInEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual obligation of contract in effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PercentageOfMoreBeneficialOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of more beneficial ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PercentageOfMoreBeneficialOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of More Beneficial Ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PercentageOfMoreBeneficialOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of more beneficial ownership.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryBillSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Bill Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryBillSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury bills</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Assets fair value disclosure accumulated gross unrealized loss before tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure Accumulated Gross Unrealized Loss Before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Total asset measured at fair value, Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PercentageOfWarrantCoverage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of warrant coverage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PercentageOfWarrantCoverage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Warrant Coverage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PercentageOfWarrantCoverage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of warrant coverage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_RelatedPartyTransactionsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_RelatedPartyTransactionsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party transactions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_RelatedPartyTransactionsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Policy Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ShortTermOperatingLeaseExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short term operating lease expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ShortTermOperatingLeaseExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Operating Lease Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ShortTermOperatingLeaseExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short term operating lease expiration date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, options vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Rent Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity (deficit) (1)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain on investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Lease Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Common Stock Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of schedule of common stock reserved for future issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Common Stock Reserved for Future issuance [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_FinancingCostsIncludedInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing costs included in accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_FinancingCostsIncludedInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Costs Included in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_FinancingCostsIncludedInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Financing costs included in accounts payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConvertiblePromissoryNoteWarrantsLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible promissory note warrants liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConvertiblePromissoryNoteWarrantsLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Promissory Note Warrants Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConvertiblePromissoryNoteWarrantsLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible promissory note warrants liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_CommissionsAndOtherTransactionExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commissions and other transaction expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_CommissionsAndOtherTransactionExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commissions And Other Transaction Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_CommissionsAndOtherTransactionExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commissions and other transaction expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesAndFairValueTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivatives and Fair Value [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesAndFairValueTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued during period upon conversion of units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk and other Risks and Uncertainties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payables and accruals incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid and other current assets obtained</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_NumberOfSharesIssuedFinallyOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued finally on transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_NumberOfSharesIssuedFinallyOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Shares Issued Finally on Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_NumberOfSharesIssuedFinallyOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares issued finally on transaction.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share&#8212;basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 9)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Acquisition Related Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acceleration of stock awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of warrant liability to equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share&#8212;diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards limitations on use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards, Limitations on Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Separately Recognized Transactions [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SeriesC2ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C-2 Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SeriesC2ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C-2 Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SeriesC2ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C-2 Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized tax benefits gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized tax benefits gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions in connection with the reverse merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_NumberOfSharesIssuedInitiallyOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued initially on transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_NumberOfSharesIssuedInitiallyOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Shares Issued Initially on Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_NumberOfSharesIssuedInitiallyOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares issued initially on transaction.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_BaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Base rent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_BaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Base Rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_BaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Base rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-funded warrants member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Recurring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ShortTermInvestmentsAssumedInTheMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short-term investments assumed in the merger.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ShortTermInvestmentsAssumedInTheMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investments Assumed in the Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ShortTermInvestmentsAssumedInTheMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments assumed in the Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AssetsFairValueDisclosureAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Assets fair value disclosure amortized cost basis.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AssetsFairValueDisclosureAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure Amortized Cost Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AssetsFairValueDisclosureAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total asset measured at fair value, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AssetsFairValueDisclosureAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total asset measured at fair value, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PreferredWarrantsLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred warrants liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PreferredWarrantsLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Warrants Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PreferredWarrantsLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred warrants liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of common stock options, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders' Equity (Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_CostsIncurredInConnectionWithReverseMergerIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Costs incurred in connection with reverse merger included in accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_CostsIncurredInConnectionWithReverseMergerIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Costs Incurred in Connection with Reverse Merger Included in Accounts Payable and Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_CostsIncurredInConnectionWithReverseMergerIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Costs incurred in connection with reverse merger included in accounts payable and accrued expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMergerShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock to Graybug stockholders as a result of the merger, Shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMergerShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock To Graybug Stockholders As A Result Of The Merger Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMergerShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock to Graybug stockholders as a result of Merger and reset to par of $0.0001, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty three employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Three Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_UnpaidCancellationAndOtherRelatedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unpaid cancellation and other related costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_UnpaidCancellationAndOtherRelatedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unpaid Cancellation And Other Related Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_UnpaidCancellationAndOtherRelatedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unpaid cancellation and other related costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_BeneficialOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of beneficial ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_BeneficialOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Beneficial Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_BeneficialOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of beneficial ownership.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale, Maturity and Collection of Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale, Maturity and Collection of Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity of investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of convertible promissory note converted into common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Par Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant, Down Round Feature, Increase (Decrease) in Equity, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of warrant liability to equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SettlementOfAccruedBonusAndEmployeeCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Settlement of accrued bonus and employee costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SettlementOfAccruedBonusAndEmployeeCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Settlement Of Accrued Bonus And Employee Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SettlementOfAccruedBonusAndEmployeeCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement of 2021 and 2020 accrued bonus and employee costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect, Period of Adoption [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrecognized stock-based compensation expenses related to outstanding unvested stock awards weighted-average term of recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance of private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SeriesCTwoConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C two convertible preferred stock member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SeriesCTwoConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Two Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SeriesCTwoConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C-2 Preferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity, Beginning balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary equity, Ending balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_NonCashInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-cash Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_NonCashInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non cash Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_NonCashInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConvertiblePromissoryNoteWarrantsCommonStockConverted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible promissory note warrants common stock converted.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConvertiblePromissoryNoteWarrantsCommonStockConverted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Promissory Note Warrants Common Stock Converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConvertiblePromissoryNoteWarrantsCommonStockConverted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible promissory note warrants common stock converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in the fair value of warrant liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value of warrant liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary equity, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of options, forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Assumed in the Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document financial statement error correction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_DeferredTaxLiabilitiesValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_DeferredTaxLiabilitiesValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_DeferredTaxLiabilitiesValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_DeferredTaxLiabilitiesValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities valuation allowance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_CommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_CommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_CommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common warrants member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConvertiblePreferredStockSeriesABC1C2AndDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock series A, B, C-1, C-2 and D.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConvertiblePreferredStockSeriesABC1C2AndDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Series A, B, C-1, C-2 and D [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConvertiblePreferredStockSeriesABC1C2AndDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock Series A, B, C-1, C-2 and D [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AmendedAndRestatedCertificateOfIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended and restated certificate of incorporation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AmendedAndRestatedCertificateOfIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended And Restated Certificate of Incorporation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AmendedAndRestatedCertificateOfIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended and Restated Certificate of Incorporation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average number of shares outstanding used in computing net loss per share&#8212;basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average common stock outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Merger Related Costs, Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Merger transaction costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_NumberOfContractCurrentlyInEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of contract currently in effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_NumberOfContractCurrentlyInEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Contract Currently In Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_NumberOfContractCurrentlyInEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of contract currently in effect.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConversionOfPromissoryNoteWarrantIntoCommonstock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of promissory note warrant into commonstock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConversionOfPromissoryNoteWarrantIntoCommonstock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Promissory Note Warrant into Commonstock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConversionOfPromissoryNoteWarrantIntoCommonstock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of promissory note warrants into common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short term investment fair value disclosure amortized cost basis.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investment Fair Value Disclosure Amortized Cost Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total short-term investments, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Transations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assumptions Using Black-Scholes to Estimate Fair Value of the Stock Option Grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_CalcimedicaIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CalciMedica, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_CalcimedicaIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CalciMedica Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_CalcimedicaIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CalciMedica</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value, Net Asset (Liability), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Net Asset (Liability)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liability fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AccountsPayableAndAccruedLiabilitiesAssumedInTheMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts payable and accrued liabilities assumed in the merger.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AccountsPayableAndAccruedLiabilitiesAssumedInTheMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Assumed in the Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AccountsPayableAndAccruedLiabilitiesAssumedInTheMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued liabilities assumed in the Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_DebtInstrumentPeriodicPaymentPrincipalAdditional_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument periodic payment principal additional</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_DebtInstrumentPeriodicPaymentPrincipalAdditional_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Periodic Payment Principal Additional</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_DebtInstrumentPeriodicPaymentPrincipalAdditional_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Addiitional convertible promissory notes and Convertible Promissory Note Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_IssuanceOfCommonSharesFromPrivatePlacementNetShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares from private placement (net of issuance costs), shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_IssuanceOfCommonSharesFromPrivatePlacementNetShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common shares from private placement, net, shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_IssuanceOfCommonSharesFromPrivatePlacementNetShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Shares From Private Placement Net Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PercentageOfAggregateNumberOfSharesOfCommonStockOutstandingOnLastDayOfPrecedingYearAddedToPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of aggregate number of shares of common stock outstanding on last day of preceding year added to plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PercentageOfAggregateNumberOfSharesOfCommonStockOutstandingOnLastDayOfPrecedingYearAddedToPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Aggregate Number Of Shares Of Common Stock Outstanding On Last Day Of Preceding Year Added To Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PercentageOfAggregateNumberOfSharesOfCommonStockOutstandingOnLastDayOfPrecedingYearAddedToPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of aggregate number of shares of common stock outstanding on last day of preceding year added to plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_OfficersAndDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Officers and directors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_OfficersAndDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Officers and Directors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_OfficersAndDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Officers and Directors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive securities excluded from calculation of diluted net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PatentsCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patents Costs Policy Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PatentsCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Patents costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PatentsCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PreferredWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PreferredWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to Purchase Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Deferred Tax Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect, Period of Adoption [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_GraybugMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Graybug.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_GraybugMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Graybug [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_GraybugMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Graybug</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AccruedResearchAndDevelopmentCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AccruedResearchAndDevelopmentCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Costs Policy Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AccruedResearchAndDevelopmentCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_IssuanceOfCommonSharesFromPrivatePlacementNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares from private placement (net of issuance costs)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_IssuanceOfCommonSharesFromPrivatePlacementNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common shares from private placement, net.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_IssuanceOfCommonSharesFromPrivatePlacementNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Shares From Private Placement Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation Expense Recognized for Options and RSUs Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion of discount on short-term investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock and warrants issued during period shares preferred stock and warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock and Warrants Issued During Period Shares Preferred Stock and Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of C-2 warrants to common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion of preferred stock to common stock as a result of the Merger, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_LeaseAmendmentDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease amendment date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_LeaseAmendmentDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Amendment Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_LeaseAmendmentDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Amendment Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SaleOfStockRemainingSalesAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of stock remaining sales amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SaleOfStockRemainingSalesAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock Remaining Sales Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SaleOfStockRemainingSalesAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining amount of available for sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_NetProceedsFromPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_NetProceedsFromPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds From Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_NetProceedsFromPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net proceeds from private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents fair value disclosure accumulated gross unrealized loss before tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure Accumulated Gross Unrealized Loss Before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Total cash equivalents, Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrual for interest and penalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, by Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Periodic Payment, Principal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance or Sale of Convertible Promissory Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConvertiblePromissoryNoteWarrantsConvertible_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible promissory note warrants convertible.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConvertiblePromissoryNoteWarrantsConvertible_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Promissory Note Warrants Convertible</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConvertiblePromissoryNoteWarrantsConvertible_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible promissory note warrants convertible</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_IncomeTaxReconciliationPermanentDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_IncomeTaxReconciliationPermanentDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Permanent Differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_IncomeTaxReconciliationPermanentDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation permanent differences.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PercentageOfOwnershipDuringElection_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of ownership during election</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PercentageOfOwnershipDuringElection_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Ownership during Election</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PercentageOfOwnershipDuringElection_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of ownership during election.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_StockIssuedDuringPeriodSharesConversionOfPromissoryNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares conversion of promissory notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_StockIssuedDuringPeriodSharesConversionOfPromissoryNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Promissory Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_StockIssuedDuringPeriodSharesConversionOfPromissoryNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of promissory notes into common stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsStateTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State tax, net of federal tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsStateTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, State Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of common stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of convertible notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Convertible Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds of Convertible Promissory Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Principles of Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Ownership percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of ownership of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_RestrictedStockUnitsNetSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock units net settlement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_RestrictedStockUnitsNetSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units Net Settlement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_RestrictedStockUnitsNetSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock units net settlement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_RestrictedStockUnitsNetSettlement_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Restricted stock units net settlement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Mortgage-Backed Securities, Issued by US Government Sponsored Enterprises [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Sponsored Entities - Mortgagebacked Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConversionOfConvertiblePromissoryNoteWarrantsToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of convertible promissory note warrants to common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConversionOfConvertiblePromissoryNoteWarrantsToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Convertible Promissory Note Warrants to Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConversionOfConvertiblePromissoryNoteWarrantsToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible promissory note warrants to common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_LesseeOperatingLeaseMaturityYearAndMonth_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_LesseeOperatingLeaseMaturityYearAndMonth_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Maturity Year And Month</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_LesseeOperatingLeaseMaturityYearAndMonth_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease maturity year and month.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ShelfRegistrationStatementAvaliableForSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shelf registration statement avaliable for sale.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ShelfRegistrationStatementAvaliableForSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shelf Registration Statement Avaliable for Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ShelfRegistrationStatementAvaliableForSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available for sale under Shelf Registration Statement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PreferredWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred Warrant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PreferredWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agrgregate intrinsic value, vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_InterestOnConvertiblePromissoryNotesPayable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest on convertible promissory notes payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_InterestOnConvertiblePromissoryNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest on convertible promissory notes payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_InterestOnConvertiblePromissoryNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest On Convertible Promissory Notes Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_InterestOnConvertiblePromissoryNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest on convertible promissory notes payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ChangeInFairValueOfWarrantLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of warrant liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ChangeInFairValueOfWarrantLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value of Warrant Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ChangeInFairValueOfWarrantLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change In Fair Value of Warrant Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TaxPostionMinimumPercentageOfTaxBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax postion, minimum percentage of tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TaxPostionMinimumPercentageOfTaxBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax postion, minimum percentage of tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TaxPostionMinimumPercentageOfTaxBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Postion, Minimum Percentage of Tax Benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TwoThousandAndSixEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and six equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TwoThousandAndSixEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Six Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TwoThousandAndSixEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2006 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable interest entity ownership percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PrepaidExpensesAndOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid expenses and other current assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PrepaidExpensesAndOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PrepaidExpensesAndOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets assumed in the Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price of warrants per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SeriesCTwoWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C two warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SeriesCTwoWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Two Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SeriesCTwoWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C-2 Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Amount Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of Series A, B, C-1, C-2 and D convertible preferred stock to common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total cash equivalents, Aggregate Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_UnrecognizedTaxBenefitsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_UnrecognizedTaxBenefitsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_UnrecognizedTaxBenefitsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrecognized tax benefits net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_WarrantLiabilityPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_WarrantLiabilityPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Liability, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_WarrantLiabilityPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PriorToMergerTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prior to merger transactions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PriorToMergerTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prior to Merger Transactions [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PriorToMergerTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prior to Merger Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_CalcimedicaCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Calcimedica Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_CalcimedicaCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Calcimedica Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_CalcimedicaCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Calcimedica Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deemed distribution to convertible promissory note holders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate During Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConvertiblePreferredStockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConvertiblePreferredStockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible preferred stock [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConvertiblePreferredStockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SeriesDWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series D warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SeriesDWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SeriesDWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total fair value of shares vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent event date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event, Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AmendmentToTwoThousandAndSixEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amendment to two thousand and six equity incentive plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AmendmentToTwoThousandAndSixEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment to Two Thousand and Six Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AmendmentToTwoThousandAndSixEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment to 2006 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State tax, net of federal tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Chief Financial Officer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Chief Financial Officer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_StockIssuedDuringPeriodValueConversionOfPromissoryNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value conversion of promissory notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_StockIssuedDuringPeriodValueConversionOfPromissoryNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Promissory Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_StockIssuedDuringPeriodValueConversionOfPromissoryNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of promissory notes into common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_DeferredTaxAssetLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_DeferredTaxAssetLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Asset, Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_DeferredTaxAssetLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax asset lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Company's Financial Assets Measured at Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_StockholdersEquityNoteStockSplitExchangeRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stockholders equity note stock split exchange ratio.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_StockholdersEquityNoteStockSplitExchangeRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Stock Split Exchange Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_StockholdersEquityNoteStockSplitExchangeRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders equity note stock split exchange ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents fair value disclosure accumulated gross unrealized gain before tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure Accumulated Gross Unrealized Gain Before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total cash equivalents, Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConversionOfPromissoryNoteWarrantsIntoCommonStockShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of promissory note warrants into common stock share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConversionOfPromissoryNoteWarrantsIntoCommonStockShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Promissory Note Warrants into Common Stock share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConversionOfPromissoryNoteWarrantsIntoCommonStockShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of promissory note warrants into common stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short term investment fair value disclosure accumulated gross unrealized loss before tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investment Fair Value Disclosure Accumulated Gross Unrealized Loss Before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total short-term investments, Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ClassOfWarrantRedeemOutstandingDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeem outstanding warrant description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ClassOfWarrantRedeemOutstandingDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Redeem Outstanding Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ClassOfWarrantRedeemOutstandingDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant redeem outstanding description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PaymentsOfAcquisitionOfBusinessesNetOfCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of aquisition of businesses net of cash.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PaymentsOfAcquisitionOfBusinessesNetOfCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Acquisition of Businesses Net of Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PaymentsOfAcquisitionOfBusinessesNetOfCash_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisition of stock of Graybug, net of cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents fair value disclosure amortized cost basis.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure Amortized Cost Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash equivalents, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConvertiblePromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible Promissory Note [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConvertiblePromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Promissory Note [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_JonesTradingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Jones Trading</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_JonesTradingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Jones Trading [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_JonesTradingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Jones trading member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_StockIssuedDuringPeriodPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, private placement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_StockIssuedDuringPeriodPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_StockIssuedDuringPeriodPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issued during period private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PlacementAgentWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Placement Agent Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PlacementAgentWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Placement Agent Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PlacementAgentWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Placement agent warrants member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TotalNetProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total net proceeds.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TotalNetProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total Net Proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_TotalNetProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total net proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Convertible Notes Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Notes Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible promissory notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrantsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock and warrants issued during period shares preferred stock and warrants exercisable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrantsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock and Warrants Issued During Period Shares Preferred Stock and Warrants Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrantsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AccruedSeveranceExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued severance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AccruedSeveranceExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Severance Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AccruedSeveranceExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued severance expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AccreditedInvestorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accredited Investors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AccreditedInvestorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accredited Investors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AccreditedInvestorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accredited Investors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_GraybugVisionIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Graybug Vision, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_GraybugVisionIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Graybug Vision Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_GraybugVisionIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Graybug</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of C-2 warrants to common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion of preferred stock to common stock as a result of the Merger, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_NetDeferredTaxAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_NetDeferredTaxAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Deferred Tax Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_NetDeferredTaxAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net deferred tax assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value by Liability Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConversionOfConvertiblePromissoryNotesToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of convertible promissory notes to common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConversionOfConvertiblePromissoryNotesToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Convertible Promissory Notes to Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConversionOfConvertiblePromissoryNotesToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible promissory notes to common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AuxoraMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Auxora.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AuxoraMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auxora [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AuxoraMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auxora</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_CalcimedicaPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Calcimedica preferred stock member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_CalcimedicaPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Calcimedica Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_CalcimedicaPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Calcimedica Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credit carry forwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental cash flow information:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expense), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity (deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss and comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ExchangeOfStockForStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exchange of stock for stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ExchangeOfStockForStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exchange of Stock for Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ExchangeOfStockForStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange of stock for stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average number of shares outstanding used in computing net loss per share&#8212;diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average common stock outstanding, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ShelfRegistrationStatementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shelf registration statement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ShelfRegistrationStatementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shelf Registration Statement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ShelfRegistrationStatementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shelf Registration Statement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At-the-Market Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ATM</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Notes Payable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible promissory notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and deferred expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConversionOfSeriesC2WarrantIntoCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of Series C-2 warrants into common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConversionOfSeriesC2WarrantIntoCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of Series C-2 Warrant into Common Stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ConversionOfSeriesC2WarrantIntoCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Series C-2 Warrant into Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Issued for Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PrivateCalcimedicaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Private calciMedica.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PrivateCalcimedicaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private CalciMedica [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_PrivateCalcimedicaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private CalciMedica</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Basic and Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock to Graybug stockholders as a result of the merger.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock To Graybug Stockholders As A Result Of The Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock to Graybug stockholders as a result of Merger and reset to par of $0.0001</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock to Graybug stockholders as a result of the Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock (net of issuance costs), shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ChangeInFairValueOfConvertiblePromissoryNote_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of convertible promissory notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ChangeInFairValueOfConvertiblePromissoryNote_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Fair Value of Convertible Promissory Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ChangeInFairValueOfConvertiblePromissoryNote_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of convertible promissory note.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ProceedsFromIssuanceOfConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible note payable, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ProceedsFromIssuanceOfConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Convertible Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="calc_ProceedsFromIssuanceOfConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of convertible notes.</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_PostMergerTransactionsMember" xlink:to="calc_PostMergerTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ShortTermInvestmentFairValueDisclosure" xlink:to="calc_ShortTermInvestmentFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_OperatingLossCarryForwardsExpirationBeginningYear" xlink:to="calc_OperatingLossCarryForwardsExpirationBeginningYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_TrancheAAndTrancheBCommonWarrantsMember" xlink:to="calc_TrancheAAndTrancheBCommonWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_PreMergerCalcimedicaMember" xlink:to="calc_PreMergerCalcimedicaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ConvertiblePromissoryNoteWarrantsMember" xlink:to="calc_ConvertiblePromissoryNoteWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredPolicyAcquisitionCostsTextBlock1" xlink:to="us-gaap_DeferredPolicyAcquisitionCostsTextBlock1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_FairValueAdjustmentOfConvertiblePromissoryNotes" xlink:to="calc_FairValueAdjustmentOfConvertiblePromissoryNotes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_MergerTransactionCosts" xlink:to="calc_MergerTransactionCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_IncomeTaxDisclosureTable" xlink:to="calc_IncomeTaxDisclosureTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_GrossProceedsFromIssuanceOfPrivatePlacement" xlink:to="calc_GrossProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_AccruedClinicalTrialCosts" xlink:to="calc_AccruedClinicalTrialCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_AccruedFranchiseTax" xlink:to="calc_AccruedFranchiseTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_WarrantsToPurchaseConvertiblePreferredStockMember" xlink:to="calc_WarrantsToPurchaseConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_PercentageOfChangeInOwnership" xlink:to="calc_PercentageOfChangeInOwnership_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_MD" xlink:to="stpr_MD_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_TrancheACommonWarrantsMember" xlink:to="calc_TrancheACommonWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_IncomeTaxDisclosureLineItems" xlink:to="calc_IncomeTaxDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_AccruedPayrollAndOtherEmployeeBenefits" xlink:to="calc_AccruedPayrollAndOtherEmployeeBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_SeriesBWarrantsMember" xlink:to="calc_SeriesBWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="calc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_RightOfUseAssetOrLeaseLiability" xlink:to="calc_RightOfUseAssetOrLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:to="calc_TwoThousandAndTwentyEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_DirectorsEmployeesOrConsultantsMember" xlink:to="calc_DirectorsEmployeesOrConsultantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryNotesSecuritiesMember" xlink:to="us-gaap_USTreasuryNotesSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_TrancheBCommonWarrantsMember" xlink:to="calc_TrancheBCommonWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:to="calc_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_SeriesC1ConvertiblePreferredStockMember" xlink:to="calc_SeriesC1ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_TemporaryEquityDisclosureTextblock" xlink:to="calc_TemporaryEquityDisclosureTextblock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_WarrantLiability" xlink:to="calc_WarrantLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_BusinessCombinationConsiderationTransferedCostIncurred" xlink:to="calc_BusinessCombinationConsiderationTransferedCostIncurred_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingRightsAnniversaryPeriod" xlink:to="calc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingRightsAnniversaryPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_TwoThousandAndTwentyThreeEquityIncentivePlanMember" xlink:to="calc_TwoThousandAndTwentyThreeEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_PublicCombinationMultipliedCashPricePaidPerShare" xlink:to="calc_PublicCombinationMultipliedCashPricePaidPerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndNoncurrentAssets" xlink:to="calc_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndNoncurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_FederalResearchAndDevelopmentMember" xlink:to="calc_FederalResearchAndDevelopmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="calc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_RestrictedStockUnitsNetSettlementShares" xlink:to="calc_RestrictedStockUnitsNetSettlementShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_DeemedDistribution" xlink:to="calc_DeemedDistribution_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="calc_DeferredTaxLiabilitiesRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_InducementGrantsMember" xlink:to="calc_InducementGrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="calc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_GrossProceedsFromThePrivatePlacement" xlink:to="calc_GrossProceedsFromThePrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_SeriesBConvertiblePreferredStockMember" xlink:to="calc_SeriesBConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ExpectedPerShare" xlink:to="calc_ExpectedPerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_AccruedOther" xlink:to="calc_AccruedOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_PreferredAndCommonStockMember" xlink:to="calc_PreferredAndCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_SeriesDConvertiblePreferredStockMember" xlink:to="calc_SeriesDConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_TransactionFeePercentage" xlink:to="calc_TransactionFeePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesRelatedParty" xlink:to="us-gaap_CostsAndExpensesRelatedParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ConversionOfC2WarrantsToCommonStock" xlink:to="calc_ConversionOfC2WarrantsToCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_SeriesAConvertiblePreferredStockMember" xlink:to="calc_SeriesAConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ExerciseAndConversionOfC2WarrantsShares" xlink:to="calc_ExerciseAndConversionOfC2WarrantsShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_PostMergerCalcimedicaMember" xlink:to="calc_PostMergerCalcimedicaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ContractualObligationOfContractInEffect" xlink:to="calc_ContractualObligationOfContractInEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_PercentageOfMoreBeneficialOwnership" xlink:to="calc_PercentageOfMoreBeneficialOwnership_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryBillSecuritiesMember" xlink:to="us-gaap_USTreasuryBillSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_PercentageOfWarrantCoverage" xlink:to="calc_PercentageOfWarrantCoverage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_RelatedPartyTransactionsPolicyTextBlock" xlink:to="calc_RelatedPartyTransactionsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ShortTermOperatingLeaseExpirationDate" xlink:to="calc_ShortTermOperatingLeaseExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="calc_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_FinancingCostsIncludedInAccountsPayable" xlink:to="calc_FinancingCostsIncludedInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ConvertiblePromissoryNoteWarrantsLiabilityMember" xlink:to="calc_ConvertiblePromissoryNoteWarrantsLiabilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_CommissionsAndOtherTransactionExpenses" xlink:to="calc_CommissionsAndOtherTransactionExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesAndFairValueTextBlock" xlink:to="us-gaap_DerivativesAndFairValueTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_NumberOfSharesIssuedFinallyOnTransaction" xlink:to="calc_NumberOfSharesIssuedFinallyOnTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_SummaryOfSignificantAccountingPoliciesTable" xlink:to="calc_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_SeriesC2ConvertiblePreferredStockMember" xlink:to="calc_SeriesC2ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:to="calc_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_NumberOfSharesIssuedInitiallyOnTransaction" xlink:to="calc_NumberOfSharesIssuedInitiallyOnTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_BaseRent" xlink:to="calc_BaseRent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_PreFundedWarrantsMember" xlink:to="calc_PreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ShortTermInvestmentsAssumedInTheMerger" xlink:to="calc_ShortTermInvestmentsAssumedInTheMerger_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_AssetsFairValueDisclosureAmortizedCostBasis" xlink:to="calc_AssetsFairValueDisclosureAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_PreferredWarrantsLiabilityMember" xlink:to="calc_PreferredWarrantsLiabilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_CostsIncurredInConnectionWithReverseMergerIncludedInAccountsPayableAndAccruedExpenses" xlink:to="calc_CostsIncurredInConnectionWithReverseMergerIncludedInAccountsPayableAndAccruedExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMergerShares" xlink:to="calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMergerShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember" xlink:to="calc_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_UnpaidCancellationAndOtherRelatedCosts" xlink:to="calc_UnpaidCancellationAndOtherRelatedCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_BeneficialOwnershipPercentage" xlink:to="calc_BeneficialOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:to="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_SettlementOfAccruedBonusAndEmployeeCosts" xlink:to="calc_SettlementOfAccruedBonusAndEmployeeCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_SeriesCTwoConvertiblePreferredStockMember" xlink:to="calc_SeriesCTwoConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_NonCashInterestExpense" xlink:to="calc_NonCashInterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ConvertiblePromissoryNoteWarrantsCommonStockConverted" xlink:to="calc_ConvertiblePromissoryNoteWarrantsCommonStockConverted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_DeferredTaxLiabilitiesValuationAllowance" xlink:to="calc_DeferredTaxLiabilitiesValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_CommonWarrantsMember" xlink:to="calc_CommonWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ConvertiblePreferredStockSeriesABC1C2AndDMember" xlink:to="calc_ConvertiblePreferredStockSeriesABC1C2AndDMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_AmendedAndRestatedCertificateOfIncorporationMember" xlink:to="calc_AmendedAndRestatedCertificateOfIncorporationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:to="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_NumberOfContractCurrentlyInEffect" xlink:to="calc_NumberOfContractCurrentlyInEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ConversionOfPromissoryNoteWarrantIntoCommonstock" xlink:to="calc_ConversionOfPromissoryNoteWarrantIntoCommonstock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis" xlink:to="calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_CalcimedicaIncMember" xlink:to="calc_CalcimedicaIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_AccountsPayableAndAccruedLiabilitiesAssumedInTheMerger" xlink:to="calc_AccountsPayableAndAccruedLiabilitiesAssumedInTheMerger_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_DebtInstrumentPeriodicPaymentPrincipalAdditional" xlink:to="calc_DebtInstrumentPeriodicPaymentPrincipalAdditional_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_IssuanceOfCommonSharesFromPrivatePlacementNetShares" xlink:to="calc_IssuanceOfCommonSharesFromPrivatePlacementNetShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_PercentageOfAggregateNumberOfSharesOfCommonStockOutstandingOnLastDayOfPrecedingYearAddedToPlan" xlink:to="calc_PercentageOfAggregateNumberOfSharesOfCommonStockOutstandingOnLastDayOfPrecedingYearAddedToPlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_OfficersAndDirectorsMember" xlink:to="calc_OfficersAndDirectorsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_PatentsCostsPolicyTextBlock" xlink:to="calc_PatentsCostsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_PreferredWarrantsMember" xlink:to="calc_PreferredWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_GraybugMember" xlink:to="calc_GraybugMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_AccruedResearchAndDevelopmentCostsPolicyTextBlock" xlink:to="calc_AccruedResearchAndDevelopmentCostsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_IssuanceOfCommonSharesFromPrivatePlacementNet" xlink:to="calc_IssuanceOfCommonSharesFromPrivatePlacementNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xlink:to="calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_LeaseAmendmentDate" xlink:to="calc_LeaseAmendmentDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_SaleOfStockRemainingSalesAmount" xlink:to="calc_SaleOfStockRemainingSalesAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_NetProceedsFromPrivatePlacement" xlink:to="calc_NetProceedsFromPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ConvertiblePromissoryNoteWarrantsConvertible" xlink:to="calc_ConvertiblePromissoryNoteWarrantsConvertible_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_IncomeTaxReconciliationPermanentDifferences" xlink:to="calc_IncomeTaxReconciliationPermanentDifferences_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_PercentageOfOwnershipDuringElection" xlink:to="calc_PercentageOfOwnershipDuringElection_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_StockIssuedDuringPeriodSharesConversionOfPromissoryNotes" xlink:to="calc_StockIssuedDuringPeriodSharesConversionOfPromissoryNotes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsStateTaxes" xlink:to="us-gaap_DeferredTaxAssetsStateTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_RestrictedStockUnitsNetSettlement" xlink:to="calc_RestrictedStockUnitsNetSettlement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:to="us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ConversionOfConvertiblePromissoryNoteWarrantsToCommonStock" xlink:to="calc_ConversionOfConvertiblePromissoryNoteWarrantsToCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_LesseeOperatingLeaseMaturityYearAndMonth" xlink:to="calc_LesseeOperatingLeaseMaturityYearAndMonth_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ShelfRegistrationStatementAvaliableForSale" xlink:to="calc_ShelfRegistrationStatementAvaliableForSale_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_PreferredWarrantMember" xlink:to="calc_PreferredWarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_InterestOnConvertiblePromissoryNotesPayable" xlink:to="calc_InterestOnConvertiblePromissoryNotesPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ChangeInFairValueOfWarrantLiability" xlink:to="calc_ChangeInFairValueOfWarrantLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_TaxPostionMinimumPercentageOfTaxBenefit" xlink:to="calc_TaxPostionMinimumPercentageOfTaxBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_TwoThousandAndSixEquityIncentivePlanMember" xlink:to="calc_TwoThousandAndSixEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityOwnershipPercentage" xlink:to="us-gaap_VariableInterestEntityOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_PrepaidExpensesAndOtherCurrentAssets" xlink:to="calc_PrepaidExpensesAndOtherCurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_SeriesCTwoWarrantsMember" xlink:to="calc_SeriesCTwoWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_UnrecognizedTaxBenefitsNet" xlink:to="calc_UnrecognizedTaxBenefitsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_WarrantLiabilityPolicyPolicyTextBlock" xlink:to="calc_WarrantLiabilityPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_PriorToMergerTransactionsMember" xlink:to="calc_PriorToMergerTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_CalcimedicaCommonStockMember" xlink:to="calc_CalcimedicaCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ConvertiblePreferredStockAbstract" xlink:to="calc_ConvertiblePreferredStockAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_SeriesDWarrantsMember" xlink:to="calc_SeriesDWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsDate" xlink:to="us-gaap_SubsequentEventsDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_AmendmentToTwoThousandAndSixEquityIncentivePlanMember" xlink:to="calc_AmendmentToTwoThousandAndSixEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_StockIssuedDuringPeriodValueConversionOfPromissoryNotes" xlink:to="calc_StockIssuedDuringPeriodValueConversionOfPromissoryNotes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_DeferredTaxAssetLeaseLiabilities" xlink:to="calc_DeferredTaxAssetLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_StockholdersEquityNoteStockSplitExchangeRatio" xlink:to="calc_StockholdersEquityNoteStockSplitExchangeRatio_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ConversionOfPromissoryNoteWarrantsIntoCommonStockShare" xlink:to="calc_ConversionOfPromissoryNoteWarrantsIntoCommonStockShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ClassOfWarrantRedeemOutstandingDescription" xlink:to="calc_ClassOfWarrantRedeemOutstandingDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_PaymentsOfAcquisitionOfBusinessesNetOfCash" xlink:to="calc_PaymentsOfAcquisitionOfBusinessesNetOfCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis" xlink:to="calc_CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ConvertiblePromissoryNoteMember" xlink:to="calc_ConvertiblePromissoryNoteMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_JonesTradingMember" xlink:to="calc_JonesTradingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_StockIssuedDuringPeriodPrivatePlacement" xlink:to="calc_StockIssuedDuringPeriodPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_PlacementAgentWarrantsMember" xlink:to="calc_PlacementAgentWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_TotalNetProceeds" xlink:to="calc_TotalNetProceeds_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrantsExercisable" xlink:to="calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrantsExercisable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_AccruedSeveranceExpense" xlink:to="calc_AccruedSeveranceExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_AccreditedInvestorsMember" xlink:to="calc_AccreditedInvestorsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_GraybugVisionIncMember" xlink:to="calc_GraybugVisionIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_NetDeferredTaxAsset" xlink:to="calc_NetDeferredTaxAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ConversionOfConvertiblePromissoryNotesToCommonStock" xlink:to="calc_ConversionOfConvertiblePromissoryNotesToCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_AuxoraMember" xlink:to="calc_AuxoraMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_CalcimedicaPreferredStockMember" xlink:to="calc_CalcimedicaPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="calc_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ExchangeOfStockForStock" xlink:to="calc_ExchangeOfStockForStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ShelfRegistrationStatementMember" xlink:to="calc_ShelfRegistrationStatementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_AtTheMarketOfferingMember" xlink:to="calc_AtTheMarketOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ConversionOfSeriesC2WarrantIntoCommonStock" xlink:to="calc_ConversionOfSeriesC2WarrantIntoCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_PrivateCalcimedicaMember" xlink:to="calc_PrivateCalcimedicaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger" xlink:to="calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ChangeInFairValueOfConvertiblePromissoryNote" xlink:to="calc_ChangeInFairValueOfConvertiblePromissoryNote_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="calc_ProceedsFromIssuanceOfConvertibleNotes" xlink:to="calc_ProceedsFromIssuanceOfConvertibleNotes_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_WarrantLiability" xlink:label="calc_WarrantLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesAConvertiblePreferredStockMember" xlink:label="calc_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConvertiblePreferredStockAbstract" xlink:label="calc_ConvertiblePreferredStockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AccruedClinicalTrialCosts" xlink:label="calc_AccruedClinicalTrialCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesBConvertiblePreferredStockMember" xlink:label="calc_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesC1ConvertiblePreferredStockMember" xlink:label="calc_SeriesC1ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesC2ConvertiblePreferredStockMember" xlink:label="calc_SeriesC2ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesDConvertiblePreferredStockMember" xlink:label="calc_SeriesDConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:to="calc_WarrantLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="calc_ConvertiblePreferredStockAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:to="us-gaap_ConvertibleNotesPayable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="calc_AccruedClinicalTrialCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:to="us-gaap_Liabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_SeriesC1ConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_SeriesC2ConvertiblePreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="calc_ConvertiblePreferredStockAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_SeriesDConvertiblePreferredStockMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesAConvertiblePreferredStockMember" xlink:label="calc_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesBConvertiblePreferredStockMember" xlink:label="calc_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesC1ConvertiblePreferredStockMember" xlink:label="calc_SeriesC1ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesC2ConvertiblePreferredStockMember" xlink:label="calc_SeriesC2ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesDConvertiblePreferredStockMember" xlink:label="calc_SeriesDConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_SeriesC1ConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_SeriesC2ConvertiblePreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_SeriesDConvertiblePreferredStockMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ChangeInFairValueOfWarrantLiability" xlink:label="calc_ChangeInFairValueOfWarrantLiability"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ChangeInFairValueOfConvertiblePromissoryNote" xlink:label="calc_ChangeInFairValueOfConvertiblePromissoryNote"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_InterestOnConvertiblePromissoryNotesPayable" xlink:label="calc_InterestOnConvertiblePromissoryNotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="calc_ChangeInFairValueOfWarrantLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="calc_ChangeInFairValueOfConvertiblePromissoryNote" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="calc_InterestOnConvertiblePromissoryNotesPayable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_DeemedDistribution" xlink:label="calc_DeemedDistribution"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="calc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="calc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMergerShares" xlink:label="calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMergerShares"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger" xlink:label="calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_IssuanceOfCommonSharesFromPrivatePlacementNetShares" xlink:label="calc_IssuanceOfCommonSharesFromPrivatePlacementNetShares"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_IssuanceOfCommonSharesFromPrivatePlacementNet" xlink:label="calc_IssuanceOfCommonSharesFromPrivatePlacementNet"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_StockIssuedDuringPeriodSharesConversionOfPromissoryNotes" xlink:label="calc_StockIssuedDuringPeriodSharesConversionOfPromissoryNotes"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_StockIssuedDuringPeriodValueConversionOfPromissoryNotes" xlink:label="calc_StockIssuedDuringPeriodValueConversionOfPromissoryNotes"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ExerciseAndConversionOfC2WarrantsShares" xlink:label="calc_ExerciseAndConversionOfC2WarrantsShares"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConversionOfSeriesC2WarrantIntoCommonStock" xlink:label="calc_ConversionOfSeriesC2WarrantIntoCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConversionOfPromissoryNoteWarrantsIntoCommonStockShare" xlink:label="calc_ConversionOfPromissoryNoteWarrantsIntoCommonStockShare"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConversionOfPromissoryNoteWarrantIntoCommonstock" xlink:label="calc_ConversionOfPromissoryNoteWarrantIntoCommonstock"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_MergerTransactionCosts" xlink:label="calc_MergerTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_RestrictedStockUnitsNetSettlementShares" xlink:label="calc_RestrictedStockUnitsNetSettlementShares"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_RestrictedStockUnitsNetSettlement" xlink:label="calc_RestrictedStockUnitsNetSettlement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_32"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_33"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_34"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_35"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_DeemedDistribution" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMergerShares" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_IssuanceOfCommonSharesFromPrivatePlacementNetShares" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_IssuanceOfCommonSharesFromPrivatePlacementNet" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_StockIssuedDuringPeriodSharesConversionOfPromissoryNotes" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_StockIssuedDuringPeriodValueConversionOfPromissoryNotes" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_ExerciseAndConversionOfC2WarrantsShares" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_ConversionOfSeriesC2WarrantIntoCommonStock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_ConversionOfPromissoryNoteWarrantsIntoCommonStockShare" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_ConversionOfPromissoryNoteWarrantIntoCommonstock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_MergerTransactionCosts" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_RestrictedStockUnitsNetSettlementShares" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_RestrictedStockUnitsNetSettlement" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_32" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_33" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_34" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_35" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_GraybugMember" xlink:label="calc_GraybugMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="calc_GraybugMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConvertiblePreferredStockSeriesABC1C2AndDMember" xlink:label="calc_ConvertiblePreferredStockSeriesABC1C2AndDMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndNoncurrentAssets" xlink:label="calc_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CostsIncurredInConnectionWithReverseMergerIncludedInAccountsPayableAndAccruedExpenses" xlink:label="calc_CostsIncurredInConnectionWithReverseMergerIncludedInAccountsPayableAndAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PaymentsOfAcquisitionOfBusinessesNetOfCash" xlink:label="calc_PaymentsOfAcquisitionOfBusinessesNetOfCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger" xlink:label="calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_FairValueAdjustmentOfConvertiblePromissoryNotes" xlink:label="calc_FairValueAdjustmentOfConvertiblePromissoryNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ProceedsFromIssuanceOfConvertibleNotes" xlink:label="calc_ProceedsFromIssuanceOfConvertibleNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShortTermInvestmentsAssumedInTheMerger" xlink:label="calc_ShortTermInvestmentsAssumedInTheMerger"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_NonCashInterestExpense" xlink:label="calc_NonCashInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="us-gaap_ProceedsFromOtherEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PrepaidExpensesAndOtherCurrentAssets" xlink:label="calc_PrepaidExpensesAndOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AccountsPayableAndAccruedLiabilitiesAssumedInTheMerger" xlink:label="calc_AccountsPayableAndAccruedLiabilitiesAssumedInTheMerger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConversionOfC2WarrantsToCommonStock" xlink:label="calc_ConversionOfC2WarrantsToCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConversionOfConvertiblePromissoryNotesToCommonStock" xlink:label="calc_ConversionOfConvertiblePromissoryNotesToCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConversionOfConvertiblePromissoryNoteWarrantsToCommonStock" xlink:label="calc_ConversionOfConvertiblePromissoryNoteWarrantsToCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_FinancingCostsIncludedInAccountsPayable" xlink:label="calc_FinancingCostsIncludedInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_RestrictedStockUnitsNetSettlement" xlink:label="calc_RestrictedStockUnitsNetSettlement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_ConvertiblePreferredStockSeriesABC1C2AndDMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="calc_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndNoncurrentAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="calc_CostsIncurredInConnectionWithReverseMergerIncludedInAccountsPayableAndAccruedExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="calc_PaymentsOfAcquisitionOfBusinessesNetOfCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ConversionOfStockAmountIssued1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="calc_FairValueAdjustmentOfConvertiblePromissoryNotes" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="calc_ProceedsFromIssuanceOfConvertibleNotes" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="calc_ShortTermInvestmentsAssumedInTheMerger" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="calc_NonCashInterestExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromOtherEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="calc_PrepaidExpensesAndOtherCurrentAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="calc_AccountsPayableAndAccruedLiabilitiesAssumedInTheMerger" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="calc_ConversionOfC2WarrantsToCommonStock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="calc_ConversionOfConvertiblePromissoryNotesToCommonStock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="calc_ConversionOfConvertiblePromissoryNoteWarrantsToCommonStock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="calc_FinancingCostsIncludedInAccountsPayable" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="calc_RestrictedStockUnitsNetSettlement" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusiness1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactions" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesAndFairValueTextBlock" xlink:label="us-gaap_DerivativesAndFairValueTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DerivativesAndFairValueTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpenses" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrants" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficit" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TemporaryEquityDisclosureTextblock" xlink:label="calc_TemporaryEquityDisclosureTextblock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="calc_TemporaryEquityDisclosureTextblock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensation1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureEmployeeBenefits" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AccruedResearchAndDevelopmentCostsPolicyTextBlock" xlink:label="calc_AccruedResearchAndDevelopmentCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PatentsCostsPolicyTextBlock" xlink:label="calc_PatentsCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredPolicyAcquisitionCostsTextBlock1" xlink:label="us-gaap_DeferredPolicyAcquisitionCostsTextBlock1"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_WarrantLiabilityPolicyPolicyTextBlock" xlink:label="calc_WarrantLiabilityPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_RelatedPartyTransactionsPolicyTextBlock" xlink:label="calc_RelatedPartyTransactionsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="calc_AccruedResearchAndDevelopmentCostsPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="calc_PatentsCostsPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredPolicyAcquisitionCostsTextBlock1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="calc_WarrantLiabilityPolicyPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="calc_RelatedPartyTransactionsPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpensesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="calc_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="calc_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CalcimedicaIncMember" xlink:label="calc_CalcimedicaIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PreferredAndCommonStockMember" xlink:label="calc_PreferredAndCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_GraybugVisionIncMember" xlink:label="calc_GraybugVisionIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TotalNetProceeds" xlink:label="calc_TotalNetProceeds"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_GrossProceedsFromThePrivatePlacement" xlink:label="calc_GrossProceedsFromThePrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_NetProceedsFromPrivatePlacement" xlink:label="calc_NetProceedsFromPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CommissionsAndOtherTransactionExpenses" xlink:label="calc_CommissionsAndOtherTransactionExpenses"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="calc_CalcimedicaIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="calc_PreferredAndCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="calc_GraybugVisionIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SeveranceCosts1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_TotalNetProceeds" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpenses" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_GrossProceedsFromThePrivatePlacement" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_NetProceedsFromPrivatePlacement" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_CommissionsAndOtherTransactionExpenses" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SummaryOfSignificantAccountingPoliciesTable" xlink:label="calc_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PrivateCalcimedicaMember" xlink:label="calc_PrivateCalcimedicaMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="calc_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_StockholdersEquityNoteStockSplitExchangeRatio" xlink:label="calc_StockholdersEquityNoteStockSplitExchangeRatio"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AtTheMarketOfferingMember" xlink:label="calc_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_RightOfUseAssetOrLeaseLiability" xlink:label="calc_RightOfUseAssetOrLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TaxPostionMinimumPercentageOfTaxBenefit" xlink:label="calc_TaxPostionMinimumPercentageOfTaxBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityOwnershipPercentage" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="us-gaap_CostsAndExpensesRelatedParty"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="calc_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="calc_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="calc_PrivateCalcimedicaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="calc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="calc_StockholdersEquityNoteStockSplitExchangeRatio" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="calc_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="calc_AtTheMarketOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="calc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_Depreciation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="calc_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="calc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="calc_SummaryOfSignificantAccountingPoliciesTable" xlink:to="calc_SummaryOfSignificantAccountingPoliciesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="calc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="calc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="calc_RightOfUseAssetOrLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="calc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="calc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="calc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="calc_TaxPostionMinimumPercentageOfTaxBenefit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="calc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_VariableInterestEntityOwnershipPercentage" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="calc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CostsAndExpensesRelatedParty" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CalcimedicaIncMember" xlink:label="calc_CalcimedicaIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_GraybugMember" xlink:label="calc_GraybugMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_GraybugVisionIncMember" xlink:label="calc_GraybugVisionIncMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_StockIssuedDuringPeriodPrivatePlacement" xlink:label="calc_StockIssuedDuringPeriodPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_BusinessCombinationConsiderationTransferedCostIncurred" xlink:label="calc_BusinessCombinationConsiderationTransferedCostIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="calc_CalcimedicaIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="calc_GraybugMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="calc_GraybugVisionIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="calc_StockIssuedDuringPeriodPrivatePlacement" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="calc_BusinessCombinationConsiderationTransferedCostIncurred" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SeveranceCosts1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShortTermInvestmentFairValueDisclosure" xlink:label="calc_ShortTermInvestmentFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="us-gaap_USTreasuryBillSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:label="us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryNotesSecuritiesMember" xlink:label="us-gaap_USTreasuryNotesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PreferredWarrantsLiabilityMember" xlink:label="calc_PreferredWarrantsLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConvertiblePromissoryNoteWarrantsLiabilityMember" xlink:label="calc_ConvertiblePromissoryNoteWarrantsLiabilityMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="calc_ShortTermInvestmentFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasuryBillSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasuryNotesSecuritiesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="calc_PreferredWarrantsLiabilityMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="calc_ConvertiblePromissoryNoteWarrantsLiabilityMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3InputsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConvertiblePromissoryNoteMember" xlink:label="calc_ConvertiblePromissoryNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PreferredWarrantsMember" xlink:label="calc_PreferredWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PreferredWarrantMember" xlink:label="calc_PreferredWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConvertiblePromissoryNoteWarrantsMember" xlink:label="calc_ConvertiblePromissoryNoteWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="calc_ConvertiblePromissoryNoteMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="calc_PreferredWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="calc_PreferredWarrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="calc_ConvertiblePromissoryNoteWarrantsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis" xlink:label="calc_CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="us-gaap_USTreasuryBillSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis" xlink:label="calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:label="us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryNotesSecuritiesMember" xlink:label="us-gaap_USTreasuryNotesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShortTermInvestmentFairValueDisclosure" xlink:label="calc_ShortTermInvestmentFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AssetsFairValueDisclosureAmortizedCostBasis" xlink:label="calc_AssetsFairValueDisclosureAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="calc_CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasuryBillSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasuryNotesSecuritiesMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="calc_ShortTermInvestmentFairValueDisclosure" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="calc_AssetsFairValueDisclosureAmortizedCostBasis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PrivateCalcimedicaMember" xlink:label="calc_PrivateCalcimedicaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConvertiblePromissoryNoteWarrantsMember" xlink:label="calc_ConvertiblePromissoryNoteWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_GraybugMember" xlink:label="calc_GraybugMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_DebtInstrumentPeriodicPaymentPrincipalAdditional" xlink:label="calc_DebtInstrumentPeriodicPaymentPrincipalAdditional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PublicCombinationMultipliedCashPricePaidPerShare" xlink:label="calc_PublicCombinationMultipliedCashPricePaidPerShare"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PercentageOfWarrantCoverage" xlink:label="calc_PercentageOfWarrantCoverage"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConvertiblePromissoryNoteWarrantsConvertible" xlink:label="calc_ConvertiblePromissoryNoteWarrantsConvertible"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConvertiblePromissoryNoteWarrantsCommonStockConverted" xlink:label="calc_ConvertiblePromissoryNoteWarrantsCommonStockConverted"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ExchangeOfStockForStock" xlink:label="calc_ExchangeOfStockForStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ExpectedPerShare" xlink:label="calc_ExpectedPerShare"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="calc_PrivateCalcimedicaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="calc_ConvertiblePromissoryNoteWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="calc_GraybugMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="calc_DebtInstrumentPeriodicPaymentPrincipalAdditional" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="calc_PublicCombinationMultipliedCashPricePaidPerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="calc_PercentageOfWarrantCoverage" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="calc_ConvertiblePromissoryNoteWarrantsConvertible" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="calc_ConvertiblePromissoryNoteWarrantsCommonStockConverted" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="calc_ExchangeOfStockForStock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="calc_ExpectedPerShare" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AccruedPayrollAndOtherEmployeeBenefits" xlink:label="calc_AccruedPayrollAndOtherEmployeeBenefits"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AccruedSeveranceExpense" xlink:label="calc_AccruedSeveranceExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AccruedFranchiseTax" xlink:label="calc_AccruedFranchiseTax"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AccruedOther" xlink:label="calc_AccruedOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_StatementLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_AccruedPayrollAndOtherEmployeeBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_AccruedSeveranceExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_AccruedFranchiseTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_AccruedOther" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PreMergerCalcimedicaMember" xlink:label="calc_PreMergerCalcimedicaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesCTwoConvertiblePreferredStockMember" xlink:label="calc_SeriesCTwoConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PriorToMergerTransactionsMember" xlink:label="calc_PriorToMergerTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AmendedAndRestatedCertificateOfIncorporationMember" xlink:label="calc_AmendedAndRestatedCertificateOfIncorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_GraybugMember" xlink:label="calc_GraybugMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_OfficersAndDirectorsMember" xlink:label="calc_OfficersAndDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PostMergerCalcimedicaMember" xlink:label="calc_PostMergerCalcimedicaMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesDConvertiblePreferredStockMember" xlink:label="calc_SeriesDConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PostMergerTransactionsMember" xlink:label="calc_PostMergerTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CalcimedicaPreferredStockMember" xlink:label="calc_CalcimedicaPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShelfRegistrationStatementMember" xlink:label="calc_ShelfRegistrationStatementMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="calc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CalcimedicaCommonStockMember" xlink:label="calc_CalcimedicaCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AtTheMarketOfferingMember" xlink:label="calc_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesBWarrantsMember" xlink:label="calc_SeriesBWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesCTwoWarrantsMember" xlink:label="calc_SeriesCTwoWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesDWarrantsMember" xlink:label="calc_SeriesDWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShelfRegistrationStatementAvaliableForSale" xlink:label="calc_ShelfRegistrationStatementAvaliableForSale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xlink:label="calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:label="calc_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrantsExercisable" xlink:label="calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrantsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SaleOfStockRemainingSalesAmount" xlink:label="calc_SaleOfStockRemainingSalesAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="calc_PreMergerCalcimedicaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_SeriesCTwoConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="calc_PriorToMergerTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="calc_AmendedAndRestatedCertificateOfIncorporationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="calc_GraybugMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="calc_OfficersAndDirectorsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="calc_PostMergerCalcimedicaMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_SeriesDConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="calc_PostMergerTransactionsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_CalcimedicaPreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="calc_ShelfRegistrationStatementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="calc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_CalcimedicaCommonStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="calc_AtTheMarketOfferingMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_SeriesBWarrantsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_SeriesCTwoWarrantsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_SeriesDWarrantsMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_TitleOfIndividualAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="calc_ShelfRegistrationStatementAvaliableForSale" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="calc_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrantsExercisable" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_FairValueNetAssetLiability" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="calc_SaleOfStockRemainingSalesAmount" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:label="calc_TwoThousandAndTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_GraybugMember" xlink:label="calc_GraybugMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TwoThousandAndSixEquityIncentivePlanMember" xlink:label="calc_TwoThousandAndSixEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AmendmentToTwoThousandAndSixEquityIncentivePlanMember" xlink:label="calc_AmendmentToTwoThousandAndSixEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingRightsAnniversaryPeriod" xlink:label="calc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingRightsAnniversaryPeriod"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TwoThousandAndTwentyThreeEquityIncentivePlanMember" xlink:label="calc_TwoThousandAndTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember" xlink:label="calc_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:label="calc_TwoThousandAndTwentyEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_InducementGrantsMember" xlink:label="calc_InducementGrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PercentageOfAggregateNumberOfSharesOfCommonStockOutstandingOnLastDayOfPrecedingYearAddedToPlan" xlink:label="calc_PercentageOfAggregateNumberOfSharesOfCommonStockOutstandingOnLastDayOfPrecedingYearAddedToPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="calc_TwoThousandAndTwentyEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="calc_GraybugMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="calc_TwoThousandAndSixEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="calc_AmendmentToTwoThousandAndSixEquityIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="calc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingRightsAnniversaryPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="calc_TwoThousandAndTwentyThreeEquityIncentivePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="calc_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="calc_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="calc_InducementGrantsMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="calc_PercentageOfAggregateNumberOfSharesOfCommonStockOutstandingOnLastDayOfPrecedingYearAddedToPlan" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsingBlackScholesToEstimatedFairValueOfTheStockOptionGrantsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedForOptionsAndRsusGrantedDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SettlementOfAccruedBonusAndEmployeeCosts" xlink:label="calc_SettlementOfAccruedBonusAndEmployeeCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="calc_SettlementOfAccruedBonusAndEmployeeCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfCommonStockReservedForFutureIssuanceDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TwoThousandAndTwentyThreeEquityIncentivePlanMember" xlink:label="calc_TwoThousandAndTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember" xlink:label="calc_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="calc_TwoThousandAndTwentyThreeEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="calc_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MD" xlink:label="stpr_MD"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AuxoraMember" xlink:label="calc_AuxoraMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_LeaseAmendmentDate" xlink:label="calc_LeaseAmendmentDate"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_NumberOfContractCurrentlyInEffect" xlink:label="calc_NumberOfContractCurrentlyInEffect"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ContractualObligationOfContractInEffect" xlink:label="calc_ContractualObligationOfContractInEffect"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_UnpaidCancellationAndOtherRelatedCosts" xlink:label="calc_UnpaidCancellationAndOtherRelatedCosts"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_BaseRent" xlink:label="calc_BaseRent"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_LesseeOperatingLeaseMaturityYearAndMonth" xlink:label="calc_LesseeOperatingLeaseMaturityYearAndMonth"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShortTermOperatingLeaseExpirationDate" xlink:label="calc_ShortTermOperatingLeaseExpirationDate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MD" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="calc_AuxoraMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="calc_LeaseAmendmentDate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="calc_NumberOfContractCurrentlyInEffect" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="calc_ContractualObligationOfContractInEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="calc_UnpaidCancellationAndOtherRelatedCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="calc_BaseRent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="calc_LesseeOperatingLeaseMaturityYearAndMonth" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="calc_ShortTermOperatingLeaseExpirationDate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_IncomeTaxReconciliationPermanentDifferences" xlink:label="calc_IncomeTaxReconciliationPermanentDifferences"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="calc_IncomeTaxReconciliationPermanentDifferences" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="calc_DeferredTaxLiabilitiesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_DeferredTaxLiabilitiesValuationAllowance" xlink:label="calc_DeferredTaxLiabilitiesValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsStateTaxes" xlink:label="us-gaap_DeferredTaxAssetsStateTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_NetDeferredTaxAsset" xlink:label="calc_NetDeferredTaxAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_DeferredTaxAssetLeaseLiabilities" xlink:label="calc_DeferredTaxAssetLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="calc_DeferredTaxLiabilitiesRightOfUseAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="calc_DeferredTaxLiabilitiesValuationAllowance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsStateTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="calc_NetDeferredTaxAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="calc_DeferredTaxAssetLeaseLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_IncomeTaxDisclosureTable" xlink:label="calc_IncomeTaxDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_IncomeTaxDisclosureLineItems" xlink:label="calc_IncomeTaxDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_OperatingLossCarryForwardsExpirationBeginningYear" xlink:label="calc_OperatingLossCarryForwardsExpirationBeginningYear"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_FederalResearchAndDevelopmentMember" xlink:label="calc_FederalResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PercentageOfChangeInOwnership" xlink:label="calc_PercentageOfChangeInOwnership"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_UnrecognizedTaxBenefitsNet" xlink:label="calc_UnrecognizedTaxBenefitsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="calc_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="calc_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="calc_IncomeTaxDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="calc_IncomeTaxDisclosureTable" xlink:to="calc_IncomeTaxDisclosureLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="calc_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="calc_IncomeTaxDisclosureLineItems" xlink:to="calc_OperatingLossCarryForwardsExpirationBeginningYear" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="calc_FederalResearchAndDevelopmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="calc_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="calc_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="calc_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="calc_IncomeTaxDisclosureLineItems" xlink:to="calc_PercentageOfChangeInOwnership" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="calc_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="calc_IncomeTaxDisclosureLineItems" xlink:to="calc_UnrecognizedTaxBenefitsNet" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_5"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_WarrantsToPurchaseConvertiblePreferredStockMember" xlink:label="calc_WarrantsToPurchaseConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="calc_WarrantsToPurchaseConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_DirectorsEmployeesOrConsultantsMember" xlink:label="calc_DirectorsEmployeesOrConsultantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_JonesTradingMember" xlink:label="calc_JonesTradingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AccreditedInvestorsMember" xlink:label="calc_AccreditedInvestorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsDate" xlink:label="us-gaap_SubsequentEventsDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PreFundedWarrantsMember" xlink:label="calc_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PlacementAgentWarrantsMember" xlink:label="calc_PlacementAgentWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TrancheACommonWarrantsMember" xlink:label="calc_TrancheACommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TrancheBCommonWarrantsMember" xlink:label="calc_TrancheBCommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TrancheAAndTrancheBCommonWarrantsMember" xlink:label="calc_TrancheAAndTrancheBCommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CommonWarrantsMember" xlink:label="calc_CommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="us-gaap_WarrantExercisePriceDecrease"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ClassOfWarrantRedeemOutstandingDescription" xlink:label="calc_ClassOfWarrantRedeemOutstandingDescription"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_BeneficialOwnershipPercentage" xlink:label="calc_BeneficialOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_GrossProceedsFromIssuanceOfPrivatePlacement" xlink:label="calc_GrossProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TransactionFeePercentage" xlink:label="calc_TransactionFeePercentage"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_NumberOfSharesIssuedInitiallyOnTransaction" xlink:label="calc_NumberOfSharesIssuedInitiallyOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_NumberOfSharesIssuedFinallyOnTransaction" xlink:label="calc_NumberOfSharesIssuedFinallyOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PercentageOfMoreBeneficialOwnership" xlink:label="calc_PercentageOfMoreBeneficialOwnership"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PercentageOfOwnershipDuringElection" xlink:label="calc_PercentageOfOwnershipDuringElection"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="calc_DirectorsEmployeesOrConsultantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="calc_JonesTradingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="calc_AccreditedInvestorsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventsDate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="calc_PreFundedWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="calc_PlacementAgentWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="calc_TrancheACommonWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="calc_TrancheBCommonWarrantsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_TitleOfIndividualAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="calc_TrancheAAndTrancheBCommonWarrantsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="calc_CommonWarrantsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="calc_ClassOfWarrantRedeemOutstandingDescription" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="calc_BeneficialOwnershipPercentage" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="calc_GrossProceedsFromIssuanceOfPrivatePlacement" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="calc_TransactionFeePercentage" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="calc_NumberOfSharesIssuedInitiallyOnTransaction" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="calc_NumberOfSharesIssuedFinallyOnTransaction" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="calc_PercentageOfMoreBeneficialOwnership" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="calc_PercentageOfOwnershipDuringElection" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_WarrantLiability" xlink:label="calc_WarrantLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesAConvertiblePreferredStockMember" xlink:label="calc_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConvertiblePreferredStockAbstract" xlink:label="calc_ConvertiblePreferredStockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AccruedClinicalTrialCosts" xlink:label="calc_AccruedClinicalTrialCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesBConvertiblePreferredStockMember" xlink:label="calc_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesC1ConvertiblePreferredStockMember" xlink:label="calc_SeriesC1ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesC2ConvertiblePreferredStockMember" xlink:label="calc_SeriesC2ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesDConvertiblePreferredStockMember" xlink:label="calc_SeriesDConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:to="calc_WarrantLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="calc_ConvertiblePreferredStockAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:to="us-gaap_ConvertibleNotesPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="calc_AccruedClinicalTrialCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_SeriesC1ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_SeriesC2ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="calc_ConvertiblePreferredStockAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_SeriesDConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesAConvertiblePreferredStockMember" xlink:label="calc_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesBConvertiblePreferredStockMember" xlink:label="calc_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesC1ConvertiblePreferredStockMember" xlink:label="calc_SeriesC1ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesC2ConvertiblePreferredStockMember" xlink:label="calc_SeriesC2ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesDConvertiblePreferredStockMember" xlink:label="calc_SeriesDConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_SeriesC1ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_SeriesC2ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_SeriesDConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_DeemedDistribution" xlink:label="calc_DeemedDistribution"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="calc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="calc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMergerShares" xlink:label="calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMergerShares"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger" xlink:label="calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_IssuanceOfCommonSharesFromPrivatePlacementNetShares" xlink:label="calc_IssuanceOfCommonSharesFromPrivatePlacementNetShares"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_IssuanceOfCommonSharesFromPrivatePlacementNet" xlink:label="calc_IssuanceOfCommonSharesFromPrivatePlacementNet"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_StockIssuedDuringPeriodSharesConversionOfPromissoryNotes" xlink:label="calc_StockIssuedDuringPeriodSharesConversionOfPromissoryNotes"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_StockIssuedDuringPeriodValueConversionOfPromissoryNotes" xlink:label="calc_StockIssuedDuringPeriodValueConversionOfPromissoryNotes"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ExerciseAndConversionOfC2WarrantsShares" xlink:label="calc_ExerciseAndConversionOfC2WarrantsShares"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConversionOfSeriesC2WarrantIntoCommonStock" xlink:label="calc_ConversionOfSeriesC2WarrantIntoCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConversionOfPromissoryNoteWarrantsIntoCommonStockShare" xlink:label="calc_ConversionOfPromissoryNoteWarrantsIntoCommonStockShare"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConversionOfPromissoryNoteWarrantIntoCommonstock" xlink:label="calc_ConversionOfPromissoryNoteWarrantIntoCommonstock"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_MergerTransactionCosts" xlink:label="calc_MergerTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_RestrictedStockUnitsNetSettlementShares" xlink:label="calc_RestrictedStockUnitsNetSettlementShares"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_RestrictedStockUnitsNetSettlement" xlink:label="calc_RestrictedStockUnitsNetSettlement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_DeemedDistribution" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMergerShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_IssuanceOfCommonSharesFromPrivatePlacementNetShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_IssuanceOfCommonSharesFromPrivatePlacementNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_StockIssuedDuringPeriodSharesConversionOfPromissoryNotes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_StockIssuedDuringPeriodValueConversionOfPromissoryNotes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_ExerciseAndConversionOfC2WarrantsShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_ConversionOfSeriesC2WarrantIntoCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_ConversionOfPromissoryNoteWarrantsIntoCommonStockShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_ConversionOfPromissoryNoteWarrantIntoCommonstock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_MergerTransactionCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_RestrictedStockUnitsNetSettlementShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_RestrictedStockUnitsNetSettlement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_GraybugMember" xlink:label="calc_GraybugMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="calc_GraybugMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"/>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CalcimedicaIncMember" xlink:label="calc_CalcimedicaIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PreferredAndCommonStockMember" xlink:label="calc_PreferredAndCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_GraybugVisionIncMember" xlink:label="calc_GraybugVisionIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TotalNetProceeds" xlink:label="calc_TotalNetProceeds"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_GrossProceedsFromThePrivatePlacement" xlink:label="calc_GrossProceedsFromThePrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_NetProceedsFromPrivatePlacement" xlink:label="calc_NetProceedsFromPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CommissionsAndOtherTransactionExpenses" xlink:label="calc_CommissionsAndOtherTransactionExpenses"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="calc_CalcimedicaIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="calc_PreferredAndCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="calc_GraybugVisionIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SeveranceCosts1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_TotalNetProceeds" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_GrossProceedsFromThePrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_NetProceedsFromPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="calc_CommissionsAndOtherTransactionExpenses" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="calc_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SummaryOfSignificantAccountingPoliciesTable" xlink:label="calc_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PrivateCalcimedicaMember" xlink:label="calc_PrivateCalcimedicaMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_StockholdersEquityNoteStockSplitExchangeRatio" xlink:label="calc_StockholdersEquityNoteStockSplitExchangeRatio"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AtTheMarketOfferingMember" xlink:label="calc_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_RightOfUseAssetOrLeaseLiability" xlink:label="calc_RightOfUseAssetOrLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TaxPostionMinimumPercentageOfTaxBenefit" xlink:label="calc_TaxPostionMinimumPercentageOfTaxBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityOwnershipPercentage" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="us-gaap_CostsAndExpensesRelatedParty"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="calc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="calc_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="calc_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="calc_PrivateCalcimedicaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="calc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="calc_StockholdersEquityNoteStockSplitExchangeRatio" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="calc_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="calc_AtTheMarketOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="calc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="calc_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="calc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="calc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="calc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="calc_RightOfUseAssetOrLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="calc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="calc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="calc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="calc_TaxPostionMinimumPercentageOfTaxBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="calc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_VariableInterestEntityOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="calc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CostsAndExpensesRelatedParty" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CalcimedicaIncMember" xlink:label="calc_CalcimedicaIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_GraybugMember" xlink:label="calc_GraybugMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_GraybugVisionIncMember" xlink:label="calc_GraybugVisionIncMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_StockIssuedDuringPeriodPrivatePlacement" xlink:label="calc_StockIssuedDuringPeriodPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_BusinessCombinationConsiderationTransferedCostIncurred" xlink:label="calc_BusinessCombinationConsiderationTransferedCostIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="calc_CalcimedicaIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="calc_GraybugMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="calc_GraybugVisionIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="calc_StockIssuedDuringPeriodPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="calc_BusinessCombinationConsiderationTransferedCostIncurred" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SeveranceCosts1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShortTermInvestmentFairValueDisclosure" xlink:label="calc_ShortTermInvestmentFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="us-gaap_USTreasuryBillSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:label="us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryNotesSecuritiesMember" xlink:label="us-gaap_USTreasuryNotesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PreferredWarrantsLiabilityMember" xlink:label="calc_PreferredWarrantsLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConvertiblePromissoryNoteWarrantsLiabilityMember" xlink:label="calc_ConvertiblePromissoryNoteWarrantsLiabilityMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="calc_ShortTermInvestmentFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasuryBillSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasuryNotesSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ConvertibleNotesPayableMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="calc_PreferredWarrantsLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="calc_ConvertiblePromissoryNoteWarrantsLiabilityMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3InputsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConvertiblePromissoryNoteMember" xlink:label="calc_ConvertiblePromissoryNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PreferredWarrantsMember" xlink:label="calc_PreferredWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PreferredWarrantMember" xlink:label="calc_PreferredWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConvertiblePromissoryNoteWarrantsMember" xlink:label="calc_ConvertiblePromissoryNoteWarrantsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="calc_ConvertiblePromissoryNoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="calc_PreferredWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="calc_PreferredWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="calc_ConvertiblePromissoryNoteWarrantsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis" xlink:label="calc_CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="us-gaap_USTreasuryBillSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis" xlink:label="calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:label="us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryNotesSecuritiesMember" xlink:label="us-gaap_USTreasuryNotesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShortTermInvestmentFairValueDisclosure" xlink:label="calc_ShortTermInvestmentFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AssetsFairValueDisclosureAmortizedCostBasis" xlink:label="calc_AssetsFairValueDisclosureAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="calc_CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasuryBillSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasuryNotesSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="calc_ShortTermInvestmentFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="calc_AssetsFairValueDisclosureAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PrivateCalcimedicaMember" xlink:label="calc_PrivateCalcimedicaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConvertiblePromissoryNoteWarrantsMember" xlink:label="calc_ConvertiblePromissoryNoteWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_GraybugMember" xlink:label="calc_GraybugMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_DebtInstrumentPeriodicPaymentPrincipalAdditional" xlink:label="calc_DebtInstrumentPeriodicPaymentPrincipalAdditional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PublicCombinationMultipliedCashPricePaidPerShare" xlink:label="calc_PublicCombinationMultipliedCashPricePaidPerShare"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PercentageOfWarrantCoverage" xlink:label="calc_PercentageOfWarrantCoverage"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConvertiblePromissoryNoteWarrantsConvertible" xlink:label="calc_ConvertiblePromissoryNoteWarrantsConvertible"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ConvertiblePromissoryNoteWarrantsCommonStockConverted" xlink:label="calc_ConvertiblePromissoryNoteWarrantsCommonStockConverted"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ExchangeOfStockForStock" xlink:label="calc_ExchangeOfStockForStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ExpectedPerShare" xlink:label="calc_ExpectedPerShare"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="calc_PrivateCalcimedicaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="calc_ConvertiblePromissoryNoteWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="calc_GraybugMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="calc_DebtInstrumentPeriodicPaymentPrincipalAdditional" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="calc_PublicCombinationMultipliedCashPricePaidPerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="calc_PercentageOfWarrantCoverage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="calc_ConvertiblePromissoryNoteWarrantsConvertible" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="calc_ConvertiblePromissoryNoteWarrantsCommonStockConverted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="calc_ExchangeOfStockForStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="calc_ExpectedPerShare" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PreMergerCalcimedicaMember" xlink:label="calc_PreMergerCalcimedicaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesCTwoConvertiblePreferredStockMember" xlink:label="calc_SeriesCTwoConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PriorToMergerTransactionsMember" xlink:label="calc_PriorToMergerTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AmendedAndRestatedCertificateOfIncorporationMember" xlink:label="calc_AmendedAndRestatedCertificateOfIncorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_GraybugMember" xlink:label="calc_GraybugMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_OfficersAndDirectorsMember" xlink:label="calc_OfficersAndDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PostMergerCalcimedicaMember" xlink:label="calc_PostMergerCalcimedicaMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesDConvertiblePreferredStockMember" xlink:label="calc_SeriesDConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PostMergerTransactionsMember" xlink:label="calc_PostMergerTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CalcimedicaPreferredStockMember" xlink:label="calc_CalcimedicaPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShelfRegistrationStatementMember" xlink:label="calc_ShelfRegistrationStatementMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="calc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CalcimedicaCommonStockMember" xlink:label="calc_CalcimedicaCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AtTheMarketOfferingMember" xlink:label="calc_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesBWarrantsMember" xlink:label="calc_SeriesBWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesCTwoWarrantsMember" xlink:label="calc_SeriesCTwoWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SeriesDWarrantsMember" xlink:label="calc_SeriesDWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShelfRegistrationStatementAvaliableForSale" xlink:label="calc_ShelfRegistrationStatementAvaliableForSale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xlink:label="calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:label="calc_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrantsExercisable" xlink:label="calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrantsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SaleOfStockRemainingSalesAmount" xlink:label="calc_SaleOfStockRemainingSalesAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="calc_PreMergerCalcimedicaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_SeriesCTwoConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="calc_PriorToMergerTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="calc_AmendedAndRestatedCertificateOfIncorporationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="calc_GraybugMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="calc_OfficersAndDirectorsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="calc_PostMergerCalcimedicaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_SeriesDConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="calc_PostMergerTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_CalcimedicaPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="calc_ShelfRegistrationStatementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="calc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_CalcimedicaCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="calc_AtTheMarketOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_SeriesBWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_SeriesCTwoWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="calc_SeriesDWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="calc_ShelfRegistrationStatementAvaliableForSale" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="calc_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrantsExercisable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_FairValueNetAssetLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="calc_SaleOfStockRemainingSalesAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:label="calc_TwoThousandAndTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_GraybugMember" xlink:label="calc_GraybugMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TwoThousandAndSixEquityIncentivePlanMember" xlink:label="calc_TwoThousandAndSixEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AmendmentToTwoThousandAndSixEquityIncentivePlanMember" xlink:label="calc_AmendmentToTwoThousandAndSixEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingRightsAnniversaryPeriod" xlink:label="calc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingRightsAnniversaryPeriod"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TwoThousandAndTwentyThreeEquityIncentivePlanMember" xlink:label="calc_TwoThousandAndTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember" xlink:label="calc_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:label="calc_TwoThousandAndTwentyEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_InducementGrantsMember" xlink:label="calc_InducementGrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PercentageOfAggregateNumberOfSharesOfCommonStockOutstandingOnLastDayOfPrecedingYearAddedToPlan" xlink:label="calc_PercentageOfAggregateNumberOfSharesOfCommonStockOutstandingOnLastDayOfPrecedingYearAddedToPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="calc_TwoThousandAndTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="calc_GraybugMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="calc_TwoThousandAndSixEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="calc_AmendmentToTwoThousandAndSixEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="calc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingRightsAnniversaryPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="calc_TwoThousandAndTwentyThreeEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="calc_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="calc_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="calc_InducementGrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="calc_PercentageOfAggregateNumberOfSharesOfCommonStockOutstandingOnLastDayOfPrecedingYearAddedToPlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsingBlackScholesToEstimatedFairValueOfTheStockOptionGrantsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedForOptionsAndRsusGrantedDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SettlementOfAccruedBonusAndEmployeeCosts" xlink:label="calc_SettlementOfAccruedBonusAndEmployeeCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="calc_SettlementOfAccruedBonusAndEmployeeCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfCommonStockReservedForFutureIssuanceDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TwoThousandAndTwentyThreeEquityIncentivePlanMember" xlink:label="calc_TwoThousandAndTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember" xlink:label="calc_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="calc_TwoThousandAndTwentyThreeEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="calc_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MD" xlink:label="stpr_MD"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AuxoraMember" xlink:label="calc_AuxoraMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_LeaseAmendmentDate" xlink:label="calc_LeaseAmendmentDate"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_NumberOfContractCurrentlyInEffect" xlink:label="calc_NumberOfContractCurrentlyInEffect"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ContractualObligationOfContractInEffect" xlink:label="calc_ContractualObligationOfContractInEffect"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_UnpaidCancellationAndOtherRelatedCosts" xlink:label="calc_UnpaidCancellationAndOtherRelatedCosts"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_BaseRent" xlink:label="calc_BaseRent"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_LesseeOperatingLeaseMaturityYearAndMonth" xlink:label="calc_LesseeOperatingLeaseMaturityYearAndMonth"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShortTermOperatingLeaseExpirationDate" xlink:label="calc_ShortTermOperatingLeaseExpirationDate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MD" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="calc_AuxoraMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="calc_LeaseAmendmentDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="calc_NumberOfContractCurrentlyInEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="calc_ContractualObligationOfContractInEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="calc_UnpaidCancellationAndOtherRelatedCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="calc_BaseRent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="calc_LesseeOperatingLeaseMaturityYearAndMonth" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="calc_ShortTermOperatingLeaseExpirationDate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_IncomeTaxDisclosureLineItems" xlink:label="calc_IncomeTaxDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_IncomeTaxDisclosureTable" xlink:label="calc_IncomeTaxDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_OperatingLossCarryForwardsExpirationBeginningYear" xlink:label="calc_OperatingLossCarryForwardsExpirationBeginningYear"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_FederalResearchAndDevelopmentMember" xlink:label="calc_FederalResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PercentageOfChangeInOwnership" xlink:label="calc_PercentageOfChangeInOwnership"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_UnrecognizedTaxBenefitsNet" xlink:label="calc_UnrecognizedTaxBenefitsNet"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="calc_IncomeTaxDisclosureLineItems" xlink:to="calc_IncomeTaxDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="calc_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="calc_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="calc_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="calc_IncomeTaxDisclosureLineItems" xlink:to="calc_OperatingLossCarryForwardsExpirationBeginningYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="calc_FederalResearchAndDevelopmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="calc_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="calc_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="calc_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="calc_IncomeTaxDisclosureLineItems" xlink:to="calc_PercentageOfChangeInOwnership" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="calc_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="calc_IncomeTaxDisclosureLineItems" xlink:to="calc_UnrecognizedTaxBenefitsNet" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_WarrantsToPurchaseConvertiblePreferredStockMember" xlink:label="calc_WarrantsToPurchaseConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="calc_WarrantsToPurchaseConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_DirectorsEmployeesOrConsultantsMember" xlink:label="calc_DirectorsEmployeesOrConsultantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_JonesTradingMember" xlink:label="calc_JonesTradingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AccreditedInvestorsMember" xlink:label="calc_AccreditedInvestorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsDate" xlink:label="us-gaap_SubsequentEventsDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PreFundedWarrantsMember" xlink:label="calc_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PlacementAgentWarrantsMember" xlink:label="calc_PlacementAgentWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TrancheACommonWarrantsMember" xlink:label="calc_TrancheACommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TrancheBCommonWarrantsMember" xlink:label="calc_TrancheBCommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TrancheAAndTrancheBCommonWarrantsMember" xlink:label="calc_TrancheAAndTrancheBCommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CommonWarrantsMember" xlink:label="calc_CommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="us-gaap_WarrantExercisePriceDecrease"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ClassOfWarrantRedeemOutstandingDescription" xlink:label="calc_ClassOfWarrantRedeemOutstandingDescription"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_BeneficialOwnershipPercentage" xlink:label="calc_BeneficialOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_GrossProceedsFromIssuanceOfPrivatePlacement" xlink:label="calc_GrossProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_TransactionFeePercentage" xlink:label="calc_TransactionFeePercentage"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_NumberOfSharesIssuedInitiallyOnTransaction" xlink:label="calc_NumberOfSharesIssuedInitiallyOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_NumberOfSharesIssuedFinallyOnTransaction" xlink:label="calc_NumberOfSharesIssuedFinallyOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PercentageOfMoreBeneficialOwnership" xlink:label="calc_PercentageOfMoreBeneficialOwnership"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PercentageOfOwnershipDuringElection" xlink:label="calc_PercentageOfOwnershipDuringElection"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="calc_DirectorsEmployeesOrConsultantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="calc_JonesTradingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="calc_AccreditedInvestorsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventsDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="calc_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="calc_PlacementAgentWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="calc_TrancheACommonWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="calc_TrancheBCommonWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="calc_TrancheAAndTrancheBCommonWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="calc_CommonWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="calc_ClassOfWarrantRedeemOutstandingDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="calc_BeneficialOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="calc_GrossProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="calc_TransactionFeePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="calc_NumberOfSharesIssuedInitiallyOnTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="calc_NumberOfSharesIssuedFinallyOnTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="calc_PercentageOfMoreBeneficialOwnership" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="calc_PercentageOfOwnershipDuringElection" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCash" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="calc_WarrantLiability" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ConvertibleNotesPayable" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssets" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="calc_AccruedClinicalTrialCosts" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="9" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_WarrantLiability" xlink:label="calc_WarrantLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AccruedClinicalTrialCosts" xlink:label="calc_AccruedClinicalTrialCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="calc_AssetsFairValueDisclosureAmortizedCostBasis" xlink:to="calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="calc_AssetsFairValueDisclosureAmortizedCostBasis" xlink:to="calc_CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AssetsFairValueDisclosureAmortizedCostBasis" xlink:label="calc_AssetsFairValueDisclosureAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis" xlink:label="calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis" xlink:label="calc_CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="calc_ChangeInFairValueOfWarrantLiability" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="calc_ChangeInFairValueOfConvertiblePromissoryNote" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="calc_InterestOnConvertiblePromissoryNotesPayable" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ChangeInFairValueOfWarrantLiability" xlink:label="calc_ChangeInFairValueOfWarrantLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ChangeInFairValueOfConvertiblePromissoryNote" xlink:label="calc_ChangeInFairValueOfConvertiblePromissoryNote"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_InterestOnConvertiblePromissoryNotesPayable" xlink:label="calc_InterestOnConvertiblePromissoryNotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromOtherEquity" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="calc_PaymentsOfAcquisitionOfBusinessesNetOfCash" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="calc_FairValueAdjustmentOfConvertiblePromissoryNotes" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="calc_NonCashInterestExpense" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="calc_ProceedsFromIssuanceOfConvertibleNotes" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="calc_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndNoncurrentAssets" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="10" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="us-gaap_ProceedsFromOtherEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_PaymentsOfAcquisitionOfBusinessesNetOfCash" xlink:label="calc_PaymentsOfAcquisitionOfBusinessesNetOfCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_FairValueAdjustmentOfConvertiblePromissoryNotes" xlink:label="calc_FairValueAdjustmentOfConvertiblePromissoryNotes"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_NonCashInterestExpense" xlink:label="calc_NonCashInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ProceedsFromIssuanceOfConvertibleNotes" xlink:label="calc_ProceedsFromIssuanceOfConvertibleNotes"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndNoncurrentAssets" xlink:label="calc_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="calc_ShortTermInvestmentFairValueDisclosure" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShortTermInvestmentFairValueDisclosure" xlink:label="calc_ShortTermInvestmentFairValueDisclosure"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis" xlink:to="calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="calc_CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis" xlink:to="calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis" xlink:to="calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="calc_CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis" xlink:to="calc_ShortTermInvestmentFairValueDisclosure" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis" xlink:label="calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis" xlink:label="calc_CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_ShortTermInvestmentFairValueDisclosure" xlink:label="calc_ShortTermInvestmentFairValueDisclosure"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="calc_AccruedPayrollAndOtherEmployeeBenefits" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="calc_AccruedSeveranceExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="calc_AccruedFranchiseTax" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="calc_AccruedOther" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AccruedPayrollAndOtherEmployeeBenefits" xlink:label="calc_AccruedPayrollAndOtherEmployeeBenefits"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AccruedSeveranceExpense" xlink:label="calc_AccruedSeveranceExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AccruedFranchiseTax" xlink:label="calc_AccruedFranchiseTax"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_AccruedOther" xlink:label="calc_AccruedOther"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedForOptionsAndRsusGrantedDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:to="calc_SettlementOfAccruedBonusAndEmployeeCosts" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_SettlementOfAccruedBonusAndEmployeeCosts" xlink:label="calc_SettlementOfAccruedBonusAndEmployeeCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="calc_IncomeTaxReconciliationPermanentDifferences" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_IncomeTaxReconciliationPermanentDifferences" xlink:label="calc_IncomeTaxReconciliationPermanentDifferences"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="calc_NetDeferredTaxAsset" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="calc_DeferredTaxLiabilitiesRightOfUseAssets" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="calc_NetDeferredTaxAsset" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="calc_DeferredTaxLiabilitiesValuationAllowance" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsStateTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="calc_NetDeferredTaxAsset" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="calc_DeferredTaxAssetLeaseLiabilities" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_NetDeferredTaxAsset" xlink:label="calc_NetDeferredTaxAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="calc_DeferredTaxLiabilitiesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_DeferredTaxLiabilitiesValuationAllowance" xlink:label="calc_DeferredTaxLiabilitiesValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsStateTaxes" xlink:label="us-gaap_DeferredTaxAssetsStateTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="calc-20231231.xsd#calc_DeferredTaxAssetLeaseLiabilities" xlink:label="calc_DeferredTaxAssetLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="calc_DeemedDistribution" name="DeemedDistribution" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_CalcimedicaIncMember" name="CalcimedicaIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_CostsIncurredInConnectionWithReverseMergerIncludedInAccountsPayableAndAccruedExpenses" name="CostsIncurredInConnectionWithReverseMergerIncludedInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="calc_FederalResearchAndDevelopmentMember" name="FederalResearchAndDevelopmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_ConversionOfSeriesC2WarrantIntoCommonStock" name="ConversionOfSeriesC2WarrantIntoCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_PercentageOfMoreBeneficialOwnership" name="PercentageOfMoreBeneficialOwnership" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_PaymentsOfAcquisitionOfBusinessesNetOfCash" name="PaymentsOfAcquisitionOfBusinessesNetOfCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" name="ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger" name="IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_PlacementAgentWarrantsMember" name="PlacementAgentWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_PatentsCostsPolicyTextBlock" name="PatentsCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_ProceedsFromIssuanceOfConvertibleNotes" name="ProceedsFromIssuanceOfConvertibleNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="calc_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_AccruedSeveranceExpense" name="AccruedSeveranceExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_NetDeferredTaxAsset" name="NetDeferredTaxAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="calc_TransactionFeePercentage" name="TransactionFeePercentage" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_CalcimedicaCommonStockMember" name="CalcimedicaCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndNoncurrentAssets" name="IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndNoncurrentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_PrivateCalcimedicaMember" name="PrivateCalcimedicaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax" name="CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="calc_GrossProceedsFromIssuanceOfPrivatePlacement" name="GrossProceedsFromIssuanceOfPrivatePlacement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="calc_DeferredTaxLiabilitiesRightOfUseAssets" name="DeferredTaxLiabilitiesRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_ShelfRegistrationStatementAvaliableForSale" name="ShelfRegistrationStatementAvaliableForSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_AccruedPayrollAndOtherEmployeeBenefits" name="AccruedPayrollAndOtherEmployeeBenefits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" name="AssetsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_ConvertiblePromissoryNoteWarrantsMember" name="ConvertiblePromissoryNoteWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_ContractualObligationOfContractInEffect" name="ContractualObligationOfContractInEffect" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_FinancingCostsIncludedInAccountsPayable" name="FinancingCostsIncludedInAccountsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="calc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" name="TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_TrancheBCommonWarrantsMember" name="TrancheBCommonWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_AssetsFairValueDisclosureAmortizedCostBasis" name="AssetsFairValueDisclosureAmortizedCostBasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="calc_CalcimedicaPreferredStockMember" name="CalcimedicaPreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_GraybugVisionIncMember" name="GraybugVisionIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_IncomeTaxDisclosureLineItems" name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_LesseeOperatingLeaseMaturityYearAndMonth" name="LesseeOperatingLeaseMaturityYearAndMonth" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_StockIssuedDuringPeriodPrivatePlacement" name="StockIssuedDuringPeriodPrivatePlacement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_TwoThousandAndTwentyThreeEquityIncentivePlanMember" name="TwoThousandAndTwentyThreeEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_ConversionOfPromissoryNoteWarrantsIntoCommonStockShare" name="ConversionOfPromissoryNoteWarrantsIntoCommonStockShare" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_RightOfUseAssetOrLeaseLiability" name="RightOfUseAssetOrLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="calc_OfficersAndDirectorsMember" name="OfficersAndDirectorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_SeriesDConvertiblePreferredStockMember" name="SeriesDConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_AccreditedInvestorsMember" name="AccreditedInvestorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_ExerciseAndConversionOfC2WarrantsShares" name="ExerciseAndConversionOfC2WarrantsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis" name="CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="calc_TwoThousandAndSixEquityIncentivePlanMember" name="TwoThousandAndSixEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_WarrantLiabilityPolicyPolicyTextBlock" name="WarrantLiabilityPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_StockIssuedDuringPeriodSharesConversionOfPromissoryNotes" name="StockIssuedDuringPeriodSharesConversionOfPromissoryNotes" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax" name="AssetsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="calc_FairValueAdjustmentOfConvertiblePromissoryNotes" name="FairValueAdjustmentOfConvertiblePromissoryNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis" name="ShortTermInvestmentFairValueDisclosureAmortizedCostBasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" name="CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_AmendedAndRestatedCertificateOfIncorporationMember" name="AmendedAndRestatedCertificateOfIncorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_NetProceedsFromPrivatePlacement" name="NetProceedsFromPrivatePlacement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="calc_NumberOfContractCurrentlyInEffect" name="NumberOfContractCurrentlyInEffect" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax" name="ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="calc_RelatedPartyTransactionsPolicyTextBlock" name="RelatedPartyTransactionsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_RestrictedStockUnitsNetSettlementShares" name="RestrictedStockUnitsNetSettlementShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_ShortTermInvestmentFairValueDisclosure" name="ShortTermInvestmentFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="calc_GrossProceedsFromThePrivatePlacement" name="GrossProceedsFromThePrivatePlacement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="calc_TrancheAAndTrancheBCommonWarrantsMember" name="TrancheAAndTrancheBCommonWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_PriorToMergerTransactionsMember" name="PriorToMergerTransactionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_PreferredAndCommonStockMember" name="PreferredAndCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_OperatingLossCarryForwardsExpirationBeginningYear" name="OperatingLossCarryForwardsExpirationBeginningYear" type="dtr-types:gYearListItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_SettlementOfAccruedBonusAndEmployeeCosts" name="SettlementOfAccruedBonusAndEmployeeCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="calc_ShortTermOperatingLeaseExpirationDate" name="ShortTermOperatingLeaseExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_TemporaryEquityDisclosureTextblock" name="TemporaryEquityDisclosureTextblock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_NumberOfSharesIssuedInitiallyOnTransaction" name="NumberOfSharesIssuedInitiallyOnTransaction" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="calc_DirectorsEmployeesOrConsultantsMember" name="DirectorsEmployeesOrConsultantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_ConversionOfPromissoryNoteWarrantIntoCommonstock" name="ConversionOfPromissoryNoteWarrantIntoCommonstock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="calc_ConvertiblePromissoryNoteWarrantsLiabilityMember" name="ConvertiblePromissoryNoteWarrantsLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_AuxoraMember" name="AuxoraMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_PercentageOfWarrantCoverage" name="PercentageOfWarrantCoverage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="calc_PublicCombinationMultipliedCashPricePaidPerShare" name="PublicCombinationMultipliedCashPricePaidPerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="calc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" name="TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_InterestOnConvertiblePromissoryNotesPayable" name="InterestOnConvertiblePromissoryNotesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="calc_NonCashInterestExpense" name="NonCashInterestExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="calc_ConversionOfConvertiblePromissoryNoteWarrantsToCommonStock" name="ConversionOfConvertiblePromissoryNoteWarrantsToCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_ConvertiblePreferredStockAbstract" name="ConvertiblePreferredStockAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_BaseRent" name="BaseRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="calc_AccruedResearchAndDevelopmentCostsPolicyTextBlock" name="AccruedResearchAndDevelopmentCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_IncomeTaxReconciliationPermanentDifferences" name="IncomeTaxReconciliationPermanentDifferences" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_StockIssuedDuringPeriodValueConversionOfPromissoryNotes" name="StockIssuedDuringPeriodValueConversionOfPromissoryNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_SeriesBWarrantsMember" name="SeriesBWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_ConvertiblePreferredStockSeriesABC1C2AndDMember" name="ConvertiblePreferredStockSeriesABC1C2AndDMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_TotalNetProceeds" name="TotalNetProceeds" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_CommissionsAndOtherTransactionExpenses" name="CommissionsAndOtherTransactionExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingRightsAnniversaryPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingRightsAnniversaryPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_PreferredWarrantsLiabilityMember" name="PreferredWarrantsLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_ExchangeOfStockForStock" name="ExchangeOfStockForStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrantsExercisable" name="StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrantsExercisable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_AccruedFranchiseTax" name="AccruedFranchiseTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_AtTheMarketOfferingMember" name="AtTheMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_TaxPostionMinimumPercentageOfTaxBenefit" name="TaxPostionMinimumPercentageOfTaxBenefit" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_WarrantLiability" name="WarrantLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_DeferredTaxAssetLeaseLiabilities" name="DeferredTaxAssetLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="calc_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_WarrantsToPurchaseConvertiblePreferredStockMember" name="WarrantsToPurchaseConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_NumberOfSharesIssuedFinallyOnTransaction" name="NumberOfSharesIssuedFinallyOnTransaction" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="calc_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_SeriesC1ConvertiblePreferredStockMember" name="SeriesC1ConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_ConvertiblePromissoryNoteWarrantsCommonStockConverted" name="ConvertiblePromissoryNoteWarrantsCommonStockConverted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="calc_ChangeInFairValueOfWarrantLiability" name="ChangeInFairValueOfWarrantLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_UnpaidCancellationAndOtherRelatedCosts" name="UnpaidCancellationAndOtherRelatedCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="calc_ClassOfWarrantRedeemOutstandingDescription" name="ClassOfWarrantRedeemOutstandingDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" name="TwoThousandAndTwentyEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_PreMergerCalcimedicaMember" name="PreMergerCalcimedicaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_SeriesDWarrantsMember" name="SeriesDWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_PostMergerCalcimedicaMember" name="PostMergerCalcimedicaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_PreferredWarrantsMember" name="PreferredWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_AmendmentToTwoThousandAndSixEquityIncentivePlanMember" name="AmendmentToTwoThousandAndSixEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_GraybugMember" name="GraybugMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMergerShares" name="IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMergerShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_UnrecognizedTaxBenefitsNet" name="UnrecognizedTaxBenefitsNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_BeneficialOwnershipPercentage" name="BeneficialOwnershipPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="calc_DeferredTaxLiabilitiesValuationAllowance" name="DeferredTaxLiabilitiesValuationAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_DebtInstrumentPeriodicPaymentPrincipalAdditional" name="DebtInstrumentPeriodicPaymentPrincipalAdditional" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_JonesTradingMember" name="JonesTradingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_BusinessCombinationConsiderationTransferedCostIncurred" name="BusinessCombinationConsiderationTransferedCostIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" name="StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_PercentageOfChangeInOwnership" name="PercentageOfChangeInOwnership" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_SeriesCTwoConvertiblePreferredStockMember" name="SeriesCTwoConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_PostMergerTransactionsMember" name="PostMergerTransactionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_SeriesC2ConvertiblePreferredStockMember" name="SeriesC2ConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_TrancheACommonWarrantsMember" name="TrancheACommonWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_IssuanceOfCommonSharesFromPrivatePlacementNet" name="IssuanceOfCommonSharesFromPrivatePlacementNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_IssuanceOfCommonSharesFromPrivatePlacementNetShares" name="IssuanceOfCommonSharesFromPrivatePlacementNetShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_InducementGrantsMember" name="InducementGrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_TwoThousandAndTwentyEquityIncentivePlanMember" name="TwoThousandAndTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_SeriesCTwoWarrantsMember" name="SeriesCTwoWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" name="StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_RestrictedStockUnitsNetSettlement" name="RestrictedStockUnitsNetSettlement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_PreferredWarrantMember" name="PreferredWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_AccruedClinicalTrialCosts" name="AccruedClinicalTrialCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember" name="TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_ExpectedPerShare" name="ExpectedPerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="calc_ChangeInFairValueOfConvertiblePromissoryNote" name="ChangeInFairValueOfConvertiblePromissoryNote" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_ShelfRegistrationStatementMember" name="ShelfRegistrationStatementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_CommonWarrantsMember" name="CommonWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_ConversionOfC2WarrantsToCommonStock" name="ConversionOfC2WarrantsToCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_PercentageOfAggregateNumberOfSharesOfCommonStockOutstandingOnLastDayOfPrecedingYearAddedToPlan" name="PercentageOfAggregateNumberOfSharesOfCommonStockOutstandingOnLastDayOfPrecedingYearAddedToPlan" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_AccountsPayableAndAccruedLiabilitiesAssumedInTheMerger" name="AccountsPayableAndAccruedLiabilitiesAssumedInTheMerger" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="calc_LeaseAmendmentDate" name="LeaseAmendmentDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="calc_MergerTransactionCosts" name="MergerTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_StockholdersEquityNoteStockSplitExchangeRatio" name="StockholdersEquityNoteStockSplitExchangeRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_ConversionOfConvertiblePromissoryNotesToCommonStock" name="ConversionOfConvertiblePromissoryNotesToCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_AccruedOther" name="AccruedOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_PrepaidExpensesAndOtherCurrentAssets" name="PrepaidExpensesAndOtherCurrentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_SaleOfStockRemainingSalesAmount" name="SaleOfStockRemainingSalesAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_PercentageOfOwnershipDuringElection" name="PercentageOfOwnershipDuringElection" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="calc_ShortTermInvestmentsAssumedInTheMerger" name="ShortTermInvestmentsAssumedInTheMerger" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="calc_ConvertiblePromissoryNoteWarrantsConvertible" name="ConvertiblePromissoryNoteWarrantsConvertible" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="calc_ConvertiblePromissoryNoteMember" name="ConvertiblePromissoryNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091594494896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 21, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CALC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CalciMedica, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001534133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document financial statement error correction</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text"> Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,740,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-2120079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">505 Coast Boulevard South<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">La Jolla<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">952-5500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text"> Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">                                                                              </span></p><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Portions of the registrant&#8217;s definitive Proxy Statement (the &#8220;Proxy Statement&#8221;) for the 2024 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission not later than April 29, 2024 are incorporated by reference into Part III of this Annual Report </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">on Form 10-K</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091594534576">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5,530<span></span>
</td>
<td class="nump">$ 1,327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,708<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">367<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,605<span></span>
</td>
<td class="nump">1,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">167<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">413<span></span>
</td>
<td class="nump">1,424<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,185<span></span>
</td>
<td class="nump">3,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,419<span></span>
</td>
<td class="nump">2,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_AccruedClinicalTrialCosts', window );">Accrued clinical trial costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,141<span></span>
</td>
<td class="nump">1,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,468<span></span>
</td>
<td class="nump">572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,028<span></span>
</td>
<td class="nump">4,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract', window );"><strong>Long-term liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_WarrantLiability', window );">Warrant liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible promissory notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,157<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,028<span></span>
</td>
<td class="nump">12,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit) (1)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">154,218<span></span>
</td>
<td class="nump">40,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(146,064)<span></span>
</td>
<td class="num">(111,707)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8,157<span></span>
</td>
<td class="num">(71,304)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders' equity (deficit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,185<span></span>
</td>
<td class="nump">3,349<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=calc_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ConvertiblePreferredStockAbstract', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=calc_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ConvertiblePreferredStockAbstract', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=calc_SeriesC1ConvertiblePreferredStockMember', window );">Series C-1 Convertible Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ConvertiblePreferredStockAbstract', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=calc_SeriesC2ConvertiblePreferredStockMember', window );">Series C-2 Convertible Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ConvertiblePreferredStockAbstract', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,563<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=calc_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ConvertiblePreferredStockAbstract', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 19,494<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) Retroactively restated for the reverse recapitalization as described in Note 2.</span></p></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_AccruedClinicalTrialCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trial Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_AccruedClinicalTrialCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_ConvertiblePreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_ConvertiblePreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=calc_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=calc_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=calc_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=calc_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=calc_SeriesC1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=calc_SeriesC1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=calc_SeriesC2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=calc_SeriesC2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=calc_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=calc_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091707936672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">5,694,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">5,754,505<span></span>
</td>
<td class="nump">84,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">5,754,505<span></span>
</td>
<td class="nump">84,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=calc_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,751,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,751,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,751,716<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=calc_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,235,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,667,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,667,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=calc_SeriesC1ConvertiblePreferredStockMember', window );">Series C-1Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,016,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,016,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,016,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=calc_SeriesC2ConvertiblePreferredStockMember', window );">Series C-2 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,291,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,504,959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,504,959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=calc_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">88,875,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,880,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,880,040<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=calc_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=calc_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=calc_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=calc_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=calc_SeriesC1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=calc_SeriesC1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=calc_SeriesC2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=calc_SeriesC2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=calc_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=calc_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091684668432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 15,859<span></span>
</td>
<td class="nump">$ 8,350<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">22,216<span></span>
</td>
<td class="nump">5,843<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">38,075<span></span>
</td>
<td class="nump">14,193<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(38,075)<span></span>
</td>
<td class="num">(14,193)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrant liability</a></td>
<td class="nump">1,146<span></span>
</td>
<td class="nump">3,784<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ChangeInFairValueOfConvertiblePromissoryNote', window );">Change in fair value of convertible promissory notes</a></td>
<td class="nump">2,022<span></span>
</td>
<td class="nump">2,745<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_InterestOnConvertiblePromissoryNotesPayable', window );">Interest on convertible promissory notes payable</a></td>
<td class="num">(110)<span></span>
</td>
<td class="num">(132)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">660<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">3,718<span></span>
</td>
<td class="nump">6,369<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(34,357)<span></span>
</td>
<td class="num">(7,824)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Deemed distribution to convertible promissory note holders</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,318)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (34,357)<span></span>
</td>
<td class="num">$ (9,142)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share&#8212;basic</a></td>
<td class="num">$ (7.66)<span></span>
</td>
<td class="num">$ (111.16)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share&#8212;diluted</a></td>
<td class="num">$ (7.66)<span></span>
</td>
<td class="num">$ (111.16)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares outstanding used in computing net loss per share&#8212;basic</a></td>
<td class="nump">4,486,258<span></span>
</td>
<td class="nump">82,245<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares outstanding used in computing net loss per share&#8212;diluted</a></td>
<td class="nump">4,486,258<span></span>
</td>
<td class="nump">82,245<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) Retroactively restated for the reverse recapitalization as described in Note 2.</span></p></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_ChangeInFairValueOfConvertiblePromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of convertible promissory note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_ChangeInFairValueOfConvertiblePromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_ChangeInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value of Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_ChangeInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_InterestOnConvertiblePromissoryNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest on convertible promissory notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_InterestOnConvertiblePromissoryNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 65<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-65<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 66<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-66<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091684362576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (34,357)<span></span>
</td>
<td class="num">$ (9,142)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain on available-for-sale securities, net of tax</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (34,355)<span></span>
</td>
<td class="num">$ (9,142)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091593479600">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2"><div>Total</div></th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th" colspan="2"><div>Common Stock</div></th>
<th class="th" colspan="2"><div>Additional Paid-In Capital</div></th>
<th class="th" colspan="2"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (63,987,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 39,895,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (103,883,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,527<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, Beginning balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 62,071,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Beginning balance, Shares at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">84,820,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,138<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,799,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,799,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_DeemedDistribution', window );">Deemed distribution</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,318,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,318,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(7,824,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,824,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, Ending balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 62,071,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Ending balance, Shares at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">84,820,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(71,304,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">40,402,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(111,707,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,165<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,039,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12,039,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock as a result of the Merger, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,442,852<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock as a result of the Merger, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(84,820,880)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock as a result of the Merger, value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">62,071,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">62,071,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock as a result of the Merger, value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (62,071,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMergerShares', window );">Issuance of common stock to Graybug stockholders as a result of Merger and reset to par of $0.0001, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,571,433<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger', window );">Issuance of common stock to Graybug stockholders as a result of Merger and reset to par of $0.0001</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29,218,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">29,218,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_IssuanceOfCommonSharesFromPrivatePlacementNetShares', window );">Issuance of common shares from private placement (net of issuance costs), shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">596,363<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_IssuanceOfCommonSharesFromPrivatePlacementNet', window );">Issuance of common shares from private placement (net of issuance costs)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,340,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10,340,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_StockIssuedDuringPeriodSharesConversionOfPromissoryNotes', window );">Conversion of promissory notes into common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">590,031<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_StockIssuedDuringPeriodValueConversionOfPromissoryNotes', window );">Conversion of promissory notes into common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,245,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,245,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ExerciseAndConversionOfC2WarrantsShares', window );">Conversion of Series C-2 warrants into common stock, share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,254<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ConversionOfSeriesC2WarrantIntoCommonStock', window );">Conversion of Series C-2 warrants into common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">442,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">442,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ConversionOfPromissoryNoteWarrantsIntoCommonStockShare', window );">Conversion of promissory note warrants into common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,875<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ConversionOfPromissoryNoteWarrantIntoCommonstock', window );">Conversion of promissory note warrants into common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">841,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">841,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_MergerTransactionCosts', window );">Merger transaction costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,545,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,545,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_RestrictedStockUnitsNetSettlementShares', window );">Restricted stock units net settlement, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,960<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_RestrictedStockUnitsNetSettlement', window );">Restricted stock units net settlement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(297,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(297,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Reclassification of warrant liability to equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">216,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">216,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock (net of issuance costs)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">246,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">246,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (net of issuance costs), shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,572<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(34,357,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(34,357,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8,157,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 154,218,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (146,064,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,754,505<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="11"></td></tr>
<tr><td colspan="11"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) Retroactively restated for the reverse recapitalization as described in Note 2.</span></p></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) Retroactively restated for the reverse recapitalization as described in Note 2.</span></p></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) Retroactively restated for the reverse recapitalization as described in Note 2.</span></p></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_ConversionOfPromissoryNoteWarrantIntoCommonstock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of promissory note warrant into commonstock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_ConversionOfPromissoryNoteWarrantIntoCommonstock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_ConversionOfPromissoryNoteWarrantsIntoCommonStockShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of promissory note warrants into common stock share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_ConversionOfPromissoryNoteWarrantsIntoCommonStockShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_ConversionOfSeriesC2WarrantIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of Series C-2 Warrant into Common Stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_ConversionOfSeriesC2WarrantIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_DeemedDistribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed Distribution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_DeemedDistribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_ExerciseAndConversionOfC2WarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise and conversion of C-2 Warrants, Shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_ExerciseAndConversionOfC2WarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_IssuanceOfCommonSharesFromPrivatePlacementNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares from private placement, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_IssuanceOfCommonSharesFromPrivatePlacementNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_IssuanceOfCommonSharesFromPrivatePlacementNetShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares from private placement, net, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_IssuanceOfCommonSharesFromPrivatePlacementNetShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock to Graybug stockholders as a result of the merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMergerShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock to Graybug stockholders as a result of the merger, Shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMergerShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_MergerTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_MergerTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_RestrictedStockUnitsNetSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted stock units net settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_RestrictedStockUnitsNetSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_RestrictedStockUnitsNetSettlementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted stock units net settlement shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_RestrictedStockUnitsNetSettlementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_StockIssuedDuringPeriodSharesConversionOfPromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares conversion of promissory notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_StockIssuedDuringPeriodSharesConversionOfPromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_StockIssuedDuringPeriodValueConversionOfPromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value conversion of promissory notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_StockIssuedDuringPeriodValueConversionOfPromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity, stock issued during period, shares, conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity, stock issued during period, value, conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091684746720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 17, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=calc_GraybugMember', window );">Graybug</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=calc_GraybugMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=calc_GraybugMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091709586240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (34,357)<span></span>
</td>
<td class="num">$ (7,824)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">12,039<span></span>
</td>
<td class="nump">1,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in the fair value of warrant liability</a></td>
<td class="num">(1,146)<span></span>
</td>
<td class="num">(3,784)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_FairValueAdjustmentOfConvertiblePromissoryNotes', window );">Change in the fair value of convertible promissory notes</a></td>
<td class="num">(2,022)<span></span>
</td>
<td class="num">(2,745)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_NonCashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion of discount on short-term investment</a></td>
<td class="num">(145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndNoncurrentAssets', window );">Prepaid expenses and other current and non-current assets</a></td>
<td class="nump">2,997<span></span>
</td>
<td class="num">(1,530)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,427)<span></span>
</td>
<td class="nump">933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(1,837)<span></span>
</td>
<td class="nump">1,202<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(25,730)<span></span>
</td>
<td class="num">(11,757)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(78)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchase of investments</a></td>
<td class="num">(6,118)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Maturity of investments</a></td>
<td class="nump">15,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">8,884<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">10,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_PaymentsOfAcquisitionOfBusinessesNetOfCash', window );">Acquisition of stock of Graybug, net of cash</a></td>
<td class="nump">14,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities', window );">Merger transaction costs</a></td>
<td class="num">(4,545)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ProceedsFromIssuanceOfConvertibleNotes', window );">Proceeds from issuance of convertible note payable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">246<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">20,900<span></span>
</td>
<td class="nump">8,476<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">4,054<span></span>
</td>
<td class="num">(3,285)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">1,476<span></span>
</td>
<td class="nump">4,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">5,530<span></span>
</td>
<td class="nump">1,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_CostsIncurredInConnectionWithReverseMergerIncludedInAccountsPayableAndAccruedExpenses', window );">Costs incurred in connection with reverse merger included in accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of Series A, B, C-1, C-2 and D convertible preferred stock to common stock</a></td>
<td class="nump">62,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger', window );">Issuance of common stock to Graybug stockholders as a result of the Merger</a></td>
<td class="nump">29,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ShortTermInvestmentsAssumedInTheMerger', window );">Short-term investments assumed in the Merger</a></td>
<td class="nump">9,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_PrepaidExpensesAndOtherCurrentAssets', window );">Prepaid expenses and other current assets assumed in the Merger</a></td>
<td class="nump">2,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_AccountsPayableAndAccruedLiabilitiesAssumedInTheMerger', window );">Accounts payable and accrued liabilities assumed in the Merger</a></td>
<td class="nump">2,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ConversionOfC2WarrantsToCommonStock', window );">Conversion of C-2 warrants to common stock</a></td>
<td class="nump">442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ConversionOfConvertiblePromissoryNotesToCommonStock', window );">Conversion of convertible promissory notes to common stock</a></td>
<td class="nump">3,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ConversionOfConvertiblePromissoryNoteWarrantsToCommonStock', window );">Conversion of convertible promissory note warrants to common stock</a></td>
<td class="nump">841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_FinancingCostsIncludedInAccountsPayable', window );">Financing costs included in accounts payable</a></td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_RestrictedStockUnitsNetSettlement', window );">Restricted stock units net settlement</a></td>
<td class="nump">297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1', window );">Reclassification of warrant liability to equity</a></td>
<td class="nump">$ 216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_AccountsPayableAndAccruedLiabilitiesAssumedInTheMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts payable and accrued liabilities assumed in the merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_AccountsPayableAndAccruedLiabilitiesAssumedInTheMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_ConversionOfC2WarrantsToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of C-2 warrants to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_ConversionOfC2WarrantsToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_ConversionOfConvertiblePromissoryNoteWarrantsToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of convertible promissory note warrants to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_ConversionOfConvertiblePromissoryNoteWarrantsToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_ConversionOfConvertiblePromissoryNotesToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of convertible promissory notes to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_ConversionOfConvertiblePromissoryNotesToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_CostsIncurredInConnectionWithReverseMergerIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs incurred in connection with reverse merger included in accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_CostsIncurredInConnectionWithReverseMergerIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_FairValueAdjustmentOfConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_FairValueAdjustmentOfConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_FinancingCostsIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing costs included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_FinancingCostsIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in prepaid expenses and other current and noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock to Graybug stockholders as a result of the merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_NonCashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash Interest Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_NonCashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_PaymentsOfAcquisitionOfBusinessesNetOfCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of aquisition of businesses net of cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_PaymentsOfAcquisitionOfBusinessesNetOfCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_PrepaidExpensesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_PrepaidExpensesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_ProceedsFromIssuanceOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_ProceedsFromIssuanceOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_RestrictedStockUnitsNetSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted stock units net settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_RestrictedStockUnitsNetSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_ShortTermInvestmentsAssumedInTheMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term investments assumed in the merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_ShortTermInvestmentsAssumedInTheMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for financing costs associated with business combinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in equity for down round feature triggered for warrant classified as equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091592797136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of Business</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Description of Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CalciMedica, Inc. (&#8220;CalciMedica&#8221; or the &#8220;Company&#8221;) (f/k/a Graybug Vision, Inc.) was incorporated in the state of Delaware in February 2015, following the conversion of Graybug, LLC, which was organized in May 2011, and has its principal operations in La Jolla, California. The Company is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory processes and direct cellular damage.&#8203; The Company has a wholly owned subsidiary, CalciMedica Subsidiary, Inc., incorporated in Delaware in October 2006, which survived the Merger as more fully described below.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reverse Merger Transaction</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 20, 2023, Graybug Vision, Inc. (&#8220;Graybug&#8221;) completed a reverse merger transaction in accordance with the terms and conditions of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended on February 10, 2023 (the &#8220;Merger Agreement&#8221;), by and among Graybug, Camaro Merger Sub, Inc., a wholly owned subsidiary of Graybug (&#8220;Merger Sub&#8221;), and CalciMedica, Inc. (&#8220;Private CalciMedica&#8221;), pursuant to which Merger Sub merged with and into Private CalciMedica, with Private CalciMedica surviving as a wholly owned subsidiary of Graybug (the &#8220;Merger&#8221;). Additionally, on March 20, 2023, Graybug changed its name from &#8220;Graybug Vision, Inc.&#8221; to &#8220;CalciMedica, Inc.&#8221; and Private CalciMedica changed its name from &#8220;CalciMedica, Inc.&#8221; to &#8220;CalciMedica Subsidiary, Inc.&#8221; At the completion of the Merger, the prior Private CalciMedica equity holders and the prior Graybug equity holders owned </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">72</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, respectively of the combined company, in each case, on a fully diluted basis using the treasury stock method and excluding out-of-the-money options and warrants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Merger was accounted for as a reverse recapitalization, with Private CalciMedica being treated as the acquirer for accounting purposes. See discussions of the transactions in connection with the Merger in Note 3 - Merger and Related Transactions.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has experienced net losses and negative cash flows from operating activities since its inception. The Company has an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">146.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023, and a net loss of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">34.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2023. Total operating expenses for the year ended December 31, 2023 were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">38.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which included $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">16.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of one-time charges comprised of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of charges related to the acceleration of vesting of the Graybug stock awards at the date of the Merger and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of charges related to severance as a result of the Merger. Substantially all of the Company&#8217;s operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company expects to incur significant expenses and increasing operating losses for the foreseeable future as the Company initiates and continues the preclinical and clinical development of its product candidates and adds personnel necessary to operate as a company with an advanced clinical pipeline of product candidates. In addition, after completion of the Merger, operating as a U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) registrant will involve the hiring of additional financial and other personnel, upgrading financial information systems, and incurring costs associated with operating as a public company. The Company expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of clinical development programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From inception to December 31, 2023, the Company has completed financings from the sale of preferred and common stock for total net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">112.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and has issued convertible debt for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. In connection with the Merger, the Company received approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">29.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of cash, cash equivalents and short-term investments. As of December 31, 2023, the Company had cash, cash equivalents and short-term investments of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company closed a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> private placement transaction on January 23, 2024 and the second closing of this private placement occurred on February 5, 2024. Gross proceeds from the transaction were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million with net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in commissions and other transaction expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company intends to seek additional funding through public and private financings, debt financings, collaboration agreements, strategic alliances and licensing agreements. Although the Company has been successful in raising capital in the past, there is no assurance of success in obtaining such additional financing on terms acceptable to us, it at all, and there is no assurance that the Company will be able to enter into collaborations or other arrangements. If the Company is unable to obtain funding when required or on acceptable terms, the Company may be required to scale back or discontinue the advancement of the product candidates, reduce headcount, file for bankruptcy, reorganize, merge with another entity or cease operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on the Company&#8217;s current operating plans, management believes its cash, cash equivalents and short-term investments will be sufficient to fund its operations for the period of at least one year following the issuance of these financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091592619840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Summary of Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;), and Accounting Standards Update (&#8220;ASU&#8221;), of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The consolidated financial statements include the accounts of the Company and CalciMedica Subsidiary, Inc. for the years ended December 31, 2023 and 2022. All intercompany accounts and transactions have been eliminated in consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since Private CalciMedica was determined to be the accounting acquirer in connection with the Merger, for periods prior to the Merger, the consolidated financial statements were prepared on a stand-alone basis for Private CalciMedica and did not include the combined entities activity or financial position. Subsequent to the Merger, the consolidated financial statements as of and for the year ended December 31, 2023 include Graybug&#8217;s activity from March 21, 2023 through December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and assets and liabilities at their acquisition date fair value. Historical share and per share figures of Private CalciMedica have been retroactively restated based on the merger exchange ratio of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0288</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">   </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company&#8217;s consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#8217;s consolidated financial statements relate to accruals for research and development expenses, valuation of warrants, valuation of convertible promissory notes and valuation of equity awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and other Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments, which potentially subject the Company to concentration of risk, consist principally of cash and cash equivalents. The Company&#8217;s cash is deposited with major federally insured U.S. financial institutions. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is dependent on contract manufacturing organizations (&#8220;CMO&#8221;) to supply products for research and development of its product candidates, including preclinical and clinical studies, and for commercialization of its product candidates, if approved. The Company&#8217;s development programs could be adversely affected by any significant interruption in CMO&#8217;s operations or by a significant interruption in the supply of active pharmaceutical ingredients and other components.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Products developed by the Company require approval from the FDA or other international regulatory agencies prior to commercial sales. There can be no assurance the Company&#8217;s product candidates will receive the necessary approvals. If the Company is denied approvals, approvals are delayed, or the Company is unable to maintain approvals received, such events could have a materially adverse impact on the Company.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents consist of readily available cash in checking accounts, money market funds and commercial paper. The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Short-term Investments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company invests excess cash in commercial paper and U.S government sponsored entities - mortgage-backed securities. These investments are included in short-term investments on the balance sheet, classified as available-for-sale and reported at fair value with unrealized gains and losses included in accumulated other comprehensive (loss)/gain, net. Realized gains and losses on the sale of these securities are recognized in net loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The financial information is regularly reviewed by the chief operating decision maker (&#8220;CODM&#8221;), in deciding how to allocate resources. The Company&#8217;s CODM is its chief executive officer. The Company&#8217;s singular focus is on developing highly selective calcium release-activated calcium channel inhibitors to improve outcomes for patients with acute inflammatory indications. No significant revenue has been generated since inception, and all tangible assets are held in the United States.</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Option</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As permitted under ASC 825, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Company has elected the fair value option to account for its convertible promissory notes due to certain embedded features within the notes. The Company recognizes the convertible</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">promissory </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">notes at fair value with changes in fair value recognized in the consolidated statements of operations located on the change in fair value of financial instruments line item. Changes in fair value as a result of the Company&#8217;s own credit risk is reflected in other income (expense) in the consolidated statements of operations. As a result of applying the fair value option, direct costs and fees related to the convertible promissory notes were expensed as incurred and not deferred.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally three to five years) and consist of manufacturing and lab equipment, furniture, computers and phones. Repairs and maintenance costs are charged to expense as incurred. Depreciation expense recognized for the years ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">58,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">52,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Long-lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-lived assets consist primarily of property and equipment. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate the carrying amount of an asset is not recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value would be assessed using discounted cash flows or other appropriate measures of fair value. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognize any impairment losses for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company leases office space with an original lease term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_96e7d778-f45a-41e2-8962-c4c3904214d6;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">twelve months </span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and does </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t have a right-of-use asset or lease liability recorded. The Company's policy is not to record leases with an original term of twelve months or less on the consolidated balance sheets. The Company recognizes lease expense for this short-term lease on a straight-line basis over the term of the lease. The lease is accounted for under ASC 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and has been classified as an operating lease. Rent expense recognized for the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">274,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">221,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs consist primarily of salaries, payroll taxes, employee benefits and stock-based compensation for those individuals involved in ongoing research and development efforts, as well as fees paid to consultants, external research fees, license fees paid to third parties for use of their intellectual property, laboratory supplies and development of compound materials, associated overhead expenses and facilities and depreciation costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. All research and development costs are expensed as incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company estimates preclinical studies and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on the Company&#8217;s behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers,  and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. The estimates are trued up to reflect the best information available at the time of the financial statement issuance. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#8217;s estimate of the status and timing of services performed relative to the actual status and timing of services performed may vary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation, related to executive, finance, business development, legal, human resources and support functions, including professional fees for auditing, tax, consulting and patent-related services, rent and utilities and insurance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs related to filing and pursuing patent applications are expensed as incurred since recoverability of such expenditures is uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Deferred Offering Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company capitalizes costs that are directly associated with equity financings until such financings are consummated at which time such costs are recorded against the gross proceeds of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss. Private CalciMedica had deferred offering costs capitalized as of December 31, 2022 for the Merger of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. As of December 31, 2023, the Company has deferred costs associated with its at-the-market offering of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrant Liability</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Private CalciMedica has issued various freestanding warrants to purchase shares of its convertible preferred stock. Prior to the Merger, Private CalciMedica adjusted the carrying value of such convertible preferred stock warrants to the estimated fair value at each reporting date, with any related increases or decreases in the fair value being recorded within other income (expense) in the consolidated statements of operations and comprehensive loss. Pursuant to the Merger Agreement, the Series C convertible preferred stock warrants became warrants to purchase shares of the combined company's common stock. As a result of the Merger, the warrants no longer meet the requirements for liability accounting and, as such, Private CalciMedica adjusted the value of the warrants to the estimated fair value as of the Merger date and reclassified them to stockholders' equity (deficit).</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense represents the cost of the grant date fair value of employee stock options recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. Private CalciMedica estimates the fair value of stock option grants using the Black-Scholes option pricing model (&#8220;Black-Scholes&#8221;). Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. Equity-based compensation expense is classified in the statements of operations in the same manner in which the award recipients&#8217; payroll costs are classified or in which the award recipients&#8217; service payments are classified. The fair value of each stock option grant is estimated on the date of grant using Black Scholes. The following summarizes the inputs used:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Common Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the Merger, there was no public market for Private CalciMedica&#8217;s common stock. The fair value of the shares of common stock underlying Private CalciMedica</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8217;s share-based awards was estimated on each grant date by Private CalciMedica&#8217;s board of directors. To determine the fair value of Private CalciMedica&#8217;s common stock underlying option grants, the board of directors considered, among other things, input from management and valuations of Private CalciMedica's common stock prepared by third-party valuation firms.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Post Merger, CalciMedica uses the closing stock price the day prior to the grant date for the fair value.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk-Free Interest Rate</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The risk-free interest ra</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">te is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities similar to the expected term of the awards.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Volatility</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the merger, since Private CalciMedica did not have publicly traded equity securities, the volatility of the options has been estimated using peer group volatility information. Post Merger, CalciMedica uses an average volatility for comparable publicly-traded biopharmaceutical companies over a period equal to the expected term of the stock award grant as CalciMedica does not yet have sufficient historical trading history for its own stock. CalciMedica will continue to apply this method until a sufficient amount of historical information over a period equal to the expected term of the stock-based awards becomes available.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Term</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CalciMedica used the simplified method to calc</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ulate the expected term for all grants during all periods, which is based on the midpoint between the vesting date and the end of the contractual term.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Dividend Yield</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CalciMedica has never paid and has no present intention to pay cash dividends.</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources which are excluded from net loss. The Company&#8217;s only element of other comprehensive loss is unrealized gains and losses on marketable securities.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Related Party Transactions</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s board of directors reviews and approves transactions with directors, officers and holders of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% or more of its voting securities and their affiliates, each a related party. The material facts as to the related party&#8217;s relationship or interest in the transaction are disclosed to its board of directors prior to their consideration of such transaction, and the transaction is not considered approved by its board of directors unless a majority of the directors who are not interested in the transaction approve the transaction.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Beginning in November 2020, Private CalciMedica has paid consulting fees monthly to a consulting firm affiliated with the Company&#8217;s interim chief financial officer in connection with its consulting agreement. CalciMedica recorded expense of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">521,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">223,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> during years ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022, respectively.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net loss is equivalent to net loss attributable to common stockholders for all periods presented. Basic net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. The Company calculates diluted net loss per share using the more dilutive of the (1) treasury stock method, if-converted method, or contingently issuable share method, as applicable, or (2) the two-class method. For warrants, the calculation of diluted net loss per share requires that, to the extent the average fair value of the underlying shares for the reporting period exceeds the exercise price of the warrants and the presumed exercise of such securities are dilutive to net loss per share for the period, adjustments to net loss used in the calculation are required to remove the change in fair value of the warrants for the period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In all periods presented, the Company&#8217;s outstanding preferred stock, stock options, preferred, common and convertible promissory note warrants, and outstanding convertible promissory notes were excluded from the calculation of loss per share because the effect would be antidilutive. Accordingly, in periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which changes the accounting for recognizing impairments of financial assets. Under the new guidance, credit losses for certain types of financial instruments will be estimated based on expected losses. The new guidance also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. This update is effective for the Company beginning January 1, 2023. The Company adopted this ASU as of January 1, 2023, which did not have an impact on its consolidated financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt with Conversion and Other Options (Subtopic 470-20)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The ASU provides guidance that simplified the accounting for certain financial instruments with characteristics of liabilities and equity. The new guidance reduced the number of accounting models for convertible debt and convertible preferred stock instruments and made certain disclosure amendments intended to improve the information provided to users. The guidance also amended the derivative guidance for the &#8220;own stock&#8221; scope exception, which exempts qualifying instruments from being accounted for as derivatives if certain criteria are met. Finally, the standard changed the way certain convertible instruments are treated when calculating earnings per share. This guidance is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. The Company is currently assessing the impact that this guidance will have on its consolidated financial statements.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091693855648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger and Related Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Merger and Related Transactions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Merger and Related Transactions</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As described in Note 1 - Nature of Business, Private CalciMedica merged with a wholly owned subsidiary of Graybug on March 20, 2023. The Merger was accounted for as a reverse recapitalization under U.S. GAAP. Private CalciMedica was considered the accounting acquirer for financial reporting purposes. This determination is based on the facts that, immediately following the Merger: (i) former Private CalciMedica stockholders owned a substantial majority of the voting rights of the combined company; Private CalciMedica designated a majority (five of seven) of the initial members of the board of directors of the combined company; and former Private CalciMedica's senior management held all key positions in senior management of the combined company. The transaction is accounted for as a reverse recapitalization of Graybug by Private CalciMedica similar to the issuance of equity for the net assets of Graybug, which are primarily cash, short-term investments and other non-operating assets. It was concluded that any in-process research and development assets that remained as of the Merger would be de minimis when compared to the cash and investments obtained through the Merger.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under reverse recapitalization accounting, the assets and liabilities of Graybug were recorded at their fair value, which approximated book value due to the short-term nature of the instruments. The Company's consolidated financial statements reflect the issuance of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,571,433</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares to the former stockholders of Graybug.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding share of Private CalciMedica capital stock (after giving effect to the automatic conversion of all shares of Private CalciMedica preferred stock into shares of Private CalciMedica common stock, the automatic exercise of certain Private CalciMedica warrants to purchase shares of Private CalciMedica common stock in accordance with their terms (the &#8220;Private CalciMedica warrant exercises&#8221;), the conversion of Private CalciMedica convertible promissory notes into Private CalciMedica common stock and the closing of the private placement (as discussed in Note 7 - Convertible Preferred Stock, Common Stock, and Stockholders' Deficit)), was converted into the right to receive </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0288</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Graybug common stock, which resulted in the issuance by Graybug of an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,946,540</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Graybug common stock to the stockholders of Private CalciMedica in a transaction exempt from registration under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), in reliance on Section 4(a)(2) of the Securities Act and the rules promulgated thereunder. In addition, Graybug assumed the Private CalciMedica 2006 Stock Plan (See Note 8 - Stock-Based Compensation), and each outstanding and unexercised option to purchase Private CalciMedica common stock and each outstanding and unexercised warrant to purchase Private CalciMedica common stock (excluding the warrants which were automatically exercised pursuant to the Private CalciMedica warrant exercises) became options and warrants, respectively, to purchase shares of Graybug common stock. Immediately following the consummation of the Merger prior Private CalciMedica and Graybug stockholders collectively own approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">72</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the Company, respectively, on a fully diluted basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of the reverse recapitalization, Private CalciMedica received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">29.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of cash, cash equivalents and short-term investments, net of transaction costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Private CalciMedica also obtained prepaid and other current assets of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and assumed payables and accrued expenses of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Private CalciMedica also incurred transaction costs of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which is recorded as a reduction to additional paid-in capital in the accompanying consolidated statement of convertible preferred stock and stockholders' equity (deficit). The Company also recorded one-time charges of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the acceleration of the Graybug stock awards and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in severance charges that are recorded in the consolidated statements of operations and comprehensive loss for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">twelve months ended December 31, 2023.</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 17, 2023, in connection with the transactions contemplated by the Merger Agreement and following a special meeting of Graybug&#8217;s stockholders, Graybug filed an Amended and Restated Certificate of Incorporation effecting a reverse stock split of Graybug&#8217;s common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, at a ratio of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:1.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091592694080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesAndFairValueTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's assets and liabilities which are measured at fair value including short-term investments, warrants for preferred stock (&#8220;Preferred Warrants&#8221;), warrants for common stock related to the convertible promissory notes (&#8220;Convertible Promissory Note Warrants&#8221;), the liabilities are presented together on the balance sheets as &#8220;Warrant Liability&#8221; and convertible promissory notes. All assets and liabilities recorded at fair value are revalued at each measurement period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Private CalciMedica elected the fair value option for the convertible promissory notes and estimated the fair value based on a discounted cash flow analysis, a form of the Income Approach. Several different settlement scenarios were considered, and probability weighted to arrive at the final valuation. Increases or decreases in the fair value of the convertible promissory notes can result from updates to assumptions such as the expected timing or probability of the different settlement scenarios, or changes in discount rates. Judgment is used in determining these assumptions as of the initial valuation date and at each subsequent reporting period. Updates to assumptions could have a significant impact on the Company&#8217;s results of operations in any given period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Preferred Warrants are valued using the Hybrid Method (&#8220;Hybrid Method&#8221;). This method incorporates Private CalciMedica&#8217;s near-term liquidity event prospects utilized in conjunction with the Option Pricing Method (&#8220;OPM&#8221;) framework, representing an alternative exit, to calculate an implied overall value of Private CalciMedica. This value is, in turn, allocated to Private CalciMedica&#8217;s various equity classes.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Convertible Promissory Note Warrants are valued using a series of Monte Carlo simulations and Black-Scholes to determine the fair value, probability weighted for difference scenarios. The Monte Carlo simulations determined the liquidity event price. Black-Scholes is used with the remaining contractual term of the warrants after the respective event date. The warrant value is discounted from the respective event date using the risk-free rate for the period ending December 31, 2022. The Convertible Promissory Note Warrants were valued using the common stock price on day of conversion. See further discussion in Note 5 - Convertible Promissory Notes and Convertible Promissory Note Warrants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following three levels:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 1:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Observable inputs such as unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date. </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 2:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 3:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.34%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.236%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.236%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.236%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.236%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Current assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,634</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,634</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,738</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,738</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,634</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,738</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,372</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,213</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,213</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government sponsored entities - mortgage-backed securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">495</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">495</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,708</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,708</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,634</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,446</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">11,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds are highly liquid investments which are actively traded. The pricing information on the Company&#8217;s money market funds is based on quoted prices in active markets for identical securities. This approach results in the classification of these securities as Level 1 of the fair value hierarchy.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commercial paper and U.S. Government sponsored entities - mortgage-backed are classified as Level 2 with in the hierarchy and are carried at fair value with unrealized gains and losses included in other comprehensive income (loss) as a component of stockholders&#8217; equity until realized. The Company estimates the fair values of these securities by taking into consideration valuations obtained from third-party pricing sources.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> fair value liabilities exist as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables present information about the Company&#8217;s financial liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible promissory notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,157</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,157</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred Warrants liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,453</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,453</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible Promissory Note Warrants liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,192</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,192</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities measured at fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,802</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,802</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following provides a reconciliation for all liabilities measured at fair value using Level 3 inputs for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.22%;"></td>
        <td style="width:1.9%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.88%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Convertible Promissory Note liability</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,157</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in Fair Value of Convertible Promissory Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,022</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued Interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">110</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of Convertible Promissory Notes to equity</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,245</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Preferred Warrant liability</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,453</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in Fair Value of Preferred Warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">795</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of warrant liability to equity</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">658</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Convertible Promissory Note Warrants liability</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,192</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in Fair Value of Convertible Promissory Note Warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">351</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of Convertible Promissory Note Warrants liability to equity</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">841</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents information as to cost, unrealized gains and losses and fair value determination of the Company&#8217;s financial assets measured at fair value on a recurring basis (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.34%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.236%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.236%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.236%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.236%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Current assets:</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,634</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,634</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,738</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,738</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,372</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,372</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,211</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,213</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government sponsored entities - mortgage-backed securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">495</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">495</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,706</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,708</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">11,078</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">11,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the contractual maturities of all available-for-sale investments were less than 12 months. The Company periodically reviews the available-for-sale for other-than-temporary impairment loss. The Company had short-term investments in unrealized gain positions as of December 31, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cash equivalents.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesAndFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivatives and fair value of assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//815/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//820/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesAndFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091593814320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts Payable and Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. Accrued Expenses</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses consisted of the following (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued payroll and other employee benefits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">935</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued severance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">345</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">486</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued franchise tax</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,468</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">572</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091592619840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Notes and Convertible Promissory Note Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Promissory Notes and Convertible Promissory Note Warrants</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. Convertible Promissory Notes and Convertible Promissory Note Warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2022, the Private CalciMedica board of directors approved a convertible promissory note financing pursuant to which it could issue and sell up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of notes convertible into shares of common stock (the &#8220;convertible promissory notes&#8221;) and Convertible Promissory Note Warrants. The funding and issuance of the convertible promissory notes for gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and Convertible Promissory Note Warrants to purchase shares of the Private CalciMedica&#8217;s common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.01</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share took place in multiple closings through October 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2022, the Private CalciMedica board of directors amended the convertible promissory notes and Convertible Promissory Note Warrants to issue up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (for a total of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million) and added the automatic conversion for a &#8220;de-SPAC&#8221; business combination or reverse merger transaction. In November 2022, Private CalciMedica issued additional convertible promissory notes for gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and Convertible Promissory Note Warrants to purchase shares of Private CalciMedica&#8217;s common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.01</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. The convertible promissory notes accrued interest at a rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per annum and had a maturity date of December 31, 2023. Immediately prior to the effective time of the Merger, all outstanding convertible promissory notes and unpaid and accrued interest automatically converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20,487,104</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Private CalciMedica&#8217;s common stock at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a conversion price based on the equivalent valuation of the cash price paid per share by the private placement investors purchasing shares of common stock in the private placement multiplied by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Such shares of common stock were then converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">590,031</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Graybug common stock at the effective time of the Merger in accordance with the Merger Agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with each purchase of a convertible promissory note, Private CalciMedica issued to each holder of such convertible promissory note Convertible Promissory Note Warrant to purchase shares of the Private CalciMedica&#8217;s common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.01</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. Each holder of the Convertible Promissory Note Warrants had the right to purchase up to a number of shares of Private CalciMedica&#8217;s common stock equal to (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% (&#8220;Warrant Coverage&#8221;) of the principal amount of the convertible promissory note purchased by such holder concurrently therewith, divided by (ii) the cash price paid per share by the investors in the qualified financing or an initial public offering, as applicable, or in the case of a &#8220;de-SPAC&#8221; business combination or a reverse merger transaction between Private CalciMedica and a publicly traded company (a &#8220;Public Combination&#8221;), the equivalent valuation of the lower of the cash price per share by the investors purchasing shares in the publicly traded company in connection with such Public Combination or the cash price per shares by the investors purchasing shares of Private CalciMedica&#8217;s common stock in connection with such Public Combination, in each case, rounding down to the nearest whole share and subject to the terms of the convertible promissory notes; provided, however, that any holder that purchased convertible promissory notes in excess of the holder&#8217;s pro rata commitment (as defined in the convertible promissory notes) received a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% Warrant Coverage on the principal amount of the convertible promissory notes that is in excess of its pro rata commitment. The Convertible Promissory Note Warrants had a five-year term. In connection with the Merger, the Convertible Promissory Note Warrants were automatically net exercised in accordance with the terms of the Convertible Promissory Note Warrants. Immediately prior to the effective time of the Merger, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,308,047</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Convertible Promissory Note Warrants were converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,308,047</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Private CalciMedica's common stock, which were converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">152,875</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Graybug's common stock, based on the principal amount of the convertible promissory note.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to the Merger, the Convertible Promissory Note Warrants were not deemed equity and were classified as a liability on balance sheets. The Convertible Promissory Note Warrants were valued using a series of Monte Carlo simulations and Black-Scholes to determine the fair value, probability weighted for difference scenarios. The Monte Carlo simulations determined the liquidity event price. The Black-Scholes warrant value is discounted from the respective event date using the risk-free rate. The Black-Scholes valuation included standard assumptions such as exercise price, expected term, risk-free rate, volatility, and a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">dividend </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">yield of zero. The Company estimated initial fair value of the Convertible Promissory Note Warrants utilizing the following range of assumptions for the difference scenarios: exercise price ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.01</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">), risk-free rate (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.02</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% - </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%), volatility (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">63</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% - </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">67</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%), and expected term (</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4.1</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> - </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4.6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years). As of the date of the Merger, the Convertible Promissory Note Warrants which were converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">152,871</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock were revalued, using the price of the common stock of Graybug of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091594952848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock, Common Stock and Stockholders' Deficit<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_TemporaryEquityDisclosureTextblock', window );">Convertible Preferred Stock, Common Stock and Stockholders' Deficit</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Convertible Preferred Stock, Common Stock and Stockholders' Deficit</span><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Authorized Shares</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's current Amended and Restated Certificate of Incorporation authorizes </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">500,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of preferred stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Convertible Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Private CalciMedica's convertible preferred stock consisted of Series A preferred stock (&#8220;Series A preferred&#8221;), Series B preferred stock (&#8220;Series B preferred&#8221;), Series C-1 preferred stock (&#8220;Series C-1 preferred&#8221;), Series C-2 preferred stock (&#8220;Series C-2 preferred&#8221;) and Series D preferred stock (&#8220;Series D preferred&#8221;).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Immediately prior to the effective time of the Merger, the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">84,820,880</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Private CalciMedica preferred stock were converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">84,820,880</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> outstanding shares of Private CalciMedica's common stock to be exchanged for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,442,852</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Graybug's common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Classification of Convertible Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Private CalciMedica's convertible preferred stock as of December 31, 2022, was classified outside of stockholders&#8217; equity (deficit) on the accompanying balance sheets because such shares have liquidation rights in the event of a deemed liquidation that, in certain situations, are not solely within the control of Private CalciMedica and would require the redemption of the then outstanding shares of convertible preferred stock. Convertible preferred stock was not redeemable, except in the event of a deemed liquidation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because the occurrence of a deemed liquidation event was not probable, the carrying values of the convertible preferred stock were not being accreted to their redemption values. Subsequent adjustments to the carrying values of the convertible preferred stock would be made only when a deemed liquidation event became probable.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon completion of the Merger on March 20, 2023, as the accounting acquirer, Private CalciMedica is deemed to have issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,571,433</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock to Graybug shareholders.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Private Placement of Common Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Immediately prior to the consummation of the Merger, Private CalciMedica completed a private placement financing pursuant to which certain investors purchased approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares of Private CalciMedica&#8217;s common stock (the &#8220;private placement&#8221;) for gross proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. In conjunction with the Merger, immediately prior to the effective time of the Merger, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20,706,997</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Private CalciMedica common stock were converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">596,363</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Graybug&#8217;s common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Shelf Registration Statement and At the Market Offering</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2023, the Company filed a shelf registration statement on Form S-3 (the &#8220;Shelf Registration Statement&#8221;). The Shelf Registration Statement permits the offering, issuance and sale of common stock, preferred stock, debt securities and warrants having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in one or more offerings and in any combination of the foregoing. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">99.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">million remains available for sale under the Shelf Registration Statement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Shelf Registration Statement contains two prospectuses, a base prospectus and an at the market offering prospectus that covers the offering, issuance and sale of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of common stock pursuant to an at-the-market offering agreement (&#8220;ATM Agreement&#8221;) with H.C Wainwright &amp; Co., LLC, acting as sales agent (&#8220;ATM Facility&#8221;). The Company intends to use the net proceeds from the ATM Facility for general corporate purposes, which may include research and development expenses, clinical trial expenses, capital expenditures and working capital. The ATM Facility will terminate upon the earlier of (i) the sale of all of the shares of the Company&#8217;s common stock provided for in the at the market offering prospectus or (ii) termination of the ATM Agreement as permitted therein. The ATM Agreement may be terminated at any time by either party upon written notice. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the Company has sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">92,572</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock for net proceeds of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">246,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> which includes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$11</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of commissions paid under the ATM Facility and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million remains available for sale under the ATM Facility.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preferred and Common Stock Warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the issuance of convertible notes in 2016, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">568,181</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> warrants to purchase Series B preferred were issued at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.77</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share (the &#8220;Series B Warrants&#8221;). The Series B Warrants were exercisable at any time after February 28, 2017, through the earliest to occur of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> after the issue date or prior to the date of sale of common stock in an initial public offering or a deemed liquidation event. Until the Merger, these Series B Warrants were accounted for as a liability and had a fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">45,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Prior to the Merger, the Series B Warrants converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">568,181</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> common share warrants of Private CalciMedica. In conjunction with the Merger, the common warrants converted into</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">16,366</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">common share warrants of CalciMedica with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">26.74</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and have been reclassified to stockholders' equity (deficit) at its fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">21,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the issuance of Series C-2 preferred in May 2020, Private CalciMedica issued a warrant (&#8220;Series C-2 Warrant&#8221;), which was exercisable for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,786,567</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series C-2 preferred at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.77</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. The Series C-2 Warrant was exercisable at any time after May 20, 2020, through the earliest to occur of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> after the issue date or prior to the date of a deemed liquidation, public combination or an initial public offering. Prior to the Merger, the Series C-2 Warrants converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,786,567</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> common share of Private CalciMedica. In conjunction with the Merger, the common shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">80,254</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock at a fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Series C-2 Warrant was accounted for as a liability and had a fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the issuance of Series D preferred in 2021, Private CalciMedica issued warrants (&#8220;Series D Warrants&#8221;) to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,063,998</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series D preferred with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8045</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. The Series D Warrants were exercisable at any time after the date of issuance through the earliest to occur of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> after the issue date or prior to the date of sale of common stock in an initial public offering or a deemed liquidation. In conjunction with the Merger, the common share warrants were converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">232,256</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> common share warrants of CalciMedica with an exercise price </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27.94</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and have been reclassified to stockholders' equity (deficit) at a fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Up until the Merger, the Series D Warrants were accounted for as a liability and had a fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognized a total change in fair value of the preferred stock warrants of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">795,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nd $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million f</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or the years ended December 31, 2023 and 2022, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2020, Private CalciMedica granted a warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">400,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock to a consulting firm affiliated with its interim chief financial officer in connection with its consulting agreement. The warrant has a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-year term, an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.19</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and vests ratably over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months commencing on the effective date. At the date of issuance, the fair value of the warrant was determined to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">120,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, utilizing Black-Scholes with the following assumptions: expected term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, risk-free rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.96</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, volatility of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">80.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and a dividend yield of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which has been recognized as general and administrative expense over the vesting period. In conjunction with the Merger, the warrant converted to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11,520</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> warrants of CalciMedica at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.60</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The warrant is classified as equity and the Company expens</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for the year ended December 31, 2022, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2022, Private CalciMedica granted warrants to certain officers and directors to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">496,970</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. The warrants have a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-year term, an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.42</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and vest ratably over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months. At the date of issuance, the fair value of the warrants collectively was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">125,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and was determined utilizing Black-Scholes and will be recognized as general and administrative expense over the vesting periods. Assumptions used in the valuation were as follows: expected term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, risk free rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, volatility of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">82</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and a dividend yield of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In conjunction with the Merger, the warrants converted to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14,313</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> warrants of CalciMedica at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.42</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The warrants are classified as equity, and the Company expens</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">90,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">28,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to general and administrative expense in the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_TemporaryEquityDisclosureTextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_TemporaryEquityDisclosureTextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091591642384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. Stock-based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2006 Equity Incentive Plan and Amendment to 2006 Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Private CalciMedica adopted an equity incentive plan in 2006 (&#8220;2006 Plan&#8221;) that provides for the issuance of common stock to employees, non-employee directors and consultants. Recipients of incentive stock options are eligible to purchase common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The 2006 Plan provides for the grant of incentive stock options, non-statutory stock options and stock purchase rights. The maximum contractual term of options granted under the 2006 Plan is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The options generally vest </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% on the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_71b4969f-28c5-4ace-ac88-38cb897a2809;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">first </span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">anniversary </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the grant date, with the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">balance </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">vesting ratably over the following </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months. Pursuant to the Merger Agreement, Graybug assumed the 2006 Plan and all stock options issued and outstanding under the 2006 Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2023 Equity Incentive Plan</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company adopted 2023 Equity Incentive Plan (the &#8220;2023 Plan&#8221;), which became effective at the closing of the Merger. As of the effective time of the Merger, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock available for grant under the 2023 Plan. In addition, the share reserve is subject to annual increases each January 1 for the first ten years following approval of the 2023 Plan of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of shares of the Company&#8217;s common stock outstanding (or a lesser number determined by the Company&#8217;s board of directors). As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">96,594</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> options have been returned but are unavailable for future grant under the 2006 Plan. As of December 31, 2023,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">394,309</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">shares were available for grant under the 2023 Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2023 Employee Stock Purchase Plan</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company adopted the 2023 Employee Stock Purchase Plan (the &#8220;2023 ESPP&#8221;) which became effective at the closing of the Merger. As of the effective time of the Merger, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">65,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock reserved for issuance under the 2023 ESPP. In addition, the share reserve is subject to annual increases each January 1 for the first ten years following approval of the 2023 ESPP of the lesser of (1) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the total number of shares of the Company&#8217;s common stock outstanding on December 31 of the preceding calendar year, (2) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">195,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock, or (3) such lesser number of shares of the Company&#8217;s common stock as determined by the Company&#8217;s board of directors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares have been issued under the 2023 ESPP.</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the stock option transactions for the 2006 and 2023 Plans:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.656%;"></td>
        <td style="width:1.111%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.953%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.111%;"></td>
        <td style="width:1.111%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.309%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.178%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.353%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.355%;"></td>
        <td style="width:1.178%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.687%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average Remaining Contractual Term (years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate Intrinsic Value (in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">739,511</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.94</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.36</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,903</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assumed in the Merger</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">310,431</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76.72</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">785,922</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.48</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96,594</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70.51</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,739,270</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15.71</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.99</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and exercisable at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">940,098</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.18</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.97</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> options exercised during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023. The weighted-average fair value of options granted during the years ended December 31, 2023 and 2022 was</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.34</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">per share, respectively. The total fair value of shares vested was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mill</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ion (which includes $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million related to the acceleration of vesting of the Graybug stock awards at the date of the Merger) for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, stock-based compensation not yet recognized is</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which the Company expects to recognize over an estimated weighted-average term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.4</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following is the range of underlying assumptions in Black-Scholes to determine the fair value of the stock option grants for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.667%;"></td>
        <td style="width:1.111%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.422%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.111%;"></td>
        <td style="width:14.689%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk free interest rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.50</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.56</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.80</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.28</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.25</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.00</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.25</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-based Compensation Expense</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense recognized for options and restricted stock units granted was as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,449</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">499</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,590</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">902</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,039</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,401</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Statement of convertible preferred stock and stockholders' equity (deficit)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Settlement of 2021 and 2020 accrued bonus and employee costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">406</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,039</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,807</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The stock-based compensation expense for the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, includes one-time charges for the acceleration of vesting of the Graybug stock options at the date of the Merger of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in research and development and general and administrative expenses, respectively.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock Reserved for Future Issuance</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stock reserved for future issuance consists of the following at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.22%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.3%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">276,437</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options issued and outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,739,270</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for issuance under the 2023 Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">394,309</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available under the 2023 ESPP</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,475,016</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091592705728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues liabilities for such matters when future expenditures are probable and such expenditures can be reasonably estimated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has historically entered into contracts in the normal course of business with contract development and manufacturing organizations, for the manufacturing process development and the preclinical/clinical supply manufacturing, and its vendors for preclinical research studies and other services or products for operating purposes. These contracts generally provide for termination on notice of 60 to 90 days. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> such contracts, with two CMO&#8217;s related to its development of Auxora and acquired as a result of the Merger with approximate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ly</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">million of associated costs, respectively, still in effect for future services, and there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> unpaid cancellation or other related costs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company may also, from time to time, become party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Lease Agreements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has an operating lease for office space in La Jolla, California. In </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_10ec6273-2918-45a5-ad26-6251eb098fa9;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 2023</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, an amendment was executed for a twelve month term and therefore qualifies for the short-term lease exception. The lease was amended and renewed in December 2023 for an additional twelve month term and therefore qualifies for the short-term lease exception. Base rent for this lease is approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> monthly.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the Merger, the Company had leased a facility in Baltimore, Maryland under an operating lease with a term through </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_01fefd8e-092e-48bc-992a-f56011278bfb;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 2023</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and was accounted for under ASC 842. The facility has been abandoned and the asset was fully impaired in 2022 and was reflected in Graybug&#8217;s financial statements in 2022 and there is no impact to the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The lease expired in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_5164bc76-6e34-4c80-a8a7-d709dbb4720a;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 2023</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rent expense for the years ended December 31, 2023 and 2022 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">274,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">221,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">respectively, which is included in operating expenses. The lease obligation was included in other current liabilities in the consolidated balance sheets.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091593785216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefits</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. Employee Benefits</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2007, Private CalciMedica adopted a defined contribution 401(k) plan for substantially all employees. Contributions made by CalciMedica to the 401(k) plan were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">78,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $3</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091595706512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. Income Taxes</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The effective tax rate if the Company&#8217; provision (benefit) for income taxes differs from the federal statutory rate as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:89.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.682%;"></td>
        <td style="width:1.813%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.102%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.813%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.588%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax computed at federal statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,214</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,624</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State tax, net of federal tax benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">616</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1237</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development tax credits, net of uncertain positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">705</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">454</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,535</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,315</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards. </span><span style="font-size:12pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant components of deferred tax assets (liabilities) at December 31 are as follows (in thousands):</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:89.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.682%;"></td>
        <td style="width:1.813%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.102%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.813%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.588%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,535</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,839</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State tax, net of federal tax benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,865</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,407</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued and deferred expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">167</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credit carry forwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,403</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,736</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,699</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82,595</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,278</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82,574</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,240</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82,574</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,240</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company provided a full valuation allowance on the net deferred tax asset because management has determined that it is more-likely-than-not that the Company will not earn income sufficient to realize the deferred tax assets during the carryforward period. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company has federal and state NOLs available of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">278.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">103.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, to offset future taxable income, if any, for federal and state income tax purposes. The federal and state NOLs expire beginning in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company has $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">204.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of post-2017 federal NOL carryforwards that carry forward indefinitely. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, under the Tax Act the amount of net operating losses generated in taxable periods beginning after December 31, 2017, that the Company is permitted to deduct in any taxable year is limited to 80% of taxable income in such year, where taxable income is determined without regard to the net operating loss deduction itself.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Tax Act generally eliminates the ability to carry back any net operating loss to prior taxable years, while allowing post-2017 unused net operating losses to be carried forward indefinitely.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company has federal and state research and development credit carryforwards available of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. Federal research and development carryforwards expire beginning in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2027</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. State research and development carryforwards do not expire.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Pursuant to Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) specifically by IRC &#167;382, the Company&#8217;s ability to use net operating loss carryforwards to offset future taxable income is limited if the Company experiences a cumulative change in ownership of more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% within a three-year testing period. The Company has not completed an ownership change analysis pursuant to IRC Section 382. If ownership changes within the meaning of IRC Section 382 are identified as having occurred, the amount of remaining tax attribute carryforwards available to offset future taxable income and income tax expense in future years may be significantly reduced. Any limitation may result in the expiration of a portion of the NOL carryforwards before utilization.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The change in the Company&#8217;s unrecognized tax benefits is summarized as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,457</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase related to current year tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">973</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions for tax positions of prior years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,506</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase related to current year tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,846</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions for tax positions of prior years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions in connection with the reverse merger</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">847</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reduction for tax positions of prior years</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">140</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more likely than not recognition threshold to be recognized. The Company&#8217;s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> accrual for interest and penalties and has not recognized interest and/ or penalties in the statements of operations and comprehensive loss for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022. Uncertain tax positions are evaluated based upon the facts and circumstances that exist at each reporting period. Subsequent changes in judgment based upon new information may lead to changes in recognition, derecognition, and measurement. Adjustments may result, for example, upon resolution of an issue with the taxing authorities or expiration of a statute of limitations barring an assessment for an issue.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, unrecognized tax benefits associated with uncertain tax positions was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million respectively. If recognized, this would affect the effective tax rate, subject to valuation allowance. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company did not recognize any interest and penalties associated with unrecognized tax benefits. Due to net operating losses incurred, tax years from inception remain open to examination by the Federal and State taxing jurisdictions to which we are subject. The Company is not currently under Internal Revenue Services (IRS), state or local tax examination.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091594640240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12. Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share (in thousands, except per share amounts):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.067%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.138%;"></td>
        <td style="width:1%;"></td>
        <td style="width:3.239%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.597%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Numerator:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,357</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,824</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Denominator</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average common stock outstanding, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,486,258</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82,245</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.66</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">111.16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.009%;"></td>
        <td style="width:1.64%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.356%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.64%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.356%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible preferred stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,442,852</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants to purchase convertible preferred stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">328,859</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,739,270</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">739,544</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">276,437</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,520</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,015,707</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,522,775</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091591675456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13. Subsequent Events</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Private Placement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 19, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain accredited investors, in which the Company sold the following securities to the accredited investors in a private placement transaction (the &#8220;Private Placement&#8221;) (i) an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,985,610</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares (the &#8220;Shares&#8221;) of common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share; (ii) to certain investors, in lieu of Shares, pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">306,506</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock; (iii) Tranche A Common Warrants (the &#8220;Tranche A Common Warrants&#8221;) to purchase an aggregate of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,646,058</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of common stock (or Pre-Funded Warrants in lieu thereof and, in such case, shares of common stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issuable </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">upon exercise of such Pre-Funded Warrants); and (iv) Tranche B Common Warrants (the &#8220;Tranche B Common Warrants&#8221; and together with the Tranche A Common Warrants, the &#8220;Common Warrants&#8221;) to purchase an aggregate of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,646,058</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock (or Pre-Funded Warrants in lieu thereof and, in such case, shares of common stock issuable upon exercise of such Pre-Funded Warrants). The Purchase Price per Share and accompanying Common Warrants was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.827</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (or $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3915</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for directors, employees or consultants of the Company participating in the Private Placement) (or $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.8269</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per Pre-Funded Warrant and accompanying Common Warrants, which represented the price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.827</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per Share and accompanying Common Warrants minus the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share exercise price of each such Pre-Funded Warrant).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The initial closing of the Private Placement occurred on January 23, 2024 and the second closing occurred on February 5, 2024. Gross proceeds from the transaction were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million with net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in commissions and other transaction costs.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091595658432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;), and Accounting Standards Update (&#8220;ASU&#8221;), of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The consolidated financial statements include the accounts of the Company and CalciMedica Subsidiary, Inc. for the years ended December 31, 2023 and 2022. All intercompany accounts and transactions have been eliminated in consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since Private CalciMedica was determined to be the accounting acquirer in connection with the Merger, for periods prior to the Merger, the consolidated financial statements were prepared on a stand-alone basis for Private CalciMedica and did not include the combined entities activity or financial position. Subsequent to the Merger, the consolidated financial statements as of and for the year ended December 31, 2023 include Graybug&#8217;s activity from March 21, 2023 through December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and assets and liabilities at their acquisition date fair value. Historical share and per share figures of Private CalciMedica have been retroactively restated based on the merger exchange ratio of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0288</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">   </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company&#8217;s consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#8217;s consolidated financial statements relate to accruals for research and development expenses, valuation of warrants, valuation of convertible promissory notes and valuation of equity awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and other Risks and Uncertainties</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and other Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments, which potentially subject the Company to concentration of risk, consist principally of cash and cash equivalents. The Company&#8217;s cash is deposited with major federally insured U.S. financial institutions. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is dependent on contract manufacturing organizations (&#8220;CMO&#8221;) to supply products for research and development of its product candidates, including preclinical and clinical studies, and for commercialization of its product candidates, if approved. The Company&#8217;s development programs could be adversely affected by any significant interruption in CMO&#8217;s operations or by a significant interruption in the supply of active pharmaceutical ingredients and other components.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Products developed by the Company require approval from the FDA or other international regulatory agencies prior to commercial sales. There can be no assurance the Company&#8217;s product candidates will receive the necessary approvals. If the Company is denied approvals, approvals are delayed, or the Company is unable to maintain approvals received, such events could have a materially adverse impact on the Company.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents consist of readily available cash in checking accounts, money market funds and commercial paper. The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Short-term Investments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Short-term Investments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company invests excess cash in commercial paper and U.S government sponsored entities - mortgage-backed securities. These investments are included in short-term investments on the balance sheet, classified as available-for-sale and reported at fair value with unrealized gains and losses included in accumulated other comprehensive (loss)/gain, net. Realized gains and losses on the sale of these securities are recognized in net loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The financial information is regularly reviewed by the chief operating decision maker (&#8220;CODM&#8221;), in deciding how to allocate resources. The Company&#8217;s CODM is its chief executive officer. The Company&#8217;s singular focus is on developing highly selective calcium release-activated calcium channel inhibitors to improve outcomes for patients with acute inflammatory indications. No significant revenue has been generated since inception, and all tangible assets are held in the United States.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Option</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Option</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As permitted under ASC 825, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Company has elected the fair value option to account for its convertible promissory notes due to certain embedded features within the notes. The Company recognizes the convertible</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">promissory </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">notes at fair value with changes in fair value recognized in the consolidated statements of operations located on the change in fair value of financial instruments line item. Changes in fair value as a result of the Company&#8217;s own credit risk is reflected in other income (expense) in the consolidated statements of operations. As a result of applying the fair value option, direct costs and fees related to the convertible promissory notes were expensed as incurred and not deferred.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally three to five years) and consist of manufacturing and lab equipment, furniture, computers and phones. Repairs and maintenance costs are charged to expense as incurred. Depreciation expense recognized for the years ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">58,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">52,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-lived assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Long-lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-lived assets consist primarily of property and equipment. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate the carrying amount of an asset is not recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value would be assessed using discounted cash flows or other appropriate measures of fair value. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognize any impairment losses for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company leases office space with an original lease term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_96e7d778-f45a-41e2-8962-c4c3904214d6;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">twelve months </span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and does </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t have a right-of-use asset or lease liability recorded. The Company's policy is not to record leases with an original term of twelve months or less on the consolidated balance sheets. The Company recognizes lease expense for this short-term lease on a straight-line basis over the term of the lease. The lease is accounted for under ASC 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and has been classified as an operating lease. Rent expense recognized for the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">274,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">221,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_AccruedResearchAndDevelopmentCostsPolicyTextBlock', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs consist primarily of salaries, payroll taxes, employee benefits and stock-based compensation for those individuals involved in ongoing research and development efforts, as well as fees paid to consultants, external research fees, license fees paid to third parties for use of their intellectual property, laboratory supplies and development of compound materials, associated overhead expenses and facilities and depreciation costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. All research and development costs are expensed as incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company estimates preclinical studies and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on the Company&#8217;s behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers,  and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. The estimates are trued up to reflect the best information available at the time of the financial statement issuance. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#8217;s estimate of the status and timing of services performed relative to the actual status and timing of services performed may vary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation, related to executive, finance, business development, legal, human resources and support functions, including professional fees for auditing, tax, consulting and patent-related services, rent and utilities and insurance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_PatentsCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs related to filing and pursuing patent applications are expensed as incurred since recoverability of such expenditures is uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredPolicyAcquisitionCostsTextBlock1', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Deferred Offering Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company capitalizes costs that are directly associated with equity financings until such financings are consummated at which time such costs are recorded against the gross proceeds of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss. Private CalciMedica had deferred offering costs capitalized as of December 31, 2022 for the Merger of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. As of December 31, 2023, the Company has deferred costs associated with its at-the-market offering of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_WarrantLiabilityPolicyPolicyTextBlock', window );">Warrant Liability</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrant Liability</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Private CalciMedica has issued various freestanding warrants to purchase shares of its convertible preferred stock. Prior to the Merger, Private CalciMedica adjusted the carrying value of such convertible preferred stock warrants to the estimated fair value at each reporting date, with any related increases or decreases in the fair value being recorded within other income (expense) in the consolidated statements of operations and comprehensive loss. Pursuant to the Merger Agreement, the Series C convertible preferred stock warrants became warrants to purchase shares of the combined company's common stock. As a result of the Merger, the warrants no longer meet the requirements for liability accounting and, as such, Private CalciMedica adjusted the value of the warrants to the estimated fair value as of the Merger date and reclassified them to stockholders' equity (deficit).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense represents the cost of the grant date fair value of employee stock options recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. Private CalciMedica estimates the fair value of stock option grants using the Black-Scholes option pricing model (&#8220;Black-Scholes&#8221;). Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. Equity-based compensation expense is classified in the statements of operations in the same manner in which the award recipients&#8217; payroll costs are classified or in which the award recipients&#8217; service payments are classified. The fair value of each stock option grant is estimated on the date of grant using Black Scholes. The following summarizes the inputs used:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Common Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the Merger, there was no public market for Private CalciMedica&#8217;s common stock. The fair value of the shares of common stock underlying Private CalciMedica</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8217;s share-based awards was estimated on each grant date by Private CalciMedica&#8217;s board of directors. To determine the fair value of Private CalciMedica&#8217;s common stock underlying option grants, the board of directors considered, among other things, input from management and valuations of Private CalciMedica's common stock prepared by third-party valuation firms.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Post Merger, CalciMedica uses the closing stock price the day prior to the grant date for the fair value.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk-Free Interest Rate</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The risk-free interest ra</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">te is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities similar to the expected term of the awards.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Volatility</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the merger, since Private CalciMedica did not have publicly traded equity securities, the volatility of the options has been estimated using peer group volatility information. Post Merger, CalciMedica uses an average volatility for comparable publicly-traded biopharmaceutical companies over a period equal to the expected term of the stock award grant as CalciMedica does not yet have sufficient historical trading history for its own stock. CalciMedica will continue to apply this method until a sufficient amount of historical information over a period equal to the expected term of the stock-based awards becomes available.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Term</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CalciMedica used the simplified method to calc</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ulate the expected term for all grants during all periods, which is based on the midpoint between the vesting date and the end of the contractual term.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Dividend Yield</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CalciMedica has never paid and has no present intention to pay cash dividends.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources which are excluded from net loss. The Company&#8217;s only element of other comprehensive loss is unrealized gains and losses on marketable securities.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_RelatedPartyTransactionsPolicyTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Related Party Transactions</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s board of directors reviews and approves transactions with directors, officers and holders of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% or more of its voting securities and their affiliates, each a related party. The material facts as to the related party&#8217;s relationship or interest in the transaction are disclosed to its board of directors prior to their consideration of such transaction, and the transaction is not considered approved by its board of directors unless a majority of the directors who are not interested in the transaction approve the transaction.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Beginning in November 2020, Private CalciMedica has paid consulting fees monthly to a consulting firm affiliated with the Company&#8217;s interim chief financial officer in connection with its consulting agreement. CalciMedica recorded expense of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">521,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">223,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> during years ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022, respectively.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net loss is equivalent to net loss attributable to common stockholders for all periods presented. Basic net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. The Company calculates diluted net loss per share using the more dilutive of the (1) treasury stock method, if-converted method, or contingently issuable share method, as applicable, or (2) the two-class method. For warrants, the calculation of diluted net loss per share requires that, to the extent the average fair value of the underlying shares for the reporting period exceeds the exercise price of the warrants and the presumed exercise of such securities are dilutive to net loss per share for the period, adjustments to net loss used in the calculation are required to remove the change in fair value of the warrants for the period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In all periods presented, the Company&#8217;s outstanding preferred stock, stock options, preferred, common and convertible promissory note warrants, and outstanding convertible promissory notes were excluded from the calculation of loss per share because the effect would be antidilutive. Accordingly, in periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which changes the accounting for recognizing impairments of financial assets. Under the new guidance, credit losses for certain types of financial instruments will be estimated based on expected losses. The new guidance also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. This update is effective for the Company beginning January 1, 2023. The Company adopted this ASU as of January 1, 2023, which did not have an impact on its consolidated financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt with Conversion and Other Options (Subtopic 470-20)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The ASU provides guidance that simplified the accounting for certain financial instruments with characteristics of liabilities and equity. The new guidance reduced the number of accounting models for convertible debt and convertible preferred stock instruments and made certain disclosure amendments intended to improve the information provided to users. The guidance also amended the derivative guidance for the &#8220;own stock&#8221; scope exception, which exempts qualifying instruments from being accounted for as derivatives if certain criteria are met. Finally, the standard changed the way certain convertible instruments are treated when calculating earnings per share. This guidance is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. The Company is currently assessing the impact that this guidance will have on its consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_AccruedResearchAndDevelopmentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_AccruedResearchAndDevelopmentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_PatentsCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patents costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_PatentsCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_RelatedPartyTransactionsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_RelatedPartyTransactionsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_WarrantLiabilityPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_WarrantLiabilityPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredPolicyAcquisitionCostsTextBlock1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for deferred policy acquisition costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//944-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredPolicyAcquisitionCostsTextBlock1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091594991296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.34%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.236%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.236%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.236%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.236%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Current assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,634</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,634</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,738</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,738</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,634</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,738</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,372</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,213</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,213</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government sponsored entities - mortgage-backed securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">495</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">495</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,708</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,708</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,634</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,446</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">11,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables present information about the Company&#8217;s financial liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible promissory notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,157</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,157</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred Warrants liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,453</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,453</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible Promissory Note Warrants liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,192</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,192</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities measured at fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,802</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,802</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Liabilities Measured at Fair Value Using Level 3 Inputs</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following provides a reconciliation for all liabilities measured at fair value using Level 3 inputs for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.22%;"></td>
        <td style="width:1.9%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.88%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Convertible Promissory Note liability</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,157</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in Fair Value of Convertible Promissory Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,022</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued Interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">110</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of Convertible Promissory Notes to equity</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,245</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Preferred Warrant liability</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,453</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in Fair Value of Preferred Warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">795</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of warrant liability to equity</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">658</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Convertible Promissory Note Warrants liability</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,192</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in Fair Value of Convertible Promissory Note Warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">351</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of Convertible Promissory Note Warrants liability to equity</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">841</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of Company's Financial Assets Measured at Fair Value</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents information as to cost, unrealized gains and losses and fair value determination of the Company&#8217;s financial assets measured at fair value on a recurring basis (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.34%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.236%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.236%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.236%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.236%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Current assets:</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,634</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,634</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,738</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,738</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,372</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,372</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,211</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,213</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government sponsored entities - mortgage-backed securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">495</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">495</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,706</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,708</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">11,078</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">11,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091591489120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts Payable and Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses consisted of the following (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued payroll and other employee benefits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">935</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued severance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">345</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">486</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued franchise tax</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,468</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">572</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091593058816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Transations</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the stock option transactions for the 2006 and 2023 Plans:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.656%;"></td>
        <td style="width:1.111%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.953%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.111%;"></td>
        <td style="width:1.111%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.309%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.178%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.353%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.355%;"></td>
        <td style="width:1.178%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.687%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average Remaining Contractual Term (years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate Intrinsic Value (in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">739,511</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.94</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.36</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,903</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assumed in the Merger</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">310,431</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76.72</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">785,922</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.48</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96,594</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70.51</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,739,270</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15.71</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.99</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and exercisable at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">940,098</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.18</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.97</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Using Black-Scholes to Estimate Fair Value of the Stock Option Grants</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following is the range of underlying assumptions in Black-Scholes to determine the fair value of the stock option grants for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.667%;"></td>
        <td style="width:1.111%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.422%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.111%;"></td>
        <td style="width:14.689%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk free interest rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.50</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.56</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.80</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.28</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.25</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.00</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.25</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expense Recognized for Options and RSUs Granted</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense recognized for options and restricted stock units granted was as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,449</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">499</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,590</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">902</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,039</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,401</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Statement of convertible preferred stock and stockholders' equity (deficit)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Settlement of 2021 and 2020 accrued bonus and employee costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">406</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,039</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,807</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Schedule of Common Stock Reserved for Future Issuance</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stock reserved for future issuance consists of the following at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.22%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.3%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">276,437</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options issued and outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,739,270</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for issuance under the 2023 Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">394,309</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available under the 2023 ESPP</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,475,016</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of schedule of common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091594750368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The effective tax rate if the Company&#8217; provision (benefit) for income taxes differs from the federal statutory rate as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:89.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.682%;"></td>
        <td style="width:1.813%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.102%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.813%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.588%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax computed at federal statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,214</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,624</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State tax, net of federal tax benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">616</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1237</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development tax credits, net of uncertain positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">705</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">454</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,535</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,315</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant components of deferred tax assets (liabilities) at December 31 are as follows (in thousands):</span><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:89.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.682%;"></td>
        <td style="width:1.813%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.102%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.813%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.588%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,535</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,839</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State tax, net of federal tax benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,865</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,407</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued and deferred expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">167</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credit carry forwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,403</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,736</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,699</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82,595</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,278</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82,574</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,240</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82,574</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,240</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Reconciliation of Unrecognized Tax Benefits</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The change in the Company&#8217;s unrecognized tax benefits is summarized as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,457</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase related to current year tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">973</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions for tax positions of prior years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,506</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase related to current year tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,846</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions for tax positions of prior years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions in connection with the reverse merger</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">847</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#ffffff;text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reduction for tax positions of prior years</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">140</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091593105568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share (in thousands, except per share amounts):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.067%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.138%;"></td>
        <td style="width:1%;"></td>
        <td style="width:3.239%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.597%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Numerator:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,357</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,824</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Denominator</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average common stock outstanding, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,486,258</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82,245</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.66</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">111.16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.009%;"></td>
        <td style="width:1.64%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.356%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.64%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.356%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible preferred stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,442,852</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants to purchase convertible preferred stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">328,859</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,739,270</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">739,544</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">276,437</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,520</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,015,707</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,522,775</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091595785760">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Nature of Business - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(34,357)<span></span>
</td>
<td class="num">$ (7,824)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(146,064)<span></span>
</td>
<td class="num">(111,707)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acceleration of stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and termination benefit expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration Transferred</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">38,075<span></span>
</td>
<td class="nump">$ 14,193<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_GrossProceedsFromThePrivatePlacement', window );">Gross proceeds from the private placement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_NetProceedsFromPrivatePlacement', window );">Net proceeds from private placement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_CommissionsAndOtherTransactionExpenses', window );">Commissions and other transaction expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=calc_CalcimedicaIncMember', window );">CalciMedica</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">72.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=calc_GraybugVisionIncMember', window );">Graybug</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and termination benefit expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 16,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=calc_PreferredAndCommonStockMember', window );">Preferred and Common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_TotalNetProceeds', window );">Total net proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 112,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) Retroactively restated for the reverse recapitalization as described in Note 2.</span></p></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) Retroactively restated for the reverse recapitalization as described in Note 2.</span></p></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_CommissionsAndOtherTransactionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commissions and other transaction expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_CommissionsAndOtherTransactionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_GrossProceedsFromThePrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from the private placement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_GrossProceedsFromThePrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_NetProceedsFromPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from private placement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_NetProceedsFromPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_TotalNetProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total net proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_TotalNetProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=calc_CalcimedicaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=calc_CalcimedicaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=calc_GraybugVisionIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=calc_GraybugVisionIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=calc_PreferredAndCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=calc_PreferredAndCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091593508320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_StockholdersEquityNoteStockSplitExchangeRatio', window );">Stockholders equity note stock split exchange ratio</a></td>
<td class="nump">0.0288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 58,000<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="nump">$ 274,000<span></span>
</td>
<td class="nump">221,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_RightOfUseAssetOrLeaseLiability', window );">Right-of-use asset or lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_TaxPostionMinimumPercentageOfTaxBenefit', window );">Tax postion, minimum percentage of tax benefit</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Variable interest entity ownership percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=calc_PrivateCalcimedicaMember', window );">Private CalciMedica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Costs and expenses related party</a></td>
<td class="nump">$ 521,000<span></span>
</td>
<td class="nump">$ 223,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=calc_AtTheMarketOfferingMember', window );">ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_RightOfUseAssetOrLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-of-use asset or lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_RightOfUseAssetOrLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_StockholdersEquityNoteStockSplitExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholders equity note stock split exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_StockholdersEquityNoteStockSplitExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_TaxPostionMinimumPercentageOfTaxBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax postion, minimum percentage of tax benefit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_TaxPostionMinimumPercentageOfTaxBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=calc_PrivateCalcimedicaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=calc_PrivateCalcimedicaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=calc_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=calc_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091754310416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger and Related Transactions - Additional Information (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 17, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Number of shares of stock issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_StockIssuedDuringPeriodPrivatePlacement', window );">Stock issued during period private placement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration Transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid and other current assets obtained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Payables and accruals incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_BusinessCombinationConsiderationTransferedCostIncurred', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and termination benefit expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acceleration of stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Shares issued during period upon conversion of units | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,946,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=calc_CalcimedicaIncMember', window );">CalciMedica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=calc_GraybugVisionIncMember', window );">Graybug</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and termination benefit expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=calc_GraybugMember', window );">Graybug</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Number of shares of stock issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,571,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse Stock Split</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acceleration of stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_BusinessCombinationConsiderationTransferedCostIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination, consideration transfered cost incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_BusinessCombinationConsiderationTransferedCostIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_StockIssuedDuringPeriodPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, private placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_StockIssuedDuringPeriodPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=calc_CalcimedicaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=calc_CalcimedicaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=calc_GraybugVisionIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=calc_GraybugVisionIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=calc_GraybugMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=calc_GraybugMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091593384432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">5,372,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ShortTermInvestmentFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">5,708,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">11,080,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,802,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">3,634,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,738,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ShortTermInvestmentFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">5,213,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. Government Sponsored Entities - Mortgagebacked Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ShortTermInvestmentFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">495,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,157,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Preferred warrants liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,453,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Convertible Promissory Note Warrants Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,192,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">3,634,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">3,634,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">3,634,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,738,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ShortTermInvestmentFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">5,708,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">7,446,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2 | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,738,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ShortTermInvestmentFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">5,213,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2 | U.S. Government Sponsored Entities - Mortgagebacked Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ShortTermInvestmentFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">$ 495,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,802,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3 | Convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,157,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3 | Preferred warrants liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,453,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3 | Convertible Promissory Note Warrants Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,192,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_ShortTermInvestmentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term investment fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_ShortTermInvestmentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=calc_PreferredWarrantsLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=calc_PreferredWarrantsLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=calc_ConvertiblePromissoryNoteWarrantsLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=calc_ConvertiblePromissoryNoteWarrantsLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091593253760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value Using Level 3 Inputs (Details) - Fair Value, Recurring - Level 3<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Convertible Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at December 31, 2022</a></td>
<td class="nump">$ 5,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in Fair Value</a></td>
<td class="num">(2,022)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Accrued Interest</a></td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Conversion</a></td>
<td class="num">(3,245)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at December 31, 2023</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Preferred Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at December 31, 2022</a></td>
<td class="nump">1,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in Fair Value</a></td>
<td class="num">(795)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Conversion</a></td>
<td class="num">(658)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at December 31, 2023</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Convertible Promissory Note Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at December 31, 2022</a></td>
<td class="nump">1,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in Fair Value</a></td>
<td class="num">(351)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Conversion</a></td>
<td class="num">(841)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at December 31, 2023</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=calc_ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=calc_ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=calc_PreferredWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=calc_PreferredWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=calc_ConvertiblePromissoryNoteWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=calc_ConvertiblePromissoryNoteWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091684427968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091685442480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Company 's Financial Assets Measured at Fair Value (Details) - Fair Value, Recurring<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis', window );">Total cash equivalents, Amortized Cost</a></td>
<td class="nump">$ 5,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents, Aggregate Fair Value</a></td>
<td class="nump">5,372<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis', window );">Total short-term investments, Amortized Cost</a></td>
<td class="nump">5,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax', window );">Total short-term investments, Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ShortTermInvestmentFairValueDisclosure', window );">Total short-term investments, Aggregate Fair Value</a></td>
<td class="nump">5,708<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_AssetsFairValueDisclosureAmortizedCostBasis', window );">Total asset measured at fair value, Amortized Cost</a></td>
<td class="nump">11,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax', window );">Total asset measured at fair value, Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total asset measured at fair value, Aggregate Fair Value</a></td>
<td class="nump">11,080<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis', window );">Total cash equivalents, Amortized Cost</a></td>
<td class="nump">3,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents, Aggregate Fair Value</a></td>
<td class="nump">3,634<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis', window );">Total cash equivalents, Amortized Cost</a></td>
<td class="nump">1,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents, Aggregate Fair Value</a></td>
<td class="nump">1,738<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis', window );">Total short-term investments, Amortized Cost</a></td>
<td class="nump">5,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax', window );">Total short-term investments, Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ShortTermInvestmentFairValueDisclosure', window );">Total short-term investments, Aggregate Fair Value</a></td>
<td class="nump">5,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government Sponsored Entities - Mortgagebacked Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis', window );">Total short-term investments, Amortized Cost</a></td>
<td class="nump">495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ShortTermInvestmentFairValueDisclosure', window );">Total short-term investments, Aggregate Fair Value</a></td>
<td class="nump">$ 495<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets fair value disclosure accumulated gross unrealized gain before tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_AssetsFairValueDisclosureAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets fair value disclosure amortized cost basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_AssetsFairValueDisclosureAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents fair value disclosure amortized cost basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_ShortTermInvestmentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term investment fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_ShortTermInvestmentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short term investment fair value disclosure accumulated gross unrealized gain before tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short term investment fair value disclosure amortized cost basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091587408176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Notes and Convertible Promissory Note Warrants - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 20, 2023</div></th>
<th class="th"><div>Nov. 20, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_PublicCombinationMultipliedCashPricePaidPerShare', window );">Public combination multiplied cash price paid per share</a></td>
<td class="nump">$ 0.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_PercentageOfWarrantCoverage', window );">Percentage of warrant coverage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.56%<span></span>
</td>
<td class="nump">3.28%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_PercentageOfWarrantCoverage', window );">Percentage of warrant coverage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Private CalciMedica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of convertible promissory note converted into common stock</a></td>
<td class="nump">20,487,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Graybug</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of convertible promissory note converted into common stock</a></td>
<td class="nump">590,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Issuance or Sale of Convertible Promissory Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Gross proceeds of Convertible Promissory Notes</a></td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt Instrument, Interest Rate During Period</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible promissory notes | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=calc_ConvertiblePromissoryNoteWarrantsMember', window );">Convertible Promissory Note Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Issuance or Sale of Convertible Promissory Notes</a></td>
<td class="nump">$ 8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants per share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_DebtInstrumentPeriodicPaymentPrincipalAdditional', window );">Addiitional convertible promissory notes and Convertible Promissory Note Warrants</a></td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ConvertiblePromissoryNoteWarrantsConvertible', window );">Convertible promissory note warrants convertible</a></td>
<td class="nump">5,308,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ConvertiblePromissoryNoteWarrantsCommonStockConverted', window );">Convertible promissory note warrants common stock converted</a></td>
<td class="nump">5,308,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ExchangeOfStockForStock', window );">Exchange of stock for stock</a></td>
<td class="nump">152,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ExpectedPerShare', window );">Expected Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=calc_ConvertiblePromissoryNoteWarrantsMember', window );">Convertible Promissory Note Warrants | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">3.02%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">63.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=calc_ConvertiblePromissoryNoteWarrantsMember', window );">Convertible Promissory Note Warrants | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">67.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=calc_ConvertiblePromissoryNoteWarrantsMember', window );">Convertible Promissory Note Warrants | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants per share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_ConvertiblePromissoryNoteWarrantsCommonStockConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible promissory note warrants common stock converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_ConvertiblePromissoryNoteWarrantsCommonStockConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_ConvertiblePromissoryNoteWarrantsConvertible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible promissory note warrants convertible.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_ConvertiblePromissoryNoteWarrantsConvertible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_DebtInstrumentPeriodicPaymentPrincipalAdditional">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument periodic payment principal additional</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_DebtInstrumentPeriodicPaymentPrincipalAdditional</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_ExchangeOfStockForStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange of stock for stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_ExchangeOfStockForStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_ExpectedPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected per share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_ExpectedPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_PercentageOfWarrantCoverage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of warrant coverage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_PercentageOfWarrantCoverage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_PublicCombinationMultipliedCashPricePaidPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public combination multiplied cash price paid per share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_PublicCombinationMultipliedCashPricePaidPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=calc_PrivateCalcimedicaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=calc_PrivateCalcimedicaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=calc_GraybugMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=calc_GraybugMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=calc_ConvertiblePromissoryNoteWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=calc_ConvertiblePromissoryNoteWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091595719600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_AccruedPayrollAndOtherEmployeeBenefits', window );">Accrued payroll and other employee benefits</a></td>
<td class="nump">$ 935<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_AccruedSeveranceExpense', window );">Accrued severance</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_AccruedFranchiseTax', window );">Accrued franchise tax</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_AccruedOther', window );">Accrued other</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 1,468<span></span>
</td>
<td class="nump">$ 572<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_AccruedFranchiseTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued franchise tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_AccruedFranchiseTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_AccruedOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_AccruedOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_AccruedPayrollAndOtherEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Payroll and Other Employee Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_AccruedPayrollAndOtherEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_AccruedSeveranceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued severance expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_AccruedSeveranceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091581671520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock, Common Stock and Stockholders' Deficit - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 20, 2023</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 17, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">5,694,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ShelfRegistrationStatementAvaliableForSale', window );">Available for sale under Shelf Registration Statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 246,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,754,505<span></span>
</td>
<td class="nump">84,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,146,000)<span></span>
</td>
<td class="num">$ (3,784,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,216,000<span></span>
</td>
<td class="nump">$ 5,843,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=calc_ShelfRegistrationStatementMember', window );">Shelf Registration Statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Issuance and sale of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=calc_AtTheMarketOfferingMember', window );">ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Commissions paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_SaleOfStockRemainingSalesAmount', window );">Remaining amount of available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Issuance and sale of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=calc_AmendedAndRestatedCertificateOfIncorporationMember', window );">Amended and Restated Certificate of Incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember', window );">Chief Financial Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants', window );">Stock and warrants issued during period shares common stock and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Warrant liability fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=calc_OfficersAndDirectorsMember', window );">Officers and Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants', window );">Stock and warrants issued during period shares common stock and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">496,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Warrant liability fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="nump">$ 28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=calc_GraybugMember', window );">Graybug</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.56%<span></span>
</td>
<td class="nump">3.28%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Officers and Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Officers and Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">1,571,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock as a result of the Merger, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,442,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 795,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=calc_SeriesCTwoConvertiblePreferredStockMember', window );">Series C-2 Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=calc_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">88,875,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=calc_CalcimedicaPreferredStockMember', window );">Calcimedica Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares converted</a></td>
<td class="nump">84,820,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=calc_CalcimedicaCommonStockMember', window );">Calcimedica Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock as a result of the Merger, shares</a></td>
<td class="nump">2,442,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=calc_SeriesBWarrantsMember', window );">Series B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">568,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Warrant liability fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=calc_SeriesCTwoWarrantsMember', window );">Series C-2 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrantsExercisable', window );">Warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,786,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=calc_SeriesDWarrantsMember', window );">Series D Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,063,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=calc_PreMergerCalcimedicaMember', window );">Pre Merger CalciMedica | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares converted</a></td>
<td class="nump">20,706,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=calc_PostMergerCalcimedicaMember', window );">Post Merger CalciMedica | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued</a></td>
<td class="nump">596,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=calc_PostMergerCalcimedicaMember', window );">Post Merger CalciMedica | Series C-2 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants converted to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=calc_PriorToMergerTransactionsMember', window );">Prior to Merger Transaction | Series B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants converted to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">568,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=calc_PriorToMergerTransactionsMember', window );">Prior to Merger Transaction | Series C-2 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants converted to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,786,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=calc_PostMergerTransactionsMember', window );">Post Merger Transaction | Chief Financial Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants converted to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=calc_PostMergerTransactionsMember', window );">Post Merger Transaction | Officers and Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants converted to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=calc_PostMergerTransactionsMember', window );">Post Merger Transaction | Series B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants converted to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=calc_PostMergerTransactionsMember', window );">Post Merger Transaction | Series C-2 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=calc_PostMergerTransactionsMember', window );">Post Merger Transaction | Series D Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants converted to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_SaleOfStockRemainingSalesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock remaining sales amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_SaleOfStockRemainingSalesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_ShelfRegistrationStatementAvaliableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shelf registration statement avaliable for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_ShelfRegistrationStatementAvaliableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock and warrants issued during period shares common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock and warrants issued during period shares preferred stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock and warrants issued during period shares preferred stock and warrants exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=calc_ShelfRegistrationStatementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=calc_ShelfRegistrationStatementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=calc_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=calc_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=calc_AmendedAndRestatedCertificateOfIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=calc_AmendedAndRestatedCertificateOfIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=calc_OfficersAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=calc_OfficersAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=calc_GraybugMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=calc_GraybugMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=calc_SeriesCTwoConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=calc_SeriesCTwoConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=calc_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=calc_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=calc_CalcimedicaPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=calc_CalcimedicaPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=calc_CalcimedicaCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=calc_CalcimedicaCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=calc_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=calc_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=calc_SeriesCTwoWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=calc_SeriesCTwoWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=calc_SeriesDWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=calc_SeriesDWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=calc_PreMergerCalcimedicaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=calc_PreMergerCalcimedicaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=calc_PostMergerCalcimedicaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=calc_PostMergerCalcimedicaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=calc_PriorToMergerTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=calc_PriorToMergerTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=calc_PostMergerTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=calc_PostMergerTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091594568704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 20, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">2,475,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">5,754,505<span></span>
</td>
<td class="nump">84,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, forfeited</a></td>
<td class="nump">96,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 12,039<span></span>
</td>
<td class="nump">$ 1,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acceleration of stock awards</a></td>
<td class="nump">10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">2,449<span></span>
</td>
<td class="nump">499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">9,590<span></span>
</td>
<td class="nump">$ 902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=calc_GraybugMember', window );">Graybug</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acceleration of stock awards</a></td>
<td class="nump">10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=calc_GraybugMember', window );">Graybug | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=calc_GraybugMember', window );">Graybug | General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=calc_TwoThousandAndSixEquityIncentivePlanMember', window );">2006 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingRightsAnniversaryPeriod', window );">Award vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=calc_TwoThousandAndTwentyThreeEquityIncentivePlanMember', window );">2023 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">394,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_PercentageOfAggregateNumberOfSharesOfCommonStockOutstandingOnLastDayOfPrecedingYearAddedToPlan', window );">Percentage of aggregate number of shares of common stock outstanding on last day of preceding year added to plan</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, forfeited</a></td>
<td class="nump">96,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (shares)</a></td>
<td class="nump">394,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=calc_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember', window );">2023 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted averagefair value options, granted</a></td>
<td class="nump">$ 2.34<span></span>
</td>
<td class="nump">$ 12.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Total fair value of shares vested</a></td>
<td class="nump">$ 11,900<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">195,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, Shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_PercentageOfAggregateNumberOfSharesOfCommonStockOutstandingOnLastDayOfPrecedingYearAddedToPlan', window );">Percentage of aggregate number of shares of common stock outstanding on last day of preceding year added to plan</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized stock-based compensation expenses related to outstanding unvested stock awards</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Total unrecognized stock-based compensation expenses related to outstanding unvested stock awards weighted-average term of recognition</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_PercentageOfAggregateNumberOfSharesOfCommonStockOutstandingOnLastDayOfPrecedingYearAddedToPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of aggregate number of shares of common stock outstanding on last day of preceding year added to plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_PercentageOfAggregateNumberOfSharesOfCommonStockOutstandingOnLastDayOfPrecedingYearAddedToPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingRightsAnniversaryPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, vesting rights, anniversary period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingRightsAnniversaryPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=calc_GraybugMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=calc_GraybugMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=calc_TwoThousandAndSixEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=calc_TwoThousandAndSixEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=calc_TwoThousandAndTwentyThreeEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=calc_TwoThousandAndTwentyThreeEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=calc_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=calc_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091684591904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, outstanding</a></td>
<td class="nump">739,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Number of options, Assumed in the Merger</a></td>
<td class="nump">310,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, granted</a></td>
<td class="nump">785,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, forfeited</a></td>
<td class="num">(96,594)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, outstanding</a></td>
<td class="nump">1,739,270<span></span>
</td>
<td class="nump">739,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of options, vested and exercisable</a></td>
<td class="nump">940,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding</a></td>
<td class="nump">$ 6.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Assumed in the Merger</a></td>
<td class="nump">76.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted</a></td>
<td class="nump">6.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited</a></td>
<td class="nump">70.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding</a></td>
<td class="nump">15.71<span></span>
</td>
<td class="nump">$ 6.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, options vested and exercisable</a></td>
<td class="nump">$ 6.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term, outstanding</a></td>
<td class="text">6 years 11 months 26 days<span></span>
</td>
<td class="text">7 years 4 months 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, options vested and exercisable</a></td>
<td class="text">5 years 11 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">$ 8,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Agrgregate intrinsic value, vested and exercisable</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in the weighted average exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091593985168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Assumptions Using Black- Scholes to Estimated Fair value of the Stock Option Grants (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">3.56%<span></span>
</td>
<td class="nump">3.28%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">76.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091752397984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Stock-Based Compensation Expense Recognized for Options and RSUs Granted (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 12,039<span></span>
</td>
<td class="nump">$ 1,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_SettlementOfAccruedBonusAndEmployeeCosts', window );">Settlement of 2021 and 2020 accrued bonus and employee costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">406<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1', window );">Total stock-based compensation expense</a></td>
<td class="nump">12,039<span></span>
</td>
<td class="nump">1,807<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">2,449<span></span>
</td>
<td class="nump">499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 9,590<span></span>
</td>
<td class="nump">$ 902<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_SettlementOfAccruedBonusAndEmployeeCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement of accrued bonus and employee costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_SettlementOfAccruedBonusAndEmployeeCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost expensed and capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091684607264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Common Stock Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 20, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants</a></td>
<td class="nump">276,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options issued and outstanding</a></td>
<td class="nump">1,739,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">739,511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">2,475,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=calc_TwoThousandAndTwentyThreeEquityIncentivePlanMember', window );">2023 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">394,309<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=calc_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember', window );">2023 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=calc_TwoThousandAndTwentyThreeEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=calc_TwoThousandAndTwentyThreeEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=calc_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=calc_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091692951152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Contract</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="nump">$ 274,000<span></span>
</td>
<td class="nump">$ 221,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_LeaseAmendmentDate', window );">Lease Amendment Date</a></td>
<td class="text">2023-01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_NumberOfContractCurrentlyInEffect', window );">Number of contract currently in effect | Contract</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ContractualObligationOfContractInEffect', window );">Contractual obligation of contract in effect</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_UnpaidCancellationAndOtherRelatedCosts', window );">Unpaid cancellation and other related costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_BaseRent', window );">Base rent</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ShortTermOperatingLeaseExpirationDate', window );">Short term operating lease expiration date</a></td>
<td class="text">Jun. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=calc_AuxoraMember', window );">Auxora</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_ContractualObligationOfContractInEffect', window );">Contractual obligation of contract in effect</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MD', window );">Baltimore, Maryland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_LesseeOperatingLeaseMaturityYearAndMonth', window );">Operating lease, term</a></td>
<td class="text">2023-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_BaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Base rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_BaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_ContractualObligationOfContractInEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual obligation of contract in effect.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_ContractualObligationOfContractInEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_LeaseAmendmentDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease amendment date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_LeaseAmendmentDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_LesseeOperatingLeaseMaturityYearAndMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease maturity year and month.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_LesseeOperatingLeaseMaturityYearAndMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_NumberOfContractCurrentlyInEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of contract currently in effect.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_NumberOfContractCurrentlyInEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_ShortTermOperatingLeaseExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short term operating lease expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_ShortTermOperatingLeaseExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_UnpaidCancellationAndOtherRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unpaid cancellation and other related costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_UnpaidCancellationAndOtherRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=calc_AuxoraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=calc_AuxoraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091595029376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employees Contributions</a></td>
<td class="nump">$ 78,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091590752432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax computed at federal statutory rate</a></td>
<td class="num">$ (7,214)<span></span>
</td>
<td class="num">$ (1,624)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal tax benefit</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_IncomeTaxReconciliationPermanentDifferences', window );">Permanent differences</a></td>
<td class="num">(616)<span></span>
</td>
<td class="num">(1,237)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and development tax credits, net of uncertain positions</a></td>
<td class="num">(705)<span></span>
</td>
<td class="num">(454)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">8,535<span></span>
</td>
<td class="nump">3,315<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_IncomeTaxReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation permanent differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_IncomeTaxReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091593258864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 58,535<span></span>
</td>
<td class="nump">$ 15,839<span></span>
</td>
<td class="nump">$ 204,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsStateTaxes', window );">State tax, net of federal tax benefit</a></td>
<td class="nump">9,865<span></span>
</td>
<td class="nump">6,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accrued and deferred expenses</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carry forwards</a></td>
<td class="nump">12,403<span></span>
</td>
<td class="nump">5,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_DeferredTaxAssetLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">1,699<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">82,595<span></span>
</td>
<td class="nump">28,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_DeferredTaxLiabilitiesValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_NetDeferredTaxAsset', window );">Total net deferred tax assets</a></td>
<td class="nump">82,574<span></span>
</td>
<td class="nump">28,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(82,574)<span></span>
</td>
<td class="num">(28,240)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_DeferredTaxAssetLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax asset lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_DeferredTaxAssetLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_DeferredTaxLiabilitiesValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_DeferredTaxLiabilitiesValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_NetDeferredTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_NetDeferredTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsStateTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from state taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsStateTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091692800336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">$ 278,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforwards</a></td>
<td class="nump">103,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 58,535,000<span></span>
</td>
<td class="nump">$ 15,839,000<span></span>
</td>
<td class="nump">$ 204,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Operating loss carryforwards limitations on use</a></td>
<td class="text">In addition, under the Tax Act the amount of net operating losses generated in taxable periods beginning after December 31, 2017, that the Company is permitted to deduct in any taxable year is limited to 80% of taxable income in such year, where taxable income is determined without regard to the net operating loss deduction itself.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carry forwards</a></td>
<td class="nump">$ 12,403,000<span></span>
</td>
<td class="nump">5,736,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_PercentageOfChangeInOwnership', window );">Percentage of change in ownership</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrual for interest and penalties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_UnrecognizedTaxBenefitsNet', window );">Unrecognized tax benefits net</a></td>
<td class="nump">$ 9,100,000<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_OperatingLossCarryForwardsExpirationBeginningYear', window );">Operating loss carryforwards expiration beginning year</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carry forwards</a></td>
<td class="nump">$ 12,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_OperatingLossCarryForwardsExpirationBeginningYear', window );">Operating loss carryforwards expiration beginning year</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carry forwards</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=calc_FederalResearchAndDevelopmentMember', window );">Federal research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_OperatingLossCarryForwardsExpirationBeginningYear', window );">Operating loss carryforwards expiration beginning year</a></td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of information about income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_OperatingLossCarryForwardsExpirationBeginningYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carry forwards expiration beginning year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_OperatingLossCarryForwardsExpirationBeginningYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_PercentageOfChangeInOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of change in ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_PercentageOfChangeInOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_UnrecognizedTaxBenefitsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized tax benefits net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_UnrecognizedTaxBenefitsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=calc_FederalResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=calc_FederalResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091593512144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits gross</a></td>
<td class="nump">$ 7,506<span></span>
</td>
<td class="nump">$ 6,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase related to current year tax positions</a></td>
<td class="nump">2,846<span></span>
</td>
<td class="nump">973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions of prior years</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition', window );">Additions in connection with the reverse merger</a></td>
<td class="nump">847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reduction for tax positions of prior years</a></td>
<td class="num">(140)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits gross</a></td>
<td class="nump">$ 11,080<span></span>
</td>
<td class="nump">$ 7,506<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091692964672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (34,357)<span></span>
</td>
<td class="num">$ (7,824)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common stock outstanding, basic</a></td>
<td class="nump">4,486,258<span></span>
</td>
<td class="nump">82,245<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common stock outstanding, diluted</a></td>
<td class="nump">4,486,258<span></span>
</td>
<td class="nump">82,245<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share&#8212;basic</a></td>
<td class="num">$ (7.66)<span></span>
</td>
<td class="num">$ (111.16)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share&#8212;diluted</a></td>
<td class="num">$ (7.66)<span></span>
</td>
<td class="num">$ (111.16)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) Retroactively restated for the reverse recapitalization as described in Note 2.</span></p></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091594371584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="nump">2,015,707<span></span>
</td>
<td class="nump">3,522,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,442,852<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=calc_WarrantsToPurchaseConvertiblePreferredStockMember', window );">Warrants to Purchase Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">328,859<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="nump">1,739,270<span></span>
</td>
<td class="nump">739,544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="nump">276,437<span></span>
</td>
<td class="nump">11,520<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=calc_WarrantsToPurchaseConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=calc_WarrantsToPurchaseConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140091696466688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - Subsequent Event - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Feb. 05, 2024</div></th>
<th class="th"><div>Jan. 19, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsDate', window );">Subsequent event date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 19,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Tranche A and Tranche B Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,646,058<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,985,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_calc_GrossProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from issuance of private placement</a></td>
<td class="nump">$ 20.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from issuance of private placement</a></td>
<td class="nump">19.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Private Placement | Directors, Employees Or Consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.3915<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Private Placement | Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants converted to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">306,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.8269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Decrease in warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Private Placement | Tranche A Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants converted to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,646,058<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Private Placement | Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.827<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_calc_GrossProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance of private placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">calc_GrossProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>calc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the event occurred after the balance sheet date but before financial statements are issues or available to be issued, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=calc_TrancheAAndTrancheBCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=calc_TrancheAAndTrancheBCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=calc_DirectorsEmployeesOrConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=calc_DirectorsEmployeesOrConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=calc_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=calc_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=calc_TrancheACommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=calc_TrancheACommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=calc_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=calc_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>111
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" !@@GQ83_5I_,X(  !)-P  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;+6;:V_BN![&OXK%CD8S4BFYT<OT(M% SV&WI6SI[&KVZ+PPB0%K$IMC.Z7]
M]L=.@)"18TAEWK00\G^<_)(XSY/8URO*?O(%0@*\I0GA-ZV%$,MOG0Z/%BB%
M_)0N$9&_S"A+H9!?V;S#EPS!."]*DX[G.&>=%&+2NKW.EXW9[37-1(()&C/
MLS2%[/T.)71UTW);FP7/>+X0:D'G]GH)YVB"Q/?EF,EOG:U*C%-$.*8$,#2[
M:?7<;_W 5P7Y&G]AM.([GX':E2FE/]6787S3<M06H01%0DE ^>\5A2A)E)+<
MCO^M15O;-E7A[N>-^GV^\W)GII"CD"9_XU@L;EH7+1"C&<P2\4Q7_T;K'>HJ
MO8@F//\+5L6ZW;,6B#(N:+HNEEN08E+\AV]K$#L%%TY-@;<N\'XI<(.: G]=
MX!]:$*P+@IQ,L2LYASX4\/::T15@:FVIIC[D,/-JN?N8J.,^$4S^BF6=N.W3
M*).'40!(8C @ HMW,"3%^:2.2QM\G_3!ET]?P2> "7C$22(7\^N.D(TKB4ZT
M;NBN:,BK:<CUP",E8L%E*S&*JP(=N=7;3?<VFW[G&17[*#H%OGL"/,?S-1L4
MFLL?(3L%7E$>:,K[YO+?,R);=W2M5_;&WQX(/]?S:_1"^HH8^$]OR@63%\-_
M=80+A4"OH'J(;WP)(W33DET 1^P5M6X__^:>.5<Z.C;%^I;$*N2"+;G I%Z>
MPB_O2Z3#9BYWG?8?.C[&JJ9\+(E5^'2W?+K&'>Q).'$.Z#Z!<QT@<_T,)ES'
M-326-25D2:Q"Z&Q+Z.RP,VB,&*:J'XR![$VU)],>I4V?5-LI&>N;0K,D5H%V
MOH5V?ABT>\PCF( ?"#)P+Q=J;PYFK3I8QJJFL"R)56!=;&%=-(*U/M%J<9G5
M[G_H8!EKFL*R)%:!=;F%=6G<O1<&8TSF8/*>3FFBPV.N#WL/H0Z0L:HI($MB
M%4"N4[HVQ[B+:Z?VC.98^05Y8HU@JNVO]@B%,(GP(XIQ!$^D\8M.=>#,&DW)
MV5*KHMLQO.XAZ$)Y-3)Y)0ZE&WT#?Z!W+3RSE.,X;M</7%_;>9F+&U.SI%:E
MYI74/..N#L/[9]#+8BPH STA$!=%0*CS%'OT:DV%N:XQ-4MJ56JEIW>-QK?L
M]F>80!)A>;XI;BA?AAB3+"/*6)&!M13-^O44K;I[6VI5BJ6_=\T.?7W%_HV2
MI/V3T!4!$P0Y)2@&0\XSQ+3DS)HCJL5FU?3;4JMB*VV_:_;M:VQ_T20C K)W
MZ3T2Q/31_0/N>T2!%J'55&!+K8JPS 6NV<YO[A69O$;E%?N,EI2)W)K(JUCO
MW,R*^BV6WEFG%7Y$R\#R&&G!+>.":_;X&XB[<<$4M/;(M=NNU_9=+3:KL<&6
M6A5;&1Q<L]=?GX+YM0M"R6I.F=ZKF'5&E+1A%"$I(T7B0E!+SVJ.L*56I5<F
M"=<<!=;T)@MY[P A39>0Z.&99>KOLU8SA2VUZN/4,E1X!X6*20HEK+N,RY^Y
MMH_;HR-8IH5E+FL*RY9:%589([R#8L0@16RN[@C_D@IB83K']@C64K,:(VRI
M5:F5,<(SV_X-M3<@0S[A.(\0Q<,0+;(/A@AS76-FQP@17ADB/+/)WY@0FJ82
MUD30Z.>)[-&@; L\94(&"J(>EVCY67UCL%;KYFKJA>+KK>N<!X[K=J\[KQ5B
MQP@,7AD8O(,"PSB;)CB2"95"H:5CT^V'5M7Z:[6S7=;NZ?F6<Y5,F0F\@S*!
MNOF#499.]=EICXCCN&W_LNM?:#%8]?^VU*JX2O_O'>3_7^ ;&,;2O.(9CHK'
M'@9X9LF@V_9<SW'.+[7TK#I^6VI5>J7C]\P6?4VO%\=2G9]L/H 'N1YX(EK7
MOT>RZW1E1PBY '<T2] K9#&8T$PLM#"MY@!;:E6890[P#LH!>I@O*]WCC+L]
MDI,,"P1\YUP+SVH,L*56A5?& .^@&+"%%ZIOE($7NM(^=MLC]P#![S1)H):;
MU41@2ZTZ)*%,!/Y!B6#+33WV0 K<F-%73"+M);Q',^QI1R-8S0:VU*K8RFS@
M'Y0-MMC&5)JT!/R#E[+SBO70S(J7GN-K+U-S76-NQT@'?ID.?+.?SR_+'D.P
M'I-9X**K]23FJL:0CA$'_)UQ0N8X\$#S%\@+2DP6;H_(9==K=[N.HZ5E=V30
M,:* 7T8!_Z H,"0"L6*,H7K@"#>/=+7H/F#DZY[@?D3+P/(8+Q3\,CSX9M__
M@H6,#70&7._+]"N8H"AC$JZ6H5FIFF67D(%7F&0(?').U3M5L$0,<)5PM4RM
M)@Q;:E6F9<+PS7%@ Q$,WJ(%)'-4^R)_C]"H-^GW_M3RLIHI;*E5>969PC\H
M4PQ)1-F2LCR,[?B2D&9$L/?Z^\>>,4T#+4"K.<*66A5@F2/\ T<B]0C)Y(VD
M>*>E9646JGM>:2YK3.L8P<$O@X-O=OKEV-+R<:6!V ??(ICK&B,[1F8(RLP0
MF/W]9I!(73^VIWS B$SWGV&ZO (_Y-4\!P\/8QTTLT[C ;K'2 Q!F1@"L[_?
M0+O'+ 7#OI:;62'PM)"LQ@-;:E5(93P(S.Y^ TDYX+H!,WLD)I" /D9S>@)"
MF. 9901K8[Q9IS&X8T2&H(P,P6'#D/C.?1/%8*H&$,Z0],'Z(+]/]2G\_C@8
MO4S <!0^/8^?GGLO@SZX^P&>!_>#Y\$H',CDR]21XLHUB@4";#M@\?-O%YY[
M?L75)!U,<.[,QXR^O1<W\[S3_:)*U(J><_7+;_E2]^HKD(<P5U:S.#;WM$>$
M\E$:LM'<8BYH$B/&@:!@BL ,)W+G5U@L\L*U \.(%W-@-CY,>53,\_E-A J0
MR(952_($ZBT93H!W64P= =*F OP+5[;A*G^1K8XA$V X'!88,*_>?($:1D?E
MA5\[%<%J(K.E5IR,G9VY1^I=:#Z'BX-(&;%B&M)VZ7:>6"^?'=4I5R\FF3U"
M]2J5@P3-9*ES>BZM.2OF;15?!%WF,YFF5 B:YA\7",I#JU:0O\\H%9LOJH'M
M[+G;_P-02P,$%     @ 8()\6!Q&?;Y!!P  .B@  !@   !X;"]W;W)K<VAE
M971S+W-H965T,BYX;6RU6EMOVS84_BN$5VPI4,<B*?F2)09RP; !ZQHD[?I0
M[$&1Z9BH)'HD[33[]2,EU=2%I.),>XDM^?#P?(>'_#XR/']B_*O8$"+!MRS-
MQ<5H(^7V;#(1R89DL3AE6Y*K7]:,9[%4C_QQ(K:<Q*NB499.4!!,)UE,\]'R
MO'AWRY?G;"=3FI-;#L0NRV+^?$52]G0Q@J/O+^[HXT;J%Y/E^39^)/=$?MK>
M<O4T.7A9T8SD@K(<<+*^&%W"LYMPIAL4%G]2\B1JWX&&\L#85_WPV^IB%.B(
M2$H2J5W$ZF-/KDF::D\JCK\KIZ-#G[IA_?MW[[\4X!68AUB0:Y9^IBNYN1C-
M1V!%UO$NE7?LZ5=2 8JTOX2EHO@+GBK;8 22G9 LJQJK"#*:EY_QMRH1M080
M.QJ@J@%J-P@=#7#5 +^T05@U"(O,E%"*/-S$,EZ><_8$N+96WO27(IE%:P6?
MYGK<[R57OU+53BZO6;Y2HTA60'T3+*6K6*J'JSB-\X2 >^U8@#'X='\#3MZ\
M!6\ S<''#=N).%^)\XE4,6A/DZ3J[[KL#SGZNR')*<#P'4 !PI;F-R]OCIK-
M)PKY 3XZP$>%/^R"O^.<Y!+$0BB<9S8\I8/0[D!/RS.QC1-R,5+S3A"^)Z/E
MCS_ :?"S#=U SAI8\0$K]GE?7L=B ]2H@41_(7_OZ#Y.%7CK*):N9H4KO7;L
MEU&$@_/)OHZF:P0QFAV,&E&&ARA#;Y1W1$A.$UV$.F!;;*6#J-9M.["N!0P7
M]KBB0UR1-Z[[#>-R+ G/U S8JR S5^JB3N?1+)BW(NP:!?;XIH?XIM[X;CG9
MQG0%R+>MGL^B&&DF-X2K9:1>Y+:0IYUH\'36BKAK@Z+0'O/L$//,&_-')N/T
M!>'-NL.IYD34"M!B-<..K,X/$<Y[LJH8ELOG(IMZRFSUL+\#.9&V0.?=$#IY
MM-B$CCFS.$2Y\,\936YCMA[O!"G3Z(QPT3MWNA;AW!X># S)!-X /Q1UZ![@
MJGFC4XA;@5F,8(@<)0AK! A?4(2>V&"W6P3G[>JSF&'L6G2@X2?X,H)*:?Q
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M=([\='ZY6E%]GJ<6$;T;'=,<)/&6JD7%"LWOS 7-0O%1J"1Y&U_7+@S40N7
M:,0 \HL!I:=VV2XMSLFJF6<%Y_?B M>5!6,EQH)IV$9G,X1P%K@XP$@(Y-_S
MUO%5!P@L4U-YHT][]P307#T3<)(R(6S+S56/?Q?R[L88M3'_'RH#&96!_"JC
M)$?A78*M^?"[=>6CJT7F=8:O4M*U&L\@#AS;8FPT"_9KEHX2>*>9MB9C&JMP
MP<1'9^8:6[;TEKVUQ<R]M\9&[&"_V+DG7$N&2U#79X9>"JX%7]Z3[(%PZQ#Y
M_1_+JT-Y:V;#Z"K<<]+@'ETK]D$/'(;RUL1>.QGO.1H_$GOW5*%S-&XYGEA
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M%#M&<%P-RE(' 1 X&4YR>SFO'GMBRSG=\S3)R1.SBGV68?;C@:3TN+"A_?[
MU^1UR\L'G.5\AU_)FO!ONR<FSIRV2IQD)"\2FEN,O"SL3_!^Y7KE@"KQ=T*.
MQ<FQ54[EF=*W\N1SO+!!2412LN%E"2S^',B*I&E927#\VQ2UVVN6 T^/WZO_
M44U>3.89%V1%TW^2F&\7=F1;,7G!^Y1_I<<_23,AOZRWH6E1_;:.=38(;6NS
M+SC-FL&"($OR^B_^WBS$R0#H#0Q S0 T=H#;#'"KB=9DU;0>,<?+.:-'BY5I
M4:T\J-:F&BUFD^3ER[CF3#R;B'%\N:)Y+%X4$EOBJ*!I$F,N3AYPBO,-L=9E
MX<+Z]0DSDO,MX<D&I[]9M];/EF,56_%H,7>XX"BK.9OFF@_U-=' -1_)YLYR
MX8V% '(5PU?CAZ/N<$?,OET"U"X!JNIY _6>Q,8AC(E9B]7>O-U8.\RL T[W
M1#6UNE94U2I[Y+ $=P  .'<.IU,PQCJH;HOJCD1=UZCKZB6P/NWYEK+D/Q*K
MD.N:_@D+!/7/!^A^$*AYO9;7.XOW<U'LU:R>!J&&U"4ZD'X+Z9\%^67/"X[S
M.,E?5:2^D527Z) &+6F@)5W1+!-O?=4VU>_28-PN-<8ZF&&+&8[!G+)%P]Y2
M^4"]1Q7)8.8%*% S1RUS-)GY1K-/HSY&Z'L^\#_@]G.1!P-?#3MK86=GP!KV
MZVPD<3^G(89 >@9HF=>$)>4V*#US((PGSRFQ/K2>4B7:LN6GG/MBAS=D88N/
M,05A!V(O?_D)!N!WI5DN5*V["">RA1=435-L]J$]/S:Q,=:%E5J$8[TXI9.;
MHKKW144$B;T(0SC0Q%#Z$9XGR.%&ACKI-;S]B(%7^A&>)TA#+T.S)A41 [3T
M)=0+LVGEA\FMK"T[N94O5*V["%+%4._BB:T<C&ME4ZP+*X4,]48^LY7[KNWM
MLGX$0N3Z7C#P40=*(4.]D<]HY;YL>[S]" 1!$*)P-L KG0SU4CZWE?N^[4'W
M(WIH)*V,1EEY=0LG]K*^[M1>OE2U[BI(+:-+:AF-T[(QUH4]^;9Z#2TCLY85
MD0C ((H&A(&DE=&EK8S,5E9$]+A2RN@J4D9F*2LB>F;I9#3*R:M;--7*^L*3
M._D:5D;2RNB25D;CK&R,=6&EE=$UK(S,5E9$8(!FT!_ZEHRDE=&EK8S,5E9$
MH.L#;^8/"4Y:&5W%RLAL945$#^U**[NCK/PXM97U9:>V\J6J=1=!2MF]I)3=
M<5(VQKJP4LKN-:3LFJ6LB$11%/H@# >83_Z7?&DKNV8K*R)(^ T ;^ +@2NU
M[%Y%RZY9RXK( +1S<J>EO,WU%V:O25Y8*7D10\%=*&JP^LY1?<+IKKKY\DPY
MIUEUN"4X)JP,B.=?*.7O)^7]G/;^W?)_4$L#!!0    ( &""?%C ]!"6!04
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MD#*X&&''5&V^]<3(E?.ON33HAFY8X/\*E W [PLIS79B$[1_P/0/4$L#!!0
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M 6SW%"!- 3*T@-T4L(<6<)H"3J< \7H*N$T!=VB$65-@-K3 O"DP[U9IWE/
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M6-3?G=4W6JZK3[>>I=8RJRY7G($4,PW@_TL)\[VY,2_8??TW_S]02P,$%
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MUFGM9""*U@=;I\VPH-8F_I7W*0[?LV&6-LS8[JB(K7PC@[PX<W8M'*V&-/K
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M?8[G^"8:/O]57ZG!^G+Y/;;4"6(2M9]P4SR9S?>[5CO.V>8O+I_/G]'F0E<
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M#@@;Q#CBSR+'O^1.)R5EVS)CB6#,U.Q>!-U=1.#;V(NLT3F+?>XXJ.J@8CS
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M^R>LVP7+0Z>A=?KFTH@'&9=*O!## 5;Z(E?&+?=X6[]/2-[8_0PY)UV&:_U
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M#L3X^*A5S%]N_J5,)NK6B-Q>,[[A@FVF"BPC@I75/.A!U0,!YVLRA4+ !VH
M(XN>E^9J1^YR&G6YOC<)AD=SV/%&;#J84NO9AI/N?/]%'9C+6610^P3MK!&*
M*#MQT5NUR'J$JWT4_24LLHJAP6F&MH^?]<2\XH\;J$0:T>#Q>8?"BZFWF!VC
M<,?\ZJNXY_+)1\\3M C5Y9,?\(/QO*+5Y[*&^!C'M<^80T29*FORR+7#JF,<
MXJ4T4%JJ+X9:,FK'0YK!1?7XB$QQ?;$K3+;B[G/8*CIL'0\0CD.V!D]Q]9,H
M9?<X-?9&_N@S..4PL8<J:C'Z:.6=Y-5BV(0XF/-'*/:,6%4!>%[1%'N4[/LI
MT$7K-UX)N8Y^R48.0Z?A?N[5W&U^+'?E?B.V6^Y^:?=.FC7-MV*UPJLX"4[.
MW+?=]461Y?R+L656%%G"'S=*HG^B!7B^RK*BOJ -FI\07OX74$L#!!0    (
M &""?%A6B\16)0D  %@9   9    >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM
M;,U9WV_;.!)^]U]!>-L]!W!D2?Z=)@'2;+;7 XH-DEX7A\,]T!)M\RJ)7I)*
MZOOK[QM2DN7$3IM].-Q#$HDBAS/#;V:^8<X?E?YJUD)8]BW/"G/175N[.1L,
M3+(6.3>!VH@"7Y9*Y]SB5:\&9J,%3]VB/!O$83@9Y%P6W<MS-W:K+\]5:3-9
MB%O-3)GG7&_?BTP]7G2C;CUP)U=K2P.#R_,-7XE[8?^^N=5X&S124IF+PDA5
M,"V6%]VKZ.S]B.:["5^D>#2M9T:6+)3Z2B\?TXMN2 J)3"26)'#\>1#7(LM(
M$-3XHY+9;;:DA>WG6OJOSG;8LN!&7*OL=YG:]45WUF6I6/(RLW?J\:^BLF=,
M\A*5&?>;/?JYHV&7):6Q*J\60X-<%OXO_U;YH;5@%AY9$%<+8J>WW\AI^0NW
M_/)<JT>F:3:DT8,SU:V&<K*@0[FW&E\EUMG+>ZN2KZ=D5\JN58ZS-IS<=3ZP
MD$YS!DDEZ;V7%!^1%,7LDRKLVK";(A7IOH !U&ITBVO=WL<O2OQ%) $;1GT6
MA_'P!7G#QM:ADS<\9NN::U'9>LNW@)9E5UKS8B7<\S^O%L9JX.1?AZSWLD>'
M95/LG)D-3\1%%\%AA'X0W<N??XHFX;L7-!\UFH]>DOZJ4WI1TF$]9P$[M@.C
MZ&8W?Y32;MG'(H&?$$7L-N.(J")E5_!<ZKQGE9_K/MUJ^<"M8-<\2^0GD<J$
M,YZJC85X?!9>GFSD;6B1K';K_?S3+([#=XTX]QZ].V%VS2W;:/4@4V$84A)&
M!)/&E!RBF%JR1.4YM#9D#JDD\DVFMD*8/BM4<5J_LE1JY 6EC;,B485!&/,"
M"8[=B41N)!0S)'"GHY<)&^ 6+-."B4RNY"(3M-&FU,D:[MO7 .J2N=^$3B2^
M;;2$FK">9[2F4"P3QI!9A;-$&"N1:>"D)9<:<:Z_(B\_\*QTQIDR6==J^ 4I
M.1E?5D"Q#=AG#.T.X9FCW*P7C/(^,I;;$J[9/K48CO(CC:V:<I[Q^R(IR;S,
MR9<NB)R-0N>T7RW"*0#K2F0(K]).6PD_B()M!<>A>)'-,E$(S;-LRQ[@(1:/
MV=O: 4NI#?FX@#':H*S0=CM;R3]]I%2[=H,+GCF@D!A9K)A&REQ K'JHU%FJ
M#&6*/@TG+'?I+&"WI2: .8C3I$]"KS#_:J6%2QQ]]D'S[:)<,0XDYK!OWS)R
M'+1_XDY"K8N&E*%8PNE%2OL><$W@$N"1("0_4<#R8MM$V O3>R2YB2],:\<7
M/+66@-A")#P'&I=+X8HFP9C6)9DRI&/E8N^'@%V9>F2W C@6^_/Z](R@>:1?
M43\,0_IAAI)R(Z"RA!2*IN_,DV!ZX#+C%&\$:'_ ;7=5U@2P&:Y()?G9[>HW
M856^(Z29<O%O:$HG"NP05!$2(#4&J@@.%_R-8Q1HBIK@\4C;070'%;ZA2(.,
MRHA&$QHH-[2)0^SR-<:V,=&#"MRE"MA:E/D"?U)!P87LGK+%]J"XA>(ZI;V:
M7'=2GQ4JJW!2ZNK:9_-)?SP?->A<<SAJ(00Q+UMJMTUI7=8KB_V#6):8( Z<
M1P/?HYL.YZ/^,)S7?G'0^.%3]BBO$[HK8!2J/C,=C8U&R(LKGX7)S?WM;5.&
M_E=1,AF_-D0JB*?.=TU=?.(^LN7_(TA(DWJ@@C?>>M$)1+ZM/UAEL:R"_9\/
M(@RV$%@O!PE*A/N>\ Q4AFNG>9_U8B@Q?^T!]!D<T1N>^%*]'[&O4YV;/Q7B
M1X.-47&O%=A%=U6%#B+D\UY!M"XF??,F_R.,QTRKI#&4?;#&Q">0&A$N#5"1
M:R+7G'4^NR/]K<HUO[O6"5I<H0RC$V0W-5^Z=7SIV?<[0>TF*77=(AN?B6ST
M'.Y.4)Q1G5?$CCYBAD03F; OCD?U)#$'51HH94XZO[4@@@!^ZK>838?S_CB*
MV!LV"9 @IP&8P1LVZ\_#8>>JJO>R:!.#813V1X#8=!),X\Z'BO-,9^/^'/(F
MP6C6N::XS#(,]^K,>\*F83".OJ?0$+635(JG(=2(QL$T(L7F>)E..E] ;"I2
M49%.=VH'Y<Q'J,#SF3,LFK%Q,)\Z(73N=08"9.J*4)/8E*6E=H" Q>1M)JC?
M>[Z!!]!C=7BGO#H\QVP;2ON4&3Z1;8X)KR$5LT=$RAL6!\.1&X-/XF V9AM,
M=FCO4TK;^(2;;;U2/J7L:U*%QH/WH)<:1<$<73>X&^&[Y_,^DF!6$JW&=YR8
M^^ZO*#)'W2N6R!.<,$QVH0'Y->>L@K^FC%6T/R*035U!:E:_P]1)$T\O>;QV
M0#!ME/J!9?$+!=JTVL*DW186RD*FA=&)6A7(!RE5#'<.]=XUFVPE+H"(3L*0
MCYJ5GGU3F]1T/\] 4S<2<3#RN'B:G:3/1ZZ9=[2+$EJV=4%$05J3[H*]SSA,
MND_6*A-.D2;-^@JV!XIG.<[AU.RY]?L8/>O\@]Q_\VQ:QTVC*9T[:;ZR)3H*
MZ A]J,_1!(-A, [9VU/Z.T%-!+:KUWC&WG9NG#\A]4$!?#(CQC\=TX0IS9[%
M[3FVG2 G =JH<8#J=NJ>=]-225TC5-]*D:4,V[F?HS<$M+ P8F_"'E9$-:&%
M%?)?NZ\D>Y'K:7OO[K*0=I<5*!IYS2;,DQ3^0]X%J^$@>&ZS5" 3J(V[M0!B
M^Z,19<_1?-[YX!M-W[&EP(2D"R%'U5 $YB&;AW%5O**X'P[G2,:C,.K<HV7V
M=TCN"J( :JV[& "]6 JM&[.:'AKH T#-7^JKD%XJEC*1]J1S+ZS-&F'0/JIQ
M%%).T52N%ZHHO>.:"XU$&3C,,8/X'1N%DTK/HQ%<G\J;VA0\]&?AU 76=U?]
M4#KJ[W*E*L2I8[L@V4AHNPAZ59IL(',L3](;)<!YDP!]2IP%DV9$%H[D'H0#
MO:^.@Z"RWCRM*=>>N?E.XJ[-P7_US=''FHI?'V7K51O5D':ZDY+&-FRQ1:4/
M5/.SSC/D=_;V0H'QJ2N>3L!.IIW['[F-:+A&Y]Z7Q_WN[%B'X7JHJKE[OO(
MV:Q:G0JS",DIWJ,).W1W.FC==N=TZG2G3^RY+*R_^&Y&FW\;7/G;\MUT_S^'
M3\ BN"&(^A)+PV Z[OH[K?K%JHV[.U\H:U7N'M>"0WV:@.]+I6S]0ALT_TRY
M_"]02P,$%     @ 8()\6 M(Q@ @!@  B@X  !D   !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&ULK5=;;]LV%/XKA%OTR?-%2=NT30PDZ;JU:-"BV>5AV ,E
M'5M<*5(E*5_VZ_<=4I+M-,W084 0B]0YW[E_%,\WUGWV%5$0VUH;?S&J0FA>
M3J>^J*B6?F(;,GBSM*Z6 4NWFOK&D2RC4JVGV6SV;%I+94:+\[CWT2W.;1NT
M,O31"=_6M72[*])V<S&:C_J-3VI5!=Z8+LX;N:);"K\V'QU6TP&E5#49KZP1
MCI87H\OYRZM3EH\"ORG:^(-GP9'DUG[FQ=OR8C1CATA3$1A!XF=-UZ0U \&-
M+QWF:##)BH?//?J;&#MBR:6G:ZM_5V6H+D9G(U'24K8Z?+*;GZF+YRGC%5;[
M^%]LDNS3;"2*U@=;=\KPH%8F_<IMEX<#A;/9-Q2R3B&+?B=#T<O7,LC%N;,;
MX5@::/P00XW:<$X9+LIM<'BKH!<6U[:N54"6@Q?2E.+:FJ#,BDRAR)]/ TRP
MX+3HX*X27/8-N'DF;H!0>?&C*:D\!IC"M\'!K'?P*GL0\345$W$R'XMLEIT\
M@'<R!'P2\4[^2\#BM?*%MKYU)/ZXS'UPZ)H_[TM#,G)ZOQ&>I)>^D05=C# J
MGMR:1HLGC^;/9J\>".%T".'T(?3OK]G#<"\FXN&DO'&V%@&C*(*-OV,1*F*E
M1IH=NG$G*KDF49 +H %1]-I!:"5SI55@F%#)(*13G@2$&,&Z4AE0 31:AVV[
M% H>Y*V'B]ZGD8W*$_'+@459%*X%XB$Z^ G,4E1P)P1R7FPJ,F+9!JXE;4%B
MI>)GH&*C<3:7N:88;50[$BFD$3F!=*2W!G([01Z!RT#EL2>5]*)2F%*G"JE9
MSL XE8@0N>)$< ?Y/F##1*(/PAU"W:A0#?*@E37HLN&"1 ]K:=HE7K0.>47:
M5M*HOR73FA_'R!G\6 @1%@Q\%XHET9,%NH!=GO8/R$+3Z-TQRCBJ<$W62(YU
M*<T'ZH*[6SKDSX>VY#JP@H415 -MK^"#B"JV;#D1K(\3Q<D0G6Q=8WU77F1D
MGS!T#X0XHU!=JY)2F.3 @3%P@3]C PQP'I_-N#=?S$0I=T"[]+P)ZJ ZAR<]
M?8C8N"@_MT"H'%&J_6!VG.H0-E9<WWQX\N@LFS]_Y1&DYM*S"<[%84IAYK+=
M6B=CX++XTBHN/]I"<FYP-K ()_V&W J^1 .R053;V% "(3X6\\DIV%WK>% !
MB'>R80<(TGM;J.A%83U["O2&XIFF=V.D'[+<9K1<8C=FJVO^O@[COO[8V_ _
M8T5K&JE*[O<"!V.76-<5L \[&CSN>YYYJ;U%]WU-#CD5%NM&NK 3<2SSO]@G
M"*PQ_[;UG0%-*[10[%0"$ZQ2]Q1:JAK>DHI"B!R\ C> U)I^A4I5"J7[-S[I
M!VPB;MFG5 M/1T8C>2FSMGK-P&G@=OU.#YZR.>[<Z]F,#J/#HP\2Y(>H6M/1
M8>BG@IWO]B+UE++&9P\\^S#,PWL0#HG+%3HSD?%=K@$O[:='1^DX4<LE#T(\
M<MC?]U*\LZCG6%Q+K2!AE)R(MT:\PW1S@KII )R$H3*V\@;XM*6BY60SJL0@
M$&>@YB,]#M^^A2! XDO+\#W]<I9\95WX(8HF]VA;4,-]E1HH;;*I:)A'!8@.
MT[Z)K+D?VNAB= -.EF!F8""O_Z]+5[QV''V25KZ3P</!D*89G8UGLUFRK'>1
M9.Z?\>/CL9)EPD2H LS*!Q8W%VQKS(OEGKI!373JD9+<?55.M)$"!G/9=E6)
M=ZVAE"96C3DMT/FFKU\"N[R]%F>G64K_8)^;*2><D#*'LC5=(=AQ'K'4#<N6
M"5@A#I7.-+:6#=:0<?ZX3F]^<G*7MZN!,Y?H<GP^\,$2D,'4SH<(B8B09] 0
MFT@CQ [L<**@%6-W?,WAK!M!#AL*IW?OXCXK$_&)*QM/]FY0O@.>(WPLLN>G
ML>J)E+-L'E=WV3=QD>( "]V6R9%]"3L/_*''-M=JE0B7+1TI1MXK6N?N?D)U
M5(3SRENMRLC.N=3,WB+> ?SDON_+Z<']H.86Y5N0%[%7TE5AV!TN6I?I?K$7
M3[<T=.I*&9Z2)51GD^=/1\*EFT]:!-O$VT9N ^XN\;'"99$<"^#]TMK0+]C
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MORDF.V3(K+*4!0W0U,$FD!_:9 -QPYG;3B]N T34$804V64$Q;+C?'G_Z\\
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MIOLW1S^]3FF_>9U"#I 9%7Y-GRW8CLTU+DPP&M8V7?AJM+5$5G/$S,+2Z"*
M[-;_#5U2TIK&W0&)ES+,^1Q3U!>WIOX:ES1Z$-0.HGPDBV32C5L+MJ3GDGK"
MK.+AX&EY!X^N@;_G=+UI9(,6'9)YEPC7EIKL0WU$;Z?)*]"L0BMKR:!2KN[W
MVMFV6[ZHF\2G[76K_8V9E2 *$I=D&G<_#2,P=?M:#YPN0\NXT(X:T/"94\>/
MQF^@]:76;COP#MK_(>;_ %!+ P04    " !@@GQ8?-I#<M,>  "A8P  &0
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M[6%>WZJBZX#JQ;+6:CT W#3*J:U&<8#?:2[^ ?-4,?2;UAK$!QPB[*8*IU8
M5B7KIV)TTP/:"ELY0%9%8D:X\A!?W5Q[6&>$X-&I'SI$:#+I0YP$9, M7P9<
MCZ[PO(7_A 5>7MT\CRBZ&]T V?50:<8#;^'\YM?MMBL T7B ZZ(NS6M=P4G5
MS;!TIC*@:&;J50.""S2F"7M=6*<TZ@0%$JVW2T"REVI:!OY8 /7J&C;NM2W]
M#GYG' ,RVKB"U'S*5[HVH#'I),Q9D4?/0=LAA8&-;Q&C*; [H&*E82^8#%.!
MY,OLM(C0HOQC,!9@Y84;L3'$LCCTM;9K;6=TSDY;TP+J@4_;P$%^0'\GG.^
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M5/S(I_@ XVT/ 3#2;$R#_B?W2_P]TT"P,A"WS80QNQ8)Q'1UP_)W+5K1^VG
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M;4&CCK-#"BB,6]MBB]9JJ"L2XJ!TO#BK):JC?6;]* JP ],&#* @B]9/- /
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M:/ H<+O)%F_;"H))W\*2#8W7ZEZV=J7%PSIH/I+R-^83I+?V9.8NJ1P"6.#
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M6Y=M<J%=M+<[7GHM6;[;6?X#+1^GRKEPTVL6-T?LU&%"O4:_Y>;WBA.@DY\
MG<H3 (NXP.A!0#;,<,^/*/Y/R@3/=JMN^#+1!\M_I>ECRC]N\XH%",0&;1$H
M9@:AT5&>3$IHF45KY4UT;X!*K"'83Y"]>KP7OE5QD&]_;4HC3$@P*/;B/8_%
MRY#R!2":TJ$Z)Q4F,)V(VS!*3FL3WY<)8K[AF'M8L+">M#)X*MO'2DV8MJ9Z
M8[">8)%RVQW468';VP7A?A8=3SW+IA>H'TC/$]*[,-#*S-8_VRW1Z7;ZQY-Y
M6V:_SL^D^+_8VB)CK^/L,7YC 2JZH]]VCG9'54'IY@6E6]U2IA]A*6I[4OVJ
MR'5^1F5=YN'"<JB&5%H[NH7<GJFJ?*C:1/"%T@V2</ST3,^T!7YRIJ<B=O *
MTF&AH&P/O+QDOGL3^GJK.#'-CD7[M ->&$X6"PD+/-#_P[:QW/T=U3;:%G%/
MY(V-HVD1'>*^<\M8;!6/;AE-<]@M03F^630M8:^/ _=0IW@H-9N%SW-TR<+^
MA% 8T G7Z9=Z_C3_SS%)/^]WR].?)+=4+DS41S!'T=9Y#\]NF?YX2"=:+.W'
M_DQH+6([#($&(,T"?#\76(RRB3&0__T9_P-02P,$%     @ 8()\6/?P^T>X
M @  ]04  !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL?51M3]LP$/[.
MKS@%A$!"I$U?*6VD%I@V:4@5L.W#M ].<FDL'#NS'=K^^YV3)G2H]$OL.]_S
MW%ONIFNE7TV&:&&3"VEF7F9M,?%]$V>8,W.M"I3TDBJ=,TNB7OFFT,B2"I0+
M/^ATAG[.N/3"::5;ZG"J2BNXQ*4&4^8YT]L%"K6>>5VO43SQ56:=P@^G!5OA
M,]H?Q5*3Y+<L"<]1&JXD:$QGWKP[6?2=?67PD^/:[-W!91(I]>J$;\G,Z[B
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MX9(^JU"S ;V?*V6W$P[0?JA-_@-02P,$%     @ 8()\6*:I]ID'!0  ' T
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MT?\)5-: SDM)>MDO;(#Q'\KJ'U!+ P04    " !@@GQ81R+R/S\%   Q%P
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M3)G3Q+,2WIQE$#R-V#U<JXK9X/5;\+K]%CKG_D>B&]3H!N[R(>!.CA\#]A6
MJ@63\K!2EF@&+31D&+;@.#<\$LZPAC-TPODJ-%PJ0',,H&SY&!IKZ@U;:(*!
MW^\>H!FV2V.(AX']E&"_N19]IZ$S":5:,S1+P!6F+ENO-J>.E[NR1/):VO81
M[Q ![$3\44+Y1FLI(L9BA192I$BO&(R4GE@[/8';J>>W4\]MPK$020.1/'M)
M[0-\&3C2+H)#OPW.N?FQX!J>@9\A&B)-N3($OF07 H(GD385@Y:DW'78L(5B
M6.+W%A0#-QP#NV_W"4TB?L-B'E$K!J?T+Q_'5]*VC[6A(-A-'V9,1I"/\+%F
MKFFQS9A4*[XV+Q%$&L)97-U6/Y2:,=X)IG_6)X?!=!IP+,"&B& W$_DHZ<,\
M7UH!O!*?J'"^!3O!#3W!;\A/*MU[Q[+79OYN$XZ%V' 4["8I_R=7![9<)8-#
M@&]!6G##6K";M@ +@R!J/D\8FK*Y_99PJOCEI'TE;?N?T W](<_1G]U;$JZ5
MO,C@(J"-*S*A[;=)I7TW;0>]5M:Z;3@68T-XB)OPS"0KJ71Q,"?/)*I;V:^&
M][6T[4-OB!!Q$Z&2AF<[=,@*F=C:#I8XO@7Q(8;X[(\T/($\VP5 )_@]^L*T
M%&4K,GE L+<N/ND70A;,5IK*K,Q_1-<</,+_+0LS5?#9KR+)Y[":9^@SY#DB
M9V^AT^8!;Z>=ES*Y+/JH"DY>GNFRB5&/UKW:JZ)#>3 ^P>?7V#(^)>?7MO67
M)#B?DL Z$\),T:/T&I/*9O(-E4L.I#-A"S /B ;P"EGV9\L7+=9% W(NM!9I
M\;AB%#YJS0*87PCP1?5B-JB[Y./_ %!+ P04    " !@@GQ8U)M8;U,$  #Q
M$0  &0   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6R]6-MNXS80_15"711;
M8!.)<AP[J6T@L5LTP 8-XKT\%'U@I)%-A"*U)!TG?]^AY,@WAKL)W'VQ18ES
M>,Z0PQERL%3ZWLP!+'DLA33#:&YM=1[')IM#R<RQJD#BET+IDEELZEEL*@TL
MKXU*$:=)<AJ7C,MH-*C?W>C10"VLX!)N-#&+LF3ZZ1*$6@XC&CV_N.6SN74O
MXM&@8C.8@OU<W6ALQ2U*SDN0ABM)-!3#Z(*>CVG?&=0]OG!8FHUGXJ3<*77O
M&E?Y,$H<(Q"060?!\.\!QB"$0T(>WU:@43NF,]Q\?D;_LQ:/8NZ8@;$27WEN
MY\.H'Y$<"K80]E8M_X*5H*[#RY0P]2]9-GU[V#E;&*O*E3$R*+EL_MGCRA$;
M!FGZ@D&Z,DA_U*"S,NC40AMFM:P)LVPTT&I)M.N-:.ZA]DUMC6JX=-,XM1J_
M<K2SHVDS?4059,IGDA<\8]*2BRQ3"VFYG)$;)7C&P9 C<I'GW#F?"7(EFR7D
MIN+]!"SCPOPVB"U2<L!QMAK^LAD^?6%XFI)K)>W<D#]D#ODV0(Q:6D'ILZ#+
M-(@X@>R8=.@'DB9IAWR>3LC[=SYBXQ^'2?TP6_0ZK;\[-6[G._[^^_O^_N<C
MVI(K"Z7YU^?99J 3_T N_,]-Q3(81AC?!O0#1*-??Z&GR>\^;QP(;,LG)ZU/
M3D+HHZE5V?U<B1RT(?!MP>T3D<H",>X#,97@EL!C-F=R!D2[1>?S1S,(;6;4
M;5\/H^0X2?O]0?RP*35(YHU2NZW4;E#J!! TXTW<P"-NQ@9\6AJ4WH:4;C])
MDATEGE[I9J\MBJ<MQ=,@Q8^ NR*QH$L?L; MAG-9A[-OB05-W^CW7BNJ%R1V
M"]*&_-W;\V3:.]EW>-.MN]DMI2]ZO-^2ZX?)N51SI(JC!3J>&8/)6VDBZGD0
MG-UQ7/]//M;]/3J[A(,#O]'G9ZVLLZ"LJ[)B7)?.\YA=A)*S(X$I.V\D^I;(
MY=G>-.P*.@M(WF))DW4&3((\/[%'4BGC0O*#2[&\7)2D ITA<ZQD''F+7>Y
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MDX<+&6W21Q!GD911D+Y<<[;@(OF"^GP9J9#/+I*G&H]/L8[_!U!+ P04
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M B/9#9INHT7E>G4KM.E\M\S-; 9I#<S]3@A]V-CV'Z9]\A=02P,$%     @
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MD>6FK(JL#58UR)*\^1L_MQ=B+\ +#@1X;8#7"7 /!?AM@-\-F!X("-J X-2
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MA$5(&$7"&!+&03!#+,%.+(&-/K_>W*;)DBR+[#;)FYM8IH:U9)TF8D66<?E
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MIBK6VX?/WA95563;EP\B7@E9GZ ^ORO46-B^J0O8/8-Y_G]02P,$%     @
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M)E!-SGH?3SR==K\]T5:!TNR,F59A-O! X<>OV#1XG)A4Q>=E;KYL'0>K:+F
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M];\"9\'G355M5OM?WN;9=5[N7E#_\YO-ICK\9K>"KYOR]_V/<_G_4$L#!!0
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M!9 (F.H@G\\I%=L+-4!]SC;^'U!+ P04    " !@@GQ81JRUBKL#  "U$
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M(G.C<<7$:;(7WU43WY4SOCM:TF)9M,7C=#SW#'4$ML=QT' <?.?T,NA2JH[
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MF@^&!Z+JD:N!X@O;9CYQI9M6^Y@CR5 8 _U^QKEZ'9@%FO]4)/\!4$L#!!0
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MKJ<4*]6T]69@9%EWQHTTU&?KSXQ>0JBL :VG4IKCP&[0O:VB7U!+ P04
M" !@@GQ8]SE*[#@$  #;$@  &0   'AL+W=O<FMS:&5E=',O<VAE970T-BYX
M;6RUF&V/FS@0Q[^*Q56G5NHNF*<\7!)I&W2ZGO9ZJ]UM[[4#0X(*.&<[R?;;
MGPTL2<#QYJ+T38+A/\/\!C,>/-E1]IVO  1Z*?*23ZV5$.NQ;?-X!07AMW0-
MI;R24E80(8=L:?,U Y)41D5NNXX3V@7)2FLVJ<X]L-F$;D2>E?# $-\4!6$_
M/D%.=U,+6Z\G'K/E2J@3]FRR)DMX O%U_<#DR&Z])%D!)<]HB1BD4^L.CR,<
M*H-*\2V#'3\X1@IE0>EW-?B<3"U'100YQ$*Y(/)O"W/(<^5)QO%OX]1J[ZD,
M#X]?O?]>P4N8!>$PI_D_62)64VMHH012LLG%(]W] 0U0H/S%-.?5+]HU6L="
M\88+6C3&,H(B*^M_\M(DXL  ^R<,W,; /=? :PR\<PW\QL"O,E.C5'F(B""S
M":,[Q)1:>E,'53(K:XF?E>JY/PDFKV;23LP^ES$M #V3%^#H!CW)>95L<D T
M17-:K&D)I>!J%$$*C$&BI.B.<Y"G29F@^XPLLCP3F;1_'X$@6<X_2$]?GR+T
M_MT'] YE)7I>T0V7:CZQA0Q:W=J.FP _U0&Z)P*,(+Y%'OZ(7,?U-.;S\\U=
MC7ED-O^3E+?(J<SQ\-C<EIENT^VVZ78K?][)<)HL"IE%4F5QK,M)[<77>U&U
M8,S7)(:I)5]V#FP+UNS77W#H_*;+T#6=15=R=I0]K\V>9_(^^R+KH*QXC(BL
M7**<<HYBPM@/6?YVA.EG5^UQ4'E417 ["X:!%TSL[6&*^BH<#+W1L2KJJUS'
MQX[3RHZH_);*-U(]"2) 38B/J%2 *4HAD9!Y-4D64$*:"1U:[38X"&<T#+MD
M?5'H.X,.F#' "Q]JT.('1OR[.&8;^4:H8I*\OA[P(A<V#MHG&O2QO0YT7X+#
M+K,QJ@N9PY8Y-#(_2H^$Q:L&>BN7W[5<3 6*)7PFZEF-3-,Z[!.ZOM/-0U\5
M#+RPDPACJ!<F8M F8F!,Q#W(-1OE^S5$QSKH43@=SKX"XPZE,8X+*8<MY=!(
M^;=8 =.1#37S=-2I.G.-2*U%1W3&^U](-VKI1D:Z9RIDK4KZ*YN.>-2#&;K!
MJ%NT^BIWZ ZZT,:P+H3&SKYQ<LY?RM^8P8VK*ZWG5_467<O;<1H/^D]L+H6J
M,;^AZ<U&%H+3\Z;Q8BH"&LD-[H@B<S27TN[;/VSLCV;?2+XA]0=/+C^Y2!F#
MEM;MH[BXRZL3==\1<SR7\NX;-FSNV#2UX:U7Q3L'72/R>NC&T"Y%WW=UV-S6
MU>BJHSNS-.)^JR9KX\#OLO=ELCCZO8G^,WHZO&_JL+FKNP?.QVA[YG3O]VLW
M6G2-3LO^,WH[O&_NL+F[^])YYB<F>MC[FNA5M#<ED3F4_XMJ'VPDJ&V?OPA;
M9B5'.:32O7,[D(EE]4Y*/1!T7>TM+*@0M*@.5T#DUXL2R.LII>)UH+8KVOVL
MV7]02P,$%     @ 8()\6.0)1LIJ!0  K!T  !D   !X;"]W;W)K<VAE971S
M+W-H965T-#<N>&ULM5EM;^,V#/XK0O:".Z"K+>>U71J@5^^P#KNM:-?MP[ /
MBJW$PME23E*:=K]^E.W8<:+JFD[MA\9VR(?D8XHBH^E&R,\JHU2CQR+GZJ*7
M:;TZ#P*59+0@ZE2L*(=O%D(61,.M7 9J)2E)2Z4B#Z(P' 4%8;PWFY;/;N1L
M*M8Z9YS>2*3614'DTP>:B\U%#_>V#V[9,M/F03";KLB2WE%]O[J1<!<T*"DK
M*%=,<"3IXJ)WB<_C*#(*I<2?C&[4SC4RH<R%^&QNKM.+7F@\HCE-M($@\/%
MKVB>&R3PXTL-VFML&L7=ZRWZQS)X"&9.%+T2^5\LU=E%;])#*5V0=:YOQ>9G
M6@<T-'B)R%7Y'VTJV2$()VNE15$K@P<%X]4G>:R)V%&8A,\H1+5"M*> !\\H
M]&N%_DL5!K7"H&2F"J7D(2::S*92;) TTH!F+DHR2VT(GW'SWN^TA&\9Z.G9
M-4]$0=$?Y)$J] .Z3%-FW@?)T36OLLJ\G7<QU83EZCV(W-_%Z-VW[Z>!!O,&
M)$AJ4Q\J4]$SIG"$/@FN,X5^XBE-NP !^-TX'VV=_Q Y$6.:G*(^/D%1&/4M
M#EV]7#VRJ,=N]5\(/T5AJ8XGCFCZS:OHEWC]K[X*%#.5Y$*M)45__PIBZ%K3
M0OUCX[S"'-@Q3=4X5RN2T(L>E 5%Y0/MS;[_!H_"'VU\^02+/8%UN!PT7 Y<
MZ+./-*42DIA#Y80:*2&-^1(!I0HE1,HG2.T-D:FR,5HACTMD4S8?9M%X,@[-
MWS1XV*7+Z<.Q='D"Z] U;.@:.NFZTT335Y%5X0YWR,)A?V@CR^G!L61Y NN0
M-6K(&CG)^NT5-(T.<FHX&98\[;%T*(B'D_[9@6!\*!B% ]PEOA/>N EO[ SO
M=T=H*&<%T^6>H!#L"VM%;=&Z#5S#;E]O,R=H#5N!1#JKZMYEHLMK4H@U!Y87
MEIR$?6I)N7E"4\0XTN21S'.*0(@)<'%.EXQS(TT6&K"ARM-B#A=5I<?C$S!!
M*CM7HE@1_H28,NH0FL'4 AJ'= VN +KY=FOAB1)I1$L2*L%)^)WQ<BO!JA(.
M>FJ=9*7""=ID%.KXOH@"(]K8Y("T83J#I@P:J270;("-=Y;U6#EFMF2FH7E:
MG-JJN)/^8U>:)[!.*DZ:5)PX,^46$(D$(@E/(?0'Z%)7T'-JE$@*"53E)G*M
MN\GA<HH&8?]PW4T.ZMAPW!\=+CNGPZ^DXZRAX\Q)QPV5"40/[;C)N20C?%GF
MFMC <E 96]D8J" QWHDL/!WN1>^T>VS&> +K4(3#MI\-G21=)HE<P\X/60'<
MP JC2I?Y Y,2R36CUCRI07<393]#:I'A\R*QV[77AK[3RF-GZ/=<TD0L.?O7
M%"<HIW.HDPLH%*:26*/&!U&?8=O>;1$<V01CMX>O92!J&8A>TO998W5J'MLH
M>T6+?:%U66OG#OP6@P?V.GEX18M]H74);8</[)X^G"T4?5PQ68W5;:MB.@4K
MR6Y#,+B.K&QZG4Q\H779;&<3[!Y._G\74!O8;P-LA<[KE.(+K4M<.Z=@]Z!2
M3G56/IQZ1R]=GVBQ+[0N9^WP@\=O40M]MMQ77M%B7VA=0ML6'KM[>(^UT&WH
MV5KHJ66OV7R+ 0"W$P!VCP >:N'9X0\']E+H=2CPA=;]G;B="B+W5+#]/5 ^
MPY^-*3?DL8O:*UKL"ZU+9SMI1/@-JF3D:3BH"?6)%OM"ZQ+:#BZ1>W#Q5R6_
M8@BJY-C*IM>!QA=:Q6:P<[Q54+DLCPF!)/,;8772U3QMCB(ORP.XH!6OSC$_
M$0D$*I33!:B&IV/HT&1U-%C=:+$J#\OF0FM1E)<9)5 \C !\OQ!";V^,@>:
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M"Q-17;5M?X/A^6'] TKG8B*F*QI/JJZ<3\NFHQLZ:W4 81^Y*0\[@G$,9D<
MP_)@#C".86%Y_J?Q#-#Q& SS-K B Y0S0#F&94,FY0?+8^=$^K"/-(J"( RQ
M&9U,K XFV+R%(?S9U3!OP,#R0*:7S36^VGB%'*X#;$T/50@V4KP2L9'B<PV(
M?=Z $47VU<;R  -;!:QV(+\]#]24G1,$L*J8-VP'XT@480C4HKU&PQ"9G1 ^
M]O7!=DD01)$= <SN( @P!'8CCF .P .&!$'Y'-Q['GF;YY2W_4?\^ ]02P,$
M%     @ 8()\6)>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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M&^IM!'K;8+.$0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]'O9U
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MM7^@IY]02P$"% ,4    " !@@GQ8!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( &""?%@>+;9F[P
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( &""?%B97)PC$ 8  )PG   3              "  <T!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ 8()\6$_U:?S."   23<  !@
M             ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( &""?%@<1GV^00<  #HH   8              " @1(1  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " !@@GQ8'F"ZX8<$  #+
M&P  &               @(&)&   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ 8()\6,#T$)8%!0  "1(  !@              ("!1AT
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( &""?%@63%3=
MM (   T'   8              " @8$B  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    " !@@GQ8A8<"([4*  #[7   &
M@(%K)0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ 8()\
M6/BJ6;MQ @  0@<  !@              ("!5C   'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( &""?%C>Y '=, @   DH   8
M      " @?TR  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M" !@@GQ8$* D98$*  #E&@  &               @(%C.P  >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ 8()\6-W3CQ)D'0  +%@  !D
M             ("!&D8  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    " !@@GQ8AJO["[<(  #:%@  &0              @(&U8P  >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( &""?%BWM=N/#PL
M /,B   9              " @:-L  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ 8()\6'7&O'"M @  ] 4  !D              ("!
MZ7<  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " !@@GQ8
MEJ)^-0\(   6&@  &0              @('->@  >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( &""?%@'&'7<'0P  $XH   9
M      " @1.#  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ 8()\6%:+Q%8E"0  6!D  !D              ("!9X\  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " !@@GQ8"TC& " &  "*#@
M&0              @('#F   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( &""?%AR/3F)CP(  *0%   9              " @1J?  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ 8()\6 >])6**
M"@  Y1L  !D              ("!X*$  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    " !@@GQ8@'6--7H#  #-!P  &0
M@(&AK   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( &""
M?%CD+5"CE00  $\,   9              " @5*P  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ 8()\6'S:0W+3'@  H6,  !D
M         ("!'K4  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    " !@@GQ8WA+NC5D%   )$@  &0              @($HU   >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( &""?%CW\/M'N (  /4%
M   9              " @;C9  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ 8()\6+-!44:>!0  M T  !D              ("!I]P
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " !@@GQ8IJGV
MF0<%   <#0  &0              @(%\X@  >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( &""?%B-U>MBK@,  *T(   9
M  " @;KG  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
M8()\6$<B\C\_!0  ,1<  !D              ("!G^L  'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    " !@@GQ8U)M8;U,$  #Q$0  &0
M            @($5\0  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( &""?%@96Q,3MP4  *PC   9              " @9_U  !X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ 8()\6/2^KBGT!@
MT3H  !D              ("!C?L  'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    " !@@GQ8S^G](M #  !;#P  &0              @(&X
M @$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( &""?%AS
M<"]"00(  /D%   9              " @;\& 0!X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ 8()\6+PHHZ$7!   XQ(  !D
M     ("!-PD! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &""?%CH!8]/=P0  ',3   9              "
M@7X[ 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ 8()\
M6$:LM8J[ P  M1   !D              ("!+$ ! 'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6Q02P$"% ,4    " !@@GQ8A(OR(8L#   +#0  &0
M        @($>1 $ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0
M   ( &""?%CO&,CD=P,  )40   9              " @>!' 0!X;"]W;W)K
M<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ 8()\6*FT7!KI P  J!
M !D              ("!CDL! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q0
M2P$"% ,4    " !@@GQ8]SV>!64"  "_!0  &0              @(&N3P$
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( &""?%B^DQ5$
M7 ,  &<)   9              " @4I2 0!X;"]W;W)K<VAE971S+W-H965T
M-#4N>&UL4$L! A0#%     @ 8()\6/<Y2NPX!   VQ(  !D
M ("!W54! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " !@
M@GQ8Y E&RFH%  "L'0  &0              @(%,6@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( &""?%B)K;/!50,  ! *   9
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M;',O+G)E;'-02P$"% ,4    " !@@GQ8\GN'UT\$  !-(@  #P
M    @ &L= $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 8()\6*&7ZI3)
M 0  H!X  !H              ( !*'D! 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ 8()\6"BT:!/# 0  B1X  !,
M ( !*7L! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #L .P 4$   '7T!
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>175</ContextCount>
  <ElementCount>350</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>74</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100070 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100080 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusiness1</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Merger and Related Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactions</Role>
      <ShortName>Merger and Related Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Convertible Promissory Notes and Convertible Promissory Note Warrants</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrants</Role>
      <ShortName>Convertible Promissory Notes and Convertible Promissory Note Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficit</Role>
      <ShortName>Convertible Preferred Stock, Common Stock and Stockholders' Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensation1</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Employee Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/DisclosureEmployeeBenefits</Role>
      <ShortName>Employee Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpenses</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensation1</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Nature of Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails</Role>
      <ShortName>Nature of Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Merger and Related Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails</Role>
      <ShortName>Merger and Related Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value Using Level 3 Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3InputsDetails</Role>
      <ShortName>Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value Using Level 3 Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Fair Value Measurements - Summary of Company 's Financial Assets Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Company 's Financial Assets Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Convertible Promissory Notes and Convertible Promissory Note Warrants - Additional Information (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails</Role>
      <ShortName>Convertible Promissory Notes and Convertible Promissory Note Warrants - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders' Deficit - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails</Role>
      <ShortName>Convertible Preferred Stock, Common Stock and Stockholders' Deficit - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Stock-based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Stock-based Compensation - Schedule of Assumptions Using Black- Scholes to Estimated Fair value of the Stock Option Grants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsingBlackScholesToEstimatedFairValueOfTheStockOptionGrantsDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Assumptions Using Black- Scholes to Estimated Fair value of the Stock Option Grants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Stock-based Compensation - Summary of Stock-Based Compensation Expense Recognized for Options and RSUs Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedForOptionsAndRsusGrantedDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Stock-Based Compensation Expense Recognized for Options and RSUs Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Stock-based Compensation - Schedule of Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfCommonStockReservedForFutureIssuanceDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Employee Benefits - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails</Role>
      <ShortName>Employee Benefits - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Income Taxes - Schedule of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Net Loss Per Share - Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="calc-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate in us-gaap/2023 used in 4 facts was deprecated in us-gaap/2024 as of 2024 and should not be used. calc-20231231.htm 7567, 7798, 7801</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 6 fact(s) appearing in ix:hidden were eligible for transformation: calc:LeaseAmendmentDate, calc:LesseeOperatingLeaseMaturityYearAndMonth, calc:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingRightsAnniversaryPeriod, calc:ShortTermOperatingLeaseExpirationDate, dei:SecurityExchangeName, us-gaap:LesseeOperatingLeaseTermOfContract -  calc-20231231.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="calc-20231231.htm">calc-20231231.htm</File>
    <File>calc-20231231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img222477878_0.jpg</File>
    <File>img222477878_1.jpg</File>
    <File>img222477878_10.jpg</File>
    <File>img222477878_11.jpg</File>
    <File>img222477878_12.jpg</File>
    <File>img222477878_13.jpg</File>
    <File>img222477878_14.jpg</File>
    <File>img222477878_15.jpg</File>
    <File>img222477878_16.jpg</File>
    <File>img222477878_17.jpg</File>
    <File>img222477878_18.jpg</File>
    <File>img222477878_19.jpg</File>
    <File>img222477878_2.jpg</File>
    <File>img222477878_20.jpg</File>
    <File>img222477878_21.jpg</File>
    <File>img222477878_22.jpg</File>
    <File>img222477878_23.jpg</File>
    <File>img222477878_24.jpg</File>
    <File>img222477878_25.jpg</File>
    <File>img222477878_26.jpg</File>
    <File>img222477878_27.jpg</File>
    <File>img222477878_28.jpg</File>
    <File>img222477878_29.jpg</File>
    <File>img222477878_3.jpg</File>
    <File>img222477878_30.jpg</File>
    <File>img222477878_31.jpg</File>
    <File>img222477878_32.jpg</File>
    <File>img222477878_33.jpg</File>
    <File>img222477878_34.jpg</File>
    <File>img222477878_35.jpg</File>
    <File>img222477878_36.jpg</File>
    <File>img222477878_37.jpg</File>
    <File>img222477878_38.jpg</File>
    <File>img222477878_39.jpg</File>
    <File>img222477878_4.jpg</File>
    <File>img222477878_40.jpg</File>
    <File>img222477878_41.jpg</File>
    <File>img222477878_42.jpg</File>
    <File>img222477878_43.jpg</File>
    <File>img222477878_44.jpg</File>
    <File>img222477878_45.jpg</File>
    <File>img222477878_46.jpg</File>
    <File>img222477878_47.jpg</File>
    <File>img222477878_5.jpg</File>
    <File>img222477878_6.jpg</File>
    <File>img222477878_7.jpg</File>
    <File>img222477878_8.jpg</File>
    <File>img222477878_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="569">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>118
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "calc-20231231.htm": {
   "nsprefix": "calc",
   "nsuri": "http://www.calcimedica.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "calc-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "calc-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    }
   },
   "keyStandard": 260,
   "keyCustom": 90,
   "axisStandard": 25,
   "axisCustom": 0,
   "memberStandard": 27,
   "memberCustom": 40,
   "hidden": {
    "total": 11,
    "http://fasb.org/us-gaap/2023": 3,
    "http://xbrl.sec.gov/dei/2023": 4,
    "http://www.calcimedica.com/20231231": 4
   },
   "contextCount": 175,
   "entityCount": 1,
   "segmentCount": 74,
   "elementCount": 564,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 569,
    "http://xbrl.sec.gov/dei/2023": 40
   },
   "report": {
    "R1": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
     "longName": "100040 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss",
     "longName": "100050 - Statement - Consolidated Statements of Comprehensive Loss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
     "longName": "100060 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_c2ab8d40-d474-4916-9e68-da10e0f82c62",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c2ab8d40-d474-4916-9e68-da10e0f82c62",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical",
     "longName": "100070 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "100080 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusiness1",
     "longName": "100090 - Disclosure - Nature of Business",
     "shortName": "Nature of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "100100 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactions",
     "longName": "100110 - Disclosure - Merger and Related Transactions",
     "shortName": "Merger and Related Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "longName": "100120 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:DerivativesAndFairValueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:DerivativesAndFairValueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpenses",
     "longName": "100130 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrants",
     "longName": "100140 - Disclosure - Convertible Promissory Notes and Convertible Promissory Note Warrants",
     "shortName": "Convertible Promissory Notes and Convertible Promissory Note Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficit",
     "longName": "100150 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders' Deficit",
     "shortName": "Convertible Preferred Stock, Common Stock and Stockholders' Deficit",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "calc:TemporaryEquityDisclosureTextblock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "calc:TemporaryEquityDisclosureTextblock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensation1",
     "longName": "100160 - Disclosure - Stock-based Compensation",
     "shortName": "Stock-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "longName": "100170 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureEmployeeBenefits",
     "longName": "100180 - Disclosure - Employee Benefits",
     "shortName": "Employee Benefits",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "100190 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare",
     "longName": "100200 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents",
     "longName": "100210 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "100220 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "longName": "100230 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpensesTables",
     "longName": "100240 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables",
     "longName": "100250 - Disclosure - Stock-based Compensation (Tables)",
     "shortName": "Stock-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables",
     "longName": "100270 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables",
     "longName": "100280 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails",
     "longName": "100290 - Disclosure - Nature of Business - Additional Information (Details)",
     "shortName": "Nature of Business - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "100300 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "calc:StockholdersEquityNoteStockSplitExchangeRatio",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "calc:StockholdersEquityNoteStockSplitExchangeRatio",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails",
     "longName": "100310 - Disclosure - Merger and Related Transactions - Additional Information (Details)",
     "shortName": "Merger and Related Transactions - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:StockIssuedDuringPeriodSharesAcquisitions",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "calc:StockIssuedDuringPeriodPrivatePlacement",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "100320 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_45300d27-3112-43ed-a27a-f1ca2b9647c0",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3InputsDetails",
     "longName": "100330 - Disclosure - Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value Using Level 3 Inputs (Details)",
     "shortName": "Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value Using Level 3 Inputs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_d790b41b-1e12-488c-8daa-9f3b3627753e",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d790b41b-1e12-488c-8daa-9f3b3627753e",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "longName": "100340 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_45f580d8-2915-4dc7-855f-9af2533ecdf2",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_45f580d8-2915-4dc7-855f-9af2533ecdf2",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails",
     "longName": "100350 - Disclosure - Fair Value Measurements - Summary of Company 's Financial Assets Measured at Fair Value (Details)",
     "shortName": "Fair Value Measurements - Summary of Company 's Financial Assets Measured at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_7f64735a-ca76-47aa-aadd-323f69769f4e",
      "name": "calc:CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7f64735a-ca76-47aa-aadd-323f69769f4e",
      "name": "calc:CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails",
     "longName": "100360 - Disclosure - Convertible Promissory Notes and Convertible Promissory Note Warrants - Additional Information (Details)",
     "shortName": "Convertible Promissory Notes and Convertible Promissory Note Warrants - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_65b45366-3e2b-42a5-89ff-61739a51bdaf",
      "name": "calc:PublicCombinationMultipliedCashPricePaidPerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_65b45366-3e2b-42a5-89ff-61739a51bdaf",
      "name": "calc:PublicCombinationMultipliedCashPricePaidPerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails",
     "longName": "100370 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0",
      "name": "calc:AccruedPayrollAndOtherEmployeeBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0",
      "name": "calc:AccruedPayrollAndOtherEmployeeBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
     "longName": "100380 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders' Deficit - Additional Information (Details)",
     "shortName": "Convertible Preferred Stock, Common Stock and Stockholders' Deficit - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0",
      "name": "calc:ShelfRegistrationStatementAvaliableForSale",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
     "longName": "100390 - Disclosure - Stock-based Compensation - Additional Information (Details)",
     "shortName": "Stock-based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "calc:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d90f9a6-e52f-451e-b3ef-71ea2b53490b",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
     "longName": "100400 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity (Details)",
     "shortName": "Stock-based Compensation - Summary of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_45f580d8-2915-4dc7-855f-9af2533ecdf2",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsingBlackScholesToEstimatedFairValueOfTheStockOptionGrantsDetails",
     "longName": "100410 - Disclosure - Stock-based Compensation - Schedule of Assumptions Using Black- Scholes to Estimated Fair value of the Stock Option Grants (Details)",
     "shortName": "Stock-based Compensation - Schedule of Assumptions Using Black- Scholes to Estimated Fair value of the Stock Option Grants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_abd03181-4cc7-48fa-9b60-969d071a9ee9",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R41": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedForOptionsAndRsusGrantedDetails",
     "longName": "100420 - Disclosure - Stock-based Compensation - Summary of Stock-Based Compensation Expense Recognized for Options and RSUs Granted (Details)",
     "shortName": "Stock-based Compensation - Summary of Stock-Based Compensation Expense Recognized for Options and RSUs Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "calc:SettlementOfAccruedBonusAndEmployeeCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfCommonStockReservedForFutureIssuanceDetails",
     "longName": "100430 - Disclosure - Stock-based Compensation - Schedule of Common Stock Reserved for Future Issuance (Details)",
     "shortName": "Stock-based Compensation - Schedule of Common Stock Reserved for Future Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "calc:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "calc:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "100440 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:LeaseAndRentalExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0",
      "name": "calc:NumberOfContractCurrentlyInEffect",
      "unitRef": "U_Contract",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails",
     "longName": "100450 - Disclosure - Employee Benefits - Additional Information (Details)",
     "shortName": "Employee Benefits - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails",
     "longName": "100460 - Disclosure - Income Taxes - Schedule of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)",
     "shortName": "Income Taxes - Schedule of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "100470 - Disclosure - Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0",
      "name": "us-gaap:DeferredTaxAssetsStateTaxes",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "100480 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails",
     "longName": "100490 - Disclosure - Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_45f580d8-2915-4dc7-855f-9af2533ecdf2",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c2ab8d40-d474-4916-9e68-da10e0f82c62",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails",
     "longName": "100500 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R50": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
     "longName": "100510 - Disclosure - Net Loss Per Share - Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dbbe3d0-7216-4364-b69c-7a1d468cebca",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "longName": "100520 - Disclosure - Subsequent Events - Additional Information (Details)",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_75c836b2-6496-4ac1-a472-f97feb0d50ca",
      "name": "us-gaap:SubsequentEventsDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_75c836b2-6496-4ac1-a472-f97feb0d50ca",
      "name": "us-gaap:SubsequentEventsDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "calc-20231231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "calc_AccountsPayableAndAccruedLiabilitiesAssumedInTheMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "AccountsPayableAndAccruedLiabilitiesAssumedInTheMerger",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts payable and accrued liabilities assumed in the merger.",
        "label": "Accounts Payable and Accrued Liabilities Assumed in the Merger",
        "terseLabel": "Accounts payable and accrued liabilities assumed in the Merger"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r635"
     ]
    },
    "calc_AccreditedInvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "AccreditedInvestorsMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accredited Investors",
        "label": "Accredited Investors [Member]",
        "documentation": "Accredited Investors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Accretion of discount on short-term investment",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "calc_AccruedClinicalTrialCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "AccruedClinicalTrialCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Trial Costs",
        "label": "Accrued Clinical Trial Costs",
        "terseLabel": "Accrued clinical trial costs"
       }
      }
     },
     "auth_ref": []
    },
    "calc_AccruedFranchiseTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "AccruedFranchiseTax",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued franchise tax",
        "label": "Accrued Franchise Tax",
        "documentation": "Accrued franchise tax."
       }
      }
     },
     "auth_ref": []
    },
    "calc_AccruedOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "AccruedOther",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued other",
        "label": "Accrued Other",
        "documentation": "Accrued other."
       }
      }
     },
     "auth_ref": []
    },
    "calc_AccruedPayrollAndOtherEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "AccruedPayrollAndOtherEmployeeBenefits",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll and other employee benefits",
        "label": "Accrued Payroll and Other Employee Benefits",
        "documentation": "Accrued Payroll and Other Employee Benefits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "calc_AccruedResearchAndDevelopmentCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "AccruedResearchAndDevelopmentCostsPolicyTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development costs.",
        "label": "Accrued Research And Development Costs Policy Text Block",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "auth_ref": []
    },
    "calc_AccruedSeveranceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "AccruedSeveranceExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued severance",
        "label": "Accrued Severance Expense",
        "documentation": "Accrued severance expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r97",
      "r163",
      "r468",
      "r489",
      "r490"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r15",
      "r37",
      "r417",
      "r420",
      "r447",
      "r485",
      "r486",
      "r666",
      "r667",
      "r668",
      "r674",
      "r675",
      "r676"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r372",
      "r373",
      "r500",
      "r674",
      "r675",
      "r676",
      "r730",
      "r752"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "terseLabel": "Total fair value of shares vested",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r333"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Reclassification of warrant liability to equity",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r55",
      "r119"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedForOptionsAndRsusGrantedDetails": {
       "parentTag": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedForOptionsAndRsusGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "verboseLabel": "Stock-based compensation expense",
        "terseLabel": "Total",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r379"
     ]
    },
    "calc_AmendedAndRestatedCertificateOfIncorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "AmendedAndRestatedCertificateOfIncorporationMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended and restated certificate of incorporation.",
        "label": "Amended And Restated Certificate of Incorporation [Member]",
        "terseLabel": "Amended and Restated Certificate of Incorporation"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "calc_AmendmentToTwoThousandAndSixEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "AmendmentToTwoThousandAndSixEquityIncentivePlanMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to two thousand and six equity incentive plan [Member]",
        "label": "Amendment to Two Thousand and Six Equity Incentive Plan [Member]",
        "terseLabel": "Amendment to 2006 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities excluded from calculation of diluted net loss per share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r159",
      "r184",
      "r223",
      "r233",
      "r235",
      "r255",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r410",
      "r414",
      "r435",
      "r463",
      "r542",
      "r635",
      "r648",
      "r692",
      "r693",
      "r736"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r164",
      "r184",
      "r255",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r410",
      "r414",
      "r435",
      "r635",
      "r692",
      "r693",
      "r736"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Assets measured at fair value",
        "verboseLabel": "Total asset measured at fair value, Aggregate Fair Value",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "AssetsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets fair value disclosure accumulated gross unrealized gain before tax.",
        "label": "Assets Fair Value Disclosure Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Total asset measured at fair value, Unrealized Gains"
       }
      }
     },
     "auth_ref": []
    },
    "calc_AssetsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "AssetsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets fair value disclosure accumulated gross unrealized loss before tax.",
        "label": "Assets Fair Value Disclosure Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Total asset measured at fair value, Unrealized Losses"
       }
      }
     },
     "auth_ref": []
    },
    "calc_AssetsFairValueDisclosureAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "AssetsFairValueDisclosureAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets fair value disclosure amortized cost basis.",
        "label": "Assets Fair Value Disclosure Amortized Cost Basis",
        "totalLabel": "Total asset measured at fair value, Amortized Cost",
        "terseLabel": "Total asset measured at fair value, Amortized Cost"
       }
      }
     },
     "auth_ref": []
    },
    "calc_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "At-the-Market Offering [Member]",
        "terseLabel": "ATM",
        "documentation": "At the market offering."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r653",
      "r654",
      "r655"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r653",
      "r654",
      "r655"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r653",
      "r654",
      "r655"
     ]
    },
    "calc_AuxoraMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "AuxoraMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auxora.",
        "label": "Auxora [Member]",
        "terseLabel": "Auxora"
       }
      }
     },
     "auth_ref": []
    },
    "calc_BaseRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "BaseRent",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Base rent.",
        "label": "Base Rent",
        "terseLabel": "Base rent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "calc_BeneficialOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "BeneficialOwnershipPercentage",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of beneficial ownership",
        "label": "Beneficial Ownership Percentage",
        "documentation": "Percentage of beneficial ownership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r627",
      "r628"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r69",
      "r407",
      "r627",
      "r628"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acceleration of stock awards",
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "calc_BusinessCombinationConsiderationTransferedCostIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "BusinessCombinationConsiderationTransferedCostIncurred",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination, consideration transfered cost incurred.",
        "label": "Business Combination, Consideration Transfered Cost Incurred",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Business Combination, Consideration Transferred, Total",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration Transferred",
        "verboseLabel": "Aggregate purchase price",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3",
      "r12"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Merger and Related Transactions",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r408"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid and other current assets obtained",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "terseLabel": "Payables and accruals incurred",
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAxis",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Separately Recognized Transactions [Axis]",
        "documentation": "Disclosures related to transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination by type of transaction."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsDomain",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Separately Recognized Transactions [Domain]",
        "documentation": "Type of transaction that is recognized separately from the acquisition of assets and assumptions of liabilities in a business combination by transaction."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "calc_CalcimedicaCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "CalcimedicaCommonStockMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Calcimedica Common Stock [Member]",
        "label": "Calcimedica Common Stock [Member]",
        "terseLabel": "Calcimedica Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "calc_CalcimedicaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "CalcimedicaIncMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CalciMedica, Inc.",
        "label": "CalciMedica Inc [Member]",
        "terseLabel": "CalciMedica"
       }
      }
     },
     "auth_ref": []
    },
    "calc_CalcimedicaPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "CalcimedicaPreferredStockMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Calcimedica preferred stock member.",
        "label": "Calcimedica Preferred Stock [Member]",
        "terseLabel": "Calcimedica Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r157",
      "r610"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails": {
       "parentTag": "calc_CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Total cash equivalents, Aggregate Fair Value",
        "terseLabel": "Cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, Fair Value Disclosure, Total",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails": {
       "parentTag": "calc_CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents fair value disclosure accumulated gross unrealized gain before tax.",
        "label": "Cash And Cash Equivalents Fair Value Disclosure Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Total cash equivalents, Unrealized Gains"
       }
      }
     },
     "auth_ref": []
    },
    "calc_CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "CashAndCashEquivalentsFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents fair value disclosure accumulated gross unrealized loss before tax.",
        "label": "Cash And Cash Equivalents Fair Value Disclosure Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Total cash equivalents, Unrealized Losses"
       }
      }
     },
     "auth_ref": []
    },
    "calc_CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails2": {
       "parentTag": "calc_AssetsFairValueDisclosureAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents fair value disclosure amortized cost basis.",
        "label": "Cash And Cash Equivalents Fair Value Disclosure Amortized Cost Basis",
        "totalLabel": "Total cash equivalents, Amortized Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents and short-term investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r106",
      "r181"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r106"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash Equivalents, at Carrying Value, Total",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r663",
      "r748"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "calc_ChangeInFairValueOfConvertiblePromissoryNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ChangeInFairValueOfConvertiblePromissoryNote",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of convertible promissory notes",
        "label": "Change in Fair Value of Convertible Promissory Note",
        "documentation": "Change in fair value of convertible promissory note."
       }
      }
     },
     "auth_ref": []
    },
    "calc_ChangeInFairValueOfWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ChangeInFairValueOfWarrantLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of warrant liability",
        "label": "Change In Fair Value of Warrant Liability",
        "documentation": "Change In Fair Value of Warrant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefFinancialOfficerMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer [Member]",
        "terseLabel": "Chief Financial Officer"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r160",
      "r161",
      "r162",
      "r184",
      "r206",
      "r207",
      "r211",
      "r215",
      "r221",
      "r222",
      "r255",
      "r268",
      "r270",
      "r271",
      "r272",
      "r275",
      "r276",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r435",
      "r493",
      "r494",
      "r495",
      "r496",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r530",
      "r551",
      "r569",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r661",
      "r671",
      "r677"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant exercise price",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of warrants converted to common stock",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Common stock warrants",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "calc_ClassOfWarrantRedeemOutstandingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ClassOfWarrantRedeemOutstandingDescription",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeem outstanding warrant description",
        "label": "Class Of Warrant Redeem Outstanding Description",
        "documentation": "Class of warrant redeem outstanding description."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r642",
      "r643",
      "r644",
      "r645"
     ]
    },
    "calc_CommissionsAndOtherTransactionExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "CommissionsAndOtherTransactionExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commissions and other transaction expenses",
        "label": "Commissions And Other Transaction Expenses",
        "documentation": "Commissions and other transaction expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 9)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r81",
      "r464",
      "r529"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r260",
      "r261",
      "r595",
      "r686"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock shares reserved for future issuance",
        "totalLabel": "Total common stock reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r638",
      "r639",
      "r640",
      "r642",
      "r643",
      "r644",
      "r645",
      "r674",
      "r675",
      "r730",
      "r751",
      "r752"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r530"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r91",
      "r530",
      "r548",
      "r752",
      "r753"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r466",
      "r635"
     ]
    },
    "calc_CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "CommonWarrantsMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Warrants",
        "label": "Common Warrants [Member]",
        "documentation": "Common warrants member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r169",
      "r171",
      "r176",
      "r458",
      "r475"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and other Risks and Uncertainties",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r145"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r410",
      "r411",
      "r414",
      "r415",
      "r448",
      "r605",
      "r691",
      "r694",
      "r695"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r410",
      "r411",
      "r414",
      "r415",
      "r448",
      "r605",
      "r691",
      "r694",
      "r695"
     ]
    },
    "calc_ContractualObligationOfContractInEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ContractualObligationOfContractInEffect",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligation of contract in effect.",
        "label": "Contractual Obligation Of Contract In Effect",
        "terseLabel": "Contractual obligation of contract in effect"
       }
      }
     },
     "auth_ref": []
    },
    "calc_ConversionOfC2WarrantsToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ConversionOfC2WarrantsToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of C-2 warrants to common stock.",
        "label": "Conversion of C-2 Warrants to Common Stock",
        "terseLabel": "Conversion of C-2 warrants to common stock"
       }
      }
     },
     "auth_ref": []
    },
    "calc_ConversionOfConvertiblePromissoryNoteWarrantsToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ConversionOfConvertiblePromissoryNoteWarrantsToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of convertible promissory note warrants to common stock.",
        "label": "Conversion of Convertible Promissory Note Warrants to Common Stock",
        "terseLabel": "Conversion of convertible promissory note warrants to common stock"
       }
      }
     },
     "auth_ref": []
    },
    "calc_ConversionOfConvertiblePromissoryNotesToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ConversionOfConvertiblePromissoryNotesToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of convertible promissory notes to common stock.",
        "label": "Conversion of Convertible Promissory Notes to Common Stock",
        "terseLabel": "Conversion of convertible promissory notes to common stock"
       }
      }
     },
     "auth_ref": []
    },
    "calc_ConversionOfPromissoryNoteWarrantIntoCommonstock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ConversionOfPromissoryNoteWarrantIntoCommonstock",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of promissory note warrant into commonstock.",
        "label": "Conversion of Promissory Note Warrant into Commonstock",
        "terseLabel": "Conversion of promissory note warrants into common stock"
       }
      }
     },
     "auth_ref": []
    },
    "calc_ConversionOfPromissoryNoteWarrantsIntoCommonStockShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ConversionOfPromissoryNoteWarrantsIntoCommonStockShare",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of promissory note warrants into common stock share",
        "label": "Conversion of Promissory Note Warrants into Common Stock share",
        "terseLabel": "Conversion of promissory note warrants into common stock, shares"
       }
      }
     },
     "auth_ref": []
    },
    "calc_ConversionOfSeriesC2WarrantIntoCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ConversionOfSeriesC2WarrantIntoCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Series C-2 warrants into common stock",
        "documentation": "Conversion of Series C-2 Warrant into Common Stock.",
        "label": "Conversion of Series C-2 Warrant into Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockAmountIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Amount Issued",
        "terseLabel": "Conversion of Series A, B, C-1, C-2 and D convertible preferred stock to common stock",
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r46"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Conversion of stock, shares converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r46"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Shares Issued",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r46"
     ]
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debt",
        "label": "Convertible Debt [Member]",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r278",
      "r279",
      "r289",
      "r290",
      "r291",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620"
     ]
    },
    "us-gaap_ConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Convertible Notes Payable, Total",
        "label": "Convertible Notes Payable",
        "terseLabel": "Convertible promissory notes",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r134",
      "r747"
     ]
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleNotesPayableMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable [Member]",
        "terseLabel": "Convertible promissory notes",
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r132"
     ]
    },
    "calc_ConvertiblePreferredStockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ConvertiblePreferredStockAbstract",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible preferred stock [Abstract]",
        "label": "Convertible preferred stock [Abstract]",
        "terseLabel": "Convertible preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r642",
      "r643",
      "r644",
      "r645"
     ]
    },
    "calc_ConvertiblePreferredStockSeriesABC1C2AndDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ConvertiblePreferredStockSeriesABC1C2AndDMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible preferred stock series A, B, C-1, C-2 and D.",
        "label": "Convertible Preferred Stock Series A, B, C-1, C-2 and D [Member]",
        "terseLabel": "Convertible Preferred Stock Series A, B, C-1, C-2 and D [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "calc_ConvertiblePromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ConvertiblePromissoryNoteMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Promissory Note [Member]",
        "label": "Convertible Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "calc_ConvertiblePromissoryNoteWarrantsCommonStockConverted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ConvertiblePromissoryNoteWarrantsCommonStockConverted",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible promissory note warrants common stock converted.",
        "label": "Convertible Promissory Note Warrants Common Stock Converted",
        "terseLabel": "Convertible promissory note warrants common stock converted"
       }
      }
     },
     "auth_ref": []
    },
    "calc_ConvertiblePromissoryNoteWarrantsConvertible": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ConvertiblePromissoryNoteWarrantsConvertible",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible promissory note warrants convertible.",
        "label": "Convertible Promissory Note Warrants Convertible",
        "terseLabel": "Convertible promissory note warrants convertible"
       }
      }
     },
     "auth_ref": []
    },
    "calc_ConvertiblePromissoryNoteWarrantsLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ConvertiblePromissoryNoteWarrantsLiabilityMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible promissory note warrants liability.",
        "label": "Convertible Promissory Note Warrants Liability [Member]",
        "terseLabel": "Convertible promissory note warrants liability"
       }
      }
     },
     "auth_ref": []
    },
    "calc_ConvertiblePromissoryNoteWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ConvertiblePromissoryNoteWarrantsMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Promissory Note Warrants [Member]",
        "label": "Convertible Promissory Note Warrants [Member]",
        "terseLabel": "Convertible Promissory Note Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r624",
      "r626",
      "r750"
     ]
    },
    "us-gaap_CostsAndExpensesRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpensesRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses, Related Party",
        "terseLabel": "Costs and expenses related party",
        "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "calc_CostsIncurredInConnectionWithReverseMergerIncludedInAccountsPayableAndAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "CostsIncurredInConnectionWithReverseMergerIncludedInAccountsPayableAndAccruedExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs incurred in connection with reverse merger included in accounts payable and accrued expenses",
        "label": "Costs Incurred in Connection with Reverse Merger Included in Accounts Payable and Accrued Expenses",
        "documentation": "Costs incurred in connection with reverse merger included in accounts payable and accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "auth_ref": [
      "r153",
      "r190",
      "r195",
      "r201",
      "r256",
      "r257",
      "r371",
      "r372",
      "r373",
      "r400",
      "r401",
      "r416",
      "r417",
      "r418",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r446"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "auth_ref": [
      "r153",
      "r190",
      "r195",
      "r201",
      "r256",
      "r257",
      "r371",
      "r372",
      "r373",
      "r400",
      "r401",
      "r416",
      "r417",
      "r418",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r446"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Number of convertible promissory note converted into common stock",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r46"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Promissory Notes and Convertible Promissory Note Warrants",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r183",
      "r277",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r293",
      "r300",
      "r301",
      "r303"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate During Period",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r78",
      "r296"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r284",
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r302",
      "r443",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r672"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Periodic Payment, Principal",
        "terseLabel": "Issuance or Sale of Convertible Promissory Notes",
        "documentation": "Amount of the required periodic payments applied to principal."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "calc_DebtInstrumentPeriodicPaymentPrincipalAdditional": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "DebtInstrumentPeriodicPaymentPrincipalAdditional",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument periodic payment principal additional",
        "label": "Debt Instrument Periodic Payment Principal Additional",
        "terseLabel": "Addiitional convertible promissory notes and Convertible Promissory Note Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r57",
      "r58",
      "r77",
      "r78",
      "r79",
      "r83",
      "r117",
      "r118",
      "r186",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r284",
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r302",
      "r443",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r672"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities Available For Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251"
     ]
    },
    "calc_DeemedDistribution": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "DeemedDistribution",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deemed distribution",
        "label": "Deemed Distribution",
        "documentation": "Deemed Distribution"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "calc_NetDeferredTaxAsset",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "totalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88",
      "r133",
      "r394"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred offering costs",
        "label": "Deferred Offering Costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "us-gaap_DeferredPolicyAcquisitionCostsTextBlock1": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredPolicyAcquisitionCostsTextBlock1",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Policy Acquisition Costs [Text Block]",
        "terseLabel": "Deferred Offering Costs",
        "documentation": "The entire disclosure for deferred policy acquisition costs."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "calc_DeferredTaxAssetLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "DeferredTaxAssetLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Deferred Tax Asset, Lease liabilities",
        "documentation": "Deferred tax asset lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "calc_NetDeferredTaxAsset",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred taxes",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r729"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r729"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r729"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r729"
     ]
    },
    "us-gaap_DeferredTaxAssetsStateTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsStateTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State tax, net of federal tax benefit",
        "label": "Deferred Tax Assets, State Taxes",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from state taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credit carry forwards",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r729"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued and deferred expenses",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r729"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "calc_DeferredTaxLiabilitiesRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Deferred Tax Liabilities, Right of Use Assets",
        "documentation": "Deferred tax liabilities right of use assets."
       }
      }
     },
     "auth_ref": []
    },
    "calc_DeferredTaxLiabilitiesValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "DeferredTaxLiabilitiesValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance",
        "label": "Deferred Tax Liabilities, Valuation Allowance",
        "documentation": "Deferred tax liabilities valuation allowance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees Contributions",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "totalLabel": "Depreciation, Total",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r53"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r224"
     ]
    },
    "us-gaap_DerivativesAndFairValueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesAndFairValueTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivatives and Fair Value [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for derivatives and fair value of assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r127"
     ]
    },
    "calc_DirectorsEmployeesOrConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "DirectorsEmployeesOrConsultantsMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Directors, Employees Or Consultants",
        "label": "Directors, Employees Or Consultants [Member]",
        "documentation": "Directors, employees or consultants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensation1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r335",
      "r367",
      "r368",
      "r370",
      "r630"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r653",
      "r654",
      "r655"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document financial statement error correction",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r653",
      "r654",
      "r655",
      "r657"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share\u2014basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r203",
      "r206",
      "r211",
      "r214",
      "r215",
      "r219",
      "r426",
      "r427",
      "r459",
      "r476",
      "r611"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share\u2014diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r206",
      "r211",
      "r214",
      "r215",
      "r219",
      "r426",
      "r427",
      "r459",
      "r476",
      "r611"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r216",
      "r217",
      "r218"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Total unrecognized stock-based compensation expenses related to outstanding unvested stock awards weighted-average term of recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized stock-based compensation expenses related to outstanding unvested stock awards",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Options to Purchase Common Stock",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "verboseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r153",
      "r173",
      "r174",
      "r175",
      "r187",
      "r188",
      "r189",
      "r192",
      "r198",
      "r200",
      "r220",
      "r256",
      "r257",
      "r311",
      "r371",
      "r372",
      "r373",
      "r400",
      "r401",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r425",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r447",
      "r485",
      "r486",
      "r487",
      "r500",
      "r569"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Ownership percentage",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Percentage of ownership of common stock",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r252"
     ]
    },
    "calc_ExchangeOfStockForStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ExchangeOfStockForStock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange of stock for stock.",
        "label": "Exchange of Stock for Stock",
        "terseLabel": "Exchange of stock for stock"
       }
      }
     },
     "auth_ref": []
    },
    "calc_ExerciseAndConversionOfC2WarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ExerciseAndConversionOfC2WarrantsShares",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Series C-2 warrants into common stock, share",
        "documentation": "Exercise and conversion of C-2 Warrants, Shares.",
        "label": "Exercise And Conversion Of C-2 Warrants Shares"
       }
      }
     },
     "auth_ref": []
    },
    "calc_ExpectedPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ExpectedPerShare",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected per share",
        "label": "Expected Per Share",
        "terseLabel": "Expected Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "calc_FairValueAdjustmentOfConvertiblePromissoryNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "FairValueAdjustmentOfConvertiblePromissoryNotes",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of convertible promissory notes.",
        "label": "Fair Value Adjustment of Convertible Promissory Notes",
        "terseLabel": "Change in the fair value of convertible promissory notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Change in the fair value of warrant liability",
        "verboseLabel": "Fair value of warrant liability",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r9"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Company's Financial Assets Measured at Fair Value",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r129"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r74"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value By Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r75",
      "r76"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3InputsDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r430",
      "r452",
      "r453",
      "r454",
      "r617",
      "r618",
      "r624",
      "r625",
      "r626"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r128"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3InputsDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r430",
      "r431",
      "r432",
      "r434"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r315",
      "r320",
      "r430",
      "r452",
      "r624",
      "r625",
      "r626"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r315",
      "r320",
      "r430",
      "r453",
      "r617",
      "r618",
      "r624",
      "r625",
      "r626"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3InputsDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r430",
      "r454",
      "r617",
      "r618",
      "r624",
      "r625",
      "r626"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r74"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Liabilities Measured at Fair Value Using Level 3 Inputs",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r74"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3InputsDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Option",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3",
        "terseLabel": "Conversion",
        "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "terseLabel": "Change in Fair Value",
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "Accrued Interest",
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance at December 31, 2023",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodStartLabel": "Balance at December 31, 2022",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3InputsDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r452",
      "r453",
      "r454",
      "r617",
      "r618",
      "r624",
      "r625",
      "r626"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3InputsDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r434"
     ]
    },
    "us-gaap_FairValueNetAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueNetAssetLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Fair Value, Net Asset (Liability), Total",
        "label": "Fair Value, Net Asset (Liability)",
        "terseLabel": "Warrant liability fair value",
        "documentation": "Fair value of asset after deduction of liability."
       }
      }
     },
     "auth_ref": []
    },
    "calc_FederalResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "FederalResearchAndDevelopmentMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal research and development",
        "label": "Federal Research and Development [Member]",
        "documentation": "Federal research and development."
       }
      }
     },
     "auth_ref": []
    },
    "calc_FinancingCostsIncludedInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "FinancingCostsIncludedInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing costs included in accounts payable",
        "label": "Financing Costs Included in Accounts Payable",
        "documentation": "Financing costs included in accounts payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r553"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedForOptionsAndRsusGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "calc_GraybugMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "GraybugMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Graybug.",
        "label": "Graybug [Member]",
        "terseLabel": "Graybug"
       }
      }
     },
     "auth_ref": []
    },
    "calc_GraybugVisionIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "GraybugVisionIncMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Graybug Vision, Inc.",
        "label": "Graybug Vision Inc [Member]",
        "terseLabel": "Graybug"
       }
      }
     },
     "auth_ref": []
    },
    "calc_GrossProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "GrossProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds from issuance of private placement",
        "label": "Gross Proceeds from Issuance of Private Placement",
        "documentation": "Gross proceeds from issuance of private placement."
       }
      }
     },
     "auth_ref": []
    },
    "calc_GrossProceedsFromThePrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "GrossProceedsFromThePrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds from the private placement",
        "label": "Gross Proceeds From The Private Placement",
        "documentation": "Gross proceeds from the private placement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "terseLabel": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r653",
      "r654",
      "r655"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment of long-lived assets",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r52",
      "r111"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Long-lived assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r112"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedForOptionsAndRsusGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r259",
      "r554"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedForOptionsAndRsusGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r554"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "calc_IncomeTaxDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "IncomeTaxDisclosureLineItems",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Line Items]",
        "documentation": "Disclosure of information about income tax."
       }
      }
     },
     "auth_ref": []
    },
    "calc_IncomeTaxDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "IncomeTaxDisclosureTable",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Table]",
        "documentation": "Disclosure of information about income tax."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r381",
      "r387",
      "r392",
      "r398",
      "r402",
      "r404",
      "r405",
      "r406",
      "r498"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision or benefit for income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r150",
      "r199",
      "r200",
      "r225",
      "r385",
      "r403",
      "r477"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r383",
      "r384",
      "r392",
      "r393",
      "r397",
      "r399",
      "r492"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax computed at federal statutory rate",
        "terseLabel": "Tax computed at federal statutory rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development tax credits, net of uncertain positions",
        "terseLabel": "Research and development tax credits, net of uncertain positions",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "calc_IncomeTaxReconciliationPermanentDifferences": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "IncomeTaxReconciliationPermanentDifferences",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent differences",
        "label": "Income Tax Reconciliation Permanent Differences",
        "documentation": "Income tax reconciliation permanent differences."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State tax, net of federal tax benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "calc_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in prepaid expenses and other current and noncurrent assets.",
        "label": "Increase Decrease In Prepaid Expenses And Other Current And Noncurrent Assets",
        "negatedLabel": "Prepaid expenses and other current and non-current assets"
       }
      }
     },
     "auth_ref": []
    },
    "calc_InducementGrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "InducementGrantsMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inducement grants.",
        "label": "Inducement Grants [Member]",
        "terseLabel": "Inducement Grants"
       }
      }
     },
     "auth_ref": []
    },
    "calc_InterestOnConvertiblePromissoryNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "InterestOnConvertiblePromissoryNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest on convertible promissory notes payable",
        "terseLabel": "Interest on convertible promissory notes payable",
        "label": "Interest On Convertible Promissory Notes Payable",
        "documentation": "Interest on convertible promissory notes payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r514",
      "r515",
      "r517",
      "r519",
      "r572",
      "r574",
      "r576",
      "r579",
      "r580",
      "r581",
      "r582",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r640"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Domain]",
        "terseLabel": "Investments",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r514",
      "r515",
      "r517",
      "r519",
      "r572",
      "r574",
      "r576",
      "r579",
      "r580",
      "r581",
      "r582",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r640"
     ]
    },
    "calc_IssuanceOfCommonSharesFromPrivatePlacementNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "IssuanceOfCommonSharesFromPrivatePlacementNet",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares from private placement (net of issuance costs)",
        "documentation": "Issuance of common shares from private placement, net.",
        "label": "Issuance Of Common Shares From Private Placement Net"
       }
      }
     },
     "auth_ref": []
    },
    "calc_IssuanceOfCommonSharesFromPrivatePlacementNetShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "IssuanceOfCommonSharesFromPrivatePlacementNetShares",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares from private placement (net of issuance costs), shares",
        "documentation": "Issuance of common shares from private placement, net, shares.",
        "label": "Issuance Of Common Shares From Private Placement Net Shares"
       }
      }
     },
     "auth_ref": []
    },
    "calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock to Graybug stockholders as a result of the merger.",
        "label": "Issuance Of Common Stock To Graybug Stockholders As A Result Of The Merger",
        "terseLabel": "Issuance of common stock to Graybug stockholders as a result of Merger and reset to par of $0.0001",
        "verboseLabel": "Issuance of common stock to Graybug stockholders as a result of the Merger"
       }
      }
     },
     "auth_ref": []
    },
    "calc_IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMergerShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMergerShares",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock to Graybug stockholders as a result of the merger, Shares.",
        "label": "Issuance Of Common Stock To Graybug Stockholders As A Result Of The Merger Shares",
        "terseLabel": "Issuance of common stock to Graybug stockholders as a result of Merger and reset to par of $0.0001, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "calc_JonesTradingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "JonesTradingMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jones Trading",
        "label": "Jones Trading [Member]",
        "documentation": "Jones trading member."
       }
      }
     },
     "auth_ref": []
    },
    "calc_LeaseAmendmentDate": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "LeaseAmendmentDate",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease amendment date.",
        "label": "Lease Amendment Date",
        "terseLabel": "Lease Amendment Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseAndRentalExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseAndRentalExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Rent expense",
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "calc_LesseeOperatingLeaseMaturityYearAndMonth": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "LesseeOperatingLeaseMaturityYearAndMonth",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, term",
        "label": "Lessee Operating Lease Maturity Year And Month",
        "documentation": "Lessee operating lease maturity year and month."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r184",
      "r255",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r411",
      "r414",
      "r415",
      "r435",
      "r528",
      "r612",
      "r648",
      "r692",
      "r736",
      "r737"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities, convertible preferred stock and stockholders' equity (deficit)",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r135",
      "r470",
      "r635",
      "r673",
      "r683",
      "r732"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity (Deficit)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r156",
      "r184",
      "r255",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r411",
      "r414",
      "r415",
      "r435",
      "r635",
      "r692",
      "r736",
      "r737"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities measured at fair value",
        "terseLabel": "Fair value liabilities",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesOtherThanLongTermDebtNoncurrentAbstract",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Other than Long-Term Debt, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r54"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r267",
      "r687",
      "r688"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]",
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r267",
      "r687",
      "r688"
     ]
    },
    "stpr_MD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "MD",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MARYLAND",
        "terseLabel": "Baltimore, Maryland"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Short-term Investments",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsingBlackScholesToEstimatedFairValueOfTheStockOptionGrantsDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r266",
      "r330",
      "r456",
      "r484",
      "r520",
      "r521",
      "r573",
      "r575",
      "r577",
      "r578",
      "r583",
      "r606",
      "r607",
      "r615",
      "r621",
      "r629",
      "r637",
      "r696",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743"
     ]
    },
    "calc_MergerTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "MergerTransactionCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger transaction costs.",
        "label": "Merger Transaction Costs",
        "terseLabel": "Merger transaction costs"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsingBlackScholesToEstimatedFairValueOfTheStockOptionGrantsDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r266",
      "r330",
      "r456",
      "r484",
      "r520",
      "r521",
      "r573",
      "r575",
      "r577",
      "r578",
      "r583",
      "r606",
      "r607",
      "r615",
      "r621",
      "r629",
      "r637",
      "r696",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mortgage-Backed Securities, Issued by US Government Sponsored Enterprises [Member]",
        "terseLabel": "U.S. Government Sponsored Entities - Mortgagebacked Securities",
        "documentation": "Debt securities collateralized by real estate mortgage loans (mortgages), issued by US Government Sponsored Enterprises, such as Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r680",
      "r681",
      "r682",
      "r698"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusiness1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Business",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r151"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107",
      "r108"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "calc_NetDeferredTaxAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "NetDeferredTaxAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total net deferred tax assets",
        "label": "Net Deferred Tax Asset",
        "documentation": "Net deferred tax assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net Income (Loss)",
        "terseLabel": "Net loss",
        "verboseLabel": "Net loss and comprehensive loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r108",
      "r138",
      "r154",
      "r168",
      "r170",
      "r175",
      "r184",
      "r191",
      "r193",
      "r194",
      "r195",
      "r196",
      "r199",
      "r200",
      "r208",
      "r223",
      "r232",
      "r234",
      "r236",
      "r255",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r427",
      "r435",
      "r474",
      "r550",
      "r567",
      "r568",
      "r613",
      "r646",
      "r692"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "totalLabel": "Net loss attributable to common stockholders",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r193",
      "r194",
      "r195",
      "r196",
      "r203",
      "r204",
      "r210",
      "r215",
      "r223",
      "r232",
      "r234",
      "r236",
      "r613"
     ]
    },
    "calc_NetProceedsFromPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "NetProceedsFromPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from private placement",
        "label": "Net Proceeds From Private Placement",
        "documentation": "Net proceeds from private placement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "calc_NonCashInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "NonCashInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash Interest Expense",
        "label": "Non cash Interest Expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "calc_NumberOfContractCurrentlyInEffect": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "NumberOfContractCurrentlyInEffect",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of contract currently in effect",
        "label": "Number Of Contract Currently In Effect",
        "documentation": "Number of contract currently in effect."
       }
      }
     },
     "auth_ref": []
    },
    "calc_NumberOfSharesIssuedFinallyOnTransaction": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "NumberOfSharesIssuedFinallyOnTransaction",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued finally on transaction",
        "label": "Number Of Shares Issued Finally on Transaction",
        "documentation": "Number of shares issued finally on transaction."
       }
      }
     },
     "auth_ref": []
    },
    "calc_NumberOfSharesIssuedInitiallyOnTransaction": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "NumberOfSharesIssuedInitiallyOnTransaction",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued initially on transaction",
        "label": "Number Of Shares Issued Initially on Transaction",
        "documentation": "Number of shares issued initially on transaction."
       }
      }
     },
     "auth_ref": []
    },
    "calc_OfficersAndDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "OfficersAndDirectorsMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Officers and directors.",
        "label": "Officers and Directors [Member]",
        "terseLabel": "Officers and Directors"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "terseLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r232",
      "r234",
      "r236",
      "r613"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset, net",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "calc_OperatingLossCarryForwardsExpirationBeginningYear": {
     "xbrltype": "gYearListItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "OperatingLossCarryForwardsExpirationBeginningYear",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards expiration beginning year",
        "label": "Operating Loss Carry Forwards Expiration Beginning Year",
        "documentation": "Operating loss carry forwards expiration beginning year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLimitationsOnUse",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards limitations on use",
        "label": "Operating Loss Carryforwards, Limitations on Use",
        "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accrued expenses",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Assets, Total",
        "label": "Other Assets",
        "terseLabel": "Other assets",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r158",
      "r462",
      "r648"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrealized gain on available-for-sale securities, net of tax",
        "terseLabel": "Unrealized gain on available-for-sale securities, net of tax",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r14",
      "r125"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain on investments",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "totalLabel": "Total other current liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r635"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "calc_PatentsCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "PatentsCostsPolicyTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents Costs Policy Text Block",
        "documentation": "Patents costs.",
        "terseLabel": "Patent Costs"
       }
      }
     },
     "auth_ref": []
    },
    "calc_PaymentsOfAcquisitionOfBusinessesNetOfCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "PaymentsOfAcquisitionOfBusinessesNetOfCash",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of aquisition of businesses net of cash.",
        "label": "Payments of Acquisition of Businesses Net of Cash",
        "negatedLabel": "Acquisition of stock of Graybug, net of cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfMergerRelatedCostsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Merger Related Costs, Financing Activities",
        "negatedLabel": "Merger transaction costs",
        "documentation": "The cash outflow for financing costs associated with business combinations."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock issuance costs",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Commissions paid",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments to Acquire Investments, Total",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchase of investments",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureEmployeeBenefits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefits",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r313",
      "r314",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r626"
     ]
    },
    "calc_PercentageOfAggregateNumberOfSharesOfCommonStockOutstandingOnLastDayOfPrecedingYearAddedToPlan": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "PercentageOfAggregateNumberOfSharesOfCommonStockOutstandingOnLastDayOfPrecedingYearAddedToPlan",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of aggregate number of shares of common stock outstanding on last day of preceding year added to plan.",
        "label": "Percentage Of Aggregate Number Of Shares Of Common Stock Outstanding On Last Day Of Preceding Year Added To Plan",
        "terseLabel": "Percentage of aggregate number of shares of common stock outstanding on last day of preceding year added to plan"
       }
      }
     },
     "auth_ref": []
    },
    "calc_PercentageOfChangeInOwnership": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "PercentageOfChangeInOwnership",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of change in ownership",
        "label": "Percentage of Change in Ownership",
        "documentation": "Percentage of change in ownership."
       }
      }
     },
     "auth_ref": []
    },
    "calc_PercentageOfMoreBeneficialOwnership": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "PercentageOfMoreBeneficialOwnership",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of more beneficial ownership",
        "label": "Percentage of More Beneficial Ownership",
        "documentation": "Percentage of more beneficial ownership."
       }
      }
     },
     "auth_ref": []
    },
    "calc_PercentageOfOwnershipDuringElection": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "PercentageOfOwnershipDuringElection",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of ownership during election",
        "label": "Percentage of Ownership during Election",
        "documentation": "Percentage of ownership during election."
       }
      }
     },
     "auth_ref": []
    },
    "calc_PercentageOfWarrantCoverage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "PercentageOfWarrantCoverage",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of warrant coverage.",
        "label": "Percentage of Warrant Coverage",
        "terseLabel": "Percentage of warrant coverage"
       }
      }
     },
     "auth_ref": []
    },
    "calc_PlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "PlacementAgentWarrantsMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Placement Agent Warrants",
        "label": "Placement Agent Warrants [Member]",
        "documentation": "Placement agent warrants member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724"
     ]
    },
    "calc_PostMergerCalcimedicaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "PostMergerCalcimedicaMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Post Merger CalciMedica [Member]",
        "label": "Post Merger CalciMedica"
       }
      }
     },
     "auth_ref": []
    },
    "calc_PostMergerTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "PostMergerTransactionsMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Post merger transactions.",
        "label": "Post Merger Transactions [Member]",
        "terseLabel": "Post Merger Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "calc_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants",
        "label": "Pre Funded Warrants [Member]",
        "documentation": "Pre-funded warrants member."
       }
      }
     },
     "auth_ref": []
    },
    "calc_PreMergerCalcimedicaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "PreMergerCalcimedicaMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre Merger CalciMedica [Member]",
        "label": "Pre Merger CalciMedica"
       }
      }
     },
     "auth_ref": []
    },
    "calc_PreferredAndCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "PreferredAndCommonStockMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred and Common stock",
        "documentation": "preferred and common stock member",
        "label": "Preferred and Common stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r638",
      "r639",
      "r642",
      "r643",
      "r644",
      "r645",
      "r751",
      "r752"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r304"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r530"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r304"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r530",
      "r548",
      "r752",
      "r753"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r465",
      "r635"
     ]
    },
    "calc_PreferredWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "PreferredWarrantMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Warrant.",
        "label": "Preferred Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "calc_PreferredWarrantsLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "PreferredWarrantsLiabilityMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred warrants liability.",
        "label": "Preferred Warrants Liability [Member]",
        "terseLabel": "Preferred warrants liability"
       }
      }
     },
     "auth_ref": []
    },
    "calc_PreferredWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "PreferredWarrantsMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Warrants [Member]",
        "label": "Preferred Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "calc_PrepaidExpensesAndOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "PrepaidExpensesAndOtherCurrentAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets",
        "terseLabel": "Prepaid expenses and other current assets assumed in the Merger"
       }
      }
     },
     "auth_ref": []
    },
    "calc_PriorToMergerTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "PriorToMergerTransactionsMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prior to merger transactions.",
        "label": "Prior to Merger Transactions [Member]",
        "terseLabel": "Prior to Merger Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "calc_PrivateCalcimedicaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "PrivateCalcimedicaMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private calciMedica.",
        "label": "Private CalciMedica [Member]",
        "terseLabel": "Private CalciMedica"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from issuance of convertible notes",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Gross proceeds of Convertible Promissory Notes",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs",
        "verboseLabel": "Gross cash proceeds",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "calc_ProceedsFromIssuanceOfConvertibleNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ProceedsFromIssuanceOfConvertibleNotes",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of convertible note payable, net",
        "label": "Proceeds from Issuance of Convertible Notes",
        "documentation": "Proceeds from issuance of convertible notes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Gross proceeds from issue of convertible preferred stock",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from issuance of private placement",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Issuance and sale of equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r493"
     ]
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromOtherEquity",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs",
        "label": "Proceeds from Other Equity",
        "documentation": "Amount of cash inflow from the issuance of equity classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Proceeds from Sale, Maturity and Collection of Investments, Total",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Maturity of investments",
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r237",
      "r457",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r608",
      "r622",
      "r636",
      "r662",
      "r689",
      "r690",
      "r697",
      "r749"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r237",
      "r457",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r608",
      "r622",
      "r636",
      "r662",
      "r689",
      "r690",
      "r697",
      "r749"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r168",
      "r170",
      "r179",
      "r184",
      "r191",
      "r199",
      "r200",
      "r223",
      "r232",
      "r234",
      "r236",
      "r255",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r409",
      "r412",
      "r413",
      "r427",
      "r435",
      "r460",
      "r473",
      "r499",
      "r550",
      "r567",
      "r568",
      "r613",
      "r633",
      "r634",
      "r647",
      "r668",
      "r692"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property, Plant and Equipment, Net, Total",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r461",
      "r472",
      "r635"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r146",
      "r149",
      "r471"
     ]
    },
    "calc_PublicCombinationMultipliedCashPricePaidPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "PublicCombinationMultipliedCashPricePaidPerShare",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public combination multiplied cash price paid per share",
        "label": "Public Combination Multiplied Cash Price Paid Per Share",
        "terseLabel": "Public combination multiplied cash price paid per share"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsingBlackScholesToEstimatedFairValueOfTheStockOptionGrantsDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r266",
      "r313",
      "r330",
      "r361",
      "r362",
      "r363",
      "r455",
      "r456",
      "r484",
      "r520",
      "r521",
      "r573",
      "r575",
      "r577",
      "r578",
      "r583",
      "r606",
      "r607",
      "r615",
      "r621",
      "r629",
      "r637",
      "r640",
      "r685",
      "r696",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsingBlackScholesToEstimatedFairValueOfTheStockOptionGrantsDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r266",
      "r313",
      "r330",
      "r361",
      "r362",
      "r363",
      "r455",
      "r456",
      "r484",
      "r520",
      "r521",
      "r573",
      "r575",
      "r577",
      "r578",
      "r583",
      "r606",
      "r607",
      "r615",
      "r621",
      "r629",
      "r637",
      "r640",
      "r685",
      "r696",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "calc_RelatedPartyTransactionsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "RelatedPartyTransactionsPolicyTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions",
        "documentation": "Related party transactions.",
        "label": "Related Party Transactions Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r380",
      "r744"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedForOptionsAndRsusGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Restricted Cash, Total",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r663",
      "r670",
      "r745",
      "r748"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "calc_RestrictedStockUnitsNetSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "RestrictedStockUnitsNetSettlement",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock units net settlement.",
        "label": "Restricted Stock Units Net Settlement",
        "terseLabel": "Restricted stock units net settlement",
        "negatedLabel": "Restricted stock units net settlement"
       }
      }
     },
     "auth_ref": []
    },
    "calc_RestrictedStockUnitsNetSettlementShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "RestrictedStockUnitsNetSettlementShares",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock units net settlement shares.",
        "label": "Restricted Stock Units Net Settlement Shares",
        "terseLabel": "Restricted stock units net settlement, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "verboseLabel": "Restricted Stock Units",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r119",
      "r469",
      "r488",
      "r490",
      "r497",
      "r531",
      "r635"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r187",
      "r188",
      "r189",
      "r192",
      "r198",
      "r200",
      "r256",
      "r257",
      "r371",
      "r372",
      "r373",
      "r400",
      "r401",
      "r416",
      "r418",
      "r419",
      "r422",
      "r425",
      "r485",
      "r487",
      "r500",
      "r752"
     ]
    },
    "calc_RightOfUseAssetOrLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "RightOfUseAssetOrLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-use asset or lease liability.",
        "label": "Right-of-Use Asset or Lease Liability",
        "terseLabel": "Right-of-use asset or lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, shares",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, price per share",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "calc_SaleOfStockRemainingSalesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "SaleOfStockRemainingSalesAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock remaining sales amount.",
        "label": "Sale of Stock Remaining Sales Amount",
        "terseLabel": "Remaining amount of available for sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Schedule Of Available For Sale Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r69",
      "r407"
     ]
    },
    "calc_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock Reserved for Future Issuance",
        "documentation": "Tabular disclosure of schedule of common stock reserved for future issuance.",
        "label": "Schedule of Common Stock Reserved for Future issuance [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Expense Recognized for Options and RSUs Granted",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r430"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsingBlackScholesToEstimatedFairValueOfTheStockOptionGrantsDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedForOptionsAndRsusGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r334",
      "r336",
      "r337",
      "r338",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Transations",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r60"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assumptions Using Black-Scholes to Estimate Fair Value of the Stock Option Grants",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Unrecognized Tax Benefits",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r632",
      "r727"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239",
      "r513",
      "r516",
      "r518",
      "r574",
      "r576",
      "r580",
      "r584",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r609",
      "r623",
      "r640",
      "r697",
      "r749"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r238",
      "r614"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "General and Administrative Costs",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "calc_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A Convertible Preferred StockMember",
        "label": "Series A Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "calc_SeriesBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "SeriesBConvertiblePreferredStockMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B Convertible Preferred Stock [Member]",
        "label": "Series B Convertible Preferred Stock [Member]",
        "terseLabel": "Series B",
        "verboseLabel": "Series B Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "calc_SeriesBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "SeriesBWarrantsMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B warrants.",
        "label": "Series B Warrants [Member]",
        "terseLabel": "Series B Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "calc_SeriesC1ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "SeriesC1ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C-1 Convertible Preferred Stock [Member]",
        "label": "Series C-1 Convertible Preferred Stock [Member]",
        "terseLabel": "Series C-1Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "calc_SeriesC2ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "SeriesC2ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C-2 Convertible Preferred Stock [Member]",
        "label": "Series C-2 Convertible Preferred Stock [Member]",
        "terseLabel": "Series C-2 Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "calc_SeriesCTwoConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "SeriesCTwoConvertiblePreferredStockMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C two convertible preferred stock member.",
        "label": "Series C Two Convertible Preferred Stock [Member]",
        "terseLabel": "Series C-2 Preferred"
       }
      }
     },
     "auth_ref": []
    },
    "calc_SeriesCTwoWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "SeriesCTwoWarrantsMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C two warrants.",
        "label": "Series C Two Warrants [Member]",
        "terseLabel": "Series C-2 Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "calc_SeriesDConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "SeriesDConvertiblePreferredStockMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D convertible preferred stock member.",
        "label": "Series D Convertible Preferred Stock [Member]",
        "terseLabel": "Series D Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "calc_SeriesDWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "SeriesDWarrantsMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D warrants.",
        "label": "Series D Warrants [Member]",
        "terseLabel": "Series D Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "calc_SettlementOfAccruedBonusAndEmployeeCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "SettlementOfAccruedBonusAndEmployeeCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedForOptionsAndRsusGrantedDetails": {
       "parentTag": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedForOptionsAndRsusGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement of accrued bonus and employee costs.",
        "label": "Settlement Of Accrued Bonus And Employee Costs",
        "terseLabel": "Settlement of 2021 and 2020 accrued bonus and employee costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance Costs",
        "terseLabel": "Severance and termination benefit expense",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "verboseLabel": "Common stock issued for services",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsingBlackScholesToEstimatedFairValueOfTheStockOptionGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsingBlackScholesToEstimatedFairValueOfTheStockOptionGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsingBlackScholesToEstimatedFairValueOfTheStockOptionGrantsDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedForOptionsAndRsusGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r334",
      "r336",
      "r337",
      "r338",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares available for grant (shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of options, forfeited",
        "terseLabel": "Number of options, forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of options, granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted averagefair value options, granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares issued",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Stock options issued and outstanding",
        "periodStartLabel": "Number of options, outstanding",
        "periodEndLabel": "Number of options, outstanding",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r341"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Assumed in the Merger",
        "documentation": "Change in the weighted average exercise price of options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodStartLabel": "Weighted average exercise price, outstanding",
        "periodEndLabel": "Weighted average exercise price, outstanding",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r341"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Agrgregate intrinsic value, vested and exercisable",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Number of options, vested and exercisable",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, options vested and exercisable",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "calc_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingRightsAnniversaryPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingRightsAnniversaryPeriod",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, vesting rights, anniversary period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Vesting Rights, Anniversary Period",
        "terseLabel": "Award vesting rights, anniversary period",
        "verboseLabel": "Award vesting period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r339",
      "r358",
      "r359",
      "r360",
      "r361",
      "r364",
      "r374",
      "r375",
      "r376",
      "r377"
     ]
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsingBlackScholesToEstimatedFairValueOfTheStockOptionGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee."
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Award vesting rights, percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedForOptionsAndRsusGrantedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseRecognizedForOptionsAndRsusGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount",
        "terseLabel": "Total stock-based compensation expense",
        "totalLabel": "Total stock-based compensation expense",
        "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expiration period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsingBlackScholesToEstimatedFairValueOfTheStockOptionGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, options vested and exercisable",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance, Shares",
        "periodStartLabel": "Beginning Balance, Shares",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "calc_ShelfRegistrationStatementAvaliableForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ShelfRegistrationStatementAvaliableForSale",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf registration statement avaliable for sale.",
        "label": "Shelf Registration Statement Avaliable for Sale",
        "terseLabel": "Available for sale under Shelf Registration Statement"
       }
      }
     },
     "auth_ref": []
    },
    "calc_ShelfRegistrationStatementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ShelfRegistrationStatementMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf registration statement.",
        "label": "Shelf Registration Statement [Member]",
        "terseLabel": "Shelf Registration Statement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "calc_ShortTermInvestmentFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ShortTermInvestmentFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails": {
       "parentTag": "calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments",
        "label": "Short Term Investment Fair Value Disclosure",
        "documentation": "Short-term investment fair value disclosure.",
        "verboseLabel": "Total short-term investments, Aggregate Fair Value",
        "totalLabel": "Short Term Investment Fair Value Disclosure, Total"
       }
      }
     },
     "auth_ref": []
    },
    "calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails": {
       "parentTag": "calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term investment fair value disclosure accumulated gross unrealized gain before tax.",
        "label": "Short Term Investment Fair Value Disclosure Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Total short-term investments, Unrealized Gains"
       }
      }
     },
     "auth_ref": []
    },
    "calc_ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails": {
       "parentTag": "calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term investment fair value disclosure accumulated gross unrealized loss before tax.",
        "label": "Short Term Investment Fair Value Disclosure Accumulated Gross Unrealized Loss Before Tax",
        "terseLabel": "Total short-term investments, Unrealized Losses"
       }
      }
     },
     "auth_ref": []
    },
    "calc_ShortTermInvestmentFairValueDisclosureAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ShortTermInvestmentFairValueDisclosureAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails2": {
       "parentTag": "calc_AssetsFairValueDisclosureAmortizedCostBasis",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term investment fair value disclosure amortized cost basis.",
        "label": "Short Term Investment Fair Value Disclosure Amortized Cost Basis",
        "totalLabel": "Total short-term investments, Amortized Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments",
        "totalLabel": "Short-Term Investments, Total",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r137",
      "r664"
     ]
    },
    "calc_ShortTermInvestmentsAssumedInTheMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ShortTermInvestmentsAssumedInTheMerger",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term investments assumed in the merger.",
        "label": "Short Term Investments Assumed in the Merger",
        "terseLabel": "Short-term investments assumed in the Merger"
       }
      }
     },
     "auth_ref": []
    },
    "calc_ShortTermOperatingLeaseExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "ShortTermOperatingLeaseExpirationDate",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short term operating lease expiration date",
        "label": "Short Term Operating Lease Expiration Date",
        "documentation": "Short term operating lease expiration date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r182"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePromissoryNotesAndConvertiblePromissoryNoteWarrantsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r160",
      "r161",
      "r162",
      "r184",
      "r206",
      "r207",
      "r211",
      "r215",
      "r221",
      "r222",
      "r255",
      "r268",
      "r270",
      "r271",
      "r272",
      "r275",
      "r276",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r435",
      "r493",
      "r494",
      "r495",
      "r496",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r530",
      "r551",
      "r569",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r661",
      "r671",
      "r677"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r35",
      "r153",
      "r173",
      "r174",
      "r175",
      "r187",
      "r188",
      "r189",
      "r192",
      "r198",
      "r200",
      "r220",
      "r256",
      "r257",
      "r311",
      "r371",
      "r372",
      "r373",
      "r400",
      "r401",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r425",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r447",
      "r485",
      "r486",
      "r487",
      "r500",
      "r569"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239",
      "r513",
      "r516",
      "r518",
      "r574",
      "r576",
      "r580",
      "r584",
      "r594",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r609",
      "r623",
      "r640",
      "r697",
      "r749"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r220",
      "r457",
      "r491",
      "r511",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r530",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r549",
      "r552",
      "r553",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r569",
      "r641"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r220",
      "r457",
      "r491",
      "r511",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r530",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r549",
      "r552",
      "r553",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r569",
      "r641"
     ]
    },
    "calc_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock and warrants issued during period shares common stock and warrants.",
        "label": "Stock and warrants issued during period shares common stock and warrants"
       }
      }
     },
     "auth_ref": []
    },
    "calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock and warrants issued during period shares preferred stock and warrants.",
        "label": "Stock and Warrants Issued During Period Shares Preferred Stock and Warrants",
        "terseLabel": "Warrants issued"
       }
      }
     },
     "auth_ref": []
    },
    "calc_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrantsExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrantsExercisable",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock and warrants issued during period shares preferred stock and warrants exercisable.",
        "label": "Stock and Warrants Issued During Period Shares Preferred Stock and Warrants Exercisable",
        "terseLabel": "Warrants exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "calc_StockIssuedDuringPeriodPrivatePlacement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "StockIssuedDuringPeriodPrivatePlacement",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period, private placement.",
        "label": "Stock Issued During Period, Private Placement",
        "terseLabel": "Stock issued during period private placement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Number of shares of stock issued",
        "verboseLabel": "Number of options, Assumed in the Merger",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91",
      "r119"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of C-2 warrants to common stock",
        "verboseLabel": "Conversion of preferred stock to common stock as a result of the Merger, shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r34",
      "r57",
      "r119",
      "r294"
     ]
    },
    "calc_StockIssuedDuringPeriodSharesConversionOfPromissoryNotes": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesConversionOfPromissoryNotes",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares conversion of promissory notes.",
        "label": "Stock Issued During Period Shares Conversion Of Promissory Notes",
        "terseLabel": "Conversion of promissory notes into common stock, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Units",
        "terseLabel": "Shares issued during period upon conversion of units",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r57",
      "r90",
      "r91",
      "r119"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Stock Issued",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r90",
      "r91",
      "r119"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for services, shares",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Stock issued",
        "verboseLabel": "Issuance of common stock (net of issuance costs), shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r90",
      "r91",
      "r119",
      "r493",
      "r569",
      "r590"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of common stock options, Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r90",
      "r91",
      "r119",
      "r345"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of C-2 warrants to common stock",
        "verboseLabel": "Conversion of preferred stock to common stock as a result of the Merger, value",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r35",
      "r119"
     ]
    },
    "calc_StockIssuedDuringPeriodValueConversionOfPromissoryNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "StockIssuedDuringPeriodValueConversionOfPromissoryNotes",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value conversion of promissory notes.",
        "label": "Stock Issued During Period Value Conversion Of Promissory Notes",
        "terseLabel": "Conversion of promissory notes into common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for services",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of common stock (net of issuance costs)",
        "terseLabel": "Net proceeds",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r90",
      "r91",
      "r119",
      "r500",
      "r569",
      "r590",
      "r647"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of common stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r35",
      "r119"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders' equity (deficit)",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r94",
      "r95",
      "r110",
      "r532",
      "r548",
      "r570",
      "r571",
      "r635",
      "r648",
      "r673",
      "r683",
      "r732",
      "r752"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity (deficit) (1)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse Stock Split",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "calc_StockholdersEquityNoteStockSplitExchangeRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "StockholdersEquityNoteStockSplitExchangeRatio",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders equity note stock split exchange ratio.",
        "label": "Stockholders Equity Note Stock Split Exchange Ratio",
        "terseLabel": "Stockholders equity note stock split exchange ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r450"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r450"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r450"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r450"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r450"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsDate",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent event date",
        "label": "Subsequent Event, Date",
        "documentation": "Date the event occurred after the balance sheet date but before financial statements are issues or available to be issued, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r451"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "calc_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "calc_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "calc_TaxPostionMinimumPercentageOfTaxBenefit": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "TaxPostionMinimumPercentageOfTaxBenefit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax postion, minimum percentage of tax benefit",
        "documentation": "Tax postion, minimum percentage of tax benefit",
        "label": "Tax Postion, Minimum Percentage of Tax Benefit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityByClassOfStockTable",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, by Class of Stock [Table]",
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r56"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r270",
      "r271",
      "r272",
      "r275",
      "r276",
      "r378",
      "r467"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests, Total",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "periodStartLabel": "Temporary equity, Beginning balance",
        "periodEndLabel": "Temporary equity, Ending balance",
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r184",
      "r255",
      "r435"
     ]
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "calc_TemporaryEquityDisclosureTextblock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "TemporaryEquityDisclosureTextblock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity disclosure.",
        "label": "Temporary Equity Disclosure [TextBlock]",
        "terseLabel": "Convertible Preferred Stock, Common Stock and Stockholders' Deficit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityLineItems",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Convertible preferred stock, price per share",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r56"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Temporary equity, shares issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Outstanding",
        "periodStartLabel": "Temporary equity, Beginning balance, Shares",
        "periodEndLabel": "Temporary equity, Ending balance, Shares",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "calc_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity, stock issued during period, shares, conversion of convertible securities.",
        "label": "Temporary Equity Stock Issued During Period Shares Conversion Of Convertible Securities",
        "terseLabel": "Conversion of preferred stock to common stock as a result of the Merger, shares"
       }
      }
     },
     "auth_ref": []
    },
    "calc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period shares new issues.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Convertible preferred stock, shares issued"
       }
      }
     },
     "auth_ref": []
    },
    "calc_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity, stock issued during period, value, conversion of convertible securities.",
        "label": "Temporary Equity Stock Issued During Period Value Conversion Of Convertible Securities",
        "terseLabel": "Conversion of preferred stock to common stock as a result of the Merger, value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityValueExcludingAdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Par Value",
        "documentation": "Carrying amount of the par value of temporary equity outstanding. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r56"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r679",
      "r735"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "calc_TotalNetProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "TotalNetProceeds",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total net proceeds.",
        "label": "Total Net Proceeds",
        "terseLabel": "Total net proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "calc_TrancheAAndTrancheBCommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "TrancheAAndTrancheBCommonWarrantsMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche A and Tranche B Common Warrants",
        "label": "Tranche A and Tranche B Common Warrants [Member]",
        "documentation": "Tranche A and tranche B common warrants."
       }
      }
     },
     "auth_ref": []
    },
    "calc_TrancheACommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "TrancheACommonWarrantsMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche A Common Warrants",
        "label": "Tranche A Common Warrants [Member]",
        "documentation": "Tranche A common warrants member."
       }
      }
     },
     "auth_ref": []
    },
    "calc_TrancheBCommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "TrancheBCommonWarrantsMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche B Common Warrants",
        "label": "Tranche B Common Warrants [Member]",
        "documentation": "Tranche B common warrants member."
       }
      }
     },
     "auth_ref": []
    },
    "calc_TransactionFeePercentage": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "TransactionFeePercentage",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction fee percentage",
        "label": "Transaction Fee Percentage",
        "documentation": "Transaction fee percentage."
       }
      }
     },
     "auth_ref": []
    },
    "calc_TwoThousandAndSixEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "TwoThousandAndSixEquityIncentivePlanMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and six equity incentive plan.",
        "label": "Two Thousand And Six Equity Incentive Plan [Member]",
        "terseLabel": "2006 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "calc_TwoThousandAndTwentyEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "TwoThousandAndTwentyEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty employee stock purchase plan.",
        "label": "Two Thousand And Twenty Employee Stock Purchase Plan [Member]",
        "terseLabel": "2020 Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "calc_TwoThousandAndTwentyEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "TwoThousandAndTwentyEquityIncentivePlanMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty equity incentive plan.",
        "label": "Two Thousand And Twenty Equity Incentive Plan [Member]",
        "terseLabel": "2020 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "calc_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty three employee stock purchase plan.",
        "label": "Two Thousand And Twenty Three Employee Stock Purchase Plan [Member]",
        "terseLabel": "2023 Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "calc_TwoThousandAndTwentyThreeEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "TwoThousandAndTwentyThreeEquityIncentivePlanMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty three equity incentive plan member.",
        "label": "Two Thousand And Twenty Three Equity Incentive Plan Member",
        "terseLabel": "2023 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasuryBillSecuritiesMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Bill Securities [Member]",
        "terseLabel": "U.S. Treasury bills",
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_USTreasuryNotesSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasuryNotesSecuritiesMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Notes Securities [Member]",
        "terseLabel": "U.S. Treasury Notes",
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one to ten years, are interest bearing, and are backed by the full faith and credit of the United States government."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
     "crdr": "debit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deemed distribution to convertible promissory note holders",
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic",
        "totalLabel": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic, Total",
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r212",
      "r213"
     ]
    },
    "calc_UnpaidCancellationAndOtherRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "UnpaidCancellationAndOtherRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid cancellation and other related costs",
        "label": "Unpaid Cancellation And Other Related Costs",
        "documentation": "Unpaid cancellation and other related costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Unrecognized tax benefits gross",
        "periodStartLabel": "Unrecognized tax benefits gross",
        "terseLabel": "Unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r389"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reduction for tax positions of prior years",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrual for interest and penalties",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions in connection with the reverse merger",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Acquisition",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from acquisitions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase related to current year tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions for tax positions of prior years",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "calc_UnrecognizedTaxBenefitsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "UnrecognizedTaxBenefitsNet",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits net",
        "label": "Unrecognized Tax Benefits Net",
        "documentation": "Unrecognized tax benefits net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r51",
      "r143",
      "r144",
      "r147",
      "r148"
     ]
    },
    "us-gaap_VariableInterestEntityOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableInterestEntityOwnershipPercentage",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage",
        "terseLabel": "Variable interest entity ownership percentage",
        "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly)."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant, Down Round Feature, Increase (Decrease) in Equity, Amount",
        "terseLabel": "Reclassification of warrant liability to equity",
        "documentation": "Amount of increase (decrease) in equity for down round feature triggered for warrant classified as equity."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r310"
     ]
    },
    "us-gaap_WarrantExercisePriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantExercisePriceDecrease",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in warrant exercise price",
        "label": "Warrant, Exercise Price, Decrease",
        "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "calc_WarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "WarrantLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant liability",
        "label": "Warrant liability"
       }
      }
     },
     "auth_ref": []
    },
    "calc_WarrantLiabilityPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "WarrantLiabilityPolicyPolicyTextBlock",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant liability.",
        "label": "Warrant Liability, Policy [Policy Text Block]",
        "terseLabel": "Warrant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to Purchase Common Stock",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r638",
      "r639",
      "r642",
      "r643",
      "r644",
      "r645"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Fair value of warrants",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrant term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "calc_WarrantsToPurchaseConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.calcimedica.com/20231231",
     "localname": "WarrantsToPurchaseConvertiblePreferredStockMember",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to Purchase Convertible Preferred Stock",
        "documentation": "Warrants to purchase convertible preferred stock.",
        "label": "Warrants to Purchase Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average number of shares outstanding used in computing net loss per share\u2014diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "verboseLabel": "Weighted average common stock outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r215"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.calcimedica.com/20231231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.calcimedica.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average number of shares outstanding used in computing net loss per share\u2014basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "verboseLabel": "Weighted average common stock outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r215"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(27)",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-23"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "855",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//815/tableOfContent"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//820/tableOfContent"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//944-30/tableOfContent"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "65",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-65"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "66",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-66"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3A"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>119
<FILENAME>0000950170-24-038064-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-038064-xbrl.zip
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MHHALEBI#J),FS[7EG*9P68HZ+$A/7.JQ61>^NH!'NL!<@-?H$#A<YI4M/'A
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M5\H)AUFX<!E56BH)+Y6I#4 [%/Q(;0)P0UKDS ./%$/91AFA9KDC0,89V)Q
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M),D/^-)NKMU;YD/HYOGC#H:6H[8YJ4 9K5N2Y(?5]5K<>J"!/JI^!H<ST]X
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MZ?DGS(__U.C@IZ>?L&?IJ&HPW_D3NP_F?X.-2 [CRY,7BY=O1<#W+ **84J
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M*:X,"OR1+@P#/\<M])_%G$9( Q^%Q<Q+5:3\3'61K[_@]+WYRQ:8!P>EOMT
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M@DB.:4(OR!%M##.Z)9THCAE=NP4Q!=!Q6F?XB\Q3?DI:*-6_TD-KPZ1=(&O
M'YS!\HR1]H=>HH?-R8@,LVDIS.9*I=U4(6]$/_Y%TPE=\/@;Z?89HU/MB#_!
MH%8-@>9JL#/HLQ7 ^KE(H;M)(VOEP&SE'MOF\"V7K7>M4X:E]7A'32*'YIG9
M]J>?UR^99/'HA**&+(?U-P<DSIIMQE3S>+S5=<H4UMG[=^&G4"(D/&@[[&%Q
M2/1D63'#RLR3+&333#^Q@Q4):85#O X6FFR"W?+9])3]EV1>L6O>L296_X>!
ME]'413A5,V^PU]7[7V:H@_!M>=2&"K-\"VM,!33C*?*<#=Y8M)C-I\F0%<Z(
M7+OBJU@2FW=NCG_Y9?VGQKN<)B8UQKD3-W2&Z"2)')\6,5!=G?)"DL0-N)&.
M0Q"KYWF\^EC3FH/=92LX85.+3T9]I8<+6MZ>]\\BH-,Y#:. =H1M:H<^F7Y*
MTO GHV W<"W/__GN[*?UKR8M M:"UX"6$5A=I/SA64H<B1-E;!NY2TRBCZP9
M6JDR6YH5DPDMH/; X4/3+HG&QA=V3AYY[2;MYL1<8S5*$^X]2"90IHH@&2TR
MW3,(*54QL48*\M3XLY5MQ4:/=!&!&26I0CHRG3(G1Y\5DMX4[:QSB6DRB?'>
MCILY]MBW(,D^\Z;*CTA6<##.9@3#>!05S#QL,IWN_(AE60_PQ= M=AI85H69
MWM^-,3_HDFH8 >8:_1? IVSNXJ_',X55B+WS9!0J,61_4O GHV2RF1'L\PW8
M^&2F*]X&M!#O:5O-AK2?2/ONTHGX@,]=L61*"ZTL+X*%V9"(%(T+VM?H.DY;
M$/>.H=\#\AL67I#H[MW:B+_WUQ_=-P?\]//.7AN['Z4D4*FJ^-3DWO@YJHQ<
MX:)-YI<X9Z@&FE<=TVGBJ%V6W+!D:&?N[H@W2%?+IF0'I)KGXNW[)8%&_,)X
MAX7W_WX_T5MYZTO_8'M)T9*084U%I^*+D:^N0PIKM[*&.?O4JU;1XT_J>)<6
MFI(G)2RDQ$YP(!:!66ULDS;1/KIHJ]4V'0G\'MD&<CA%;N)%!KRC3Z"-^B(7
MK1$C<<$R +$"3*1];#;'-^O9LSZ[WL^DMA#4188;;J"^BO$H&6>X\6M!!NDF
M"N*3=[^M7Q#WO&,;<8X6'=+S-TA<CK)@KV$9L.]0BD'_C(L\%4C6!D[UE]-?
MUS_5G<I)+4VTBGUVRP,\3<JE\.=D15V%=)<RAB/=<:G45Y9'=F'H1YVO8 "<
MG+L>%YORTIMHB01OH4U]MK%<\W-$%APDVL0<:S='H_=+#?Z7D9<;CF$CY8T&
MISG*KIAI0%VXP9B&T-PF!<C6J+.^51?HN&AI!JLK&G.@#8(R%Y6%N<867DHP
MF1Q+]CM>8- $.2D],Y@E'12$9NQP!%#G"VT4TD"24KHLF=&KJ]B!3E-XTD:D
MJNI5>X5R/ 3\9&!4&RAUCW\^6;_4%<.#P[(""^:Y,RFK46.>86N3)O&GLX_K
MG\6.9R/<(^3]?_[\V]GQ/SZ076K^*9$%=>%'!<*K_?V=^M[E6HN!P#WYW[LO
MT:N@0U'&\+"XDE)(E>,XZ(2I"CG,,D3T)>Z&\87/1FUSAJM#,GXR]<;(P)+#
MP<B%."XBGP'=,-)F8<YIOAE2I[S?G=LW47Z<?-H L&W/.ZW$SH9DJ7!N>QQ*
M))2K0MC ,2E5V=WPEFBM?7C:=)]&L6K@!WU:_<$FNJ97W><01A?Y5( 4BDP_
M7+M0 J2'VH"3V.\-]KW9+S]\G4C\5X)?"'QT-@?RWI:F/_*$#]K2](TI37^V
MUBWOC!(HNZ@*IQ729\<(GUS#109['6_OJ -$"-3;ZP,)RL_3$&0FJ 68)Z'X
MAY"*8NX:^:J-B"5,T)0\%E)Q@;] O(W+AUBMQ4IB1C1[%ZICM5J2=L>I4KJF
MTH\6Y&WR+V2UG',"V1V*EL*26C"E;L@@L[PFFZ<[\B&\9^0_TXORQ?TEZS.T
M7@+%T \.M2%?.&,_?!(E,Y5RL>HXC SRB[O2;*!9H?[Q\4QK]_5-Y';'!C[
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M7BP_RXQ);[EA,I(P2C/'T*YDD4^7%ES9# L5*I>_FKXNA)O'S#YI/B9!F7
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M;.*Y.OFE>[#^<_76RXL92:.87)6$N\:+=/*C^=3?Q&G[\NO'AY^U_SI?S&B
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MQ*D7X%(G)^C[(\U*"(29A&6#1(/5;(*/?]'-ZI<P8ZA[4GZ43P'*0#O/CBZ
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M'LT#-FYWD875ET#\.LN/5QIC?3@WQLC+*??O"^*[#W4!-<TZC9(2IDHR/4+
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M\K+<#8?SHA7F?_&7E[(&95^%?\;\_IBI9?DDX20(6SQ9GRV9+D5ZTZI>KN=
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MBV?/OADH;*?0-H$6!KQ2GM"XEDW/ 7E8H8HHC9'+6*'Z&B"6FI%*DK<8NJ8
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M 1;K!-Q.1:)!\ZG'8%L>FA'0I=1Y"#8G =/3#M=24DD8LT2BR<(/4)JC-/P
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MMCN#A"NW*6/W(:P%:]JBB]UPH,5:C#/R%@N97W9QW*-K&C]$.- "EP4:WR
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M;N"M*ISR-U7GYO)(25<.NF6+@BGV-6:&Q8Y$V V7V;GV$:PX7KJLUH7P*:M
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M=!5'OJ8%B&HOH93=L&&A"]!^Y!&<S(K)!SOR$7E/&1#&6X@K5^HB\.,ZSW$
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M0Z3%9(]\XJD,M14)9XJ0<3-0GA5T6*:W&SA>TFBW'CWD\ ,#C$QU$\!\1F-
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MLM-T2)4/#$MI3*#B:U_J1)]YU<L-==;J&XW2,%E+\('6!;(LO-'L&5\XS@C
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M@6$\TT&N<'.??I8+NNU4MX&O\V=*5=QQ?!=N<GJ0^:XP*@U4Z6A\B%13'4-
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MN!L@3+%P(3D?V\?:TL,?'<"=BGVA'Z=>3D-J [U,:(AP O&OZT>7-(!0Y\(
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M15(6ZB$_43ML/&I]="6@?=AP2[<+1D--">J2J-B9$@1:#A<6!+:(4[GH*4"
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MEN]7^O,*98Z[]RVS:^$@CF1Q]UJ@SN:KFI#O!&X*E3S&403+4#5VI,JY#AX
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MQ9/GYL7I;=NY_'1J.J@X$>VJ"/]-7L$.P@<XJ+]LW[UCY&\PE",=KLZY-U.
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M>/.@ZWOK)AS.7 P^[T/]5,F3X3O>[/W]$HJ\.@"X<KC,GA.FJLBZ;5%!$89
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M%/<-!J^DSJZ>"(.%<C@%$K1E53#C.\'QB'JHFSZA#=4'N978I272F]D;S-Y
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M_ $$%O >([;?>N.;K62VDA&TZ\A<$$N7]N4*<GH)Y 9SX\)+*@+<W*N^&]<
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MO.O7<OREN@8IOD;0MEO[NY&))*V_Y@9($AI3^33>E'LA;2.5W*66?X6>C2K
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M#@N40'"72/)&Z9Z-PZ4QX'?QMJ'S"3:_WQ"^*Y?-VM>A8RH";!N?*J#YB-H
M,<O2/Z/,'QCS_ U*IR,Z$_U'_U/$0"8'XLIG![!$^HGN0)E!*)\3!MD93CK*
M3D T6.\Y;$!Z0X+ ,/_@P$1,"/1\@Y:,#GN<SPDYHZP^+LKJX8RRFE%6OQ%E
MM?(_WQXNLQ?L>M^9 WU8KG)5*[\1A17+9=\*4I1<]']X'_)>I 5),EJ^IVZR
M0I^ZR;:=H,HB?H ,LM6H\W"B3!F"W^E@ @>_*:R:H1\+@ZX=Q7A04J\['QNR
MP=K\="8@G"<SSV(R\X2ZKI3K\L#7'+M\NM6ZX\UI@%PZY]Z@(%W_HZ^9*[^X
M*:B02,KP1B;)#:/=F3%A-M%WFZAR!IM&^5W1UAC!$11&52Q<98L"DFW[X-.M
M)-,,7V)D5M?UA.9=$Q=Z4;F6>NF/7=%F/R"Y0V[G@YU;@O!FE=OO.;UKJ>7B
M@Q_P*)L6M<T3(7B[EP)HO%7]K/RH1:@5"Y_ 3M=BYCTR[Q'9(].U*.J6$B!>
M*O*PIYL>(LO]OF(CC%41=>5)1+0>5B%,T7*VO]G^3ML?3ZF0B=W1J,Q$=:ZD
MFC$T=?9 -/!T!$.8HU.?Z91FPSM)4#JP*K9%#,<"_174-F[G0W.VG8'36KDE
MQ,\Q'T7@X6F;"K-,7''P=[]T,\W1;%"3IZ 9L5M383(W*7# M]!$45<&(I;R
MM@268]EBK*3*?/9=0*%LIB<"I-I6@HDD)Y25=^#,V1/F1\9M-J6[#:"2,F1<
MO'45_2LHO7>-5:$JJ7QH.D #/!,WO:<&A<^QFGR.%O%'2 NBED6%*. F,5]"
MQ5K)QP7H<'RDA% ,/A!-/Z+UK]R_\;W%2W51_:W4 5TPDE%F97^8#<D))D8G
M>7,&B\0+,CIOB/MCSI$Q_9*TA>?!D//U8M8@27"/4#,?8)"*1YR<*-*)2!A*
MSC97=-G3HMMGK]MB^<;^$OG&[ZBSN]^TH'![#3CXP7[F'-W8O;"29^MCV3(-
MH_J'7QG)#D7!@%9"D5BA^\G20C0N*CFTG=+E,68?]M8=X$@#Y"74Y%<H;/;U
MUI^<"NVL7;B#LK.=UGC7W<Y?5-#IWD'Y4Y(^?\060W#]]/$5Y!_#UYOIE0#B
MY\C%-B3 & @C=->@H;ANT8[;\TQO(?&8I0'WG@M]00(?"W_&WA5;Q:GIG0R\
ML5(UU-G/_GM U"^VY7XO'GV4FHK"GB@%[OPKPPB!_*! ]ZB63(R74:8%($*W
MO\RN/G!) E/)\*=5^99_F>!/CF7SL !@>Q.R"OXXWV#G-)+E.Z6'!H)1+^=S
M$QK]=@38MNPG88EQ5^DZ*6!17OR.*^Q$!]'1>',O=XS/T+>ZSLS%3]Q1@++S
MV#@/LC%SP-3],YVC( &[B#@+/TZEJ@#0CSQ@X7Z)KY)<<ZB ]1VM&OUROVOJ
MB9M>EVT7;L;<"\A74BZ48_N&%%-YH'#2'UR]2#A6Y'*GKL:-B$E0+M\SN$^^
MS3;-'0V^Y):^Q4@M^_LIJ*0W'.9= J2AQ#0&XLDH?ZD;-C7%\US[PPO43^E\
M3Q?77^W4>VLB?@&ICK.SP+(^,K/$SZ=/S4/,(^7HU^:ZWOLM2_VMZ77SEEON
M%=1L3"?YC!W Z'JX)X8:'"%<G)B"!F61#B3@.5BG=SZF/U5*.AU!E132K0$H
MEF@.1DRNC-BUZ34N2G^#-^62C<6<Z]ZP*X' D)YELUV48D',<F+1,6S*X.LV
MER0-UX;=@(D'T+M?NPM_K]040CILIH+M$3[@V D6Z<@?T^:6X9?$U/U=Y%).
MB]&$=WG=ON!8HMQB.[)GNJ7&**!<A$4-9.-A(I%.$_NH>@\#H(U?L5WC5ZZ+
MP:[]R>@*PVS PJ\'_1(/$EC%T$0E^FES9&B_V!O^)>-%_"]/F(+@T4.H$=@W
M(G!8"0^#E0R.%3D5>-('M(NNVH&W1-%,J$DVW9Z'DWEHM?"FDD@!6V_B=X,_
MSJCILN71F_VTK#%*G!B&\*8<&)H%8$P)BM\EM7A+Z^H0: AZNL/8E#S$$?>I
MF&[;I;<J=>,XA5F@<6S'4W7V@I]*\=[GL@#@T6S?0FMM7*=+4MM2!7E1K-M!
M^GQZ #>P(R%XV3AX.OESK2$'-F)@MAN?H,H=0KM%3ERR&AN!6KVIPZA(0S=,
ML_TM?>(R,P-,JR;$4H.#OM.["SG/'Q,B$=K*[V>J8)Z>D@QL^X'CC73DSV?O
MS)#_CPOY?S1#_F?(_V]ZZE@EB9G2>[N?''%PN$*>Y%CDA+W+KD&?D9P<?U"&
M=8XQQ#D:T!_:MVG:'0VK(74:E2N.#&>:H@<84TQ?)C)F]+7.X0:ER63&L.BZ
M9EDBON?D:_I&;-R:UD]1=^2>HWL+OKY;']#.[9GS]6TOI]LN.M?]C[XMNU6Y
ME!9>^MY_J<'[\VJ/7)$L\$E/#'F:%TNR*!D[EU,K#(I06@MJ_C'K$$B4C>'Y
M?.L7Z+O3+S[GOW],!GFUW.=)02S^H)0=R/'6B1&S6RU#82(T%TP! 81%TY6"
MH*4@U*)$%"IU#Q0[QD]#@?[:W>'V_4T\>O @]V\3!87;<M6#1:2N>UQ*=F.R
MJ@!H3U[X!F6-T74G7DPH<0=:%*ZBP1?PS+KJG,DI0R.S8%&++&Y:\V!](> >
M Z4@'30L[#/U^Z#?F'RP:2]'KF0/E2"@% Z"*9$A-V^!](%;I7R9;'W@2,W6
M?<VFVMP5[:H;T@&)+-*^>&N%MD!WU/G([?^R]VY=;AM)MO!?X</,MZRU4#66
M[.[VG'ZJENVV9]IC+<E]_ R28!4L$&#C4B7VK_\R=EPR$@!9);ME\8RPUCG3
M,HL$$HG,R+CLV'M'[*-Y2>W]EWA(?A+&Z0U[6!4$4;"&V,"$<83%I&R^]MG+
M9J\%!ZR [N0:8[J%B%;H0;E>UJXL\<T/-WS!OB^X$"/&YP<J"0*O) V@3&91
MG[Y9C+^O]2*3+_E*)T'.PYYJ>@VV$P(DMJ;6!O_9\V?3&NFVS&_KIBNY34,"
M9^:Z=\6227Z4K-U=VVCF<5L@(<4D-V8&NS^O/GOQ;%64R%%\EC\3DA_Z$D7\
M>RZ!A8?<,=/QZCD;)^(8%"HE/2?"#3];/T.2@]NNJ/<C;O%,K/505^7;@IOX
M54-,2?[9C,L55P_*C$X,7Y(<#-,IJY@3?P4Y1I3H907'/9='YXP=R_9]]L4S
M3"Q;_V ^NS C'9.!'*D\>==LF7-R9M*S=-:I5(M4JC*JAI?V&;,CLSG3ZQ7O
M2C9/#INIIA=,:S$I;* 98ILE CM^'S$9;Z_N&6QQG/RG&V#?!>K?C]I@E;DG
M%[+L&&H&TC^\ AHI&=ER4Z1D;NBVB$EE&=&>=YBZM<Z]+.C< <$)+23.K6'A
M"IE>6*M#U"?@C/),<?&<@WV^NGC*#LW4',]Z\9=6=#Q7<)RSKW#V?O@PA<C'
M[N<+E*<F>:E0?J(NPU_5,V<4J_JL1!MZ^H2F&AKC9"K;OYU#+$Q[[N=D@N,9
M4;*A'Z?7,W=B=6IFMVQ>:4_S,1)OYD)HC3T@HH,RD_HHCCN0L< 8(9<G>$4F
MHZ_\:'M5<7'9+(Z<ZNWXR7@+D90=#Y7(?( M(>XP88#=E.UFV+/YE\WL$$;R
MB"63$]>K8Y&W\R$#FQ[_%;8)(_O@YD<O+A1A."1X:KORG5Z&N/G8#("543$I
MN[ XZ!OJ;02?(!=YEK3>Z\S%OBAZ?@>&58)=/[' ^(3W;S_Z)Q7 C6$5,SV#
M\5A.\RBIQ>)M5A;;Q=9\?((_*:KY]^]?G!T19^CQPRL?"5AD_*F_D#D!6I[F
MU=.C]^*NF2<KAUVPEC 4H)G]. H712""[*")'CKLA'F24AP4VKI1DJ5SW0-J
MF^9Y31,RTWQDB-6-4#N&B\\/9X(@U L?13ADZYT 9D?1L7JHQ0 STK)1(IP*
MLP7?D6HR4^51QWJP%$R-:!@!I#W?PF7>Y[]PTFBNA1@\:2,^TGS& \;8]%W/
M.92)5;"DEG]G.?08%&VS;IM\J]FB<^?6Q$=VX.C5#^&I&_BC<V,IW$G34M+V
MA'&79'1%229Y;[1"Y*W,(!*!8>WZ)%H 0(@4>9T,5^%>AUS8,6ZT'$EJ!IRD
MD]HD3OP'T2P*%:V9:LJ5!ULOD6.Q[1+$B %I3R8-3T?\M430876UQ(HWB?5Q
MV")I:BE:!>B6+(Z=Z['4KF[-99$#_!BS6OH:IA?RL8'V4JQ^!ESFX8D%"7?
M.X[@L[4*#68HM+'5/6D8.84_F.DL\=%1_4MS3*L:>)W-")MQ08?F @#XL "
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M[BXO*QDLW?3Q"Z8GB?DE0 @Z!2&]S@6%TI^6X_$*N4J$&M*0<LK9.)M[1A#
M$!*]&%7:MVOJ6TJB%E2YJ=@;A:8+UOLHQEK,XO]LS[KD,$C08(%5K24K!_0
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M0S /MZ";VM,6$FXE3")KR3SZ.L"3$S\5A($88!@>I 8FE/AB1-SWS^(?C$)
MC/P834DY]9]&@U5Z6]QH?$4FIM(/@^]U:$J3K:/%!&L84]1D%UC9G6>^%G-&
M\982]8DW@D4M) ^V3D?QO"Y;_W;&0TPAVVQS:S4P!(08;0$81?>NW&L97_I]
M]$^4 ">ZFCYCF?B:)P2SQ9X>AK #-IS'/IP7J T>J"5="-:B9RNFHNR00XI
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MTRNA,82_K(?M;;&(HGTL!X?B#%KO?C-8$.6Z(AC-6RCNZV0A.ZU+A-.M>_R
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M;)^P79_LM!7H!X%$@1X@VY'-H$5]1'VZ!J'#<PO Q-V! Z;QAHNT_6C%:'C
MC+ZJ)47E#U)/I>Q' PAROJ=:*%G2LN\<@B-_T+K^-C^&)7"US8\>S5$Z5AM!
MF>2^L\M=6)3SFEA>94BNY Y<]>HBDP5+Q\<'Z/CXP]+QL0B$?Q@J2 6NF?A
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M!7BR$05,5]P:MR,J&@G=03;#!Z-1 M-8*:^9:&%9:825WTS:VXEJ[\*)0J7
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M1(2E!'LHK<AK!Z8LT@E&-R+Q#:+\-F)?VO4\$7S"EP2IW=/"$TA@6&^B$D.
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M>UY!+Y&Y5I2H3!$))0XL/J22LPY\RM:<63!XS6.59^(_J\Z8L!IEBC:GT\.
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M2!W5:(;4<0H+K*$;/V%:5^L;YI8_QOOB3O^XY.Z:_EI(<:4C^;-0DH*7/SS
MYQ^OMC3 (^1YZ'-O@AL9JL+-@(FKO:/&/@$PPXJ$.^]*F5/K+G*N\I>7KYX^
M5<TDP"IC/;U4V)0L;O';IBB"1W_^^9_X!%55V >;!VG2Y"C-\IF:*PD65T[H
M.%89-@>M73%8IN0<4@ET];:N5J^YMT%5_O]'?,#83@^\(]D7,8"/<A?)_AJ?
MI9G.5:K@<J*JX'IK!2UC2?XA/ J7B\A/(W@&<C"_G([#@HIX7%3$BP45L7 >
MO>M1@>;\;SCG);4?UR4$!QI2&G@9RL"Z<""R(E2<P_CXQ<?9*80O<ZP2R'>H
M\[K<<X"*Z--Z,WGP8L25*%%LL3^XH,M$3UV2%L<+4Z?,.+E>]*-;QH_]^+?O
M$ZGB/>[:GMD51M&'2:^8<JCGM18(H8G,2%M^&*H)DNX/&O%RFB%Z0HQQK=48
M&YI;'[64B2,JA.?A#O*E:?QT2N8$S=GT!MSN3B .QCFYO7V(O3!,*"5)3,O%
M,(B0NS4M$2<82I6D[XCN #_*18@TDF=,B<=)D&PLZ)<IJ& =J=JEH3J@3IUM
MLCRH4)"VLM:Z)2AZ=[#(,T)A\ 7?&V:$2GF6,>5*&;8!32B/Q4H?6'&G[:E7
MQ;<S5@U9%PBAA*M,&;%7+5-W9!"#YGP(L\C"82UUAI:\HG+G2Q374(%A9EHZ
M[&P&8SM6_&5W/\EH_C<#"<F%'_]7C4*N;3Y&'GB;!UZ+V>4?/GWNYO'CR+M.
M'VZE4"65REJ+7<R%MI-C20X%MG\_ P C)DT:.E<V+2D$X)'^-?XBPU_"UH^_
MP%6+7++]"'%4C17&C:2I/ .E^O+9=;GK^28_TFVLO#BO5S_>'#O"I=<A8I#=
M_'H@ $B-8M^?77O>MKLA0]*3EIKO(4 0E+FD[MJOW"DZYB)A59>X8?X(+;2\
M34>8(M7RKLT' =JM0<;F;2M+X3UT5G&Q'Z6MV4-W3N,/(CAW?!>1=9*GZ1#X
M665T-V!&FOX"\C-DR\R9A(E?8G%!"W)'/;94I^E]#'<NQ"N/NB__,9KS-DR5
MEZH2M@]4O*GR@!)]N:<65-M45N\CS"TU$K:Q;IN4;.1 D,ANYEP0)E214Q W
M^D[\)3\,4<^#:V5,O=VV5/!BGPJ+-FVFLKZEMM@U'46 5(V7(9O,QF\E78GL
MFM"T+$37;-TV^;8ZGMGB#]^W,6(6?"XFG(POT:-IDV?DRT2(8>Q"V2JJHD4F
M"YDI@0RT#X5)]@32EX]<W/#X!D?\-(SQM=8/"Y[0TY*OB7(F?[V<D\K5>V03
M4X&%/,*++_^4UN)&_F"V[ 8\P5?8^<]*HK#YZSH/"QU>X,1'Q#LD]_/%GY[0
M:7QZ]<5G+YY_\>7GG_[EQ2=??/K%B\_BHY<UW?TSK,"91Y8B]^=6+7(+RS]"
M>CVCJSZ-4_3@UY<4Q_V?<O-F3>)YKVU. ]LF[(2;<EWVK&W.<K@0$ Y?(FA\
M2);F$39O:B 017">'"N?LQU /KV@@RGWQ/]L*'0%\I!Z54?&!%.:N!]JP<QG
M)DB\DD%/E2>F>$'^>2/_FS49B<X7GUV]*0FI3U"+&JK?8*%">ER4UG;G*7@>
MY$;EW^:X=Z3RJ(+6TFS*%#W;CL\%^3IA-2&\S3R/FD*0?\P8.$Y'"]\?^5_5
M;\GMU4QA>9GT);JT(A=A0V5,M-EG]46[UVE4OYPZCVH@>/7BCAR6%TSFCNHC
MWBT]'5@64X&B62MBQ O5^/ +HROG*)[1__"._$0",*)5X?.8>N<W.K0A)_$Z
M@M]=5U"_8.]:#J/P.3Q'RY%BOJH'Y$NBX#(@7:,RZ"&R]+I$KLMW= ?MFJ('
M4<4%(0*1NC&[@J,UTUI&TP'R0B8M:EC2]7(_DEP9QT=8I8;F=K=M?E?3M+]"
MD",W=E45U[RV0O*+PDNT>ETB;#E=GFYJP5P:=6\^YF>4BP+Z3W(SN]PF&M@F
M3 /,!?XV1,%]OJ,*1P$/LSM*Y2D^/_9,?/HQ!?[4"5EUN"[X:1G)Q.KPY(>J
M8GM=:$779JT<"!9+A9N]+1N4CDO4IH0 0:Y(*\18TEP^%^XHM@:H+1"; \NA
M^L$=JD9Q OX?Q,LM. '"^1&<8#"@*B_WG1)W.S_.W_@6'WK%'[I0;N9O7UT
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M3!:*W#;54".U=9<CFJF"^=Q4O($XEF[S]%>-C8HZX$-UG?=1TF_:L.=PMJ%
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M -&^;=.F/0M&5(;'[@G3F<5?).;(K6X7T$C.!3A*GI,R#,BW5"\\V5:4<X1
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MD+\IX.(1:*&3D1ON9,LU9N<KKE9_$ZD0+IPU=S14<RN2=>$L(JS=ED#L%&W
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M44A-S6\QM\7<9I-A B2Z)-41N9/HM0EMIYI1V>K7)ECLBL;]@4B83ULC-:'
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MTQ;$B95)Z$+IDB"VR#XTGP?'">7=+>A/M@G?F5/ !I,)L<,TN_ #3(0RU*E
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M@%MNW[#(1$5)H\YU0]0 +*21DNK!7/J^F59KE.V@]*;EM*H0CE.+'1!)(K^
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M'6%899B14VPE(Y,R$.4'6X-92WV;TQ -4#!#D2-2%"U#D:EZ[>?2,:3<S(E
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M<Q$CU[L2VYOXWEF0!&%@4K_M-\#F&49"VUC8)2N8FBDW?HV/5GY$7ONJ:57
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M8#I7Y]SR.C2E6+ 2[;M%*\^?N]+P]H[]T^O]RQ=< ^.M8&1;!8C53K2R4<4
MC%.<Y\,SZ&@,W33-<YI50ZTM<"Z='-Z-TPV0B&(RB_[%ZF]ATG];NFC?'$71
M4KU\B6J,,N[9JJOIE/K:I(96JS7FQP7=T@#9ZGUES14&\" ;D[,IU21+30Y2
MM9IP^&@B/\'\0U;N#80IWI.[93 -9U7XZ48(N$/&&EAKB1ZUPYU3?[7F!YQ6
MYP?4>Z=NY/YW>SX&=G9=80($M5*$/UO,%RV.>H//4* 1$E6ZDEM26*_& HN'
M*Z#3!G@%2TG9\:/" V)Q15:0[BO1[$WD#)QLFE+AZR0H@-!AG7$)QS<V%$A3
M6+6PIS?@-]1WZ>_ V:@3=DM]DSKP(0,Q?28B:]S6K4*B[9U7(:7!R?D=36U0
MN0%Z0Q]4#5<M]?7:QIB]!AM>=5BO'M4W6I8U;LW<40T!]$3CNE*X"M+8LA%C
M7;)^_GNAYZ+B&(>\KA$9%]]*C8EJ[4"L7^H3.#A_VE+IZA#0JC!-%JH/YN!!
MK6I1.?LDCKX)UG2HJ:WYM=9H2VJ$*/R:E$+\/"%ZM0Q"7PNA("N""E-K<I<\
MI=+?1CI>9":4\M0E\5UZE.*(YS)E92Q7O7AW5A.@[ F0N;\I3A4D73DO>003
MT/DD*B>JUA)[MU O+Q4/N-/($R=,-3NFR_Z0D,-P3\K/EYO3KF;WA*.>Y4,W
M(EG;2V.1[D4ON9$A]D@B&:2]MJ,@RCQLHZ4C$M7)D^DD OK(9CQG\@TL!6OQ
MZ[JD;GX-.1X7B-BDC]*'X75XG_>+D^8;#/N[$UKW>%M&(<B1!]8<!.!3CO/8
MDR) #\E-O[=_DFQ^MV!0*&(<_$?/Z?8;R[Z^DA=.A3YSP0T",1../1N*'"PM
M:(_8#EC6<+WYRWK?C?N![]Z^Y07 ^V'N93RRC"_/)QT$99&^D7YVW NZW6'W
M^'@K#F9@W<#RWT7XAC]UTFEW?E;/4_KT-!>O<P$T!^J1@@*E0/#2/^'GX?LZ
M4G =Y1%/Z'FMWI</P5-A-7Q_T&ECD@('$1I^[[9[O64_+_GMI-T]ON^[[K/V
MS_![QSSPEU=%5K]R&=Q!$3P(AM^N,K#API9D'B/ZOV;F<0-XQE&EUQQ;PC\T
M8 LI(\,@E@3'1-@DLAH$X_$C47ES?*[Q6'<(#!7ABH=]VL.M'!Z[Y]$ %_"7
M__[I\*?EQ]01016YG8(1GL91Z"DIM FW?A_%81'D4'UA[>4O@^S57VT-YGZ8
ML@2$3(N=_D8 T9'.W4CGP)%.W18@&[0)<DY*.5)[ *GU'*G5((>VM!-'CD8<
MC2RED9ZC$4<CCD86T\CI!..[CDH<E3C*J$+KYSO:,>0_GC=DAD &H^&C&C(
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M9*%!L2O@'949::ZAR(=9- #-8"#B],9'$ _C%,W1 ,WW:[#F/!#L<!/PKE>
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MY=78S#6&.X0/I D/0:X@XBC*0&VNGNNW] :]/7[E]NYY%-#P%X Z2-!PH&_
MI2'.P>I)&(4!V@3J#)FX N@6:"P0ZL)W?5@TX]6CAL6G99:3B:3<0;"I$,#
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MG<$4S%,4&L9@L@U8VVY5)F;=;M5[8=D<1M<"5>DD**00U/;L0!!_4[Y=9ID
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M52I95P2<G6;5P*8YP#%46M/MUD>#\<'M/X!HD"_OC5[N=5\BN_M";02($5X
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MS+"U*N:!WN@YLI^J QJ^R)D+%\9\AD> ^K)=#C6N*,E[]Y7DF\1['XA%:TQ
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ME!X3[F [?S!'=>X.W1VZ.W1WZ.YPU^]0)BUOTS7>EC*^E4K\0TK2VUT 9O_
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M"-8$^8< ^.FI\Q&@V8#:"J"$T>K[<KNXM==!6:1O)#AP1P@=.  ^W@*\3DO
MT.B["-_P![N=3KOSLWH!D"0.IKEXG8MID 6%4)#(".BT]D]UZW@0#+]=96F9
MA"V)9"/Z/S[R#=_7((W#-]=1'@VB."IFK]67&@QFWMAA^^3DY&>)%@V_=Y?\
MUC^!EWOW?'G_ 1_N=N#EX_N^W&OW[_WR8;O?O_>N>^W>D?GPDB#N\2/'<)G
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MA!#HY^X1JL<753%,.!0M^@8L#!7=MVBHEQ%0KX(#( P( ZD## %#P! P!,*
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M5]NX_GXPF]M30Y:G6[*_ZTL,LCR=,AI=909D>;8MP$_;Q[4&@]'3$!9X ;P
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MM&>VI:#6VCE/K".&TQSEG 7"J*4H;K9%7+A,*Y=2I1:.\6B+L%:GD,>V>3S
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MU\VI553<@[;R*9%$$S(MJVCHR;B<!XGQ7:+J#Z\>+T?!92@GLU'X1]-'9?@
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M41DE.CI]A@G$LUP@I:1#E#MKB"7*9KA-5?BX,>N$D('$<!YV'\0&M"-HQX=
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M[0(GD!Q[N=97O>,3GAWRZB:B<D2+G43YD%=WY]0$2T&A5!;DH8FPD!JPLB3
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M\NHF43ZBQ4ZB?,BKFT3YB!8[B?(AK^XC1/F'?C*>U"G#I3*8HAP04RI \]P
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M03!C")1:B]R6"FFVT5P<YQ8)PPW +/>5-74!F,YS4%JE2R0A(A(^&P2S"7I
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MU&4]LN&F77R0RWIDPTV[^""7]<B&FW;Q02[K00WWR;, PSBJF78O$N_XD+3
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MY)@4;"=@Z-NN7=13-\]M9)^[JOV8 #$!8@+$!(@[ L1<*&T+3  O2E](!"'
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MU'PE\'>=H/T:Y6Q7(9 ('M3)<60[.N'5(:_N[GNM:2(%@QI@3AU>B<(":;$
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M9!-:)G/('MCS'T+Q7P>'KV;*#;PUV0]NUX6??/W22.U]3]3P@V^,^L7MWU0
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M9/3]V??I,W-1K4)]0Y1#[=O79"$2:+;P5-<DQIN .P'WSNO68&FA8"6 .;&
M^FHT7*(<0&V88#A7F)%',]Y.PON(O-.9#MVISJ)TGP;AWI4]=P)YXKN)[R;8
M3+"9^.Z^\=UDSG7W.;TMWVU:"5E-0Q>71'<3;B?<WBW=59:Y/24+P&AN !6.
MQ$I)2F QHJP0I"SU1M7W[Z:[-Z:D_+82[B<S^.()SE,\0R+ "4@3D"8"O&\$
M.!E\?[Z>Z>;SVKZ*IA&>$J?TM831":-W1'8%$[D1! $M& '4<@IX[OX))2.,
M&:X%WJ@7^-UD=YR[=H;_NQ/DS_4HIG=7=<0I3KPV\=J$F0DS$Z_=,UZ;#+L;
MO':]2D-]6;5MW5QELWIA$L]-F)TP>V<\EY9,88M*("@L =78 B&U 3G/D6)&
M&UGNF.>N1/OC(-GOO6 _!>\E$TR?L ?G 9U;B?DF%$THFIAOLNCN*_--EMZ$
MW0F[=]_P%^>Y4 4#&)L<T%(9P!TK!I8Y>EMB"R7?Z#[Y- SX*0W C*;R98D&
M)RA-4)IH\+[1X&0 =O=Y6\W$3%6S<W?4=@TQ;NQRD0AO0NF$T@\N4"8AHM9P
MD'.M 466 ZD+!!3'&C(MN)2/+U VB'-?EWY[R?E=A3<D&V\BMPDV$VPF<KMO
MY#;9>-U]5AU_H\4VG'IM-C.+K#6+1>R%FEAM@N<$SP\NQB!S8K2@@*.R!%11
M!B2G!I@"$@8)I8SC1[/:E1P'V^R?7HK?F\6G08;OSV=;-S7NISM+[):)V29F
MFZ S06=BMGO&;)/9-C!;-15M6UDWBD47P]#%*0SU&*Y\P(+Y]]+]E#AN NH$
MU ^VW!)>% (;@*CA@/HR#-R4&.A2%<ABSI1^5(G=OJ=:%XCPIOXZ^\,CWELC
M%LO&O)LI!W"M>6/BW^]FOP:ACAW7=M5KS;UFHKR)\B8D34B:*.^S4%[WM_?%
MA1^?\JU7&^A.*!@]';NGW_K ^X[[989WCZU[[5T>,MC/%R9$25RZ)U_Y((J8
M*B<:7R$MJ]QEYXV89G/1]+W>6N.)0EM/*RV\7=I&AZV[J%VX#T)E_9-^]IY_
M0-FUA=/5EV'IIN8;T%43VYO_Y-YG>3G[65?M?"JN?O*__7DNM':S,"S325[%
M1W4:7?S@G\MV4=FK_JGAJ\#,M)/Q;_[UW1U^&L3]VSUE^N[]NI\[Z"UXN<5F
M:^CDECHL^<6@A\_%N8DJ-A#6S=!/8OI57+4__^5OU_=&O_!!D+>O^F,6]^FU
MR:< OM64[B_\?8U+).NIWL6..CO][>S=[[^^>7=V.LG>O3\[>8%S("AM 8?_
ML:C_X=Y-^PK.^A\#TOYCA;3[,6OO^_SJL_')\/8QP+#C-QP.J4_#U-UR4-S_
M>8/&_7YY:9I*]=FQ!/,280UR6B! 2X@!LP8!3"5!O(!,<+T+A?M]T*\_V ]S
MTP0S6ON7S#CM>>ZN631+\_1'3W<6[HGXHI,L3HDG*[\LVVIFVO%"WV<VBM<V
M&?%2_ZB?JH5[$77C]+QQ>Z.IYKV]]?H$[<$"9EL7*TQQY7%P\1,]R0GYZ_5G
M[<7Z/?+H$5-5_6ZT4QW=T3-3)]D/7@?%\.?1;\(GZ.>L;D)YXOZ"R-^[7_Z8
M_6#_]J^_B:%[\]\KGT 4;_IC]E6$(.FZF==-P.FNU'$X5/RV>&.FXJO7 -PO
MWAK9+$5SE6&(\DEFZ^FT_NKU!/\-M9:!V#UMDOWVV]DD<[.D+L*SZN9<S-S,
MA ?]+L*MT"048+[PK^+#LQOW0M7<P7,] )F_^C>1_5_W1#<?;@HJ6S>S2IQD
M7F?I1IQ5OA>UFE:SH'"[(9R;3%;U_$(TEVZ!ED$1SSK]QKV^6KJ3-',OK,T7
M,ZWGW5#<$H9KW2%V(1;9PE%&'V'35/72O<ATZJ7$+:)NJB]FEDGWW)F=BLM+
ML?!)EO.F5O$"/ZBH863*3*?+J6@R+2[=6YWXQ7$*_MK;7X16VE\OW!BOLOKK
MS(?Y+&5;Z<I->1ATO^[9I]'G?ATG&VLX7K8/:E%+T[BIAD6_%NVR^>)>7X_J
M6OM6WI>U^XI=^C?0 1ZDNT2ZN?EZDH!SY:WR&WV8ML^-F+71Q/P"V'G_USYB
M-/W@L:9QVQ[#B?L_)I.M<#A@;/?+ 4(]9$R-%RW?ZSZN_F5<_<5J]?LDDT;[
MIMK9UVIQ$<3+]PV-:.#I>Q4!+=I/LM/SQ@0&&G[_<2H">O8"Z3[ZPW20&8!P
MDD4V+<(-WM=?S&60;!2&A2?^%XX3SG3$M0&P43?N[(?10=$]97B%?K@3CVFA
M)/YE[1!Q@/(SAUU-W;^<PZ >?&Y$K=%),,SMZNNKY_F'W7SB?71 ZT^CS9//
M?76^;'P3\X57."*TK1X0UTC'E?#/J&;NJBVWF\1+MORF TI_,MP&SVL#W9CB
M_FU/LE,=UU^XFTS\"MVT+=6%F/E7#P&>;D4SV]27V?KV7-N[/1=P ]PD"NN7
MA)VV9:BW/O/&NVU]X,8)U5]]NNC(0A"HCBRLSJ!)^-DQ $=IMKUB]/]G75?Z
M,)+5%_IIN7917*MMT/P=R+)S+VQN!+:BS $Q1 (*)0=2NG]2A1GC2A=:;=3!
MUZJP1$(.2@LUH#S/@717 R$8QU9C5C!S72F,SM7?S>*BUJMVIQ_<G#3M137_
M:!IO:7"<9,WQZJ3*#)Y7@,>N5WR'Y[6\N4;H\P/_7\,6V;>UA]!(Q!$&F.84
MT$(8P*35@!6BH%093MB&!UYJ:$E>2L!+A@'54@!)?&79TO BI[PH)7_QM<<W
M]SUX@;6?N+.ZG7L#OV/W5SW0..B1E4>$3@_PW#DSPJ&P$JT)H"QZ"EQ-E_ZT
ME:)UJH77CZ.JXS4"=RY<=6'XEV&"PTXSWWR*FK^N7BY ;8&['+A3U+C'S^/!
M[R_K:[!L)]5'0<D^K_0.KQ=VR;G>A50W\:CMB993H,0\<-N> ]UX6$L3EL@K
M;)$D+8)'RXE!XYX3[AR?XR]S^WQ>.SWM)/MDC%OKUJF#[9B;C:A=4$#=R\^B
MNVC%[;HAN-]ZLV=&,K!.WJ;A348JP@UKOH\+_.0:R6^56QE]+:#O^,1@; #P
M+5B;RCC]08?$GFD]F!)FYEQX*/,X=9%9IY.WD:%U9A)/43W6Q=95#JR<#E+%
M''@3L.=DT]P0%);EY3)N4VULI:K@V_V/?3LS\USF14DLL)(4@#(D@<Q-[LX>
M2"CB2O$ROWYFXMPB8;@!F.6.8TE= *8=:2JMTB62$#DR=?W,_,,LA#\>?A7-
MS$UI>[J:GS=Q>FZ,4"O6(M3R^V9G(%J<W%Q6YP6<YN[JJ9_XJ&2^,2HJF03U
M2DK0#8?MN9?;16-1EK L ;:.,U&""!"Y@( 1A-P^("7/'Y6>/OA<S,*I-_6E
M^<W-Q*YW!J$G=!\WANT,SE=&-%DT-FSL$@<V]6)EPW7@-'27OL_7LZ^F,?NW
MK91E3O_"CG83Y5@X40Q(42  .4=2<84$>E1^6+^M/O2SUG?LO?_6NGU'L;V$
MFMXJ/91KV;N%M\J4%GLH*?PB&E$"1I4[2G*&9:&(TAAM++R!R!JW.VQ!M,<@
M"CAS0,2LUF5>Y!CQC>/GDR>]WGP8*E[<' W]?<N.BI-]TLH'('$GA].-P,)]
MSUN?'&]N@UK65,$QLX?G"K=2YP7G "L#/0UQ6CL33BLG6)4HMV5IRUT 0.^-
M/0O::M![3KT>TP;S8:=7A#VRJRT"3VXN?_*R6Z3?&4VG32WJ3J]39MHY"/UE
MWKX1-.^HO?76P*BC>V>8=H0WFA]UY]P<.[]F>X@Z;FODEA0:0,'<SJ$\!X)#
M#"2C4E#CM@X4N]AM3X,Z^<G-:<=[MZ/:?@IZXT.[G"[6]\A)L&HOQ&Q1>?M]
MYO[H+QCYW%'Y<SMB/9T"%^_GS1M>8QNHD#OPEDT37;;7S0M>=W-?,\%#$'S)
MT4L=O$7SICYO1.=6"O<\-S/CHW,#.==N%JIVT70*8ZB%)MJV5E48[W#_E8=]
M3Z)TCUC]]YM"Q;K,85L$)2&D1+KU'G9,=&.%U*D =M<W6D^NW=]N[YC0WMHN
M0Q149P\;HB6<C/OM,+@FW6V6INT<*J:/HXB_[?\QWH-N[\=XC5HO?8R#NS $
M^[7='G1XZ]ZN]=MZZK1%'Q7A765N?/&M.U'KXS$Z+YW[XA<1[!_#0^?5W+B?
M V1O/NTD>^>_%!UK3CGUL;VW.)A&UA+_]#]//GD#H)OOKN6W>_5?OT57F)\J
M7UG7WZ5W1G[Z]6QP"S?F/ B9FXNO#ES<C'ZIIT[>_.,NJJ8[C,3@\QN%Q_O'
MU#[69#5%DVPY=S(=K,>K"ZM9Q%C_#NU5NS"7[:3?! XZ5J4.KXOWM7'.EW):
MJ7ZRUTU!P\[SX2XC6%CMJC \.W43O_3K-MJ9#@<#_/Q[*1HW\4X:0?=C>$NO
MX_G/@JZGER8<WM5E-S5;MU4/;0F17B2"WR_F8#+TR[7% +2X9D=<Q4?8OF)?
M9YL,L62..T31-=:$TRX"SJKV?$2M8"_P5J400F7T?EJ6("E-CJ!3XZ#F@$J2
M ZE(Z?Z@B""!"88;O6Z4P#(74H&"<0*H@-QI@AP!PQ@W' DD+%PK$1-L)^_-
MXF,W$[LB^0B?W)P7^Y*FQC[^KVV7P36WZE^@C5R$_;'W.X,*7"B$2T?4H=,-
M/0<7DI>@A*)$5"B1%QO&(<?,&1>B *)T&XD65 %A<P:X+76IBY(0H:^S]7Y3
M>%$=E8%_XR9J1_N$[>4N"0?]S4ZX=5AR!,:$ $<Q=YOFFQO7PCN!]V[36&-9
MCAD!&#L0H=9@P"41#B0X+A"V.-?FB0P*/C^CTIT"$%R4$9YWI?]AOI_F:T\\
M1'LQB8XT'RWTQ8W.5X;V,-1>U,T"^)@]S^>ZF E',D]O\H:L'X;Z^^\=2.)^
M[U**B<IEH=PNS7WTB3O%N''''Z8\1S0O1,XV4E@>XGT[<[/F___K:N).9_J3
MG[;/;M9602R[.Q'WTC*ZSL^58^$>R5[PO>9=M,5\ZFX=:/HX\-7][_^*64P-
M($$NZ!";UQH?]1K&,%CGJG;+#6O5V4+&@:MYO-M)]E^-=S4.Y_] +L>OL9\^
M(XLL*7.B0<XD]U%['$AOR3.E,5*4"C&YT1J&&TM9B2#(B5" F@(#R0D'D+LC
M 1I%F5XGC&%ZQL3 [9\N0N9C/\.[@G6XG[ >Z,!UDKCGN$HDL00C#JRB[B07
M6 ,IK-LE EF_R-R8#0/O=^^-D1[A=\83;0O$3^ ^;HMH#]+&6XT\ .W='E":
M*L%I"52!F$\/A4"6P@).6*D=P=,H)X_> RM+EC]0/WC+TR@H;<=>9K2? !%L
M[,,TC$QPXS.D-[0FZ]-+V\-]O9&9;J-SQOQKS8ZZG.D8C-O4R_.+WKCI5[3G
M%2M#U*0S(8P^4#Z/4-:=[U#T"3#N-\%G8L[]S=RF\7;HN%'<[=VV"-;4X6JG
M$TP7%^$%KAO$I#%NYI;*V[SMTEMQLT94X?M=,&N?:#D7[2+H$#Y7K\UFM3?D
M+J,GRIU?W3W\U;7TD6G^%N[#BRUF9<^N9GVVD?(6O&#]=_.W=".K%M[[Z48U
MZ:G9EB?&A,?18(+A5YJLOU.H2A#S:-8FT6=V=M(48IO/^REZ9]>=#JV#F/YF
M<43#:GZ]<)/6F!"MJ\/]9FOC\ -;5[<NQ95_N>$[?JMXP,I\G4U_!Q_5VSDV
MHL\X^A9Z]T5T=5QW*/BX<?>1R2Z,T"%<>.*F>!I\*N[.LW\UR_E"7?G+^G36
M24PUZGT8<2+<0WP>BON2\H7NDK/MA<'E%]&E^V[SV ;=P^^*P?7A-).9VPON
MCB+N9I\(6YDO)J8I?[^:W\M2N[0^D-3$I#6_^Z_Y8@<GGH\%KD,@C!/+J=M$
M"Q\O$P/GUK.OO>&TQXQ8EVF/2S'UY* KD[&MM,P+;\BGFH6MY<125:JG]FF]
M8%4JGJI2/4]5JNTE>^YZT TE>R36EG&$ )$^SM=R!20B!!"J<@Y+PC7?29C?
MIY4C_73(3/I83_WQT'YV]_YE&KKW?G\9GU>7-G33DF,?=G5YV259CR8L6\U8
MUD_9>&?LMH83XE+D @-2$J]P8^Y]>QH(3$I9&*)TN9NX3Y]J^,%>VPQ7\<_C
MVA#WSR,+D^9WQT<?\S1;=&I=3'/WM62F)OQZ59!L5*OC^'CPYXM[5.UT:NP7
M$_58]^RY6 4I>M./UVN"KA/"I[K00Q\2&=0U[ZL8Y5FNUJ /H@K?^J_3TX^C
MR@C!9VN=4AKRUF8=BYWUQ>3$?.ZV0% $SY=5K+#A%OW2=+4?PG>'T."ET\N;
M:A'#'X>G^4@H6P>^'96 $8)\6KC]$F*$SVJ]:D30O_'II[/U<A5;O_KG/$06
MK[[TY^I+G;KY=ICKK7?XI79_#3=X>_KIE]44W6_=NAR*/D0ZMKQ=#U.]7F]C
MHUK#6HI.>V..CK^-+SOB#2'38*]I^F"^X<G!UC!.I%WM*Z=-77I7]+"S5L*Y
M+XK*<0'#IY SNBVQVJ=H:^,UVI Z[\1,KNVPF'S:Y5G?FBH]"7LK*K9M5[BC
MD]IQ&,?=^SPX^P9H"EG[/C;;'<E3KR/'G'U[0QV16)I+>WA9$YBA.$"PW81X
MT)A2&\PXJ_>8US$1(X:$._V_4^:_?Q@QR3)$<=\G+:Y_V5&%HF"^&%XS.$:[
MJC+]EWHSZ<;M7D[*NB32MC6+WL :V[R$.0\VR*J)6RK.=,S9L,)]^D5,E^8D
M^S]5NW @[\-'VXM8HUK[C=7]RU;GR\9TM&!S!ZQ@J#&+IA9]E0CWE87HBCZL
MK$5=L2?3!P8'0XV_];XYDQ"GR@K) ")%":A$$C!B2H +A*S2%)>,/;J!76A;
MUY77B35&?/&#\.DG=THO^OCI/_PLW5Q;!(Z=2O0.GQ(\@9CM4WF1DSL-6KO5
M0 PR2 O%@)64 $HQ!A*+$D!LL$2(%P(_:F5[#>3/UGRPO[I3R/O,'U1!]H U
MC3_;8&$=IF>_"_YE1\QE/E_T[&!($-QJ]K_S@.Z<2^W8$>!.^DOQ+Y.9?A_T
MI]GRLJOR$U,IW+-4]*>Y-ZF;H!A=#HP\GGZ3]:,O%!$:Y?J$=,6J]>%3727C
MZ- Z#S4#MY^?U0TNCKO)R$QO:0 1-8_+NEVLIR0-@W_P\V+^75#OE&J6[B (
M+.C&K+=^9B:! UQO%7?]XW$4^=S1HJIM?8'6KJF%N_7:U5W5N)@H&H;<WK;
MGF(,%*%W'EFWW.XM+E;,9%7/I7MBK"(;'83^\KII>[]2SZM];E<=G:1.5S61
M%:JJ4<M+SW"5Z;R@,:<P;*68/N\/T/";%?EUV]2OXS^7^KQ;8EDONQI\;M;"
M(@<^-=J1FWRLVX>-\<4MNRB^89>&K>ZGPY-I]^ZZ\H: N>?E?DI"A9HPW+9>
M-LIOIU.?1C0=WM][<9W*[?5W/]=-EUT9<LA"":@^QVBQOB:^Q$1X+P<Y02J#
M2]N_27^;[K8FN/&E67SU?"]\8WU=U]YGLG4S=SETHSD?^>L&+[E[FN_K^]S<
M(,>$&D(,R/,2 <H<+>#"** %S6&)RU+JG5@GS^J9]^/$8?]1M?\Z<[J7(W?N
MIT04UNMWCV<JV![#3&5^JD:11_Z?<0_^Z:YO?#C$XIH9^[B.[;>CQ,?6[:0N
M+"?BV[SV5T5X:)?RGT:M!ZN$H)1K\]ZX&9Z$H\B!\JJV>*P'&+SW(1GMFAM_
M+?YZ=:#YJRIO"0GZ?Y]I>2G^Z8T#1G=&4/?F2V^3"'9'NS:@:K&, 2 ;I;AF
M7IVT0(II,&VV%\8LUD<30$?%;11'%>.  M"[_=P?0^IJI:?ZB6WBH13K#ZX^
M607L7!A]'@PXX\"=X]V"URK*N\4V8<39:/8\&5SZXWL9LWQ')9I75NZSWS\,
MJ<(^,FDYGT^O^GBC.YC.C;G5D\X$%"WK-V1IMPMW@>D2A?US?-RC:?PV[-[R
MU@=T8=..D6R7@ZV%"%2]G.IP" Z'=G\<QGK25VOL,5B+?2!5%YG93=:X>D(7
M5>:_?.M70Y9!G%S/88(E)[M6]-]-EY><@>7&G>^9;CT[\OW^L=^0W;+&]5K/
MI0LJ4+<K?,!AGWWQ]LWI"D?"NL34LL"FSGW9/,^XG=HT\][9E;EWM1]#=G#$
MP\9STIG?0M=B$C=WX):: X&#=5E_X3NKB@/]>V\-1W2+6_5I@OZ:R>K'P"6U
MTU&NC)[T73:V1C)>^H/;QS*NOMLG('8P[>;6[[TH)<'X*-;8;A2:7F5<#U)[
M=CJ92^Q.,PN@5"6@AB' 25D +:%1D@I*Y$9MZ@?127>>GL[TM82OY.N^E5CV
ME"7\,)JVXP6PLYM8W$#[/ _L%=,OHIH&L8ULSIWI%T;]*SJPHL]RDL6*S6Z\
M_W(DS =H]C52!M2:NQW97,O2Z])IVU 8Z,+M _>X:2AQ>RT,--8YJ9O*3:>[
MUZ5O4A5<3!Z<&N-M+;/%13C\IC[X>X#;OF[5W"G2%SZD.!H,-MCK,^,%0I)@
M*PB@2F*/%QBPP@AW%S?IQLJ<\)T4V_P]+(A?O%7!EH@6"236';FK .11RFSR
MJ;^T-A'6PA=Y#CD= P!=@Y5H#SCYE)T["M[, LUNY]Z8VHP]T\!W:UJ<A_A1
MH?[E^Y$,4M';+\>X$[M!=04VW6-O2D:?=2;$D2+J%.BI(V2.@,>RZ@.( J=<
M@%#?Q;_SRLB]&'EJ(^ M9PZ!IZ'SU[DC2IV1,587&K_5N![UBJ0WYL*GWSC6
M](/_SH]_\_>8^&S/D^R/&^_;#:6O/Q/-A^VHUE,3;9KG0T>ROJ;QOL2?/ -X
M4R4(TIH!R9 #;PP-X$81Q_@H8L0!N"4[JC$8+-!_A#V2 AOOA^-QSAR(#T7
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MO'(XY1.386H>^;2C[9Q5&HB((<LX03QR4"&UX0DP(J,<RX@/XN+ZFYDE.=:
M?IG[@Q0+\2H+\;<PS_ZL"K:KROM5YM<-4T/[K7,JY?8-_[T E6S<)='T[J;*
MS.>SD5W,^]2>]:+HWB#M2Q.Z0H0^!SME4OUD&N#6Y=W.DZ?K-'OL<WWU^6)5
M@Y7[&.7#3MI[5TP%4&W;GK27U.!/%_-E3Z\.,U>Y?IMQWN3TR=45#2CXX_SD
M/2^V>IEL:N4KD_NL,PU2SLB\+XAL7Z%/XQQ%U#6E6I:3'%6Y BPW>((=2:.
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M\B3)RAZ+DS+4(W#7]^*2)R\?XCNE:YL11BX<;[U;#]5K YE3N7X73<O]NQ8
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M4/3\H>A9:XBUX5)X19&QR>-,5(U4U 8118,BG H<XJZ7NN:2"8.< =622V/
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M,\DR9YW$]L?PD[9D (P!4V?I@:!"C5I! !N=%)V0'S'.LN8*C:9: *AG40)
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MPVO\\IS5B&=A#Y<C?_F:8SGCPM;ER M;/_<S?M;-"T50AM4VHABH1)QAB73
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M^M@^S8TA]^NS3/_ZG,;<7SLJ\\;[=)]1L$!^ORW.PFSD^D&P3G%FK4<Z<-!
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M@=:&1FI&*:8%54@:J1.I@?Q-(IQR A+&>NG\SHBVNX#;IN#^T.W-/V%7?EZ
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MQF,H)VI(=N%Q]7GA3B\CKIQ; >0U&3IV.V,,5H$C&9E,Q>D,&0I6EL Z1"?
MX)([5I:IK8[4<B1$'8"<1'(QYR9M$KY%F-#8/2EVPPL<838H579%)W^?F0N[
M^+(#TM=I& FP0$^8SGP.KGT;S4_7/SWY,@L9OUZWEQE^F826P/,.!0-,NK1>
M4P[>58K9E?X5X-Y\M]/IV,.&P[V:A !71?=O8%Z_JH!6)&#!!)'L:I\J@KU
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MYM9&H0&M6("@[^XTS4GT:>V#(Q['G(]2&<1PR@@PC"!+E4(V@E(MHJ;*[PS
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MC:"LA4+!>((XC< _@N:>$L()M9HZZWH6)&-T0$6O:G_VJ< YW6/WT6)0DLK
M-$8\Z(QYRSG*/BDB*0@3'!.)=KI]#T;"?4B;475F>A7^.-VM]ZTZZGV\Q824
M7/:IL+,BYWL9TCKD4$K$7K(H1;>A.'$6A4D>6>XRI +%(./!WHF6)JUDD))U
M<L2/$V_I%<;'*FCWM\MJOJU%9)?E^SPB>51C$HG0B 654>-SLT< "S>8Z 4)
M5 K;:1(E0(S$@U5LA )+&NL<3"8)4>4DS_*7Q,Z(H,>AK%[I^IY'\DJQW6-#
M"R[AI$!!33Z,X7)9/LPF&6:LG;N;G95->9'E3W?8XK79V#]YHD E!>N0%BZG
MWQE&.A(PRZ20C(8(_C2Y*4^8=CZW;")B+,T-. K9Z )2P7'AJ8^2=<RRHU7'
M*M._IK/3W1O46.](+$:M)4D">4[SY KF064%AI+@45!,N.J6-;&07,K3GY4%
MO<5-'B*>$YI&8^$$T5+H3H7'8Z@LUD^D]71"7[,-]S3QJ"J.,[QA!YVO,:_:
M\;_3V. :#C_%T0Z,EQ>A7MZ.JU\FG]I5VEV8_2&3[D9E=I_S2M)'XX-/"/0'
M!],46-Q1T V1*:4LECS1CBHA."C/J 7WB,$Y&7;.>2=0HM8YYH7"TCXHK[0V
MXO*0226.<=^TS8[:EHPNVTXC'#7HKVDX_5C9E,#?:3 _FZ#5L!F!/8-U^P@F
MS3"FY<1!F_%-P>&.#5#IS7QJ.TAS=>D55FV;>5C2ZD7C8QTG.6")B=P8L%A<
MUBDX!C!@(OA"5">O-!-$=-T@I>#;R+*O!"=:1W)1%:BEQ$WBTCMK.YUD#TH.
M9%EX$JE"<.\R B@O1H,U.W@BJ4T9N7=1"R2XR@-UL4,6A!%BPH1 $F'!=F(W
M#R&MW@8J\1GI4X7-H+$>\HS3NIK:F76CJRICKQ])L@@KG<ZM&@KK''.&770T
MC^6+1F*L9*"ZTZ-Z'RVV0D/-&_1#GM::W<PXKIM$UGG>[P^-,/WAZOJ0!83E
M.8C6T/SS=UB.E<8C6Z40J(+9Q4G$$.6]$T-5LQHM'G=L)^HN4;Y7@R9S6O)L
M.?+L9A:\#2UVG?W/:[6"(;:8VFT8V\7^R38:A'1!9V_?:)!3A@)Q4P)NE8R2
M6B4LZ9IH#Y!MQX&7(;1OQM>@FL_@M?+4D>J'D?7_1+_YBTG&V%\EH!/(X\GG
M%G^_GG^\S$]<OVIPZGT#U XD<\26(N&D,I(BEK*QE!&;M:$!!:($U9)1H?G!
MI)F[79JYF]+LVFF_7IV?%FN3#:SMLJTT(VVGQNFP_B=*8(U7TX7\ZIL$XCQY
MPEA$W@0@2 P$:7-[?2;%A+&1(74+QQY3O6XCR/>PK#_#JK[-KA)HWO>PN!N"
M#'SR:V,+T?L5DID^94&^'52?)B,[:]-B/20@XJB+P1+$>.YMT"0@IUE.K6KL
MF7&!&-H[ EI*M+^OEO8^),1N[;?I553RVW:24A6&>=H)?+P:QE'H(RTY*367
M8 1I0S(R )7(<9Q0-(;+2"6HSDXE]'ZT].?)).1@PB^3<?QX.9I<Q?A;G'X"
M9Z_^'2BK;A\ODT]#;G^-LXM)6%+/CXL%O0_MT*[^!/I9Z<]_Q^FD1Z2SA)7(
MH:-E;<@J]5:OQ@DU]!7@(HN97Y_B<A)0ZQEFN^M3ZR'ELEAPD>Y6(+@TYJ^K
M 7M8"Q@=T]P)@A+#&'%#$[*YQE5Z*;T5-"?Y;Q*M%$+98#&*E-!<2PM$JZ1&
M&D[1R>6AFQT\F]/6 A(R$+1/4FUG]=^3 :Z(G)E('$-,XH"X2 XT)Y;(X"@L
MYHI[WG'^,)AJ1">"O #AR VWR":FP'^025N*@^'^R02VY)GL$T5M1LN'=;56
M!I<!*]K"MRSKUF=;M8+N=$\=>YAA3H330&-$BBF9VQO!)J1 WHDK!O(P@#KO
MEMLYJJTU$BGG,C<HG =L602ZW&LE7&"\H\?_W.H?T-_G&]KGIU;Y[!/;$'T+
M;9RP!BJMY91WI)1+)GDMD_S.SR:+1#+]>B)Y?="!!PO'YA'M;9ZOG9;8#F">
M3.M>9YI=!*V4B$'"\Y3YG2/+P217-LJ$.9%1=8((QMKH'<FSS;!!7 :"+/4,
MV0!V!J>"D_BP#L9C99J-'!C5*XFP/=.\H<;JMJ[[6&E?!_NK1-"(^0";B F8
ML+!((+05\[#I09 N]+,RTFE&D8H2SJ'&H#SA%@5A XN&8R%+VK>D?2D#XC%Y
MN*8VV1X TC+68"2D3E8!>3E\$-+JK75,\!GO4Z7_==[W,=*^N3X^"F=0RB.7
M>,IH%](R)(+WULK +.ND?9VC+FCPBZAQ*0]LLLBQ!%:HD/!_R4EC.]@\SSCM
M2VCOQ%!#0D>J$P#6]U)0Q%RDB#NKD,[CT[DA4CNBHK,=//84!),R<93R/SP)
M@K2,'@4*)SA*%8N=,,PS)ABN^T<P;9W 0\L <H'!:+3T2IJB@-XI.I6HTQ$3
M9+C/@.K>@@UL.)**4XT]9U9WYH$]1-$=JP:@?^7^><K\9OG'KJJ YM \;M[%
M@X6V,[%>9YJJ>=VBV30'+O,(BPZX>E&-\'CU!V!0T8@50QAD(GAJF@+9P2=I
M/:8&OG1=G)#[>&JE_J!'PK.M/ZAZ77\@1 *K31D4=(@9&D\CYP(#+<XH$*;0
M1G>0T!Y,D$^A_H"?D3Y)T_[7'RAEK+<4)>X8XMCE25(@X"SH2,N(DM@<3J+U
MH_[@-L]1]\EM?#K5!Y%XJ[T..0,!5*&-1492<!^58][1I+CH(&+L1TFE^N"6
MA-P]B@3J?E<))$:3"9$A&F( ]Y0[E!'D4> !;+* <T% Q\H'S:B94HB"($/<
MRHAT/ANL?!=\LES>L8OA\:H$^( 1UB,2>OI5 MPFKI-6",0)2!B5QT4S#'24
MM*'2$4:VA-@/13@E#GI+F0"XD!FM;$NAP*!4"MR!NC6V/((*S41J$4^6(:,4
M18PJ;8R-TH=.I8!F*5$I A()2SC'R(RFG2'8G?21)$="!S[EB)4"IG>5 @<(
MLAY\HRVA4AO&$<G@^5SRA&P>J.*B9BQ*%33KE GKY#C88QX%G^'&F,B(U]PC
M!Z<SSK!)I#,D]H@;377?-AKLG#O$J1;!I[LA IPT6K&K@B0O>3YP.&X-8?@&
MW(D__9^J^B/\=PMYTP>FLU,(G@"1VD@R++O(K:8"=*U5WGHL?*2=:=\X.!=S
M'X^B),.$28Z<-!XI2P*7VD?G.W5+/PYK/YK48*>_2^O>Y/LXRKW@;R;UK.XX
MD_7O<-,?1A/_SV^J"(KT,E?43.?QF[4*FZ.4TXQBFCVTEN9SS(;"*S<9A4/0
MB#ZKFL(.U,0-J_6UVX=P#_R4VV&:=N\-/N3.W,*>M]+!CG?Z?_^72/SZE"]V
MY,UL#\VW>C6<P5/XW>VT&,OJI[8:].W8PY=9VOXZLN-&BH+A.PZ98;-X;H[-
M/[W<@KAM]6\V3"X;()7QLJQVN%K(RU&#-]PNW1+9?[6.UXC^%^#"74XG.0A2
M5\L2Q?6I C?A-Y8AEGI0@>1'RS_7:NSR]BUP-+)M?U:]!]U_.8P+__'Z&=MK
M3A8IGNP"1%CH80;Q7J_3ZPRWZ7B<\/:@O.&<\:0:Q;K.K[7H@X8M^]@@@S39
M3=C=?\;9=9*SGON+Y6.,-U*C36UAZZ2L5JV[4,U17WFI=HUJ<.;FL#17-]]X
MO 136[WKM/$(V_M^M%^&'^<?&TV9S:3F'1=YK>4EEB60<R#_]I&NGW:X?6C5
M_NFO$)1E.B1D(A:YJL0BD\M$A"1!*F*\2IVJ$A63BAIK)$2&UI?2(:/A1*\)
M PO!@,,A#Y;^ C-U.&T.;DL$2K;KGG[YBKQ:NWATU58L]<T=<B%Y)2-')K$
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M@+$$RA='I#5.B-/@D,YF&!$2OC8B$-:I.7JP\?4\2X69[)W]ORH5_G4^S4&
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M$T<.AX2P\U2*%"-(M)[IC%-'&(DX4R7"^ R8Z=3F>MGE$T"?<N=<!*,8)Y-
M=H&U["*C2"9/*+5"21,.EEIY=M"G\LR8 GWZU#FCF-#%A'ZY5']P$UHQX@D+
M&BEC&.+)4V1%DD@)4#&"TI2H[)D)?13H4R6+4;Q'GN !5<_/,T_P]UCG.9Y
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ML/8*)$27<#: HF)+..M 41G!88G>G=$2<B$@4$+VWUO AVRD7 -[9\A66R\
M)^KJN^&X OMF7L.I]?<%9:$Z(,H"P:>!69!GQK!;T0WDW@ )]$QKAJ__MS=L
MP\F?J32+G]ZS?T;-XK(TB^\'WE#ZQPNB11%2ITUHO#PA51 M"J)%X:!CH5L4
M#BK5O >'_(@U&);^H@F A/@ICB:7N8BE%/0^P7K&33HXV&C;)U'8>/@Q=(DK
MY21!G." N*$"&<PX$B0X++$2T79ZUDE(#%O,D6>"(JYLRC-8# IPMK)$:*\[
MPU\7H=T8MD=^%P'O TUJI0/.=X\4>JIT_ZCUJT64%5'VQ$29"DXGR2QR5&5Y
M%A6R4:F,TR PCRX02KNB+ ]#U I):WP>"!5!E!&"\@2(I#VF&*>3BC)NBB#;
MQP1>QK5>O G\YSB.4SMJ+& ;X*AA/<MCO#[="?BN:(ZO\=#M#OR3X;(';OJ]
M0AC/2>D(AI6/N9LN8(RXQ0YI+3@RU EL*-.<=-#EHO<.@PV-0N[3X-I;9%/$
MB#FLM726.M?!SGA4I6,&PNPN.CPVRZQB.,^=:8JD+)+RY4A*)JB(4FA$>&Y,
M<X8B3;Q&3(=@E:#!ZBX\A) XY"(SJHU&7&J+C,S1":9H8E$R'3OMAX\K*?%N
MA(<B)TL4^Z F?#/TK>B@%^/QEO#.1J0Z1ATMB\@G"?J#^H0<U0PE[P@38&<3
MU0GO/*1F^5'U!Z$#S$J$IXBPLJ4O0(0Y;;&F3"$J+$6<:(I,Q 8I%X,P-"CF
M\"%Z&1]7A TX)D6"'2!&_>*!)7Z; ='FNHP\D=3GB<?P0KG7 LY,<3I=M:SD
M(';SZ6(R O>H_L\J_FL^G%U5WX68AGXXNQ-46V^(K0]@%"^P2_ZEO'*AZ&>]
MO<_NE4N8:#\M&F>ST4J-4DS)<DHVKJSWTSFH43<9S]MVT"7$!;!8/:N+:U8R
M'"7#\4#W+DBKDI4!X:@PXE$89(4RB FK+#9&)MF!Z[M/A I6VK^ZYNYWZ;SE
MYA\R,Y^/P[+'OFF5?YAWU[0GHW_'Z203AZ:$OB[YC1+ *E*R2,E#24E"@Q$.
MFSP;+>1YC J97$(NG,782\*=(_L$P1Y!2G:K-/'NF2)%3)ZLDG,=F*2YZD,,
M_G6 C^8BZU?%7T$ZZ8L_T*2-VW#95R!CBDX[+(_2,YJ9-$SF.8!Y0JUVFAZ#
MNRS&,U5P.)=P&F)0C!P4'%4.6>(#4BDRP4D,6'9*0A]UWL+ZX5D+DB>4S/XJ
M73T]55BD:Y&N1;K>*X=.?)(")*4WF(*D!"%I8PJ(2<^<,<%'WD$:?S ><*^D
MZT!C583K _V,%7KQ+2"D+P(^\O>+>*L_T.!&SN# /*VCBAU(KFH=!>?Q7V%0
M#<<-K&Q=3<81S>"TR@,_?HCUZLFM]W$4I^UK35+U*<*:CS_DC_GG/T_ME9M_
M6)04K" R9\V/P<[B\L"_1KCL-/_U']M>^!YO<W!I&#F-7&"&<-)@:PJP.HVU
M)*.Y$F(()B9N&SF/D[$219''U L2X?"8D"+14B<8-]@=N*)(;D@Z<9ND.]MM
M1#X^I55P]"BO>,Z6]8X J*%4Y<'+A!E0;9X39 31*(&3X83SSME.-$W1: G/
MO10F@K.A'$4N2(T"3M+ #X+'>%("T&<'&]%[2 (8CC-X[E8@F>;O#SM;;)="
MM1[D*^1) ?#EZ.IL*YSN4?1-KW&P@9(^POHVJ,95QNJ9?EH %_\\G\VGL7I;
MUW,[]O&$1' T+&XM@C;$"L0\S7U1& Q:+ 0BW%DI4C2&=?JB[I\U7 %QMVO=
M+/5RI7^>3-MU7B[S[]E4*EC;&\396@G3=>),+7$.%ZN6]Z@&EJ^7=D.+H9TM
M#C J3D>Z':OM "C>>\R<>&XHWN8D(-X:G]%;P;#/N-X7+UN>W8H47A"R>P:F
M>=P7[&NYY[, QCP,Z'4?5J4 6C^A%2XRY:&5.<]"ZA1 ZU*A_I@5*1LNU6>;
M<RJE]/P%M4F6KN"-":?8>^F41O#_"7'M<FDD$TASAKW")O!N5S 5>:JRB8AJ
MD8-&02(=A$ J^:"(PZ3I)-X,X;X9V;I^E_Z[Y;=WT_?Y[=[-9_7,CO, PXW@
M;9W#O/5ZU/;M+S_?!KNKY("S(^<HGPR1%[S*/7N!U[-R.<860Q-9GUQ3;%$9
M+X:;BLK8Z#0**F&J6 9LSRI#*F03?-+!$(LY]U*;0ZB,'6,Z.T4P/]PL@GG7
M\NV:=OEEGN,:>^L8,E#,#*@Z,CSED^&+XHGLIV4:$JSL)SL<-?F G-=9)71@
MQ6);2I(]Y.K7D1T7E?-B6*NHG UT?9^B"LHCF8Q W'J!C%4&!>=(GB7M&&4W
M50X<Q:@A"5E+,.BJ9) SP2$GDU BL,BXZG@IU_GI-_8R%PZT/+HS6;VW2F&&
M#Q@N(&S%;3F&0KFA0W[Z[==?BPXI[<.E??BA]?\22Y]A]JW(4UXHJ" C.$:"
MT^0DUTK'3OU_E(EI*D%M2<(1Y]$C\($\2C[/>7&44"5.KX>D&, :E3[B_OD^
MI8]XU4=<=-<S;60[H?9Z4?UK'BO!$[A#*6C010HGI(T3B)B8. Y6>Q<.DNUY
M=/U%!UR!"B./"H7QDIK4MGX+I[[(&M[#%N$3Q133EB+,91[)I#TRGH%]&3P7
M01--V4%Z]C-7#F<Y3)ZA:-[ ]8;C#W'LA['^<5C[T:0&CKQ#Y?USZ1'9M>/F
MK%I;JB;OM[%8^U33'_A1-SI#7E9KQ,_3R<>J:;V<39K_#II 1\X5V?%5]=%>
M51?V4ZP\"'(['#?\TVSAK!H-;5/N#GL)Y]A99:?#.N86JWP%$/'#L9U>P1GS
M:=TT8@Z!#-R\'HYC#?20&ZB:D\^JW]?NV,);UAM7SQ']>NXOX'%F8$74U>>+
M.%[V;C1]66&8/\-5IQEI>N*:N$T#,9U/VSC$PQ*[6('#4$_&<-Q5E7M*/^;&
MN+-]:+*0X!ZMS,O=O[!U=3&L9Y-IMAKRWF2S,0:@*J#/?$XV2.HED8VS,3-:
M([$5>7T>SBY6QW?:_.!QY@E^F$^;9N+I!SL>_KM)C-:#5>_QYD% 53Y?^.:E
M\I&P&GXT'.='_L/R U#>Y>7H:O,J@^:4S >?@" GTY:TUTZ_[DZL9_.0:;^I
MEX";  > T3?TN5LZGS()\[P0^?S)9=,AG1]R/KV<U N6JN/:@BT:&^&!X-1/
MP[!H#H]3V)5%=_48EA.,M68=)<[RP. JV"NXVGG3$-6KWO&\)+'A][[U\UJ.
M:7(I(JFP0=PP@RRQ&B6A+*.:&Q[T/NY!TPW8YN)S+V"[PV_FTRD\U.CJ[?BG
ME**?;?@"RZ.^Y@V@.OKL$>0@2AW'W_QI=C&-L4]-O(TL7Y'TH.7QV>=)]>:O
M[QJD4_6Z!@8:95&>R3?SV3J[ @F?S[],IK9M[_7_F@^S: &18S/?S4>S&W !
MS0WL)7#,ET9!G.[=1U<G7/?>=<PK9AC)%KNGV"(N:4#&B("P-U0KK;"C'0><
M62LDC1HI1> <' DR$>S]((5.A"L7.-G@L"7/S.WHG0,MV4C):X;;RF?[ ";P
M/K%:KP$3'%/!8D]0<(8C;I4"8>DC$I0PX9-73O*]!>QC;__N(90G-$8?_]9+
MP@-!;.MZXH>-,&^ [3>!%P;P7'!LM@1CLQ/K_=Q+4VFP--'@N\^QA[8"C20F
M:0P*>9@T3X(@:SA'QNNDC>(,B[TFXC6D_+?QI1V&-SE".!JUY7_C\"ZOROM6
M6>[ T;V'K3">](E\Y\T+9T]O]<;9:&[-Z*6!T-#4=OB.%^=V93<?-GH"SD\W
M'N"BG\#?EW8ZNZH:3]S](_,;'/ )7/[)O%ZL["A^  ^F<91BKA=MG1<_LL./
MP(EQV!P$7!VG>?WA2O/Q\B\PYBZ&&9/EEA#"TK\[JW[+S]2::W7<N&D3KQB.
M/TU&G_*%6W_O:OG-\N*MI!@L'F\9P(CK;P<?<^GK; AO-1\O(B"SI5.6'W[Q
M71-M"/:C_1!W4-1S"?:UA^9;W08(\V[EE/XE6MBA\P_@332AP,)RRT@'W/_:
M=Q\UR]3X\REE-[RY?R;7O]CJOS*@Q*!Z R\!1XR']JQZ.]Y7F]U8@RS4T? +
MNA@&V(97/_\OP='+7*).#=&("RN0#50B206)#AN=K#G-0OZ7'<^S8-CH>MWX
MSRE"$G!'4+KCT#B;GV%_XY?HY[,%U(P%5S5F ?013KEH0B_7U@D<$*M_S?/V
M+@.>64C5%Y/I##6'MN01O_C8U.6W0=/VRWRKYL:+]III',?/3<SL.F335*XU
MCP$/&<(P7P/$VF$?*?<0Y+O/%D</Z\4Q\&'-C1Y=]<^GB &+(%A$3CN/N(H"
M&>XL$L($PRFW7/J]#;&\/N_A*;YF:N';/ 7\U1*C4_B*F7AV(:&]"+E^OBN"
MM)E,N;"AY0=@TRI9WV %92[]P8[ U)ID<^2O(-9&K7F1BTZW:(@V*-4RZ^QB
M.IE_N#BV(L DQ11T1-C0G%H%#C&&6I2$Q(10I5UR)U($\W'LE19HY&<CD#U8
MK>.E\&]W\_RW-Y7FM)7=*P+(EH"+$>2R@Y,GXX44;^!/P3QN54F:Y]C]$ AI
MV*9#\EO3U=U 7(_ :FU_6:"BKD*B"2S4L1\V$R06TUGKC2NT#C((Z?&DN45K
M_BZ18^L%=&R/X,^6T_#HZ9YI70''+Y?+73DR)PHBN?,*;+#(..)>8V2U52CD
M)G/GN*+8%DYL-^CEZJ-L8VP%@:YWH4"O&*J1)J?;M-[9A9X;;S3!V1!DB)-@
MD:4R(@(<IZ0W7M-XB*JBQDD^'X>\=7:T$XOW[G8B5;QOAF(ODPF<8TV3 F/&
M<((X5AXV6"04'4N4"&^LWVN6V?$VF)*>;?#@A()C,S70!A.']1)AOE'-UX;T
M$LIY78=/5DF>1@1NG-@$+GV;8=\H3%K$$C-J;.[ :.+*SHZ:SN/Z(L8; >8#
M5W\^5?6T7NMT\#+0(+'7,C%$9&;0R!.RG#O@S: Q)3H(VH'B>8C _A4H:"V3
M\NNDGDWC#,S !E,ACB.\<RD(7=]V@L^JY>3&:KE"/4AROCS[\.VXNHZ@8C6H
M?IT./^5I&6_LR __&L/0V\J&R>6L"54$V*EQDS$;SZ9#-V^$),?DNW]^7UV"
ML%O49ZZ2):.<3!JMQI+79TWA[_+,NOIH0ZS<U<;=%O[F^E6;A&WO[ 65')6:
M<U#$N7D1]#X"<>,0%U(G0H46LM-$_Q#Y\F.[Z.LKE\$K%@PTS9(ERYM)3I"M
M'W3^,8<=#C2P2.F>F1BM#;FU\/"D:7S'0\(DHB"C 2-21^0:@S Z$8QB7,5.
M1<I#C,A>$$7?S,ZM'FX)5FU:YCMGENRT2=>MLE'\@@+8-LU69W3[^<?QZS"L
M04Y?O<J_OK[,2:7QA[6VY&'[.(M.WO:+A=9;/EES*H(->^TF7_(K9IS^57/8
MESMV@)$]NJ#V ^;=L_4"G8X@*-Z@@>6>7ZP:L"_MA]CV5B.;8(E>V=%G>U4O
MY@2L$\=RYYMFO.W;OL_N'K]Q>.W>MU+2W?L#U]AHNZ,BI?74!(^L5 %QE=%X
M$DD(!R)8)(Q1TBEB?8@A\7:<RW=^MU^*,[+NC)!<0=$4-L'2Q(VBE(/ZH\8+
M09D4"*Q#C7BR'AD.]F)4B<L@B;'X(-M\/1ZH+4P%2;_:^?=@V[^/<(^<<6IB
M'&4\T(VRG+A<M&IFOU1Y[$LU3.O9VT4VK6V?R9Y_]9UK?=CO6\2YEIAFF9BJ
M,(3+Y>Z>IIHN)_MB:.:*Y03<?#8!QZNY14[L-1.&ZNJ[)I8TF==@+=3?'V"^
MS^%WX\G.]]'F%/-])#V3^O8!/YK<;SS/EM_%&<&WWN@Q'@2(4M]O7E$9#%(&
M@QQP,(@L@T%NK-[_Y-F_/W6ROF562)E>U*,5?E%"JDPO*M.+CLXOS_&%"P=]
MC8-HX: ^(D\^3Y#DW^T78,>/ETU[BYWM"' 4J,DG"#J^216W5FH6S/UV0;Y[
M8#;GGF-C7(K):(*$YQIQ:0+2-D04O0<.3!0'*PZ:-=B,&Z^^7A0P+LIXSF<_
MM_S_VY+]-V+/=T\\U[ S\.FVLH0!);OA,IXWWWW_]&7J'DQQ[[=_FIM<A.M)
MA"NU3F*7D>@%3QF-PR$;J47.&49X(I9$=8@RGEX+5S*0M C7,E+EH"-5<M]A
MSHT.JG%L>F27_D+.MB[RJ$]?L;U 9Z',Y3I 2;$1(G*5D$C4(TZR]K"Y!<E3
M206S-."]L =N43L-<YZ/PU\FL."K8^(60*B'E8L^.UWRJ#1?Q-BSV])G*L:"
M# 0SSY$PD2$>11X::"4*8!G;Y+R+NM,J>T#KN8BQYS6QZ7E:PK]&H+%Q[B-M
M:P3CV&\6GQ:5\:S9YZ6JC,<)X.CH61 X(-B"C/*K09-XL(\=#XIA0K2A^\.I
M[M _*\[^\9JQ#QV;D<>>S'1R8?J,P]Y%1A89V0,9*;1/5!F'J,G3L0@663Q2
MQ$Q0R@G%7;#[F.FGEI&$,E6$9 E?'Y QWR^'\N1.WO6)(CEZ[:<Q##,Z_2*R
MO4**KBXG=8.S6NS[I\AR17?U3W=QCQ.)CJ$@1(Z4VX L3P113SG16G.NCUG]
M\LLD]U',X8G<*"Z2M$O9<#X./UY+AD/A;V!15%F1F4]F;XO,[)_,%#$)+B18
M=9$:Q%U2R+H$1K^A/NJ@20R=[.(!P_*/+C.Y*-4K)69_2#[]NQW-6V1(FWOU
M,[ICT4Z'G0&_K47GN>NO>S4I/4T-M\.*E]&[/+0Q1,41IX0A0PA%DD=O$@M&
MB4Z9Y0&M^#<7=OPAOAW_&%.<@O,.!YQGG/UZQ>?G2S8_D$K2 \&.;,C?I8/K
MN3-4D:)%BKX<*1H<M<XDCGR2>70D)T@39E"2V"@=L8WIF,7JCR]%V8"1(D6/
M7:GS@*#_.BP5@27;3MVWN 'K\$[-1=:OBK^"<]47+^'M"@!LB2]?U-MA^9&>
MT<R083+/L& G5'"G:>*ZRV(\4UTG2232D8B45PYQ*4#72:>0=CX%Y01.[K >
MPV8'UM,H(?TJ?3P]]56D9)&214K>*](O)?7..\0"^ %<@77ODDW(<4HM=\K*
M[@S3O3R"(B5/+B77C7SXG!%0_[0=T[TW,+*/!</?^J6;P+R+.9D-)F^NUVFL
M]0;ZM\ZU.]_9[ZM9_'@YF>;9*&L5^I6+L\]Y1F<S[LE.IU=YCI1MQBKD$YM!
MG>U<^/7Y4!D8^'KZYC3"A9L!5)?SZ>6D7@R2;P9]-E>JJWF]&!AZ_=2K@]M1
M]M^Y[]='PD[JU656M4CM \)5/MMIJ,]NFTEY&^CY-]N!K15F.@4+5A45 7'B
M-'+>2T2CD)HQQ0TYR*"E:V#K3J@A=_M<K_97,:V;!QF.YS&<S^[Z]/]+3D*Y
MOP'O#!-(+B"M#+$TR063#7F&)4WGO5Z0W'=K]/9]1F):0_FL[/1.&-,WQ<6U
MJ-D'"GVQXG:]T_6NJ]X7654@KPOD=8&\?FK8?B\*3;9 7A?(Z\/36!%214@5
MP-XC"JD">5T@KPL'%<CK_NCT6\J #ZS4GUX9\(_=Z,NK0ROW)Y6GNK-LZD>^
MY52ZZ*6\<J'H9[V]S^Z52WW<HZK/7W)[_$;B:C-/5>I GFUC6H$SOU/]AJ.<
M)8<3<HECQ)F"3T(9Q+$,-AAG:7>V Q6)V&@BHEIDQ*L@D0Y"()5\4,1APAR^
MF5'MY%'?+=GR+\"5;]:9\D U'>(1.F">3,E&$6@]WM(BT XHT*P'\<6H0]I0
MCK@G 6G%'(I2IN2359*3FP*-BR0T#AI10P3BP2NDA4C(V$0%8]&'1$\OT(@8
M:&:*0#M 7*D8TF680E$^CV]//%.=HW0,U'"'A*$$<:49<L9I)*RQ445L&.OH
MG(,8T0U;'A)QW RT+#9S$5ME2U^ V/+>X<BD08P'B\ (QLA$SI'#R1%*G&;=
MWHV#F,H'%UMRP/'S V M(>8G8!F?>S^=YWG$#4SK(EN[:,8N\>67PW9%M:RK
M%N.25<Q)Q&S4B!L6D V<(:)"=,Q[2EUG*,)!+&+XL/QN#?AO^BGFQIV&5T&C
M',I89D7E%'%6MO3YBS,M$^4.Q)EP&*S>% TR3'MD*/;,)1$9ZV!!',12?DQQ
M1F0QH4MPN4^C#M9;BZM2L_'B^+ HH8THLZ)*@BF-K&4*<9(\TI%&Q!4&PUE+
M0NEQHLSPX4W#B1M9S277'DK[T ''Q: NLJQLZ0N09=9R*PBWB";)$8^&((U3
MMJJ%-1&3("(_ED%]?%DF!HH]OZ&))1S]!&SIOT1;QW4\H*)B7@RK%16S$8(6
M@G,2(DK)8,2Y4L@FBQ$&'1)89%9PMX^YW,R<O*E?&O9;PX=ZF$)I0'70O^-T
MDK=<4T)?%VU2I%;9TA<@M1+Q*@6%''C[B%MLD69@)T=&P4I6UFLB]S&,CRBU
MNB[]D6$UGPR)EWCRH]K [V87<5HT2)GS4N:\/'1:5I)$&&>1C!G[/EBP@Y.*
M2(8\P-%YH5@\3E=@9MU#J9^!-$=NEWE6LUN*9"R2L4C&VY)PSGC/)4&!>(FX
M=QKI")\(H52E9#B(R..T%QY2,A)=Y&+_(M@/,=;[;XW_/IG9T388\:*'7HP#
M7&(\&S-3#$M&T(# PC:($TR1Q@XC@[DVA!(-_Q[%NO[S=%(?*KBCZ4"8TBI8
M1%;9TA<@LDR26C-ED'=&@0G+$W(R6! 'CHN0XP'$'L7L/:3(HGI U9$MWR=#
MWP68]7# K/<LM^@-Y10HRP)E6<!9"T47BG[<0$])TS9M/WE5T22A>1U+2.BE
MV9_%O]J 877>8&4<TIY2Q#U.R 9ED<0TZ>"BQ+K38+I/L>):L4_#AN_2W^K8
M>ERE9+$7A%YDU[/;TB<ON[[;-M7WX+*04$$29@11Q07B*FBD36#(X]P7I!(U
M:J]8TU%D80WK#9]N2[SB9R<4[P9>_'TIC>R%S?UW.UH,1[9Y/+,=^UCT5BD'
M*N5 /=%]'D<KI"0H$<K #T@66>\Q,D;BP!)SC*8C^0$KT7"^E R'2KL<N0V@
MI\5&>RK&(GZ+^"WB]Y'%KTB>1!4PTEQ0Q V%3]9%1*37*C&J"3MH]]6CB-^7
M6>MY$K^D%'WN+OHLF 1%YQ6=US^=IYB7 G,06)$%Q'7BR ;A$?6&JYB4T/&@
M$^#>COWD8]Q4?L73*)Y&D;I%ZKX<J8N9C9@RC)QT('6I\\B$"*Z#PTHJ3Z-*
M'72:?0IJCRAU67$P^ISX>,X.1IY%5SK+BJ8KFNZ I4@$"Z] *<FH0,M0QI!1
ME"(EO'$R<*7D7MUI30SLESB[V>IQP+XTQ5^D1BKU244H%J%X%*'('=<&2XV4
M-!YQ*PTR!$?DF>*&)V<\V[\FZ7A",7>^\2/7'CTKH5C"_WNB$-?UJ^I3*38J
M2J@HH=[&H$ +>6TD0]0R @K*4*2)M2@Z*B3H#B=(9_[K07 HCI;K?L'&?TD"
M% %<!/#3$L"&F>B-2DA*#P)8!@X".!%$<8C!<T&-/ Z8W!&+C5ZLHW'<?(#I
M1SK ]-/?^.5&'J"4&!V:S>@9S7P6)G,WBK=HNL<CDEW+\1]'U7C;UZ(?.F]S
M%P[?G\"4LN 8(*N$!?-?262$]D@FIJ.D1!I]T&*AE<;ZY:&QL$=O3/XJK=RB
MH([).24[4.1ED9>/+"^E%HK$;-?C/+/5*8$<DPP%+86VUHM(CV/A%WEY^L0!
M?+;P%G]JUB]?8#ANO2[X)@P_K;W1>ALQ/X--_O8KO<02_GS@>_YC7L^&Z>H!
MEO>-Q_GJ_7>5[%S$ZLWD(]SWJKJ<3CX-P<FM;)7FH]&V5$$%?\S@E.TU/I6+
MWF;@(+BC_1";<>$7MH8C09+ $^1C+^RL&L+_U=7'";S':/C/.+I"\/48C2>S
M]O?9VD-]'L*3Y%^BG0(#-Q5S53U/:>B'^?JS207>U0@6H3EM2^%1%>;3X?A#
M\[-?&S!:7<;I<!+.JO.ZFJ3JQ^CC1Q>G%2.#BF+*'AAM.,"F##96(*]@BL".
M=M0,8Z]G=A:K7][]I:[L)SL<97+.+V O80._@ 29P8I6_['M\>_Q;(>7ND%9
M;0)%6+",( %6JF,A(>>\S>4M3NS71;L;I!_V&<AX_.$OD[K>F##[(] 2\)[?
M*93EAE 6M\59E#Y3.^7RXY-1!4>/&O8%JND=/1"O5& ^(N(\0SPYCFQD&BE,
MJ".48R:.X[7LIH??,F>=C\-?)K#]!R(*@MG9;D3NTQ'% ,1F?1GA<3Z!N!AD
M.3I)*0OQ-)_-IS$+T$:RM")W4 U!PHSA0'C;+>)H(9BSU+V<3R\G=:S/JJQ<
M=DBN^.5R"#=Q$;3B.$OGX;C:DT)7A/;+_"-(=K]LI1%!*^$3B@Q+L-QB+NI.
M!CG)%;86A\C833H32B7J D9129K+[3 R<#""\Y13WEL9R4:52)>F?E[0U$_Y
M11LM^L/R7?\'5-F.AQ7:<6&51='#$W,+5I]MAJ0ZJ;CD(27>R?X%JW"TS",=
M'4'<N(2L(1@IBFTD\ 9&L+T?]O$)%52P7!ET&VNUY>]3<5-+X^N:NG=RUN(8
MA8X*>9K'AF&/\U1W@@PVUC&CA(D=;R<E"5Q!$Q*.:\198L@9&Q".SD3F%?Q+
M]I"SA]*WF)_M;BX[H;X%8PPDX Q13-1* (+8VS _Z];6;;ZJEB9I=C?2$!8'
M9/+9D00BEEAR&002E@-!1&9 (!J/8B0@]7R@E.N;!(&#RYV(6:@0$*),<I"?
M<(ZR)'"I\_@Y>Y,@=N__7X8?A[-&S-3OQG^KXTGDRUNPBT(8SAI=.(=UGS96
M-Y!O=>Y;'\1^G,S!Q8#MS/[.9/D^U0A>".[Q(8[S-S%OVTI=MDY%O:;9; +O
MYZ9[0=2@Z^N 4W29':59OB8H9/#%YO HPVS!7:WN< 42.1\ZRJO8'JCQM_DI
M-U5V/J^>^XOFA$'U^2)VM'J^S)IS]GDXNYC,9V 9?,C$"!=>^GJ;[[YXL$;&
MS.HX2F<[!?7)>/'WM;UL-VH$7E',BS:&/:O;#6ZZKJ[RF[9\F+-YS6)O>6DX
MZ!+V=KJQ$75>V"'\T;C(^=AKSI^/P1<.VVD'+N9:=W0(AVQE__5HQLL*2CQ-
MCQSL:2 (X+?\58A@5D\NFQ"(!ZTXG-T0_D_)=;<B@%%*P,*T8 ES'_+\Z^21
MHU@*+$CT/-S4&(PH)UV>46H)N'<N17#W.1C3FC%C.>&:\EM-"/CPIEF\#?7Q
M?K'0A_+0Z-GNZK3BM=^(XKB@(L<.21$Y>.U1(*NU0M3)B&&K@4XZ8#S9QDP@
M61%)%IP:!X:D82(/KI4A"6ZT9*(?I-!/2MATU<^JGQ>B9[? V9 TC^=J$Q,X
M,4XC(32X#<DDD!,QUT]YSH0BPI".G. !J 8D PI<Y&0,%\AX(Y 3.@=UN%6:
M/DWO5?7.*#JK?KM%4VT03IBT@?>&?EZR.?+K?%K/;9ML>)NSHF/@OO>P;N-Y
M-@I"H\,)R+%!!98!D.HX9U&^RR9#SM91_#H?U'PDK[^O,B\/4TZZ@;)W5]7;
M]V^JG,!2KYFF&Y9&D^M3K^MU0S7G5[98IS=<RZ]'\];=AV':L&U@MX%*X]C#
MTMC*SS_.1S8+GLI?V/&'QJF8? 9SNKX87N;7SEF<[,GL+5,.KJH2F!J.9Z X
MHL'NP(8BJ\#MM409[*@PWG54U7W\W$8:_1JG.5%N/\1WZ4VS0F_'[Y;KLZ&5
M+F$;5FH)T76]1&]12V)W\>;C<\.WC9N8?5+8]FF,J/%'9SF1DKV?14[M9E@L
M"Q*@O,M1S#1GUXEH05@6F.JJSB[P.K<!:_P6VUT%YCBKWJ;.F?7R@3(9?XRV
MT7% F3?.K2P0ZC!+*N"]_ PU/-BGYECOY]G6&-QP^J?QHQTV5VN2B;/9=.CF
ML[C3D+^-Z;*T78N39TX;UPU'+8YO',KJH[W*OF$&+V^DQ'@&8F*:/>Z8DY6P
MH*-5_*0Y&,3Y?-2$"?+SQY46;#P+\$>GRS_RS]TPE(LI\_!\!B+FW\V)&[(>
M""]^\:-YB'_Z8QA^6G'V*'Y! 11#L\"O@/;F'\>OP["^'-FK5_G7UY<YOC+^
ML%84/&S):E$^VWZQ$.U+"FM.12!!7[O)ETRJ<(57JW*$+W>L1R'TX;KFNO#E
M\9GK9W0ZQLY 76OU$[D8HJV9^./%JO#Y$@1=6]2,FK#6*SOZ;*_JU]_\88,X
MECO?U']LW_9]=O?X)6IK][Z5DNY>DM+4E_QA%T/M;7Z#'R4MCADJ+H!OIDQ$
M-B:.L);.8ZL,9YUY-0\)[/[F+T :C4#C_6T,_#\!.?7OQE/[(8XC+$+]?C(:
M+8SRW[, _!WN]\-HXO_Y315! 5YFPW$ZC]^\-$,R*\5K,VJ;G3=?6]!&2;C%
MDF:+K9Y_A#=K?LH!J$F..-;5=\VE)O,:U$O]_:LU@EM6/#4%3ZL*JK5I"78^
MFRQ+O?+;9F:$U<J'(Y#BD_FB\NQU^S(&G^%OE\?#BHWL91U?U?'2YBCX<M6;
MBK[VTM]LZYWX-*R'K37[:GF-75T1S5TU/J-,?IM%S.Z#R)GAMQURV^_B3%-V
MKXOL:@_9W81^X!&M7RWLU4^OKO?6$3W+9SGBZVY7_WV88?F5ES^8AGR<MW]1
M;UQ Y?9J(_O!CIK*4SOK)(3(78BL-$@\R>%4A^Y^Z$=GP^&[E34U)#&#L(=_
M>,(..?@&.<4]D\[8)#K <)Y:IP/'*' %?H(!P]]$J5&P!$><-/6RT\NPP](_
M4(>R''"QNW+VJ1)ZSU&.RO"UM@S(PT+5.2DRLHMRFB8<.)ZUE39-2>ND;@J%
M2@?SR^'#HF<VDBF:.R\#03[$#(U-/+)>1O@D"--82=_M,;8N8$8T0=Q[E8<8
M6&2<Q,A($[ BUL1<>7HG/;/DTISPGX]RIN'GZ>3CFY9/?VUR#G#TKTLV/9!:
M,HH5I?2X/DQ12ODZYXO"U+KIMMC00$UQ<5.&V&2+BD(JT%$%.NJAJ-I2&HR#
M0-A9T<Y[< 8+Q(+'A#L9A(J/KM1^S<Q]-)6FY(O$@>JY*_;B(G>TZ*TG:#N6
MR-TA1[SA@+TC%HEDP8]24B&=N$#:)JZE%E9W6ST?@D)RW,B=&@A\9)7RS-7%
MGD[2(7RDI^@BE;C=LU<W)6ZWOY8)6'-M"$7>:X.XI 99S!D22H-SHS5GJH-^
M\)":L%[%[>A \Z*4'MF'*4JIQ.V*0BH*Z;9$$E8B",H0XSX7+%B+3* .!<9Y
M$)*H$#IP)$=72,>-N1U[ O:3X83B()U$%PW'F9_&BU:HW"S5U)Y/(ZQ !FN,
MTP]Q6A32BV'#HI VT-,#D=(Z4$/>6\0%.$=&)(R,]IKBR)4QC^\AG?M_S8>M
M%CK4%"9>"NSNKH7NHVQV>D]%"WWSI_<KI*A#>$3W:ZSI#9T>23/M-I5>>.W#
MG1:F%$4\SCPM(BCVN2$U,07ZU6*--),*66I(="PZ83H5Z@?4KS_&QW?XR .G
M;1V5H9_O&*[20?7@.@Q6W+[3C9CI <N]W!DSA\^T)9V<20$9S#+.N*;(>H,1
M\=1BZIU@N@-^]A \^^/6<Q RP/I19T7>;[A,#RW/G=-E-C#?7OALF17-9E2Q
M-6"+*H$UEO&@YJ"AIC/;(BFOG,2,6CQ>FQ=3M?-B6L"QC7DQUV?D@3$9/PE>
MW3:PQO-+^#I^L0WR;X.G.!QG_)6,[#2-8![-5_YH^ZAM08F]O(S -!4XJ".X
M](<64^ER.O$Q0_@.*F<SO.]B(LXL^HMQIO4<3P5^/*O>KHU$6/F\'^&IX(@X
M@V78^D*+A6KNE?&UZHO)*"S@@J\9?P-@:X4><MFPJV_@W9JY.(O#X7U!S$:X
MLQV'/\#[7,:Q!5L8-F.M>F8-F@KD YS01(Z[@%4WP;U"[Y#?*/@*$D>#L!()
M<<4=<M%8A(/0DC'"A>@@OQU0%+<;G_V*Y3*?C\/;Q1:<>S^=Q] 5U]="&F_(
M:%1'G^5T-EOK.-Z95S,A$D(,DBS0C-%+D>/4(\Q3E#I*84UGO,X!RPF/_,[C
MR1:5U!M(O,KF%P36SS&N=5Y;8[3\UQ((;PWC9X,SJPW67$ $->#2&9VS$5 +
MU,<L2O(5,Z3>-(*,K#-$8P,$V<39+I9@<BT4Y>F6IN-P-(^=*\#/JK]M%?EU
M ]07V^%C\.RME&UD>'ZM!+N]>/?AU,\_PO(T6)6-(HA?AGDI\[ P?P'+W&#?
MK:$2_C9W=?S7O($Z76 'PMW_,0\?&OC3M5N-X<V&XY8DESA[HVC;,L/K4]>D
M]0"H>>//_(P?HZWGTV;[SJKSD-5QNY77N'WM1)VLGBY'<=#>_5HKM4H)!'H]
MC]>I.UBO9K+ ?'8Q 663J:6YQB;R7Z:<C%<(?UPC!M;PEM-F'AI<-@](J^OF
MW?-#+&_T@K%>=R#/#U9D>TH,^MWH8+"1$S]L^*4ADNW65%U]SOBT_0:;5S89
MZXC*L*T<<98'&V%/D8C,R*A(LK&3C[N/\FY@6W=HL:\-Z+P?DKCIYV2:7F+*
MJYBD%E*AP&'C.+8:V>08DDYHQY+RENPUC_5Q=ESV<\<WH>/?IC7C(^/=@J?P
M>3('#\.F%!=C;V+S,1L467AD;+\!>%/N'\WODVUC09<S-'MD9_1E5D@8ADV;
MK_$Q=QF)'3&^0^"?53_.&\#AK<-EP&=; AK#.:TAV/C9\$.\G+5DD;&-\ZGC
M?)DU[S@CDN<7^'EMP$D+&[^P.OXQGP[K,/2M1H&382'!VOH<&\-M02B;3N)P
M 0#=UGV#UFGG+76PU'^+TT_#;,U]]_;];]\/6MNW<<#S1,:%$[IZT@TS96O
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M*X>Z3F<Z,ZJ-DT24Y419-.$A>$>2$X@^3K4 W:(S80-/DA)J8DE26$<L?HU
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M*64Z(;K*PY#+O>ERW:WN#:'DZ'I!R_O-$SMPW$I:<Y=4FDP*017X@9?L-13
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MO[_6:6P@1WM^#GY#=LH:XKX*?S8LN6MYG5J<>V?1U\/Z'@':2H??<  A"P#
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M$]W<UO1#D=<W95)>B[Q>UVYZ:Q.[L!$ 01EONDQ$U0ZF!?*FQ.@JHGP'QL9
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M?N<&&O.Y'@]"L:IV,0]["''VFLNH%>^PONU\0VLZXEHT<=)&6(VAT6?P2E2
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MY(.!=. IC.5)^?TMR,?(_RZ6XQ/F&5U%7*HH8?GB'R^8*J%L,C.XE?B,(<-
MBJ$57&5L0B[< (X>R4ZTP2GK:1IRF1]A1/OO)JQ50I_8<JD"RU^@</$0G[=F
MLBF01>2A(V(DK.-!!-:_ =BF'T'G0F4$<W=/LRP)'G89.DZRF'TY-LV%Z"67
M"8KW\0UK\L2.="&=2&C"^(".SY14J9_ FQBNE$PE56\<\;@Y+T4/Z,QO)?,M
MYD>[:3O6N0^';;GUK&"PWMTG'CSI=_O-0QP.1^D!&H03F>UL2]!)#J;<5@YX
MS$L %Z4OSTIF$Q# ) =M)D5Q]8,4((2H,(Q?/ =67JTDJ(' 00%,A>3*,9%'
MPDD9^ED:"QU%"U;#ELK!*'D8R;6L06LS_@8&(3B*_0ALFSS7QJ\MUW6A.%J@
MCDOVQ0-9*)U]05<)90_EN. C3@/T*X&?1J@8!'*/[%\R)CDK2A-0#DIP@E07
M1-)UIQM^BF,?G+)?XHANMF&\IU2&?FNIQ.IN_TRSI]B7Y9HN(&F#1KZA6ELX
M%S1H:;-1D>AZ.O5">VWXE+326G)6C@MK3;:2M86T?+D(^X"&UB]\)OU"=8&/
M'(&#+0*Z&4W$G C*1)#&TX'$B>-H% LL%DHX"CX%B G_#&)DU&W@B@T^*[$K
M6\&M:R8YEB2[<T&??82RK*)2[O(E8IOQ%&Q'[:$BC,Y:A3P22^+'PU98QU&.
MI;(\/H[*8*9=>V7-;I%FV^1OGR^&0HN<WO[U^O2+M6*I V>G?P9G7I@%FQ@*
M37WVDCV;@=6R,^=QE,9AX /4$\8=,=%W5%:J3I!(BM;S4@LPQ?;0IJ? E[8"
M*CTIC+15[.@26C39('GK"5J@4%]%:9;P&L.&D!.NX^@QAZ8B^0"IJZ01;D_1
MW*QC-)5B%,+LIU[V#7]$*H3=T&">DT:N(V%#]_GG!4H<\Z(9ZLZ];<"$63[N
M+86L<4S4OMQENX3*N#TCQD@QE,QDEH-AIC8?3F'1'/T"--DPI0DST9E?<^:#
M[X;Y:MJ"O@13\JZ5 $&5L,;!/.II/UV>7S6XCIW!HUOCL93_KDJ_<%-&BV?=
M-L<2V8A-X2&(4!;1\.I&I@XKV"2->A&&SUTFL!U&:^ 2P:9Q*Y!G-<.?<]3$
MZY$.E@;DQ&O[/@7C',T/0E&'=KCQ]FR6H32U?13&XS,:T75@!CYJRX?0[&W*
MO/X@ACE"3L,BDS<:D_Q>E0.0L^-EL@&\8T)F*XECY^S'97(?OPRUN)33Q8 @
M9(L!R2/@HBWSS04K-6F6>"3NG[P(]&\),_TECE9&T!$*8 '\]&5LK)*ROR#Y
M@-/ (UA:A4+E&V 9R]4Y3+P_#[TT7:Z%_6F9W$+X['@+!Y*%)U$0AG.+I)T:
M/4PSUZA/OKBP@=[1A!V(,Z.F0DZ3G#DJ*&>$!6E$DU-W:[<UPD(A"*?,APOK
MK#G%#&VQ$REBACCI6;J&.]+G4-MF;#X&U..F/A,K98S'?0R_$B%$8#"93:(>
MGRK'9) !*5F,OU8Q3S#A8\GBL[7TA;3G:MK6<[Z,-!_*,92L@;NR!"-[% R$
M]7-W9HDL,3&V0DR9#5<58LIHJ&U(MWFV>:$84![0.M;#6H5013E0)-+Z'$MB
M*Y+X4N'N6^4Y^:620:F:F%WY:](U% >H#*I+FF$XI)-* S-8%FM-Y;/Y?M>M
M*I[((U2&9V(/8\''XS&1!1P]NQ#3*J!L%;<LNX*CAE+KJ_@Q@@JB]]XW:4ZZ
MBGAL,CB[V-S8 D+=B1NVA@E?22R9*6HCC#):^CXG@EZNS/M&MI*L*#C!?KVG
M7O)=KH3XX/2AT08O!X?:P2(D7@W/JW+@!.1'"%W4'*R[S<2.>>&-%_A7D?"-
MCG,'*IH$B)X$D?*"._,&FF2K[H1+WJX4;U8O1&Y)67]-.8CP,KF&8R3M90>C
ML)6>5Z1^$J]/=A"F#0. _2C$DRIM8WN[+Z5A!L5)5(PQNCSJ'!A#T@H*UAKJ
MG V^"K \?7;-[C/]$M\_Q;N4J3E,P[I_82=*O-CLHF/_")ZAEE%D)LCN)68/
M*A\,]:H,AY. B($<$*H919:E.IML2ZF-L2L'(6P4PH>1,IP:"(I618XB*&VR
MK1_L#^\^O*MGU*$#P@P8]7SPID?R4X=_J[E-W(+@&@(I=K\?1KB8$(JX",MP
MXR7+!/%!.88@DU]1)1N>+Z;C,"P@@@Q>-#Z"0)-F8W M]3A9+>6-Z=KD@FP]
M1VCF5YNM%R2\=C-X0:_9_>KSL_EO-(10R*\#4G^U^,=\@ 7W+.,(7 );$!@#
M,[W9* N"L9)'R7%X*+-'R66A]I8: -3Y$)@-D5DW"8[X 7+VJOB7(Q\%11LX
MJT7]M/],H)AU$21TE<6,+1$5E"X3R&O:A9D9!Z@:8*$"CU*RA%!6-<CQ,1CV
MYLV-L&R%R4HPI&*6*F;9@[G*Q[&>>O392WZC&/.=&UQOXC!8#579<X(%B!!.
MD_PJ_NO0Z6V.PX)G[2E.,AY]=!6!MW#CHDKCU[O[!.NG(%IPFC,TZJ/[>D<D
M6>&XUY%,'%G\#+.F[]77G^Y^*G'H(E7QS%8JZ=D4J:1&N D[&'&:2FJ$HX94
MTK.I4DEODGA+DVP/UI8,PB:8[+.%"0Y''I,D%VC"R52]CRT7F1GA8V*JJ,%Q
MNCS.(V<I.C*6-,VM>[,<:6PBEA0E\7&8 #(T5J [6@8#R(/3S]F*)5YX%?GT
MV[_3H?*0B$H7Q A2(XS<)+&\/-*)[8IZ7<^],*3^V5[>@J+A4-]I2QQS'F6E
M21=\> AN4T^ [#%-*+>]%:J/.%/O@PAOX>%Z>E2"]9N(=?SB;>BHCQ2]&$#%
M61'Y<=,NO )R[G;CH&$OV44OCU%S.(S*<]9:CPU;5]7(U'FK"[V2>=[%H!BM
ME^5H=Z=+I.Q&9I9FLHJ(-BH]'@TSNN@CJB)/4V#4&$?%PC4<B( '!]0SMB"G
MCX\)?713X4!+Z3A_;Q?M7.1YG)^\GQ3MVR;'\@KZ_CFM2>!A[$X W%_O'K0
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M,] 4@(>.%Z-^^6\!DT/85[8?Y6O34&D40;S)OYS^XLSI9I71!@R>"K=6#S&
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M'0QCN]D%+)O58E;1DUO.UP>[8AF3=+#D"5-R;^(P6.W'AA0(BCQU@W":6E#
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M'B;B5A=DN]$5-IXBS'8"IO"CHHS/XP&U0G#6JE;D>H*0V@EX85S46E+,>FR
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M/^D'T<_Z87&%7H,HHHD1F(C-).5:AZ7X-O+-Z;VEKM8S)#8TI'%THX<48TG
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M4U[L.EYN_G$,$D!]QRIM=GH, <(C\B'-C" (=K70L0_ Q<D^L>#?^+ @7_E
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M2/)96-"L;(,,,:X3#,("$YF-%SYZ@7\?,75,H\?H.M@_(%12V'Y-:9#;*GF
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M!3-:A.UR-DTB[3+@G2JPS<CX.WF-@>LX\@'*W!=+(EUY(: &/>\0$NJ]38[
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MP4!#M'<\74S /CCNTV9IJ>-@KMW\YA)QBP'.\^CGYPNOX2%.O?!3$A\/$ $
M:QKAUPUK<DSZP(+P& >_[10&/O9*6YVHOQH]N1U'>M\XTTSAU[^,6>VV0']9
MMRDWK.HVYDR5>E.[F1L.8X.2;DO1;K2AM63^I'!_@]R5(-6.#;N^5_G57H=L
MF6_B;]$3YIM_A\ 6A.H2*8MJ)U9=E1&XXV!NA+_J:_AUBT6<191U^ZC% A%P
MB*C!09G\5\KD"+V"$=@E-H\935C+TI4$W\UB+YL$[TU=[=2E'('N878BU\2X
MM5ELJ^XQ<!6V-065S8*;0]0>G-L)-8AQ*VVU%D%C,WE_APHQ$Z3)48*Y9G$%
M=),Y6X2#S:*(ZU0BI5FLVBQ8/HP -<["S7D!#$6QUK&,@_+4W<>Q623KLO'G
MO"'["FPEO^9,=N&0(III-.PL]N@(XE:K&-QY56M^KXAN6V!M")*>Q78<1E)M
M<W/,F:UM38%M0]\'Y:V[$D!G.50K;LUY8[:50[LD*<R"OX/;#P>JZG?I53S'
MEAFZI7MPU..+WO+#B!!MTDM&86N,I90S8&LK$Y9AWLLLMFEGH4'+\5FP;ABA
MH4VNTBQ.^."R@FE*U2PV[202@2HIC''XLFO)#1_O4LI.FP4/FU^EJ=/?1F'[
MQ5^]9AEVL]C24YEONZ;_L448IA*-NT:R86[G-FF&@S+6U9MCY N[=>[9&$RG
M=94PI4GF$NL'O[2[YD>.LM%=N\;=VNB__B5G^Z E=)TLM#9"$*I!-N<8[#W3
M7=V/^8R1EUVK>-P]:IK'^\[JT5BMOR4&K2I]^1PW3H%F[!VT_/3EL]<@7YM'
M\+TGL+2/CNR:/LYY/D'8I)W*0 7[OA".%.'A>?+\>90"6B6O7L1,*$65(YJ_
M\2A,?;5EF\@+BP)(#?#:PXQM#VB)K6PCX(NDH1M7PJ"+6S(.25@S76*:G2/_
MA/_GU^+</Q_W>R\YK;;/P6L4;''G*&./.BE4'P8; 8+K/"Z#^OR;ZA*I.]@K
M9*%;CS7F\56H+M!AV-F-X]V\7*6D:4.^7/HY+HXPM>H16Q4)KUUC62?U-J6K
M_CP.+A<^L,+V@F]R0D'#T=5VL5X.6IA5L5Y-A]>PLQN'UV3)9!5,FSASZ<>W
M\@SGD9F?L2*"_UU"^CR/PYN34%#5='BU72S6+$F"-\SE-^(&S^?8=&P;N[EQ
M8$V6J9P5W\2-2S^J@HU!7I+H/,ZGB;.0AWL8B<NM1K()LMPX6?.WN>MH;IS]
M'EN@$KC2C:7SN2G4#B"28M3@LCBOB^4&O63&M>H4C2T^]N)\FM]X>6LWCK=^
M(<J/NH+JF9Y0$255\!;BLRHFJ-V@;; )LO,ZG6NT/\2)EYRH;\/XH#;W&QBS
M6/E!V)XODD-IVLN-PVF\#KE3T(0A\SFOY""^5 %?S\Q-59!#TF%S,L3$>()L
M2PCEZ?--3VJ_0>T]O:;SOA+GW?A$]QS5C=MBF(U2>O+[<OO2KYJ*10[$@("E
MH!&1'?P,*#H_;YB&$/,*TZW&L%@3UF":31=(RT'<N"\Z+7(90*P=ZR[]-BB(
MOMT?POB$T!6*L/Q_;LJY>-43%V$64.]"F[-O/(*]$H%XAG1^)&WM$;]F23Y1
MOG+F=T#GX9RY#=HN>BFCM3,S+_U6J,@(-"%P[7T_-YD@G[CQ+:#K8;-L>G52
M32=;V\6-TVNP.!7L.@T39G8BOR!2L.,1)427.:]3>>LE$9:Z\MDW'$EE<VOG
ML3JCIL.H;N_&26Q:$/$8:FB?V1E\/KZDZ!]'_(';M_,+8ZG.ON$0*IO;"QRM
MS*@Q5E39WHU#V+0@I>!0->VS.X0F<=WO\=WV0D2]-""U&4I3.]'_;0P1->ML
MC;BO*5IM;],LV'N9LH!WI9%%JV&TP;N=9H \!>EOU_C\!QG\I#2)J'M8+1D-
MIKL*@)+1?C+K:XVTSU[R&\H@UN@9;0"HEU]=)P4]F@[VWF7T"O:3)W0 M)]V
MY]VLKS729-'+;<@S[V_/P*BJ+&=&H7%W>[:4_0&O H$$3CBDR6K[$$.-BS?D
M4P0P,V([#66-\ <HAH0>( '8D#Y=CX&#8EA@Y1.6Q[#$#'?T#7I#84SV#O'9
MZJ?<<1"+EV2(AWO]A"*4>"%$EOK[( I2\M:^(1YY;7IK=AILX"5\Q-(-?DQ-
M%TO7W&*4)-6*Z(2$>F)DFOD$5177C;L/S'H63\O#DD\F;U*+CO9.B;3X]>K
M_#WW1#K%.QQ>&[V@U&4D^^9^PV=(U=QF? )6K7?@7GMCSJ,V8I)Q]X&/$0L1
M>O2P ",FEQH<)-.NSIBLS5:BJ9<]L ?T33 *)'&$?]S0;,(V.ZWU,&Z8"MME
MDIM:8&91JK@=ZZKVG5F4%VS'(JU5:1:EA%KRR\Q\-0_H_U:<TUG'Y@'8W0Y
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MDG[3<:.-;!8FX"7J0=IHN&UE;>WS&<NJZ![_V'BU%0VM5E"HX,_A79U+?(5
MI"*FQ0 6@>SQU#+ 'J#IIMI=I6@\-$(V5^V(&U8O71AT&'AVGQ+O]')\_3F
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M:AG8#FM]]5,2,+,YS?7K2X"WY%^/T39!N/$=*O_?+N@3Y@1W*YC^33*6<BW
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M3 QMIO#FU/L#EU)0C#%?=@(H*?:JTGVVF4_G$V>/:7^-PN-S]IC++)_F6*C
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MJYV"7TE!:8DOI7X>']0ROC6(I%/R#)8N[J>9(PPR 8U/?+^!O=KM$18C4./
M\9G\2./_1862UP/:,K@TP>^SG*789VS/*$58=M^3M!WH'87QL8B6*G4[U".B
MTA,4,V*?&U9KHZ+(2_!QAAS"[>W>-=E5CY7J(7R=D85Y;]RJ0]I_"VK=(>Y1
ME.NKF9J+M)4$U$U\'F%/&TA[T>6)#]$>(:VB*"#N45YRHHI[1G]JAH?3!O=
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M>"DI 4;^CSP?WKVP4-^6E8SP7OWBA<2WNK7@?D=$_8")[H]_^I,$!=M8].?
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MC;L:F5H&*.B,.5/%Z$>'IH:ID/(YK71]\V/2M?=%CI]-NO5-DZ]02P,$%
M  @ 8X)\6$SZ%#>1"   AS<   \   !C86QC+65X,S%?,2YH=&WM6VU3VT@2
M_KZ_8BZIVX4JV]@&LD'V4>6 <TM=%E+&5&4_CJ41FLM(H]5(?KE??T_/R/B5
M8*"RP8M3%4!23T]WZWFFN\?C=I3'ZO0GUHX$#_";M7.9*W':_5(];-0:[0-W
M"8&#4J(]T,&$F7RBQ+_>Q#R[E8G'>)'K?\@XU5G.D[R5\B"0R:W'WJ?CUANK
M-I##Z:#R:377J5>O'<ND%<ND&@EY&^5> Y<#/:X:^3_2,-!9(+(J[D!/.YVJ
M"'62DXCP&O4T;SDSG,*6?1;R6*J)UY>Q,.Q2C%A/QSR9"@YTGNL8LKD8YU6N
MY&WB*1'F- <-GTXSBF0NJB;EOO#23%1'&4];<W,W,?<WI\-<(QGDD1?*O.I#
M4B0TR<]O&^_JK?8!C3UM'Z3XC_C8.'U/%S.*\+*/OE8Z\][6[;_6_1Z/W/L9
M:!6TEFQ[2@BZXT@.9,X<RNX"L6$('H[\_5'P88#(7D@8SKJ]_L7'B[-._^+J
MDGV^Z5W?="[[K'_U^)@\&18O*B"]FT_=:]8XY-7&T1[?9U<]UC@.RHN;R_-N
MC_5_Z[+K[ME-[Z)_ =GNE[/?.I?_[K+.69]=?62-D\.CRFL-7^>:=<ZO/O>[
MY_-@HG!9@!W6FQ0B&\%.[T/GLGM=O?KRJ?O'-'C->KWY^-B]>SH;URV[F\;N
M>:&ZJ+!.C?6X'PG%/HE()),*\T66RW#"\HCGWE(@YE)8($VJ^,0+E1@O@NB_
MA2$%TWFL1-7D/,M;UN$JG(F--^!&*)F(E=#,K#VJ_7KR[I\_*E;E[%-'94+6
M5JV_WW#QS6FC-HW:7+B<RD:]OJSP![UY%O&A8)D82C$2 5ZV-*R3) 57K">H
MB&$Z81]U%K-&O?H?ID-VQI4O?Q>!]'F%721^;9:]*7//\O<&("&VO':8-+<
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MLN5VD?AVOV]_M]7PZK<:.@I%/Z(K003:A:+]+%\*P+:LK>Y:_I'@7ZE8<DV
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M5C. !U6.)OP&_K)XY*G)5,]#:!!WT'YEV*<M2 ]9.1BXW2"CQ(Z A(-6$R+
MR*?><2]TH'/DY8FD;\):@A76%@Z)#1W4)<ZS"@HW0\1[:,>_9])@=]-:9#_
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M5R!^@4_GB*G._"F] ?Y#SH2%1+@_[PZP@BI+B%"/!#M@>!EIY'@XB\2IK;>
MI7%4AR3M2<AWQI?#;M(+'A_HY)LG=B!O4CFO/8QE=82X[>JD@#U6)Q4H.DD)
M1)Q9E\= <Z?I#7< Y]Y;7>,X,6TQ$ U,!GFEX3>V4'MLX=IF0X8MA\Z8VYY
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M)W2QB42A]\?'3_X&4S\0A_?9%@_$_B_F<Y#M8JH*52]1N6#-^#AY.)$>5YC
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M!V]T@'WW"Z$<)^V>CRSD"# 2_(#Q7E)T\0FE+FDS\!S3=T6FYP[$258@_LH
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M*0"9^R(.<<R*Y(1/'ZY2@&B]/TT""LRH/*SGGX.\YOUGQ\?D]Y/5]@6*IRA
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M[XK1ICWRE5H"W>"]@6<R(^]EDXMG.F/$VIL?ACG"EK0(0Z._$&=E$-SV8*8
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M<8Y2J\WC+>0JC_Q4T\-9D^V3Z'&6B=IG+KP\W2*>ZO1W"CI%'X=[/? G]5
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M,P*,2= #!U_D>S+(VZ51[D*#OYN/JP+&O[1KH Q3J!)W]H.PJ\NEE//3,RG
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MM0M08@!'IEU,48DW,CM"7E7H6ULHEX?^K#]Z).<#?GGS8'Z/A/&T=>G9]RE
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MC="]#=:UYG#A:B":.47J>8#"B W@82"<%B%?MGN_JW#C%.VU]5'HRZ7:$*Y
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M^L 4_3A^5Y-I+&F[53OO- -,>[7^^B.,*,( #<#IS(AM+.VWIGQHIMG\(#%
M)QF@%8W_(6V]42BFM%J)V!T:;&=_T1Y<BYOI!XR*31,-@XUD+@2.CN=DZI*9
M+S(68YEZ>BS!N8 !NO270<U^WZ\^_F]$;Q-,CB7.SC7[ZWY*\A\,?SQ26<[^
MRV5HRP^$*XDLG@EN_27?^!9&]Z4\9@V1&-<:15ZM$SZ4%X)=D:COEI>CH[IM
MVN>]^+\)JQ7;8QTK=D+2'B>9>'/67[*%\NZ"<Q>YK; U4;_$_V+=#Y/\19+C
M8H=Y9L\\%IJ1&RD6JNDSR\<6JY%1^SUB3_N[7AL?"[5C#-"+,@:(#-G=>TM
M55JF^U2ZK*\H_]POMP0N\T2L?SK%^7>::;+8_M9G8/&\I[&+,EU]$[_1@7Y1
MH+C_SUZ5]7_OJJ62<.T&!P*^I/&LTAQ),J]7?CC[9.!:"VT>]>F(NQA?^]BQ
M:'"9+W6 95[1Q/0YS3 ;&&L6-@A3] NNZ2O7-</*V=O$\D4(&<QH.O7\XXRG
MC]8S!LBQFP5))<$CU?@7A*-*@)KF<^&(=\B*EN99+G$4;98S]UX,MV\=B,_0
MRBZ3XMUL 6_UER*TMHX7$.N,]).,RRL.7KJ.BZZH$3I7=M#O<#)H>3ZC!&5)
M=)9G RS-*/LROZ'M%Y[$3X[[Z%;1*GMJ[GI?9(\ #6;4(P TU8^F2-FL(V"4
MEVVDR>,!)[U"-0=J-=.[[&US;S2[:_$W?E(X2ZV=)K-T@':/_VZ+,N7/HMTE
M#Q935%O@X.55NY168;9?A(,W<G&/"[B:SR6Z7RA6"Z1<$<7PSU0C5N0(>1@:
M2*E.JL4&_!6*\'/+65!1#O/$X>K6WTD]3F2Y)RBM?%HJ\=A643O]<#=0E48.
M13>I8AF@CPI4 RIZ&48YS0"9S^ZFK8C@AQ@@@2Z\]YL>=J/_2$*9N1(-X5]"
M-W/_T2G< S1FW_&9TVM4+J:GF/]19%&=%@S[?@<ER@#=2X'MBB5VFM[$/X68
M!QA>S*1OP,CMZZ\,-?D_/_E'[XMCMFOOWI:UD6: L$QNF1XQ+8,'MAD@R<A6
M^ : _L%KQ>;-7+^3BPQ0!#P%6IA#UQQ&D[48(!UU33Y3EL5?^Q7[IZMX:1=B
M5CI4-N:O85"I6Z :/'6T.'4_/73 :Q\>5M!3STNSJ@40>3ZWUZI[SX@H"Z1_
M#\UYE1J],AZPUS]5*Q4J8H;2J%,NI<,!]F\HXZ;BST3**R6G3B_:U"[.?LC.
M/TG3J'<C\K*?'FY D?J\NK32FM(I-!T[[Z]URVDV "-T6O)433;Z\J?SS]\\
M*.QARN+:;Z)P (+H5_N9W)TY1?.OF43P-J<! \3" /5H[E'(S8C8]X_*PKTM
M$+2@%?12/ -TW"JTC0$*+T8) 1K$M:-Z#EYL/9X+6,U<EWH/:5I>#3NH8I];
MFS.V'ST#83I$JZ3M ^](8(X%&RBY"$/H<N]%E/F;#.JJUM@O2.AGF?D]]MU,
M#YK#/Z<?V<TLUZD5)_DCB+C0#3D%$S/7#3@;+E3\V>"7R3M<)H,K'*_?7[FR
M[V;!(8\HKN]X(;PCEHEA,ZY"1>X'.P$6+._9=:2U9YOWG#/F2J4.M"_KQ17N
MFK-<+.N7BKH;(*7L+;%LBV(B_:YJ:DO)28%0596ZF&?)E^OJ9GK:0"&3B]MF
M9;VY@N+W7XH:W/1(@I/U82S(E*8 9?@1?:@6"<\W.>ET",!]C)]8L7L=_KP5
M]"KZ ZV2+>:QCU #:!T6!1&CN2&H&JA[/7C">T5$T(Y4L)RLJV*TN$F?9V=0
M+O1E_:.PD,<E^,_[K@K :@7;]Q27RX\&$4UC:]W(JYW&0%=6P)=!X:%F *7Y
M9"?[=8[>7AQ&]?H>D<\'1<\2E&=8HNQ/UM7W;[+W>C53>.!B2SW %VKKCGY*
MSEL-JJ1+T:.3Y3A>__S37"4'5S^5W+5E>ZQ[8!XE3SV!H\FN@9%#[9/B_?3C
M<,> PW"N3N[-P+ D_=+7 LMK+Z]@<;/'6.-U/GX9!5&FV (&X/QT)<"2 '^&
MNIR_8"-,P48:W:FLH90Z/B.RY(S<Z)6;*"]X@9&8<SS0?E?HXHSM()T+=14(
MGL;'C*8U8L-3Q<LH7\>3SU)X(HD%_I<4MW."NKYG/2/N+Q5\</]""4D\MUL?
M3TI:7E8[;8V$P\G=X:YJ$.124R$#-%R]&YUO]?Z<]KN'N)<C83KW'[+.2MP-
M5%_D1C/WX-*LM4"H&P:@MJ4J5 *1%$[C"KW+Y:_+@,)CY:7792LV-RDO>?,D
M!"1?%8-ZV#__>L"2 UAT 5]VI$U/%.: .4Q0BYVFJLK40=0'%=]>0*]H^<$O
M:"=FCRD\3&*_9R=VM_VN-3ET<YM2>($!XJW5(!FP(6-;GO@:Q\05Z&7/"SQ9
MX@E'R$7HJ!Y)S+3C6JD\:=W I0_JV'%NQI?R!&?3W(&G%(@9_0OE:/VI"_M&
MVZ@WHE/TG!UJ2VZ;V(U;$2J-VWJ',/9+D)*IS7S:$P@YP0=.+I,C!=&A"KNO
M2P;&YG81:Z5OIQH7UJX<0NGNYI\ T!D+R1-I@31UHMZ^+5V]NTX7<+Y>)=O<
M0B_>NXU;:\GVY9^V%3X.C?$I1.^CCPE#6M:$H@\W3')3P!$KQV/:+%>N#CH+
M<N=;7XN_S@#9)\^>]#2.\ZX^;A@R0ZSJYJ,WQ1*Y'UBUDD1ARS@;OE)R^8[3
MI%"H8;(B+BH]N74V2:"PL>3.^R#H1N/1;Y$,T-Z-(?$R\H6W1'"XQ76\/<%\
M.:OLJRW92L!BYIS%AW-C&OY'J?$G0:QUUA]4UE^PS*ODK+02ZE1(1@,)30''
M:\C[D@I$!1B@MA<B1HYL#2^N+1]3B P-/AKL:'+BXL6/_$MP_MJ'1"P'8#>Y
MWJC&@8 X;1U^KW-?2=L3N!_U[&9?U\G'@6""B41<N^_V:#N=8RA]GBXW(/FA
MAOPF5:!^4,0T?LR$+):6YT1A=UES%MUM(Q^7>^,:_/8.P<Q++(]J%-!=/;?"
M3=XR(,>$DK+)8F]%1[L"XA:R%^0)QL<L50I[XL2T)37N3N\YQ=H(5:>Z(Y-:
M4GG(4F&*:^ IP/T[)(P9(T4L):LE2*B4+-Z(^V@A8_Y)^F/1&.@>;J][ ]=0
MS]0!IL'-JYU<M%$DTU+!0[4*)/2!]^X3@+T9]6+E:\FH6C!?W*?>\_4'YI L
M3[^P*\V93A7/17EU[P$TK@RH29N-3" -;"(M>M>@L&FJOYJJ<<R1:X&6VU^>
M(UQ:8]S/5\X]7JOGH'?OX)JG1)&X]M3SE#!*=S1-\ZA /%PC^\Q;A(OC?C4K
MWJLEL"<2Q?<-Q-X$^K WPL94K8MWDS80X6F':;#\C\FN)8,09YSN;=?>M9NL
MG1%,C;PT-WX4:)8G4Z,T"LALA@W0#"FA%K@D#4I,:@6=Q]H5PC9E-J*E "[7
M#C^1IO X6=.0BO.ZM?_+?J6G.?06X0U<(P-T&*50!;Q)"A"L'SSQM2P+ 9;N
MRB%NK;B+5Z9MC<5V)N!<%8+Z:@PBIDI0<'[H0U*T*YK?:L$0F=;825!@R\*N
MR55\[@NG=2O,[7V;?3F=-ZXF&42$NE#M=?*04D23:/OTQ4DVRI=$@NZ$GV[R
MXIS!P(FX$Q-"#^-'?4B')%Y]1GPD8?QL@B@W^IMAI5_B**QM*B&=SFB>L<71
MMVLOS^L\M1X^$7A>Y^(ME1=L2 DTV6"I$V/B?W6KW4+S/2[@4"TY<0(72H/L
M2T%(*!SC_<QO9[?.'_)M_+-(QO;].K36;JK]5YC=")T7R0"U3)&3QKJSWY[>
M<+Y\R7/N.XB39[CY(VNZ\7;X)9EXU5OL^Z=PV>'OS<O;(Y@;&[ZQP.?=!#)(
M@SX<,LQM,[F?-G3MW&>Z5<W92:L4?7"_JLW>W3)% T%@ZDH/HE:(&'M@!!FJ
MG6+16U[GM-^VO X7S/JI039: FE4B3"6N#O]P#YB '8OC0])TH\9(K*W;M>:
M**:!;1S4Q+[38*(9(R)AJ*3JRCUVRH>VD?#:H*B-DW7BMW9?'Z\>JA=<Q*GT
M3UH"XLVX9+YDU).G(D;F*_%[&C]G=ER\2?I&G4+:*K*TCM&G1OF2[4,WMNEB
MR$Y],CS,R^Q'G7CKD1>6DF^_+!SP><\1%9?-]^%,D'M0#!(#YP@83Q6CJ&$(
MCF>@1XAUX,9Z6;R*W5,2]_5)MN+ZRH[]!PJSS5Y>S;%5 8V+[7/[WH5MG!(!
MB)V$G"9=[?IC3C8'>F@ZW#/)\(A:R&["OJ2<:]WU,M&Z?I(DMOMQ/H+L$F\"
M*W<4&M'%8E7I!M/^G)9 @0\1$E*_?^!ZSCO 89ZB_ECB:MO$F3/-"=*:E=-[
M;V[-G]H3^ASV:-[3VI74[.&8*@<$81=3)884=\^,#G[J.\TW4GMWK&CH&N_3
MXR?,!>_=6;W4<%D/N])%B.P.\46$WR<GA4_9#*#4Y8,QM6(59&;TKY8I=$)[
M.Z'S0+KK&3C(:RX"T8P='J(?A$1:&$3C"?)4]+!2M+<Q%;QIGX2GZMJO;FVW
MB]ETUY6M=FL6<1+;E_N5FV&L8T["KAABP=3!,6!GJ;7Z"8X YXF^KB>YZNVJ
MLWQM;/7>V/=SL=^VGS9%S;!^I8E2S36)$[IM*CJ &TE.M46,W^6R$K> I=G#
MZJ[^1"/!&!/3:Z :E6*12T*7^->NS+#VU8L"(M/PJ.1O&$I.NXE*"#9C*4"R
MLD_N!\:R)9G/PJ6U:>S"V$MA5$W403Z[.^N<:FJNELG4<(\R^X08!Q:'_P,2
M)D/$CGK<H2BW3HV6-L+ *$D"!M8FD,K^ <VW9.%:D*\4_3[A"X8M7WN)#W]>
M1O'IDW5\A0+<J?<*)+X/F#,!G,G=C?7LE'R=##TRFEC^]"LT)/Z;C)R R[JE
M=I\TJX2&QS&73%6C0&W^I4EAH)C<3[1?4:=>6=S9S)%L;Y8S:GCB?6+Q.V>D
MF2OFGIK5^EB2L2SKM&SXU\!1'?Z=0_,EXN*Y#^X]*SR__T<.DV88-+W5($*3
M(9'?AHI0VFI2RH%VB.><^3[.T%'M=66HTVMV0]YMRU)J5Y9_EP%9DR[22!&?
MAJ:!5I66TB),E=W2PI[I8$6\TJ-V*Q?O/TIW4[CP&5S7#W 'Y/2;*)K8&1O;
M7;K/+A7E =QBGU-NQG/,[Z"#T8[H2)60\")D?TLJ/P4>MOPC6GK(M!IG=B)N
M3]?,>]D+"K*AGH%'#@2Y'HB81=O##B-MFR'EH8W4--;% &%<+\THV\9L27<Z
MQ5I'-J>:"GO+73>0=$@[03_4PW7[@:@5%R8@H]]00&DTG]^?[^XMUMS?:R<*
MZ*)(=TZO-:4)(,=NL6#*+JLX3\E60-N-5<6["RY\%5NQ?LO'LFU.F! A(I:I
M! 8H""\,-2*(JMXL*1V<Q5.4PS ;H=7U-66#$OMLW5QF3D7?*KL60(GXA14O
MJMR:$ON\.G3E',6<N4*H7387,P024&JV<M^OR*+2K0O5NKZ_KIUXO3B&GS;>
ML=1[8#I6I>%R24@4C $%/'*$"=3*_7H.VLIQPJX^U:8BK;5>I-^H<>?)NWNY
M!KF+89XCXM9AE-?F6R6KDZSV;HCJ%A_3)HYZ(22::+]<3C(0VT_H5Y)GZW0:
MS6H:AZ44C$T($DV&.29#6>-P<6^^X>$73C^>O4[>SQUSY>+'7?;9&W?.[0V\
M\2;6"43#[&:=3"9MO@+*V5M]4*?9,M19R*C)"U4#A+,CV\Y5/^(<@F\V66=%
M?+,F";8Y+^U*Z5-,$JA[%E^F*@SB"2<H>VVXZP\M1N\E=[A!1F;.*8:K2&08
MR-]U610YEM#E+]'[/EA7NMBHRETA:!&FX@4*0*(.[::AT!3+34= /A]9VG;!
M-Y1).CG-S8$4 W+JT\PRE>CE"G(2#A>_D'U7'REYR_YRI7A3+8RTQC4,9$[/
MQ=:>V6$/J57W(SI@4#J.A(VO14JZ(GXAR-&Q.]7)6N:O7TD3K]V^$?_ZEO/F
MH>3<O!JGX''WQRII%B#:LUXZGT.RU'("V8C$7[M32M.$BUJ,-&/T"JRJ*BI4
MGL^[$*/P+^,('H&U+Q\E)-@44'SJ^:P"^O$"6BM:7H57Y.B=4H'*NOY'.1^(
M[[O^@:K\R6[]JGV!*P/TU'3!6"D.[CK+73;SP%.MC(7,WF007,V,04<]2&>R
M7'<VWT-E' F[6DV#ON4;,WM4NY>7&]T\^+)LF!R: ;+A458SE1CJFN*4W9CB
M50ZV-3C(M'Q8V7$*>,<N\\G..%U&6>;,@YC-O<$]8XI.Z<^@B59'8YPW;Z3,
MYKQZ,%KS<=3R**D?%@T*L* /V9P@KT73_"G9W+K:/9X0"!!PBM239"2,F:Q#
M2SQ9.F&]D"%D+)?!YGY '!R7;+7'"3Z"MP(\G*GWU(E@OAL%1'DAI)3F0"W,
MWTVTT5_C=O*4RT#ZT^C/C>MXUJ"(7<WAFJT5$4KT\)S8+S77IX=% ALN,T#=
M?"S ^F[L="3\*0-48A!-/V$I@W2=:E$I#RG/M^)XS^'J*H7LI=56*(= N2CS
M,B,PY\XN\1:XV$;8D;8D,2[R8 XYOZ<=T^SHY;;GZL[[AZ@?H8=DSY\4]Y9P
M,;WT _;^YKL0P3T*J?YY#JPD>4 *'N;).02$9R+13:E'^S+Z764'EVS(9S*]
MW0@KM^VBPR_T?F&/7ZR<Y*O0Y4I]3;V0'%:<>^=6OHIT%(O^7X_2_ <7^-/.
MJ0S\6_#*K7_TOJ,\P(@!DM1JG-H4*F6 >A>LRKU@?TP2%[U&[U$KH66X:>TN
MH@FQ<V<S(F1>K?S\,L5_OU09H-BT[V:UQ@P0/)0!4N=O,$53UNFZ1R+P2TR7
M.W^B\L!:.P-4]Y4!XL-?\#$WH$5^8("F8^GQSR).%;%^_:V?$7+L<R]Y$>?'
M"[Y6:H^^NW]&:@_5%"^S,T"6&#%><DP6R<555%XWM"M5WSR60WCKR>5 !FC)
M"UL2((I2Z0\X.A_Y\$&]R^=7SBD5@CXI.Z>65?W=G1?.HU*S'QHE6QA9UM-U
M=WJ 5$FBA;FHO+W!)$8N":$\.^(E"?A,J\)" T0B=<OBYEPF'_1?@M6^".1@
M!;180;[>T"$]37XJO_2M3#;]Y#*3]G43<5Y3?A/CI1O?$VKN:?*99/^6^_I#
M[M7$Z_?)F2M1BZ<RGO[#]-5@"@-TC K?F<%_-$[&9#- ']6&Z%7RW_FC*:R-
M!136)N'8T"F+0104EY_O)0^>+'^[?/'N2,1=CJMNS[3N:^X5Y><GFR[7D#>_
M]Q,-VKB]6]"":J>=1DV;$7Q6%A8C3@$RJ<0^9VW,H-'FJU?WX;6304_;?5<]
M86/.K7V. ?LIJ7CRERD=P)'D3,EQV(FN+Y];/%CVM+Y+L@L?SW_;.JUA^8Z8
M1T^@OX\FRH-@,.;7MF7#269OD3^$4N@OPX;03PVD]XX9E@W=W*J([Q2_EE K
MI@V7^%B#'A1HW/MTRSD^E/@2DQ7P&<:_T65J-.1E+DN7LAINZ'$VLAC7!&]&
MG8I[W^PAX5RSRK/_X[0PB/HE NB^LUN%<LN9]UV+N ? '[I-XWF *II\GM,A
MYWKKSVD+NJ"7^U&9-2PO*K[!7W_8Q^*40!RB\9WH;Z"K4NK#,\>0:KKH?>=;
MT>!PJ$FUS;N\K@_0.#/UF4KWH-GQY7<I3_L"U3YFU.H2O5<TLY RFWY] :<<
M=N[0C]&G=/EZ?B1(-TI.M(X8[KTY=_P2XM5Z= X&.9'3R@"%5\-6#'U1B&S'
M>A%Z%^#AE1=]$L97W'M&U'6@L.\FY51PH*30J'C9'O6[#JPKPC+$5W@7^4/
M8G_[)+CT QE'DW #U-;A?5YH;N#9-^* [(.VQ17)][<E(L"O8O(_T>[&E$L%
MPAQC(8#"IAM@BB:RDQ5'Z779A;T3R*164T,]KT/O'SXX]=*]0R*Z-NG8HUA6
M68\&]M$[ID^1\IO5O2AUZND)E.M7Q3S%3DX1W==8Q3&_X,H39@\<HMPZ@WF$
M!M@><84<-4T$Y#>I7Z$/B7+*S286\*=>:%X@\F95;8\+5)E(R=TV-=3\%BE#
MF3D>/*%Q*DZY:+9=_[?9S#! [/2Q) :(-T"4IDX9#)JNJ"#//?NAE0PX]9<I
M@PNU>..=^?72W(\'.QK<#KAU73M%9[>8&8#L.C<D00Y!66T)<'9@\I/S6QGC
M_@UL1=<CRIA_9F=U["?-VY00<=N+>^\F# :JY6?4"Y'7:'SK&E55Y-5BC#I!
MQF"_\Y#=B-R/*7[)P;KLT]RS73X/9Z7S*WHK):*,D%\>.W^E@VD!0#$E5+^7
M9IA#D^G#0#F(^Z52;M:GM 2M?#AF<N'[>.-,X*';1\)>CVC8LQ\-](=H!J!H
MHKLEM=9DW*9/SP9,K"(V?TGM!$5I-2YC47@H['T(&X=BO2<.=^@J*O?>*/^3
M4-D+4:>5)A>FR(9REVAL).><WA_^Z#8QL0%9SQI=^0-+G?[92X=M*L9LN4>B
M;T0W-H?&RI36.[ N)\O,I(767P:2"@+&!"SD8\J&:><+IG5<\25ET2YK90M3
M*[D"=POCB%<X-*H4VKG4\VW.[&:?40,O394)5"$RG2Q^I!X=]%15M_4HJ(V[
M<<8V&CQ"O%>QAW6WY_%G%HE;[,.>IL]HXL N"<*/<AZB'T62&C;5^ 8PB@Y*
M2Y?*5FQ7%B1KXP5I50I\?@]NGW5[H7V1M)>Y*9=#5M@HWM/XR&,(GG;FY]O]
M1:XNZ7VUX@HV5D"DY?BGDP[QYPL.6N%4K:^/EWI$@'8^10 &C;[H<+R3'J0M
MC9=I!"FM>$[)8@KWM_!TAV0QK&AT2.K@ZB&EZJOOK;57SW^:>S%F*H1A@+CI
M_6F':PVI,@",R)U:3%YO]F"KQ@W5JI-.2^DZ2CR['JY7=C!QLJ]$@$H2Y>>Y
M#E+KRJBW+MTM*I]@WS0F;\72X 2!$B <JRDA# ^6,^R9FN">%3JD47_QAM2;
MUB^&"O'Z"DOHTJ06?P/B5@-^+[+?_-G@D/&08B6BZ%[Q=3/>"?>K^^SNJA4&
ME+',__@O/'#E/W,%F/;" ]#-9VCG&*!W]@R0U"H>6(&0._%<Z'EF4-Y!Q=)5
MX;^@\Y%K<Z&3#-#VX9TC]!-B3(^KMNC?RP#-= ?.8_$P0E* ( /4P_3J"5MP
MVI-8X.%4".R'+//WW2$&2#1SUZ@=#57;8CJ94-HU: '=?X":R>P\C>7/!]?:
MR8FA(_W7&* X,!#F8TJCYFUI,<=18\VHIS% (=: +0-TM9MN,(&FC/X-D T#
M41J9.L4 G8!0#G[';F\9K<8R0"=1[)K^VPP05PVYG1Z<1DNK9H!(97\#9#%5
M=9NPA:=?@Q&/S\+75W,F(/2; $\$=9TNY$V(W>6$;<.\&*!VA[^!\17JO=Z\
MAJ:%H5LT/N'G)@RJ8;379%'^K3G:^;5FR(X ^GO $@,4T_LW&/Z7H \R0&&A
MB>CNZC1/]+8"L?OGFU7S%Q*H%VFJ/1NZEZ]W-D_JS;[I<-N;YE+E$B^^SRCH
M./M>GOVMQC\#&R%7*/7?FHON1W@/3DU\OT1JW[; 2J=^R4K6=?CA3M_ZCV L
MC_VK1E3^^R4SK2*SUOVSO?T-BCN4J6YP'0/T_3C3DX"E&: T+[5YYD?[!D_3
MJ;2?+.XG)/0\$CX5XL?L7.-_B.E?_>E&8\!3(';3G2P?L='9!;_=?_+ES@JM
MP]IU]I:EX!?6NR8(VOG89O3.7BOT]*,IFC$B@O#&Q6D]3^AZG\OJ#EXCB;7=
MW$:$X\9S@FK;.0/-:AWT.;(7/W/[^T,K"/D3C)L95/.Z,8E;*9IBW$7/)^&3
M84RYB-?03_ 8T1*H2;\^-R-JJ?9/PN8*&.&7 !&FP$Z0&"!6.P:(6( A>S=!
M#B!Y!AT47<Y:AJ=XQBL6K=(#BR\U_-A2Z@\EW-0JAYO%SRS9K6T?O3AU\(/3
M\_H<??T<_0?Q&T\0JQ=AH7">LJE0E1,CYO(I'B>%OZV$B-G1(U1YIJR2%Y=*
M&*#G <UT))JT0E=$-\'N,4!0&&63 1+>E8X6O)6==]LD8@02>O^<DIO70YO:
M-UEREO8BFD_@Y-AA=#>8YH]OBP6TEF%SH72U*9+ET:V+HS+_N,L]<_^PZ14K
MDK-6"^2[0!J=]=>[Q?-H H1)1E(A !4=K>.6.3)QLZ^39\XUQTVT>.E*D9NB
MZ4,&:/]N*.W7LV?': Z_'Y/GGP[C4-1)YZ6"MPE,=H0#>O_0"^<;%_Z1/T"&
M_0X&BT=T1HW\7SO3HHEO0M:;&2 (@I)^QJWLGT!B^W(A8AG_N[X@?X476&6K
MQR0I_MA==_B,=->%BX."@XJ"FBQ7-OD6.:#K3)P-4V"4ZE<HVN^AW H#1#LY
M6IA<D8/(A;I?*X$ZBV@)WK&Z;NQ[SK;C6VV!QNYSJ A!M^Z,)>(@@#?OA5Z6
MW:H7(X?D%<@FF[QV)U24:8N;N@3'-$I$'9$:K'^5$:AV=I=)=>Z=*DL+F>(.
M;;ELT,IK#?C.EIM#P6>PW&W18NF23V+NAQ7J"('+'PX+)I0]?/K#D=F .5<K
M1YN+?2*M:O+T9HIKL5B-1Y9_]3Y<:;5E<*7<H^P]MU2E0\8MCSU6_U8?GA$(
M55O?U"1[S34S@V^A#;G'CBK,?<JR!6<D2]Y><!_BN'0-(>,0ZWGW;MY%J6_=
MBK]&M)^JK^>17- MR9 HFNVT(_3Z/1?W]F;A*),>)WG!40G)#,?C+W(/V+!'
MAXEZ=/FY\+$TT4R <P1LU!1W42TO47LUN^^DV:8!?V<D,R8-B7'X]NA#G+DZ
MET?"FSDI-75O*BN@:C. V( <1G:WVYP9*.?F08"M)YQ5RO3[+6K$CS5=S<<<
M3O>49O^LXS\SU*]XBSUP 5Y<_]2%6 /C79Q4HN2$;S@HRF"Y.TYB<J_8IK9Y
M';!U(#[EXU\4VE,L=<:*6 R5HNZ?%^-(:,8):[5@PYZ,Q@2YG$EY&. EH_5:
M<?N"7>>W<ND3;"RW05ZR+1=)D)N]5\0TIR$C?HVI>X!+&)H\.!\9U+A3AD-<
M+JKRFON8][@U53+.V-)!XH7.&8Z.^SZ%&/9-<Q6Q<*\L!JAI!$CP<?6LZ%WF
MVJGEW'W+"N*(OCUQ6^=)=(;YH*GAEC9TJ,KP"D0>Z-Q4ZD$=)N.)QCE-8[I+
MHAHM8KPNG'3>8==[NB)+8<0'(01:ZUZK@T_*4N^'L,MR?,L"5*G\\S8B\#W.
MJ=)?:_6(W!K-.](CPP#">B"SIM_3YT&@9$/PU8>5LH&U,7O(/'M("]6G6)MK
MV:@GY_%@NP\E'RC8:%<4)$<H.C:HR.N.\ /.D]/W[QUU5NP%M<@:Z9X :[3)
MT.1W7WC"GE=OIKAE(.?:<YJ3[R3H9@/773RC3_9\;$G<'U:B'9F6*.EMV+VO
M[EL$:#M3;_<93>3]@H>9!8!OZVGEP>Y6990LWEKK.=/Y<750Z^,T++GQ)?SL
MV;;KUYV+O^(?XL% #2&F;AHOB$QHM5&(-*^TK-IPL3?JFJB=5X_1O2<L83)V
MX-E>P]RER@OZ_LD1(/)4*+[$-78:$B$ .YA-P4?7&A,+7"[H'5^M5<]K51FW
M5)"15I$XE7G/JJBK2K85=S@9'05[P*13(_7'4E9TK<* L5O]Y7):R^M-T#S9
M39^K1UN>Y TK[QO7U]^/160$7G0V>"ZLE-:FVQVNXX'R&L,(7.98&;U&/?M4
M\GP(9^F3W9;U&L&5R=K,5D@Q3S11/I)^'$BTIR@3I4)0>IA\3;>3D;DC;7$M
M$?SWHNH*JMLNQ"9YVS@O'#C%^@T1!O\ #@PX#G=V1S?ID.1Y'.G'SG5@YT<%
M"E^8.2N<AD^-7^T]NV[IM/I@6$=HJ4NY%?X!]AQJ3%@+V8'13J8J]LG1(0T]
M\]BL\>$6XW#!Q(%1OO.!Z>P'<J+>Q.OY*VN"4.T4UDV1?I1+^J@.K 41=H1^
MIJ^L<XQ;V::&PO+,8VXVXF;/M93,B7)MSD^GV"]B-79?!G#9T%@ $4+:WD6+
MVM'!=SG,?:(R?E$W+&C+3#?0Y#CM]-,R-YO2__Z@_Q]>OQ9A;@_]M>!Q%_L_
MI)3R/]/V$>KGTJ\RE+G#:2KW&/R(,]K[<R/2V[<D:Z,N'LW^A '"S_RE]-4$
M_;^*6XW0_V\INOV3QCB*S*UJ>-CD:>.JUW><<%=8CC?LKILJ[V9Y,T P(_14
M,UVI7%\V^E*EGVC:.KKA4B[@+3U ,EHRJ3:89D:A"$@>4]CXS<0IVB[3HZ/!
M0._OFZ;M3$&V*<SX%-V@]"LRV,X!)DP8U7;C1 0-1^^K84;=>?@UIK\7_@%[
MCA9"U++D^1SIT_7+L%)>R["3[15+Z;^\J^4[WTRQ%BZ_(]T_:X!90S0>->L&
MNRF>NI$M5I(GN>GC@M;RSMOAU/1Y^3IO=$D%=610(:OK_:+8)=M+7-P6V&H]
M'>M' 8:G;G"WW>CZ2]5I1_&\IVFJX16S'RK_JS(U\0^%:RRV)7^_+O7G9G\H
M:#7Y77E:Z95G?Y(>_[]WR737JZ(\R3G+"^35M;;4\U6I4]=QR3(HB]9O71+Q
M%[[>N1F5^GZ]5V?EBEB0YD.D0:LP(KKVW'L@2*O2LD[F3GG$]T&O>8KVNU_H
MUTPP?W\?Z,C2/N$C<3<NXZ6=;2!H)MF?&?0+0L&Y*%W DIC&L> [1Q/WKAY,
M.Y.:C!NI[W%YJ3GZ67PR)::O =6\-VB,CX6":T@;U6@7QJV(9B.Q+1:T!)H4
M\"[7R0(6HECUX8A!?.\O%I4@LJO )3]W](%-"'_ L,5;?'NT!R'V.8K3GNBO
M>_5"QHYJ-Y_%0E+_]D<)NY+R1)U*L]Y?2H_HZ[/?=ZM59X#VS@*N>![:I2S@
M?+\!62N:!KL</9L6[>+9^G*E2.ZU66U!G6[X6?>LG1<^;=+M[0S0,!Z^FUY>
MDSA(/^9H0%@H.I;*5TWV+QNM>)5K^#[B$TT[^M"EVP$/GEBWOTSG>FNTN4 )
M:B5-Z#:G[=E '$(Z-U1W?7N-=>I=&NQY%#/^[/M84V?]$XZ7YP)!T_LN75Q2
MDPP8-D)Z7R%/UDTSR>M\_8F>C2XAI0++J8/(MD[UP^)[KIU]_VY2QRUJUICE
MKO*W6E6"Z7(C1;<M&=W.+=9,%"LE]S?7'Z/48]A6W^8B_<]$[R8LB_D7EOR"
M_!QF?C.PNH(OZJ"W;^W4A]I4$4IB4<$T1$234'>N5L&18%ESV5(]U.2UBTNC
ML9_C Z^#'QO>CFA=;7?3Z N$Y 5,'K0!T(0S[Z;70JO;H^35)"S@NMF.CR=:
M$5!3@08[*?O=8>O6TM-W^>]4B#S5:I,?TVA![[M6Z@SA40P[WO^#ZK=[8W"K
MW=>__MUZ&_;\J 4AF?2IL\BLM?;=,(^F'CEM4SR)$-W=^!(M6E$,;C970I=F
M+G!RVFCX[M?N,'\<<BQ@4P2=\14B&M#LFQ,!U:/HZZD2)50,0NK%E=\6C(PC
MW3DGKIZ&ILD_4';7^=[:]#;D_)T]O+^\;6!U;H-4J+WS(L'!@"[!H-EO+7QG
M\UUZ,]'YH^6=4)U(@P^OP*?*X@MD;HP(1MGF;E>3NFO5J58:%*-&-0X*Y[S-
M&;)E,^4ZF.M"BBTFZVUSA]@RYMOP&ZC$&RCH^Y5MH,B/>*1IUVC3GS+T;./R
MD38;Y9Y:0UL")YQG44VZ3PWRUD]WZ%YP1#L'+G@$4W0G_P5\5APDT&PWM$RE
M2B(SVV%LGN90<_\\X#8=%NX.; IZ=?(E&%8%GMN?9)AY_8.NE.R5O6?<<!]
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M-B,O1W<Z>%]K=NP.O%!^!4X5!*6_S<GR1;3A1])N \$4Y<;ZR^2<B.5:F2+
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M;8:__8_6F@0<X8+C#4)?IZ &5N>,,.*Z$7M:WEA$0]S%65I)6EO&Q,11SSZ
MA[Q).X**H(N_1[B#0V'I6KG#._JN.)(HQB1<2LW4KUUU>7C#AKG64A^?6R/^
MJ<82;Y*-JR!=IL9LM38)3TBDW,?&U:%V+AS@0>;8Y-@<A?[(?$O*\#C'MHO=
MO!?%8BZB!N0I#OO8%N'BQ.HF;IS(6OMX6N]9:'YV;H>CF[/MLE!/R3V/NS,]
M!=3NQQ^\KKV[U )25/DN'0&N8H_%9"U9]>"Z.NJSP@E*SHL?C[XU2+KG-*-$
M_,J8E>OBM#\42+1*7WM>@'7]S)CO4)IN0RPN5O?&G*"IQDF<N'!,C?$0#.16
MI.6'CK\<\CKB_L/9N\77PHR?_8K2>=KQH)-":("@@G^%RP?%+5R"7:E_7(,>
M8,1%M_QPJO%M74^\X^GO)OB-XV&DXJ^<)PL-AAFQ";+4 /\\+:@%?(K_0CPJ
M):+!65BUW?B,H7Z>NV'8?$QS@?A9Q#1$')A:%2WWC<;KTEJ5-3&G2<@*RB =
M%@]!ZY$!ES.<.Z;A*3?--VZ!T\=2X"["!\+@ZQ:\O>FI;LTJGQGM<IJ,L.$$
M5F?41/ J5F2/#GI@7('I+Y6*+]E4M0ZPJQA>UJ%=U5=)$- 676F1[KHI*S=#
MFLCB]$2$(LH'HC4%<++[U*/;VXOU/^K2F"1L7R??XLSUI+8\.OK,Z)[3)(F!
M= U$(NA)JC Y3'QL@S\J/M)<.EZB)%\RS]&Y8&Z][XJF=QKJNJ=#1'?2I H7
MY[3[>CUD9VI1\N[6XP95T6A)=<9OFT(/R[!'XW\(#>[:2S"YW7C?]]R^.Y+_
M^MT[I[6?&7,=2N,UU> +F< APG7LPYX6542TJW2#G*.G/1E 6Q47X%JI)FEX
M-21P5:WI!?Z.)%<,L^RD2C$9$(;DK](; $)?+5AB'Q=_DT?2%3<8^J%ZI!GO
M"0[(V!Y(Y68*K<D7=]-YQ$-4:-2?T(S^8=*K*4&LV9;/$&]79(92=EFS8YT<
ME'P[PU^B);F5SRM.*C$]SNK';3*8W236MZG* VP<K> 9V1MDP&L^T!)'NQ6'
MT?#PO-C%;&'V&[S>DL+1G&E3CPH\5-Q^"V!FSP$\3'J?D$;928JX8DRYAM(3
MK$FP/)_3DDDT7MH2T_Y6JZ0#\B:I>"!#/EJR :!XZ&F0E=!RNQA$19JU9L"%
MHXD@O4&8T-(6&<"X:5)<, D=EJ;O/KL^V[RC)O(4[/I.J?*E]OAO@%V 9E1.
M$YA8"A>'XEN03"0&'*B9='.D@1?VTM_?V:=PT]S#NZQ5,/#UO;(IOV5_U,1T
M77P(J*HTNA+,3GB(D8[9WM64=)IG:2@/&S#%>>>R.Z/<67ZO]'"DKMS%GKHD
MR]Z\$O!81P!H,P06AKTBUG'H$S/@PM"*EB;>"8\%'IPV6IQGA[+=_-67L]?E
MMVXH=$O\?"21>FW)J]^XY@W(08^(Z" #**Q/GHT3F#-O5HR*-F)VL[,MWHQ>
M42Q<6<G(DW:*<!=DI6^XRG.>3])RFMZ-(%T'*)PXS#U10^IFCHO^>H;<1O'Q
M)979_.'N*B^B(Q]E.N5J/G^ O<G,V-?Q$MI&NJR V6HY@+[W#B7X%)GA[(U3
M="8\^:3OR)EMO!,*.1#Y].NJ$,O^8LK2!RXNP%EAU"FX$U2569<#G[2FQ;GG
MX2!/QPA\Q>O :4EO^X)(X=2YL-]+[F+$UAO\+\43?"FMFL+Q9NO68KA =U0C
M2\N\PKC'EI7M(5T\F^F&N,@':O2+!W%H P4CTQU9'PLY@NEJ@$;G__$N-]7S
ME+=O2# B UY:E!)YQ_HF=+%RI(>@*.2VN"<9D)M65[_>CN"&EQZHW$+LCB);
MD0+G\CYM_<O]XQADZ!&0<^N)HZ_E1;]4@R%#OPK^9E\RP%Q=&N6OTZDZRFV=
M0I&Y^NSPN?5VUP]^Y'A3%\X1,_$8!\F)=GXAVO0'I2>T)^Q#(TU.7-O9Q-#R
MJ<:C[@+YROP:1,X!(3X:_5@X-W%H);[1W$)J'M)S@)_.0B$#=DA\.#N^F[3+
M=?Z=9GGOW@Y?E35"A+@-PM4GGFFQX?EN/LG6?YI?S)8#2G/CC*HM+"\UFW_J
M#>D5RXD:7?O/>^?U?>Q?/RM60G<<-R;M 9HB ]":N?GSEHYGH:7AI6LU/ZL^
MY"1SL=/<7-^\8TQUX9(*U9,[ZZ,F:\GQCDO@  0UB0'V<D13 K?48<(O4#_D
M4K7  $6:JF;D+7O_-.HH_Z74(5BQ:_4=:@V]V&C1CJAA6PMINNDX37^<OCBG
M<Z\!RPKG@VR#6/2\OYDW),D[2B3R:(4L?EU@[NY/#_-]0C-^:-)%!E0@.^(C
M=8O@@V?QT3Q:]<,PI=+Y:(,:7)0IJBI)>2BT-LG4J^T-ZUKOMN[I+3DKZ6;0
M-&D+7="QT4!9Y$CB<4Z5#QM_4V5P>8ME84;>\59D3H*^"V41K"488!2X.$@S
MXF'25K] 8!W1&?&4!#\/FVA]A[NG-VZAF]8/8?UN+50;>YU)8U;QHF0QI_"/
M>V)V1J(Q48<(?M)XI@ &TK&,LZ$)>F:(!45<KTII.='SV++Y.J4LLNJX//E(
M9%8HV;"V^AG$''#F&G7JW &JXFAOQQ9T:'"<\SEZ^2PF<X+&OAVROF$BK6\W
MU\]0)>Y2NW0JG*3$9DF]G'3[X 9B\5N::,3VD89-J[$U"[=FO"-]QUA6%.%Y
MO74!0JA=.(E.3#W%Q.&@PKT\#$[S:)!F_KE)[U/2!/\U7"SZ)Y"1P(,Q2HEV
M1:!XJ[ *Q/[&(C+ _AZ$OGLW:,ZKZX;CQPL^K24J&ELI.!TL AURG@N4.@R7
M].CTZ5I]M0,+-DWJU=-F4^P?/(,(D5:,03?FHK)NA5&N4+'W ?RCM6!RJ 7<
MC?E(=W?4G(U%<*MQYM6)DKYRBXVFFWJ-?H^>\O2D[?=T&QFYY+[5Y<S'?EH<
M]XY#.$I'@5@:Q#%^'9&H.XM95+B4+NXG(WN'>TQRUGT.(\JTWA<Z X1_'[B8
MN'5R>G]F;%PO92#FJ;^ B:,9@Q,"OV;M@+FF)\]=W<G  2G_]%-W(>.G3^X\
M+WCQ)N^=@36B<?)$'C#V/I!NVU6= [7  0H]DKRK[]U3]YXH=OMZ$%!L%R#+
M/MMSH AHEKP-M#6TEL0_(MS!=K65TDT[:[*-PRA1&5+7A#;-N^+6:O>76N.E
MQ%Z%E)RX9Y9FWF*++!481C@91,-!F($6),-&)M^0.A=6O,MX8N+DO?/X06-&
M1E[I1=/BD^]Y>;,Q7W<^/'7/K*0XUF+#-B#.N7^'OLTB<;[F&!EF?7E<7>[[
M)C='E">$>=8J0WW6XBK+MN$-$XB20,"P*V>SL;"Q: S()3YB&MBR$.Q;=902
MU,2':^M,FB,V&?#2?:WL<89>390M_%5>D/;(UBB:"4DS'J"YE%.[$$P2'(.9
M82;NC"L4F[2EK1;XT*1+9:.X^/6E8&73@W(5,E:UFP8J)=W_;CS]SQSJ]Q9+
M6^B]45U=C+%PV=&2P]/# 1XG=A-?#\7R!R/W$V9.746N1!7J>4SW=>5!O;+Q
MPC!GS$(HZ1I!$F,206!'7E%W*;0"_RYR&K(D ]XX)EK]4+KUY6'^C29KIM0_
M]G6[./%!40!<41>XC#&68(@F\K37(R(/,V3QJ,:X+%O,_/S= ^U.^C!'!9U;
M>R)6@8J=I@+7PPPN=NW<P+- *X[C<(E*47;CE0CZ.LR'DBS(\F_)D3N%+;":
MVQ]D!/S<@]++>3YM[X#MAFX#%7L6$=,L:),V)! '0;.MM:5?JHIGF'4T]T>&
M:QVFERQ'C@PD.][>7SH-_U56U^46H\0ENOT3"VZ95\1QH <N@J&J:\\PD)"4
MUK2YICJ%P:#[K9#DR0[^575-I1T2;]QCS8Z< )#&*D;J/?8>Z;*&7RX.;*)O
MT:+JD3POC?7*<(UY434A^=3"V<-^HS%:Z(^CB#.345!E04LL9$F4(&ZP;5%$
M!\9IPVQ>HGD&:GYMK%JT('V[JGAD^=H B[Z)UBT0&Q>[$7EV[.T1E23MV LI
M-F/I? 9UW]8IER5-CN]@8T^V3_"WH<P:>O>XD>V,S O.JI9]Z@OV85QYH4/V
M$/%WM4S5=XOB=$0:>8Y#<$RE!#-B4I5!Z+36:KH+FJ[X9G^'%,0VT>5^HKQ6
MI*VV2T&/\JG<KT63GT.W^77.B_]CB_.TN7:O-O@N1COXLU/-M-F(=)7DS6[E
M@D2^"[^HTKU?9/K_HHH37S$(1V(>:SBWT>;B[ED,P>C00)J-$]*;^6N-HT?)
MR,8*!BL;1=J;=WB;%R',K #*'Y^BB#0Y 9K7:HF)37(XO18D"YP=)]JN>8D,
M"+5?$B_"3U;Q.8E7%#F2 4[/5F\+Q?B\NX(ROCM%Z<ZF+FF>?JR$RX(/SI9&
M>X 9-K<P.=*4"(?U@UF?A(4OW:0W/K$/0G)V%FJ59Q\8=OA_TP+ &'-(K63
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MT5KXV-Z\:/KRRL![?#\-^L /SYD>Y5=X!^GJF (D\IDE-+S#(!=*O.X";EN
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M86O&RKV9I%8_6+DAN30*,[+)"<XSYXH*[2T5E _@L.I4>"L79\ FNF."US7
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MTQ&JKS\EVW2ZW>8?^/.XNW\R_JM]?(S:X*6-6Z'U/4='NEG+7I10E$RRG0:
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M3P:,GF?9/TI)"SJ$6PO$Q\C3A^<,Y1!1-)5%.#N_-I?TDE2W##ID.D^# V1
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MVTU,OT!NR B?'-:.6!OG&S8*DJD<ZX%TR_ O*9U/EE;\U+>/S6L1HN OI0G
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M>?3G"7/,_X$3YE0.("<S EBKRWO7/M:[$F?6V%F-X\V^5%YZU^8J_S+11O[
M[6:S$F]9"<?F"M<S-Z!SATXQAU.22.':E-P"N.JJ<0T:E=(\^MGBQ].*!!Y=
ML,NG(MGO#_*$O\OV]Z<2Y)!V,!8<0IZL%/1]H*HIAQ+2HD^ %B;#$6LUT">O
MWH!^.=M087'M)DL$ KF;5 D:!;58<P]5(?G@I=CA=('SNOERX4O%Q-@3"(?[
M%9?DEH&;S&SWBRA)&]I]]<9X&_;9[? 63E$]@@''-P/W/'BOIUF2>7@W0>=S
M]('8[#-[%L^M&7;[E'J_"=0P&T9.OI[8,[B&V3\R2JEH&Y5(Y__P 8.J+QMP
M'?4KFOTFCT*Q*]2G+0D$K09^$ :D;%LS]M#$*18@UIY)?8.?NQRLJ\NJ?3@Y
MH"%[L7].35*,-K<Q>MA02_%%R\6S<RU!-MJ]%T4-=F2IW"D;_A2E'+CJ%(U=
M:T/0L:XVM?MDU#<]^6*IG%,MSV/U%N]L"#9V2PW]7Y"W_NMBN(8_6:D5PN-,
MDQ@L=EV'R!Z0G8J2WP%KNQ0]W7_M.TE*B<9'!Z(Q,S*,W.T+'2#S3F,J65H:
M6/$@Z@GK$V213LO9H>%5V>/Z*]<6I?;%\M=Q4SPE @^6<O31 9=8(YE;6HS0
MGXTWC0++94*53D/MBZX7J4PL1K1\*1CG6[YAD*D.7< +R]6Q\/JK>OI!H5:I
M:II6&8QLJ!E']M[=AUFQ -&.QU,L:;*,A )%TV,,HBVF/3C. "4+"O8.>3$Y
M&^::90FW,:-]XK\UP8X2MCOWC>>T\DZ-PJR,'TSH<C'X6C_R[;Y&.=R/=:J4
MDR'V=M2KN^\6-JR\1*J@50R"ST'\G80\R%^;KJ?Y^UVOZK^1I9CMS!LH(50H
M:1QQ6$?<77GNP/S ;:Q1)92WGO]FFN+-9N)G47.6K/%7]TOGUB )_A\M1(:I
MC'?R([]8,K)7Q@A(.$4'0C&$Y6U6Y/=*"%7SH52Q\V*AB+*-I<@5Q[2-2^>W
MZB -%2KM:*D,$BQJ/=;[-AE\%!W.%^N<9YWF)_4<'8>LOLRR/60\);=IF6J-
MY?1[)%?WWGG7?[H4^6?:8LZ=MPA L7;FVXS9M,26Y52]M#.^-\"5L[IH#27C
MB,_;FU)(50TI80YDQD@<(6?1-CK$6H6"70 *.D^SJ+2[1#TC#1![3DDY]]>5
MCW@^\&*(8P&Z^J=-?A8]N)NG54CLE-M'Z6^J16&7#\^=Z<H_F=FI7C75FUAX
M'E"RK3XWIB(FRC!TP-E!3]<KK:>+9[XXF1PUGK_D#/<\,,7_,"A#)9 .&-/F
M/:XZW\LI%9""]J,ZM4O&DO)PP^M9"R 2BFK%2$AAU.1P!N[LWSMJTVQM57*5
M$\K"_T?#;A$7']39Y*K$PX>?=/+,YE/="MW=88X%%N,];EY=/-Q2E=J]@2HL
M\Q;^UF'?HI>N?&%D)W@8I8X6C-N2861C1[1_9TJIGI+Z2[E?YPY_O>-BDKS9
M3P?>5B4_-K>C YZZ'=33VR55^3,F!*(1IJI_4J92S_-\2\ZV?81@]MR:TG>;
M1R*U(IM_X1O>HU7)+^\/HU*2-Y)=F)2X/Q4*L&1]NW$&:ED <R6F3SA-!U^J
M.1$9(L5Y4WNOX;HOZ"/ZNPS'V)_[LE0[B#<#B^0"\T\V7##0-S49MDN&/G>N
M+W.T/\JUFLC4,1Y81#43%R]^6(M9-'8O@&XWA#.2^_!:7(N4^E'3D)N#TE;'
MJLU-E[6YSVI .2_%D&."V3TZ[HG7FUJ_+@Y(DQII*,TCHM;G43W%=2[^-G2
M%=F*6V-@ZG!"4J(@OU&I]6D2BB@91I.!:ZDC=3] S:BKSNZ. 7MOC7[C;&"+
M,F!?DQ0C6]FWU>2-CG[[UE-@@75]0+NSJGO^[54L"Y3K87Y"TSHO9I"T:'59
M$6>/<I=2CV/PF#^57XXHU_I1@Y\J/@3VN.?*&7&L3"==^7[-0>&F'SJ4I_MG
M,>J<UWK(CFTHDO\P-CIZ5U:YDI/W<W+2W$EBFE#D?=P>WK%5*>&2A1C;? 71
M'O;/Q(\EJ9:>R>.J(>6FZTC/TJV,RW_:+80TH>LN/RVE)I+RY_9WKS3\MSOY
MU.1^^Q+#WRF5Z)0]-_ SWDA[V?Q%CVCKU1XL0![?>6JV@/ES[XY]$U]TDZ:Y
M*58V\A<"@4RRJ-%+EVS+?XO_=YVS1#%*H_C*%O^WX';[/W6*.ZX\_A;A*W(U
M^^(Z_]26'T9/;5=Q,OH2Z_]SJERPL+AF01$7^\]L,OU/<C&O2M(.\;[!Z<(<
M"99^IQ7T(<T3<E8V1N]CO05=$TTYW'&"T^_W)O55EB*A<J%?L&\44B(GAV4]
MHR,6B]\]#G1S"U%IE#M$G6'Q;P1=U/=#Q=Y6BJ[Z<?> TC 0@MN,O<,73FIO
MFA <S!E\C#PXXWNC4.SN9K7J@[.?Q^(L9=\*?%_QF4)/Q*JTFU4YFZ-W)&AK
M*7FEMW2MBMK]+%>A2W7K&MHD!J=B1>@,8YS&#5J\C.8\G$>+)\MCET3N5R-/
MCW7=-F)Y^=SPPW0H\S!X(B-/LD4NC Z4MSTO,O#8L.SL'#L].NH5I16D:R#G
M^RK0T$OXR$JB<FF=-%7RC3,=& T;UNI?C"M8/$$'DEPB-ZK%]^4V[N+%GNHY
M%IM4_YS(5G[\HOCGG"K?T\63J0E?6XKLNCKEQ>26.I9,!=\="S(TC*Y*J:A=
M_KA$VPU7ZZB1P4%H^JAOB&PR:[/H/M+TX@D\Z !E2DU?'.^6AN^0^"*]+I0<
M;[!CDXKH.3?^WG+O[A1MNH E\ -4"A(*J<Q[.3D67DNQ=U;(V+B24WRBWGO_
MU0OOI%N6[A"?N@>&O_J^.TU [I_14"SCLS[6*[_[J,OR45/!:,Y,\1QS2,C2
M&64J*[Z >AZAG"[:EX+]7'<C43I[YY@0ZFXK"F;MZSGUC&24F*HO52BUCNC>
MWGZ\IBFE9>CL],HF]_F[^HRM[0P0!85W#$?SPU$;7L-K0L[X84]]B[T#GJ>7
M<I+]<.>5.U^:H226W%X(W#\7)Q5*"?=P%VEOF9$[^0%%LA]NZ82#=17*[G;:
M77%TM[[\G;/=-2 0!]>^,BAT72E5-L/K,<I<FFVC##,B##!K)NR4 P)2<<%I
MG"&5K':#1B*<^I$*CLX*O'HZC?7WSUH\X)S@4CY187&[:?7&#45#U\I:RTVW
MB?@$W,"G<^77MD>@T\Y%VSN=2V _O&@T25R7\E*)*A4]+DUYOM8[-39C$5,^
M5E7[RGY0N*7K=<UX,@M+8<<T\H&Z4<]5,JJ)_<K-VK"VMN&6>>E-)0XNY=[+
M7)_; X%EZTV\3?@$/^G4!U$ATM3S3-9@-MQ(LN'8UHMNI0>&K^R(ZA>,*-F-
M-&%R_=DK! CGK"_U[#EX]J!T=HW9UQBNK(')A%G+[IC<:^=BDV[(=>J>#L@(
MR#;LTUW7]Y]K_XP3TA!SLA&B25-/D-JQN]=P+:DE*27MQ=8XY]*I)GNHJ%+*
M4T3]MN/;0)][&2K#\D(@7EUR]+4ZLG4\/CI20ZQ=O=):[&EN6+:$TY+,M-AT
MIW*/^W/#F 2;AW#'I@!1DE5]-4WTR^.N_0<M'R<X)[N/%648';EXLF@<H4)Z
MO5N2[^J!CSU*&+O]X@X.*YO!?>);=DYB\ <O.N!<#DTWT]6M4?):PA7CMT[)
M;F\YF91NSSK+[=9M?Z/$FY%SDC'[ \[/!APA!23AY7B=@QNAWA/L=1>^6EE4
M'.XY>.-XL]NW[%?\TH\X%.1!A\SE8@)XK>!GB/C\)U4Z)=E.EMCM]:ZNB7QH
MI<^7SV^&ITY<ZM3Q_>Y8[)^!Q^RE^#6-VJ5ZA60YURH\>5*97,V7@!5*/*MW
M)O"@>$QJ(1X7IL%)"LC5R,Z"FVKVED[MLZOM7Z-D)@1]#_Z4.9GPRO@*ZZF!
MF._+;M89G6,==" ];N.".Z+:&AEO8T,Y.NM-FF[5M\1F' 8KD&VL*K^ F3.[
MH 7CEDN#);G(PST>@H#>D;T^]E&Q926F82PQ21B"33EE!8?/B#:(1' 3%ATZ
MF_D(.\T!2O6W=5%L'6#I=M@K<T$SE'Y@4A\:FX2/#YDB[]U>2.?IM1O*-]'U
M9.DG7/@H>.V]X]B''[HLZ=HB9]"YI)#&U+;7]_)Q<#GLII>J[[.*ZC2]H.QJ
M(V_>V&MX)O#3<ZEMRBIM?+68NLW<$WZNQ1M5M3ZI>N9*_3:M>>CY@(:>4'D;
M;F>T!GD8^[6_V7=_PB1D02J\%PPA[)J85>;66Z;HA7'[N$DFJ33:MPGZ'M[G
M?V3G^(SW4=DJ,LL.Q)0TWA-Z$J.%ZJ4J(-7'J],\0J:/RS]MJ[,\\_!)4(QI
M#13$B9 AL'/@- <8P6[NJ.;[/:RL::=R@@_OW]\B%=HX&WC.XBA_^!J&=3;!
MN58QS3EGEC3=65D6="_R_*.';P'A86,VM5S#KKIE2MW\;'_ ZZJ>YR-R!DV6
MVV,EJ>DL!*C-0L;8^3[+(<59@L'^GCQG;\TP/H)*],<0]8W#XQ -Z//=9V@9
M^)7)9:P:AHF",ZX@A4>!U?P?IPS59D=8$#U2S&TE:"1>,?8:22?B7NZUI8;)
M1?Y6_EK-J:*\)C_/G#N[Y<W.+%TPQ0/?\F=\'T^*9AK;<"&422DQI<?JAJER
M;^93;L:6&10ZD[Z!;56:*PK%'/N>.0WD?<L<-BYUE(4U* ZGHJPJG^<LS] !
M#E.*Q*Y!$,(8"HD!LQ(YCXYJ>^; 8:V8(](@77CG%:GC@L8EM\1_2)L)TP$?
M@UP_TS80.YP?GUY&VL&W/<=SLC_#I*[>#-YI,TW2R'##\^AT"T:FF@HPNS>J
MN0_'YZ_#6&=&UV,;DO-SS.84O?HDWEN.CTF4M<QN"AH''3(M$U&[+7J:9!!>
M[^[(6QI1*:-D71U)_8@?*!;_<!MV4U@8E&LOS)7/+[ %&SS!"VNX8]%1HSZ*
M]'L$6RW;(OH4:D-)[1M)I/'74W';B/.S*4/5&B+/,PR,W X;G'A_7^?Z GM(
MX$7F0*F)  @\6IN,6L!-JG-?QE0-5<E C?HJ=YCSNRM</\1D)3V7W <<:U!B
M(Z#C#,(#>.(7U<#GLB5'7?F:_6L15[JJ#8.8$1CYNTQ/P.Y]A<ZX U3>[(F9
M35_OT,IB57^1J<3&D=$<*>9/67;VMP$W^YL'Q<'&MYJ[69_7E7K0 0G8JHW'
M"D^2\UBI$NUZREQ<E=8@\.JI:E^OIN^)?U2W\E<7Z'Y?G]'PM-:EORBY^6>^
M]G-2Q30$Z$"6ARX=:!3 4%(A>"92^RYKJ@$-:&4DKT/K/$PA=.  9QADYDX?
MDK1?CG8RGG(1<8X.7)Y*H@.!YY!DA09-X"Z#[3/CX[?YY3.H3-%T(#*;=AC$
MAOQ2DT,')MELJ/HPPXL"$%(@Q986VB5)!X#[C S:B0X\8<&"UF2=(11F?CK
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M,,* )9"JF],!]?%^9TD1&^_QP.=$LK9NU'R'25<0W?HB6E8 D4=@EATSA,D
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M16$$%'O-'LXAV.!W*?$Z!<*?\H.^Y?^)+[)S&EE/@,2;6H4S?7X"ODE;/'/
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M*^,SN6"N_SBNIW%8G9**,<_#!;"3QG:-FTEM6=*2__G+>=YB$++^&HOPT&6
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MVY*8K7M<$7QIKK7'\]./J\VJP^WW_Z;/LWA9A\0 EV2MB5$E) T(,+%Q9U6
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M-9>5^IJ"-L-$&S/C#M2$7;&[F"C)=A)#)5[6F=L"GRM9Z%Q7XL_MDLTNG[=
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MILSG,JJCUP !$;- >NI'-"=1.@6D66_K*S S7\CZO1GQ.%^U?[*K\%6Q1V_
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MRM=^*O\TE<<,KWG^=]7IE/A=.W[('5DK=%TA -[\O'>$9D%$.X% EJ$@WL.
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M4K$WYR$ODEMLBMT5?BJ/+&!F%CB)P-IS(M!GDD($.'((7"^6;,_HLH^U*XC
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M.Z&#T@_!!^3C'V,+XF"VH/#MQUC!^+SIG@+G(Q\KY3?)B38@L>]8WE0+C]J
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ML:6","5*++A=A7*BFDM4UZCSV:SNI;JF*#Z&>.<[!A%V*Y4W\A7?/;JA%B@
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M\7#@/[G\7V$:.JFLW;R#'_?:5%9*@SY+'J]E'PT7U5LY3THS1>DK:WPK#GX
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MX8>A.C'&\79$(B1+G,WZTYXT5'JSU^)(9Y7DT@RFWS0E'4WM-P/\M!3S).P
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M,:A.J::C_@WU1>V/WX@*^08?5\L57S8-L](U>%@0-IV@A0>CQS"ZU5> ;M8
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MP\;?3O&$6\HDO^1/(Z4Z2'=D68KJ2TUW6.Q;#M)/+KU"F"+*%:AS G0<G:X
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MIE=4S8<Z[W7+]Z'-+4QWLIWBSY;,-'3VVKY:LYLJ0$<UFMDCL%> U8O#CU<
M1S$&J,^<2H;&[/$"Y*EG@4XY+T[[*TJ <72>111=ILDAF*KT:,^BL3-[7G1(
M!_\*18<;"<_U1,?QVF6)<+^>Y6V=<JF"S3T:;-AY&)%KH'R3;8!;>DSGS8XZ
M[/+(H%&[WG'^S#DL=]?H>I\;>\ )U.;;^;TA"@LQM38WDTTM^MRD.R%%/$U.
MO2_FUXC&I).47#@^4DAY)#!WJ[X4B>W^N?4C^JDF&4^6T:\?@AZ(V&#=YW\;
M^ZWO7$I#][I:1%*;42NTX$OQ*81R2WRAMR=\/D[0Q$#]T44\L40))%:^#--S
MX]V"6LD5P$$W,NJ<#0_OXNX15#0-0@=AF%S", UVH5XFGOQ?O[M7=KG@)EN
M^1^T/ UGZNH^!UXTG$?8!<BB@Y">J+30^@M5]1F8_GU&I+^@U5^C-%I5IY%3
M(]/\N/S8Y'[F#V-L(.Z+$B"C+OIAW6.8)0182#:8K$%.JYEXDS5S6>UI#-/]
MOV$A_G-)L,?8[%ZW8$GH><])$!4K^J;\99L,W*:<0AUYQS[>,G<24P#9?BW
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M9HMN[[O##F.]9E?T[8Q,?O!15PU*CJ Q4N!@((,B$T%@I4O>*[5\P\R_*K(
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M-RVX[>N\A'@-.^3F\SBY37,/,CRD.^NUXFU" >ZDK\$(Q8!_/KWKD:X#?-R
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M%$$6WX/P>P7&Y-IR\=2:^]@E>=J'IV%>\M8H>=>]J3]1]")GFA!R/XH.B)X
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M@V""02(A&F$O^1L?94FI*;/X>+OG4;OLPESM$2_C6ALG^#Q=PU%W\1J]YL/
M+LC+!OSEG,+10O#<ML&H9M*[4)I;PE&QK5&'PYZ8GS^(AUFB!;M.AX^?'/GK
MM_:6^Y&J\0V]2U>(GA@%0:Q,?,Y0-CQYVV,.YJV4_-0<6G@2+J6_=G5ID:;]
MXF&/[UH,TB>;*(T;G@D#:17W%?R4:=P7X[O4)$BFI*=E!0=0)UK2X'D[@-?.
M,V.)"2ZL.PT2$G^-8,W>B-\T3F%.2ZKK69C\&L0;P_]F7IRZRQV(%20HN6B^
MQ2R,=IGL2&\+G %Z+>]/<BO%.S0<[_4G[-CJ#ZU]5F=]FCSPHOVFS4?C6*,,
M*H.6AQ;ZOBZ%S?EG@(N/0PRSMAUQQ_N8UJIH_0V"8TK*FG9-W0F[](^%_KZ=
ME>!7)OLD>&499K37A9;X:+(N6EB7&>W5E'\W<@%H7 LU;S0,,?P"FZ*S8^54
M4 ^0J":X8('!9P :A)#;BKF<(A=4D17_**T^J=Q)AY&4>G]>?G5QV5QS^UKG
M!=OG@ [R!,I?H[,HF'=?6UU*-X1]8>FG;WVZ2YYJ7AWIS2JG7)$H%24V_O?[
M[/ &V4<-+!>-/1&T7%(;C].;C6M:IW_RUV7&HE8^*W1N'KXG0.T+:!X&WE"E
MB457ED>-PNY1*2 #;/!W9I-L'[NZZKZ<$<+;'V;CCD(]6NX1Y;"[=-\V[T:>
M=_!K)DM:=-_6]/O=KCJ;<C#>9J]_)3RHJ$ :1(GB&Z*0!GGPP,?O")+=*;S=
M"1!6K%'-%$]-4^S@]9K+/#YF"ZGM[>R?H<#>P!IP-X0%<6NJ#MI&JQ[ #0_M
M\4H+GDYE_/')7%0>+<<3=/.DV^;V1XQYWJWV7O*"X':_1$_9^A0+OY\3YL=B
MZU[J1Q%@YVA]NM S +VG/_/#3VQ9(0<K13]_^ME[O&BL82@/>(DLG*7T/)U]
MWG72>!GU#D>W3;%,%VYVXA# A>?P#:FL7UTWKRL_)+U46AZXGG1#LVDG.!A1
M@*=:!O;H:'0"69'"17 VZ ^\1N2/F2UI_BF1!*;7\Y<-T1,4U$\3]\FB?&<:
MQ3NSZ#5.'A$5\$]]'Q:%>F11UB=Y>]1T7Y0%*O+.MK@![_Q0MO3]&I87Y'':
MFSA5IN41]3*KK+5^@^;F#$H2H30%=J2!8D+?;2-DJ7T#PM+:D=-YC5:_'=X7
M[<Q[O_=:IQ'OTD5O*DV#!(L7X,MS!&N+"<\!)%@Z*34!9_&L$+PRRVN4H.0^
M)G3S5-VGC2E@)(#OG!3K8$?I==S+X2Y=QBAF)AFSP\C2T[07<+9KC ER%Z->
M4UB5R]"_10D/@L G$D0UW$);UZF^R]7YN06X(NF0G> AJK]X/_HQZVMRO0:O
M..PSU_X3D[ Q:GNJ)WEO2G34];70"B]W[?T1B^D.HG1E@9A"1;; YZBJ,\"5
M!X'VVC\F=-IF[4_LT1]L7YR(IZRY@#!>]F_7G2IS3@R)HN.P;3L47N/;\.3X
M7,^EWBR/Q%3KI_91W5:+[/1]P;>OS$NDX8:67C.SU:*+P@]<@A=%FE&MD["=
M2X-PU+=-O;!KOXTC(NO%I5\]%4SKN_CKIG$&?$!1='V)"75U"-LJOV_15#]3
MI_6+1E:_N98TGCS,-%6O*Z(QN/\PYJXO3A-;F EY5R:L[D^:]!7^V3;<XL!1
M?&S?!ZRC"*T$T:/;@I 0S"8T$F;&*;]/HC<7GKJ60HNH?\-HIW$_0'^HX8?3
MPMO#2H*AIZ>?"UTD;YHV8WPELD4XV>0"/>WA=<QC90!#,HAZ9BB+Y5RM0"*
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MK;GB2^R)=S8%D01%;!E!8LR9LX,6WV+2TMZ@9HN=@5;HT\8)V50RJ+4$<$N
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M^<K]FAA0>W]GC>"VR$Z*40I$/0T[/!H7>A,N3<33+226/:!&5U6-T'FXOCZ
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MW('/KCUQ%\&TDB"/+U_,1*D-X8I&@,_1,NGFK^K&MC^U>*:NW-,(<>5+4OS
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MJ73;MO>MJ8VC75301<V;-3>-!GDR#TI2 Q88WE^@VFJRBDR=E^H2P,=L\\M
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M3?':NYN: HJA#T[?D<U6!3C)]Z:JZP[C:LC:..#E+605:#Q6OVG0)23Z#=T
M0Q?3E\NTR;T>&[LW\.8D]&H?6G3RSS"45BNC.RO+="E(?L' +0A2D3>[D<[F
MF,ON&H?DN0-\S^3YZUB"^B>,B:P[$RX=/B9 -[YJAE>O$8N]5!Y6H;=L[&SL
MS+F:_KT[^[;16)^@55JWB,C=Y_5,]WB#"WM,8M&*XQ19&[(A_B(W?WV%87$J
M<"OW5F>0]%M?S<:F[\;L/=X/3,?6LGW>#;B&%U5\J[/9)+8%-V#GM9]7!\K&
MR+XL-$OYX_Q2W6KBGSWXXVW5D2 (^U'T;S*D'-YVTF-I^=$SKOK6+NRY<W-+
M4R8*Z6YOHVYP;S"-.[TD1'*ID\2Z&L%NO*IQC52"6:0AT,:%&I\6NLI$*=+G
MQ2L,*,R;J*TFPT#)9P"(_()"0>#<4&VOA>G1]F:N!/7JT6EZJ-,G]S;+RDID
M=M G]^ _?>4E)(W'!*8/(4Z>+FKO PZLSZE@&WU2#O-(W5IF4OZK*]Q;3J?Y
M?_3)PG6MI"#\UH;IU&]H>@33%D=SLZRA$UV ?L'IZC/6F[5/]<#0"D,)!I-W
MZMG%+T&%1']2$*XP-IQO1IILZ)?6&U;)TZ&L'6O=.K4ZMCLB)SXWO;]F::.5
M)I)!<Z\\!Z$+J%,8"P>0]C7BIMN:N$VB0?1>#3]&:QQ(5K;H?9#>!GB4T\8/
M&>T4G53'5G,CW88JE2K/6_$/'QO5P5'4>4_N7777N*1^$:Z+.S *,_P2V ;]
M6G[39\ I![I;%M\CTD?/,GY!F6:9=[7,A_Y$F:SG& 7!2XWB!TA/1$ZDX!F[
MV;06*E:%ZZ?9.P56V1L[/0X1!;KJ87EHV^/N!,#?JE6.G9KJT >$]4;%F'98
M"4G/2O]/52)\N&8A7 C9'!*BVM2]*Q>MM"\KKKKS83G&(X_"U=^KO,B,U_90
M/@:AY1+[D8O*!+5)$\GYD:UO:"D?EX7N.R.R_:A;C]D7M/X-.]XWG0'F^GN0
MG8W-\:"+1UC3:449-GO/%U\;AHG^,<9NNT/5BP[+%*LAS<?*WNGJ'@>.7/!1
M-/T<V0/_-7-5X,(9X*G'##:EC!CF00D)"WR(ZC#>QUPK7!-HOIF.=I(2"3I0
M2CX).G&H&BS'COKSC61]'_3E[#8:>[VEEFHZ2?&CVO^V*U#J (^@7*ZKVPQ.
M;L=Z7%._A$"V-F?LZ4AJL[05OM 2B/9O.\( XPO94- 52*@SFFM"08!NV#?,
M4STU"#3#W;&--?;D3>7I+IX6-8RW[N-W!KLOW/MYLMN+LGJ$NMV3<7^5D3>!
MRV22._VE>A!^;^< 9RR^'/%E[])@Q6;]UN*E]HGR2:\/Z;KQ/=<:[ZU?<*%)
MV61+WBIZZ9N2B2&Y$:T)B,P-3%7BKGBW5 W)S*ZQ<PIDZ>\YG*_= ^%&^8P*
MPC7\A45JQ/J"+OVY&G,?,S,S^8AV) (_$G[C#!!C< :(!A-/A2DL0))^)X(R
ML6%(=!2GL,CLJK6C.N91A=D\<IU)J^MUY]PKVO53!,8PHAMS<)[EZR-6KE*^
M["MW8L/'B-\T GZT!T!751L+9M<[E!( I(/NB(;"%)"H6Q'6HRTB&BT(08YM
MF9X!7#S:.J80!?G>ZG6!P=EI5%XX-W<OH62,9*8L(,7BW70=)G6N'R?>I>I(
MMUW K\XU@S(HWL1FO0HI^^%H9S.W-&M<H?8#56_\<^B[4=3R!P.V/2?4+D-X
M;?%+]?"I<!ZRE2,[R1'W7+Q;I3"UZ8?Z&4"O\[LE;FOB8<OGE@*N]#NU"0]P
M[M@?&L%.]&*X*^+L(Q$811+E6^]E@BW/&8#I&\$>I2V&\"YKRJA-$RW9),R&
MO7*;6[]T58>'/I+C%I/+E1?J%>?/@K:0K*JVN&-[]UC(3UKPZ.05 2ZX;;]!
MQ^M^T\R8+.1N,*?"?B_WP)7%2RPX><XGXE2IM/B]Y:4DBA)EX$@EI:;"UG!U
MB<]#1:Q5_4/%9<'DG9W::NS2VI61Z-T:T(\6#53+\[1TO3EEI<^+FGB[^QG=
MJ\!S)[$.9@Z>3/A@#I"E!5P!X)>2"R^BK C4O<'H^I51G_G[Z1O=K.Z/C-QR
M;T1C'+35Z7651;S20% AI3]+F1<3]D?=B(8$KPYO7,B/VYB"RWCY[4+@GSU:
M9$[Y5J RE1?,\L>'MJ#D!I@]/O,)LWPMCSPK(KSO'+F>;2]_;59.0=-N&_H_
MD0X%.H5Y5EY/.QJ:L-&[P*D[(LL0E=\+[S?K#3IMWBG!W4#?BNC6KEC:?.PN
M#]\ $]B^:WO+MB@IMUV!#')3=J@DWMZ^VDZE?SW^K^>6AP1U%X69I+Q*B[$7
MZ*)<<%K>1/&LO!.<Z(_+Q:T;GFQSNNSC$G><%?2?S29P.ZK-W+G.]""EJD>
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M89^3V@?HV)-J".PH6*7))V,<F'":?2T?!B2:GO#-SWLVRRD.1\4^]^FH>.W
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M7^<F2+@UW>H>## =)V+7?\-#MC_ >76DH^*^H3ZZ5%)9,DU>-ELNF%2#@*=
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M$ZE&+\$;,S]GH7SLQM4QC31Q+,G2$855&<YM@Y\$1/QTW:C__13?T!-C\4:
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M10"3A@BRWTI[VMA>AE_/C)Q%X3A4OCALFOS:MX+\ZRUOZ4C1:1?=:.P(Q%_
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MPU%H*F,C;"H'>\( 5#@D6XV$$_6]=Q3[MO:#?<-7+_!4KU[[[ Z 2[AQKI9
MAR7Z>5_=3;1\2@QQ.*4$)!XR?;D[Z ,U).3Q!IQ)TP;R2&OVLD9AR!)37_-F
MN8KS=:KHUN?-=L, G]/B#$V*!Z!GNU,G]GO"XE#WB)L]Y;N@7/ @+@S@$W(Z
MO"PLRL(<Y?K6.-8!L5:6M-=>_'!_5V7>7?+D1N$ D^==\_VW!&N?[T</@Q?.
M"T%5[.=-5#>I5T'GO@CGYQ&'!FL>]N<4:3" D-3=.3VT=0RT^1[>EK>[Q=::
MCB_DW*62?)U;C[.NY">7M.K3)QO;#!EX'LPS'XM+:.,SMRF2C"4V>%0Z@WD
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MUAG<X5\BPP2[C)D,A8+<[-I6$XIS6AD%M8L2?<C#*A,@^2_>R% RH7?:7*N
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M$=V26R?[ )7LOG.[QJ]N5?X5KG3\W?9;X=JB6!C@<9X!)K>]1>UIG X,D,A
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M'I6/E)+(G*O<>4Z,QLA9H'.@9G#KT2KO+B_A"VH9_0$1VZR1T<X/=X90(PO
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M_4-HQ%\3J1KV=M"GY6^!8[,U\.#PJ=Z(%GH]_2ZLH NBT'/\3"Y!2\O(;Y(
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MR0!XUO) =<N@*"2/H(7$XDQD[1C1<=:)QC6&62,M_UD'8VBSH0B$(Z4?0HF
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M-,40D1!N+. DM, 13G_'LD!!>,>! *L>CN3X ^'P('_])LJOP OV?J+[H$)
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MG>/BY5> US/_]#8&_K_^VQ\#V^(ORNFIYL$17BY<*_8<5L:_O5>\/UD04U'
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MO^0(@E_E8PQAB&7PR=Q,'?JBW5SL]FX>S.UQ!QTM#O_RJ?YQ>^3.7X5^?%3
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MU?R[?TUT)+BXOJ!2GF1IO.I1[?V=1_"VO<0.G#_^?_S$.1L._P"'_P!94/\
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M\?,?B;!/]G_?J(]470"JW^S^NO@_R^OTT0?[G?T#W[T+!_1_"O#O^?'S%X?
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MD'P&IX2T\ @TI2D'7S%GF-.UL$#0\OB6=5JY'H-./=+J>AKZ0%=VC2-5*2V
M$@J+BB  .I4HGM'"5K0KLDKUJ$@&N+GKN^M-Z4O1;<97AL">=^]\(2&X2]N-
MO;>"*'%IS:&RIG<;<%0FTN-O,.ZAV!%1/M$G4+8:_%QUWH?Y/]4]9017;F_
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M7&=S+S;_ !+%MV-KI>[NZ=I!R!X7%S9/R#!BKG]C+)<9X%S-/T!%&=.'I_\
M2]Z)]H,\N-J,9R?-4[@R8&1[6U.+[AW[6'WV88UC]5LYEH_@R\PV'B&49)68
MSBVW&/D6C,_YF3$=6J8'69#.OJMICXR,_>%=7(M@E\$!)0ZVH-N-*U2MM:0
M4N:Z\_OY]>/""<1E4T1<6@N'BIKA9IB-M<S,<K\KQ>?D=>LMV&.P,BIYM] <
M3R*)M-'FN6<58]CC23P^2UNHHA<212-MW9.+7!I[G(A]!J1OE2N+=3=8S"C"
MG"67$GL<"D* (4A:2D@^&H(Y:\0!P-2"!P"M0LYT)V"6G$J2M*5@@\E)U!T'
MCKRTX(>9BK<ZIOM(W-/F-5M"$2KKS>UJQ$8[VERWTK\M'<DIB.MZC4?"3Y^G
M+P.G!%UT[X-W.@?\.M!N44K6>)A<?01^FI&0TLJ2F,D><X0D) YNJ40$HT(
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MLW2/]YRH.=:+:3\1?L9GI<I'94_5JY,1Y$R#)>BRPD:O-JT"P"H^5(;(+;[
MU_"H'W:'C'7 CE!9*T.'#LYI74[75; 26A+'<A][DO=4JU^6N/QVV;5GY=Y9
M\MJ1&2MR/*(',!CXI$=>G@>]',#NUY< I-O(D6W(1I5#ZZV6W;Y(X-CO6),2
M$1<0N>-5SSNR=C[I*EPH,B2J?A5;&9^%+:?.BW5H5+=2\I!#;3;P.NG,G3C:
M[+:-.QI(YNELQ/K4UR;?KTQ=6-GC8]PEVZ,=R2/ -%E$[9!*>V,TTM9*W'Y3
MY><+AZK*&4I!(\!W:> Y<4KUD('O>K*M!MWQ( 1H<#CBOJJ08D9UT-F?(7*(
M(46B$MQT@<^3"1VN*!\5E1X ZL](2M';LDF=JN'N>G X?54@UK16$*6/@24Z
M)'PZG734CV \^ \[B20:U5E$@ 7P#(<J,XQ (!/,I)(Y\M=1H/=H.!S@ 2!P
MHU$"I3A3LWH4@>P#G_P'$0*%15UKB<\Z5LK*!J #RT_X?HXAD/C45;C]VMWS
M!',A('O/#%.=/4#,H*TO3P!\.A4>>H&GV>[[>'-8"%)ICIM)1J$4,29#TV2&
M$C]V@A;Q4=05'4MMA/10Y:J\--->+90!0$2ASGOFN2!^6W.EH24CWGFH]>XZ
M=2>O3CS4#B:L- %:W'4-]01UU)(T&GVCA N<=+<S3#* JD:1G3$N8[.)2ROR
MHJ%$+E::=QY MQQ_O5^!(Z'B8M9'VO.8/"J[I?,< SW.?&E\5@=OE@*9; ([
M==7UC7_>N'XDA1.NG4^)XB>_' 858$>D(I-.("4 (0 E(\!QXT88U*!SI0RP
M7>T DE2NT)2.95RTYGPY\(E,> I=@K\X?JM]4OJP^H[O9GWH6^FE<?P1LYMQ
M/=Q;U3^LH2IL&CBS''W8UQ@6#Y)5!5@J%'*'8ZTU"OS6[>0XEMV)7(7)?[WT
MSTSTM\OMF@ZT^8S//W:X;KLMO0%Q&;996'#D1K\# BATB-$K&0M EN!J4*UB
MIJ'[3SP9^R$5V:$85:STB?14]%?I(@T]O,PI&_F[[/;+F;J;O0X5FB'9-*\R
M3)PS G$S,5Q-E<A14VXMN=9Z#5<M2M3QFNJOG)UAU5(Z(2_!;4<!! 2U6\!)
M($?)VA6LY- J&\FFO!HF<?)_9;X6CL09_P!8GL RKJ&C&6WFVTM2Y42+'1Y<
M9E*TK9;0CX4MQF'-&F6$#H D#V#CG/QYS+&DG,XJ>^@PVJ/5X'N:%R"84S7-
M7*A1"8]I*"DK3YOPQTI#*M=2GRVD+YJ T.O+B>WNVOD1[6A.2U3O+2:,%L<K
MSZJC2'&/YA9>>M\*4^R\@*7_ 'K*V6T%X'FI>CB%!1U//KUX,S3_ (;"P!&K
M6?L['1<R-(TL>B)Q*8Y]M/\ 1):<R-)"W$HCQ%D_$-0M;B4I(U!Z)!XISR'X
M,X?>'VT7LK5@O\SX5JNGJ[]/FV/J:Q:MP;<7>2TV\@X4]99?;L8]>8572U4U
M_36.+";DL;)&9)KJ9M;ZU0YJPU&,EM25^</A2'>6R@-/ K]%6M R,QR.D:3J
M=5<$^BWTSV=U3-+WFC9I%P#)+?!7<)6G95M;U6;?;7>B9M1D5M28M79=E-I%
MKZ*MF3I\N9+N)5+9J4^Z$+2]Q+;Q,DP:A<IPP["GLIEV'QMU E4XJG)>S,^F
M@-_Z?WINRR;CLN%Z@L\RR?B&(R*RQD.Y%MCEK\^ZN:O<MNSW-S;LHY$>7=7H
MW!G6$CYIH0Y#L%GL[8R'&53NVYSVESR UH0XCBN/M^JJ[+T,<V-@#IW'( I@
MF [OTTW*^GEZ?D6WR.,;RV%9&NX$_-Y5G)NMILIDSMM9>5U67.P(/YY57#2*
MZ!<T+<@Y<RMJPAQG%-)D-AYU2W06UM! Z9KUD7^:B9\NS/VU'>R7MQ>QV[&M
M^$:"XE7!P<00F! R)P-3G#](?IPW4WLKO5L_O%/RMG-<OCS,7IK*SP:7M[>W
M.'Y+MW)GX[0)N:=$O(8;61; L*##2G7TZ3%I<=;^76P,O'FXD^(<?>.7#T>J
MCFWVC;> 1EN0SX\?TU(&WWH1V/VSK<QPF'NM<R*G<GT_[C;"Q\>NG=JHMU%Q
M3/:/"WMQ,DKKB-CL'*LKGIB8I#GLL6#TZKI8DE2&6&X:FDI&/\+BG+[**-:$
MH3E^B#T@;G6]KDN'[OQ::2J3OACMPC$G=HQ5RJC*LJW#O-YZZ/67&+2H3_Y!
M#W>E5T?((J''L?BHCK9D@J?#]9?74PB8<BM$.*>D[TB;/[W[![J5N[T.%E>-
M8C8N8!26&78:Y39G5XS$WORPY^Y+C,I0S$IZ7=G)G)UHVZS%LTLM*>D%U#R9
M/NJDY@7#*B+//1#M[F^V\792?ZF]SZ3:BS?M9VU6W,&\VMB4]+12;"TR[(:V
MB??QE%]N) KJ^Z6B'+F2Y3M/4H0DK=;7)7(:[ $U8;!'[I*+]#]533M,[Z4-
MDX]!M)A66;9U]W3856YC(M';&E9G7U.Y44^.SMS+')VDM8P)&7MPHQG2HLAE
MN:^H:I)T CU// 4[1;M;[RE.7H[_ &59*:XN.I$Z.>Y*0D/!*@0Y'T&BTD:A
MP-)YI(U/:>1TTXM0EDC"UQ0I44D3FD.;[I-0KNYZ>/3UO_#^5WDV<V_SYQ*!
M\I>6U%&C9;5J'X'Z/.:?\NS*BDM=4.0Y[#B2-0>"^U]0[_L!U[/>3P<VAQ,;
MOZ4;EC<.QS2*]-O#*=3V@NYICZZYT;G^D+UP>G2,]FOTZ?5MF64558E4ISTC
M^KW('=Y, NXC6KAI]O=T\M=5GF'RG6QV,1IEF&2= 9S0XZ%M?6'0_4)%E\Q-
MIABD?A\?M[?AYFG]J6!GX4@YEK%_F&F^2^,K&7%@Y%#ZCX7=WA)YTF]&/U;L
M&]1&>3?37ZBL"LO2CZP\>FNT-IM/FC[\?'LNNXR.Y^'@=W:HC26[A]L><U43
MO\1(8(7"?G-GO$W6?RHO^G+!O4W3L[=VZ.D&IMQ'BZ-IR,K6JC1D7MP!P>&'
M"O5!8KSX24#ADO(@XL=V'#D5PKK%3K*[AY13_P VA$<ST<DR$I /L/8P=>.4
MW,PAMD/WG5#:6WFW!=R%&:)[<%0FO+9::A$2WG9#R6(S3<;]\X[(?<*6F66T
MH)4M1"4I&I/%%H!( RJZ]JM.K#[*Y/9U]+C9NPQ!BLP?,7:+-XV'YI2MS77:
MFLC[E9#G&0Y+F=*_G$F-&NI"(:[2V?8\J)"DMS8"7DJ8?0IQOBRT?<%#+B+2
MA;C3EZ6/1EBVUF3UFY61YUM]8[^XGNKE.1Y@UMI08G2T&*W.0UF_-\=I*A+%
M9475/CT;%/4DBUDUPC0T/.0(LKY<-.]Y(P1L8T:T=W^GT\:"7C3I+HU8]W$=
MXQ3+@!23<[T/G<;:D>F.[]3F:-;98E!J:C!,&:PW HKV'X;<Q,XH*2FM+E<:
M+;9GDPK[)V+4V*9D!YIJI9$F)-#TLS)X]OMY00QY&.6!^F5#)MTNH&^.,/*9
MXJ3FM7)VFQ+:?9:'7T53C%773*-B;.7E=@]&LKY%GE$:O;RNXEV-I8S9V/*S
MJ72-RI2(ZHT.4ZU^ E /%J7:0YGF1.&OD4]="K3J,12_#7L<FG[I ./9Z*YR
MO>@CTP;1/;BB7ZB,YJ\E3MC3Y*_-G2:NLRS ,/Q88#09QFS\V;-DU4'$\BQK
M$#1>7\A'%76WDYME<CO84Q1BVEY<?->UK1B4./;A[:*W/4D$$+9(8WO>\EH"
M?>.0[:%[OZ8^TTJ7G98W)O:V'E^9W4^MQZ2Q&N:G'YUG;9KD<'%IJ9V2L3K^
MPQJTSN2(#D1VEL(\"-%::\MYM4MS10;3;0L*$EYXD###+[>=8F]ZAOKF0&=@
M#0/=!.2YY<L\"/JJS-+4X[AN*8UMW19@G-)VSU#B>V63SY+M1^>M286,P'J-
M_)H=(Q$JZNVMJMM,@L---H0AT )&G&UV$AP=:EVH, *\53U"N6]4LDCE%^&!
ML4KBF:9XHN)'KILNW/-AOE/(]BNP?ZP3J-3TUUTXU-O&!*&\ZYWN3G&W>\9M
M!=ZN'=4@8W#&66U! 4GNC%B+D%M_9^1A%B0TP>1YS+!3;9]J4K]_ 6_>RQMI
M97'\1Q1O<<#6LVF%V\7%G!-^2UC7O X-0$'^UAC5F7W.Q"BKEKS!]IZGD/MX
MQ(;I*DDG*NLN=J:<$ !2H:S:U#;+VJ_!7(GD->O(:].-+M$!UJ HKG_45YY=
MNXE%6J[[!5AS'U!9%DCB0["V]QC\OBJ([D)O,LD*9^#3HZS45\CW@.^_@]U9
M<"UV:*V9@]Y]:%:Q'RULI-TZPN]UD;J@M80QO(2.*$?V2M=:L2B)0AHD=-"2
M--.0\=1SXX9N!+7$YK7V%L=J(X&:L34G-)[2H_LGM*3[1S\/#KP!K4UCJ2H#
M0 ]=>@Y:<21D E:5!=S&!U'EZA0.HY'N3X@Z]=1R/NX(6TCVO1N8RH+>P1/(
M9)C'D0>(/\M52QR,<>M+O%5%0106;K, +U"G*:=_CZ=9&O1N'(#.NIU4T?$<
M;V[D;=VD-RW[S/$?_4'OCN'#C7%MLA?M=Y=;0_#R;AQ:T_\ EN/@]0RJ78+N
MH04'7EJ#J="?^!X 3$R*TUN+*0ZP:,X#VH'< ->1Z]-?#WZ\"Y8]+"1P_36B
MA)8B43^8?D^[3EY_]'D?U<4_O=J43T?AJM&!ZG[3^O@;1:FZ<P%L.\SW*!(
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M%'W*VOQ+<!N37)R/.<AFWUI%N+5NN=W3AS\U=B4&5*84]15\)F,B-)2"1?9
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ML@?>JH+S?YJAB*QW(=2A2>/-#=*$X_3Z+E3M;M2@!$IPD^A[TXRZ;#LE1O\
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M3<5MQR) :"6&XY"?A6E"!_BGDCD77M5GPTZ<$XF6[?PK<!KS][MYXT.FDG;
MZ6_<7L ] Q1,$&%*<3FN3+*OL6AWM.UQCNP ?WH 3\TE\IY!:DK04^P@Z#B*
M\=&(C$X@O/%:M6<#GR,N(@C .6:U.$&9'=;"VM- !J$IT(()!!.@(Y^WC-/;
M(NIZE>/ ]U:EHA(#  !QI8)2F5J>966CIVZZ'L4.>H='10)'W<1/?"U!(]H/
M:0/K-7H8'.&F!CG'^:"?J6MR,PK&043;"%&=1^)#DMD:^'<D]^I3[NHX&W5Y
MM]OXY)6KR#@?MH_8].;W>L!MK.Y>Y>+2T>T4C=W'QIK72T2XH:C2.Q*D:_84
M,J00?M' UW4&SM:K2\GNK2P_+7JZ8!WPPC'\][4]2KW4W.;GU2=?EX]K)Y\B
MF,VT-=->K[R#I]W%.?J6STK"P^VC$/RJWDD>?/!$U,5*GT)2!W<N0O\ YK03
M%ZZZ*?FLM)]W)MITZ??Q2/4[]*MA!Y*M%/\ E7;@#XC<6M/)K<_738]G>3OC
M_#55=%!U!4\Y(E$#KK\)8!/%=_4][(C8X6M=1&#Y<=-1$?$W-Q(\<&@!>_"F
M&5<Y;/(4]/:C!)[DF'$::4/ A+BPXZ 1[^?%=^\[MBTR%IY ##N*4=MNC^C(
M"AMA*>3RY?8X"AJP8GS4K1/LY\II:>Q33TEWREI*2%)4VAQ*"D@Z=.G N:YO
M)CJN)9'GM<:U-E:[19)'9VL,8')@)]9!-"Q_Z+'EN+4[#UT0ZI7F.1P3H$/E
M6I6V#R"^HU^+V\4W.(**?22?KK1-TSX,&E_8-/U)3_CT!NTN&5J'=&K4IF.:
M\TJD:D1$Z\P2E7<YI[4CBQ;1L=*'H"4.(_2*$;W>_#6@8%$DN':!Q]>50WZ]
M-N\#W;](N_F"Y]>XYB=%88!:2*[+,KMJVBHZ//:H)M]O%/6]M(BP(LN7F$"(
MPV"XE3GG% U*@#U[Y17N[[7\P=MW3:(I9I(9AK:P.<YT+O#,T!JD_AEQ*9(O
M"N'?,*XLK;IY\5R\"<N!C;@NH%0>>)"=JFN O\O7ZL<2V@W7W>V-W/S2KQ#&
M=YZG"[S (EW)?0BUWBK;Z+B<7&*&,RT^[+R'*Z/)$H0RV@J>%:DGDC4?9G^8
MCI.\W?;++?\ :H'RW%D^1DQ:/=MRTR>8\X ,C<PJ>&M.-<2=(R)^MWY3VH<#
MFOA5.:D>JOV7V50J?6V=6B9.K'+&ML*T6=<XAFSJUSHCT--E6/J0M#5C7J>\
MYA9"@EU"200-./C=CM6)-4YV-\12N1U']-;-,=L).+L[B5,; \QQO.'MSIF%
M5^6893Y)D\+:?;K:W9ER9BC6Y\W,I^35V0T%QF>1VT:[K6[.=8?*@IT0H2L8
M]S=$;D/.@T@CC_%D"L^KG1UAGTV[S&'(]KB>_P#2U^6V^/89A6XEE'V[NJ=Z
MZQ#$;S'KJ%%J8%#N#CZ8=]20\78J*J=+:EL,UTJ6MR.MQX)#F,N&^(..7*A[
MG[;=>$D!P4\OIG37D/TK.^!)K:W=JOGT-S@+N(Y5CV68;DV313D5QA^-XYG&
M\6(-?YEU;5;NUFKN.EN=,G">R_63WX[C;BBHO7;=[B1$Y'!RCN///Z>N@>Y0
ML8/-@>X2L(*8-U#$@$EI48X <107,^FOE5C!KZ]_U"16J]J/'CNJK\.R^%94
M=)'L\\>E[88+/;W.#=!L_E==G26;JK>CR)4EZE@J1(0EM"6"7PK0\'4X#D%X
MGOR^G<!^.D(+&L4 CQ$@$89D(A*\?UK=7;;::+L_A]%BIMWK^CQRRS'Y6NB1
MWZRN@XSD>=Y)E='10XJYTZ7\I@]1>,5<-OSPU\I 0A"$(*6T:.WF<RW%I !Y
MQ/A)X<@ :QFXV9%Z-TGU/C  >S'2B#5*2$Q4$\L:79#8U^3V3*:M,96-4?F1
MZLQ$I$6?.= 3.L8Y;"4.,(2D,M+&H4.]0)"@>#-C;RV,1^))-[(5)7$ \$R]
ME9O<[FUWBX:+%#M=L7"/)'*<7+QU9YIRIGFO)8BR=1VH;;5W*.@"4I&JC]P'
M]'%M@,DK8A[SC]5#KJ8102/?B!$[T( GJH]VT;>8P''%OI\IV5 <LE((T(39
MS)4]K77F%*8DI/W\!MV<U^XR%O8/4T#ZZTG2\+X.G[=C_>+"[^TXN^VAO<&Q
M2Q"< U'PJ!\-3I[^73@CLT)?(-/+]%".J9?AX%:4!%5)VSK_ ..?4ECK;@+M
M?M_3V>7R^1*$VKVE+2=VNOQHDV"W4CVM:^'&IZAG=8[(6$H^7"N6="V;MZZ[
MBD=XK>T8Z0\E.67'#!?1787#(.B6SVDGEIH!XZ>W[>.%7LA 0GOK[*Z?A(B+
MG<3E4P, A)3S &@&OV<9N0DO*UM6 !H K=PRG5G"I5\.(*TZ Z<]>?W_ -?'
MH<6Y4J$KED!7<--0=0=#X:#]8XOP.<(B3F M!KIA#]3,'C(^SZC55J>.:#),
MHQT?"S NG+&M1T":J_'YM&0@$ =D>2^^R-.0#6G&]N9#?6$5U_I/+#7'FYN'
MK1*Y!:QG;-ZN]H;A R0OC'!K7H<SBA=J0DG%0,L)GJW 4MJ\2>FHU.H]FO3G
MQF[I0A/*MY8%!CRHQU_Z/]_S7_['@<GB3L^VCRCX=*D(]3]I_7P'H]7G"I4S
MV30=9="NGV=>7/BU;%'&JUU^7V54?>G#F<RQ#+\3>2"QDF/V].DE(^!^;"=:
MC.C4::L2RA8UZ%(/&_Z=O?AKN&9BAS'@_97'>L]NCO;&YMG Z)8G-]8-<S_3
M=>OOTU;'F:IG0'%5TY"C\;<J$ZJ-(;5U4%(>;(.O,$<=EWJ%DUH)QF\!WKKY
M4Z#G-M=G;RH,#G1^AI2NBU.Z5LHU\0#T'30>SQXY/<E'XU](V#O,A.C-",>=
M1=F4!VDS)JU#7_1F516677TI^%C(*UM3?EN\P$JLJP(*#^TIA0ZZ<:#;)V7E
MB8G$_$1.P_HHOUUD][M6[?O[+UPTV5VT NX"9H0+R49&M<Z<(5<]+2 IU/EM
M16SR\R2Z0VR@C34I[SJ>7X0>%'"ZXN=.6*U7N;PP6QF((D3 '/5_+0=2'(,5
M>?G8]/CAR>\95M6V+#DFLLIK@^.:4M.-R(4]?13K2OC  6E6@((WC+;<6B.Z
M8DC @<W.@NWOW+93KVV5&RGS)F.'A?(<T.) [46I@QC+<MO7D1W\>K6FFR/F
MI46]D!/8!\00T_5]Z5.GD/B.G7PXSEWMME:-/XSM/ %C2?22>=;?9]]W7<YW
M"2UBC8QP5)'E<N;<5_51MEE?;9'C%S2+\B%!G5<F&VS!:*G4.!HKC'YF0I1"
M@^A)"DI2=1KKP+LIK>WNXI" ?'6AWV"XW?:;G;9$9;21E0U?ND. ]8J.\3@1
MD1H<E25/2%LM*6_)<7(?*^Q&H+CREK20O74 C@QN$TGG.#4#25PRQK+[);AT
M4<SR2XL"KFHP^RI?HW4EM/7\7@!X:ZGW\9N[:6YUN=MD'E\L:.XSZ$?$KF"?
MA2/Q'EI[.G/@:YI=WUJ()VM(&)IW:>4[HM21Y8(/;J25:="=-!SZ:#BB]0]#
MP-7PLA495R=]0?H7]+U9DF,;@;D[S7>VTK)KW>VKC-1Z%4R7FF5;M9;NOO/+
M<IZO' N1*R3%V,QL&Y<A^%9*L\>IHS$@QT,%PT+B%K"#CB3]/I[:+P7#PSRT
M5 /9AC4+1?0+Z3,\OLFVCV]]7F4RLSN<_OLNL<=16MV.0J;QR9D5U=PGK/(Y
M3!N,PP"ZW)><E2Z]QHQ(SK,>PK7%)+PCBB#WG'!5[_H:5Q=RQQM;I]X)W8\?
M1C4Y;<_31VDI,ZVKW,QS>7+<D3@.:M[FX[01JJ!38RQ365]AF8XY$K*J!<1Y
M..+F7&!1W)<V2F:F?%>?B18=?&:BM1+4=F')(XC2N79PJO+>RQM^'B;J=DJ^
MLU-%!Z']KZ??JGW[>S5%_D53N?EV[>&4S^)X"E]-ID\_<BVR9-QE4>,YD6>.
MTF1;ER$TUI(6)6.5<5JM:44+>=7ZZV >4Q:J_IILER8V:6X3(/U4GS+T;_QY
M@V3;81_4EDV.[.6^39%N3CF"1,5V^L*ZFD97NY&WARO\VR=YQC),SQ2/E,B:
MQ6.LRZA^I8LUI7,ENMQUM1RP:=35][']->P7<CW!Q;D$)QY)A4_[!^G/9WT[
MX/@N+8W!J+JTPJ'BE(K.\B>CR\EOLQQ' *W;LY*M4N;,A8[F=OA]2B/-:JDQ
M.^,/+*/*2D)B :W!%/KJV)7N<1B,">RJ+S/03Z=,]A74C;3<>F<3EV19!?OY
M-3X/MED52Y3YQ6[IW=_68TR_"%;:2ET/J"=L*F[CK?-/+;B3DI?4Y(9<N6]B
MR5OF/.!*@>K#Z9U2N]UDA>(HQ]W$\O1^UV85*VROH2V6V5W"QC=RCNVOS?";
M:PFR["PI\1C6^2R6,=WQCW\7+LDB,(O[)^7%WE?L;$.N+D2G:.&\^E7:2F63
M1"XZ"0<N&&?Z:CAMWW@+I,6'FO9P]'M-09COTVO3'N!MG%B;=[Q,7,-ZYD6-
M-F^!X]A]8[.K<9_RZJJ?$KPXK)I;+(\(Q^WVS@N64%$N&S8SI,E95&>=2M Q
MS&$G'%:T$; UHS6NEVPFVM+LYMAANUU+-G6=7MWC-%AM;:62BJPFPJ6O;9;?
M?3YK_D!Y?<I+06M+*"E 4H)!XFNW 0QQA<&TK.'2Z1^&HNJ8'I*4H_>$<^NH
MY:>_]/%$ Y"B<;3I11G0D]8-NO\ E]Q#2'E<O[0#6I3KK^#GU\>+ !1!B:\:
MW4[2H';PH(R"U183$UR"IQ,9*"&8Z?,4A]P%05VHU [6B!J>6BCQ=A#H@KP0
MN502L;)(8@-;V\NVF%4.<PM <\B,VM/=W..-KD$ A/)@+"4* //FKCUTXQ !
M[Z=':O!&H:6KD<Q]=.$9<"/JKO5WD:*>7W+<7X$:\M$\N@T'$$ID.#L4J^(H
MFYXK26=DU'5LK?FR0PPV=%+="&QW'HE *E+<6KP2 5'P'#8XGRG3&%?RJ5SK
M."(23. !X5$]_GHN%.1JA,NK@KT"YSJ FRD@IZ1VCK\BT?[1)=(Z=AY\&(]O
M?;C5*S4\<>'MQ]E#;BZ$HTQ?@M/)-?<@7 \:"%.5=>RKMD1X0)4XM<E24O.J
M5S4O5Q16XM6O,_$23Q!>;O8VXU7<L<9 3.B6R=,;OO4GP^U6L\TI.88YH7^D
MX ?90O86L26P^S"9DSG76U(#@94PR2L$:EY\([D#KJE)XS=WU_MUK(/@8S*1
MV!#WX^G*NK[7\A>HMP ;N\K+&V]#W-/'P)I)X9]M;J)Z]@F"]&:AQI$9L-%>
MKTGN1VE*VPG_  X[5IZDD\^G&3ONO]]N7%MNR&* Y^'4?:,*Z'M?R/Z-VUH?
M=S7%S<#B3I:O8T% #12J9D\AU3BK1R-WZ%?R3+474'EKW(27.[3D3KKIP#EW
MC>KG&2X=IX 8)Z.%::UZ-Z(VYYD@L6/F55>=6([#GZ<Z^#4RI:@J7,F2O%7G
MRI#NO/\ LK64C[.*$GG3NU3RN<>VCT;[&W']TM[:,\PQH^RET>BCM@%,=/4G
M7M^(G7J3X\(6[7!25-)^XSEWB<$]7LIXB5".PJ4V/Q$: > T(.FO(\^)O+/8
MM#+K<)R[2TBG),!I/[*21RT(TY?KX7EG/C587DI][/LI2B,@)_"D::=/8.++
M8U #O=JNZYD>2 :WE+:4\T@<O#IR&GZ!QX^-K/<R-1.DF;39(<24J"1HG33P
MYGH-/9Q"YP (XU:B+W!KB#G]M#,Y]/:=%:%((4" -->?V=>*SR",<*.V\3I'
M MJ,<GOX5-"=E2EE0 (;8:279$IUPAMF-&CH"G'WWW%I2A"02I1 XK2 ES=(
M+B[#"M5:Q%D1EE+6Q-S)*"I:VRP?)(5;"3D25UC5LDSGHJ70NQ:DO:N_ECBT
MI4B''B1R&T'5;I*%<D\:W9>GKQS!\4/+CX@^\>[!*XGUI\R-F^(,&S%L]XS
M. _#':N:^BIDRG:_!MQ,&R;;+.L6K,HP#-:*PQK)\8M(Z9%?<4UHPIB;'D=V
MKB7R#WM/I(>9>2AQ"DK2DC?[9>2[%=176SO=!=6\C7QO;@YKVX@_81D1@<#7
M!MRN9=SE=/>O+Y'Y_P W')I[,QVUQ(^GO]&/_P#1)]9^ZV]V96L',L!VY6(W
MI.D3'&)=Q(.8PI*[;*LMA  0<GV^I7ETC"] )4J0[.:[0EL)[]\P?G1)UCT7
M9[%9M=!?W&-^@1OX9&ED9XLE</-</N@!AXT!+922V7W&<?VSP*<$&)'[66 K
M]";,Q#A[%CR7 !HV>B^9&K2C^+7V<B./G_RG53DE8YI9D:W+(T!]_P"K_CXL
M,8Y #0>[(#=)IGFQ69':5MI)!U2H@=Z5>!2L$+01[00>"ULY\7A !/%>596\
M;&"="ZN=-PE7\+1,.P6^A/<H,6*?G&DI3U"7%*3*1R_\)Q=T6SPCVZ3S;G6?
M^)W.)WX4NIO)S0X>LXU'>77N15J'+&#CL":%:JF)3<.P60Z=#Y[;:J^4MM*^
MBAJ?BY\M3P>L;*PN0&322!Q.!0?IK*;U?;E:L-U%:1D??61V/(CP\_54#W64
M9CE+3U;+=@T--(0IN6Q3*DO6,R.H]JX[EK)2TJ*PZDE*_(:0XI)("P->-7;;
M9MU@_4 Z21N(+DP/9V5SB_WG>MV:8)-%K9N!#M#BYS^PJ @[%K,3(KV7*!*$
MM,P&P[7)3HE KRKL^6;3H $Q'3HD#HA8'AQ-=Q:W?&$8N&*<#7NR2-@8[;W(
M- 5H&0;P K?=19-[)@8S7@JDW\A+$A23_P SJ&UI5<3W2#\+<>#W)3[75H2.
M9XBB<RV8ZZGR:W#FIY4KN"7<;R+;K7\R:0!Q/NB,8O4A2I&6&)JPKS:(T9+;
M2$MLLMH98;2/A;;:;"&D #0 (0D#C'DN>]SW9DGZZZ?)''!;MAA"1,;I;W-P
M%5NW7LO)C/!:NT!"U>&G( G3V'3C==.P/P<U$2N1]=79$083CI^PT&>B>C-B
MK<S<)Y"E*R++6<;K'E#76KQ6,52 ">7:Y:6C@Y=2U[N*77MY^+#:YM8T./I)
MP';A2^2MAJM+C=T1]Q+I']%B?IPKK'BT<,L(7T*4C0::=!RUT^WCBM\]KB4X
MFOK;:(&L:'#-*/$\TI_V1^K@71VOKA4JSA4JSA4J8;%CS&.X:$\T]3RU)]GL
M/%QKD<%6J=RPD:N%5GSZ**W,\>M$Z)%S5SJ*0=3VKDU3OYK7E1Y_&8\B4E/N
M'&UVB036$D#E+6G6!VX#[*Y1U);BWZ@M+EP_#NF.C>>R%7L![RXI1C3N=P:\
M%#F?< =#]_ Z[!>U!RHW82AX"@J4_34@=Q_+M?'YG3_]1P%UC6G%*TO_ .,O
M;4C'J?M/Z^!-:.O.%2I/) +2@=22E0 ]I]AX?&XM<$YTQ[&O".X5!&:QA\:D
MCM(^('F.8Y\C[>-3MCG><T'(+[ M8'?H YP>F =CW$)]M<;\5AJP[?C=C$TI
M+4>/F<VX@-D=@^2R$-7L<MIT [.VQ*>7+5/'>HIQ>=/P7'$L3U5\5/B.T]>W
MMIDWS2X=SL:Z+8V^'6&M!^)MLG0^.FO7PXYG>QC6<^-?1.T/<(^VBF[Q^!DE
M1)J+%+GRLH-+2ZROLDQ)+*DNQ9L5P@^7*BOI"T'F-1H=4D@CK6]GL[D3PM)(
M*'EIXX<Z-;AM4.[;=+97*"%X!#CFUX*@M/ \^RJM9*Y.I,DK\6N]!+BL/V4>
M4W\,2ZCJ>7%C2XW@F0VVTX7F3\;2CRU20KCH-G+;W-N[<("'!V"?LGEZ*XUO
M+[NTW:#:[X)X7.U?MZ2@=W$8TXIEAPI2V@K<6H(;0DC5;CA[4)3SZJ41PQH
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M]07WR< T]A6H#V]M9!JF0\^ER1V(><6CDCN<!*TH2?B"4K!'/GRY\^-GNMJ
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M161)>;2[2NE?Q?CM5;RS KZ6=)=-G5*D9:J)*O9C:9+$P2W2N5'U/FB-[&X
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MR&OC.0W'/+<[&WB>U6FAY3OO7_0KK*>VBZ4LFS/A>QLGFXQN<PAKP/+S83J
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MQLQ_$2NIVGO-3*G^17L6,.1"EL-R(DMER/(8=3JAYEQ)0M"ART"AT/(@\QS
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M9G@DO,7<0RS%[JR9HZVPDLB5(N9./.Q9>/W,6W^;6VZN2RI;1<U7JXTGCT.
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MYJ=XXX34Q-7HLEG,90%7J!SE=N*(JS%.__6T)XL8C@^<X2*>$-XG74V&GHD
MA8&]AI4:<VKJ+;.>"L5LQ#(H1%^@M2M<44!+@EBJPK>U:M1>FI1'7<M58RIB
M6.;9F5F,9?_&3;%U2'>QUZ;JX"FQEMVF::DZCPZ#UW)KK:!(E+%)^.Q\N/',
M#'V?]XLNG(MY%\/BWI6AP4J%=O++(T_,,';RXIBDEI8X*4XI^%?L84[]K)4L
MTYH@&07 )X)Q?/7U[GARBK=[:GU]!"M(R9$D)8$'*T<OQM&N+E-KA0>7IU8.
MX%TE(YG+ %%Y&L^Y8$J/]U1&EK)H623E_<>.-9QJ]D!6NO'04./6U9H@A@C8
M7B#;CT$@8B*,790,KZ!6$O8+3)*@^Q77ECCHI>7&^94>]8C1+T"ZYG?*1+/O
M$*:^-^++W$.PAH"U/'6GRZ%,1+RABP&JLB920F.E]13V*!+H7LH\..D:KP*W
MBEN%"EO_7,RS)VB?4Y[?2AX2]!3=*/X[#S8\.Q*2IVG#O5<C,1R":*;6@Y_$
M^<>!09Q2&BN?R%HF$&[\%Y+;<86#H&HN=QW'L(V/I%_WI6Q<M_#C70P=CN8:
MM;MS37I1^7U(%?E&;?5\G-6D!,E+$C>D%<U_9K#TB/+O:_=R. @7D8O=?^R7
MQ20Y'Y63H B^74HY]3>\P3GN8WWJJW)D:V:8MUCNG6\DME_2 A@FD#=T;#NN
MEV*N7DZ]C=:/J<LZ%-.8>26%R$,?THZS811/U2VHFPQ&@/+_3FHPE4![,N8P
MRGA[W0?[Z^QR,A'<S^P&WNJ[E;3<I85-%27*[EA,672:K.H#)6A'$T_6T#;9
M? 45S+_$?SF%/G&;*NFV=F(FHOHJ)X[@D%P.!?&RN>NLG4K1C#,E]5UY$9>W
M\Z-_$>6-_K;W:=$">/^L)4Z"*+O2/%8WSD>D\ZC1ZZC,?"'DVMS1K->#&F+_
M.0GNP9 +OJ [7.#7<J,,BPQU.9?$&V:DG\!<,@\4M[&@T;NZ4J.D\>X?NHW@
M-3+RL0IE[V'6M@%[17)7&+4U4RRG&$#:!&I [Z+P]UQ/IDQ2RTW='F<+K#Z2
MBX2<^X#?L(8KZ./1CYHKQMU8A;+=3D?=*3Z'R'B2K7K)Z&!P6V*TYF, "?8L
M8#%]=LK/4B8NZ?<ZM)J7\$G;B=M=5/)UQVT]^5)O;AWP&1_-&@B%;K*5T?A,
MP]]3$5JX4CXX.7J+?;<FUU%X<!1R_\/?&84:01D,7)7I\A3 JJ/7WON]Z5QV
M0OW@XI!GWIB?X(VK+>7\33J@RYVZ0@7O@2&L!)RVC3 1652+A_=UTH;/$#+E
M1#6U2(J<2$,'51>70X8,4H"F5WF@%SMT^R(7VJY5Y^D<[3EY1/:9PAAU@N]!
M?U$EJT[UP%Y:[-:LT$S_/?^"]Z#!1[\K7=O.2>VNOY[CE8UJ%/"#OO&-C?EB
MX-BTL=F3A)G,>)-JYWF,SPTIN=2G92TSGRE?F7)7F"0[_.:['\,S[[6T@!)R
M@FANYPJ-<U=FU=EH+Z9D-U2H;W:5(M= P%FX8E[GRRC@''VH/3F.NIG^/A1<
M(!C0GT[B<H19JF![PM)(#3@MHOSG%W+G)!@-_?\Q*Y2E9I6%3M*-KARBG'M!
MQMR[2["G>4YDL,JO:;,VA"K6YP$BOR%)9#<4'7+(5XR&N3KC(K2Z@,1&*+42
M6L7X3$>HG@'";J%,)Y%+Q,P.(X,M"/%BL_ 8,IH7.1\ S29(WOY:.VC\W:3&
MV(KLR'/(=C/OL4+$[%&FT^UIV4=3M'JYB>Y_8C]V4 V#.[> ?[: Q>K)+V%Y
MI-R0YX"9@827.Y*>-)^*GGWGV>-<F1[4<N>BZKP+;%5OT)DV,5K57KL1%ZBO
MK?GUW^;FJ=1O_4.!9]OT]Z0[1]S$SY6M_?6U437MS$_,MN>"8' $Z:_R5V?I
MG=S$.^VQ#19SEL>R/I =^/VJ.A1('YY)+2FNPG4!%V?B44ST3-1;G60C'347
MT%3SC'BR^?T#D(;XX[E2VRQ332.@%Z/V P#L@?0N10,$9A;8S?0-Q#T3Y[!E
M51J4C80? T4F1Q)2=@C@.!&Q>A]NRERI_QJ%[L0OU&X?&V20C393\VJ\H17+
MLTR:NO$"4=)A7++.]3!Y'#714/ NCTY;O X<D_G"#6ELA&6I=5@@X.+FA%&'
M-2T7?A'B(+,@53TO'ES,;-=RYRB[ZB9\V_FR;8Z4+;':%)KRN9M_Q\'HN6LB
MKY:[L>=MUZ8423?'50/::(^.T<E?&P5&^P]3B;7KKZTF-!H+F.J;4D%8*71-
M')O"::L6P3G<^E%))>4V5VKW,'^/?I&CNF%+P6H9P5"TN9;T3R6,#>P0(F'\
MG,M!H&ZT'8D?/)># _<8<<WB_"FQ8U%X],)2W!>/^+&L1INP*7<.ZBUIOJ&Y
M.0?MWSK7^[H)DI-Z2<JRV]B$3J"+W%G:ZI2:8&CNLU.W7I8MO&#4.^\NJJ\T
M9B3.+(;;$ZC9*"(S&H^-)'\N^(E MLLV!DSR)I6@#EY821'DGL89-QP@Z?KO
MIFWW/];UI^K30G["+ 9S4X7LKJU)FSROX'ZK2 %* 6D(4>+()5!!0QLLM!$)
M^(EE"G=G)V!X75N;(V)7XJ;&MYG?A'AG!5.=W<%T^FM\\N0^0=0TPSDH_2.3
MXU<F;0*<?^8Y.'*"IZ) Z69EK HYHF9Q_!!YTN$$>7@7P3@D13/:/S*2?8L8
M[4J?FM;R_#\ #-?>R<>SXOUDOC;=#KD,/0DM5KSC'-G$W@^PT@2M?BW@$V8N
M;^M:D:+!30W[O4;?&YPU9JH;IJH_(_8N5:,W%BQ<UJ<]O+$F>N-<)Q 8J.GV
M5]\/ .:!J3:&K*?G/ZA&<S2<%8DRD=L^NNW&^&$3C)ENRWR%,*.93X2L%$KI
MM(E.A+6?F'A#+&%GYK.E4'KKC2?6B:,G*8'5R&!9T7<;%,\J(9(ZC,:VJ%_R
MDQF/F/)%6-T$?;"Q8"&1@>?TD:E3$\FAZ]8.Z1B70JZESS&N$/C8)30NVV:F
M -H!Y\,,MDOQ-=0*1>94?!XMKI)__2Y?W,QEW#GTDK&"5=7E2>^<6_2".<80
MV<#7LRS9&7=?@[1;>5:RU'Y-M@UV\?95+J4:]X3KL6YX_3#1X1]>ZQH]N>:S
M=^1D6@DU;$NAFI^?+YUOW>8NI4QJX^HCH_)!E^O.3.*+6&WRN^TK-58F@)8+
M$&>T987T>"Q5U!W])B,-/Q,520'#E*9,&GKL.-SEY'Y+WQ:R,&%#+U_3_P.:
ML%L1^DQ0$7]]5JL'I)&UX:THWY-A"6W_5=(/R.VTOO$T^<)<MX0@V!BF AH\
MNBSY(>N>4G:S7X( >I\F\*^)FFIM\?QL>[B1U")OUKK4)+S!44U6< \DFN-M
MQLP1J^>&*$NI'.WP#H7'4C-NK//_"B-IG8T@4%@A1YH9%B<C>N 7%NT?+BFL
MY-5^C #,@V^_R::(DB]!$A%5K' ^\8:)JE.'%(^HSG?I>MEPDY;/>01B*,NJ
M%4##Y;%$S\A6+H@FB'[?E!ES@!M>NW]$/X?D D<4HQ1C4S'=B(Z_K-2HE4&#
M()RJ!AEF^OK$M?NA@-;+%X87&Z;?L<A#"7 >#DR*88*SV ^3-&1^HQ0$%B3+
M9'"&_BQ>1UWHO$-G)<VGY"05#R0*'C]M]QUSDQR'_>SXV#".1@DK8.<!*;(<
MBSG*9-&_]8-8_X7_UE.#82TR#I(8U6-2?K\L+O]\35HTX"H*%Q=$$FLG)Z_:
M=-,9.[^%9NWXHXC_]V_Z,XXE"HI;!!$YR)7M='I#-&NKK61EQ5:T6.<_GZ.T
M?DP.&LH;& S>]"PUY@)14Z ^$.\R,.XBHO=DX)_AHX) /YF[D:T7:D10FWIP
MW67WH):4OJT>4/&<KDX/31X!'K/@G%J9F@MS^TB>H]RX'HS_'&@NCHR# @U
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M?[[W.[XM802^,-+E# HS4EW&+Q1F@K.OPEYJ5.SA.X-1I*&AO"L@!6)Q9#F
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M+FB)W/[6X-_^%%'PJ>WB@&PW_:8UP'!K\R<6FN&8!N8L#U&NM ND/X]58/=
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M<)!"9F/?(=XB77-D)+>L;>6C9PVE\/3G0;'U#)OYOMT5BOPDW4G-$H1UN,$
M7%E:R,J3&5)B('Q5/K?X\R?JXI-T6_72MD_D:]1 R\B9\T9LOJ?(LH>F9NJ/
MM.8+#=.50\Z:)_*QQ9B%(T4']_7SNB0"VISLE567,QM*.1_.-?27"NXJ:DM(
M*7BI6DQ]_=L#VB14QQ_SV^,-*N&9 3:!Z$!.)=V[\OI_ !GR2B[+&_40'\,
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M'2AT(C=&6=YNO*2,,O#39@<)J]CWJY5Y?!B6*FK&7Q6!4B;&EW3ECHHNJ'\
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M_EC]@87(K$L/EB?JE]"MG10T)#)/42HEZQ$F/-0P54@-J!%V5;FH]@X;*\_
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M;(-5/_S:0:OQ;W4]<U#,>JF(]!3.'-Q'FW*31JV-D]?SM:-93703<O&YTBW
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MJ,0[G!-\XUQ)'=<\49&6$,&N^9U(*TK?H26QY!@'$G=<B\--5 J$WY7](-'
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M<>#CN^V>Y>6XUJ5/2F.Y!^SEU?J0 8/7&QY+J-Y>MW$<_I8589$__:2/_F3
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M\_UI<0VXH\LF'7="5^*Y[33AK:MB'FE(?/,'<3*B>K20T2(W'O?FU-YCA^6
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MDUAME<[NRKT!'UJ_I:P=PV3V34#G]!DPZ<)%E!HP1+(M'ZRV^ I^/+C>,T#
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M]MO40J]P?STMVQ,S5-@"6F9=_@'4J"-BO7(A5!$#GXWJ555_D>8R)92]E8G
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M=2^(--PZ-H^D@G(_7UT,'QITG)<@I=9V%=I4SV:!BC*].N2VSL-/ILR((/T
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M,>4_0-E_)-(MH8.PXH_LH5>!M__J]K9*A5RA9.FUJEI!/#MYK?[&_G NX3]
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M<WIB$CP-3RUNPJ+A4CP@U+4>Q":BY5ZD._PAVA^2_5\3S.O_EF3_$NPON:8
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M=E_GD5J*KM4G_Q+OU2S>*F(V9@W%K#]TZSU+S)ZLS\.BA YVV>,+YB<2W$;
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M ((+&;GK*\8H_3,1DT$UG8.(C>03@C(XT/ E]$+:5NX*6QTR/RA)6XN4*VX
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M6)AFX=]?R*W95-)[7R@9+]:6.:8:)LGXWMVA%CM*;+%W<QG7D_:0HL4-\2-
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M1F<1R)G_/09EECK9M)EIK#$805#/  J-3W=V$\5(+-E9LF'.PV0;R["NP\M
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M=#5<A*)1!AE.?5K]]&GIBO>=#G WN_N1,Y_CF3[G#.K=N1%"$<:2%KWT27+
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M3VII-($VRA,6!T,Q R<"<!-](P6$@#Q'_RI)07&%!9?Z^=Q0MM&5(US6T&<
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M(Z'_67O_@V29Q%P<S!3-HZ.NBX3_.4HNX-%#]:/S'YT@XK*#Z!GXF7XDGC+
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MN"LT]19JXH(BN1VE,64J,2NMV\#*0'#5 ?]DVF//5R'DDT#NJT^?-1OC97G
MN-BR>604(FL:^:3V=C4D,#>,@Z:T4[D:U7ZD(8]94O-A ^QPI"<[O$6@GPR;
MOM1+ F")2J\&95SBELOUXF? M"?ARJ%E83U=+K  XC,I,;NW6]:&-=/Z;V_S
M]D><S%ZHJPO-XG4)6DUL#-5 O54^6%HW:&39YWAI(T^:Q/\!AZ@GC7;*A.';
MB'E5R!)R-%OLD&T.$:++" AAD$^9&'W5/EKJI*?/:2]WAZ9R]4FU;L9U%AMQ
MBS;Y, !;C+E']^-\PVTPW\3=I<Y"'-0@K?;#T$+C26]@V4=K6\:]JKSOS?(:
MIF/]Y_7V(Z*PQX2.,?.%O:OZT-WFAG9-J2N_T*696C*L"<:7XKZ8$XF*1O44
MRF8)?# *W; T[F/;@$E$6G4>%1NM1<[BDVPLHX ^FH?;H.>%WHET.U;8CVN+
M%JZN6!D9'E][!I BV!B#ZWGH"M+DS._?NOL[23.E-?1(\W0KV\.XL;:<,1?2
M#SH$*K#,JZ5+,&HV,J*0,+KC]N)V*SUUW"9ZE[*6D3-5 R]; )I,W.TJ+==J
MNA[5:$<51F_-8TQ5]B:.&[.1NH4?R]C^\X@\+IX9E0N+I9NN*]8PV.(.]XUX
MO(:Q8(_DP:8;EU7/!NJ@2\\LS,F48"6W-J^C$784V)%%% ;V,>2SE[T;H_ZM
M*D)S(BUAK%^WPE7XX4EV6^7N\N+0SYD'@IQ][5#I-U\L+I+LR-.W%]]+I^9^
MT*>HI"!A%6PR3UZ6P_BQFSML^)C7($VI##\TN$WQ3C3<'[C/_71=(J@B_D5^
M,G AEQU;[3:'U!Q/>,A'(C=#JF[>6/4LP\:,&]W>$AZ(5BDX B%,K^_3F&,:
M53WP2Q?RH\NNVK^20T*3+AI1G]L$(^EFLE7W;[/U??"Q/S9!,+@!K0H?S%:
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M$!8-7U<)_YG4?#\]X3:$V#/S:6;;I.4GO^RJ64%Q]:_+-@^4'F;+_S P-LE
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M<&$AS0A>/!.M.M(K0&XQV9$JG<.Q'A__RQ?(T0C'?.6>F<9[FV@K5&A(PH<
M*A -D5!6A1"<I=+U4PAM.!^-2E4X@$9$K:DDP#6NQ1K$O7=C)*&:U!K!S]1!
M4(-89R\W'"]+ 5=%3)HTW]/L733M&Q ]YDY4P<DH\:=7:G.V&"S@VW5F_E;V
MZ]O:_\-CCXJ/&5.VW^;"P76$!Q3&F$?-W>X;:8GX_3:8PN:!/4IST\^FGPMS
MXT= J8SFPJN&=UW(TUU[95R;AJ&.-^5NEIAH\:;MSDD=)!L8#L1M4M-V>YYR
M5X#;Y#>W8X)LO3!:Y@<C1Q+XC2>@B>D;+LNR!9F+%4(W!MUO242$80&?R/9D
MET ??*GD6PY+C51#8#:2 R-!7) TZ:O3P1#/5LX4@)2:CM^62IRGN =[S8)2
M35>#^OQN2S7'>)H,-=.B4DGHAV09@+=DO_*7K1=U:XV0G66O9\H,B4U"A 7#
MJC(+5$#B-WS/W!:4LIP:]L<YGF8E&?L@6#R:+$(Z5@KH%0>'JVD^&TZI3XC)
M4)0Q?HDUNH,63!B@<7&XRJ&>$_.0BPL4YA'Y!;V/RW!T(@!QW.HN?<0T1?JD
M/8M\"6*W,M\RQ[^5#73)V?RN0EG2YX]P#I_,LI^OD^8CB1/O>4>O.,15LF^)
M6<?(.?);US3A5HE]'-=9Z"Q523G81Z=%A<.\^016%R"=H;!;,GF+#<!4C\LK
M,IPZ:BS5.UI8P#.%0V-E"E_Z^!ZR$O]+EV)N4SP7%)U>)\E!0/EKJ&R]$Z')
M<PQIT.J/C N[V[=U-QTP6I">%-PBBQDA](2:&_G';=>\!,B=".LWGO2J+Q_<
M/PD>R,*\<W9HT9XLK/<.Y&PPM-.QBA5\W]1-2D &  ES;>!5MK"(Y$/L;#K@
M]P)E;3JJ[!WFY_;Z6IW_:?]KKQ"L&#ZF$F=Z?-UD86/*0X5U<.S.?CJ'+Y>O
MVWI$]:_-1EB OJ$1,L2]U/R]A/Z=^#)+*2I#NJNWT<$L("T75]GIVP%CUBR#
M=HD,IP=GVFSG,7+"7T/>MO+D=4-68M/N;_.*Q]H\](H^XN?QB-\3N'Z2!J6%
M$"VY9YX_]JGA/=/P8F3&4'M(3',Q6+G;;\.D//FI)\_'?0VRV8UI?=5/QJ>M
MJ0_ O5+N=>G6F>K#]CCQ7)4#"Q9,(OU<.?TC2"ZQ((J91A"*IXY+YXPLE+--
MU+[Z3,S9O\T21=PC=^WB,&T-^M9-,GA3<E3W/S _9^RD**-"\*GX_)C3RPS5
M7J$QZQ?$(V:3FGW/@X9Z@L0;'P_+NS_<5?AR,LT R]GR-#=WI)^F_[%@PMWP
MK9DSX493U-[(O0XIT5.U-&V!)%*)NEMNM6J8Z76UV<2SRN'FQO%397<H,O3K
M9]ZF [8+WJVB+HJK410$S9#:O9@CUHK("FCN++S)*T;N2AC:2GJ.FPP+ *&O
M&U;VR\L70^B&A_.V^W!HZE5W-IE(;>1"KW!,\4;"MQY+=.XBE*_<32!<7+=V
MZ2KB2^I#, _6?/]<ZY#'4^?QVHS1(NPJ@U;_LF&JZ#=#J\Q%F=S>F[/3;_PZ
MN'<!WMR'V<;=JJI?@4J4'GKV :=M]_7N,@O?R/5P!9\T/"12WU44>#I-4"XI
M(4Q--$\W,NO347S9.+13A(OLWLEJC:\5%P?R([WB\'"3,KGX]6I!. 4!Q=,]
M321NMG4ZJ(#4#:F.J$P\,]C_>&,( 61Q\+%^G-5J0'02$SU20*#Q _C&59&4
MUG/O 1IB&W,5"Y!P!B^A/)_NQ4Q 2&1O>460DEY"OP#$50!)"@04:8IM>>Y[
M\U0)1#WM2CMZ]XK^>\U'"MU\%[)%&F-[BR9IDF(2)LP#RX,NHW=#43\TO:9I
M[O(\!'J\-_4(%PWIW"\?+\1%CS^KW6P>GEL!6BY0],#[J"SCZKANXZ2P38MV
MPZ?@L;WTWG[/8S67[$"[+6-8UT]\K#_?QF5U]:@Q)"Z]FCO=-.*O81>_BI:
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M@NTEJLWN@M:CVH_[SAU[/OV_N8VOQ<X"_NO/_P%02P,$%     @ 8X)\6'^
MM,J('   :B   !,   !I;6<R,C(T-S<X-SA?,34N:G!GM5AU6%Q/EGU- XV[
M!H<.'BRX2_#@TE@2$B! H+'@'DA(0J"Q $&"AT!P:=S="=8$=W>"Z_+;V9F=
MV6]G=W9G][[O_/%>5;VO3MVZM\ZMVU^W\P"1FI*J$@ "@0#SNP>XG0(4 "Q,
M3 @F!A8$ L'&QL+!(\/'P\7%HR8A)22CN\= 3W>/EI81RL/&R,S-0DO++L+!
MS<<O*"C(P"8F)2H@R?-04."/GX"PL;'Q</&H\/&I!)AHF03^QW;;!!!C :<@
M*3"(&4 C!H&)0;=M  , @#! _VK OQD(#8R.@0G!PL;!O>N ) +00& P&CH8
M P,=_:[5[ZX=0"?&(&'BE\,DU7D.878F$W@3E8[%(E_23*X[M ]]^,(E"!N'
M@I**^MY]5C9V#DY!(6$143%QA4>*2LHJJFIZ^@:&,"-C$PM+JY?6-K:O7KNZ
MN7MX>GD'OWT7\O[#Q]#HF,^Q<?%?$A(S,K.^97_/R?U16E:.K*BLJJYI:6UK
M[^CLZNX9'AD=0XW_FIA<6%Q:7EE=6]_8/#C\?71\<GIV?O$'+Q  !OW9_E->
MQ'>\T-#1P>B0/WB!T#S^Z$",CL'$CTDBIP-Y[DS*+/ &BTP^*KVD&9OEH>X^
M^0N7(1P*J.#"_8,_J/TKLW^,6-#_BME?B/T[KTD #PRZ<QZ8&) !3B_8,P)Q
M_AY"5U=Q)6QY>*Q4TL,])!%.9-XQNBA(>#Z/FQ;Z%H6P,[6#-=(5P7_U6!DM
M4'!;R!3_L8J](U/581<!BY/:6K:R_>C(S-24P^_L1YPA\MC+[$NB1X6D!OL-
MN5;60C,QO5X! 4+E'OY&Q%@+8<0MN4_F?)(K9>3,EL[LV@FSIZ;-C)^JYMT"
MS]5?LI$&=?/%<-*D;,TE B=\"NSF+EA=@A,O0]'GN#_>6\;O<Q+PAL5EOU\B
M1-KQ0FOBDU&G\FAEO-&;0R 2A N5L'-3\V"!HM?"$Y<G.(LH'Y^MJI:->#3*
M:NY^3NO!2=6MD2U9^G2/7*-?5.]6IOFH3>U?*.-67;Y\-YK_]#J?8I>BUF#Z
MYWN:I@L8^5(1X:;)MZ&XGK:9^QTQ0D%H3516'DHPL76^[U$;!O9U'+D19,QF
M)L5O> L++>MA8%^7EAPRVMV92/\O9*!UP_&X\0P].V?:%@X\7:I?PN-T^DM5
M1SF4QB,,.Q)NN'HGSX[//OOO7>]IOC\L-&V^AYFYT"^B7XI$!DU2H%CCR+[$
M)+F0H?'/(8Y[V(*02]_K&T^<"&U?_A3CJ:IS1&)[KD4AM69W?QVG$1J(-R36
MV(XF7DP;@V+$(NUIEXK&0TN$^B@VPP5SJ:):6)?"^[Q!NW9==1KS$<1VTH2C
M2Y5OB-D:4DX>" W0?:K9A@8C (O*; UW?S;5CMP%; =9/F5_] 40YWU^/H4C
M_*MU\.L;D@<TV^H^U[FV)X;Q7<:^0^7=R?#!(N33H$6:+WV1:M&,+[)R![!$
M63;Q/6FN1 ]$3B3=<;\SE+&P9I0X4E.^E*,AJ,_$:+QW_ R<U5RGR'$+1-BZ
M)<S.A?G6H2F7F(^"4#J*9,#_!73)\?B:B'<Y;-+0HO396P(A:63EVB!%LK\/
M,[;0;3?4N%5BAX:2AK2ZT=7ZS@JG9\PJ\1*52]5J;0T[N/O;R)5U]<U/-Y@9
M(?(##]9O3+W>P^KY0 9W_I3S C^Z.O5OTGE^.?E]^TU/^G>Z*;8Q<78X:=!Y
MMB/KDF'IAFR?;@&DS +)Z"U0@A "@XCYS+_YJ; %-EF&G;:#U7;;=QBT;U _
MCZZ5>P\;QN&TER+6#L?X8:<=KW:<4K$=D;A[X!;>7Z5--QH-^^ /084S33[T
M4B5/9J"[A6*=T9HB];7V9#J* O*A[&EH_RQR-W-7;4YSX-%KK@22[QFQI?4.
MDP^"1Q*K#9!8LT_$-P5C%ST^QEK*XG(T+UL2I^:D$<BT?+]DG6HM\YMZ GM<
M^?&:PNT#7&;_?M=%3N%J]1->C9NQ,^O,R3S[I$OAB868RVCN5_HWYO[4!?64
M.C=CP^8U7*7R.+W4F]$<K;D7?,R!O$/_1QO! *Y$M>O:F\.J<:"*FU>HTL6X
M[&SXJB*M5#K)M;B'.;*M&<I1:]O<W!GP#; ^4[AY5 "Y:4;= A</7E')+.HM
MYA9$4-1D)"P>&8_Z;MT":&8B5QCUKQRQ KIBTVZ!7^)SMX!B@4R;(<F<[6-4
MX\&E_>+BKUM@1'&9,'W97Q!4H&@PXK@X)CCELRXSUO>F24HY1WI^V9_\U=]/
MP?\0\OL5GI:,L!+UGR2PLGC$P^'0/D@NUG<RT'=%_>+1 C?1QQ6%;1RM7)DL
M'$><343^2*UV<?N:QG?'7%0BY[]-:]HHY!/\OCNRS)&!BG2>!'1FS1WW-\9Z
MI:3/7_O;;:Q2K'HB1@3\\APGW^^>$#3RQB/K'R;69ZXGGKQWS#?K(WXI7->W
M?8KFCA[MBV0JI5Q90D_I"!0O^MM5L4?QOI595OT9L$WG> MDH"IRP.#'#!/2
MC'7#$12GLK,FWFB:4+DC>Y&A+?^2.E5'CI((':3\N+=OJDVX,DRG]?L5MBJ#
MF;?A-V0;+*YXNFEA(0']0VM-5*0-FLD?B\"5<F#]Z>@6P-[@]7 Q-/Z$'CIA
MAAD5(;<MM=GYKDX1$NJ*Y6;$Y*D0IQR.4"M-)DY9FHT=VWY6ELI67A&/O.I/
M9,](^"]3PG^:)FZ!#\>]!;3LZCZO:7MTQ:!5D^W[FFCOH/-XXW)F, 34NFZX
MY;RX(*O#.B$LB@DO[ M)1C2!ILHN.SAM?WP*$G(WX<KI3TF-4*\RO*N=K2Z&
M'N2K[/B8;U,DS654YV^S90/FE6..A1P"<=(+WHD3I-$M*@H/6V6[?, <Z>5C
M?+,IU__LQV3$%]?>=!RE0R_>$BLHDZ@H!#@XT\;T"+X%_GJ]\RA;& [OV\B<
M$%3> D-VIOJ &Y50L[%GYZ/]CEJ?A:2MTD]DM3O)3%8& 4D]4.M5]&1">:[Z
M0N\ ]'41:58MHFX;C0NB"0)Y"C H] A*</3U@I) PVNO(FYO9)GWY"3=KR,J
M8V#=V^QI*K-,#F2599\LX,7F^-5FS4@&?<6%][GZ$8]+F[_!3YW'P<R\N.M.
M4^H.@K76JO'VV?J_[\G=C BK7FG _*B/='DD9="=.S)/:[RO2GJD8*6-C0IS
MJ,KU-)Q$_TQX[M0Y:MM?#[GDC%QRV&PMR7.+S;'5/&68O.?ZR3&'O1GJ&\-[
M:DG7F;XIH\"3\./;>30UBYW/KX!Q4['S^&GOW&U%P.9_FC5@'$O9_,;&C\=I
MF%2_J.),4YG8=S0!K3\7/AQAUM2L^FI8!WAYO$2=5(I66$ ]A,LR:LHXY'&*
M-X+'!8$&K)+ZDB'AF2?WVP3(/:GO"_ ,9T+YMS4U7)'O%TQI^B54*"I5F;GA
M%??C#-RG-M4"!33M7 )Q"G(RNK.?9'8=<,G/UTAWZ 1W.73.YH_YG&4F:56'
M&J%49ED-E;45T CD(#EI>'O_,=1$[D)-[=]=;P-DA++_!?G7ZFJ(JTX!%=1I
MY&_\O@ OJ8@?*?,')F3:D)1?OCIWN^,MLD[LQ^3]_)*NGS0EO%W#O)=0*_T3
M:.K6TR!$*:.E>8\WD0N^'ISAL4^UPYQFN=U'F&7T%_VRHG31;O+$&_+*-WTU
MBF,=\4QB4PX3'U(]I[@BGH>J7:LG!5=R5J34)!W!9$[FB#;JGAHIYLK+K""C
M)EBEEBR"_$,^2L(7MGR,V6I'=4=Z.\X*#3(_!S1A30< MM$Q#EWK[#EPGIV]
M N9:9 )K98)")S-M"*0J-X?H'_(AZ1*^B-ZESRMLIU+;PBAEH=II58J^AR["
MQ]/&K^>6Z?(J"BW:$BO2;5U0%4/5X8N7O=^FS<R3(^H9&-Z; )/##WBX73^I
MF^8%.TOJH'NI#BQ*#;)MOMJQ/'LQ:2J#MX'ZK<5]V(F%SUU2;M\YFN<B'8+,
M 7Y,!@G6P$?MN-KZ24',%B[[7M3HUIN<JCSPQ9E5K7OVS? !S.FC?F7)(56X
M2U0/HNLMGR%Z$=TU.UCF;T-5Z-T"N]R^0]!EJLS$22<((1IF6%6I#<RQT7A7
M[\B2ZFA_<@/P#YTCEJ00-I?BMX"_UN7VQ=K5I3;ZJ#[KC*:_E]B@LM2 C?"F
MA^_AZ]K,E%M@+11(#/U8,/;I[D,*PB=,&SX:\[N[FVTO]7% JC<0%_I!-NWZ
M7'SM3^\4,_JYA&Q4FVO%[8"ZHOR#4?CY\I(C3*IQ4!#7#? ]=$84^M#^1!][
ML]B(;7O#,Q*-.L[ZN!BI2C9DX4W_M7D^R,YZNS>BD>WZQ._UC5^.\*;<^?*:
M3(=/\K"MT$M]-G95-9Y^JGOXI9ZZ-(Z$W:DE805?>P.H)3_[-U\LE>P,D@^/
MJ=<+3UZ@3.TB]\C>!'.\GEYC^1GFY&-HE1^]<6J7O:FGMJC;:^=N%B$BTS2+
M );&<]8$VZ8<MF<S,B[%HS7/Q:#7OZ=?1#"]/EV^!1H&L]F)'Y 35>I$I&CR
M7UD7MRN+3.PPVJXEMY.94WA!FP#O&%D*FR+A T1\X=EPRZP,H6"D4=NY+8^U
MC?_(]7 :FA/V@.;#*4G#W=1O9[5:(P5I\7HC>[/LL=3?$(_<65+,^"%;%;''
M)0X<<FH7)SL7K]P^PX0=A<[D+I7>K"*\2D?!I />*J3G/WT5\,ROR]11.Z^3
M8^P/03&I]?3S')&NGV%2E*&2$LY,'^R(E;FL^;LYPD/\DM -R[7L7O>)R#]>
MOMFU/Z;:MD&;(:>,K+X\#)BS'B'#(B/^W=TA$W9"E89MD_.N)NQ/;M%^,&JQ
M%A/F]GHR\'Y&&E_'!^,LIQ]B]P<!VK$'-&WWE.IBZ+BT0[;EIRP/IR2TSKSI
M/Q,,C NQ9X2BW\E'X \XS;+L6PUDYLW.F2C;;$BZ3X3X[L1F>F'/-&]O13@;
M'#5B;S8PE(UE&Z>K:A2.IDPR0<N(U$D,BK$[>P0"[AW=2R_$FI(=?=1_KPV>
M-3O<OLI.HZGZ;)%^9AWM^]\*@CS*YEO@$+K^5R?4WXMF?<HXIV>3]<B^YXO.
M74='C">,A_A:BH"%\=/!Y^XU+[\QN3L\<$AZPW>SY2UZ[7V!ZH?5EP9K(WWL
M/L_0^,P'_PK^%6'R6P/<)LV/DH2Y+4PA[4Q%1?+CU1T>Y?QP:A234!>A?;,7
MJO&K2L]%HS!Q[_K9LL=%2"5^\N+ +%O=*)45/'T3DI?RH6%MOQ\6_"CNT+5N
MW$H]X?,N8D)YETFZZ7KU%K"Y 0P1J=DFMDY4<&8LJEUW:)S[S6_^E8CJ/->N
M/TLWED0L!Y;#M5 Q[6.8=NNA4(S(6U\9X8!%/3BQU&/<%89^/KM7H<#:+;!
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MW?8+?[!\$ D[SMA<[IIBI!E/_4S(&SR2ZNC=-\;MP'U?^-E^RB;?)B7$KW2
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MC0MU^N'#IJZZ7&J=$'R$^*4VI'#\X:(CI'71;LK8.E%T\2,U Q%FY'( [BU
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M0]RXSBL%#0Q+4N:26 L> DSE_I3/H$F40V5689DU&:8<-<)S%;_,8\;\U\D
M?^)"S")K9G;2^E[Y<0W:YL8#J&H0!;'*)V2(Z.52BC?,-'T3=BK>4&3A7Q)2
M8?,$W5H"G'8?>TG4?'HIG0PTH+C?HY)5 3;Q8D16VYHCC-3/;8Q-<=2=F@I!
M&T'^)D?W[B1EU=8<FK*']"V E"6:$YHP1.+I"\_%FHKI'1ZONWBN*ULH B\\
M'15KA])K+]VV8964I DFKH%M*MM5TTI $U53YZNINWAM&Q=4+WAZJ1'%,X]
MH9YSHPY-XW]W,1;U45F@6U<-8$/(HQLP/-WRX&KC!M&8H5[T*D-8L/!DZ3[,
M3D@U9)VKY+^Y)%8R<+5TP\OGDZ-&UQV2)9]LZ7[[O("160@G(<PWC4B6UDD
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MXK<R6NE@<J9KH=YGGP%5BL47/?ZN*E.]J7P64AKCI.F&Q%^TH5\>>R)9!?V
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M)!'O LY352TFAKMI0$GJW: -TM;FQJWE((-KP.4%O/YGN1"(XORBFX75&4[
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M O8R"_J%AY?*AQ%O\W:6KC)Z:ZG-D@JME1;'OG(P'8EW:EOF'?H=&1N*EG4
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MY8&&%M(E3I>6+G"?6?2#0. 3 NZ.X<BQG-JOX2.'O$\R:"IO5*YNA%?#]RH
MG>CC+9[F!$8SRML:"0-'&X]L<LN5V(QOU;'RE&#/(("M_%V^SUY5N^^B562C
M6%"K]7GA?,,Y_?UNNO?DM&@-;\1HT(!N2Y"QEQ>*F+*484Y/O3$DY'?]6^?Y
M\T)Z0=CT P*\P9?"+UMB=[C  Q8(8"_#@'MKQ^E^&#\%?;+"@/MZ5N\MTPI)
M<([5A=F"LYFT5IB(=XN<(6_'9]8A3?2=/5NUR'SX,-85-!)^0>*32WB^0P<[
M9EUQ?^'B%6KB@*,G*OF93$.43K%"-%F\#/_5:2Q?F0QNW',/V1<1=;Y\/@]
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M0'+YZ@N=1O&,SSK9?;P:I(1E(]1E=NQH7),.TYYJYH9]41DR[TIZX$0*6/"
MKO,0T +)5_"Z*.1M]GZ%/O1R4+EC8:D"ONJ4_'OXE: I[(^%VA7H]!&4Q\A&
MX.3*]/JP-I:J<N:PV%O)^*>.!UI%VS?,J+T,82Z5..@%$<!V5.&-IL7=K?M[
M<Z.@+>CCZ3^^I_ZOK$],X^SS=0DC#QW8HDW B92&/#R@Q\-%X??A#R?'8<ZA
M"$ J)#^GT) 3>FQPM.*% 'P5Z*8&P0/Q>[!S_F(I\DA#'G!E)@* L,Y='EK
M9T/AWJ7@O:YB*^8Z+Y186#WYU;D^LHS$ROP!;ZTLM32!!]E9;USK/H5?)8-^
MA[?6#N&D;3)% '92R"E)H_%T>? /#-HCRNY0-*9+3\[SPWID\;@;^3N&L<S0
MC@^44,\Z\DIVV[(^ZO<IT.X41V'U0"2JWG$$8 NYY"JV8HR90(I<@$:HA "B
M2]410,E3!+ ]6JV;!RW7M@OEYV8D)[8+8?-03NB8W=)H7+CW&<F6" *XW+=
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M<K1O/*7OU)B,"YH<45/3]?L) ]W?FK&PL$@J0FF3W C2V&OB9@\3V:NNFA"
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M*&,EZK25"X4VKKNSUDD4;"Q-+/L>IPA S +UI!B>YH6J8,='2/6RVU$(K5[
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MAENEKAK=F88^<F9ZQ]^XI:= FEG(5Y2"EH   ET60!=H.O!R<$O-/@2&4HP
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M7((&E\-[\MSGRMSW_V%F/LQFU5IG=??N[JHN^=6NYOG[\P: I2BK( O P,
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M5R@RGE1R07W?"QINC3-\<_=I% ):GI]TYW]8^XNS_SW&POZO./L78__F:PE
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MHR.!3':*M!/E-MRB^,0_I@AU>;>(I/7YPV'40KIC)(,^CFL5=EPM=YQ'KGN
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M7+8;8?*%-&:<89/:F0%=V!5 U:0$$(K#5(P]YMNJ/O_=>S<X4XPDR@#T7I9
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MY NFJW>#.=9[F@V-0;BJJ"(51&8TV[ 2=<0F&\^ =YWM,W#!>1!R=44!><M
M=%5:AE%Z'[,BN2N')N..,*3MBNDJ1P1)\WA0/">YN5;[1D@I_#'?>V\9SS[+
M:[< [Q/=I6OO1F"/S4H_/'G'N[(2&T.[,50#A?(? Q>4K+%2A)7A"3[7 *01
M><7AX;5[O!N6V1P!$:G-G=;T2$JY)64%$;PG[Y!R657#'LCPP^/J]#+_&YC!
MR<6>+1 KNS5.OQ5&%6!-8H'X-6XCI.>7+5QI84,ZF9I0^IS3R%[RM1276,?1
M:\^_XR*4VKID73#D*K@.L;]=E_Y(]_UP0B3L=Y" $8!Q->-=ZZ(9WI]RF'_(
M)>7"!68>D1R>F$+J^:/3TM)6 0&E4B@?A\\DAQYVFYB9I9";%Z4X"F2V;U%G
M3[/F\V%;0V*6NHL*? EV'Y0Z AQ*LGCUM& E6"?U3Y@GNOE"AOG:GX&ZJ)!+
M)N!L6(S6=T:3* 1+98!O+8_ZS-^FK*UV^:=+?*=JG>\AF;#60EEK4\J2-8.V
M++(QILK\MO;:(_&/9P#UU?K88,:U4OQRNX7MA"W1:8V=4VE33=8AJ*>;3M,N
M:BN?]K'["E[!S-Z42\Z#2;ZV@,V;\8WE&4#F=[I6Z]=-*'*7Y?(FZ*J28"DR
MW@W-W8_8T>S#*>@#+*( S?G66;Y,K++_PIJN4\WE0 2=6[H&O&EJ2UWPJGB)
MISE4";KS;J9J69M$Q4?BHCR/O_)!D$C/!T[?!'OY*'=,.5-Z=Q [OJ& <4<B
M)(>TY6,4RU>[5F-.S581KST#_0O5XRX^%MAF81HR1%44RTNJ3_ UXJ?[^>C$
MS,(/ 0K/0'Y:V=,3OOD"9.&2LZDMQK3'=Z"O7H+@CT]@(FE ;OBP(C;D37;<
M6CL_2$]3HJRV6LF;/<H2R3""-4%BIYZ@$J"&Q+&PA.>=PI=^-DS=U>KTV86I
MH\^X+*&TO5>0=RC$W':!+T4TW*^6%OR;[2E/3)(\<YAW,>$2^ .S_3 3(&R'
M8MCG@?>LW:D.'J3J--&6::'"D?XPAC4]@_'Z/\J8"[ZWY#"^W[792!(X.-;-
M(P[9KC1^!A8[Q>^!6LPN.+&2L^ZF2M_U_BSGYOHE?:&QAY\KOUYHAH:#E!LG
MS%YXE)2^LE*KW?-('MJ^JJ9X2S#I=K8TZ#1WYI1N>/?:X[?/$.\\7Z93Z8>B
MERU5>^,76W;"DR$=$E&L5+/FNL8.[Y+[^F3BTFC)!N&(!B0&0FI<EHPE?8GR
MW?O<4K02BFCJZFO=E?F^B>1/!L,I#G'A.8EL7^YFVE*U/*VFVB-;.J:!)%/3
M*%:/PC!_2I!YR[!:/P/6(R&[]"'/0!#[,X +VD*@T689#XT?GWNRA;G4L/D^
MG6<A@2I#*5CRE]D@-KD)69VDLB?2-C1/*S>MV+$D>KDK"E_ 7$Q=(8D&,3<[
MS^_YP]=XG:,<@G)V=,=B\=2'.>4S2B\(G00IP9)PX:$2Q'P+S\"Y!]L.A9W+
M"I) DI_# & JN[489PF2*]]O#ZX^5PBP;Q 1O/B>@K)7RVEXE=UN".'W@[7G
M7#OU6N8Q,%_#A0^?VQ&$$SC5OS].* NX#OFUG.P\9#!F0:4F23@ "-Y?W^0C
MV5WKW =_=CHNU-U2XE%/*$84&#X);FHRA,0Z^3F4LX 6Q0*/K @M%I'<)D4-
M#AWR\V$K',0OX.;$C_[HY/Q22?4S,(2I!C55._%+7 D*?/:SD Y08\@=86//
M_7WB,R"%+Q,2_K34500=-U@"U8"YD'NL?)OO-\2NK9G%#U;;?A#"G:6BL\IW
M_6>\D[F+&0-&'^&(AK?RSGGK]80V5TK>+_+=I/1.ETI55L#O=<O $J^1-7ND
MMW?1.T]>W=X%,=;?6D\0B0R=N&CWT6(+'OHOQ&=S29/3MJ:X^ZU2 HDCU5.(
M+M<24(N)+'@&0O8A0Q276'/BIT]VZA)$/3_@(&'$[YZ>@;+^TBAK/;%E_P?5
M5;_/F'/:]PPP"*QX:C!+;>/2BM/.5T3&]V=^)^;H)"NA+41+L,\ AKN_5VU"
M6Y=F/P%Q0O%B1H8[(AU'QWL$.!JX'D$>F((":CD'SZB8&';Z+^6]?[E R7CS
MIK;7\ R=>4#V,T $12G_Y>DN]7_7Q>==*-?V'&U2/*& Q:QJGX&-EL?W#^+W
M5WG08(3?"PHY,X H!N4]^4]"68I!G"P[$T4@) ]+_V 51TJ$A3U'D"_=G"AY
MIQZZSX"&#(\E>1"C#R@7305K.9&'7Y04@G%M+RG2".'R2_X&*75!2$O5]"U<
MC<:65B+?@+2A0^[!/1VFKJ?ZSMD3UO"W7 /#K?FF7)S9Y)@S8,'TL]6$#/O9
M?IJA726W80"V&O$7&Y=*P**1H?VM,1G!FD+*KA[1#MCIH6@G^/9H[LP?9"X,
MM9 _;NG.8TOU,4UI_?[FW3,@@=]W4_O[OQKR@S!+Q+ .%EK6T:N5QZRNE=A6
M! VMNN*]QW]VT8VD-ZYH[2@DWXJM+-)!9:!0D_?DG0'5KSJI?%F]LY/WWU<=
MLMVY:<[O9S#1[8!M/7!0L<MYC3X#'#<$^XD;$K0,@?3<3C\#R)#,9T#L&*H+
M)H\.*C' V#/P-N3-,Y#G_0STU$%X0KZ(EX9,=H2L+SX#Q+.%8"P $?@G&)(V
MQ/CHY&1S+G2!ZHD58?@6_O$AB5,DU\]B-N;T@'-2']AL?!!,'9PU9-$<1V7&
M;&P9X]NBV8.#MV%Z63[@8&.TN"B3LAH\OM>X#)$)JN:+VR/<]G\&],=F1$0K
M;.]7/O=1\GT>&NL[B66;4>A5;H.WO/GF.3/N]$)3))E*<'D7BSLT->X>!1B>
M]L*N/&3VIO0-'"5<=_#<291>"5B4U-/Y+,?6.O-ZZ+RKD(N+-)(DD6:IR1;X
M7^ ,K_=_VN\4TC>E1XJ3^6,*B*PH.Z0;:J13$>K_$XRY3AU*IA'^I*V>;C&%
MJ?]E@;>&39EZ1U.MV9JQ%P<NUQ[2+KXI61&R6-US#U,GE,![D;ICTB[^UE^-
M9AK78&9BGCBBGA[ Y'!WD"!=?&]('?5BJ0MT*U=>!X(%$_PK#X?2)UY5M+Z*
ME8^)@C^3/@Q;&@=+N?I?W<6[+ I6WUHU&?ST(+O\%#B=KCW\T'8PB90WIH9P
MC,@;L[#S4AB*+%:^YG4'Y/Y)!VA_.'EV_#CW$V?Q@YJ>+5 G= O% [1+1Y!N
M*BB/5=,._X4Q[M([GH&P]0O-7\_ T4+($SP(QN@9Z'.Y8[P.N3H2AX0QD(CE
M3=I_F^<Y$N1%%UR;0;1C2[A0L^KQW,L;J;A=E=Z?JIB8]<P$DG.;!I["OH=^
MZ*-)'MZZRI>KE,:1)AXD9J*.0U ',TFY&7O]+*=Y]XU/E@/$.8(YYK<!4MI\
M^!CKQ+6R;*@ )SI"PV.#1"BBAAC7OIL)/X[6DEP<XZJ5ZP$R3Q<LU+,P'>IG
MZF^MX_8[M4P1I-#H9"6BP\SRI;6XP]7/)>OJ#L&61%M<Y'Y]/MQ&&Q@F0<BC
MBW$2$QE0[J0F^K7^Z]L-[D]PO-$>F]SXEVIR8EG#G$&USL'[<"+G:V A8J:2
MVB(GCR:<PS6%YIT41KA@XWE;-=@Y$$=LK%X!;2@U'BT.\M"@^KB2NI&L=6,6
MG;?4OI90-O[0@&0^AGHC8^-^<4X=65K6/$KH30Q6F[G'X*?:KH GAT3(X%PU
M5;I2E_)>7%-EI65VFBF&QZR(YU&"PR<XO+_P1&#;>1E$L>3T*: ?ZM10-AX6
M_?ZK84KLW6P/0L]V%O04%^W^N$JFW^O0XU)VA!X7--+@^Z0:?G,A4>*N=JL#
M68 9L'GQ%=%-5-HRS<.NUQ0(-YCD7_!Z0QU>\3C BN==*A)+G.ZMK3Y7WYN/
M-*U6,\?6IV'[(U&"%%<C/#D+T/\[@<,*76OP4B9?!.FF;_"?Q')Q;=&XIXE
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M)\\J5KYKYG#4D5*I5F$YE2Y;.$VU,ZWVFJ^I1O9C^E;DMO( 0A@7K."&67N
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M(_F'H'<NJNGBAGLG5\_ T?Q'90PEPC<Z2SEC;JDYA0)0A<E70UA6#TA_L#"
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M<,IO6DM67!F-P7'$ ;CCJGY=O!K27U 31_\ J+(TV@(J3C'4BX+LU5+(#PT
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MX/S(UD]&,KA['\H!'X?;$H>]=;VK/)PY!V_Z:0RA.\K3.^#BV9Z)?,?N0,X
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M7QPNDI)E3FLU5E6Z\41IY":Z#9>)K';SZ--0S"!.[-91&0\(+WXXV$A@6HS
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MP3?A)=3 N'J(OO_-U9=RDC%? U79L>(N$:J1OAF!+F3U2]]?>KSQ]Q'+6'C
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M]UFYDY_4O[[6D+M*E )*^1NX>_M3NZO:F$MSM5TOE:2 OP]5"D7MQV@8^=O
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MY\?<CNX<6?>5Y]QO#/MQFOH:]3PL3:R2N^O*LY<V[([H?6W!RS4UQ8I!TFU
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MEN_1?='B["3MA:5RY0_^\(MEO6>F01&]H'UV56WGX81?6L6.;Z#[GH++\HM
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MZ#A^(S19A9:N[(X>(.$HN%++V_HI0\%)VT:Y?Q"R_,LZ"RK.1I]5S%_ 088
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M13<]#\+&!=GY0JJ35'2:UB^YEW$W):->*S6O^=*QZ]FW*LK(RLD\D=%:>0G
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M @G!LFYOXA18VA*9^63GHJ+BS\4AD_"X\FD>2@.^>JNC!L6HB)?VNGC^4 #
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M:?\V+O)G_!>9BY;Z;Q%7.W%:Z;\8U/IJ;ZEEG& 0:@%.;@XP-S>06E"8DT>
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MQ@XS8KQA]]I.DV,JR)L:9&T1:2QB+Z.-<P>0Z$</.CYS_ (-^ %!M]KU*;5
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MD>35MZ$<F1\1!\[B%=_PU#?B"ZK-SW@:SU=W!%8]&>(-<'LS$P]02&M&@>?
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MOZ<E*,\)- 6DI#/G_[Z]1&)Y6YNH5F9Y>A#?.<FVRB?G^[K7'7A#^X13V_T
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MV2T6@2&3&9Z91FN2SJ1F3(^GV&SHUHW;R<4F-GAO/T!=S OCDQ8VX>P0T@C
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MMBEWQ+9P,3 %61KWZCAJU [S>Q6S!;!$D:F]T$Y-GNJW65OPC/Q0HE+K'/W
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M%!R"-LY/@!3VA4XEU)2"Y8@4)\[[?9X]HVC15($DM\P.=R?*S5T<C[JZW1^
M$22?1)Y*)5$'?&[I@BYO*0?L7+S!)U?!@2>>NJ]2>90:9G/TD.7$WM]#2JPW
M\FRH($LOZCB(J]E)!=.K>H/KIS5-DD(X8NC;!>Y<(L47MI:WRGRY@K;2N0_
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ML FPM:)=C4FW435";5G2V9Y[# <-]XD:XXHMGNFO^Y#'%']QWDR^&HW5;OP
MF,E4BSV6_<85LUYI[%V_)[7 +#<@?*G4G%PY<'H5,&QU9>OKJ.1.]_Z75YCG
M\#@;\!L22$26U]U6N:>J!+L__%4F9J,T56"%Z$XQ.,21L;3MU%'T<:#ZVJ3Y
MC0.$B['SJ#.[4JSB,J3.3,<<7WBR ;K2_Z??X93M06T1V5!UR'6R?7E]1<;-
MX"?X"B<*K#_D_PW[4#, 5 ZSAA$1@Y.2-4"M)INSYK#N@'MCD;*;+UQLO+(C
M.]<W>R]],;U$?6,=![WM_;=;9&S.+[)*^XW1V9D<>2EL..-MM1X%UL-#$3S
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MHG'2%A6>W;9-.=CCN)U?[6/6%I*]H)3?VY?RU M?] /L_:4'"$7N*X_%HV<
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M"$J!]_V;0RXZM\JJ(C\A.?4[P +GAZ+<B\7(8>UKPI:<!-Q/0XT+"G$_/)U
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ME7> YD8,**J-SX*V[E^269 Q%*-VOJ^(0*0YG3*4%Y_GR4:<1&EEQANV:5Q
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M] [NU7G'=N_T[7;',H,;H^+@XJ'N1JS-]&2Q:^F<R A?I-3T$Y="RST?AN[
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M]"D7O<QD.SQV*%-0:"P1?Z+<2&)C<\[>UHFF$%$I5U=L^L3L%?78,U%+VN0
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M\&S#Z5S^^DPB5)P)='F1=C^ '_M#A49H'DZ+E>BTN%*NU12U;M6\?Q*86I2
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M<GVRUJH;YFB.R;+GB&QHW$MM^K88K%'5:>R"#9Q4=J\G@U!<*/%E"]H5T3N
M_6O']V<VB-[15IAUB^0C)%N!W0YZ<3WY*HC??&@?HSYUL'.KXI@^.["].!]
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M3MU2P/FSK=W+XHXRIJ%9:PJ==P5"]\Z["3N]K-LPMX)=!*J"$*CI2$/=+4Q
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M=I(V=I+K9*4$!"'9L%]=B!U<O&T5='1V,E\+CL4ZNL '@=B2!V/@(20?L?$
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M%K,ATR[1A\-*[85F;%STH72K(>]T2=;.+S_DT5V4@NE2D,Y=Y,48;@4);9#
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M9FZ4+/[<J*]3J:4T3Q+^5)VDL+),U5.E IMG+1__6[UZB< BBX?C<H?C\EV
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MH9\L+:P_42/=;:K)]JXD],!5_UAJ1T$U-P9<E5!'E&_&=X+)JBZ4F\SF$XZ
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MZDR#$<?$''2K(4C=HTGV!I-Q85Z%P\:&N!3=FS01(:%8"B0+\%D?$SBX]NU
M-PGT)[@=A@- ETJ/57V!];RHXU,KRU$V*=T=27;DB++?#XM%5CQT$61N\!P?
M19[FY'?K&.42?)BL*TOF"U6D6<VUT]#=B,;CR3=,(F5Q^]&@)KP]GTQICMLZ
M ^O_"#/\&L5L-58Y+ MX3N,A6+W1F*;]-)97A><Y:-%/,[ ZJ6Q6G[5#6P6/
M%RA7K!%^DL^D#RKR.>^ 1J7]Q_%@2%+_> )0J=N"OKMQ*OMW#]4[X(LUF_ML
M"1^ J@"KC,R"3-#CVJ)R*^OX*GK[IS6&"MXDW1(FMWZP]-J6TIV,Y_'08T#O
MH-FQ;)QL^-1T8_)B1<_LHV&6.0T$8$8,'_F1+<[O2"YI?=K=BBFE<M#S >J\
M=/DK9ABEI],0TJZ*SRL/=9AH;U*]?;,7X'1-:'EU*Y*ZILV&PS*D>\ '_K7M
M0S109S(@RPCA7M&02%(@'NDK+,2N;"BL&2WZ[Z'G5';4B>^ R%>-'O<)DN1J
M1=:@;]FZQ&J<4).]=6N"SH%'.H8TY)1@L]Q!!=("6*SC1JT-C4=ARGWD3X77
M-./ 3MEUUY<N9BKD$+D$\70MJ?KFAHR%?Q&PCYE_?QXO3_6!]^.9AF%(^),(
MG>E\,Y@'9S/VQ[*W-06&><P%;8?Q2I#];<4(L@B91/)_Z"7PV2,EX]HR0/TD
MB'<?894LT.VH?G,'7I*U0Q6;3.J.K:O5V)P95S9..Q&))S_!Y83"@.4#L:0@
M??S4#":Y,.MW?N4$8#8]J6/5;C-6O Z539+:?/D>$.C23M@%O'OF0HCKCNF,
MA?\=<3WU$%@(TN&>NC"C1IA4O9T;^61=22&<_OOQH<(VFY0/2[(T"\D])IPN
M7".93:$Q+#!^S&#:H'NH/*]B^3H^6?E>#*[*[^FMH]QRGR_>UA^?B8]+C[K^
M[,N :.N/+& HWF2HK%2,W(P9FTO- K6O/G>GI["Y+ W#<=G6.8K:#X&Q9=6(
MWS[YM)!OB[N*XO0L>36_JQ5>$"FS6&FEW;)+S3]@+>C3A:&4.JD!4K[IT[OO
MDB00RV^7J;_1G2R[,[!S]UP:KGE2;:2L+0^[\Y^6=KPHB;@X?T=FV>Y.MO%'
MFMEI2V"2Q(_D^E[_-W<)R!=JL^"!WIM*XY)598*-K3M1L[$QGTKHYAL;LI$O
M(^*-5F&;WCS^-C\0_Y;W>1OXBXH%+8<R\:D;M+>X89N^[WI=($N&'&FXIFJA
M4\"FOW^']*= *!M:R"<VLD90G9B)M\UF^;UA\B.U:N*12]]#1X?[W'_9A&DC
M]IWBZ$(9MFNJC-O:)FAID82*HT,BB#E5]3DPR?X=X(?9L4CRQND-M:Y_YE\-
MF!D?[H=B[D#]?O9GS8BH04B$:+^X40<UU2PBWW%L&YC2"* <N)'+H/Q+*N&X
M,-@K:/O'HBI3*]$%)NVL5ATZGU?7%49>,YP;=X]N$"5>KZJD20>_"05QE!9K
M65=)DX6W*RSA[CKB!&9.5(LL%*& !ZMQDW["7D*)2J/YJ1NB4^;^M09CX-7M
M*:>;[-M):J),4X=#3Z5LDSM+G]E;*)$GK+;W:CSM#Q0^Z/G%,HB4$$&I\-=)
MX27X9DNT?<M:.K4ZO+P%H->[E][L'\5]IBW^44A]'43=; !:($F?_35<)*SG
M'1K;J>1ZGO*ZF)VY;!&GC :S[:RE>>L7R:=-UA0.[V=WES9(8[QH44),E4OK
MJP;+H26_S1Z#1%NYPV2Y"UD+R@T??"W6G5P>\GK&#OX/)=?X58G#=6]N:IHF
MF[?)MC'9O-FV[:G)N+G)MFLR)[O)N&'J9MMX?\^?\'[>:Y]SUCK:Y\L9H!V]
M;;Q>%P0#1[Z-5S4%#XN;M6&ZTR]?[W]6.!49(FM]#41O]3[X>3^#E).,Q4T
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M*I9H_-4V[>[7=J.\O?5=Z^)7.R>&6A>Z[Y_6M6<9SZ"#3\F?"?1^UUV%:'H
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MUM:>-AYC1FZ#D3,4MA&_,U+1F/C[AV43>Y/+>#A=I^<)@,NNGM&=,-DOKZ@
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M6$MFUT^M9*M".8U_:&<1)P&HKZJ.V!A67\\UI 7\0D@U--6#T_*34ZF59&T
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M\4N6,QIX)8-L:C,)9>MS$E[5<O,4]D!/Y./EIRI;5^<4HSR.BF.T-&/7[9I
M9[?62TKD]D=:%R5=H2(1TUE96:VQJ[),]"X%DAT2E<#_>D(6C>#LWUE9FZK5
MTJZNE?(2WI?JLDQH\8+*:^/SX\\769'_2T[Y]JLO;8P.4R5GMS&*T&/LO-R2
M\=L84;59I-D7?A6JR?IKFQ6_]05@C("J)?R1G^!&4H4=0P:TOASUV$AP4VP]
MD;1NU\F1W9ESY/(&2)I9G[F^LZ[#A$[);3Y:DT$U0<0POTKU=;,I-1N&H<[U
M@UG@$T-"::)#2=E.$&7A+K\9S$!"BSVF HW'S)5C_%L0*)"@9/=8UH;C:+7$
MR<RT;TO83#:^%;$;_QI1BI^%0S)^)/"2FWL_A4JRX8"\M?IIK.SSXU!9)YS3
M;72QJY#X9*;8L-%A1?Y>BZ5]$XMNZ'0X?G6#@(@8#R.!0<%C%UD 3W3VUO7"
M'+%I:!*T>BHD7_#:I57)>YXI)P=<VQN(J'/P[7=E'+O'OP[6=:=>]]T?=%S_
M<RXL-M32W81;_N_W/;.@&36*T;O0<L9H4[00G'!C-&2N !IR1)P09:EP&ISE
MJ7!I<K5*B!K9?!XMPW!Y',"*E60VX6M!QHME:07QH6"D'>S[NS!T*B9\FD%V
MK<,J@OPF/HA% DVN2J5+@BW3M"(>73>P#!--(H55[\;9L?/?9L'>_=D7BL!$
M\C#]?^]K413.6T2H198,Y]P[.4WNA"=WU.!1PR&]S&IN4C #,Z3;IKKG$7X6
ME:K/[X#W;X#I,^8=715;< Y)5KCICV,3A8ZF9C%4G#@3>8K@GJ(8(G"^:I9P
MWGFJC$PLO7_X_C/3@I$/M:53Y="@X,?L6+:O)"M!^M8M'Q#$Y6>S@UK1.WV/
MC^_;'!B)F^LDGD;-/U_0EHE4^.4E<=*XZMLAQ^4=Z_5*.1O\ +JRKM8Q:F2V
M,=82-SO4ZP>U5# !L%GF)D$^@G%.1>)?C",^%IH)9481QZ9>HA V$S;E1R;T
MXLF$Q3)5Y*6CK?&QIO;4&JX5M17[*+6U,#]4"$U\ZKQ!QT,0P""QX?Q+B4 \
MT]/T!JCOW+AXB9@P8^0A^?$P1=M6LF+BL10IK%9.@_$G:"4&#;5/J_R\N<A>
M*2U[NUDW69@7>Z VJO7IH+"93T!'7[[H%RL:O^L/D^$$=P'E?]L7!9*_OR"*
M%AK>0%RC;@>M+AV='/>=F ^DT.T!<;JI+HA]BTBEC"-K_,T=4W<I#9=/VJR!
M)VFO3T.6,B9L)3U"^0Y-8V!VN-T<"*D4]A'3*SW+WCES5M-P@6.X$U[M_S>K
M%:XY&)H$6/E<M"^%$O)^+G%@OZ\^D*?5JDUNZTM-M$Z"3BS<C;7;DI9C->.
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M!%]H\M\?EK<$S*ZJ"1KNW)8+)NZ(HB/1)7,LD1MH9N^F?W+364PL??@,N _
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M -R184-:&J0>>6QI4,B;DLJC]&C>(W^HH&RD,;\14E"L.@K3-_$IF\0TWLM
MV6"-9<R4%$=*))D(^)'2Y/!8C'GDN\P71)GGN\>V;8)&+:U;!/UW\$VF1G0/
ML^BHN^>?X;MX78+6+YED7]Q;FWYFH)S_5&J+S1$C!;^/T=45%3G"IR-S0HUG
M/6TPF,I%N.-F_V4*UGE](GTM#%07['\P,2L(#Z3YWSS8OI4$76MQ9=DV:G&
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M>YC?$\S2<24X1M"2IST3B6J<%)7WQ;:V3N7*K$TV[W;,BE@C\SD-U3$0#S@
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M'(]YT?B-(BGM%SE7#R]92'AE>4BR,?[^=;J6%M8;!$6ZQ=R<\7@XF$"\;'5
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M^M3Z-M2; WC;:'%3GR?(H\P!SC9R@ =,KA(SM$@&!2;8!_5LJ$/XC"^=]'/
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MS3SN?$0DM_''_%::+P77ADY9#Y6F(X,8]$*^QG$F'S,6]HT;;W ?Y!,'".(
MPV.(=1P7.,L_?)(!^9@XL/7'O\,:,'L3-XFPC^CGZ\@FL)^=AJ0299COJ<O(
M%3G(=AS2'>0Q5>66T)T#H[1^/R83>C9BZ2/2^C=\7-5R)2&<X9M"A'T/QS&7
MB"5=1%P#!Q!#P_[0'(^>0](@.[\VR!W,.@[ S7UB6?]>&?S>_)X;I6L<X+T6
MF;@!YFCQ$;%(Y^\;FXM2DZT_V*Z(%8PE27'I+6$ZP-\>B>( E[9]<.G(+UN(
M1AH;]@N'_AF = A':+A^!U6R+C3MB%7L)#1]P.81[! /=](TL/Y@=%=W*C/O
M#'QJ&\G7@WB,Z'%"SCEJ[^43^8<&:]^.YU:/9D1<6<GGY:'/5':6.(FU-AQ!
MK0FAE)O$$6L0C#!OG[IXQ]F0=*:\3]$X:CL1Y>MJP $$#9LBB$V;/\(4*UC2
M$.2DXD+E9FX:^.P]\0*+)%K?6A?3XPMO[;<>H.]@_J/;ND?L7QL<8!:CC-KZ
MS6^!Q$FD!6C\/YYATE<19SG 30HMCRMA;QRW<,U0L2S1UAPHLQ]!![LV-,G<
M53AG%/A?'_\'4$L#!!0    ( &."?%A%1%7WJQ@   @?   3    :6UG,C(R
M-#<W.#<X7S(P+FIP9[589UA3V[;=(4"H(D@5,-*DB12CB+0 AB(B16FAB4AO
M4H2H0! $J2*H("@=*=(E2!4X="ST)D@'J0%"+R%YP7?O/0?/+>^][[R5;_Y9
M>WY[S;GFF&..'>(@<1PX?E550Q4 @4# +=(/( X#*@ 5)26$DH(* H%04U/1
MT#'3T]'2TG$PG6!@YCX)/<5]DHOK-/\YP=.\9_FXN(2DA<]*2,)@,*B@C/PE
M*;ESYV%2AR\!45-3T]'2L=/3LTOQ</%(_:\7L0Y@I )^@#S (%Z C!$$9@01
M&P$H ( H0#\7\+<%(@.34U!"J*AI:$D.I<<!,A 83$8.IJ @)R<]]24]!\@9
M*9AX))4H3^A:0GC=F*4>1:=2\2D7_\:BU[7*?_ZV>P U#2L;.\=)@3."0L(B
ML L7I2_)7%:Y@E!54]>X>N.FOH&AD3'2ZHZUC:V=O8.'YSTO;]3]!X&/@X*?
MA(2&Q3Q_\3(V[E5\0EIZQMO,K.R<=^]+,*4?RLHK*NL;&IN:6UK;/G7W]/;U
M#PQ^&YJ8G)J>^3$[-[^ 6UO?V-S:WMG=.\P+!(!!?U__-"]&4EYDY.1@<LAA
M7B R[T,'1G(*'DE*)B5=B*7;"5ZI1U3,RM&IQ;]1\YW76V6Y[=Y%P\H/FQ#
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M=D,$6*G257,@.?$UH-=N^)@19@H) 7W# XP3M;O"->>(@/L $5!R +!S:6&
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MG>6"OI<(5#85AT!HPEN L+(I]017&K/&7(<?JI$^5>^ON,;I8IY1<\RWR%R
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M]W_N>^>^JO_WK:FNVE6[5_?JM=;N[E_W(*>0B\#=9S+R,@ *"@I@>/L#D#.
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MZ^I_M+:U=W1V=?>,C(Z-3TQ.3<.6EE=6?ZZM;VQN'1P>'9^<GIU?7/ZR"P4
MH?P^_M(NPEN[[J"B@E Q?MF%<L?C%P,A*MI];G0B214,(R=B>IZWF"1/HC+*
MOF,Q\*KNDQH[#V.3,?(M/3CX9=IOEOT]PP+^5Y;]8=@_[((!N""4V\,#$0(0
MX.R2^8L_]M^EMCKO_)/C<NBN'/V54.2.LKQ0YTM=MS DP.N%!"83D<#0>T#I
MYK,;$I"T*;WZ"?D1L;-=>HFC[[? @B#-E@;,D8#YG-^0SC;B0FD_\TI@&Q$P
M:7#6X_?>2D6"HF6ZQN"8K!X)-+^\9D8,W#ZD5TW>'*8MZ:@IHSN<NDW>H)6T
M['U" MB0BI*6#8Y;+6]RSS5B25"2;Y+_K'+FWU Y^7]?Y7]KI=W_8ROM_[9*
M0^NA!:W-QQXJ6S7H<L86REV!IOC7&F.X([IMJX==6-<%0<%(8%5OK&5[&@G$
MOJI$ A&"D.TD), *)$&9T^_\#4)E(@US6PX3'U05X+EH-BXOY%*I4G#=BSD'
MZ3ZL2T8"F*T^^;WNDP^>EH0O-*!+STR#"R)4),CBVY.L$A@_:!D;_Q!:?<[X
MWO=T=/(XC[U*A$.VO:%HE\RP.LA]]N (VRWB@^K Z;Q&0[0<A_;\/)&_+<<D
M4\M+:,5_N<^VP](D@,I?D'N1MJB2&6W5H[CA6<\#Z;4*3*T2\:HJ^4HO973[
MD.(9FPF9K?&'<JVD;66?A, ZHUD _J?*WV:J$H>/50::^_-4MMS5L3Z[%SG#
M^+V8\7"51T:-&)Y:5:PXU?QI"V#^ OV-NCZVW558IN SLG-^&/8X\;E? T3F
MNO!5#%A'Y[?W+%C?LK_X<^\V2J'E--EDB37U*CIFQSV-8!;/K?'KJ?K>E6F9
MCHN+#?0=@*\_)L7?>$,."R?2#M8Q;EP,?JJ]D44"]&O92.#5X'7!2>ZUYW<D
MH#=YH8PZIB(-D/Q-(@WU6W4PN#R&7-XM3NI  HE-?MM#2&#CB;^ Y9=")4_<
M>P+[0N*FJX& V[=^0/M+I&OVW[@ ST>&4*1)E/^#)->7]R5K I*/SI=S_PL?
M;@LA$NBJR_>;O#TWUB8K)$#KZ#?)CU"7;?,[?&1M<+*#!'I*=?PZ4\ G_7ZQ
M@.(?(O\UW;'/@RV3^GS0:O5SK>WG.1P0F9'G6/549R0W(?YDZTW854J;?'5W
MZZPZ:J.9/%!7:34FWYJ]A@ QZ3(XX2^63CTR81^2,[,9QT::[T3LO_2\G[Y$
M=C\.KJ,&:' C@:C?=Z?:AOQVZ?,M)QM^Q_<EJ' =V=*:HQ;:DIS!]>%3*S=)
M"[ZQ:X@'H[N+!VA-8\XRVJ9+9X*.W-WD*X+I!/+44)T F&G2! M#3)^&LA02
M\)[/_1\VU,HQDUV"-FO<ROZ[S)4P159G#XE36NDSX WQQ9I!/!5UZ:O:_*-V
MHTUB [DSJF5U6B/&[@ZJVN4J=[W'VL-^<TH'?"CBEDP@)NB[G?;FZZ/'USC@
MGD_:WU,2SL :C$.@L#ZV"35PV&.X4UH]#1*8>V(M#>6["BX\)L\=0D=IJ:5<
MO#/QW':FPD'$Y:PB1:,3%NFS&NM;EA1AXF<5]'UZ=47\HE K'?/]+ 9"IW39
M:IO^\9P;1.H%'6$ C]@6KQW([3T$K1U0D$]ZM^,8T= $F7-F%MC!Z'7BNHST
M2TA';4C\H@5=68M56Q\:?SM2QJ_K_>-T];EIZ+-,2Q'\G7UG-F,TM[=D&G-T
MY.:@_'1<)/#OW1MSFU3&T6L1$AYK(KE"-E+%8)TR@C8D@(<$!FW2KO9M&):G
MP2:C?MN%?JR'U0R@U)-NC<8,-H:-\NN<N(<!^0]W?5ARK>]:Q]V=G[G-QDI6
MV;F<C@NUX:DV:?L&UU!*>\AZ<(''*ZJF9.4Q?DSS0PL>AVKN@B!( T[OR4S*
M=9-@24)#UB!Z$0FK8$GHMF6)I%VC)NJ9C%!H/D4?#EO) PIRU!-J"U%\2VAG
M.Y[S@9(G9TPCB-W6/W909<-I$IK)6_JE[K4M?\M.V!,L'*J&1!*V7CK6 G7U
MX,[G1K4%=S>$5UW:U^#1\V.LF.K[-:SD46.K=A@96]* ^[$Z'N6\C?XC07OT
M![BK8=-;J^&^@>J7?_@GYB\Q#!/^9+<W#'ORJ[R;%2.W7J_M+M>#CU3QFZEL
MW0XCRWNO&LD^%@W0I?5ZT/>C+X4N"N]VUI7J-'R&%\]KP5=KS2@(9636+DW?
MOI+TR"*9<.#D9-^YKYMX/03+B6</;YX9BY*@;;6+LL(40J5?%QQ4LH>PKG&^
M,>!O+G.Q_\H*@SV+4F#K:#-K@5%SKMKD5G9.WX>I17 X*ANZPN'JC_C$A-?.
MX"[:F?V1"J9+P9M10RNSRN@/6J .V:GCS9TD7^<;0U"=JJ=)<GP/F*A79DC-
M>Y:W5MKKZLN\53GP07*E:0E^KA.QS2&YL%?\LP+!,65,CHPK8H["N%=JX*/'
MI3>>:3>8RNC?-[5T/M=_=E$4D2<2"3J^JFJ2EZ"&?ZS^F%\5F'M#Y-['[O<V
MPB&C)+SB1%^(GTHF)*A_7&X+3W/88;56IKI>L*%FZ>C:I$(9O9TDD;:R[E>,
M>2@-<)"H2*#](BD/!FDK]F#'GCI2[DUMK[%#*=.GAM'7-)F,!-F 95M[IJH2
M(^AI-*/)HZW,L11U*FX/L0*J$-%FKCN/L&@;CPOE[8@$%OUKSA)6AT"^XRTW
MSQV8:LG!B9EV?6E>TB$^=TT1%M>L@];,=^IUGN*OOV3P\Y)*2KL3!P4*[7">
MFL]%I#YII?U0_"_\OY03D"#SV&Z:SJ^$545!&C [CT!(]RL@FM(NU+>5SH_>
M(>I*#PO$&6Y]GXLJ$BBU0*A[C2)$%Y% B<UU'BAJO,CXP"<L*UY8?ST:(YE*
M5IB%+OPDW)=F,R@G/M]O4<?OO=Z$6R^<X$<]@U9]ICQV(9G^P@^V)''( 0 ^
M.+AG<+'*5B!X3]V%,5P)GK_4XC$PF;%1[P#C^RR.0V5'O]B*#=<?O2]X5F@
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M67UQ*-REWOMH3V5H0F)?O4^!*^ETUG.;DMT[4=)LESM<:0C!AS*V&0G;K)Z
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MN7L3>$T_)%7N[,7V(@ZE7'VXSW)%VJ=1D:7XX RF!CQ)Z)2+^!*Z#HJP_F
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MY/%?\OK$-E'$OF908V)6>V'$D:\?8E/((ZPH'V:?^'+8B9SW#L$52+G\X#V
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MQ+2 ')1B[+5#2\^%W@JSLX.BN,KHYS.'Z#RK3GNWAI 3%_6DLW0:9E5^CE2
M@KA_9N >?^#?>U0LUK->*GG]J@>+%UGQ>P'Q7L6'P.O@ MH<U*$! B"G9FPK
M5'C:0U%I>*_'R+$^U$K!J'TS89+/?R_)^_1Z?8.:UY1HK376$53DI%4GRY:]
M'=J$TAE$%ST:%!A9GG,L\*9RY\/9P8[^3LZH,;H(>DO9#9O)>WB, ^8=SX*M
MP::R=S;LHF^)A<L5X[)>,HS7RJ<?."0Q)PLJ\_6^X_4H=-3)JE,HZ^M[%R2F
M^>9VY\BX1>HL>W]E2L[5C#20-W3 @B&ZQR-^8!C#M;$O- Q/XZ-.PW3A[>+M
MT98>&25MES5IFW$,_;E.QB@OY^3RQ/O,K$7>YW&C#?,*R7 YM/)\9!L_KO8I
M7G/^V%/15<<+2:[I&W@&-A4VZ'1_MQS@DR2?OBK(S.CI3YD4Z))VVG\[]D,?
MXB)RAOA&QH0"E;4*&,7*3^'^V&"(=5-O<.GN0W1R'>QI4\#:FT9JF-7&1AN5
M0)ZV"SEVVKBHE(&F52"^83DUB5<#&/?1%\.5S1OU'9@<3^!0HMBO0JIZG8I"
MZCI1T"7BN&*=&EO,C0;@*>U?%YLK"L92X7(S5O%KV?_, :EH/@CK6S..9=,-
M?P\>$%Y@MAKC%=KFMT[S4F8K?,T\KPM-27)[YC-C2@77:=(I5NJK!"Z/H@_=
M-A/"Z]E*9Q_%GB;/''9R2C4.6S-_L1[3+R9+9E<G5$JP2OX+4 ]1@P+P7_9W
M!3G*(<>2>7GW!U@/9.L<-Q=2U$G@2]+R[!'RAJ;4*^A7<I3DJ7P@_OA>K0)O
ML@IF9H9HXO<!7WNDC^XYXA>D,$_0V#:@V[&]]F- A)--FU/[V2I!,!1;@-8V
MB"DJ,,"*NLN\:[=(5TF_]EL_6./U!>T V7(*^)]W+K\3YJP!TY._ !E"OP!2
M^NSWO5\*'ADE'V@#OG7^ NQ#.]T#OI?^ K1^^C[?^PMP)?GE%Z#83\#SCZ8I
MX/>FR=_D=A#TZ;M'4D 7WUVKFTN ]>94#7KSOL>_ZIB>B$AJ3% T(Q%/LB4B
M7F#/ .T8NU7G%&8]G$LT J"]B? #9.5Q59\AOR?L#7&M;&%YHR*7P<E)U:L@
MJ0R9KU!(<K56>KM)EUJ^U0FFSBM+DX4EHWX74U![]DA^3<] *$\,)G(> ( 2
M#6#&F>%_;]&[5P>2]>#1RU0J&[QD9/GA4(2#COQ3APV1.=(?;U31*W$:4;"6
M1K>CUJ"QA9PU=&6E@5M0N"NVQ7XA6F"[5WIKL5W%L"W?DR5EE BWEG78YKVU
M(>*=TDZ&3<J9CAUB&C\Z8H(/.G&ZSER!EI9:J^V29>N;FB:7*LB<X,QT++:-
MML"9 ")/WMMN+:FIUPEK4\D8 \7[Q^!A/0[?5R;%Z#+QU#JUZ_TZR:@$:6Y*
M4B$R(8P4,6B(&UMP#*@,P<1;2X+-;A5.'S&1*H%DBV3Q9 #ZRT3 C";I3!;&
MD$HC^(Y8H];D-6L11N*5APKJ3D7D%C2-82T=F[VE8\F;"2'(WEMPB<VQT>!H
MZ60',*<UAZ#=!^EY\3:?2'?7W_9@3#O\L"6(Y/091P:'WNER<OQA1EO8,KY:
M"IY3L"JNLHDS)R*^E6^-X!)'^8;QX@<[\9LX)5<[3 0N_3$A2:9QF#T?9(%8
MU9$6KQ[3JI)[R,8*V/AJZ0?==I,(V3( 8C$#A_R6G&)KMT=86"RW$4B#\]0*
M&V2P?=ZQF4#7Y7#1D!W-D!.NDA-+CX!%,)2C01;IN WQF"BM,K4^-- V/C36
MMVV@X![RA(PCPINPPFTC* 3ZYME+S)M<Z#(FL=>]8T]2UE^&Y#TW6#8+V5=/
M?9%LL5<Z[RD!S@*=%OA;$N$$%U&?&WDVN[UWJJI@"6+N)P_6CGGF+&<_M7D2
M\US&_IXX]?S\3BV&<(/R/*(%@@F5]Y*_4U@#QJX*IV^D1;NZ,PHO&=:]>89K
M]F!Q^QS#Z:1#CJ9_.WK@1&]*;S:H)(7_W/!M2]0( [J"6+J 2BAH>&>17T43
MKT#=S;N9""^-=[<-RG%?M7[1M?YJ/(MJ7_]-H!:<RF*@R^7BET5U[R^7[RV*
MJB]0]>"LB=."V3"T02&5<B=;"580>*79$$M")AV30#9T&*)Y3$TE*(JPN_FM
M[\I[=]R.%JH!D>1B#.EGV\6HQ6PE680S^3*FA>\5$GTT)HJITK^,)%'I9NY,
MJA7CAM*KZ&8AP7&'H,I95DOU^F*^"S?#"'.ZC>;!E8:H*E%'HN-Z2T\741V=
MW^E5=W=(9)KLQ/B^XB\5L.6",0]Z$:##+%R0M4?7(LD2B+9:KF-PD5T72-\"
MJO'0;SO.M#BVD(IX ANT.U&G4 !D_'!K"#(AJ_N8D1-$G@V1LG:^^":^8LM?
M5R;6C!*[M%E:-4;9VZ.2M:T JALN\+@K"XU5$)-"V^;YDT;7DPHS8=/0C]Y@
ME4=^=0HRYE9!17H)@01*^H2LR#6)\-@ +P'*YK=Z5N_PTVN4SS[RN.X05WU=
M%%_=_&'Y38O#*?/4*9;[ISC'!UB[RAT*]0Y:88A>S]#DF\&W ^&)_$WUPA)%
M?LEB= PN>S>RI)7VUH[7BA[5K%W,#9PG&@*U5:3,TV^T%W5<<+3@U=A(0#7^
MVW=)H^ML1B8#F99QQ(LP,L#E7AZ.;U1VL!52%3U)7I5O>33"VPA/SG[AEA1K
M1_6(6M7Y9'S'].[,S+XE%.1^8Y:!:)"1F!"0))@RC?#";UW/+J1J]@OV!0X7
MW"X%JV'+>_KDP$!$91L;0%-O!@8<SOD^H$F T3F9)Q"I"E5J).^SRY@RQ%AX
M<+V%Z_69J6!3W]P@*<-29\7KFBTOE 4*N#7^\_>/TJJ(Q4KG8C$Z^6L]&"J@
M@:(KL[EBZ!T+UC:I_XZ,%_76,X[BL$#*U&9$,<XMRRV$T(^4&Y*S7RZ+#6ON
M2AOEBQAT=U<*M&@1'.#UVEN963# "H@[[_"(W!+>T($5 73P;J?X,MQ+!E@A
M$(LY#&\R90@)1K:NPAO= 7O^G'V-3'OM?!E8[TAPMUSQ_K8*M;EY5X1L_9NC
M7B\$>%@<$DVY0LY:@0N\ %7SUUVLX!>X3W=A$ZK)J1,0X0L8"W"T-:MR=.[J
MA2=7?'9E'2M8>W5EW;%"Z[W3G"; >L?1+L*?P_\J/[?5:1G*3D6,)''6T(Z<
M7R,UL 4D(=6Q)P.\WYY6 9]?W3E$]<)B6ZT9#W/=D*$_;,QVH5)S+G+8W+Q0
ML60!"C@SL=&5W:V-V]6ZNXIT4Y,IPWOA3XI3Q>H(=(F(XKC#-E8X=!MB=9/G
MM\U)S1WGS+>C[+\ 94B^=]H!!9LK)POCCNXGN]7B ?J?7I9V?_U4];4S!6,$
M5E&>@,O .5$NEX)J,A.AFK@/KS:'BYK7R(@W&'N\TJ-U3LZ(W,-.OK%&F=91
MGH_)@2@0 VC'RX.O/J8D,_]R^<A<X1VKFR%#QFO*1Q[3+&*!7$&N,M=BKO(U
M-4)$::?.KBA&@:IDK\#@6SE)"&\Q,5QH!"ZB%I2*&'U)R$<_^W1A5F-=L#XB
M'0FP@"P1PSFM0T;OBB#5)STK1TU&L,::)<]H83K#%+:*;:^,/LOL:I,JIK30
M,)18*EX,;_^:#*5D, 5+94"*W07-2#JHQLDE'<^DITDMM3:=$O.Y]0XJ-M"(
MHD>>1["* YMPVB!A /UU#$8;A#=@B+<T(SE;&=TB9Y*^MR>&S'.AZ8M](I.3
M'1 (5H"?JAL$CATEY4-EI&1D^)5'Z-N-J!OE4Y))_2LX.-[@<7LITR>J9AT*
M'\,V=LSN*#E=Z8^9 ?!OW^@\8?[O%B8<_Z_"!/8+\+WP;Y7)R]\J$Z!GAR^\
M"U'CS=N%O RWOE4D3=N0?"IY=:K86M6"ZT.#@2]5RO1O[#VTYMXG2ODZT*H8
M6+$&9QL<,:*^HX1A\EFO::S7GXT-D\:K0["^1M.?1&T<;9*;J4;Q\ N+I- W
MX!G,!9YHH>^T^ZEW25&[L-/\*%^ZJ:Z6/7!CNNEL?IE),?@^[S;LOM'+60)N
M1/>Z CC1UHJ3,90[<>\W=2"ACM(@.5^R\0HAN73?8##;P^TY7X)D]I?O^6.O
M,G'L RK4/WY!8=$<J8H3/=E[84<;('9\(YO^E9]JZA? X)W/$;9.;HHIE<?\
MD-^$W$^OV8,PGA-[B?R?58(W4Q3%DJQ-XI\KXK]G1?RX*!W'!LY-^<H^FC@=
MYHFHO-9W]%DTI+D1(?B^J?EGB VKDU)NR7\??BZ_2)RN]!G.5W!S3N ^RW?]
MVD-SL["Q/<U#_Q?V,*J2MRO/3V;_@^L_N/Z#ZS^X_H/KWQ^7OB[Z#_86EFJ=
MD>UX#^T4)I<O$&6M!QQ(4'^^@XU2)(D"1&FOKUV2#:+4(-AJAR5"I-U.>&?[
M3.)MD\!AW[D/1\5NS2B'93M'H8U[7#SWEQHK>U<*:@*5RR!^9J$).EDIR6)_
MH4>JGM=QG9%^F9![D6NAH[NAL\&O3 GB$7N;26:F(;\ ^M?$7RR0-Z_,QQL/
MQCOO+G Z/&(?!LVK%@Q[%JP'8SO8+0B]%[#470,(]4%&#O^BCC""5*E%9%\U
M$#W;+1TV8+'-5:ECAU$J[K3*4@Q? WCI<^S+L,;P;F7I1,3(WQ'2I!<L2$B(
M9-M)%5DY&O@G_2S9*6!G&S6Y'_]VH?\=0B&8'9EC^2U76Y2B1WK =G ]8EC7
MOJ1LMRHV@XVF7BDR Y-YT?I9+'H1/.OI85X[ NW4>^[: #7JJ$VDL\)N4MRF
MXFDUXU1ZM<2Q"K&>E@-9TF<,Q[D,>]X01L8ACMIOD1]8M2\'Q7M:+68980O&
MM,#EW?,[[I[SY/8<^9HJ#@=>EO*/7!3C>,C-W@^^GX.S4_PL%)3#]WE8,!64
MCHGC^_>=2G'3#S+XR.N5BSB5J#>C<O#@>[@%:X-HATS^9:'U3PD.?(?<AK=Z
M2PAZ%]Z&1P/8B4AL&0/YPO<N523TS-27&8C-2KBN)]A^1^/QD;J>"Q$&>47V
M:8-FIG0+ZIZ>24%;8 QU;CD=TN?@V/QDZRKQL02.'I+A:^?"<?<37IT"9Y+7
MGM%C!R9RN=9'>J*2Q%RCWSY'40CQT*>QN0(B!::'@I[1[^Q(!DI\)URZ6;!"
M5AP\6ELEU<Q( PJ_0$DY+%4H)2E\QT@ &RO7[MNDX\-?%*N73#Z.X.V=U7.3
M,[8/MJ8S#]?B#LY[;AU>_TY-M"/FQ$$ZW9IYB^^C.6]/;/SMLA\=0X'2(J>:
MWG0V+$FLZ]WJG' S5HQ#DQ=B1 J345E]LM![=D/F:VSZ.O;V_^Z2_8WX.$BG
M5#075J:2(7V$0U:$0B&MD!FA'!&G8!T<BDE+!AR(T2XVLVR1=QO#];R4]S6+
MC$HN'7#9V1-Y91E*^KQ!@_O\C&GH0OT,-85'CF3UV0=?H\],6E+ZA=:.8 UP
MZ9J=4>(PH)K+%#)-Q"63Z6[()(GGH($4[TJ0(Y19A/D2T8>-:5"IQCWQI23$
M%:3SB.1L38.A]HE]-/]XC@=Q]AF7F:J(2GP1BS"."]J><?Q SR )6*:;S!8<
MQR.0U/^.U&@UH:&AF:DF6 PWI!&.9;J(*51L,] (GK*YX];+/M+I_V@IDN45
M6 9)KJR7=3.'*'A,DX];Q>26N]7,H[_6$R5'?,M4:-6IUPK_CN%FDUO.'F(M
MG$?\V9$<I57.(L7%2/:-Z[5A;T&%2H11E+R*(96]CIGML%16PT)<X!X00R#I
M#8TT"E&M'\8S#%,[Y%74*O<[=>\TVJ'T(LW:N0B%=19YKH1FGJ::!KKAB;&!
MY@^Q!,E$C+;709;#E &V4D>RKA52P7?(7T+96)1T\0%X%LC>8U!Q6$\HZ@,=
M601&_H7S87TCM:/(U;%^%8CS KE 0VIM_9F1X':9Z"Z_KUA!!Y[&T;^$[Z#8
M**8M44Z"QDG(5R^D('QC&&ES8F<Y1C])?U3H&<0$9F5E5H[Q,D[F:4RQD(&\
MS8[96K=#B ASBMHVV:6=>YX%O#)X'"7S.52..U.4TQ0>W*EZ2.6_F4AZOA(;
MGN,:UV]ZQPX^S&:4;*3$$]]]'ME\;C0[*:H6X"!*ZS,@2>B\5EN:XY[^<\Y=
M[B;Z->MF*U!3_)CGL>PHXI#DA_XGMX$<GQG@@_8TP03/MXK7^S'B-T6#MX4%
M3/^7W!)5-%:LB*SZK&"DYON'D0ZJI4LJ^D@:0G'S;)!(9E2:[/BMNP<Y7M*D
ML*:P6(U\QRN0(-0FBRYW<5-RFFWA=%!U\S06776VG$./82#,6OCAQ?7YN9:W
M:CVP]A= I6E>(5R,E"+OQ(U=&S-'!/?-@=\WW<S@Q%9DJ8S*-.GO+G=,@FD*
MLUA0E_JHH/K<5%Q.3K =,93QH_YDE?+6CKYP+%Q7LPWV],M^ R,9@"<;> T
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MG0G>NJK4\3QF"5E%O:3*R<4V*,BDYG&?"#0=*R@!4G-+^D-P0AO0J.N6J5%
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M78ROAY-CNQUY <++9YW]E''Y"J[%+:.P%P+GAPF^F )ACGB8^[^1?R/_UY!
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M:PI$2G ^4+CN?0?(61:2>= '5S;<=/+ARK>8;AJUZ%"HR]64+:XU]A $>Q<
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MHRQA!BD1_N;]Y!"%W7ZM;*DMD7Z@%+YXYU%S (N;IY#]J6H]S=&]F.]>S/'
M<O8",#9 6.'D6Y;4\SBPID^P%$V ;"A_[I=[NO@J_*F\G._OW@X6RU/8XT2;
MQFT3T$B7KO=FVO<0S0NH_T'A11$<\^'5_\KEYBF4=CR-C[U&S(]!M59"+!;U
MG$D*_=1O2V4\[<&_S11EH:VFB;,USBUC."6D\;T:%W)VF%86G01J+EZ6Y_?/
MGP?F7ZML#JUY2<E/#@5@ [X,[:$39^KWA6LKDE[N;Y+%J#1SWD>0O0&X@5_<
M29H9O=Z1[6X!*P&8Y<S;N2U?U86_^;8W4]$G>GMHR!]M6!N=GB^'\.X*(,.M
M6=J#7)R$M3A>T8/FYC9AS:ZB!$=/+*JX+ZO\ET(J:Z)>?/MRKUYK&PH(824'
M#G!6[:^2):(/C]<$V+MRB),QG#SQA0M"S$HG6N&!?OO#< Y!9$?C9*OUWNNI
MC7]VD9?B:SK<!O^>3DDT'QV<1&:07%#Y24;0,'K$ME"(QU,<94TSFUR214HL
MQ].MN P41D1J5D5^V.63\VH'<-?+",DQ+G"<P-'()ET%H=$_>,3)4=.2JV6+
M5\G&R,V-#G>E*SJDPC"FK;*HWP[12;&OUWORX=: +Z5(0?.^#;\8./JH[&H2
M).:0S);J^=?[U\4( JEL[6TD[8R),#NM15+/O]GAE9\P<)S6BI'-S5))84UR
MT=BG(6<Z6>;(RK-33%>3HI8*89]ZA8Q:K95D6.&<'9!'#Y+74VY..D@/IB-^
MS6[/ZQ#V@H'7/Y[S8XAC$OYQW]T?IO1QN]7](74 X;-O^GVX6R>SJ55P55:!
MQ-).E+S3_79XGBULM'?&YIZ^:/#!Q]CH[;%ZUB'GEXD4'<7,K4,G JG8$8Z(
M*;Y?-EZBV#%TPR.?'G,IGNQNCTW$\(=O__U6Q5).ZTV,Y2!AK'Q9W=[O&'8O
MI17[WTSH?=HC:S>5Y]/8/A8DL?)Y0TI7S>(Q4WEJ.-.L-DJ%$%R9C[\)/V]@
M"KP!= BR^IE)U:$V/-%BM85_,I7Z/)(F;Y^3;K0_VYE^RQRQ:"WK)R6:F)/K
M5#O6@I+R\0@R&X/PC->NC2^;6)B2,(AQP*%%%/*X+W.?OG ?:>E5X)G?>F(Q
MYU )!LC1@=*_TJ0;T&#<$"8JN @[B[;#PE%5E=.&XMOK+@D0*P_&GS#;=Q$R
MS>.8:U;:X1D=\SKD4'M1Z=<QK_TA9$0Q*>,M;:9R4XR-'#E]&+[(^-:O]^%L
MPFKE")Y3YMXN:7*59EV+S4G-;#!-=Q+M?#!).F/A7V^;U)V5O/RB>W@EB_4,
M? -X_AYX93PJ>@,D;[\!8G-?/M?7O!"\T#W QR7WEN./T0%]>.Y9*D,AG!UI
M&BB!*"%R>\@2[&'B#7!Z'#JP$4V/AG"96:N55F?>^DM(VSV7RU.?PGT*V<>]
M55.YD_CUMPPDJ=G.M6EYZ1K)4)1<),-V8,ZHU8+OC[8-/.LK+VJ%?&)6ZI97
M/[\L\'$\V E7MT5/D?!;6@;G;\P3]_+8Z?:KE-%)RQEF1SO*525?+2F=_T;1
M_WE8+KI?K,)-8@E ZN>0E+=5E 9CNNJHV!#Q?T&@B'A ?;KJ*K ^ZTHXF !6
MT2;H0.!R;H@G6H$*Q]88:RT(V-%#^PFV'3G&PWQVO[5XF9.O#GEG#(90YZFB
M&X:A3G^HYZ+C.CO?AX.C#8BQ)?49JVMLN&FV*( 6.(PQO$9P]O(O%Y1=>)%1
M60$B1'9BNU@:1N)[W.>,P, $[5TIVT&S3*A#:TWS7;T[8;*137:E5;VN; "R
M7:[S'QZ6&%J>!0=E90Z!>.[6A65E9>W$*ZM.=^**R[,<R4SEJH[NIHA^K#\4
M-^L*CR=_* ,Q+)U5+F?@G#( ]-U]3,=KCXS_M_81QZ)V&8^O'P]%Z<B$Y?!1
M3D'=A".&2>S.V42Z6)H[-CO(TZQ:/Y-U[]['.&N]@)!1@'C^]JLZ7AJ3H7Q0
MQ1?M&9R?"*7U3,#2\U6?\6!JO1U84@$*^^"]4_^/_A:=11F8JF 4":U#_ON\
MOYC<0_('?:28H9OE-'(SG=P?W.,$<O/D(D]]Z80D,D[II)GL+P<D ^^7^O\4
M1=23D0\]*F/_<B4"^XTG*]UDW3$)383#,I!Q1 5^A!#NASE7FL$)AY#\G./#
MPN7K":I#V%$>>X]I31:RZ<P<J$"@!V6>)JTWEM8A_.PE!7DE.(;U >L:W+0Q
MS'3*;E*RTPP+RF:.TS1)IE(VX]PZB_/C9!4D W@IQY[^XQ951&K6]U.MGM=?
MHY].D]T2K5Y_X[\ OT]]D$74HLWNV7B&?P/435B\%G%JNU^^ ;:6MZX2OU<Z
MI[ZX/.F,H?44JCKY?CEB$BFJG73++,[B!N]O:\1#0L3\VR8KO0O[N7]APO82
MJ?MI8_!+H=09M'GK0%[7F!TY8Y:X7-PW.(W"5\.T! 6(EAO$9PXO:P/5M5-R
M?II\Z\9O\&GQ?"7CLS^8+B0?S[9A?8_7+I#G$S_*N"80RX,50&][WTI*7FYR
MW$.PT:?]!L"FTB/S!&<S.0.Q22B0.RCMN".FP/L8$$:\F9Q@9O6>5C6<$JXG
MU0^]&'(88CH?'SL\HLZ'4IJ6-+JWVS):B1X'Z_>B:Q66%@OP+M]S/[KEHU!4
M';ZL7_@U6=<()P@O;3+QCI!G7%TI_?+D<>D^W[A6/V_[OL31U6.C)#['W?9;
M?!43U]5WB4&#UG),T31(C':*C3;-:JK>4G5'I7=PLTK93]VF0J-(!VVS46B*
MT?246)=O=<4$I<UM\N@+[--B-1YOBF;;_G&AY0]P8S8NF+83MA4)3B8F[?%\
MJK)^LS<[V1K=;.*&>6Z.WP]G\!&LRAWM((\*-%#!#M5?2I"?O],TD5X>_+^1
MO*]Z9KTHN?8^&T^9?7\,%26%-D-*DYG7CC6\%U^>LE\KWS#G8_3A;S0JD>'9
MRCIR.QG.%;1XKFH;$5/[M%\X5.-J\GAPL<TBPV3I7/8=</)^CS4:*Z'P(P77
M0Q>SG?4@@70+!\%)FM\>3/4MNQ?D>5BC-?.+(4 ,_)1HIW3#WFAIO[ =/&FZ
MP/N5T:.+.FO=S13,3C23K&6S?6O>H]:4$]%BWO6E TZ;3'[!$?WT0CV*YO'D
M8KLO1(7$^V-IZQ(+NS]H !*44[PHJ\(&:\*_0O=^*VN+#<B:AF<VC@&"0PA^
MJF!,<!#2,BN,^K\<I'"09?0E3!1P!D>J.>_]""MC#,1917(HXHXY"6NF^4^7
M!77TX]@( YN0&W0?MB?\$U']@2+<.$MJ#?K47S#V?II-'Q_2EJ]<D_LC7-KZ
M9=HR5P2"H8'-'5P>:);>7)L<""7GLZ+&5FA#,>VK<$JNEYYV$3T#^LPAYJM;
M"F857YHCC:SKEEIXE(NB@!4H3],(HQZ>(&(5@)=G%,2B A!]X+_Y&S>=90$/
M;DQC_3!I?Z\51:4T4;%5VCO07>CRK,(]>%7FYWUR6[3 *4UZ(_Z*67M$= YO
M.QTV&26BCXH3&D<GWBY!9O":CH<[&_3P#7!/G*[HW>XBRZKI?'C&JQGP;'<9
M #<N#MQ+SHM;-7<Q485?2=^N% .>BL2FW&.3W6&3&Q#!]&',-(D1K6TET=56
M@3''QO99SXZC,7BA7I8R^LOGEY\".H<<+Z,MH9TZ7OM3M>]/ZE>CXF*80?%G
M[X\7<V>ZPKU?J58+KW<G.ES/+*:074455ZF#J_<6>1%_.-5<_LKX7MD"'W@I
MPS'?B(HF.*2^NY*&E<$3B<8]6^7IZ\X/[Z^Y[K]P<8P&*@]0LZ>(-!4#!-7W
MP_8"WL]#"]N@/:V_N3A%UOTD+>?#![-4XP_](%13J9TS=H( F"J8/)CMZCDA
MI2W6);X,Y=,M8(-+ADA^)< T@L"?IK:/X-(BNHD;3IZZ[6#:)<L1W@%9XO^4
MV#K4;R+^P@-B99S+<Q1+NJM8KA+^43I+I: VK56E7SBLAY103%Z',H! [@=
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MF; FY,D9:G7:!#_784R1W0!'$L?=+.S@K2\_I, ]V_]#7='"U(L &I*KDO&
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M8Z[ILJQ(/H1]77_XTLFN/(2FQD%3P3F!Q/J[U5))@>T2)&LO$'(-<>>4C,+
M6C._1%!H.X,KS.P#EQ!3U":2(-R@L=,E-^:MZ]1:7X ]S)>9W2TW#L=I/,-K
M%NH2":/MMA%2FEJ'7*-,/Y RHJB'["[QW=J5[WW\M:5U,Q$1^K'LM&7Q'1+G
MP;1<<)S-W!_CV5B,X&RJ@#P6P^OU\\M=#;K,O#JY$!Q)S.)2QGY$9J8PII>A
MC4B2KN6S39]Z#\!\>81 -L.@6)X=4-I OZ-_!F9'$L=41W?^B>GS<K3;0[E/
M) <K94W]O);G=B#Q#^0+-@C6A/$D.K,]2\2Z@B//4-G&G5O6QPE%RZKM>@._
M13H\S+#:S3V40Z'P#D+?G*6-HW%6-%I40^;T.4^I#[.3MH5 '4]] />[G[+2
MQ-)NT70_RP.)@,]:OW'O@)35XZ2:>\ZS0S^<3;OVT[79K"ST?7R[?T$B"[3F
M+O_D0:2BQL'NNU)RB#S2]P1@L34A%:N_L3*UE];ZYL#CW=BP67"BP !A,2?)
M4A3*CE<9N1-W]E^ Y8"[Q/T:40K>[+E3C\.1URP]K5F4^=3HCDZ1D51(,78%
MY/0B/'V'X:66M@+-R0EJ=B1O6T>X+0X*.D*!K9UF78*ZF_WE8KJ2M7$T=LZ3
MV"PH!<G2)9%;$JURH')$SF*4!1>1HCB4K'$O/."S*W\_R0'%.%?)6H64D^\&
MBZ\7!U%G*UP!-=KJ0_;F$@B42)H?4IT$E=<KB_>4DL42Z @^D YZ.@+U?YT-
M;$32]0[_#<>B[>[#2O;9_>S ^X3/50,$)4$RE(S"6"$$0Z*SQ27'<M]Z[E19
M+$8=9>]U3W(H+1'HD22TY7TJ\%M$]K&'MQ6(A\ GEFQHX=D'TBD."X;!-A14
MD2E,*[]B V#8^-#=6>A:@CNFDR?H4F%<[=.:67!'&%CL@$+)MN R(H8B\0AV
ML24^^2=7:@N3IY*$P7KN'YOCJ)K#,2.3]C%VYO5>QJR23*,67N[[=4U[C4AD
MAIB=@EQP3_HSC!I!\-1W?82!=TEM?\-Q2WM+$_%T\B@TE!^_+A%/.KBU3D%1
MW-9C$82Q:Y3GQUW&/HQ(-'S\\JG)FWL>,/F4,NWP-+UXGO5A_D<H1D.W!'=\
M].08S01M_&B*)!!+J8YY'+4N;Y,,2:O^6)U63-XFB_:681@Y"4Z*:KK0\^+:
M:'W4J U:E);5OWEVEO#DH%+-!\&N@"-G>U;"7)P"DYN#$7X E@;&"28-;7 ]
ME?E;Z9N3C2PK_V>%<+K.@ X]SDOGFP^W+%\HKZXCO_?$_Z'.M=%NNG1='<.3
M@;@=_KA2Y73^-WJLC;(/*:]ST"IKYT(.PZ&*NN/#]:>@^-/CFL#B*;5,FN6,
MQ"%AR!C+ZZOL98)(-L\_YL"V;+_1\"Q)%Y#NV1I]Q9)M*.Y&RQ20L$\U_J**
M<T-'W_+\^V._W+WK<M^\#;URPJ])^=T<RP.\-\!WJD=YLJF,1T'[ Z1Z(Z\R
M8<V)K(*MB_WO2%2K\R;OE;/R>15K>.@BO!*3#%[^Q.Y0>PL"MX\;DFC_G\S_
M3^;_-3(;YZ$@O*-B-B. =\@G@#=[IWW;3[YYWU6^3=%?Q?-A/..0OVD[%&UG
M1NLS8]+_J#A6XQ&4*Y%VII,N>A<L^T#P;"V=Q=\RKF2GG=\%K) D1JJFYLRH
M8@C^:#T$C(:)^%!;95$I)\&2UQKXG?6/YM%J\^=V=T*0 7<<=,M8H,$4#,P9
MW6/%3(5%@]U%#KTR _PL%?WS!D#OFM[8V#G#YYOFZM"MKN',:N9;"]=?KF>P
M3F.?(-HVJ 3" $FD]:+:&MT0?^=M,3S,]01_?%:XI&U626Q3%7R&*0^='-EM
M2><[\;VMV9%]G2LQH)-?+\GF4?O=^D?[AO9%M3OY#_T;8$WS?P6=WA/R[ X>
M,G  &M_OR9XUU;1873@<0O6?&2H3 [$KGE0%LZ5<JZN2W@ TG6,L3[F^3(_J
M;X#&XG_39K26*.@3;B>D1_.BZ/N'3_=)2Y Y#X8CY7\CCV$R\.-U#=?).3AD
M@FAL])>@ZRWNA_;GFWGCY+BL;I_DCS3(H]>(B9'> !2=H[AT:%"Q.KFJC?-@
MO>46E]GSE<GLL6S+I&HZS3^%4S$!O!F"O'"OBEY)!G>B3SJ7A6\ .V7[;#KG
M'#>B4I_U;TQ>B=\*M[Z\8GUO**XW_H=P7_)OP(]5AVI7A<W&?]Q4QDT"O:\:
MFO6?W>V['K*GSHXK$W^<:TZ5J']$J$K^AP3CV4^QLM$5C^JO4QF0KRH'PB?_
M1T<T2?0]>54F_:JOZ&\ 7YZ$V^PQK_G/B&\ V8\1FU93+[+=B_^F63VV?]$L
M*W_???<4?X5#%7!SW?:E@VV]Z=Z1][3KN.J??#/2RHP,7?^I5C)NCQZM-X!@
MWQM 4<CQPPOTO?7-[^66RW]8:I/C2+,T=K)AR)'S0G5D,8TS@6"_=&Z,^^:#
MDOD0@E_0 <K=^ZAZ$(=?T#X>19K06A\ #OSAOJGF:UG(KJQ9+'$6##?\X,R'
M1/%U.'EA@)T@;IMT)2IZ>FU=<"_L]G" H:0^##>N2QA0%HD:1D-'EHAW=WOU
M2V:D]28ZL5!P_6OP/T0NYZEW,G?[/B9\<AS SD&0'OHGY(:^.N]R[:%]2+NI
MBWA#_7[US_?*LG\SOE:8N3#F/W:82X_ZOWN%_+]X!>0ON>F_(_^W/O2_FCSN
M\1+11FOOKC#66F48/-F/; O#I:7$M$361"P5C)-<EC84#5 SZ\S"QT';_9 P
MM@W8P=&M 6&X;RU__$#X:O_GF7-CU2;^M\P@G3T([*+'9&6!G(9T">8Y(G"
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M=99=$PH\[J!X@T#3?@G+Q$E;SW/!XW0IKOA,SBDF$0-C,7IO0[HWSP0"0UN
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M@8MWW4<Z:_];WKNHUC:;"F&!]D@7*Y7S1G*^ YV2F^!RUZNJ$64OZPL9M@A
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M6EGA.T(6MLZN7&5+--#)V%8PE)5 JAM#B-UB!@L&14.3[>/L&6:P E#TO/@
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MPT;U,XP;38%\<"6Q:+!H@14N9:TN/?RZ@64;S3,VGL'&"?H2BYJ,[FC"@6U
MXL\K<M((&G35 Y7=5.7?8HI-A#N,)F%])Y\)H0!CC3W[3J[&Z=J'$!(7ZSZ^
M36>K<-*F#M9.6#\ZQ]]!4=;&EKDK0N"^)(L313&J-G,=9WT'L)K-X;W#5S7+
M^^WK",,-?*XW]$.3UQ].%[3\VAO>MZ0\W.X6""B/W:KQFRPMP/^\B;-TM&H9
M8S30C'CX9#Y&=74)"])M,8F7QG#ET3P7%-!W\-";Y2=:B(A1 [);T;*S??^8
MV3/#<JOJ#H+\S-[7"'C*G.<L*JA_C0$Q*J:R)CF1@($)(M6Q+)#'[8("+%XH
MVY&N1C62-5 VX)MSV_&2\ZF$PVSU4K^M2^FM]QOV(2!Y6W,CN%D2UM,6$U/)
M(=Q_4-"/7\$9)[A>!VN.RP=5) @L<(A5*V,42&>]:7VTIY1;R0OPS"4SR6H]
M)8: L.)6A.()?GRDJ4WD2;0NCR0Z@7BODWEFV6G$W/Z6C>]G#=PRO]!*4ZL(
MC6+:@JLH/\*!>TV)7YI!>B;>'EP;PJ5I*=!@E8"2%Y>ERX._4FN:;HB?<^0<
MQK#/3P,B#6=N$2V1,]'8&&3R3//JMYE;1I/:Y1/)-VGW/4D3:Y_JW2(_<?I]
M_.66%VF'X5CX%J^4.Q.#T1;$^+Y^ZO>P!:-XO$THB%<A23_N>^ERNH=)7E1_
M(JYBK[FQJ9M3,8=TM5J?_Z^@83(^SW28@<XQ/KS<+S=6A@<DL#.VN=-D@2>C
M79 3B.MVZ$H>V^BYURRMJZS3G7OJ7@O/^GX+CX,3%BX*31HO\(<-T#$3(&7O
M7JI'XO8Z*ZVO[O!]W.N$XF4M20OF$SVI;]<3Z9NN5)[]",CL4E@L49RF4V#"
MO5]C;^*_C'0YL$N+.']Q&;SSS@K5\-OF(#^5R"7^P8_4"G[N#E)XL&]0>1!5
M>)]*>3GZ>V/L\TS[^@BF]CO1)/E4HQC(QH;V8#HZV\+WW2DGQ:1^#4?Y;\>V
M#M<,EC&6=JZ \XTD,@RW04 T$BQ@VCE#N+(YEJ(.=]^<^F8>?JD/[J-U[X=1
M=R.G_0$L"Y0$#+-GE,8IID="PI6/4,#\:P>Z+SX>.W0*]?L95[JRISJ@K /+
MDOUZ9WN==TY$,:-XY)'JX:5^K\5>N5V5IZ[V</-@6,S!IPI8,YL&NBWK \7A
M!ZY@"Z<)NAK/'MG,JS]S#L]3IPYI-L-\\U79HCCAW8T4MB(B^MJ,G1-XJ]DQ
M>>NBH;G3&JFWZ+$T'$"6HF.2D(PV?*&';I%?>,NA6SE5FX;35IVZ]%G= ,,M
MMJ\ZD$\=KT(@_GI_Q,)<F*QQZID4"N@2KVB9C'FU/  GG<< _Y#U+B:NSZTX
M*(+<S; ^3'J:Y#B+1\Y&67F2:%V]6H+'(>#P6"+;++U%]PV7AS7M?*^/09<<
MO1>WI-XFS(XY=A#)&M%L;1N>!^+CI\7P4YE<"Q4[QG7E\**)+DI""58W?.)[
MI9&S]](Q[V/[1I^O!3PX6U/6P_4I].P_2VWI^?&?>M&_D+L(*\>)-SVS<R)Z
MT1]7+6&<89BYTTWM2%D'84.%UFJEO$G5=#5OS9W>J/%<EQ=T[>S:KP=B4= 1
M5X;R7M$T->VV,)1"+!)3>^I=$XZY-$O-$KD \1&5N8>_U;Q1S@)VBIH<+"#?
MTC1B-X]B@N,E"7HT15CY!/7L^2?-J^. 5"ZUJE2"/H7#3O#YH(BKD9F>&YPS
M<2R]1#-$]%6 0WJJIB[IO 6;!A1@,J^KHS6",GI=)<'3%;R-]A@-LXP(*SA9
M0\K./\3PH_4,M+%Z./Z4ZB$CPT0C,+_K"A-+T1G"&!#HKH?&A\#EU.)F"/=.
MVKK"QMHJEMS+ TML."!%E ]_#.!GEVZ2R8#+SW_ $.,3K&$Q8E<W='=L7:'2
MYP$.=P-28N"FGZ-)RBMHV^'Q7N9;ON&\?LEXHO^:[_]5ZB2E^T QD^ "?<WL
M@$W=.TRN]OOS)"A E.O\RDMN8]BE^32R"DXOR8/OH^_R,==Y!Q_@?JX^R1-]
M>HCB91'9B\=2$ ?\WV0G5O*31$S*%WVL*G+OC/C%?^>K\3]O\1K.[OKKNSV:
MYN:\DFI2%1'?>O:K*7WD^W.:Z=--43D3Z&2<^M=;V=!.OR'?[Y39G;\5)W2I
MG.#A7B&284@@"NWE?.=-:P\:$PZPRQ(MET.+(*<1,+0I'_=SJ.3C6\B8'[.:
M"3R%STM] TF^B65+^FK]F2Y<[TXQ<?GU5#?,%$(1UYR"?$K<4"2_[2NWL3?=
M.DLH13:?]C [<3!?)<P/H*G9R[_WG\RIO?6<?6/.55ZIN#/W)>..:+%\^9<O
ML;/?:_[-*:ZE%P]!%+S'(ATXBXXAJ#P8/X7Y($8!1S%YA"$"J$$_L](C.:92
M%\9KX<9;Z*RS\KMEHS^.AZ1\DS+X; <%O *%TFE'B%-&"\/4$7SVM22>3/N)
MPT'$(0>(H9+ ,W9\G[W9#O<UYU1F87GQ (<@5=.BBBIFF'\A*]+('FTVW# ;
M%H%O,WU.4QS78%N2]AFC5:;8EDE0E%.UWKG4TD-@J33E>M?2MT,%)IA8@J[]
MM.)RJWF"!.)F4#]%$?G>'Q"6$%'?WP(%5-_9]C4MTC:C*=G3K4F13=L8^VW
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MDWN"FT6&Z@ WA82)4&=A44:83C)2,8FKY]/'PT,^QU9A4Q:F@+)P]YJN/"B
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M.2)'\6/ )ZM"O+9&^18-OHJ6P+K4W# @)N]LM_46K60N1<^CY%T9K:>VDKZ
M,0I&M !D;]/FY?LQ-V_^FW37X"!>R:^K-0KYT4<'I6K0 !+QJ_/1^YHBT(CD
M%A2:W)PL77SJ<PYB'"0^W*6$M.$X=DLP4D^H6U8)+'P70+)GH?QYMB)VZ7$@
MWUVT^SJ-ZMS(D>9RLA &2&"FW]U:0F<GQ+<?.\, D"*)EU5UY4/A8//H!RQ7
M.B\/D=67IKM*D'MA@%"0%;]# =HPXREDUU;SLHGYG,W[67W(G8TZ?$<.&KZ_
MYP'96J>?XS7 -^>\X#$+;6IE+MKM@I_$1U^D\$ANPKY6NVC;;W!]PWO*B>7\
M&!D%@B"0->']S2Y@^_O17@/J/V='B(IU7EN*YW7Y5SHYY%>>MAG4XD+B%78*
MR+*AJ7B53':F],0 %!BU_F[B1?7Z+A@&_)V%J']3U!A[O+#NI]@3UG>$99OK
M"?0(-X4%AR6&DP>V:7(#<0$2 FI'\HVAAOLY!?QFB?,*?U?K;\9Z'8$_86%E
M1R=!2>V42I-J01/"DR#DPL_QPLP*N:HI1\_13\-Y>/Q$P[JN!@80V$M.5=Y]
MA %_OU_V[_)9338:S>X3FWTA-D_M+-@*OG'N:4&2;GQ30/Z,GZ61;8G+3@!Y
MK,;@ G-$,2\A30KTSXG0C>5[JSD9TG]$=/JY/>=XDQQYVJU -DE&A1G3JW9E
MQ:_*4MO_,M!-WF@D\9^;*&V6?CO-YB=&!U[#YUA49*0YT2X%FXS>J\('@Z.=
M9/W^38EMZZ6O(_3F7E-^VS$<.&3Y7;DM[C].1;[3?(N5M7 +DC<79&A6:BG^
M 3IEVX$!%^TV3:QQKE1+4GW#)J2C4<RUK9F%TH1:U3YMJM*$P/_T4"=8G.W8
M>-(0S$_3,098>ZVNC%8OZ/4DPX#+H' 20WVW.Y%Q[+JG0]Q::/ENMP@3("MM
M&#!\4'=_;W22??>R!PJR;3W:A0$1YC"@@V*E_!9A&K04(PMY_)T<KD6JD/L;
MP@/E)NAW8ZO_QIVZZ>[W/FUCT+$*&) ^9W]WV[HF>QD?!8'.@98F8 #Y3QCP
M@?^'T3G2-[B6::.NI7QX8<!S8=R[4Z8:L:/;&__<^UQ3&"!>NW1U >J..F"A
MN;FOA4\MAO*FP  T^^#6;503&/!>FN8X^-H&ZN=&<[6N:NV[='&&I/ [AS2S
MFN)G=[;P):8%L>&'XBUA@T9P?D A8>(KV,=3]\"^^%%OUOA=Z]XF2N+O_(E7
MEX"V+N>@T/+K2?O?!0/]76#IPBO0U"#VL]^8X_E=525+OXOUA\"?U YA0'D2
MN=%O[%G^KBR=UM_D^D-@XOP%&&#$P=/Z=PY'?]=5%>CODF7_)C#;_]F6A:L)
M@G$^K^E#[]>-I4U_DTR]&95 (MNPBP Y4E1F1556&N$:,83TM(X854V:4-.8
M4%4:^&L0 'T"B&$;/I9G!J"WEHXO3Q@*G3>4:2DY0M6K -^3J&X_AO2>-*K@
ME16]J7J/(<HYR=.B]%<%M%5Y)_8AN0UIZ\KOJ^3Q0O7V7U/Y41YC7(F^CY^<
MT=:UFHR9G9GK0<:/*/I8#VB$X[X$EN,ZQ4B(T:U8%OL#U@ZP4\@XAIL<U^PX
MTR:PNVM6O%,VZSTO\(+YPE_4.CU042_L&6AKW]DS#/'?D4'-11)9N##":O[$
MV3BNV(:@*V7Z&*M)0ZY['NL#$6OR<% R+AOCN.GCEYG$3CX-#O=\M_[_<A_@
M<"G&<GP??[$P7=_J5D_G=!_V/)ML"\'K;&I'+IV0)_&$RXK&HI&SO\@T27)F
MWIN03N"J; MIK)@]W;SNZ#U;UIU>ADR*_<]J%[+S33^1_&[0*<^B+QQ/2! E
M$F?2JTK0)#XL0:[VGA*@#TP?JQ&Q@ %TBEL3H'-\G61]/ -KCG;GS7<Q = C
M8/W>9I-Y:4Z>_>A,[##DV83Q>FT8)"A11:>,W(JU-.F[ B(NH^"PKD_CS_&A
MLCNNHEV.EO3RT_SI&;W^W/PS-!M_NQ12+ N1=,/ ,.=M6SP0WR4R4]$0FFDU
MYR-J5)$P>77K;3MUM2H]O-IB^MH!6Q&./O(@E9>G&=@-U-?YM55"?0ZTF.N#
M,Y;S9ES^U4C7[VNHH&F3,FA1W&++/T3LL+2B^DOGMU-,Y-GF#]A'";:*UX'L
M)4%(P?WF=PDO<C?0U+8\<95EM,]Q=9Q0=R7?" Y>@.#1B ;:A??V2@*-2-*&
M9) <*I":^IXG4=>QMO9L<O5IM/P&W^ Z'_?2S42Q+7I>[-1@@WJ8.;.>J4^^
MW;Z3X"VX14?X\1-)]+X#J#23*_JR-J+M?;O;J\A]0+R_!-MZ0U](%J/!^)3#
MT.R1L<4QXUE!"5MVVD6F99H+31?%/F"10!^95$PG'SYCI!\2G84X.6WT/=./
MU;>A,*JZ!@R-47-1+WURS]727<AZN;K4'_J8PB&LV2<'GD=EDM-/6'@7ZW3(
ME-I"2Q!BID0VXQ0J[GQGLQ.T":-XQ\W\E 2N>+-<]%RK&J)OOH3FDK$C4"BA
MD)"]NZ++%2B*U3*:"!)4#=RPN7W[U/7+INEW@7[25T]PE/N5O.)2-[-JQ]_6
M!/:K1WS3B4ER^A!.((X1V467O"N0$[I^AJ:!=J<D?]%>#$>DE:8^&@QXDD,$
M*SFDO93LG'T,L<Z)+4XYA3\6-J"MY<VY]@6*[V)H;3O5/ =B(-I=2J[%7]LG
MWNB$OAX+NDFWZD7YDJ?[9&Z07/")BV(?UCNB',%NA'OK]5GRGLMN>:3]-]]D
MFU%\LUE]+T\%\HE4N_=,E-35#YZ47]R#?A Q3N0F3\^AF402<-:0W)<N#:HQ
MCN>FSOG$9-1M &1':?<M1=Z^3^VJMQDB'>H(FL/HC-_#\8S 6JLNR8LO<P,Z
M6=Q/5>E]-D7"PR_%@[#5C7,EA=Q:;T"O%%KL=D]1@B80.1ZMT9]*B*0[*AFX
MK;]BL,SP5/TD,]CJ3(=*1+#SFN))HV>6W(QZF7-<['.:I +[DN0.T)-UK7=F
MR_A1P^63<?'21QSA3.*.[##@^.7$#CE_A(L-%?78I'GCV9MP%MN:F&#?CZ2\
MFQ<'8A1(4/P6\:@;XYH%.$HG, Q)3 >AB+5F?H$GTD@2T(LM*,+ O^35OYU.
MJ?ZU/7A;]*<V7 =F("3$'CS?54RMI[D^L)^V)O8J_>R>P(\_K]?+52GCA*W=
M)AKD)/0./0LBU?*M!H'U@D*\-BGQ,*?H3MM_[E'X"*J1-*$*PO_DT!^"^RW=
M%ARF[7VM@_K9Y)59R,$!^5DGZ&)H#AZ>>'/X$O-W_7:*V6GPMZ?(LZV^[;H-
M>^4$8O3RF[G2&%F/E]./E9$HGV!8>=$/^&+_[&H_96?MU]<6Q%(XHCO<FBJS
MX1 E]$B7$LH RQ1;VV.^.WT1*-PB]GV\=I%AY/#H9\3W8ILGTV^^RT7;]>YR
M[NF# FI\497@8(7\%)=.)]*(7=NLCD%9F)%=28CFR+SA*_/8?7EUICLAQX[X
M'%BN#AW];%+#C;G$FX6:^^5:Q6Z,1[YDVJZ>98V>11J16PS2:>;[$_&7>L\(
M+;TBW_<4Z2D&J]_07*<<1O6@-/=(-L[E>P1W'='BP ![EK>77$\$A\4L\FLT
MM*#CQP_2OMYGQ,DQ5DDF3$80)BRG.BUURI;7D&!2MSJ66M7&#A!U[7/VX0QS
MZGS3\NS8VK4:VYWUX8LSZ//$F.O8%*1GZ^ 0:+_ZZ8E3;%$JY5HF79R9O(+]
MP<HA3*Y>.B7D=JV\ON#"]YG.'>ZG9ZP^?;8,$[K"Q9IJ'<5TZ&H[(W>^3/7:
M%Z6RG8WL,5Q2!=9NDZ?U_3F1"#UEPKA>8%EY4QTZX]X?S/U.:!?E3,WCRB$7
M- ]YQS6SU1OBG]3&WB[D1*X"@?AYHU./PKVF<K:UU!:WR7TGQA'1-^ID8Q\U
M21((DAZ\PL9@RO+_(]MU%D.% =&&F3# 1#C]'FM*47\X0'R=I  TK;0% Z1X
M<]ZCGB+E986Q</Q;'6NC61[N/T9!XGN;]O?$-H5E>IT@_D\^S-FQ[ SOO#W-
M_822_Z'T)1+X6ZP+11ZV%7'N?![+AY43?LHRQMN*K%!L#38L796A?W3 I"2
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M<O\Y4;RR&6XY*5:::\36-0/>OY'&L;ACZ0*=<\']U(\%[FEO/<JAP=KBQP]
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M9E'NBX"9\S2-FIP%9\ZU[W+=\5EM:A]GPK)A;/-G8XAX 2/12[!<H^)#Y=I
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MZBE?&(.#UM7+)M->D4A!ND7_1(8Q'D\V>NTC:DS5SU_?-'0(B$HY*\5)C?I
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MU6*)=W1?W]2RVQG<(N2'L>GS.ZXK2VY(1X*GZL]48,"WK\/08!LY".[ZWUY
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M6?5SR=<.&>57 ET-!_S0P@'$\O]O @!02P,$%     @ 8X)\6+FQSGG&Q@
M,.0  !,   !I;6<R,C(T-S<X-SA?,C4N:G!G[+ME5%S;MBY:N 6"N[M;< *!
M( &".Q02I("BT*)P=W>W!'>G<$MP=[< P1T2( F2E[7VVONL>^]YYYS7VFWO
MUQ[U8XX^NG[#9I^SQORU_&L;0"KG ;8" !05V0'H@/\HOTX!>+*N%A!/  (
M^3=M^;MI&YG<!@9S$N/A<7#A-K-T- =Q6SC:\WB8.?'P<?/R %Z^\G RLX"
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MV>OX$:B<C>X_NR>NAQLA+UNX=J&#2S'JK[%D FA?JH>)A>@4+2DU587VX4+
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M-,NDSMLK']5$Q5O8UZ/831(%V=5V[=&= 11Z&=.D!COQ/H&SY.%I"0S.9I#
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M##=B7-.<^<+HAC/'W\A/-"=9JCO0IF)H+4I (LI%Q.;VWJ^7J#&L*E?$H2J
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M#2.Y"1-*C:LDSUI!NRL/5O@]XDW-,2SVC$ 8ST6[S[RA5AY$VMP=GU!T=7X
MS$H-, 6Q[COPK;11/:>BV^>@&O?>=T0N:Y6FTV\?ZV[,-+-P=O4VWW^+OL6K
MI) 2R5WH;7@62_Z&,?&LG_6V+97+N0 ^"6",-:'R.V@M&^$&U)./5!W;KVYH
MC!F#*<#D]06F4^V^@L^'CHDOVXKI6']ZX2G=AZX:KK]P6)I(1U1L(OX%0. C
M*.7F>D@PNM8 ,U8+,V4<DR,9NW+!83:0^J@ZD0[<+7'B+M0.8X%2]].$FB+'
M4,M*[YH!AON?<:Q97Y+Z9Y2I#$^02RH;Z,B!69K6Y\.M(6W+Q>"9&<W&9Y2E
M!]@H+%>3<TX;'U,>$Q;&%F,<&EI6/J+<# )'%2QNLTE(QV-CPN47AXT66\G%
MJKW?&FT0::]%V<X"3;W/*HTQML>K=K2_+5]XS;4!!7C;3=C$@LZ2K5_>R8$W
M#DQKBU^>+^=Z5GJ*/';F:%[/J=(69(X,5F2F$7!&OK 6UC='$A(G0]:0#%Q3
M6BC8WUF9["6+27C'\RQ&Z8YO:TXFJF;-)-;4+K[^O-*@Y+OYO3O$U[^.'<A,
MIM<B/A%N\*K@ 4@(M.2Z;M 5:IE1!HZNYU/H,U =I=(8DG<C-:E8#(C$(/Z8
M2>#O,/KBDYFT_V+9&/@*F9??C,LX<$:R"H>IOA4>'</;!G<F76-RVD$\4"#=
M09_GN)7L#O6J>B*]95]_C,/#AH].V^;6NG\:%:J9_NRU(#2DMFA]-D-7<Y0L
MI%]N'V^U<JF.9L(%5\R1$SJ&Y8P0]1KW9@%-&L[.W\59&V8TUP-%2$9Y!=8E
MZCL@#/K[O<,F6]2F;W)1ZM.RHF4_'A6SH[GW?+[0<)S^3D)A9)?[Q4R?@:N)
M0S=]^>M\UOT^OO8(2G6#C]BR]V(L<V%='5E[31F)#>KE-1=F1?4@""FO+%()
M%K;V^#-IZYH#?8-H72]1Z TBHP."/Q$\MH1\5G_=TB("S4HF+ F3##8-0=;;
M1NJMKF7T>,XWJ&(O[MUQNC\ZTO?IA'L_(U04+\O%O6?"P0;#MC*26-C AE%?
MDQK\IM25>0&,G),DG6Y&CYA;M7Q^_B37V9;,:5<=-W&1U6 O0B^2[;#?B41A
M;(#2YU3_*>2=KQ%8SH4)7RS YA> 94W/_B)LG6+LW5!QYPE1&@]G:D9)PFE^
MSFK,(ME$3S0,R-A3Q2_DH6'\\[DG=TBP?+CCLG[B<WS^(\(B+4&-FVAQ+KYL
M-D:/V'-N[F>5P3R6%DZH8@'1_$-B[<]B:*GH#)H%YM6^_;ZU5,9<CJ5D2"@2
M SWZTSJ-A F)K+*Z*^O(MYZ$U;K7G*^=QS"U-LMD[-F(7#5TN*"ZN@+%8+&!
M3R:LJM\QLDP:"D.43,'?R^A;7';76JRP/P; 'XP+\Q&][/6'+@N\G9"4FC^Z
M"]B<WQW=SE+TK>:![Q:6LG?8C6;#VYJ"4S!AN78S>(3O#4_>\W:V5U(PV*!8
M6I88K:6EFJ$>5B<+*&"%4A'NTI(G.SXN!Q@U#XSW,G [S-3V'W&".O&"R/($
MY$F/@%KQ012O=90'4Q$_[%;$WQ]$7JU:15R8OUB5K9,G :]_&U/JO!%4LK_A
M"JVI;A;)[N=<\%]4O(BF>#U'L72JT'5&A5;->98(4+2<1/V\Z[W$[.S#?[!Z
MNK=;OT[2K%(DSV9A4>!B'-C$G3"&Y]#<3D)%&V4TE$Z.IT+TW3^?1D/&YQ2M
MO8%9YX]WGZ-4"CU*IBBO'KA$['\VISR*-1],FK3Y9ZX,G6 _$D)47'^X>Y^P
MD7UA"N2-[GUSD^M?&E;Z"P :;7ED/GMV%[Q2^9W^XD#X*8RHJ>$A\JEEV03J
MLAS*I91+-Q@&]%<_?VQB:+0HC_UVE4^:;\QE8K[&\XKM7<VZ]4ZNHG"PWN0)
MX1T/.U.$P&@$]PP\)=E?A# 1B=33Z,33<M0%PEDA;JU\TBG;0V$!,1P:' (8
MYU\C,,]9H3M;4(45ZQ]L.]D+EI^5/0@WI>C>E.$?M9JYG</+3W5HW>14N;MG
MB>4]X3BWR7,$/$3B]@D%B5Y5W>8QA2L[[1PE$YNT4K:T91PYS/:+W"!N1;9&
MN&\)B*N;U9*'&YN[F00;L>[H@Z*%>5](6NN7&;G8V0XT9(U^F^\<E_=1P]E]
MFT2I8H:+]ZYLW$=QJ2WV^NV/KS/)&/</Z(P65[6L"T*QW=VM!N'3>.!6XM"D
M#':5]<:LFFZ%ZC@4/#68\$_KC>:9-+,JUUTGDA$Z1-X?-715>?).2BJMB8GS
MX6\X,)S.E^P@2N[@FZ&^@HJS\]KGV!H<=2T#M7H7Y(\,>CI$:_@S HO:1Q#X
MF3X\-\47.BE&S]]CUZAO+_;8& H4=Q9C^EI$WLH>)7#J\W+!<N.=53WH5B@S
M-R79"AI!?O0L-K9V5::9:=*%=%!)SI!^WHB5QAAS<?P8(&=<V/'9>'PJ7(("
M>CJ:0UW8I'V3:PY*QM??)1LM=="LL,KBB7RNE>J/+>@1IRLOY&_G4%ILH#"C
M,^9"-9+*DMW,2A=$7><(]6DP:-0O;FLS$T%PF*)R< S#W1^T :)TV-!(>=!2
MJFXCGT-4Z;3NU)8Q^4V_=VC4?6XF\*(?T]NZX2'P:&LN!7]KINY8/Q,Z>6J=
MGQ BGY[!7]3O'N45%H>L1/.70%\1\"N:C+U##"0XLA/..M_L1=L,9+SSK#[%
M3I)IC$T<$-CG5(50%<\,+F\3/EB4Z[FK[,B$Z+7O2/9\PS2UK4&QX8+45?]^
M"'$$5GCG?V%[1-<N3K4'Y??R@JV]VQ/A**HJ!H.)2\?&S9*-6+23X*@Q9NPX
MV:G]XZC05RQ9CHN^&<MR_JDR7-E45 M 7:4=?:Y+"P=\\R3^'^2'ZPC5"OVL
M\L+*UP@@^9ZZ_-NHR\?Z<Q6:&G>LV&@:/:%/K>V!T=65!"2"=%RF9KIKLT/)
M0>(<YEB5SNGPHYO*JTM-["_:[BQ\-#/JBKWR>C63=S^?%8JUCE(X',GBAI/L
MN,B8F"+9'#=>VX,^IEX+= HFCA14TUK"\FNX2FK;;A= P*W]>A?%"D,NH'G?
MF[BNV8K&>&O';_(SW$UV\Q<\DA,U=.E!8<MO621$C>+H-6_E5>-0(V/<. HP
M*<MW.7)OQP=.FQ>;$R<8"23RZY6,6"!VHOI.+@5;3?OUO?MQ%&LATSKJP\?3
MF(G;,SI:ZCX\.<OI:HM=2WCHDZ^\CV.)+-T-HZO6#/+%P4VSAT"P I@X?99V
M=Q5ZXBJ7F09-=N,_+'#'7CQ_""3_!:B:<9CELGM_US[HG8:6/NA4G_06E=:\
M; ]OT%@^Z7 $V\4V[)T@M@#+:7RH)JL3/7Z?27PV"%X(/A9:N')C\SB*L!!)
M#\WV4%4:8Q-M66EMQ?0:;-YH#G?$N7'S\TDVR%S^%K7>FQ\#;^QQ65L7(P&*
MO7,P&DQKCW5YP^! BAY_-<6\.SQ]RC0S0#=0**<\+T#?[K=83>ZZH'E'C89,
MO3:?55'88B&$51UML]Y4OD*,FZ!NN_ 40C'X=F6O,'/8-*>QCB^E1A'SJKSL
M*KJEAKPBB+4LKP@MU;I'WJ?B0J #[MIAO]/B+>V2&Y^2+AC+*(N%9;+Z<MO%
MD))R!\4&?Z&X7S/E\E'.1?MR)![++I30DT?-VOR-54]1W<MJG4[8BXJOU')#
M-LAV)Y*&US@S*3FJH*IO,"<A?FZR'"V24 3Z+U6_ )G\%/*;.<UZP&LSNMYK
M(VI[*I@^ZF1H=>_A^P<=G+E@H([03XZ0V0_FE=&6.SBU+0Y@*C.UU-C%V$*/
MKY_T?@%(C>9AB^8O0 [WNO%+WMP.GTSM(1XC%+)&U3^E'\9%-ZM67Y9QR]XG
M,\HDG?B>C9_QN^V[V[F.Y698O4Z<AO?9C66:04PLT!#LE"VAJ$''\*SY(/Q6
M83RBV0L4M65CQ&[JQ%&Z&LO\%D].=7&AKR6'*L4[-O7'Z8:BJ[6Y0SSVZQ.*
M=>E<0HG$MQ(P_79%=UM%3I-/4<L?Z9+>Z..C&<D)IDUZVW S<<'"KWH!Z''K
MISUD#($H$W3YP0K]V;9);&4TE:K7,UC;%U3@L'D"'8G-F!]"&Q7'$]G(AR'F
MG1(,QB/VZ"<Y)ROA) SS!)T?6Q89:+T:DBR3W&D$AD\'1@/R483U\5<GW+$W
M$F-6Y<A8P.I'3+@9J^0,JW8;S1^9GWU<&KQ\H _5@]04ZJV4MIV?Z/298BU^
ML4P.2=A]^4)(<,1^<[#_!Y4O]_Y'M]6@A]Z\C07V@!<*J\WLNN3SD9P'KIC9
MA[L,^,9ME.PW!(R\N8N0MA=6\3R>2?) 8NQ*&<A+^=>,Z1B6(M1"(I:]U]=+
MQ&'DE6X[J4A=&Q=W]QM[2BJ7@ZE(A=]2/&L%0<TF/W;3@FL&S]JD=(E##1<[
MO$T,%Z K617+1"X\&&_AS5)V<1MOAD3BTVP*J?,P,E28J:ZZ/HAWI9O1CME!
M3THS*'H3OTIS %B"Y=OE">IMO/LRMIX.=?#QOVQB2SZ^WG#97@%RQIXS<2M^
M&E30V>=J6AZ\D_"D4V(K91,KP;)1*X62W;]E62@+D5?I-W^^TI1J>V6U9XQ$
MQ82,[JBO)T*;L#?EPF3IZ#:IP8*JN($EY*$OL^X4GM9:/X'#Y50VNT9%Y-!]
M=6=34])W>9!/"6YB7QRV>/L^'Y+)VI4M+ P(+.)L<3E_K]TGN$9BHV::FU_;
M],SWK<J L*X*2DZFD L?SK-YU<->7Q/31:KO:\;K:YEY[[?$B)L&8^*35T0^
M433+0$23MG=YPQ9F1M>-\-[*#AF08\Q<J-O>P1Y=IPV^LY31"T[VE[U8Z2$Y
MC2K>&"@HK3^[.3Q,<Q=[@4,K=:'G&KHFN(Q#)C-'I<]HE#?HVN&)AD/#L$&%
M2Z>267WW62B;KZ7=MYFS75^&YIDC-]^HXX8=-48$B0(Y LP2CIH5K*/!$8F:
M0WVW4'#QWHE""[+L( LY0?U4]=EQ'NU2D[=%48@XUB<%BBL&R5@\(>1R36J,
MA+=*K3.[8D-?<YMEQ9.)R7V153:/7"\H(;[8A/@+F?JC=-;IJRX)S@2-V!H[
MIP\.O0Q;%)9?V;/XX@3),KQ#R"_2LE,EP<9^I=<N>=S4D1WBE /]DKOJ=R1(
M8+5*,.[QA<OH%3A;K_U8O@\NM,%@/6^0A;KTKM9(W6FPGO!N:H8_%%4U010S
M@6U-RSK%L>A^H%/]D]704)J\P^JCI1+%,WP9NO[!;GZLS77F'.96\MF@JI2N
M+6SLN1M7#>TE_V<B62]+9D%,PXNQT16V=VS@Y7(N+5[@<:WM&K4_L"';4;K6
MX+31UK:28EE[L^4#B[WVBCA[A0"[+)$*]5C5B*-YDX^G\\L*_=4EC+6&PAV[
M@1*]^MBU.A'X0%E;$=K\#/)-*9IIQ[G>]AT1:3R"Z['\<G'*[IRE7^SZF'P/
MZ88KSB_ ES:Q\X3 S:_Y: <49H%&\@]R(KBGE.BW[U6*S"DCBJBJ,MR_\K[\
M $I+'@70-[2:0<Z-[=:U Z9W'&;Z+BQH@U1#C2OA3JZ/[>X]>3H"+6%TA78I
M2IU^CP%-KUKMJ-(!>UY[4D,1L?FV*X^5V."6YD8%0X,%4V"^P0GB*W==DA$E
M*OB<!N@@=Z7_ROR$!V(OT9^&+T<I=-EJD1P"RJP334Q#)8E8M^I=J4O3%;;X
MI"'U05K@_'G(W-F)'OO)]G:5>>$-HY?>,"OX>(7[YYV%:(8%PW.#==V(B:ZQ
MBF^NHVT62H>5M\0V7H.Y(;!K#-1RVACQ00?E;6DC:7O[M%^ ?<WN<QFDS\C9
MHN;8=%,M%GGUGK&G*P'Z!^L*%'3.S/)=K?+4V 76Y(=+I9O3DJLE;I^Q!(!E
M]TW73;:&B88ED#?I<XLW:XBGV8Q1 F?^O<F&'<N1:_-O+;/P97S5)G)U1]T'
M20\4:0IL$O!34R[2/%;HZMLBU%P$AZ,I2\T_P=/Y/O7:J0H65VE,1SFMRB=!
M=(=_AB5JF7J;\+BLJ],DD[/54@D99LU(!*/4;[9$*GG.3SC7.N/GO'S(J3SS
M.V)Z^233J?NE*HQ\V/(96S6U8H& ?M<U&E_'Q-H43:>H>U5LQ]FR<8C@06AD
M?H$Z[/G(!#RL7>86M#4=FAHWN#K[8>[L4.-.^$"S33'^AOD7H/G5X^>OZ;\
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M4 ?O@UFL0#F0LO8L&P?$PM'F"!0A;O_B2F+2V9DY!;$HBZ]0AG15L%"]G#$
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M^K>+Q%]&[)1V:]B>SUW[(/YXYH+VZ?EYRLGF\\L/<(G:L7FO/=94#C6GB !
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M !XWD\ +-YEKD,0&FTXU?2H*O@$];A1]/I'"1\T;^A"^9UIHZKAW6CS)Z[@
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M**X_)^E$C1=V6:MC,@@;U\P@0&34 !PSO#<_OJ_AG*L\?6_T?G1T=8?-X=G
MK.CVQS2^#'E\%-:/WC=,BF%[TRWH@*@R[+\/QH'[O_J@\=\3X]_@_@WNOP<W
M]'^"\_@'N-:>L$*91]Q'7-^2.[6!#TJ_ &]I*+U::OWXO@_-^VL\L9[[L7U5
MX_VJ-G5[+W'AO7NR<FW5 K?R/'$$>C5/04;<2)W'E.S=6KL%(<94QQR>D'KS
M7@XE'J7,DX*0_S/QD'+$KS$8O3R(U@*2Y]PV3$$V' V_*(&=6Y=.;U=[@1RV
M:PPG5=9V@DIJ#W4-2ZPZ<R,K(#)Y_[A:$LRM\L@WVPC$$H*?X\3!OBI#;^VZ
MPWWMTIMMV;GF$EV([BT,(53&(&"ZCA^.75G4#?4$\=/<"RZD=NM!N2KQ!8LE
M4GJ*3B<]VB0']&Z^JT_Q+2N"ZQ J81[9@-85^$T-NW%74B/\H,H0:'FV<5$>
MM?A)*<*PC:VZV3!> 'A@.W#7B E'0V^A;8/B$$A%-\9=C=CST,C%QW^A-^DY
M_>XEMY^(^0N0Z'43^VQUS>HJVNFZ();!?M6DMI9(;_FMYK>41@RE&0,)C9"H
MT[CHH1@CSVWT=BSWN#-5/?W////8@I" 2AK]L_#VS3V+C.I1$_S5]K[PFSCS
MT0$CN'"NK&*_.D$^$,]JT>-K;M\*3/H%_49VLUH.GL/P]RW55<LJG6KQ0='P
MJ9.'I-DLN=@^JV7+\OF.9TR-F43G-*<C[N=3>G*IAI.#<\R%9:BQ'R;A3A^?
MH%=N)\V&G+LZ#NE7J29K3*60QE4EASXBEV8;P] 36WC=4L5FE=)U,/3:6O,X
M2/9X][EM4GTI&=?0&P1>-J4"R]4NQ5X48W5QS40E?3_[SQ>=:SOG=4L+/_-;
M\X>I,$: WW3V1_ :;-<*O,UL.KA+@[TI?5V]*S2IU=DN=[O+U V.U?X?:MXR
M*(X_VA8=DA ()+@[@WMPAX3@[B[!97#7D" !!G<8)+@-#H.[NP_NDN#N>O,_
M]U;=<TX=>Q]>O7I?NJK[0_>O=Z^]UMJ[=_T,1IFS2*D7>3^!A8#U5IYI/^LG
MVZ@$FQV[>G7"NK]IV[&PR\_=[^9,K5D7:&',L-?6#'-Y47X\-!*H.2P?2<AA
M:?YY^$F320TL)H%<1-0?:2XIJ6:@P>)KLPA'79T2^R86K:.QI\7=]EIIQ8/4
M)2$)DC4R!^6,7G>EL52E$\D2CHST9Q[JQ_D.,SO24!$'"]!L]9O7:<)8YXK.
M<KHQ%9*LFRS*=*^[@?0Z[B0D^'C%CS]G LLJ\-QQI%,:I2R;>"V_2F@/ FFK
MZ1099%29>[NKF<=/FQ,<??NW1K_X='7508L%F5S+YAD5_I#.HZO!)LK5:J&X
M7H=!B?89'V7PL)2E3M+:0R.^S?S&T>>1427(DF#\'WEW5L%Z.VUNY[N+!,)J
MBQ5+^Y4F#9XC",P^-<EQIVL_)0P8\ Y#WB7E4SX]<NCE>^"%:9\#:?%HZ%P<
MYPTC">)*?5D3WDZ/@(0 SR2T%*\5>^!9PR_>>K1<TR !/(&G)RQIKPJS3$T.
ME#\S17>PB!/'C>.U!=^)WZ[URLO!OW9'5CM%O[HIX9:<YUSI5Z:"\/0LZ]<M
MDXB4U\_%*JZGM*UH>(+Z8B#Q\3&V&/N\$1HIKTU+<Q,68E5=_4GYE.&7H-XT
M6:5%XT@H+/Q@M%ID7*MX4?]H-*.GN9 56IE8QF5NZXSF-@P6IC_\M?#N8PYF
M=;F\^)*@S>!%W;9!SJK@Q]">41XR+@'N\QJYJF/KW4]K.)]R_-YJ\HV6>ZD^
MVR#9$"%3TEWOUY)"!B&N4SS2(AP2YNCTTAV*,F(LRL^\$Z'V/;4;KDDC\\?,
M/HO.15.*1 WGU<>II:NKM4DUA8*ZI%!!+V9WS=G(CK0PL[R,V<^E( WQ .BD
M;>\@+EV!D!7/TP!$!U6+G*DZC<[WTP%R2519@5%NK@W[#4OVP*KNWNX[+[\*
MGH3T<.VD,R%GRNV%()0#+A4UQK!DCDRK5-S?RV3,*CR&6"K\J+EV<&'2*M;%
M&T4[;JC>FJK=ASB-5'N"01QK[T"58)G?K=G'D3N>\]3F;[NX$XL;=6HT9M)F
M)B2JP&]49>K9>$;(*1Y%KLAFHN )G[8+L6X*UE=*B11I.,:JZF"N_L2XDC45
MQQM\VM:RS3+"93RQ28="^ ,\]B5R"+*F]!)X2/U?M*26>:V9F[#-Y[CZ0A>J
MU1]F+[[MN8+<FH3E8M :)BOK$LN%GPSYD>=MVOHY>:VY(_VY<L&;!\*.4#H6
M/.,@S79+S[V1V@I[V2/!\.1%D<%\)YZEQE1YHY9S[W;Q192S5Z 4@>>*RNR-
M[!Q3??6D'&!G:7S=Q>X@%=_V"+A#C]8+*U9A#/<VH7KGV]/2HTLR? CD8U%8
M2C9,3'^_/F7@E_H.U5(LVJKN<T=E$+*[1MVU)3TN)WM&ADIA!NVLW @U2BY'
MK#G=?Y4J$CB-4L/>;-BSD\.'?(,TH.9X:Z6#Y#I-6;K?ZF]Q_<CK;VJ?IMQ2
M59VHZ#!)M:<K5#G=91@/]\M38G[N4E!KFN#W:@5K:KXGU3Q)>]5+1V?&[9?!
M@?K9(=4N+I<#5&*_(KR].!I5;WB?6<E:/N_HLEH-X:.4%-&H^M&1\8D6T]'R
M48\/5RLM,3!SN5K%IO,PK:XD*<$'RC.MNR0H4E5=67"$GVOI)"V+.,JIK6=!
M(#EOB]R@BD5S&&B6+D"9".AB3;:^A=QZ:OXYCG2'5:DMWTY6,=J&8YI,$@OH
M[J#ZM<D<?C#0_#53I0B[*&[&NHAF2M(.LF#:-N FIMY&<+)9_ZD?WICK</+!
M#]JVMBN0P).3NL+KV=$PU"MMU=U#!F>B))?>]DVG;HWJEHB*B%N8/+2 WEAK
MTRF^=0/W.U#L-=DKLT\!>_!)[UYW9I .KF&\NST6&"0VL_;2XXY;81OX /^2
MM#@Q9),IQMS7+K2E,*X9N^BZ?[5XUD2FO9><L*0_%P?6P6I)CMX?S,24#Y^=
M.]5K4]3*^5-RN;WIJCE?;3M?0HU.4!YY9;\\+\BQ0=>Y@*J'4FJ18_AKH&OT
M*+PIT6(\]QW+XJ_/W"A%L0T,0?H?:C8Y.V9KG.J\\?&92()KG!%"R%V_\%ME
MB,^*;)D5GX DK[,&E&]<?$2JB!78C$#=3B5^>1'B7?;!ELR*(P1TRP2W$K[<
M-TPM/->1[H-6I*(*\;$+32'Z)Z3GQ[]ZFS7GBT7VR@\>CN/5YQ]X<@M_S;(V
MT^)![H(NF3FO%/@8"*N/=#$U,"EB_<I=VKN"E&?'H KTD<)N227-WYF5".P&
M&123\IQI.W-*5)/SJ=R\8N##DXW<]G[(G3.=\[X&7],%RL:,1#B&8FVM'7#+
MR<]?6^\GQ^'(23;Y6,]M7J@=?1BN4"\?EY(Y%-ZKO_3)L(<,]XHFY-*Y0;9L
MQN7O+",WJ,&:+(J-F3&A"/A^_BO/F/?G:*W#D?%*6ZT&[33<'Z#6$L=+=,2+
M=;"C2#6N@N:"Q4SY>:W9OOK17"MCV%<5)T(*X+$BPXDG"]P*_$<:'/30U8!:
M[OZS!KZXI"PV3ZQ>Q^(2+2#I(;O_)I,[2\>#I!Z87?'>V)2J./9UN1MDND4-
M8GNO26D^KT2_C,=HPV7K02&AXQCM[>EV@?J9KPZT*KI_9(W^H8S"PWX2CI^!
M@"IO)U%QKO@#>*\XL6Z^&Y,H!W,QAI=,J9P<*G?=LSJUR.X6-17G+[QB(<$^
M(]_\.3V5R'4@T+$L&:SFWK7+8IQ'.DNY.;3^0*7&,,C"]C6@_, *_I7Q*K([
M=P4RTM^F4&(WAD94_M4]-=2$J1YS$]:16I,><=.M'DP*-)03N!V*K#:1[8^V
MF<R]?JTP<3NE\38?5)Z78XYA-B6]B=S\ZV,WU5(2Y4)">,Q2+_[/,?.O!S2-
MAZJ&%H%6A&,P7O*;A3JWSZ3L'U2K#@N)L0USRQ+K#NK@34_W[TZ\."9C#7D@
M)NXY#?QRM1)4MSN#?H)#1YYU$U,\6NZZ4";S@A!6#K>##XKVK_9D$E3)IK4S
MRQ=-@;2;^1MYV(?TD"*<-P4,8%J&[^+@QXW_7.QQ='\;T<9MT@:EK02*)2R<
MZ*QPT[8'YGX9D] T5%JX89W/WR>J<5$:C95N^"D];W^4Z-R4SZYF_R7Z,]F/
M(!7%7YM_^BR.]:<:WW/JVZY</?5:3.&W*EC(WYRH'<+RW:P^M#X=&'!EE-3-
MN+QS0 F!Z)CA1%B@T:G:KA?QR7198^K?9-*U")DM1[_=JB*KBE_"A$C&4Z%G
MU?=L&\XM8)UK[6HZ0NPUR?6%HY98PCFAMA^T_ #0:Q;U<.5A9HBEQ%]+YE6!
MYX_.KV!96ZY45Y/FWIA=$D'6<_'A2VU9!%[1 H$1HF!Q#J%*WH>OT_'L]YM]
M*3I8,C8/%>!T"BTDY4':8EQNEC%1E!N'8R<.I#DULTT[FW!#I.VMT2B;9GEC
M;IL9NKFF<36E>/W&@(1,)\^$7 @'S,! RYA:&JYLMV2&P@L,:?F=>'H1.;-L
M=288-N>LIV7TR:Z$RP AP]V1ZX:<(6D\_R"J4\_&&<&REM^+E!M)857%(=HF
MANEMOX\UIT7\@ !:3AANKUJB" FQJ&$FI^6>+%FEE]?F[W(XC.OR2K&LD?>]
M>\4.6L'*-*? DMK8&:2X$D<V3&&6:*J?U9IQ)'R>*WM28S//>B65"M/%E-]T
M_4YURI;;OCG?1G"'3?=@D/3/E_+QL]^Z; 9*>D7ZNJ';(V;=98$F,Z9?C)L.
M23S?)G$*J"L8J_*5E)A%Y*  WQAP?^D)_S&74>B0/*]O5@PJ4N!ON!%<+-]L
MM[EF/=8TF*R@XKM,O#\J+"ESRQV..*J;MEE.3)%4VDKW[N3:CO"F,-9I,@?&
M9P\Z?"#U<IF.=198K"\Y]OEQ&5QCR&:Y23JM.U#7]$71+HWQR&*[T$V(J'84
M@F=%'!' 0IY16A*-X[H;C!DKHR6N,F?N&7*K:00K*(,KN(I[4%[5]%J2'41J
MT/7,%1^ ?73[<>S3"W*7L8N.A'W0/ZCG&[D>RL64CW-$J8##!/6?-NV(136P
M&!"A/.T_*_A+?%WS9*W]:/P@NH&F1GJ[3R%97\N1IB*L$OSX^2OW,4MM<>BX
MFX0T%/&M9G0QW;]9XS/']XGB9PP)KYF!EQ;N-C9H9PM;#[EY'OU:%LL6"WC&
M:ZV#9MZ$)"[AUGN[V!ZCU+Z=<[W1X]/89G?['5=%?VF)X1KQRA81/PQ873:A
M#9Y=;%%^Y*>NIZYNUHNL5HB88HMODC(_\4DF,M!5#<X[NT>2Y%^8.%GKFSAT
M7Q@3'>YQ1OSH0E&L$F#3&[<OG1>@F!80I.J2\%B\V1XB.3%S[O3H47J_,*3W
MQ;_@0V()8]-Y,9/4]-42;7OV\$G9J-!*NNM*3K!L@QUXQNN[NO-Z?ARN*MI1
MTPIR149W#RA$_6,5T62]'%F&I)%W]Z*&;+)_C&1+!6'IXG5A6YXY/ HJ2,7X
M7)ZXJ%R8&,<7B*/=H++.:!%IP!R&KT&\:=K-$,9BTL5F(]T*JB=0M6!T%W?K
M&T4QE18N]LZ8A=AWNC0R*-& ##N.'V!V2T1J@_WL1T?" 2PDEA]F/VL@-Z'X
M@W^].U'B@N >A;D2'$OH3>3L0>5GHU>N; Q^]U.RVFP36Z7Y_3+LT>HM@PS$
M34Y&*:Z7K0G:%ZOR?V\M!0XD_6=&C/B.JE?AR]"\KAG:FC$_):E8I>XA?//S
MN- /#4*]S.P%71$G*=F:6\58U> Z"RSYG^>T.^))Z$&QCF >_E/H9G_IAW*-
MJQL6M/,9.&W1&O?8=M-D>=BLS>(7_;.]7AIB&J<+0EJ8GGWMS"GR4%[8M'/N
M[>4:KT%-)>*G\*/NKN@0_-BY_;$9YGVAV2533[NA2PC/'GK$3,*V_;1UH\<'
M0YF#A.72WZFV;7V<SBRA#$TV::IY*T/B*AW,$G9)IVH;Z I+OS&;30B6SKI
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M9E4;9.@RNI.3\$M8/82W*O@TFCGK@$$?OR&U6%4,U=1)V8Y6RUWH]5Q=^8#
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M^"HQPQ#S1[AH\I8#)"0#/HELAEZX]N,1+*@\^]^7'/A1N@@.OP T26E.+E\
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MMY\QO@ "1:]#V(?/T%LTI=OIUWS9O+G6+L2@SY%_RWU:[O'J1J/C88=#JD=
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MB?A<S?9L?;N*US5J^:K ONT=R6=C!(G<:2]WUS?M3*]<_.<$2_PBYU/#F^\
M;[6EJ*\8GGT1Z5+\UDJMXA7%9KL&Q20HT0WVD\,5@FOR'++UA0GD\L3YNH^]
MT!+07\/\/=X!3I"$,J<<:"5594]=FYSWZ31<+TNU ^0&=1NK24H"$.0L/54E
M19%L]UB1'FMWG2>L57RCR?:N04-D3:,'+4%&% UJI I'VMK3B,DLK CEXG8@
M61'ZX*?2B6RJ=T"'V]2%;[G8V,OWI5<+OJLIKNO(Q=_2Y\Y_=! <],]**+G@
M7@8CH;+Q8L&MGV=8*SE8F2"<2?S%M4!F=Q0MP(S9XTZ&X@NZ5Q[4N?ZZ32>;
MYI;:;4IW6]%?WZ91(/" T0W@X\V#F.9^?H4J^8UX.!]X_^_LK;O?7]FG9RZO
M =&T^8(7;!M4?RPJ/@O'U#GB0<D.K.7N L_[JQ:=Z\MYK ?ZHZ0%YYSK>1A;
MG?:O8GD=K@WC;+%4ZCD#,;@PA'=U'U_=J]&JG-,1;Q 8<,Y?&IB@%;-6&DJ+
MN4>QE/(I&AGSO>:6-M1,HZI.I-9();K"A12-9&/V9#NT[FE(#O8TADJ[0#2J
ME9*U;AH?E=@?S,:W8O2PH]/:HZRVVWO3%!#(#5LE!3@1_*#[D1ZG@I=@RQ!)
MAUR)G<VH+NZYI F^NIP)JG:6<#S3UH"]QVC "WG#;WR-ME+L&7D:$W*5%-ZR
M=,H=JY,JDF*RY"2[*#C,(HC$HF8M^U4=@MO5M>"-4U:5!Q'V#_.\3EECS1^7
M"DF//D+0"EK_5FT77!@4ML>U:*BHN"F@1Z@1C?^=OS;.(]I&'<_>7KG&JN.T
MU+7903STL27JTA[T\^NQQ7TB05@P',3F>>SMT)(24\#H9"7:2"/](OQ$F=MZ
MZVHNE7Y1/X]?^4@+A4> 4/DGQ*<Q>W?\#70IY8BTN&C9S2+["][.N-_MRZ2H
MZK XY'9/;;3L>UP_#>,UD/3Y_J0<;*[H6E*S,B)H#=R-EH3'3V#'0^K"?W/=
M6ZO2_QV L*17H5Z])XV)HJW][Y^KF"NR+<@<TPI1Q_U@L:3,%3@N2?TIY8 ?
M!$$S[! M"'$-:X".NWL1O)BT&_E&^:S49#-F07T+]^I><+3&;S&NZWQ!Z'R;
M^YMN9=4TI8I?$.VG"*]4(^X(.U%+O-<L(]]'A@S2Z;S0D%QY9.=B)M7#II.M
MM:&(:\THU)>WE<^=688<P6MP3@8&X'E8J0V?TFXPL,@K*VX1C66AT7B7Q#A'
ML)Q"A1D+\Y<2:2RF;<U?</MO4B(HQ&[+W=R^C5::E"4<.X$0R!PRBA ']B6&
M>I2K,MUHS!/I:60E?DO,((OVT7Q^61VFU:-T;H]@G/RMZ<!Y%[4:H?VQ*W;>
MR!46GU,LPS#*ID8HW$.=(3-B^ENW+-_4-<UZ\I7%[;WGA_LV7P_"^\Z,N(3&
M;338-CA)=R R?#AWP_BLF$090LN]<_]GDOXAZAQ#:;G!5@QX:"C8 $.Y(.0@
M%#!$%G6^I^6C>I^."&^V;\ L+VU9!%M@BG7HA#?1"N]X8N/NAZ^L!?>;+@7Y
M9J( JLI,GJIM$A0.W<YJ*GE?2MBS5IK@!/%H\T\#\:JH_!Q;*C-2RFK@UT(-
M,1FIKX[KO&6RPF0;!/*\/M=-;9 .H8"2.]+B@DS7,(@? IY=0T+1BA#'B^0U
M_8,[QA7N53F$G]X!WP"798K*. 2*_TB/FX^MT-O/A8]XOK'=FF?I;1F>D4H?
M_5M+G\I!4]/4&=^7%H+KY8E+M;(ZT;]Y#"#W\+"E"ZK$S=0ADQEC&;<G:F*C
MT* S7@DM:M>L/<M'HUMS#>Q:6PN+VO+[N((>JD.?Y1(BEVNC<TE/5">(1GGX
M( FY+:O@ZN*J-$B-H[9KEYS\T/TW40SIYT7#>R*B< !<>N&8 0_%= [XA.YM
M/@XP9*)JEL(!&U4YL9,IG^XI/Q]Q_K5>G\C.*]/K^QZ1[S.AWM@/!;R^QY!!
M52[2G\Z_OY9AKK>NB3Q]]=/%&.<S:T004\9CUFV;B: 9_OWIT/0<E410_".4
M,R>V>/46S!DC?7:3\X##D2_VJ7IF;[PNJ4Z^:GR):X(T?]@KMB^VDVLCS6U&
M0-*_FK,VKI6ID/2<[@&T>(+KC2E':$(61M27E>C-JA3:9)?HGN-5,#^LP)>P
M.:U*6Y.,;\HFPLM2F*2'1/3O@$;M#\])L ,30!4[:,($Y5/ZLR^GR0WV9^X
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MF.T<[6R=;H)B/$B6H/=SJ4TRCR1WL[:ISBU-D$ZT'LHD_8.?U)(VK#I"*O'
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MU^+C3/W.=_1^CO8>Z ;(SAY1]9NSF3#Q"8PWI9$"=L]T>RO\:P"@L^=7BQ\
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MU3]?0#M^"=CF5T.CO2H.@S@3;0?SO2T%7QQXA)2_#I$&R]A3 W U)RJ3_/U
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M-.(XLJ>L,!A\;$^;#9\U^:'=O\RJGNR0RHL&M]6.Q=2K%)H]&SN@7\)LC-*
M9O'S!2(D,2DQ64RG6@>VG8-5WT=ZY159&7%!UX&'H;8SLS;5I:7TS&B+,0=[
M2L#HV1G(#S=(C< .$@+Q(2_ W\:COF&@I1YW</*&E7RA-?6IV^%&T*8?3#L
M 3K0^9DSH")G++ERFF>4(@$@Y0.!-[9[ZO8>@T;]#%:F@B)+S8MP%0OB9J38
MXJ54-$XRQU:OHS3BK_T.>3 WES"I_ CMC0;4_* F+'\!G 403#:$3;I5S#Z!
M>0B>@TF_<=D]U=NXM7]':UQF#<RH41$=EUN^$]GAXXZ6=W)88>EX,\.:L/:Y
M;]=P^L:9[944YU/6A?_LQ)"R7%E]G9*G_ZLQ&;,")+B(BWN)IPD_FYA3]H3!
MD +#[:^T0IQ7&HNA#+_1W:&"/K59%%9\0S@;4E3B$J:(0B.[#SC9'RJK?TIV
M +V(*&0F+!!; #*X!?[\PO#O'<>$D>X4_5 %UE:G4:DEL(_@<.%P):95AY5<
M<+Z=ATLN0XO &]Y3E&F&11N#R4O'-C[8H=4YQY#T<SNAQ101T0@(S<0?^AE@
M)B][KN&45A"H6U1 7?AY^AOS#+05/DP:)2;?/\HV@H3H= HM(8@MIN%P0[6_
M+[AX!$J$J0 U?P@HH\,6NNPX$-.6E)6%D;.2T%(JJL'C]RI ,,\S!Y>D]')D
MU+OA0^E8IWQF]Z&UQB!/LW-2CI/WBM^B0W/LG#3*N-/=AY@LE,B:1Q, E'Z:
M$UCTUYQFSS&'3)>8<Q$VD6BWM.FW:A-(5=+IU%T..,9 BQ61BAL1CQ49#0M-
MZ(<,@9!1^'Q$C -RR+CC@*E;?*Q&ST61@2V*%<*ED8)W3;RV_7@LTX>_]/AM
MU]F2P-[JER4L._0>;H!@R2P<C""=TX).EHGGS8*+QM([X/]9O6W9H]06ZR=W
MOKSO.1'RGZ%ED6OM_<<<P?4E 0([GLX^$-MS^QGKW[]3KEZ/K<@&!5)IPQK)
M>\^VSE:[]^21OHA_=GM@WIJ2'TNVAQ]5W=7)73!U[8K)B^V\-F^^5%-L87E?
ME;G$]^6Y-TN5-\^]*3GU8,^;5J952GFK&!UXKS 8/7MZ^\A-L[/-AL)"%4Z6
MA[?\R1.3>OGNY>6[8;LM[BP_I'N_?++5';:&PZ8+$W@O79"*;V&;-:VKP%,E
M:&FN:M#-#CV^"2MS6F*9&ROX M=&3RI^WA3*I6_]Y89HOK70FH+W5=_G\B6\
M_M"^=NVIS]_L,TYG?U33"17TX=.UT6J[+C9Y>1RP$ W?;WN7,^G&R=HI5C(2
M!;.[D^Y(68CH*_,U%+Q:(67"NO&5W^$?]I_4$]@3DRTT6OVN7EG'>U/80N-/
M[)5U/"KZH<P/^U-L]CF<MO6?^TOUVZY_;KFU_QFZU]^]OD!GOL?V\"5%>W4/
MU=_+W;+=G^6?\:.N6;Q1?KW:&SAXM[#X&JQ_&_=6[+6)JWYGWM];.G?4[^S(
MZ&1<GZK6)\AWJ%.$H5U]P@'%)V?N-%=F2&\\LZ%M AOG"RE7;H=E;1,7]+ID
M*+I:+GL\7?S3FNG2\^3\KEU:^M8T^^31H&=S=0LO\4UPC!)9^S:T8Y-WV+>F
MDSNRFMDY5S,7AYKS2$W?<+7I2>#,KLUB2WYH+DH0N:P_80'CE++X/7FLZYH-
M=8N=/0S/.69<N7SPTL4[F1>L&V/.W"]:7!PO>\_G^M:G;Y6R':*^9Q;?<GXE
M]WCI.9'BODE>CRV7Y[2W*_5K[A9\U+EH<I'6I[4Y)0NE%\2=XA!T%WPETZ$4
M^,*)H=%+[@%;Q)_EMA,/7KIUW_8  _>B&1/8%G "K6@.B%QT_KL7V[3H^T\#
M-^S8T19SVT1<-D]Q/</DNU;G2PO_(KHBNO!V<<K0;W2/6HW%:EVN@/=[F^M/
M:%_?8?^?@1<4YV6^<P47G?K\1/61]LP]MS=WU/^TV3XW^N?1=[NV!8OM9@@6
M.6J8F-25-(-EF69C%X.JH0NPMR)?PG[G_(9M#-T2CM<W@;K5J\Z>L-QZ4<IQ
MQ^0/=W:OF;;U9$O\_YL,1 , 4$L#!!0    ( &."?%BG^T$R9RX  *\T   3
M    :6UG,C(R-#<W.#<X7S(V+FIP9\UZ!5!<6Y?NP1V"NY/@!'<-P4+PX XA
M:./N$B2X)+@%=T*01H.[.^G&-6B X/KZWIE_YM[[_OGGSGOUJM[N^JK.Z=YU
M^JR]UOK6^G;MQX7'5>#)*UD%60 .#@XP@7V 1R@@#: B(Z,@(Z&BH*"@H:&B
M8Q)@86)@8)+BX>,04))14U&245#0,' PTM"QT5-0, DPLW%R\?+R4C,*B0ER
MBW+P\'+_]A X-#0T3 Q,$BPL$FY:"EKN__%X[ !P48$'> ($.#H 'A<. 1?N
ML0>@!@ X)+C?!_#O PX> 1$)&045#1T#-J'^"0 /AX  CXB A(2("/O5#_8[
M@(B+A$?+)86,KV:*0N=$P!V4\!F5_D5-)Z'ZY#$#CYES,!HZ$3$)*=G39XQ,
MS"R\?/P"@D+"TB]E9.7D%5YIO-'4TM;1U3-_:_'.TLK:QL75S=W#T\L[Y'UH
M6'C$A\C$I(^?DE-2T]+S\@L*BXI+2LN^UM;5-X ;FYJ[NGMZ^_H'!H>FIF=F
MY^87OD/6UC<VM[9W?NSNG9S^.CN_N+RZOOG-+C@  >X?XY_:A0NS"QX1$0$1
MY3>[X. ]?IN BXA$RX6,)Z6&8NJ$3\<=A$KP(N%S32<:/8_Z,:&9\R0Z$0/O
MVM.3WTS[W;*_9UCP_Y%E_V'8?]H% 3 1X&#.0\ %)(#+&Z:\0/1_!=;$$XYB
M)^0VZ[>74SH+;76UI'0LE6Q1T33O5IV28J\J8EAU9NH/G4=TEPT532\(/T4)
M]_1<ARH^@4,IMF="F&2JYCZ^:"]?\LP;6[8=_DP!UG[U"%A]WWH5T</2'Y35
M'==!EKW3+YQ5U11@"K)%_/9F*M RX0LA/4X?BC=P9L,:?,+1[FL^45Q_ZRSG
M@3#*QB_S.E.NT>V,+X.Z1V2?U8]J3A;<EKTM>/<]7-4@OCB6FVN@W^ L%T<E
MKW5:[BJH-"J+:EHU=LJM%?35H,L+TZ!$/;]0]\0CB@]+I)<_?J$UQ[3F.T<>
M'GOGIS& _4Z05"(4\"8DW *M+WGWZZ2O*RXPU@IHE'5HDR<\X2[+T4B?FVQU
M*-^[]/;[4E,3O23O0C=F@(C6 CYQ[\S%OHEDRH7_;_&+FM1SWV#"[?[%T"@[
MY'EM2?T**<-KV8V6&1!R'>B!'BF2M['&^BGNW4%L;NW[17_ESS[VN=@7D6N%
M5Y&TD6H<R9/C^/SG/J$8=33^Y)_MJ)#8<G#7/Q2\F]I^PI1DFP8PY)4_D;,G
M/\O%7H_<D%@SU6OK#,/03,+[^ NKB^4)_PZF)^/V[;=9.>6K*'J;?N6FFD1K
MK)&H;9E0-!+GW-7S#HH)E-Q) \.4'M1ZUA"DF-1&AWKVYN;7_$^TW0\2=J&$
M-K?Z+50,C5\>)FJGU\'R:4A=]@)/QP6%*-PW1"=0-&6\#MIQG[4N)Q/A2=)]
MBUT8YD3DY- ,$R[=$)UMQ[I:U[\^&V9_ 7T['_]3,5!2@3Q14W)P .$;$P(X
MKS%JA4H\)Z!$_Q&P''1F-WK1(U]:CV\B>'[["!3R](ESS-;9[LN?0363T2H@
M7@46X]]GN$-H28>1$#/1@:.2:H$Y<;K18KT]1TB%!_$3^CIMO(&$OA=],0GW
MZQ['[7IM3B<D.G+T2]8N))-/H0S."&WY:#DI7Z[[Q?L"1<I88T/Z@[6F-Y)>
M93-70RV:DQ%%4+I/1>#"Q@MU9GTMJ=*J'@&+*/Z$D)>A=QUHUCQ@FW,3KD%*
M"71@SZI"!<W8>,^?O+YM)CK )I6',]I4<K"#.HS5_E_GUC^P1=S/7VM[^B-Y
MKIKO3B-U,UJ0G!Z=9&@Y:@S84W)S&QI<51+<^VH3/\Y+]C[%V$H -W11=J*(
MIY])\H>?%=Q77\DIO+'EE_%*O$>1M!')$#*EP.0^%)KS,SYW"7)/9YVB3V[R
MP2\PA"PL5OFGHV/][04K,@+"+OAK&#AM!$JQS:W-KU$_%H3.9'-S*E"HMW>#
MN!4)ZFU;\FKRR[@@\NS/TS)Q0X*%J;@DR7*.DZYLU<*QO$!.),RG7^VW,JPV
M*#V<#I6:3V03"FU2M,!![/[C%)**X)\_&=$!TL.IVI1.)%^Y_&4T5:CUCX/#
MKM8C95G--TS *<L1>#6#TMEVT++QD])47]5GS8]VC!2<XG5P?.,19QAV+(.8
MB14!5C%X$JKR.R3JLMZ_WK@^ F2>1K?R2NK:P0L#9>,4-7>KC:NNPY8H";OJ
M^E=4RY-Z(B#U!\&G0:;98D/+]K,T>/)CCCZ:UN+DN^-(S1C#"4];'?L)0M5J
MMG80R^&QG5T2)(F-^[X1R,4$U+$O5"%:T+.)F\;#(912AG)ZIG1+#C+?,B80
M6-.]2C@2M(MW)*;_7**]MIV9Q!;EYHR:Q=@!0=Y2;PN7SIRU]B?9G7I)3Q:Z
M%_B!M&\*U7!)BD3"<P(I1KJ7#!1SGJDE#&J;S,$B6)OB)0]R:)4C1>!C3XEI
M%7*S1@0[2UNRK[&89F)F58(3!>E%$983Q*EWC<WKZANM.<S )DY,&JV(3' ;
M$^FAXE2Z,D\K/O@(\4]>LU )0EU-MK2?.G--TZ,0P+GY:JP)Q,K>&N;J\- N
M$2W?.C=19)[T2KEM2&!:0[R:ZZV.^%].]U-6(-:0=OX0W E)'ZN_LB6 V$B7
M&X^R#51\B>@Z".<F7B6\;O$[F"N[HAHT3>=QX>+1(]<V*6DE6M0' &PK^-F4
M*-?R#,%WZ6[@A"NK'"%9: OBQG1ZM.?\RP100? %<;#'VU^DD4&A2]ERHIH.
M5U*@@+JY ^.E]UCM ]?N1]]KA?J\W<=8HHTQZB+6Y=/W=A,LK/ECRIHLH!T
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MIZQ.H)A"OB,F04+2Q+LF_4IZ+<^0)=S2M\&3:*)?!'?K[EJI7.8*4I1F&-K
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M@HR*CH>!CH:&3HR#BX5'3D))04Y"1D9%PTI/]8:9FHR,@8^1F9V#FYN;DEY
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MLZ-QWZZ/XY8W"<O[4K]DA>I&&'1N' ?IT;4$C#[]JNR+UU!^58:HJ(C \DG
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M4-_+/X99BT'/66X7=[RN<C!G?@K+YJ^NCA6M[JOI%5X%5>PU4'U?XDPV=AP
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MV+_"%H#7=YS  N6*GDV3X;0;F=;P>0_M[I9:P?&L^1 *0=L2,0\;#.FNG@9
MFA(@%!A6MKLZ^&)W-6Q66%O>XC@SW%>5?]*7VPA<\!*GNTM#&WX$6-L:*YYE
MW[N&;=TG<J>@/#@W(\1&>@GYN/O#D'".:E$HXH^SX&9R$HY 00OZVYRQM4>
MO2EH)_3Y+TB_R(Q;Z(B(,D'P%8M4M??;SOT* P*MLA:X3 H+P3"H0Z!$!M[4
MG;!T'8H:^P@PY01U4)H@/ 7\TLKA@;46M$NI/,RV!0L\I&?9+XM)V(^>F,4L
M]I(=K_;V #)]9R.6LQYO^*B"QBOHJ)-V&F"!"6_5^[ Q.](2774W2U$(>R/7
M\D6;A8NSUE^W\:,A6SF&?<S25;&5;$M+EP>?-7/)%$@[_\AF!I8$\MOGOL@9
MKE;M38FA=![5Q4F,R:@*.*Q5 AXO;TD6-!&./'^OJBF[J-H=UY#&VBZ!KTK]
M3X4S,= 0=$L?G);QC-1VV^-QK^]EM*C%X@&I'AL$(V[.,%7C8AVY4@LX5E6Y
MJ-=!DN:+M["\9YY8]E!-VS*HZH>S3VBOZG+%W/ $B'J(WL]:8>! B;=+X)AN
M6!/.<=7V#,OGV3>X_#N[0)2S=*Q]M/5&/[JZ.)K 'A7I.8[R*V3G GXUC=K:
M:XT*G85.TE=G]-*0B ^%]+L LF>:,Y2I!Q_;ZFJLZW 7^Z+3)!E%'\R? N7N
M!:Y<JAK]UR07=;LIK?/&(#%"D@/ >>:-)K_C+"(W#5$]J?H#78J 'WL)KWDV
M/C:75\N1 *6"#^]U9*:BAO"=D:A85'5TFF"206Y>0BQ9'3=/MQU?XD@7/Y__
M&!#_Y3>)XB=BP!@TUMA"),#6)K<F2"[,V8!64U1'L*]AP2/\7M- WWDC202/
M+HB+@?7*"NTK#\.[G%^:3-NLSX]V4I,A+:]J8JI?U?W-C_<(?OSRAQ^M_O#C
MF.>,?DZ>E:M.3<URS4ARM$X5IQPSZY KZV0,H<>=1L[%(7=;2[S09/[#PHXK
M2L"NT/XR_CZ_S2YQ?5C3Y]6(N1VR]W(2!%$=_S?6'R<>4T4D[Z"C\1)Q[M,C
M]=@X,]2 7AL<K."='0?F23EC*,M;N[_4YO %IQ@@OY0AF(;*==MG'V19D3-,
M.I<8N8-_<.Y"U9"@M:?\Y(KY)=Z:[:DX9P0;_?F[=][3$P\W<\@!#Q ^V/YV
M8"84)"F3/G;XU;J6NU^BDOY-"V&DXV0)X*O&EYHR+?-7!4(7?<C@2LY0[NCE
MBN1G2C)K>#K.0VZ%*W="XA+3A\79K:_PI$WKOOL>E@8Z-*RMC3UO/$ATW#58
ME+/#2MMR7S%'AK4I-%SGFB?"TR O+&C+HT=_W%-':BWP2/;8J0=)(1/O>(D\
MKUI_!*  ]Y0M@KPE6$SJR8V?8%V\$5;^^G#(,QD*[M21+*$IK95:Y#1I:= N
M6;&.66+XO:*5[(]&2#3R#/7%#7W1F90"8SI>SA*>W^Q-]*RZ+DUDFF>>EVR%
MW++^AHK9)!WCA>1W)??H4VZ_NUE7';6)%7^)CW9<3+XFP2]P<=,-9^.WP'EY
M8],L_/LK\E:J:/9XK]RN?==V-O$;LTO(6HM5M%QI4M<*1=SR,/NO+^^(3\'/
M5_>M( =47S2 P0Y/91?5X2I\O)>EEM/K"LHJ+:O&"X,.C3\'" H_R-"7MH%V
MO<D0" :SH(-5C*U17$UH4EWBMQF=?4OSU)Y\\P@H=?FT.EQPK]"?;* F!RD@
MN+ ]_[1'7VI[_Z*+PY$M=-O _.N&P4XB2J!-&EQ84+ZX[3ZF&!$0CH_^P:\K
M#R:/HLV<NVRG'^$#6<RBY-FS/(\ 5/DP4-D4ER?X[L!GYVXRX;</"0I+WB^$
M.-BTW9[2]VZC@")=NZFW2)V'/IA$_.(20 7-K +I[B?RX362M@10G]4'FRJC
MMNME>0X1%*@#L_4XLPS9RLO>JZ*Q/6+35L$4X0E!IWET\)[4B6# 0S3H_7W"
M[2_YC3),<$-!=MX$OAG\PZ]' %K/C]5]RJF\R_-#4WBZYL<*R31G I\ _#L6
MU<;[MK7@Z@Z6##88&NB<CM-+CPJ4?[K2P.I!454(GLY'B+, O=@'J6_'X ?G
MQDB1?:N<S$@9$,\FA59F;7:KC4&6%-=#%F0>-+W+_>X1,&NUO(JPR". (#M%
M,ABEGJ/MDF!B7*K*VZ3[*K\L*%FSOVVX*A$^>N:4!M*;A%Q'=J5M3[7-$1^F
M'7AI.PEEU(2 ?G)-*$M5ZH,\L4L1,6?;T=PC(!I!41UTG $/5%V)4VG'2ZB/
M@$L<&81U)1-7#XZOY,!W1]YO1@_T6/ ]Z5TH9L^$Z&SE1:B2%9^Z66!MY#+5
M.5*7SL,62B361;#%_1-I@J0^C#%1#(7.9R;F/:O\*$<2DM"MHK@]4+Z7Z-UV
MET1B_@A8"I$Z)S!4?GU<"$[/4U:+D<1-SFFJ1T1*_?_TN,3O$;!QQW:'X-)A
M2X__\H,%1T:#$+[RIZA_W8@!FP&:>>>]$^9$1J4WLSU1;59;GRH5":)S*JJF
M5:QU*RX+<G71@6=D[WL\ L(3E*;7-<,4)Y'7W W%] ZS3AJ49.AF&A\!KUKC
M7#=2J&2F+R,8KQ> )"&PQ3GU%"+T-09!@.,P^=/*T]2\;(O&AX3@2V\1I3CM
M:.L-^;,H;054P"5%"<#UA_*G1/.CM1@++6;[@K\6-)H_N=2@]8,D4>!P#EH1
M3'%\+*(=S/_T]:QNV9EL:FUM2@/^;I+52W1!T,)Y.X2<("7C[>OHY]H$3>7X
M3Q+..&"+4(7MR4-7AS#?MK90P=Y79#ZWHT1',TVR_[(.2^KTKX)+E=MK$H.5
M0?*]*9\C1(#3?DE^95-H(-QI=;]'M<Q?UM>PW'ZKF'Y3Y(QM&/C7 IS_"T">
MT>02.>*J&J0U%W 2FIC1;%3+@Y&'+-GEH_;D?#@H;WU1Z'WG32(HI-1IV>=V
M,PS8_&PYGF=$*Z#'#8!SD'A3%E3AID&!V4_Q[3CQ>$K!9]QN*ZR?'8DF[,D(
MNRZK'Z1%Y)[D=^:Q-[E,V8K$U()YY@I @ZD)G!#%-.M44%UP]*LZN,H-R3 B
M0Z6IY?HL$= F01 "(;/9D;4B ;Z@:6IKC8XA7%%DD9Q>ZJK%-KP;>[Y,$& ,
M4<Z'\CG? XEVC/%XJ\.V'?:EZ87<41)M@Z[N6_2]/XPJE0,%!E]+1!LG#(DW
MN&)PHU"22P!,66Y;H"6V1%6-=??":?:$[AL+E?!SD5]8[@8>1U;Q38A@+2,7
M-/>/3(6%:EYZM,K[)I7Z#V,X6W1]*"-\MBU'>] 923 R$R3%JUC9OU*L#IWW
M86Q/!QS?U"R12"W\8:VG(4[XAF[*PQO3+2^P9O65!9RWR5K^RNI>BS"LW<*<
M+)O2B&/05\UZ)]*M9-?0NS%61:84[+IWZU%M*_?K@XO"S(/R":<F TH7Z(7T
M(MV4?'C*Q-WK (HP@(C.+O.5O(B2Z+7FS"RZI%BHNNVF%?]/RZF:@N<MJN]4
M%(V6\96U,/Y/DNI,PMX?!L@D<(&#3J:2&"6,_GSZ\R7H?H?6- [G.K\//:HD
MT3A3[HA5[117:)%?_K7\7@<  #P''$F\?_=OCLP+C<Z#&JC/-@OD'? +S13D
MZ\N.+>8T%Z>J:3_;M,Y+7YNE.(6SH8EO++ZQ7F<J85^1^WEY?]WJ;OP+,M!X
M)&A&Q+6[\O[TNL:UP"*5\G3JNK]HKT,:EI3NU0"QXV&@RNA#)N[_<[B&EWP^
M-+-3^XRE-B%W8<_':G[. A84+U:3,CHI$I*.+578F!*SKZ.^',8];O^B"SAI
M1R52HI/IR]OR0N*,//G"0(\VA69_$3C7B>]0+QG*X7 HN\F.H<"^6"*\*']&
MXK9<\V)1B.MR\XN<41T&.3+EEK]UNPMO/UW>TR9B>J01F.,ZYJO!CKOXG&?-
M@T[%E<]Y5,J73'1A.15+9Z&7LA X;7]^62"KRL+*\N$<VX*)NVRCUT%$43@/
M1,(EKGC13KX5$4?$;\GMS%F#O*F!>>JWKP6@(@Q_>[S,5I+!:O-?'[K L0>\
M45J Q2N=Z$''^R0D,J6E%";L;UQM11DM=[S4$GB.\O9>Y:,U),N]YX_QIS_M
MXA9I=@%W38A^G3, [KN\U%]HA=(J]76]M#_&%C_2L!I-.EK0.]#1RT*UKI$^
MZ8K?743F.,80#MV,W<54;R*.F$Y9GWBUYZS-9;$RW,>(+*#I+E"_H!GX"# O
M(-! FM@MXXUGDJII9+'VK+OG?Y/-H,E:"5CT[97AV>#;.<T3^G&6V^+I;,N<
M4")4S/+FR\)WX^_2DJOK(Y!%C[6)<O(P"?L5M(NL:2XHAWSB\(O%RM_CDHM9
MMZ%/%8G(/)-GC<4!_UH&]C]MJK3LWZDY'@%%"ZYFDZ23>V3JX]%!ZD&H5_A/
M+M8G+X\4.[D;:\%KF.3<4S7*%GDL?2[8:)@7K=B#%RP>BAV_K TZ>90DLG7V
M-./K*A=7%A=VS!+KGP5Y2S*]FNQLPX%1(9FW$J5)-H_'_5R0\:Z7LRF66;"_
MJ4@\],);#Q%DR6AIF5Y=9#LV\RP:C*C'E=VA]ML3):/Y# 5+M$QE3YXX->5;
MGQQ2FWT?)7*;XSCZ+$IY68+0S7'EI]<5F5 '(2JYUFJE^,A,=R.CCO4DFE,L
M[G.W@XE,Q#S_1E=]^M #+N$JZ<*MC\ZNY9"B+DNNZKOM-Q+=NRQM#<6KS<?"
M'?PP><D6XL)N<29#+)>K,$)N%DLM0W$3TNWJW">RT+9N,>^=+EYUS[TQ<-X_
MLLHATI+Z") ].)"-:.*9DRXB>@2$I/Q>1KFK7I<Z06&Y:6D1(<[(*02_/ C'
M?VH23$<&<F&$F<%I79'>@8H47C^8:=ROK*1%*$^*;(J4(*2--.A2JRCO='3R
M2O2..!;8[I!$%\2G>5^:$7R@:_L=QK?FB8?<& E&YM =H-*L$<?;O#)2\@<<
M>VI:Z\;G9:^Z!1BTDG2W)+\*&L88>X7+&< ZV+?+'?Y@H5*F$=O"Q[5[B$G7
M0'3*7M4WX:5<,O>2@\HJ6M!2R*5>9"3VL)6W0F7,JE$RA]BEN?9=Q5TE*?9
M?CMW.HX-6W$9QDGVX.=%RB_+''QDC3:D_FXWA<-YR[^JM>'MKM<"<G+JTV\!
M8"%?DG?UM\U5@YZD+B7P)G682T*AXEG-(P#'H32H%T;=RE#IG0#'O3CE&,[3
MS_Z&K1=1DV\0DHCQL32'/"NGG%?D:Y4SX#ZNCR)%-7)@X^CEQUK-%\6LQ9-R
M3L8"GP3Z1W^-%8!?U FY=6O63.94C5W21\1V%'_Q#-&9SGMS<1XD-A6E@-9'
M>).UJ)30K;"Z;NWCU6ZV=' HJ)INF7:V43RW1'&<O:^XE3Q33AD>$.4YB[D.
M1K7@#PYD,9ZI)G&IC\C1U04R]F4-??6,9)\H20O6^80!_-0R75TK<K'CM>;S
M23JG/S!^XH>W"BC4ZAS;[2"_5/P>J?M:_ &I>] A*]LC(J8.+A@H3[&@SU_Q
M" "GH,A/*8$(XM9#P+#G8N 9<"$#""O;8&3U3D5L>)G,FZ /U.%1FP6G72&;
MY81Y[W"W.AG#D;]-+[*10S4>_,5+=9B#LQUY?JS>#*Y-#3[['MI&9=4X[;V_
MRQ<]KOPIU#Q/_G0@AJWP'=5EWBR3QE+Z_SYMAP8P27XB^ES2/M6\C&H"9OAY
MA3=,BSBS[CIB8^_$4@O"*_6R+8\Y#P[7@.=!3G" 2P>5\Q:-7HT^$>^T=;1_
MF<2Y,+U,QWCZ9-]JLB!.,WQ*H.@@#P@T$+EX(T^V1AGSA(C,PBJ@Z8RK.W"F
M@#8IMYUF<'5AT?><X,*KKWV0?&Y$!#UTHWN%J398 S-[+X(6',(ZIRL\KY3_
MF6KC347R3F3<"Y82)BZ;I.JZNK1$L1&P6'9?/Q$1P8XP'13LGJ4O6QMM<2Z%
M(<<6=40U3*MI3_$V#@Q S*K,1T"7*[]P#H1,8V9N2$> G,)>6OW'UAP]'=*<
MNA13*21[NK3Z8IIM]A++R4.(8-1-I O7+4PV9EN;F=IMDZ%U0&6W$^ O#AAP
MW[7**"6NSI&U2;Z1H'.V0[!P<<]_3:81 )6:P0J3-F6FR+VV>+*_7='?/S .
M2SC:$BP7UTZR[N9\B&Q-#R<&['BQ0UBDU)OB)]4J_1= 51+NKZ/?.+/W)R.E
M00@+BJ_N!\%$NKN3%H\ L[K0V=%03:_F-N&E-2<#A:M7"6M;$T9I?=-EJ=L2
MH33U/XH$[24=*B+9(Z5']:W4+'"P<<C,AD"\"P\)9J='RTTB.H M+T^(/-9!
M!W]*1&N9,<L\HS]RBEP\+JOD^^1PXN.#2*A?GE;W6HJ"^>'1A-++$ZT?W%[=
M.[RE/?]9MGB9JEWS<-_=Z&P0QV.[!LL;\[Q7;RSPIHNW!OF,VZ1H;LDO_J%2
ME-F%DAE;PT#[A;10VT,XHWDJ400E-T^MPR@31]H[CN,>+/M(%,M#JT'GP2+'
M,T0@=8X&F6LT_<W2_)E4B%)(-E3B\P"1-*.D&!DFRW])4DH/$<BQ Y[$*%H"
M-BY7\5>78>HS7N_?BC)_+<ZL#XE3_*E=NT/'VSODJ6FL#\Q<!H(7D+HFB" X
M*:P POKV^Y2#J7_?C*I40/9,_N&DF\RS4R7[:4_'#%&FJ>KV*[OLS1UD!T_-
MST/Y.3\#E3AD>)\VMW7><&]LK(9EO^^N*&;QM=Y /I(%7!'_3[9]VQ%4S+=4
M6K'@UT\0U)@E_E::"Y&&C;+\H[YO1J$I7:RTV[9Q>WL",C\4I;LH/$]%_7F#
M,OREO2B^ET#9RCX<+4#SE1$$VK/63H*,RU^AC[;V5-*[,"^H694S]57C=+,X
MM5WU:X=.NIC .(!W.F9Z[%ZRQDA<NG@62S&W*\\+"VL;0Z##[R+<Q;!4#F#9
MMJ7\:XD \>K$E149,M-4F?ZH\"#'&.$?;._X/%E<Y6=;:>8&<T<FJ75,]C>[
M]OQ-P!1NZ,=%_Z[451: Y='R8M8?ML0[LKM^,L"KO8\5Z_(VU Z=&+[6H+&)
MU++M6$AS9&>RE/GYW2CA]&80>(C<HBV!$%&\1IKK/PA-)T/MAZI<OA93RFEK
MDVN)/C2()"Y$4V&:?(*"19KF*=73>3HZ9F\F'QGC0%>YMYD[1,9^NB*^-B4]
M11LO;=X^N]KCCMC8?IC28V)/6?ZG1XVJU/&\:IR5;QEX!]\A<3[I@[[OYH%3
MSL+4C=VBF'4TTJU+AF3%&$97^OD$7;J=ZAHED_(+@(LO@%$>MQ5,('9]U],>
MR),-;(IM\]Y?Q61IO+<--JDU^P3*L6'->KY;-%#[]2#KZUH5+9GY8AMR#!]T
M^SM5D76<F>(1IS8BR^\B#9ZDKE1[,4\>K$HS&S4$<*ISA@\L?%SIXDB#O$!&
M?'K8:LJ[)K6.CX ,C F$&Q@4S2=;IF)-&RM/'P[H(4$91O?TG/'A-6A>3ID/
MK&UTMK_Y#"0=RF&2ITUM"?;Y7.$M&RV!:U3[6D_N9AY2"_+VZ<D'[A:V%,4Q
M"A\!?5,7P,Z_!('2(^!%ON'=S+,=WV86[S<Q\J]F^!1A-7Z?%$3PVS.A,DX_
M?/9 YV].R,C^4 S:M<$M,C16MZ)W&7PDC* 8)$J1D81#<H$*D=V[E;@"RB/W
M+X;&T![[.^4K#Q4H8UFBU:75V8O6_(.BB#%!=5"AE]292/".]+/4^')"(OQ@
M@5DZ^Q'L388C"!N!%@,_^-NW/CZ..?TL7R&[>WGWDT"8=>;>(^!5LV&^98Q\
MGH1;[2!AP_?-E[XO%QU#0S[OY\;HSAY.PI*P3#PC"&(-(2E(:KP5,U_-;(^I
M#^J])1V8U%Y*BB&30RI2^"9=$BUN?Z1T9X8R AAK,\QM+P^2V-]W[O2,WT8_
M;"$;4ZT4CRNP="\_"7->]^8_Z#28TS=(L'FC%3T&V*LCT:)0$N7".<UIFK/2
M*'-\#[(BFVPC4JU0!;<[ J^Z+#TX^1'T@79D<UP6@^JTN_FQKM$M:(/*7V'B
M_9BF#7&.3&T.=\QLF_K=XC%-SMPT"%5'1C F*:2*9NGU1_N;3*5T;RR^@F/!
M]]9VB9#J"?"1\PM6]G-#;J^V0(>@8WGT[?N/C0W-4RPE95]UYC>3B_-I';BK
M(K48=->N4)X7#Y]Q+[!H2'<7HRB$'AR6L;>$R[>Y3'20YXC!/"&-J11$=/=U
M0]6'U3<ZJZ4+[LZT9_LZK5!7:_?KOECMJ2-K-M%[^6I<>FU">MW-\'!?#G[B
M5OC+[R6#$@6KP*5/4?2I*.A]1BI/2#_O" 9T.ZXPG'W)<<^RW%"8V"9V;EXU
MY??7?6;XMC'H#?\1"A4?C&EL\D'GX9F9?BYK'&]CS&IN"I]^6Q!8CXM8V5:<
MHA-.$B!ZK^N_[UE45(<M>&'][#LA(3H @+Z0&7I1J!8GPS>\_"/.=UPL,]WP
MOQP!^42"0$ZK(7%0HK6Q3OY"W)8ZNJSH&;72LP6F;Z<*6?8/&4+-=U.-<4US
M0+U?9L["NI4V2^F1 ;ZB1VJ7$<8(_78]T5\X_*:IK:DF0?&+2E0O(0VJ$@<V
M4NI]/I(BQ#1 UTUA^U!_^6/MNB.R#;*CZ>Q)N,E&+6KI1#W;*X.#Q)E@4/8B
M5%49DP$]EK/\Z(TNZ0-LS>]N)@]&PS_Z@.91]P /> 2$E20#_?5;-*-YIE9:
M8P>YV_8PL?:FW?[FO-&R&F#IVT= CT=*\PR[S+JWQO)./1KQB>]M-@.-\".
M]*GCD6;;.L,,:%=NNNWDD@*F)Y?'!&H7;YB:[=/9Z6Q8AW:L$%0'J=K:.Y#C
M+8FNLO/M'$=TTDTFWK'!\<(> 4=O\D =-(7>Y9T[M_I?^<XOZEQ7>_49BV\T
M7PN_K9XU/64M='XAK8^:??%YW8 (+IP5);+"Z<D DG\V,C,R@BG<LS(PPQ6Z
MLL(52JW<41@.$'FB.DMBNQ%VWQ16Y"9(4RC#4O1]1YE9A(H X\GM ZI(A#8B
M!,I#O&2P:3P"VL9 9TZ>#&Q0I]=2JA(.2M!.M?H/9VX"ZJ98?=+QV,W9!12@
M"F25?LBR#F&JMB!)8>';>./M]M]DH$BP*=M>>L.,LFZR/LMT;@@-N+VQB"K?
M5/@K:< D=)\$81J#O7A;=\]U%A42)TK."&9JC"@4J2M*Y<.<NGW_W</"VBS#
MYP6Y>GLWC#HK^Z^#1+$XBE$%'S 1L'GZXT#DDF9_]>8.&\Y:I.L&@4] %M!@
M5(79=0K&@9_*88?X%12@,;S1'/(!13C9L]$T0;0UHE+A=Q%89P8#$Z7$%F&T
MKLS6<:-*2&0MGJ2:,S7M"\MZVM  I9GU4X6*ZT4H)/*+Q1H5CO]S81]>P6M>
M JN_QX+M\ 3ZL4:QUET8%+?=F<8FX.H-<X;\?:?SRKIU_SQO"F=6>-N:$_=)
M0&B6,3)6=''\(8:W%$_*?4 ?L#>D*A,NQ_3(X@@&01VJQ8^ L80BT.JN"+2Q
MQ' C[$%E0&"0#<TR%MB?$L-<[FLG+60P12STHRW7?\=4PGZVE7N*\X"HS%:0
MJE#<^NGK&,EX7 (IU<ZI?DB+WKB>%U$1@6&4UQP?Q<TR^8#!I)AC46;]8ANI
MP9P[A>5I?,'K!5JMMT/EL D>B?7[M>DTJ*QSVAWNE>W] \HCX/5_=.QYABE6
M3I[NW%)F\VL<3A4F#/_B=PY,6VQ(,*'$ \C9F&W&Q9%34Y!GI?#!6XH?Y/SL
M"^R[\MZH<-XVL%)H.V(LP@JR+*C P\',A:+&-V<]Z[?30,^B,(.7*P?1;J_5
M@?=S6:$6@G-\:B,BX%WL^\R_C;BBK/M5F+>MOJ6A*JQ#)VM)Y_ B"[?SQQ)'
MP^U]:-4C $T!\?)!'Q$$@](? 9#=:Q5XXHNL L3ML9$:[+^KGO'!G::-,''[
M]:T\G#^FF,^G"T=ER:U3K:8V'@)"L2S D-9;&D092#=):]N3JHQ?+7R159+9
M0 (BW$]P&==%>+1Z#%&4#$G(YTX&(I23.S77%=[62>NNFU3<Z3??^Z*#+ Q%
MWK]3)Q5Q$,V:E[U^4/I?#B!/)-O1"4OQ]FE\?L)KX#><7X:#1T1?O1X"_QZ,
MRLP&VW\VN4:U(IY,X7Z=CO5(M&N>[F)'+$&]B4!<"!*)#'PO>Z^?*7#XCO[?
M@+,/.N1=ICSF5'"\4UO1G"IF-S9D]&61R%1O ]D1EH]4FMF\OPJ<PFZ/];EQ
M8-GU^Z%KMC-'S= FW.0)YS+KK%/=G26GJBR7&]:9&=#";#8PQY5)$-5%<=QW
M=3"775.(9S$[TUF1;&FL?TWLW>5'9Z=!L2)UG@OX_:="^>*VALS%X-7" 54'
M\<]0$CZ6(9^O B%?-%!.-B@88 <&<-P4,_BW%B#\$2#V".B>N0APN3P.^;0*
MAG]PI=@7F<Y;?@1H3[?>("2C1E$PN$?';Y:512K@"KOZ.ZZD&+7 M:DO]4G/
M^V0?+M"_?-44OP,\D6RP]=TI3)_^-#4G:^#[L/T+U+!+&<  #WE$Z.WBFMFW
ME7L(]<WKF7D](NT47=Q77X^4HWO$,$ 8UV5.-6<M#P>Z+'7?G+4QFW.)1.-Q
M*GXCE['M2NVH.86%7))$*$!Z?R]46^?KDA0\ CQM(^Y%>6\O(M^#5;S-_YYL
M;9GU!Q0DEL1Q/S3C?7"FO]3]<I6BC'])Z'%^10U_-\UBO56?UKY0*('[VH6C
M_3R?B.[D[C\@[<"\5':UASAGNEKS)0)"W4Q%=R%:PJ94E ^/ -G0FYZ;.Z>G
MGFVH^Q4?]8PQ3+_!AC[DK]_'/",? /KDLT8.A&[],X]H)O7<7-_$S\1 I=2
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M!DQEA._&X[DX2V,!LTD:L$=S5A*8O8W=,D:6( MH?];_FP!02P,$%     @
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MOWBE_BVOH)2[M3G8Q5W+Q<51A%K%WM+=!>1B QZHHU1S\;)V5W.Q=_X-<'(
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M(,3J;IP\PPP*08V2S=S28 $NF38L  P<+"P\ AHZ&@H2' +@MY5P6/#8"%1
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M58^H4/,)?)6,\HJ 8SZ>>S(4 5<-S@U9LJ>&Q-#I<W2$P!MV\4>U-.6-UKA
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M?,YHCF8[H6'^E7 S\(."@VI10%BZ",PL<=_M-%Z/1,Q5L0%M7&WF!>K&1I"
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MBN'N4FH3R.6S2GYV*1S4-?))OI0;]C-,Y0:LVSA;X^8"65[KS#QT_^ZG_[L
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M<T$?/&]&)Q]UJ5(D!RP2&Q^U^,55/R J8^8_?D"KL.027M+?#TW-E1O5C>X
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MQ6_G"7Q3KB^*7[+_2TA)5$:5L_*PQYBD3-M\C"69/K&U8KE((4QB6@]/F>N
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M4$(+],PJ<X<@EQA8&0$H2\0RS&NQK9C_4K5!7WY"08FY3):S'JU 7-H9.9^
M5_X:'C6T6+M+.5RR_FML(!/U$TK0S# ],%Q5I[<E-#4;.J^U+5M W.0=U!M
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M.F?0SCM;[**9:XKD+X; ?[<3ON/@F"WV!F#DM)),;S<XJL57K(>3\,-NN?1
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MS+0U#TGD=]V9*'=-L4)/,_JW">/WM@SX;U__ E!+ P04    " !C@GQ8Y@(
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M?!@H2@ T)A0,)M3#5P Y   %!_7S /QV0$'#P,+!(R B(:,\!M0^ 4!#P<!
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M[^-X3)=H,?U6X].VOYZ(&]OY+EN2\,PA<ZAI8MZ/\!692TXQVW.;WW<&/@#
MD#K(SB$'6BX%\OSI\,)VGIP7^4^,3SY)HAIW=-4H7T]5C]K*\\.2=4?\<*=J
MV!(Q5Q61\WHPMNC?M/8LW+N.6F@36R:U%3I3R[Q=A7[)3I$:1X7LY 7T$]AK
M&R*_2#_+_OXX&3T? #),'7S9@5,N/I)@@0VV7<7ELC+\@<88-8/JVP"'E=.
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MS<BUDAGCUQ7*T5J%2TE7G(;Z#U:\_?$RF$%,//LG\",3+)*%97TXDD19V\@
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M8@9*^'@A]PE,QW.+?I\HT/&IYSL1ZF@7^7P.V=<H=&:_X=(_Q;[W8MV6N'P
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M(L"$ECX $-.B;)AMLNOC^<!:28M9J=-2]22I9>@KZ%YF4=_[VTCC=?0TM,9
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M9QZ^2;F:(/%7"B>G;&G&B?.W]']!:\>U7.,ARW-ZQ ECM:Z5A<\"?5O8C?4
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MWZPUL^N?L_>S_9Y][EEWU<O"RP: 6-;;SAH 4%1D!:  _HU>C@&X,AZ6#E
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M1?!KRD4P_Q^)RGTY89860H7JR2IVB[@\43Y'-%_Z1*&30P45B5:/')!6:(P
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MS8V)QRZMP[PVY-']E)[N*8H#]+\+./S&5J*X;=2"E/H36Y<V>\?D<D 5$-F
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MD_(8J%TO +RL\2HL)1$D69EFCV.HCSK]D5!EX0-'&O]&;4Q87'%X@K7%Y3P
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MC9F#'&GR!+:REM)91_!# #V$B_>3SK-8?4$; 8^?&JH3\2\K][#L]8/LM6R
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M6PI/SD5UR*7SQNB1.BU*-LQ:)DG25'%'[QMJH[:A/E)(,DM%G*N.![I.K5Q
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MW'V4P8\T>1J=2%1+\+_9>LOE5LQW/<6@2ZZJLG\7HH"%(-!<.RB1H;;TE]B
M4=6_-\]YQ(R;BHN-=R[;CO:EP\+(SHTEBB::% 1P4G3Z!W7O;TTU9I4Q)'!8
M1R.>'<?7^.L(:A5IX_EEW(HY$,Y]JPUCLR.\,N732WG)=U)8AMMOBU#8BU;;
M9D0 "DI*""O[*8J3I78LR+(E;&C629F]]>##4>8XV!%^%NVK0S,N.:*(2$KH
M%Q?@>'+]VJN34U\>?BM=&GVU7;9%$:C9:V\TY-L7W)<R/#AR45]H6HYN!(-P
M03M5N(B*H[[=VNY7E[L,IQ8X&FAX$,39B_=JN#8GLM86J:'=<GPI2X5E4^[Z
M*MP4 S6,D@5EQ6G58,4JRIVP^^_<1677P6++EM.@T#7EIY;J[=SRN)T5-]8N
M3RW<9$YP,H1QH+I?XB>/NLPM9>RP[34_[8T+&\D0\5A8^CTV_"U3K'NH0UD\
MXSI5N6.O,56/T%@_'6#>0S;@^?.7>"P$YYUWRE5%1&E#VKX8M^ENM-OPHCC2
MF1GD!\.)V55?O?4;D \[&GKE;=D%TE4ZTN2UA<CM J[-9IGU.Z\Q(?L[+(*!
M5;NZPHOS=+&JVHXK\_*D1F15Q&XI"\KPNHXZXA)X*J)D#O'7VW;@$G1I3%%>
M1;7C"@?%<#CZ;&_;31A;-D0@H0B.;*;^]J[C<_DK(J[EFX.4]6-.T]T;C(RX
MUPZ+D""UVIW2H!C%)X9+X@0$'80J %N>_3>?&\RMPBAD;)ABGLQTNFI$![8S
MJ!NR]MCVBHY.GX2OB)):W @<2;=O?Q]59%_KFK/X?_'?PB=V_-?A6_FL?)?C
M/;V^3\SW>;^'>?\ =^8\KPZ]FL__ ,R=J_9_SOA3:[Z--A;Q-&K3?^#?AJMZ
M;50_8<WB>'XD?+5S-]/V<_16Y]=(K!USSSGZC<?X1LN/L2;PGD'E?D_E:9D4
M?CWBKBVNQZ9EV00<-K(]MF61OSLRR;"\+QW%\4B3X@S)UG;0VOF9\6,UYLF2
MRT917-UW_,JXQI%GNGP;ZIYU=B'$&.\W\P6$?B:OA2>"\&OLLY0PQ]SDO%+W
M,*?/7K7'K7AO(G9T?'JF_P!X,!)48I+#\<W2BMA85ZY^-.1N8[;BG \'Y7S&
MBH<ZC<8W7-&,4..7_%E-GLW!*_D:!57351ELWDRCQZQQNVB_*Y-,QQC%9,N2
MTPW9$3K7>45L#G_U)5/ TO$*J9BMQD5IFZ6WX.<>3$K:9HJ;Y'YQJ?9O_,OM
MR.VQ;(&VX[BD&Z[IMKA?G/YXX/D\VW8^3MN3G9>Z-*L15TBA4Q!2PDE;4P8A
MP0JQ/<7XBNR^4WD[F^:@SY\?/Q\/%VY8VE#(\DK"0L%,<:Z5(NA!+2+8VX&O
M,#D7UL\Z9QCDR776L+CR'790S7VE;B#+K-F%>$QZO<:>R.>Z_8;JZ8&1QPB*
MNWL3=->#>M_JB\V^J]MREP\F+9L:#) *82LDOA@\FR79I/>4W)C$7&UK<J]I
M='_3GY8=,[ABOE8\F[338Y(?,96BUD<QCHJQ^Z18"0R\+\^=9WZ9\\EU7J#Q
M&TM[>;/3.Z>=BUE.M)\B=,E2 !N14E*F37GI#Z^=(C- IDNPM;(O1$UL?D+U
MCEX7F_M.Y[ED33'=8)<&6261I'<D"2#6[EF;WF1%))X)8<!6 \ZNE<;+\K-S
MV_ @BA_9DT>9&D<:QHHN8Y]*( J^ZK,=(%R]SSK:7J/"GF\VSVZU7;*NYHX6
MSGC*9\NP8M2,D_"9<K'78[LCR&)/D7&/0$1P"445>BKTWZCYS':(?..=%<2;
M?U-TKG;;,%%_\I6)FQ^X$B2&$ ]ES7*O*K<<A_*1<CB,SICJ7#ST[Q \JI-Z
M@4FE)] KS-;GD[6<;Y"2JALR5JY2]?N_.1T+L+V)L_'VZ[=5UX!29_V9MN<_
M\Y#*(VY\/S"/M->[7B7]H[AA+_-S1%U_M@?L%>NW!6?Y5.XNQ['J>;*L$J4M
M*FS@UT1K\4IZ.HF+(;FPY37:\+CU>^#0^8I&>^S6QHFOI9Y']7=6[MY>X^R;
M6-46"DD.H+[ZI&Y9=)O8MH95 [N7&OFGYW]/X.W>8^9FSD*,P13@$\"TB /?
M_&*Y-9_(._LZAS)#8DY!COS!4M&EE*>>LJ=XR0SGO@J/2T:>E&@-D6\I.T!#
M[IM[],DV;K?>L*'+R)2%21@-;:74<M5@#S/ ?G<.ZU<L\;:\>4PHMI;7-N*M
MPY7^_N[*KF\99"\QS%[K)&)57)CQ;2DOZM&SLY]M8-F<%^23CSY!'2::DKO:
M:/*;2'VHXI)F,?RXC;*";QF//CVU*5]V36>=WXFP/P\SZKU!)O#'',F+$J-<
MAAV6'=[/LJUA AV&,W=A*=MIN0QKBKA)D%6+K46?$E&Y%&K8!Q(;3;1,"CP"
MI%YAOL*A"ID(Y+$Z$Z=_9_AE'EF22_B,QU-8GW6Y>[Z^9L::^ZY0G5%;3C!;
MA>V]N=N^_P!U9<R 0,JX[NX-)4XZ5G5U,60^)@Y5OB]+<A''@@VT\JRSA* D
M:N><T;['>JB+O=M4.W;;!FPY>/CPQSF,#587([ #W@=O/C6.:2>3$EC:1F <
M&W$_;W#[N%4K(NQ(O(>.O6==2N@C=BE*R+2QQ6-:?,RE@NR"D@EF4'R@8[0Z
MB4?N^^V>SOG=OPAD8[RQ1-'=BH(6U^)-N\\/7<4YUDF>&8*[7 %R.=N'V<ZH
M3F0Y$+#2CN6ME.H0>&TQQXGH;D!AFU;GN2D EA@U%E-]@Q&=^X/+80%7R3%=
M>R>M>GEQ(,R*4S1ZK$*.*V/$N.&D=U^9L*LKMV4&D5@ C\FYC[?N/[]1.WU#
M!/)KJ/7?B6.9,;\./(D/)&M@LW)[4EF6^:MJ['@QK)M179?,1IEGO!?*W+!2
M^9&T0Y4ZXT#/ ZMI)/O,Q Y(;G3?XNT6%2Q;)E:5B9RLB&Y'YMCW'M-OQU0R
MKT4:KL:FV$&$U2>=8Q<DJVR:5L);PRV*395=8C W*9%X!55549:[$ @1=8IN
MO]XR\-8,: (Z<Y$NR@=BGAP[B/Q6JW#MD <Y#$,2"-!X<N%_3^_3"R+(;"2[
M>1_Q"#E]@BQP<AQ"A5+E0ZVVR4HB,'&6G7XL<'%=,ED Z((GW0%-3_-^8>X9
MJ9>+!-C23*0%,=X[!>);N-N1YWM5I-OV['C,,Y63&!N"3QOV<.[\E1L1;'SP
M^2IG&J)D4)_'K2</D2K,VU:6S9;4I4;SF&$1M3+M[]]T3=-]-BZ)Z[SL66&0
MLMG4A))+(Y-[L ?ATVY=MQ3?F,*W$:)#^>O%@!^;P[&I@X_:G7/5<EV"D6?)
M;DR7=WWIL!L#$AA073[A=&.TV(-&2CV)T1-MDUEE\J-YGF@FR\\7T_K?=U$'
ML /YP M:E.Z0<HX@J#@!^7V\ZN7X-,?DL3IEP]\[!96-7/PXS,;Y=@NCOG-G
MY[<HWP$1)%[13;=$1=9B'R@VDZ_VAE3/+PT.GN"W:"HY7J+]I)&;1Q!D;X@>
M\<O7QH'&X0@8G)GO)(=1^Q I1 U:/HXKBNS61%&R[E5$V#L101!7=$UEX?++
MI2,0EHYR\0-_UGN-<CBZ_G<OLJ-MSR'X6 '8?X/JJ9:6ABM2GGH\9N*$=XY+
MD^02PX,%A%E/DCLMY&*Z'&1M7#-% 6Q'=504UG<7HWI;$,KPX<7B2'CK =.0
M'NI^;^[QJ,YTX[;V[3S]=:69AAS:,5&(JU/!,1SOC&C!0+7F=1<[U5DR%JPI
M^('G1W(]VY>4)[6ZU=YF539]KB6-(<?'7PC[AT"Z]Q'I'95;YO(S/=:1OE?O
M?_\ =^]O5SU-Z@_2YD_)^&\:</<:7_&V&<$8W)G3N0>-K^@OUDYY(A2XMA@D
M"-D6..^95XQBURY+LYE8K"#=3$BLR7?P]N5#F6Q"!+X@">):Q8"Q<<[M^+U5
M'-%JB7'C-H5[.[M%O41?]ZNC<'RZ[M7+C \_..O(6*,1G+M&F4:J,TQZ8XXQ
M3<BX_!<4VDI[\V2:FQ4[OPJU!Z*?W/(-V<:4X)Q6IX<G5^JE_G1S[B.QAZ#V
MCL/#NJ6WXDXIOG5D7/&>"391+NLU,7J85COX[I9UT:)8@:K_ &A=0OCI-1I[
M0XS\61;]^D7^T5JS%/3=B7%T/E>TP69F4[(>3U?L+V%<Y;:SZ&2^UY/RU=3X
MX](2HK#_  V,D!N28NS395!=D&.^G!B3Q-5&PHXX)ACE_&E4\R;7MV#D+CA?
MGZ:P_F^BLN2. .;\2PY@+"_SKACEG#L9@NOM5WGY)DN!Y#05-5+?F$RS5OK;
M3FV'O/)L8Q*OF**"JI78$7!YUJ_ <^!'#U>BO+"9Z3>9N0*R5A?'OIPP[TL<
M6<K\2^GK@?GG$LQ'C8Z+.:WC*[R3D#D[.,KX[]/7(K42S@9=35T+CIB1&N8V
M0VE?DLUZ3Y$. T1QV/("P(_#]REX7[S>EN?3;ZI?X+L:[DSA+"O4KGJ>G"F]
M+6#YC;U_#N:T^+/\59[R/'8Y!EX'S3R!C3%%A7J>XYNL9E7=I56SV6T=G2.
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MZI]WI#;U'+Y"'_RUKIOD!>W%1\$17H0I];K6VM^W6W[/'K']L*X=TD"=]O\
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M'>-EN&OX;(WP@CF/0KT2_P G;TTQ+3*^8N4N-N9+7%W\_25Z?^*?4)DKC%Y
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M1U.I! X\;4:32.ZG7(I47;Z=12 "UJD4W'&D+=4Z^SPZ:C(%B>VI%8W J/\
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M;(70CEV A-MJFKZ?!HDMJI,3<<+*!AC8D]@((-O1ZNST5D<G%<J@.(==/@Y
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M-=UW3IM[/ZUT4\.";"E[T^/V?KTM.I4<'HG7V)JJT;7)[*!P-ZEV3^_'\_\
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MW(8C,PZU]=U1%[2C/(?QV37A%HW39\G%%_&P<G4OZ(;4/^[7L]95?=,?*/\
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MG\0D-(JJ9#WHV;I$:CNNEL#Q[:>.'$<ZUWB*?PQR1R+@Z_<KK_Y;E[%F_!L
MR.2=-R#7L)X(,/,H3=B8IX%>;^W3 !J([*:I8,5XV/$?E_#TUMG0Z]H%2*>^
MM;9_PYQ7RJ_22^1L&I,MEXX%C'IY-DL]EYBNNG*]V\HI3E9-@%<8M?.U$0["
MHG?,U4\HK*R([BM!M"4#?$+TZXK"H_I3]-<6XCWT?A?"&;6)+^?B2QBV"C$L
M1R.1EC-I&A%8'71[:)>RW7(TL&4DQ8[A1&7&X:K'T@C4<0O&BXJ]P_3OP57T
M.=XO!XOQ:%CW)EE&N,WIXK5@S#NK.#;/7]9+81NP1W'#I<ADN6->-24%NNL7
M#E1A:?)7%70+$6X&EN*UO3>B'TN4T_-9S?$]#._C5^E,X<UVQ^4Q6+08]@M!
M7Q<%^3FPY.)S/-XZK;%VVBN!>OV0$\Y.).P /"7NX_BHO653_2=Z:+.+CT&=
MPG@K\3$K-ZZQR.,.=':K+*0UA82)"#$L&%FA(+CC'W'&9*OQSDTL-\@5]@'$
M30O=2WKCCU(4'I0X"&/A^.>G/!+O+,EI:U^3#=EY)6U>/4M5.K"H[%IZONV[
M"KR!R3C$)MF56N0IY0ZR.R[)6.RPRG _.;SKQ_+&2#9]LQ$S.H\F+Q;2,5BA
MBU%59]/O,[LK:44K[JEF8< ?3OT_?3KD><<63OV[YDF!TGBS>#JC16GGFTAV
M2/7[B+&K+KD8,26"JI]XB+A2U]-WJ=F8[Q1RMZ=^.6K/#>.',*X[KF&K*1B3
MG'-# *(.$-5C\X%;#&*V0X_5A**6L%5>?A.1I/<9U?)KSSB\R\Z7I[>\2+#Z
MACA,B&)F:&:-2 X >[HZ7!TEF#+<@@@@Y+S^^FL^4>VP]3[#FRY_2TLXAD\9
M56?'D<$QZBEDDCDL5#!597L""&!KK9/1KZ6&&&F X*P56FYLNR-7&KA]^9+G
M6$VVL2MY;]N[,OX]G=6#LZ4Q..3&E3U"4\!R&FG ]%>'#W"O+'N]G.IX?I$]
M,-=-M;"%P?@<>9=UME36;R1;!P'ZBYHLEQJXJV8SUD[$KX%M29I<,R68P,@^
M=I+>-"D/N.DH2'L I1;LK+K_ (#X5RF'5U^1<:8O:PZ3,LAY!JF7F9C"P\RR
MZQ=M\NNQ=AS8TA_^*[)\G;2*Z3D"P79'V'!$1%2D9Y@4IN>=6X/37Z?PML4O
MAXDPT;?!G<=>Q.>W'FL/T:XF_"DXTU%)B>V)L4LFMC/1VW4<;!Z.TYV^8T!"
MFB+G87I/360\5<48OP]07U%BR/NEEG(7(/*N6V\UFJCV&29[R;DLO*,LOYS%
M+75%4TY)F2A9:!B,T#46.T&Q$)&2H$4>LW^VIX2%)U&ME[+\/?XI^OQU)J7O
MJSK3O%&R_#\Z?8F^ZZ-2]]&M";7%&R^]/IW3;ZUWV31<4X,.PT;>Q=OH54^Q
M%\=(2MN/*C4*:H^[M3PZ[BFWYO!=*"MN=(&]X<>%,55153N\%]_]&^FZE[ZE
MU+WTJ$J>*HO_ &R?IW7;1J%)J7O%+YB?#_NDW7Z$\5TH-^5+<4PE1>OW4]_W
MD^'C[ET7[J+VI-D^'YT^Q-^NEO2W])^VDZ>]/SILGT]=DT7HN>PG[:/S?G31
M<4^,DCC5DG9)C]9;T]#9W=77760C,*@K9\UF'*NRKT:*<Q4C()L+"7$;? S8
M:(GT N[L[454+BG%U5@K$!CR]/JKE'U3>LK%_2UD''.-7F+UE_8<CXUR;EL&
M9D?-'#G!F.5M3Q8]@T>[BGE',^2XS26N0VCV?Q/D:^,Z3SH,ON&H WW:AEF$
M1 ()OZO1W^NHYIQ#8$7OZ0.[O]?[M5,7UW>F-O&L7R3+,YM.-QRCC>DY.9JN
M0L'S>@G5===X30\A?PI83@Q^9CLCDBLQ;)8<B3C\&=,LT%U%!HT73A-'8$FW
M"_&E$\9 )-KB]7/G/U><:\(>G]CU(SJC,LPP$\LP;%GH%#03*3,(3>9<@P>/
MK&ZL,4S9G&[NNBX+*?DS;6-(8:F?*0'D9;<<5L31Y BZQQ'X"GM*J1ASR^_G
M6N>0?Y@?%7'\_P!3=>QA?(F=3?3/E?#N#2HN$Q*2PD\MY3R_26N2I5<3LR;:
M,MN6 46.6LBZ<E+' 1J9@L*Z3*HK&G5;@\;6]M*,F*-FY^[;VW[O55+FG\PC
MCK$N77..8F&6.68I'L?3C6N\G4/(_%;#EDOJD"E+C"SPKB2YR6OY2Y#HQ#(X
M3MC(J(4@XT9QUYMIX8SR# \ZB32+GASJ3Y^'Q1$ 2#VCB.=J[_,5;,@+;<"4
M5450AW%51>TDZ$FZ=%3QU(_PFKU&JEB.=.C-FX]U&DJ<$'E1I#R/JI:$5?#V
M:KFGK3P_:3Z]%.JZ?Z*_XU_X#HL+^S\M0_YS_BOY59?D"K^-VB>Q)COZ4UL&
M)_1H_P!&N(Y7](?](U9]6:KTNBEO3>U/=HHO3%!=^FVWY?#11>L=R['(^78K
MDV)34$HV38_;T3NZ(J#^*07XC;G5-MVG7!-/<HZP/56PX_5/3.X=,Y8!QMPP
MI\=K]TT;(#["01Z169Z=WO(Z;Z@P>HL4D9&#F0SK;OBD5R/: 1[:\-&GI,*'
MA5G,16[#';J;B5RBHJ$TX1DP8.=?NHW85ZCU]I:^ ,D.3MN-#%E C/VO.?&E
M!YC2[1,#_9"OM\DV/N&3+)BD'"W+"3(C/80R"12/8:V+QI=%A?)=BXTO:%5D
M55ED04)4184MUJ7, >B(HFVY(!=NFR[:WGR_Z@?HKS)QM\C-EQ<W'RQ^@K@2
MCVQZP?0:T[K?8UZM\O\ (V>7BV1B3XI]#,A\(_V,FDCU5[3-.-DK3S9"XR?E
MNMDG47&303 D\443;5%^A=?>*.6-PLT1U0L RD=JGB"/6#>OC!)J75%("LRW
M4CM##@1[#7B;DV"7L:PY6P2CI+>UG8CR#;/54.LK9LY]R&S=+9UXL-16'2/S
M*J2&R)XHNOA7UOT!OV-UUU5T/L6#F9>3A[SD-#'!#+*QC>0RQZ1&K&VAEM7V
M1Z/ZYV7(Z,Z9ZRWG-Q<7'R]I@65YIHXP'5!%)J+LO'6I]M=%X5A7*E33/RYO
M'64R:>046:U\K#9_'8DI^*#,QD\?DR(UE*A;Q0-'&0,P-Q1(-MB3Z9_2Q%UG
M@>6J=.]7[/F[:V'*6@>=/#,T<Y:1E\-K2*T4FJY90&5TL;AK?-SZGL?I?<O,
M5^HND]TQ-Q7+C"SI _B"%X (U;Q!=&65--@K$JR-<6(JU77I^QKGVR=I^?.-
MWGL)Q!RKM<=P?)K&XH<CEY>S;U-_2<A.GB%]6V='&QR52-+4J,SSUFHXZ8M&
MPVFO162#P5@;<ZXALN(82V1(1J(L!W#GQ^ZK[/\ 15Z99U<Y"_U8L!-2!'BP
M;Z;EF?9%>09M3.N[?%+QV;E&6717US@E[D<Z;1.VGSOX4[+?",C;+[S1UK"M
MAN:S#B_TU\-\1\3/\+XGB$3^"[C#*S!LR;LI-A/LL]IZ[!H/'!)E-G*FO3GP
ME8C!&&$9AUF'!CDK,-J.T@@@  +#E1SK)KSA/B3)[S!,CON/L?M+SC.+65^!
MSGFI8%C]?23J^TH*T8D66Q MZW'[BIBSJZ//:ELP+".W*CBW)%'=+25N;#(1
MVUX5\B=U72,SJ^ND^+=A=35"/9/1R_\ "QJF(T4=7$W$Y#S@HO[HM9+$B(!D
M/"_*L=ERZB$7D.=;9U>JI1HJ57"BQJ)]]F,P_*E/,QHL5AZ5*DON"U'C1H[1
M/2)$AUQ1!IAAD",S)4$1157HFF2&R$FP ';R]M*TJZ23P4"Y/<!Q)/H K%\%
MSK#^3,=AY9@.0U>5XY/D2HL.WI9;$Z&_)A/^1(9%V.;@>8!]J]JJA=ABJHF^
MJ&-DX^7")\.1)8"38H0PN.RX_#C5?"S,#<L89>W313XS&P>-E=21:XN+BXN+
MCGQ'?4.)<@83GQY$UAV3T^2'B-X]CF1A46$::M1<L(1%"F_+..HT;@@2AOMW
M=A>T534F-GXF1K3&D21HVL^D@Z3W&U['GP]!IN)N6WYS2)@S0S/"VF01LKZ&
MX^ZUB=+<#P/$6(MPK+20=^GZ?;NNKA#<^ZLH&[*;OIA1C:W=2V[JL.3Y5CF%
MT<[)<LN8-!0UP@LRSL'5;8;)TT;88;$1-Z3*DNJ@M,M";KI=!%5U;VO:-TWS
M<(]IV>"3)W&0^ZB"Y-N))[ JCBS,0H'$D5@^I.I>G^CMEGZCZIS(,#8\8 R3
M3-I1;FRJ.99V/!$0,[G@JDUC@<B5UYBL#)^.(G^LU+AFNDU-?CUM3UAE"M?F
M$BVUQ(OY< J&G;6*?FN.LG(1146V'3W%%W;:-VV+-DV_=\>7'S(I&C976PUI
M;4H;BK$7!.EF'$=XJ7ISJWIOJ[:8-[Z8S(,[;,F!)HWC8$F*2_ANR&TB!]+!
M?$122K"W U<WJ.^LK6V.XR,5Q.QHUJ8^(5-<M7+COS8[(6=I.S2/._'GYPDC
MC<3Y%*YMAL^XD<=03'&7OSY5G-=SQO:KM14%-B]-#Q[&ZV+2TE>!A$K((F,9
MI''7)#QKWD;K[[\ETW7'7"-QUTR,R4B5546 L+TH=1P JXZ=4M'5%W32T]6"
MBU<\\ZYYA_%5SQ-R1E^1U>-0ZW)[C$K.19/^0L[%LTHW(]HU%'M4I\BKR.JI
MIOR[?>^K3)F *@FJ1DZ2"::\J*0QX<;?;^_:N@631YEEX1,!?9:>$'05MT!>
M;%P0=:+[S3HH6Q"O42W1?#3P:D\0'CQI^EIP-^(HT4M&BBC110I]JCLNV_[7
MM]W@FVH60CB.52!@:\ZO6AZ<\QSVZA\J8!$"]DP<<"IRO'?G(L.R&'2E,F0[
MNG6>_&AS1:B2'&I,?S =_=@;:&JF*>5?J \F.H.N=QQ^J^DPDVY1XX@F@9U1
MG5&9HY(V:RDC6RNA()&DJ2017M;Z7?J#Z8\M]IRNBNN&DQ]HERCDP9*(TBQN
MZJDL<RH"X5M"LCJ&L=08 $&N6>&>#<FI;JDY(Y1Q.JH<)2A9N\7<Y'P.ZY!P
M7(OXFJS"/.R1W [:1*P%*JLF>:R_9M()./HJ@* JZQ_D%Y)]1]'[Z_6'5RIC
M928[Q08X=7?];8/)*4)50%&E5!+&Y8VL+WOJB^HOI'K[IF/H+H5GR\!\F.?)
MRGC=(B(KF.*(,%=KN0SN550%"K<DD>EE*];37<=SF)POQ7R#^!US-5B^<\1<
MAT-G)K:J.RZPU7T89A3XVU$CL1WW 2.U:&H(:C[=>N*\,\20VE3;M!_%>WXZ
MA.SX/JZ:VQ_*^);3CNBO;!FUR"OR_BF<.+6EI'/S&K&SO,9BY-B,F0R[]X7W
M9B;>.Z:!:E5X5!#*0#WC]SA6R,;A\1Y?/I<IP]OC_)K3&*]JKQ^\QQ^DN+''
MJMAIYAFN@R*YV1)JHK+#[@(U]SM$E3;JN@D=U6%:%K,MB0.'HJN3B_C<*JXH
M$P/$QI;^P:M+ZG2CA#7W%I'<\UFPLHGE(U+F,N?>%PT4D7KIX4$<>=.T)ITA
M1I/9:K@.#X8-M17PXK0#=XQ :JL;MAK(J6%#6,-.L,5]3*1OS8,-IE\P%MM4
M%!-43QT[0*72MPUAJ X>BK>/&'&X55S1!@>)C29%/9M+^I2D@I7W5G'<5UBP
MLXJ->5,F,NKW"X:*2%U31H7E3?#2Q&D6/HJX#@V&!:T-Z.*4 W6+0&:O&K9*
MR,EA05K#;K+$"HE('FP8C++YB(-J@H)JB>.C0.RI(U42!K#4. ]%6T>,>. J
M[FC#!,3&FR.>U:9!5#204@7=DPZK[$^TBHUY4R6R\JF)FBDA+OI=(JTL$&G3
MI6QXD=]7 <'PP+2@O!Q6@&YQ6"S68S:I614GX_6QVW&8\"HE(WYL&(PT\8B#
M:H*"2I[=&D4_P8@0UA<<O15 /&7'(5EU2!@F*!3Y)-9LLAJQI(20+NQCNJ^Q
M.M(WE>5-E,ODIB9HI"2[IHT+2>!" 0%%CS]-5'\#X8%I070XI0#;XI":K,8M
M$K(J3L?KHX.M1X-/)[/-@166WC$0;5!1"5/;I-"TO@Q@@V%QR]%4 \9\=!6W
M=,&"XJ-1DLUFRR*L&D@I!O+".\4AB;:QD:\N;*9?-3$S150EWT:%IIAB TA1
M8\^'.JX<&PL;+'[D<4Q\;;$X3-;B]DE7&2;CM?'!QMB%32/+1R!%9!TD$&U1
M$0E]^@ 7Y'A4@2,L#I%QRX<O55&/&?'0UMY3C@N*C4Y/,:L<CK1I820KV>P^
MLIB;:QT:\N;)9D$IB9HJH2[IUT!0. IP@ATE=(TGB1;F:K1P3"@L<>MQQ/'Q
MM<2ALUV+625<5)N.U\<3!B%32$;\ROC,BZ2"#:BB(2^_2V%+X4=PUAJ7D>[U
M51#QGQT%=?5 X/BPU643&K')*Y*6$D*^GL/E*8F6T?RO+G2&I)JX)N(JH:JO
MCI-(-)X,-B-*V//AS]=5/\"X8-CC=HWB>/I:XG$:K<4GC51?G<>@L(01X5*^
MC?F5\9H7200;441"7;QTND&I(HH[AM(U+R-N7JK2DWC+TSY_*PZ^>J,(OZ\^
M3[^)C,*L-E<9R+FO&I&2U5TLZ'6"W'R3/,0D8[<QO*E&X,%Z/+16_-151ON'
MC?A>FMBXLA5F4$!K@=A;O-N9''U5FO)'IXXSY@R6JR7DO%!S%FIXRY6XE=Q:
M^B1IV)VV&<ROX3+S5FXJY,%V0=B8<=0QARF'V'(K9/J.YD)MHT2/Q;C4[QK(
M;N+\_OM7*[_\LKAV9D43*[G/N?\ )LJB4LBH:R+*\AP;*<DFM2N(X?!DH[W(
M+_C&QO,GKI&%0V/-IK%^5CSMD<J4Y7F[83?/9\O&3JN;^NHSC1DZB6U>OT6K
M9%!Z$_3Y2\=8SQY'PYRPKL7R;'\B<R63 Q\,GNV,<Y(?Y9CX-;V%5CM?60.+
M"R-UQIO&*R)7T]?4H,."Q%9:;[7>#'IM^'?3O CTZ;</W[V]7HK4(_R^/1CQ
M-7X99<HC(RK","H^T,>]0>24.481E=M@>*<LW+G(><0+^FB+F.<XKA>?99/.
M89J,6"X_)5D1C]X1F&)+$\AW_AQH$$26U\AV'\?I/$UO7T^^C7@K@&0>1X!C
MKU_8SJ#!*;$LGS.%C^4WF&8+@./6E'@.,<>Y.6.Q;NCQ:BPVS2#';;D&I0(S
M*$9*)D;?#0$$=U6\;'C3]8OQ<@;]G#\/_;767RLG;_>[^VW=OY3G[/O_ &?#
M3N!JW42B0*G<)#W")IW(J;@:;@2;IU$D\%\%U$ZEN H-":@92IL:FB%E]M+I
MAXBU24GAJ/PSZ*>O$VJ=!3Q1-OKTQE*FU.JX_P"BO^-?^ Z/W/RU#_G7^*_E
MUE>0=RWEHJ*O2<]]W=-NA?TZV#$_HR?HBN&9DA&2X_C&K3N7][]J:LU6\4]U
M-\SX:*/%/=1YGP^W11XI[J/,^'VZ*/%/=3Q/;K^RJ+TZ[+TV5%TG;<4GBD\"
M.%>5W)GIZY%N^2N7Z'$\3GO4F07L;,,:O7A;A8\W/MDAW<EA;.03;(%%N%D-
MNH'<;:+^RN^ODYYM?3GYD[YYR=3X'2&SY,_3VZ3IEPY1"QXJR9"*\JF9RJ Q
MS:]2KJ8#\TW KZ<^5_G[Y?[-Y2].YW56ZX\._;;"V+-C@M)DLD#,D;"% 6(D
MBT:2;*?X0K<V)>C@CM*_(L[RWY>='IVJJ338J"/L2P%QQQ2E6ME& A5OS5$?
M*8ZHJ[KT375.C/H>FDE@W+S%W@)DQ1:#!M_O!P?B#SSQCT6T1=INW*N:=7_6
M5''%/M_0&U%L:676)LZZE2/A*00.;]M]<O=PYUVS7PF:RO@5L<GCCUT*) CG
M)<5Z03$-AN.TK[RHBNO*#:=Q;)W+UU[_ -KV^':-JQMJQB[8V)!'"A=M3E(D
M"*7;AJ;2HU-;B>->']QW.?<]QR-SR%C&1DSR2N$72H:1R[!5_-6[&R\;#A5:
MB]BEV?=4E^\H_=4]NB=ZCLI+LGMWUD%!2^G@3SMPOZ^_VU PU6U<;<K\;>JD
M\='KHX=E8]?XS69&#'SB/QYL/S/P^V@N#'LH"N[>:#+Q ZT]%?44\R.\#L=S
M9%(-T148\:R#2PX5)'*\3:D-C6OY.(9="54CK2Y PG[#B2'<?L%3_=8KS-A6
MN.;>*@^T*_WHZHOA'\QN'IK(IN M[Z_95&E%F9KVCB[3*_\ C)>25 ,)\56'
M\_(5$^#2KIGR4O>*D.X0VX!C5X@X#+F*A9/:,_*+T<I*!93#4D?_ !5A=OHS
M8/L%X$W':B(:="(A546S'B(O%N)^ZJLN=(_!!9?OK9K#4:*PS%BLLQ8L9IMB
M-&CM"Q'CL-"@-LL,MB+;338IL@BB(B:M@6%ARIE*6WBB[[[[_EMHI*;HHKGG
MU6-R9_ V:XQ%R:!AJ\A2\-XMF9/8E-!JHI^3\WQW!+]R,Y7QI3[5I,H[Z1%A
MFHBT$I]LG#;!%-,%U*2=EFA\58!-HB,AO91+(L1/ $@D,0IY!B"2!<UK?6!9
MNF\G'69<;Y@1X_BMJL@R)4@8C2"0Q60JA(TAR"Q"@D:S].>2\?<:VOJOQRIR
M#'*_$./.:<ASBJ@L./1V,<Q*3AN'P[9EULH;+2Q*C.<>LH.\;Y@?,!$15)P$
M+:L'RNZQZ=7'&3@.N%O>4LFWJA5C()(H0$*@DQ,2-:I)I/AL'Y7MSCHOS+\N
M,;/ZOP-OW3#&#T[N#S9:^^@Q(D@BCF)+(JR)'/!+$7A,@\0:+ZR =*^C"MJL
M.N^$I--E%',L.9/3AF"<H8_%2W<GR^2.)^3UO)&6@9U;,4"KG^6K&FFN2RC.
MO=L3R1=%%4=-;HC?/+SJ>/IWJ14Q]^?"<Y$*L'#,L@F29)$O&Z6R'77J&K4H
M%R"!#Y0;UT]U!@;1U/TQG0Y.%NVV9*S!4E5GGQ<QG:0JZ(R-"^3+#()0C'7'
MH#"O3E5!?%?=[%]GU:V4BXM7?0;&]1;)[NGVZ6G:FKBCU18'-YHY/X$X<KLP
MFXW\]"Y+S[( AU86B1<=QIO$J1+KM<F1F6;=ZPR/\/KB=%UL')+IJGW%0NA>
M6WFAMOEMN69#+MIW#>MQQ3X#>((TA6!@SB7@7,4KO$"([,Q0 D#B/+_U%^46
MX>=VY],])0[S)M>U09&7E92)#XK21JD,8D2[JBS)K:*$R*ZJ9V;3[MCJOT6<
M=VE9RMRKG-%"1OBAF'?8+A&4,3?GJGD&+ S8FJV?1V"EW7=7CU;1$P4Q$\KY
MEP@;5?O[=$\UO,3ICK7R[V.+;,V'-WB:49,_ABWR[K$T4ZMPLK29!:RJ3=4U
M$D:2>2?2MY2]4=%^<?5O4$N))B=!1PR;=@2E]:9T298;'>%KDRQXV/"$:4@
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MS%%8N?BU3VI>XQ;0Y5'EV/&?[(7N,VC4:VKQ)>@/*V49[Q:=<'8M.#7Y4])
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M72U8IVDM11NNBPJTOPCU4N^HW34.%J6U3-]4^O\ 5J(Q,.ZDJY?Z(_XW_P"
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MB;IMBY+XUFFRLB:8E<)0S(JI'"&R7DU:HI(DN" :]^&2C-HD"/$;C,Q4!F-
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MT_??PTREI=%6E^$>JI!+V+T]WY?7I+BEJ45WWV]Z?ITUOW:0U<?]$_\ &O\
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MUPP:9: G'773%IIIMM.XW'7#(0;: 4W(B5$1.JZF9E12[$!%!))-@ .9)/
M#F3P';3HXC):-0S.2  +DDG@  +DDG@ .)/*N6<\]8_"&$/R($>ZFYK:1U47
M(F'10G0P=%5$FG+R2[%J5(5'KY3CVVN%]5_4;Y7]+R-BQY4FY9R&Q3#42J".
MPS,R0W';I=K5Z5Z*^E'SCZR@3-DPHMHVQP"),]S"Y4\BN.JO/;NU(E^^N6^0
M/7319KC628:YQ)+D462U%A2S2L,Q^3FML36#:;F1#K*DSAV$)Y0?8<!SN:>;
M$A)%1%UR+-^L'%U%=OV"5H^^7*53;U)"P'_:KN.#]!F<\0&[]3PK(1Q$&$[
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M%+LS1R-[EG9'(&DGB2'S9R-$=G'7W=?"*24D9[$+&,:A-%/DNR#L)\J%'IV
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M:-@FK]A7&6BB*W$F+%RJQ95]I >5B6;:EV[(F=/4^^NTC/.294TM=4(M:47
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MWDC/.S3)]Q83BDR*J@)V@G378?+O#GEQ\GJ?*#I+N+AD0L'"Q(+(4?XBK#@
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M(<E$\THC8M;]NN8__?O]1G@!!G;9\UXY<R?(0<4*A1"4MIT!@7U "0DD%BH
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M;[@.+$#C6F['E3()1$E5 KZAC?[AS$*TGJ/O-!<C062_P4%Y$_OEU\R^N_\
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M^?K?_P M>_3K+XG#$C/\05YNS_Z=-^F:LY+V[+UZZE4ZS9N55.=0JJJNZZD
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M!''J]OM4P0OO]Z*"JB+J>'8MQF-A#.?5$W[E0MNL:\PH/I=1^6G(]/<(04"
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M ;)F$ABF6,,J0X_R_P +M,6!&O[WLVTXO3\69CJB9C"*YUDEBR,9!QD<-I8
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M_)%?2'4A:SL0MV;>+#&^KDMZ&23S2(#]?>5:J_#E->9%E !^4X2MN(+%=7^
M@^JI3<<^%;%]^I5I#Q%.[NFVWC[OT^&D(-_11^<#^',5%HJQ2%T%?HW^W32"
MRV%+I+<A4*:E[/95@7"6/.U/3P3ZM14U;D6%(NBID! XT:*?2)U3=/#2\J*I
MIL2-/AR8,UAN3$ELG'DQW4W;>8=%0< D394W%>BILJ+U1=TUC]UVO;M[VS(V
M;=X(LG:<N%X9H9!J26*12KHX[0RD@]O:"" :5\;'S<63$RT63&E4HZL+JRL+
M%2.XC][C7.]]Q;=UCKCU"*7]=LOEL&ZRS=QFM]T8/SU:C68!OT,3!PD\05=R
M7Y$><W_3WZOVC/FW?R7FCW3I]F+K@3RK%F07X^''+(5AR47DA9XYK6#!S[Q\
MN=7>1&[8D[Y72#C)P2;B!V"RIZ%9K)(!V$E7[P3QK7TF#,@JK<ZHM(*H2$H2
MJB:R*&*H0DA%&\HE%1145%7JB;+KQ1OODQYP=-3F#?>F-_QY5N+G"R'7V/&C
MH0>\,0:X[F](=7;=(4S=NSHW%_[C(1]JAA]AIC,61+<08M98S'24!VC5,Z0:
MJ!$0(JMQ2V[#)53=4V5575?9_*/S8WZ88NR]-;_D2DV 7!R0./>S1JHOVDD#
MOJ/#Z5ZJSG$6'M^=(W'@().WGQ*@>OC6<4O'.26S@%8-+CU?NBN.RE:>M3#V
MC%KVR=;CF2>!R"'M\?++PUZ]\I/^GYYF=3YL6X>:#IT]TV&#/"'2;<)5X$HB
M(7BQ]0X:Y7++S$3&NL=*>0W4>YSI-U,1@;=<$I=7G8=H"@E8[][DD?P#6_ZN
ML@TM?%JZUGR(4-M0:!24S(B(G'7GG2W-Z0^Z1&X9=2,E77V%Z2Z3V#H;IO#Z
M1Z6QTQ.GL" 10Q+<Z5'$LS'B\CL2\CL2SNQ8\37KG:]LV_9=MAVG:XQ%@0(%
M11V =I/,L3<LQXDDDU7$O:FZ>/A\/T[ZV)@2+"KU:ZS+ &\B>_%:M]JONT:;
M:>\\36!:-,ILR$SRD)YB2R'W ? 37LV$Q)$'M\?_ %,?25T_Y\Z.I-JR$VKS
M'@A$:Y!4M!E1I_-Q9:+[]T^&.=+NBG2RN@4+RCS&\J=OZ[MN&)(,7J%$T^(0
M2DJCX5E ]ZZ\E=;D#@0P MI6QQ_)*<E;L:.R:1>Y4>AM%9Q'4#;N,'Z_S_N#
MNG[8@J(J;HFOD_UO]*'G]T%D/'N?3N9EX:WM/@VS(64?G#P;RJ+<?UD2$=HK
MRWO'E5Y@;([)+M\\T /QX_ZY#W'W+L/4R@^BK.#KA&0--S2<1.XFVX<TG$3I
MN1 +"FGBG54UQS^I?60D\$[1N@EOR^4R+W]7AWK5EZ?ZF5_#7!W 2$\O FO?
M_L5D57B>6WKL!BNQ^T(+)Q6X<NQ:.IK344(C))=BC*&((B[^4#A+X(*JJ)K?
MNF_(+S6ZEE01;5-AXC&QER[8Z*.^S_K6MW)&QK<MB\H/,?J%PD.W3P8_]\R?
MU* =]G]\^I4)K;.)8,N,L65Y8R*^5>0WRJB%9"HQ!1U 5YNL:$7'7O-0P[WW
M$ W 1106TW0OI?\ 3EY9='>04<F]I%)O'7V7C^'+F,OAQXZ-Q;'PXSJ(1F"^
M+,Y$DH 4+&@TGUIY:^3N%T"AS<AQD[]*FEYK$)&A-RD(/$ V]YV]Y@ +*O [
M*-MEB0;<BWBMP4A(^S91XY.LN3S12&M^^3K7FHV*EMW"9#[MEW])S^:?4DR
M8>"HFU<3I8W'8+'EZ[^P5UOY;&['K",NP5O*FHK[3D^NRFGB2';COKS<9B5:
MH#XL3(J>4^\PV\XI H&3@(1*.^ZB7G3SU\JI_J PH9][A^4ZBQ%88N2B7,:,
M=1@E7@98"WO:2=2,2R$:F#<\\Q?*_I[S!P$667Y;>H%(AG U6!XF.1>&N,GC
MS#(>*\R#I6PP_+ZD(3TO'[%Z+8BXM=.J&RMXDP&G4;502$AS(Y*9)L#[+1KN
MG37SIZL^EGSOZ3D=CLF1N. .4V$/'4CO,:VF7U-'[37CCJ'R=\P.G9F4XC9>
M*.4N*?%4KSOI%I%[[%!QK&2-62,7&I;)M&@."[#EM.-.*2B@.";(FVXI(J(B
MHB[IMKE$G0'7L4W@2['O*S?P3A9-_L\*M$/3W4,<FAL#-64'EX$H-_\ L5>Z
MVAR2W=2/6TEHZ2Q79GF2FEJ80PF6%E.27)MJ4**D<8^Y[H1*0]41==&Z1^FG
MSTZTG6/:>F]PAQV/\]EI\G"H[R^08R0/XJL>X5M&S^6?F!O3B/#V[*2)N&N8
M>"@![S)IX>H'U5MK#>/8D'\"MKNRJ9DZ^=DUL:,"D^QBSZ20ANS6VE5MRWL3
M:=5 ?1&FHZ*JAN7WT^@'DE]'K^6F4G4W4&5%F=:*I"&,'P,74+,82UF>4BZ^
M,572"0BBY:O5/E9Y08'0N2N_;Q*F7U(H(CTW\&"XL2EP"\A!*^(0-()TJ+WK
M:ASEC_-VB.TGS&.NMTB0Q:18M@$AQYAR6+_=LDMM(9[@GWD#OV+8D)?3@Z"S
MY1>6?C?O^\]YXFN[_/-:P)L?33U;8;<"B2QK1B1H898$UV(BF4Y8[ED%?-:0
MT.%&V;[>XN@AVBJ;]5DC\O<QFU-/<Z;<3V=WJ[*7Y^QN+WH^<"2U%ENOUS3F
M6OO5<MI8?>58S"<!MN1#:%1*4B 1&2_=1#V7J@JFJTOE_F C3/R-QQY'T>GA
M0V=PXD\*:Y(",DZ6#M&\6%N+6M1AV\N\CR93D-V2;RD32.M.QB-&AZMD)*B^
M"Z=_4G=3<>,>//CS]??58;A87OSYT]*YIY]NB:.E1RPC#DC<YI58>(76%GE3
M"TBK(9%]MD@0E/L4-MTZ;*AZ+ZF3W\7-9&Y#WN('=SIPW/$4AG0F0"U_W_52
M!\N346V;K:\8F0&M-!@,2U9"KEM]HK-D]G:VR$AN0"J;8=PB@[K][?5*3IOS
M"Q@%BSG\(DFVKM[ZD3<=N(TM&P4&XYUJS.&&86<<),SX<LUI>0LG@WTAB2X;
MT]YWBO.Q9?C-M.MN*PZ0JHF(BJ#T5?'6;QXO,/;\#,S)LQY9O!4KQN=7B)<C
MTZ-0X=AILF9B33Q+'J74Y[^'N-^%ZV>4>4 2(C3%PML\C=G3PT;"4*T)M[M2
M)1!NCJJVAFYN:FBHB;=-EK8O6/F%CE/%!=5[&4$'](\S]O95]9801^L!4#CZ
M?;^6IT*(;G>S9=E6Y%(X5A,BD)3+ /O.5[:(C8ND"$FZ /?T5$7?KJY%YF=7
MP IE8:M9OBTGEW<"!8]G:.^G"9 .+ \?NIK!O&E6JE$)RW=)EN*+Q#)A.@#A
MF4L3%40!$/O)L)"JHG7?68@\U"79LK"=4MP )O?TDCD?M'IIWCQ\UXC\O=3_
M )AP&9SSS!(U6R$C2WF#&0RA].YQI17S39%"1=U%%5/!%5%VS&'YG=.9++'D
M>)#(1[VH753?OX$W]5-^87@"K GGPX#V_N5([(;8,6Y"/1G2 7$:D,/MN>42
M;H^HJ"JD?M7<G/V!3]I4UL4'5?3N4AECRHPMP/>]T\?1W>GEWU,DJ%-5_=O;
MCPJJ;=:/[H. 1=HEL)"JJ)"BH2(B[J)(NZ+X+OK/)+#*VF)T9K7L"#P[#PI1
MQ:XXBI/R]NI-)J2E%=EZKLG7W_T:;2U>/]#_ /&W_ =';[*@_P Z_P 5_*K,
M<C+>]MT3I_ESZ+\>NVLQA_T6/] 5YUW![9\PM^>:LFVK%ZIZ_11MHO1K]%-5
M=OR\=+3P;B]0J2K]'NT4M)HHHT44:*<JZJ-%6%&E;4:*6C1135+;Z?=HHI$-
M579-_P Z?J324\&_"I <["1=T[A7?;N1%^Q45.FD/$4X<#7G7PG_ "\<7X6@
M\:44+DYJ[QOB?,^,,XQF-7<#\(<=Y9;VG$UG+L,:;Y Y#P?'Z_*,^&0W/>;E
MNSR5YUTUDH0OJI+0& O$,QL1;\G+E]U7OGY+@V (/X<>?W\K#L%8Q+_EA<9R
M\-A<9N<O<JM<8):,9;?8=&K\"!Z_Y*@\,Y!P55YZF3/XY)N*=^MPNWBO)6,=
MU:]95;+K@$R])CNRG%0C3<Z?9W6Y^JD3*;7<*-7?QY7O^.JJ\] MMD_,&0YG
MDO-V1W6,<L81D\'U%OICV&U.3\OY-<Y]PO<0:2% A8Z=3QQA,/!^%Z^L5^I?
M2S4B>,B<>>&3'B^2]Y1?]6+^OD /0>5O4>_C5GYMK,2!J/[M_P ?&L=9_E:\
M:M3:-V7S'R9=0L:QJZQJEK<DQKC'*HT2)D/!TW@FU@?+Y3B]W4'B+E),.U&B
M^22"=N_)<D+(;? (\GR:=K-R[;=UJ:,D]PYW^^];3XV]!>"\;RZ6P8Y)Y&R"
M939IPGF[(W#M:[7L2>"N5^7N7,3QBDBRALIM#@B6_,<V Q6#+D?AM;"C!&=0
M_,,D^3704))N+?9?]VGG+)-PH!X\O9Q^ZK#Q7_+SQ/A27!LN,^;.5,;MCHJO
M"LHM JN/I\O*>.ZVCX8J3Q-$M,;G1<=ES)/","2MK$:66VEE.:$=EBG%5<-5
M(8$W!_);\/\ V4IS";@@<?W;UL3F'T98#S#<9WDMME&24N19?RQQ!S153(<6
MLFUN(YKPWQ?;\0T@QZE](QWU)=X;D,\)L>3)!X7Y".1WFB;#3I,-)F+L3?\
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M6CAOQU(5)2<4-@ NT1=V/=$75.3I?JG=)!)FYT[R:;7+<;=U^ZDCR\>)B8D
M8?;6O).0W9<PW3:7#["5W%<=IVNKA>*JDR'^04KPEHV:$3=B4./W"\HDK;*=
MOBNVLIC>7K1[=X&5*6F\?5J)-].BVF]^7;;OIK;G,<H"YT>'RN;7OS_)6TVX
M ?BSU4%=/?@)BIS:J'831\Z#,&L9FJY5*KG[Y_S")$/8D50-1[=NW5O%Z*V'
M;V,V:D<BD6%R>!YWYTS(W+) 'AEM9/$@=GIX52PG=V,'M%2KC+&D26K*2 N2
M'T;;G1U'\084.]T?EW735\T[R[M^A;ZL>)TOA,(UAA"WM?CP]/.D&9ER1,I9
MC<5)Y$HJ^_IVGVT=FW\:PK8L>)YL*Q2,\X,MZO<=[FC)%1"=+=/\F+M'==].
MGZBV' _H\JCU6JO##.QNP)JJ(VCLI=TZ[<.PW*=F@*2;K82ZZU<@1H7DOCW-
MI+;COLIWN[[$KY[;(.L5_P Q,&-SH4-;MX<?35LX,S<=)O[:@:A!"_!XSS+2
M3L/!RSFQI%DXL>PA.RF9C2-.*1$4TRB[=ZILAB*HFRZHY_F3 SH?EQ*0#Q[N
M/HMSJ:+;LE^(!%:OR,Q7DCBNF8N68-1E4/E*\EM?-NFTR]6UF,E5_B['FMM6
M<F!\X?EJZ@HVZI**=Q*JN3S(EEVS(F3'*M&T0 NWYY?T]FG[Z'VW,.3'$Q8J
MP?AQXV"]WKK996-<X[+ME2M21,8+&YE<C3Z@_$;;9A/7+9"A'UCQ@,&T_=H@
MIUZKOACYC9)/& D^LU9.PS'B5XWH^=@QBC-Q[%EU<8$9=#,;@HI6[SSPRW8$
MHA;(%9!YK9$;0%^^O7KJN>O=S/\ <C;VU8&PR_P3402:UYDH+CZMPKE1L[1&
M:\T*ELFU<<:C172 E9$BD$&[@D78B)OJ-NN]VO[L;6I?V%)>^DU,[<@9N6!D
MXEI,8_!I\?\ #")LZ%YIF*MBZVJ=[TAV. DA=RBA[_=Z+I/Z^[NG'0U!V"8]
MAH2SC1D;5F4;O\-/N2\<-V$O?:O..E(>B/JC:>='&1]S[B-JGF$NZZ9_7[=&
M/&,GC1^P9#^;QJ/SZPV7JWYP6X5T0VUE+2N[$J[1A'MHD3H+++;I23Z.;FO7
MJJDFI_Z^[F381M3?ZO./S?QTXK"$[(2V=6O*5;1RQR=&)AR*<>)V#$;NG%1/
M. U!D7$%$0! D'P5=Y%\Q,B.WB8]Y1S/'C3#LF0ON@</52"=7&;CJI4SXX=)
M=D(ZG:V=VU,DA-D-1XVRL-$VH(V)"I%T%"3MVVF'F3.Y&O'N%]?;43[/E@ <
M1?T5JK/ZQEW,^&:J,L59]UG^4WC<J/-=[(T2-Q5GQA!DR3+Y@WVW7TVV[1+R
M]^FZHF?V[S"2?'R"\ 01QJ2?7*B?RJHY.V9,3Q7N068<OXC'\E;B3REGQ+>*
M-E$B2:1RCQT&9+<AR);C"9A(PW',B 8KAMN]KAET[E5=UVU;BZZV^3XE4TGR
M,_\ !-4[$=XF<4KGI4EENIMSD7:O1VI T\PI#",/K,,&V@'Y)E%)6Q+N4B5?
MO:O/U;L<R 2RK;NX</1[*9+CSJ+ &]44YZ0==F4Z4%>4FYNH+;K/E2(AH R?
MFG+&"[O\RL<S#]VZB(.^RKT1=/@RNE-PB8LT>J]NRJJ#,5KKJL*N9PX[-Z_&
M?KVGH5'BS3]RS6S/)CV<MJ #S5L$9M$WDA(FMB/FDO5M5-5\-5FZ1Z7SGNWA
MR*1\)^X\"#PJ\V;F+%8,;W]%6^*]*8#&I!RK<KJ[==@/$]&&47X(CK#+$B*R
MTW\LTZCTEPS[CV7L(M8W(\N(9&OMT@B7N![.[G2IFR%2LO$?E_<I1=BC%GC'
M<K)U7B<]N,"-$34J^8EOFV2=^W:B^#BHFZFB)TV1-4I>A]WPKG"RI$)%O=;L
M/,>JGPYD41NR\3^*JHF93+TR#'B2BL)(-W-*Q!<"96MTSH?,$;RBH*("'>I-
MHJFJF*#X(.H<?+\P-CE6-,B6;#C(LK6*D<R#PO;GVU>3.C=AX=@OX=M(T_YS
MRA$GQ9,-8/SC=A-_R1EQT-_.BL&  S(;'HO>)*H"OWD55VUGL?S+W/$NFZ8H
M8D\"+KZQ:W'T&K0>?0& 5F)]7"KW\Z7\*?BGRSOD?-_/=O>UW_*?(?X[;N\/
M;V_M;>SV:W3^O.T_L/\ K!HE^4\7P=-AJUVO_P!GLO\ =2:C\U>Q_F_Y59SD
M9*E_<]?_ ./?]W]]KI6)_18_T!7G/<?]83?X0U9N\O@OT]-6:IT=Y>_[$_5H
MHIA*JKUTM3+\-)HIU&BBFD6WTKOMHHJ/O+W_ &)HI0Q7E1WE^2:*=XC4=Y?D
MFBCQ&H[R]_V)HIZ,S'CRIJJJ^.BI:3?MZ^[113!7N+\_L1%]OM3KI*>#>I=D
M^/YU_7HI:%%%3;24H)!N.=4Y+LG5/'=-OU]=%3QL6YU!I:?1HHI%5?9H%31J
MK"[5 X6_3VIM^A=.JPH %ARJ/12T:**</AJ%OB--/.FD2;*G7?I_1I]A5H<J
MC7P72TAY4:C/.G4FD(OPHY5$XB;BOMV_7IZ<JEC=A<5&FG'E5H&Z^FU/V143
M?4-(.5+HIP)'*H7/9]?]&EJ8<0#4>BEH_5]O3^C?12AB!8<JA.2RT2@3@]Z(
M*HR"^9(+OW[$!@-W3(U%=D1.NVL?G[MMFVHSY\\46E;D,P#6_1YG[*N1QS.H
MT*2I[;?EY526!RTA7+K3 I^%PWG);<LRBO(A0W701EH@(W"1-E7HB;+LB[^'
M.]W\U]EPITQ]K1LQFYV)2QY "XXGOY"W;63Q]O+W,[Z/9?TUK_A86&N(^+'W
M'95G51N*,*DSUJVC ZV<]0UC<9N6X!]Z-&:KX]-D5514V36E[WUEUOFY$N#M
MRC&BBG<*Z ZF525%SPX<+^DU8Q,;$AQXY'(=B@X>L5M&-&=8EXW"DNPJZ6XR
M]9UEPO9-*;+="04:+8,B/<A;CLZ2?>1 ^[MTWPT/2_4&Z,<C=\F0M-[S$@\3
MP/$$]GV5/\YBQDF.,!AZ?Q5;/G2*JA7/;,D/R,DD,7T9T1:I)IL,#)8[@4@.
M(P*,BVBDJ^;OYB]R**KL.)T)T_BKXF21D37N"?=T^BW&]^=[TU]RED.E185=
M)L56'\SHQ&%#C$Y$M*R,^!3/-4)??&^0EDGE&_)AOH++0DOW5[5VVW7)F?8=
MKC(G$:8HY\CQ[/OJ"^63K1R3W6_+50:*$Z';2'+.:W48R,#(&B<&OL83AQ'8
MZN@Z7E-RY),*1-DO04)4Z[CVXN?KW9<(_P"1Z64>RG#"RI^+$\^ZK<P,& U4
M5S\FO@JP;]["MHR$^]':/Y+RZ^4UVF"D\[$;)7#W$D#8$';?6J9'F#GR_P U
MCZ3^G?\ DBLO'LDKFUNSNK5[=DDKG26\L%]PK7AV$Y?5S3+<>(^PO)-A);^4
M\U41MIUQM'>A=ZD2HBHG34,_4>]Y>S_,(2K'+*\^P1 _C-+'L3G</ 87(A#?
M]XBMG%\R^Q*8&.C*D0!5RY,I7I=+" 47Y1ML=E2,+B*J!W;HAJFZ[ZUU\O?<
MPZ9IV51QY']VMACZ40+KD?A^C^_50CMHLB3,%Z!%=?A#7NM18(J!LBB^8Z0F
MK1"\JK^TNZ;)[4U <3*DX23DW]'?[:O1=.P*P%[B_=^_5*C3@!#!+*9VUH]M
M;V$VT4-?#O1QL!)U0!5$>[P'4J;1CBWC$O\ =^[65CV/'3@;<NZHUAQ"!0<\
MQ\#<5YT7WW7 ?=)%4GGFU+L-XBZ[[>/LT/M^,&L@LM7EVW%  TCE3TC0442*
M.R1BJ$BN=[A;IL(HIF2F8"(IL*KMNFI(\:*($(.??2G"@3DHL:UADB1QY@XJ
MV98V/&^7''D%EL4<V8P)OM-$#M(54]9>"-1M&40 #XD'_P"+6)R($&[XJJM@
M8Y?QQUM;S6T5.U$3MZ"J;(8BJ;*(DB(HB@]$1/#6(LW;;[*S@QX[6*\:C5X.
MB(HB@^"(B(J+[5W1$ZKJ O+R!'V5*(4 ^&G))1.GF=/;U_:7V*2^);:>LLBB
MQL3ZJ#"G\&G?-)T3OZ#^RFZ+V_6J;[)[-,FFD*<+<^ZD\%.U:3YGV]Z*O@I*
MJJ6WN155>U-5O$FOS'V4>%'>^FCYGHNQ!UZ>&Z>.^ZIX*NI#D3VY"_J_?H\*
M/^#0LE%+=5#P5%Z"NZ;?X2*FWTZA=I6;5PN?133CQ'\VHB<;)655MDOE]_(_
M=MJK*+XBWN"H**J^[33,\8MP-_13#B0DWT\:U7G;45<UX/'R64[LYRHC[ [%
M4EXJSI>JBJ%MNG5%5=]6\/5+M^?<\#CQ]G_]1%6)S\2/Y_#72-)E?_RI/W*V
M@$."!(0-JUV$ALBRXXT$9P.HN1FQ+RV7$+=55$Z[]=8F-0GIK(';L?D%'V4Y
M61\N0T,V8#,PD.:VCW<DMX=NUY\G!(N_IUVVW30</'8ZB3<\>=4Y-HQWY #V
M54)(G#*^=6:V_).$5:AR(C9 ,?9>PNULFN]Q"ZGO]T_!4T"-<?A"2!ZZKG8H
M+$?D_?J-KYB$Q6L?+1GXM;YK,A&36/(MHK_>I-2CV!L15Q (A55$U#V:MQ9^
M;"]X9&#^NL?D=/1(I=3>_985*EE)8&+*;CS6)U;*-:0=@F0*^L>D><^QV"2
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MT!R'F1J[6[EO@Y%-9&1U\IJ1W-Q2-S[S[C3:LN]X"J^5]U-^Y%6@W1.=DO\
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MGEWU@?V-!^V?D?S/EM?MUVK.\F+?(;E-O"PD?_.37K##2^)%Q_,%>5=Q;_\
M2$P_\0U8_#5N3B*J:[T(J>]/;TW]WL^G3%353E.JF*YLNR)O\=_[NE:/2+WI
M;4>9\/M_JU'24G?\/M_JT4]6L+4*Y[.W[?ZM2".XO>D[;TQ35?#I]?\ <TOA
M^FI UZ3[5]^GJ+"U+2:@I:3=/>GYTT44SS/A]O\ 5HI#Q%J?NF_BGY]*!<VJ
M=9.0M49%[$]_BB^*:5ETU+0+G:FR^_VKMIE.!M0K^W]G[?S*G3VZ2G4(]O\
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M2#O :_#N)XJ3VJS#MK&YVR;?NF7C[AE)?(Q7+1^@D$<>_F"/XRJ>RMD><O\
M>I^==8.LN%%.1\%7953?V_!?;HXTWP.VG>9[1+IX*B)^?1XFCA4,F/<VM3O/
M/X?F32^..XTSY7T4\91BFW3Z=O!%\=)XX[!1\MZ/P^VIOF=O _S(FCQ_12?+
M>BIP?111>Y/;^G4Z3C2+WJ)L<7L:E%]%W^_MX?LI_0FG_,7[Z8<?NJ^^:O\
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M5MC=[#D*Q(;JKB*/82=[@@XB;IV$:+G/IG^L'9_)SJ[)VWK#&RFZ WCW-P2
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M=+X2@^[260U3D2"FZ^_;IUU/\NY[J?X3GE:L9RRZ=IZ&5,B*B3''(\&&9AW
MS(F/"R,@P7[II'!2-!7H1"B+T77(O/3KO+\K?*S=NL\!%?=<>-(\<,+J)YW6
M*-V':L9;Q"#P;2%/ US;S=ZPR_+[R]W'J?"56W&)$CAU"ZB69Q$CL.T(6+VY
M$K8\ZYSMY[='3W5V^CDK\-KK*YF&XZJR9I08CTQXGI#B&1//(RJ=Q;[;^&R;
M:^%>9N&[]5;\VX[SDRY6\YV0#)/*Q=W=V U,2;FU^ %@!P4 6%?(W+S=QW_=
M7S]TGDR-RR9"TDLA+.[,>)8GB?0.0'   6KSNC?S',<NJGCI['^,;1G(<XA8
M0%SCF8Y([2/\>Y/E>,<L9//Q#*BQ7$\_LRLZ6)Q8I,OQ8+\.RBV\.8TZ,8T<
M7KS^1V;C9.<F;N$9PL1I]$L,0<9,4,N)$LT/C2XZZ7.79E=U>-X98V4R"U;:
MO0LBRSK+D#P(2^ED6_B*K1*&74R"Q\3B"05*E2+BU9ID?KEJ8<;U%LX?@]?F
M&1>F]^I=R*C+DJBITR2E)V;09=;44B-47TZ$YAO(=1-HG8UC#AG*=C)( A:=
M:0L7@^4>1+)LC;GEOC8.^*XCD^6D?PY/=DA20%XU(GQWCG#1NX4-H(+*UJV/
MT<7.(^3,T<&6#9A&3I-P4!X@'4C*X*L>=N8-NW:PK*=45[F0U<6IN'8L=VSJ
MX-H=Q%K+'M0GH\*Y6!4NS@BO)LW(2/'(MD+L!>FN5F;]G;E\SL^1*#!+JAF
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MFRE#9N&EO&\15"G(QU_NH=5'B1#WPX+(&#$+X2^I#Z>M]W;>\CS"Z$@;*;)
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M]$,-JT&^*:(J(MQ9+O7NW7YA1 45"V+N1'.N_A[=>)=APOE]S)]W2(FL>^Y
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ML+<8[/S,H8I(*.*C+#?> *B^:*+V;=53E&W[%O75>0-TWJ9I9@ ;L /='98
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MVZQT.EKNI<_]UDB#ZVT614NZG']]SV!=7OZ)%'O6Y8^3]A4=_KK1/7"F=KK
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MI!G*!%*SU9'5X:!8*7'-R#N <%9EBRV;C_'&KBK9H*Z!(_Z&]06OZ1/;V:%
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M)\5%_M'H85EVG?V_5?JD8W$'0]@N16 O<HG2C-I(@'ZH-RY=U%QP"-;<V>O
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M2FW<8ULCP-DFJTNA[&F6&',X4 ^/_M=%]]WWC#&TJ&W8"EOF5SHK;E#.TKG
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M$"984_:>FN/Z#E!-!;GZ#]\\IW3N\<WI/WQ+G[]GAM%+G9-=ZR\F)U5W@#M
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M1SNW6P['&KJRRW@7R>>ZNS14- )%(1-E;B2;9QG2ZR7J%F;N<)7-=88/JQ^
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MI['S@F9\L,88N9%<A?U"FG9RLH=%Y>'8\HD"E+BL"IHE7,FXX]*_L"!U]2)
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MD)0;=HIVR+K4]_N<"H60L2+>ZZB\=,B68,;V&63(@7X+ZZK@#4F=6,S ',9
M^J"G\M@7%T +"#R [JH<&M"@DYJ!.(9GWP&$I7).KU)7SG1D[R5M"T""L1N#
M,5L[M_$L8"RF1VI=_CILZ?+P>O1"[P[P%M)\!U@-H+)=',504%U#-T/:!^L3
MLZH1MR8+WE@ZN.9;^*(+9/WR>D3J>O?6ZBH)<EA^"3F4:M^?XEOX[R@I&W+N
M*35ZA:G]/2?Y!@O#1&F(W0$VY?<3H5#H19LDQDDTXR$$M#%SS0F!KIB<)W+D
MPE:7;G]@XC'P%W165^+#G4.0MWN%4JO& _E2+S#?+OQI)1<L/F]A1KYA3XM$
M@!I8Z2N(TBY]Q@M+"3%(#8KDZ+[,.P#=_I47[QR&$C*C=@<(0T@$8T>ELK%S
M\C.J=(=*3O78Z)8 ^,'V#3O\6#S&CP23[J^O5I5G_ %CHWP'T&E;D&>UXG7@
MO=7^CHF_ UC1CB(*L ,F5Z6@^T1QR0'3+2PB'W>?]4;\ AL\[O\+TK6SL0K?
M.T4='2'4I(8WKFTZ$V_44_?N:[)4#!X\PEK5)=9C"E5XZ=#OCK!3X_ O64['
M?O?C'CX.F>@IA!S89!PKA4%L(#-3$]=>-B$9EY1U&</0\U(QH-3V[B[2"<LZ
MIWJ?^X:]_P[0#"WO!8LPW?9R?,!>Y)C,OKAP7=L[OO"RK4<+"=X!6HMDCDPN
MO,\Q^J97T#/;Q&I,<9]FP"CZW6T]4F7T=BZ>]U8=BFY"U_1<08;_JP+XODTI
M@2=W ,%L++M"&SMV)* \7ZM9:JB(:113^MY7:F:IOE?Z?E(72!W:1L(OW0OR
MUJ4RQ_.E+DJ!4I;_I9Z5%65@<7+N.]838X2B&[[O,<3]I*E90C<A<3-N)!.Q
MW*ITF 5;/&_HN5,=]*H6?^4.(&^B$_T'")_YQ=HE-8F<P'R__PHRMI('Z4"9
M8R_S\K]#JIT>3WP8Q23*WQIG2]&AQ>\ M4='*G+S=X 9P\).S*$2+2=VY%:B
M*5S59"_\Q<W2C#HK%$-CRS2(@2G> 5[EW_N\F_<SX<=] RG^C#ZXEV]2C2G/
M#5A@O66,J\>4?Z*HQORV@<Y@\PM)ZC%.*FJ8>13%E1HZ/><.$*D9]%\=C25'
MGVO3'>@[W9KEJCV^EW ?(\\"W@%FSR+N1Z*5'SY?$X(YOB].Q\?IEAAZU4UW
M[IF-Q9._-8.BF\?N (^SL?P*;5)GG@4Y5_#I7_#C\/@,XGLYZ:,SZ%NW,>QZ
MGLC-TIR.VID\MAV2#L&,7M\OM_N:MTZIW '&I2X\T4MW@)]7D%-.^3L \L7I
M'>#<\^HPXD;I;@;P_QW^#U!+ P04    " !C@GQ8F&;Z)9IF  "O?@  $P
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MK<,+@ML/Q+^,>HF$$I"[O9IU)<Z&\&HA;LPLA^@?#L4OXT_#$[F(#G,VH8R
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MF6LY"*UJ]<ZOHJES>(#@41?NT6"'GTB&P#S1##=,T*$UF 0%WG4C4_$T,L!
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M\X>CDDG,C9;[K1Y=M*.F'S''2:1B05W!N8X(:.V&X&*DI#12GG&3>="^$%C
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MIJ/+,G=5MS_FFP;BB_-/W!0^BVS/&"1^+9A%'8 &2)^V=N2^V*%Q>@"@Y"*
MDJG/.YSMZVW:%WOGF\!ES[QE'=A6YS. +7Y95)4!; 47 C78+UN/"EB7CC,G
M?>K.>)"1?9&I31L9HJ_7MHK.HFJ#.RVC"UM(O>_/?%6QLNY:M+X[>O@%  _H
M2X8_%CTF5"DRAE)TB #3]H*[O[.AT%]GD?_MIK[O;YWH$!E<N%6QEPS[)M+;
M#W_'\\*-:#JTF;C\9?*Y#^]YJ8J=(6_UD6*P!QU2MFD;-\E_]BVVP^3U]/+N
M  ,ZA*%#E$B 8D!WMT&B/[<;Z]6K/%JT?MI)8E9KK(M%H;_"(N,*-XD@C@!V
M%&]#<5S\JA?Q)O9<)C %J6< [)&:1=,JS5UE=,)][#-+5&8Z- >.HFBISL!*
M8"JBW%"*U2-C 3W_E6J8Z^^T!+RJ)/YM)GK=DE@/Y\S,=C9\"SCACI-6?J[@
M'W.E.C.\I>H,PO' U4VH#@ 8UD+ULSL"KN#OFUY!TJ&!X^#R-<@[- '6Q6"K
MV(@"!!7_^QH O[TF6]E+XJ5#-6 -P#/A-[&VN@$<?;7>+YPH/' K<;G5PO5A
M;DSDIBU[OGMOID-AOGTA\( $O ;M'":^KTB:HJX?Z)X@/EJVV=?XJL=E5TNE
MW(V\V)1/\7BO0^J'.T2^9AUY<Z;I^(Z?4/X$[AX;+?/O7.!OW('CM:O^[VUV
M/E?9U-0G8+H4\0Z!A3\JU3H&KTZ JA[Y4#Y!"(3\+3* ^<QM\P26=EV)_G$,
M,KFP&GV'@##_7W"(R-!4ZRS 453*]/ ?&Y&R,X!?+A^ _WI])B(V^6WR_E0K
M_]N<%".K5J&S[X6JK"Y+7AW;+S+BR/2T92$L87;OM1PECWWG#"VVQ5<&%-6*
ML/"IMX4 *J7BMG"]OVA.)N'(O??V73J]84=X#-J3JO,=F2Y]VF/!REV:6\,5
MMGTFQ^5T4>_<K=2KU2>ADD=8GRN"L;[BQF51VZ+C0J/B:P=X[DP9&:AC>(.1
M%#F?4KB_E6=X=:Z1+3;9  N(&-.KAPZ15<?SQ)\<CLM0QCM?P*G;$K]^?AYG
MD.YK>#G2WM+9N9O)TX,B-]QM#T[@)A:1,5@3PW>&L,I=K4S+)%Y?,4?*/W%<
M-'O<D;U?XRR6[$K#GUPOZ%9T]ZTU[-D,T:JR:0-X!E"NPO&3E'?]X=@C;W\N
M_-B#&MGF3&DY6EVNY! @K7?054EQIR,6CZ:);'6CL /<]8;K-:TN;P%0829[
MD(I*(1.9@7;<><7U&S^_>E,=NAB!KB(LI:4]^5PH76W!.&UJ&DWV<NH:,!@M
MY/T!D($O!+9BE9Z,IS39<4!7WV4PMJUM;_\M!O63S YDQ #Q\F:1K@&@K]R0
MCO%/TAMU_A?I'8Q=WWOM.%=L:=MJ==.?''8'=V7R*&#*7+^FR"?OY"U=R\MZ
MFS5O(">C(1[K-)KL)(9GKOHG,^[]6@P#6DFV R6Z3I5]UZCR.ZM_$-MZJ35O
M[['UUU]F)-U/#7S2M3^9Z2\5H&=U+4\#LL=ZP8I9V#5\@?=K*M'_:/_)=1DK
M^"NO&WYR8<D&T,\<OQRD3H<X?B.[S*=3%T5[5PVWR16I1>.,13UW\A<NDIB+
M9%]K(?;U7JKP_VJV:W^ZU:-5S3</(]R#CGB6D72JD >7"!QG JT_WG&)?[!G
M1U4"I''/,K3K05>X@6[U4Y:"V[MB[QHVN,C9?>ZLLSO^WFJU7W18W\Y SYPM
M_-[B[8(+[V*T;@_J'747=#YB$C"'U8)JCJG_T.L17O_:12XB/5_U#P)G&\WV
MQ('6B^%71(T*= T3$3<W5>50,P=-78GV H82/"\*7404.SR]&OM#')G3NX3=
MBPCLJD*JKQMPQ+$NLCE2]$G'LOMH<MCW9E/RMOL/'3+\UM+7;J:-LCJ*7ZHX
M?)8W>_D2+9#4L-JG\!K93M$&)&;%@3J3:,4\$20&P&"@)HU\0 FQB.:&&][=
MH4,!CX6@550X<;CW((CN$1SS^;Y;K6O/L@365?EP<-K&W%N;9N2-LI_II<PT
M$Z<3'];XG%O$<H-CFWLG0U_(A&%M'Y'<]X3QEFXO*(N.@)T FVKUK@YN.\':
M'GBK$IZO-&,8N"GS^Z#"&Z[L[#WIU9FC;'5ZVG'=:H;FYOOF[$DKG$>R#PR?
M%9)F.PIO_Y@MLK=(Y\S:-Y$J1_!)D/8UZUMAXR, W'79DK!-N(W.UA%<33AA
MYS,WR>9,+C?=R<<!JE!I+Q7 B1U35;]Z)J( % (C_BQ=0M/%#%3H_6$D$;IG
MVWWU3&H+5&)+.@"99;/IJV(/0*>S_;9 TE8%J"0_/W.FR9M?%!!,'V[-9=G\
M.?0FZ.CX*(8+Z ,0:FUL<*U%8.$2PM:5!O[4'FQ;2P8HBK5+^*$YT_8/#6LC
MY;8-""^,1&SE5*I"-17Y*V.39HW?%+MT[=DT8'ZZ]-V 0*W(&2X[F:*!F5T\
M1?KF;#:4+1:^;2'*)F8)Z.W8G-PV#QFYG77[QE/]W-78W!T12U+;8I<JN"^V
MRWCRI^Y[\R+/_3U/AJ\KNMC W9')M$'06,37+^_Z>Z).S-!6J6.&,W*\>!_7
M2O1)*)NP?!<9:?=BK/CBI[<375Y2ZK?*RH>S&U:M)AR9/AK*-%9?5Y486T2(
M=6YBZ=[*P:UB8N.!$0.@:P1%$FTFSFP!S%3QHI1LDV'ESHXKF?H'A15OII#1
M-P@;GNJ;N2PF"UPZYOQP,!*O(?U$N7(0K5Z%E"D);M8I8YN9E0J.)6\8[5T6
M 'R:[]OR3:,=MX)?.@TDZC -&@!HW>!4G!%QVS3W^+OF/>SF? !VQV:N?5(S
M:<,#-S!>.L'I:V\/.M])@+2FJH+3VX3QRN#BLA<-)A%7J2C&6X(7?0UD.M1$
MAZ9),./%0%8$>I@.F8*3_@OC Z+_#Z4WO=+&\HJ_V&#C5"B\W5J@NMEI_-/!
M_$;'7EK[#)'*<AG/D&H],#C";#U3MTOCHM_)UP;'KI9+H/RTN3DBKI,0=$C]
M@1ZX6RPHCCF2[]WX1T2QR_='O\'#C'A=9";VR3:B1S0SX.\'X&@Q7"L(<!'\
MPRL#W.[X1! I;:%0QA0DI>KR-(4#.YMNWN@T*Q5:$FV''074;!M-ZV5%/V,&
M.$QE?AIRBL(N[R-Q5]+D=_E@R60L.-<!A(H%()+P^0$="@9"4/,/9>:/J%G=
MYF(4V1?KY@?Y4.3\D%2V=2L$%BG9QIUPC<.AGT8@XM^29R--P( 90-4;GQ\T
MTX+ TA#P[^N I,$R"NG0^^'_ _E;=&CCK\C]U^$L"B5CN9&)#E68$.!&AT/@
MAF=$#3+Z80!M_#]4P"S/"*#-?PE@Z'L_))H1/W":UJU]EB-W%QI>_4M#^;*7
MDE?E#Z=S\7(W%KJ2CQNSJ.FY&PDB.LV1!EFE8]T:3K,YI[0D=GS=SOXM:N"*
M?'"CY_[1$(0I?%U_O'+32XV]@_L7O1,?)G20.: KY:-E59JA=Z&DF*=S!V0V
M6'@Y:YB(;-GQ2N_*M\) -#.&]]VN;(V;CNDFXG6LG;6Y,IV>EI(?9M2;15<:
MV=[S9]W1230^_I':R[7D'8/6;V2U$NBE">CUR#+>51B@B<J0XT0!;<(FCL"Y
M-,8:5MUQE+4ZN><$ISAW# ^OI".S\/Y=)6.^[ZQH=3ZX>\+2&YQMVT5I,E',
MW8W(O6]Z5[.#=N-DWIK"KQOF/M R2W@/0(.YGTSWG5;Y='*J12T,P=IFP+I^
M"!B(TV!E]'0>@7D5:PPRO!Z[.ND(T9J_$(?GFFFK)R%T+LF-3,D%5TXKCO?_
M_^FYY^@,EKW4V2AV@_HX'6X8S* NYK(]I$-.([WS9$#K C/%V!["%QU+<*OG
MGV"-2AV_L*43<[5BR2MY##-)C2<21IM'E\3JV.5"3NTFLQM5;[/8&FE,JX>G
M/I Y0]YWN!4&9)-(@E"),ATJ$1Y00'!:DT,'8],F#)XBO*WID+=JC3F3<\&W
M);O1$87?>[J#K%;\."'O=4V0HVE@]6!L!H' VN%&;2?*8-CJ7=8[F,\3EVPI
M89"T:0 ^&0UD?^XU"X?;K;GJMD9SYOQ?6EGR:\EVXR,*T$\=$$/$\%T(CCN9
M#GV[.2<(L12LSP">P-X,9=NMO=:4,%T+U5<ZNVJ+TT5'I%E>):AB)]??SVV'
MRMNV$F.\3^O*70J/V+X[A!#=_MG$HM$3*2\?";U8Q//?<6,Y]F3?^R.!#P8[
M[Z6@$N-T&[++RB1U"4BL8?:=:]R&%0.RN;(R:H6V3 O=UE&!7YK3"!RN&:W&
MWZZ/!92)&*=%W"Z89C+I4>YZ31EA:KVI\G2F3EN;.C01(J@@&70XQ"N*QW\X
M7X')"CU@5TJ'LJS0)%U'Y@,X19L;T5%TZ(*>PUQ7O9Y7>+5$H".S['[\T>1Y
MX<@O[R-[MYV*T.U'7NR'I K'FW [JXU2<Q'<PY2K#73H%,!U&X9S7\+V)^ V
M%CK4N!=DN(K'Y$'FV(N0SB+A/_Q#8(Y44KP9J22\X?#90MN;K)6"5BHB#\O=
M/PAQA2N\/J5F /X*\Z!F9\!OZ= *XMG=QJ>EAW#\,5_C"<W1_:/[E/1D6U,X
MX@N].G'"LBWFBFF/8M6\VNG0 >3KB4@(8SQ5^A3AJ8! 7Z<J(%J@+TL- #UA
M1/WJQ[8)VIF9-6GVQ4IP9X8VK!KYBT$?5TVNI[^+[+%7O?@RH.-'E"LS2]05
M9$*Z#G+0+K@*(\3Q=J][OE[ZJAYR;^%W"4J,U1RZ]+5'?.J %T9@SY5,WM>Y
M<36G[["^]\?\<2143L)!IN'@"DFBD>TN->^52CQM7WZL3"/O(:]4'X<ND>I2
MR$Z)MGE^TNA&Q:;8SWK"X=L:^DIT2?V2(\Q/SCP!3G)+8EO!/^R["EIQ0C@Q
M/:HCH@51'8"F0W<R:)5M-JO*D+<6(BPSGU# H]5^\_,Y<:^<L[K.KMU>8VQH
M"7-6CQW$H=-A^<:'!4.Z:RQN-]18(QOGU+M:&IE.&;X5Z)_(3JATC_@X%R%N
MW-W_;F+5!5 &U\&O]8K6Y=FFN./J<;)=+?;4"9H(Z"<=:[G+08?R-T?J[GE0
MLF.R:QFVH;V&DOGY9B6GOZV]VV4DC\D2>B(H$6JSNN,=0DCM%R5L*-6YN-LJ
M>E[&Y%K.!I7#]?8J)J>8HTC]/3AMDUNQWZD*3.+EPNT9JX 0-#?A= )U]16I
M]YR&N!7AA'MO9#][].1;BPH%$#E@G_UTJ.8RB7N/PS5BR2,Z-+!+BWM/_<SM
MI<MX2H1Q\%/G_^&QCC'W=[F_GHV>X;.RPL+#K@Q$JW[LJ"J7\EL]:I&3U*%9
M?%)"ZUG?E5POKMT.G(4LT8]N-;B6\5"I+S)U>M,:IGT3O1[#WFUT2#(3[>-Z
M;95V[H'B:CYQ>5(H8T!JQN$ ;3*+IK?W&9FW9\.HS3=PYE4[YJ&EET)W'5]R
M@6<[E;$U!M\_)U&[;"C>-RWF>*]J_M3VL(42"D30/T74EF(BRBLQ+B?/75;:
MX8N4.GO0P7V!<DFL3J)8S&+H789+3H7-MR:TPGA,3>]A$"8>[U$4F>=:%N%,
M^>!5T]5B[*"DH8V,S4<;Q0H8S)N3W)KP]3;KMH#M?0/+8-B$MN?I4&3CU\/W
M5I6PJA4GJK1B*1%F6HN;S>\';3FWXZK)F@:##0O<J?RTJ7BRR5I(8]="JLS7
MTC(S-LI$(SD];':X+=7G5B!:O_#AX,N3NY3VCA ?&^T.&O=8?0".:]B+5CV*
M8=?/K)ZZO$A@I3:LHAY#TG-OO'*R\B#5*;@=%"9A[ZTE] '(6X8.V9$(+$Q*
M^*(V4,_KZ83;>ZOBRN^20<,V%Z%3>]?4LIRB?G[7 A'VINX8PNFJ1K171P+,
M9_3K2Q #%(OGU7;>C29/RYV\%[^G)8]NYJH_&U>M7%,VH8$U9X7.HP0T&OP'
MQE?VW?@1[T+Y=D _W6%0/O16[90Q-/H).DB3R77:.A>PQT'P?->%U>4;''GN
MQ*OSA3L-([(.0H:K[Y/G?=\9ESZI5+%A,S#><?H>SY?/:A]F]E<SET*GFO7-
M'C\JL'&>Y4FIL;<37K&'?;SL)$A=KP.-5N*0E3\"$0%&5X>MFZ]=Z-S$O?BH
M7.9QS7B7[/S:VV,.&\!61]!/X.^G&'A[.L""4)HX[O9#>9?N06?^UC'-W/[0
MD+(K"YMQ&J1> :O'<]079YJ;V+\$HUWV# E<)9MFGT*,>6+/JF/$X9FD92^)
M\<X+\/@4>I; _NJM15]5SIWC9YKW*V"8IM#83.B<4S$-=_?\0\/,)R^4%#CO
M7:O166E]]D*T))G8)S,S3673:J"P YAM=!$U$[?L0PL5<Z"QR"\W%W/OH0F@
M>,!!;P=8=MDUQK=@0LT!*HRH)))$FM$S,NBJFX06].]*'HYH\R[O"P 0U"A:
M$^#0C13'_QTU28WKMM]E@9C\ ?<?&G46L@4 =6]?PPK7*'YY(VJY>8A+#0C=
MK,23A(#05O1LQL>0<A!+X0CTB#(0.PCWFZB]!(SOJA<MI!,LH9JF5?3O&5;H
MOLTSPU36W 8*1RS%<8@+29$[ \@1(?\.@+D@O:(ERL_^W5!ZBM+?U7J%75OS
M_T%>H!K<50%'2U3F& %#O!'PB#HPM!N.5B2TE,T>*B"8N=D*'WY]1VCPX$V)
MNNH+/%?9\AXU^=UI.=0E$?B5%G/NL(L^8OZSS;>(N4X855%LIV"3%I68V5+S
MKB3?L47Y/<MP#N?WCY*CK[!E*QMN5&B?G\R\=$6!^A!%'A>FDA1K+C[./;A2
M:%GA&8@OFZ2)C!6?C\D+W#*Y\+A8"U(TW4Z0]WFF_67/G8#C^DH_++?43[C,
M&6!I FY<8#?<#H#=>$J'JHKS]!'(&V_51 ![F69TIH#.:(S-\OZWJF ?2Q7!
M/C(8K#8D)3_3E-WU:M0NINTP")0R!J9L"6+$CG8/Q,Z#P33E*5O.2'3#/P*?
MD "^!(2H*H7KGPG/KG^\[U,U37[%@<9:O4:4DI;=:*&_FJ$?@B1J 5%:O-=&
M"^I??T]]@+(3N$)EI%3_.E<A\C!^TW'5;!RPK37+JL 7<88O=W[Y(CU[/+P<
M/6O8#,^HH-<)358E3$*!766T6:049X:P%&SN9^+\$FJ=$1WO(Z[P@H039K1Y
M-UUU X1HQ<V&O!J[1J@40>8@0>9P,9K(R+>Z#?\4SP;D=W+G+S<KESWT=ZI=
MO7O)]X@5_G31^<MGZ\K"I$-V-2(O822JBIZ/MHHUW/;U9>$Y:WPTOB)A)R J
MFV_,"D4PB)HI>G4E%\+/Q#O:T6R3X:4%1RYH5B@</;3-J9JJ#:!ZW^9&$-1M
M )'#Q];H)5)'+#/5Q$W7BT)]"C$2=#<(Q^,,*A75C^'4WYL6<S=SO0%N>PZ>
M:T"3PYHLJ-C+JBN<)^'>KP1FFH D+RT$$  2'(UX#3BL(TP2!/R!^.(@&%,&
M8_GXI06X*@[4S4D4E170B;%&0/DYUET#"H]3'!G6;^[Y:=V&\?T! 66N-:U
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M[ZZC^(.>[%!M;N[LR;RGQ:E]:5:W)A%;,-.&K=UC?NSSN9.+JZ6>B,X7D >
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MO(H$4B].4S<HD+;;_C>4(Y&FH;]RI2O^;VB@B'=^U$@(%*!F-N![4G"5"$V
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MCC6[DIG@=9L>K1[:$/P[&)Q!Q@2LY(#ORY,'OB\X83^F!]_)?ORQP#UT7WE
M0#<.:$'*MS)N7A*2-^%Z!.:3,"N8I3'%K0UW?#C":O$EI(<RG [>!#0\M[8=
M[[]D)J0AQ!AI'Z7D,_.2-=2[+!Z]P9QXXXSFB%X<A?6>(BD.7..#!\'HPQ6(
M)D-MTD9C"YD9SA2?'BMH@YX/<\#UPW<?$[BU$N6+G/^$@?KZ*QY=<6VH5T)_
MN*["V>I47"F2X6=#Q:!=*S\P"Z>D\QH@7^#-@SL$8R[]B1GFG+L#? LGM>L
M%[P\JN$1DWFZ"7C J>N>PLMJY!9U<*P-*2,#%"0T5S5MC2PC/UC"_2<LF8,_
M.=+ ,'=7UCPF.7)R[W4=XZDCH_H[] 6.5&T"?UN3UM1E./7;HISY=R4]S-]6
M\S^6]W]044<NZL3,6V.@SFDB"7MQ9,*_+PJC?]UXZ&Y(1/RO58B-OY[46BKB
M5S^X13]X\+KO%7/A,)=*IS@QQ;?66+9GPC$K\CMFLV@5(#V^HT@UR-V;_9Z
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M/T<.\F_6L*ZG[5Q)0TZJW"RF,]Q;GL[#R?U0D/&-WDA$_),P_/9MS-=2UFH
M0]]GCH37)HW\R:(/[@K?22 :S3+PU<H&OEE)VW["\:L@2=XH\0I/RQ?6AXW7
M==6OS0<FVY4#"NJN%G)Y*N=\]<OH9:1E(]FOHRX/9[6XIZB8(+4S#=W=K5PE
M.B_N_T*K9HT1%%(B[Z/Y!+ #)@A-^O_C#QK%+_*()L=B#:'7[Z(*UX2B^U*E
MFH@WW<HU=X>>'F;KX+\/#+]=H)U8W55X@*^RV?]-I7M! ]+5/- _;+7.2I-+
MPO8S_^?JAJC;!L6]VKF"GK72.LP:A0ACD]*NQW&4O?/$NM5'G[T$N9"K/F*R
M'AJX$.#,N4V O6@)8;?KG/ -L7CCYC=\JVZ^0O.0!7@QJM"$9M@$8)BV!_J1
MUP"+C/^A;M];M:?=/E*4#BH7\Q2>N?&T]4E^#*GY'98&SL_6^JFL-%>H$1DA
M\.*FNH[']C#WE%&L;$W=[?9OP9=?WD@S*04 [-D4S_?"**O652"'D,I]EX'C
M<M7Y6QU^<CJ*BJKYZ5BY\-!,G"939+]/5/3@D^(>L9K]M]U"]'L5;,:4OY2V
M6K=C]\I-X2Z''6:>.E\7>W^?,(]TOQW&,T5S;!'849)47772J_AUZ+3?G70;
MMK Q]_IE=4P/Q!O=DL_3_2YJ\?[=G5&<>.XO3?'*ZPRDJ^JJP-F"I O1(YR+
MBG<&9(G9'(S'ZN(*:8RNC857+0!]'2,/E_O.E)D42^Q*T!Q'TPHMI3&IA@"[
M?_D36>C%[AS"<KFET<)_[( +_S(04K&21M^O8H)XX]=*XX(^ ERH\!["[JQ2
M2J/_%]OOO_- H(X ]6_S<:0_8WH_AEX"7!_<>0XH]5QG_* V[SO5BQ6K=QAR
M3HJFM++$=[>-B<:LY@T$=827+0N@R@J[RGIZ*Q?9F<^G)5RE5SUC/]$A6+ "
M,>5U^EI[;]_-4FU9O1Q!T1';1AMKUT?HB Q W"PP@S^[8..%0NEJX24=4>Y(
M2V:L)YJ_;@&('NHXK8 K*;WW<I>KC$<I1R0S"UZ-K9,T5@0<]\.PZ]K?IE]Y
MT>Q?.2/VL.S5?BQ7AS+ZJ E=JG47^79U<9M\C<W9!"Y['A/VJ. /SE]:N(>P
M>YV<[?N.XAS#CC#*2*.G6>06E_MUT3F B:F:EL:+O86V@V?5NF15+NYGUHUE
MGZGG%E4C#&'%6S*=;F>U',Q9O/54[- '@\M5GE@=9&.WM_HXC;WS08=I@J-'
M[;F/XI7MNL9?9I00-YFO6D\BNP183;N=3+I?^7TBG<]^*VZ0;<FL]V$X=8V!
M\$$5R\?WM,R\L]&7LZ:[/00OCFI&-JZZ=ZRD,?!754<E&+[+8/@Z@KN6-*^6
M 2""(N(5 @L1:@25SD@1*18#WK[.FV(\_MF6WSSH;B1[5; C>&,#]_0Y4)(0
M!V1Y*HZGI?4]?,-3+UB2?!&[VSYESYOV]*;YOO[;=V2B]QC'/C^CA(^UW-V!
M7 )B:[NJ9:9)SLN[@,P#NV:4/]0U:;7PM/!=,Z$S.;L6=?K@VTX!-WY9_\)>
MM[WT04IC^V3Z8B8T&44BLH7S#)P"/PR9VD;J'_@0\?"KV8P:/0\/+9]Z"*!/
MV'FLL-1)V>7<C"KH)ZM7@4Y&EP&8JV[DPX"^@UUVG:OWCE6]'E/._NL>:?C&
M>B'A<"WU>=51K)AVYMI#NYB/N&+IW;<2W*-K#U;XC_@([U-S7U+,2V/,S%M
M''IE\2<ROEG1\WVJ1T1I1R,1;+9'/&VI;G17-N@SB380DO3H8XL01Q1WCZ40
M^1@$Z!^\QCGM?6S^I4YY2>A\=2C  -FEY[_9"?.Z=[FV8U6._ =[XW_P0;O9
M _RW__T74$L#!!0    ( &."?%C1!U-1/&\  -=T   3    :6UG,C(R-#<W
M.#<X7S,Q+FIP9XR[=5B<.],XO(M+<:>XN[N[N[M+<=W%NGBQXN[%W=VE6/'B
M#FUQ;Z$+Q;_VG/,\KUSO[[F^[#])1C*Y,S-)9B<OJR]? 82RO@YV ("B(A,
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MWXU_V[FMZV_C]OQMQ2_G  6--V[>;EYOW-PIN-DX  )2BJIP<'_Y$@P2H!$
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M+N3,$[_A@STD#0YL@R.VKDVAA-(GA^6<9YOKA_B,2L<&_3L\TMC0?M56^Q<
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MN?6+K;U92 [IP@)7[Y1X!1$YKM ^A$X-8\K/V(SE"P($(85;74XVSC/OAS7
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M<?RJ(9%?Y8^#_YV0Y+6X_/<AW>(5+!GR')/WK&99BJY1-<,X<Y ^>WJ =WB
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MLL5[_"/I.N@7"B%]2-&AU$&$AOOB6=8ZC4O[HW*@: $6/\7>(?5LZB>S2O_
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MS74%'.@=M9 <YG9;;5GGRW]F4;BI_P[KM$F],BM+-N4QBZS1[4B)L;,>Z8K
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MLMP&29M:4_N8JZPN;JFS+D!/3FH/\E"P!S[N98$Y!I#$,6: Z%_]2M*,^?^
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M :EC$,+A7M_)<>8Y34Y\\M%+HK.\F9L;RXB#N88/T1JWNG1U,%/0P-_GT$G
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MGQHD\4<9# 0]!/SEZ_\ 4$L#!!0    ( &."?%C^(*T3\HH  %3'   3
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M_TD@]NUW;,/PH,] +"U_T?ZIG.<K )#9(MCFT5\TNV< 4'87 (X/_D7C>0D
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M'QV?M[X@7RO?<A@3X3#5 N>'WX5/^"GY)?KM^)OY%U]GN Z]WG)#X$;XC=D
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M5< 8D )^QJ/(OL=<* &J[VW@)VA+?KC3H+Y"ML0SF)"]IX?P=5LO85$A$6%
M 7S=R];>#0+CM(,XN4 5N5:JD%R<+@Z*7.:2>B)Z7JH09Q>M !^(<8"^B7V
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M1,34924T5#0D9:24U55%140EU=4U9%1%5<3%):1D-'[R:$-]8;908C!+D8M
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MW6&L@O\,>D40DX*$]+= .245!3D9-2D-"0@X1"!3D/[E+B:DR,E(*4FH0-0
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M>:SN\#Z[SN.B@3;.>9:YI2Q3GU&*::J'15N_K9<_["'S[IQ\Q1I[M88WX+[
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MA)-7"K(]94^_.@P/C%BMC!DVX8'-EF4;M$0T;BLXL&P'F8!1#,0@UR-P(7A
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MAN^M5)W2Y(#5L\BQX*XAF</%58A[!2,CG@,C?=5E,XS@>PV&/753PS)-;/-
MR[?'ST2G-2.,XEX'+]._"ZI%#;OYAASN[796N)RE'K1#>B$H4E^+PVW#LJ0B
M;75A-;@NB>^7_$3]LRI7\J<3N\=.5VEZ^XUNC%4GW1MFO6-KYNI1I=07=<O^
M(VI0@<F9\RM*(?M(^R04+EHY'->(!OFVC<P^N8%^]G:FJOK+PKD!F-M#65/$
M80G>5$.CS,$2,G*4A9!<L["KTNXP&D7/[7XJHF2]MT/Q;OBCXJ;$",9O#>L%
M<DY YHU3R<S=VMFB//^#O?<.:^KI]T6C*%A +*!T5 24IH" TB(J($@1Z2"@
M5"D!*:$%B(*"(D5ZDR:=T'N/2J^AMP"17D-H22#UAM]^]WOVN\N]SW[N/N<^
M^]SSUWJRULRL[\Q\R^?SG3636[S=7HMK$O>V6E:8A$9O%0E)&TF(&GW3%PDA
M9GJ91$D>G2#[]F/<MWC@'I07*K::> _&F6<73P;,V!4(N&!8\"KS^F(/KR5P
MGWQ[(@/^^DKP-\;56H*\HIDG,)J&;Y8M>Z>:!XKZMHWTMGZV+]%\75MXIAOB
M"*B+>8[76CI@T<1XG*S^6<N./?0F'1[L40'>J,9SMYL2>O^\3 QY-[].AC,G
MF+LLP7>/DE(;)>NG9K]65FOUB0SX>7E:58D9'<;$(+*A2NA6O.ZRQ#0M1#?$
M8\GGJ("@7 MBN\)0U ^O)?-78E&'#AK7EHJ@/_,Z?T.?>I(:T/!CX? VMEMS
M:[;/2$+]NI7G160MM2_'5)V]M/:!/JH]2O4/9)"8O_<->M$%60(W4;) :I4
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M.P^RN2J1"JB2XRE_"S$$.Y'F'I^::33W55ALD&8R.'\G$#EZ'Q%15)#;];I
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MY*V%$BV(LE2 L388NOXUG>)>2CX]UG25<H$6FIA!I!(X1A0'I[PGTWS -!6
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M+>#<2:ZJ^.VYO1LUDJ)=]PU>ZG_@4SF3>:I@)&@G^5VGP>E@):DU&@[UA2?
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M!_W:YF64(%0#]N]7H^DSQM55XI*[FV\':W.L];&7 J[:T9'8J !=C'KAIRD
MXXQ]*+D%GGX,H[]%B$-4 M?XI)57I%IBY=V^YD_ZGR9O1?\.X2L&(_[ZR\O1
M_P7Q29T*$(%'"[:E)RE@&RE//%LPVUO2N+E%Y[ 6&?OMXI10Y)G&YXZ#:$9K
MCX,DS:]1B,QTUB!CH]",L#4CH]L\RR5Z^)24AS)O0^)PC::>2(/LA^IEMT:'
M8,B89?-X5:^#A<@XHBM1]B[\@''BI_811E&+"ECSG[ @YS5_AO^)Q@M2=&I0
M1[]E49BS5$ (V:*2AH4D+4X 5YN.Y*B 3+P9%)=&PS>WFKNI@%A0+>5=1#/Q
M-W2>"C#<HB&7?],FD7+VKAMTF1-$!7SG*PW823^$CA%E\60ZJ9TK% @B!D[@
M!4]0 ?:88XCS?";]2 4)73VSB6H2I/!B P:.P56_'RURI.TO82@ALS2B- U!
M_4LY\?]=Y6P^4J#)B:')F8I;)5T../XS9.DI*N"!ZA$!CSD?^8=W@]30/%>R
MN66G"\ZS  >@4F[HU!"0-J#PD)#\7G6;;KW7TI[(W)]6=H6I3ATU1FN+HQU]
MTVJU=5<)>R"$>\.,\^7H?N&NI:7*>ICDE9=J^X*"7Q:')<!^QFN:.(3)?PPF
M_N'&@L[94X719Z_'G0K4R[P>]>LVB%++0[N_./\9=B-4HDC-9K#!J/*:Y>]Q
M_M0OP-$4XAA#QJ8>3^I%1!+PK@Q#.Z/ <,]\@[L[GMOS#ZS'8.4=\2TB/.%*
M31E[<7TP8GFQ*)XK."QVE)B"R5^?2DH.X7WQ2YE;['%+R"A/JG/0R(^"/;I5
M1+=HPMB1(1+*L5F#V]BZ$-OO(OH%[CH5OM[TUE/,MK)8#N8*$C%?_#GJH?S8
M6DX1YH9M9O3N8_P\J3XEZ>K?\8SAO;7NP;)LPC107F[?$IV:5/$.R%OK2401
M\Q;AAMN3M>D[LPA6 T,_G/G_M5-O<HYY:V\WV\>_MKSOPMI;=XVGWA18]JK?
M?,:AD!=G'38>N]Z04GM]Y:6JW4_79_XI/)3^>AO[D3_L25_OO;ZW.VUW:E#)
M5-FP2T<O/=G.'_XG>'[)NZ<' TKMS&4GW!#9?7YSN5C48M/8R9+"OEV39A6[
M*64\_AZ=M?](5EWEBY,Y_#/N;@9=PES]U/B^I+;9DKG:'[]G?[>3:HK]_?>9
M;.-.<S%[T/3PF=L[_R[=O)WO4E641=6W.5=#+CS9+&GQY,3E5T?O3HWUF_I/
M\-H+*X[OQS]S_N3>:'[FMK7IA[]%K__$;]KV5>W[[=J)&C=NW'\GG_*V=T;V
M]KA7;WI[K^Y.ST[>'F=>XACJ_5W2,\QMX81/XBUWP^8R[][\O/V4[<G[MI*;
MS/XS^.>_6WCKJVROWKTW:[=Z>K-]/I'WR_;PIEW%]4GFHFGANE="(V(7;GQZ
M/C_FGKY\J.]<S^QCXAI:HC6LA?=>WW)?[ERSW_[[G.KPM/>%'Y>M6UQV[4GV
MQMN3,]3\BY.WSP]]L*EZ\:J%=W\[5X;G\RV['>A\2[JJO_K2M:NY>[33ZKN\
MF^:>69/$"@SY"Z&;ZW)J9MW>*_OA>7WZM[Q';W7?[MUG_$WLQ7O9_9/Z,[^Z
MW5WP-G?NGEWLF>]*[N9.?_UWK7_C_1\=Y66/5B\YN"V:M?.D3>BT\/R'N>*[
MOEI%Y_UG>)9]4SI8=,?GS37!=V^>DBGYO2E&97>^_:P[\O5-=1/?Y5VY(7+U
M;.?-DMW3L][W';A7Z^N])?GVSCEV>MNZMEN[VA@]80[J:0>:5;SZ7[+M*</;
M\^W[?\R/_6//L67KJYE^%PY>2C.JCMU<)W;JD=FKA_&6L6;UN9N??KNKY[CA
M_-QPDQ__&7;FU?Y>'[RZ:/DTK54964R>,L4KM&46K)Z]KCM$4SWPTC:K]6]=
MV1>\W+=,XK%]B/.I[5K\*Z6CY-ROQD_\RV_W';3G]?G[N]G8\S#T+"K:5EJ'
MC\LOOS"O._-+OV^SQN7C8F'*_0?MOJQ:8;* L9;-ZB/C/L6XG: QW-MW;33V
MW\_^S0ZJ<*_)7ZC?]OT]E_[W6_\.7@<=! 4:^ 66TMU_O^W?4/IJ?AQX\"N_
M[L.B_PRUZ]_(5BV_#AX)OGU_#\24.&J:4GT/O(KRJG],30:GHM!SWW,3BQ=,
MB_YX;IJY_(7?!9,.M5PI?;?S]W4<Y21.@369/(;_&69WF>QFMQ(,>[-1A^O>
M!%MO+A;V5R*,7T EZ1MW"7/!!5;-=[3N1SA*5-_^RG%L]M_<XY?O;>EWO+ZJ
MZNG2W&SN6MW$[/JU7[Z_5;X \M*.BD5?Y67*J[.MQ*^GI4GM^!HY8V+]2;N_
M2ZKX0,?GM!@RKW"52/KGY*2AYBC18GM@WT8![OIU\^SF@1/+BX/,9IMY7/\J
M1_9R5ZE\5E_1_4OM:_^+.W]K7WM\D<U:OBY5Y,[4((]+G@QW_:_ZRSO_M?T-
M%*]:OHY)(MQOQJ)8KA73>MU:7$M<H_F]%GD<8#S X_[\/L2QGQVYC8R=A4VR
MEYEE7-B2%:?)M5#IU3X/P37V&LM?L>\/ +KO>I)&8Y%RCZ2,QQ.ENT]"7<.+
MLS>O.K) ^ 27_0*(_^;M?=CMZ2]2Y5D4[O12S?V3A\?6SDG.*_>O?/+Y_2WW
M!< .9_&E/;_<5S<?>/ZW_O7[VNIU?_%?57Z-#EE@B K\O\E -   4$L#!!0
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M,"@8Z:!(@A>'@/C"^A(.Y];F1I[6[7=3]U^=+IX "D\ .3$!GA'P;5%!Z1/
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MUF'=#YVA^P@W.37/X90G$N3TJ,0[R@,,^[:O#*F8F+HCY&Y%@]>J[RDYX/4
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MYN)SI5P-Q=F$[$QOIZZ:6Y,Z*_8AO@2[LI2G9^NL]0(PS*+UVWX=9+B_)\>
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M?&^+)4Q4FOC_N 7_'P0S-'=[71,76 BV-8G64D.(K0RL1X:S3N[(+WCBPDW
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M"$TV.2N AXB<=>W'JT1O;^LWZ&7A;+,E8UER+>OAQ&^11U,'Y=]*@3. J3.
M*83BMU]\"$S$LX@@XVHF-V?F=<0WPN'X^=6;'/,VZ^DGMX)T6,U5F8L $VL
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M?)"@M YF@E >XH%]V6F- +_1$(&]PZC6Q2(O8[,I?.J%4151KK!2N^+^X94
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M7QAKY)]#$3OHXIT#V%L& 2.:B*\;NB-SNGV1#HP9R0R(ZY2HA93NAN-"'WB
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MPAF970H:=*S5)#ZZ?]E_5[0<M<S%^L->;&XV\*<$246AV<H[;\9/T;RO"_!
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MY?]^$3MJ?V2G-755#.<Y65S##Q2,+X9^QC6!W26 0B;?T7R<!+F5SKLQ?N5
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MQ H]<RS88'KS<@I,5M#=F;<H;V6'QT+10I\,5&LRP^SXI3^S L][-I?LO:[
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M%WD!=[@"X;EOK\R/AS<4F*R84P[)'0O6:[-Z4N6M/"E<+5XL]E8.@(+A%FI
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MO%*RN2T@3OMAA>7$PX <21/UD&LMCJE/?KFGS_OQ*ZKLL\S8DJG#K?W[3\M
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MGH+YA&].4IM8(H/EHCI=!7 CR?"[%I#6=&5)"*],[>F["&R>SD1U8R<^*.Z
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MIZ?&#N8NQD8B#K;61'_PR&G^&_L<3*P"@B A!B8VD3_L"S )"PH)L[]Z)"+
MSB@L#/SSK-%OXO[S+.._>Y;NU1DC0T[#OWG_9X$H&MO_.;,RYU5T-M)W<#33
MMR$2,S8PT'?@IOM30/2WV=^4Z?X-R.O"R=S)ROA/% $KI[_P?B64TTK?QO35
M21HC8Q-]9RLG(*^ LYNM@SZ1L+&)N8VYC2F1/I&<OI,9D8BM@ZN^@]'_;/)O
M>'3_9(7N?ZKKOV^]-LNOZ5]=^KKXJ\^-;5Z;V^&UBU_. &)R9K9.MHYFMG9$
M3+3T '9!<6E(R#_N$D0\, T !"ZI*!XX  #^^O.'C/0/&=+3%F'H8..0&QVS
M 3.,FNO)RSD X8\N!QAUOLK!7E8  0"P?WV _V- _#7^+OM##/;/DG]QO'0"
MD&'!,,#Q(,"0 >#(8!#(8"^]8!"OER,8Y"OZ/^Y-:$@H&%@P< BX-Z^[X'\8
M_DOVN@T)_2J&0WK5 P= 0$##PD' (2/ _"&!@@; (*/ HJ)])D:?P\!498B=
M BJKP&$+R#,JSLS.)V$IQ+W7MY]FJB5)8''^[M\EZ%!'"NHC8Q5I(&=S'<BI
M-OA8(^3([!18'R0:?*&42,$N%H+\"Q@" @$.!AKF'0S4J[.OOD- $J- ,21
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MNM-N=\'9WDR!!XRNYM^3ZNEZFM:-Y;LJ84IX,]_UI+D>ZV\2Z>WXE$6#(5+
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M,.^O$\GB:W;:>]<G382&3IO$,-TWU*;%JF99HJ;)X(==:9AI@2>)RVH(%FZ
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MT!T_C.+TU/$8:UIHC4JL^.=A&(4D3,G/DY#;PZJV-G:IEQ $#R76]%S[UW#
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MWPJ'8'^55<M>'U-+(-O1I:XCU!'\<HSB$ONJ-ZLEPN&[%JO#/2,+D#:!JNV
ML4_Z(Y'\_AW*VQXFK-XBA98P:^&%:9ZMOL IJ$DDUOY%E@[^!I+#G_#26J,R
M()(4Y\N]SZR&FLYC^K3APM3@=$Y6/QGD5Z\6RIM?&;66?0%,O0!> '-?;\6S
M7B^;K:_/$S]W.^A> ->J/X=? +<2N'-8OH_Q&X0W90XO@.V1@\1EV6>!_A=
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M2;W0_HF-;87+] BH0.0,&D'?B)TQ;/A&^;& XXU1A!T$ /;[P&\P!%PP17@
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M(TTN!<5'I9R\/$WI2 B_2I4OT9L,032[G9TT(J#:3)6Q#F&#E.3Z@.8)4OH
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MWO?N>\^YI^I4W:KOQU>S_DSUV]W/T]WK?;MKK5J5:BQA%K61*KD!"33C H
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M?!040A=1SQ*^HA)#PXY55,];ZV&=17WP3%.93!GG&PJ-G+%!-A^B\D2\(0%
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MHS7$S*9QCV+=..PS[[DQV,!4XR=V!D3DQU"9F!AGO*$J7OS;2^/7$!;$9 )
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MOJXM>OE573R+6X';NJ($DI2D2]:W^/G'4;9#F@O+,SCZ9)]:RZXN/?T\/M'
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MNDY;$1U3U2K[9J4V!+ZVY].,VB<RGYN$V$K.*G*['L7=UN>3YUGUY")[4E/
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MM>D?9,W9A;S*G6,MGGZ)S!=&OIYUNIYP="B\>'%55H&$E$ L951<0Q]C"&5
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M(NS PV>B<?)&IA*.KWT'?[SW$_<?0-'/EQTC)<^:8GYIG(YHKK-"I/O:D3\
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M>@N L2+ZU0@CFVH!A&MJY.^19&R5R1V-9(>ZF3V%O#Y2<'P7X:V)U_$PN@O
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MV21\UJ=F3_]<%HV8$J=QUKEXDAB;K-#P- ]<0,*^S1Q>[Q<.F<^P[HCU(3D
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M)82;V)QLO0YE"[9.^FG73P_*O5!V#)"U>OI0-<:IY6H,J&*R=HW+).O*427
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M4='%6R)86AHLL5$2_,K<4-,8GYN<]CEON$69KHUVS]_B&(K]S.H5J3D=!^!
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MJKHJ3!D>9Z=?J7VJX=*TGIG3E7AV/S+(][]L7]+<FZ.20)""UOE[BVU;!.Z
M\+)D4TXC)7I'?:5ZWGOLK8Q6SXOCXUR]N><W89*VLY3V>_FUP?RT_.QR,J,
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MP1@O?=ZM&H<IY.#HEV>3/_RULZC1+[7 ?_D_T7>HO2O^!^1*\XDOA;0>BQM
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MT[E%$NYHMU,8@HD)BG52ZK=KGO1[QTO:_;^Z/N8R_Q^BPLCELRA!N/0QZV*
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M4$<'D)_HBD"^_]V=&:PJ7W7@!=D<\D^<F.VD@ GR&WW^+ P/[@D'BAB#V0$
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MX%>M7ZVDKJ&EK;54@;A15W.CJJ;66H@+B^7!\8CS\HJOE</+K?W'C?40N@@
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MI8 3;]_I&%O>E&,!<ZR(_0"H!SN9C:4L0-U![BYG"@&R4S<+T%>4OG_) EA
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MS3\FJC'0X739$N4+FF+OGU,T_"1<(WIO'3V,K(E155"&PGN8@5FH@S0/+Q;
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MX; ]OI>(%17\8H?D1PCQAMB,@[;7V+D2F.KPWZAS[]BI&_1Z/X. 5^"\8]"
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M*QV K(+VI=^][?YBN!P\37HEY!SSQSJB'F^L&=11P'^XF&T6<(CQ .P\<7\
M_.0?@-[)FB.Q/_C0+_/SPW'&O1)IKJ$V+S=9)GVV%-?EV5&^2WR-16B I%$
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M4_0;TSBP<[?X^40@J>&'(*S!O7"I"#C:MC1:=KX,N24AOAZ7-YTY!*_'WPV
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M9!TS"10,YAL0[J?S!\\"N,'_!T/@E; &^B]RP8S3@=B1 "\K\!T@)P;2:.I
M)#W!PFG7J\[=4D/IP!_$NF2M\P. 0=V#AS:7&U%+Q4%6Z36@T64_ /PB65%@
MXVD1ME7,]JEQ#+ON^^Q<*6-G)Z)Z%JC<4RZ-@(#[/#:M*C&*7O%L->4V,^=G
M;X_S6&JP\_%0.;RSN#E]S>("^0Y^?+L,/#_A DN/%0N-& 6V/X1A[-E:G=/?
MPOHDKAD"AJ!2^V;+H*47WD0N:9)T?'8BKLPK7C3LEXH4.(]K[WZ1,XQ)T?F5
M_8JJ9>E#RC-"<@.OCR/!\[*#>.+1S>0E ^QHO [?N 38=\GDBW<GFAUJ%_'8
M^*]#SFES:</++K!V]&NK!,_:SM5FGG#E&2@  *H7X$;.LK(X^<Y&KQ-13_]Q
M:(3G6!J-9@IP?G1I3\8T0*%]W*S QGP@[K\?OV;CX@!4OAI(8T@6N(]Q].\G
MC3$ RLK>]!;/0MU9/; "R\B&Q B1/MW$2]/\#&2=]XH<.3)]<DSOBJ1^,_8$
MU'A;DDWFK1YW*$U8V5E<I]G/%3; LY45?3,<R]WV'@'!QCZS1H*<4H<LCF+V
M;\H1#HZ4ZI'8+Z>)VXOTD^5B;$S_^L/YLUDEUR0T4CQ5S!.5/=!YH+\/S0>0
MJ=A=7S,1LJVI>ED?1+:HQ^7'JU.%)TX!R'RQ^1WP*R2UFZO#T%(!-$#63\:8
MG3F&$F4ON[PG&SO4=+@HJ26$IQG7?T4,<ORW!AG\U1W,*T^D>3I9_GC!Y\YE
M0"N@-J:&)NT3)ROK0YRAT4Z*Y=3".:D\6M<%B?*)T?(\1&RD^X @,Y[.]54Q
M*MF:K)1SQCQ; >W)Y+=\$U'TMI)BGU,ZXI?J_A2$HKY:R^:-F0P$.]"&'\K'
MVLJ1W!W$+HKM7/'PZ\U&0YX/W1_1@D\1!APA&KXW4S61[N.5QE80?B2ED))F
MILO[YQ<%TE/Q*JVE1W31_ .;4&"%H<W4;&#;B3,!W@96D9[2XW*P:$O&X-]=
MB^!KL/(:E)((-//[@Y3U^";JNW,#57;K1BC$ B6T,+PN;3^8%DRSJ9EKR]%X
M58;36AGMSC@0OU,CG]JY/!08@/VK*-?6.9O_A,J?=4;\1WVZ(,^GNSQD7R'7
MK#D31'1!T)\9>;:V.)M4[<(MR"3=B6(0W3B-=V%=VY/DFLX4EM1/M.18C3@C
M"GRM<&?E"C4[NA)HGZZ52\I,<?=/48&Q)$/KP '22]IE-/]%?Y%R-U$!6H'#
M33N'E]#FQ$'>-8MP;\7QFF]283Y:8P8Q0D*,&H:F)2],&#-B!ZJ<LS,:?=V.
M%8)*%WR'FK76"B<JZ:S#-(TVF(T[/;&=Q]P1!AXRI?U?CHWG;0P56N%*IPW,
M\9P35I7H+J@2_?G] AB.QP7!&$0*+7&;([][XE"C]E.Z1ZOY]5%+L$YU>],;
M/Q).<XH*/H]UM(FT<$#&_^3GY^MZ45'ZE=<G]4=B I34G^QWCMXI;H*[P"WK
MT!.V_EQ^N#=CPAW/J/%3'9C903"LB'4/L=.8PH@P9FDVXEW]7K-R1_G>]WZ5
MVM-^=]2@C.E@_(U]EEOC3!S"X:5B<VR_I+L^ RKMVR'8 ]#E.E%5(S"55.F@
MJV'H/EELK6>Q^%$U"E%\N%)$*CMEW[ZUF/_8XB-Z'KRECUZC&3-':W!1W*;]
MB\=V,3ZY6C&U&8GR8,*KD_DIUP;S.SA>B$'P6TLH#GA[U!HJM.A\*\Q]XG2Z
M3N@3-F2Q<9<Y%D]:T/MC?$JU>K($WUS*9H4VV6M4=:&]1:L&1VF]HRU^VON-
M8G.DTOVF*D2^\!I_$Z\GT@=/D^;^XIV6<X$1__"-:E,\YY[(9M:-\R^1GTFQ
MMI(J0W6M84P31S0B ">KUV6?NH;,NTQ?L'QL?=.:IXMC8>!N;3EKLV'PZ8$K
M G!8^A,TD9U,T\@8>7UZ8)GU*RIU2RXTJ#"\]0[=OC.-6!]+\TOI&Z;$EUQ1
M;F?-]+F$<LT\B_$WWI<L%:1R4ZE+KZ/E[<.R1#[ ,K).#ZC<&#V.';)V:G 4
MF+8V%A<5YG6^*E)40U_$'2;"@YSFR*_ RU%T4[8KQI2D3:(28ZF2XPX64=XT
MS2N-M'"O1\/2=W1D#%N6G^"R\/:_YH@#/[F9,\%;2X?23<6^7GP ;"@=#^9N
M X5;5FB^]?DX+,W $ZTI8"H+?79%]FQ;S^E2!^(Y5.$9_@Y\]].BDS55MMI3
M#*+92>1M8T=,/7G1&>+ZPB,8?QHV.M\H<X2\Y-WXYM%'$LJ?L48]S^$">?D\
M?TE(A,W?X>-W)X_MD*#Y1TFSWHM87R_6<*4)M'*$N;5IHJ.<49+3BFQFDQ%<
M:UH\L93ZK6!?:=;J76=WLL"SI0+!VZ:JYLB-!UNF;FY\(=9'F?-G!UNMY53U
M%AH/4!W3>V%UC;0N9=4V-^!#Q5V[>TEE/+1H*'W]M%BGYZ\-T> XK<S1S[EB
M&)$0=*M/R-"Y!>$%D1S!!SDJ)P>O#*+'&NH[:A:+5/NM/0:^PI$V@SU"XD'K
M472MD/%?%Q/Y3<T-8P[TB4 4P8VP-ZKWG\3S([W-C>G'<@'+CO;("?($Q>9D
MQ9NQ\CC4F#V5P  DZQH<**2E664VUTC4,Z*+4]CKDJ6:LI$F*VC_T;+WV0<J
MN1Q,D[_ZFF)06L26Z<M +#T2=L=6SYXB6<ZC$H.T3O/URWOBDLUYT%VOU)-O
M;T[C?D_*6B:5D345(ZT_AGZ>1_I$]@\(<%CQ 9#,VT%5>W]=.Y@82 0T4%\U
MEMCH7O;LG3Z_/$52SW3Z'#>SKPI%F J[[MHEOML*4:D.GE$8KV2))F9]2M$C
M6=BQN/V%O'!S>4LAD;[H )8EI3;S[KUJZ3YS;]&3R,#>R]0S09CK68P,C. X
MO42SJ73V?>S/]I%(3F?SB.SKP9]#CBS?I0?1RBR8I*_C]!<=)*+YTR#2@W)/
MR9&I0K3EKCR9>@%F5J"7$C +? 1ZZX%$Q/^<@2(?&X+U]X#Q]X#Z^ C ]0^X
MP?XW@F@6B!\)E" MXACO9EL*]I%]< 8/-KQQ1C0M/ #OTSVJXCQBOP:R+]8-
M,35%R+RD)_3EFKYO*BYG5FMG\R"KZ_K/T1,(3QFP>:?QZXE<3FV$N SKU!=\
MB7(7VNH^]4'IC6'&/,@V^0X/O+C(UI[]VU)$*R-$L[;Y:RGD#D4'5IF\_=3N
ME/9;BD%<C9$"W4+X,A3=>1(97L*X$'*81?V4R95)WQBAC=3?+,RF^).=[_EA
M69B9.N[R0E&=F83@GCKG!EJXA?E9$G5B-CJ518S/J^I/5].M!<I&9M/,K1K?
M&>>!M]JO$_M'S[9/B8<1Q2582J>2O[.%;_N60Z6-MR6D!G[Q@XCG+T);2.-7
M67&JMI2^^;CMPYUGJ#:(06:3FHT=L/:ZSW34S@NWF3&E#(&<8_\75!R) LAS
MI/ZTWU@#*7>87R: ^"6!H77WD,XMU0C#O#PE4VF2RA!R>^5!? RUK1&AZ&A$
MI[!4*/^+"(1RHL:>R7]1[<<B@!O.NH25SR,NU#*J3O%\J,:.=BDP(%+\%B:9
MZV\R8<!H6]$X'*VRH-U>ESPO*ZM49$BVH]BNY<%M Z61R[VE:9ML@Z)<],ZC
MYRXPH$ V@W$Q$(XS"Z6[218;YFDO4P1+:H+J?6:>_FCX25.G>K$$ST+G>'ZZ
M^.);H75TD]7>('#K]U3(U<"FM)EWT,M7';YGEQCR[KP\BCTDA,X%8^ 8!DB@
M(:6EF=\(/A,\4_ F,V+5U?("DW4=H1F+NJB_E"8N.NG+<7::>8(^,;S-M$ 9
MT2<:%,O3)^K[-I!SUD9PWB)!HJ;*IN'CD 5U,V)C],T+W$ 3L")#(-$CU"(-
MQ#^5QOK??GIT&U#6NQ-:_#<*5219]JO/N+S<.;G&8\PH[Z\O/Q'REV&S(M6/
M?1BRMC2C4GYAXFD??2?T4M9B?Z+0O"SP/Z\3L :ULTJ_W1,D31'B_@XIQBKM
M/BN*;JBBLO AR'1R$=7::E9^WYJ$/7^1@6^?.V4F'A;1EH96_:I?ZG5,T1-+
M)K3I'IMUZ%9S\C0GZ>%1'C" G[U88U6\]M,YG>L&<_"R633 \0TTC1!'%#0%
MWE9>B<'L_'V!4?7^L[U*LNAK49^!S3"KI*L!"%Q_\3H^($5&K3\-.K"?ER<=
M'(@?*YH.!!N&&G63%)KV36UND_?Y@"<K1<=-L5^UND-DXS9Q\E8@/B%PM%55
M">"-H/4"X4)6$9R<C!MP@SBY^*':@#@\"21EF_J[V<<J?2P\<BTI#\WF^Z3C
M'3C># $FKHV>6M([-D4N4PZ5'**]A1-L[((;?'+!HKS!ZF?\^GDN=<:1Z^1I
MR2(D<UXFN,X+UQ2R]1&L^/]\.?)'W[3V'SKKL7O4,+A&OKA3YI+:82LP(W29
MKF+Z6;:U(4:%W+F8C188%: H;]Y8RIL<1M<[*0KK%U6BVH4\4_^%RP%RD?E!
MZ[1/N,2AI/4.G Q)G(*H,N00QP%RX>,NQ -0V5)Z-OOSL[]CW*XDNKW.K0!X
MGU?9$<J4K/.-=81G\G:;9/35P$W1^&^205%:6L);#;Z<^!7:JX-7M=#)\$D'
M#S$>/8HP[ZZ\P*-$$-9KAH8)?Q/0/*H:'C4*H,"0O$4YRBP@0LD8X-_:1+<Q
M>9&+T6/;#  8 PCR7+D=L@\69K$DVQ\2F1E(321?;7\1'A&-L35C[[6T]]PT
MCCNG4@9$R%F?_'G9'J554XWEY=-]1.BAP%$4@=)DWQO#V"$D*%GGBI>M\ &?
MX]G3UZ8+PF"R5;Q=^0'[&A_9?YJ.R@?,7A:8C)VK$]^^C)&965"% U_!-1XL
MF2<**]\D?.]$EHF;DT9L?CC;R[\^_I6E)F&H&GQ); FWQ 9CO^+4GUWF.FWV
MHI#_G_HH+);81)%B:8.RR'H8/S3$DR?68LB\X2 H^P:OZ"7ALPDR#13?!.[X
MQ>>\8;*02Z.*.X])68MO1<ID_Z7'^AN.(I4*G.181<CXCTVMM9JG^?>?OJ*,
MZM=Z2ZXW]'[[A&JBV?99=82YE;GI.N6AW6'*D<,/.<8%8<T@>*N/.=E]>Z7.
M,^)P[6:C[_NJ!E]_M\PMR_&Q+&L[*=\IVGX72]R - C[\>F=1GK%NY89'#9(
MXPR;2BK%XI9]%&$9L]IA5R67X((?L8>U/8\GU"+%[$YS&D;?#>D_G,GN-,AJ
MQ%J,%UYOB H3TW89Z<ETWTS7E:G6<5_BK&%H#WOM?%/0^4=[":77R/6%S:MG
MC;(UC4N*?H5WH/PUE]^VYCA3W7&#]Z_?W:B0D'^]D%(&W A2*S9@#>N?0'2@
MG"Z-+N]5#60S'8[!<JQG&GC*'#V6ZI6B1@...%6><$?6K7"T3=U1X#'B8A81
MR:,B$.M86EM,[H&?$P-X N=!=$(2<%PIKKI%A=VZRJ@3(T4GO><W#9DTHE1O
M\[_C_X@B1K=C=6@;0T.KO.4<%XC6WN.J0=#'27D2H1B% )?[4]/5G];+S=D\
M/<78L5C=%L@X<OO#D ER65C 16^7EH9@WCI1MCQ*[;W_HT')*6&2[EL++$Q'
MSRY3>CW_/,N\*TAPP?0 L)54Q?TK9*6X-7P<P6C0\M@^OH7Q7&^?%'\8Z 9<
M;+ ]%"L <IHZ((TF/_ )/V#A,P:*VY?&B-MC_6<TQ>F"&$#"D_U[0?RW$&GS
M\8%8L3&DO^<\-&UCJ.RJSI^7AJ@KAN3-<<V]&6GY8S))7DD ?1A4VWED1<WY
M=23+6Y^I>;\I!TW/+PMKWX[,;L5\YMF\4R6MICK/WM2PN]:^JK D^?7,I5RG
M )<777C[G#9+%Q+?#KLKI$F!=(P?"* J9J.<%_P4>;GE)CDL0B(H\#*>O=O5
MV;R4,^G73[WM!R#&.TV:8W&+DLH*!D\CWX"-9>QI)UH>*QX]>[-< :-O2(D;
MZ8]U]Y0 ;CM!"=!6!\MJ;>OU X7YVKM*^>VA;KV@RQ?G#P#2=T@0HR:!IL>G
M4' @T*O3%F@Q)N-,)"^N.43II#F%'_#(;*A&PP^>_?J"M4?XV_^GBHUI1*&2
M-&Z;BVPP+BX:V<9\7G$#?\G0<',#[SV5%VSEM[_>4>5V:VOD*T8/B]@"8!#Z
M:S/0KTS+,V(\*K]TJLY##,6&F:!M3(0^J0%\EG<QT.><H_["A=VRND])<GZ3
MU#H?3!<ZE+ CLT$;5XC<8>B$7:E($U(RYIE_26ZPH%Q3W]G<'HG/Y>#\4[FG
M%E\4.V%R/JS77K$HM.5U^U?$S8S+@8M/$M9MHN9WL^;L;P&U'/>3U(AX\=EO
M*(YO1:0J)$W/E:=I^-[-Z0TI]*:ENL@<=NU+9S1;DG&CB=,D-N ?Q!@ (X]V
MOV-EI]L&6S2_4Q;<Y=FO<U7>*4)KBO@LC4]JF'DE99GR $3D;VSZ03D%_"3/
MWH8M7SY)4OQ.%I#E_WE*TXU+GROTL2*+3'A>B5=HO=U ^9$5OL245D_8.SH=
M@F">S$.1V+B]+)%-4)\Z*?4HL9ZQ1WF8Q(J+6I/PR"D-3Q^950= R[020=?0
ME':XK"A-0S9CNMSZ /QHX/5,0C!BXOD P4RG[[3$WRI8SXS01RIL1=A@YG1P
M<YMW7=*M!XI&$3E-<U,6+3AO?4D57JL>59-B VK_1C39I:G]QNHH(UC#28+4
M[2^4PC\!J\(L]VC:EX2+8W_#F@%,</(NG3UKUAM=M1#N(>1\F&Y[A_$6R>9Z
M*_I[O-ZS:UX$YE#S-XLC1^YX!&,P>I_WQJ+R.2LLACR50/LYA!7ZEN!$,6T*
M//63PR2N>^#"Q'I1_@LU,Y$C6\4)+&6PDKSQ&=D(7Z/G>RNJ]4!6*%H4C39!
MC:GY(M8'0"J^RPUR=\;+$[0GTP785S1&,::8)EC62I[0FHM^?@%%J;T*IN%&
M/UR(Q6)^1B"'\G.49]L[W\*L?^WED/2-=BQ?LR$L:$2Q") C^1*Y-E&5P#*O
M=F5I\B7LO#8H(21UH*L?"-W$'@-!:%A,(F4XR?%B^S^MT&V0CW@ZC*B)FL\B
MW6?0M+C-1=_$U"<ZTY"@4KH>"I.3+]0VTTXA14\9<^A&V"\*TT>)H?<C2PVB
M]Z]^$2'?;LQ%SO7Z>/"=%6[ASBI>XJ4B12M"1JDHW*?^XE=_%XJOUZVBSZ=)
M_O 3(^@Y4FDED*: 9M1\]EO* (BT6R$R5&_P6GD7OLX/YQ=.8'10&M' *Z#Y
M%A*(%8OCM?-[2H7_YSK^&H'V']]$:'3AZ54[+FA5 T7JM_RQ;NJR]:!?62)6
MR !O"/X^HI\G>Z4(>"+Z)I*+PC?"*D8(NS2VQX,,7ZD2PWX6@C/H)-*_30QR
M5*C[<5@?8='.I;7Q?D3HZ#D3/6;!&"HAZ#!A&1Z\I->X)JBY-J07A2=*A1#>
M>1Z8-7?%PG):%CDV75N7\3;IEFC4G/_5.8<6;RQUBH?P]8\*['2/L1,\G-]"
M/?;KK6_3I[<XURWC%H]BGF8[>8G0W;=M9+H/.F_5"&L;1S"N;+<T3AYB3S:F
M8)LG!#N_5EUXV=RNSC%#U(.W$94X.;'%D'[$_*'CN?S7ITLANR&9X&/MPWP1
MSG!WPS"$G3U-F?VG71;#YL:L_B2=/%A^^0>N\7AO8;Q9;=7/.VY<ELWM9091
MAX+K"V;-\;Q(C2\V8J9+QX:GRNM5?-U"9/5R87(,^;>?RNC[ID70V*]:7#-]
M3D"I;BN$&2'>VV:F-#\&M&0&[FE;QZ[O&:O05(B?<68B73!X_]#)!"7AP95&
M.ZS)-SNP&IO')2'&NQY0)[>Y%[%_JGN4Z60-.!K05TG?E)73I;?#KW\P:D4Z
MKC\ 'R7TVB^:!Z*YS/?/J.%2X.[;WG>5R25X+4MQ_5Y7O?-A$8XF\_K/O;-Z
MLMT4&0'SD-M]T=I-7;$388'P'$C:8 [-[Q[]HF63,^K;^@"(RW*6'9Z]F*NA
MW-3]T+<6.*8A 5[X,H>4>YY$4^,#L#_V>:@Z8(Y8JS7EXNKC+8<C*7Z)F[ Y
MXEKJS71\#_0N+L!BW+"?=ETHRMQHQ%1GA-?^A._/A%>*W6Q1HD9"3=QL290
M_<D/]X9PE?<+,RY<)-S#8((=;CZCJ;M?:>>IGY23%)&'? 2+RO=IR+)]T?,_
M:N@/HC4ARS];8NI#=0Y6I.[^-'%I)9X G9U4[)AV8 Y/KJ^.NG(8%\%C? #P
M7ZV&4L%@A(KO7+..?@G6!,^\LIFS:4AW8V#7(V3:4X9#+UC*)']FQ3,-M,^N
M.6,N9;SD\+?#V?L0W>.Y,?%IGK"MW[$N0T+Z6<Z3D9*G#(25'Z>X-_W=!>5=
M!]C?R-:7-[Y*CZMJB85B1[4LO_Q&Y;?ET //A1=(IC$/NT#[3MF6'H"O<G>Y
M_L-=AAF! $]?E^*'[60M$5ZKLE63EW1PRA@"CI/!2Y<ZC#HHZ8YGY^!:N @
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M0UG7N6Z.+;2B=PAR %MX0R"Q5(Y#D\8_<U3(;Q-"%: ON4.-YWK@K%4T7"F
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MRS(/']XU381>*W'^24Z(E7W5;OK[DG&DG"V59(GHCGK=/VDF7D^^T?Y"KGL
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M,W^U$L<;Q7H1T]7<M)IA.U>QA>L_V45K.3CS7N9J=I0B5LF"L8,&'B@USCO
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M*-Y0A^ (CU[+.2O$G.H^]=8FC]=R5ROL/U4IL(K)!C'@2),(.&P4 91WG0:
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M78O#L%=/KN8QYHI4]4Y7(HZ<'W2^3?,2[MK)3TN.R5U ]/7;O$5]F8$8]3E
M3"$">$J!*0UTN.L3X2.D8HZ3+LP9UG?4K6=N/;W#>[Z]-^R-_@T",*!.'B02
MJKWDPDPO%DV_6$L 'F *SL:N-C"\+!_6R[];/!+'JD_QD!5.JU:8)T0 /K7L
M3I;OP/-,IFC"6ADR+'5GJ>DII"300[Y1,^CNF2N/QUILSKS+00JQ[KTYVC^7
M"%W#MJ-NF;O=)%4%*9GZ.;):NB0YV_H5^CKJHY>RSV_BS3Z%:2!>YT&GYBOI
M=HK5R]]BU1@T.1YE:A5X"4B&57U(Y#<E*IX+)DH/[(_8(;S\9P)0$(QM8(2L
M;D-P;DXSUA4$(+P*LI!. $2@G5C?3N([DG4GL;!$>8B9S4DPE\W6<,3_95A&
MXNG0M(2)B%M=B*(.9ZBUIY_!>)_##2V018YYEX$_";8YO_U,@[FZIY"_*IN_
M@B1,$GE7N,W/86 CWZ9K*UASP8GXU'BZI:G;@R4 S5-W^6M+JH]REYTV F/[
M:"Z=\K6[ZSFM#E9*I4 :4MNWKO$_FX&?5)V2]*9Z[3V]++2<87!#)#OO4H-^
M'*MJGH&[@R%]@VS>^07%L/2:]D0=?9$/7(]K<S7"*\-'N$PBE]:3?"FTT:3Y
MC_U]?$N)+_UJW^(L2F?2%/W1+!W!Y]6P!E=5 2><'[L&7/ZK!-^@H[=O 09/
M *2^HG=Y40.Q\(&B057JRV,V-OY1O!C9H*E[#8;6GZ>\],;Z4>:="0$C*">3
MS9'7Y=)=<<HX>%R\G-82#IYJ<?>M6X-<J8MD+5;^5M.TOIE>9/X@>)*.T31D
M3F!CY6$2S7:!O]U3^OE=NJ-I"%:&1&%SL\UX-@RJ.YE%<(O>9*C6OB_4_ 2N
MH1'WWHJ=I,$Z5U4R&I5A):AF(Z-<>6-+ADRP@90U"'$,82'-&<#A-JWKUR//
MN!PNOKI14#SQ]/(22++)>$_TY%/^&$J7%K*L17-$V#R:-5B@^1:"+*?\S5%N
MY8>!PQ[F/2%6#$(AJ.>[2PM31@U9FV;HQ%V[Z@]!6:9#CE:F8S[T=*GYI%X]
MKM2YC>,M])42:-MSQU*S33Z0ZV7=47<.M*TX=OCVV;YBI9-S&U4.*9N#9]SX
M,\C!8F4<(J_SCX7$#>++"< I02/OM14"0 9_,V,TBF>-+A75B*K6*MYY?\R;
MHRJ'.3OL<KY<[<<8 F#@N540?%U$==)8%*]]I?%X?^U5\]2Z N7391Z#ND6(
MOI;DK!-1"%62YV07<[;T'5SMEW8HT8D(!\?"KU*[;/X\JMR-#TJ+J5ZX\_9D
M/U&W&66.R'CJW.K#TOMQ$B'P^OF<*IUAKL##*),O5>PX.R-IAY5!@3)YNP]6
MYXK7=0Z)OL1F<V1X;.4$'+,>W<4']+Y?TT#W;(ZMR;"(F3K\],"_Z5K8S.$K
M?CIU&Q6B>1'*%SW<&@2+A-5+LX>&WBQ,XZ+MC\:+]%KE615Z%^;)FJ+F^_!O
M6G:GG"Q0'WS@M1LR+&XJ/6J17!0C_CD=,A)H,UQ*GV:UC[5#0/TU>I5[APXW
MR/N^[:WT=O&]L$4+EBN.Q[=SA9YP:2;/&E7!_,2IYS&VVX=]7!R4L61' -X1
M +&H6*DG^@BH +>(GG8_PL'FZQ.#Z;Z"1%$F4H9X-TN %"YB&-,IG=.2X:[]
M+!J4JF/T8]&;;VNVQO"&>/\3,Y/&DG<%?P:$IY@%P:"JMZ"@ZR3[0_7AG#H4
M,*CY*?'+Y9+%(U3VH73.(-W[,*CDD,?M$!W=B)O>6C>]J8S.T@C_\E#Y?OS#
M!PPWLO"&=7I&T3LD\:4 I!-' PAVZ>2Y5WQO$!,J/#05<V\UKU]\Z6-0""\Y
M/Q.@OQAXNZ,))<.$M44'^HGO75.[/G]Z@..]^?87;'AK&5?O1F>IJ?&+LS=3
M8 :I*_(6PUB/R? 7!8ENG[L]2DMQ&A?*;<]*?'!+Q$$R"0 P71'IK\ \U\"J
M(CVH/&YZOT^R4R[H8MOE4</>!K[$_.F0*=$"::;/C[2-1XP$*T+=Y>0M],]'
MK0L^/A5:'"5[8C"Q_LQ2FWJCJL : 3!#!X+TG72;QO7CE-_8W XU-VDYG,3^
MCD)Q..63)7Y[*?%H;N*=J#E'WLYKM2)-XT:BHT;#AL$D+BQR6\=?1*0P]$;!
MPNU[&Z-9/>YTE%^)B=,G +2[\8SW3AB^<N!2"KNZZ-DO6G%AC;^",M.HINQD
M9./1-BV5]\MADL,G5N>>Z=HQY\FR'_<(77$Y3%FXGM'_E@ D9,/4%KL7'1NV
ML>VLC&/KXO/@U]3%KRE1,];]))UR/HGN(-. ?A@4]/A_OTET(4&1FI]O/(2"
M=&*).P7X.T/=@5CE.L/[H/C;P:E?]U+Q-5+KXL;PIF'.S2YX?#H&+X\A^@_%
MMNL/\"Q%PJ ,IP.(::?X9:B##AED15R@!9.5I1CSL7GWZI:_&#$>JO7FBSS^
M6J'2X[[JLUV]Z(E, ;$+I<Z!HOI#ZR(A]LC33&3#"!AK42N2;E'@1:\[>'E)
M(GYTW(0UP^X. ;#BDX53/=/LC1KMNQSD"&.P=+TK*JTU[+A5*Y&.9!0PV_T)
M]3E^SVO-+,[L*^/2VJ8PIF?YW.*Y%5/E2)?D$-KL?,9$WP:$<7E=P/KD^G&K
M)!_T1DU,E(*-$]APZ5[S#?%;:T41)7Y)OD>M[#Q0CI4]F38,,W201!"NVR3)
M3P>C1A=LLX43XG>W;565R!Q;<&IN3D<(Q"]0@=,??#]DA\*/S=&/7./!9?M4
M6];36"0&X^F26?$I\)4THQ*B:,]PDU<+O;JRB96]>-ZGRL:VL:]*;DZ[Q/2]
M)=;Z(;-C&^L$P)>J.SV.6+SE^(U6KI=*_>I!&<MS00HG1P#&+I?E((DEH ['
M_QW 13C1GA?Y:9,Z1V(O)VJZ^W3J51*%SY0Q]?B;-#U;(%3,D0F!\Q7MG7\:
M?.*V%J(E_2AHW2N_S(LN;FBS2:VEO'?S"/8ZNEC3R?5V*/<PTR1/,]?]1_?\
M+#MA@^'$$O2ZKV7A>JGBGP>:N5\4<U;F8Q?;B?V*E1(!R$[=FR6V*X<[0@F
M)F3[8SX_>#\JRO_7F,[P>N\+K2$HFV$FNEAVURLIK%V#^I9[&NKTSO4%=JKR
MNS@H#VYK-]&O,>8MZ+R3'@$X(0899^Y"S6'PN\0^40P)[^G$;0BH(6X0F[JT
M/>^QCO^X(PYD\OD?0?!AN7?YMATA*VEX4 HWJJK'3>#Y\ROG[E+Q7CH%3X@7
M<KXP*8,5."JGX,%C/"B4Z<06MGZDH.!<R.TSES*N:$,\GXRTS)[=HX*W/EZ5
MT!^R7"&ZXR2Z$\&#:&FL'Z4/AW\]GOD%G^.>?*CGN@55=^XP8Y8N(NIBF*A\
M>:;Z_BZ%O-*#.^!FG'[;%>&_16<#4]Z_62[^Y(2Q_/\$83Y-?![S[34F?-5[
MEIK\MFR8 "3I8;/Y<]-2O\*^ZCV!=X [=QK8TI9H"$!=>%V9&-Y%B3@W36MM
MA0?Y,:2EKB.(4\I@'T7(%^27?"(J"4:<DU$<9"8  =HUW?;G'Z-LRE3OCZ3<
MDOE@SULXI=K@&/(,T5F$?N4NI5L6KV)$XBQO<C\ \6@G%YLS36LSI5O<L^36
M/R XOA;3,4,2U(*]IN"0-E<19SD_VFX>7RISY]SV\Q4V*[:IODL&8,'WP"'5
MBR^3!AN?.Q:7]6TUEPAM"'X^9 9;THR6Z;M-["3K"C.">>VX14N$:5Y=..[3
MC<%.Q/V'<#D#K*VP$R'[DZT<'SNQ8*R (@0#(LZ%7=]Z A]7'C<BPJ21Q+F[
M@67@[+$;L@C6E4KV=C/*&4ZC(SOA:"(N,6'L'SH2V_\AD.HC4>>#R>B+?] ^
M>$C;R_9C4-;#( J+I^/1CR(-SXU[MAU+W\4LT;=9)=ZC:E3B9XQ0D@9(YA#S
M*9[(*.G1*_H1XZ#(V(N>['-!/G:"4<KL;8*K-#6!Y#G;V:U\XKO,:,GK<VCA
M@:%<@UNF+VGYYGT[C5*_Y.E55O1U,9]SY$XF&322)">;T[;:UPN7'?G?V \_
MZN)*?.#TV!2*WU:B>)W2F^)F-H;C+WBJ&IZ>@('B"$!W^(7S*_AH4XKXW;,'
M1O!Z.K%WFH-^-/P;D*CS- (!'U]MFI+:Z<>I5E5Q#@0Y3ISDY G*L.>L#;@W
M^@,ZR3#&Q<I5SD/;5*Y2SU61 '!]?&C <4R*K*5 HT\U$4XY*\_TIAO[O.79
MXO9Y[D,BQMEM4U(. U204?F86?GO7=5'(IY&-A8WIM$!NM>E 3?0O%4RXS8!
M4).;1:%V86ZR(AO:W[Y^(Q#\HI03*M81O$< ,CD.'-50_PV(*'2O?D'1=W(S
M2[!KF1,"5V.QKN1,164R*EA>0/RXXDGSV2RO+CA\ _G-!1$B_R\@5A(3K,P9
MJ\J!*TMEU8X<Z,]E?8?KIT*0!<*:>60&4=9&82\3G\E';S%&&5^CJ+J6=Q+M
M_%[LF&$2>&JCI?#2-W64O[GT8.21P9%VN.3;L@3U0$K/9?DS:?5^/FDAJ!XA
MS29L=E]?^>H/>'U%V'^'PQ\ANG$XM]05ECOR9IO=\#<V,0DU_<3NXM#W-29#
MV\A"9<17?V/>@6FA-"M[T3>+L9*6V+L4;I_"?<8_J \%%="4$MOQ>I<9I7[^
MU;.Z/%_.))Y1W1 7.I]_[LP3UN"G$U'F%1+F_DW2D^L,;7,</*]1O9]C+:U?
M%63''M9]41>5Z?^  (S*JFX4(/HTC3WKVL7C'/.K+:I($GP?-K'S)W&PE?EO
MR: -!\&6-N,55KCANY)WW\'?/9][IO1@V9Y862-^7]VQI?KZI4?B]WRO\?MN
M[B*4]Y8VQ:ESHF%0LM\C1<NOW=H84;Q:L<?:PKY4]ZYGF<2<EUX^&Y'I.F$C
M*,%\;L7^,>PI7S+S'9I:;N8/M./D;A)PO2[S3].E4<9Y\7XMX$01ZIN,[$>P
MG1C#/GF.MV\_G5R>F>_;AK6SV1=ANRF9J/EN(WNJ01NGUAGO0_(Z7QF)KT.=
M.$C';\6K*"DYCSXI7V!4[L*4] JM+*>,=50AI.^_MM[BTAEY%#:U#'G 4*X:
M7>AP&0%^\6OG^/,X]*B),WY H;?G?A4!P,3G<JY4HI\;&<Q<"UV;)  IM\.%
M(#LS9WMA%K+%;TW@ZVVPZ28"(-=P 2'HO^@4QXE=!WFY$(!.$8WT8*[7K-^,
M'/M [9ST9J'&G0,C3/UT!O-Z"OC+$\6?B@/8-3]:^+E?=)&7K4CQJ%F[%77U
MJQ]>I%QU)UCQX::TG _,XLQ +S3'1IL Y-94W!<VBU7H_4+9^ZEP R[56N?U
MT,.^4[I#+/QJ'V?![ D3ZZU8_:RSL;YJ_;)&"M.@JTDI%VEEEK2L>73-F(=K
M7RJMG"Y(C,@?'8N:OM^MBQIM@LV?':!.2/;X(?:82'WS;P(@/X3CO1#N($.*
M_K%]ZN!O,B1#3RK<DSJPR1W@LF'0"-/?:\1X6]!EF9-K02'L8M,4N\V'[4#T
MD[VF!2(RY/?(_\IRYO=S]HUIR""=4NX ,MX4H$#__?:AOO=O6>)-35_B"NV+
M&E^9K[7=/=K^$+>$3*SKH_O<>][!GC=QF76$?S9 '<EC(BV0%#X^2&W>ERG+
M;9(P*]G3/ZID41[%_)'M9.@C $[U_""*22S38]O!5T]G)BC]^ZDCG:;.WJ&A
M(G\WY<XWQIY7DFDA<>;G5"L?Z#H/+F'_=X1^KPJF<6O*?3-K=1YR(?/\[AQD
M5+PUY?:GBT>/753&*',@UU_M@F<X2\6E-SF3V;S#.TIGD?$7$]*:<K"SD[U^
M[JE0MMK%]N^QM);6+D1?^W@K-%O-"-9[PL8NP\F&QT9+LPR@$N!_%N*^$PAR
M/5(WHE$:#MOI(KI:" YLU!.S22P?;.!Z=C42;<#ZY(X^F-U7)\)KBSL?6F!B
M8EMY[]ZN]YM[E1"K*+TJ*M7!5RHF%B'"V-QAD[SJ3[\NV*4>7_C=^EW*PCYB
MBK\L(H^0>320N$\BC!BOX0:LC:/M(Y&$VSZ^,SWLYI;ET\;QYH4%A<9)XJ?.
MB97"7BW(F%,N,OY&IQ8!(!)$$GVA?4&NM'_A)_ [+.4?Q7N)=]<:NEI46A4U
M,8@^G/5LY0)P! /I*'&_>+=>A6>ID/NLZ>('5M%T#&M\V"/QU*%!S][&E.Z:
MMK;63.0IYAB/XZQI7!9XT$Y \^MD1HZ\;_12NS?SKMUB7B+?(WU"RROX\.&L
MDC<Z0.CF=93V]Q($_N=T_;5<]U$+&03 LX=_*G;6XK9A]9GG6]8$X$WOW>+<
M/ ;K/#/+\+UVY0$D?EUK^E8'HDRWL%09-X-<["( 7CE_=Z9<89']#=0I=X65
MNRR*-'XJULV> $R6EWY;"75'4R^]36;"V3O0_\:*@F27Z2NI"</6CKQZJ&#[
MJ=! %W_YQY85@O<A#@YYMA="NA1/-[2/5R&NH<3MBD'$,N^=)L:4<S]"V#=_
MBPV>,3\&;HZ!&O'W?0>Y6_1O9]SV%C9!X=M#\[:#0UPW/:2,E"K"77:>Y\OK
ML<U/J_T KS9P3<]GL/LFPYXX?-16YM_.(&/ZW/(UM7\*_N!C*#X=CBE_[DPO
M[QI;.V7.QE(H%/RR,W?$] :K<7R_6L5G,8'+(0&7-&K#+_>OF,9]KTO+&PW9
M^I/Z]SQ*^(U'C>:"[=CL*(9?#W501KU).EK%L=GSZ?O$E;)$P_00Y=^N]4V$
MK$@(Z<F[Z:;G'WSG/)!7X-B_F3" OQTS<I!9_XG8]'&J?7P/1E)VAW"J ?_I
M+!"\JH?TLGMY(X-15"GHENT\0Q&91+\6G&'B]55.M5R/3(.Q(.A(DK97\=.,
MT>KAAY44\N_6+\7;>B-L<DHDRMO&4ZV-K;<CEY5O&<9>B$7RA90?%5U8G$#+
M2B\[O+^Y3)+<-\.'^O!5+^9)C'EF$$7H2X49<[_:T/XY[%SQ;(V;4=Y\T!WZ
M,>EZ$XJ=YHUVDEQOA+ ON':#6!<PR4??W"76!']^)BT<Y31B7>',)Y,-1#]*
M;EJX=.0OKOCE3"E5,&^4P?+J9,W5CQ^<[U=(^FE,%E4P)Z^O"8F%385MJFTW
M!DCXI-TN,C$P-C1M/>Q\PRN-2L5L2TEEFVM77\']A8U^)<J^NNB)<1)8M 3;
M?R-I3\=N//^TA(^OA@"3>?5#7BCX =F,N8M\]C1.,Y^T%&Q=$XO$%;,';$[_
M-%O5@]ZQ""#=L7*F\)S/ECO1>:A&+3-[=O!>S S.OY7527P:6];HTO-E*Z]*
M/OHH!>CF+NS1W*6_.C/<B540>["T'>YM]9QO>V@]_9?"]V-4$0&0U%RIQ"@?
M&+)@*H*!.R5P7]0%N0'(V[%D401I,_S A&Q_MK>TTP-^\4> J\9LR!(/Q755
M3-'+>RPC;S,T!X385VE<W7BF(N@#5X'>GEP?&YB28>2#W4B3L$"GE[,:Z=<X
M)J;DDZV."'_@;%U%'J)T/383GX*Q[J-YVK&VI,ML:?F.K#>Q4#+?SC[BS>YC
M$<&IPPDS@&KJ\GJ[A6V-0WM'<DYP[#.M)YX$P/VF>>@]*:?G(9/#6P7>['PZ
M@5?+US?$/'AF<[/B;^C@W@='&"1-FENPA?G!&DC] E]\'[YV3_Y4:?>K)<NX
M]E@FGM I_![_ \T)J&&&;L3OA+ED2+MN@=_S<_,ZN/P.B.*O$9'<ZF<V=X9R
M5A35SVSM#.6N7--\BX*I$ #?MUGQAB8>/PB;<5(1>Q 3AWWJF%-' I3$ G)@
MZIIIP6UAYZ*O_PT ;^^I)YZ?8]>D9YXM*ZT]:-\@G^I1RB:[41XU^M[QDP<3
M.=*3X[5WW^E)<]O5,KHKK+!SU$P!>6+#+YPO\SZXGUUX,><:"\Z=R6%(DZSE
M4P;*5^4"?HW;8*EI=%B1G">+0M2IH,GL$/+H!Y6*[<BVKB3IL.L-FF]I&:0.
MF!2<5Y0L^=JA6O:UMI0%'DMJ% ^M/G:LJ9DU?DTYJV?!-)3&MNW'S90A>PI_
M0";\0,FKZ0]*. _(S'Y3LA5,_9< [M[8]ZT8[[6FXBQ<# J3CE?*)Y89^9*%
M,4RY):@!8[SW^2GK/0%X)Q0;:I >IB/OQ8!O'5OO@O,H?S/:-H#NOL!$FBWF
M$X"+C&OBOM^\O((I\Q_[NUA]D1R[OHK!Q2V7>&Q&3='3.S)#8M)P'+EY=Y@.
M'^PY ;CCM#.+BD3^<MU0NT:]AJ?6UA:U94+%^],19UUGQ?IR7D*^1%S&@Z_1
M@V\H3JNL#9.M*2V4[?@M!9+ONBPH\]-:M].65&(WS)J[MO2(E6CP#DLQE"WG
M_IK S\3#OUD_(<#3"IW<?\*=[9] N8RUV#4V%V:M[;1_"B.>;>MPXYMI;U=W
MNUH#.EK'?F0D<1LA<WUG2O]G#YS?K'D@6.NC%"C\3Z*6^<=8WU^S8/=L53.H
M_)R ;M63]FBHG1W;'K0XQC2AF5N?<EO@@;"OJ,_M0EL.[MZ-]ANCHY.:I7:&
MCTL2N*LM([E"/<0#[DWN(9GGZU+Y^0;%?!:S]Q9V6.2_)=G0^P;JXO12>?E,
MZI;DFPJI>X\U>,>8AB+ZR>R ><]F3"%#M7K,T6LQ?]P3:>O-A;]$_+,S/3 R
MAE(.\?O4'PCE^@_1!S^:V6*B'V,<.'3@(PSW1##0"_R8&,YMZ/[_H+N!%\YV
MZ<L1VZL:\!H2/XN,ENG20%1/*^.ZE/=!;&D="#?=3G[(,N(;:/J8F_8K7\7Z
M6*.0GK:UX7KQ3O(G*A:#K1^CKA=2<GIBT#6:OX%+C[F9]\\1 /.0C#@/J8R*
MS]OV!1\6A2D9(NT^[\D>O=>I55;]^DKEB=B'R^R?1K6..&I0<DUY-&\4H%K#
M]]+#]QT)UB> 9O-2]F/U@A$ -U@KVVPVU.0@UGU0V/5_3BCXYWY5#YNQ[T63
MN,K_N=/?J^3*DAJPZ&Z<BXGU:8;V7F:M6IH!QX'% EPV>%T>/4*D]*D<7V <
M#"EY%2YGXT1*_LZ?@=/9>SK(?.'=DBGEKRL;!HI*MY/5P0<N% [-V&F*2K,<
MUD.?47C"57J\S65;B<$9F6HT-_];I(;^4?\\G^D%WZ0]0(%=TY,97'_57T8Q
MF9,P /SMXW\!4$L#!!0    ( &."?%@8 B$K*[<  ,'%   3    :6UG,C(R
M-#<W.#<X7S0P+FIP9\2Z95A<6[8N7$AP"!)<@D-P"O<0W-TMN&L5[A:"NT/0
M0'!W".[N[A[<'2[9O7=WW[Y]SCWW/.=[OLD/UIQ#WC'>56-:U<O<RSH 1\3%
MW 0 D)"@ < !_M%>#@%HPHZ&EJX " #T:]_H=6@=&L\,#+;C9F2T 3'H&]D:
M&#,8VEHSNNC;,3(S,#$"> 5<[/0-+8W!Q ;&IN8V?*0G3:VDQ.9&?*1J;#),
M,G9"QF;FXFX.QDINLLJ&;I:&7$:D OS$O"[<+M9VUL9@?6(7:RL;$+<+'^D?
MSKE?GW\/,Y(2_Z$"MN0C%?PM(%:7D2<6LG4P)F9G8*(W9&("$G-P,3"SL[)R
M<M(1 YF 3(Q,'(S,3/1 (#<3.S<;"_&?C?05S<'(A%M16/1/K-<>'^F?23D[
M.S,XLS#8.I@R,G-Q<3$R 1F!0/I7#7J0JPU8WX7>!D3VEP=A8Y"A@[D=V-S6
MAOAW7]_ UA',1TKZ5PK6=C(R?W?\;]FRMF;\2QL$5C0V^<^U0<JN=L:,BL8@
M6T<'0^-7=;)_@OK/3?]2-#+\NYZ=HX/5'WD:&3(:6QE;&]N 0:^ZS'_HOD;.
M+6QKZ/A[5$*8C_1UA,'(W(@;R,G.QL(NR,+"R<S&S"PB(L@F(B0LS,4JR,S)
M*LCTB?TO6PD;$%C?QM#X+UOS?]@"_U-;;B$'8WVPK8.RK:T5'ZF,N:&#+<C6
M!-Q12BQOZVSL(&]K;O.[ V1B9O_]&OZ,U-C!W,G82-3!UIKX#QZYS?\-/@>3
MB!"',"<G"X<HZQ_XHB(<@H(<'"*"P$^?N#B92?^T-?HW>?]IR_4?VC*^!F-D
MR&WXM^C__( H&=O_^61ESJ_D:*3O #+3MR$6-S8PT'?@9?Q30/RWI[\I,_YO
M3EX[8'.PE?&?7@2MP'_W]_N%<EOIVYB^!DEO9&RB[V@%)N47='2Q== G%C8V
M,;<QMS$EUB>6UP>;$8O:.CCK.QC]*^3?_#'^$PKCOWRN_QIZ+9;?CW^OTM?.
MW^O<V.:UN!U>J_CE"" N;V8+M@69V=H1LS P 3@_2<A 0_\QE[PE@- $0.%3
MB!%  @"0KW]_R"C^D*$^KK\/[JOK=V%D-6"%57<^>#D&H/Q1Y0"CME<YQ,LB
M(   \5]OD/]H4']O?\G^$$/\L^2_V%[: &AP@!^0!% 0: !(- @H-(B7+L#E
MZ^0(@'GU_H]Y$_H-#"P</ 04 B3BZS $--0_R0 0D%"O<CAX6-17L]=@H."@
M8>&08>"1_Y0 8.'0T#'>84[/J"7BJ,.38"5@,Y.2N23A(@C&UW(XU\UR*@#)
M6>.JI]@<:YSJN?0G)I5[YNPK6(0"Q?LD-++&%0UB*"C95;^(??V !H" @H2$
MAD&$1X*%??,[%  D%!HT^AL29@P80072B3A8^VB@8NP[94P5+#C]K(IQ!S(6
M5>Q3W_;U3S&5DU.../!G5>2LU1RX!GY"(# ;9[:2<)>8D<C+ @#I-2=(-"@T
M@ #@YBQ FE0? RY)N(,2C2GXWW5$<FW3\@;G&O<SB(;+3A+N!;^O6F5+IA3H
MQ_GBDE9:RK  ?^+,TC\J:"8/^"6]+_NLS"'7P345:>'Q N#KR^D;D7!W-#/V
MG.$+BXS$PFH/PH*DE4Q14Y&\-+SS/O;:/S'NN4+>'Z1C08/6<(WL^1QA_8U#
M9Z.]VK)\HV-)^;M=R"]$T><+WO"KB[JG+$W>[72AAX^KK3(FGI0V;I?^A^Z%
M>D6X;P7KGC3=A\XY9F=6KP/-+A+XQSA.)C7R)5*_91@N*SZI][DAM_Z:7#&-
M_OFS]@50S2.65G'MV^J5,G0OO73Y0/0K\5>/T)CU"T#UVS\A158C/US.F$^8
M[.;/W2BWJ@*)_&WOJV^2MVS+TEN/$,9WZ3PS;5?SJF1C.?CX>QN_WU=$7>)[
M3^<WCY)Y>AR] ,Q4([F,[E\ KSC#W/\9CM[-?Q2LTVNPM*_!'CP_W5NR[K.
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MV"-CZYHJQ!8V9CH[5!]=*P>8$WNS6&S#JV;)6JG5*(=U%H8.KRMHUAX\E>@
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M-Y+:LKJ*:>LE2@ZMG=9JM9.+DC0-QT.F @:7!AB:V@2#US6B>+X]6HTXL=R
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MQ[FO"3>\3!1?ID(+4\S!)QRP0U@M7ARP/FQ6;8\99JN6BS]O5/?7(]N.%-+
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ML,](XV?#67=-M)ZO N=VYD5W >V/",+\CI)0G[[-XW*HU89^2D, $">]@P9
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MSOA76I-V<5LSB!2V*R[SMR(#BO+W8 <% !I7B9BYKUIF0KNA3YL]99=?)E\
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MVTO.U+U32&">8ZJ>LE3C4-JM< IR1R+_UML))RHW8N4LYM1!J)IG3X*5;'5
M11G@AE884IJ2_!ZIB0W01=-/([OB7LQ1:FXX9/QS0;*O 5T";#&#IL:R*^YB
M9I)8A0++Y >5LJ[#ZUJG5CMS831FK$7K:L/O &>%AW<G5%XIM+'6LT](W$G@
M^R J.3&+L]*K']#TR48JH G*ZL-6+F&-1QC-</I05WPZ(:H?+HG&MAOJ#]%I
M_8F"-J@*%I/]7*?P_DL$/\5PW):\RYU$::ZE]O.:#6[L*N3Z^<VB[(BP0#^<
MLW--"$,Q9,B^Y:%..R BO.BO16[J][AQ7!52(:='M6"K"X.8'240?Q\\.2B@
MS"EONN/3C=02?O%@9YA!6![9NE'126XN7EM*6\ E355T?W=%K :'),-Z#H=/
MLC0  3=D.?H> :8ST;%*?6D(G^5=1<_>TB[<M9_X4#B291]YU.R8W>&J4&$3
MK5>Y [QAK'DM-I,4':B2G=O3]XL^TA>Q'D0AS=TN;? ZAIA"[H0,1BFE<;"R
M"D<%/)5E?)%H;E2#\DDV:D-+E*%60H(%=5Z(PGE0,-C!V9(Z2SQ2!2'#*KU8
MRBKF>$N+J^PK^XZZ^AM92OBEG:Z;$ #>XUO2"'*( >0?I1T/[L ';#W1VUW0
MX>>&J#1BH))9#[]+MA.IU.9"#PHE6VY3E%[@5#A_5A, 54$4<XTS4M/8!UC>
M7<]:C:B<_..Z_=U';91S/-YSN-S&-HCE4GTJP4,"*9?C&=L[2.P9%C*[@<X(
M)OP04?-MYN_#*,Y0X=1FYA'+#\O+/&+:8E\4,,[:R9R4..N!\"A$PF5(H*1E
MSB1F90-K<_.!N&7[,/* 1JO%' .SMQN*LH(YB:',+$ZE<%<FX5,*)N%Q9!T0
M2)G8U5[C'Z$E;5(.FAN/>ZA-&I LJ6PH 3N)6&.H&V,29FSO2F@L.!&6C1MV
M=%*UEQ;4<=]3Y)Q*2A',P&Z I*#2 "!?\Q_69M2R%9J63 GS?RWN577;+54U
MQQG;QB87U0RHK)+N-)[K_D68T>?VX^)\L6$B<->%W&KGQAH+;132L _Z2 ^]
M50KY6JK3YW]^QT698?JWG<@LYM[!5>"IC_=5]F2&%8[WR*B$4_19X/KS@&";
MBL]V(F^]Y>>-5HHU?=</!>0[)K=/#08&AII:.,7'GR3%M.=Q*XRF2;\FJZ&D
MTRFB9ETF]0 &],B8",D45,0(DGK\BSUH^5FCI668?PQ\1D]J[/%3 CRC,JF0
M?OSHO0TQL%B@Y>WD3J']6*#X7S^1T,FLYY_I.3]N-2@\GS:]YU*]]5Y:?UHV
M?L;"U$YY/KW%TC#%5/XW5X?>@W(7O6BMO,B@QS<+7(/.:GM5>LO %X &0A-6
MOH?_:6 2;E=\;@<=_:X>=W4^H#HM8F5Q@M*9^'#$P+&G(<1AJ?8IW9;6ZZ[%
MZ^>R/A.'R1*2BI&1"G5-F 5I=GI.,GG\#D]T ^[(TR[]@$/"!+.8#*WO?"<A
MN*'++EWZ\S;? DQ(M!-U.LMIW3VV_]QH6A"+.LAUEU.YF@5D%"_X759/ 5-,
M_%?O@G5 :.+9O0_9"P"WP[Y"DD^C4\,08BLF04,MVQ"A,-?K5&+J>(<')+K+
M3L",HEZ?>1;>\J&.89U*(:*>R0'P[HVU3+4H?3S_"P#99;:% 1UD*'XQ*-%E
M8\U&0\B=@^N:/4 ]5_MD;@NSI7&D.=&-\5;_TQ4F;I/TF^)0!9J])$G2-WLK
M=\<FH/KYP7./]8PC$5K+JA3N/?>WS3O?E C[G9L*$JB$#QF>XY,(_;POI5X
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M_A\S:4+9Z&P8(V-'/ ;TU1BS;]4BZ[JEI&9K"&(GJ'\1XDS^B(Z5F$BO%M%
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M@JM3E%.O.[>2;$L-#E"PIE^E;GJCZA:0JKHE E8#_B@,%F1!E;AMF.P#27?
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M_J_(DJ%?K! %)P%*+R;[W96JICL009.M1L$M<BPG/W-WQ,,RP5]!#7:[:^5
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M#8]G]8!>_H8Q7(4+.98=+IC\0U/F;;L9_[^'>FQW=B5,>,C^X?[_2R"7^]_
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MBP%W$<U!2T7+1OU>FRNCKERG57(@#6?5J>:K@5&%_"$YSE*&@&]H:U2?5T6
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M\_\CVP_.OT.*_!7RX,Z ]!\AV_Z$Y)"([,[X#S:"DHV_0YYP6$1VUE1L3D-
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M?F&H[0G\@/?QD FM4_0K:_I%8L>CEKXG4CTAV3"M&<Y0,M=O@$W# H!2O'X
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M<$]TCH!4UYI\P!-+JJJ*2X[^JVO/7L\B7'76=+-&8Z$D"!%P$F5P$NFAL#
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MF2YVK%.7)@[_Q_9S&/MG :>T@$X!K3@"/T4^*W!9;$T17*4.-G/DN84J)\5
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MOI'INX1S5OM)Q[?3/*YL17/)5IN6,Y&<F0N3CH:"VT6;Q^XT-[:=MZ4%"$Q
M =&^/,I1> B#N+ GX3],U32YF?%YR%/76%.6AJ\JE-1_^< M'X^4I)3K\IF$
MP$=W*0>WET4OW:?=_G@EH:F&B7?*3&V<"K\N0$&PX_#\9C%.!:=H8O9 7TG
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M?VG%'+1IT]1N2V)&LY/22(,"XE+Z-^8N<(L^,^W'=<0@\:75#4?*5M1C*5!
M=\9G%#"6.'<!*HA9T[)2'4;>74 ![K WO(B(/.K_0@^FF*' 0V,-;RGG,')!
M*8M43AH.<$('()^SX9-2\:[VR^MZML@0[?QN\;LWB+7M,'X"-\E!O6?-5TA&
MIF.JY^<B@#=:!O\23*.[1_D! EE=KM#EFYXHP)3N/.5<$@6T/\O]@;[MBY>?
MR#P;]CBN0GBAFS7(>XWAO$@R&5\!Y,T?D4?]XO_J5AH6IWOC' SA#V3I*5ZD
M?$Z7$;LQJ4+X":*2I%R$/:_ZNKWDX$"@<_A*J1#P%=,<'/^^ORS9V>&3Z9GJ
M'LKP+&T-#-8<$;'B]*VJ3K\+W9F]24:!Z<Q:HE.7QY*#K90/9+3&WZV<3*CG
MP1?-%.!<)JT_;6$Y1A#^ZM5\/ ''[\]=/=]NVBP^$OGY!(HAK5ZW9(LI:0@/
MPA"^DD8!-S?Y+M:1(F//D7<T[]KN)6^T90>ICI^'\0C\.P]Y^(^F!6 7V^0Q
M^*P0WGWTH0?HZ16"/V<^NJ./T[(0RY('C(YX.T;+&/64\CD-L3ZS?8=(LL0(
M-;MZ+7$++OSC58PBMB3C!SA#N;\VY@/!#KHZ#'U%96VC^0"B<M#[A?RA597#
M)2)2M8@)WTSYYT+'D-=!T6+5<:7*CV5QE;3%=QEA70T9EZOGAK')@9#")!1
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M04Q1A45*D<YT:MRN3^_(T@POVUA.&09@6C:G\CTB^D@BRW!=XAU*:4#(J=,
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M$):&+]?[HG/WINO%YC7A4YK8YM@'O&<3+7A[L4&TSQC1&O<XX]H+!="N_P+
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M\(RI@^]V0Y06&K@TZ!0B.U58@J+:GUJ$:FNZ":KLSL)%\L Q^]@OAA@4%U&
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MG\"%]=T0%MI_R'T8:@+X'Q__"U!+ P04    " !C@GQ8BNY4IJ%Y  #@?
M$P   &EM9S(R,C0W-S@W.%\T,BYJ<&>LNP547%VS-GB@D> 2(+B$)D"0X.X.
M'=PMP:%Q=PT:7(*[2X#@C280W-W='8([3-[O?O?.K/GOK/O/K-EG]=I]=E7O
MKJJN7?U4=?7+W,L:@"TG)2L%P/V]#/Y>P,LS0/%14E2"4LW4V,+6SMK.'&KJ
M1"EK:\Q,J<'*S,(*O"P"0< K)"1D),17R,C(J"BO4#$(,#'0T3%(7N-A$U"2
MOJ6B(*4@IZ9C9Z!^Q_*.G()1D(F%DXN7C_<M@["X$(\X.P\O-QP**BH&&@8Q
M)B8Q-Y@"S/W_>KQTP>4! !PBW+\&\.\!!P]"0$1"?H6"B@8'@.#^<_PO1&P
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M-0<SX_J6K %#X[\KW7@(D0,7J=]5S6L5V@R2TX[3_HP?@&@C^)D9M?ML'(D
M3F/V;#ZEW07E88';INGI#)Q3%78?4L6[_$$9MH:SQ<JWOFJ)=]:H/AB0^8J=
MJI18$TDQ^Q3>S>JK8[%F@A_&HW51#,K-,]:V&W&;=5]L'K8=:XZ$N5!.%.Q%
M+H]U&IJLG9VDF(>.KN1)(-/, J5%B_P2?0&?$T?Y_?>SO36@=2:%)J;0FP6S
M./0XK?E^IB%F Z^O_DMS!]IM;/3S-5M;3^C'G[MN]GU>^Q3F1Y(&A2+J><&J
M+Z^_*VN00I<6&J9,"68<5T;*8/*QT5P-@L#C@4YS#8M#[?B;$[O+!Y^P,G%^
M=/-MY%^^]1FJ#3FKQA&S/[:3NZIU/_?]'J=P-N,R1?K[/=QU13Y=IR*S5VCZ
M^KW:@VWSS-D=#'%<K9K7(.+ KT)EG 2<5_>V;L*VI]2J'IRVLB)F9C&'$43Z
M6' QNOU$=A(P3&/F?'-]LV/QHS*=7<Y-FKA!!9_P *OJ<%0GV#RWT\6*RH9Y
M(\Y$>\L(/40P@-\?BY<T&OJ+<@OZ[0/G;LB]NXVZG(==RG6B"LI)9\;9XN),
M0M1(F-C!44)'0H??]V]5XAAU%D2QE)2^@A[" U]M2C2B$N=G#SQ;B=4G= L4
MSGF8UV7X >0? N84(]5R.W),7?V*.+4R%X@F7SC10FCC?8*A5J_[1KZ,/*,U
MWNAFJ5WT"#^Y8'(1?)?27WD-US(!I]ZT1M9610>7+T!HSS[%DF/V*3#[5DX
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MO/(GMCY'>3)WW_6986M]*$G8$>^F,+/(8334B4L\Y? 7[MY]XG%]?N>.@,(
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MU)+HN@LV,8I(K%I=P94""ABP)(U\O;.WU0T4<R'*,Q7.G;ARE:-4"^&! B^
M'!0O<< U[:I[DT7_O0N0I;N]YN,@+B.O-0;[&7SLO1:9S87*K01M;$SP(LHB
M21X^H_VJRSO<)7CONPW-S2\I(_P71C10? &HMT.?W/5>@#W72[A63R5$,G&E
MZ)ZEZO<FUF'3Z19F/2*TL)DH:QQ-4[)WYXX2['*S'_5K*95RD>" F-Q#91]Y
M<Q(2_S,-$R: * ?$ ?3H+],93FV=VM@J5,8JK%CJ2ZGLXF*[7L &E7Q5+]"S
M13SR9CAW;JPA[Q(MRQB/"CS,U0V*-!FQ*3Y)>5U,W7"Z-I3WN/"F09Q(M*,N
MSX>_C\3/>U0'Q5"SP;=HIS?"Q9#N$FWB>4M-S:ZHKS(FQRY\7J"I_Y:\0V\"
M]PW"P!#S+=HIP]%]/YQIH-(Z,W%FKWZ#X+FKL;JVBJW+--$LKJM<JPPH>X7L
MT-_;X#D1E88O[,/5_^.#RJP,;)*33/3M+[IW3>="\O,'[H1$O)>CF^&)7D'&
M-G*NYX+76?<^B<GS>:@"N>^K2$S !.U[]DZQG@G[BHD5HN>]G[9'D3#81JZ.
MF#9!2L':[R3 85.D+CS] YBIC_3U2VFPFB/K0]=QRWN5Y87D#*F/83.5 K^E
M_*83VGDWA8*F>J5,41QK$R=6>@2E> W2R'@(L3M(PRI+ YNES)#'&A'6O+MB
MO-RX;U9S?5W3-K85RO[H+<C;S_C*P(7A(G8L(8-*>P6EBRR=O5!GHT..IZ,S
M"WK.%Q<]/K"',D;$ZR)GVQ9?5%!YR/7B>PY+:YCK'KQJ1I^)5K=U-(X,@'FV
MN%!D"W^\*>:S@:3T9"JX$]U?7:>^2:"I6$UULN* >E;3Q8:-G1/BLK#9*Y8^
MYKN.W+.V6H^4#1SP?P^;&7'V<E8Q%?,U%; !C;D\EC'9],6?6&-^P_WGGP^A
MN3G_%*Y>@#[8?[8WYF 0 YUGT:>WXO4&9=H_AVY!O\CH2'W!]EQ\$$N=[N-?
MUU#]7RU01V&71+*O>QYKONH",U+#BZ7+BQU6QJ0.4B@R/6P^OV*?&&@J=P7O
MHB$]Y&^G-%Y13U0*E&PAI!IO]PX' ^1=7Q@L) 6UE6*X=O"2=7X6[G9ZSJ6:
MR_]X'\R:V \R)-RZV:U0CS<K0[$,!3.5="6SB5O4+'''#CT2:36LUX>"C2WN
M8RKDCSBNJKU4:XEY8HZYE$AF8._-58:K S8M,W8//&/IO26*AR[Y#V54=L;S
M4V5?O^]3;ER,.S[5=K(P'30W1E.:W'D#LAJ(>H-*;2!>VB/Z^?!4I^+C25[Y
M<->X]07I,"J1,8EZ=3QRH7@"DS>7R6MW19E&GW.=+T[3LA0#:6;ACM%?]R#"
MH17,$LI]P]=:L90P"OLG)Q7Y!_R"L<MCP<*6NLG );H^-2.4WF*>88Y[4$96
M,F_Z*8&5XT>FM08"[??P+$_K(X*2*N%2U4$J4S\<W,ID?5Y#H-87;TL21H*U
M5S."EV/$A$*R&3]MUO$G3<HD/1'EP[(6"!AI@M/IYI\/7\?=N>5=TPQ?<ES&
M8([B?W\J(XSHDFE0V@K60\<:(E;(Q2=V;'[E36E'K#'5Q[:%F,5]EX%UBFY,
M^3?U9D 69H[C8'QD+]*I[-<^T6/E=?2Z;B]8--CVB>)E/'X7SQ6_PG;6L,7/
MIG;9=U/0WT+;CJAI_/I0))25WT<X$[3GQ'<387-I9B'&+I<I-1E3Z3?J:_G-
M5HW^(O6&[[JTQ-UQYJ3?9)G7*?VC, 6+<D*D,Y%0W<*V9R)AX;M4U=\WGA><
M$\MZ=0'@\]412D1?GKX#*2]BQ^T]=;6D7G/G"L2F-*@*81Z1HP@/Z*>E#SJN
M&X^^I!V)=F/"@X0DR<=443J;DE<]V.3LD=,5.&/QEEVJMPV2+3BZVFV-L;ZG
M7HC\7EGNF_C*FN_4K"N=5U"7GRHVX(^;ALX(A*^[H75Q(2.]IBI*_VU\;5YF
ME<$T[G)M4)&9T/_$ED ^'=#/&A<W,H:IB,=M;.GHARK5D&A!U8!N!BTPTFJI
MQ!):;E:C*7V=N!Q%U6TA8@(G@L&<S\O333FG;N 4/37&^MN?LE&*I4D,O[K3
MN) S_W7+V$8E./MH8H4QP2>82^:K97DR^F+U!4YV M$F4<?^ >\%/XE*,2%T
M^IL+RFNE&::"QF FC!'#N)-*UFH8\UR["N_[PH#=!%E]8OV>P^K\8C_H/@Q2
MK*<[Y/PG8IM7OAL^L$<S<\BA!VCG6/T@1O.C-;+-7*VJE9UI3"WQ7&A< '0"
M+]6>@VN_J( INC6I#$U^!2M5> %<NK-V0K9-6R*7$>#,OOX162CIS?[DZ7)9
ME)A:>)SW%I::SYT\_+;#C4$276'>T9^.G]!?FN+DWKB!>58#/X&K;NXT7:(-
M6^R0IFN1,H-7[*QZ:22_Y,!G=%=)W"VI!3G$!2W=QAKJ%N)@/5ZSR'#6B-'$
M6&#..RJL-W7"5\KIK$E.D2X6J],WN9R;B6[TZK$B#E<4O=W1TR%;(1&Z9)_F
M1VW[:D?VF.G8NR\-]SLE)0>4."%DA$6O1+W'$62.SW5@M-#2V'R\Y%0CY<\J
M(JNRK=A@+_HH>&C),EX[4L$@JV\1?H^4I&+UO>)CV6*7$\'F>9[QP^X/W[H#
MA8'.2/H!6X>YB99Q2GG9$]R1=IUA$@)<C,(=L$$&.K:(0$;&+.=1N9ODO#;Q
MO?XW5U?EGF#MZF2'F)3[+9?<&MTF;^<<49%7"LAX<'@)O81VK-/PD?&*HC*N
M]/_9D_3VGYXD5F(UN)B-7W?X+A_2[4YT,S;Q,&R5QZB:K2AGW\"K#,>W[\:(
M6!'9XGJFK+R;-HYWFSPN))=[-]_ BF!^$LT7. PED9I]Q]KTE0&K86Z!+#JN
MO8: ]=Q1%D3;H& 1J6=D73=56_I^9;FMO@Z%14M#_(.2%KDF>7&%T%#*O$1A
MWK[=]WUY/YJIAA=@OK:E.*D)703A6,_>49B//-YBO)])6172V#1EEF8C;][B
MLX<0$;66W=PI@,G;OI-Q.><H"Q[?'R.B_!D"/TR)#>RN3CV\ %%&L\U.JRN$
M7;(E K.2R@;Z3<L!_;3WF/1'7VE#E1J2M')#U >_N":$4 N*"#T=J)!OGZB1
MGB." %VB'M]OP/LOOU@>Z<C"5F:(:#3=$U,]$$-DA'6,6L@-OX;1L$E7"$J7
MG#+!]5%D4F)\?QH7P5C(A_T-/HCJ#SFH!O144K*@%7_"B9)"!R=GGE4\]Y2Y
M@J2X[P61[#L4"0RKT"M\Y:AA*J0KGO2(NK8% ZNP8A=?DT[&8M[^T1\"6T8-
MV]M\B9M-CA,F#8TA(++N*I"KBH;6_.WS*7)<C/U[&Y\^Z  W96/;KY;&#^"3
M@7@D"?!NX$6&,^F]NJ1V8E^%4SXY<_.W^K9R(0^"D<XAXZ84Y_;3L>OR#-MT
M-K4KG@[/_9*(V2BUFKN$+ B\)DFTIU/"8H5EO X9*4R#CPE+:LJ%@MDUH+4E
ML+&?GG)3 #0&NU5:CO:<A$BX"N'#(/).72R4OPO& EX 7XVB&]ZX::7_/E95
MG0-:]O9\*C]S#'5T]/7E;II#WG[=TB0X1T^YWL)TBG87I!<<;IH(5UZ:D%>9
M'XCP(##<L3:*Q)P\%7<="T6A<=5'V"W>%"7 Z/I!39ZCBI$X/S)8JHA4R-*6
M:6,X"$95PUT#9,G^@N683QG*QNI6%M+%ED-C"-7QD):O2WQU3>_QXC$QD5CP
M_GAE/=&1YMN,%!(F[J2&L2#*"$0JD1"Z<27'ZR](O;:ILQT9B:H#D >XHO]J
MH!,!MB*29+CB;?0F<7!R<'%PCD!LY\_)YI]Z'!K@XA;#Y!6X(CK4'#91+:FC
MF;(Q;Y@LEF7.9@M&UWAKW\=^7NF.\ 4)TX.04X[^>S[AL)>":O;XB?/#DY0L
M,Q.Q2>:0,IXPAP^F/9\Q[V81N]IF]2)_H8G0_?7*@R37:>FWM@#O*EUG2VZ<
MA'AN;&FA8M+HJ;1:]D][3!53ITQM>1^_\*1F2(B3Q/]B5@];OS>?2A"WI%D9
MV)7\#IW\M#]&DFX5"B/(QPZQX\V(226$BW;J'UW7[I75Z^#TD>4@>[?!$&'>
M!L/VR?@17U/&CE/U!41/&QG],U/PG4ZU')2!C.8I2">JN9>=1SW.1"6J[@N?
M4OJ>66;F>%3Q/$TKC* !ER-$%K*DU[R=>GL@3=0CG&E1IVFB8.M%K"F3-$[3
MBIT+98\?S,#<NK\J52S]D"=%%8[B$I&NT>0&(]A8X4DRH1O],IS8BX!.D7Z>
M6^O\S2!>,I-=WH*1<9QX1^R4*AX:07TN2PLE)+V^5ZNR4\UO".'W<E__*B9-
M'*Q.!I#14:;YHV_X$R7(\&7,P(J(. E_('Z;S.\Y4R@;&*PE)2LNO7R"YDM,
M1WW&/%NOH'-^ 23^E7AC0\>HJ;OI=]R-E2,O+<(*>K[2H)A;484!;\,V01,U
M.M6R5P)Q+NPE(R'G6NV=.UHH/+Q4TI\5/"I#ZOGPA=1SVQ#X'.JB-V9$CO$;
M@\Z1B*3@GSS5NNMS,RJSBGFM_/@.&N+U]2"VRA<['P;)6<>B[T"E[RHA$&I?
MK?-YLIT8US2RYL*5 MK:;QZQPU0D6\C(?Q-*\%4Y9U)YC\;<Z,Q5&]]VZX/!
MT+B_0Y(Z8S'#U4XI;2UQ(</<?MT\N8518PI>LWNB/K+9@?1Z6O\CEQ03#??<
M]J-NJ31)OY4-U5\H:A"S8EZZ27B#7Z>>5#@1GC@DKZG67'.6IM]EX!Q.0R=N
M:TJNA6 SXGD6J4Y#Q(2AIAH=FF/A^WZR/FQ&6)"Z!17M]SR"UX4V3^.>,5WC
MB2UC7(+_6K:(I:S.$5]$2("(=EAE.5M%+.9?6F A?#WL-26\(KS_V'>N0D.4
MI^TE.9\E'^&2O$ZY;5YOZ2+Q]UVSD+8P5#P"VCU@IU2R#IQ.M^+>*?_ES#IN
M*VLO\*%Q[+$ ,W3L07G@V%6EF+:I1\\]7;7QE\3%"IL6I/UW)0J_#&EV,BW9
MF8YC01V?!S4>A.QIILWN72)%H@>";II4XYU>D8=-+Z('+7E*;J6*$!DDP=VM
M<[S7"C/9AWNAT'#[3L4C!Q/-E]1SJE1NUI"H_U%:V*_HH&HD=DF:;(UV-PJ,
MV"C@G9\5*N RK&>26F[2C'?Z6BD>1-,=8*&$C=:C">6AC@SWQ'QBANY?IVVE
M!2E8H[WJV7:?A/,T!I\==N-:=JE]4QD[+O>F-47<U!_XZ=-5T31(B8JE%Q"=
MVM\QJM,_F-MW(/N=Q,EH.5;2]DCM+)B68AWB2-R4OEXJL(ISF_BEZ@60"3*(
M-+YAT B75OYH^$\7)-S0*H3T$]_D8S^\;4T36D)DYA@I5CO%0,*8:Y,1D]:H
M^YFT#5V Z% D5V8G3&@J,RZ_:*/20&]5SY+Y^DQ\IY>!K*9O3_WW123<C;O@
MA:*$#5Z^65^=@XU5F;@=>&;5BNV-?!#VO##+Z$W )X=>^-Q\N?B="'-S#Q^,
M2#%9-X.JS]],SAVRBRMTI%$5/FY?D6FJ3>>G,H()JD)>#8Q7):,C3?:^=_3A
MPSE5E'"6RC!ZVE ?OUGF[,FECR<,E'GVC(?'I[0QCLJ\B)[#^S&GDBT3IW/
M_0$OZ?[CM<)7W)IN:XD<W*6,A[6 4WF/+\IM.RX:\%KEQF_8!>(W&2<0,6XW
MPS6/C-^ECS5Z$IL<*?FH]!#IO&L.DRFV>K>F10KZ(A3DZ\QZWG^@UC8]3E81
M>QQ;M+6;=-I.^BQ>G4MU+KC22\4%HX?%H>\>JTC16GFPH9(M(2Y'FH^=LVL2
M;%S.C?\?K7U54-O/'VTH%"E27(.4!)?BKJ5(H$!QISB$0&@(3I%BQ244*5K<
MW:W%@[L&*2T2G!8M+:7W]Y=[Y]Z'.W,?[K[LS,Y^=_;A.[/G[)YS/G,1Z>65
M<$&!G5>\X"@H*Q_. +!MP_9+VO1GK!5P='"TK\+,#69A/K'D.<G/QU_9CEI1
M4W"2>UTSK/O9_J>Q@1N=P'$<)M#JX.S);Y)ZE0\<%%0L!\3";"0L90S8BVJ'
M-;&T#V+"KIUI&[EWOD34A&MAHNG]>8_2+!\HC4SIRB4A]JNYQM)2Y*]KO#NU
M@B2HJ891M(')1H:AB)^TZ*_::OUZ5JHS@I@S]=]>G6&;_">YL]MV6]NXO^9;
M-E+$&9/Z:66:):YK'O7)3C%DEO;CC /?H&/+"!:F\WBL:-WGMD4L7U!/]488
MS 0\MM4_;N;ERX(TUD7$(Z'X2" ?$ER'S>QJE\)^ >B[#J?.&<N0/V0G !!H
M C0!$XNU\(\)JNUR6 X3) G)%EE$7JXJ.ZKC@VVE+KB-'00>IOX+,/Y),KU0
ML0504SI*#+@I/8Y#04B;?LBH2*ZVF!5!'#(<=(%N(!O_E_3?=622H>W[7+I:
M6?>L?P$I'EJ*ET=T]Z&\;DY0 ]RG@R'G3ZW_H? R+P@VPQK&U)[=NL\OTV2M
M9Q3*!1[3^9),=+JOID6O',"?VP!13(DZLK^758]]2JOAT%;=TK5JX6%PUC>K
MB+60<>:?P/"%A([['I@"#&[+9Y@>:3BOV 1",5LO3_A\@"1-$'7A[B4#+P^&
M0V0\W7M(.00](A9^&&:]2?#@*RZX*V8"#8.FA!X['AU-\=J<RGCF6$>]>O<7
MT'A%D":H;!&])L2GP< I'[J%G(^_,#R-J]+W3)C,)_T99=R52*I&12<EXN[F
M_RX4@%T(5BM$&'=*^]-4QT_"-!8O_UC_VA4 =T7FB5DD]([&>_IMV;^=:^YV
M["@&HYIX#[^O:KCAE<K&#-909Y!O>9:! EET7_J=Y2$,B MJ[1F9U2SPZ8R_
MHYGGA<!U4TI]:.N<FR'H#Q#\^:7327ZTX!P/HX"Q<\>;5D&J2% =?>\_&$MS
MLH_3Z8#[V+O3.5[E%K&A="P1=D.AMFF>CSS9+!D>UG]GMU2R3:PEA5XMA)5.
M<R@<UBK\D!>>BR2.46W*:_FQ5!)@YG9B8[-Z/@:2E@O /3$ZOM6ZAL*AD@FT
MLQQ:H[87L_64XE_]IB<@O;^<Q>7:. P\I9G^ H"NYJ$NL^_9TP1V6=3EA:3E
M/\NTO%C5UT)XK3'%@,W@QL^U/X/J!T;\QA_>GPK_7)1EYW XCNMDBST;%/KV
MA+EW?>5]DZWRP4&>S.\%"+CVQ?OW;AQ+2948F EJU4(L0::+!F)(%DJ"1>G*
MQ=)4FS3':?+/U'_7WCU^K5TE902Z2>$9MY\'O9U+S; -M(!2%64/?!_ZNI;+
MNQ!YH?>^>S)WYVKZ'QA7T#JRY^GK3%P.S5@B#[&'.",%<QK"YM>45#R.0C<_
M;!\D:<[*?H*7_D"E=EAO#YBD7S\[A5DD23A#)'?MA<]?TZ-D -Q[)@V:;R9+
M?0)4HTJ"'OP%P+)EJ_Q!!#8X8_4@5@EIU@2575V5M!984;G&<UNU4[K"MZ$\
MEOEZM[>?TQ[,O"[%YPP#_%"/:4"?_?O%W3#*RUOI/T;QT@:[C$]B\[/19K1C
MNT6>H@UM2J))!6)T#)YI B?BI/P?GH9/TA11,ACEYOIL2> ,^P\+'QP8<"QL
MC(FT)/J)551!;-VE?MM)_F)G9[<AMWH'BO^N^,>RI6'E8Y%N;HU,]C4&TG+Q
M1J4<6BDN];+9YX?4(5V>.@,X-3_$W.0W%[ T__2@AY!C,7501$4@Y\=P;#%X
M>M8L]+"L3LZ;H.>Q-G[!\>)J\+F[Z5E4/X8K_4EG2#.(O1T]WC*,[X?-XX90
MG/:8,;1W?##1;4SFE7W?3A;F)#LB&Z4CX3D ]CG0!N?VSR96I\C),N<.O??<
M!/M(K-%S&ZF(E21* @##&NC;22O3))?J+P;%*2"[B)SD #(DYN/8-<\A"]N\
M&S5:_NZEIA]3HH:B[H&V5?K'W9I$;[M9<6.73\O Y0SMG I'*.'+@90PJH)M
MUF]K*76?B6D]MCX)8V*^-:2?@*Q:Q]8@PRK'7'F9:)W[%CV8O>R1]P5(M:4C
M[XM7&T3@TXN4$T#J,@%;Z@C:&EOGBK#!C@=ZBW0;%9E-NBR[>\UJ+.N->L[C
M=(I//3NUI)C'Q;MZ@')W@1()8P2FBFSW;L\A MV\M.SL3H)_ <(CHZ/TUC^Q
M[%6EI48\G*=M,G':GIOW2  ?>%9XO?P/(8>.NJ4S>\&0EW!W:G/R49!Y_R91
MC5TWI+39KO9MAO3HDT! 4*7;:J4)+U0HUR)H/^N0;9XO].?O+F0SQ:*G_TY\
MXL*5JN18M3O:%H]<H*=;B\15B *?.IB96[N(MJY]I7F_X%7&F8\ YAWGJ.&W
M:(<YVL F;]D&[X=V1L-4(+Q$F92C(;XF:Z=6L8($NQA[U4>50H 3I1AN'!Z
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MG_GZ;0=RKR?Q?KEQH'VI0BM'Z1FBLE3*T^(CU;>F/34PL/X3I@DJ6_WW;9!
MHE6"II*CW_OM@;;!D&D9 %9.W[:EHR6EUB',]RF0G@MJ1S"FCOAE6&, ] Z@
M%X51;4*OH?+ML8NY;6.F!0GXU)3RWST)@/K0&E)+FDM).1-'3R\^2.3TJO6:
M1^;X$^7$"(= %L5'[/.<(F^&'YY,F.AI(SV\0.1L=,JV_-8B&OW *W P?:6)
MX-0O<JO#9,OGUZVMQ[,GSW8M94=H#,^+O:7[OE58NA+):VMS0O?RSC4\*/5_
MZRCUJ0[C;TE-_WR):NQ(@(J=S"SH<L(,T^\?>AMSF [25SG7 9!)9;JCBM[[
MSK0G]J)6,C4](XDKW:TK4(9"I;'V>R(1,C7YV\M"(O.][WKF6IZ?8H)38->/
M?KF1#Y_[(\:IW#%FGBIDM^ MA %XP9>GSWS_X\V-Q"979R*3;UA(\[%#<I0*
M@QM)_*74G>2C#E5YM<(.0>A&::[/7#:!T-'YX DU(IDA2H:GESG)VE],P*JD
M@<+=M564<@HF"WEET)PGVP<O*?;AB+W-J=CVL RFA@6JVS]?R.\<9X1-M2YG
M20E96VB3O!M)D#B3ZAT@PYFF$8!Y\0P+6!9\/D8QRQ]'Y@Q+?? =(5:-QUW.
M[U0$&EPX>E0N=.ULE$4!,>&>2S?@B8;XIQL$*8M)(8,&$&D7'O%)*&7<3D?#
M><EYT3IZ/*&Q8UHY!RO%6J*=Q8&V*%S*+;#4%F]O3AI[FRGZ2><1%NQP=5TV
MK^\_I^[021JV7M,7RD"]@T3#$?/UY1VQQK.,#Q=R"T+%0<"J9@<6%YR%7MD9
MG'A]')Y0>^I'?>%*0[@I2O19='<)+)Q_ ;7?_P+VTRJ5O(S^JT%/;ZG$0!4D
MYAU[,L9BCD]?2LRMGX9>_])_,/ 3K;Q.L';^N/KI_'GI0VDYC^*>O<%/KYK>
M3MF^^0O@E7YY_3PC^.GL$D:M[=/$8%BEW1L'KY.Y.%-)RK-A&8:N9O:?=\4H
M/(]]_(# +)BM>(6;W[PRD.D"_4<XY'O%@]**[<>DK=FO4ZVZ&TY&51/ZW#P!
M4E<E@:Y2ITB)+U1B(\[O\4UK>LE\^5$:Z$3(02(B<2TX3<MJ*LDIJ\/ \&=J
MW"K'?(OBY6N:" $"*7H"O(K[[_*=P;YCK;Q"8;,I!Y_)+?06'K0<@BEW5YT3
MXO"8J6F8U71W>(H+M341.^[,7L'<,]M(]B]V:FS),Y2B^58=!3E$*^_]OFAP
MIZ!]V&UO8F)&  $(/0?S5/!?0$2;JO?X8?9RLM%'3^%U>^#,'*.#=O5/?2V_
M+4E>]B19&AOO7BXI>KVW!L'ZMQA"\7SBM<>\3),IO&GG$;IMJ3E_OM0%[\5]
MT;OHVC=Z9_J]-A_>.%HN5[HB2C*XA1.^PLU,?^\4UWC&:3Q[9U9L$6<+!4K\
M0CH\^*;V 8D2$8YWCG\ 7>?LRD@:9!9OR:Q.?]$7YI@/(^WI)8[/,N;$,'[Y
M_L&%]>(^Y&S\7Q7?R!V.\A3F4+-?ZQ?TX#_:&9ZDNKQ4.XU;9A@BUM]J^8<R
M,1W,',RO![7NFN(WMUIV"=_&$8#CO=#M@*MM1HZ*TM,A 9.A5GV,61NF^T#_
MX3HMK1[UNX?1T_IDTV[.RU&YM>X/[4WZ-I_,@KH7LJ>%^@WQ4HJ<DEMUMGM[
M@;CS\])#//(4:2:5M-]"'A]G<2W"'<*)0!I?,]LM[S(QPNB0'V*UXD9CHSFG
M2;5]_N7O8ET$'%HY-=[LHIX#'Q(GOE8?GU),LUAD,MS5',XK^&;+!W&YZ3O!
M9F-OK1*'\2A52&S(A:0/?LYI#D.':(LSU+H:^EUI+YBS%_=:@ZH'9%4$-]]J
M(2^W6TA33VC&S-,;W!%X$OHOZIM];4%!U7W;BL+\PB-3.H1H>:EB0U</^X5N
MV:2?:LW57K_!KWX!RJ6?(G5"15OV.3MFSIZT)4U\*'I"Q097^""G;^,I,^?W
MSB!K!OUU-,4V%8F+?"POG)1?1PV6ZB)!39MW+7!T='Y?[+-^,-SV\IQ :16>
M$]S<^?A#.C9_4!(U2?HEBL5*QA!C*TF>FF]Y6O!D?2S[V:*!-JW/)^8.Q/5;
MZ=^J$R2/K15NF%UK!7WT/<A^ADF!P^8'M-S"7:)C;)UP?[[E:#\)7XXM'C>P
M;SX1'<*\-K("D!O>1M:R@ULA]+>=)#-7P*STO83=_.A: 11]MZR8$J4%'8(\
MZ$=7C::PN8C 4]T?:OD(ZL8#D]2[; X5;T(3;&K"1N#+24>^=-6HZJQUF;"?
M=HB&-I&X:/SM,)S?&_XGL43QU?&_$W"MTJ_W#L3BOO+'SX'D)TA;I@@5 S^"
MRL3ZC!L;C 5 P\F6:)E][B%"N?7GA.@"$B&B(TCA[;=?S#2#]YP]>C#$US+4
MF"H?;W9FV^4])>OR4@D?0P_S1)PVUR"M20J]G-@TE.I4Z4;8XV@F=_WF[J#%
M\_8VO72XP%&BTJKN#1VHBRMCCS@:]^'EU"_:*%?++DHS=/FJLAC%3^,M-,@9
M_QL9/@"]N8/08.H0Z.AN?JXA1[M?-4.TM?6ORJ2$[>+N[J\)(FL!S)_F"?X"
MZ%1K'_P%N,'R+_G6_P*V#%GOK 1?4OU^9:YXP6?YS\"+?P: 'W%-EI;O'0,_
M*AX=/KX7C ,4F2U+3T?6(OX"7KT,^>'E&1KB=A1R^;]]\/1ZJNTOX%G+]/U#
MY;^ H=FQ!R%NL/_.,/SW#.XE[\^_:&I#OO/^>\7\-9DMKGN>P/R[1^%_ 7&%
MO02F2]-W8\N@^TV;OX!O!RL/OY_T_#K,&KJZBC/[TVBZ"H+23-$*%=\5)Q;F
MANY7A/Z_%<+]_]6%_%T%_#^W_P%02P,$%     @ 8X)\6*0+T"D%*0  4C(
M !,   !I;6<R,C(T-S<X-SA?-#,N:G!GU7IW6%/;MN\, 8)(%Y'>A4CO15I
MZ2I1 2FB*" @O4B7!%"4WA00$2+5!HA4*=*;*(0NO4KOO28ONLO9>]^S[SGW
MOG>_]]V5/V;6-U?&''.4W_B-F87_AA\#-#H:VAH 0OB8$SX CP,<%]15SW/J
M6UG8.#K9.UG;6KEQ:CM:B' :BHN(B0/\('@ R$A)8:0D9# 8C/P8&3DE Q4E
M!04ERPEZ&@9.5FXN#E8.=AZXI" /GQ@?.X>0DK"8M(S\67EN095SRG+G).7D
M92''R,DICU,R4U$QR_)R\,K^ER]\/20-  @)Y.<%?KT@1%!B$E(8V3'RXQ
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MSR'ZN:Y:%D'A 7U\: 7Q3C3#_]OHA8_.Q0_$F; DMA[%WRL-H]!@4P6X++3
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MAB=]=_T 9*"/.-GWN&65Q)M*,>1E'.&$[HMF=B<I_+AT94XI;U'MPZ'GGL<
M\6&&6QLEL/+C,!\]OGG[+*V(RLH"$N9&V*RJK;73+?OXWGRREWIEZ9@9*8C2
M;W:0<-H2Q<UAR-G9"":PT\&#/*VJ30B"6?]7,T%85]7=C@5;4C,UZN_4$*"_
M\]\A90)#=QD,$VA,A\SJ*/J(WXF7/[0EFWH(RQM''+=]93Q/JQCOB1SBEM>P
M218S9%-M4H-#)6M5UD5J\,#L#AYTY"%8GOS96Y"3]4Y"0C&?.^19SZ)U<.91
MG6@Q=F%UZ05?R+NAQ*GBV-L7+EN>M(3NJ@RJ9 +'P09>L3?:DE\FWY:"U&H"
MY/K\\73@Q(1[P>!L<5R3&STM2P!]EO9T^$FE*L\6%5$4R@0,KV9$R#YP;V%8
M<@Q!WW:IHE[9B*V_?Q%X+R=DF\RKT"UO+AS4*;X7_^B55A1[FNZ.K'"<(,UQ
M[JWKK.8<2.H+%5C"_,M[]VQ9AMY=I/NL^>5-/S%T\/5A>PX024VW'9"N6+/M
M=3'E?6?6*UTMC&#MJ^78XV-6Z;QYQ-P-&?KCIM65ZF4Z]N*^Q'!.NKV_O)<$
M7HOD9R8F4^KT*>@=%M]<(SB-HV>S>W4Z,>>5R=OC1C6D5L1^Z2-H&8?EI5QL
M95&]&UR.3Y8"LCF!YOLGCKH0"DS^N0O5Y#!43O5))&TYKV=W9!;LLSZ[\>AR
M.<S*-2/EY)L4(X<U]-%W=J_5#!0'I0\-R.1-M0K7-K.34$?SZ/.NP*9=,]L_
MSOM@2=N#@OB#A9].28AY![@"(;_>&6@H&/D/ZXEG$2*OK1570<#DCA@DZ=<_
MI2BK9[T6)K4.V^0652 ]I&8HQF1P*CD>!$.'M7A43 CM8GK&IQ-=[(*J=X*'
M/:IYQ/<LV&1BM0YMH$D=0O>,_/GM3J'ZQ^8^Y'9Y\I)%E4+6!<T51*<)^XM?
MJ??H]><I[+ *MCC=^=T*V%]]9)Z=//5XM%AN!T.^#PNSKSB7.3*J25'\WI2!
MPEK@&%*R'"13^$R@)7 T- 3\JG>O_[W4\9S0G$X,>AT-=&:BE6R(='YM3;HF
M,X>_1M79\A6E&/$>Z)_SNZ0_R5^*H4[ @W'NWH*V? +E#*#&$;K>-:H/H2>E
M[7J08J#4&1"8X>Q*__SV_$'-P),$3XFV!7]]J5RC@._9K%A8WC^IXE?S4XR_
MUL3=X7D6XQ'NK.0]C1;Y>^@[#6[M:N+4OZDLO!O=EYZ%>OS)(<3\])"ZZX?(
MKJ7<F6*[X['8<B[.W&,P]D+(,_[Z,%B?PTK#TVJMI8P'N==X"[A@>0>D:%$\
MJ.WI0LURW-O+V\7"?')*H7\Z&1G'\?0/W34Q^)3J8.&F&*=#X8IX^4""B*@@
MD*P_L#X91=8DAZ%T(AW4M1W[*L"4\SW0LH0E[<GAV$X[E/6  @FC?GG7IX%0
MS%D>GUR1BNXLU[6_HSUY^[DNZ97Z7-7QA-NI?JZ0N6L^,B]08J4?"X.UZQUH
MGD8[Z2LAE#2\,43MFEV%B7Q1ESX$=O#>7G[?2"-I\;H!N.(!F88RXRP>:*,V
M[9 P%X)AKH1;&!$82"XM:O8*DF3@5R>63^X<QAU#+<R+3MM OY_H)6QHWWK;
MB1"T_/IX\#Z $+6V"/:O?S$SF:D#X-O$K1[.$D4FSI+T?9$O=>L;08LZW:CG
M,+>!J#;_!R[Q,_,(/.-8GO#2]^ SV:'R? [Y;]^3M&.V,"2!\\<S1)VD7%_=
MSFBL0?,$RBW#H?RUBEY_6[2H7TC?(G"<84W<)P(KPD8  P*M :[R4I#-) IR
M<.\?R%I]J%>L+>5K^L@V_4!Q\$&8.^?59A(6"<WHT>MK"!8<#:D*;$ZG2ZK!
M(4%"\FW\Y&LK(>IN\7TL[!3FKLS.S9.B)L?WIJ_91HM%2[04\G^^YETKXG_U
MO65<2SLGFV/V1%SF;FZ3EE?:NL@)-ZV;%*E"C^0VV6^JK%#7$U4%']HH:F<M
MR 9^UDK+?QK#@S31/M%*036B;)'L@"%/):,B9%E3-ITS:B$="7-L8H-#IUOS
M!@3KMW?<U,H,GYQWU*>+]5!9P9)</CBW^\SQ!FHQ1]0M[>4>;R-]K$K443J"
M19EI=V="R:Z!^4:"\O.L#%E/\=K%,+XQ)K3<7MD&@D,M4OT'38!\QP..JJE$
M73RX>1DEB>" ,P,X="ZUOPIW_L557"T,#]0S@:_T7_+([9,2QYK3X7E?/+!N
MQP,,,]B-^X):*9E!')^NVHF:0;!G'J@4R-97,/ ?4=W +2 X]%]5-_PS7D+$
M3I#FSX45*8JXION"KTC75%NQQ2*>Z,L,#Z-Y'6.C;SA:3P=\6<6#NM;[_%K/
M]<H^E99>BY>'FK:>SH=P&SVA"S_&*Z(GQ[LY1]@S98CY:L,[P7)[)XF(+T9C
M.G6QWBI7$2R;?ZFH&[DY>,#UCP#1QX![](3H<*<'[YSAT&>ENT'CIMHI3%OE
M7E,1VV+VJ_V-9WVP)$<<]0/*E;SY<YYKPU*(4\=2G["_4 ?V/X4ZJYPH.F&;
M-3!865M#L=B0^"XCMMP9$O$DJD+O90-P3V$.'1FLW7<WS)(ICB0AZQ 4B(FL
M"3%7SI:"--CN;Q?<F_AX3:VS,"Q"Y$PMTU*/K+?Z$VNO.$ZT4;2^A9,?%I91
M64&WP0N?L;W^(:AF7OD)>!?ZFLL E/!#\^@AC7Y<>!!KD7YTFI"0.0BV@J,!
ML"N*Q(/HIWU']YRF;8B*@/L-".&9A^.C!V3G\.!E*#AP_ZFW-ZII98^/#@_Z
MNF]^P<(^PW((]MEL7QS% ^Y+K_'@%A0/TCK12DE_25CY478\:%%>.W441&@_
ML)3 3YT@S2=[\0@/3DOBAC)Q=@@. _*_J[,ZH'XUZC#L/:K/N&K3#DOZ_2^1
MX;?P%M7L>9G R9ZI;/(@3L(!FPUT3OH@#<V&8,VN9U>4)Z#0+4'1HS.1Z+-E
MOZKDQ#HT,K#KU6IU3[J83T]&Z_*S!ZB&0-KM[;WB9+=.M)2?O&*?,DO7=&EE
M\+8QUY4^&M:,3Y/ >IU#%<'J$<&V>9-^I8-N;_%;"\\S [_2%BB+MMDW.25J
M"P3+_J>"-W,X@8( X6>;45P9I=&(KR7D4R\FT:KZ++XKVQA2+U.#WI7-X4L7
M=8;#.W342WT]BD5DH(&,*1$QT5H[4A"]<5+4N)'-U*K+3^*_-+J<]-]V$>F_
M!\.L*U&HJ52O,%S-!A[,DJ*5N0DV4KJZ[4]8Y!D>.%[!@\5"R!9R[K=6_\^)
M22+XU>1SXWI;Y\0]T[ FRV#%]4']?!4$C']N 7%RTXEFKNRHHF"NA-W>1?M[
MOH#^#"2@AJG&D)A]+!0$U=Y<%ZE6F?NEQKK^Q?G*]WJJIA1>$;;S)76?%D/^
M!'ABJ#/ZED-!:_<6TV+6^<=<Q-;3])"';S_O]R29#(U?Y@]UMF!42'>>EU]Z
MRG1H0X0'V]]'E!=O[A#:7&8PT#7M&R8W[>=HO[F/)7E#@*_@W=#B#2,3TW;*
MAK[G7 ;%);;09@VR&G5S\<B<@'83,+LI=2#ZR/ZVKW=.J!JF3C%0^T3DPT?$
M6!AL7*:X^Q#E_:8F:[3FQ#,*/0DMFMA3(L<0I"[8_$8Y @/)ICN&(?;S=HC2
M 9/*M*@6\0Y<+,&ZO1BJ_D]S&.K +>J]8V:H/D/<';0@$J8^QK$'OT%H+]X_
M4-EGQ%"7J/^P+"S![X</;HD>W5<__ K\TGP(M(;C NXK'JSSSJ=NTZCL"\.A
M_:]^&(OJ"7B&(?D'ZA)^=W]"] #V*^B&$HRZI==_@-.Q/OJH>]B+5G[#!H?8
M_+.,>^MYZ^14\0?=Y$$MRPN>"L;.]]\WHB7<HTAF?:0?Q%\V.38>J\IU2BZ!
M!4GH^C^_H?<E=',*-;/YNW>':=726L0,H(!:>A=#.5F-(:9,Z0:6,YD /O?O
M9*R8].CN7M31Z *"21]X8*C2M0AA?UTE:D,*XD-0;$H1I?R6/<J)(39A2;(M
M$U?_T4G(];,I<>Y]EP&T3*&*]*&*U4R3XI5$C>\OPK2R/TT@6@[AT/;-YPJI
MU(>(8^S/WYF9B-M$= F>#9\D3@::-]P:X= W/9-]Z6L&+[XG).U?1^8G\5K5
MO<A;7U*,YVT*FF59 U&UV_M'GQ)>O]!K-PUV=7@XU2++ N/-9N3GAS*VD0"#
M783>H2 EAUPSW0S'5L\K:(E3F0UTK/(<3NW:S:V>JF<8\FY(AQ<,IW/J$6J1
MBQH7#(<N=?RL+=]'_UQ/4PH)'N]2*4 =AIS-/GI C0O3 =MW?YZ@L.DUIK!T
MY)FT7NE=S!'1)[H=CWP'F=62@H2@UOAK%[RSPYSHYS[I?C$<\W[C_)QQ1GYR
MFER%&7Q2YO420GUI)S0/8VI8F!Y]B)2VD#T3*ZDA&YG2+(10[& *DZ-[_"/<
MA,#SPX-]"(;Z,2&:J/6/4JNFLE"#3ZH.A,%]_;-_=RI&A"3E>% U=3T(5W81
M#])OH$_W^5U,W[U#EMU[CVQQXFDQCW:*::X<AEIYC3\<QW'3MBSSZZ=/5&G;
M*U-[GI+\[07'T61L+@BZ7<]&/*!V7U!@B>_K<7I8%G(AX83*UT+'9M[P:;3"
M\/'Z,LT0AZG2CKS)BF#^;TOLSE22D?Z%D#P$4UECB?7+.M:2P+&,B$)OAO4+
M;LLT=' H@^AC'XHOYU$#(@;%K+8)K++._CI@ :;Z?Q-^8DIP4+V)@1)X^PFH
M$AR2%\!B3GA*<)SZ,(Z-8^X7N$[]K\"U)P&N3Z__#M?\_UE%A4ZU1RGZ7:UH
MXI@E4)Q9*<BT.TC/ ??'T]9>VN+!U@H'+A!.M$60T+:[@]/>>5RUR*&"0]M
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M3]&4,V#/P)*8L=E?C"GKFM[(66'+A<YP+F]N8RAITK%(HB7V0#2S6M[E7K2
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M)<==JR.^6=VJ:=K)[Y."%(TO$;%Q]Y@8A)JI-SJ*&#A;6G1'(5QVMQ2QI,.
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M=89XP9.I5KWR3Y_FJCY=G7[BXDL_*R*\U"S)*+ACBB%# '_L$, ; P2P1HL
M@BIAD!LL!+!>*GPGYKP$P)7RW9,[*BUO\A;G!+N@ZV6EX4"4[/(W=LHTQ[8/
MD4:M5@6//R)>C;E^F$0 1^>0.]MLI=+)(WA&(IN'#6\]#T.9$*%'\O_D1IYV
M=[1MF)"12R@"@.0B )@SI"/R>.0. >PB@*L;E@=NN5G5(WC<Q?[/:^*')]$C
M[6?+.G!AZ:8)J.^LFY-M'0[WU\IUX6'42=@&)K'@2>9%G4([BNK4R?Q\5]P'
M_"_1/!/T.?Y^  A LXQO4CAC=[,)(E00>25&*(_T"+38.XT3M_ [IC4&HK$C
MWZ'\A3D381>"PT3MH]M?%=>:++;N1]J"T.XC$JW%3J[AO,MOU'&ZD@*A2D/R
MCFKVGR*CV?E,F^QB4GWO63Y,"NQ[$+-K7FOY7GU+.TL_B:$AZ>5O,LK"+7]Y
M^M72?*1XH% >&G3U/6U2=P !3!7,GJOJ!=L>LMS1Y2[I]&]J+ZAW,D+]N/FI
M&.UY0 EC-0SUUZ:IK@9Z_/! &&4HE&NPB)-_HGIL\K?K0 5U"BY!&$GC^HN]
M:%96MEBIHP<V]RHFRDY\\Z2S@LOH_$PM<70F\H8^-ZH UAE:CL S?)P!JZU,
MX)QH,+1XNHE@J;^"K<AS4F5J8*O*F_M$+\I;:^U+\)Z:Z[A-\G C@PW^NK/R
M O5*Y4&L:W![7^Z:6Y>.T\>3W)W4%R7KG796)/41^]OSIH:_/5QXKU]RM/?"
M4H]\R=T%!5ZMUH0K9(@>64];#S2HSK&14/.J;#6L5Y(,/Z7$]7[[QUL"JK-'
MG.P9Z48L)E/*3B520X2*).I)>Z32+VQF?,'[4!GDON0AYLB$+V5U*K#5H8=[
MYU#N7B<]WE9]!]]LD.,3_MG1$$H^YE0- 8S:1T!.>B)J&*L(X,L-<?#%O([N
M\)&B5X1A]PL+W.R%R! J*D&2J_+#\J\F)+<C2EFL9:)ERMOBHW563PD5--.1
M_GT-_&>@_6;SUCSI%(UT:8[_GG4N"8&'0_YE!3.$!#X(KB$ >PC]N5RP$.JX
M@+F+0I&<&_&L0!;+_G!)QNU9Q@"D45CS3+E86O73K<98A_SWXHG\LH*/2O^R
M^/DH(WRYHMW7?71,E/6'R.:ZB'X).Z^*M.^THRVH?;<41CI/L9ET'C*\G+.Y
M-FOXF"*]<DSDBNL4[31S,D)A H,\L=3%: TSLZNQ.#O!VGT[:=8CS;Y^8(N!
M3$-E3(%.3#L5W@0)&Y%NU=*53C<L1P!-1I-WST]<*7&7>_.LY#^8^+#@?B;#
M(QR6ZM!?SS4R)Z5Q&!%]+Y2E1]K)67O6*X OH-C3/O;1L+046P3%$?T"6M),
M5,8=ZDV:9^G(&<59$92RJ"+3]R6WEMCO.1TU>>B*<]FVBI.J5Z:NC5\T:=$X
M7&]EA ]>!LO"@UMUUU[RB>=>6IE51)O*O>8>3 &C;'S-#!>F?YR\56OWY8=
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M/0C@E H>\]#N)GQ#5^)9X6V' %[CA"* ?6(G!)"3&LQSZ)VA]][[V:.,H$<
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MO_,6$0A@P?HI"@J=/7+]R>P.1N]#(Z]RV+64D8MQ'7&.\%B]-JCC709SBTJ
M'(+HOY]%PVY4?9<RI_DA595);30;#V:5"NJ9+T],8];F7S2,E<M\NPS+=ID'
M@R/].L](215%VGFXZC1I?!0Z:0=8DJ1_TT)98F!M01M1.M9<D:Q]O]D@)P/3
M$6O3P62=0Z5#;X::3=WJPI<DVU/-E+%%B^/9@A7J8Y&HP<;*Q7&VT]Q)V,V&
M/U;VAS?#3U*$A*@R18B#9[,Q/UI?-6DD"^ _P<7F-X9-3!6$M+[;\<S_49N:
MGWEC.# 0-[(59H2R=93.W)Z.N1+M\8NTZ"\/3QUDZNX1.,1>9AET^C</3W,_
M9-J0,DC\T NV)M61[*.*1J=N8;^\&?]<[=6T5\ADD]MS71#[FED2F=&=%(S3
M4\,CM0U],RG$OQ,K2R ]>FAGA#EP.D+KAXLST,?:%=A_'1#7"SJ1>" ^NI<1
MOA9^S(+W:'13Q[:\V7]K3[.'K#\R(RV4:;259SLYFGJRU-9YBE'B6\A(E#*S
M"!B8I:%&DK/UA/TYNO"2P7JRI<FR-=MN>>7U_55SWZ3,AJR](QIHK9PCLO6%
MDVKGY/<#Q7>LWAZP06%D=2V!I!$W+]<NK7G4&1)F[I]"V'^0L;OB)4CZ*87<
MH3V-6Y'O'EE0FR8.;YFH%*.*=MZ<%#E>3E<]GOL=*S:#VQHDFG,$)),KDR_B
MAC];^F VIZ"<\:#+5A-SA0UYMO+-1/*"J%?SIV.U;LB828JW@=1$"27D]ZUH
MJR=\XY$L#Z#W@:\1P.A/M>\6RZ3-_$6[29[>[S1S!EWXW@>M1=*:Z7]/%_Z4
M>H8 HO5.A>8>]0([RST9EXVFM/*\1$:2?)$$&9&"QNS#IS[XH[1XPRV! &J7
M;][L[0Q<!ZXZ'\_=B8W_6\)K]F\URP!1*1H_X$@WH?3.><R&.8F)\G.:8@1\
M*_Z#;8&?^!_EREV1/FVCR,#42 '82[>$7;NTU=WI[L*QJ/O)ZY^3A="7$;!U
M4_>N)9!Q:#T^N^ZAB?;I>UIVAWEJH9P6B<X'JO$[N=S.HIVJHV!94JV0L-O<
MZ-\<=Z%@7+F/EN*0YP+A<#ZXBV=EW<6ZI8*8DQ##R6'0RDI8T6=PLN-;^ '3
MN'=ID]\(F#ZZN9)T;J:?I-B&2>.+$5VK>LG/_)QF4[V84)I8L=5:\P]Q9(*'
M4R8C*/ZD *Q65O"SE,7)X>QAG)V ,..[+?[UX&U)6#1KGC*%PP)$>F1^?&[+
M[5*5?7K]D>DNZ1D(.G491^^T#*?Y5/J=*$8YF9N,O\3%DO@:4=-+\M"@UNY]
M/"KF,2$5.^W7R*)V+WF0$'Z,'XI[?\4/US9DR+IWXU_[16TW[UZN-:L\SF%6
MJ/ ^G0L"R,ULTO-O.Q72@<RPZ]V38=F//W O^9BR/(A!+O<A'[:EZ?,+BF;-
MYZQOHG,=DRYCF7?>^/HY[TS$VS_*JO>@U#,L)5AK"LHJ9QG%YB7K(93Q-!0)
MB"H-Q)04R/I&!W(8(:]*-SKAV-A^G!+7 K+,&C'WMCN6<00@.O+P./F7C7L"
M;"=FG4O4C0'==P="-S;A<0N HA0ZK[)#+XJ^[?/T2,QTY9YJ\'Y*BW83D;3
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M?=>>5G.KV>B<0E"(NGT7B,RR09PEEM8HY##P"DH]QA7!,B&1H2+']!T[*35
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M*O0,N6B]!I2O 08D3B?Y"5'$BA(H)!/W1->557%__Y&E+=<'2(K]\_ P7GF
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M/6K:1E]0@?G6>K(_6K(7++7_@\)#JRORK$Z/>A3&(VG[!ZNP. 11RSEI-4H
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MOZ]@>A!9^EFK@$OLKJ=VF!^^Y4S\GNOR.6QT]<\:5)?@)5/LZZ6-YX1I)!B
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M1(_FWTX,<][^*"R^VUDK*Q:_71QEZ!9OBU&YNZL!_6WD"<4?]F8A L_-E8A
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MA9X[71)R^HVE_K9/H/U3UB6/14!?<]\U,Y[J2+Z?%$_PD4 ^:D[[UU^ 42F
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M24TR6'7)'_*\:[L7X6W->BT[:J.7PO6=B+6V#BP[K(FP1U6FB#>1C8%YC^8
MG'!Q;R)\[@M-Y1UA[V"K9%W&4947KBI77&-B5*G*U3+U.\P>FV[RN&8:U\L?
M?5K/+5C19UZ@YE)L5BN@2O7F^373=:G+T?4:""[! ;BY\#YU6KV@D"7R%VVO
MFGLT%)QI#RE/.D@>?\VS3D<UIK47OLB?JLX:O&9]^8GLPX>G"RY0+.WGB+V-
MJ#]U')W8@)T@T(T,SA(!EC7VS)05M*41@TMT7-3I\YSN.0)XMXFR&O1R(*P7
M3QO_+)?;K#=:.$%E2%>AAO&6,N11J.K,ZP8YQY7U@/7ZN-<#<P<=W%RUW[_M
M*.]P*7ZD6#6V M$#=D;*R6P,=JV&9,_M*.XWJ5RQU)IY*2$S?^-D%I]K[:DE
M#C4EZ3O-L5(P:ZF=7?S%D1&KDE\R,B;<4F.JE3GOWG@67 G0J?+G 5Z*.S+Z
MK?0U#^-B^<\_O1(S<><*>69CG^"<Z%M1&3\9G8Q>B)^G-!&@BO,7+Z-M^JQJ
MQ;IL<%HQ,MAUP$[>\,.GQK93B5;>/OM6B4!8Q8J*\^@.&!MW/ICO$&PGG 8W
MU.$^Y.(H$;C(FT0/WWV"_&Q)! HT=S.,%73:B4".,+X5O@$N4E[ZS+XO9X9.
MX\&/PU9K*S;V_3K!D$%GD$#R[&X3QCN4ALB95UD/!,@7X)0XX>H"(TK,>EU#
M8*YE:MRE?-#[5A\U-V'\@JQ.2Q2!M\SO#V[E:QU$ &-(#]IA(YWQ+!\CEEY/
MP92[<8<"W^>,])^S/](@KGCNS%Z>.Z+VT7-65PGL#55$8(VQ#[Z,A^/O^LB1
M$Q@T(6#$G_:<"(P50PE'(W"*LE B</95$!'PFT'BXL%OCC.'DJY1,R "%1@P
M!'D#'T_P!"]2/.E(( (U1*#^-7D'?)P"@]S=%P\ET("Z)BR(P'TFTM\Z;H'$
M"8'*@K/@1"#0'KR&(J]]APB MWPH^>?]_+R?7^^G7E[XTXU9%'/>4QD:E9,G
M359.GZ.X+6Y0Q2YUN;()S)EFOGF=FN6/(&S:J^5ENG-EJ/FC>ON:/ZV^$W(]
M'^Z@0)[.W3/W]<6OR6?^=*[N_Q99':7U9,5$!.1=ZQX/F=M>XF=4V.R$,+QK
M/_[F#?6T-,^8C])^=Q9FLC%X;M\PIJ)WGC18&N5Y +1P9<]WA>!KYV-F_LM?
M/29;WT4L+[*_R<CR.R'>4X28+BNCO7VE4HWYKIHY)P-[LI0<1EE#+J1(\Q B
MJ.K,]=+3(\(H=2=S1F4K9ZK">^,^]FS:/'8U+J<&93L@=1L;JX9#=;;6M-&:
M@J2R;HX,DP_ &:5Y=\;6&XJHT.A$=V?BI5\W6,PL&52JAEU=9F=V9%N.)>>-
MC#16PZG5H6B%\(HL<0%QZ@^O%2E=V!&*[1![S?'IX$JW"4T"TR>=YQV0JGB-
M#.3SN=C_RZ>7_HI/K].?"&##*L)E^:S3SZVTP1U=V<Z^D*[V&W?0T'FDS.\G
MUJ:PQ53?BQE +-<>W, JTQZXJ_-K)L4H\J5*EG5O-U[8!M8E>^YFYYT!]J1X
M\0$I5SJVZ:PCXOBR5L#<4P^'0MON]U0H[EQK&7VG>X%9B6Q#9;"--BEN:,YQ
M]:"1B/PE$Y[IH._8G,[KN\QDV+K->GKHW8,.>JT3TIV2]9<.*-.$,B"<M&I2
M3=HU8M9&:]2]=^J@].)A)E<M!E:<(LV<#)\WJS25<)$=5I2J;)("[(UT=M21
M'S*(@"UR1ZF,?"P.'\5%0QB!K[VX"*S]Z1OU/T $K.)M-]J#UD\*MJUX#UJ=
MK'A:X-(ZHR/5V":68*H#/O8:4=#V\KH2KB)WK#W A^X[AJ(E M5<XS1<D$6D
MU8[P$]"L"[<,%RLA2Z)#;1J,>BHN,)/5(W;&7SU$[UBTSGI8GZ4T\UMAD 04
MJPOA7F32#9!,JJ;VAT/>K81C^L':@]H?4TB]25$70UL2J;7NDW\9Y+(VS$RV
M.AU !,P%?\D[CZH[].QMK/V9@OY[:M%2T\?;JB[2+LY0\R1>&^LK^]2O/UOL
ME1>0XFV8EZM&>RS*Y84/L^F*'3"O+9"TI_1J_6C.8F"&H_SS\8>Y79EF#HOF
MHF \'J6R$Z!D D6@:445."YX&()_#H(7BW@(1D-\H!L:W4+B>MR#:B+\]5S]
M4A]>KRC<\<Y/:#ANH[*X$G#CFOETVV>.7YSJ]R1,=\W\VA9>"KX6MN#V=24,
M@\[MQ9FU[\.]&7(PFKMCO!6/7.PB E8Z'2S@!0LM1$!,<[<8N7AW>\^7)P+&
MD:2ZH"Q6>-<ODY1YU+)L$(%P(C"9B(@C5.D8;Q]+G]@'[-!7>8MC,K)\/>7^
MTG71=3)*9;(B^ ;;^212WP6BS@99[3I&!+8/K<'Q;*"#K-.A'X??YZ;HQG,\
M'QVQ,#+KZ479BK=O%-5/6W1G5WK21KEK-^"/"0>AUH21DXL-1( SB<Z?P%1!
M\KM])-]<#R4<C\!IX*$DLBJX.?S9D+@WTT1@7-53E@@\]R "_#9PW!04DU+.
MC>PH(P+1!5"\@\\9^N\_ Q^7 6."_>Y0 NTM$GD6!=H7/LPJ(6 9_ZP07,C'
MR.HHG!L8 6P2-(:0V&9@YKM/O 8CC652%"$!A@>G0+4AF4@"<UQ-^S9KQ8H+
M&ERPRT1@G]KX]"[-Z):,/1%H$"!/^LUGDK__<F!$C+MB3 ^?,0(?P6 $05KY
MYWK\_U\/>02N FF>AK_2:WM":*PD+[JQ7YR1^D VQ<WQ( C% 9Q.,N%#Q:HX
M$1A,)?1FB>!>OK <X<1%I%N>4:_H7[BYXEE8D+,XO._45#!_E.;1,OB&&1%X
MDDH8AF^ N=N?W\#YOT<@/H0N8]=J(J"?M9MLY(51)ES<"%HK)'6YZ'1 F;S9
M0<]0?TB7T$=HWZ%_2@2$1FQV=^"#!B;F%7K3^ ,8,0+#*.NG^5%,Y&[.0KGY
MDGS-U-(P!__(*MVI$CD9+4A67PCAHSPKN$_H;R#"1\1'4Z5#)N]KU1^CVJ=F
M#A/$L$)V;\G>[,N[YEBUOZ<T=O, K.-BP-<5+!]YYHZ\]':Z^7R],O_%HMS'
M%Y_ ]C9<O\=P,?*1DAM%R.;#BH$KC3.WWI;"[8I+;/9*O]Q+M3U>$"I&!.AT
M[J[+8J/:60AMEG)-A9A7*8\$R_4Z\=G7*+*W3+4T(,U['FE>T5W+M +SESI2
M_@(FS<OX"C"!D4TD;$]?Z[:Q78:M"F6^M'SEE63C HOVK9Q,C%EOJ!JE'D$H
M5XH,CA9L7U]XM3XA<*VJC('BWFHA)?O8S2CI>@TX:)Q]MW7N+Y_,\]*>WM'4
M#IH.<YF@@I+'0&+-9-XU<"D.4.TM^[5K4AZY^ZKBLS81**@ 'X$O1HV@2@>Z
M25OH]F4^T$ L2A !T8)=\-5:/+1&[V>\HN(D3&I#Z@P6(.\@@0<_Y<^3[^&>
M+(4L.&Z0",!(Y_(4('<%PGU ,_F5]?(B,X9_;?J2?D4K4=A1?'0[(VD(.Y@
M79#P5#2VQ2T35*>#D0LLSD3@17PY3Q+]"[P$=K.Z6#+ *4P(K=FKYR$H8#UI
M,?X@S50A);213E2.\BZR1AD!)_@63^_B0&L=WI>$8 *U!%8LL%B!6F*+]P%8
MT %8+),,O"0I\68 $^\!^'AR*6CA%88="?ASH">Q^B201 _^(# <]$CDSNT[
M6##-YTHF')(A.9?]8)I?"\>[E/F%_-3V6VTA\D<04>UU(S+=>2U4T^&]\\V?
MHE_3G:Y]X$#&^R9Q_1L0(MV'M%OX/'[=+?SA)42@/XYP![7C1 0&NLG6_O1B
MT/]R@<)!][<JB!PDG?2N@.,CO;EGP6<1L2L0!8;_&_'@BZM/&"$=[N .J1+>
M@IUAW2U%SIY_3#;S9_?U_J<+"QB%<B G'\U7;"P3@9<'^B2Q%55&(ECG^L?%
M5%&;FF&<+:9\X7SA6HA'L;=*8VX#!*[4G?K2J_HX?;0PG<7JW$!^V(8'V^FM
MJ-TWK(-%?N$L3;*/I)C)9K\#Z+>^L]]?]@WG;_.W'60#<D535HW4@DRJ.&$I
M 2_6\0Q7] EYELXCG7C^9,W4EX\%K4Y$O39_P/.I81,=52@'Z=!.Q</@H+J9
M2Z3@8X4(K%QPA_C"0=56A"KMBNUC5DE?#-3](#1JESH>NDLP)J@D$QBAX<BU
MHQ;(S2WDUI&_FB<5;S#5['A"2G:GP+L+@8\?QH&K=/8.Z J0<40@2O OUNZG
MLB_*<,D3?/4EKNBRBTC&?D6S](*8C0<\/"]NPVC\V(LSN[K7\8(]WR3X9-@"
M,#X&C;0-F(1K<KG^Q)/_4/D9*?_[RA\>*3_W-'M:77R^V/BAN(7XYON C-M1
M?"<BF3F8"6,KK.1IV_'=H('P  T$G3MT=\N8H)RE@.$'5>]'?CK>!VH^Z<1,
MAB8"F A/1R+PO!T,[RH$B4#C&K):#MM.")*C)^"SB !OW[O+"MQP(D"UV0#?
MYER#[ZQ4X".4\;RC))ON2++IS:!-E_.@_*GM-]J@S)[G"_JL95W3%"?T/PD[
M.Z^4?Y0%*#QK ^SV9%T8.$.'"G.O^ I/'9,G;2&C7[>0*CKSF_WR$Q?Z_XX5
MM1.!W#Y\\^C&)O@/JPYY:F33X8Z*1?!I7X1EP?]KVPRX_]EQ_G^\@.ZQ?A1,
M7Y9WP>AE]KSSS/?A<P<$]8VU%9S^.A7M6:/\$G0[?L]*$5S\37&#F6S-.+"<
M#*%S Y,9^<;@[J'F=@^S_;4/.3]2TLZP^?[25*^9EJ'YF^)_]CC\(8&B2Y;C
M^2<CJW+#GDR4+6W3AFI;GVZW2.,E3@92)4-H- BU)@+&?#$-X-TGT2&_(QY$
M_$;K#'S<!4]"JL'8$)8)QPU#,27>W,B.&O!KZ$#Q-J3BS-_G(:0GD:JEF-4O
MU5(2>N^$K%XDH??GZ FJ!DAL,4""Q+\G+_R&)Y'I3V"UK6G?9D.N7 1?FK"/
MI D[X]-?)NS8DR;LD*/^+K>BF!YG6$$/G[D%+KI@!$%2^>>B_$&+(F^!"QXO
M@5/AEJ]T+, 2U?2-!4W:*HN&&:6; +JW'CKIWY4T,F9'>'$1Z7<'U!L&3IBO
M>!:YB-H,[CLV[L/[2/G(SY+&'R=&RNB*<"V<6%W<&5H]BKCV>P_,GF3>YW44
M\!3XU,]QPTUJ6M8^>CZF!1<TWG??\SI"6"*,D7HIZ$9D(K\WL/6$ZJ1/TO[^
MAGM:D%8HD_=14D&$ ,8DP<H;R$^RHUMNJZ[+_81J-(?<=E\%'@Q,H\X]1PXV
M$!ZK&BEBNZKDN3"N&_0;>U$;\#ROY+;=M2B;P:G%G07[L-:NWC+D3W[$OY3\
MF_ Y0[R/=Y4*IMS0QY_JM>4I>!\HL&0BNOCD.D!WBIJ-QSQMOKLW%7^2"+ A
M/Q[M@TM7X.H =PB>)Y$TG?$J:3JC$QRO#L7X(>"$ '7PAY2@=JP$:*XQ!:2Q
M5>>?&N _@P:=&5D]B@W:9;1V7'U*!$*U($G(:FH2_X!%'(YG!?74?OP;]X<$
M#3BR'KJFFM?>9DLXI?SS1OZC;B34T_A=3I?\,:O3+@<?Z>DU3-X+I*JU*/(3
MM4OVC5+%6WW\!E%[['F^5UABF6M.[QDA6C[:63*FO-ES^>&!(Z%3UU8 .8C>
M.O)G0>0?$AUI= 2[+HZUYLH\Z\?2!KL0*B;_$RF,K'+,-QE59\CF[*@@RA<\
M9290K//>IWJX=W3+HJX8Q@N0'V &T%-AC@%LEY?LHU0_E]_O]?1.9,"QC.^T
MBLY!NI=R=SSTS^YK/- KP7C*8#6'@IN.\S5OM )7Q0/O(PBUZK[;7;J]8WZ3
MZP$L+YW&H$^T&(MHJ=K$!L41'A/\]TNONEB+>]E0+RFK&.KQ>U-O7:\\Z9.2
M8,Z%-6:*CHY6D))F)MO<99E"41!X"AYZR@]HOQ1K>FOY1K+E1(C>YR,:?>M\
M"&U^>+4J7^'ZF=^-/6W]H)(3,_V#I#:)7N%?H)?E/UGV)+Y,MRR6*!ZZ&Q_P
M,I1V_*!:6BS?23\[&@8Q'PVY,#=4'1$XB+"]BM-_V_\)X7^QI#BZL9^6-;MQ
M,1C-OX]. ^#'I,D+>9[H+O6R3QV9=4^QU[P7>#2_Q(7!&O9L/I<1*@4)5S!2
M&O%TK(-3RJJ.0^D,Y^,VBZ_%YI=(IC V&BPY*_J8D*?3K9$-_H^EQQM$X-L"
M3Q8-IK<$&PO=-WO TIOI8VI79S-+7JSJ-;%:AGLF.]@F V[_&<&KW]8O?.3\
M0GY7,42 _)- UM\IAOQ4]KVRQA]!C6[*M6IA+LL-[H\)?._]6G1L!1<9%!3/
MUZJP4H@Y&Z:FS>.^20:3Z)/^;/3]WT4$IXT']*\$JNLK=/88J-M2%-#5[G]I
M:G:=/&'ZU&G$$IS^1?KGT0%-C7AAIIF!9%$WUH/6-B'40X<D3]1B0V]?;Y"+
MF""KPQ_%6!>$E=JSA&V>/OA1HN?#K6;Q!RE DN_P$\>NJ6$_.L$4W/K)\&?I
M,]XLG<_S_#4[[SV$:27DVO(Z9#5-W^5U;!I1Y9?0'#M=\G+&2+8H6KO"KUGP
M(?7A\!NCMVU'POP:?*L+KIPQ2=M3!'\@SZ/)C-C4[9DP11Q->$L7TLP-(SOP
M;LCO^K6$37[?3A_Z( *4=(5R)]\UQ-'"_6=D1(."R5P-LGABM,F'PI7UUN@'
MR*O/" <YGSQ"!%3>AS>.ODT7%Q%0R>'^(/J:[<HYQW ZLGH'U1V9V7=@YJG\
MUFK3^FYLL5EL;Y0#67#"- )V2T%EDF+2;N1^#S*"^W2G[-6WEK%GY&I=[69;
MA)\XLLOH*=_<%^I#M4?$=8_B<(.&PC$\T$VHPLH+VO(C-P)2>G<*3%HJ&9?J
MP5=")]2^3^Z==V;68V_ $F6+0[&T/\W9D>^T"BMQ_&Q*E;^.WKWCV#[<X!F1
M_OIW-V*"+]: %<',=L<#_(?$#)2B8O+1C/$&^!Z^9-1!_=?T"Q^Y/?\"YX+]
M1\L?38!'5J)6-&4E_C+$/:]#)P!G-6X>D@<Z1M9\,'_)>RHE=.)YK(Q%;<DM
M;86SM)?V E(S9YQ8THC /G\PK=%V;F^V)< 5N*LN((@ _C@]F-O<Z(,?J\#M
M0C&O9<&LY8*Y ?X5^*W6R!:8=2+ %RH)S%U8GCFN@+E+Q,>?:GY5,PGE0$YF
M67VI#*1@^Y [HD3@ _B ;5 [>J7)$T<CW))PRU>ZA-<MUZU>>V9LYDQ[%@6S
MF9]H\%&8<__I^OY!UW<?ESWF@FWP3QQI$QB\GHN4_Y!]?<A=W./!F.A&(X>?
MZ9B.ZP7 D\;>5N[EA_P^D29:K+0J;^3%]R)2I'&F&R_^TNS\/,IRRBZRX5"L
M^6T[@#Q*=='8=GY;,^!56![\P.RV3(H P_!=D=JS0DM[-SEI"RZMRZ_7I-;:
MWD]D*RR)4[,^S=$8B;9=&!9/5_-_%C+GJ\N8#''IJFJ33MH7Z2D348/*(>0E
M&[7"!\QRHZ\4 UE+T^=U#H2:LNSEN^+@V$1A:O)9T,,M<^EV?GZ@*JGIFOG_
M-5U[18[;'L*Y3H2'O1G4.^<\>7PW<6ED2C;_5&.**<MM$85;58U5LU72*/H3
MWJQR0WU&-.%URU>EA3K%L3XB-\Z/GLE:%KFA )&"3?A ,4'C^!$*3'?% +?Q
M1M[.VX+#;)&,OBO*"6,Q+8S*+KPPP*ICYB>OY#]!_EA>R3L\*UISWP".M:9W
MDYOOX_/$DZ+]L' U7$SD_8M4//F*D%#MZ>]/P;$C,.$4Q]0UJXJY=C\'?#8T
MM-Q8O01ZRP0;ES U3DAE$__+>_^KFX%^-D?]2Z['=,3#S0UW5-W).RO52S0E
M-V3#HA5Y(CD8E.C8[.P4H0'N\*\BN57Z$+VCS\;;'VSG1Z<,[B;6T_.W//20
M'^Y(YM:-<H.M6'5]'0AJ03K^;'KPOXNP^*+A!V_@!*LW]7HFMLJU#PJ0!UBF
M\.]+0M4FF ;0VMF'C&8E(BW5S9TW@IXGMY4;:+H>-S]0CLZF$VO9'^7,N7=L
MQ8*\$7]U8M>J_DSRJ!5KQ#&A5F:R!R& _4I]474HV1<4]UUZ&>["6 N4 ]>W
MH)<0?B+#>F!.-]I?1/MZ?\D;/_THZ4J>FPGAZ(T'G4Z+W%TUI[?OH*Q,R.4&
M?UE\KOLX__!?IE8QD_$O3'O8OII-%*DHB6[)SP\?L419REP^7Q<.X?=QUPFH
M<91[.>1ZNDN5%BN%F P+>2\B33K&>#,+L?OT9N!<5]VO#5[Y33 ' 3/G(S>_
MC)TW&&W0W#-KQ-C[UGG_8<\'$IH2\1]UJ&E>#3U>NUJQM%'50 &0+2"IO'G4
MT!7[U7:?3X$;3/=,G<-E%<9C4-@O]63W1'A<K]B1[2FC*[^,(TO;]9_PU![1
M +TUC6K&IDU#G _?<*@C(8L-G>EQ<]?P=T/H/WL#_C"QYSZ-2QTG F1S!WL/
MI;AV&;2S)C#V\ED'1Y'Q/5&&25[:[4JP3S0A')(DV3CZ7B*P7&N,=RB"1Y0?
MZG-&<>H.6;H??>FU;_9U&%]&>O/STB8Z:BTE.V7NB=)T H,F&[(C+1,Y5FQ+
M..HC[TL$ L-(S3[K%3M85M"H)W^OMOQN=VZ8FE*AOM=5S9+L)W'N#<XTY^L<
ME!1NTHG2R]>G^6@JQ@/;0=]_+ )G,4IR#7!](E!Q +326P.;U4:P+FM8206&
MD&YES2W9*O?XP<,HH.6 ;Q,Y]JT[L,-;!6>1A:-;SWZN40O?YOCER&J(X?GT
M,E$RGG21L9CYB-)3B?:#?6WPG!'_MY8$D>)N8?'T>0_!L).E3Y]8#YM$.T6*
M#-3>G'0XU:WSL1NX?('YGQ(=%-Z:Q%_(!$.C"L)C92-?(R2V  R&_\)XO\P%
MN'V7WY<CORF'_\H3A*,KMO@3P1?FW?4^0LA=G%_YZ&^B*P7H59SF!!'P%6_?
M.^/"&K\<YVR5.E@CZA7EF-<K02O*!*'@CLG^C@LTI_F/5,Q)W1K?$8*2O^4<
M]2G^]E/*W]=" 4?P5]]0@B*^91T9_MWRJ3A9.YB>?T.2^IYUY/2;SWQ?V.V
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M96645QX6MJ)1R^M5AC$4\089E;DUG(O@)XT.J(>N'9]'XH3CB$!P5L$;Z>G
MWA&UA\%7V(Z<75'EI;RF):K*[P,L*T 90:M%B:;?9G&NP+.V_&5 !6LH?.9Z
M+V@3C86) ).QM:*LI#9V2+\Y6O$X)%SEDRB):L_)H.P>OK'=I9X;M428H]&W
MP)9;3E(]C/:-E:53@88!GE=_HT@9SV,$FLKG.OJ@#?6LP*M[L:9Y=\A391?J
M9@Q>[F;(1)_,R&?F1,5M!M AVB\Y2,\;*@<08+BK=4N/+/7>WL%&ZB]$^S,7
M'==]O7^S$9B^=?-4'UL2/0Q'/@YGL""(=-NNJQ_:KA]<V,NPJ96K_RSE++#?
M#Z$TVQ6ZSKY]Z+^QVF\UV14E^GSQBK:V3*VRQ=;5RIQW;SP+O0< #JIRZ38A
M ,[_VQ$_$3A%TCC3LZ_ R-9OM@(7O^.=(WLAZQ/.6*&T-^^H<VZ>0OM4YN?;
M*M>UY%1Y''W;8706Y..[:JK=N2185GRGA/V)Y%M7K=Q+.C#3O0":9W7A[G)
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M9&9C091+ZM8:!SM#H+T?OY"9G=#&;FV*F)>C!"%B,#&6'T2$Z&>H\=RX;;W
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M,2RTSLN%?J#G,A^<MHV]S8@#=#[P\IP?)#&?X1A)5?ZT(S[^//JU]EEV!![
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M&$PK[##%R';!V"]#Y,:#(F/D0L,[NSEOV5D_M"]+7RMVR\5"7Y!QV8RI2(K
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M"W!F?5@^T.N^*8E..^=O>,M<F&/E9<44!T.+@-YT;\E[R1N.HV^!R'<F,>'
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M?<]IQ7G]=V55T0L/0E$[5.0)>"0&, MU\Q*+DO%*,F;6$G VKBS7Q^_>-<'
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M5]^>5"\NTQI%I @U[_BO:P0OXE[O:J<E&'5J>.A459XX_6KP1FNKUC=M?,8
M5JIHE"Y19<PN6CQHWPP7S#0PX$JK;L4(_S,[V0<:[%UHN:U)>#SVW1N&DA=
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M/P#3+EOM_ASNU\/!9-KEPUQVNCQB$3=+_3YJV;)M$4A(WF^7)4?G==;/SMV
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M08GYDW)], Z>0([P!H6C-[IZXA<B;SH!QG*>&XW;]7)>-8OHG-V*" ?V2YX
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M3W^;;6,9Z=]2L_GH%+CW5"[QF'H 8Z>FH89XPC&]EEHJS[ZT+.%J 2@D_DL
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MSX,I.P%^DUB91.CSN_JSZ&'];4$^3Z'?8]-D)?X./?2O\?@GC$<3!+(\9E$
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M;@O.%Q5?VE CXXW_DO\=U&M+3P9AUW(\NI,^-GH<(E/RMOW5_,T(@0GRD1.
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M]$I+FX*B%FZFWR8X124V3A_9>T+\X3U^MC6X2U;?J._2*5>Z%O!SLB7D+E:
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MBG(_V[F?O>[#S@E 8@RAZ!M7'(+J%1;BD[J<D^->.N<I1Y<.T&&(8D"9ATX
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MLN83@U"4?4><L*8WLCZKNWOOLNQ[.2>".LI#??*/DF#%#[FX )Q^U&7$^9*
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MGU^%P19#?+8IDTLUO,)P$+Y=P+KU>&G .IUVU]B);5JWM8VJMK4NP]P<->A
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M6EE/_/0%@PS=B+<"C4Y]PC^+D>%FCZ@J"[7J^^Y\WF<%N877UYIF_8 MD;8
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MMQV+/8J;6/ZLH2(0#02*I2Q5D\(S\;F?-<0:M9B\JQ.&%M_N\9<,=GD[ )[
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M<EO&B<*?/)(:/KLO-C!<TR$+X'3HB&7SJACS#24Y5G*EKIS@D15]E=BNO\_
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M:3M!LA*'=6FOA(BU21]R-]&_<RGL[PL%KM3=<N=-4GB#5E>$JZMRZ_3>YM1
MGI+/#ENIY[1UI7B9J?Z;&LY?=[P/57)R'ZH(_673^YNRT+ ?QKYC['M"@0*B
M@^4L"S?1,4VD_(8EB#QY@J/4E&P&IUI[G&#)B/%_1"CP1\,U1#S47$;1W%T]
MT?QAZI1^?W[5!6([<^9TPC:A)[',SJ" 3NUUY-+Y1*NR]LT:E<&6P"5.]_L7
M!YQ?MHD;EZDEAY><) ?8'P  &Y8R^A-R<:O2R$][NL5^)$=_\HXF8//M<KD;
M?*I2#9(.S#N7N_]JE?SBE NF]%(/^X,AC(_2_K@IXW(F Y?OVBX!;B6O0ISN
M1Y/61B[H;N4.Z2$MMMK8ZC::>8\!PBFXCPE+SA90B$T86MM006)O])J=S'2Q
M77OL0N8ORC5]O3Y%NRHT@:#BY<FH,6S(?O[J%<602 ?RO+?+2D\\D'QT-^J)
M3QB<A6]GARLCKNZ_Y1^_72)J>U9>*K/IHK?BC/9:DX]K.*D08<'DXFTHH1_<
M_R+N1]9UUCN;.CES@VO]UTF%<P5&BG.GO-3H9R6DJ21 06#*^ FZ;"L.NDZ]
M^=YK\S8TP1DMMXO"QVRO/3YM+S=8.=5^%.DM5DA73IN'OAOUT-D623;Y0*I=
ML8U81M;D9GWR6\M%BYV +:<.V>%)MU(]50_4?&^R2?'J=.N9@1*SA)?/'K%Y
MV('5_S:5G,_<I58YX8_=G=\NQJXB.3,1\:5L&@;+@>UWJ(AU6!:'_XN'^K_(
MSAKPEV#TY1)4IA"(N<\U"]\>]. P&=HO-0O?,J*%_899[=<*B!_6OK(F*XW.
MG304JX?QY/=<?"\P[L/+46CZ04&'CV60W?)"';/S9E;4MUH,P#QG'(0"82LU
M\3)H#[YEQ90#JG<<VLJ(_\:+'W-<@7T#!8R(P: $C-V&+!B$Y9"A<$=M8Y[J
MZ>Z[X%#@RQ.SHJ =7CVQ?9?"M9@/( IH0_X;:%\":!>0Y7 3=TWYB="^>.AY
MR\Y,#(]GMLQ#)90Y- @8)Z4W46*)\Y(%_4"+ZP< LZ#BPU\@3F/H%\HO6OZ,
M9]>\=0"85UZR#%I%8(++:'"7A=R'\1S^+%1>Z9F^+O_-"?A<W[,]A?N>@EBO
MS8$^VE405B'=9A<#WB>8JX<6(]M%!+=5=EDR'6 X?SQ"4., 4 #=%;),_!9#
MF0=AB?:!4^;!!P"G5"S]#I,L*[Y_KN%^6!RZ0:#T!#JEUP-=;+/9!W1\#1II
M( $X?*6++9G!/7MRX-KD]"XQIAHZ6/[JQ9C@#A5>Q\X<AQ"8\MQQ#_]L;_H!
MP,@!.G<LM^0H[J,1[M*M0!O&.F%?F>]]5#YLC*7=8>PX -B'H76GS"!? ZLB
MY-?@K*/W9_#8E0Y/Q9]!VQ;0<7!$[><$9XM9;/EIW-5=P_?/77S_(/<]<1 X
M>J 7 MR&N#).ER^';X@CCD(;FB?*/T/3Z4Q!W!TWQ*9 !T'[#/GQ8P@<Q-7]
M G'SWTR.[E!M4NR9X6Z%[EW WK-2SIW<.#CF:?(\J!5V'@>KVD0W'.VGRFVF
M=Q.D00< 05EP"EZ= ?A==087W?J5'4H^Z"<N(#8HID2J$KHF@W;#5CF-[HI:
M#GF"H V!QC@<)8Y[U;3RQT=(<7>W4CVZ15V <Q+3P8FH P F$.>OV# [0I]X
MA"C0Z,X2W_EW1R)_LX^(J!^E6AP0"^6SVBBUU,SVR^MV"NV=G[@Q8N++<?YS
M_K"1]F&1// -R."XK-]DZST6=:WB[E=QI^VLTRW/\D23M485,<SRN>WJBOY6
M<8S@L!DE#!?L GYW"3<O53XNQVB[_1F!LS$@"@:IQOJ7.AP CE'A]Z!B4RUV
M8W)M"YG>OG+V$'Z+6^KO1_M,)1RI2<!3!GIP';X4I4,_ K %':HW'9>F1L$O
MHUBS+R6_&5ZXJ2Y:A)OS(A@OQ^@T# 0Y1+,L%G_9%?]O:A+_;ZA)>CA-(,DU
M=%A:5-VKS&'RCH&K!N>4UYE1@>$GQ80T$^P28-R$LV&!0"+'ZZ<U8S50^0G;
MNS_!0?T3.S,%'-YY@B..LS["<L3.U^L;LOAG\M['C,PPGH%QX7[BO(XB,=$I
M%R+6GDVS $]IB)3>VD1IG,?9Z9)\7J?GP<6.1Q0:3E"LRK:1R+[?($UG8:_1
M<P=9YF=W?X(_1.UD)W44*#4M)OA6BK-GOZ3PW>U["SD]5OBD1"7MZD!M2&]$
M4B)<5O_QVO3#.TM7K>T=MI\,2"PH=FV>>_YJGDDP?C_ZS:V/+N_799NM(VSJ
M[%Z\-&,$/4_?(%!7[?STZ+K Z/4NJ\B!MN%+"E0G::#"*HT<:RH<:Q;3?\[7
M^*]V6*#0]7#T]!'![#\QJ[A\3'V'"\:$5S9$8(/TYGBK,*(HTJH/2+]'(3<F
M-7IUW :YK3ENS3SA-I.K(:M3$_:X;@$]I*^G0?Q.TPCTW7'F=I06Y[;\9DC_
ML/8=:R[_<VDH@AL=.%X,(D&OW&C_Q %3U0?S&K=5% U3230"3F:XZ:;_Z\M(
M_^^W(HH@II%7XZ,!>@7I;PP\8%L$]+$"M1[%;Q2^Y*'*L7C<@2"KG#Q%4:6]
M3R$CNO'^0;;><8P$3>^(5XD9.%7)@F?*P/@D[%4*K#\%)K(07SW46<;A?F55
MS7MLE'!T/BXYPC'UHTM?V!8DO@4J0)T@'"[A-!^:1S UT%>%9'H0YSN@,KZW
M^$Y8QY)!#S)L+\>6(MXFXNOK(WSL08<G':1+O_M&)XAB5(_09QU\N5WQ:?AQ
M3J\VD00!-8(*<9PK@RK&TW^TX]S@2!Q"P2@ #W\!\"!,A5Q11=57>AA?*2SP
M41[O3([4%8)FO;C'U<H6M6ZMH<1E37,2@(C!\(^3V]1)OKXUMW7CFFI:L\2-
MLU[,F,Y+%Q)/>+1=()#65<(GAD\ ]\F .YPV!X :S4.?-8B[8,0HJS!O=U&Z
M,&/V%N?GUER>9)WA! \?:?H!"-H)NJ=@H27_C[TOCX=R_?L?48HR;;(;12E"
MEK(;)21%&[).4MF2D'VY+4G)$AVD,$I2Q(008NQ+=F&R9.S[,F,=S(S?/3KG
M]VVF4YWO\SS?[7EZO<[\H7-?UW7?UWU=G^OS>=_OS_LCV)-4ILWJDE_!%LDY
M]&HAQ6*"]XIV9CDOMP8[HU#\G-D2)O\'=I/59'D!M+]3ME,#,Y.ISRQ?>#Z?
M5&5(+QK 04]"TE5=&6D$2 1I!4E^W[$T\BE98WFZ"2SI">U63F/CZP??.V][
M[;V!:8R=WE?MIJ?%NL\[_QE"L_^%S$K6 1K^[1Q=_Y_D7WZC5??FK#(OG"9]
M4/V;1$3W]3M_=?=GW<%X/?0+\,:+@:E7\7>B+9/&UE7ODDF]*/$HIY"]%QM;
M'F!2&FKR*US\%2[^"A?_,\/%?N0NKX/6A?1XU;3HQ [+3)7#X5V2QFH3Q??S
M>FP<V4M"NK.*U^2S2LD^>3 2 =RC(1AWO'FO4GY_PTZ#,3?C[MC-A]I%\D5:
M0EY?E,]6:^%G-\6VO1.C9*I0LKHHYF5FK3 0I<Z!*06=@I(I61M?T"E\P!>)
M5NDUB5:.4HI$ZW:*J0)MEU7H/ZB3::4='A<Q'JY]]U,E+[S]:.K+M>^=;E9P
MZWU&U>*N"?$[BBF?QBN]=G@(8CP8P6O D/CC"U_K?3DZ66'M?FQJU5W>9DQ@
M2)S^>WCC@$>78N3 6;)^D67;;=E\?^813&[/&[MPM4.OZ[#R-S><=CML#]MY
MN$"E%,WB:*-W\MV*XL0Z,5'CP!7GDX$NEX[VA#5[*QWB/M20ZHE]9C+J%A)P
MU?%9-<-CLS+TM4-;7FZ]N1/:6R&>0\]>L4&X]_YXNR-7M6C2Q5WJ%<>W"APH
MJMSHO7_TDP,F%7ZZ=5Z$LS=-JN#85,4UX^"]K^MVL%;)[#TA4\7MS@19J0\D
M^)%W-+ #C9@TH*<$018*)6A3I+553$#WP&\30$B&K'@%SF"]'V<GOB9LGQF^
MT"**2C(^>7Q[5VWSF[/<YI!T00[!4 >3Q/\>6;:.:$L ^D+9NRSUW&!1KNN3
M%=2J,M2:,KFCZ=/I?)B2U5PZ-C(*\AY()8K@HP*D7.=M#-56%(.X/*J]6IDG
MNXK5F0;B3G S0>9H*+44=)KJ@^!:4,_R38SHB>Y'@R'B7DJ(B"$'6A%\O95*
M<8A@!6'K'@34L,LE2NV.R]N:*^&R8GVZ:MOV\_FV,_"*&R)IN3*E!.U>1I_#
M\ TCSHN/V:(='9,ZZR1):7:Y'8</WH31"\11DE&IB3#T\=_4_$N@95Z!+X.:
MMZ-.38.)9_&C;1)*T"+"*"\2[-"/'7R1E(1(:MX.C5R?MQR4M@V\5QX'D+:X
MP<B;P471EX*D9>W0J/5!1FA:O/RVGB% 3=DY^VL^_@GS 8U3$L.VCP$[LY[4
M,+\3G;PR<^0T@^_QZT?994R+BQF\6$=HDU M'E,*C8]U:#VTI10:1XJ*3*PX
M'PMRO:PQ\+#Z/S()]4*6C4&ERL>K+8X<Q"<G @,>FAUA/G2VQ-?M#<^!/)/<
MQ/&S'%*=*^[QK,9MTNL?'/HP99*L!66@+YY+='1GK18U<;?$/HUZY3);:J"6
MJ(3T?.6J=V:K0&A56/:@"LNQ!RZ7 ,XG:O@0OS[FMLSF:>**?]"'\]5A-^.]
MM?25QTIG45L(=]L)$2B4W4'8LC:K(VS#087/SN=:/"8\XSXI7^Y<?%^Q)5^V
MGU=7/,39W:&<^]1GX.I5L]&Q@7<7KPIS)XI:BXBF.DUVK$+N3<SIFF3UB?"7
M9M<HI7KR9.1TG8]T'J#/VKGK^@V.(IEZ;5:SDZW7LPJ.B*AH/ZG/^NV-^J>:
MV-<7<$6\\0MIG2F?EI#F2FL/8Q^X_\4__=7IB>.92Z/B1'"BB4\_:3 X2YN8
M5,;>/9JMZA!.I[AS(2TNI1NK/YIM;XS]?-3:AE>Z3L%GF_U-B4J?:GI\//0Q
MO#=& 4%)ZJ;$)#643/ "_'!)L'.Y$BON3M15YR1UI6#S!?<[C]69ZC+V?C#=
MQ"\>%^^TEF(V7@*;.VP!;J'[7[80:B/0V+JV@\3(0MY*P)IB/$!B> M?60MW
M.+]Q' J]_UG=*,SV2I=X.A=Y[<]KF=<LD+/8EV'M:*C/\TC\UO78J@V'DM")
M[JQ71PL%&K/NW\EIGD^56W8\/<F3VGRRV'[#B7-:$NI*?5G?_WB?)ME7D7@D
M I=3QG9(2#+K7<[N8O[KK]/3>T)N#O,2QIOSY69@'4*KD DR)/.M)DI4,V7N
M\\:'&RZV<L>@\/MM#\8534X'0I8"N[NM\Q^EIO:Y)D64J'-;Z<?>*X*P: AF
M.2-!4TK!8BBV%'1^B?:YVENLSEAT[_N89>@?UES1*WK<SB>:@V701!OR!I(C
MPQ!SY) GBLQI34Z$$5\!"\F0V363MA4,&-=L&D"615QPT?W0?QKG=<_4&1;E
M8&/*(+FOQRFOXND==<8';GK2/<!])6Y\::6Y+7_[6*U_<$31X)OX[ IN&0ZE
M8']!BW7Y>6O8U](/ (N(X1]\#(^'*J\1'Z@^<&,::=$-R$QH@)OB4$%_@?2I
M-ZU)S3=>S#J9%,?B+PN:!4G$*?._'*=H$5,50=F-RS%<JXFJT9IE'9KYJ7C8
M-7S"O#./#;1.V@(LZSUA?Z9+0)4QFT"5+/M7A!I^D%S[ES0:J%K J>L _25U
MAA\E /\E889?$_#?F  H4ND@P?8<#AV8>CU+>^OG\<R"\),YTD=S]D39O;GA
M)+->8YRH'CA*S7[6A5>@=XYTB^(C8LD!K@OY%^?F_)$?7'!]&IO8;T+58+$T
MDL;QT*01&NBY#@\EWC= D5SK5B'QG#BYQ09PCU=E):]",#'893H4/0I9[R6S
M#!,#GV\[;P U@]@!#.,C4KG([SN7-(UA >@!@V;T>#V,!-&3?04^J$$3>KP.
M_5O6J"Z9%7XQ+IN?((4NA];QI-J9@!LT+*H$.0_N_LQR8]I_T LF,\\C'A^N
M!3YC7P-SSYVRRETP9#4$$T!A_K+2_,F.[4'K+,5_=;&'-@7'Z"2CP;!2V8T&
MYYDS0W\>'N&(6GE.8FG+;?@:N&C"R'X-5KPM!]9YA<Y(50#Y%\#W30R&?85?
M)7Q%)K>@@KP4J-":T"6[&1(]V10]B6VLQ[$1[[D!I+?@RPLV4*)"T?2[UU$@
M)O#.LY'+XBGJ7W/5Y1!3E#B%& 0NRUQUHO",)!4$I*=N-.R-'M $HZK))'*0
MU<CX*3'<[A$T_RG82A8<AZKJHY0ES7)8A5"XI/%[*3-$@_0H0%?>*VZ>P2Z>
M<./6\T4/7,4C2%[ Q$Q;5"@PH-D"GT22@PSJ<'K$H$+A+WB:03-^&GR8 %(F
M^##W+ZJ0/IB$$]OKM,FJ'^>00PT[40DIPYS+<KGVB)P9DA8O:#*CD&(MX));
MA#ZGRJ46KBG<0S1!;++23K#4U7!\I9;\44/I^)F'=YA]? =>-3#0A54/L$#)
M;(N!Z!%8 H"-!@B#[H]N\%3V60J]"=28=+:1CS[Y]GSZG WK;!11;)H5:(2K
MK4+08)Q)R8T 7%+(/LO2I*4HT)O7786,I9FU>_8MX)2"GQ7:@WN6U(=:9AS!
M+@XA*&XZ;?-6H\J,E=+.HN4C@4LUU/< PZ'?@R]/F<1%)M9\2:'0<>"MF8;:
MTH]T" ^+$1#=X)$=[P5.N=?5+\$(&:]'HI^S79D5H^1*D'1JW<7>*[YGZ?\A
M7SRSCU+^ A-\Z]';SR<QVH'L23M2#-7&.GTS^H?L*5!(1//\IENQ!@WG?,Z^
M>!LK&'R%X=652T7<6^W"QA%FOPW.O\EU+VTAQ*Y"=L0];TFZY8E2]1@$E_-*
M.6(.VH2>KD53TE!H;C8"CUV;J&'U')^_,K%GR<E#BE'=O-V,36_UZA'?3@WU
M/"^G/%I N+B[P-2:$+*T\T(SS6OWT3O9X\GU[7TG99+B/92C3F ZM*(/OZDG
M]&P_/AQRJ/P1BQU1<+G90^11HI?.8@#X"(=9G\1;1YH(-$X>]E2,Z>AZ=766
MS?H @^]S-]^-_?PAF[C;(CR(O?LU2D[66=1%/E7=><'[7QX@??7350]4D#7O
M:V Q'G&>T>9);:N;I(?T6P>P"VQK5;?"//-6\/M=!FD;108)\3>E)W4* PT/
MX),?]D$KN:";QAPLEE4?6SGC^0\V1SN5VXI=E6'(99R&J,F9RW8..&-YWGLZ
M.\VJ)!^]RF6V]:@EQ_$>%N8[-]QFM!%:^^G;_A!^XJ%H.)5_K>'D2-%C LTM
MY^O0.]BMQ/,H@G2EW)VD9-=%.>. V&NK$/-['DDS0]=[+]!_$#.:2_9B)CT=
ME!:V[&>V((:_O.=NOFTSE\RU"$G?C0._T;/W:KE YE<AZUW$3N/V!8M&)=8Y
M2FWO.EQL':5K4ZYSD^GE&N[9U')3>TOK>^==,\\;3_KTAQ_9G/;\RE9UAFW=
MSW_5[?VWKXW[[]S;?UC=WO_FC_*QD>NP3J0GOXH*%WL-HI8I>["G<A?T%'=-
M6/62NA;9U-9.,;'$R%#[X(X73IK,OSE6\7U1LD2<18PLFR0W'4EXT=XM)3M3
M5\:\^U2_3!>+I$^,&]-L*,S%NJB;MVDX-[S>PI&Y<E^'L&:DGG.5H%7VP'&.
M8OF;\3V;(Q@;RDV39-U5A2\N3X3*E?:^/"@P*BNK%.F,?ICS=/!Q=HIKZICZ
M&;1%W.BSBP,1>RYVG&,V1=Z@N[XUM_*X090F9MYX5_?R%@E\JN[<GEI\:+>I
M2I PP.)1.V#J<]97?O"%V6W7M$UG9Y4.*39DG<AW3L,-2F\I9A?>%J<LL)5%
MOJ>_$?,X61OY>'E1J;WWT#1TPACN:%U#Z'2WG=D:WJPAG*D0+NO*<^_@A):F
MN$*XML#C!;3?XWQC"[;'1OZ?/GW@E= Y]MK^BC^#O=:@O0.IM\'4O,1D!T[T
MU8OVL3R;T(X@Z_2ZEJ )@<X[VRMCG^0VG+)GPOL9IX8\,4LL:1Q=T&T+DY^^
MDG//3/<Z73B$NX?%T]_-Y;K4:$WLAT4EF'P]CI ,T_$7Y%+*ULV)+/1/WO\L
MO^'A/UV-N\<+=,^K]V"\'@ CA/'"UR3;XQ^)JL^U$ZVRP9@[ VD;O6OA=.?%
M0U_2CKV5MCXK1/\,BEU:%SB'#/;:U>3!W\\LOX6E82*R^:) ?9QU=93$B4TU
MX6[[B2FPWFL!22ZA?4>B$JW:*"/%G!Y2+7CH]"DV0.@HM[=;(R./JB?PTU36
M 5JRX9""-&ZZI'!;BP"Z<0Z=852]S1\[N;WZ-X'MAR;4=6 1M^:^CY?=)C>Z
MP>\>[IQDVB*F7%B0G1-H+KTK_2U:GG4]T\N]-[=I:1M7PFYA\O4B/90)38P^
M6>!!8=>[DI_;RA LD'&7_RH?JWB,N%UL4<QF5OZX(EZVWNG;)E+X+?W*>5++
M'I:+PRUA\:I5 I>VY>:9#3)R<%0X&(NB5Y1<HC2:.Q9*9C#G+5++'AJ6O<Z(
M(N\-NA0 L6>YD*.<6Z2$Q,WV*RC)X_E'9BPWO4"W=UR,11V_HWM.2=7X_D/?
MNN*1I,!Y.0AA>W>?M>:C-)O!<([>F_AJ+M8KE^PW\C\X.HVX[L)<ED% %W->
MR[>[\>"T??"0.L=>%?Z,[9)5#&EV]9)!,=<*]P*%=N.(\^0&7;U=Z"TFEOV=
M/)^)F<K.] 7KGIF'("4.#7_\N).NVL.(H-^OO=VEV]-<TU=1K?[6\3OBMY+;
MQN[&^PH(00X:>Y]S"[^IK0 C'A"["ZRAXN!RX4:A1N*A=Q6T>Y#;7.0GT)W+
MP"=R*[J:-&=_HS,8:Q<BGNNVC %M[M?B<'K([U-AO!77#G<J<@M"F5I'SH*^
M7FGK1?TQ8.=;:_F5$Z*35V872Q4N'[]^=#?'^>)B")EU'D[DBZ-D9)^G9&3?
M@A-/>X3AIB^^;_1P?C'FQ'EJ.:M%Z4;-?LE"H[(Q.W^S(H$Y16%*%L6_I;;'
MK]OXWWD;"A_[IQZ^&.F62\]IGEO19.<Z%=PA?U%WK\C0!XECWI+>&SS]C:AI
M/D;8<N1V*Y/]>)W4J5>]XP5,MS).1':,9 ^?F7(.KDIB2.>!WYXU%ISHIZBX
MGZ&HN".7CPA!EKUH?.?-6%J\R(,&45HB#O>'/IU9 CVRW2/NP]]%B9H(WX.6
M3")L>\_/WQN_#/?3))XA-G5@J'/N:?]V60.$$HPJ29^7*U<A)]6MC?2"@8&K
MN"0*IH'7H_[S[!>P:?/75W^=>I_6]@YU;Q4R(V((8,!0? 2J)D_J]O*)!O*T
M&R>M8[Y&08QY:(A"I_1P@B.K$/Y3YBM9VCAT5=./@*+O@4NKD"B86"-\B(O\
MF;1Y^OO9^#\F#262QV$X5%5]Z IX%*/YY8L0,WM'5R$+H$%5.WS+L9Z**/2V
M9!6RCO?^C!2X#///4Z"G$.'> .)]/?@\ ;N\CC*#I="E76G .!X]QY#6EED$
M7E?:V""R"KD5\+3<Y;MY^J^QWZ<-W89W)8Z*U<6T@/&2,5R#?!U_<EFNT Z5
MD!*U=P40:^D%%\:2ZPSI6.!^U,UEY:\^H- /(H+@,SJ'D2NFX#;C3U;:C-N0
MTH\$G9-K1OHJ"W"QVA7-C&&O"3,KY!2R&>4!7A7^ZC4XB922RPB"3C])N C;
M@>UP6LSTS*R>(=<&?FI'RW:5KI3.HUK-%%05XF+>),\.^*.9R6PRUV/5Z]+=
MR3NA@>B1W0D =A2@X-'Q'CI@7+R%Z_=ZQ^/O*)!'+V*9<1R^."3V!5IB A<V
M7!^,3L1!!PA76% &GYW&J;U_ZQX#)^Z'L0*-*FI_R,;">Y4)*61?3FD2.0H,
M13%V%."C!#T';0.F:Q%? !M6"F #KCNORQ0OQ]/]+C",[?&+#'4 388_?1]J
M>:,%=DT_5IVV]RD*>J-']EEN("W=__*1F[IWE!V4N$+<:M\T=7,50OML(S3=
M&U?2/AMM]_-3NU<A2,"7Q4"Q'O;?GCFE+Q-WM$8]%]Q&)3YX/1*#E.V7LM()
MU+T[4T Z80H294XFEO^!1'W=.>9= -F3O%'68E$&()Q1HH!@=X)7(4#BEZ\$
M5)VG]9/9%OV!$1BX=+"/T%\@0*K>EQ=!:]B +F84X1T&?08FQG+$W-8F]._U
MJVFZ=^P"2L@X%(E^'KDRR_8[\D75O0FXOQ<)?(,)793R"E0KHHFF]_QO5P1M
M[^-=H$50 OTG[C];<;/&Y[6C-%I14NWMG-8:W9LX)4Y&J@F=J&+DX(V88_MF
M]6IO'=MFU;VWU7$_:QM7?G52\!7((3W[(N[MDG[C)O6G[]:.U6MR<0E;)F9)
MOHR/RG/'%L&6MHFA)P0%R8&!!;KO4WJ@Q+M1V(4=X&FDJFJ2@F", ZHJ4*]:
M-7N.JN[4^^WBOS(>-EE8;CC]-GR*/,9L:($OM!S8>/^A3Z0"RPE8L.N+Q!5E
MPIZ*WLLY-NIGSOD$96=_.F/OA>C>*=NO*%XUG.J25(ZXNQ@G@[F2[6OSF"?F
MM<CN4SZB$@I#5>"92@?;+S/^+D[^5*-CL&T=N;K9%D5\[8J\FN/J9"Y3WV@7
M ZMJ9/SXV':2ON?^^)W WBP>Q74WMG\VO*I1M00X&0W'S%4RQD6,+-](?3&^
M:](N<6Q73J/P;Q(=M1DOK],'O>*7X0^U0[!8N;&D/W-%=.2=G@]X@A2;U)W>
M1323Z=I@%[84F-X;NM.J<"MF=^O;>\3<_MZP7(TS\^H\+?US#%N5^>BGW(1C
M</"@UQZ.O2^S[K-W[WA?;D<_8_H;Y.1PPN9#?"'Q(0%\MVY]B81VX^7+,+S;
M<1L2DO6U&?3ZK^A6&''G'V*T0KXO=C[$3>IZH'P8@XDD-W)>QV W/^[;IQPI
M'69TDCTF0CZA!(^1$#.Z"6WV5C)K?&O=L&T\VTW5US8O_S>U: ;_!MWKZX[Y
MA&O)0!Y/*/$3I6!0J<];ZUYRU8RO0F0:TH]4\A;SLCI4#SX9DJFJ_"!;CR@5
MVWK1!=''^S!E[/JH.;/<AY'\0,;@ATYR#YC7V=73%0D&SC5T2"Q_/)>.2_SL
MW\*FV\Q5\/ HWZWK[#ZE+%"^T!)O224F"TF7A!(EZ:9++3!M]ZS,H*X]D4+Y
MSP\>VEAUB2DL+L@K8JA;%!>7V(/>JIDPYBLIL2>O9M>TJ*IIS*M+FSBJ!'DN
MA+1.P#*OXSHZ7#+Z^B[<V1C9/A"NQO0R_I2&  [",WZ?@.WS%"OG5="_=8_<
M9&MNE1TL1ZKFED_?#]SSNB2)9>1@%Z#'D.E<XD[;%J%>&#4,&5M*+ FQ])5L
MX @]Z"*SNX6NZ:R:G'GK>"EP+?6(Q=O3[N>O:>_IZQ.^=4:KI^G5-<$@L^UI
MLA, S/[?'?[\K\AVS$'7 =4*. S)-Q68.X<Y^F].S/]?T1U>O4PSV&FZTNTW
M\MX,WQH]6^')K<I'CY>=8&.0=#1.>C5.H$KW2J,'UU'$Y)=U%"<W_?6B.</8
M^*\N3_Y7?D?=1<IVL4D:&'HF#\E$/_.KW33TCL&_R\4H9G-<-"IJWD;O3-N\
M^Q.2@:[[3(7LSE='69J!6SMG?+34/M;;:VD(D+2-IN^]W_:,\/IY#EZ#I\LZ
M0_XE['I@;OW'UHN.*T7]#F8,0[GI4E=U=]U/GQB(CCBX'K#4Y<8TD_22YF<5
M*GO5[W"=;PO)NGFW3?>@#IV0L[:W^H>CO2HW&AAX'C7(#!&O]IKC0N]>23>Y
M?FV#]3ZF3]MNP//W9D9JT0W@+L3L*EKFU_@H,F>\#W/Z+;MO]Z' $Y"<%&Z(
M](YP+5F!Q_5X^.VWJ%WMY1L2N.[QV>"ZCAVKWN6%8_ ]I%S,L*UQ'A(T>-ND
M,LQV.?8M(?!9;9P0@KX9"[Y*);1K/XPE:U);#;_IOO;'073(Q)ZNSI)HSZ=O
MN*5QDV*M=Q%/PF7X1T[6-1'ASPE>&P).I@=^@F.O<C@/A.6&Z*>_ZQ?HE^'6
MC; )>#ZJ$I$?YV3WZ'SE96.KFX-$[)-1DB-H/'(4XO_YLBE)R5:1<ONB[%Y9
MZ8EWZG>^6+KJ4!(ZI"$#8='@8SD-,7KV#D8P!BBT#1B!\?>J5F@*;2.42.%[
MW(V'PD@)H&V*M\0N,(>"@50-):\:MB2<)]@,[L3C&KI*1UP2U/"V00=1<_)-
MSC8\OL<:!O-,R\*W'RKB#8++51+T4T>[N0G!B6-Y60WM$_$[7,,GKG7F"7YA
M&OU&M^#("H96)>-K9)6-JY B"M,E$-[KN$:'N0WT<*]EUCFWZ,GVHGD)9N6+
M.SI'#-XZ.Q3Y#(36N'PZ(%/%0L>O>*)>0K)%3_W[!' 7U.3ZGN@L&Z'.L@[/
M_!J'2R^$LY0UCA#?>!5L'99AZ*T69#9I585X<"1:Y2SSOK)]-1HE86AB6$A(
MU(H'P\R-57RXHWPXZ[=X:(4M.R%4A?-T7=>NA6FV"/NV].ON817.,3'FC+N/
M^+WS%2]WK[SKQ4@0*V/S';4Q;QX@B[_(* LMHA\0NF &*]E@KU']VFYE+6E5
MCI*T>G\M:;6>S(ZK>-5'<N+AU_"KC=/2[[Q]CU'/H5T-X/:6.,$XJ<TRLDN)
MK?'@G/%A(P.#IQ=FN1S$!3+%E9Z'NQ0->S.RL@6\%WE*T*WM&'&[LNML#G;_
M)E=9@1L.D==OR%3+U#.RIG\I./V/3:S[LQ*&6.-\?/<3QCNH2QFMG74K"K/>
M9\5W1%8)?=:[.>)&/DQ)M*,IJ3OW1PD^1="J!RA"R434*H0?C <V+H+VG'L.
MOC*#)H;^4=&/'TNQZ@X4J_X!M.J*L%_=_;R[OU"]L*;<24DHZWX%9^R+IR^Y
M!"P&L\XD[^DFG+^MY;Q!43[$4^ZGM2PX"FFRZ$R6:/+L9I<:*F$J@^"JZE-I
M7&SX;O)<PG<S[@J$L"5)XSO:RH -482G2PE9:<(5Z!D)PGDR&K[@DD+]9S)^
M+4-.+3=T)7\^E/Q;2!N-7F4:[3\D?$G"X_BJ 1529IQJA]@!VD>#;/ AP0"Y
MD3?(>>4]B5YB%7(+^;2#FFV5)S>LX$YA-8%S=AWT'RZW/4+U:#>1U1XU+%HA
M>X&PA._GSO%^/^%N%2*JA(@':J5)^<L</^!840-B%H2ONS?7)+7!>Q%AL;!%
M"H#@I>9,3;>*^9K79<QCZ4]F4&0;L/1;A3@ED5F7N*G!LG<H:L5+<Y]5B'/
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M53Z^?'\]4V<NK\&.=V9/NV4598:K/53Z$3L)*^<#18Y-N8<)%!E^,GRU[8[
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MU^0;96;KJT431V])TB1T.8':^.1EF%_";_"#U45[2=+V=X,RX\56\([;-X$
M&QWNAV=)U?R:8M<-Z\OXM'K\.4^>ZQ<%%>+]ETN\+L[==6K0S $GW@!ID489
MQ2R.(B"LACG$$XE1,6#0-9=AI?C@]O9.R\X#18F%F364#@$MBUA6$9A+'9<I
MG/3 ,XAQ6S&)P5+!X!:S]L@=.$SJ-F2S+_#^-H]=4PP$Y(@J(<P2WP&$M^"$
MS)].F1#5:U3&Y;9:F'H]:R-^J9\LDPX)<XZ@-)_1Y3>QJPSGL,XTKR^P?&F9
M#*IG][WE@FCBUHE=':A"DE-GO4; >:+-KDK6NK!FXK2GDT4\=\P>7KW(P]Q2
MBJ9Y1FP/U5DC3A7SXR\%#,6>;K(*EA6;7$CC41N(U.HQDDG4CQH*5A'PY1!4
MW!QJ+RKB"[= CGH3_Z!W/7W-TANR]^A64=<'-!.B0QFGQ ]V$OD^]<LC'E^'
M!FHVL83O.J],6G3R.&[-((-[@T@0CE@+;B\X/0AM,H!;W7D\S\3TU:5+9!P$
MTM.1FKNLA?PWJFR1"TG+I=T/VC)HT+ %IRW8L;8#$;TW06W!9UZ7.@_:*+R6
M![CU=:5.<C@(9QR]>(K/1N0V;,\Y>W!PQ?O@2[!1#)E-A'PA_7$WX:%NX,Q;
M^^/X]^&F?S0U=Q>##9:NI/H&-"<]>Q[O(RXX;B7_C<@'?W[Q]73VDY"WI#(S
MV6K^[-%;06LZ;RR)A'\@@^,QJY2(FPD*$KRN_Z8E7+A?1;VFP5.$P#/KNI"[
MLQC9+CX85!VB W\:X/%RN$1%?3YML8= "UT$YB&%7$JQ/5#J];M#E<G$H3@E
M_X2[S[WESBM.N=Z"\CJ\)/W12<)/+<LJ1!9 >[1%B?'9&8IF0$M^1O#[G.Y5
M\I2A9ITSTPGX17-==8;6(];;D;#S4IH<_"QJ_.@1Q$Y/R9/3:7$YWLV8V,')
MHV=#C+1, C<9P>]\_AZY0?T3%D.S)K&:UQ=VU&ZMI&.OYCD)L3CJ^5F%N$;!
M#E%N?(W?<5NEY N"2UFR7RW=/I=A.%*[Q%.WO9IFL4'+CQOS*([#EJ>Y=IV<
MT8Q9YZFHE=!2;JG\"/^-RMLTKY'W>XIDY3WI[CN\+U[DL/#-PT8:;.NV>:T3
M;!Z+WT)>AJ79=1MB?KW"P&>82V(>YA["':KQUKZ]B]9Z15=23; WF29&.HX=
M]$TJ.7YXD.C4=K'#5GYLD*>KL=BY1C&F;Q[55EG"JWVCW3$QV;A6:/)7);'Z
M4W*VC@VLVT/N1->>T)X:%N29)@3YV%X7KL_>-?#TX(CX5<K!\(":"[.WC;>4
MB,:SR-9#%K4\^;0'B5K&NSMZ(8MWP<!8AF\F1'\31S#!0^QXK^)DC>[Y^=&Y
MOY.HQZ!95F</U]F/3=FBCW(R<\_-?"<&P*LB;\ $(M4$8F3/Z9>?:IB4%3\S
MI(16<B6(I7GJT2I$(+ O2P4VTN^@S[GBZ86DP3+AG'J'SEBTOI=58U64 *]0
M[FDVUF0Q%OC7J5]SX=MDOPT8^]4FMDV:R1MO(5]W]! BQ]KUW#@*JQ6>P[ H
M\Q[/[DOO.UR/R)Q[TJ.S_;),59*=ON?WJPHJZFWE"@*+)8A CVY$,T?85>@M
M["D?%*SPE>'*O$*XTVPBRAN6:D_6OZ>IO&RSW[DIHZ7AP'UY6(YBYB68<5RD
M<X5P'9O"M)5^[!FR61_[4QZ^]DZSAST1.4;&K21->9=P'[<1%!^^,UZ,E!T>
MDK7)U4'#[&UJHO7-EH;QZ\G?:B^4M-W9PWEAXRP98>NTH<2%&^OV_OROO3%\
M$D*;>^#Y[F5;.<]O5.V[K6HN')\DF]<+\([Y<3;OH&H61>[?8VK,SL7=8SL8
MX1*XRVI2^J'Z4'%M>(DWMZ)YOKFI1%R,3W6QV>EL=:Y<@4=EFRC(2"7.,Y23
M?5-WQ92Y^E'I]F%#-:-=CJ_N4XX&VE@\&_W$TQ-_0TU!2)AU!!$DJ)@S30SH
MPVW8.+\+YW$+S<4UJ'I^*Z<2.%NPSI$7FYWX:88D4$YE\Z.WG!<=F4QZ4+/)
M?D?.UPI89%5")/\;OY$:^=I?&;7>M:VJ^XKCIA#1R:;*Z-WPJ"K=[@V7X[]G
MP+P0<B]E)[OER&C07!*DQYPS% D<)=S+S[+6WNPRL^.B?Y["P T7?ZF;+*#E
M7Z+IB6#<R2?2R: M'88_-@TV()!FT7-.Y^2'C&:K_/R9'.5IC6T.CP4&[F\:
M3LIV_;U%;ECE<XI\N!>WD<RECQ>3=#.12/5)O:^<_D@I\93"+T>]CTVI<3'Y
MXR$T$1/6=T6)<5F;0D!TXG?9)+E9%N#^-/M>,]0O9._N_J_Y,M*E;\R$(RJ
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M/6"O ^F.#29E/LKYN1G3+;'.'L[<VT1B\[7-]Z==N2&ENT>+9\SR:&'&M%P
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ME%?%EM*-W]OP*K-U5@(#K -+F59)W:,>]O:7[:&7N)]<9Z-Y_9?SW!SQ+(@
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MC;%1ITRN^$1&4>J;14H\%W9LJ3K\UWD=)15+1G<+>]Z5P%V.%CMDD/L,+PK
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M*NB5Q1/%-E/Y27!/M_GWDB&(&4-9#!5LPBNA-&R/QH-$-!R4T^W>UH^G'B\
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MNJLZ4;G@$XST<7KEK.48NGNA:$'Y21&Z!T,K1T Y'*]!A^RZC#=P6B0X$H^
M"G ]O<4M8.D%%$LD?;% U3;G&$&V7"-DN/KBV_<1<\^>6 =4D3(^]PQ6ZQME
M9"(SSXTVF(DT_0Z//:=+ML#,2P(#H.*-3F#P>-"$"=.JC%:JW )FR39BP8*!
M>C8[T55HRY\>Q]'_(C5]A_&CQ^(.=#?ESIA'&::1R4\E3A^P;IEB=.415SH+
M!W46&3%W!=^8/4 @I>!Z^99A]Q<7RMN!3$2C<GC&^*PR#N,X0>3K".GI5]FR
M>H U!'4X8E(2EV%I=^(:GKC)-U7B%8,S(<BPD['JOY':>(E[XVE/))?N =9
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MFHI1$K>!F^NL'.*GS.%8PU?%0F,?)9<VH,C<R["JD<'H64'#GU&7>Z=R^WJ
M5H$:6-PO&$J0&.[I#/:GW.GH9KN$5:]0L*:5/_XIA;9ERFFXQ6>@3FH9]BF)
M<;E2<D@YY:<,WO.FAY8FV1EWHAGK$;-;38!C@ZB?,HCCW]5KXF^@YCAP)'#U
M/;U920D_\E,&\R*C8-4"?W#V6R_#[NC22IZ@JKR0/V-0EQW-TIOOY*6S2M(V
M T,"&0RK[S^G< <'(CRM!S?,!_2 ,_?HOS,,EIOZ^/.<:#KONG6O+43I>LED
MF%4\KY=6.+!536%=_XN1AN(Z;)@/N(J$"+\"XR*@%99@6IP0,%:78OHJ4?OD
MZ4PG;*R-;*.V17S_OPY&7X%.)=N"<Y8=\JGBE@Z/PH.>Y"P6*S8Z3$[TQ;/-
M>F@>83/Z>EY#O?_MAB)TV4YW2SY2]B3VU4C+3M. XMHC?:):)0>)AO*46RG;
MR?CG0:_:%_ -DC--5.5^Z1 1>GR"EV%HU' >EL<E@YD'N@+X4C4-T,&).F,J
M"9H7X4'>CQBR/_#72A"',C*"V/[5IXBZ:,5.N,8PQ(N=.B;:IC&"([M\>OGH
MRLUK#^ F97J!(W*^OMW)'LK7BI^3<FG!NR7IGJ"]\:HE?"W,>;H+7=X-(:9/
MZJ8W[617,GNVUY\[!T),\QC")=5@/$>#/U,;/7!6U\]Y.>^X^&'L<0FRBCI2
M+]W . A4J#0C)J(9H6<H0T4BGQF2+;1S?;'B0J;YP8NZ'PE#'97H[<CVD!*$
MI,T%8/.\[MIW&R3-YT[LG7"0%=T2ZJ/"^>Z*4-7@E*6DCHIB8NML[6HR:$NK
M:2Y]S&<4A*S6A,"^$++:..A9IDWGX"U'IYJ/ -DD'BSV!8ZA Y'5&Y9OYY!:
MT"] ,P2(V$=77&+"X:?+CL57Y/JJ=-]?D%)F9H1.^$*8D1O&S2_#V!@AIHO/
M>4]![. 0(W8HQ YN1XRWS8+8P0-M$)+ZVC)HTX,1B<.F@2^M7MO769IV:"MS
M'7A]*R'B8L8'BK<_R_OBUU,3DD.@'?@^BZ*:/-[%X"?HC+L^'B#P(X;8($ 0
M]7R>)'-]D<ZD*7U,&0X",Y=#R'$(S&P<'HWS&[]\:P+U/?O)_EV/QQ-<"32%
MTI.'O@XT[U3-#$G8TN"X1"W2G_1L]E7J=:)PRZ"62*#1=SH5RBM]BW%;$<5@
M*6?P].?CPPMU$L?R S%6;\5VNN=*J:\[[+"SM=_HR#M5R]NP(Y=Y[BZ^F?(K
M:XV9Z1-.OHP7#<0^6VQ\99ONF<0XO07-*!0!5Y<#ZAC2XQ69"J'ODT86V_TA
M]+T UY>%>H?(XY?>)PT.J^\O>K F?.!^J97*L)+9Q\LIE4$&B;^:UWBG(3O.
M)PMZD7095AB(A#=;M 5=Y;?_F@%9E"K'V/YV F+$+P8BT-MFCU_OB,,Z5%/P
MG."&(@WAW'E!!<8.1PY^V[<OT/([T@$H>8K_?DRA6C/\5?^NVJL=Q?%3IZA\
M@LR,+$BSU8<65\EDT6Z[7+^+VBI#4>NK2S1W)\6*/A$;@&W0GC(E; "%H5,!
M^"0X3O41^#T'KI^95PW:H^H3HTO-H6:I?(&$(>WC?]0B^%L?HC+ZG:=12<EL
M!SE_J%YF[/6ANAIM>PW-3D/*_77)WT.P;"$VQ4>;H\]:&/78S5@4/\<=Y<\R
MC'9*6"]\U?7;6$B/+4M, 'THR5>\B]ZYZ"&A04EZ6)"S88/QC"?,CZ>1?+(W
M*-C'/L="L;PB'=SVDBRB!!"EB^<W^5T,?R0@8,O-4HZT[X$'QN"^LM_?\K@T
M,?MQP;M.7;$7&5?#(NY^C)32N)%DSW^'IZ ?Z[^;>.]Z3<)EN86RY]P:.L^L
M?M4@79HYXRB<MO6F=,AQ-581?](R[-=Y@/W:@V2[7*R]Z[:7;BQW#X_R:>T+
M.NG/N5?PQ06VEGA6LL5+SW7\#X['$PTB)8^@\^)"O[M'OKL[:-B9QU?)T>^<
MUOU1-Q"S8UP92'Q\Z4E[=3ZKFQWG.M=9H=H#FV@7XP1+"_+_H1Y?R1!1RS@.
M3J!]>  Z63PCA%7#(B"2"N&@'R05A\)N*X,J&B@JGR4QNA +V2OQX:NST?Y0
M?S"_.ZA .:WE@W[!F4P3(=W]%(.YZZI$K6:ORL]OG!AZQL#+=T[L?B+/>2=2
M]TSKFI#DQZ5D=/]4@*O3YI'=%F68]UD+1A<ZOM67;-?_=D>;[Z' 5>_-36LA
M:5"X\$^#DD4Q:Q])6 .'@X*G?Q:1G/;'^#DH>/JG <E0U//:AQ!KX790^/1/
M8[2)?PS1^[,__OG]H7RR[\G])$^7/M74UR/@"K)-OULQT]==F^MZJ/R)<+RV
M<LP<4Y+F0?AV96W;OJD]HZ:#]US*T6Z#U[6;V/BOG%* 133K>J^.'?B3".9/
M(IC_@40PHG%XGUN]P!8+=@ND<2!_5 NWT>/&VWZ7;C_^=DG#.;XY\8BLJ$[D
M(W/,U;1E&,OQ)T3-TS?^$+K83(\.6X9AI$'5"$5ACU>IZ0L&36PFS)HF30+.
M FX*D)]=!/*S,RK+@=IGR[ >2=K=?]43'VC@$MLO MIB?"Z0,/NPI@ 351%R
M<D^1YA?OZM"TS"'SSM9:#NT%DT"B72M+Y%.!B):<$NN/S:9;ZI^,C1<S_%U"
M<U71V/1"7JC0(-PX'S@$KYX4*V 3E8]-&WSV]K@WA^9/M:W,RTGWYS,8S]R3
MEOY6:-]1+[9$WVB>WA1DPCF]NX]CV^0:OPV]:' D)NF9(]:V #J-Z$'\.(U8
MAM%.^R 6+)48/N#J9@$&W%S*\SK_ P_!VSRG*+,(B%'^X7_G(Z(N)8QCI,5@
MN5#^BX%#6K/Y8MP/64)RREAR:/^/O2^!B['=^Q^/)81L25'C$:(H5(J602KI
M24*B;>RCTD+:EYNB2(LB:1TD;6HD:5&-=JTC+:.H:=^7:9MFO?M?=\YY3S/>
MA^?\GW/><\[[^GSTJ1GW?=W7?:W?W_7[?;^_=[C5I<7FDJ=W'(\F'7T0-%2C
M/3IW<TYH)K!T?]WWKV:>_)$?4UG6/KIJN\&'RQ,L?NM=E@K.3?/;YE;P119V
M;SSB6;Q$(:5EMFFEJ=H(J;CY5^K5'LU]M:HEM.@KW>Y=NQ4L1VF<"<7B]IKZ
MZ\KX%N\[XT1^^D1,73=+):<ST7#KX*3XU9YWF; @XR#ILF_+^8"DQ!;M.\U=
M7:<ZEGD'E[_TEU>?$T%-0.D-H&:G&=?(#^+4QZ!7:1;] @IBN 8KTVWT*MG7
MONT28W*S)MT$1_C8$E&(XX%@_!?' YH:Y5@ >^6 .3%O.>+_GT7C"(X1WLDL
M[V\D^<LD3>A8Z.7>N$:V\^_K[3S2?/[<NAWBBA)X6ZSZWR%J^!TGP3^&7E(]
M+#\LVIMUP2M)];Z=0O@KVJ+AN\N4UIYY,#I+5--P$N(6Z1X)N"E$<\85;1,9
MA8?XM4^R.6.ZZ_R$MA^<=Y*Z\R#:#TF'RQO-,.W%6>A9C!X_84<JLX8QFFQ)
M@=50]2DR9@N1SG'FXXUV^":P8A; -=0X9;":J^.,V<\!\!F'\A^/>',$(VU'
MPZ=0 >3'O+$7>C_K\7^H'DA2H<5]ID(C^DD/X]O6Y-@[O-(ZT=6SJ^/HT*[%
M526H>!7H]HB)!(\W)79D\D2-'5[TY!<SYULQX_S/-?PVOBB7]!J[H+A12SB/
M3ZPMV;T*,WH$P)*Y6@"7G'TL$-O#8T)6\GA;)DF\_AA\E;LB$RT#9MYR,>]<
MQ]]SLIB@?]<STWL"%L2<C'HC3I<C%@E4BB9=090A D/R\=,2.D4FO%\8?'6I
MR%= 3907T/BS[RLBK9YVUSR><3%/6@YNGL[X.6)3=X]P".L99TD]=U:4:FZ:
M[>NO@3QRQ=#;XU,H?K8?^O=<+-]SRS"NC')FPV>(@Y0/7*)$AJI<+*A3W%KP
MFC.5I_9@AU(0%.T+4'RF)J)R]/UHH/[?IN&W^&]_.AJH/F1&8%,EU8#MFROU
ME0]E^'&FY^JD&J?,-(C=4*D+J]>,X[M(*Z<9T<P]F5>QZ:.<PV+ I@O!R]2"
M(3<I\&PF@U%5_^]3AC?WGJEY1+9E*4$5I5,H*R+K!/&WHA/7KJZNU5+:+R)O
M1W.6]9&<L.RS^E8LG4>]W""A&KN,DX1A3(#61P4P1%5)E9SNX#]RGR8-]&5W
M'8;]"Z9#[.==_U9W2>4IJXD.F&ZL.U?[7(OP<?1"YL,=MYQF1U8HKEUQ_X/;
M7+<GV+7T&E@3.:SX=!AL!1II;IK\[1MO)^DI:NS2;O4Q<?6U*"X5^Q]TTOC2
MG>RL+[0G[6H;:MN\3E?A6E"&NG%AR_FH/?>DZK//.%UHL^8W[161CC[C$F=\
M>32I[:UOZJ#=N8#P5_&86ZX<$VLN'HN]6*KVI\]:&)+:P)CO*UD\S2,XYI""
M=G1G=G#!G\OM2=ZJO+V\L7B00#_W[DEXFVW8W5FG-'9$#4JXJ0PET50$X.5X
M >B#"W)H_A[T1+:#(57@CIV.PY':K=<FHJKZNK1:0J7/?MYPN2C8N_*#QV*;
MX/'A6\2.(]50?[X 9U7:]J!BE]03Z><NZRRPZ=.W&0XE:5:\M:B.+F.C6Q=;
M%ZAN>54WD7CRQ6N6&VQ9F*XW5^=]F>R8P\79(X3CB.A, 65<["/8GG=B1EX$
MW,&/ZMKILBZ %?UHKE/,'OQQ]ZJ%D^2C+S])%&YG-J\W3E8=?/KZ%3G1C72!
M?N<YJ1T[0*%K/$NKA4N[&+!ZK68Y)=7J:A,MO1-8-CSZ24ET8.#L(+& J=,8
MW"]_I:!@><Z+9( <O';W=]$CPJ+?Z>D].)-J1L&Z1)M46:O7C_O)[*\99PUB
M#WN,UC<J2MP::F]:Z_/DE&YE[5)UD?KT9^9AJY[$?NIC7IL,.?%QWYPM#F*]
M&RY()JA:/;LGE9?]/2]/>7\R7-6L:<U,T[W?[UY-:4M[G=M%Y*UQ!MWA.:F%
M,"A#USJ?5J-*[G02<ZM5JV@@VF]O2I?I-HTTU9G!OCEUIM7+M%[!$BI8>US6
M];"MWFFIS<6R3<^&8W/J<DMXQ8+\^TUGC4C')_>)W/*/2FUH,BY57K&QPNB\
MWZ-7+QE92_<E+^?QW3U??I)D;UX_8'GGB;3HH631L=T]C!!+9SG'H;LMZ.6]
MSD/X.*Q9_]S(I I;DNR7HC>*=9ZRZ/#'J#":#*\4#H_4/N%17,1#@2:/'):7
MR,V,.WLRO,M:GW::3/0U#!"7R36P+3B@D^;7/LS"-RA3,.^S;C-<:)951KGU
M[$1O8.'BV@#FFP-U5&#9)G;$F8K[.1<3%!W/&J0%UT#48OEO$_625%4E0\*V
MQ8:O(.&>Y5G:I+PG=!ZZY?GKNL![+B?2\XB,-4-3J'[D-/*\72D71<O$FOM_
M2[0HRW-TGY2HW=\4! _"'%T;1!H0(_V'9 %^YT>1M-)5E]KMF:UI&6VA8S?[
MBQ'GL?$+I3;UC=<7OWY8=<1_Y808O9;:[<>6;Z-LO^2<+715,ZCZ:A!JQ\-/
M[W91'BW^5'Q8-HPJT(B!#\V+G$*=S@!5O?S:O0H]>D0>S9I;^A5E'J&&O*/P
M.UZ[&ZF.>3.<R1B*_D605=!Y-_!#0+91\)RS.7LR!7Q$FI^T4KP-WR3&&+M%
MT68)A4@7N;V-45?>OHYZL-=TV5/X@_OVEY?::X^6'/<M$VX\Z1J_ZTKPT4=Z
M'UJ"E:/:?5#,L%PG>BQ5H]6JHYXMBNO:MZD[L^;LNQU+%VQ;.A2+MKFZ8,T^
M/OYQ>2?O0@@L=51"]C[K&.B,&[$JS2A 8=#]Q,ZAC.)BN,LV:GQ6%SK5F_U@
ML2:<=Q7J^938VS>"O]6\@8J_J[H.V[_G8J!;3#]YU1+K,TO\S LJ?\L07W0>
M\ZORK,FL*-W4?\ 9 H\VD?-<)[!F4A@;]@PCZ3QZ#UQ#[)090N0]T[*_,[TZ
M7]/S3J'\IU =48XA<)X!EKDEL6TA"RJ!1G65P3I\.I' 65DW,A?E1N11'I+*
M9\LGLR]XYV<=,,3>'#<;'W]UR_)"D/ZBD3EK5L/LJP9\CYF(FX8K6NRQP.FG
MV1!WR%C -Y%G*-I"*42%@"?^;///PKY3V*B 'W'4((V";"H?'?N),YD1>B/+
MVTW>CC3'8.Y<?ORJ[G,9Z\#2I7H[EL_-6]1D8-;G# MR2=;'S>[Y5C"D>%IV
MM* JMX0TKFI]&]-)(8VK$+A.\R^RN0RHC]\3,LI*@#*@SXFCFG98QJKI/[Z;
MB\O$D="B6PUK6LER&F/IV [NL'R>E%N_FZ<+*@\(Z4&/ >AD!7LY<-L^$=S*
MKZNG-0KV 9/=/A869*SE]CQD$+S0H]N,@;7;#O4L,$G"W9A".7@_B3*">P74
M?+CL'6!&<G^^E ?-=296>IG 0SE@,L;(^M1@.I(L,!-=Q#)$/6+FITOYEI@1
M[;%% @7(+\6DF6G7ZC.X/_I*3V 0.L1JC ^!CN_PY_8[\ 87^F"'!57$F;?0
MDUFY@9S#MK_/><#-= HES;1EGT YP$RL])A"N4&MV'#E=O!$WS<44'7FFFIJ
M :QAA&>.67,6;_Z.>-$(L>O<F+( (VP*];GD1;6ZX+AW/;<7[$8[JW0X=UW_
MF'%IKGKNPZ4V?.]]]33%?!Z["TYP7&W;=1EBB,OOC!*>(U)'6[LVI%X2(U/;
M77C9=X]4#X6;">[L."3)3%Y_326884*HM/YP^T.7029U4'!24+ 4SIQ"U02P
MPY%0C#X85_#:X,MQO1E?"B0R\$NJL5?T-)E@OA[&C%K#M:J$+E<E=;<B=70_
MGH.H0A-91YC$T.D25T+)T'@[ %!@B*G]4PI,:W9=$W4R=[.9UMKD.Y(509(I
ML\AE]GD3POJ*$RA:,IEV!ZSUUG SD19L0^$C=B1<HM H4Z@#6J8=*7C3TKZS
MNRTKA7MSR:8FOIE.YAO<]($1THFS^5='[?^AR/Y9([*MC^@^<B_MH &P)S&(
MHX-=PY143DSQ+I>)9#B[H)VOT/)<*[.GY-";E/#!Y]:R@P<'_<)W^+T@4E1S
MXF;? V#[ I:Y1A?F)[(LT=2*1# :P7J9!Y9/RV076$2I&#V^^,,4:KB0\M6S
MO1KZH(#H,ZV $+\VU!IJ 'N!Y<-C&/ZLR9:5!%.E$:*:@&%L$85XDD>\.;.O
M85@C"G_Q),\L[KJ*9FM)_BPJJU!()(X,EJ-(\_IF@P;E%Q>J4R,'.17G1/MK
M$A&UIY-D5Z>VNTFRQU_7G/%8LRGC1)I?W5T^];PO SN\5!(_]?QA*G'WS!2?
M\CWH.<2.>SU8!*W'+#? S\@&NA<)D]_@_35,?G/0=96O2G70C#-W[%X#KO/Y
M2[,K5%?UA#G<AL5[]QQ.LJ;=%68/[]PV$/XF?V#WT?D=L_,(T=\(M;M64X<+
M'R+,OO!D; G"[+,:O['/-DMBW_6#HB<=D/C]GP$-/P,\_H<#/*+;L;=>6\^G
MEU45J*6R-KX(<_ZMM"L[U';#]8A,B:<!96^X\ZH:*(S@BK.L Y3U+1+,;$P*
MYIS0LBJ_YO/BI-(;C?HSOHK#_=\<OO^D,ORD,OR'4!EFQ3AVLXQ8A]MHZ!2&
M*K8ATD!ILEOI :B@>YK:S-P"#BTD7SGT K!Q@G\43LB@JN9]5HC;9]=*BMUA
M56I_/S:V[N'ZW1O$1-CL>VEIT,4IU(W"I$&WP32E@!])X"=1Z,:JL[\2177_
M2A3EDA/"O,!Q$J 6&;;?H/;[_!_)W#=]$XC $ZW2+SR%,L?3^:=0Z])DQ/E_
MI+;?[\ 3WH*P8JGH:58L!*\/^&OE/&JS?67^],NJIN!I8,9?)X[R'QW=_H.4
M ^G0]^-=F,508RS\"Q@_VWXVW#^LX4P7M(FJ;I,HS$H.GZVD9N8DM^SUS562
M_L=77)]GHR+5&\!=48-*4XEL3[V1BZEN%A*AEK9NRM6J\[_XB2^U<5J[K#[W
MKK=YEVPB)MG6L-%V$U%-LFR!]+%F511X\ATW8/+LQHP?U^]+Z\2BH(X#N6"+
MB< S)24G#.GL,5A#WNVPSY_3MXIR:(U< 2_'+&WLQ5YB8?#$R;<*@XVWLL[C
MGN\A/X7R@46_L!^6) X*# J\A,H)]SNM*2PB,3/%C]'C?)8[-VL.K@W'OM]T
M#&Z >FJ3M\IOSMH9;ZD_.(J(6_6-5)B=KB4ZZ*EKG3*/V13U-C&YH@/L^#-R
MLC*V8B?FPV4(*E4 NV+NKO;RR2J7L]E<$DE'HPWMGL?7.OQ6\R_+:JI#;#T[
MA2K:PL%S\#2PV#J/93>%8YPF=R7;IHIJ&E?/%'$*+G65!6/_5@S8B["<E1/C
M\LK*XK<#5$Q,*76^8[XZQF%9!2WH#2)=%FY&YI/!S:5B.K^CZU7-I=(UHT]'
M#?/3S*K#8W4:Q.O+KWZ1QMWREQ46,P_*:6K,"=<^\+%!VCOI#XAZK?QZ#6[Z
M&C.XXNLUJ16C,+@F F<EZ^D[+O]=K2Q[-\,0&96T+PSB8#:4SB2^GI0IM]A&
ML# E?QHC<2E0:0MQ]F->$0?;*\>@8;^,4<Y8U"?"1H+A3)=)B<;K?IUC<4.A
MXZ$/C6Z5;W]5?+J]_.BNU+?V;[5Z/ALI?.!2^0I <LTB^7>]66@D_RZ2;/:-
M4Q2V]*U5@>]@U<XK4<]S+N:>'=%E^S')'(B$[/UO"M7/!%U[39RH';MJ_JHJ
MX5#4:4:M/ED;P[(O 2._>KK%-F ^3:&FFTQM#*Y#FDSGL_VB=OLK@1%VH,G
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MT6.?QJU?[,^MTO9<BKYB' I\_D]2$*CF,A^^*]GV<0IE%T WZ,!I<LHPK=A
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MS"73FE)."6(C?C> E/;;%*I[$,->@ND2^WG#/^N&8O0@&'\[*9P<:%"R-5<
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MYA%-M7M[]OQAJX>'W.;,ER?#V+!'B),-]1X([OY.HJ+' M/,$^[D0^0/@F/
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M+O;X6S&GOWE'I>HM*MS7FQ^C2[$4X&5Q@]=(:8Q<*-!BZ=BNRY\C"):5#+(
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M$N+LE(/ JAS032V9T;98%P;!8=C5O@O6FT )GJ'-.> ,UUY+I "4NP"3BG!
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M+P<-,"<FWWXM7Q9ZP>*78KW0%W:.EZE.+0W;,_&OYZRH=>WC[$$RM8#.H]Q
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M"VV PJ-C9/#72F$0PNW0U9X6>J./A3;9)<(EJ.FU!U!L#HGS2)LCC8+5<4[
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MTI\R<;"?,C4 ,#\AOZ#$2/W7:DBC<(#E-^OX+>1N,NQFSA;J4N2NR%'D3N/
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M?I),4 &)Z/=/RWF>_8^4B(!YA#X/L;P+KKU9@B=,@4A0X3]S+/*!<)W/MA2
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M4TEQ'JURW@GV<_$3%6>MR[?XVY2'JCUL; *Q8=KK[*@.XQJ1S_,2!2)DI&!
M/M2ID1P&5$.]_A[%MHB/\"2MA?,E F&ZMB NF'72^5Z"W<>9C D_5J@1C*\3
M+2D3T&-'$P:_*,>WCLWD? 1C;@?!"'^PV9F[ ,6!POC,E=8,#MKP3]Q3_W2F
M.?0=6GX04&CZR[_M/>&[".+ YZE.)'O)5VB:-A)O"-PB=DGG)HT],A]S4B+G
MJQZU=CVP.OW7];L>G%U[:]%U==E!)6RHN$B"BLC&Z-"Q+)R1A7EIG(,[A5]6
M)"]1P $#)Q<#?"XFOLZ7N[UPG3Y6_\)_9D>Q)V<5:33B9^=XNE"WY<)ZW:/@
M8$@7QY@"@ZKD.WH:\L,>I+?>S[W[]+9:6ZUNAXC]VMM!+H.'X/123]B]O#WN
M+Z[D!'B//+N15I;E-[*?G-'P0,.V[ 4H,C[I2%H./6_/K $&3$)7=_WB5BEG
M<4V:AU 73JO:_[D*:%EJ%+*C;6]@*!TCS#3RDH,&1!L\ <M--MV@C9XD?,"U
MX&A!I?B7GL0RNAK[E6]XFM?PA5Q;7%6^"G^R[-P;6I$<7B*3U!'XDX_=O2J;
MW0LM-Q2[IT=/3.5D?9E ,77A]SJ'J="?F"_%0XB/M>'?:\#B>T=/I]8UNJLF
MALO<N90-B^^M-T(J'EFL4(BI*^"K/:DOU!,;J31M"T@]L*WHM6%1@94Z<C^5
MJ!4H2P-^52 M9[XLQS0F7WQ;1YUB9:UI.R:B*+6#7-GV1+@XWP!<0Q &JMWA
M%--G:)J\U8! D_H,: K09?4^'O349RO)4LQUB\X35A4-N=R[^8Z=Z5=;CDV>
M4@_KW!Z)"@!@9;X@.-,6V<<2U4?*>55FESNW4$)@E<<D#@Y:HP,YX=#DOY^2
M-3M%U5 BO%R7\3;'#MS01XSLO&D3.$]32]^G,M[3<R3 63E_;GG'=7C3]D<)
M5TQ]"!:) W7MYF8Z"U;%?75_\>AQPBM63M AXB(^QSA^RI1<2BY;U743:;!!
M YW,U@;\&FO9$;^[VJZY%>[<'&<GJ)(M?7W$W(W;,J!PY,;IRC'E2LU;2;$;
MR$[!!3%31FQ)7UBGPI?4KPZ+.5X"NK"JR2Y"'W->YKZR6:_B1K9RM)>FG0C;
M=RWHX,6RHM[^PXO>Z4X[SV;P/=&Q4&].-$O-W/[K.\==[YPK^F)[S3/Z:[IR
MY&YYZ,4-Y7@]\XQ/6N^4M8^L1K9?_Z7+:'F%E^VMG_!?2+-E(:] W>(GWL1U
M@:*CYRT%%Y_?-$8Y+9T:V6"SIE-ZL!,IZW,_Q+DIT>KMCW04D0*ZAXT<OMS4
MJXZ.>]A&S$DH7MO0!'6'@O:MY[$[BB[7%11,:>42U)C,!.R5S)BK:/68X(49
MA25;22&[UB__]8[68:J@K5V3@+V%(TG@_V^2\="=U/#=M/)$A!X[BSVI7@AO
ME9QW@B_5_R<_=-)]PC(%.>0YZZD<[.N-!JU;[B6GM/TJH2/C1EW@6S6OZZ'H
MHRS"QC'T!_0:%^VB,+<>[DC(MN24RH$%;T55HT^?W_!^L"C?T^ZOE >T8ZX%
M=?I\2,,B< U>:,Y2&FF%QT^TE+0.<ZFS[^H50F(891+WUBL_7RI6O6_^OF!_
M@H$IX7]+U/__5G.'H5F@R_B/68#>Y/P[P3M;<J&&:GVZZA*9H,:FLB_C;_8Z
M'WMP\]#\1,F&OP7O_A:\^W<0O/NBL9CIKMF0)^JJ$1<[,!6\]VG_VW.MTOZB
MY?Y=NY<4ZW2UY\N"JTAPB)X6"WQ;@..<= DL$A8?PFZD-53&1'ZC'C7U'A4W
M>I<IEV'\? 5A]]7]/_W21-*E ATV+HG@/9\T%K2P%N-W-RU\@I8X<Y:0TQ[#
MP714*.DNW=5GST,LQD$!MTD-B?:3'+@]D'F$ PW[D2IHC&ZM!L84BN8LU<<"
M#"=K* [:I<U#!,G&(&M5"0(-'  *1:%(?+V#'0<![;/W4B3 ]?%^I/XG>%04
MB7,YD&D: Y?97$@";_(08Q&HM+13T*"?07$>VA=-:_^+EZ<]Z^I6N@#'1X".
M91 "6::B",)@XF.-0//O[ 0OAZ\+KX!5E:H\1,]Q'H)^F"P\L(G,V>(%"_U;
MP4+_BTE,Z'B^]IM6S"5,@&QNC@<XKY'@<>4.KA3L(B '0:K=_13F/-$9,1R!
MQCM(_%<#@9S7G<3I[>+D/BCF%HMEJQX8Y2%"I& Y/S74"V<4S1O";-[1$A!6
MVLI#=%X1_ OG%.>4.@"L+D=#=_H"8&WN\YUXT"<P"9$"S>-]!"^(?Z2'A^M(
MX-E 6-J/!CZ"?03X)D:L0//7*7.+3G"C(Z#MHNP1;((.33QEW(/IO2&Q/,1Y
MX+)UJ!'6KD6-G'8H=;0DQ)\Z7ZF44WF3,%L/$ /N8B8:CBDRT R"]Z@#*HW5
MCFO1\V([573=E#L9VS2Z]!G-'=1]"<VS:SS$Q+$0AK&;HW6W@;?=O2/.C3Q$
M9<-!^\QH<[7 F>S3QW\I^]3OM<K:U"F>F\9@+S,CR7UN[BM\>XT<'G7I1I1P
M68H'M&WZ6;%EV4+@-MR5\;S1-UY=%:UIMM0G58H'Y>MD&E]S-C<X4.795M0I
M1F:,U:,T<KA%6Z"\4FF?&#+Z'!/J$A%%!H8AS#GI1>YSI9R'=N.PW,MMK?+^
MU*M6*<)Q%A*>!E!\NXFL2T1-O^?&<0F$(IIG*R@##7ZA02=R6MB&P!2383:]
M94KHUF60%GVQ$4_V3N9.M%N%VSLN+9?JU-(//:_S'N&)@)G>OYI]1$W,:T#1
M5J)I1$O:P<3X*S$KWM1-FK'-EO5[D/>W#%KZ':OP+]KU<?7#P].K]7\AI7O5
MX1T5.S70"26#H;V]N)6,-&J=Q7,!,ADQ!M6Q<TR8*Y2!YBP/YN#[ 4' R>H"
M5]NM@J:0$)QX5485IA=S"59]J:5%*/K4$*$M2[&*02KKLZ+5#G9]]))ZE]:T
M=UO#GC,U<<9V455^'=6+EK(0WQX1[(>P@JX"6 RMMK&K*$;J75[3GIY:*K;F
MN0GQX7O_GFKOY<P%W]8&6@S Y_ A(],.94\"B13^@<#&I9 2<:'E'?FD%<*R
MS##'&QWDU:W-_<YK!IR(5]ZF']Q[7NOFR#*1$S]=1Y#?3*3(0U@6O@UW^#9*
M4<6YJ'M.69)28YOR>WWM]KZV";V_]N1%'P?,RN[7ESX++=CH'FC:A>I8#_4-
MPA'-F1_,D?4AH=(]LE(G33 -!7'HUIOC9F8M/(3JH'OF[:=7FMHWUH[*';B_
M[/YKZM90ZY>9VJZ;'JZ_?'&_CG00VE2!.U\KE=;[VM7JA;%9VV'KW6\J5[R5
M*A[\-5%VWL/#B#LJ^D_QTPJ!O@=R52NQA>V#RXX_CQ!+T9=4/#LOY''4G<6;
M?ZD- ' UQ#SE!)/F08:HJ$&+WKJ?BVX^H*MN69KPM#OH.&)EQJ#7:/-$?J W
M!*"GFUIZ>L<SB"S)M0(2B/=HN> N.RJ..LJ,X!)*Z5X4-@\AY\1M=>X3:\DN
M.2>L.TYB:N9!>^JA30;0&M3-0RR=0'M3QDY S<)DWH^)5$ET,(.'^.H:Z3S2
M2A(K[JE2N>36%.G3RT@DV,E3[4D7)I<2,%D:H3T94V9FYH%'!>><^%A5XJO^
MF/VDNHE$=N*R#1ZDO2V-E_T.5-B4+'TQ+TAG.AA;+HB(%;JB9?4;.9; *VLC
M40Q#WM7+O#)ISVZ[NPVGQ X++5@]N2@G-92!;Q[U\B73^E"-<9.Y= A6X=N<
MA[*CH<ZMG+H[ 7<NV-GH_@[N7//:8U9PYZXZO/F7QOQ602*OS*%JA4CDZ@'G
ML A-;GZ2Z V] W5F*M)74I;)[]N 0.C(Q+EG<;9IP+10!K1RWH96S(#=(MFX
M="B."(MLJ9M^V>C<,SEDX<\,P]MUD%>:M5]Q&K-V1CNE'FC<L=GIR /=T!-K
M]L\K>3-!E.57C22>A2:S72=JI1DTF5?;A.DXP9-9QO'0 V@R/]Q_B/QN<N:4
M62M"B@=.,7WJ(%W]W"_-GCJ>E[\V 2)$YN U;/GV6%J%C6*M0@-]2/)0=M3H
M8^WND>9WXUG2459BRDDXOA<?-HR=!T9]+$X5!"3;11J/?TKONO02)6/+C8_.
M7F"UX?.GBTPS4(LK"I*^P8&X<7E7 "?P5$!!LED8OJPMV=:W+EU?T[VO^[:
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M\O($:FD"1A5^7W$MF-T]@NOYR*B.7E?(\<&38:.^X87=8T.EIX :+)AQ&NT
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M"%V!3*!(]/PDC<HZ"\LNV1/-G?YO!D9]GU152CE(.R2YZ3IW=&(&78&*DDL
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MV$2E07X>^@WR\Q(O6GXC;YZ7S#H44 \:(?SWNZV_@7:@?NB\1=B09JG*HX^
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MH9IO]<6*&#'B\^W "\V.E=?FA(6/Y-_CF=G-[GM%JDI4T"RD@D" ;7(@[*]
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MGY>I4J;3RF3PVH)CQ 7E_]#;<K16$L\7MEDM/$O9PZ)SGT4OGRG*H<* ELT
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M04+JK&0H.>W&=-BA5+XQI<G#24UZ3[_":HS7Y]);@8D DQ3?QQ# JLQNIY(
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M<9 __MUNQN&"@#-2-G"HPK*C1THZ_<V'?O#74]3I[1$SC78RJZG6N)^PX["
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M$&T]9X!G%!71CD*X+,O,"<!@8ZD^>&5$OH_35+=*E3UW-%ILGM/WU6@U#0W
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M%+ 4K$J!TLC?&2J9T&\V?#ZULO=STKC4W\M(1@FQ?O>K/F)&!>@C_H0L:):
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M%R<M?G%KEKI?-1Z=-;\H2TO^:^R8,:9989^E[9AL[ 3 /R7:^0=D=[:.0U[
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M]E!/H?T<PBV=LGUL/*5ZJ"T<> J^ QS:U^.%"[!#09\&KYM[:&U?:(:T!^F
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M4;_ ZKS\K0F+25Q;^4>!UC1(Y,HR=&2P:14/5%=YFPEHY.R-"462/1R@H9+
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M+C:[4PL5Y"X)]B5,O3F+@Q 2Y-PDQ]Q[Q/FQZ;,UC:<^=JMKO#K/JRIEU?$
M$ 1(%B+?$*SH3;$/3AN-I?2>7LKAM2:M70'.PL?3(R1S^FTD'_FK>.90O5YY
MZ=21Z9/+[N?6SGZH3J"[_O@B7^A#OQ@R!UF;Z5:IISZ+9R;C,LQ6$C-JWW\Q
M;'?V=#B\$B(=>X3\H^>IQ5VBCN3(TS(#Y>52OL#--E?FCV9_Z'\0C@ZC5KB%
M*@.'[D!&RA242P9AJE<^NCF:4Y+9=@ 0#LXOU$\;9H\R,Q%>:1 _PQFW4@W]
M>"52NQ_1%V7TW@'-U,BHG-BIYSNY/2!$^^W-H>/ &W4[+X8>83&W@]5P[V$_
M7U)DC66@WW"2TX;P3DC'Z!3 + H.4K3_A9X&'H9MNF,K,I/RZ01XIL91H[;^
M=*08?/96T6.7J\KPA1@G[]EC5S/!4Z(;>2)*AO(4):-PX02PJK$ZE)]A6?JQ
MO>\5E]-:\'&?*N2PODMD1%\!PC._<[7V2WZ8+],+$6L$?;6,XYETF<F,4Y#F
M\1@[^0*UXT9$#?\:W_]QE<;_+\9^P#_Q%GL<$T-&  Y2(-VYL'?, -JZ&2A'
MZ5'57 :,#[>GC_"OQ7CO"!&\[G!/%PK,*7G?7X+$3!=GU21M]LI%TN7-%0C?
MI-RCI(2X'@/GB0CY*$)HD:\,7-C.;TGUWS8RKJU!LS F3AJ< .I]MC^+;C<?
M+[YUTDGY*K>AN[59IZRK #VC3;J;(&PTKLPETCS'%:',UU8_[0_A"!C]]L*P
M-N/;^(W6["R3J;LY!1:5[S,>5_  !3S,/)'.9@XO3%E^EH0%E@^(FD@?6&J&
M<0]\O4,D^'FL):S-/I\=>0:GX+*9=RI@6H=+!/9%ZJ<@8OEL+Z*;+$FCAL%7
M,#HQ(G.WR2B ':LF*EXI*38RM8.-_[03CY#UP'DO7I*%U'!Y<+Y\L156(L@V
ML\HH^VY"J5  5Q@GNX7BP-O8CM_WG.3,JJ:/ A9M-I8[^ZLE/MHP4CI^?5[I
MNM.1=%$CYT&<_VSRF?IDBQ39;@"NGKTRVEI"9,\:&L+K$]FSJJM$PC&.DC_
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M#&&G1- :3.^)[%5Q[5Q[F<,X[:93?AL/Q)WBBDB9JV5%$1+&X:R"S*QT\I>
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MTC7WHGJNH'7S>BZII7 )R1NS WO'YE,>A'OY,#8QA4/<.65#*R^*4'U)157
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M97&G&^&BII9!T'OT->%IBQ)]S.[Y7S,/ZS92O/)^CG3Z9:24%$?XSO0LD@*
MT@@VT2[:3!$2DO^B*\@'S.-Y^H=ZH47/WL_BG(T&X./'7]9N'.76N7=HCA6E
M.,]CF##V\$W0ZG^7KZ$IDT+RUC,JRN/F$PT(RT'HF1L/5XPG5\KOWU8H!"WB
MZ9%T?,<U-Y,7,;F%@4GFKU'=ETER!(!;TK[;J4K;\H$P62+\?&F4+7MTSRG0
MJE[.$)0 IQ,I46*U2G[LK #5/*+X=?47GMFH4V[S('S+E'Q2.) !S9BOHT="
M@J*2R^Q=KOD/'&CU)+D/_Q\)A?Q?,_X9+6#T^Y_.40"<;VW:<7+=;(H98EA?
M^_C"!7B=Z<=-# 9RQ'\"4/=\)B2C/G7=E3:I$FN^^L)958X%=17)"S6 C]G#
M%,&AOD8\S8#K%XOS-G;=C.^^=?2FQHM=]FQP2B\S3<_U^+"Q=M.=.STW.(C#
M?Q9C$3O)K.,D$D?^&9LZ XV\LZW-?*2*A49\8-2O>'.#TP?[:.Q+6W2I7\KG
M@I5.^C<H)C #J)T^1M.'Y%!L\9V)O6G\5%ZGC.?>"5 _9U)Q N2I<OE ##=K
M>-3KAER-?$3NEGHG=0:/L*I)\>P#9.H\2!!/Z*%]XR2T=#,_<.>8>J!,U9KF
M%HZSR\EIPU]+0L@\')M,S4LRKQWIY3(HSY"7QV5QS<?^?+.B>IM.K2F$S9G%
MI8?4AQ^*OII!G8"]KU#^P21Z07R:@W0][I(8++K5V&I,ULN@T/>G+Z1\4)1?
MGN:AD6>1==7@HBJ-P&,[=_KDN%L0)LE)%/(\O(N:6IEX3*&W\1^[\_*9-LW6
MP!G:F8:C'@56I77&GQ,*E"H9 0L9OJ,.U,=SGZU20(U;J?1RDA(A.W6KB/,M
MKI;FTK2>HFC]1XH$ZV1N+7G75:K3BI5J'<"6SD4.UKXZ?K\V;Z1-9RRJQ1&]
M]HN+SZV(-^H[^".'\*S;N*S-PHJW9][Z4T)P-)]B0,'JF$W8;@ @Q94R\#L_
M6(Y]8K&.'-I4FE"T=##0?W5&XQV/4*$)J^#9MZ4,MK>YO;*XG)Z?F8J0H\<Y
MHR#<<\WV5E\+SS*6+L0W1E7U;TY;>(DSG*\_AZVQWW7#*D>F7HWU-L]N3((7
MCS].O(N1YX<'D*;DM[%7&\08-SA:.]\HZ7)2AFG=4YN]]RV<FIQCBUPV9TCN
MXM'SR(8#J9^_QQZMBRZZBWV.S_JBUBG^B(D.=$^=8X%CUHE\%+0P.N4'OX_N
MD2TQ(3N89!+?3V#7]3!P$SILZ7 GR3>5'I(W>V C7PP-<-E<R@Q;NZ?-6R@J
MN.^8L$#>>E=P4?A6"L2Y!?Y=2UT4M&/E=^3H,[,1("=0.&#I'79\4_/#^29J
MRQ"T3U*$TX]SWWE(.*T)UGR![T!BUW7SJ*E)>NWX=Z5<ZE=IA>B.5R%Z),%<
MM$%*\[8;'=]E^9N.GJ"]-\"XQ W5VC<-;]J#]#4_>12ZM55'^X/O)K,&M(F"
M1HZD<+(G "5)4]'RU%C=XZV\Q+&.0YZD9#YQYQI$71];3OX)$&1Y F17G0#7
MZHY+R[4#ZQB^X'P<G6V=;;C7X]P6>U5BHGY^EQ1 'GV.6Y;\,; ?Q#\$4SQ4
MQ#WK4Z);M)'=S11]%$'QY'DO&!.BWNH8VWCQ1Z^P\'G >>JO$L7FFQ@T^(A_
M@\;X1=U8G?UVKB'Q/N+"*TN=:^HJPLUKX.@3@&(A7.0$X#0E[+P "@3NZX'V
M=+I'WD)#-V+&YC#G]3HK"_GZ6V92X]C+B.J&,,>J- 554AUPQB]E!A"ZKCCO
M@VCEU8#L')Y8>\<;5=D\CM8,PM&M0J^38'O0X!]*_OQKVB'LC/:,./I[O1]O
MVS3ZV]QK^QRBLPY2Y[CV^)Q=#ZCG92BNEDBI\-XV[ZF'54B'.FNH7K1? RF[
M(K@$\$%GO/B/PO*Y0UWRE+ZBJM/'K(M>:]_VI%UD$GLU'MSGLDRZ'DX!>ANC
M)M4FQ>HOOLLN>IRVDR6ZDJ--\6U/8NU5Q.Y#MT9D>(*>_?MW+J"W5-MM3(\A
M/+@6;_LLN,'0EY+8KC?<:NH-3!Z8!XX]Z?R0I@B^A?HQSR^XDL_MK%I+Y[2V
M"K,O,[:[=GI1%8:GS%+_7ACZ#VHC*TO0D;T&$6MIO9Z0$DKWT/GCV_JATP&[
MODQUIA&.X4@'9$!0&F5JL?U1;!7T\!R*$'EDY"?D+$-')?#J$Y''@>8$ZWYO
MJ+,?M ?Q.P%F4W'V^ :WNH-K-E[?X?]ZFJ_/$RY*BE5])69R(8[2Q*BP95Z$
M[UOZN^&X!5!CRK$T>UP9(8P]HT)!5H/9=<3"'"9>^#*5I]JGAE7=EE$0(.,"
MCF=:;K$Z-PIADA>.7'#VQY%9\J'%[ZR\^4<>;0QMW*CN4NU)GN6/\7[,+K+-
MRRYF[RB6T64@WJ=.A97TF'T36B@H14K;QK&7!JE=EEH(&IS4" NYQ_3TUI8Z
MY]D'.L*G; MFHL^AQ6:OOW$^+,F5Z]/7NP4;D+>*>U>J^!1D#(I&!I3).G=Y
M],QLA%3;9GQY[[UKI"$X-AO:S4S:;,[2*<1U1AA, DN.$@29-]==A&OR1+JR
M&=P>6O]8R$A=&LTIA&PF:['GNYMW!XGBW*!S@&BKX92P1BVF-[!<7NS9MM:>
M9XS:18>R/EW3(6D2!-M0Q=WE"VB3C?!U6K99B0R0.XL@PZGU> EE+R?Q?+A3
M^"[6OIV>#,\]WKPI]52J7A34_\_\%_GE_^2)S2 _P0.IYXN72B)'YMF$)Z*?
M51?6EKWYS,5K%:-'.DT?GGIG7R><CI^0[_LCMM1<;A[:$[*.V?Q$.:[G4\-0
M6M<)&!=M:YGF==UZP1#6U&IE$A(F?1(2OPC)-&H[[Y"\SW3:_!WHBX(_6E[K
MZ7R56@4 ZGJ0F3*^V\LJ%MUMK[?MO)M43"P33%V3L)):D+,3BA#?ZX%*#(VD
M4NR,$#OWH:4?HC_D=M?SJK-8ND6K<C@',^_UF!:#MGA>BTZMFM$N>QE\6/ )
M73="2-A-'++F.<:&8R3;\Q_B+ELZ9N-D9M@"/_M:=G?[*]'9D3@7.P>>MDF:
MVOZCJM4N9"0A,U1^C=B'K /N^;VCO?IK5WZUAV9U&S^VH#B_CDJ80^_:;E3)
M/7-N%<?4>)JU0,]J3N<SC8]E5'U)<)JWH2"7N<-*AXQ1Y]7JBXU%JNT'WO\#
MC&?CCZ_?+]UZ8I?+]CTV#7]7V&&B:)R.'#PZL$E/1#+6>03L1D;84BFCCZ]Z
MB$E]:NIVZ;@W@IL#>MX?/;S.F,;%K@P_ ?I_@JOQ/]Q+#^R2,"R'%; JF^=K
M\W%$3MJ[#Z>=', O5C;JGIN=-31IIQ):+HO.$X)=7*;%@9&KN2@MA27<0*I_
M+8TF%%U8^M&6-,;F4?E[=NZ7]1UG.%D_=!C<".CKXF3^X6N##0[<J(;.V-2P
M'TB025QE?B0>,M,^=F5+A9Q-V,$)PO$3/(0_A\U+PM1<,KFO$;3,=*7<QLWH
MLYYM@UY1X#.F)NK?OX9:ZZA].:?@L/[UJT$#-Z_G]=]H*1)O;'$NB-N\$_5P
ME\/?XP?YQI'CH6)I9D9[)DZ_=[T]4Z'0S/C"(QWG\BO9'*SF"Q/1L4CJ2TC8
M?=U#Z.Z'J5U$ZNY-*7S/;KAGBJG6! [C)I3LF+B'^/L3,^CY_?MF_=2YNE?5
M]*YYRX4952]"$U3A.87\EO?:NKRN71Z)Y"&Q<U!D (W@%E#29LB=J_TWQ[I2
M[N;F?A)G=V<+_A0>7O9RCXL$>P*$'&E_]:@S3C(86-@6X$+K>:A%N=QF>VN%
M;2=D 2Z^'+A6#(K]1L6 Y;[MD.!(J\XU-1*ZC]^UC&*T>6(<6X'YW+F'=D_C
MT!$NJE2_U![R(WV71A4;EAK XSK@K*.K. V)<#OZAX.ZZ)]7?!FY#;%^<P]^
MDT.HFA:EVLVROGU[N3,FN7;]QN.2TDB9R_Z"KRND)'7K9V-Q0UU1OC_Q?"5E
M$9-3:IM'IT55&6L]785Z@$(08/NJ_4\":<"!;W5?,Y3UZ#)Z[9F/@'*_W4*9
M6X2YK9TXZDJ!_BV3!"[:_C-23&+0_XVP3@3<<?/M)#MV_"#F5DCF\NH0S86H
M@FW 3%00%E!3YO4D2)H&D-UH@%Z R6,F;LTWW0T]H'QW93O4Y'9.C3"((T=P
M.FXELEHHQ7%LJ(F=$2N7C3[OQF:FGMI9'CEG87?O@:PNRE42&L5)>D:V<6/W
M;:$TD\U-R/AYDS(2UMX 4A^',507P67$C=9HPRR0GJ@_R:N)N'^>/TJ!Q]6(
MQ1#^U_TWUUTU519TJF.[*BOCOKS?]:L8CM$"D\1X&53@>]@IDWK*L8&C','F
MHR.?H^E:"JLR]&$ V7U.J<X(H3;P3Q==9<"ACIDC<0$M7L-*"\NCXR'D@X&/
M=-]AAP%U6>356NG\*IAJIN8W#S.#OALC%VTZK^5BK"G.,?_,X@&2+0X,&BV(
MA"2/CRZ< #'*'T_K-5OZ)T $@N #8_\$3<?B(-E*/IMY'9/<#KLBW?;7'@L^
MK(CE3$FR,"V?A>:ZID@1_ADQHWUXU@2Q^"4-$DS$KG42'.O><2 7$3]MT#GP
M&[(Z1\38'^(;8Q"+65DD==@>(OP,\5?2HP6BT9?_.^D1) MA);_/XSZURQ!+
M>).R";@U?Y_+:X,PD5 VYQ.@*)7@SS<.SZD38=MY 1B#HYB_'=W+Y=L-B"[E
MUUEJ7IRYJA O\<:1]ZG3@QY1#U;7KK A5I*=?-K\'%^6Y]]QD;N^1;\6ANFV
M)I<Y-IBB5%JMQ6O[^K.;J%4YG'A)YO@.[Z-3,JAS-GN:RFCXOW+'&$5-DU1>
MGBN83I&XC"J5=LF/$+.]2@0#B_X[,#!_.<X6^^(0_;MD(.SAU8^96OCGK]KG
M1)VFSS24)OL#I+3#-*I2P,%R+3/6]7=M)D;6Z92!?T$GY;D9J9U*].M37B_3
M?(SV*!WF05]>\0;5L'9FB,,GO#7P[C)4\('QJY>;+([ULX^C5(-_@K__@2^'
M'IYM)^++<R&C]^]ONQY#U+<*=KT-*K;=?3:$2C%,&'9]YQ1W-Q3AR9VVSZCB
M&YR([3.1N-QLHD"A#O8L*F[.TUUES&YM9 L9)E6_4B2YENP\B)0Y 4;R[Q(N
MZ:Q/+)4_*"66RH7*B*5R?:$(PB7E58?>P4GZY(OPC V.\QOXGY6)"W;CGAY7
MKEO!3H"O/SQ6(D;D4A6@0-V4?:X-SKSI4F;8[V'BJ:#PC/;[#^5J4:[NL@2[
MU4;"A72";I0-_IW1%;'V L">=U>NWERO\OYL]F4L2?VN-E+AI8ME&VDV$P<F
M2C'_Y7%*M5-!<2UU75RG6K=<LMHS8+HX>D%2UZ^<"O1A7XJ#);48ZG?/AAL;
M%S/S7%P1[O> [)9#(7W#=8H'&U$&:?=34XL/B<BEDK\CE]+67#D" AIFJ8M!
M>SRO=P@A!^7RJ&75E6Y/2[%JV\N7E:0O_!%QX.YNJA$B%<:93OE+.-,APR(S
M_NZ.3I!#-Q42_38:1YM,EZ%%YFAV'?YPTP?UJMH9+M<]MU166-,2^UF1DQ?%
MS7!&85AKW+$>#- JL)<=BB_K=*(US>_J(>0F=XQE:,3CHL]DL2Y(A12A'''>
M)G#U:7OF*0_ZYNCE7=W/'3HMCB2;W*^C[BQ\348JLI&STD;Y^._MQ@4<"H@\
M0;>3I2VBF_=(.D+JD/YD%FQMC5YGO'Z"KQTJ31E-P%6#R"TFN+^D,HB$TQ9T
MROCUF,7U8U=6$M%'9T\ ;OHFLUV&4L)&SGED6)J#R'N1<"DETVE/(@%2^\@L
M6[X-$ 18 8!5/_^OW!//2=:6]\MV8_N?)30?B+_K2-&L23+F!-PO1G=\AV&8
M0AQ1SC@?;C,^_$^OMQ)3=/CN2^7>++RY<]?)*.EZ+3V70D[[UA18$4UM5RMP
MD>AB?YZXU@R2..7KMW*"S%&/05R[0.+ABUI-'.67;A^L5N^\N$+\Q6WC.TS)
M<?QS:(^5]XQYDN ELT?_ ^VM_W_\[P:XJXX)S[A<BK\9:_#39:7JT$1OTBJT
M=U+=D,)CJHH9'7)=VO4)DL&J#$<V>;FO.%=5<<BEYLX/)A.K0@FW6!7!$3K>
M9RP*8.MS@DZKG@OL*&6 0?<?AP>D%1HP&HC/EP^I%K'?C75,J"X,YRO\;FJA
MV+HV/.?Y%,7IMI'0L%%\."&,7;NYQE-<$<F"3A&.J&!FOM\V'8 ;FNS7 ==?
MJ"+DWF0>D2W"?(N5LA/_3)6>@NDW&'^@ Z;=[$1/E#6M4:!%?-+O5XWN%67+
M4!BOW0;C#!QGMYS448#;SC]2I-+^#?NN^(_8]WU5E/S9:F5T]SV#7ZMV);;<
MXYYT8YGO^19X;#YM1T=6D_6A;KE%?LM*@R#5.+-$/]AL'/"28%+!1[Q8[3#[
M&[M+V\/6A2_=:RO#/Y$/TS&#&F(Y',LB5-3 8K]3@UTHH92+%[T$$O-*X[/T
M8*WC7>K7N[2SN5($I:9!+=:_%*"B1R^+L?*A1_9S2Y-L0SQ]+KC ZGO<R=VL
MD3$F_;;ULX%M/Z:1L^$&5IN<Z-\]P:*'D33+/V&7WFPQ72F+EXA0NW)^V_Y\
MQ,.O*<EG2:'O_%9=_H^OM?_Q>.3+U?=E$'8C9\EM-4QV[NT@MOA5(-7B WJD
MEK#/^1=$#2Q$DR2N">]O"#T^ 9).@#>Z)P 5!@,YH'B.V,/;X\7,M'_]FW?I
M=4OLOARR+'_RU:;2M9B%PJ!$]4.8A8.>/R"4XCSLV -5_Z7 B@JH!A'6'LG(
MOK1FWM*8^WMO2?T4!349#:2<*>,<$ZL5<[NL+.$N3:]A[$=VF_3+4W4V6T:M
MAX0KW(K>(WZU<_DTI@M%5CL&,7.<_U23%PKLTV&FW9N9[+A#92]*_6+]VLDV
M>]F89"]H'@S.YX#J\&E _>3DJJHCF'?:KJ>_G/=<Q_ FT[?=ZN[1 JTL=?O8
M*P.>"TTGP"OIFWX"\L6PA7Y7V\"S_5D7GI(F[UO_Z%4$8M2G,4"T:; R V@^
ME0Y/,^RQU)IA*6Q]T'M9_]V7>[-G]_7O.I%+LK2JL3[Y7HZ5V2!\7G&5Q^,^
MCIHWCB'35>&<V!22.#MI)["VELV*%R_)+.1/35*S/S5)35 !)X"539&GO>=,
M9]O%$3>UP8O?'LU.QT0<G6VHEW&W2J9MR/^XF$8^[<]BY)&[-J/V..2,*NN+
M"\2$@1H@*7%*D<>Y9QPI]J7Y'UBOK=NZ)]F\UG*[R'3Y[69GU.<(2&<#L]@0
MX9'QV2  F%6FL6U?3)^>WP?_:I%O=[]".DPL^$ <._>&&Q:^.)T :'4X41,;
M<0+PV)X N#D?A#( /YRN&YG1=2KS%:R(;#\7$:_O%--2%/_(C F@)K_EG!S$
MM#"51KRYM7^].?4_+->%A50:.9K%6IER_,_M5*V!4E()70[+MV>$YGE87@-(
M17!T,O*L%QL#:.M9QB8CRDV"DJTD[LNG0'=FV[SH!ZRI;_>3_D9ZVW#S-6+G
M)@8_];<;],CT1UB-G;\Z<UZI><\Z:[P9/?B#$+RKDM+O=5*UR2VU,EC0N)_;
MK>1-HZ:?0?F7W&3#Z8]I]"X4!WGDWT,G+HT8/%<U/O\5)?5D;+#:'L^,:H7N
MT/T\ 3:.IHY>U*9^0HK I#(UTW%FZGT"S)>\97AM3^FU:*Z=TFOI?_AS;YFJ
MS]0AV5F'!,X/1CI>#9&I7:*3/!HVX@YII#N7'/W+'RG(6.,UP0#:!ATGP\W&
M[IU^0MW1BV\/\=V3G#%K%T^ 1[UII5)3W'7O^2.H!3,>L#L>*6&7S#1^*; [
M3IL%F$(W7W[:=3[.S0ZW+:\(N75;R>[\)>>2VHTN=?F;I!:A.UZ\:51U=-9]
M-NP7!W:JW)13MCIL/$9OW0IRX:.HYV&6"ZIU.0&"'+'!QZ3%\H<G@,0)<"D_
M<S&-VAR]$'P3QCVM*:%4%T,AD N?V""A"W;)PY BO0373!%8@VE\ <;^HG+.
M8I^U_J_CN"M):U2+6VK?IH1&@^6O*<8X;V'2+JSN$)P@R:XCUE?%]08$^GO2
MC& M-!O^&_A,7_,4<'3_&R['8.!&_HZE_]:NS>M!]0RJ"^/?P;31R=#[)@N$
MK#;X$JH)2Q0)-Q[NWIWB[#SD_U_MG6DXE'L?QV]+U+&,J(ZM06%D$-D&DZ4.
M60[#H= PK1*RSD4S-;81DZSQ1+:12K:0QIHIIF2HQQ B>\P@6QG+I-3,&4XO
MGCKG>J[GS7/U9EY\7MWW==_7=5_W__?[_O[_W])XQCLK]_U1]MKJ!U2^)8 F
M'EBT2J#G:6J$8O)U3-<"E)2\KC+S[N*US2F"$ICW? IPOT@2!TA<F4OT*?$I
M;:914#)]JD>%)[4>[@12+^V[<'*YQXP;@BLH@O#?K4Y4P=L3 ^PA6[(L(0&"
M9Y_W$A,KK%(5 D+30_##],FW./)[P>B%%4<^CZ)DML(,V+2[;\@1M+-WZT3W
MC/24D'^#"3I.V)<!'J (9\^^NP7ZEWY^%%&_9U68X% ;XU+#*&QQONLNHRCD
M+BWQ!D@]8#3K!\=)KA$XP"&VV0)KC!MUNO9SO^HU#(05_J [0+$7CK@(OH.6
M(B!AKE_E)1!C&KJ*ZT723JD6P]!>^*DB7V/J%7U/71N_HV1RG5^HW^VGVI5+
M#2H61H-(>7 P$1JPD;OXPQ^>LN:M(!W99;>QX; <R2S]'/$_WK0,XIHN\= 4
MPMS]I.-3K8&U&V-9&FL- FD7U3D [M+'"GK+J,S&K/N.N[Z+V-JED/MDN(.Q
M,?C?NI]30[8)H[CON=BB0.J_5CTCLX(M#\48QCI6*&;*A;B5Y=T2H(HC%.D5
MVDW?;-+E[VP2\RTWZ!J<'T6.8AXN;:GU3-./+=N%A2G?:>(+"A(?&9@6#/)[
M!U.,ZQN%7L:D2>\QW^QA[Z@-"$0!"W]\TRRX,TS$LZ;%Q"^6K^_?27A9DW&B
M>F@+X05""W%373S')2U+'D<HLF"%8D'4,2$.X(\Y;B;A_NS1NFUG3E5(9P"B
MXY6-B;A<&B!TV%S^XWQ_^9='4S&:5/O,5 L2FP\:0/T:+ UY9]Q?BTEWR'%;
M?%)Y#_E0XV.&,[*U6W*';H&C Q^L?:4RU5064X!3HH\8NA"/( ^VRI57-&,=
M#-*:^=WV*;'H:3%-^JP; ([R@QM&M2_F4XYG1L.AZ,+9],$.>%UE4+GO_,OJ
MVUJF7LZY)0LSGEQ;DS5A;^Q_YNG@DZR -M*HNWV@G+6U(RW6 B9(AW0_0?^S
M-9 :-\.O[N?''*/;O8;49&,#46_URTA:W5?K/]UP""FJ*_3%'5I<F$Z BY6<
MSY"TV-W1GUDU?5K"_[H'(PIA>;"L:*,-W]\?C5G#CK_LW(:1LN_ZP,#;E9TP
MO-S<4C "K:<H@A--7!'N8.C#^MXON\O?'#\RY3'BAA"UJ1>CO7K@E-Z\T46Q
M\\MO:UZ%. O2U0[(FQJ8MM(3ZX^I6>U6'DDO>Y.M0(I+%LS&E(&FY]!@]2'?
M0;U4X3V&:39.66B*ND14\! $?(^,QT VDL<FC)2($)WV_SCLN01YMC_!E2B8
M86?RKJA7+SXL&D1$^\<I5]M&H"[J0%OI*3?/I(J//5,@)3S'BG7&KYY7N684
MP@JS;?D]*DBTR,>#>&N_!460@9E..AG73XU0VJSYUK0=WTR7O&VU6?6M@^J_
MS^[.L-ZM9P8:MKN9/%!9N'T^/==+*FQ27H&\C1'<]^3R7PV*<[)0/XR@, >3
MUDVR,JFR9<C;-MK=*CIWDYW<R6T/1 !KF0\Q*8<19J3,1!&IKX4%RQS ?HH#
MT(\.1]"(X/H>LF:Q'SKW2*EM&?_)\+:ZI$_"C;JB$J936$%74M<6,9'?V<\7
MV3F;Y0KEIVN7PQ;&JOB_E2LT<47/LD@$#;5? \'*(+1S .(2!V"6KG" C76O
MGT*@N[/[&JIR%IX<R62YAK5VZAH-EWUESHT^-KT&5(9[!9;X?#3X-?A31K^.
MGJ[JA.%>?NFS(3!((6Z\.()FNI?]ZA&;UEM=^>!3.2NR&@')FF0LC-5J!+3J
M)NMN^CR;Q:+Q#XED@9)AR\CBF3I9S1?I*N1?)273F/$[]$YZ"_@PSDHXA$6C
M"!.!HC,16EU3W?H8^!#6Z!@*#-F]&W1.YJNUD6!,U8E=7^R[*U?RKP[.CB%M
M^!H>9\]*CBC',\X=<^["F^W9"L>K"33U-IWK"(/&RJ(:BCPH=1H?;1>U+Q#Y
MBX.L=&B7B3!&3R3W,C).]EY#$=*"I,XJ7:ZZD/S+ W,A7=IE<2,Z#2Y%][2C
M@!5C_B!A5:*TURVSLM),8BG2)V'*0BHVPL*YX!L+%T]4WTO,QNWW&5__%.@P
M9B#C94UW,/6O,-Q%:99QNMZY6TV 9JJWYFVWF!*OE[37.N9%78KMH8W<::],
MK>E&^8@H40"8_&'[X4@2#HFE!^[PF'/UF<3>M#XI[GXJ,6B'U%IZ(O_S9*%@
MSZ;YK^-S20@J!QA2#SL^HZ-KU&Q"M#SK,G>=$D8##5.#S16<^UM,33:ZLNUA
M]M64EE,'E8@S7^+#+HS\DE?%C$Y)56-X]V=_KIS(OR;U-!^T*M?\/M-UJ[^F
M:$#;4U=!(5$^BJ/,>OCP64DHPU[$BLS<U>AUUTUU+J?A-Y]4:X_5<\W*:C+*
M]*AMMT"17.%CPO(4=F:*OCIMUVY)WC).V5ZD\6*ZE&2P5?Z<%B-X836_X%U?
M!+AKOCI!<,#/1[(E"]A%/78!$)%*<S!2SN[Z^0DP/'C\O[A#W!I0SJBKCU>-
M<]FG'*+F%;J7JU\5DU^K[. ;ER7,]P<&EW@BO"<0#Y$V4+@!!SAU &MMHV0H
M$_)&6N9@,(HR[@^F/V-+]ZPDE'& NG9OB2L>V#V:;3"+:JE$K=>SZ$2BO=^K
MO\VV ?O0 _$1\LS0EL%8DDVA;[H.%A)]D0J5/( Z8$[CF[1E5$%"L>'4^;&)
M&_4W_&O\P=8"U^7:ENX<F,:[* 'T6H>#]N&&EM]$R@0'^$NE<.6_)R+.S%O.
M#WNJ@6E0SBHG/\[+OG'H<) H84K=)82_9#JF%='H9+Y],T9 _E.,\/T$]@KG
MUA/B9!-Z<=<LBU;GI-JV<;10W!C=&G18G*P-&P[&HST]N5[K7.&Z@5^5AUKW
MZHCQE%B#]Z,CT3%G%W<>QNLDHX>95#VNK<O%G>( %IH@-@?HX "M93.?U02F
M[:58%WI1]+#'%<>?\3_*RU#KUDO(OQD05""N$Q,WUY,<WO-?:\RX@O:MJ0H.
M1EZ+T^ *H"LQZ\8O^M&?1'R]EI7A 6>FU-X&P=I>HFE;S AFPO=Q6TJ&9YW'
M5$LNM4F.'JM=2JJ?CAC+BW.3T*4 VU\E7?+\^:V">/#@P8,'#QX\>/#@P8,'
M#QX\>/#X2?!Q!OX$4$L#!!0    ( &."?%C$_V4=6RT  /XO   3    :6UG
M,C(R-#<W.#<X7S0U+FIP9Z5Z=SA<7;OW'H/110UA$$0GT3LC>G02770&(7J4
MR R"1"_1VT0/(2%Z":*+Z+TE#**$Z*+.-Y[S/N_[GG.^<UU?6?/'FMEKSU[W
MVNO^E7M?&S.-^0'<>*"BK@* L!\K[ ? 7 ',FLH*2BP/[6WA;D^?/'5TLO=B
M47>S%6 Q%!2X)PA@YH"7  $^/@0?CP "@1 1$A"1TI*1DI"0,E!1WZ!E862]
MS<S(S,3&)<S+QG&/@XF93Y;_GJB8I)0D*Z^\HIR$HK"$I#B(D(B(E)CT%AG9
M+7%V9G;Q_^N&Z03E 0 (#_17 _[10#A@7#Q\" $A$3$( (/^;O]M\ :  P*#
M<7#!>'BXN-B1(.P8@$N!1WE;4 &?2L\:PNI!+12<\): [7YE.XW^R"Z[L(UG
M""$1[4TZ^EMW.#BYN'E$1,7$)22E%)645535U!\8/'QD:&1L8FIK9^_@"'=R
M]O+V\7WFYQ\0^C(L/.+5Z\C$I#?)*:EIZ1EY^06%1<4E[TJK/E77U-;5-S1^
MZ>CLZN[I[>L?'1N?F)R:GIE=6D:OK*[]7-_8W-L_.#PZ/OES>D:!#1D'%Q>,
M"[D.&83S['H]%+AXMP7Q*17T(-8>5*Q"P034]Q/>5K83L@GK[]+8>(X0T;*+
M+-W9NX[ZKZ#_SV(.^7\*^I\Q_S-D3!M 00!$@YZ#0=CH*4!@"A!F%B !@[ _
MP!2 /'!R!G !&S"2@_R?:^L>HTAH HP8A@?0=P$<2ULP_*4ME1_TU$ UH O"
M'J6^[BATO/"JGN;8O1:ZZ56+K]Y&+U<<*0:6O-!;^K/S+7_+E]B3V?K5/,I]
M03#ZI]SXA\*.WMJ,PI<IP_,]@>!V8;Q8Y7@:SP @@$K'VD)H4AE,BR3"1H#"
M^8^.*/6L*+<0QCG^U'6;E1/NOT)0<&8WC$N;PS+RH4TLH":[3>"&OT&9?9Q"
M^U8[2HR]<;*ZC":YXHC7S.=U2*]]NI&U+*@/+0*<0PUT)EB%-DXF3SS>S9H2
M@I%!0EPX"_^Q@K\6@FLPW^[$G.XAXEX$F_]%;;>+KP7<F&_W?#^LF5A:J:\7
M:A5+@&X!U$Q4#2(!$#[RGW%2?-Y D=%7\_;=4D=\(COQ'; ?@W-*6TKV66>M
M'&RH,:VMSBY.*SIRC;-[CG40=_>'$?#1M$8\:S6U,6/(#_X&OED(&(QGK!AK
M3CXIDWK'VT"\<F9%,;6EOAY>)_DPMYOSBZ<PG4IE=MG-I+':9VX]GSUBI?1D
M^:T5#7?42[\NK^[69#HM<TX8A_*<FL%V5-3;UE7\!P,-4A*K"+8:QDWHOQ7P
M>RID6GVO\8U&YPAY:*UW1L%&Z?ZU?8S?8_R&W\2VNM1B@)$^_1-EI349<9J#
MSY6?'@1O(ZH%U.M=BHR8!=<SW1%28LC<3GMC6[7=DW"1-3Z;IL;:AE"V/Z\'
MHG)M%.BO3FK@HVNW^<E^ZD_6B-2>*\>\OG% $;LFINI$3J J_TP"LK6M&RG%
M\%3ZUXC_^?/M_!<CP3E_BL<I1/^U"^'QT=O.BY*'F84)XB &I@*O2/T1N+Y$
M_6%8TVY=V'(=!WU:00DZ2ZJS2YN\Q7 4KS+E[MV[1]*3YXR>WXFW'B;BQW=_
MMHH))9V66"N2)Y K+H#O?H.^$J?UF-4TWHF5C$8%/.\D7WVHY&.:H5B(A_?W
MQ/A(R3A&1CA+;*M3* 90(5)DW0T;\'"::D][>K,.EX6E\G1(X9$LOTW &QD3
MFI3J>+[)*:KY]_;EY>0[&>*#,MWLNU+N"%,SH?29Z?>O'7'ZVPLH2FRDJ&*U
M</C^=:,)JQV00C4C42XZ9Y=_S0),HG Y<9#W]'RVNE/4?*2Y;*C47L78#<*,
M>(06K89T%-0(Y7J6[YZ1&"-^M&" /]L L^W>S4M\/OG=QQC@PC>-^HC[N4*A
M:8\/1Z&M5% >W:R@7;^:_R,R\C2/C@!=B&8U%J<OEY%4/H#4=;+BT&];-6@E
M=59Q*+IZ),1[DO]0!M@-#2?7-T@HNJL$'0E0^)SOY-:2JS\^V5'Q;L*/7.2H
M?MGCUOY6D8Y52(H&6KFM%3)B?)>O:[3SLRV+NJ%BW9_:K&4D/]<R\M]!"_IP
MJS'9.ID-E^D01&DRIQ*?!XN,1Y3IYA-V2QRB(X%HIQ369UFF]SD2.CZ]9$A'
MMK&?!7?#(>_@7-1 R_5%X@DUP2+7%(-K1/O10G5U7BFQ2&%VDZ!WA0F.$_V"
M<<2F]=P[X%&>Q<[WGWP\S,\J/":1M!B@8U:NC.=KB9-OJB?7["WXHUZF=-88
M9"NC.HD+HS,--=XC1@#B# 3]&^3QM5LQ --D[M$YY"J:&O2>"X?W-;JV+M%?
M>QK-D':NBZ<EL+_X0X-1L%DSPHNM@F#AP'%O$ Z^CUUEYY[C!3+B,F@6 VPH
M>8.JI71QAG'%]:,"_3G85F,TF& _2(YD]&U5L_P0E@WCSRTH[\PUZZNSQ4\E
MB(W/G?CRQ21E>0)M3"MCL9TM])-;IBF%]OZW9K_8A25EEVK@]_VDDX1*1RKB
M30ELN]XRBR)N>I6<*=S]"L4B[U=V3U86\O1+&D._5P;@\]=J(J_O/:X,$= U
M+J-C7[3)VFW-G0E_SL7(+3%D_N,9=HU<IJ'LDQ\^N/);I_3+WTME""=[<.[N
M?S8Z$S*=;UONG&/0?&8_T8<F)&*EEEF!_FK8'ILL(8WAU8M[-+;<$B[)%JNY
MQ X(Q:NQ_$@89SI$-L'^"1UJD.G^,3'=RSHA@N':>;1(!9[E-GG=!N6"4V*X
M:_%7QYC*A*LA" :8TK$2?E]C\5#+XSA*/-M0Q"X6H/D4UBM]C/14/^\)AL5H
M<3[4,AW:YJ;^N*S.ZK<&"%4)JD"<V$IS#DF&_U:#?W0D" KG47B&P:(RI=KF
M-&BZ-.[=!;>X=9[KK<L:60&&#CH=84Y@A2(G?S93*9]G4\O$<.MKRM/$E33D
MR^R-CS=:N7[8Y<"Y?XD_2C+RK3PH+]?OJRCODW.A5YAOMG63VIL,T1MW)$[T
M@/5?N19N-Y=4J8H8\[*0$#"AAO%<!>:TJD)4*NWV7W^MCZ_3T5=?Y\(YO'EC
MOF=-@4<M6_QV+XJ0"TS>E;N/PWQTXH(!"BF&\:<WL!I*ZD[T ZF QM6%@/.C
MTB[,%6X;#7JL^4>M2L5\9[WK %3X0<E%%*V'O%I[4<JD[AB@,QP#7-7+[Z-(
MB0 A+A#Y ^!+7&>\^CMGVON+[D]L%[<_A8['RY.\""JU.<T?(%>UZ8FHJ9ZJ
M+F@Q\^??]ZWV)*&Q'G\D:K5E:XJ]:R[>!6T'LB_Z??9,3(H.;C\S(5B0)$"M
M@%_#MK/P>JB5/&4%":8+&*,-;A3LP>AR*#! @O/<Y0;BT%87?P&P\XO]^;!Z
MQ#%5I<8L<RF8T75XK3#&^)M4[FNYL0+.8[L7YAN9M3]/5*'R\@>190(NWG>:
M5+8\!R,"*^:=S]Y(9;]Q-U7" .O[ EZLAU<1!]3\C[H/?545LGQ0>"A<62[P
MF[WZS',AF3:.:HA0F5H^NZ<$U^FZL_$RW$]W9W@D]EEU[+?414_CG":C4W>>
MZ9A^F+6?T95"'>*8H@DK6K]A#!&1@%T5']PBEIHD1UB]"338&E-M7/UH(GJ4
MP3"I'_)5<B$+<;116'J_94R$RO)CT&-90?NG-3*/W2WY+K_OPS?)-6[E!4?]
M@Q4@41*C8)Q'B8]X;\?G=?NOOH* +YP?YRO'D?4?P(=EHDU.O][D8X"4L)/$
M/:A5+ZO+4!0Z6HHR^R>MMWK=TG#ET^[2&W_'@@8B@94B#5>A4>/ME?#3XK@^
M:Y(1Q4J@C=/+,V@=)R7)YV>7EZN76WR7]Z)Y8OD 3PD5[XDBY8O?:!C4\+43
M:96Y!LVX$:EPN!<!$1() :ABWX ^P.A>\&& ^!L8X$.3Y257+%*LYP%@"D2N
MV5V3%QFEJ$#/,"@)9OI3MK@+I1%X<_I(K<@^H2ARP=&0:#N[$S3D-3Y<;4CU
M[!G?%A-;W>A=UW(H<9_<LIR58!B[SU$[=?BC<=$YIVJ&WAW(S(X)>U3_^?=[
M:" X[H&5=]L:DM=RT/6)FQLUSHC2(&@C7AA&[_R9VQXR-.I/CP$,.#$ #8R
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M$KS2QE=HT7-L>^_@<$1XHL1A?"6$B]VJXM*.OLTMM%;Z424#E!L4MF1YBK^
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MBHQ7U=;S?:'.7(4V00^^8Q?P9!B'Z0WHZ_R?<*A\)\+N''J8--_8+?6DFWP
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M!F9:0U*38*_*C)D!_H_;_P)02P,$%     @ 8X)\6),$Y5Y_+@  A3(  !,
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M0^"$K5<.SV,V1HL98\)$OH9W_&3$'D;]]-?FR6R#*=\TH%:FI(@*)*EP][=
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MCIV.L5)OK;41D/PHK4KLL4L)CR0$*>_F$WLZ49SM"0/&."4/)77R(9C:<WF
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M_V&L428V#06T)Z;X#ICZD'%U+_->XT.$723&(>RB['> X?^56A-C10X;[XK
M;8$RW@%6Z0=J]['LL"YC^#D!UP-9P168<(180N5%Z#?>M^C)S8A;@WZ=)Y L
MT_ W(UAYZ8=XV*F)TW-<[Q?'2B519)'L-21ZW8D%!9/E:=)4$84CSHNF0V=0
M"IN3TI-\ S.)=H+7ERD;"7H\HUE!^0M=1#^#75/?83E]5!ZY0FN]91,0^BF2
M%5C0U$*?R\Y^.DOVD^N@FSE__X#H8=>C;9(J=BJ[4\6"5XDG[S>/BDT)D]NT
M<^OTRQ9]J%>7Y]__>;#9\'W-103GQ962P//$ S;+.H_S%5;X#S,_O\,!P'.O
M D?6@+LYH@2CL]^.O6'O_N=-VFIQ6YS9LO13T%;2I%O2N<7".>NZWWN"+\/1
MSA+ZP*H)?##PA)G?B[ZV7C-RE+3,L=8'K4=,AF>,^A0T:X3UUG[1 C+Y@M-,
MO?T$117-/FEYUX"Q@:";<L!5J-:5E9_M/GH?KM,8PFO*+F]U^Q>!28$6FB.$
M5GCQ7[7"*&DE!LFMY3*8QG2[Y02K$K&G#V\".!_[A0)=QXYW0.@SG4VXD1E<
M$V2#X DQ4&7$K1"$[L 'D_^I#+2%'A?(FW%UC)2ZHU/(" GM@ZG=L]MLK_;+
MOR\NOM276DK]'%8MS9Y.^'#E^34(3)T,QK%'5P!.GI!=6*Q*3N)6Y+<S)KKC
MU+MJ#25^7[ME^_1AHJA-A)3Y0*1P4LMXD555@GP"PO)9A)W<@(T"*JQQTI6W
M**$L;2[28_,LJ"5]LX.\8,9,C1P@%HS+QOU5]&:$7TEO=LCL*HS0;>^TN^X
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M@5YUUUN?=61\K*72[9/S H)'BO-EHSZ_@.3^][&)>[J(R [")Y3X=6'ZB^$
M@BZ_.?[_+JE\M[%901K_);C\\C\F[*IH3\):UE1_O7E291U,7$ES27+ZQ]$2
M^%?9TR_E%_!Z ?; F KQW\XO)851X,=!YY&K.E)+%Q^)<?C4S1VY7_39T9:5
ME^_ 1I(K6R?)H7C_[@?0%/KVOA%GL2\9QP9[P)IB/N^(R'T&1CP?+^U>:XW9
M9RPR@?>WHFAI/Y3QY20D!KJ)V-2YW#Z125)K?(_TGK6N:T68]:S$R(#?3>X'
MUNUKC8D-;OHP\T&W+B$)C85Z4R*J[X.+_-U?;L2G\N+:8Z$V"U+%V U$Z\:Y
M_CR#'@BPZQ!)?:CDU:>OO,)IOY$9.TMEJW WKVL<9<)9*T,Q_0(<:^9!](JE
MO]FIR+SP+YTN@R"SZ52,<\R,;__,'EEQ-OHNX,\?$U%'G0U[&,&@YSTK9%_U
M_H#._R5G%[N4=RU#R>HNF I8,OE_I6R_9%"HB2K=@UO'*U6>/3N6?^F@V'W
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M^ ]5F_]JD.^^ __7U_\'4$L#!!0    ( &."?%BSS;P)0H\" "O2 P 2
M:6UG,C(R-#<W.#<X7S4N:G!G[-MW5%-?NR?P@Z 4Z1)ZDR(=I$DG@-*E2D=
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M;&-EA16!MD0=:>[_YWD1;3/CN64%R\;:2)^1H_[@B+UG8XK[=W 1S$@J]%$
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M08V0NZO!"4C2$4KLQH%C.L8OQ\O@6+4U9V?$X_5H<T&!M$ /I=FU:''Y?5S
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M0V65,:;]?2C69\'VQ76SFD'T91#IF@9_Z003<:&G-[#=;6V5J>EKCBR===C
M3:YWH4P&_;;TX?TCS L.U:,SK\J?S@#;B=I?)R,J.(]B+9B-R[$H[L3M*!Y=
MQA(%'X#+BI=E=<5LC*;E>^S'GYP*3VAW@9\6W](7,Z=9FUASF@*CG?S+HJ3V
MO/-]H,II,W,?2G8(U,P"G?FXTG U+#A>9L4_?4RB_)-VM'ZW@Q+H+(357E6K
MPTU8*FFSHCI?J0 X\3N4(:#EXY5T(A0R#%GS<EQ[WH2Y74E4.3G<?\%2$?=^
MV:MF#=BF "]6M.9]P^]<NAC'Y](CKL?FFQP]U: JR"3S+9'Q;<F^DWJ .26)
M\P];_!LU+,\D)1\P$S<OQ?S:20'I4N>]%0R0(QPDIB)[S$SD6=6(TGQGJ9 [
MV5!(:%8QHB>P8AM*I&S!IF5YU++>VR+>+Z.2+C1MANK-%G+O.[J%C[61<L#4
MI6E",%2D.F79MCFF/2>Y6,]>O"*L,# R#3GZ=AC:2%4=<Q<^.SCYY@B3R+8]
M.F*T0I /'K=1_+)J"II^3+S/@_<@6ZCW)*T-6- \*7..Q3&]G9-9&%042J)A
M_'0XQ-D!XZ_>"_]O,5+EZP(ZUZIJ!A(DV,TW-^EAF\Q!9M^<60H^,*YD9_96
MV:RTC??3)'SS<HJI#3=.U,@V\XF*J$XL01W'<,AFSDC[B-)\J_5!CG\ *8\)
M]1@Z$.B=[ZK.>A_S__A=,GHN3(+%#6&*2:!WMWU50[(;R[4Q)C$B!:]NRP0:
M;$L"M_F=>\K&H3:2MZ6QVL=<?6ZU0WO"C./+#[&VRHIOH">X6SK B?REVMNF
ME<%DCHG,- N#/-),3JH?,8K2*J:?MIN."2*VEWHS)^XMDCWBXA3(_36]@DKA
M*/WESW]<VA!?XHQ";,%<FBY>(5B&\]YF90-AR5)V>6J96K'B8OSTF8U'B=[Q
M+1X5@W93ZFS:X0)T;\ IW%#MXADOHHPYXTU][HW B<J(.U2$LUI5:[%]XSX2
M$+_M,.Z:9"!.H"[]MPD"79Y ],ATV(5FB]UWEE7W(M/: I-C07H32I*::G>I
M0]_CD),RZ>.5M%1_$3USHO*SUI#M?<D'OTY/E]5%K.HQKW[@XIVQ2/#FB4ND
M,(AH);_1HLOP_:M/F?S#_SH4U,[P:.TOQY_4.KN_1L8\>UYR/5G\M9$.-HL$
M!!>>]GV3?1?B\B+AH?%'_"[AB9U R='I**<Y=NF>UVA( *:3EFD:ZA<I*^O,
M2 ]VT9\1[9A[]UK.1&<AD+% H*AC*&Q^^0T)H$84(P&ZDH@OC-OZN/=^?%4V
M$C"5I7\-*$YM?'G_&0DHN+^@>.]]AEP3M2$!QTP[X+,=(L1GQI%.\*.TLV%(
MR<E4N^T5'6G3G;/^'8KEW"W/\AVN_/#>!.><^:M/D>N)4GX<E1Q1"I/U8JL\
MMS'8^HC:8L3GBE/3!"2 J@!TO9QVC0'Y%JUBGG7M$T32?2N.!'R5W(OK:K?R
M6O\X7$BY^\,L$K%ST;6E4]CT3)#4Z6),O4WI+K2HN5''*$*OGK*S1B'X1(ZG
M'5O$S+3=\RD*@F 6HVM384U70-.+N6S8J,Y<"V9+1TEO"F:;(\?8'] QE^!<
M&W#U:;9KQ/G>M6;]:O45>'08-YT7H3IZ:XP$1(Z"KD\5-B?ZW=[YK0G1^/J>
M5Q\)"1OHVG9^,Z>&ZV:WH/?%C:,)P[JHSRA3G&3O5H5#O154CEAN@V9Y[CR9
MW-3;%?ZV&BZ_3RD7/5)HA^*TM;I,:B4?H@UD6,U2,S6(K!&?%]/#":%W=:N,
M^^]?B%?'E.;!B'ZB+P'4>+64P\PKRY& +Z]J8&G$3>O*(^#=7TC ,$-:RR'V
M3J)_V$&>IR5Y?P]/-&EO>NRC86G !=\=PU8GRQ7!J?[U'N@4L^)(&2'N^;L^
M!KI^,*DS8,!Y>!TH%GI9]G-FNY&Z*JZ5>#D 1K[_[ E@^;L4>2G;]93Y457K
M[+M&O&]*-:5?-C?WTQS?^U;FEWQXY.$TM*9!^?NP*Y9L\!3Z_=<HJ+Y41P)H
M#N60  _].])QV*"^ZK>FLUPG0;.N:T%2RM##PGVCIW//2M]]WOID@AHQQ'50
MX C1N0555$^ELIEPA<K9F0B2=PN<#7JX#K@==C1=49K=AS=L2 ##[.4WKM9;
MP:.O]&EE#;6<7\%N[Y(D84NQNE*U)5E)2[>?H]_#FWR].!Y7C'%:%A35'9B$
M\4@/Y?%U5:*/5K, +;1,H45]GEG3%;'U/PF#U@XOJ' >64*.N%.6/:&D[E[B
M+L_@QC=14A]0UXB[]"IZ+^/D*.1L;/>(]9B$WJHL2C-+JFWE6'HHAN3NI=R4
MI(FY$6X<W.)F]M$NWO"*#3I6;0SMZ&([4N+<+\;;$21@-_)^-<*<SM94$30-
MFO=ZK?;QG_%VBW\VG!/NDD#C<7;,][D_IH*_6R8UO":)^L G@7U%"BN:HIKB
MRNUJ*<SQX'4Q<$M]01EDDV!?JO1*2>!W94)P4MSF,OC]]YUXC9MSA#*E$R]"
MHY#A^I;F:EM43X*[,N5+"%U1Y-_$3!&^YV.:#EGR10(H713CA+X5?;@/D]7S
M6?"[SB,>3\NC,%DZ')6<JJ,$PK =5N,BXQ.@1!9!*XF97(PJ$J42$WBS,LK2
M*H8#<@\1HK2(FK2=#Q9MI%E(P >PB/(VY?%3T%D_$B 3J'$?.A8N!1X#UWZ/
M:!8VM5QG-NH?,-[JITLIA5CSJO^R>[&K])/V,[NGBJPV!5GYC6M0^:X-Z\7C
MY--F/M#/PIR](F?E$9V#BFQ671&3V<%9.J%2/+,SKB0UE@/LR71'._!&5N%2
M0O[9@HS@+T7>!R%TT'\)&DH;%.AVSL$GAQ:?D8!Z=]!HC3:6HW.NMG9X:6_>
M4$U1T49'9YDC5><2:_ZR"QGNAAZ%,\@%C_MGP^ZY1,H7.T:7!3M&AAYA16U6
M'#2W$M;"LS>T,M^5590+Q"+]_STCP5E)9^2K8D/+*,?H:]M/4;[A-<DS&WY0
M88$5-B%/79(MSH8C+OQ3Y#_E&*@__*^"GKJ[A/FF8M]A5R5>N3KX@)A-/!2/
M]^&UNK.1126_=T5&B<F75Z%L,)=0L]," K7H KYL$B$\"L_B6[K2J8H^J)*N
M_"IM]<<.0M:WR[@[NOOU+Q<GZ5!H)'Q1A([8E$;>P0;-Z84^KPL:'=W(PQVS
MV_K/XW/K4+?3_5@R64AN.^PGTU QJA^=:#T"N..U!=BV)^-.-GP)J3:T:!4L
M\<#92M&X?3GFM.]"+K.D6(WU9-7XZT\J@ .1D'>9KD*(%Z/!Z@"KEMZ!I%@M
M??2A!#CW#%@C_KY@/"8F:0)S*T+\2 @Q<;-O+U<-:K$-H(9;X4Y6,".PS/%U
MB*K&F:W79G]*EO.\1>$3SC*#%\MEE+OU#ND9+"0/A=P^1P\Y[9,E*5KWM4ZS
M,_X@ZU5]J.0FUFIW*2:?.HB5QTRHZ34Z^!//[A'OM;JXN,F^64^/-ZH#!=L1
M=E4H,Q22>JWM^(  !8]L?:O!ZM)2-*+- [LQEF"(750CF.QC2K_V]60% 7^9
M_0?;=^B/5R,"U%+I)I>4DQ13T9U4IX,PB(D/M:L:\<<J6+"TMWG2LP,PE'@W
MEOEC==,#TY$ TL6,)*AB5G%EBV-7SB4%$O#I;K"Z403497N"<LF-NZ.E<*0L
M\^G%N_&#N'?*F\+-KFDZ+A03.Z=J$22:=^D+";,XWQ-Q BVSNQAEXF J D_P
M>T"3Y9\R:N:L%WYGB-[^'U-T_Q*IK@?Y<O:5B>H/)N&[\NA<,<Q7NVKIR:R[
M<NTNS(I2D)=Q6?]L/7A &M8AXZ%B_78DQ:F>=*L"=7E*UHX=VT ?\J@T<D8$
MYI@8XMY(AIY76;NS703JL$PI*C!+,,J;,WJU?$* JV*%!+R98M27C%%(PNV;
MB5?5LKI?HK,GOVOF#[)3015N1AJ5+6\BLWMQG:SPD0"ODMS\S1\9VF56\]!^
M6Q2*NAC?Z]62HN)[#T4;AWF 8V!>14ZY.YNXX E[\M-#I6GSPUP=@L42,=+#
M1+.;DN(\A%^#P^NH.@&+C(J&PHMH#.MT=V,AX".Y3V#C6:VU&S$E<9^C.9;$
MMNED?\H$R (LZ#M7>%R8K=E($D)+X6!K["XU-E:3O]3S$]UP8RF/TRZ4M-?%
M#<IB:EA]M]?K1U%/GWN8]*Z^+K)/?T[ *.J9*IG'$]+^2B1 PR=F+N*L:T?'
M/D0#H@RMXC=!VR/PT*EB#N0+AI3$"6RKQ[&:>40X"88, -]PR-HR]#T)(PMQ
M* Q$5>L-\A+-0I-R_LA>)S%><]YE=H?MFA_F)4F0=[P[W*$%$P02D[9/O7O
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MKG=-U$#[]+/@]VKDW@&$/J.A)NL&EI_N=<SI7SKW<;]]P+;KQHSD? JB/ "
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M315HKO[EGZ%AP] C#C!)KK+[^]]U6?VWC/^C?,QJN/:3!7*4W@7DV,VI33X
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MD\FYMPRS/(YSMK/(G!\ 6+X=7G?1H/-WY;.B.AMR=1ZFDYE[;.*##+&NY:*
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MDA;>KH"$Y)''7_V@]Z4".W:\-*)D+Q! T9^^G\F4.[U\?M9)=YLGQJ,_THE
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M3_^]*-Q'9,.UIL8U>>Q#]*4IJ<AL<+]C:Z4P^4X&V71JA)R(OIN8X2-L_>@
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MR_*M1=3(-C*MN>1O:PU;5_&9>/Z4"ECEF5NKB2O;BZ,QW^VHPP> AQ/H$W"
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MUX9Z6NV](:J"W35Z3(+?OD*WA;69U"I:NNE)5<Y%I=/4(8\-&^:;_V(A/1E
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M"X="@2*E.,6+2Y&B15-H\0+%W0HMDN*N08HT6($"Q34X!(I[<2BEN+L[)&B
M$"Y]SSGWGG/>>^XW[H]/Q_=C9XR,/'FRLYZ]YYIS[[W6HG-1/AUY.7Q:"E4S
M3L@]2ZCTIE]GL7VN3@MY2DO^00I72LX;IU/8"$P!NABI/R)[DE>'^16HG&R
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MP0H2D2XT6WV(\-,RJ8=8?>Y\0J5,MG*:?GA1(7O39\J&^-C,F[*"[-9%D*;
M'YD3+;$VO/-]7+MC^B)3Q1%[[Z1[WL3># ?>X[4<6)M%MFOX861$B .6&_]I
M0/#-[]< _D8"<6M@M+4\EYW.)]AX95Q[D9G?6WCJ'<#&3)7N-M5\,%1/Y^EQ
M(.[U=*Z7=?=% .N(GG;XI85+M?RBI;F PODU]<J1GP:"Y&C*R+:%&5..B\R=
M7ZF?&0>Y!_X\QUN5+U+J6&)[:F3TN^@7JS&V9#"064Z?7?67KJK''O8G4TY$
M5HQP<P-*6-)#UV-1L#YGA421)2%DK+9&]?4:1<*:D;^H7BUZK#8K@2NTD]?;
M? 7P8L=GBJ<OS,]DA>[]/7'HBKNMZ-1JC-/SGGLL^^.\?UC#A#U4FM-H7Q2Q
MZU.>4M7N,9-O;2E:0,3E'Q-0ZT[9[..L)G(5=2;>@2B NN=[O=9H__%5P1F/
M4YZ1]D/@CG^THQX/@@&M=/&WL,[T'>"UX6I^0C'93:Z&RL],Q@EW&.;"GM[X
M(]ZX3;S55S]UL)RX0T90CNOMQ%=-'[];)FV@#ITT]'ZI92!I;U7=@?AW@(T4
M4_"TTAW@C%@;C=L;HCH)Q1--B5/Q!7C=JGK4XOHJN11^+--(!*^I,W@Q:]:E
M&7\W->AWCN)4.,<(Q!*]VJJ0*?.31:0D:(P2^ 2D/TUB994_\/VJ)(W"6T)V
MX2FMQ#%C-DE\XQXN8JI'X0+@O-%!L6<Z^7L*LUPM)9=UR]DQW!UHD>GR%J._
M0 R1MLV L$1E"[0)8"M@$8_O<6UW#U/N+5%-NM6,;^$3% USD>,$4#G'OURK
M:@&=H*Q'E>'JLU<,QZFQZ]:H,"'P]<8])CTIC7K&5>FQ^$D:"DU8BVG\-%=>
M]L4:*\1/M^M]?&LEE75A\59US3W6+W$UU5/3ZGX1J3FYLGWQEA^SB'N<F<['
M'0:*C/A*= 0Y 1+T?D$,ZN$% M@8,480:+;<1$559;@A=\X3NTLSTA;ACTW0
MP[U!ARC)GG<QI)*$/Q]G*9_Q$7FEH4GXL#-,A8C5F)UVQ!XQA5S?<QS5=7.B
M8.&R0/ HR_Y9A<2J&2JA7!W=-/AWI^5-:JE"1GZJ/V8.%-[<G5KX16C^JE:I
M>YCL5Y'LPY_,4J6OUT1J_;.]-& UNV^TOHR*DA-V_/&9%H0KH%]=PV[]V-$A
MALN4]T]3SO'Z*O9ZE$-AW[AN;$<\B=?]5A[X>;_B^4\[[%'64Y'8%D6L]4*?
MM1HS4I0,PK]D?E>=-D#F]GQ5YUUW>E#\BY\'#]WTLDYDIM$MS'> D:0::9+N
M."3V;*+3F"JWV+E$%2JP1(V_D-.EX"IP@QF1'(FB6:/BD=3L7)MZCT]">72V
M4)97#_4)CT"]!JVVXMEKKE!J ^0A3E:6(WCWA#QZKWUV3F)]BZ0?X^+G'0 O
M?)V@XMZ)(H-NYTFZ?;Y&QF[9WKR<<ML$F5[6?W60*]S+(I%\3_-NG W2VU_U
MZ&M)X>Y7I>OQPQ;'-1C./O\,LHU/>DH+W<#1S["DV4+KXPX=0VD@'HPKU=17
MPZ&-=3'D^A%!5\9.7@&W((D>4N1^3ZJ;A^<2A;;^!@G+U\[5H%Z)JO7423DQ
MEP&%Y$WGS'G:+\]M63X]I<76I<,5VNN :^O5H0G'5B:>V3CDA@_:S)@'Y@=E
M_<1;@@FH)*F2>*$RN1'A42T*GA]6OY!,C4UDI0<*" ;J?_66"BPG%'V'C,SU
M"I[JTZJE+J\==&4Z[(S9]L*DVN\O&WK=N<0%5X_@K74D8)_[M/W^K6)SA*9K
M3:%63+>K4>939"D%M%@!NJ]+:.'-C#L9YD$AA8&3> L:26UQ5./L71:(0!FM
M#8$ZT9)52KR8-O425+T:7@SN83Z(:01,>0'OJ+]7,'55^OD.>"Z3&-0_+3@C
MFDIT@Q/&T(\F3[D#//IR!P@5X'N;TG*"[DJ8:%\<GG84#BDHT0J!3']\AB9%
M?*Q:BZ4WZR,?H>:IN\!CIJWP@+T<E@+C#2;W!/ B8K]4'$B^$/)(JLM']3ER
M/18ED=GSP3!AZ#0AO1'L9#IYTSU]O)5^!W!R:I] "P_9T9,A]()1K]U+O4RD
MQVW%GK^7(Y!-R"C+4),@-N+[</B!+'$*<D,P.NZ(9K;)?%;[8^*PM]3>Q=MJ
M/I36ZAA@W]>JBTQAB)(>+FGT:E^E_V7ADE9U@@;ZU+2\0.A*O=:(59E^'AVZ
MWYY$:_7,49:(R[7/9PZ9<0=@N=&Z9D>'U7+^(L\;PLI"T?5,K+2P$G6+P ]3
M1J&!MBU7%E'>O>N9+>=#GM+2B%](Y3$.GER#<^ZO;Q47G[@M^'NO/+ZWDQ)\
M$*V$3CL#WQ),IR.O0<-((PT:D%Q+)C%1G",CJW'H C8&W4")DD[%1/R/]N$)
MW^J/2]-K=7GV%Z-^2?.]FT$7W):[];'=4^$A;8QVFJ#"KDR.D('V/S.;\S5)
M!V4XM#&?P8;W:/XHO#OKFFSE'_$\"/<_=G69@@BB+Y^$C6"/I<K@ @\N$ (;
MV/WL+&<E&UJJJG)\W!B3J+>(L/+5:+.WJM+FE?VAFU%%$O"NJ+@^\M0??II3
MAVJE("Y#&<9E\LJ9?)A&H#Q84$=:^ [0;ZTPC$(XWN+J51?B9OOHJCE#E0GE
M1(X;FNA9+1$2/7HBZZ\AH^Q3J68\K!R8 /'@5L$^TT1IF"="HDLDLL1TJ:QN
M1^%["7'G]LU?O*M:U<\SB[[NUP9PI!?1Q:RBV5HI>W9^>$GHZ^[8L]QCB*JM
MIE.H8H^,P=P=X$4T/#8BH8>>KGXBZ05M]+<D?A?R/F-?3Q3(I>5X91KU91P\
M/0_>X3;]8JRSEJ.I\:8Z!!FTO@T?["G8K7H^E[]'$]<@7QC4Y\&>7>$CH1Y)
M29'UB3)88)F_WI+*S_]%WTAJ,(=E._**L=G\C29%M!%M8NPF0[A99VM\$SO'
M2)0FQ+ZT.=8R"(X36=OZ\6A?>>ILEV1KQ._RF4@1<-%BYI)JWZ"-&QE4,KR&
M#=\.?49BPDVUD<Z[WN*.GPF@&SB#J?\TZ08\VHA;:O. FQ:OX1-::[2,G'T_
MYRY<TXM[^NM!]P5S,0-4AZHS'ZJ5:#L.[:#[L $F%P*]+E+R2=;H%AT@P7+!
M\8LB0)//($E[J[S:U1)^1UNTU_],%99\XB-P ^;: J_R(Q/N ++I#)=KZFC>
M8I38J/L-'^VB'>7UVRG=2V)%8WNNP"0LC/1)[>!$D:UX$(C ,QRXT71/-I3
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MTUEIHJ?Z95JRM9J<$=SDBMH?M.56M\0980_/10^<;86OF7!WZZ(=,MQ^/!%
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MI[O"N).!/DENIMSF8TBV5YZW_,I&J-536"&CUML&,X3QVBH'G?A;<:9JO[9
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M'E+:S.T:S&XUV,G96Q+D7=\5)CWX-.MW<J5'HR#^=CU9.-[S@%J&9Z4WJBI
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ME0SC0 ([BV^5J-*W"[%^-CL2E9Y'SM/!LM4=:(NQ.3[- 6V=2XZHKLV;_+7
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MJBVR(RI\^()5*T:H%]@/-ESOO$[@T&H]NPJ>.9^[I/\;7;O1HEA_ZV>+P4O
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M\MCL[IQ4LXC[]H_+6-S$J9%]2<'FPC]%#BZ(G4S3B N@28[B3$\N!+IAJ,9
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M@YXE[&;*,Y"3"E.KI&0=>GFA,+R8)N"M@K,LE;).[[8 $<_,T(#^ >C+@TM
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MM0!4G:Q\Y__,7X7OG>0C@F0 @3W9ADHR@6R?=.<LEYKU@\7TK>,_GL6$VN[
MFAG?](>\*0Y%3^S&+2@R4[PZWC];ZZ?!"(Q.>"1Y:'ZOP\/4Z.Y RRZ>[;!M
M)G6]M5C0IPT*('77.9=W>)^^-U0Y2D1'_2[C(6>O^):"!^M,#$I?71)NS]A/
M&_^8J*L\[>4'0\I5T0SR;"12<FR4ALBV7$_*KL?#8_$[*PV1!AD4#Y--,)M5
M/N5]046O%?]\?/K=776V'@:]CJJ3C?22@#8+'V)YV6+*QSJYJ:(*("0\*UDM
M;;X!]9*EH%@V%SF;0:[S\6V=^M17OL.^XK '8JR;MV6^B' DNP,[^3Y#$VVC
MWSDGTO>3S5#E685WG7#>>_EDG@H4M<V /L^:27]58E0B)K=4(P3L!*+MAK=:
M=-IY9C('[=*F3ZXF]YW17T-]]7$U)[K@1D>55Y4NLYR-.$<KQ06H,'0F>V),
MPZ2T%-*!AI&R#H (-Q^MX/9S$_8W-/D>3/]$OI2Y36)IML=#S:;9^JM5 WT6
MF-RVPSL;1Y$24YL;9+0[(/S+R%OAG"3Q($=)J[JH)]A/*!9QL%:0?:[2NW'?
M.1WLY+E'NNO:/+.T;G0^ZDZXGS\B,%S\KGH!%TF6G!3,\<B!"2948J=!D-PC
M/7D,68$>PE0X&Q1C<GS('["KA2$KZIH/W934R-0M*U+.;\'2HT$.8I^6?4Q.
MNT?4^#%LR;/TQJUO"0GV\C3#(%*\Z0,VIIK508-Z1#?YF7NPW \PLU(-$O/G
M7'*V%FS(EB[":@UBWPUU%(;QQ_U']P.5V[-WY1[(T,>G8-'BLRAVLW9)!ZW:
MF$L 73"J %G$Y]8BY*-#E;:LG&=VP*W1Y!MPGE7#G5__+7F##+,X]<55F\.+
M;S@LRO_K_/,N@\%"$NN+9S5!'DXY[P.<Z#6?!;VBRVA[#[^O1W??TQ-3[3)#
MX0=>U*X)&<X>#9Q5/0["8=E?^' ?!DU8.,O3UDJ20H+_F@83_QLX]_I?,/TR
M462(2[E1,40!HHLW^'H)6&\=*[H2_\\[2?%-T; 38Y_U;@S*[@?CMF>GX+[R
M$/:'4\@<<;);S=0KGW5.6I&C1EGI4L-S6*\]F\*11K5+M\2BG*_/ZB;<Y=J(
M"T$&M)B:]&EVL2&]G+6MZ/B&:-> / ]U43"7$?A[>H9$2)]J$S2MTDXJZ&M\
MD]V[2:T3)0,5@=FPSD/NI[DPG/3L\<'ME#[+!6ZYZY8E#H+/\6\JY@A#D!#Q
M:1@F;Z<FB#O6:,' ,MD5M<\7P!"=(9_VH7]?\3M?F:OPS&FUBGZ91,(SA%LO
MP17+ZA(*3W7,6GVHI_=V8/SMKZC(_4/:SW!(WIEYC<F^[HMV#?-HAZ 6YV-I
MH$\WE%$'1V"JNK3:Y(&$/Q&)=F_>SUF+D0J-+B=ZU*L5VB),I2\ANC*N$!LT
M@'-L';L$^%"JWTVV-A/ZI?.@,]!@&$%P""8XD^VODBF8E#HE.IYKCRJSO>BT
M RL4[Z%IB%VP?)_8A"K6N\;$:I*J'M9? D@/B!YV%@Z73FD0 IH6-7SRP4XN
MP)[JCH8+K&K^_\/>6P;%U75;HQV%D  AN)/@= C:!.\0@EO0#A[<W?T)!$AP
M"2X---!X!W=WMX;&71OWQK_DU/USZU:]]SWGGJKONU7GQ_BY]UY[K]IKC3'G
M7&,&G?>9)"^HST7 _8$]Q<%II ?6<AIO1_\K!*V!=&7S!Q-26-XYSI4DGNYA
M6O)';IFS%CK\KD9TD\G164/5@M#D*^M]BX$0'_4@J2T'#,3U(2O2YE1<2D""
M:$UEG\@-M$L2:]OS9<4#OP],D;#KZ(G85.VGJPY7_S!L\/EY+\_0.$9#9SP^
M[Y2:"D3:JUQU\R.=.?* ]=%D$F2U3FJY2?5@[">[<A=D772>M2!^3.SMJ^2-
M3."="8ZZJ11$DJW/D8SJI<7QQZ/;Y>Z\O)U/X_R,Y!(SL@,7P\]OY,=,#K,A
M%/-78EX/CG-4GEE@;[5^Z.VY=9*%DC6\NZ!1UCZ57QTT?[J(P(6.->"$K+I3
M*%1)1!:=WDH.JY=%'+>M"(5ZB.YD]OQM!V=U#R PGU%+U[W+M["][.IE!-RI
MG]A&KJ19B5745HUSI"\ (YN('HJ=/3X572FCGI&AD"%/FUI/BI 1W?BMZ=:P
M?XJGNJ,MUV^U]?@\@4")@!^?,(C\*D2N?T=!<+K$SM:P.M"SH83(M_)X(Q2!
M3J>IOU9,<#T4N.X3@- $*CV-U415BO@>[ FFS27@B6XQXP2,X/DGG#MM8"KP
M5+?4,,'+[U/Z*.:KG,)2 V^.0B:;4<Z-[V5L5#;.B<L?O5&W:6U,H%;ZC?BU
M[5;Z(3"BQ9%4&&=T_7"K_=?IGM<J4XZ#D%26=K>5[;.'F@G>82(.(SX"161-
M+)@F@4?4GZ7!=>='JZ?*.B[$$U0B+(6.F5.G]7;A6DC[NKGM<R<!+*O<M=:]
MZ-CDDSTYE8:)@_7&YK3-FJCUM,@M$:Q*]:P"(@,L]\(G_B'1=-%7K(^0$X%5
M$5QU&G?^^8/T6>DD.0HJ9?M]_Y#P Z YX)Z$.X_J=0U<I#D7A9^LV2S#L$3.
M(',9Z/R+^S;K_.6;VB>*V'378^HG56BJU1=@<37LUE8XN4Y?([Z9&:GSN9G^
M81LY$^8;W,,XDL.KN@;;KP,R.K&RB&7K3"G7>W-=G-S9O9\E\Y343(=U2P;<
MUYC;X.V,@(RL_RVF(?NO"YC_P?\-I;LW(/@,FG"QPM=EH(QTGJY'/KW]:K*3
MF/N[\;B5D;1Z*J&R:],?VJ9._M]1/$V5T%'\99L&N]'9IFS.<![/H=_E'M#M
MI"_03G.^N1]R=A!^D:V]38)S#_!8,-7/ - B47&?4N@?-7N><X;&A%^GN<OJ
M'*.,1>-C0FII!J1PI,C%]P9%Z8(^4$7!PR*0EX;FQEPUFY<HWMQ?M9XICB<2
M41]\C4X+WQ2T=]0<C!6_5/\A3#!96EAC *V19I/@IPOY3A&MX##$;*SIJ9]$
M(H9!"M5VRA"P6ZZ.\Q?T.>G9\!_0=,695"?9TL=B*#S36:-*>I)F:UIR@XIT
M/+)W==1C:KE$SRA!3&@KJI"\\=]RJK48_;Q+BKW.T/>]3B3KY'>,]X =PDM(
M,60XG:2)A(9MW);\/"\52/MAD?7.Y93:D]<Y/#)NT,!R;G[D;]>5C7_G(])H
M'T&U^:[4<\,)#4I2!G_A[W.(8:#K>AQ$B!>%##:5R#4*M"@]NKC0?>7VPE3(
ME>1H:<W \ZX6U =I#,Z&24@47UPF2U06"+&__RQW[3/W#!*L+UNOX_,=8=G/
M1ILB(B*5XZ*!8G7!CL9'>E)@!F;9KXH5/?T>W0@W]UP+-Q/MJ,KZD6Z8Z5HP
MR?T>_2JYR7$W:-D52F3Y@[. \XE@TKL#UO/;/3AQNS:I-@&9:LJHGU;:9QB.
M31_0"5^M@6? 4/RZ IQ4="5P@&HDOOCB^3)31C6HY]!2S85AG>ZO9]S?LNZ'
MSW\<OX_LRO+WL+&EK_&7C#!/%!1,)::/DM#94<M1B(SHSK'"\B'?7,G7/(%M
M0Y^Z)],283PI)U[;$EZX$6S&.: .122<02=^[8O$M"_<PRG,.L,GW]1@944,
M8VA'DJ^$7[:\_&O9Z#Y5(-KG:3U$$OCGR8EB_V5Y II_$YX=':<LJ9FX] !M
MU=K@<_1F4[<F5G',U)VW@U$3N6<QC"B[PKO=L21BU-(0E]W,P@QW4]BF92W.
M;,]DXQ<F]G52*=3^.F6F_^=#[^98D_M;S5 NQI^]#,<*.)UDW*DO';'W(('K
MV7/ST_N^!X0VS&A!2#Z.W8O&J1/F&=2-#7Q@(?4UHQD0+-+\,%"Z] *4CV,^
M[D=T"-40('Y;1__KA-U4)K::'X3/#2-WG&@ =Q0UW3835J4_M'&2'#OUR]U0
M)V;X+??()IY/?)]-<#?L5]S*_D\+N*E6^4_MH20D=UO*;T_"F<)7FC]%E(1Q
MQE]2ZI*8_K+QF/X8@'I8MI. JZR>)@-W3DOH!=Z]?U^,)]W%X:5_=?D2O "R
MDW&-_%+F;%A4GOG8!<N^X/M:K)8H3=6UV4_>?K^4BVIE1#\JGGB6_<V^!X?3
MZ!V_7_=^Y#U 9_W.2D]!K_ZH[>D\3,?8YG;7_2 =UX/8:>D>$$# _C-V'Z?V
ML:&7#,I\\=5E2(M3Q$J^I&.S[/CHM._DJ ! /I"-J\P>QEJ\BIAO7O),_)3#
MTGDV,IR54^,O9Z$E0.2/KZ_O^>-%ZH/8/5V"7R;$+/6YXJ&*PPY%WYHJ"5E5
M!ZVTMTG=J'X=HR8PMVP6;WEG#:HVMK/]]KMU8@?,)76BO8<KU.\!;Q:>9J\.
MH#A21MH04AC5E1I>8&&_KN*A&+PO,SJ;V;(_BI-_G^<2\NK$0MK/S8H'>K[6
M<LN6?<$NH%RI3+J?]>*!EH < 8W4TX2T9ES-3L'/_I,RS?0[SX'7(K+SMF]+
M,FN^G[JG<MZR=7H79F""50XW,JJ3G3?X:'WP6>E.#1::0@\C0XJ%-6'%:P I
M0>_RUM3$V1M\(SU7^N=L@L7* Q/A5RQ9M8__,[D1XLX;L</X\*)M'K3;D(TM
M^VM34JY5A@=114)A]P#!/>#0'?=\O]T2YFO8\KMW<0S=]@^L?;]J3/F:J;/4
MX]+@JLZ\&#XE?O*E_!Z@Y1MWH+1LID&L5^'SJ5X 2N.?D5_2O+K<C!/TPYOE
M2X+GV!E.-%,,N&[.DZ(R9QLBV-FO-?W/A=#S;-VU;@:.)H%NS^RMT7KZ?(AJ
MD 89W16%I\@+F(#$PKN!JH00=Y?N,>CZ[."% ]0H)%-"JER75XB$3T$K2T6B
MJ@S<=@](^S0YACC<W);7S-:+L%1OB'+!\<,1.:6:DME/E985/%,!X]AHDS;E
M7U+H5W9Y9L('W[6=D[D=(F]PG-6'*]KO <+W #&I&8-[0+I?!BQ9-_#,4__D
MR*=36-5?8*O(#Z?ZO*?[$^^XIQ?SAOE&@L$UE> "?.DC^SJXQ8\BVGKNC$Y5
M80Z>BS6B9O,V?&)X4ZJIT_NMJ\+=D\CRC] =AKM?32X-^@[</@YJ6["8Z]]7
M8Y&'2PDK_?@>]#XC)!FF;QT[8@]D)%1"M,G4BE7@7?M_IH:'>R)AT6'O\]P+
MQ25/Y+G<Q>QA'K/-N,!%$:IK")UL\-KWX(RL2#V ]6\9JL?3II1#T5*^^J4]
MT:NE^+2H[#"_G[_BF(\ZO;OU96[>5UAQ +;-+U]LF;3NU8;Z::T-O#JW.*O=
M[$'G984</_O?74;V/_A_0EA\52YVQ0:D-*^MXL<':D'!O&TK39#.*0VX",+.
M],O'M#MZND2=7YZ".8X1=G@(27;J*=F^],A\VQ"6 K."0.+,>P"MEN]^67LW
M4L.]L,YJ9=/@N@3[3<.-LQ9\C[[A#Q,#MZ S;O<AY2.12C\H\YGLZE_MWUC4
MA[Y24G&",/R8WKY@.-3\C9]7 $"!R O&TR2J?GHGW+RZ]$G^O-.\> ]X(8O+
M3Z7V=8QDSC4B#;U.<*))X8KEK.AE"R\N*#0#<^2P9UE7Z_M:/@_U'U!6ZA.\
M1@5;(!&,"M/4?:.YJ=4,R5\7V6Y'E6WSQ%6K(3KF+$!Z9J'ZF/W<^%S;['FU
M_-!$JRI:NJ6SQY J=\(N!TS0B*8N<:3R-TE)]SBI(WP_93UJ>N\)QHA,AUQ]
M<2^+UQ'NVHZ<=_JR6]]YA8ML6"851*YHE48U:2A0&4<T/Y]FXA$GVL0+'T<(
M1AZ>%WOBI\8XN/X1%__:@RR/PU:CKVUE>^@56;*D: OA+9OG9H.+HXTP;E'?
M ^;=@50JGX.$JPDQ)QDZ4=-DLYJ:& \\/:EWW7.IR69:K$>X8WD7B.QIBD[=
M;!WER@^GQ*9CVWM,> WYU_UHMD;B;I54R\XVR^WT.8:E\4CQHA"U=,88GCA+
M'Z=DG^V*!-Q80I_E[0/=5[]-7L#IPOR!RR<O7OR.8V_0&[Y">TUYHBOLD)T3
M155<-6'>1;[V0K1:_26UOP3C#*(DL4&#B],I,H?<1K9J]P#9"T?K]IGN*37?
MX]E!OQ9^KAI;R!Y]J48("\+]I.VO+H#%O8?7;*LH*PCA**MHF/IX';1!B:BM
M/@C:]&^<*#W@5N*@/82VPY> ;<P*Q37.H,)E$4\E7$S,N+**=Z5-+,L=R_ "
M+>H01B"C 3>I754+"'4P0ZJIODX6^D&?3(I/%$)-KBC^D!L;CO+_%P[9_PJ:
M,_NE=AE;U5IQHQWV3+M^[J>/COB)QFRF'VSJD]YHV=@DM$\Z&FJB?,99K_.G
MP33PV1T]#HU*]H^K&L@2COVYA@L\W6%4]8AS08;Q$F3D<W:^V*>*0$!LI[ $
MVF+I"1E19?%0WJCN)\"#;RKM#NSUMB&2XKN6@FR,9+U:LELS[-U?MJPZ$7+5
MUH?9,*0#1 7][.W,QM@HQ:?KG@]/K%(*DTUZJYK"-M><*H-+$;2D<<IJ<UM=
M@U96]6 .C-%(9GC>&DQYZ[0I0<\8 HG5DVG2&!)\,*)NQJ\*.=,VL/%%PW 6
M.6F2BK:5Z"#P[\[KDMS9Q205_%PZ1[]^S4]3N_H]=^Y">KN8KK^7LJ1PZ^DA
M(]-'AJP"%WQ?FM-.+U#YJ!AW7.S%]:Q)"OJ:,1_#2%5C8D]&3I*8NW"Y$-Y4
MU<J99N5IQ@RNXL?0#6!+X8[5#G_E\^>A EV&Z7SAW:5DB+C*<&X;RB_UXV;W
M $T[UH]^#5CBF#"*=HY\=W[75VQ=]E-G^=_86K^U4OFSU?#3(<_F&5Q&/;\L
MCB-R&F_G.YZ]H>N7G6^JI$H>>%G_W$J-7Q@L/VY7:I3=;IDJW,P#U>I"/'K^
M3_N*3B'_#.XTL-X"M7%E[04J53?/4;R[@%R1OG,1*BP*BK7T<^$G5@P!SN1(
MIK$<CX?(]9S 553=4NK)1OT=\5C# BTM@=J)LK\T]>HXGF#2[9Z[^U.V?)D5
M.-ZGI^T(OHK(^DUM[RBHRO)+;=6L7""'4HAG)X\Y9 -[TU\BAI6(6S U""LS
M']C?A(_)7O@BDZ$K:EI%N=<K8K3?_.T6O](SW/O,TC9U3O/O@>CR?SL=4S3H
M)35>.?C&2D2%<[+#ECV5K.>.SHM RV433 ::KEC$:X5_T*3][ IQ^$,S4$^"
M5Z-$DXI9.H>RPMP>N_OLNA[IZTA9 15L8[@[Z5^0?G;GOR#2HEV\(WXB9^U@
M'W?Z2F][(MBUF'0C>,$/<?,$4D@*W0D>*QS%#\0GOK'P3(\\#&XOSK/:*ZK/
M\V]_K?9^8(RS977DH<<?*8K*P<"6SW^N.(XK$%0UTM^)?EV"7@1+WOF>+8N^
M.GJ""A86M_*PW:5_]\J]6^9ENACMG^4JTUMNA;_BN830IP1NO\(P*/(:$INH
M%O?L6F,W+'\L33-/3+=\D'+IUU'5-@A#0N?!-!<0>8W.0C8133&E2L8A.AWR
MX$RLNL3&YU2'OA6#<IK-$[G<>CKU5TSVA:?4;!%*Q>XQ*SAS"^B1B_PUCH3%
M]";I9<3;$N?KA*H&?VDFQ?PW2TCB[4G![PX]T6B2WXO3 2=B]M\.P=/,^] <
M3]N$9>AS80)]3?,J(>//?5W$#+X^N%YD.OMI[C=\5ID;1O8@SG G2ZCJAL/C
M+D+.$'%L?FX;(:>S;7E$$<=I"KN<'%2A]AMN48]R%(!K7P0;#6RIO <$^;X>
M/:"V*5IKKN@]WOC'>+5J'8WK2<05E0\;69)?92D9%\/HKX@8&IR'^NWN^*W$
MKSEA.%2OU \(;A@FG>-XMHM 0'ONC[AEB!NLYN5+#02!C%Q"BO+<R0R;5'6Z
MP$VPOWH*__$TMO654;$G<X H\8)E&?M&/56\*WW<]YNR_GM 1^1D0<X7U4C>
M1!H[":^[S,. ]O=)?/U.QMWPN'=+X*>#CLGP-B UKUU"Q_9C]R4YN]K(D:>T
M?;63HH$(9COE3@$A"=UTB,JLMI*'$W5E!0?O,74^Q8MXT;:Z9HP$;V()P$8+
MO4+GP:7UH_?*UNBFL/$P%[[,@5NJK<NW0JYC4)+3$2&%^GU.W*\JV"8EW;>[
M>S?4J743UE>- 0K74<B\RWXS06;+93-@===+GWH]J5O=NF<ONY<W/ZVE)?E<
MN+7_!I;_Z%%U"7"NF(,=L3?II1GS)5)2]<L"?XA% T%13I-WNV5WI%CO[8.B
M[57+WIGK5(XD(9X-K^B'\[)50P< 1WHS,E.=0^E=2S86A'G6;76O33W:,E@U
MN6F1,1T\74"<)J)MYOI^/IS?54IJ"?K"KPVR\KC,8HR%GL9ZFM_T@^3'ZWL
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MV!,W>Q. NV1^/T ;+@O>H 3"Q?;8/MB#67^IL\(6V0E44KH=GC5#0_%ENO\
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MDY$OXTG/WDA)_CX0T.3[:U$@9;_82S8\+F;D9/UGX$7]VXW$<9;MWCS7GGN
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M9*O9]"4G\][&K&FS-PIY-],5<YB77*#%]!"''Y=*<@IFC6W,E8\BEJ)OK?J
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M\ SB0L4D*DA>$*$C4DG+$XH*.-@V3^2(J69@#GPQ!^8$XGMYYM[3*7UC6$]
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M/K2V(K2 @9U1..4HM"7\ OX=CKFV)+PI3(N\+=C>Q1VWO@-LP:/AE;X!:M!
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M 03'L78=WF)G2V[P',T21)Z#E5&YU_B,HWXRB^SIWD#NCR&^$97V ?S1BN/
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MUX]R$4LHN;BLK+&D81_8L%W? M5JMYUW G(6ZL]R[]EC.LWXF91U!$1N,Z%
M(O7IKJJE7#.6ZNO]G[ASC\(MOQ^P7+.R9!P)X#S]8+#+.A&@DK%]PI86^'+A
M:%,I%ZO3>[-\,2KD$90:XG@6;FDR(U*Z&KJI?!.UO(<_B!0[V(,AM6P&J=['
MF1<@N!\3)3N(.F.P3V*_=1"1S'(^LM/-7-#S'YXIT<S\\>HPF8X79G&6.%"?
M=+HW5YP#?MC_BO5X(U/AF&Z_OU&)]V!K*DI87PD]Q'?+<W,HBFNE>3+U[GX6
M% #@!.S(ZXIJAJ3E]W.7:D!C>/XQ/.3^C^<KS;^8\RAO.0MZ!N,C?GN-ZWNY
M5NL7,LKT8,'T?@WWVM,V%\N,\ECH3+1CD'>$W5A-3Y]2!)=T;5BCFVSO,>SJ
M#K 8T"C/":4PL,;%%%@-YDK]3IV:].ZQ^3J_YP#!@%?GG@T_2U\BY^?0+Q>S
MC[-I%[]8JO7,9$LWPD+>'V'/HLSRT?4#+!0^& -K0&=ZMF9/WJ/O7JQ\8_(N
M%$K)>#:ZF*,#.((.HJ=#M2.'W?G)B-!4].@E/L[.<H6F@U?'Q)8"9,W4-:/N
M!>3GJ5@MU5RTECED/&-]! ;Q(:O18U$:<;,_#42(E249QYE=25N%'G7J0U>N
M=D[R,,,J42G-OV<5GE6'IH8F9TN5A'_;1XFZ4O992Q"Y!NPV=DX.1V]T%>F1
M8*40_G$(_UIUZJ+7$9QS;=F<+\-<1Y>AEH_(Z91U2A(E>EN'8>L?'OU(B7")
M( ]/D"5G?1T4S91$1GE2_TV,..2#&$/MNQ8N>4G]AO:'M[7OKLU3TJ%RU#T'
M:WWC#6*D>GAF3\FR"6[:&"KU^PB-^Y-N7?*S T!-<3,K*V?_^*RG_3N1DU#H
MO-&FO!EVVA \U/>$MH'T!M1"(B*?*'>B%. TCQPS+"&(*E>4KERK&<EZ&&R_
M<$#52CM+S8YIK-<;,183*PFH!'.W2#J,YY'E.BIG3%?:3HK3@RW-!IB "4$J
M">,/@DCU(+"H=54TV\GK$>@OOWM(K\E;[:5?$?='O\C@W9.4'?&+8.4*"CKS
M3W+NR/OVO6<3:OGJ*7J>(/BL4@.ER3K.$^.?4W;XL%75QE>NB%@W'JD[A0L4
MO!)4'XW>_C*MP<_]B#&6=X5/-%OD1;Z[&,$G]S;U((FL&>5CO>9)D?Y["(((
M+UMIL1[IXWQTQ9[?84T"3I$4P$6)P9#V]\_;THD1M?/)(SM8I+@DF1K)O]H;
MZ%+>VH]7ADEC+#:G,,\!OGZ7&AV(N0/4*4'>FS?E;(U!'5B[*&0:'Q@1Z_&[
MB^^G.FNU<!2R7#WL,RK_8BVJBH5$@T8;X%6G5BLJINQ4GY?'TK-/N/D6]W0#
MA<RZMPM'33KQ8QZ^ZR9S]W!$YRGYPWR,4,\H%"4--;E1@E+")0ZJ" 7^/UT@
MQ<M!TV"K/#@+T[SXJ&;BLZ#G;_E.]?'N $[UR]J)4VI L&"U:-[8#33X%@/M
MCV;=JI=WXC;+,WP4Y"EN\])JS_$6JKFG:$9_E&+#2S>O.Z^9[7RI&A$4&>AF
MQYC/LI@)M!\N-[5%T>-CR$K@-CVC72>C[OQ55TRA)1GLI49A+1YG+ !/(SB;
M%'G T/YJ0\D!7XRU['WAK%_AX_?\6 /1!"[4[+2M!QE;7?OI>>6"Z&W:.'VU
M1"RH*6>\3D#1:TG!HCRHF]'KE:Z$]OD;)+.\@4PU^A=E"-?A\)%6K_9>RH7!
M3_%,_XSIYC<M*0(Q;%YR]:?FS ()ZW9G:CNZ)J_SA&Q77>LZ=1)0Y%W(*X[M
M7,HXVKR\]/3VYV</^).S'D;= 1!$X3XNL].TI6TY@ZAA1_/4P7BQOI32TGK]
M+J7)-,/AEX1Y[W73:E!D@<YU*QY*F.ST'#FRF=2^L3M .)@Q<E4'-SHKS9W0
M]2G4R1V]DRFSG*?903XNOP A@/RLD2;[6+\1O2)O/=>P7_]W+_6T4L>02N,S
MZVK\]P/]%;2I].!<%_+4C'@J+,^!:8_#""<G85Y\ &K ZL:,J!:I*GWVDUCY
M?A;@WE=<I ,9/,SV?[=MZ'$7C=R?#OH'\,Y+5.HD]BPZI%J38HZ[[I<!:(MR
MWRM@ZLFP" Q,/OS\TF>O7__EXO?EQFL%QX7L0T&.M:@8W@C3IS08_3BU#";F
MGS=3PT5F/NYS*%+N)QXY">J7^99\$Y="SD(V?L,S2:=?7C"HR;[RR[%%&)@!
M ":AA,Z.2L3G_M-*'W_,ELLMGW]R@ QCD?L3Y<I@J,;?8(^-J<<MU#T<.QVR
M*IYM.I MX<07\N%^? (4W^F[#M=3G-L0TDTW!Y:N1JE*D_@I-*-P!D(D[0ZO
MN?9GAIYSSKR%.)B\A"GG,$,<S&S9'"C:SS S!\+RA +Z:M';@$XP[')*'C'%
M0ISJ@,WGE%[4DT7H4@X>*WYA,_C9#__+]4W1;0>9WGDUJH\3GFMY2'%]BPJA
M]G*H;R^5%%10LXT<R/RE$OE)N6C76;(T^9?K"-RQB<UWK/J*SE_WC7PR6: %
MF4;C[]X9+BQ@K598=C\!E8' 57(SRX<IFKJD$JPEJA!:B4_%F4.AE06[: ,N
M<K,A661_K&%8VZB#I>X[,J.UVKJK12:_W77N5F!KOFL:]W5]>*_N0!VULYMX
ME5964L22O:!TA<4T818-SYX.*D<YJS(/TRQ-L3U:!12C=(8>T[S:LR*U.-FE
MB HQ%!]4JK>[ XSE+P6 0A3*'6WZ+&UM]27)5/ZE%Y__A7\/('Z]079WB52E
MC-F"SI<76M2ISX+$_$NR,GXK;B F9RX"U8?>\HHJ:CW=Z)*G6#AUV&X>H4S6
MD]NZI1P6D35[.?)R!GZCG6V]X1%ZO*FK@[E^/;HS41;O\'#& W4'<+P#C'B6
M;JJTM,G/#2;44ALQU-Y0K/$S [VI3:+G7C84XU_B;>[>4I_7>AJF=*A1$T2T
MM=S>*U8L/O=8ZB0K.&7K@B?&#WK]AFOE/%/ZZ;$N\D9.W?^2>C.8_'-6QB]Z
M>BJ;75!EZ3E\R3S()5Q+RW>\YQ<)9"]N7#KSFNJ3!%*S4'^6/;4=.[^H7O.1
M_C0$,]I\4BQB2[_:6Y)0 ]=+=GZA,QY+2P7SF4@PC;/0=O4>N05NHZ6_7@NF
MU/^VR&@[\NK7N ,X3Y[V*S55R:WG!-<WA) ;S I4-%+'^(O1;M)2VU>"3JM/
M-FU8;^;/I*T*]%RWS%(JC 5EYSZN1L4E\I;_0U?^TPIDFC%<)3<)0_XRR%=>
M$O!IV-Z<X.5'MB1BE][*"Z;]]?)2O90 Y8" $FBX:ES&1=IN4['[.Q^E9TBD
MG:_Y6Z4S!80J8Y#"@W#.KBH4_42 _@L$H_L@Q29,;11AZ&;^\U68_K)MD.AC
M 3 S<A&#LV/6M?&',KXJB4"^JC*>)V4E/9OB;P)0)5^!OH__&9V%GMXMAJI<
M_3SIU0R[>/YK5PI"V<ONBQXFH$7(F3B8=J22S!8O?7$-\-\P6+P#"&DY]C81
M;\DZVEG?SL 5!*:)#V_$JX<O4+V<P\&<XY@'=K+!8)AC]_)0KK"%"C*2>MR8
M^41DQD*>0YE3MH&"Z2NNG9[*N;G";<=^WV_]KY14#K [@!O%/W?H\]XE7CO]
M%(C3W.ID#9%-KQE%E\LXPK:ZV%RNHRG<0&7L7Z;BTO8OF:']3\AL$U/T2U+P
ME@8NS<K:)SY%O@BR5GG]8C;T;YI7E2TW$L@I"7UZ((8YO7$]M9A\I/((]-01
MO@6=G.TTD&6*0'Y.8[Z$.U#S(N@D\/*M)%/8FBK!F005#KE9B8\*VNU*;=!'
M-OM9\U6N]M066=T_3DD#4K;%<^SDZS!BLOE!9+QG'05, [8RDNJRV572Z+CW
M[[);6"TFU+2C5R?R'4-*\8\L>Z$&L-B*4CN5)G'Y>,J^G%)_&5L$2N 'VEPZ
MX 0!\SE3I(Q*.V']*.8 MASCE,D>QN?P(%"PXIA1#JS!7&6R\Z9"9\Z\_%KN
M $TOU8[E8P&7UEYYCJ@6=U:+6T*3DZK(2[B5KGG5S,'!\].A<L>_*TA/]*_6
MQW/?OG!&$I)MD*K+^\7L-;+085=H"(<+3\'5DFI&2R/1"^[A;L8VF7I*IDX4
M(4LOF#?<B#_E6 @6N)S'+BCM7*EF;Q::JGI;=]2:BD_?+$Z/ISOSL,!8&_QQ
M'Q#[$+B-@%@'JF9*+E,^VW*S(!\:9*3#\-_1*"%'<VC"LM*Q]I3R-Z$?H]=4
MKXIL<[:FBCAV5VNB:H+;]POTX2<FAQ9Y7QJO BCJZM?!D;J*>N]YH@HC-'NK
M7=ACYEP%LD-8/BG)Y'F\S]74$<V-I>.U:$[>:,H9U(V7L\&\>)*38=.F^!8M
M'/$Q*[*JS?;K=>94:DJ #4R6B]_)]L756BXB\1!8? ?([[P#)./EMK,IF)V[
MCLR=ARJ4J8A'KX$[*-K4H=TRQ?Y:Q0-B_)$WI6E!!Z=.=X !/Q<+U[WVIR;S
MJ;,+%BWAIG7.X!5HOZ]3*@FLI?/LH=!OB@N6T6KAY/V4]2F"6G0S<7/GD4QS
MOC#AT1;T7EI*H1]YT^DLMC=>0]B%$%_\ 37Q4#GOUEA5<))C2[(G["07?V1L
M^+?;KU6ZIID;X7%:X8?4DHQY>^RUBG%\+$-H#Z%OWJGAX76'<926V,H\J=>U
M1[@S* F<+0T+1F=@/C![Q%#904K]9S:/M0=N]2F0F#<VO_OOB?9Y<P!+7Y_)
M88RQ;.ZS3-"_74I<W]3A7LVD1=!:R/4IKD/W(QO3*@YHDU]T<;,-?E>=4]J
M")U2&BE+/V#!9\90 K*S.0$T?F(U0J,Z&D<\\=5^9,H:_]MV92"?\WI\P@5?
MMAIY8(\):4C:"O$%B1?>GGG[+1\VK2XV+=4:1UN&YPYP3^\&7<59N)9#)K"7
MO(JP[>)"4SKUN:27^;H ';5(,!&@_#QM4:&X/*0;V>9XO' &S-^V_<'XG^O7
MQ8&=(U;6^+'JWL<T2L<%S[^TG.Q 'JX>\7JH3BUZ'5,V \41*L(4T!:(/JOM
MS#&6.:6BG^W_=/K^+_Q[V-?[(:0_=*WOY-<"%ZB0N#W3&Z%<3W7/<Z-KF2<L
MRTL*W'*8M3.,:;AE[I^C\[]W#6HEWO?(-GYFY,&(0]RKH)?AUSMBF56NLINK
MPS.ZQL N3]?+&NKZW4'6TFN(),.ZA.J06F>*SKT%I3R-[C>$Y=/QU(\#-77A
MHJT6?IG="O3X<FN6,@ZYWAPX=%7<2JLR>[6!KG&C!HB4]_5*<MO!=&Z)F$YJ
M:=95M^=/,BBMXC+K6"D8.YIN'88?<V)TB>$5DXEVG^V!]WB7-75I!G9%I/.G
M$=$7CV 7\W0VN'-6#? O%D!'Y])L07Y&U\3&>)SM2X>Q2N[K,Z;.[S>M(HE_
M$P/KB5"!ON&CW_H/4=D/?!X\#A"^!P.UYJE.*70L66[_7:(>\7\GI>KJ'7@I
M6Q5-(<S:2>BXWXGB*AWMZ";K\A]H$R^9&TAW67C3Q::M+&<+%UTB';;[Q>2U
M0U ,819 S\E4G+6L? K9ES#BUA&'+_WIP8^EA"B^LR(V6H:JC(9:*L!811OK
M>E7F)KD/W<3Z"LZ.Z(&R)_\/>V\=U=;7I@V' J5X<2<4*5Z*M;B4X@4*%"E:
MBI/BKFFA0 D2G!8M[J10@KM+<2VNQ2%!2K#DXS?/]ZYWYEW?S)KG^6;6\\Y:
M_>-:)SDG9Y]KG^S;MMW0U-R&^;FFHK7\ W'MZ9U2TZ05[=31XX2!8=^R]H?3
MQ2WC:NLBE90E&@6?5[G*[U50WG$02^'7C$W.TTJ<,3%^M6^U[NW^C->E/[7<
M];[)9.7"@8G-UTS'J5XET<#RI9X$UTWA+9-<4H>">#*#G]XV);YXXRTQB:O]
M]LPDC](O)G/\>SLH&ML!&,#$9.MXX]Q*R_TH'S;F%!T,0.T(]*/<V6[?YTQ@
M^/#6L%K)_3W;CQMDH/96HYA9XC74U;@=BYFME-;$FT=R_<]O0&-<Y=Q_C0DJ
M?CBN*%X=LE7\W%MD7_LX[EH17_?4HKU@3IDX@L8@H$\\AJR?<_*2X+(\SE2M
M(4RW'<>*_@+:O40]&2!:9L+Q V]_Y(&=K>(%G6H?W7Y@Z5BH;:1F>I: OQ,&
M,'@YNQ2MAS<$:@F3JM5P%U;GOIC]E2!><FJ03<N53[L=%[2DL624S%7T%*BK
MWMQL/PMS:J30-?TFN)2SM%2=:*A3[FE%M7S-.I;U$NG2PG;^A,LD2Y\E%%@L
M&^HRG9RP;-H- E&H2Y51D=U5?=B2A- *74<4AJ]_[P,5DWYQ66^\)+48KW=-
M2N0^/K.5M/'NYJ>"@W$7I-0;0$]H" #]+"Z=Q^QHJI/R0+_MBJB8[*2P>VS!
MO%M (.J),R%(@%VP<N(18S4Y5L=61OA"4$[]\>7 <-H%OG""TIR+WRNX6:(@
M$[&?!D,'C.<[9T[V+>.TM,DQ2ZUW$3OY;4<O-R['%",\EY_;]WI2'7RM;G@3
MD[5K+8U7^;LD5ZO1_OKSP4;225N$^M8.!$+H6U&HPK_F:^T>^MPD/C TD JQ
MW.DMPX!HZ R I+CWV7@P)N( *+,ZSRKHT^O4Z]Y=^IZ;-F$ SQQF?D>XEQN8
MGTC-=X )1*5U/.JF<_T9.%@^S]^\RYQ% XMA+A.G5QH\/;R\M-2$/F&3B@=H
MSJ6R,3//=\_W9'VVG%85*?7_:S92N=A:^P'CA![JQ3QWZ2K=?[)UD6"N8/#I
MVG[<B-AI4$_[JO%S4X%,5+.LPJ6!#6Z^@7;YB.SWSP^H<J41/L&7^H"WS=P]
M^JRUL!2E<D7AZ=S/$AX7RL/MJ<V]*UW6 0_<-HBDU]^<B^G![G&*GD([C2DL
M5O@%#0$GO)JNZ ERV1?ZG[NRY9^?.(QDU'@FWGKP=_\N=?,'_W0 Y%B"A4BU
MS1B0>.WE7\V?9%L#K]6=& Z+, "=7I16Y<&%0?TK@R>C9L:JCN[D@T21\+$>
M!0+[V;E0;S4#Y<&=1V+2/*8_MT$U2&BG>C/_TKFB<D,5)S^ +AY8>!Z^=[TW
MXGU?95O9:$I79XKYAO%MHL=D?>JKP"I>/\8I_JW)L5^/T6Q:LXN&\WOJE4Y*
M"_N!&@;)<DICVC2<Q2(=($/MRB03+:$JRE1[D8\3JA6?VU83VVX_4QCYT81[
M:I&;13H^^9G'=M3G\YPY#P-(,,[+J1CV[1L.7@(U?CXHS[&W20K.LQ,RS.QH
M"4?0!*\CDI-[WL8[/*45[L,CD&3-DK_,ZDAH#\*J1*3+N).Y%]5U#BL3[H=\
MN]'P/-M:<Y5";WB);4GNWQH UR]_]^)/5R!Y@*!KQ8Z@J:'R+[,Y\F<D50]V
M\8JWY2YGG!5%<Q]EJ.K&)WK+&!C'YQ7WL:R$3-*#/YLU7W6988TVJ;)IN6/+
M>RE?!QAGE 4UIR&IVI:O@5..&6D:DXX5N?O?BZ-;!>.,ZG3BFSQLRY6%C%^)
M^63;T.UI>!Z/2!F\7+J/5,J\EZ"0K'VSS:X,3':_U"?)M2QJ(S39,0JMV_OB
MF '.=^N@#=<9E@C<*JBL"S+N<=C4RW)6T(AW["RWT>!6:A_(4F@OZCKVLC1+
MDL*;LQ4Y$2M\>R(KRFZ5\'K-F^D5_7?BMA$6R!R<04$N-S(JOU3T34@@.^)=
M?FV#'I-=7;T!^H$9WE%S>0-SK92XLUM"I1'4U5*5+S*K258BVEHN" %S2Q)P
M^RUUF90B6F$*D>[(!TD]='W9+L;NIW?Q:*:_EY$ B10NIX]XO@/]GNXT8H$R
MQU98\7<;H%3EJQ!<<&*3S??2"UUI5+!>&7I(W;/N5 4L#5B^$G6:>8%^&!"P
M+)+VG^JL^3]15,&_VOAAI2Y,/-LU3)52Z-OYW?R<]U)[)BC9[%V&O FK!,W/
M)Z$7Z[((BKYK8I?4E X@Q6OJ)SESOP5'NQ].7Z=1G>)236G1Z=.;H7/KCP]Z
M0P+4'>:M1V$GZ0&Q*;=AI/LK!N4I*DA-FL^]E1!LUTN#:1&#9S^LI]E^R1B&
M=V0^J'M3N>T7P6Z;9JL-+:8:VS''#] H>OQ44,&"QBNCW?EJT]W\F;8V7T?N
M3W;>]-J/37CY/IJR0O>=!#Y;'.9A>X\I(R"[=CEUA>(:)ZJ+GW@*\@M^[OXF
MGUV62Y@?>-RW/#)[-=7 _7"B ;O[6A[Q]I";WO3N >>GK#,:/!!LK '82]5M
MYD/33<W784I^\/Z(W/?]S9-?+1DYC1;04BK;HL. [(<1I<\V.<:/XGKU0-YX
M%Z^^H9Q-Z^8LQN!X1"[W:@* O;2PDJ)RV6KKZ]Q?,D[?4+9K@[]IQX<:LM;J
M/+4F8#NFF5#$BSM5((D"95WBDO43RQN\=;-F14LIS]>.7RNL[#)IQIJDF1>%
M.K@,HT0^#]9.045ABE3]W.*2E;=2I?)?-@_CFY3MZAE2(.Q1&8#9A]FZ7CK/
M+"N+#5E^R9/+29WW_H+<,"_, /**FU700'\WST6^8*;\VAR1 6^ ?3IXS>K+
M3K:@F.YL.?;^;#UK9+H)RC9I,*I=4M*N2AW-CZ><93;#+]*'Q2_U7A"]>V:)
M(IJ9HD8H@QRIFA3(NCY0^@$>\[Y'::^F24O*05^3?#=;*E /Z;+/:I!&_6HF
M:4IW=+:7T:OB^)8#X8WZ8U#_!\*D]5, 5C;J8U.5G&/%++BW"\C-N> A.[+4
M .$NF"[Z*P>\<)>H^4>_S5Q)^PGYP/M77VN3MQ!20?#^)92EV<3)[W+6X\>R
MGYX;!EE"+IT@<Z(;M<K/7=V-=P.^CFKFA06_5'[Y$JGQ> @#D++" %J( \TL
MG[EIJU[J^&IC *Y@GK&W36%(K<KCS9K0,K.:>5.>W[KH+B)POH<1N&.9<GFE
MWYXIW195P7X;^RRS<9YT!^(KDM(\^C1L&"$\)*(5DFJ=R]?0O)!2103DEO4&
MKB^@WS:3#P_,:-48@R1]5D*#=I6RY:Y+_'@S/6UE(S[7/_UKZ<7_;X>69]$^
MF>9K9"FO[PD&(,U*?+UWYVIU)%3@V%P%\E#J\$.4[:W:O55OI=&JRC9X*0[F
MN&7L"W,VQ:Y8^PE%<6#!$).8?$1AUZ6/;3"M0*QW\(NG-\>S-\)F&( BB%%/
ML:4@KE1T\L+L<!P#4 ],^6U 7;XC8@W.>&5_+#$S3=Y)B?S\*YI=8<I4_F[]
MHL(J!A *?\C_!'I''"TF3'9YG6>+++\UAD=<:656!S8!XP<-L8STYPPCP0WL
M]4]2SFNVQB!UZ&=5'"C@HZ.%O0$:8*]C0E9[:8-8 S7\!^/AH>\[=\MFD)V7
M,&AN,3/EGHUP'W;<-?<4=#/U5%TK^#XO=]/TAHL,(NQ^_;6JZ!+*NX/^:>BZ
M1<'<05(/LR_)#FV@/ZG%!Y,DA]'F]5()F5I1DE>./9&,('HBGO> TSL9BE1;
MZ1;_[';_=P"76.OY^%D<[6092R/9QM<OV+@C)C;9S+2C<FUC9:X8@ G--:\^
M)%^<PZJMW+;PY\YVORV(JD&PWS"62S;I=0XD^:CNG[WMQ1_\P1_\WPWFUVL8
MP*<6EK$ \T?1!:^-3$ACE<HIOE>^(1&SR&Q)TKCV1C*S"W"&3FDK&:;1U0'/
MIUXB.:]3&&0O4;5H=;-%TS,.S42+0TX/X5"$05<DF&*12>)PX?4N"WEQ(^]#
MB0^9[@>F4S[.D61\:.&Y)Y^_:DZT'5:>G,0+]];U!,&74;"N%I;*J;?C(L1D
M%14<42J/@)\G;9G;+!<F];ZFY^SL>(+E[/:W8;R3HEH1EQRY#C0NAB..]Q9Y
ME$JZ!-SDVGO'&TGO^C0L=U\JF+*_9?B49H4X')Z8A5K>$%M*D$?Y5J0>$S)Q
M4/TR@G659E#T>C<X[K;?I+P+;7DE V+Z0D#B&M\[_ET@P!YY]WCJS%16Z>K)
M9\J&+$[?^9OU3*U)(KTR?F7;G!=\_KA4G0'BR!\M?#5UM2TJX^C9NP\%/[ R
MH_:5P45YR-8NPP!AL8FR-S1^:0"UA./>S"^][%>O LT*JW][3?)YOS* JJYI
M09Y,*^NDO)!_5^^E>V=#P.P54YN![8HS8^<ZX6N]\J'F?5HAEGX=TF>DIR69
M]"[0)]&^N#$-D.,B&1Z3.8?+#8D\%Q%JZ_%IL9?A29T'+U4Y:U37:@*8UIS)
M'%(,SAMN4F9%JD.&(E+)(8]]+Z"<$(ZP8LIY0J9-JDTWGZNN%J[)S6J$5WJ6
M3<2W&6&N#2].*2XQ*3?[[ZB1GA;R!F6D3!IQ=TBLU#: ]I*LQP^A*%LR BK]
MW9)M.554MNT9Z;^(=V6N=7>7^N,@/0P703JX[R9X5D$B[;XF^TEVW*/YT;Q6
MM:S[ <#) @.XLW5*E<XU8+#CM";]!')<ZOQ)Y@'B5S/UEW4&KF1NE>XN.>(2
MS:>NL9UG%5==?C>UX2)T9Z][/W^ZVZ6+KH3*$8N/IAL9+UO,SN0TE6K-R'#X
M0":NU#5J*FN_)\CHU+TTM#I=<#_(Y/V*2/D4H.5=JI&'"E<\YH!(_]J5H:C
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M/I*FBY_^U]K(B_@9I4IF>]UD^UE&%]=A+$[LPLWG=IJB-[E^YJ[SN@TH:PR
M?;ISYRDZRF]-AF1G>D:&=4K )DIJNB2'M5-2G2)>&G6CX0G$AU-XKH1_?TR+
M[CI,B[0-6C,7ZV5R-03C3J7HS%3EN0*U#T_5D'JM%3F2T$^0\A4F<Q<\LCM"
MDH=470%239D3J\J?;-]7QM-\R>U%9'%K@LN]@?<_R-R9:J.34?EKJKL[$(]_
M&GS7X:7FEQCU6B4=B1!Z[-<3]A9I@9W9W0%2,W!I<LD=D1'2ED+VLNS-%YMX
M8HS8,[!5T[PE":1T%[F\P(=#9G'*W.+E/C:<P+FV6NAKE-::9(1&>DH#?R_N
MA!B;%.-OB\QPV)ZQ1$KW2.U\(+0SU72CX>.Z@W"1)/XAI:TK,,E##UJ=)?(F
M-=!)"/@Q5;^\8-<H[^EO&NKIA(Y[KV-#^4@DKRCTI 2R< ,,&\<,][\W<[#A
M($-.E&\,D# U1,E>KD)$DP*?\ZV-?#+Y\LDC,>(8_+,*@35T'.N\/9JUFN@1
M7Q[!?O.S+1[P7;1GHL.56M7'ENDLF>!=;=1[\VX@F0B4J,.=4LR^&<OY2RL[
M]@G,^+EAKN$HKB+6*Y(V@Z0 GMHLXQE/*-42=$FMA[WW13IU[Z@C,-JOV3(B
MH*:@9>#:+^363M<__\^NTOTWV3Q&4%OHYXZVZ&;S"P/YUS*<$UM3 8)%LT:A
MPB/8K'?%Z&3./!8+T@[Q"!'J:#GZE)M TAL<@R*#B!UF0E3DUW9V">LN_;&^
M^2_Z5N)B/;Y4V3=0I"4Z&(0!@"TQ (+]<C51'G'N\H">H:,H0!8V.=Z=7U)H
MN/>J^UU48.&;K;MRX*.:(KXFX?(],X*6<2D]SX9#>V]%+IYY ,$K9,P*VK/7
M7H8:!5WM2>Y43Q:I\>:O4PD5OEEMC)L8CX^R5AW_9:"UP40(9CBT8%.M(>?^
M$M#+G?DL'0!6N##0+@'W,SA?X12BW_-^F4)3[::D,J8(+1-B /=5A9J@;+&-
MCX/T.!="1@KN\I:$R$\#5T';WO[FND^&[N&V,VF.95FW%7+KOOQHR?OS0QS"
M$&M5O?-#@H\;>(507T80 ^A+S#H[S>HON0W#G4D<9.A&G?A%V:.M_4-8/[IT
M,KP"*^A</T?<8  14B(U$FYL+S@-'BS;M>&UKK_< I:[FZN'Z\8D<Z;\#I"G
M3^8-$]O'N4[=#B(SG=-82:P-N>/ST%5B*STA%LQ'VE$3P/%UL-"'=5YQZFUT
M.GO<$*UD8IB-V,CH#)YL9Q:%C[-1_'F'P<";!#']6%Y<]!YV)ZE?B]TKW8)%
M>$,@X!#-TA>'(C40DJC8?A+=2\<>1;")QK^E#R\"SVRA^^!):T BG^2]3N_+
MPDA/;9;JC_#F,HWC(ZF[8FU'1S-PT#55=$K'S+#RP$PX,)B?A$?,GOVHR$/Z
M$82KXA_N#&86_:O+1.1O72:S52C9KPNSQL,S!NUY$2;O]Z)B2?.M ISU04,,
M#@E7]7ZDGOEPU @'/)WZ-BZ($?;5+G&Z,A/^$'4S<,9:*G'_MYDUZ*T E0]=
M$SX.,_NH<QZ_(VOXZXY*NA6R7BDDU.^0_PRYYAQFT)"5S!:W_^OU2P\2RA"H
M$P80[=O[*< 2%O L6)I-8\P:0NTRSF[59QCSY1W@*SC!++P0%:1%'"#0-&'M
M<A*INJ33%/TC+U8F@X>G(!L(0IHCL--0W(5&:4S*VG9Z%5T=5+''>EXA'W;2
M9P+7H!2O408JH*NVD>2?C*K32J>_+V=H$-IJ*+#VPCT,0(T)O$B5BS3O/&]8
M#G^0W/$D65V<*)H\ZCLWK1A3WVE12:Z47L$IQ4*IQ9H6<*^F P/0'.-C^1[G
MK;C5Y[9>(XY^;X"WUMALMKYV-^W1=TNFI-W/2K-9+F^ 87B<UY ]$8'(&J]+
MZ>:D7RE>SE^CW^(#<%3DVGHTE<?K!>C[85KEACYINA/$9;I45U)XXGK/[A'W
MXFRD;N?BT4>+Y<_:'06)@/MR;T78/!(#^ HW@F, \2S@?7(,X!*_; 0RPU]T
M+3M>T:5(=*+XJ,V]UN.=Z^5T?I$L(N]3^\AO=20&@"4Z7)V+>[-*!\05V;/(
M77:0,7RJ(9O0%*/W+.3#&>?I;=637J%X'O+@TT2$Q&3QOI+%G82%"F#A@ N>
M:J,[IJ!1:L;M7 #VFRJ9K$/XDZ.HBW!=W=5<:A0X_U"\HPZH<6!J[69.U XD
M/6V3QR.=N?E=45,/ I.;E<G_9W)!_[NZ< U,"]YP'V_=6P2?/H&]@U&B6LJ6
MA,;[=)1_SGS% !Q+8;C7%N7#YVO*UPGEZC=]&,"I:!DT)#6P6H8B_H+5O'I$
MDK<_1JWBL?".$09 UBY+<L:"Q6D5*+MLE(_X1(7@>Q-,.L>^A]+5NDFZ#%?@
M77?@'A69X7D:F8-M&4N0#AT-TFLN4#F^?J#LQ=>K&J1U%58I(UKL3+(S+R^[
M$]BZ(-K\U5C=$U$P-TWU8WRGG)Y[G>_5>^[6<Q^_<(54%!L&P))AC&XLO%6_
MP'6-R7+83LTP]+?/RJ.[A[3)6\S7!-T([VAG*=+?>WCC]&NJZ=9T/]Y%"0E&
M,<[XKV$ Q$L^1QWT3N7$Q2$&$/Y?B^TZ;3<;6]E]?2-G%1$"MA&_$WYB +&7
M<0KK(Y0*.*Z**Q'3(B^+:(( V-#5"LL>;V96Y/MJ>RE.;Y!HI5@<U><DZ08_
MR,)8"]^3I+>IX$^G@UW-M::A4W)";\#WW[V9:F;H#N)!0B/>IJC67-T-I^N"
MBEB$$)V,>$D_EGA5-)!>?T%>:_R-#]7:WI "N1;,'<)I%)54H:QVR\COUQN1
M3F-KMBJ,N;9=+=*7!G<>2 D2%[@0Q./1\0G!IU 3YDCF#Z[V[OD[=\ZU7FI,
M"QE>N0[<N(#(6H2V?PW5[J2TVO5(A1$&!PIG9H6OOI[X'1^LR:-^3#:),NCQ
M,X]TW  )"(FO]:;A?+UK<KY>= Z3G<8 -IH-,8!64O0'_19R._J/])G9%8M&
M\/+F+NL'T3.XM8_??=A^C-<"8EMCG%D"HM*<8?S9/J^4D,+8E;^CR#)[2C+$
M>IJR27X$:H'^RC=E#UZ0'6@"KQ1>A\);+[> Z(]3TS[*O31F D_7-![L'ZR%
MNZG6U5F.1L_>J=<*'A@LV?-/A,;+Y-X4%'WD(-!CXS\ET]G3JIE$2ZD[>M/&
M4P@U/J CKF&1D_E)=1!5NIG4-A]ER?BVR8_#&66'?^LO?YD!GO8T1[3L7+YZ
MF]76%"O<A29ERA2<8C.CZ'-.]%CMX670G'8^0',L[[K:.Q>;1=C,WQM^M46W
MPAP"F4,]CVH1F>S7P8N]4;YZ"_-I[6QH#6UZ(V6:;0SO(D);C;&P9TN)L;A7
MGXR\F['*IS+2#GQYF9J%^"9E@ $\TQOYA0%<:[AG,E?/V*!R[U;/,4UGX7:5
MV9B&V^%J[J=[2TV?!-A/1&=:CCL3[]#>CW^R=7-8=\WKWI9BQC=IF8D!=#%8
MU"0F.#N-.;HFI%^&8K\GE9W!&U(C=\(WU^ARSV1#0"-.8;1#:V#BQ#I[59O(
MZ,%8+!W2);SY5 \@M2@QCZOSFC/IR#MWJ!#+*PQ@F7\&(>K\$O6A N5LT@ U
M&667 *D$C8@P/?N]=5@[$:4/C IZ8(BJ57"D4!T_W*JOMV)I>I/(LK6)S9XI
M>/JPY'[Z?HFBZ()MN7UJ4@&L4 %LR96\9+T0)1MWREH^([K"1+\GC_!,BMXF
M='FJLG,S]$-3IFE&W2Q@7,=!\J^=5%3^V1,5_D="]#96C\E./",2(I:  *Q<
ME0G>0405]T)I*:^)MA@OQ_ZW&G_._Y7"-X?V>KCQ-Q':D_]O<\"P3<F?<^V6
M%99\ZQ.)ZV3DK>$:HQ'O*+J3=:OV&8S;CB/,:.?DQR#!RNLZVG)XVB&WM^#H
MS,N+WS6TC(W!\L2CXJ*E9?HO[%1C2[Y7"% G5\%CD0B!Q ( @#<$7%]Q %QM
M %('H[_-&P:\5[K7)\JHCY!3A="NCYA"[CJH<0%NC5+X>M^UHD/#W21GUZ8%
MJC2WXTW-.T5,;K[7I7-[,O//QAT%F ^7->"0S>%?26^Q(LZ&G)_E<0^FJAU]
M'5-O;^"\9D-354[,OM73.,8 6A:R!L6N>;T@O-RJ_?4R.01_YS9)_Q$(_."1
MNT8:4XG>0L928XD4SX.L1ES-3&UINK+PE'\3&JO C=DYWO(]#66>?1 ^BN"=
ML2LOGG;1Y'_8U.O>"R<67J.)Z?)*S2B3L,EDI#%QQ(G9L*J\](!I(M#ACJN+
MU,LOX/TJX3]Z2RMWER/*);B*7P^YS0U6$892:AO^.RE<_CY$&;=57>30=F4M
M$PA?3&;8_?=TK]):?!K@$,R.)<*;$\*;SE*DQ&*L08Q );@V>C5V2;A7<&\;
M!R. V^[KG9PGHR(M]L'"#]V;OHYLZ8S)X3Y1&7_%S<I;O$MKI5OT%4>/(/L5
M  ] ,EG]OP6'C- .I\4N3)#3].HN6"(9PH5UC^@>RWT?EDE7XW:LAUR649GY
ME$23U?_T69I_\ =_\ =_\ ?__1!=9'MV.% B\9T1Z_5W5,JS&IS!,L,*DGM7
MS^))MS04FV/I$_4YKQ_*,&  7Q>A-VA*<(?E:NLE\>QM_+"JM[_U\T.MXMM_
M?4[Y7__87_SW&\<QPRS$9Y0S.L1+]AREC0'@0\,P@.VGEA@ .)1Y./ S@\>_
M_P3E[UDV=Q>I(O[M7<!_5=X?"G\H_*'PA\(?"G\H_*'PA\(?"G\H_*'PA\)_
M$X72-0R 1!B7?C%&M>WF>.K*45>KV;&F=GJB-D^7%S@Z[A*_B.4$X2K^I^<=
M_!^'V-BO\7+8\1J^>#$M/#4[(JTD@^^%JI9(T/T80'>0&;R<1ZB4]SFY)(S"
M9T\142>XJ/5K<9UU#O@% V >1,TD@L T\!O%GR)(Y@RL%1R&9:3E#: ":\/7
MRC;NRV*,NF#_PS2S9CXF,>=2?M:I7X7@HI:K^?G(L+/D9\O#)6.*GOF.8?_H
M@/D?_#<C&Y(>+']&F?CR+CIIW9G,[H=,?\G".^#QL/X)S?&[F5P?_W4IG:IV
MV.L+Y<(Y_F,#I&[?M? IC#[G6W%XH:X'+]#8<'G.P2O"T]J5J8M$",9@!;Z\
M*>D.@*\N4SIDTC;3T'MLOHK[]6PA+V04NC?=$H)(B?+  *AGZ1RA2>ZTS)Z-
MP"^D16?,9YMO'\?GETR1CXUI*U+UL?S3A>9_!#9E6'R^^EAVNJE3@ L6@G87
M_)@/4*0S5"]#TA,-7HJ!(4%2MO%:I/:Z]R.[%_J"D!A IN7\S/$9C#W?QM;M
MA[HP8[P6^[C!J'8^O?9FA!U7#F32XC_LU)(1R_L"Z6;H4V9G3;@NBJ>SZ$VC
MZ,U,FXQ">P &_F6XJ>\LEVWZK^/_&G\J#LV8 "B6;3#+DV6"U0!A$ E&YNK_
MMS@JH3F3!CQC^R\J?19T+)#;B_]Z?"]9$A2A&^"BMG>S^4Q1::!ODTGMVTKP
M8T4 !Z5.CD@,&>5WP38].D[$5YP<V-*V7T4:B'CH=Y:K(U$O65-QK>O>4I&.
MAO1?"S($0_\SX[]4V<[9#C->0LO&.S-"1L_SERSH9@&[[J]/$[3^6N?WPD*1
MCKG:ZE^_D*)HMA+6[XV,N-KQ6M_^8F%NUY#YQ1GG_#?%O*),0$'2D\->HUQ5
MD;-GMZ_B<\>_5"K@\: K%^1>YFN&'-9D3@25L\X8G)\IQU1M *2?Y*W$84+-
M7%T!LZ"TRX%8_N<&^/[VOO_7M[[_\W(Y[2GQ6U,)4WF1^03;^PLGG_M>2KOY
MZSCR=]EJ*U+V_$T3R.'$ OJE +=MJMI)A,EL0L-4:4NC/FSHD[9(1#6YGV?9
MKFKAMV (5\'C_\^&& 41DK:[/4"-_G;\ZURU[#>X18%,GL=>4M4+IXS<!TH^
MC%E%99?_84'_@G]3UG^3[)1>RE3Z9SNX+,^^&-.@&V&B]<;QOENDK9HW]1FH
MC3+HJLGD'K-LK;D '@Z12?7<]$[4R235FC\-D$:JHVR[7+^81#+$L]:9(/!L
MKDEW4B^?WY=CV6 ^6WU;Y,_]\UV?0[LBI<'CX/\+TK/]7XT6/U1I!9-Q#[DQ
MFPTA[C%-)J&GY0429=!J9I*?$=T]^1$G[$E<A!@ *VO'G-/41'IQ848H\,(T
MHR7O5S-C"TU"UMLX8DIMLTKY_T!GX482,I1K7C+P<AF!(M(<6&-4,0!2O[,]
MK3LHVW:)9[LM/$E.AY+/?366%_70;&?%0<0^7F(B]?"+%.$%00@CM)%6*JMK
MZ[B"=$VS]5'].B'\!!_^W1*'-_.N#/):$ZRVEKAI5)I/8U7+Z5Z2MLX/S[Z_
MP\P$X;5><7;Y CPL:KL>>CV!%II='&"9]M!F)'&QBO[XGM23+0[M:B:I:(?P
M</RV#_5"VH8T"9;Y:!Z9C1_DJ)(O5K"F3FP:M(WP3E2>P]@0O1$53;S%TF=E
M]S6/Z*+RVN*"Y0].R[,(?7YZ.!.!C#BV4U6<#A8=:TXV&[EU3_%8T%0].KEJ
MVCH?STRQ@!HHX2Y!G^^=.T4WT6]B5=[&B;&Y]+)<NO%&(H'=KT]ER<SM(W*-
MU6K&WY$,RSMA[4#])E'"& #K\]:S*TYT,'R3618#B#M__=="AVW>^&A:M::5
MZ4^J#MZ7YET8 +'#^9UETU'^@Q]YV(**2?AG[RJ4]PRD;!$PS8:)_$F1>Z'P
M23OS/H7/OYA<I$D+Q&#WI7EW, "<:MA*-%,%_HG,P)?%G1A9M;+G03#[":]C
MO.P3/$W2NQ!XL2-ZNOEG=*M= NU.=$_)3 %<$3>0&[%AEG7'/LOYET;X8-_6
MX,A@5D<37J<$+RJDR\OH+7:-O:R/W%61N.6%0;%/5L].3L#S<9$K]^^:$Y,*
M+A$36P#P>J[SGHE8UZY1NO="LLLR>8#LS8>U*RB_*\@7'4>"A\WYR[QM"\%:
M3W!)NE;QX0:^^K#I@_>"(5#ZR4F][*<@$S35R2;H8^D!-^]A6'"C #;JSE%W
MU4V!P9-+*T?X+Z#OR/DKL-G4CQT)CX86F'VA KKJEUX4\,69[/M^&!CIN!!T
M#^6%M+<<$,R9-XZ;4G=MW)N\L7\+4GOR\>F;GT/+/I'M,H#8V1T)'?/E+E>V
M*/+"L3R6DWU>L0#'!AQP%V39R0\?JC705!3_XW4$>_I?UOOEMT3T$NP'G__A
MAS48 >HFM>=*+5ARO$G!!=(='@B-P@#8S$!(WDYZ<.@9BF4BH#MXC?2I9<U!
MN"LM7H58A=+<&DC]<X7CAN 0!9ZR68FR@JERS+6NX]I\^9-CRGCQ-3B99E2=
MZ47_G'M?OTBV_'A)/;"AHY=#D1*@"B!*:&.&3PN#.X+()Z6,BP-31WU=E'^<
M$PE50G<#<?VL%V3NHD#T"J)%DYZFV=]VV6.O3HZ_W@3!)^S\ FL_2 '&*779
MG_Q:6VW=ROL\@B*XF$-?KNNV9EX>#(Y(IGC)%-2Q+CUT-E8,8C_T<P]PK",*
M*+^+J]GV0Q7XM;R<8DTK/$!7R'[N5PIQ4U5&D0TAWPNM>B#W)=IS]52_JGT<
MI&@Q>P:$!!&,BQ R.&JI?YK_8G.<>5]5H5V<;F?BK"2+,$#+L="AID$J5;$I
MP?2'GK,23G'<Z(:;V+ZB#2JD9Q"&8G@Q[D2M6V2D1A2?U;"+!=B:P=&W?8\!
M; 2,R>YM@-ETB@=GQ2:G2B.S=\QOX]D-PGSPS"!X6W0MZ2"+02]+>5SOU7>&
M @!6O.;<ZNER:!#/Y-O71N.2SYV4YZSFEL_[^H$Q/"Y); 3X_?,NQHRF5..@
M)1PD7CA_RP38AK@6J4%XI'=Y3C4T8V5+Q]N]8*%H,B&2=F.#,+*?CE\85O)2
MDB#5\<,Z!%5"5_$@F4(_DEW3K7BU^F72";Y,?11)^,9(134*0A/,-(D$FRKU
M?2)E#E#VP]Y6V4'-R.K1<=^6> <R-2[UM&QOI/;%1&$=7;M+G?R99;<9$B]8
M%$I\\T% 1_QA\P(;Y([I!Q,KCZTCDL0,%6ZWY9?B [PUE2C=M<99G)YIAC>=
M#VQ30$$*8M<@MBYFHAFIQ\4/\^VH\23U[=+\;">DH=/QY1HM>APN]1\4J9IS
M?02Z)'Y/5TX\?%RKFL_ =CUBWBGJ%@]IRGC?GE,K*H#O,.?]23.,Y:E!NUZ-
M\9T%LJQC4!#PHPQ/,JE@3G7$MWO16UO(-M;LZ4+*-/_087+(U(R4> G*;<?Q
M3%TI-"OQ79@!<Y>^GI&#VO8=R.BXAX:6:<.3.>OT6B&LY%DQ[5W5E2#1:5@[
M!D!%>TY91=S;9[MU\4JSC.6 \XT8SRQBN!XO_,S"WS5_WH'K/BQ);(4QI,[%
MQ>?T2&-&2KC,Q\T:^JK*1^&F7^98=BP<&&J5F62VO[[X6.;+C #%2Y2SOS]C
MD)&)?3F7UF'8B_4SV)=&@[$9X+&*["%1ZR67P;!T:22@+*^I*[@V@'\M#4;@
M0+YD9#P_/-Z[636,3]LG#85;:)N.0^*_S]I.F!$AF5HC/:@F<4OD>>IC#,-_
M4(5G]RJDS^"O:T6<4],WHZ,+[6OF'_P0$&E+YF2,Q=-LWC->J;V&>(//4,N7
M!#.)J'6T<@8(W9+:-"#"LC? ;_<QN0"72C0_8^BL8W[.>-!5V$,EME+V?46.
M5M@2:\W8([CQ+&MUV!(;+WL5\0:I17J0Z/9 GF7>YV$ER/:IP!U4>)>V[_03
MCC<'(EN#2I<4,XAR)O556XC'O&W=%9\!5PB[<7]])?H02S:4TR@UH$)MU3T2
MIHZR6)OW)WXV\MR1?G;0_6&[7[IJ/^>OO@VO=2;>H=M@ #[F0XA6;F9 MR@?
MBXJNY&L4$!VAQ?JO,JBEP)3E6>V@WM)9F:=LJ@_#/N5G1&7K*:G*"@ ,. NN
M>9'ZV00#TW%S;&ZX/]*,T1=T;,@R%_@# C(W+PP@G'QV;;LBTASQI'6U"+<G
MVTYF6)-HM.9,]^BV_4N::B=:P6A<,Y,0X<_&1?VO+N"TK/6IB[H#P7H+7QDW
M*T<OW?6"^+;]-",KC, VRHS$4HH%M=#W=6+$,3^WH X=B.6P:UVP*]-T!,B;
M;/M14I0Z]#Q&2#K,09;&SJ@BI)3=;VA\87&$-K$NMK['-5AKO'X2#!X:.28I
MS+GF0"K"NR*^1K,NX:]_K&^,!/1'!:Y&)8R83'/VY&A%\H5IXL:O@-N62@.8
M;BWO"@8P4Y;U0Q_:W2QS\@HY%)H?79U"0_JVT3+:+>@*K;!4N1DEZ.=%HSM8
M5'%X*RB\R<!;08G^=D\Y*ZL7 -F"'Q& S!@\Z3,2%!D8^4H4V(!O92MXJT2+
M^^>$%.HCS=81@QT-N.<A;YOK)PX.#VUM7YM9DQC@1!'=+ D>#?GXX'X"D&O)
M\58C9D*:'#V@-^FU?IY-N5N^UG9ZX1/%EVO?NY53J7]MWGV+:ND85$<ZY5L7
M?GM2J?X1L.6,S8MBA'94\DSG6S_Z4KSX6G-@?'Y@K)&[CYT9-"4##!",LZZ=
MAD\"'K$'CYYD*8&WH"/CZ;L]22(;&,#*AXUX17:!*L.E)SU>#;%@(VN_K2X@
MED^X&3+@_#(P1_4=4JFD1\],KGUE)@V4>C=W=7#J^^2J8:$5.:X!\7&\LO:I
MR(Y^Z/.RLWT:8:[B<OY'SH<Z<^/XG!G#U&*3WX%M!K8@1$*WMV!I<S.\1<EK
M\/&"+%9J_>1'F5M%X,!;/"W#[)/VO!84F2$[]$')2-WKY [41?S:U00N-BQL
M$%F'2Y6?[P,VF%YV2BLT,3D)[LOBNJQ<"?+,79/%=5BB#A[64.@7\.K6$?M<
MB6,9TMOJH)GWJMZYB'&3ZJ= !P9 @0%8M61S5#_.>1#;S5Z78(>3*<DL8<!I
M;^\*]F2"YY%K287C,X*2+4]S1!_P'C>_#X,<'K20^93X!/1"QK%K'["G_1K)
M;F/1=X(ACKHN^8BE>S*M/]R]Y4F.R[SB?OFJY#2M*IXP'4ZI;10U-GH64<UD
MLZQ;&R/.\3Z>7#M)G';K!/;UFG!->^T %U;P'8*?\[F3M9!'!;!A.SLSY+F/
MQIU4#FVA,-E3I'ZQ2$=@2\<P=>]RA7ZU5U<'8@_R)Q_V7[_[T0,#(%<N4<J3
M#PCQ9L2G!"BO/09+G*1>*O0:/3?C04@-.8;'W3<U?GPH-RQ[7P66MHOP%-_Y
M>5A-3W ._4A/,QL@\#!7@E0(K3%P;X=^0^"7&Y@':<KP(L5HNNQT5GG$E>O%
M)<D6@D[T-":CQ$A^C6TUDIV0*1HB"9 Y5 '<^F*BF3+."7%^UQ^'.=> 7=S5
MICI;\E43!_/G#-:I+]V>PA ?MDG]D&\>"YI%()/G!Y")PHYMJ6,D7NOLU$S^
M2.AXTV%-1X=@7KI?-"Z53:=F\]2CZ>F.:>,O\[%QC[1F9@VLG1&1W>[*S6O5
MX;RQ,%GQTQ7Z.4\+THA9$G+(CF@K%@K:B:@^K\$MG[0N^-#495XA#OQ4X91N
M3?<OII6W;#R( 95K6&/\Z1W.XV]$T6YHL]5]"72BFFOPK;4K7 62M:^6OUPT
ML=>_#/Y&&!%T[%_,\AY,\'OY4X)O*[$H72PEN2*%Y2B-&>^  )K2IZ2',\DQ
MN^'Y@?,C0ZBU&$P7>5D5P-NDCVLH?X\EZKYWON]LN*:>!9?D'OJ9[?"D?A@T
MQT'B9N?[!']TU^K3)"(:PEC\#:BVZ0LP?L#+M_:VZI(^8^J"OB?O\;Y57.A]
M9,K;%P[+2;SS@])-M:UB>'[5(+)"[F$'UVTL(%VH??U=TY/MKYH_:LP*0W/5
MC'G:O;,9YS\T._14;! C[X['PPGIK:4:0H5WGF?23?9D!8S17<-C+QQCL4;H
MKKD0O=?1?LHW08I_):I*A8ARM[3Y80 ].<JA[]ZS8_L(20?IPPAA[JB9V\ #
M#KT)(KW!*NWD)2)%O$QN5_2@IPD.D%\3NUZ4Z6Z"7AQQSX9O:YEWU'*@Y->*
MUHF*;1_TJ)5=A^STE6\:I9NFQQZZ>.@-J:NUCAW13VC#D^<\MZQ"BL[PLIG7
M\L=$)#& ^[OVA3MC^)P6"0GO2R3B WDUK9U V[BTJ\EOGVLWA2JMD:FVG:U]
M,5="N;=-HVD14XO5M%G:#1^2[4<8/A=W0!7O-D&T0I?X:FM]K2H_L=N]AF8V
M 81 J9F/TN<-X*WWZWO'%)WMS(AGFI2>[DSSC6XQ!X1;@;_LH6P:K#FH?"6Q
M0A2]$P(>(%]I.ZL<<$BZ:7-NR:1'&="!"\WLO:'V8$>.YH[ [0T3(+KNO#C4
M4&O5^PZ<B^$SJ2Y$+4!K<XCQ\_ T,32[E.ZTH'F-6* ]B+$F>4=J^EZE_#WL
M@#RL"__4DQ[4C&M"K1P<^YM0%J)"H:?E44KW98/IYU1"GUQ\2H[OM?7B9YP7
M!+\:#8@9&2F=M4WCX\[XC#XG=*B7!Z8^/K#^#>.M\7+J 0T:K)OVO*KYX*#L
MPB&[:A8*P@#8:P2NL*$W5.8BL$6@6B_^L_2+^N0?Y#)?$!C I],C6A\__U*N
M+AU<N\W0MD4&R_FB4]%59C(D56OHF7)=_;CC&4#N)7O/=I_TJU@7,$%">]"C
MA Z)LEIF=1-C+;H8.P7'Q6WW7=ER]PD)57>VGC2R]*H*]VJ*MHI40VL\L9L4
MB]E+MK7GP>9A#1_?OY%XWN9G/=WB#LN18<$ ^OD;,8"*QQC MKJ99$Z +/)A
M*Z"NNO+X8-;:NLZ9WW@G4VOS]9M\6ATGS;D(QB&JGPZMA-?:^<;]+HYOZR&/
MU1E\GS[!"VP"#M3-'7Y<%_5IC.+Z>D<3T"\=ZD5OW@FDW(WEVWM;,U9S[ZG
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MHEQ8D9P'X'%G5AMNT\8?VAZ3D^%J0\#>US,942Y]RS'>K9Z&]_CR;;**EEA
M8D4US6)^IV=R]D-IKP<JR1Q26AQO'4?UZIQ3B"9=K%XI!8W;&#H9H\&IW8T4
MW=_'E\VAP-JNA68#Z/<.BYQ[+D4I2][<3S7UIDY(R @K2=HO:Y(L8CF\<0E]
MYXZW#-X-(/F/(B[WDK$)AI-!XL4[+<:Y)?/*T#=55I.2#9+V>%/3\%LW@,'S
M/ AB\%JYMGCR?<H>^WP;!*EA0[Q]FG'DN.WO]SNM?GE";  (+2KTQX'1M5D
MNU(D!Q^\ ,< IXJQIM07"'LT_%JNQ>0JJ/$ZW)K;$BPALJ&FKKZGQJ8!-C&Q
M8<1P:042N69;+ZT"SM68F8.5R==LQ$;94KV>*N1)\J][6)^C J\5C7 #+9$M
M!$N?8=^[PG=K<1)3.8>2:ZJ$MHK]5P>5U=8%Y/V;'%"9*5]!\YNT@@^\[C)Z
MH\XFZ4XY'#.<"+[*&T!]9=SYGE%>=E@H.9/<\WX)XXR(#I9=&9[W5B_8&VI&
M[O2>GS=O.K! Y ^M\,"@U;/(><:99KY"SZBL0-?/QY(!(4]Y,FHCU"3_/)M
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M:XF@')J(=?!/Y )_<M@SUE8X24A3N<W[:X;ZQ&X(K1/E>1BP>U']8(XF:(3
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MIC3-?-9+ZJ8\Y58/0"\N+G&9I&P^-;RMVD\X8)W-*_&AUR@\OCRB9#+(''4
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M/O^&,E@%O#<PVW> )'F9P<"QTX> X \#=B<X$*D3?8)AG=-X7]_@$17[R_>
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M,3I=<XNOJK;RC%Q[@,Y*SM6B,)PM9)JX7@RD9\R>2.C\L\&I"[?>O %46&V
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MS"Y$P"K'XE\?K(-T)T_*;O'[W0""@ %I-/^ _ /R#\@_(/^ _ /R#\@_(/^
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M.[RHO6/^>TJ36W.5[ [U-C2^P:;N!EIQW5O>Q,+'?O06OP,P*MND+7X.^,&
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MUDZ+F/O^O V:?.^VUGOONL*FG*8\67/20"0HA>W'_XLM);TV)N9G!?3-41_
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MW\RRV]&8G>>6W@53LL?/@0(K62>8N]H!A@Y'@JM6E@01" K\!*3XHFH<] 9
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M_BBR>=W9BX,#ML1L&B>^RJ:"N0YNGU-A4T1,INK4*+92_^QYAWLIX$1#IH-
MVV^N!,74);%;V+HH+&L[P_0/&Q54\_0S@Z7\J!M%01#8:5*M$S.O/'4&?E!
MFZ3 Q>"!U"O<>6^LR42A+DNM>-P:Z7-4"5U)[@_H07@.EU=T ;:[$(6^CSRL
M")E62W>U"[\'&LCND^5=-:0I_8;U8+\-T?$VLMSY[=\"WP#I2(<WG2DOW23(
MED5X"KG8X [\2#S^Y> _460 JYRY<1=*'5F8+ ZBFV[K?=>S&] 90PQU"@\_
M#=R9!^XG4EC]Z#ZLI-):R(//9X"#-:^)^A+K""/*3'5A=T56AX):#+]Z6T0W
MN]5*QZTSK:G,L.!I#>[I93VL2Q":W*IK_*9$]QL=78I$1?+EDMZ^>40(BW(6
M.WFPS([PE\PO1 ]7806U+:+F,5MM:\['H-/@T?[)KC:Y=/A\/,*94$O%#9.R
M\ K%34-P7PM- ?#SOS]D^_\&:YNLDT!)Z(UNM!5_V59#8F%"\"7G3' 7=5S;
M^XOK"[@BDK"JS>:+#\?N-EZ.R3;8\PZDZ>!E?A&BM$^RVU@#E$ZK[>#T'<F=
MB&?@ B_3U+=[)7@AJRIKI0,(@8&6 U=B5_+H5P053;W<9.*&*;!0A- NSAO
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M75F<5?3OK2H$9OO4X7'=,)ACO5 BK5OHY:SW0ZES58RNP(2P]!KU'>.509,
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M:A3@DDA,J:.MA54J8Z2)0'OM=YAHKU-6QO4'!W5\B6 [)\J^AA:IJ=Y+?9Y
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M ,PEA^[:?M%,<BIP-)=W$-]2'143[(95@_:CY^;5A8K"&K<O]*4+- ?-!_"
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M\;56(+K'5T2&E?>IR_U4+AUV,@R6M#A'[JC#I/'O2#Y&7 UU6Z<:*2M(8OE
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MS)T]*3UAM)_;RTT;SEQ$BD@O/QT<X"7Y!J)O0DN3AFX^/-$V>(V'@H*KFKE
M6'>&O'J.1R1><*#3NJ2\FGM&L()CR77OTL _P/V??!GIWS=&!<1(+ 0+JO-T
MRZ./HEZJ,M<7:7;M[AQFWHSQ5WSH7,6=@TQO-\<M[ZN4F;[^C3$FMU_7XC[J
MM2:1J/+!\<4008#%MK+#9QM"I!OUDF3=PF(9OE(9=.@@DQC;OMA/*L2BDA$M
M_X#^CC8'[-%2F8WPBS!N6PVA>3K/9.628JK(6/9@VQ5M3A3'=$@;8C7+@U[V
MREH:O2OAXCI7MFH9$N>N W(4#KL':G5)P:+BT*,20WIZLUE=A?[JLJY$Z<)2
MK;OJ4@]KU&<*&U$--S[=4$IS8)='2;ZY191[TK Y1=E7=O43:[I^B'_N&]ZW
MPQA=:@UB]%V#XU1M@HL0DA:M"MLMG ^<:-2.$]^C F_5</Z,,0VR4=?ZL^81
M>B:SDX7^LBO,+O]6G1NIQ\R$_QP*M^GI2["M!5W.PGXU:Y,F ?1T%4??4(V=
MIR(Z% H:@)R<^X\&5O>\FSM'Y[SKC\N;E8JUR=<.>N'H.&4!#,1T_=#F2XI@
M_*\*4GBX?-A*.YXV2LD[O.M1[(>S<3@3*F4PH4_%5#4?'2G5$@J!]?OUP)L)
M9)@>J%\8ASE>MB7I.U0*_ZO<?Z[N(, TK/<N0!:S&%0*@M9AD*33G61J]."0
M?DVE1E2:>G"&!/0G=5V@]M0$=Q]O35_!IE)SPK;ID(F9#!T_(8G,IT,?M=)]
M'=Y@EKX:[,R)!2-V9G+'I!_07T)W3WB!T [5VB9H\_Q2WJIIIO"^R>][^N_M
M6IR%!<O.,1:(8C@W2SJ3=6V2_?+0QX)<S"RK%+7A]WEQG"'+CK7%1P7U/A00
M=YCT3YZ>6<DQ"!J^ )5<4.FY= (3DQ_GJ^;,0+)G_F+2MZR^"4H;]&$\7P(Q
M]:+D&PK7-*BB;/$S*HD[K[:<(AQX\59N]+9.OJCRU!+9:XC*B4Q69^NZB]7G
M$"=[=F$?KYT4WO+W*607&+Z$P^(D.X1 _"40&-/Z%X4M[))?;(/Z+W=;XBT<
ML-6^OE78/C[;)ER+,E\2J"BI:I6! Q0ZJ(_!!'! 2@Y4Y[3PDFE7+$R4-0 K
M*GDN(E*D(I[&L1FA^XT3' BCB2VJS,F+-PK?<@Z28NZY0FQUWH #@=P4.,L'
MBP7Y>;W<"E1A,Y%?A<RD3^=E Z&5:G3E(;\T7!VQG3ZQSI[_OK^<VA&0]HGN
M73*]>PJMH-U2W8_TMA*^T:'@???F_C JRM>2&\90&V/]@SKDP!2+LT\LD@SM
M-"8K6*5ARK#N'C,K?R1Y5@/C)TNN$0B9K,1SW4D1*[L\ K9MSKOY>WY47[5E
M_Q'<^2IBP_0Y@J,A.^.^(XT*MG%PU'=UA.D9S>K03'5;[FVCI\$!#W'^952E
M/VU4?-K&VF^VM5!0IXF+)?*+UR([-;NE66MM1ZOQ<A6O'.HF&75QR8V*!S#6
M4)K@ #:XIU1OTD>\]6/E%4DW'/B<3VU-<6VR! =\B6=,ZZ9XZ)H3W)4:FJ6J
MHBI_( #W. "%7W&=+2^9L6S+5(78C.ZSGELV<9!I%'["2VC1.(C1Y9$BTM&/
MG7HB47NM"P?"-:-J%;XZ8JP><V[!@;;S'C#J"_"ZZ_0<8?7R3<W&3&]ZH5TY
M8BVK=_XR2_<WYI*U#WKX_B4%3=E:!Q:\CP5X;@8G#3"V=2>Q5R=I5S\\ONAQ
M@U,?-0=H4=&>M?YS.J?R[]D"X>)8O'N1A OE-*T*,PA_Q0\[\41\95RQ[5!(
MXN_I<:7]B>EH@M++<"K)H&*BVY"_!%'K)F\/]=3Q KN[1I6*QYF9:56^N#>?
M/[5$2S$1%QOU *_)"U<;RYG^+"9J22^&_.((>1U^\F[JX;MRA=X5SN8.]<ZX
M_L.<O92K9&[ ;[[J;?9]4;I(S;\1"P?8M#G:TGT,J"G;+Z?E&W^R"PPPOMDE
M&I7+M_A&Q<22,:(35^=]Z);@:??JTP%1Z\AQO#]AG[;;[F3;IX@52-[L@&YA
M:GMPY;SEJFFJ%9?NH+TG>LEUE&(7_1DPC(Y-[AB MJ?$D[]!@F&WU.VU73>D
M+T4]M-.C&]_($.[HWW85?=_(;-V84Z 5_HG7PDWX8$EIA@[$E$%+SK^Z.HHO
MWOEB ?W@ Y:4V^=8G5^&Y*76OE2@_;L_P[9X23U7B:MH-#_"=3\-IE"C+D?/
M[S%-S^"A8$M&)?IQ#![*;1?^,)EO-R21-T[W,LN:U6]^$<N?VMV3@D8SJ7U
MA4:NF3K#*CDP0=*VA!O2:<_V-X:3DTE3;O)T RI=;95\%YQ^/NITM;_+I,M8
M?>O0&[82JW9S73$9\=.(1*-*ZVQ)A$N/V+7,*S.E5,D0-_%%P.1>+X?3V^%X
M_^])RA_],+80)7H-&J%/E47+*Z]_%95]2JE\&0-+W*6B8$HRS/RP62]1^2&G
M&&+J/2^@^.'/%1^Q?G')L*NAV_OVY)5%IXWXV+A?X;>-W:6!_8Y+!87!OUV:
MM@PN<?1UY>SA@.Y(E 1Y?X)(M&VF- 9524ZP^G,>#A "&FK%H]ZWWQ ,+9Z3
M)<-_YV:.S6+3A@F6BE^3YM.+JU=$4;Q;X7CJO_4492B]H,Z!LT4/@I&*(*9]
MEV,2[:D$.8(,E6L"Y9?J42?V\3* VZ@"[/TJ2<>K/"Y]G24F?4G)U1/\\[@%
M[$^:<=%1Y@6.7[X1ZW2;N0YLILG+\-&;5$UJIR[^/>I#>H-@'%4OZ"A.3+"*
M.:U_I5T[3G"(C_UY>Q61.@,W,;%F1/6+MSE2G>U>*O^$S2*2K[<O<^R.G*,G
MZ[59)YD?X/@78/H4 3#%)D\I-\-FHD>\/B=/Z,CQI0DU<W-*[_L=H%)).F"1
M M*>%7\B@"T>!=&G.;6_)DVS=FS4@@G^N'$]V12LBDXE&*Z7HQXQ5Q3';8C]
MUYGN2[,&EPHU]BGT]S=+638[S3J3[K\;X\<\SAXL5U]-;ZW5Y<<.J)WLVN^A
MB04[BN+ ZE,VRA''NHXKWJ?JS1%@$1)*.S>RT2406#PP?8",_-:O"-[8 UVG
M1J\C8V:CLX)A#T]XX>4>H@=@W-7%_3<$#1H&S:):PX!;XA)25CYC$ADI4X*F
MD]M]RL'V=6[IHFJ^_'6\TT1=6Z+7^Z.TR476AA6RX^1JTAQM;C)6".PD:S3!
M$RL%'X*J:=>X;BA1:K! G/EKK+R$L\]K26N'YH[@OO^B7$%TE/M1<'%,K G9
MFO !A7%4LE8]AU8']^(7">NIYI/\5GSGZ@/3U/N6!&]04_G$;PV<7TF@ \^E
MX[LY]5PKLS,!%CLJD/>]+@T4,W B90;+^,:M_-/0+'>3G0[3(:I6'=-7GT+[
MYL-5ODNU.W(I3:[DJ+UDS@(&1H]P_26^J;EF7Z_+,R^N+KP1?=V)O,BX+BT3
M$]+ VVEBV^DY-WG:WA;0&)H<M4@8__HU:A$/>5*)5,GB3SQBAEQ[5@^*TX^;
M)5E[WC&6DWG0@T@GNWB;5#862-PF5M;WRCD:BC^_$QS=A0^JD@3NAP?A0-;E
M<F_H$\VJ<#)Y<O.RJ)/7ZS _=+%UN=IG98G!UTT!8YJK6P%@Q)_9CF4>.=-H
M_:YP4!]ZM6'1Z5-[9F>C[@:6_R:%F3N@M,L=T>96UW']Q3?6O6Z5:7(#-1G]
M'N; +S$Y1/":=#,T\SP#:T?'JUSSH-ULIFU/NG#PH6/]FXRQ%*ZF0-S_9%]R
MY.94L6G&AWO6;=9)/YQ627"&[455JNC!F,2M$A%2HA8<P*#B92FW#)2WI64I
MC [V:R?@Z&V3QPE"+Q)QD-L588 #.)<K.'UCXW*S+F[3&G>?>WX/439HZ(?(
MA2,(WD] 2U8TNYW6) KV=5SSMT;^=GT=V;*E1?,D?-AEZF-_UBDK_X0>%07S
MSREJOKQ"]V[M$LE^LGPQCR*.BY6::+B:?'#@3=+N)&M9[3U:1KF.D W+R$BP
MOKGC7V,_H4N1(B3O'C#L,AL\KP*^^)+4HBMRDEBF=4B,._=$E:8<=$#YDGR6
MO_.] +M3KC!8YWCP57YX)Q+-;*(<;5'\CB;G^U)8XS #A0GT*=/4>5X ];([
MZWZG^?3ETB?NP3J&K17>0H861JR792@S#RA,8ZWLFVHULW4$S#0PWIHKK85O
MT(8/Y]@W^'A'[!)D=:T.DBW&X9)4,9WHK\JD8W#A0!);V^%=W1E?V<PMN!RO
M?;>4)B>"Z>V;?S)K O6IDW?-Q'W)?JM]+6:A_ 0JL1MBQU@;8J$?-+"/A.5R
MZM&\+>>LL9H'NJN?#A'%$)D^5?&\MJSU7N!)>[DH:[)S-X/*BOI0*_$(%8R%
MD-\43"9LFW_V='QSI;96F)7X*'I</UW=%G*DA&MZO21K&&]"P2L#_D4H<%TA
M/?4)E$'=H_\JOMY3P/O]TY&JZ2;U8S\RN%/*!7*\D]QWJ"1;P6Q7LS.0(=X_
MM'#"WW4Z4,9&M,H64E'6JJ62^EK=VGI&8OCC0^4VI<']WF3. 6.\PTVBQB.Z
MQ>I4OMC9C#4<0)J>AA:TD'=D@W13E.I*D%O"L'\4D'+&+\59V[4;02EB7:W9
M2/6&">8'9W=%;=Q9!]_$_T@24'8<I.8_U3^$ VA88;;@33CPAX\YMW1>KY\=
M#K1KE7Y+.C'[*:++\DW=6D2CV*?.ZLJ+%%J4%_.<=\"!#=$)PTUEA0\*]O)+
M1,84U[.OGNI*C2$L!&I(1X)UT5TB.8T:8LG.^E^@=>N5]-QMW-P[GZ>>IP,A
M&'<@/\9D#3>2RB1Z8($(%?62L'"BZO_YV):F6-%-M\*4#ZC P\D-#GSJD':U
M@?ZXSW[69B%(^Z<ZJOF"Y45,M6FW+%II\L[9SY_Y5WV6]%G)^:AOM"$8U\%>
M7+8B[FOE.4OK\I-Y +"!"M!&?<L&(56D?/5T;?\<FYQW4%7X9H2&7C]COF1L
M2@6PKZ//,@.9\#'=N,^0/" 3^V11J'U*$\0>_Z1751-_QK#=-O3*X(45!31.
M_^":Q1&_N'#1X&V!%0J0SNFSEX<0%QQQ0B8%N$W_:Z-,^;%BZ3AG?#SV6%J,
M:W"9SV:,S[B":]5/X%G+KBV![2R(P6E/25>7*<.+WTY3Z,>\OK0+S8"K6['*
M#%"Z\VNHP*UK](\*<A"QF[N_8D?T'7>,GW:>&)9EN'7PH]^1JV]#4]>]NE^N
MPH')9@8U=;J7(IE/&6#$8H,LB57$286L>19BYOZ\_7TB(T'=X7":_D;D5Z>'
M)-WX-4L6I;1S#SXKLG.JL2<I OWK[&*O%LIH5=5I#N3=3J\C%(Z7&I]9*^C?
MM_N<":[@P#R6([=W7[1[O$M\ D8IG[8:V?/:>T.&)5IK[6RY!@VRTK@KGUMZ
M%S!E.M6373T$[32OI(RQ+C!%S]="S/L:P,^S*\H\^7[2)5JZ;W)9SKRXA^57
M4A:%*0TT^JE/";7><0H/CRQ%<(5,KJ]L4]5N$M0.@P,\-Y4B>S<@B$%(I=%D
M[6$+JF!>NR[FH54:>@:?N<BX"/^H5[G/?:X/%4R]HLE8&$)H%.%BGDR2M.KW
M1DY?,&;FL&/^&U4]'(@5PY.CB@GW-B?-*CGFP3U03[@>:_5%9S9K"YKM$!LD
M8U,)U-9\(OSK*IQV3-[G)M8#9; ?)RJ# WQ];FO?IJ0Z5." <$$"BE@@"D4Y
MVP--<W[' ]A#34WIJEQ?R/^.72S?_M5DP2G^%#\YN9)9UBBX._YY6;W(^S"6
MX5B\'_J4?KJE_KRXY)CN- 4VK=NL.]M)TE0B>VO&$Z@"5L]FZ<R=]PYPH9S.
M@9/-CIOE:)A+314V!O<-R0F]L;TI%.5F-Y5]F7BU$T;MC?(B5A3\5+UOI3A4
M)7:189,M]&:Z=;BE[1[E4S5@[\]9Q;.)VU%Z"SO@E\+JE<O<[22_VZ<VC?1W
MJ'W?#H#$?#6ML:Z;KBM!]VPQ1$TSM32$3R1H2N?)3>,H'G-_5BEAN&XZYJ'X
M0WO2D\QKYN$.P&[2;IN7NHMQS2>MDI.ZES29UW*'U]C"/)^P$BJB=E"R-B7E
M;,%R!N+-UF!M2Y2D31S,T[?S >"6?*C8&:TKKB;=[.ZBV TZ>"#FRW,*.]_.
MPA0(N?$_T?RD],08^,LC>U.4TX%K;(7WC7513FS%EV.*!Q2Q+=*B';$-<MA;
M=I9-H5;,06, #BPH4$"CK8,2GKBG'P.60+&/!=:%_^4%U&!7KHPGSME!NAN-
M9? QH]+-1]8A6WL"#[^[+,%W<*#V\)\/:)S=YSY)#,5\O>&9!WQ4(,+>^O1/
M<G)PX*7JVW./V!YSLHY:+? [/2E<7[>.\V\O!52&G^<1RPKD?/B-TCG*9S$]
MZ^]D+.+^ FT=F>V@P+!5(ABF/C4A,^=(,=:=1-KQ0"G(NE+.6[;:4@>* </N
MU*!PH#L/F+V.$B%1:12[5VWVHK^[HGOZ)G]J.$S>S_Z-PN/KV:)+;(Q_Q8[8
MZ&'O)45P.W\C#+TY(R8)+_OM;?) 0]AG<8KOB"!A1P.9";U&YE."(-O"4?!.
MRZ-<$O] <;Z<-V^2]?M<Q"ZO";8LG*JOE3$.,H2CH)R(,Y.3I;IHQ CZ/-2T
M\2(]!=@K)@)8TO<[RR;3%$6J=U2DCFBJ>0W\NY2QLVU$V-3B\24Y])WJA(A-
M;6[#/1,'U2LWYO=$JK(#S?);#B:.T='?B0: &"6O4(78_@1K_,K2T>S>0FFM
MD60J-9HLAE>BCGY<@3?*J-K_Y!VZ>3KTM3??%Z/;TI@UB9W#3]AE+7UZ.VGN
M,5^XNBBCDA7/'R0O%@33[OR>BR>3$P];HO$0U?TA0#HG ,$C?W?3@IE,>*N1
M'/EZL^&'?,<3?S:XL[0"1G;9<;7J;]C6/O7,EW9]?6NL*AGS_1OI<P+028IC
M6_L>?88X.P+W6+(6BA.&?HJ <E<6AD_V=2GCX(>4'V_EN.^N12B!$EQT@!W(
M?PYE_Z4(7S:.+</=3CIM',"3H-'@4-)-F:Z106;!^-8A(6'/@R"DCF14K(=W
M#G^JB;8SWC3%:J"PB!F<X77]0%,C(1;OF:LOP\M53Q!C')MM\Y3D--Z]J!>\
MI ?28?PD 6S%95\N8B%!2\LM;:Y?.US!N/>O3>A?8_TZU)ZZ*M;Q@@-Z%P_1
MA5'E.JL+##I#QRV+BP?EOG8S,[-S9LHPL[A"@K?#5JLI[,(>#[*]%B"K5-\=
MT5%?6UYO&<:&,^[X?3?E925'TG>TZ=C4*&*\OLUF-310MT3:[_4[5".[5)9
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M$>SQWH,$#IC@KAW;.MKW!F)0' >9R.P,<?6!6_;E,6O*QJ9H&'+D:03.U=E
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MW&*SECDZ%Q790<PHJ.^3[<D\C%:'5D_TC%X$[(Y@\Q(F<SS"HDSPQBG/F*C
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MK&J<?VG=!7*WWY&U9>__30:B 0!02P,$%     @ 8X)\6&K&N-F 2   5E,
M !(   !I;6<R,C(T-S<X-SA?."YJ<&?LNV54G,W2*#H$"$FP0'#7$-S= @0/
M[@SN PP$=T@@0/  P5T&'QP&)\$)[C"XNPSNW+S[V^>[[][KK+N^<\^YZ_[Y
M>E;]J*?KZ:KJI[JK:KKK:?9I!?!:049>!H"$A 0P^?,#/,T#I  OGC]'>X[Z
M @T-[>7+%Z\P\# QT-$QB''?8..1DU!2D).0D5'1L3%0T;#0DI&]XV=DX>#D
MX>&A9! 4%> 28>/FX?IK$*27+U]BH&,086(2<5&347/]+[>GGP"<%X"?SUB0
MD6@ SW"0D'&0GKH E   $BK2/QK@GPWI&3(*ZG.T%R]?H?\AJ'L->(:$C/P,
M!1D5%07E3Z_?GWX "@XJ+C6GQ/,W:J9H-$YX7%]B<U[02E;]PE<?.Z'C-G,.
M?/F*@)"(F(3^+<,[1B8>7CY^ 4$AJ0_2,K)R\@H:FEK:.KIZ^N86EE;6-B!;
M%U<W=P]/+^^@K\$AH=_"PN/B?R0D)B6GI.;FY4,*"HN*2ZIK:NOJ80V-31V=
M7=T]O7W]O\<G)J>F9V;GX*MKZQN;6]L[NWN(T[/SB\NKZYO;O_1" B C_8_V
M/]4+YX]>SU!0D%'0_M(+Z9G'7P0X**C4G,]Q)=303)W>T'!]>8$G&9M3]>LE
M+;?Z";Z9\]@K CJ>57K$7ZK]0[/_FF*!_Z\T^T_%_F^]X  ,9*0_'P\9!R .
MN#*44JL9M\]O:6^,7EKB/).G_DGY$&![-K\<Y4W']:.VLK5)[=Y3]]>MQ?9Y
M.?J:8YCUC*^&DTTU9>6L8,B[7RL-JVG[F6*!#247-B8F:Q -=W79VH .1.43
M()M\^>%107S5<S9@%.OX\0E []F*/W;!)!IJX2-[STZ*?8NT^ 18WLA[)(P*
M?0 </0&.3W4BQF0GBR[1:>%_?X_RI,5>? ?-XPD0$-=B%"X&D:W4HQA[ J#W
M=#Y^]@BXNGGW! A>-WT"O!=NO[M/6#M7^\,EL.\RYMJ(C_(<N?D)T-[_=XX5
MA+DQQ6H'!/]/DN+Y*<285(O^73BUOW%D[M[)V]/T08T]_+MP?V=HQ"Y-J9XW
MRQ)C\W?A?OR=(\+[W6T"Q:__U>E@NO\T,8 )IU\A[TO ]*S#:_MK/BCE;"AQ
MSK%?]U'!XG0=8N085,N6I=))=L46*:^,3ROB<>#\>CCA3>FER(&8?L@K?E[W
M$JM%#@R"C=]NU+/4A1]YM\T_M76[=)JM$K42S_DUB1^U;\K.YSWN/VI)AI_Y
MY?%<JK$__.M3T3QL2]PGP#]0S?]X0_-='ISCORG_?Z?4QNGZ1F:--EW-K#[_
M*)IWJ]6AU/IQ3T+:QK>P#-=M\4-\G,/F$V!T2"N<V(%>-SML,R$:GU9]T/^S
M5H;QHY1WS(/?P!,@)W7__KD#U<E,N,,YA$$__$5WH_0B38_\DF9 9F!;IL9&
M\,,+@=(TQ31&W])F$'2CQUV)6"K&@"2DE50QU&CFV)>7,GR%4,@"QD7'ZLK)
MD\5(1Q&I$S/JHZGO&.IZP^.>N:YB^ 0XB86DUH00AWY"%4N@6&2E7"$4N0T_
M/Z\^.;-;8OIZ[3QR .>MJ>4,]>W[>6'>?./.T^0?LZHUZMHJJUE?_<VV0.<[
M."/R/1E*J-7[7N,TGDQJMIC;238O/P&9+6XJ&<YB0-O$9Q6)U/,A<863 P(C
MXK!S'Y^S$J,A^QEUX6+.4"H^)$H^3E7; 7"!K^C4^;4]E>?*]-(BG5]W*!KV
MS#%2;P&JN$-:M?'4 :'(6GI57]]P5>.'NT&\5?_".@^*5Q/GI% FJTDP%'Y1
MKBVP]$#_FBMK54<9.7X_<T%[9$XF:942#Q0PF]@]H1;.&SIH/7P/OFD8YN+\
M>96K-9[$&KB=J&:44^II)Z>":3OH6BJL>"BX8@ <H(N$5,725K[JVK[VUH07
M!*WNNF'C@#ALONO7A62RY35%R[*W \X9B+8A]&$1NP^@1U.7 5-8ZN9O"8RX
M!M3P'L@WY.+U.EFC]H+9W2;Q;];C![6J&/I22@_YY ."%AM9J[\.];S%0VK[
M7>GJV\<.J9O\.,NG)5@JA)T2?+]4R=Z)I!KK 6?9O"!R]6>UV$*=M))?T;Y3
M,^6?HYSC[VC?*H<*7ZLH@-^B)FG ]!P<KCB^KYP;?7JY.]$JKNZC?8+V+6Y"
MVI"3>M(\XL7PAR] 0,;B@],>4VM;,?V#T2^7H1([.^'2.=]215 Y'3(]=61C
M;SFJ&PE]8A9H91_JOJZ@I+UBR-K42<LA]^.L(7B;(;O\]S2Z./H3H$/&]4Y@
M4BR)?/G'T5TNZS27!!KY@TV&/S"_O6(W>(3*TM*L[%6E %7D:Q!SR4EBEK4?
M05WQTMQ#8QDX$@&OX= Q\ZX7I-(.2;&T+C(RL&7H^*ZOUVE#/GWD]>%5U\-)
MMH.)']JV%E,Q'[22C!5_GU",].0AI+1TT#79.I"<GIT69O4I4-*K5_BS6$CI
M[,X2OA+ZQ[;)E3]6:+KTD>5@S/QSE7T?T?Z9II\57VNRP9D<ZW;3#VDP2KR<
MC*1,</+CLSRJ0 DBVD!,-_]7U759O<]F7)3L47X1<5.;(/U:1]&1S[<1HVP?
M6PUD1@?Q,FJK[WJ/=[-$OOP5]KB+O&-;J"<QE]VX>;'_!'CQ\K%[\KGGFYA-
MHP\[YK'KIB':3#+>.$;-)T&/[^&A#Q[&FP8W,7?--X0J:Z(DU?;W\OG+^S.I
M]'7##Y)#4BH$'7Q!QZ/3=3+U)W0C7%(DO]>Q:;(QEC4F9X8S2.)TB!$,722A
MH:ZDP PQ!)@"" G;XEL#EWC?M^[7E$7Y2"BYV4LMB(A;- *#F;*/F.'!#1#W
M6H$(;/Q]2I-Q!I*]/7F/$G3K[[O+5M2<OP_%AYN$ RAF#=DRS6N:C&&& ]84
M[O>1*?TBYVMUO(NHO'/G<Y8-GFV=SFQX3-M>R#GGY=X3JQWZMHDPYG+#5BAD
M(4E5KU:^COBLP6'/>\JFKS86,Z8+E<05A[4MK]26'U/P0\B+L837WW6CYC^)
M-?)"5K-P%PP]D>\"-#!9OE7+[17A?%/W['WOI+E^_:D^%MX:TNAA[87TPZ]
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M\[41)\\#I6O]-=ND6]/FRH0?M64%S7J+[<_2)] ^VP.EF\;+>0V-]I96:)X
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M0=^A?^_+>\2_BFC?079[ O@Q/ 'PC3^.R5Y&*?<)QJ2TKQI[-C]^YC>^&@]
M: 9TM"$\'@ .[<?Y3X"UTMW4=X]CQ7-HG&?\]\S'A &CS_<?;U4>F6*N=9;8
MG@#9F#,/YUGW6G[<TI1P7F&JK?^2E'EW,H469+V#RR<5+89/@/>D%7>[XM<E
MXG\71.M\""_ 9O(@*/DF[=]DE_T72=I2<F,.23*^NU!R_ZOL1?\FB<X$C]I#
MGD8UEOF6X[]*3_FO<MQ:A8O_[TXC=F@;&P/E++]XQ+^289X<=[ JVWW-,E!#
M;4I/IOTT_-@5#:@ AG=G!U.'8,;F!FL9?<::JI!VTBD6.CJS[,D#TK(?G 6,
M<,O.;3T!,JWJWI6)IC+/<__;P[RY[,O!@3N1Y;/!L4NO]NT4J,*[2QO1&J['
M$?[[,QZ_3,>;+3OU<-%4;/O!]IH_>HD,45JG/7JE3N;&6 7]]W#_^\/IOV;4
MQ=$U^=)7_*XD$I=&BRPA6<W@C\G<&Q=<*_RR;K7RRN\+61)OIZ;L\TD]]5F.
M?*1.50>SVH/S1E[UC5-V;00P[4%"BK6,F"7M?;KQSX[OV; ) OQ[GP!((_\P
M^G]!]1\D*[[K94FH&8L] 3I6$-97!P$G9$^ OQ;PWS&__R;[/TN6MXX6_JO?
M[IFHV'# =8E8CDX?RTBV3<7;D^T>3H]/B4U39=J#V^A..,+<CZ,B,5!ON79W
MP.>O.-]EO3>A+]7<4QDU',TEPW,N=\6;LJ"4#O%WQ;?38N.TE^KL8YIBBPQ7
M&A=YA^,!;N+ZHOE2<W+MTJIWKEF+*M,Q,/F'R0>;RUAL2YH'?*G_(/DG/?R#
MZ(^(<RWL_R#Y)SWH]7\/^?_)D*7?&^/H72)CX:EQ/J]4G19NTGKUNYIF(NN8
MP\B2UQ*R@WV8J*G\K1D0Y>[EMD^ 4]+)@/TCXP>,*:%;3WJB_,_O<L-S_LLW
MO'RR.D6U#14[2O$.]!5E3X,H]B=U0G0J[JF> -_Y<IX AC,W.L\M\78,S]FR
MNKQY\;19HW.@0VN*=\*MU%3C:ZK@B@^-W!3KCK8WZSYIFL$),GJ?;]/59[)\
M#3XO>@8H?=:+Z*2_M[LT9TBD?P)8>]C?CB;,YA^4>P.H0S0#126&6#T=@OS<
M5H7%<??<22R\%3O,ZA][N5NV"%D?ZV#FM#M.AB\1,>'@VOJ0C?G\TR5IQ^=Y
MHDTT)>WJ8Z7?7QS&#^DP,N6*RE*E/\,2.I/V7,J [GE30,H''G) 3B)-4ZTM
M5YP]* Z03Y^X)+-ZZ@H0/54L5WR),'>G%+>8RE^>"#0YVOGTV.]$#TILVA1C
M%!GOJ<ZI'C"]'*!.T 4[?WQY$<5"A;4CW26@P)>H\)@UTJIF,O,ZK=$6^9)^
MU.B8@I&"74PWT848]\N?O:?\B^C?^2GRMZ)5MT6=8Z!>OA1<B+>5/+HLY?8'
MV\W X%2K^C.<0=G0]RI2%]V.N_#-Z:J3GG6-5CFC[8/Q,(!*[.\-OV6I75EF
M5)[A7JK(H"P(_H:39U87R*)R5T>;X).^3=4R$7Q0@*$I6@:IO%</(3T5^IEZ
MQC2<O7:(3'<).XE4[/GZP3LGDX*4J3$CO2+/@2YO31)(V&3MW5VS)2R.>1;<
MD7U&BDKL+$O16$I2\>U>R=S/PX07*L3(<RA@),]S^1F]P'%5K7D3&9&7$"HD
MRA9^ZG-,N:^VRW>5" /1G<Q+L$XR6KQ"IM[VJ<&PKGRO M6=%C%<L_-9M%T;
M/QT69N62XW:X;$Y]?]VW&!O=ZCWVNQ-..\D%Z*="6A@S\D-H,Z<] =!!L5+.
MU-%;MR@)&#Z=1[N9LL@3K9H4S).N#P$JE56-T7X\QIBB8RQ?G=@(OY/5KW7.
M@G-DW[O4B+([/P&\ H3T$6G F22=T;>ZV<&YDQ> 7*++0"U/.@_>"NOU5NVU
M>6EQVWI0>5EY88-6E#,)ASMB'B*F>OGM_):Y?R121#.5X OMLN25_IRU'DVE
M]IU0R;:-^HHPI;H,<]M)05ZQ;28%K&D*FH@^KF>H&@4-^MR)\B6S800OM7*R
M'*PFC4__?^"Z)*_ROR_;OH/(P+J 5=*IF%"L]DOCZ\30N:TCXF&G=+<>SR%K
MX/R APM^[2M]4+I,N'"5 /Y!'YQX2B4HI.;'X\CCX!WE7)ICQE5DII53^IU;
MF9W6I[KV? R$P;B%]TRIS2W]XG3,ZKN<>CU*I:E\Q;/3&&;L>[U;_]RZ6MV)
M/VD92;Z[V:#M 4^><\-?9\G!O2?G][;T80JWX$=W]$R&V'T96:AW00;E-YHQ
M.C#%$K&(I)NLH2Z/S3#AM0QI?H#RU%M(@&/N;B9[\ZC8",7\O*L>C;1EU*SI
MI07.#*^Q[G2_O_A,'YN7F(Q3K,[Y(LV5-J',,&] ]<^)@<:.532-$6.(]V%(
MAK,()R]T:Z!9WM4]D9N\11XM6<93I%E^(1/5Z8_%B)P%E#TDTRJ[]IYV?0:S
MQD9N1UI/)TVS$_..LGTR_4*,%L[%F1Y^F2%&M-$ZNMSU2;*-[H[U%\[7* LS
MSLT-O\7986ZU3HX (E"%2]XBT @2_"M.\2+4[R?Z+\N8R)A/C'[6 PCT3-[8
M/::AX(2>0C_,A'1_<-=0U>O77/X%K2IR#;4SK+[T1?L##F>B@XAC3IKGU/+2
M5!CF CU^)4^ >>N(;J%G(P7&\*6ZR=B'DD,33)8/9 6TA^DFZXA<W<1R:'E[
MQ0WJ"%OS25NA-5/'VK1\INFS;M1)9T&7>< VHJQY &3/_K:V436^8Y/.("A0
M*/PBS5 AH!*^]^9C8,"U_$<E3FDTZ\5>Y62HHLQ40/U%?E-E\QG)B9>.>S%R
M7U7 "PN'CWY>MY,/5HJNP2Z=MD!%+W:'U3H84D%*!Q4#,4,A[^@>WRX(02"G
M<Y"T!RM1*)_-_;Z!VQ:QXZ.3ZQGXDL&/;R] :+2WN MW^I0(1A;;I9RAZC-=
M4S$ YB<?(6NM35-NS_R]*;GP?I-.]>?*@[1.WS 7\XP;L'L*ZJN'5519!XTZ
M,-*>3?AHDI4<^-S99PLRE=?04T>1YVB5^4;QO>L-SFNV \PV():B-2_ZZ]N*
M?94S]$SAV,BM\F60A[=;:_Z57#'Y@K\]'8=PDL ]\W2\?.8ZL&YJ#19UOII]
M<!:R"+DDBW'1XODAJX1L)GG[>8R>C_D="K&'TV?/(4J]@W:HY';R D@G$6Y9
MGL=BR^H0\4)7@"YV)GI*H16]-PL></+MVN?.C#?ZOI\AO:2D4&S5<\CK$*S@
MX-0,J#"^EG@"4(&E'ILK3BNH_@4M-^A]6+R/*$101$GC1Y@]THK1M0-WRI*D
M7XGU(:K.%#T6C85<#>!E#[H@BH_J=I@V5=)4GDN[4UH&KE3QT[7,GZ^K4)*$
MV))05($J=*F1ME4&VP,N.[.'D@OJ[K(:Y(6A=2F%;2&B0K?RYJ=O4[FJCU6.
MJHC[;L>P@\_1_?C 0N0$W2P%@HFH7\$N1\(SL;,+QM=FXGC+TG:F$#N.,M7Z
M#$N"V=Q(V"VBX?NR469=01O+S-HH9+@57;_U0/4)  K+3@5:.+:V#]R@5=&4
M)J04EQ>="P=@7>M!'<[GP>P?;8B3#OG&<F,;7!?R<HJ3.FZ?@<Y ^WFZ$8+)
M/-]?R/30YO1"O41#&MGB^1I]K"LBBH! 6#3X \HSN=\K1U3@W@:HH*]=T0+]
M7*C!Z]WQ?7'+QW'5R/K1PY'?<KT,C7\\"->!-^VU2^> -=CB5BEP7O)NY6M7
MCM:#IO>D7;:GN<8$:@FH";P8_GL81\T0)>4FAAS+>R;3U@4Z7;PJ'()(,^I(
MJOG 'DL;Y8P&B., ULL^SYX04?('N]XQ7DR.L3BPL<&5I&G"G/N6F9SY8HQ2
M>/1B4MQ%36QN;5MKH,%-=25$*\Q$%.J9.7ZHZ(6[]?H&B1&.CJ@AT\L4SWJ0
M[N8N*[CK$=C?+G*R@5%F=K1NY,-WWTP_#A=?&3PG(KXLCY>==G1C#X[?(W1Y
MZ4BP9 E28!_4H<+EC!F/_X@7+_2"1^F5G,B #RE_B"X*:1Z@M'O.60AJ>(=9
M..O? <[E2Q-IIRIBA$U0)&S80:\#[<SJ4P^FU> V:DO?5D-$N!]>G6#7N5/0
MS%2L7.NZE?IDU2REV>2?)4C Y8D%=I4*7LDM!7628-8%S?[*FY.V.:*S4:?"
M3W9E6- 6CQ#!$%%SP0M5#5_$%6>WFY46?B?JSNU<>%8N*4Z\",>4P;Z6+YQB
M%6EV(3]_W67$:"'2V_S5N'A7K7.M_;4!"!/%>Z"7RR[" @;HY?Z6[,H"T+Y=
MB^!TD8;&2!JC>KK"YR6<\N&+1-2Z!'KK&-TZ!4I&?FAR"6RX2GQSB=N.Z:\"
MRN:O7/;#S_@1VC!PNT+SS-(+VFF*WV SN75L,E-G[IY1^74Z[7#;U,R<DFL/
MI4I$)$S[2LPCPP?\C/$']8KSBQ'[<);>(8K>',/=:9V3;LS%,HW>-V6Q^1'?
MRUI?7.$KJV#88/N[H8VS1"TA&-.[^!THN[.,O<_\F'O$J+*Z["?VG$IZ77@T
M=L\4 <RXR(&Q"&I_[AW;%C&&R0N?B '\:;;\FM:Q<C:TU-$49#:G8(F[2EE2
M>08\Y\IME9S=,5 F1?C1G!FL$IA@W0#38FYFO5J4\;GBD5H5QYHW$.TBH?^J
M(78X3D?UIL&T\:J":8*W>9%99<SX8ZNAC-PYXY9J/^F/3[(#W[F>W5K#>!<\
M:;4(:X0HB<H;:>?S1QPWW^X07=Q\1XJ>5Z$)246ENR4G>Z08*__KE#V*;1SX
MHFISOL4DUWS4O=0]T;W)K\R]WAT!G._AB/WP14NV$G^+9+AY[06OJ/\IIKL-
MM'9(@<B\%H=:1K9'@LZ:;-+)L[G+0XP[$6^2^FMO$;I3P8@(3FEG= [P*K*W
MB#9<4->EO!>J9@3,OLX\??1H:D4X__(_=H[*27Y],(NU8.*@SIF>B:D%FW&;
M;>%=O2L]?F,@05 E",R0E%M'MRK!PG=N0&W53WKWD"OJG&N7YMJ@Z)%)G_E>
MCX8-F8-<CERN@CZM6_\ 3F:?21,,SFE/16W%[73D/5=X/AV53Z'W:]C;JI""
MH:D]3;JI:K)GEZ>T@- [$B<'E[%GB^HU6E,Z1<O8;[*=BW#FD4>*ZW"PPN-I
MQ[%NTR2;>1B]<.;+7(,+1CJC]D63%Q7O\Z?"E?=6I?'4__-D_.^@#8'=^\B>
MES5-UC\!8FP>$R"B@W;VOI#2)T"?H]H3H*(QX)Q;<V^KX@E W2K[V/:/(E.-
MBK+HOCY5.4&40.%P+I=F!@^#[50%QDC#H9'AA?2LY#,)*U&]:$'BMW'A ,/#
MAOK+!>^,WK>0.];?<^@5-*:V(Y6*M0<LPM8%=@$_4[4RJ]8L8&T1(^$"%LD2
MZ5YE>=2>3P 1'3N+Q*;>$%]>\IXPS*BZGGIMQ0\8.#WCW"';\WN8INK5077M
MT( ^'9%J4KM^Z&;F"VM/<(^EJ[HVAY_<;NI77"%<[IGGK43E*;Q)D13D%.-P
M49X2*3+@R8J<C#%#G).Z[2/9&(OK?(8AZPK0T&"^MZ!8\+4C98OI$0?(Q\V'
M]Q\5F$/R=!MQ*L4B8XTPAX7Y5F<7HY2U0](..#BZT!3O4Z>'3=BE50@\@*->
M?+,L= .\E(<?L=+*]=+>H>*8IYDTS2U5X,.,O_DAW6DI"4:5X)Y<MWIYNN !
MH<!"'(?\SQWN;B471P\0$W12HY-1]3<]*A"T(^.C [%]I!P[?[-&.@ F8)6&
M'JT%,NLI5G>49\<'"^YYGI<NT4S8YT_6B6JO?P0VUCZP+706]ND6#3OK8LGI
MQY05VK&*K[8/LGEA;?7PD[GU@!!AD!]T1G:_%P I+'X-6ZV2O9U-HCUYYMZW
M9"9+(/6%_@++^M)B4H6SV-2L3NW+9W>=WI/ZK'7!4QOQ[R_W*!WPY;&RTX-Z
MQ-](=>77&D^W;Q"*0 \<\NH(N?0'ZS<'S;0E\2KW&G>S;+_6X+ZT$MB-\ZS0
MJ!^K/?0>4>;7=H(_Y.FET$7C_B;6DG^%)&(1W7:AO2P_7A<!*K<ZN2<!SMDZ
M 7-[B%@[N%=*GXM\%^PKO B>0AWA6UBX'QHQ\AZ+KV53'ANU_F(44PYJHN])
M6/MBESNO)Y\_'(%26>-@HB)<[63DJ*]15%!A@L>-]'D0L(/$X^ @9MZK[*VN
MIH^A/NA=):XA_\?._RT)__YO.);YX]&CM,9UC$QN>'?5$^!KS".NXA, 1DIY
M8)AW$"ART]Q\5)$AQ ;68E4^5JR&R5^ #E:"#<!QNPF:_/8$QSIVPX\<]A1D
M$_=SX%P56&]28XROK:B>3XPM;C->1L)P3\^?5&4:$N<GMJ_<%JMC$?=^EQ95
M-(QX'0Z%!/]P'P*39U0#84MA9JJA>PV_*A@FZIHQV3MGC,VG:U/>9FX)1#:A
MINH=HM4T1[X37_K5+6V])NJA63W.TM/NA*P"E;>Z>BT7)_B-[?TB#/.B6X>9
M-H,B<^+:&S]U+DLQRK<[1#<F\?G9E59H13:OIZX>"]=[%NA7=;_K+N:ZMCPB
MW@UN@P50ZG!#_176R$.CW1N1-+UT^^->C7WUG39&!.;Q-XLSWF]=(<"O#1-;
MC9%>-MF'G%V$GK1!<5YY/P1GS*>5@M.DR)X/+W02_Y8Q,RSQ"^%@*L/,6;ZY
M?!U@;?"-DAN8+8L#NU,0HH2:^(H*!?^9W?7).DRSRU.?;L>+8">LE\A6:,8N
MJ6>'K[S.#7')4Q>'@C-S2D?PC_*^+KXJ%N@$WRA2Y&]%("<!*>!@Z$!>,@TK
M$3Q2U5(V^QR/OA;GIXD<C:ZR"TGV*Y>9Z(2-_36HMB%?#VG6:R5POGQ1OX/;
MIK1.'#TEXX+,6'S/@<O'F&[]LLLF"_XVVLP!N;@CFY#ZHJ*)W(?!N&:OBUZ>
M/XY-MEB_/,'CC;Q-HH9L$#J/0B2'4$ZOZ:[6!9BFMTL?I<DT"9R>S;9OUF)R
M3BYKN^%/^J[QVJN(1<=9["XBW8 **2W^#(OCY:T.0_;>L67N3JJ+9_FV\@3]
M&]ZA'5=6C!+/"/I/;0TBJ2QDO^<I?M;?*N7*0JKU&#,\81;OK7YN'#ZR^S.Y
M3I31JA:;VV9SF!#@DT6'%AI[GXH?#IGMJ6#O50>)Y9!#5K\,>G('WU7 %ERT
MH/=Z:V]6,_2/*%]'!-8K,K[=$WP+^U%)QE0$;ZU/CY5EQG*;O72OJO'<C#ID
MG:,7SM? _;X]%2(HKJ]56R^%HVBCV<5)K/MS5I0P6OS5:?N;?8];@BS,?'^:
MR8TV('8]L55#.+Z5P#&,/?H+H+>XP-9[J=7'*8"U_1O;P?2$=. U?8-2!379
M-M6)SY<_O%R;*,I9#J7'F@@JT0,YK$YGO"B/S7GZSO=?6)S15-5%W=S$X:-E
MMGQ9:OG5HN;B5I9U:$PPE%VF.B]OA^'$S#I]PH^;CWLC8N):9(I0^<8F J83
MAR-^T7E__N)Z%_%M79[J B=A23=:ROJO($2V5-K4$IE9RAK\YAVU@F2)C/<Z
M<JL0NB)0Z0E@51^(N<VZ*?/&Z4* ;')2DT3W2QF4<G#9#MDKDO@,-V/#E2%:
M93K(VG:&V1ELPO^*XRTGVXDHOSFO*!YJ+*"ZEA#[$ZO)FP;XZ8UB8VB.0#^$
MS[U@YJ!@&MDQTNLM[]P3P'<=G_</J9$B.B,T$0X4!E$9-[_I@J"-XGQ1OJ.O
M5WU()<L]D-J,2?!#R[XL+BH@H*JOJ:O1!@)U63O)*D/H/V9I?-$8DZ;ZE]M<
M?X?_X923]!.7$8>4X[6%C5'@F!]U?Z\%-9AZ FP(%CT!9A;:;XE+W"YBYXA1
M\=0^FDKCJ:+4SW#/+?2ZV/%\'R%>B).9M13KJ2U$Z'QCRV1HF&:GM[' [3(\
MJ_K9L[KCI(>G[J2B_15( KV%K*'W2QJE+T0^ <H%1X;V^PN&BI86](!S(VXL
MB=,WIV96OWLS&THFU2RXE;>[]*>V,NL)A: +];: URWYY6@2Q]>3WNZPDEUT
MIEUXU%#NP&.EY*:'UBM&YY[IRBC=%J7R3A_6#?U6N,%@CD6"1:< .?=^N.,]
MG??LI(X:"72V]>5FV/U(FF.!3_A@;K3<)7+NV#W0P[1T<<^C>F')4,7VY.7'
M!C>&G!%8G;72&J;5UB7Z?)3Z$; ![:@ A+5QZZWMAN<L<U5)PJ__6.6+9VBK
MPQ6<-&PX,H:(ZES*\%@3=7B4HVN9<MCV<5]\&??QP%'M^%COQU^EL89^YNJQ
M;&/'5I8M)C-4L-MQ(8(2334ENOJ_8J>?[W+# ?_3PCG"?Z*A_U$X5WPOFZ<F
M;38[9U?E&?>X=Z85 GZK]6QZS*SS@T_<XOZV<I!M]<4A4'JL#+6G6;2%#](1
MDBFZW[P;I)_0Z:M2FWFE. X^A-A8^OU?U5=I-!OH&L[0J5$M+:.6(K<-:KF)
M6D*HM4;1WHHNEDA0HT-)43NQ1!=+*4&*5F]IFY*:"+4E8FUM4Z8:2XB=MH@M
M*E00(M>M_NC<VW/N_37GS/?O>[[S/.]SWO=\[_>]IT^H.#=OQ*X; ]OBJY\M
MI/+%+BZQDL"J^)_0FJ30RYD;]@#=@8/FG;[D@IITQR'IYBL_GS@1@PDMU>6$
MYM'>\:7LJ \1U;454>4!I<>2A@_>W[",W.<,B;J!<*(JJ90M<?$Q?L]=W:$3
MV2^--DA5J&WVZ^O%9P2 B#1?FLTT988+0G^G_##B#K@:+SO)X_O$TB5R>Y)
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M">2PK5((=3@/F-V&R3CWMZ *D["SSJJ:T\.M1]UDHB^S>=X%0OWBYI24K*%
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ML8C3>EIO^17^"=N4WM<XH_N+ !";AR-W;U^N,6Y(7I58OR!/Y>^]UOBQMUL
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M"Z"0I3((FBWF3Z"LHZ !_\W"LI#?N?(;X/\V;G)$;"AL2WZYH2?_M[J6"6I
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M*9=JAL)3W+?>XJ<]K\8 )'8]6(D1WX$@6+@1([^7T3782#5#_4 6 U!NTF,
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MYL<$I>?P\W2S#XU'48W!7M8%HTV*':V5+V&M,:Z^;\C4U9/ZU5K2#V\9J6(
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M3.9%PP7&0X=M9G1'MXV%R2);[[ ^T!1^I48NR7(3'J$]ZL;[S6F//5F^,MK
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MU Q)%H@!(GZ].K%BC2+IQTKN%PC<[;!UNF[Q'"Z(Q,< <1<4IQLZ&$!6&P/
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MC!6<[X0&V#FR_)>O";W#3MU/W!(,L/0O-\U'-(P/D%P4&. !"]98XR3_X\-
MU[#$99)C+;D_5M:ZGQ+*R[NT_C,2,8@G(+2_Y# :]U^NHM.^3E#ECN:*GYQ4
MB.@<*5>)*/Q&YM6VU,W PL["T&NJXYTB(#._RB/3=UIKJ!9)>*&<02P]A1(V
MR?V_VCFS>"C8>(^/R$[9%4+&WAA+&NL@&6EB4/8M6;*$Q%@R(F4),[8BR9HE
MC'T9^SKV4)1]UUAB,&ALPWMZSW+QON=SWG-QSL6Y.!>_^^?S_#_?W^]W\7\>
M(F(;<N\#ZTI#@!!FC'<Q0C%:XMM56.AY$VH 0 4@ 8C@)=IC>!W,<] W@2X
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M     &-A;&,M,C R,S$R,S$N:'1M4$L! A0#%     @ 8X)\6.+^$OYE6P$
M]>44 !$              ( !7) $ &-A;&,M,C R,S$R,S$N>'-D4$L! A0#
M%     @ 8X)\6,0HL]OB 0  ;PH   \              ( !\.L% &-A;&,M
M97@R,5\Q+FAT;5!+ 0(4 Q0    ( &."?%B>UG:6$00  ' B   /
M      "  ?_M!0!C86QC+65X,C-?,2YH=&U02P$"% ,4    " !C@GQ83/H4
M-Y$(  "'-P  #P              @ $]\@4 8V%L8RUE>#,Q7S$N:'1M4$L!
M A0#%     @ 8X)\6(%-H[6%"   @#@   \              ( !^_H% &-A
M;&,M97@S,5\R+FAT;5!+ 0(4 Q0    ( &."?%@?_G;R1P8  %\C   /
M          "  :T#!@!C86QC+65X,S)?,2YH=&U02P$"% ,4    " !C@GQ8
M-.%E37\%  "S'0  #P              @ $A"@8 8V%L8RUE>#,R7S(N:'1M
M4$L! A0#%     @ 8X)\6*#Q;(;-%P  7<(   X              ( !S0\&
M &-A;&,M97@T7S(N:'1M4$L! A0#%     @ 8X)\6*=DJ(2A&0  ]\8   \
M             ( !QB<& &-A;&,M97@Y-U\Q+FAT;5!+ 0(4 Q0    ( &."
M?%C"_1GVSS$! !2> 0 2              "  91!!@!I;6<R,C(T-S<X-SA?
M,"YJ<&=02P$"% ,4    " !C@GQ89/)R&5(Q 0"'> $ $@
M@ &3<P< :6UG,C(R-#<W.#<X7S$N:G!G4$L! A0#%     @ 8X)\6,N T?X[
M0P  4%@  !,              ( !%:4( &EM9S(R,C0W-S@W.%\Q,"YJ<&=0
M2P$"% ,4    " !C@GQ8"/AJR0^_ 0"KP0$ $P              @ &!Z @
M:6UG,C(R-#<W.#<X7S$Q+FIP9U!+ 0(4 Q0    ( &."?%B)UA[:>$0  -14
M   3              "  <&G"@!I;6<R,C(T-S<X-SA?,3(N:G!G4$L! A0#
M%     @ 8X)\6, \-Y"L)   3"D  !,              ( !:NP* &EM9S(R
M,C0W-S@W.%\Q,RYJ<&=02P$"% ,4    " !C@GQ8SFV"5^!<  "V9@  $P
M            @ %'$0L :6UG,C(R-#<W.#<X7S$T+FIP9U!+ 0(4 Q0    (
M &."?%A_@+3*B!P  &H@   3              "  5AN"P!I;6<R,C(T-S<X
M-SA?,34N:G!G4$L! A0#%     @ 8X)\6+.N6#86+@  \S8  !,
M     ( !$8L+ &EM9S(R,C0W-S@W.%\Q-BYJ<&=02P$"% ,4    " !C@GQ8
MXBN=)+M"   65P  $P              @ %8N0L :6UG,C(R-#<W.#<X7S$W
M+FIP9U!+ 0(4 Q0    ( &."?%@H@N*/J$$  #9%   3              "
M 43\"P!I;6<R,C(T-S<X-SA?,3@N:G!G4$L! A0#%     @ 8X)\6#LIS,(@
M@0  DX,  !,              ( !'3X, &EM9S(R,C0W-S@W.%\Q.2YJ<&=0
M2P$"% ,4    " !C@GQ8(@KO8UN< 0 >H0$ $@              @ %NOPP
M:6UG,C(R-#<W.#<X7S(N:G!G4$L! A0#%     @ 8X)\6$5$5?>K&   "!\
M !,              ( !^5L. &EM9S(R,C0W-S@W.%\R,"YJ<&=02P$"% ,4
M    " !C@GQ8C@9N$OLL  "H-   $P              @ '5= X :6UG,C(R
M-#<W.#<X7S(Q+FIP9U!+ 0(4 Q0    ( &."?%B[\F^%@M$  /$" 0 3
M          "  0&B#@!I;6<R,C(T-S<X-SA?,C(N:G!G4$L! A0#%     @
M8X)\6-_A'P" .   E40  !,              ( !M',/ &EM9S(R,C0W-S@W
M.%\R,RYJ<&=02P$"% ,4    " !C@GQ8&+PTO]E%  !;6   $P
M    @ %EK \ :6UG,C(R-#<W.#<X7S(T+FIP9U!+ 0(4 Q0    ( &."?%BY
ML<YYQL8  ##D   3              "  6_R#P!I;6<R,C(T-S<X-SA?,C4N
M:G!G4$L! A0#%     @ 8X)\6*?[03)G+@  KS0  !,              ( !
M9KD0 &EM9S(R,C0W-S@W.%\R-BYJ<&=02P$"% ,4    " !C@GQ8..>4R-V&
M   ?E   $P              @ '^YQ  :6UG,C(R-#<W.#<X7S(W+FIP9U!+
M 0(4 Q0    ( &."?%A#JIR>>&T  %1Y   3              "  0QO$0!I
M;6<R,C(T-S<X-SA?,C@N:G!G4$L! A0#%     @ 8X)\6.8" &2S30  _UH
M !,              ( !M=P1 &EM9S(R,C0W-S@W.%\R.2YJ<&=02P$"% ,4
M    " !C@GQ8=3DH-+[^ 0!1 P( $@              @ &9*A( :6UG,C(R
M-#<W.#<X7S,N:G!G4$L! A0#%     @ 8X)\6)AF^B6:9@  KWX  !,
M         ( !ARD4 &EM9S(R,C0W-S@W.%\S,"YJ<&=02P$"% ,4    " !C
M@GQ8T0=343QO  #7=   $P              @ %2D!0 :6UG,C(R-#<W.#<X
M7S,Q+FIP9U!+ 0(4 Q0    ( &."?%CVU1;S$"<  /,S   3
M  "  ;__% !I;6<R,C(T-S<X-SA?,S(N:G!G4$L! A0#%     @ 8X)\6/X@
MK1/RB@  5,<  !,              ( ! "<5 &EM9S(R,C0W-S@W.%\S,RYJ
M<&=02P$"% ,4    " !C@GQ8'@Q;) $[  ",5   $P              @ $C
MLA4 :6UG,C(R-#<W.#<X7S,T+FIP9U!+ 0(4 Q0    ( &."?%AXMUMU!EX
M  1Q   3              "  57M%0!I;6<R,C(T-S<X-SA?,S4N:G!G4$L!
M A0#%     @ 8X)\6-(,.8(1"0$ $BT! !,              ( !C$L6 &EM
M9S(R,C0W-S@W.%\S-BYJ<&=02P$"% ,4    " !C@GQ8X/G:H00W   ?/
M$P              @ '.5!< :6UG,C(R-#<W.#<X7S,W+FIP9U!+ 0(4 Q0
M   ( &."?%@\!\6XLQ4  'DB   3              "  0.,%P!I;6<R,C(T
M-S<X-SA?,S@N:G!G4$L! A0#%     @ 8X)\6*H.IO6!0   \$,  !,
M         ( !YZ$7 &EM9S(R,C0W-S@W.%\S.2YJ<&=02P$"% ,4    " !C
M@GQ8EIM,KMD@  !>+0  $@              @ &9XA< :6UG,C(R-#<W.#<X
M7S0N:G!G4$L! A0#%     @ 8X)\6!@"(2LKMP  P<4  !,
M ( !H@,8 &EM9S(R,C0W-S@W.%\T,"YJ<&=02P$"% ,4    " !C@GQ8,D",
M(WPY   [0   $P              @ '^NA@ :6UG,C(R-#<W.#<X7S0Q+FIP
M9U!+ 0(4 Q0    ( &."?%B*[E2FH7D  .!\   3              "  :OT
M& !I;6<R,C(T-S<X-SA?-#(N:G!G4$L! A0#%     @ 8X)\6*0+T"D%*0
M4C(  !,              ( !?6X9 &EM9S(R,C0W-S@W.%\T,RYJ<&=02P$"
M% ,4    " !C@GQ8GCGAUZ>/ P"(FP8 $P              @ &SEQD :6UG
M,C(R-#<W.#<X7S0T+FIP9U!+ 0(4 Q0    ( &."?%C$_V4=6RT  /XO   3
M              "  8LG'0!I;6<R,C(T-S<X-SA?-#4N:G!G4$L! A0#%
M  @ 8X)\6),$Y5Y_+@  A3(  !,              ( !%U4= &EM9S(R,C0W
M-S@W.%\T-BYJ<&=02P$"% ,4    " !C@GQ8F_)'N_(W  #S/   $P
M        @ ''@QT :6UG,C(R-#<W.#<X7S0W+FIP9U!+ 0(4 Q0    ( &."
M?%BSS;P)0H\" "O2 P 2              "  >J['0!I;6<R,C(T-S<X-SA?
M-2YJ<&=02P$"% ,4    " !C@GQ87Y?F;_Y1  !M5P  $@
M@ %<2R  :6UG,C(R-#<W.#<X7S8N:G!G4$L! A0#%     @ 8X)\6 M'B+O0
M0P  O4<  !(              ( !BIT@ &EM9S(R,C0W-S@W.%\W+FIP9U!+
M 0(4 Q0    ( &."?%AJQKC9@$@  %93   2              "  8KA( !I
M;6<R,C(T-S<X-SA?."YJ<&=02P$"% ,4    " !C@GQ8O33_F&51  !+90
M$@              @ $Z*B$ :6UG,C(R-#<W.#<X7SDN:G!G4$L%!@     Z
- #H BPX  ,][(0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>calc-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:calc="http://www.calcimedica.com/20231231"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="calc-20231231.xsd" xlink:type="simple"/>
    <context id="C_9759fbac-1faf-4bad-935e-6d6df5498635">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2bc4190f-24bd-4383-9a76-813440aa7079">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">calc:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-20</instant>
        </period>
    </context>
    <context id="C_8c333f4e-ee8c-4673-aefb-c953498d5405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_18921a4e-cb36-49f6-887d-24dcb1c18c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f5b9bae3-0548-4930-bb40-f87d4bfbe049">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_63f79bb4-c719-4598-9f7b-e5ab26777c6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f0893edf-fb0c-4acf-a7b8-179db40778c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_79aec6d8-c918-443b-a31f-3dd73301431e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">calc:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6a19c8ff-3eec-4e73-bbb3-c3b561d13063">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f0c2863c-d6f8-4c28-a7b2-bb4074acd7b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8f5cacbc-880d-4602-b949-fa5d6761652f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:CalcimedicaCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-20</startDate>
            <endDate>2023-03-20</endDate>
        </period>
    </context>
    <context id="C_bd0f357b-9782-4dba-b331-d7e9654967b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">calc:GraybugVisionIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_90312dd6-a13b-4f5c-9a39-28a177879bc1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_a560d69c-2898-468a-9634-5372f3e638e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_45300d27-3112-43ed-a27a-f1ca2b9647c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1ffb1c4c-957c-4089-a01f-27b641fd51e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesDWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_44e3fe9d-1f45-4346-b174-97527637315a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d14e56e9-7918-4c0f-9cbf-a1b9ce18ce28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1945eb61-653c-4d34-aedd-57f80cdc4177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7ee603a1-e520-4a05-b7a9-9cc94a461856">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1625384c-df1a-463a-9b14-131ec9a67ba4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesDWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5405b9ae-90f7-42b7-8ea1-97fedf79248d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesCTwoConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d7864a30-f755-4c98-af75-d219e66a55a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">calc:DirectorsEmployeesOrConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-19</instant>
        </period>
    </context>
    <context id="C_bd0bc60c-d4f5-4ec3-a673-0505d888ab7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c76b6693-5f6b-44e3-a453-7bd33b5ddf5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">calc:PostMergerTransactionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d790b41b-1e12-488c-8daa-9f3b3627753e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">calc:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c8e84e93-e57a-4e7e-a6fd-3469c8f77e9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">calc:ConvertiblePromissoryNoteWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_69c89aa6-a735-464c-af58-9f7d7d6733ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8b2b8377-2a31-4a6e-8ded-d5abdcfa46af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">calc:OfficersAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">calc:PostMergerTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="C_fb58baf9-d75a-4814-b11a-5c4bf3132842">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_83ff265d-5f06-4f96-87f9-d5b6ce1fb1d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">calc:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_53c249ce-207a-4c43-a71e-dd5b46a497f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_42abc17e-9eda-4860-b3f8-0efb13eadeae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">calc:AmendedAndRestatedCertificateOfIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9aaecb1b-b009-46d1-a2c3-ad52042541eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">calc:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="C_31761f11-9358-474c-ab64-43e5fe6dd846">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1d04e9a4-5ef0-4df1-8750-14de2723f9bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">calc:PreferredWarrantsLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5d90f9a6-e52f-451e-b3ef-71ea2b53490b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">calc:GraybugMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_824ded8d-e1b3-4524-b35d-2636e88b1f27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_38bc6d68-19a2-4497-aebd-7db45c2ce63b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_80eeb444-2e22-4786-9e02-a20268b73e22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">calc:PriorToMergerTransactionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ca2b5abc-6893-4a09-9891-e889e91a1af0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">calc:PreferredAndCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_033e18f1-c526-494a-af37-d16f8a20d94c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">calc:PostMergerTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a6b9f2b4-556e-4252-b411-7c709e13590c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">calc:GraybugMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="C_dc6f3b09-7f0d-4955-b288-aa892fd2868e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">calc:CalcimedicaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a0231b6b-5eb4-4312-ade8-abf82342f64e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesCTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d26b6223-10d2-4e75-97a3-b8b6a3c39933">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">calc:ConvertiblePromissoryNoteWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="C_a3e0ce3a-700f-4c36-8d35-fed370e247a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">calc:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ea3403be-994b-481a-8da5-05ce7ae02175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f099418b-2bfe-4abc-80ff-3d27b357e283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c2ab8d40-d474-4916-9e68-da10e0f82c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f9395b99-5d87-4344-87fa-5056b48d26c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">calc:PostMergerTransactionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesCTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_da70ea3c-8eb1-49bf-a910-720ae1e76953">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0812ad75-b2cd-4dd2-8c00-aee77ec17b71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_53e9f125-e7ca-4cd9-96f3-b398eddc05fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">calc:PreferredWarrantsLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7f725abd-da2c-4ddd-87a7-b41ccda9c06b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3238f60f-57e8-430b-b3e4-81f554a6a7c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">calc:PreferredWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3e9739ba-3899-4e58-81e1-44a9a303fe9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">calc:PrivateCalcimedicaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="C_9a978bf4-30e7-4478-82d1-2929b8c869c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">calc:PostMergerCalcimedicaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-20</startDate>
            <endDate>2023-03-20</endDate>
        </period>
    </context>
    <context id="C_4d8a1b34-d457-4b45-9c95-b58fcd74a782">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">calc:FederalResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_71e8ce45-e272-4f48-9eff-ba31844ce0d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4ac3291f-aa10-49f9-b9db-b6f575d3e347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">calc:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f68eaef2-f138-447b-b9cf-bb7bd3b96085">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-05</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <context id="C_0a6fe6b9-36ef-4f25-b46f-fe2f867d0a7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a1517846-ee85-4222-be99-133ea3be307b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a3e2c51e-9ae5-48f2-aa73-7734ac756106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">calc:ConvertiblePromissoryNoteWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-20</instant>
        </period>
    </context>
    <context id="C_132f40d2-5814-446c-afac-5f97f6db9fc9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">calc:PriorToMergerTransactionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesCTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1f3e1d63-5125-4209-b819-942e8859a17c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_efd6e33a-c854-438b-b83a-602ebf9ebf8c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ccf97b7e-0005-4bf8-ac80-ebcbb11b741c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">calc:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f048298b-299d-47f9-b5bd-5b7c905187ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">calc:ConvertiblePromissoryNoteWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_17715ce3-d9ea-4ab1-acb5-cf49f46cbaaf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="C_8fb13e5d-773f-45a3-a1b5-44eb8a210518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="C_c1e00f56-e042-41d9-8c27-e58be2c2e576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">calc:GraybugMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_73195b53-1edf-49b3-a1f9-3ae2ae46a761">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">calc:ConvertiblePromissoryNoteWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="C_515175dc-1ad3-4b7e-8b77-14527a01e9a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesCTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6bf7869c-2d29-4936-b2b6-f5c3f0c8389e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-19</startDate>
            <endDate>2024-01-19</endDate>
        </period>
    </context>
    <context id="C_2d6b7e2b-1799-423b-80d4-f0ffdbd4249e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">calc:TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e9aabbcc-ba19-4328-a90c-b2b531c98d96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6557ada0-e212-4e78-b768-866c8fb13b00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">calc:PostMergerTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="C_13a92f01-c445-4a91-b998-937547a6966a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">calc:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-19</startDate>
            <endDate>2024-01-19</endDate>
        </period>
    </context>
    <context id="C_28b5f7e3-7c54-4635-9e19-0a894d5bce7d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7fa15f5d-da9e-49b1-ad4b-7ac0dffbd31d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9aec901d-664d-416c-9998-1ef7272a19c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesCTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ba4cac3d-1b7b-4712-b4af-b00b36992550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="C_5317cbe0-64bb-4729-93e5-b7c5d402fc35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">calc:TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c53f262c-1896-431c-b404-2f2cd328973f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">calc:PrivateCalcimedicaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5472c13f-2db0-4124-89dd-bd16af205acf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="C_5ac139a0-0917-47cd-862b-6898ff89d717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">calc:ConvertiblePromissoryNoteWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7e197c94-c9cd-4e85-83f1-c4bac6996bbc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_38046496-ba8c-4f7b-a2ab-17742c50658a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">calc:PreferredWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_923510ce-a803-41b4-a562-244fd50617fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_dcf336c2-04f1-4bf9-890c-ca0039d7e325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-20</instant>
        </period>
    </context>
    <context id="C_4ba994e5-acb4-4356-85f9-d557fa3db223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">calc:PostMergerCalcimedicaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesCTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_faf992f7-2c83-438f-adbe-c70b73ea5b35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">calc:WarrantsToPurchaseConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6739fa84-42ef-4c69-a6c0-24f4f1d63ab1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b6a7e660-bab4-4faa-a6a3-7ce18a7b50c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">calc:TrancheAAndTrancheBCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-19</startDate>
            <endDate>2024-01-19</endDate>
        </period>
    </context>
    <context id="C_72ea148a-99e6-47b2-bd68-d0f6914854ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">calc:GraybugMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c654b3dc-d8de-4e32-ade7-4c14b46e29eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">calc:GraybugMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d8121a99-b58b-4059-9f6a-950088ae02aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">calc:TrancheACommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-19</instant>
        </period>
    </context>
    <context id="C_9ef48710-53ac-4e62-b939-0912f0ec48d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cf933ca0-5d88-4990-aa20-a3cc722c7bc7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">calc:ConvertiblePromissoryNoteWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="C_c9ffcd5c-d377-492d-baf6-7c7ef2c83293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">calc:ConvertiblePromissoryNoteWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="C_77f977df-d971-4d4d-ae88-a3dd669b55f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1c46001b-5fe7-4131-9a1d-ccf9d2e7cfde">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">calc:ShelfRegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="C_01acfa85-0d49-4317-9517-f41c3568951c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesC1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bb2bd826-29bf-448a-b3fe-756756fb69a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">calc:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="C_ff6e332f-5b48-43f3-b9ad-0eb9e3c7b9e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="C_7d82e695-1745-41a7-8cb2-68d786a08457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-20</instant>
        </period>
    </context>
    <context id="C_5d9b48b9-68d6-41ad-994c-2b74751e5df8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_12eaa057-d9c1-42e1-b525-a11412a82bab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">calc:PostMergerTransactionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesDWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fd5366f4-f6f4-4f51-86ec-d2b17b2273e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">calc:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="C_07aad975-11de-44fb-9c2a-ae67476d452b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">calc:GraybugMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-17</instant>
        </period>
    </context>
    <context id="C_ef21a00c-f705-4ecd-b756-6e2bbd8fbbb1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesC1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d046d1dd-275e-4ce7-b43c-2ca79d4f0e9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">calc:PrivateCalcimedicaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fdc3b56d-3340-41e6-abd7-2a87c4565e5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7f64735a-ca76-47aa-aadd-323f69769f4e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_577f2bd0-e762-4230-970a-df97b7cca6e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_638c2e40-07d4-4e89-83a6-af9e3d6013a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">calc:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-19</instant>
        </period>
    </context>
    <context id="C_f6acf339-8a66-4359-827f-f1d8c3fefcf6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_849e11ac-1955-44ec-aed2-b66fa055ed0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">calc:ConvertiblePromissoryNoteWarrantsLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_eccb0df3-d3be-48ca-afe0-3b0886ba2bb6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d630bef2-91b1-4374-b30e-0dae725036e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_bb55cbd6-a773-4301-9abc-12c18795aee6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">calc:GraybugMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-17</startDate>
            <endDate>2023-03-17</endDate>
        </period>
    </context>
    <context id="C_7547cb73-f5f8-44b0-ad5f-4fe05452061d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1f065a12-57ce-4dcf-9b28-c5b350ecafaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_75c836b2-6496-4ac1-a472-f97feb0d50ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-19</startDate>
            <endDate>2024-01-19</endDate>
        </period>
    </context>
    <context id="C_45f580d8-2915-4dc7-855f-9af2533ecdf2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_666c7e89-c8db-48ef-beec-8e67efcb35b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">calc:ConvertiblePromissoryNoteWarrantsLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_33be579f-9303-4157-8599-6e2e245843a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">calc:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-19</instant>
        </period>
    </context>
    <context id="C_0e01fe61-f63d-4314-9813-8fdd75652190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">calc:GraybugVisionIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_317b6ba6-8a13-4bfe-b342-48339a414824">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2144abf4-0a9e-4b97-a97a-75d1e0d63184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1d913287-6a9c-4c1e-8311-ffb8f8c0200f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6584f473-e3fd-4960-8c14-afa94ca4e2ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">calc:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c7b1abbe-8b62-4f83-bd11-82bf252ed828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-19</instant>
        </period>
    </context>
    <context id="C_e6f38265-4614-44ec-85bc-fcffb8b21275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">calc:TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1df30a04-c352-47af-8399-d9257a158c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0605ef80-c201-4125-b549-78eca9b466e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">calc:WarrantsToPurchaseConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9155f47b-b723-4d6f-9e10-5b401cf33a46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_47c16d4b-a330-4cfb-83cf-9d9c1168ecac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cab222f3-c29a-438f-bc50-d49b23b8991a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">calc:PreferredWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9da5c1b9-5f0f-4c2f-99db-43a1ecdbfb83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7ef7e808-55f3-466b-981a-c813c5b91fb6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">calc:TwoThousandAndSixEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3dfbf602-7a4c-49b2-8b99-9805b5186589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3815767b-a76b-4eab-8224-c12657500927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8796b832-7e69-4299-a51b-d5ad3e94056f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">calc:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="C_0e691536-6f2f-49ff-ae16-8151a9648a89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8ab25aef-aa0a-43b5-80d4-c77a6790fefb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesDWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_10d7c32a-8834-4078-bcb5-f2abb3c5706a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fb28aa96-7bbd-4570-8a6a-cb5c875bd34a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c13bf6e6-7b21-47f6-8c64-15752b0689e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">calc:PreMergerCalcimedicaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-20</startDate>
            <endDate>2023-03-20</endDate>
        </period>
    </context>
    <context id="C_a3d1cb01-530a-4348-9ce4-14d88694eb11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesC2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b409b108-40af-4cb0-85b0-9bb871670447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6c40048e-5e83-487d-95e9-572612a5b2a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1cb6ffcd-9a58-41d3-a749-d0783461107f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesC2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3aa562e8-771a-40e1-9e64-d658f147bd41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">calc:AuxoraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ec132aef-e24b-4108-817d-1584845fdc60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_70e26569-927c-4f36-a60f-3d66c9bd4f1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_abd03181-4cc7-48fa-9b60-969d071a9ee9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f43e59fc-a4b6-4320-b729-ea2f876d663d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">calc:PostMergerTransactionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesDWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d04970cb-4761-47c7-91f6-85af5efbecc9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a90b884a-f2e9-44ca-a156-3042948bd1e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_73969220-1a8a-40c5-9659-158f6f3ab8a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
        </entity>
        <period>
            <instant>2024-03-21</instant>
        </period>
    </context>
    <context id="C_d824885a-bf88-4997-b44b-56b06f10352e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8b643f00-2d89-421c-b960-b0008cf81a56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_345b3de8-3757-4586-b754-d61ef7ff0cf5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">calc:ConvertiblePromissoryNoteWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="C_e88cb3f0-85d9-47a7-b525-8fd14ae13f26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f3902d69-3631-4f29-9f8f-24d3fa1a5357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_65b45366-3e2b-42a5-89ff-61739a51bdaf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="C_cfb02dbb-5b66-4ab2-8c28-3198b03e30f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">calc:CalcimedicaPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-20</startDate>
            <endDate>2023-03-20</endDate>
        </period>
    </context>
    <context id="C_8fb4c8dc-dcc1-4352-ad4c-b46434309f12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">calc:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_047361c5-453c-47e4-8ce1-9373daa9b02d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">calc:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0e069504-00ad-4b62-9b5c-575c0a9feed4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">calc:PrivateCalcimedicaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_Contract">
        <measure>calc:Contract</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_3b51ddda-abf2-4ef5-94ee-71739a1462f4">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_ba2097e2-28b9-42c8-a826-10962c35f8b6">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_b06479d2-4d1a-4c24-8588-9ad960f4520c">0001534133</dei:EntityCentralIndexKey>
    <dei:SecurityExchangeName
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_da62bad0-a016-423e-8fae-6da09a0eaefe">NASDAQ</dei:SecurityExchangeName>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      id="F_74cfeaa3-ed05-485f-93be-ecdef817d1a9"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      id="F_b94405e4-4bf9-46b4-a0c9-907b7b37b530"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      id="F_96e7d778-f45a-41e2-8962-c4c3904214d6">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <calc:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingRightsAnniversaryPeriod
      contextRef="C_7ef7e808-55f3-466b-981a-c813c5b91fb6"
      id="F_71b4969f-28c5-4ace-ac88-38cb897a2809">P1Y</calc:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingRightsAnniversaryPeriod>
    <calc:LeaseAmendmentDate
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_10ec6273-2918-45a5-ad26-6251eb098fa9">2023-01</calc:LeaseAmendmentDate>
    <calc:LesseeOperatingLeaseMaturityYearAndMonth
      contextRef="C_9da5c1b9-5f0f-4c2f-99db-43a1ecdbfb83"
      id="F_01fefd8e-092e-48bc-992a-f56011278bfb">2023-06</calc:LesseeOperatingLeaseMaturityYearAndMonth>
    <calc:ShortTermOperatingLeaseExpirationDate
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_5164bc76-6e34-4c80-a8a7-d709dbb4720a">2023-06-30</calc:ShortTermOperatingLeaseExpirationDate>
    <dei:DocumentType
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_f61a9f38-0a3f-45f5-aa61-da91cf12eb7d">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_a3545b76-4096-4ad3-93f4-250d3dd0c89a">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_6ee18d0f-844c-43fd-a8de-4bf5e24dc98b">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_e3f8a5f3-5083-4675-9934-e75f9ddc3a79">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_bd9db630-8703-440f-b727-21725bd74ae0">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_d69faea5-20f3-48ab-b681-13e77e51181f">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_0c1e2e97-7d82-49e6-af17-e3d1ef186495">001-39538</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_6b5d4f52-555f-4137-80a4-06ef6987dc84">CalciMedica, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_edd4f524-9950-44b8-8c81-36b8c60fd194">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_fcf091a6-c55c-4b8d-987a-922af642ee43">45-2120079</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_83f48718-06e4-479f-9ce3-ffd5748933d9">505 Coast Boulevard South</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_7a4deb60-bbdf-4197-a0eb-6e4d1b30e7cd">Suite 307</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_0017bdf5-d29d-4307-ba7d-ff8e952d0ccf">La Jolla</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_19054b65-f263-4d1f-8949-996c0effc8c0">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_609f49a1-8a16-4145-8524-15968e33a6f0">92037</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_41256550-ae1f-4eb2-a61d-d5194ac7733d">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_59cbb0bc-59b1-4fd9-87d3-27478b53168b">952-5500</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_cfec5d68-c64f-4636-afef-b880a0bfad69">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_ff07f38b-cb70-4415-8068-3f96a7a4c0cb">CALC</dei:TradingSymbol>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_b54d4008-e61c-4f8c-b644-bb0cf0e5bde9">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_250c0c3f-2feb-43c4-b1e5-6bf9405bf213">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_f66d8dfe-376f-47b7-8fbb-b9337bdf70aa">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_67a67b4c-fc10-4a74-b76f-bf0e60bbdaf4">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_4b151419-7b9b-4ae6-953a-f9d6b45e49bd">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_ec9ec724-4b8f-43ad-b036-9f92b64ee894">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_7d2f1520-e760-4c07-91ff-19786b5d4884">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_d4988321-a1f9-47ab-add4-99b876c7af6e">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_ef3bff86-bb98-469a-9c7c-1c2b5da4f855">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_a4a1daa3-e082-4bb2-ac05-451ef6920458">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_4e30a62f-446c-4143-b54d-bee00993c8af">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_90312dd6-a13b-4f5c-9a39-28a177879bc1"
      decimals="-5"
      id="F_53133c08-1101-407e-b1f7-d148da4508a9"
      unitRef="U_USD">11700000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_73969220-1a8a-40c5-9659-158f6f3ab8a8"
      decimals="0"
      id="F_8a2eaabc-8e78-4dd3-be1a-fcb717b63ccf"
      unitRef="U_shares">10740115</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_1b0e54de-480d-478d-9f0c-70f8bce2546b">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;                                                                              &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;Portions of the registrant&#x2019;s definitive Proxy Statement (the &#x201c;Proxy Statement&#x201d;) for the 2024 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission not later than April 29, 2024 are incorporated by reference into Part III of this Annual Report &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;on Form 10-K&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_8fbb48bd-fe4d-4fa5-9cde-a76003d0d3f4">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_355726ef-d9bb-4fa6-99f5-2b3d8d82fafa">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_8bfe8678-164e-4d3f-b4d7-211ba7aeb8f1">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_a2bedd12-1ecd-40c1-9450-b7b36c6fd78a"
      unitRef="U_USD">5530000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_b32203ac-4194-4133-8b43-b68396f002a8"
      unitRef="U_USD">1327000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_23cdb46e-8ade-480d-b660-d5d5f2cf43c4"
      unitRef="U_USD">0</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_0cc2db1c-21ba-4b14-a6ce-7df32ad944bf"
      unitRef="U_USD">149000</us-gaap:RestrictedCash>
    <us-gaap:ShortTermInvestments
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_64da60dd-bb3a-44ad-bdb0-544260b8b1ae"
      unitRef="U_USD">5708000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_88eb81dd-978c-4d0e-9eb9-73271f25e62e"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_7c8359fc-f1e2-478d-96b5-602c77ce84cf"
      unitRef="U_USD">367000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_0127ab3b-56f7-4cb9-8af8-02b8136b0568"
      unitRef="U_USD">254000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_dd470b77-7324-4a93-9081-2fdfb8b46091"
      unitRef="U_USD">11605000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_a9d436a3-c0ee-4c32-b0ed-ec3d8dce45aa"
      unitRef="U_USD">1730000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_edae37dd-91e3-4e5d-a779-af390e514efd"
      unitRef="U_USD">167000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_0ace8d82-20e1-47bd-9e0d-91e0894b3a85"
      unitRef="U_USD">147000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_057641ec-d284-4d9e-a6ef-1a67367cb52f"
      unitRef="U_USD">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_8d479690-41c0-4945-a262-305cd1e4485b"
      unitRef="U_USD">48000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssets
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_b21da684-3e1f-4047-bc3e-964ee261d4ea"
      unitRef="U_USD">413000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_ce8ec5d2-a29d-46bd-b771-7486bcfadf55"
      unitRef="U_USD">1424000</us-gaap:OtherAssets>
    <us-gaap:Assets
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_aa313d0e-f1a0-4bb3-8291-648cc18e73d2"
      unitRef="U_USD">12185000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_2b2bf5ed-eadd-4f86-9ac3-366e2def34ba"
      unitRef="U_USD">3349000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_9654b1dd-2709-4ea9-960c-4dc03385ec7a"
      unitRef="U_USD">1419000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_0fceda99-9b34-4cc6-af9a-afcf4454b887"
      unitRef="U_USD">2866000</us-gaap:AccountsPayableCurrent>
    <calc:AccruedClinicalTrialCosts
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_189c02c2-986f-4bcd-a37e-ae32d648f3af"
      unitRef="U_USD">1141000</calc:AccruedClinicalTrialCosts>
    <calc:AccruedClinicalTrialCosts
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_9d19764c-ef35-400b-8624-2a2487de6cbd"
      unitRef="U_USD">1143000</calc:AccruedClinicalTrialCosts>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_9f12ec36-8b24-4d9f-92fc-9c83a2d1f377"
      unitRef="U_USD">1468000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_8211d927-9fd9-4b3d-b446-4338afc53552"
      unitRef="U_USD">572000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_dff7cf29-7384-48cf-8232-d32ae83af5db"
      unitRef="U_USD">0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_4ff3eae6-567e-491a-83cc-bd83bd0f364e"
      unitRef="U_USD">199000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_b005c1cb-4aa7-4075-9d9e-7606217fe936"
      unitRef="U_USD">4028000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_c214a553-3190-4916-a285-bbbe1822cd27"
      unitRef="U_USD">4780000</us-gaap:LiabilitiesCurrent>
    <calc:WarrantLiability
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_dd6e1c42-915c-4fd7-ad14-60a8b7c13746"
      unitRef="U_USD">0</calc:WarrantLiability>
    <calc:WarrantLiability
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_fca9f1dd-e858-4fb5-8e62-048a99c5e8bd"
      unitRef="U_USD">2645000</calc:WarrantLiability>
    <us-gaap:ConvertibleNotesPayable
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_bd0bf320-2834-434f-a72a-3270f2f6f40c"
      unitRef="U_USD">0</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_be201ea7-e5c0-4e78-be46-4bfee9a1c662"
      unitRef="U_USD">5157000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:Liabilities
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_4a9d8b32-d875-4ba0-8687-8699a36e4524"
      unitRef="U_USD">4028000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_d76a206e-b903-457a-965f-bc6d2ef30b8a"
      unitRef="U_USD">12582000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_f5b9bae3-0548-4930-bb40-f87d4bfbe049"
      decimals="3"
      id="F_37b41ebb-e9f8-4fb1-a3ce-7a59d6a61c1c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_923510ce-a803-41b4-a562-244fd50617fa"
      decimals="3"
      id="F_27f61a76-4876-4215-9ec4-e17764fa22b3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_f5b9bae3-0548-4930-bb40-f87d4bfbe049"
      decimals="INF"
      id="F_dbbdba5c-512e-47e6-b086-8e2a3261b159"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_f5b9bae3-0548-4930-bb40-f87d4bfbe049"
      decimals="INF"
      id="F_c136b1bb-ce4c-4b69-9e36-064364ee1441"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_f5b9bae3-0548-4930-bb40-f87d4bfbe049"
      decimals="INF"
      id="F_0225b156-2484-46a3-88b7-c5e23d08c5fd"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_923510ce-a803-41b4-a562-244fd50617fa"
      decimals="INF"
      id="F_58895544-5312-4f6a-bc2c-d813d3e6be8d"
      unitRef="U_shares">25751716</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_923510ce-a803-41b4-a562-244fd50617fa"
      decimals="INF"
      id="F_7f53d2ff-21c6-4185-938e-877a6068120e"
      unitRef="U_shares">25751716</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_923510ce-a803-41b4-a562-244fd50617fa"
      decimals="INF"
      id="F_b30d389c-7aae-439c-ae7c-4e8a4a45cbad"
      unitRef="U_shares">25751716</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_f5b9bae3-0548-4930-bb40-f87d4bfbe049"
      decimals="-3"
      id="F_5c45a1f7-1ff6-4566-9069-569f0ca46101"
      unitRef="U_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_923510ce-a803-41b4-a562-244fd50617fa"
      decimals="-3"
      id="F_1b52430d-a0b2-4f17-a0c7-ecfce4c3d065"
      unitRef="U_USD">19107000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_1f3e1d63-5125-4209-b819-942e8859a17c"
      decimals="3"
      id="F_0c3222dc-b853-470b-911e-533905b02050"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_9155f47b-b723-4d6f-9e10-5b401cf33a46"
      decimals="3"
      id="F_595ccf8e-93fa-4361-a4d8-abc0c67738b9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_1f3e1d63-5125-4209-b819-942e8859a17c"
      decimals="0"
      id="F_f05387c4-3e60-45e2-a2ed-aedf67b1d85e"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_9155f47b-b723-4d6f-9e10-5b401cf33a46"
      decimals="0"
      id="F_71e7b27b-c61e-421c-bc77-a3cfd429cae9"
      unitRef="U_shares">11235460</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_1f3e1d63-5125-4209-b819-942e8859a17c"
      decimals="INF"
      id="F_cf42a7aa-62e4-4bc6-aeae-647972d0b739"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_1f3e1d63-5125-4209-b819-942e8859a17c"
      decimals="INF"
      id="F_d780a1d1-dfa2-47b0-adbf-43fe7634bf45"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_9155f47b-b723-4d6f-9e10-5b401cf33a46"
      decimals="INF"
      id="F_749589e5-70ac-4b63-a932-c7fdf010580e"
      unitRef="U_shares">10667279</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_9155f47b-b723-4d6f-9e10-5b401cf33a46"
      decimals="INF"
      id="F_71d30eea-c6f5-4e0a-8223-31b11747a390"
      unitRef="U_shares">10667279</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_1f3e1d63-5125-4209-b819-942e8859a17c"
      decimals="-3"
      id="F_03d54f45-c1a5-4d4a-9a28-32070eabb422"
      unitRef="U_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_9155f47b-b723-4d6f-9e10-5b401cf33a46"
      decimals="-3"
      id="F_d4952996-012e-4692-a491-43a995c4d8d9"
      unitRef="U_USD">8224000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_01acfa85-0d49-4317-9517-f41c3568951c"
      decimals="3"
      id="F_bdf47de6-c4d0-41e0-ba36-b388cff7a5db"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_ef21a00c-f705-4ecd-b756-6e2bbd8fbbb1"
      decimals="3"
      id="F_2eda6f6d-f30b-4673-bfc4-2bc7516931f7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_01acfa85-0d49-4317-9517-f41c3568951c"
      decimals="INF"
      id="F_2265f112-9c5c-44b5-ab10-491c1b999c11"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_01acfa85-0d49-4317-9517-f41c3568951c"
      decimals="INF"
      id="F_2e94fed1-fe95-41a1-9dca-92b76bdb8697"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_01acfa85-0d49-4317-9517-f41c3568951c"
      decimals="INF"
      id="F_17f0af88-9ace-41b3-89da-703cb62ee2c6"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_ef21a00c-f705-4ecd-b756-6e2bbd8fbbb1"
      decimals="INF"
      id="F_a993735a-f576-4d3d-8941-c58d867f68d8"
      unitRef="U_shares">8016886</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_ef21a00c-f705-4ecd-b756-6e2bbd8fbbb1"
      decimals="INF"
      id="F_979ee9bf-d413-41ac-848d-b8f16d5b8dc1"
      unitRef="U_shares">8016886</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_ef21a00c-f705-4ecd-b756-6e2bbd8fbbb1"
      decimals="INF"
      id="F_0318f753-3fae-45cb-abb0-82efd2e92a8d"
      unitRef="U_shares">8016886</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_01acfa85-0d49-4317-9517-f41c3568951c"
      decimals="-3"
      id="F_90ae4899-6842-4417-9fe5-9801924f5fef"
      unitRef="U_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_ef21a00c-f705-4ecd-b756-6e2bbd8fbbb1"
      decimals="-3"
      id="F_b4b9d705-6796-42ef-a91d-aec0ddb50eab"
      unitRef="U_USD">5683000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_a3d1cb01-530a-4348-9ce4-14d88694eb11"
      decimals="3"
      id="F_d56f2d10-7a45-43a6-a5b4-8adf475a48de"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_1cb6ffcd-9a58-41d3-a749-d0783461107f"
      decimals="3"
      id="F_00cf4d9a-1e7a-4e50-8826-98a3b09d15e4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_a3d1cb01-530a-4348-9ce4-14d88694eb11"
      decimals="INF"
      id="F_2198fa13-87ff-4534-b0c2-318ebb1b0a75"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_1cb6ffcd-9a58-41d3-a749-d0783461107f"
      decimals="INF"
      id="F_cc3c1492-cf01-4150-a12e-310a52672ae6"
      unitRef="U_shares">16291526</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_a3d1cb01-530a-4348-9ce4-14d88694eb11"
      decimals="0"
      id="F_66522ed1-76fe-417a-b668-d2a7caaefab8"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_a3d1cb01-530a-4348-9ce4-14d88694eb11"
      decimals="0"
      id="F_63757be0-8630-44dd-a580-2401177dba20"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_1cb6ffcd-9a58-41d3-a749-d0783461107f"
      decimals="0"
      id="F_de4c1aa9-453a-4c59-a1c7-0cc219165808"
      unitRef="U_shares">13504959</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_1cb6ffcd-9a58-41d3-a749-d0783461107f"
      decimals="0"
      id="F_7e94a7cd-e5f4-4d8f-a277-e6901688429c"
      unitRef="U_shares">13504959</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_a3d1cb01-530a-4348-9ce4-14d88694eb11"
      decimals="-3"
      id="F_0e89d9f7-a495-46ff-8746-cab5d2e34678"
      unitRef="U_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_1cb6ffcd-9a58-41d3-a749-d0783461107f"
      decimals="-3"
      id="F_831e9a1b-d722-44e8-9393-287e05172dba"
      unitRef="U_USD">9563000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_7ee603a1-e520-4a05-b7a9-9cc94a461856"
      decimals="3"
      id="F_57ad08be-e5ab-4c03-b7ab-7114aa12f3d7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_1f065a12-57ce-4dcf-9b28-c5b350ecafaa"
      decimals="3"
      id="F_77a5b69d-4ab5-4903-885b-bf597198aee9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_7ee603a1-e520-4a05-b7a9-9cc94a461856"
      decimals="INF"
      id="F_031bf55d-0d09-44ef-bbe8-e9dc48cfa87d"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_1f065a12-57ce-4dcf-9b28-c5b350ecafaa"
      decimals="INF"
      id="F_d4be7615-c0e1-48be-871b-55c2fc9c641d"
      unitRef="U_shares">88875077</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_7ee603a1-e520-4a05-b7a9-9cc94a461856"
      decimals="INF"
      id="F_0afcb335-5f15-4fdd-bc52-b010e8adb676"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_7ee603a1-e520-4a05-b7a9-9cc94a461856"
      decimals="INF"
      id="F_a32e2522-43e0-47c8-8152-7e46a41b15c1"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_1f065a12-57ce-4dcf-9b28-c5b350ecafaa"
      decimals="INF"
      id="F_f0f6ee36-0f52-40b4-98c1-785b97f9b4bf"
      unitRef="U_shares">26880040</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_1f065a12-57ce-4dcf-9b28-c5b350ecafaa"
      decimals="INF"
      id="F_1cd1b42f-f432-42c2-95c4-46d9a8d52883"
      unitRef="U_shares">26880040</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_7ee603a1-e520-4a05-b7a9-9cc94a461856"
      decimals="-3"
      id="F_02abfbc2-a746-4913-851b-b2395bf99d3f"
      unitRef="U_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_1f065a12-57ce-4dcf-9b28-c5b350ecafaa"
      decimals="-3"
      id="F_b2ac0ee7-483d-42b8-8900-12a65fe8b20f"
      unitRef="U_USD">19494000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="4"
      id="F_17d0a522-4654-4784-8369-9d67eb10fa21"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="4"
      id="F_3974021d-da97-405c-b4c6-0ed13fbf3266"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="INF"
      id="F_f291d768-1671-47bc-8027-28c7cbb3679a"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="INF"
      id="F_afdda4d3-44cd-4bf8-b27f-64b32f1a59e4"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="INF"
      id="F_eea01db8-24da-43d0-9ed2-1870b9335d11"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="INF"
      id="F_cd8d173a-0c2d-4f70-a1d5-c0ec845a68a5"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="INF"
      id="F_eac08a4e-2082-4dec-8ae4-162ac31aac3c"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="INF"
      id="F_7cf54ba6-3089-4845-b283-cdfbb7b3fcc1"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_8bb455e8-70b9-4732-be18-0165b2cbda00"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_b1d275c5-c0d4-477b-89db-8c7429a395f6"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="4"
      id="F_d3568561-1033-4d5d-9159-ebd9e3ba2111"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="4"
      id="F_42140322-b91c-4c58-98b9-fc03f11be555"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="INF"
      id="F_af43c63b-22a0-4b09-b021-3406a98d161a"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="INF"
      id="F_d9b7a538-6b8b-4e1a-a873-407a222adc21"
      unitRef="U_shares">5694626</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="INF"
      id="F_b067f1c4-daac-43e8-addc-a3d5240624a9"
      unitRef="U_shares">5754505</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="INF"
      id="F_b4518193-e367-461b-a4f4-e7d798b54793"
      unitRef="U_shares">5754505</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="INF"
      id="F_713a3be0-0ac2-485f-9a57-bfc2fbdbd8b4"
      unitRef="U_shares">84165</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="INF"
      id="F_be6d5c04-6160-4977-b1ef-7a6732d1bcf2"
      unitRef="U_shares">84165</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_acfe5755-3ae1-4a5a-b7b0-5f043022b2ae"
      unitRef="U_USD">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_3fbd2093-cd96-437a-be94-3a27dc8e2bb4"
      unitRef="U_USD">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_77a8410c-4e3c-4060-829b-0d8b55ac4402"
      unitRef="U_USD">154218000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_6e50737b-dc7c-4bbc-97ea-d00034ac8717"
      unitRef="U_USD">40402000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_a07ba786-30c5-4eb5-b907-fe5e65ee816f"
      unitRef="U_USD">-146064000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_bcd704f4-ea19-434a-8fa8-9bef64fd9dd0"
      unitRef="U_USD">-111707000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_e9c6e4f2-b585-4330-83ce-ae3565e5cbbf"
      unitRef="U_USD">2000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_eb32f7f3-f91a-4e57-94ed-8a2cd6277afb"
      unitRef="U_USD">8157000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_27361f8e-d2e4-4e18-9632-df1df55eaff4"
      unitRef="U_USD">-71304000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_0b10ba49-e638-4c78-a54a-9888966766fe"
      unitRef="U_USD">12185000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_bc510887-a4b0-4ae0-873b-595e6b2a11b8"
      unitRef="U_USD">3349000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_858639b4-5bce-46d9-bfa6-88f9cd9232a5"
      unitRef="U_USD">15859000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_01b152f1-1ff8-4be9-863f-2a38a9f9517b"
      unitRef="U_USD">8350000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_5d8b5919-4250-4506-af50-419773c4e4ca"
      unitRef="U_USD">22216000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_dcf08190-0b11-42c4-af6b-acb23e58d70c"
      unitRef="U_USD">5843000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_876c462a-a08e-424c-bf29-e217770a1c48"
      unitRef="U_USD">38075000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_0d8ab2a8-d7b6-4cee-a22e-694cb917a3b3"
      unitRef="U_USD">14193000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_a4e2374c-8a68-4c04-8ff0-ebb9917856b5"
      unitRef="U_USD">-38075000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_bc536ecf-6c25-44a1-9b76-e6a280bbaac2"
      unitRef="U_USD">-14193000</us-gaap:OperatingIncomeLoss>
    <calc:ChangeInFairValueOfWarrantLiability
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_f7f1dbb9-fc67-4599-9566-712a35be678c"
      unitRef="U_USD">1146000</calc:ChangeInFairValueOfWarrantLiability>
    <calc:ChangeInFairValueOfWarrantLiability
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_ab345c4a-ac00-466e-a1ed-59cceeb7298c"
      unitRef="U_USD">3784000</calc:ChangeInFairValueOfWarrantLiability>
    <calc:ChangeInFairValueOfConvertiblePromissoryNote
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_18ff4ddb-1c99-4e9d-bc70-b9626c405f2d"
      unitRef="U_USD">2022000</calc:ChangeInFairValueOfConvertiblePromissoryNote>
    <calc:ChangeInFairValueOfConvertiblePromissoryNote
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_32fc00b0-862a-4143-9f88-71db40940c48"
      unitRef="U_USD">2745000</calc:ChangeInFairValueOfConvertiblePromissoryNote>
    <calc:InterestOnConvertiblePromissoryNotesPayable
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_0ad543d7-24c4-46fc-8453-1eb1649bbc54"
      unitRef="U_USD">110000</calc:InterestOnConvertiblePromissoryNotesPayable>
    <calc:InterestOnConvertiblePromissoryNotesPayable
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_78072663-0a4f-41b5-b4d8-142bf7a21476"
      unitRef="U_USD">132000</calc:InterestOnConvertiblePromissoryNotesPayable>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_2b27024c-c918-4248-8bd8-6a7fae4470eb"
      unitRef="U_USD">660000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_41fda656-1e27-4737-bca2-db4e10afb5f2"
      unitRef="U_USD">-28000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_d023c234-8782-4880-adfd-d5623ef1c964"
      unitRef="U_USD">3718000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_eec38c97-3c22-4596-bbd6-b986dd0cd36a"
      unitRef="U_USD">6369000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_c0a364e8-ff01-4ecb-abf2-7015e18f3d5d"
      unitRef="U_USD">-34357000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_9988b3aa-2b37-4d97-880e-d1687d76463e"
      unitRef="U_USD">-7824000</us-gaap:NetIncomeLoss>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_6873d706-3731-4900-9f36-10094971ed4e"
      unitRef="U_USD">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_b4ff2930-21ec-4b24-8eb4-9f2d96e70aa5"
      unitRef="U_USD">-1318000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_5ab9a246-4e8e-4d65-a2de-73b1338db7ee"
      unitRef="U_USD">-34357000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_4b537570-0d34-4902-9889-334588f40502"
      unitRef="U_USD">-9142000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="2"
      id="F_9dd614fb-ab1e-4c1e-997f-46419645d78d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-7.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="2"
      id="F_b6f2c2d6-da63-4555-a581-f13b70e16611"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-7.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="2"
      id="F_b56248a5-71d1-480e-be8d-013a22dc22e0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-111.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="2"
      id="F_b987a0aa-f0ec-4b13-a460-adea7cc15d39"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-111.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="0"
      id="F_d0eaa272-8741-487d-a61a-ea08b7bec13b"
      unitRef="U_shares">4486258</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="0"
      id="F_49315e85-d9af-4fe4-af41-3b1613d7b7d9"
      unitRef="U_shares">4486258</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="0"
      id="F_b33ca86b-a796-4328-ac0a-9dceed2ab92f"
      unitRef="U_shares">82245</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="0"
      id="F_ae7579bc-a117-4507-b3bc-158deb590d48"
      unitRef="U_shares">82245</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_d9956d8d-87b5-443b-9d8d-20053af9696c"
      unitRef="U_USD">-34357000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_ae410bef-a8a5-46db-bd92-ae15d9852dca"
      unitRef="U_USD">-9142000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_2532b4f8-d1bb-4be6-a618-03f916e35b4a"
      unitRef="U_USD">2000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_0a045b45-c407-4b1f-9801-e07427b74c06"
      unitRef="U_USD">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_8e517ed1-c1cf-430e-a7c7-6f4ad1e14812"
      unitRef="U_USD">-34355000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_10e8c548-39b2-485a-9084-2b6cdb0e9628"
      unitRef="U_USD">-9142000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_6739fa84-42ef-4c69-a6c0-24f4f1d63ab1"
      decimals="INF"
      id="F_df2a12f8-eb45-4e92-a272-43e99d7d9bb8"
      unitRef="U_shares">84820880</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="C_6739fa84-42ef-4c69-a6c0-24f4f1d63ab1"
      decimals="-3"
      id="F_09a89814-82cf-4b05-8abf-d22651e40260"
      unitRef="U_USD">62071000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="C_44e3fe9d-1f45-4346-b174-97527637315a"
      decimals="INF"
      id="F_1b4fc4d8-0455-4e1e-b160-f78a2794e368"
      unitRef="U_shares">84165</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_44e3fe9d-1f45-4346-b174-97527637315a"
      decimals="-3"
      id="F_4bd1ee4e-cab4-4321-a744-19504259caa2"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_fdc3b56d-3340-41e6-abd7-2a87c4565e5c"
      decimals="-3"
      id="F_ba2bde47-7ce9-4d0a-8bec-2f13de62590f"
      unitRef="U_USD">40402000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_18921a4e-cb36-49f6-887d-24dcb1c18c90"
      decimals="-3"
      id="F_9e6587b8-a085-4060-bcbb-02a3fd9cb98a"
      unitRef="U_USD">-111707000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_9c966614-f625-4a8d-9dde-653f387df670"
      unitRef="U_USD">-71304000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_63f79bb4-c719-4598-9f7b-e5ab26777c6e"
      decimals="-3"
      id="F_d24222a4-9cc4-496f-9e81-0574361a9d0f"
      unitRef="U_USD">12039000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_ee267117-88d5-4c13-9d78-760837c10b4a"
      unitRef="U_USD">12039000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <calc:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_e88cb3f0-85d9-47a7-b525-8fd14ae13f26"
      decimals="0"
      id="F_3fe92a40-00d5-4f4d-9d51-ba201e8548b1"
      unitRef="U_shares">-84820880</calc:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <calc:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_e88cb3f0-85d9-47a7-b525-8fd14ae13f26"
      decimals="-3"
      id="F_6156894b-b994-4825-92c5-a20feeda6f9a"
      unitRef="U_USD">-62071000</calc:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_f6acf339-8a66-4359-827f-f1d8c3fefcf6"
      decimals="INF"
      id="F_3bc57a73-6098-46f9-865d-cd33dd29edb4"
      unitRef="U_shares">2442852</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_63f79bb4-c719-4598-9f7b-e5ab26777c6e"
      decimals="-3"
      id="F_1a403483-c1eb-4aa4-aef8-786ac0860ae4"
      unitRef="U_USD">62071000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_3413e6a9-ccc8-4c18-8c50-c6061bbd956c"
      unitRef="U_USD">62071000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_c1e00f56-e042-41d9-8c27-e58be2c2e576"
      decimals="4"
      id="F_d117bc76-af0d-4ea5-aaf8-efa32506d1b4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <calc:IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMergerShares
      contextRef="C_f6acf339-8a66-4359-827f-f1d8c3fefcf6"
      decimals="INF"
      id="F_78c4b749-8963-4e45-bb44-d0aef4a6d688"
      unitRef="U_shares">1571433</calc:IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMergerShares>
    <calc:IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger
      contextRef="C_63f79bb4-c719-4598-9f7b-e5ab26777c6e"
      decimals="-3"
      id="F_42d97ee2-c7aa-4366-8679-e884a03ce5ab"
      unitRef="U_USD">29218000</calc:IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger>
    <calc:IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_783fa564-4dca-47bc-97f3-3e5d9c01b0d5"
      unitRef="U_USD">29218000</calc:IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger>
    <calc:IssuanceOfCommonSharesFromPrivatePlacementNetShares
      contextRef="C_f6acf339-8a66-4359-827f-f1d8c3fefcf6"
      decimals="INF"
      id="F_10cc939b-5ce1-4639-b488-a80d9817806b"
      unitRef="U_shares">596363</calc:IssuanceOfCommonSharesFromPrivatePlacementNetShares>
    <calc:IssuanceOfCommonSharesFromPrivatePlacementNet
      contextRef="C_63f79bb4-c719-4598-9f7b-e5ab26777c6e"
      decimals="-3"
      id="F_999730d1-7102-4c21-bf43-4cdc51e24089"
      unitRef="U_USD">10340000</calc:IssuanceOfCommonSharesFromPrivatePlacementNet>
    <calc:IssuanceOfCommonSharesFromPrivatePlacementNet
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_0daf86bd-cdce-413f-bf85-c3023130e6b8"
      unitRef="U_USD">10340000</calc:IssuanceOfCommonSharesFromPrivatePlacementNet>
    <calc:StockIssuedDuringPeriodSharesConversionOfPromissoryNotes
      contextRef="C_f6acf339-8a66-4359-827f-f1d8c3fefcf6"
      decimals="INF"
      id="F_f98fb16a-7ac0-454b-9295-7ee0edb4619e"
      unitRef="U_shares">590031</calc:StockIssuedDuringPeriodSharesConversionOfPromissoryNotes>
    <calc:StockIssuedDuringPeriodValueConversionOfPromissoryNotes
      contextRef="C_63f79bb4-c719-4598-9f7b-e5ab26777c6e"
      decimals="-3"
      id="F_2ba40bcf-55d9-4abd-8773-ed253f675fa7"
      unitRef="U_USD">3245000</calc:StockIssuedDuringPeriodValueConversionOfPromissoryNotes>
    <calc:StockIssuedDuringPeriodValueConversionOfPromissoryNotes
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_1672dc8e-6ca1-472d-b80b-7931f1e515e0"
      unitRef="U_USD">3245000</calc:StockIssuedDuringPeriodValueConversionOfPromissoryNotes>
    <calc:ExerciseAndConversionOfC2WarrantsShares
      contextRef="C_f6acf339-8a66-4359-827f-f1d8c3fefcf6"
      decimals="INF"
      id="F_153af6bb-ded7-4c9a-8b33-85731bcbf9e6"
      unitRef="U_shares">80254</calc:ExerciseAndConversionOfC2WarrantsShares>
    <calc:ConversionOfSeriesC2WarrantIntoCommonStock
      contextRef="C_63f79bb4-c719-4598-9f7b-e5ab26777c6e"
      decimals="-3"
      id="F_e42107ad-c401-42a6-b191-acdfc423824b"
      unitRef="U_USD">442000</calc:ConversionOfSeriesC2WarrantIntoCommonStock>
    <calc:ConversionOfSeriesC2WarrantIntoCommonStock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_c1b327e0-8559-48d8-9998-2721f273b4b0"
      unitRef="U_USD">442000</calc:ConversionOfSeriesC2WarrantIntoCommonStock>
    <calc:ConversionOfPromissoryNoteWarrantsIntoCommonStockShare
      contextRef="C_f6acf339-8a66-4359-827f-f1d8c3fefcf6"
      decimals="INF"
      id="F_6a5455d3-ed7c-4191-95d7-b8d91d7b9853"
      unitRef="U_shares">152875</calc:ConversionOfPromissoryNoteWarrantsIntoCommonStockShare>
    <calc:ConversionOfPromissoryNoteWarrantIntoCommonstock
      contextRef="C_63f79bb4-c719-4598-9f7b-e5ab26777c6e"
      decimals="-3"
      id="F_127ffc45-deb8-4560-a841-ffe8b3d340b5"
      unitRef="U_USD">841000</calc:ConversionOfPromissoryNoteWarrantIntoCommonstock>
    <calc:ConversionOfPromissoryNoteWarrantIntoCommonstock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_bb357d5e-270c-4f21-bb17-b5f2e72366e5"
      unitRef="U_USD">841000</calc:ConversionOfPromissoryNoteWarrantIntoCommonstock>
    <calc:MergerTransactionCosts
      contextRef="C_63f79bb4-c719-4598-9f7b-e5ab26777c6e"
      decimals="-3"
      id="F_9d57f2fa-d28d-4d69-a3fb-eea091d37120"
      unitRef="U_USD">-4545000</calc:MergerTransactionCosts>
    <calc:MergerTransactionCosts
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_27bccf6d-312e-4c64-b6f4-82580d3965f8"
      unitRef="U_USD">-4545000</calc:MergerTransactionCosts>
    <calc:RestrictedStockUnitsNetSettlementShares
      contextRef="C_f6acf339-8a66-4359-827f-f1d8c3fefcf6"
      decimals="INF"
      id="F_4a151b45-9c5a-4075-854e-649bd711b527"
      unitRef="U_shares">143960</calc:RestrictedStockUnitsNetSettlementShares>
    <calc:RestrictedStockUnitsNetSettlement
      contextRef="C_63f79bb4-c719-4598-9f7b-e5ab26777c6e"
      decimals="-3"
      id="F_963b7ad7-8132-4212-b560-c0efe257944d"
      unitRef="U_USD">-297000</calc:RestrictedStockUnitsNetSettlement>
    <calc:RestrictedStockUnitsNetSettlement
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_fcc11a0d-97b2-4407-8fe1-bd9786ce7985"
      unitRef="U_USD">-297000</calc:RestrictedStockUnitsNetSettlement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_63f79bb4-c719-4598-9f7b-e5ab26777c6e"
      decimals="-3"
      id="F_4680ca76-0261-4097-98be-ec9a5ec5316b"
      unitRef="U_USD">216000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_620a8adb-626b-4096-939f-4307204899cd"
      unitRef="U_USD">216000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_f6acf339-8a66-4359-827f-f1d8c3fefcf6"
      decimals="INF"
      id="F_278c6ff8-847b-4962-bd34-02fbdc762c20"
      unitRef="U_shares">92572</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_63f79bb4-c719-4598-9f7b-e5ab26777c6e"
      decimals="-3"
      id="F_eb029d07-feb0-46d1-a78a-f11248c8b937"
      unitRef="U_USD">246000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_a01feadc-734c-41ca-aae7-9f239dd349ae"
      unitRef="U_USD">246000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_a1517846-ee85-4222-be99-133ea3be307b"
      decimals="-3"
      id="F_4845c48d-f51b-4b6b-8e8c-540e735b40bb"
      unitRef="U_USD">2000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_b73d297c-d85a-4a35-a7c3-95d4c2fa5775"
      unitRef="U_USD">2000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_f099418b-2bfe-4abc-80ff-3d27b357e283"
      decimals="-3"
      id="F_9bce2415-3e7c-455e-9cab-a68bd2090560"
      unitRef="U_USD">-34357000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_864b9721-627b-4931-8d4d-0a3b9671890f"
      unitRef="U_USD">-34357000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_77f977df-d971-4d4d-ae88-a3dd669b55f9"
      decimals="0"
      id="F_9b3f81f4-28a0-444d-9a2b-0091ef14ee99"
      unitRef="U_shares">5754505</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_77f977df-d971-4d4d-ae88-a3dd669b55f9"
      decimals="-3"
      id="F_f21e5d3d-e9cb-4007-891d-59ea88ab8639"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0e691536-6f2f-49ff-ae16-8151a9648a89"
      decimals="-3"
      id="F_b666d448-f970-4020-bcf7-89be2b0674ae"
      unitRef="U_USD">154218000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d14e56e9-7918-4c0f-9cbf-a1b9ce18ce28"
      decimals="-3"
      id="F_fc6623a2-7a87-4909-b23e-325b0d8c80e2"
      unitRef="U_USD">-146064000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3815767b-a76b-4eab-8224-c12657500927"
      decimals="-3"
      id="F_60582995-92fe-4e92-a20f-630a181e8ab9"
      unitRef="U_USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_133bf32d-885f-4ce2-a881-7dda5f7c1d87"
      unitRef="U_USD">8157000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_28b5f7e3-7c54-4635-9e19-0a894d5bce7d"
      decimals="INF"
      id="F_653e16b7-bfd8-48a8-adbe-099c4cbd6e40"
      unitRef="U_shares">84820880</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="C_28b5f7e3-7c54-4635-9e19-0a894d5bce7d"
      decimals="-3"
      id="F_abfd3d94-e97c-4d7d-93da-21000f70a852"
      unitRef="U_USD">62071000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="C_bd0bc60c-d4f5-4ec3-a673-0505d888ab7e"
      decimals="INF"
      id="F_7fa10f53-be99-4967-bf37-e3fa0474e69a"
      unitRef="U_shares">78527</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_bd0bc60c-d4f5-4ec3-a673-0505d888ab7e"
      decimals="-3"
      id="F_8f2f002b-1bd3-437f-bf29-483769287156"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_70e26569-927c-4f36-a60f-3d66c9bd4f1b"
      decimals="-3"
      id="F_a90ba9c6-3e69-4a14-9d5b-e426367ed758"
      unitRef="U_USD">39895000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f3902d69-3631-4f29-9f8f-24d3fa1a5357"
      decimals="-3"
      id="F_b9d8336f-3890-4043-9995-6e780f43215e"
      unitRef="U_USD">-103883000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c2ab8d40-d474-4916-9e68-da10e0f82c62"
      decimals="-3"
      id="F_b1745aaa-ce03-42da-b1a6-98a0481feb87"
      unitRef="U_USD">-63987000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_0a6fe6b9-36ef-4f25-b46f-fe2f867d0a7c"
      decimals="0"
      id="F_cfd884d5-1492-4801-8aee-6abccadf0736"
      unitRef="U_shares">1138</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_824ded8d-e1b3-4524-b35d-2636e88b1f27"
      decimals="-3"
      id="F_df4b8ac7-51da-463e-9c9c-dbe9dcca068b"
      unitRef="U_USD">8000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_6f53cdfb-67ba-4237-969d-ed0611146511"
      unitRef="U_USD">8000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0a6fe6b9-36ef-4f25-b46f-fe2f867d0a7c"
      decimals="INF"
      id="F_517b309f-2bec-48a6-9421-c2710b7d70bc"
      unitRef="U_shares">4500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_824ded8d-e1b3-4524-b35d-2636e88b1f27"
      decimals="-3"
      id="F_05360190-5bd1-462e-bf7b-62f5d8dc51e2"
      unitRef="U_USD">18000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_ca873050-cc96-44d1-8bfa-865790a418df"
      unitRef="U_USD">18000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_824ded8d-e1b3-4524-b35d-2636e88b1f27"
      decimals="-3"
      id="F_53a10c95-e0d7-4999-8f71-8d0c4e705b49"
      unitRef="U_USD">1799000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_26fee8db-fd6b-4fe9-b409-5e98d2df61d2"
      unitRef="U_USD">1799000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <calc:DeemedDistribution
      contextRef="C_824ded8d-e1b3-4524-b35d-2636e88b1f27"
      decimals="-3"
      id="F_be733402-76c9-42b2-ac17-f92acf5177c3"
      unitRef="U_USD">-1318000</calc:DeemedDistribution>
    <calc:DeemedDistribution
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_77023610-40d9-41be-b2fa-76e7f8dcce92"
      unitRef="U_USD">-1318000</calc:DeemedDistribution>
    <us-gaap:NetIncomeLoss
      contextRef="C_f0c2863c-d6f8-4c28-a7b2-bb4074acd7b8"
      decimals="-3"
      id="F_f773b99e-e092-43b8-b105-11fd67e300ed"
      unitRef="U_USD">-7824000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_4246f750-75ee-4e2a-abd6-1a856a263eff"
      unitRef="U_USD">-7824000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_6739fa84-42ef-4c69-a6c0-24f4f1d63ab1"
      decimals="0"
      id="F_4b5f0346-0c24-488f-9425-b68555cebfc0"
      unitRef="U_shares">84820880</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="C_6739fa84-42ef-4c69-a6c0-24f4f1d63ab1"
      decimals="-3"
      id="F_86f8a34f-0bf0-4a83-8f0d-9313acb8deb6"
      unitRef="U_USD">62071000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="C_44e3fe9d-1f45-4346-b174-97527637315a"
      decimals="0"
      id="F_d68003c6-190c-4d89-9889-20ee5b4c0a7c"
      unitRef="U_shares">84165</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_44e3fe9d-1f45-4346-b174-97527637315a"
      decimals="-3"
      id="F_2f2d26a2-030f-4324-88bf-764c72e52368"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_fdc3b56d-3340-41e6-abd7-2a87c4565e5c"
      decimals="-3"
      id="F_5acdf623-9679-4211-80d3-17ff2a425bd0"
      unitRef="U_USD">40402000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_18921a4e-cb36-49f6-887d-24dcb1c18c90"
      decimals="-3"
      id="F_2cd1ea5c-d08c-4219-9e67-70e302644367"
      unitRef="U_USD">-111707000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_4c6fbfc8-5564-414d-9678-3a300de013b7"
      unitRef="U_USD">-71304000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_321f8514-869b-4786-992e-c17be69b64d0"
      unitRef="U_USD">-34357000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_0c70256d-6b70-439f-b9be-bc38fb2803d8"
      unitRef="U_USD">-7824000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_9b05dca6-aeb8-4cb8-9627-26e879ca7c0d"
      unitRef="U_USD">12039000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_ffdcdc82-2903-48e5-983d-4f5493465944"
      unitRef="U_USD">1807000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_d40ca9e0-bdef-4ac4-a2ba-2d3536073b13"
      unitRef="U_USD">58000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_27241647-d9d0-4f2b-af61-f39a029f0d0c"
      unitRef="U_USD">52000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_50f5d0ab-10c6-4f98-bc04-7ea543da3c51"
      unitRef="U_USD">-1146000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_789b497a-e979-4889-88a8-ee33ad9f40b7"
      unitRef="U_USD">-3784000</us-gaap:FairValueAdjustmentOfWarrants>
    <calc:FairValueAdjustmentOfConvertiblePromissoryNotes
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_c3b7caf4-c2c1-4054-a2d7-3924958bd389"
      unitRef="U_USD">-2022000</calc:FairValueAdjustmentOfConvertiblePromissoryNotes>
    <calc:FairValueAdjustmentOfConvertiblePromissoryNotes
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_5be64326-5ca9-409c-a168-2ac79b235b87"
      unitRef="U_USD">-2745000</calc:FairValueAdjustmentOfConvertiblePromissoryNotes>
    <calc:NonCashInterestExpense
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_a4c6ffee-b65a-4d1a-b48c-c166da4c5837"
      unitRef="U_USD">110000</calc:NonCashInterestExpense>
    <calc:NonCashInterestExpense
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_4d3ba80d-294a-4a6f-bf2a-50a744e67265"
      unitRef="U_USD">132000</calc:NonCashInterestExpense>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_cc8566b0-bdab-440a-889c-3120c64642c7"
      unitRef="U_USD">145000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <calc:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndNoncurrentAssets
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_e8d72dd0-7725-4924-9aeb-4b1cea6a4f61"
      unitRef="U_USD">-2997000</calc:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndNoncurrentAssets>
    <calc:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndNoncurrentAssets
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_926faf54-2a2b-43d6-9117-ac5bcf002d56"
      unitRef="U_USD">1530000</calc:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_66710324-ad46-45aa-9f92-bdf34677e9e7"
      unitRef="U_USD">-1427000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_ce6d4772-4c10-4843-b806-9e1fcfc03bdc"
      unitRef="U_USD">933000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_4f6be1bd-ea90-43c9-bba2-923217bfe5c6"
      unitRef="U_USD">-1837000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_2ccb06f5-e94e-42f2-98a2-4535182e9653"
      unitRef="U_USD">1202000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_f0fc7ed5-5aa8-432f-9ac0-0d08f6e5af90"
      unitRef="U_USD">-25730000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_25613843-20d9-4e16-bab0-5dc22124952e"
      unitRef="U_USD">-11757000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_dc0f247f-c31c-434a-97b8-61c91bab4b8a"
      unitRef="U_USD">78000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_9f0ce381-8930-41a0-8716-a6148210fdd9"
      unitRef="U_USD">4000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_8620c546-ddb1-4e3e-88f0-aecad1882ca2"
      unitRef="U_USD">6118000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_89c332e9-0625-4246-907e-296e36d719e0"
      unitRef="U_USD">15080000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_d6e0e707-ef53-4bc6-8383-4261a7cbb8e9"
      unitRef="U_USD">8884000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_f812ef6c-bee1-4b1f-875f-dfc12f359a87"
      unitRef="U_USD">-4000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_5040611b-8066-4845-b152-d98d1c16de0d"
      unitRef="U_USD">10340000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <calc:PaymentsOfAcquisitionOfBusinessesNetOfCash
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_f741cc88-5327-4c56-8b3d-0d4273393e57"
      unitRef="U_USD">-14859000</calc:PaymentsOfAcquisitionOfBusinessesNetOfCash>
    <us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_6353625f-15c8-4cd1-b060-3b380e4498fc"
      unitRef="U_USD">4545000</us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities>
    <calc:ProceedsFromIssuanceOfConvertibleNotes
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_a962e11c-bbb9-4cdc-9cfb-824eb76cdd55"
      unitRef="U_USD">8458000</calc:ProceedsFromIssuanceOfConvertibleNotes>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_9f2e5d6b-007e-4481-8408-cfa84156ce32"
      unitRef="U_USD">246000</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_d29c1113-3959-4079-9d86-85205935cc44"
      unitRef="U_USD">18000</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_6caeeeb6-54e8-4415-898f-75a8629293fa"
      unitRef="U_USD">20900000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_2edddd36-8a10-4c10-b98b-ed1e1e4268ab"
      unitRef="U_USD">8476000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_b473ec85-46e3-41d3-a631-e684421185b6"
      unitRef="U_USD">4054000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_fd3a650d-fc54-4136-aec3-fbe1cf281cbc"
      unitRef="U_USD">-3285000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_9072f550-56bc-4cda-aa75-b6aefeaf7fea"
      unitRef="U_USD">1476000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_c2ab8d40-d474-4916-9e68-da10e0f82c62"
      decimals="-3"
      id="F_0973619b-4d90-4af1-9672-802c23ed52d6"
      unitRef="U_USD">4761000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_d75c3c34-5e00-49b0-b62c-cdac5c0ac8a2"
      unitRef="U_USD">5530000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_ea8b36e6-1623-4b53-94d2-a49013fb1f19"
      unitRef="U_USD">1476000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <calc:CostsIncurredInConnectionWithReverseMergerIncludedInAccountsPayableAndAccruedExpenses
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_2de02041-b154-45aa-830c-125bb2b2e088"
      unitRef="U_USD">1313000</calc:CostsIncurredInConnectionWithReverseMergerIncludedInAccountsPayableAndAccruedExpenses>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_8a2da30a-8cad-4d30-af5f-542511f03065"
      unitRef="U_USD">62071000</us-gaap:ConversionOfStockAmountIssued1>
    <calc:IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_e9fe576e-27a6-467e-abe4-fda7403d4744"
      unitRef="U_USD">29218000</calc:IssuanceOfCommonStockToGraybugStockholdersAsAResultOfTheMerger>
    <calc:ShortTermInvestmentsAssumedInTheMerger
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_4ff603a2-87ae-48f7-8863-5a340a09e710"
      unitRef="U_USD">9776000</calc:ShortTermInvestmentsAssumedInTheMerger>
    <calc:PrepaidExpensesAndOtherCurrentAssets
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_02bf0a87-053f-4d40-9b15-0de8a825c283"
      unitRef="U_USD">2096000</calc:PrepaidExpensesAndOtherCurrentAssets>
    <calc:AccountsPayableAndAccruedLiabilitiesAssumedInTheMerger
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_cf8160b6-845e-4ad0-bb37-f21486a377dc"
      unitRef="U_USD">2258000</calc:AccountsPayableAndAccruedLiabilitiesAssumedInTheMerger>
    <calc:ConversionOfC2WarrantsToCommonStock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_a8a5ea31-da83-4f94-9531-0b8388e9da29"
      unitRef="U_USD">442000</calc:ConversionOfC2WarrantsToCommonStock>
    <calc:ConversionOfConvertiblePromissoryNotesToCommonStock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_478c2f17-a407-4d2f-abde-5951c8edeb79"
      unitRef="U_USD">3245000</calc:ConversionOfConvertiblePromissoryNotesToCommonStock>
    <calc:ConversionOfConvertiblePromissoryNoteWarrantsToCommonStock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_9255ac68-22e5-47ce-9478-f872172f0b96"
      unitRef="U_USD">841000</calc:ConversionOfConvertiblePromissoryNoteWarrantsToCommonStock>
    <calc:FinancingCostsIncludedInAccountsPayable
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_eb014fe9-59dd-41f9-bd61-c92d08da9bb4"
      unitRef="U_USD">45000</calc:FinancingCostsIncludedInAccountsPayable>
    <calc:RestrictedStockUnitsNetSettlement
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_0b53eda4-9177-4c48-b94e-e60380344892"
      unitRef="U_USD">-297000</calc:RestrictedStockUnitsNetSettlement>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_e3966a2e-14e9-445e-9e72-d7c61f298cd0"
      unitRef="U_USD">216000</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <us-gaap:NatureOfOperations
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_4329712d-5461-4702-8fe1-24b319608a9d">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1. Nature of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Description of Business&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;CalciMedica, Inc. (&#x201c;CalciMedica&#x201d; or the &#x201c;Company&#x201d;) (f/k/a Graybug Vision, Inc.) was incorporated in the state of Delaware in February 2015, following the conversion of Graybug, LLC, which was organized in May 2011, and has its principal operations in La Jolla, California. The Company is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory processes and direct cellular damage.&#x200b; The Company has a wholly owned subsidiary, CalciMedica Subsidiary, Inc., incorporated in Delaware in October 2006, which survived the Merger as more fully described below.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Reverse Merger Transaction&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On March 20, 2023, Graybug Vision, Inc. (&#x201c;Graybug&#x201d;) completed a reverse merger transaction in accordance with the terms and conditions of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended on February 10, 2023 (the &#x201c;Merger Agreement&#x201d;), by and among Graybug, Camaro Merger Sub, Inc., a wholly owned subsidiary of Graybug (&#x201c;Merger Sub&#x201d;), and CalciMedica, Inc. (&#x201c;Private CalciMedica&#x201d;), pursuant to which Merger Sub merged with and into Private CalciMedica, with Private CalciMedica surviving as a wholly owned subsidiary of Graybug (the &#x201c;Merger&#x201d;). Additionally, on March 20, 2023, Graybug changed its name from &#x201c;Graybug Vision, Inc.&#x201d; to &#x201c;CalciMedica, Inc.&#x201d; and Private CalciMedica changed its name from &#x201c;CalciMedica, Inc.&#x201d; to &#x201c;CalciMedica Subsidiary, Inc.&#x201d; At the completion of the Merger, the prior Private CalciMedica equity holders and the prior Graybug equity holders owned &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, respectively of the combined company, in each case, on a fully diluted basis using the treasury stock method and excluding out-of-the-money options and warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Merger was accounted for as a reverse recapitalization, with Private CalciMedica being treated as the acquirer for accounting purposes. See discussions of the transactions in connection with the Merger in Note 3 - Merger and Related Transactions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has experienced net losses and negative cash flows from operating activities since its inception. The Company has an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;146.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of December 31, 2023, and a net loss of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the year ended December 31, 2023. Total operating expenses for the year ended December 31, 2023 were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which included $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of one-time charges comprised of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of charges related to the acceleration of vesting of the Graybug stock awards at the date of the Merger and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of charges related to severance as a result of the Merger. Substantially all of the Company&#x2019;s operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company expects to incur significant expenses and increasing operating losses for the foreseeable future as the Company initiates and continues the preclinical and clinical development of its product candidates and adds personnel necessary to operate as a company with an advanced clinical pipeline of product candidates. In addition, after completion of the Merger, operating as a U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) registrant will involve the hiring of additional financial and other personnel, upgrading financial information systems, and incurring costs associated with operating as a public company. The Company expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of clinical development programs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;From inception to December 31, 2023, the Company has completed financings from the sale of preferred and common stock for total net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;112.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and has issued convertible debt for net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. In connection with the Merger, the Company received approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of cash, cash equivalents and short-term investments. As of December 31, 2023, the Company had cash, cash equivalents and short-term investments of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Company closed a&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; private placement transaction on January 23, 2024 and the second closing of this private placement occurred on February 5, 2024. Gross proceeds from the transaction were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million with net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million after deducting $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in commissions and other transaction expenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company intends to seek additional funding through public and private financings, debt financings, collaboration agreements, strategic alliances and licensing agreements. Although the Company has been successful in raising capital in the past, there is no assurance of success in obtaining such additional financing on terms acceptable to us, it at all, and there is no assurance that the Company will be able to enter into collaborations or other arrangements. If the Company is unable to obtain funding when required or on acceptable terms, the Company may be required to scale back or discontinue the advancement of the product candidates, reduce headcount, file for bankruptcy, reorganize, merge with another entity or cease operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Based on the Company&#x2019;s current operating plans, management believes its cash, cash equivalents and short-term investments will be sufficient to fund its operations for the period of at least one year following the issuance of these financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_dc6f3b09-7f0d-4955-b288-aa892fd2868e"
      decimals="2"
      id="F_5ea2fa75-3e3b-40b9-bb75-4c2889cd6dcc"
      unitRef="U_pure">0.72</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_bd0f357b-9782-4dba-b331-d7e9654967b9"
      decimals="2"
      id="F_00eb1912-2454-46ae-8bfd-86a644ce9380"
      unitRef="U_pure">0.28</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-5"
      id="F_55b5673f-fb36-481b-b5e5-de03419cc975"
      unitRef="U_USD">-146100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-5"
      id="F_d2a77077-2f7b-4313-a5a0-8311bd637954"
      unitRef="U_USD">-34400000</us-gaap:NetIncomeLoss>
    <us-gaap:OperatingExpenses
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-5"
      id="F_cf8b0921-d3c2-43c8-ba61-0991bc9c1a12"
      unitRef="U_USD">38100000</us-gaap:OperatingExpenses>
    <us-gaap:SeveranceCosts1
      contextRef="C_0e01fe61-f63d-4314-9813-8fdd75652190"
      decimals="-5"
      id="F_fce7f27b-4616-4ea7-84c5-7582b6c3cd21"
      unitRef="U_USD">16200000</us-gaap:SeveranceCosts1>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-5"
      id="F_9fbd5699-2ce0-481d-88ab-932c715f77f7"
      unitRef="U_USD">10500000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:SeveranceCosts1
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-5"
      id="F_ceb5f36d-0a86-4495-a902-b84ba4e8ce0a"
      unitRef="U_USD">5700000</us-gaap:SeveranceCosts1>
    <calc:TotalNetProceeds
      contextRef="C_ca2b5abc-6893-4a09-9891-e889e91a1af0"
      decimals="-5"
      id="F_037e5103-80d9-4b35-bc37-bc4131a23209"
      unitRef="U_USD">112600000</calc:TotalNetProceeds>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="C_69c89aa6-a735-464c-af58-9f7d7d6733ad"
      decimals="-5"
      id="F_4a26c127-4400-43d0-ab97-70a714aca562"
      unitRef="U_USD">8600000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-5"
      id="F_fef85283-2237-4fe2-9b3a-4a92612f25de"
      unitRef="U_USD">29400000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-5"
      id="F_423c5b6c-2252-4d93-9ed9-24951456a58d"
      unitRef="U_USD">11200000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <calc:GrossProceedsFromThePrivatePlacement
      contextRef="C_9ef48710-53ac-4e62-b939-0912f0ec48d0"
      decimals="-5"
      id="F_f1f3753d-58b9-4959-b495-e7eeba7c18b6"
      unitRef="U_USD">20400000</calc:GrossProceedsFromThePrivatePlacement>
    <calc:NetProceedsFromPrivatePlacement
      contextRef="C_9ef48710-53ac-4e62-b939-0912f0ec48d0"
      decimals="-5"
      id="F_3b3f3219-fc46-4a2d-baf9-4a1fc48d9eea"
      unitRef="U_USD">19000000</calc:NetProceedsFromPrivatePlacement>
    <calc:CommissionsAndOtherTransactionExpenses
      contextRef="C_9ef48710-53ac-4e62-b939-0912f0ec48d0"
      decimals="-5"
      id="F_cd4ca947-c618-4700-b7af-9387d216d153"
      unitRef="U_USD">1400000</calc:CommissionsAndOtherTransactionExpenses>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_b2df8911-3bc2-4f9c-b133-34c590739d97">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;), and Accounting Standards Update (&#x201c;ASU&#x201d;), of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The consolidated financial statements include the accounts of the Company and CalciMedica Subsidiary, Inc. for the years ended December 31, 2023 and 2022. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Since Private CalciMedica was determined to be the accounting acquirer in connection with the Merger, for periods prior to the Merger, the consolidated financial statements were prepared on a stand-alone basis for Private CalciMedica and did not include the combined entities activity or financial position. Subsequent to the Merger, the consolidated financial statements as of and for the year ended December 31, 2023 include Graybug&#x2019;s activity from March 21, 2023 through December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and assets and liabilities at their acquisition date fair value. Historical share and per share figures of Private CalciMedica have been retroactively restated based on the merger exchange ratio of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0288&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of the Company&#x2019;s consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to accruals for research and development expenses, valuation of warrants, valuation of convertible promissory notes and valuation of equity awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#x2019;s future results of operations will be affected.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk and other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments, which potentially subject the Company to concentration of risk, consist principally of cash and cash equivalents. The Company&#x2019;s cash is deposited with major federally insured U.S. financial institutions. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is dependent on contract manufacturing organizations (&#x201c;CMO&#x201d;) to supply products for research and development of its product candidates, including preclinical and clinical studies, and for commercialization of its product candidates, if approved. The Company&#x2019;s development programs could be adversely affected by any significant interruption in CMO&#x2019;s operations or by a significant interruption in the supply of active pharmaceutical ingredients and other components.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Products developed by the Company require approval from the FDA or other international regulatory agencies prior to commercial sales. There can be no assurance the Company&#x2019;s product candidates will receive the necessary approvals. If the Company is denied approvals, approvals are delayed, or the Company is unable to maintain approvals received, such events could have a materially adverse impact on the Company.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash and cash equivalents consist of readily available cash in checking accounts, money market funds and commercial paper. The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Short-term Investments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company invests excess cash in commercial paper and U.S government sponsored entities - mortgage-backed securities. These investments are included in short-term investments on the balance sheet, classified as available-for-sale and reported at fair value with unrealized gains and losses included in accumulated other comprehensive (loss)/gain, net. Realized gains and losses on the sale of these securities are recognized in net loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The financial information is regularly reviewed by the chief operating decision maker (&#x201c;CODM&#x201d;), in deciding how to allocate resources. The Company&#x2019;s CODM is its chief executive officer. The Company&#x2019;s singular focus is on developing highly selective calcium release-activated calcium channel inhibitors to improve outcomes for patients with acute inflammatory indications. No significant revenue has been generated since inception, and all tangible assets are held in the United States.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value Option&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As permitted under ASC 825, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the Company has elected the fair value option to account for its convertible promissory notes due to certain embedded features within the notes. The Company recognizes the convertible&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;promissory &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;notes at fair value with changes in fair value recognized in the consolidated statements of operations located on the change in fair value of financial instruments line item. Changes in fair value as a result of the Company&#x2019;s own credit risk is reflected in other income (expense) in the consolidated statements of operations. As a result of applying the fair value option, direct costs and fees related to the convertible promissory notes were expensed as incurred and not deferred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally three to five years) and consist of manufacturing and lab equipment, furniture, computers and phones. Repairs and maintenance costs are charged to expense as incurred. Depreciation expense recognized for the years ended December 31, 2023 and 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Long-lived Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Long-lived assets consist primarily of property and equipment. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate the carrying amount of an asset is not recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value would be assessed using discounted cash flows or other appropriate measures of fair value. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t recognize any impairment losses for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company leases office space with an original lease term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_96e7d778-f45a-41e2-8962-c4c3904214d6;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;twelve months &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and does &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t have a right-of-use asset or lease liability recorded. The Company's policy is not to record leases with an original term of twelve months or less on the consolidated balance sheets. The Company recognizes lease expense for this short-term lease on a straight-line basis over the term of the lease. The lease is accounted for under ASC 842, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and has been classified as an operating lease. Rent expense recognized for the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;274,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;221,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development costs consist primarily of salaries, payroll taxes, employee benefits and stock-based compensation for those individuals involved in ongoing research and development efforts, as well as fees paid to consultants, external research fees, license fees paid to third parties for use of their intellectual property, laboratory supplies and development of compound materials, associated overhead expenses and facilities and depreciation costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. All research and development costs are expensed as incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company estimates preclinical studies and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on the Company&#x2019;s behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers,  and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. The estimates are trued up to reflect the best information available at the time of the financial statement issuance. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#x2019;s estimate of the status and timing of services performed relative to the actual status and timing of services performed may vary.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;General and Administrative Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation, related to executive, finance, business development, legal, human resources and support functions, including professional fees for auditing, tax, consulting and patent-related services, rent and utilities and insurance.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Patent Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Costs related to filing and pursuing patent applications are expensed as incurred since recoverability of such expenditures is uncertain.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company capitalizes costs that are directly associated with equity financings until such financings are consummated at which time such costs are recorded against the gross proceeds of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss. Private CalciMedica had deferred offering costs capitalized as of December 31, 2022 for the Merger of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. As of December 31, 2023, the Company has deferred costs associated with its at-the-market offering of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Warrant Liability&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Private CalciMedica has issued various freestanding warrants to purchase shares of its convertible preferred stock. Prior to the Merger, Private CalciMedica adjusted the carrying value of such convertible preferred stock warrants to the estimated fair value at each reporting date, with any related increases or decreases in the fair value being recorded within other income (expense) in the consolidated statements of operations and comprehensive loss. Pursuant to the Merger Agreement, the Series C convertible preferred stock warrants became warrants to purchase shares of the combined company's common stock. As a result of the Merger, the warrants no longer meet the requirements for liability accounting and, as such, Private CalciMedica adjusted the value of the warrants to the estimated fair value as of the Merger date and reclassified them to stockholders' equity (deficit).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense represents the cost of the grant date fair value of employee stock options recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. Private CalciMedica estimates the fair value of stock option grants using the Black-Scholes option pricing model (&#x201c;Black-Scholes&#x201d;). Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. Equity-based compensation expense is classified in the statements of operations in the same manner in which the award recipients&#x2019; payroll costs are classified or in which the award recipients&#x2019; service payments are classified. The fair value of each stock option grant is estimated on the date of grant using Black Scholes. The following summarizes the inputs used:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prior to the Merger, there was no public market for Private CalciMedica&#x2019;s common stock. The fair value of the shares of common stock underlying Private CalciMedica&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2019;s share-based awards was estimated on each grant date by Private CalciMedica&#x2019;s board of directors. To determine the fair value of Private CalciMedica&#x2019;s common stock underlying option grants, the board of directors considered, among other things, input from management and valuations of Private CalciMedica's common stock prepared by third-party valuation firms.&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Post Merger, CalciMedica uses the closing stock price the day prior to the grant date for the fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The risk-free interest ra&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;te is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities similar to the expected term of the awards.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected Volatility&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prior to the merger, since Private CalciMedica did not have publicly traded equity securities, the volatility of the options has been estimated using peer group volatility information. Post Merger, CalciMedica uses an average volatility for comparable publicly-traded biopharmaceutical companies over a period equal to the expected term of the stock award grant as CalciMedica does not yet have sufficient historical trading history for its own stock. CalciMedica will continue to apply this method until a sufficient amount of historical information over a period equal to the expected term of the stock-based awards becomes available.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected Term&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;CalciMedica used the simplified method to calc&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ulate the expected term for all grants during all periods, which is based on the midpoint between the vesting date and the end of the contractual term.&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected Dividend Yield&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;CalciMedica has never paid and has no present intention to pay cash dividends.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources which are excluded from net loss. The Company&#x2019;s only element of other comprehensive loss is unrealized gains and losses on marketable securities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Related Party Transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s board of directors reviews and approves transactions with directors, officers and holders of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% or more of its voting securities and their affiliates, each a related party. The material facts as to the related party&#x2019;s relationship or interest in the transaction are disclosed to its board of directors prior to their consideration of such transaction, and the transaction is not considered approved by its board of directors unless a majority of the directors who are not interested in the transaction approve the transaction.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Beginning in November 2020, Private CalciMedica has paid consulting fees monthly to a consulting firm affiliated with the Company&#x2019;s interim chief financial officer in connection with its consulting agreement. CalciMedica recorded expense of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;521,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;223,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; during years ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net loss is equivalent to net loss attributable to common stockholders for all periods presented. Basic net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. The Company calculates diluted net loss per share using the more dilutive of the (1) treasury stock method, if-converted method, or contingently issuable share method, as applicable, or (2) the two-class method. For warrants, the calculation of diluted net loss per share requires that, to the extent the average fair value of the underlying shares for the reporting period exceeds the exercise price of the warrants and the presumed exercise of such securities are dilutive to net loss per share for the period, adjustments to net loss used in the calculation are required to remove the change in fair value of the warrants for the period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In all periods presented, the Company&#x2019;s outstanding preferred stock, stock options, preferred, common and convertible promissory note warrants, and outstanding convertible promissory notes were excluded from the calculation of loss per share because the effect would be antidilutive. Accordingly, in periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which changes the accounting for recognizing impairments of financial assets. Under the new guidance, credit losses for certain types of financial instruments will be estimated based on expected losses. The new guidance also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. This update is effective for the Company beginning January 1, 2023. The Company adopted this ASU as of January 1, 2023, which did not have an impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt with Conversion and Other Options (Subtopic 470-20)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The ASU provides guidance that simplified the accounting for certain financial instruments with characteristics of liabilities and equity. The new guidance reduced the number of accounting models for convertible debt and convertible preferred stock instruments and made certain disclosure amendments intended to improve the information provided to users. The guidance also amended the derivative guidance for the &#x201c;own stock&#x201d; scope exception, which exempts qualifying instruments from being accounted for as derivatives if certain criteria are met. Finally, the standard changed the way certain convertible instruments are treated when calculating earnings per share. This guidance is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. The Company is currently assessing the impact that this guidance will have on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_419ba5a2-373c-4e29-ab9d-a237b6e3cd77">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;), and Accounting Standards Update (&#x201c;ASU&#x201d;), of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The consolidated financial statements include the accounts of the Company and CalciMedica Subsidiary, Inc. for the years ended December 31, 2023 and 2022. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Since Private CalciMedica was determined to be the accounting acquirer in connection with the Merger, for periods prior to the Merger, the consolidated financial statements were prepared on a stand-alone basis for Private CalciMedica and did not include the combined entities activity or financial position. Subsequent to the Merger, the consolidated financial statements as of and for the year ended December 31, 2023 include Graybug&#x2019;s activity from March 21, 2023 through December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and assets and liabilities at their acquisition date fair value. Historical share and per share figures of Private CalciMedica have been retroactively restated based on the merger exchange ratio of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0288&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <calc:StockholdersEquityNoteStockSplitExchangeRatio
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="4"
      id="F_194cfab8-1367-4b1b-83e7-2611fcd42788"
      unitRef="U_pure">0.0288</calc:StockholdersEquityNoteStockSplitExchangeRatio>
    <us-gaap:UseOfEstimates
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_e1e1dac8-fb43-4422-b2a7-02e2b1196a28">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of the Company&#x2019;s consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to accruals for research and development expenses, valuation of warrants, valuation of convertible promissory notes and valuation of equity awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#x2019;s future results of operations will be affected.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_5234e33e-5571-48a7-9aec-da4507277bd7">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk and other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments, which potentially subject the Company to concentration of risk, consist principally of cash and cash equivalents. The Company&#x2019;s cash is deposited with major federally insured U.S. financial institutions. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is dependent on contract manufacturing organizations (&#x201c;CMO&#x201d;) to supply products for research and development of its product candidates, including preclinical and clinical studies, and for commercialization of its product candidates, if approved. The Company&#x2019;s development programs could be adversely affected by any significant interruption in CMO&#x2019;s operations or by a significant interruption in the supply of active pharmaceutical ingredients and other components.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Products developed by the Company require approval from the FDA or other international regulatory agencies prior to commercial sales. There can be no assurance the Company&#x2019;s product candidates will receive the necessary approvals. If the Company is denied approvals, approvals are delayed, or the Company is unable to maintain approvals received, such events could have a materially adverse impact on the Company.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_55b2edef-0bc7-4e81-9376-db0ecb4a43bc">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash and cash equivalents consist of readily available cash in checking accounts, money market funds and commercial paper. The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_11b32fa3-4cb2-4e82-86ea-faeadefb5394">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Short-term Investments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company invests excess cash in commercial paper and U.S government sponsored entities - mortgage-backed securities. These investments are included in short-term investments on the balance sheet, classified as available-for-sale and reported at fair value with unrealized gains and losses included in accumulated other comprehensive (loss)/gain, net. Realized gains and losses on the sale of these securities are recognized in net loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_4ca31dd8-b812-420e-9ec3-934183eadf3a">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The financial information is regularly reviewed by the chief operating decision maker (&#x201c;CODM&#x201d;), in deciding how to allocate resources. The Company&#x2019;s CODM is its chief executive officer. The Company&#x2019;s singular focus is on developing highly selective calcium release-activated calcium channel inhibitors to improve outcomes for patients with acute inflammatory indications. No significant revenue has been generated since inception, and all tangible assets are held in the United States.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_3323028f-4f6f-49b6-b534-447bad76ad9e">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value Option&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As permitted under ASC 825, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the Company has elected the fair value option to account for its convertible promissory notes due to certain embedded features within the notes. The Company recognizes the convertible&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;promissory &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;notes at fair value with changes in fair value recognized in the consolidated statements of operations located on the change in fair value of financial instruments line item. Changes in fair value as a result of the Company&#x2019;s own credit risk is reflected in other income (expense) in the consolidated statements of operations. As a result of applying the fair value option, direct costs and fees related to the convertible promissory notes were expensed as incurred and not deferred.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_2cff8d0c-87a1-4282-80f7-5006b0874b65">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally three to five years) and consist of manufacturing and lab equipment, furniture, computers and phones. Repairs and maintenance costs are charged to expense as incurred. Depreciation expense recognized for the years ended December 31, 2023 and 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:Depreciation
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="0"
      id="F_2a661bd3-532d-4052-8e40-e3a925233784"
      unitRef="U_USD">58000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="0"
      id="F_b1ece8e8-0eef-4444-b19d-65e51f3a4110"
      unitRef="U_USD">52000</us-gaap:Depreciation>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_ee8f472f-5190-4d4c-ba02-e49fe89c8447">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Long-lived Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Long-lived assets consist primarily of property and equipment. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate the carrying amount of an asset is not recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value would be assessed using discounted cash flows or other appropriate measures of fair value. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t recognize any impairment losses for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="INF"
      id="F_079dd36e-c5e4-40c9-9f86-8c0981b5171c"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="INF"
      id="F_e108528b-b612-4718-847f-4893b4021351"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_ba0cd446-1ac3-4268-99c8-1de22a783101">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company leases office space with an original lease term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_96e7d778-f45a-41e2-8962-c4c3904214d6;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;twelve months &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and does &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t have a right-of-use asset or lease liability recorded. The Company's policy is not to record leases with an original term of twelve months or less on the consolidated balance sheets. The Company recognizes lease expense for this short-term lease on a straight-line basis over the term of the lease. The lease is accounted for under ASC 842, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and has been classified as an operating lease. Rent expense recognized for the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;274,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;221,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <calc:RightOfUseAssetOrLeaseLiability
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="INF"
      id="F_00ee5f11-cf9f-43e3-85f9-03fdc01a0579"
      unitRef="U_USD">0</calc:RightOfUseAssetOrLeaseLiability>
    <us-gaap:LeaseAndRentalExpense
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="0"
      id="F_4b68643e-4ad2-4f8f-a4c8-69e4ac4507e5"
      unitRef="U_USD">274000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="0"
      id="F_9a2039a5-f443-4d4b-8803-1f9ede734b86"
      unitRef="U_USD">221000</us-gaap:LeaseAndRentalExpense>
    <calc:AccruedResearchAndDevelopmentCostsPolicyTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_039e3ed0-c27a-4067-9e32-ce07d58137a7">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development costs consist primarily of salaries, payroll taxes, employee benefits and stock-based compensation for those individuals involved in ongoing research and development efforts, as well as fees paid to consultants, external research fees, license fees paid to third parties for use of their intellectual property, laboratory supplies and development of compound materials, associated overhead expenses and facilities and depreciation costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. All research and development costs are expensed as incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company estimates preclinical studies and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on the Company&#x2019;s behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers,  and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. The estimates are trued up to reflect the best information available at the time of the financial statement issuance. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#x2019;s estimate of the status and timing of services performed relative to the actual status and timing of services performed may vary.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</calc:AccruedResearchAndDevelopmentCostsPolicyTextBlock>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_6fcef053-4469-46fb-b24c-1319141d2e2a">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;General and Administrative Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation, related to executive, finance, business development, legal, human resources and support functions, including professional fees for auditing, tax, consulting and patent-related services, rent and utilities and insurance.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <calc:PatentsCostsPolicyTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_cd327fe3-04a9-47f2-a64a-c27b4a190005">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Patent Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Costs related to filing and pursuing patent applications are expensed as incurred since recoverability of such expenditures is uncertain.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</calc:PatentsCostsPolicyTextBlock>
    <us-gaap:DeferredPolicyAcquisitionCostsTextBlock1
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_8cde8100-f8c6-4544-9376-263ea5b175f1">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company capitalizes costs that are directly associated with equity financings until such financings are consummated at which time such costs are recorded against the gross proceeds of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss. Private CalciMedica had deferred offering costs capitalized as of December 31, 2022 for the Merger of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. As of December 31, 2023, the Company has deferred costs associated with its at-the-market offering of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;</us-gaap:DeferredPolicyAcquisitionCostsTextBlock1>
    <us-gaap:DeferredOfferingCosts
      contextRef="C_c53f262c-1896-431c-b404-2f2cd328973f"
      decimals="-5"
      id="F_db83b54d-5e8c-42ea-b3c6-0af1238e26ba"
      unitRef="U_USD">1400000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="C_ccf97b7e-0005-4bf8-ac80-ebcbb11b741c"
      decimals="-5"
      id="F_33a79c37-be0c-447f-be90-df0469ce2ea8"
      unitRef="U_USD">400000</us-gaap:DeferredOfferingCosts>
    <calc:WarrantLiabilityPolicyPolicyTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_2822188f-ea9c-4627-94e8-ee9ed705ebf1">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Warrant Liability&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Private CalciMedica has issued various freestanding warrants to purchase shares of its convertible preferred stock. Prior to the Merger, Private CalciMedica adjusted the carrying value of such convertible preferred stock warrants to the estimated fair value at each reporting date, with any related increases or decreases in the fair value being recorded within other income (expense) in the consolidated statements of operations and comprehensive loss. Pursuant to the Merger Agreement, the Series C convertible preferred stock warrants became warrants to purchase shares of the combined company's common stock. As a result of the Merger, the warrants no longer meet the requirements for liability accounting and, as such, Private CalciMedica adjusted the value of the warrants to the estimated fair value as of the Merger date and reclassified them to stockholders' equity (deficit).&lt;/span&gt;&lt;/p&gt;</calc:WarrantLiabilityPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_5e806b44-1d40-43f5-8a74-abef8444e54d">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense represents the cost of the grant date fair value of employee stock options recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. Private CalciMedica estimates the fair value of stock option grants using the Black-Scholes option pricing model (&#x201c;Black-Scholes&#x201d;). Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. Equity-based compensation expense is classified in the statements of operations in the same manner in which the award recipients&#x2019; payroll costs are classified or in which the award recipients&#x2019; service payments are classified. The fair value of each stock option grant is estimated on the date of grant using Black Scholes. The following summarizes the inputs used:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prior to the Merger, there was no public market for Private CalciMedica&#x2019;s common stock. The fair value of the shares of common stock underlying Private CalciMedica&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2019;s share-based awards was estimated on each grant date by Private CalciMedica&#x2019;s board of directors. To determine the fair value of Private CalciMedica&#x2019;s common stock underlying option grants, the board of directors considered, among other things, input from management and valuations of Private CalciMedica's common stock prepared by third-party valuation firms.&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Post Merger, CalciMedica uses the closing stock price the day prior to the grant date for the fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The risk-free interest ra&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;te is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities similar to the expected term of the awards.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected Volatility&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prior to the merger, since Private CalciMedica did not have publicly traded equity securities, the volatility of the options has been estimated using peer group volatility information. Post Merger, CalciMedica uses an average volatility for comparable publicly-traded biopharmaceutical companies over a period equal to the expected term of the stock award grant as CalciMedica does not yet have sufficient historical trading history for its own stock. CalciMedica will continue to apply this method until a sufficient amount of historical information over a period equal to the expected term of the stock-based awards becomes available.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected Term&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;CalciMedica used the simplified method to calc&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ulate the expected term for all grants during all periods, which is based on the midpoint between the vesting date and the end of the contractual term.&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected Dividend Yield&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;CalciMedica has never paid and has no present intention to pay cash dividends.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_5171a2a5-22d3-41dd-8500-827f0e449c7e">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <calc:TaxPostionMinimumPercentageOfTaxBenefit
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="2"
      id="F_b4e69cee-ccc5-4015-b589-3b522d3e817c"
      unitRef="U_pure">0.50</calc:TaxPostionMinimumPercentageOfTaxBenefit>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_e2dd1248-9cb1-46f0-aa6f-48dbce374ec9">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources which are excluded from net loss. The Company&#x2019;s only element of other comprehensive loss is unrealized gains and losses on marketable securities.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <calc:RelatedPartyTransactionsPolicyTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_4139bca2-52a3-4efe-84df-a72b51c99940">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Related Party Transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s board of directors reviews and approves transactions with directors, officers and holders of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% or more of its voting securities and their affiliates, each a related party. The material facts as to the related party&#x2019;s relationship or interest in the transaction are disclosed to its board of directors prior to their consideration of such transaction, and the transaction is not considered approved by its board of directors unless a majority of the directors who are not interested in the transaction approve the transaction.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Beginning in November 2020, Private CalciMedica has paid consulting fees monthly to a consulting firm affiliated with the Company&#x2019;s interim chief financial officer in connection with its consulting agreement. CalciMedica recorded expense of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;521,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;223,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; during years ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and 2022, respectively.&lt;/span&gt;&lt;/p&gt;</calc:RelatedPartyTransactionsPolicyTextBlock>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="2"
      id="F_11c6bcc5-1bfb-4ebd-8f34-18bead2a0f34"
      unitRef="U_pure">0.05</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_d046d1dd-275e-4ce7-b43c-2ca79d4f0e9a"
      decimals="0"
      id="F_525c6930-1573-477f-aa70-a6e9f6356a91"
      unitRef="U_USD">521000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_0e069504-00ad-4b62-9b5c-575c0a9feed4"
      decimals="0"
      id="F_2c36d987-1163-48de-9633-961dfcb3bec8"
      unitRef="U_USD">223000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_cb896953-b341-4f44-b9a4-b43f32407f09">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net loss is equivalent to net loss attributable to common stockholders for all periods presented. Basic net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. The Company calculates diluted net loss per share using the more dilutive of the (1) treasury stock method, if-converted method, or contingently issuable share method, as applicable, or (2) the two-class method. For warrants, the calculation of diluted net loss per share requires that, to the extent the average fair value of the underlying shares for the reporting period exceeds the exercise price of the warrants and the presumed exercise of such securities are dilutive to net loss per share for the period, adjustments to net loss used in the calculation are required to remove the change in fair value of the warrants for the period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In all periods presented, the Company&#x2019;s outstanding preferred stock, stock options, preferred, common and convertible promissory note warrants, and outstanding convertible promissory notes were excluded from the calculation of loss per share because the effect would be antidilutive. Accordingly, in periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_13726212-0945-425a-aa01-5d67cbdad87b">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which changes the accounting for recognizing impairments of financial assets. Under the new guidance, credit losses for certain types of financial instruments will be estimated based on expected losses. The new guidance also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. This update is effective for the Company beginning January 1, 2023. The Company adopted this ASU as of January 1, 2023, which did not have an impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt with Conversion and Other Options (Subtopic 470-20)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The ASU provides guidance that simplified the accounting for certain financial instruments with characteristics of liabilities and equity. The new guidance reduced the number of accounting models for convertible debt and convertible preferred stock instruments and made certain disclosure amendments intended to improve the information provided to users. The guidance also amended the derivative guidance for the &#x201c;own stock&#x201d; scope exception, which exempts qualifying instruments from being accounted for as derivatives if certain criteria are met. Finally, the standard changed the way certain convertible instruments are treated when calculating earnings per share. This guidance is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. The Company is currently assessing the impact that this guidance will have on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_8f3426f6-f735-48ce-9fa8-721e30b4e3a2">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3. Merger and Related Transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As described in Note 1 - Nature of Business, Private CalciMedica merged with a wholly owned subsidiary of Graybug on March 20, 2023. The Merger was accounted for as a reverse recapitalization under U.S. GAAP. Private CalciMedica was considered the accounting acquirer for financial reporting purposes. This determination is based on the facts that, immediately following the Merger: (i) former Private CalciMedica stockholders owned a substantial majority of the voting rights of the combined company; Private CalciMedica designated a majority (five of seven) of the initial members of the board of directors of the combined company; and former Private CalciMedica's senior management held all key positions in senior management of the combined company. The transaction is accounted for as a reverse recapitalization of Graybug by Private CalciMedica similar to the issuance of equity for the net assets of Graybug, which are primarily cash, short-term investments and other non-operating assets. It was concluded that any in-process research and development assets that remained as of the Merger would be de minimis when compared to the cash and investments obtained through the Merger.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under reverse recapitalization accounting, the assets and liabilities of Graybug were recorded at their fair value, which approximated book value due to the short-term nature of the instruments. The Company's consolidated financial statements reflect the issuance of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,571,433&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares to the former stockholders of Graybug.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding share of Private CalciMedica capital stock (after giving effect to the automatic conversion of all shares of Private CalciMedica preferred stock into shares of Private CalciMedica common stock, the automatic exercise of certain Private CalciMedica warrants to purchase shares of Private CalciMedica common stock in accordance with their terms (the &#x201c;Private CalciMedica warrant exercises&#x201d;), the conversion of Private CalciMedica convertible promissory notes into Private CalciMedica common stock and the closing of the private placement (as discussed in Note 7 - Convertible Preferred Stock, Common Stock, and Stockholders' Deficit)), was converted into the right to receive &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0288&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Graybug common stock, which resulted in the issuance by Graybug of an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,946,540&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Graybug common stock to the stockholders of Private CalciMedica in a transaction exempt from registration under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), in reliance on Section 4(a)(2) of the Securities Act and the rules promulgated thereunder. In addition, Graybug assumed the Private CalciMedica 2006 Stock Plan (See Note 8 - Stock-Based Compensation), and each outstanding and unexercised option to purchase Private CalciMedica common stock and each outstanding and unexercised warrant to purchase Private CalciMedica common stock (excluding the warrants which were automatically exercised pursuant to the Private CalciMedica warrant exercises) became options and warrants, respectively, to purchase shares of Graybug common stock. Immediately following the consummation of the Merger prior Private CalciMedica and Graybug stockholders collectively own approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the Company, respectively, on a fully diluted basis.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As part of the reverse recapitalization, Private CalciMedica received $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of cash, cash equivalents and short-term investments, net of transaction costs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Private CalciMedica also obtained prepaid and other current assets of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and assumed payables and accrued expenses of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Private CalciMedica also incurred transaction costs of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which is recorded as a reduction to additional paid-in capital in the accompanying consolidated statement of convertible preferred stock and stockholders' equity (deficit). The Company also recorded one-time charges of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the acceleration of the Graybug stock awards and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in severance charges that are recorded in the consolidated statements of operations and comprehensive loss for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;twelve months ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On March 17, 2023, in connection with the transactions contemplated by the Merger Agreement and following a special meeting of Graybug&#x2019;s stockholders, Graybug filed an Amended and Restated Certificate of Incorporation effecting a reverse stock split of Graybug&#x2019;s common stock, par value $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, at a ratio of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:1.&lt;/span&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="C_c654b3dc-d8de-4e32-ade7-4c14b46e29eb"
      decimals="INF"
      id="F_49ec7c40-8bd5-44c9-bd2e-a09b62444d2a"
      unitRef="U_shares">1571433</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <calc:StockIssuedDuringPeriodPrivatePlacement
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="4"
      id="F_2951ef33-8775-4c68-8414-9618ff476270"
      unitRef="U_shares">0.0288</calc:StockIssuedDuringPeriodPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="C_f6acf339-8a66-4359-827f-f1d8c3fefcf6"
      decimals="INF"
      id="F_33f83587-0e0b-4cd0-b1ee-5b4f456778bc"
      unitRef="U_shares">3946540</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_dc6f3b09-7f0d-4955-b288-aa892fd2868e"
      decimals="2"
      id="F_8c5958ab-f9e7-410d-83fb-5711f1dd490d"
      unitRef="U_pure">0.72</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_bd0f357b-9782-4dba-b331-d7e9654967b9"
      decimals="2"
      id="F_0ca4bd3f-110e-4faa-9022-554c1cd5f2c4"
      unitRef="U_pure">0.28</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-5"
      id="F_c87be83a-10b4-43f7-b5de-154530397ed0"
      unitRef="U_USD">29400000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-5"
      id="F_28fbeca1-adff-47e3-bc1d-de5ea62f4e8c"
      unitRef="U_USD">2100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-5"
      id="F_ecdfc4dc-1bcf-4d46-97e7-fb36d867a205"
      unitRef="U_USD">2300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <calc:BusinessCombinationConsiderationTransferedCostIncurred
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-5"
      id="F_ab95b2c4-e49d-4e6d-b348-29b098fcd952"
      unitRef="U_USD">4600000</calc:BusinessCombinationConsiderationTransferedCostIncurred>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-5"
      id="F_ecda2acc-8f48-433c-982f-37c99dae0de3"
      unitRef="U_USD">10500000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:SeveranceCosts1
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-5"
      id="F_5b94125c-d2dd-4611-babf-80c4de9155b2"
      unitRef="U_USD">5700000</us-gaap:SeveranceCosts1>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_07aad975-11de-44fb-9c2a-ae67476d452b"
      decimals="4"
      id="F_8239a426-0c4b-4e6f-9c4e-8bfe879f3ff8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_bb55cbd6-a773-4301-9abc-12c18795aee6"
      decimals="0"
      id="F_131b667d-3b49-44c3-a8b1-f0947cc62801"
      unitRef="U_pure">14</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:DerivativesAndFairValueTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_c8f7472d-0734-441d-99a6-712c6edcfb42">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;4. Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company's assets and liabilities which are measured at fair value including short-term investments, warrants for preferred stock (&#x201c;Preferred Warrants&#x201d;), warrants for common stock related to the convertible promissory notes (&#x201c;Convertible Promissory Note Warrants&#x201d;), the liabilities are presented together on the balance sheets as &#x201c;Warrant Liability&#x201d; and convertible promissory notes. All assets and liabilities recorded at fair value are revalued at each measurement period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Private CalciMedica elected the fair value option for the convertible promissory notes and estimated the fair value based on a discounted cash flow analysis, a form of the Income Approach. Several different settlement scenarios were considered, and probability weighted to arrive at the final valuation. Increases or decreases in the fair value of the convertible promissory notes can result from updates to assumptions such as the expected timing or probability of the different settlement scenarios, or changes in discount rates. Judgment is used in determining these assumptions as of the initial valuation date and at each subsequent reporting period. Updates to assumptions could have a significant impact on the Company&#x2019;s results of operations in any given period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Preferred Warrants are valued using the Hybrid Method (&#x201c;Hybrid Method&#x201d;). This method incorporates Private CalciMedica&#x2019;s near-term liquidity event prospects utilized in conjunction with the Option Pricing Method (&#x201c;OPM&#x201d;) framework, representing an alternative exit, to calculate an implied overall value of Private CalciMedica. This value is, in turn, allocated to Private CalciMedica&#x2019;s various equity classes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Convertible Promissory Note Warrants are valued using a series of Monte Carlo simulations and Black-Scholes to determine the fair value, probability weighted for difference scenarios. The Monte Carlo simulations determined the liquidity event price. Black-Scholes is used with the remaining contractual term of the warrants after the respective event date. The warrant value is discounted from the respective event date using the risk-free rate for the period ending December 31, 2022. The Convertible Promissory Note Warrants were valued using the common stock price on day of conversion. See further discussion in Note 5 - Convertible Promissory Notes and Convertible Promissory Note Warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following three levels:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Level 1:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Observable inputs such as unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Level 2:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Level 3:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.34%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Current assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Government sponsored entities - mortgage-backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Money market funds are highly liquid investments which are actively traded. The pricing information on the Company&#x2019;s money market funds is based on quoted prices in active markets for identical securities. This approach results in the classification of these securities as Level 1 of the fair value hierarchy.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Commercial paper and U.S. Government sponsored entities - mortgage-backed are classified as Level 2 with in the hierarchy and are carried at fair value with unrealized gains and losses included in other comprehensive income (loss) as a component of stockholders&#x2019; equity until realized. The Company estimates the fair values of these securities by taking into consideration valuations obtained from third-party pricing sources.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; fair value liabilities exist as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables present information about the Company&#x2019;s financial liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Convertible promissory notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Preferred Warrants liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Convertible Promissory Note Warrants liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total liabilities measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following provides a reconciliation for all liabilities measured at fair value using Level 3 inputs for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Convertible Promissory Note liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in Fair Value of Convertible Promissory Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued Interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Conversion of Convertible Promissory Notes to equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Preferred Warrant liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in Fair Value of Preferred Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Conversion of warrant liability to equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Convertible Promissory Note Warrants liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in Fair Value of Convertible Promissory Note Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;351&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Conversion of Convertible Promissory Note Warrants liability to equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents information as to cost, unrealized gains and losses and fair value determination of the Company&#x2019;s financial assets measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.34%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Current assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Government sponsored entities - mortgage-backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the contractual maturities of all available-for-sale investments were less than 12 months. The Company periodically reviews the available-for-sale for other-than-temporary impairment loss. The Company had short-term investments in unrealized gain positions as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; cash equivalents.&lt;/span&gt;&lt;/p&gt;</us-gaap:DerivativesAndFairValueTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_6d4a9901-118c-48b2-85f3-bfc99b64f044">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.34%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Current assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Government sponsored entities - mortgage-backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables present information about the Company&#x2019;s financial liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Convertible promissory notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Preferred Warrants liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Convertible Promissory Note Warrants liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total liabilities measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_6c40048e-5e83-487d-95e9-572612a5b2a0"
      decimals="-3"
      id="F_27b73af8-9855-4395-8fd3-43d18f2cec97"
      unitRef="U_USD">3634000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_47c16d4b-a330-4cfb-83cf-9d9c1168ecac"
      decimals="-3"
      id="F_0ee45d7b-6d0d-4909-8cda-a9bfa880a422"
      unitRef="U_USD">3634000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_efd6e33a-c854-438b-b83a-602ebf9ebf8c"
      decimals="-3"
      id="F_3db82384-cbdb-4414-b632-f111ef9e5b88"
      unitRef="U_USD">1738000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_7f725abd-da2c-4ddd-87a7-b41ccda9c06b"
      decimals="-3"
      id="F_839337ab-0e91-4341-b7db-cde9b0018ac0"
      unitRef="U_USD">1738000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_6a19c8ff-3eec-4e73-bbb3-c3b561d13063"
      decimals="-3"
      id="F_6648dfa7-2015-4cd7-aaa1-6371da64898a"
      unitRef="U_USD">3634000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_7e197c94-c9cd-4e85-83f1-c4bac6996bbc"
      decimals="-3"
      id="F_36868f76-ebf7-4907-89e1-c5a90d625c60"
      unitRef="U_USD">1738000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_7f64735a-ca76-47aa-aadd-323f69769f4e"
      decimals="-3"
      id="F_6a475d82-ab2c-4186-8f9a-182e814250ef"
      unitRef="U_USD">5372000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <calc:ShortTermInvestmentFairValueDisclosure
      contextRef="C_efd6e33a-c854-438b-b83a-602ebf9ebf8c"
      decimals="-3"
      id="F_ad08648b-ee71-4719-8df7-0de36603276a"
      unitRef="U_USD">5213000</calc:ShortTermInvestmentFairValueDisclosure>
    <calc:ShortTermInvestmentFairValueDisclosure
      contextRef="C_7f725abd-da2c-4ddd-87a7-b41ccda9c06b"
      decimals="-3"
      id="F_139eac0d-f520-4ee5-af34-fec34ea2a754"
      unitRef="U_USD">5213000</calc:ShortTermInvestmentFairValueDisclosure>
    <calc:ShortTermInvestmentFairValueDisclosure
      contextRef="C_31761f11-9358-474c-ab64-43e5fe6dd846"
      decimals="-3"
      id="F_a225a135-1993-4338-9f88-3a16c76a29e6"
      unitRef="U_USD">495000</calc:ShortTermInvestmentFairValueDisclosure>
    <calc:ShortTermInvestmentFairValueDisclosure
      contextRef="C_8b643f00-2d89-421c-b960-b0008cf81a56"
      decimals="-3"
      id="F_28aad148-f271-4525-90d8-b1590295df64"
      unitRef="U_USD">495000</calc:ShortTermInvestmentFairValueDisclosure>
    <calc:ShortTermInvestmentFairValueDisclosure
      contextRef="C_7e197c94-c9cd-4e85-83f1-c4bac6996bbc"
      decimals="-3"
      id="F_bb8de645-87b7-463a-962a-e7b5b508baee"
      unitRef="U_USD">5708000</calc:ShortTermInvestmentFairValueDisclosure>
    <calc:ShortTermInvestmentFairValueDisclosure
      contextRef="C_7f64735a-ca76-47aa-aadd-323f69769f4e"
      decimals="-3"
      id="F_73d0c120-757d-4168-8f02-a71cd6dbd2f2"
      unitRef="U_USD">5708000</calc:ShortTermInvestmentFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_6a19c8ff-3eec-4e73-bbb3-c3b561d13063"
      decimals="-3"
      id="F_3b4a338a-1f34-45e5-9a62-420a61ef1674"
      unitRef="U_USD">3634000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7e197c94-c9cd-4e85-83f1-c4bac6996bbc"
      decimals="-3"
      id="F_9032dfbf-135a-4ccf-ba2e-cdef5cb0fb28"
      unitRef="U_USD">7446000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7f64735a-ca76-47aa-aadd-323f69769f4e"
      decimals="-3"
      id="F_6df5d966-7bda-422c-8111-7fb9256ce27a"
      unitRef="U_USD">11080000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="INF"
      id="F_0e1bb07b-dd20-4d59-bdf8-1ad681d0ce6d"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_1945eb61-653c-4d34-aedd-57f80cdc4177"
      decimals="-3"
      id="F_b3309b19-14ed-4eda-925e-e147c8c02596"
      unitRef="U_USD">5157000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_7fa15f5d-da9e-49b1-ad4b-7ac0dffbd31d"
      decimals="-3"
      id="F_3e6bd083-8b5f-4d93-a5b8-06c28009f031"
      unitRef="U_USD">5157000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_53e9f125-e7ca-4cd9-96f3-b398eddc05fa"
      decimals="-3"
      id="F_5e8a36bf-fe27-4307-9e0d-c9be9794f5fe"
      unitRef="U_USD">1453000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_1d04e9a4-5ef0-4df1-8750-14de2723f9bb"
      decimals="-3"
      id="F_df8e1fdf-f2a9-4ab3-8c6c-8ca0278bc905"
      unitRef="U_USD">1453000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_849e11ac-1955-44ec-aed2-b66fa055ed0a"
      decimals="-3"
      id="F_bc879b6b-70ee-4fbe-8c5a-e32b843cb928"
      unitRef="U_USD">1192000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_666c7e89-c8db-48ef-beec-8e67efcb35b4"
      decimals="-3"
      id="F_0704ac47-8911-4db6-9924-5706a965040c"
      unitRef="U_USD">1192000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_a90b884a-f2e9-44ca-a156-3042948bd1e5"
      decimals="-3"
      id="F_345b0282-7bbc-403b-ab9b-1e5f633e9727"
      unitRef="U_USD">7802000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_45300d27-3112-43ed-a27a-f1ca2b9647c0"
      decimals="-3"
      id="F_1c1e96ff-2162-44b8-b938-387640a167d6"
      unitRef="U_USD">7802000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_6c843bbd-9e49-482c-a775-7d1a43f0b274">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following provides a reconciliation for all liabilities measured at fair value using Level 3 inputs for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Convertible Promissory Note liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in Fair Value of Convertible Promissory Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued Interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Conversion of Convertible Promissory Notes to equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Preferred Warrant liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in Fair Value of Preferred Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Conversion of warrant liability to equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Convertible Promissory Note Warrants liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in Fair Value of Convertible Promissory Note Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;351&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Conversion of Convertible Promissory Note Warrants liability to equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_d790b41b-1e12-488c-8daa-9f3b3627753e"
      decimals="-3"
      id="F_5029a464-149a-4cfe-8eab-fc8223d286b8"
      unitRef="U_USD">5157000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="C_79aec6d8-c918-443b-a31f-3dd73301431e"
      decimals="-3"
      id="F_ff7b555b-7a4c-4cb6-ad2b-3add73c9b770"
      unitRef="U_USD">-2022000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="C_79aec6d8-c918-443b-a31f-3dd73301431e"
      decimals="-3"
      id="F_fcadfd7d-82e5-470a-a4c0-21a3b159108f"
      unitRef="U_USD">110000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="C_79aec6d8-c918-443b-a31f-3dd73301431e"
      decimals="-3"
      id="F_4bfed076-d1c5-4bb6-9347-f6662f0c81d4"
      unitRef="U_USD">-3245000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_a3e0ce3a-700f-4c36-8d35-fed370e247a0"
      decimals="-3"
      id="F_11e66726-b7b3-4b04-bf8d-e17015be30a8"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_3238f60f-57e8-430b-b3e4-81f554a6a7c5"
      decimals="-3"
      id="F_825e47f3-e98a-4948-b45b-4cd23ee09416"
      unitRef="U_USD">1453000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="C_38046496-ba8c-4f7b-a2ab-17742c50658a"
      decimals="-3"
      id="F_ae8a892e-53e0-4bca-9520-45144481c654"
      unitRef="U_USD">-795000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="C_38046496-ba8c-4f7b-a2ab-17742c50658a"
      decimals="-3"
      id="F_3b8db551-9124-45d5-a982-f8ca0e539828"
      unitRef="U_USD">-658000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_cab222f3-c29a-438f-bc50-d49b23b8991a"
      decimals="-3"
      id="F_28fd740e-225b-421f-bc87-305748331b64"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_5ac139a0-0917-47cd-862b-6898ff89d717"
      decimals="-3"
      id="F_97e99fac-f2c2-48c9-8361-2fed2ce9ac9c"
      unitRef="U_USD">1192000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="C_c8e84e93-e57a-4e7e-a6fd-3469c8f77e9d"
      decimals="-3"
      id="F_5c98a6ef-bcee-46df-b280-39fbd4be64d5"
      unitRef="U_USD">-351000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="C_c8e84e93-e57a-4e7e-a6fd-3469c8f77e9d"
      decimals="-3"
      id="F_b89489e9-fdbb-4a22-b1de-f207d5158890"
      unitRef="U_USD">-841000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_f048298b-299d-47f9-b5bd-5b7c905187ca"
      decimals="-3"
      id="F_f67024a1-5cfb-43f8-a27e-5d25a3c2d2aa"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_6ef12950-0f12-4e00-9580-6bc9f5f0c2d7">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents information as to cost, unrealized gains and losses and fair value determination of the Company&#x2019;s financial assets measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.34%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Current assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Government sponsored entities - mortgage-backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <calc:CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis
      contextRef="C_fb58baf9-d75a-4814-b11a-5c4bf3132842"
      decimals="-3"
      id="F_c78d69b1-a79d-43df-b1be-47b1221370b9"
      unitRef="U_USD">3634000</calc:CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_fb58baf9-d75a-4814-b11a-5c4bf3132842"
      decimals="-3"
      id="F_eb24c338-30f7-4bbf-9836-7f21c4fb77e1"
      unitRef="U_USD">3634000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <calc:CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis
      contextRef="C_e9aabbcc-ba19-4328-a90c-b2b531c98d96"
      decimals="-3"
      id="F_f857e860-8d2a-417e-a020-56639be41a9b"
      unitRef="U_USD">1738000</calc:CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_e9aabbcc-ba19-4328-a90c-b2b531c98d96"
      decimals="-3"
      id="F_7f84c93e-0b89-4c0b-bc19-83d03306da54"
      unitRef="U_USD">1738000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <calc:CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis
      contextRef="C_7f64735a-ca76-47aa-aadd-323f69769f4e"
      decimals="-3"
      id="F_1d8140cf-0125-4f1b-b2d0-a407c4eb33bb"
      unitRef="U_USD">5372000</calc:CashAndCashEquivalentsFairValueDisclosureAmortizedCostBasis>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_7f64735a-ca76-47aa-aadd-323f69769f4e"
      decimals="-3"
      id="F_6364a6cd-2195-4399-8bc7-75e3965d06ea"
      unitRef="U_USD">5372000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <calc:ShortTermInvestmentFairValueDisclosureAmortizedCostBasis
      contextRef="C_e9aabbcc-ba19-4328-a90c-b2b531c98d96"
      decimals="-3"
      id="F_d9e8ad57-ab7b-4d45-899b-95797270e9cd"
      unitRef="U_USD">5211000</calc:ShortTermInvestmentFairValueDisclosureAmortizedCostBasis>
    <calc:ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_e9aabbcc-ba19-4328-a90c-b2b531c98d96"
      decimals="-3"
      id="F_197bc75c-3795-4607-865c-c3eeca1568f5"
      unitRef="U_USD">2000</calc:ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax>
    <calc:ShortTermInvestmentFairValueDisclosure
      contextRef="C_e9aabbcc-ba19-4328-a90c-b2b531c98d96"
      decimals="-3"
      id="F_5d57bf60-6f1f-449b-a7db-f60610610eb4"
      unitRef="U_USD">5213000</calc:ShortTermInvestmentFairValueDisclosure>
    <calc:ShortTermInvestmentFairValueDisclosureAmortizedCostBasis
      contextRef="C_2144abf4-0a9e-4b97-a97a-75d1e0d63184"
      decimals="-3"
      id="F_2f3fa10f-bf9d-4821-94b3-f1166efa2b8e"
      unitRef="U_USD">495000</calc:ShortTermInvestmentFairValueDisclosureAmortizedCostBasis>
    <calc:ShortTermInvestmentFairValueDisclosure
      contextRef="C_2144abf4-0a9e-4b97-a97a-75d1e0d63184"
      decimals="-3"
      id="F_7bf34894-b0fc-4c15-adbb-694e02fb7b35"
      unitRef="U_USD">495000</calc:ShortTermInvestmentFairValueDisclosure>
    <calc:ShortTermInvestmentFairValueDisclosureAmortizedCostBasis
      contextRef="C_7f64735a-ca76-47aa-aadd-323f69769f4e"
      decimals="-3"
      id="F_49116411-7c60-4618-8264-baeec0956f1c"
      unitRef="U_USD">5706000</calc:ShortTermInvestmentFairValueDisclosureAmortizedCostBasis>
    <calc:ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_7f64735a-ca76-47aa-aadd-323f69769f4e"
      decimals="-3"
      id="F_39d0ace4-6178-4657-863b-f7af01064fb0"
      unitRef="U_USD">2000</calc:ShortTermInvestmentFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax>
    <calc:ShortTermInvestmentFairValueDisclosure
      contextRef="C_7f64735a-ca76-47aa-aadd-323f69769f4e"
      decimals="-3"
      id="F_d815a63f-eae6-4def-a7ad-b4fc374a0f28"
      unitRef="U_USD">5708000</calc:ShortTermInvestmentFairValueDisclosure>
    <calc:AssetsFairValueDisclosureAmortizedCostBasis
      contextRef="C_7f64735a-ca76-47aa-aadd-323f69769f4e"
      decimals="-3"
      id="F_040a70a7-0652-4b5e-90e8-6bdcac174fa6"
      unitRef="U_USD">11078000</calc:AssetsFairValueDisclosureAmortizedCostBasis>
    <calc:AssetsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_7f64735a-ca76-47aa-aadd-323f69769f4e"
      decimals="-3"
      id="F_83740d3c-2049-4802-8e14-e6cd45530016"
      unitRef="U_USD">2000</calc:AssetsFairValueDisclosureAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7f64735a-ca76-47aa-aadd-323f69769f4e"
      decimals="-3"
      id="F_1f5b4d31-1339-40b6-a549-8b48c7d74915"
      unitRef="U_USD">11080000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="INF"
      id="F_03f86d63-4b05-454a-915f-a9145771240e"
      unitRef="U_USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_465461bc-1813-48a0-9a6e-a87d3d3453da">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;5. Convertible Promissory Notes and Convertible Promissory Note Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In April 2022, the Private CalciMedica board of directors approved a convertible promissory note financing pursuant to which it could issue and sell up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of notes convertible into shares of common stock (the &#x201c;convertible promissory notes&#x201d;) and Convertible Promissory Note Warrants. The funding and issuance of the convertible promissory notes for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and Convertible Promissory Note Warrants to purchase shares of the Private CalciMedica&#x2019;s common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share took place in multiple closings through October 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2022, the Private CalciMedica board of directors amended the convertible promissory notes and Convertible Promissory Note Warrants to issue up to an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million (for a total of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million) and added the automatic conversion for a &#x201c;de-SPAC&#x201d; business combination or reverse merger transaction. In November 2022, Private CalciMedica issued additional convertible promissory notes for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and Convertible Promissory Note Warrants to purchase shares of Private CalciMedica&#x2019;s common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. The convertible promissory notes accrued interest at a rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% per annum and had a maturity date of December 31, 2023. Immediately prior to the effective time of the Merger, all outstanding convertible promissory notes and unpaid and accrued interest automatically converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,487,104&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Private CalciMedica&#x2019;s common stock at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;a conversion price based on the equivalent valuation of the cash price paid per share by the private placement investors purchasing shares of common stock in the private placement multiplied by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Such shares of common stock were then converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;590,031&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Graybug common stock at the effective time of the Merger in accordance with the Merger Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with each purchase of a convertible promissory note, Private CalciMedica issued to each holder of such convertible promissory note Convertible Promissory Note Warrant to purchase shares of the Private CalciMedica&#x2019;s common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. Each holder of the Convertible Promissory Note Warrants had the right to purchase up to a number of shares of Private CalciMedica&#x2019;s common stock equal to (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% (&#x201c;Warrant Coverage&#x201d;) of the principal amount of the convertible promissory note purchased by such holder concurrently therewith, divided by (ii) the cash price paid per share by the investors in the qualified financing or an initial public offering, as applicable, or in the case of a &#x201c;de-SPAC&#x201d; business combination or a reverse merger transaction between Private CalciMedica and a publicly traded company (a &#x201c;Public Combination&#x201d;), the equivalent valuation of the lower of the cash price per share by the investors purchasing shares in the publicly traded company in connection with such Public Combination or the cash price per shares by the investors purchasing shares of Private CalciMedica&#x2019;s common stock in connection with such Public Combination, in each case, rounding down to the nearest whole share and subject to the terms of the convertible promissory notes; provided, however, that any holder that purchased convertible promissory notes in excess of the holder&#x2019;s pro rata commitment (as defined in the convertible promissory notes) received a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% Warrant Coverage on the principal amount of the convertible promissory notes that is in excess of its pro rata commitment. The Convertible Promissory Note Warrants had a five-year term. In connection with the Merger, the Convertible Promissory Note Warrants were automatically net exercised in accordance with the terms of the Convertible Promissory Note Warrants. Immediately prior to the effective time of the Merger, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,308,047&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Convertible Promissory Note Warrants were converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,308,047&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Private CalciMedica's common stock, which were converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;152,875&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Graybug's common stock, based on the principal amount of the convertible promissory note.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prior &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;to the Merger, the Convertible Promissory Note Warrants were not deemed equity and were classified as a liability on balance sheets. The Convertible Promissory Note Warrants were valued using a series of Monte Carlo simulations and Black-Scholes to determine the fair value, probability weighted for difference scenarios. The Monte Carlo simulations determined the liquidity event price. The Black-Scholes warrant value is discounted from the respective event date using the risk-free rate. The Black-Scholes valuation included standard assumptions such as exercise price, expected term, risk-free rate, volatility, and a&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;dividend &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;yield of zero. The Company estimated initial fair value of the Convertible Promissory Note Warrants utilizing the following range of assumptions for the difference scenarios: exercise price ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;), risk-free rate (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.02&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%), volatility (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%), and expected term (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; - &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years). As of the date of the Merger, the Convertible Promissory Note Warrants which were converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;152,871&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock were revalued, using the price of the common stock of Graybug of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="C_8fb13e5d-773f-45a3-a1b5-44eb8a210518"
      decimals="-5"
      id="F_7092ba1f-7c65-466e-afcf-81b9b4efd87e"
      unitRef="U_USD">5000000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="C_8fb13e5d-773f-45a3-a1b5-44eb8a210518"
      decimals="-5"
      id="F_b8473a44-7278-4ef3-a19c-a5dbd9849c3a"
      unitRef="U_USD">3500000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_ba4cac3d-1b7b-4712-b4af-b00b36992550"
      decimals="2"
      id="F_74f2aa16-8d82-45c4-bf6c-36333917374f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <calc:DebtInstrumentPeriodicPaymentPrincipalAdditional
      contextRef="C_cf933ca0-5d88-4990-aa20-a3cc722c7bc7"
      decimals="-5"
      id="F_68e86ef2-ed48-41b7-900e-8361c4d8bbc3"
      unitRef="U_USD">3500000</calc:DebtInstrumentPeriodicPaymentPrincipalAdditional>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="C_cf933ca0-5d88-4990-aa20-a3cc722c7bc7"
      decimals="-5"
      id="F_028c791b-c1d6-4665-991f-b850afa5248a"
      unitRef="U_USD">8500000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="C_5472c13f-2db0-4124-89dd-bd16af205acf"
      decimals="-5"
      id="F_5a012503-de6d-4988-8809-eda29bbd5fe9"
      unitRef="U_USD">5000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_345b3de8-3757-4586-b754-d61ef7ff0cf5"
      decimals="2"
      id="F_84165a6c-04da-4ac9-8a26-7cfb850d618a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="C_5472c13f-2db0-4124-89dd-bd16af205acf"
      decimals="2"
      id="F_a8839528-7a79-4ac0-a1d6-241ddebd7cdd"
      unitRef="U_pure">0.06</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="C_3e9739ba-3899-4e58-81e1-44a9a303fe9b"
      decimals="0"
      id="F_f4317347-7d35-4848-900b-a354175768f3"
      unitRef="U_shares">20487104</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <calc:PublicCombinationMultipliedCashPricePaidPerShare
      contextRef="C_65b45366-3e2b-42a5-89ff-61739a51bdaf"
      decimals="2"
      id="F_4ae69e99-f69d-42c6-891c-670e0ae1df78"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.85</calc:PublicCombinationMultipliedCashPricePaidPerShare>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="C_a6b9f2b4-556e-4252-b411-7c709e13590c"
      decimals="0"
      id="F_caaa08e4-7f37-4de3-a209-509efc580979"
      unitRef="U_shares">590031</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_c9ffcd5c-d377-492d-baf6-7c7ef2c83293"
      decimals="2"
      id="F_f12c1e59-8ad2-4bd5-bf3c-f4cb88aa5b2e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <calc:PercentageOfWarrantCoverage
      contextRef="C_dcf336c2-04f1-4bf9-890c-ca0039d7e325"
      decimals="2"
      id="F_f9b9afc0-c6ad-430b-a359-db0a8d2918ee"
      unitRef="U_pure">0.15</calc:PercentageOfWarrantCoverage>
    <calc:PercentageOfWarrantCoverage
      contextRef="C_65b45366-3e2b-42a5-89ff-61739a51bdaf"
      decimals="2"
      id="F_41b35f8d-7135-4709-a74b-400075a0dbb2"
      unitRef="U_pure">0.40</calc:PercentageOfWarrantCoverage>
    <calc:ConvertiblePromissoryNoteWarrantsConvertible
      contextRef="C_c9ffcd5c-d377-492d-baf6-7c7ef2c83293"
      decimals="0"
      id="F_543bf9f8-633b-444c-a635-bd7cb1d431bd"
      unitRef="U_shares">5308047</calc:ConvertiblePromissoryNoteWarrantsConvertible>
    <calc:ConvertiblePromissoryNoteWarrantsCommonStockConverted
      contextRef="C_c9ffcd5c-d377-492d-baf6-7c7ef2c83293"
      decimals="0"
      id="F_b0eaa57a-b694-4178-b11e-7b38139079c1"
      unitRef="U_shares">5308047</calc:ConvertiblePromissoryNoteWarrantsCommonStockConverted>
    <calc:ExchangeOfStockForStock
      contextRef="C_c9ffcd5c-d377-492d-baf6-7c7ef2c83293"
      decimals="0"
      id="F_2e2c1051-7117-4b20-84db-62dce5ade405"
      unitRef="U_shares">152875</calc:ExchangeOfStockForStock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_c9ffcd5c-d377-492d-baf6-7c7ef2c83293"
      decimals="2"
      id="F_96ec2f5b-8ed4-4353-8700-0cecb1c40c95"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_73195b53-1edf-49b3-a1f9-3ae2ae46a761"
      decimals="4"
      id="F_2c596112-97af-47f7-9695-1da866bb27ad"
      unitRef="U_pure">0.0302</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_d26b6223-10d2-4e75-97a3-b8b6a3c39933"
      decimals="4"
      id="F_3dac68dd-31b4-4a5a-bf91-7816c2649e55"
      unitRef="U_pure">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_73195b53-1edf-49b3-a1f9-3ae2ae46a761"
      decimals="2"
      id="F_23d5f976-1b8c-4167-a3ae-e3f80eedcdaf"
      unitRef="U_pure">0.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_d26b6223-10d2-4e75-97a3-b8b6a3c39933"
      decimals="2"
      id="F_ddec1a2c-9144-4853-90db-c140c0b5dd38"
      unitRef="U_pure">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_73195b53-1edf-49b3-a1f9-3ae2ae46a761"
      id="F_c78fdd8b-21cf-422e-aa12-413f33bdab13">P4Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_d26b6223-10d2-4e75-97a3-b8b6a3c39933"
      id="F_daf74f78-5790-42ce-9f00-21bb54a330cd">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <calc:ConvertiblePromissoryNoteWarrantsCommonStockConverted
      contextRef="C_a3e2c51e-9ae5-48f2-aa73-7734ac756106"
      decimals="0"
      id="F_95f09b25-4040-4721-a9d0-0aa30571e502"
      unitRef="U_shares">152871</calc:ConvertiblePromissoryNoteWarrantsCommonStockConverted>
    <calc:ExpectedPerShare
      contextRef="C_a3e2c51e-9ae5-48f2-aa73-7734ac756106"
      decimals="2"
      id="F_87fdb714-f098-46aa-abba-dfed32e2857a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.5</calc:ExpectedPerShare>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_bc38ac8f-84a3-4fea-baff-4f403efc1d6e">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;6. Accrued Expenses&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued payroll and other employee benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued severance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;345&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued franchise tax&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_a54e9bec-952f-4647-8b63-2bc67295a25d">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued payroll and other employee benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued severance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;345&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued franchise tax&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <calc:AccruedPayrollAndOtherEmployeeBenefits
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_59314677-6b12-46ef-b9b3-3a863a6bc64c"
      unitRef="U_USD">935000</calc:AccruedPayrollAndOtherEmployeeBenefits>
    <calc:AccruedPayrollAndOtherEmployeeBenefits
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_76440eb9-5cf5-45c7-a016-2210600628cd"
      unitRef="U_USD">36000</calc:AccruedPayrollAndOtherEmployeeBenefits>
    <calc:AccruedSeveranceExpense
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_c2a581e6-38ef-4e33-b119-4fc72c045237"
      unitRef="U_USD">89000</calc:AccruedSeveranceExpense>
    <calc:AccruedSeveranceExpense
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_1f4750a9-40ef-4351-9dbd-ae9e2ee525af"
      unitRef="U_USD">0</calc:AccruedSeveranceExpense>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_031a0a89-92d9-4780-8c0e-9b2010797d86"
      unitRef="U_USD">345000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_5fc94bb6-0df9-4242-8fd7-1a86eb91357f"
      unitRef="U_USD">486000</us-gaap:AccruedProfessionalFeesCurrent>
    <calc:AccruedFranchiseTax
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_f750ae96-9924-46f8-8d59-eb48906cdad3"
      unitRef="U_USD">77000</calc:AccruedFranchiseTax>
    <calc:AccruedFranchiseTax
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_f167337b-d098-4888-87c1-f74e41406008"
      unitRef="U_USD">2000</calc:AccruedFranchiseTax>
    <calc:AccruedOther
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_5d8a18ce-06a0-4935-bdb6-e91406830c12"
      unitRef="U_USD">22000</calc:AccruedOther>
    <calc:AccruedOther
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_dff82ea1-4edc-42f5-9c76-4ae57e14bb51"
      unitRef="U_USD">48000</calc:AccruedOther>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_cead25c3-b475-4cb9-83c8-7530f00b49bd"
      unitRef="U_USD">1468000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_578b09f8-e4cf-46ef-a998-dc0fd12c4b5b"
      unitRef="U_USD">572000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <calc:TemporaryEquityDisclosureTextblock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_ec37da14-202d-4b8b-81aa-fd87a72d65ff">&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Convertible Preferred Stock, Common Stock and Stockholders' Deficit&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Authorized Shares&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company's current Amended and Restated Certificate of Incorporation authorizes &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;500,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock, par value $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of preferred stock, par value $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Private CalciMedica's convertible preferred stock consisted of Series A preferred stock (&#x201c;Series A preferred&#x201d;), Series B preferred stock (&#x201c;Series B preferred&#x201d;), Series C-1 preferred stock (&#x201c;Series C-1 preferred&#x201d;), Series C-2 preferred stock (&#x201c;Series C-2 preferred&#x201d;) and Series D preferred stock (&#x201c;Series D preferred&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Immediately prior to the effective time of the Merger, the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84,820,880&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Private CalciMedica preferred stock were converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84,820,880&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; outstanding shares of Private CalciMedica's common stock to be exchanged for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,442,852&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Graybug's common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Classification of Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Private CalciMedica's convertible preferred stock as of December 31, 2022, was classified outside of stockholders&#x2019; equity (deficit) on the accompanying balance sheets because such shares have liquidation rights in the event of a deemed liquidation that, in certain situations, are not solely within the control of Private CalciMedica and would require the redemption of the then outstanding shares of convertible preferred stock. Convertible preferred stock was not redeemable, except in the event of a deemed liquidation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Because the occurrence of a deemed liquidation event was not probable, the carrying values of the convertible preferred stock were not being accreted to their redemption values. Subsequent adjustments to the carrying values of the convertible preferred stock would be made only when a deemed liquidation event became probable.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Upon completion of the Merger on March 20, 2023, as the accounting acquirer, Private CalciMedica is deemed to have issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,571,433&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its common stock to Graybug shareholders.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Private Placement of Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Immediately prior to the consummation of the Merger, Private CalciMedica completed a private placement financing pursuant to which certain investors purchased approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares of Private CalciMedica&#x2019;s common stock (the &#x201c;private placement&#x201d;) for gross proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. In conjunction with the Merger, immediately prior to the effective time of the Merger, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,706,997&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Private CalciMedica common stock were converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;596,363&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Graybug&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Shelf Registration Statement and At the Market Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In August 2023, the Company filed a shelf registration statement on Form S-3 (the &#x201c;Shelf Registration Statement&#x201d;). The Shelf Registration Statement permits the offering, issuance and sale of common stock, preferred stock, debt securities and warrants having an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in one or more offerings and in any combination of the foregoing. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;99.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;million remains available for sale under the Shelf Registration Statement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Shelf Registration Statement contains two prospectuses, a base prospectus and an at the market offering prospectus that covers the offering, issuance and sale of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of common stock pursuant to an at-the-market offering agreement (&#x201c;ATM Agreement&#x201d;) with H.C Wainwright &amp;amp; Co., LLC, acting as sales agent (&#x201c;ATM Facility&#x201d;). The Company intends to use the net proceeds from the ATM Facility for general corporate purposes, which may include research and development expenses, clinical trial expenses, capital expenditures and working capital. The ATM Facility will terminate upon the earlier of (i) the sale of all of the shares of the Company&#x2019;s common stock provided for in the at the market offering prospectus or (ii) termination of the ATM Agreement as permitted therein. The ATM Agreement may be terminated at any time by either party upon written notice. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, the Company has sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92,572&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock for net proceeds of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;246,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; which includes &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$11&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of commissions paid under the ATM Facility and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million remains available for sale under the ATM Facility.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Preferred and Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the issuance of convertible notes in 2016, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;568,181&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; warrants to purchase Series B preferred were issued at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.77&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share (the &#x201c;Series B Warrants&#x201d;). The Series B Warrants were exercisable at any time after February 28, 2017, through the earliest to occur of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; after the issue date or prior to the date of sale of common stock in an initial public offering or a deemed liquidation event. Until the Merger, these Series B Warrants were accounted for as a liability and had a fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Prior to the Merger, the Series B Warrants converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;568,181&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; common share warrants of Private CalciMedica. In conjunction with the Merger, the common warrants converted into&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,366&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;common share warrants of CalciMedica with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26.74&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and have been reclassified to stockholders' equity (deficit) at its fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the issuance of Series C-2 preferred in May 2020, Private CalciMedica issued a warrant (&#x201c;Series C-2 Warrant&#x201d;), which was exercisable for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,786,567&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Series C-2 preferred at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.77&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. The Series C-2 Warrant was exercisable at any time after May 20, 2020, through the earliest to occur of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; after the issue date or prior to the date of a deemed liquidation, public combination or an initial public offering. Prior to the Merger, the Series C-2 Warrants converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,786,567&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; common share of Private CalciMedica. In conjunction with the Merger, the common shares &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80,254&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock at a fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Series C-2 Warrant was accounted for as a liability and had a fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the issuance of Series D preferred in 2021, Private CalciMedica issued warrants (&#x201c;Series D Warrants&#x201d;) to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,063,998&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Series D preferred with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8045&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. The Series D Warrants were exercisable at any time after the date of issuance through the earliest to occur of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; after the issue date or prior to the date of sale of common stock in an initial public offering or a deemed liquidation. In conjunction with the Merger, the common share warrants were converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;232,256&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; common share warrants of CalciMedica with an exercise price &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.94&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and have been reclassified to stockholders' equity (deficit) at a fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Up until the Merger, the Series D Warrants were accounted for as a liability and had a fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognized a total change in fair value of the preferred stock warrants of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;795,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; a&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;nd $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million f&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;or the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2020, Private CalciMedica granted a warrant to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;400,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock to a consulting firm affiliated with its interim chief financial officer in connection with its consulting agreement. The warrant has a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;-year term, an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.19&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and vests ratably over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; months commencing on the effective date. At the date of issuance, the fair value of the warrant was determined to be $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;120,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, utilizing Black-Scholes with the following assumptions: expected term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, risk-free rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.96&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, volatility of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and a dividend yield of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which has been recognized as general and administrative expense over the vesting period. In conjunction with the Merger, the warrant converted to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,520&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; warrants of CalciMedica at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.60&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The warrant is classified as equity and the Company expens&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for the year ended December 31, 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2022, Private CalciMedica granted warrants to certain officers and directors to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;496,970&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock. The warrants have a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;-year term, an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.42&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and vest ratably over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;48&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; months. At the date of issuance, the fair value of the warrants collectively was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and was determined utilizing Black-Scholes and will be recognized as general and administrative expense over the vesting periods. Assumptions used in the valuation were as follows: expected term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, risk free rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, volatility of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and a dividend yield of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. In conjunction with the Merger, the warrants converted to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,313&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; warrants of CalciMedica at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.42&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The warrants are classified as equity, and the Company expens&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to general and administrative expense in the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</calc:TemporaryEquityDisclosureTextblock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_42abc17e-9eda-4860-b3f8-0efb13eadeae"
      decimals="INF"
      id="F_8fdb52a6-0d32-4ba8-a9cb-719c62f6286a"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_42abc17e-9eda-4860-b3f8-0efb13eadeae"
      decimals="4"
      id="F_f9839ca9-e368-46ab-a46e-8a26ce0eb56f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_42abc17e-9eda-4860-b3f8-0efb13eadeae"
      decimals="INF"
      id="F_c87ae4b3-d2eb-436c-9ca0-0e5204cc69ca"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_42abc17e-9eda-4860-b3f8-0efb13eadeae"
      decimals="4"
      id="F_f220159b-1356-406a-9fd2-e174afb60ce8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_cfb02dbb-5b66-4ab2-8c28-3198b03e30f6"
      decimals="INF"
      id="F_6e77a7d9-1b52-4cef-80da-5ad8ffd2455f"
      unitRef="U_shares">84820880</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_cfb02dbb-5b66-4ab2-8c28-3198b03e30f6"
      decimals="INF"
      id="F_518c7715-a87d-4428-8b4c-cc831338b0eb"
      unitRef="U_shares">84820880</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_8f5cacbc-880d-4602-b949-fa5d6761652f"
      decimals="INF"
      id="F_c3cdf78a-3075-4a31-b288-bffb65f928d5"
      unitRef="U_shares">2442852</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_7d82e695-1745-41a7-8cb2-68d786a08457"
      decimals="INF"
      id="F_371eafe6-2e06-4644-93e0-c821af738876"
      unitRef="U_shares">1571433</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_9ef48710-53ac-4e62-b939-0912f0ec48d0"
      decimals="-5"
      id="F_f0bb49cd-6dcc-4adb-82e6-a90fa59391b9"
      unitRef="U_shares">20700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_9ef48710-53ac-4e62-b939-0912f0ec48d0"
      decimals="-5"
      id="F_6519241e-1bae-400c-a0c7-5a97fed39ea7"
      unitRef="U_USD">10300000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_c13bf6e6-7b21-47f6-8c64-15752b0689e8"
      decimals="INF"
      id="F_af56b2e6-9a04-4d5f-b5a3-33dcce52bf0f"
      unitRef="U_shares">20706997</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="C_9a978bf4-30e7-4478-82d1-2929b8c869c9"
      decimals="INF"
      id="F_0e104726-5d09-442f-9ab2-6dc766f355a3"
      unitRef="U_shares">596363</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_1c46001b-5fe7-4131-9a1d-ccf9d2e7cfde"
      decimals="-5"
      id="F_b4391c50-73b8-44a0-b53f-5de90ce29919"
      unitRef="U_USD">100000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <calc:ShelfRegistrationStatementAvaliableForSale
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-5"
      id="F_00db6ec9-3d1e-48b2-a541-3ec7a8564808"
      unitRef="U_USD">99700000</calc:ShelfRegistrationStatementAvaliableForSale>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_047361c5-453c-47e4-8ce1-9373daa9b02d"
      decimals="-5"
      id="F_55d8862f-d1c4-4613-b327-aa51b12d2256"
      unitRef="U_USD">4700000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_f6acf339-8a66-4359-827f-f1d8c3fefcf6"
      decimals="0"
      id="F_86842aec-6d79-4af6-a250-3a5ff1acc11e"
      unitRef="U_shares">92572</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="0"
      id="F_93dc5af2-a95d-4c6b-b078-845a7ea67070"
      unitRef="U_USD">246000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_047361c5-453c-47e4-8ce1-9373daa9b02d"
      decimals="0"
      id="F_7c2dfc3d-51ff-4a69-8ac3-527969e8d160"
      unitRef="U_USD">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <calc:SaleOfStockRemainingSalesAmount
      contextRef="C_047361c5-453c-47e4-8ce1-9373daa9b02d"
      decimals="-5"
      id="F_0850eca5-2f91-4060-9b00-d9bf6fc0a1ef"
      unitRef="U_USD">4400000</calc:SaleOfStockRemainingSalesAmount>
    <calc:StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants
      contextRef="C_ec132aef-e24b-4108-817d-1584845fdc60"
      decimals="INF"
      id="F_92cc538c-74f6-4485-a154-6ebe40ad418c"
      unitRef="U_shares">568181</calc:StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_71e8ce45-e272-4f48-9eff-ba31844ce0d8"
      decimals="2"
      id="F_4556e805-2e7b-4df3-847d-f560936331ae"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.77</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_71e8ce45-e272-4f48-9eff-ba31844ce0d8"
      id="F_1d05c7d1-ea97-4f81-9fbe-42c8786d68b3">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:FairValueNetAssetLiability
      contextRef="C_d824885a-bf88-4997-b44b-56b06f10352e"
      decimals="0"
      id="F_64dd2245-efce-4e74-8f8b-7e54e8258b89"
      unitRef="U_USD">45000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_80eeb444-2e22-4786-9e02-a20268b73e22"
      decimals="INF"
      id="F_fd514b22-8366-4490-a776-e40ce08b89e3"
      unitRef="U_shares">568181</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_c76b6693-5f6b-44e3-a453-7bd33b5ddf5f"
      decimals="INF"
      id="F_4dc64ec8-dee7-4213-8d04-79613ffcbf2a"
      unitRef="U_shares">16366</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_c76b6693-5f6b-44e3-a453-7bd33b5ddf5f"
      decimals="2"
      id="F_c32bc889-13d7-432d-8e26-ea32c124bd4d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">26.74</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_ec132aef-e24b-4108-817d-1584845fdc60"
      decimals="0"
      id="F_6853b382-4164-4ed7-a8ea-a143da9a216f"
      unitRef="U_USD">21000</us-gaap:FairValueAdjustmentOfWarrants>
    <calc:StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrantsExercisable
      contextRef="C_9aec901d-664d-416c-9998-1ef7272a19c0"
      decimals="INF"
      id="F_c1d6d446-ebef-40c1-911f-1b5dcb492595"
      unitRef="U_shares">2786567</calc:StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrantsExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_5405b9ae-90f7-42b7-8ea1-97fedf79248d"
      decimals="2"
      id="F_79b9698b-03cd-4133-b57f-89b7431dc8a6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.77</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_515175dc-1ad3-4b7e-8b77-14527a01e9a5"
      id="F_42b0fe10-5a6f-4657-a1fd-4f1599b38067">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_132f40d2-5814-446c-afac-5f97f6db9fc9"
      decimals="0"
      id="F_5c370256-505a-4e25-bc62-1d1153e96bb8"
      unitRef="U_shares">2786567</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_4ba994e5-acb4-4356-85f9-d557fa3db223"
      decimals="INF"
      id="F_29eea3e2-2f33-4df4-8268-18b9021af2a6"
      unitRef="U_shares">80254</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_f9395b99-5d87-4344-87fa-5056b48d26c5"
      decimals="-5"
      id="F_7d3e1af9-a020-4ac0-8c58-b0855ed3d848"
      unitRef="U_USD">400000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_a0231b6b-5eb4-4312-ade8-abf82342f64e"
      decimals="-5"
      id="F_06a987f4-8f6b-4cca-9cd8-b38aec65fdfb"
      unitRef="U_USD">900000</us-gaap:FairValueAdjustmentOfWarrants>
    <calc:StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants
      contextRef="C_8ab25aef-aa0a-43b5-80d4-c77a6790fefb"
      decimals="INF"
      id="F_e2506b7a-f9b5-4ae6-8ace-c6bc26a10625"
      unitRef="U_shares">8063998</calc:StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_1625384c-df1a-463a-9b14-131ec9a67ba4"
      decimals="4"
      id="F_d00675e4-d4f3-49c7-b132-2f7608882236"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.8045</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_1625384c-df1a-463a-9b14-131ec9a67ba4"
      id="F_b6e192cd-b61c-4e71-be29-7ea99bf8deb8">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_12eaa057-d9c1-42e1-b525-a11412a82bab"
      decimals="0"
      id="F_c57f11cd-d61d-48ea-b7b7-22b2f3751338"
      unitRef="U_shares">232256</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_12eaa057-d9c1-42e1-b525-a11412a82bab"
      decimals="2"
      id="F_7626d380-4d89-4444-a987-1fd59db35f20"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">27.94</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_f43e59fc-a4b6-4320-b729-ea2f876d663d"
      decimals="-5"
      id="F_9dffbace-0ba5-42b3-88db-5ee0c63e65ef"
      unitRef="U_USD">200000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_1ffb1c4c-957c-4089-a01f-27b641fd51e7"
      decimals="-5"
      id="F_2801e158-3d71-4797-bd14-d9ec51d265ac"
      unitRef="U_USD">600000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_38bc6d68-19a2-4497-aebd-7db45c2ce63b"
      decimals="0"
      id="F_27ee0dab-85ba-4e30-8e17-165632de2531"
      unitRef="U_USD">795000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_3dfbf602-7a4c-49b2-8b99-9805b5186589"
      decimals="-5"
      id="F_ee8861f5-c427-443c-bdd3-f54e52014767"
      unitRef="U_USD">3000000</us-gaap:FairValueAdjustmentOfWarrants>
    <calc:StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants
      contextRef="C_10d7c32a-8834-4078-bcb5-f2abb3c5706a"
      decimals="INF"
      id="F_6ce9cdcf-e174-47d3-b297-e3777a064f21"
      unitRef="U_shares">400000</calc:StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_17715ce3-d9ea-4ab1-acb5-cf49f46cbaaf"
      id="F_a19e499a-4b27-40ed-85e7-b28fc783515c">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_17715ce3-d9ea-4ab1-acb5-cf49f46cbaaf"
      decimals="2"
      id="F_6e4cbe85-5475-410b-aabb-359dd1f13daf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.19</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_10d7c32a-8834-4078-bcb5-f2abb3c5706a"
      id="F_5a6b89ae-7081-42b5-b264-1e960076d28d">P24M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:FairValueNetAssetLiability
      contextRef="C_17715ce3-d9ea-4ab1-acb5-cf49f46cbaaf"
      decimals="0"
      id="F_2d56bd8b-8598-4a92-b221-986e62a75a11"
      unitRef="U_USD">120000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_10d7c32a-8834-4078-bcb5-f2abb3c5706a"
      id="F_45b67962-3f9a-43d0-892d-d17528632584">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_10d7c32a-8834-4078-bcb5-f2abb3c5706a"
      decimals="4"
      id="F_44fc133e-c9da-40d0-a108-6325f0096df6"
      unitRef="U_pure">0.0096</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_10d7c32a-8834-4078-bcb5-f2abb3c5706a"
      decimals="3"
      id="F_1b2beda1-3487-481d-b83b-5e80c39bd192"
      unitRef="U_pure">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate
      contextRef="C_10d7c32a-8834-4078-bcb5-f2abb3c5706a"
      decimals="2"
      id="F_b6684692-891f-4026-b40f-e9946e266795"
      unitRef="U_pure">0</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_6557ada0-e212-4e78-b768-866c8fb13b00"
      decimals="0"
      id="F_eb384b51-f300-492f-ab14-6c66ca52957c"
      unitRef="U_shares">11520</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_033e18f1-c526-494a-af37-d16f8a20d94c"
      decimals="2"
      id="F_e439e1b3-360d-45fb-b806-90e5a0474c41"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.6</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_fb28aa96-7bbd-4570-8a6a-cb5c875bd34a"
      decimals="0"
      id="F_f142d2ee-7376-4ccd-b2fb-f473295d994f"
      unitRef="U_USD">50000</us-gaap:GeneralAndAdministrativeExpense>
    <calc:StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants
      contextRef="C_9aaecb1b-b009-46d1-a2c3-ad52042541eb"
      decimals="INF"
      id="F_be3e1f19-5c4f-4cc4-a42a-7ae6f0416e76"
      unitRef="U_shares">496970</calc:StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_8796b832-7e69-4299-a51b-d5ad3e94056f"
      id="F_be6f75d8-3cd9-4018-8970-cb73ce76d513">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_8796b832-7e69-4299-a51b-d5ad3e94056f"
      decimals="2"
      id="F_23d51959-889d-4518-9a90-568fa773cb03"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.42</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_bb2bd826-29bf-448a-b3fe-756756fb69a3"
      id="F_1c4ce5b9-f154-4f12-a6a3-5dccaa6d3a3d">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_fd5366f4-f6f4-4f51-86ec-d2b17b2273e0"
      id="F_596bc652-3be2-4ba7-8327-49168b17ebaa">P48M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:FairValueNetAssetLiability
      contextRef="C_8796b832-7e69-4299-a51b-d5ad3e94056f"
      decimals="0"
      id="F_7f2b8e01-94cb-44ca-ad94-674280c43a8e"
      unitRef="U_USD">125000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_9aaecb1b-b009-46d1-a2c3-ad52042541eb"
      id="F_9592e073-08b1-4c82-94b1-6ac02908bb36">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_9aaecb1b-b009-46d1-a2c3-ad52042541eb"
      decimals="4"
      id="F_55fb2b79-d8de-4348-bbd3-3b324b15898b"
      unitRef="U_pure">0.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_9aaecb1b-b009-46d1-a2c3-ad52042541eb"
      decimals="2"
      id="F_1779aca2-f4b3-40b6-9e73-a879a3176096"
      unitRef="U_pure">0.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate
      contextRef="C_9aaecb1b-b009-46d1-a2c3-ad52042541eb"
      decimals="2"
      id="F_e1ca8c8d-7bb9-489a-962e-77b3cb2f7450"
      unitRef="U_pure">0</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_8b2b8377-2a31-4a6e-8ded-d5abdcfa46af"
      decimals="0"
      id="F_f32f9de3-2ded-4b4b-9b38-d4d959d0557a"
      unitRef="U_shares">14313</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_8b2b8377-2a31-4a6e-8ded-d5abdcfa46af"
      decimals="2"
      id="F_4af48f87-0429-47f3-8303-2f8926b13113"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.42</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_83ff265d-5f06-4f96-87f9-d5b6ce1fb1d7"
      decimals="0"
      id="F_80a4eaec-4a6a-4fa3-9772-327899ae6cdf"
      unitRef="U_USD">90000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_8fb4c8dc-dcc1-4352-ad4c-b46434309f12"
      decimals="0"
      id="F_a1268934-14e5-464f-a657-be833e67d832"
      unitRef="U_USD">28000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_bfddc134-ae1b-4c5b-aa53-2a7cac05ce29">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;8. Stock-based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2006 Equity Incentive Plan and Amendment to 2006 Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Private CalciMedica adopted an equity incentive plan in 2006 (&#x201c;2006 Plan&#x201d;) that provides for the issuance of common stock to employees, non-employee directors and consultants. Recipients of incentive stock options are eligible to purchase common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The 2006 Plan provides for the grant of incentive stock options, non-statutory stock options and stock purchase rights. The maximum contractual term of options granted under the 2006 Plan is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The options generally vest &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% on the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_71b4969f-28c5-4ace-ac88-38cb897a2809;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;first &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;anniversary &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of the grant date, with the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;balance &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;vesting ratably over the following &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; months. Pursuant to the Merger Agreement, Graybug assumed the 2006 Plan and all stock options issued and outstanding under the 2006 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2023 Equity Incentive Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company adopted 2023 Equity Incentive Plan (the &#x201c;2023 Plan&#x201d;), which became effective at the closing of the Merger. As of the effective time of the Merger, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock available for grant under the 2023 Plan. In addition, the share reserve is subject to annual increases each January 1 for the first ten years following approval of the 2023 Plan of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of shares of the Company&#x2019;s common stock outstanding (or a lesser number determined by the Company&#x2019;s board of directors). As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96,594&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; options have been returned but are unavailable for future grant under the 2006 Plan. As of December 31, 2023,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;394,309&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;shares were available for grant under the 2023 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2023 Employee Stock Purchase Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company adopted the 2023 Employee Stock Purchase Plan (the &#x201c;2023 ESPP&#x201d;) which became effective at the closing of the Merger. As of the effective time of the Merger, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock reserved for issuance under the 2023 ESPP. In addition, the share reserve is subject to annual increases each January 1 for the first ten years following approval of the 2023 ESPP of the lesser of (1) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the total number of shares of the Company&#x2019;s common stock outstanding on December 31 of the preceding calendar year, (2) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;195,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock, or (3) such lesser number of shares of the Company&#x2019;s common stock as determined by the Company&#x2019;s board of directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares have been issued under the 2023 ESPP.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the stock option transactions for the 2006 and 2023 Plans:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.656%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.111%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.953%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.111%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.111%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.309%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.178%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.353%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.355%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.178%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.687%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Average Remaining Contractual Term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;739,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.36&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assumed in the Merger&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;310,431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;785,922&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,739,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.99&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested and exercisable at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;940,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.97&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; options exercised during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023. The weighted-average fair value of options granted during the years ended December 31, 2023 and 2022 was&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.34&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;per share, respectively. The total fair value of shares vested was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;mill&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ion (which includes $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million related to the acceleration of vesting of the Graybug stock awards at the date of the Merger) for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the year ended December 31, 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, stock-based compensation not yet recognized is&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which the Company expects to recognize over an estimated weighted-average term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following is the range of underlying assumptions in Black-Scholes to determine the fair value of the stock option grants for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.667%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.111%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.422%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.111%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.689%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.56&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.28&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense recognized for options and restricted stock units granted was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,449&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,039&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Statement of convertible preferred stock and stockholders' equity (deficit)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Settlement of 2021 and 2020 accrued bonus and employee costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,039&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The stock-based compensation expense for the year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, includes one-time charges for the acceleration of vesting of the Graybug stock options at the date of the Merger of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in research and development and general and administrative expenses, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Common Stock Reserved for Future Issuance&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Common stock reserved for future issuance consists of the following at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;276,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,739,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares available for issuance under the 2023 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;394,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares available under the 2023 ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,475,016&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_7ef7e808-55f3-466b-981a-c813c5b91fb6"
      id="F_dd7a38df-9e05-4f1a-948a-561d6719c7fd">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_7ef7e808-55f3-466b-981a-c813c5b91fb6"
      decimals="2"
      id="F_bdfc76e4-9f3d-4a45-a1c5-a4a92260a526"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_7ef7e808-55f3-466b-981a-c813c5b91fb6"
      id="F_c5b28c0e-880f-42db-8f3d-1568c095d13b">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_2bc4190f-24bd-4383-9a76-813440aa7079"
      decimals="INF"
      id="F_ebb2ef6e-64bb-45ad-9693-2f3a314b1c56"
      unitRef="U_shares">1000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <calc:PercentageOfAggregateNumberOfSharesOfCommonStockOutstandingOnLastDayOfPrecedingYearAddedToPlan
      contextRef="C_6584f473-e3fd-4960-8c14-afa94ca4e2ac"
      decimals="2"
      id="F_0b92ebbc-7ee7-40e2-8507-5ef70c593b18"
      unitRef="U_pure">0.05</calc:PercentageOfAggregateNumberOfSharesOfCommonStockOutstandingOnLastDayOfPrecedingYearAddedToPlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_6584f473-e3fd-4960-8c14-afa94ca4e2ac"
      decimals="INF"
      id="F_0652a831-ba92-4310-88ab-65317811e768"
      unitRef="U_shares">96594</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_4ac3291f-aa10-49f9-b9db-b6f575d3e347"
      decimals="INF"
      id="F_c62f3ec9-04bb-4950-b200-0ac46ccb9396"
      unitRef="U_shares">394309</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_e6f38265-4614-44ec-85bc-fcffb8b21275"
      decimals="INF"
      id="F_6e6cae5d-bd39-4444-a620-8478fb5f7ad1"
      unitRef="U_shares">65000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <calc:PercentageOfAggregateNumberOfSharesOfCommonStockOutstandingOnLastDayOfPrecedingYearAddedToPlan
      contextRef="C_5317cbe0-64bb-4729-93e5-b7c5d402fc35"
      decimals="2"
      id="F_b236b5f7-f7b1-40f8-8e49-e5f37acd94bd"
      unitRef="U_pure">0.01</calc:PercentageOfAggregateNumberOfSharesOfCommonStockOutstandingOnLastDayOfPrecedingYearAddedToPlan>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_e6f38265-4614-44ec-85bc-fcffb8b21275"
      decimals="INF"
      id="F_a8038fd4-124a-44ff-8e24-743457ebbbd6"
      unitRef="U_shares">195000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_5317cbe0-64bb-4729-93e5-b7c5d402fc35"
      decimals="INF"
      id="F_f05e3ee1-8311-40ba-88f3-781e157f0408"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_cdf758a5-c1f5-44bb-801d-0007d0adb8b0">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the stock option transactions for the 2006 and 2023 Plans:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.656%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.111%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.953%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.111%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.111%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.309%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.178%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.353%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.355%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.178%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.687%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Average Remaining Contractual Term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;739,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.36&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assumed in the Merger&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;310,431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;785,922&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,739,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.99&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested and exercisable at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;940,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.97&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="INF"
      id="F_978c2d0a-b34b-48b1-81e8-e67ee9c17e7c"
      unitRef="U_shares">739511</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="2"
      id="F_33f5ffe9-f4b7-4f53-9838-fdc7a5576e75"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      id="F_3c4f4ff1-3613-42ac-ad56-a376d536b62f">P7Y4M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_5b5f2c94-b406-46fb-9ffe-795458482047"
      unitRef="U_USD">8903000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="INF"
      id="F_11f02576-b61a-470f-9f30-c77289858e6e"
      unitRef="U_shares">310431</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="2"
      id="F_17067b6e-bfcf-4598-9e21-500232dc4dec"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">76.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="INF"
      id="F_8ce7ad64-60c5-49a5-9a1d-c6a8d09c5fde"
      unitRef="U_shares">785922</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="2"
      id="F_51693d55-662d-4487-9a6c-79e5ee792543"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="INF"
      id="F_2a888512-67cc-423e-b79c-3d7bd2a6d314"
      unitRef="U_shares">96594</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="2"
      id="F_e7f0e0a8-1bf4-4dc5-90d6-a1660f0318f4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">70.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="INF"
      id="F_69c4bdae-4dc7-4851-a480-af331ec27443"
      unitRef="U_shares">1739270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="2"
      id="F_5609df98-5c98-4af4-b0df-0bc265feef03"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_34bbbe80-0f9f-4bae-be32-6fc122a5769d">P6Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_731c13d8-7993-4fc2-a5f6-75f9f522ff26"
      unitRef="U_USD">76000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="INF"
      id="F_8d43fdda-db0d-4fa5-9d25-4fd8accfa014"
      unitRef="U_shares">940098</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="2"
      id="F_e24be56f-85eb-44c8-92e5-bf5418bbd957"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_10b9b15a-78d9-47bc-8fdb-e941cacff5a0">P5Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_0e9007ad-e61a-4e11-9da6-07a5e5e7bbd5"
      unitRef="U_USD">76000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_5317cbe0-64bb-4729-93e5-b7c5d402fc35"
      decimals="INF"
      id="F_5f3b38ad-4c78-4adc-a8ee-bb8022b0d2c4"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_5317cbe0-64bb-4729-93e5-b7c5d402fc35"
      decimals="2"
      id="F_444df1b2-9e45-4120-92ef-48557a819867"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_2d6b7e2b-1799-423b-80d4-f0ffdbd4249e"
      decimals="2"
      id="F_c59e970f-cbbe-4f1c-a9ea-8339132c7f5e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_5317cbe0-64bb-4729-93e5-b7c5d402fc35"
      decimals="-5"
      id="F_65c05e12-5e2a-4208-8b7d-d86c9b613aa3"
      unitRef="U_USD">11900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="C_c654b3dc-d8de-4e32-ade7-4c14b46e29eb"
      decimals="-5"
      id="F_104b0790-2866-441a-839e-89236221a1f5"
      unitRef="U_USD">10500000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_2d6b7e2b-1799-423b-80d4-f0ffdbd4249e"
      decimals="-5"
      id="F_2cb908d0-cb3a-4815-af55-847ad20cfba9"
      unitRef="U_USD">1700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_e6f38265-4614-44ec-85bc-fcffb8b21275"
      decimals="-5"
      id="F_0bc6a6d3-5ad0-450f-a962-b57751072d1c"
      unitRef="U_USD">2300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_5317cbe0-64bb-4729-93e5-b7c5d402fc35"
      id="F_332afb97-0699-4546-b645-401524eaf8a9">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_cd110862-0457-451c-b768-3d3dd1150203">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following is the range of underlying assumptions in Black-Scholes to determine the fair value of the stock option grants for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.667%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.111%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.422%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.111%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.689%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.56&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.28&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_d630bef2-91b1-4374-b30e-0dae725036e6"
      decimals="3"
      id="F_95e09065-bebd-4f27-b55e-8c17a63174c6"
      unitRef="U_pure">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_7547cb73-f5f8-44b0-ad5f-4fe05452061d"
      decimals="4"
      id="F_b3514cb1-880e-4db3-8780-0f08838d96df"
      unitRef="U_pure">0.0356</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_5d9b48b9-68d6-41ad-994c-2b74751e5df8"
      decimals="4"
      id="F_c93e95ee-de2f-41dd-a7d2-994fc0694887"
      unitRef="U_pure">0.028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_ea3403be-994b-481a-8da5-05ce7ae02175"
      decimals="4"
      id="F_5da5bbf4-46ad-41be-ad4b-6c9162c52b73"
      unitRef="U_pure">0.0328</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_d630bef2-91b1-4374-b30e-0dae725036e6"
      decimals="2"
      id="F_f14c56ec-a2da-431b-ba5b-d43ffd3394be"
      unitRef="U_pure">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_7547cb73-f5f8-44b0-ad5f-4fe05452061d"
      decimals="2"
      id="F_8440f6c8-d2d7-4230-b61a-7aee3f5072e5"
      unitRef="U_pure">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="2"
      id="F_7fae2c70-eecf-44a7-9d78-8e151ee1092b"
      unitRef="U_pure">0.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_aa468320-5d82-403c-a46a-e40497844463">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_5d9b48b9-68d6-41ad-994c-2b74751e5df8"
      id="F_f74f8f59-02f7-4346-832b-06a28fed171a">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_ea3403be-994b-481a-8da5-05ce7ae02175"
      id="F_c4ed1fde-5e23-4eae-ba8c-37ae91fa9625">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="2"
      id="F_3d4c411e-855d-4160-b3f0-d80bf1ae0876"
      unitRef="U_pure">0</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="2"
      id="F_67336a1a-d1ef-4ee5-94fa-4cad0f86939d"
      unitRef="U_pure">0</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_f9c2a566-9649-47da-b32d-5b4fec7b784d">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense recognized for options and restricted stock units granted was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,449&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,039&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Statement of convertible preferred stock and stockholders' equity (deficit)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Settlement of 2021 and 2020 accrued bonus and employee costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,039&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1df30a04-c352-47af-8399-d9257a158c80"
      decimals="-3"
      id="F_4f477b61-410d-4925-9034-51db06075ea7"
      unitRef="U_USD">2449000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1d913287-6a9c-4c1e-8311-ffb8f8c0200f"
      decimals="-3"
      id="F_7db8f63a-b271-41e7-ae77-ad4504ebd122"
      unitRef="U_USD">499000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_eccb0df3-d3be-48ca-afe0-3b0886ba2bb6"
      decimals="-3"
      id="F_5307ce6a-ed00-4a0b-8854-92b50923841f"
      unitRef="U_USD">9590000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a560d69c-2898-468a-9634-5372f3e638e8"
      decimals="-3"
      id="F_3525e658-144b-4b92-81c8-38dda752da8b"
      unitRef="U_USD">902000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_4ee8ea3e-cf6b-42cf-b283-fcb135841172"
      unitRef="U_USD">12039000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_b8a08237-25a2-4182-9e09-7bed592d73b0"
      unitRef="U_USD">1401000</us-gaap:AllocatedShareBasedCompensationExpense>
    <calc:SettlementOfAccruedBonusAndEmployeeCosts
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_d6a7fa6d-0e70-4e59-a579-35a7a0996f65"
      unitRef="U_USD">0</calc:SettlementOfAccruedBonusAndEmployeeCosts>
    <calc:SettlementOfAccruedBonusAndEmployeeCosts
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_12d95b09-a7dd-4db7-97af-5ba00c614bb1"
      unitRef="U_USD">406000</calc:SettlementOfAccruedBonusAndEmployeeCosts>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_06ba2919-ee4d-427b-a1cd-7fe3541ed06f"
      unitRef="U_USD">12039000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_b1cf65d0-c902-439c-aefd-36c3b99dce46"
      unitRef="U_USD">1807000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5d90f9a6-e52f-451e-b3ef-71ea2b53490b"
      decimals="-5"
      id="F_e42e4503-0f8d-4519-9aa1-b321191019e7"
      unitRef="U_USD">1900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_72ea148a-99e6-47b2-bd68-d0f6914854ee"
      decimals="-5"
      id="F_2922730e-1397-4c41-9518-f06fb5bcbba1"
      unitRef="U_USD">8600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <calc:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_85d891a5-3c2b-4b0c-a055-14ba65fe993b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Common stock reserved for future issuance consists of the following at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;276,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,739,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares available for issuance under the 2023 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;394,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares available under the 2023 ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,475,016&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</calc:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="INF"
      id="F_60cc6b78-b78f-48b9-a735-8430c709d4b0"
      unitRef="U_shares">276437</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="INF"
      id="F_dd7f0273-492f-4867-af2f-8d91a044c689"
      unitRef="U_shares">1739270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_4ac3291f-aa10-49f9-b9db-b6f575d3e347"
      decimals="INF"
      id="F_7cfe7d7c-6f95-4ac5-9a79-dbb12a56b323"
      unitRef="U_shares">394309</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_e6f38265-4614-44ec-85bc-fcffb8b21275"
      decimals="INF"
      id="F_b606ca0b-a571-4279-9540-542fb64878e6"
      unitRef="U_shares">65000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="INF"
      id="F_c0754f10-fd84-470f-89b5-19ef40da8cbd"
      unitRef="U_shares">2475016</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_173738a2-046e-488c-9c31-4dc45d81823f">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;9. Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues liabilities for such matters when future expenditures are probable and such expenditures can be reasonably estimated.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has historically entered into contracts in the normal course of business with contract development and manufacturing organizations, for the manufacturing process development and the preclinical/clinical supply manufacturing, and its vendors for preclinical research studies and other services or products for operating purposes. These contracts generally provide for termination on notice of 60 to 90 days. As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, there are &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; such contracts, with two CMO&#x2019;s related to its development of Auxora and acquired as a result of the Merger with approximate&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ly&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;million of associated costs, respectively, still in effect for future services, and there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; unpaid cancellation or other related costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company may also, from time to time, become party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Operating Lease Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has an operating lease for office space in La Jolla, California. In &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_10ec6273-2918-45a5-ad26-6251eb098fa9;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January 2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, an amendment was executed for a twelve month term and therefore qualifies for the short-term lease exception. The lease was amended and renewed in December 2023 for an additional twelve month term and therefore qualifies for the short-term lease exception. Base rent for this lease is approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; monthly.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As a result of the Merger, the Company had leased a facility in Baltimore, Maryland under an operating lease with a term through &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_01fefd8e-092e-48bc-992a-f56011278bfb;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and was accounted for under ASC 842. The facility has been abandoned and the asset was fully impaired in 2022 and was reflected in Graybug&#x2019;s financial statements in 2022 and there is no impact to the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The lease expired in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_5164bc76-6e34-4c80-a8a7-d709dbb4720a;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Rent expense for the years ended December 31, 2023 and 2022 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;274,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;221,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;respectively, which is included in operating expenses. The lease obligation was included in other current liabilities in the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <calc:NumberOfContractCurrentlyInEffect
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="INF"
      id="F_a402fbfe-6709-4939-a1a8-f57a328494d8"
      unitRef="U_Contract">3</calc:NumberOfContractCurrentlyInEffect>
    <calc:ContractualObligationOfContractInEffect
      contextRef="C_3aa562e8-771a-40e1-9e64-d658f147bd41"
      decimals="-5"
      id="F_73931216-c20a-462d-995d-0c9287870b2d"
      unitRef="U_USD">1400000</calc:ContractualObligationOfContractInEffect>
    <calc:ContractualObligationOfContractInEffect
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-5"
      id="F_b37da0c1-db94-4a77-8dce-52135cfc7b64"
      unitRef="U_USD">1200000</calc:ContractualObligationOfContractInEffect>
    <calc:UnpaidCancellationAndOtherRelatedCosts
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="INF"
      id="F_2e1ef699-ddf3-4f51-a944-9c8f89743052"
      unitRef="U_USD">0</calc:UnpaidCancellationAndOtherRelatedCosts>
    <calc:BaseRent
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="0"
      id="F_ed05d53e-b8bc-47e5-94ba-559d9424a46c"
      unitRef="U_USD">10000</calc:BaseRent>
    <us-gaap:LeaseAndRentalExpense
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="0"
      id="F_c49c9810-5593-41da-a26e-1d7076c9c82e"
      unitRef="U_USD">274000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="0"
      id="F_44082f7a-f941-407c-a25f-eb3f215c9ac1"
      unitRef="U_USD">221000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_d60c86f3-1681-4e4f-a44b-96d80218d520">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10. Employee Benefits&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In January 2007, Private CalciMedica adopted a defined contribution 401(k) plan for substantially all employees. Contributions made by CalciMedica to the 401(k) plan were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $3&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_7fb26844-de71-49b6-86fb-4568f1258563"
      unitRef="U_USD">78000000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_2b4df01e-d6e9-408e-bb60-9eb5d97347e4"
      unitRef="U_USD">1000000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_66ac29dc-a67d-47c5-9f1f-0d153e13321d">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;11. Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The effective tax rate if the Company&#x2019; provision (benefit) for income taxes differs from the federal statutory rate as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:89.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.682%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.813%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.102%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.813%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.588%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax computed at federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State tax, net of federal tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development tax credits, net of uncertain positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards. &lt;/span&gt;&lt;span style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant components of deferred tax assets (liabilities) at December 31 are as follows (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:89.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.682%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.813%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.102%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.813%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.588%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,839&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State tax, net of federal tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued and deferred expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development credit carry forwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company provided a full valuation allowance on the net deferred tax asset because management has determined that it is more-likely-than-not that the Company will not earn income sufficient to realize the deferred tax assets during the carryforward period. As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company has federal and state NOLs available of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;278.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;103.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, to offset future taxable income, if any, for federal and state income tax purposes. The federal and state NOLs expire beginning in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company has $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;204.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of post-2017 federal NOL carryforwards that carry forward indefinitely. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition, under the Tax Act the amount of net operating losses generated in taxable periods beginning after December 31, 2017, that the Company is permitted to deduct in any taxable year is limited to 80% of taxable income in such year, where taxable income is determined without regard to the net operating loss deduction itself.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The Tax Act generally eliminates the ability to carry back any net operating loss to prior taxable years, while allowing post-2017 unused net operating losses to be carried forward indefinitely.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company has federal and state research and development credit carryforwards available of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. Federal research and development carryforwards expire beginning in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. State research and development carryforwards do not expire.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Pursuant to Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;) specifically by IRC &#xa7;382, the Company&#x2019;s ability to use net operating loss carryforwards to offset future taxable income is limited if the Company experiences a cumulative change in ownership of more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% within a three-year testing period. The Company has not completed an ownership change analysis pursuant to IRC Section 382. If ownership changes within the meaning of IRC Section 382 are identified as having occurred, the amount of remaining tax attribute carryforwards available to offset future taxable income and income tax expense in future years may be significantly reduced. Any limitation may result in the expiration of a portion of the NOL carryforwards before utilization.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The change in the Company&#x2019;s unrecognized tax benefits is summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increase related to current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions for tax positions of prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increase related to current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,846&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions for tax positions of prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions in connection with the reverse merger&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#ffffff;text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Reduction for tax positions of prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more likely than not recognition threshold to be recognized. The Company&#x2019;s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; accrual for interest and penalties and has not recognized interest and/ or penalties in the statements of operations and comprehensive loss for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022. Uncertain tax positions are evaluated based upon the facts and circumstances that exist at each reporting period. Subsequent changes in judgment based upon new information may lead to changes in recognition, derecognition, and measurement. Adjustments may result, for example, upon resolution of an issue with the taxing authorities or expiration of a statute of limitations barring an assessment for an issue.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, unrecognized tax benefits associated with uncertain tax positions was approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million respectively. If recognized, this would affect the effective tax rate, subject to valuation allowance. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company did not recognize any interest and penalties associated with unrecognized tax benefits. Due to net operating losses incurred, tax years from inception remain open to examination by the Federal and State taxing jurisdictions to which we are subject. The Company is not currently under Internal Revenue Services (IRS), state or local tax examination.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_9c552365-8f18-4fac-94fb-e7f46d619a0d">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The effective tax rate if the Company&#x2019; provision (benefit) for income taxes differs from the federal statutory rate as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:89.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.682%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.813%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.102%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.813%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.588%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax computed at federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State tax, net of federal tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development tax credits, net of uncertain positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_dbfef981-5c48-469d-8ade-eccedef20da5"
      unitRef="U_USD">-7214000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_2ab60b40-554f-4f5b-ae2a-bb9314f1a1e7"
      unitRef="U_USD">-1624000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_7955e47f-5f2c-4160-9a5f-ec26253a2d0c"
      unitRef="U_USD">1000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_d6d103c4-59e3-4e5f-aaa6-d4ccafbcbe8e"
      unitRef="U_USD">1000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <calc:IncomeTaxReconciliationPermanentDifferences
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_8ec3d50d-160b-4b80-9c16-b4d730118922"
      unitRef="U_USD">-616000</calc:IncomeTaxReconciliationPermanentDifferences>
    <calc:IncomeTaxReconciliationPermanentDifferences
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_58cf279b-2931-4105-b4d2-39d77b574bda"
      unitRef="U_USD">-1237000</calc:IncomeTaxReconciliationPermanentDifferences>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_4c0f1eb3-d55c-41ad-a4f1-2c2418884485"
      unitRef="U_USD">705000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_5ef5456d-ce29-4bf7-abf5-b92ce8d81edc"
      unitRef="U_USD">454000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_46ecb62d-de74-4213-9112-64ec9f3d9757"
      unitRef="U_USD">8535000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_db2ab9f4-cf63-4f41-8139-f60978e0aef7"
      unitRef="U_USD">3315000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_61e16b1e-7c7b-4651-86b7-8bcfd7b50fb7"
      unitRef="U_USD">1000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_5662cbcb-3d39-47fa-bfaf-b422a4b7a66c"
      unitRef="U_USD">1000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_7038fda4-b25d-41b8-bcc6-2e5683374910">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant components of deferred tax assets (liabilities) at December 31 are as follows (in thousands):&lt;/span&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:89.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.682%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.813%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.102%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.813%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.588%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,839&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State tax, net of federal tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued and deferred expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development credit carry forwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_b243fb0f-bf40-437f-b579-406dad9ba2a5"
      unitRef="U_USD">58535000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_ac57932b-8924-4c1d-873b-e66ffcfa7641"
      unitRef="U_USD">15839000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsStateTaxes
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_78ed294b-5921-4783-b9b8-5a9ae7e09331"
      unitRef="U_USD">9865000</us-gaap:DeferredTaxAssetsStateTaxes>
    <us-gaap:DeferredTaxAssetsStateTaxes
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_ccb0e369-34da-45f0-9e44-b0fb121b836c"
      unitRef="U_USD">6407000</us-gaap:DeferredTaxAssetsStateTaxes>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_9bfa73b6-3ae8-493d-ad43-17deb3cc22b2"
      unitRef="U_USD">93000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_86f24bb6-5b05-4fe9-938c-920c3bf5e337"
      unitRef="U_USD">167000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_77276493-aa37-41fc-8e2e-470f1a861221"
      unitRef="U_USD">12403000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_aa4a514a-2f64-4e91-80f9-935a9e01d5e4"
      unitRef="U_USD">5736000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <calc:DeferredTaxAssetLeaseLiabilities
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_955441de-ff90-4477-afa0-080dd3e3a54b"
      unitRef="U_USD">0</calc:DeferredTaxAssetLeaseLiabilities>
    <calc:DeferredTaxAssetLeaseLiabilities
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_9f1c7fd7-b727-4a0a-834a-e324e97ac816"
      unitRef="U_USD">11000</calc:DeferredTaxAssetLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_4f6159ba-6e7b-4da6-8f7e-6d92cebc573e"
      unitRef="U_USD">1699000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_7b9cc461-d1c6-4cb8-8ec6-11227ff946d9"
      unitRef="U_USD">118000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_593f952d-9ba9-4102-80b0-904891218891"
      unitRef="U_USD">82595000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_9f688379-cb97-4d4f-b6da-deb45dc5731a"
      unitRef="U_USD">28278000</us-gaap:DeferredTaxAssetsGross>
    <calc:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_bbc9079b-8c22-4c0f-ad7a-602f8dbe6087"
      unitRef="U_USD">0</calc:DeferredTaxLiabilitiesRightOfUseAssets>
    <calc:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_1251f031-2745-47d8-89d3-c001d57f297a"
      unitRef="U_USD">-10000</calc:DeferredTaxLiabilitiesRightOfUseAssets>
    <calc:DeferredTaxLiabilitiesValuationAllowance
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_c0ea5661-f123-4cfa-acc0-9960d3f3b32f"
      unitRef="U_USD">21000</calc:DeferredTaxLiabilitiesValuationAllowance>
    <calc:DeferredTaxLiabilitiesValuationAllowance
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_5fc1e7d0-8452-4920-8abe-16c87f328136"
      unitRef="U_USD">28000</calc:DeferredTaxLiabilitiesValuationAllowance>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_73c6504d-be3d-48f4-ad5c-2c947ef758e5"
      unitRef="U_USD">21000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_03ae0230-b6bd-42bc-9de7-8b0767c2e7fb"
      unitRef="U_USD">38000</us-gaap:DeferredIncomeTaxLiabilities>
    <calc:NetDeferredTaxAsset
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_b105c7bd-6e75-4233-9722-75c9b6d47761"
      unitRef="U_USD">82574000</calc:NetDeferredTaxAsset>
    <calc:NetDeferredTaxAsset
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_4b489068-769c-4a69-910e-c37494fb9c3a"
      unitRef="U_USD">28240000</calc:NetDeferredTaxAsset>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_253c8963-2a31-4d92-81aa-eb256decb51c"
      unitRef="U_USD">82574000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_939ec97f-66c1-46d4-81f1-20dedc452969"
      unitRef="U_USD">28240000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_c377acb5-a75a-4b76-958c-6f38e6216985"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_68571ed4-8037-4b75-b363-d8658aac5e29"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-5"
      id="F_6d7a89d2-0535-4776-b3df-bbcab105b52f"
      unitRef="U_USD">278700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-5"
      id="F_1c77d3ce-1bc3-4fb4-ae38-7012b1240355"
      unitRef="U_USD">103500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <calc:OperatingLossCarryForwardsExpirationBeginningYear
      contextRef="C_577f2bd0-e762-4230-970a-df97b7cca6e1"
      id="F_75d875cf-e306-4dec-9df9-b6470aa0de33">2026</calc:OperatingLossCarryForwardsExpirationBeginningYear>
    <calc:OperatingLossCarryForwardsExpirationBeginningYear
      contextRef="C_da70ea3c-8eb1-49bf-a910-720ae1e76953"
      id="F_58b45a7a-eccf-4aed-a477-ab67464dff4c">2026</calc:OperatingLossCarryForwardsExpirationBeginningYear>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_ff6e332f-5b48-43f3-b9ad-0eb9e3c7b9e1"
      decimals="-5"
      id="F_a0ee58e7-c27b-40c0-80f1-909ab39759e9"
      unitRef="U_USD">204100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_060646d5-5a4b-4e39-9d9c-ee17f2cd2248">In addition, under the Tax Act the amount of net operating losses generated in taxable periods beginning after December 31, 2017, that the Company is permitted to deduct in any taxable year is limited to 80% of taxable income in such year, where taxable income is determined without regard to the net operating loss deduction itself.</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_317b6ba6-8a13-4bfe-b342-48339a414824"
      decimals="-5"
      id="F_a5d5a71c-8a30-4cda-83fc-b2065051ec4d"
      unitRef="U_USD">12400000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_9759fbac-1faf-4bad-935e-6d6df5498635"
      decimals="-5"
      id="F_6bd7e40b-65e4-4fe5-a887-2b6e08a15a76"
      unitRef="U_USD">2400000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <calc:OperatingLossCarryForwardsExpirationBeginningYear
      contextRef="C_4d8a1b34-d457-4b45-9c95-b58fcd74a782"
      id="F_19d419b8-5588-4f9f-83e4-81c43571591d">2027</calc:OperatingLossCarryForwardsExpirationBeginningYear>
    <calc:PercentageOfChangeInOwnership
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="2"
      id="F_f483b4be-1182-4092-a7d5-a1790b259cb6"
      unitRef="U_pure">0.50</calc:PercentageOfChangeInOwnership>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_8636a0e4-add4-479e-aef4-086bc0a79437">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The change in the Company&#x2019;s unrecognized tax benefits is summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increase related to current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions for tax positions of prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increase related to current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,846&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions for tax positions of prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions in connection with the reverse merger&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#ffffff;text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Reduction for tax positions of prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_c2ab8d40-d474-4916-9e68-da10e0f82c62"
      decimals="-3"
      id="F_98291f39-0c39-4f0b-b291-b74c36b9af51"
      unitRef="U_USD">6457000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_f84bc6d1-cded-421c-ac6e-425138076c85"
      unitRef="U_USD">973000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_b66900d5-0ba5-42bc-b905-3dc014b6d57e"
      unitRef="U_USD">76000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-3"
      id="F_70d0cb1a-5fae-4767-8f45-8af48685a84c"
      unitRef="U_USD">7506000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_d0848912-cc89-4629-a043-57857e884373"
      unitRef="U_USD">2846000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_f075d523-34c9-4faa-9d2b-d344d5617dd9"
      unitRef="U_USD">21000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_cd166aba-9cca-4543-95f0-98c820e47993"
      unitRef="U_USD">847000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_1520cdd4-f37a-4a08-8367-a291eb3eb591"
      unitRef="U_USD">140000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-3"
      id="F_df8fb9fd-9036-4d82-ac90-1c2a02cb538d"
      unitRef="U_USD">11080000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="0"
      id="F_269c60e9-075f-474b-be9a-0d5863314556"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="0"
      id="F_f9de1119-63d2-4cd2-b42c-04fe68e65a9f"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <calc:UnrecognizedTaxBenefitsNet
      contextRef="C_25f1ae9e-285b-4bd6-8d55-7fcd71b013b0"
      decimals="-5"
      id="F_7af9ab17-1184-433c-80c2-5e396e71fae3"
      unitRef="U_USD">9100000</calc:UnrecognizedTaxBenefitsNet>
    <calc:UnrecognizedTaxBenefitsNet
      contextRef="C_45f580d8-2915-4dc7-855f-9af2533ecdf2"
      decimals="-5"
      id="F_7ef68567-d4d6-40a8-afb3-6b58b3f7ca19"
      unitRef="U_USD">6100000</calc:UnrecognizedTaxBenefitsNet>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_399624a6-26cc-49cc-8bfd-208d86a51e84">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12. Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth the computation of basic and diluted net loss per share (in thousands, except per share amounts):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.067%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.138%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.239%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.597%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="8" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Denominator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average common stock outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,486,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;111.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.009%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.356%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.356%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Convertible preferred stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,442,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Warrants to purchase convertible preferred stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;328,859&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,739,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;739,544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;276,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,520&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,015,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,522,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_6e58edcc-f799-45d6-b32e-58abf4b5c8b6">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth the computation of basic and diluted net loss per share (in thousands, except per share amounts):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.067%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.138%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.239%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.597%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="8" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Denominator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted average common stock outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,486,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;111.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="-3"
      id="F_377fc435-be30-463c-9b20-fb9a6ada02f8"
      unitRef="U_USD">-34357000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="-3"
      id="F_9945632d-a48e-4c74-b377-b09fb136af3b"
      unitRef="U_USD">-7824000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="0"
      id="F_3508f4a5-a8d2-49f3-86aa-caf12f38d10c"
      unitRef="U_shares">4486258</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="0"
      id="F_d99816db-cce0-4f96-a7d9-2f636cb223c1"
      unitRef="U_shares">4486258</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="0"
      id="F_1c939bc5-a825-4965-affa-8c12a0d1f0ba"
      unitRef="U_shares">82245</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="0"
      id="F_f975e95f-56b6-42f9-947e-93fa4026fafd"
      unitRef="U_shares">82245</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="2"
      id="F_6a5992fb-420f-43ad-85b8-bf0f5698fa3d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-7.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="2"
      id="F_a3bb575a-fde7-4f6a-9d56-9654d994c30e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-7.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="2"
      id="F_a41a89f6-c916-44b9-bfeb-75cb8f71b4d2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-111.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="2"
      id="F_57e2db04-a78c-44f2-97eb-06c577fea617"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-111.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_ecd93b7f-3d68-44dc-97ef-51f43d3d5d8a">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.009%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.356%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.356%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Convertible preferred stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,442,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Warrants to purchase convertible preferred stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;328,859&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,739,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;739,544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;276,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,520&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,015,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,522,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0812ad75-b2cd-4dd2-8c00-aee77ec17b71"
      decimals="0"
      id="F_fdf34c1f-96cc-4f23-a1a9-57e353a203b4"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f0893edf-fb0c-4acf-a7b8-179db40778c8"
      decimals="0"
      id="F_54563c67-e50e-46c1-9218-dadc7921d7a5"
      unitRef="U_shares">2442852</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0605ef80-c201-4125-b549-78eca9b466e4"
      decimals="0"
      id="F_0c68b8d3-471d-4a96-a719-95bd92a42c1e"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_faf992f7-2c83-438f-adbe-c70b73ea5b35"
      decimals="0"
      id="F_6aa14352-a803-4c21-854a-5792a906edce"
      unitRef="U_shares">328859</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_8c333f4e-ee8c-4673-aefb-c953498d5405"
      decimals="0"
      id="F_7c569093-f437-420b-ae80-e8c257c8f7f0"
      unitRef="U_shares">1739270</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_53c249ce-207a-4c43-a71e-dd5b46a497f6"
      decimals="0"
      id="F_bf34f287-95f7-43a9-9eb4-c2c07d5d9371"
      unitRef="U_shares">739544</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d04970cb-4761-47c7-91f6-85af5efbecc9"
      decimals="0"
      id="F_f66b7b8b-20e9-4bb3-9192-de3ae20422bd"
      unitRef="U_shares">276437</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b409b108-40af-4cb0-85b0-9bb871670447"
      decimals="0"
      id="F_d8cd678f-c1fc-4812-b9fd-9b7b9667c932"
      unitRef="U_shares">11520</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      decimals="0"
      id="F_a269c029-ca85-4b60-aeaf-a2b9d44c9993"
      unitRef="U_shares">2015707</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_abd03181-4cc7-48fa-9b60-969d071a9ee9"
      decimals="0"
      id="F_02085cd1-ba04-4e79-8cc9-33e52c2a3677"
      unitRef="U_shares">3522775</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_0dbbe3d0-7216-4364-b69c-7a1d468cebca"
      id="F_a4ef61d5-c9da-4438-bf4c-595ff3e7dee0">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;13. Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Private Placement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January 19, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with certain accredited investors, in which the Company sold the following securities to the accredited investors in a private placement transaction (the &#x201c;Private Placement&#x201d;) (i) an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,985,610&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares (the &#x201c;Shares&#x201d;) of common stock, par value $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share; (ii) to certain investors, in lieu of Shares, pre-funded warrants (the &#x201c;Pre-Funded Warrants&#x201d;) to purchase an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;306,506&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock; (iii) Tranche A Common Warrants (the &#x201c;Tranche A Common Warrants&#x201d;) to purchase an aggregate of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,646,058&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of common stock (or Pre-Funded Warrants in lieu thereof and, in such case, shares of common stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;issuable &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;upon exercise of such Pre-Funded Warrants); and (iv) Tranche B Common Warrants (the &#x201c;Tranche B Common Warrants&#x201d; and together with the Tranche A Common Warrants, the &#x201c;Common Warrants&#x201d;) to purchase an aggregate of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,646,058&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock (or Pre-Funded Warrants in lieu thereof and, in such case, shares of common stock issuable upon exercise of such Pre-Funded Warrants). The Purchase Price per Share and accompanying Common Warrants was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.827&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (or $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.3915&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for directors, employees or consultants of the Company participating in the Private Placement) (or $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.8269&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per Pre-Funded Warrant and accompanying Common Warrants, which represented the price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.827&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per Share and accompanying Common Warrants minus the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share exercise price of each such Pre-Funded Warrant).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The initial closing of the Private Placement occurred on January 23, 2024 and the second closing occurred on February 5, 2024. Gross proceeds from the transaction were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million with net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million after deducting $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in commissions and other transaction costs.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SubsequentEventsDate
      contextRef="C_75c836b2-6496-4ac1-a472-f97feb0d50ca"
      id="F_09046eed-c941-4f29-a07c-5df977aa210e">2024-01-19</us-gaap:SubsequentEventsDate>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_6bf7869c-2d29-4936-b2b6-f5c3f0c8389e"
      decimals="INF"
      id="F_19e3e7c0-3499-40ca-b526-0a1889b262b8"
      unitRef="U_shares">4985610</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_c7b1abbe-8b62-4f83-bd11-82bf252ed828"
      decimals="4"
      id="F_ab66cd02-bc50-4774-8867-ebbb119f72e0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_638c2e40-07d4-4e89-83a6-af9e3d6013a3"
      decimals="INF"
      id="F_6f106794-3812-49f6-acb9-e93c7b2063a6"
      unitRef="U_shares">306506</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_d8121a99-b58b-4059-9f6a-950088ae02aa"
      decimals="INF"
      id="F_be370833-5500-438f-8615-d4c29d0d4f2e"
      unitRef="U_shares">2646058</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_b6a7e660-bab4-4faa-a6a3-7ce18a7b50c0"
      decimals="0"
      id="F_9169f46e-d5e8-40ad-bca3-a76cb3c53f0e"
      unitRef="U_shares">2646058</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_c7b1abbe-8b62-4f83-bd11-82bf252ed828"
      decimals="3"
      id="F_22124bf6-4cd7-4bb0-8ab4-79c77a1abe6f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.827</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_d7864a30-f755-4c98-af75-d219e66a55a8"
      decimals="4"
      id="F_ae4f3450-b4c5-4421-882b-d372adc48917"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.3915</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_638c2e40-07d4-4e89-83a6-af9e3d6013a3"
      decimals="4"
      id="F_89ee7ff5-b544-4f0d-a850-1743464aad29"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.8269</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_33be579f-9303-4157-8599-6e2e245843a2"
      decimals="3"
      id="F_56a1ad9b-22c8-4e14-adb6-f30d19fdc5b0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.827</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="C_13a92f01-c445-4a91-b998-937547a6966a"
      decimals="4"
      id="F_87f454de-bd96-4ba3-853f-cbd358c633a5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:WarrantExercisePriceDecrease>
    <calc:GrossProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_f68eaef2-f138-447b-b9cf-bb7bd3b96085"
      decimals="-5"
      id="F_aecfd3b1-4887-4ff4-a1d3-0b5707c8454a"
      unitRef="U_USD">20400000</calc:GrossProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_f68eaef2-f138-447b-b9cf-bb7bd3b96085"
      decimals="-5"
      id="F_543473f7-6a34-413b-a1be-c8e175d5c9f2"
      unitRef="U_USD">19000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_f68eaef2-f138-447b-b9cf-bb7bd3b96085"
      decimals="-5"
      id="F_7534a828-c2e4-4f4a-937c-4924d3da87e6"
      unitRef="U_USD">1400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_6e50737b-dc7c-4bbc-97ea-d00034ac8717"
          xlink:label="F_6e50737b-dc7c-4bbc-97ea-d00034ac8717"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_eb32f7f3-f91a-4e57-94ed-8a2cd6277afb"
          xlink:label="F_eb32f7f3-f91a-4e57-94ed-8a2cd6277afb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_27361f8e-d2e4-4e18-9632-df1df55eaff4"
          xlink:label="F_27361f8e-d2e4-4e18-9632-df1df55eaff4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_acfe5755-3ae1-4a5a-b7b0-5f043022b2ae"
          xlink:label="F_acfe5755-3ae1-4a5a-b7b0-5f043022b2ae"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_77a8410c-4e3c-4060-829b-0d8b55ac4402"
          xlink:label="F_77a8410c-4e3c-4060-829b-0d8b55ac4402"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_3fbd2093-cd96-437a-be94-3a27dc8e2bb4"
          xlink:label="F_3fbd2093-cd96-437a-be94-3a27dc8e2bb4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_bcd704f4-ea19-434a-8fa8-9bef64fd9dd0"
          xlink:label="F_bcd704f4-ea19-434a-8fa8-9bef64fd9dd0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_8bb455e8-70b9-4732-be18-0165b2cbda00"
          xlink:label="F_8bb455e8-70b9-4732-be18-0165b2cbda00"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_b1d275c5-c0d4-477b-89db-8c7429a395f6"
          xlink:label="F_b1d275c5-c0d4-477b-89db-8c7429a395f6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_e9c6e4f2-b585-4330-83ce-ae3565e5cbbf"
          xlink:label="F_e9c6e4f2-b585-4330-83ce-ae3565e5cbbf"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_a07ba786-30c5-4eb5-b907-fe5e65ee816f"
          xlink:label="F_a07ba786-30c5-4eb5-b907-fe5e65ee816f"
          xlink:type="locator"/>
        <link:footnote id="FNT_9f0bb873-815a-4c02-aa18-9b124c54fb6a" xlink:label="FNT_9f0bb873-815a-4c02-aa18-9b124c54fb6a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) Retroactively restated for the reverse recapitalization as described in Note 2.</xhtml:span></xhtml:p></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_6e50737b-dc7c-4bbc-97ea-d00034ac8717"
          xlink:to="FNT_9f0bb873-815a-4c02-aa18-9b124c54fb6a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_eb32f7f3-f91a-4e57-94ed-8a2cd6277afb"
          xlink:to="FNT_9f0bb873-815a-4c02-aa18-9b124c54fb6a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_27361f8e-d2e4-4e18-9632-df1df55eaff4"
          xlink:to="FNT_9f0bb873-815a-4c02-aa18-9b124c54fb6a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_acfe5755-3ae1-4a5a-b7b0-5f043022b2ae"
          xlink:to="FNT_9f0bb873-815a-4c02-aa18-9b124c54fb6a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_77a8410c-4e3c-4060-829b-0d8b55ac4402"
          xlink:to="FNT_9f0bb873-815a-4c02-aa18-9b124c54fb6a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_3fbd2093-cd96-437a-be94-3a27dc8e2bb4"
          xlink:to="FNT_9f0bb873-815a-4c02-aa18-9b124c54fb6a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_bcd704f4-ea19-434a-8fa8-9bef64fd9dd0"
          xlink:to="FNT_9f0bb873-815a-4c02-aa18-9b124c54fb6a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_8bb455e8-70b9-4732-be18-0165b2cbda00"
          xlink:to="FNT_9f0bb873-815a-4c02-aa18-9b124c54fb6a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_b1d275c5-c0d4-477b-89db-8c7429a395f6"
          xlink:to="FNT_9f0bb873-815a-4c02-aa18-9b124c54fb6a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e9c6e4f2-b585-4330-83ce-ae3565e5cbbf"
          xlink:to="FNT_9f0bb873-815a-4c02-aa18-9b124c54fb6a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_a07ba786-30c5-4eb5-b907-fe5e65ee816f"
          xlink:to="FNT_9f0bb873-815a-4c02-aa18-9b124c54fb6a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_9c966614-f625-4a8d-9dde-653f387df670"
          xlink:label="F_9c966614-f625-4a8d-9dde-653f387df670"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_df2a12f8-eb45-4e92-a272-43e99d7d9bb8"
          xlink:label="F_df2a12f8-eb45-4e92-a272-43e99d7d9bb8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_9e6587b8-a085-4060-bcbb-02a3fd9cb98a"
          xlink:label="F_9e6587b8-a085-4060-bcbb-02a3fd9cb98a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_1b4fc4d8-0455-4e1e-b160-f78a2794e368"
          xlink:label="F_1b4fc4d8-0455-4e1e-b160-f78a2794e368"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_ba2bde47-7ce9-4d0a-8bec-2f13de62590f"
          xlink:label="F_ba2bde47-7ce9-4d0a-8bec-2f13de62590f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_09a89814-82cf-4b05-8abf-d22651e40260"
          xlink:label="F_09a89814-82cf-4b05-8abf-d22651e40260"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_4bd1ee4e-cab4-4321-a744-19504259caa2"
          xlink:label="F_4bd1ee4e-cab4-4321-a744-19504259caa2"
          xlink:type="locator"/>
        <link:footnote id="FNT_92a35516-dd1a-4ef7-8468-5d018858e544" xlink:label="FNT_92a35516-dd1a-4ef7-8468-5d018858e544" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) Retroactively restated for the reverse recapitalization as described in Note 2.</xhtml:span></xhtml:p></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9c966614-f625-4a8d-9dde-653f387df670"
          xlink:to="FNT_92a35516-dd1a-4ef7-8468-5d018858e544"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_df2a12f8-eb45-4e92-a272-43e99d7d9bb8"
          xlink:to="FNT_92a35516-dd1a-4ef7-8468-5d018858e544"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9e6587b8-a085-4060-bcbb-02a3fd9cb98a"
          xlink:to="FNT_92a35516-dd1a-4ef7-8468-5d018858e544"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_1b4fc4d8-0455-4e1e-b160-f78a2794e368"
          xlink:to="FNT_92a35516-dd1a-4ef7-8468-5d018858e544"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_ba2bde47-7ce9-4d0a-8bec-2f13de62590f"
          xlink:to="FNT_92a35516-dd1a-4ef7-8468-5d018858e544"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_09a89814-82cf-4b05-8abf-d22651e40260"
          xlink:to="FNT_92a35516-dd1a-4ef7-8468-5d018858e544"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_4bd1ee4e-cab4-4321-a744-19504259caa2"
          xlink:to="FNT_92a35516-dd1a-4ef7-8468-5d018858e544"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_7fa10f53-be99-4967-bf37-e3fa0474e69a"
          xlink:label="F_7fa10f53-be99-4967-bf37-e3fa0474e69a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_b9d8336f-3890-4043-9995-6e780f43215e"
          xlink:label="F_b9d8336f-3890-4043-9995-6e780f43215e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_653e16b7-bfd8-48a8-adbe-099c4cbd6e40"
          xlink:label="F_653e16b7-bfd8-48a8-adbe-099c4cbd6e40"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_abfd3d94-e97c-4d7d-93da-21000f70a852"
          xlink:label="F_abfd3d94-e97c-4d7d-93da-21000f70a852"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_b1745aaa-ce03-42da-b1a6-98a0481feb87"
          xlink:label="F_b1745aaa-ce03-42da-b1a6-98a0481feb87"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_8f2f002b-1bd3-437f-bf29-483769287156"
          xlink:label="F_8f2f002b-1bd3-437f-bf29-483769287156"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_a90ba9c6-3e69-4a14-9d5b-e426367ed758"
          xlink:label="F_a90ba9c6-3e69-4a14-9d5b-e426367ed758"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_4246f750-75ee-4e2a-abd6-1a856a263eff"
          xlink:label="F_4246f750-75ee-4e2a-abd6-1a856a263eff"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_f773b99e-e092-43b8-b105-11fd67e300ed"
          xlink:label="F_f773b99e-e092-43b8-b105-11fd67e300ed"
          xlink:type="locator"/>
        <link:footnote id="FNT_817b6b4d-bd23-4519-a81b-d710bbd95793" xlink:label="FNT_817b6b4d-bd23-4519-a81b-d710bbd95793" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) Retroactively restated for the reverse recapitalization as described in Note 2.</xhtml:span></xhtml:p></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_7fa10f53-be99-4967-bf37-e3fa0474e69a"
          xlink:to="FNT_817b6b4d-bd23-4519-a81b-d710bbd95793"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_b9d8336f-3890-4043-9995-6e780f43215e"
          xlink:to="FNT_817b6b4d-bd23-4519-a81b-d710bbd95793"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_653e16b7-bfd8-48a8-adbe-099c4cbd6e40"
          xlink:to="FNT_817b6b4d-bd23-4519-a81b-d710bbd95793"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_abfd3d94-e97c-4d7d-93da-21000f70a852"
          xlink:to="FNT_817b6b4d-bd23-4519-a81b-d710bbd95793"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_b1745aaa-ce03-42da-b1a6-98a0481feb87"
          xlink:to="FNT_817b6b4d-bd23-4519-a81b-d710bbd95793"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_8f2f002b-1bd3-437f-bf29-483769287156"
          xlink:to="FNT_817b6b4d-bd23-4519-a81b-d710bbd95793"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_a90ba9c6-3e69-4a14-9d5b-e426367ed758"
          xlink:to="FNT_817b6b4d-bd23-4519-a81b-d710bbd95793"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_4246f750-75ee-4e2a-abd6-1a856a263eff"
          xlink:to="FNT_817b6b4d-bd23-4519-a81b-d710bbd95793"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_f773b99e-e092-43b8-b105-11fd67e300ed"
          xlink:to="FNT_817b6b4d-bd23-4519-a81b-d710bbd95793"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
